<SEC-DOCUMENT>0001104659-22-038887.txt : 20220328
<SEC-HEADER>0001104659-22-038887.hdr.sgml : 20220328
<ACCEPTANCE-DATETIME>20220328172305
ACCESSION NUMBER:		0001104659-22-038887
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		132
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220328
DATE AS OF CHANGE:		20220328

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Alpha Tau Medical Ltd.
		CENTRAL INDEX KEY:			0001871321
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41316
		FILM NUMBER:		22776464

	BUSINESS ADDRESS:	
		STREET 1:		KIRYAT HAMADA 5
		CITY:			JERUSALEM
		STATE:			L3
		ZIP:			9777605
		BUSINESS PHONE:		972-3-577-4115

	MAIL ADDRESS:	
		STREET 1:		KIRYAT HAMADA 5
		CITY:			JERUSALEM
		STATE:			L3
		ZIP:			9777605
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>drts-20211231x20f.htm
<DESCRIPTION>FORM 20-F
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.8042.36810 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 3/28/2022 8:46:47 PM -->
      <!-- iXBRL Library version: 1.0.8042.36816 -->
      <!-- iXBRL Service Job ID: 283d5258-75ce-40e2-b0b0-97cbac1ba366 -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:drts="http://www.alphatau.com/20211231" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_5pqBXfvnT02_Y7HmmjGsmQ">40433578</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_n5Y_55bTOECPCpxKVAXYuA">40528913</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" xs:nil="true" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" name="us-gaap:CommitmentsAndContingencies" id="Hidden_RVax8oe3G0GF7oatptiQ1w"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" xs:nil="true" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" name="us-gaap:CommitmentsAndContingencies" id="Hidden_FZkUOFEMHEG5Lz3h0rPFGQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" xs:nil="true" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" name="us-gaap:CommonStockValueOutstanding" id="Hidden_G6MlAfQenUC5KMBm8hIoeQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" xs:nil="true" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" name="us-gaap:CommonStockValueOutstanding" id="Hidden_fD_C-mmYfEiNLNqRvC2r7A"></ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw" sign="-" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_7qMY6mzvukmls5BKszmgrA">0.25</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw" sign="-" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_MNJz6Zx47Uu2O-_9bgST-w">0.22</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw" sign="-" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_DePBOIqiEU6BF4SfDX1SRw">0.67</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_m0PgDCiYQU2PjrsApvCBvw">33815448</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_uci48Mn9D0itSoXcTjZpVg">40274935</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_pfkY8QG510ql5k4pesQm0w">40534697</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_drts_SeriesConvertiblePreferredSharesMember_2rsemjdtU0aLnNvzSudxpQ" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" id="Hidden_H4lBvGB-oU6yVIxNiespoQ">7229885</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_drts_SeriesConvertiblePreferredSharesMember_Ciu93EXH3Uu0zKZgtaOVHQ" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" id="Hidden_3KtD8Q5Ax06fscVib8RhUQ">7229885</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_drts_SeriesBConvertiblePreferredSharesMember_aujqloiYdUqLgyG-IywV-g" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" id="Hidden_MxvarQWPQ0O-mGg8xiB4BQ">6509301</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_drts_SeriesBConvertiblePreferredSharesMember__unz0Gwr4U6xfvew_rt8qg" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" id="Hidden_yaEd_DzkAkqnvAweRetrqw">6509301</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" id="Hidden_WxKj4-VumkiLILEX7hOihQ">13739186</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_rUqKycjoM0Cr_UPRnYxNMg">33815448</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_3p4tQ6odvkuoS9ntZhhmVg">40274935</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_A7oAnHWdcEGrp4QFwGGNfw">40534697</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw" sign="-" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" id="Hidden_9qrtnq0_HkyyxzR1T4IENg">0.25</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw" sign="-" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" id="Hidden_JuWMtT2ZnEKtE0_4yW3j7A">0.22</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw" sign="-" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" id="Hidden_FwbXf4amSkamAW_TRYb8dw">0.67</ix:nonFraction><ix:nonNumeric contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" name="us-gaap:WarrantsAndRightsOutstandingValuationTechniqueExtensibleList" id="Hidden_L9Ato0C33E2LNSpyydoKvQ">http://fasb.org/us-gaap/2021-01-31#ValuationTechniqueOptionPricingModelMember</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_drts_AtmKkMember_srt_StatementGeographicalAxis_country_JP_7CxdZ9e-1k-8KSkiHCA2Aw" decimals="INF" name="drts:IncomeTaxRateReconciliationSmallCompaniesSpecialRatePercent" id="Hidden_Z-DGe3jtHEK1rvKDxu5T2w">0.0015</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_FM5Dlv3n_Uq5VkWGqLzMYg">40433578</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_4TC6wvDOF0Gs_JaCVjlbqw">40528913</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="dei:EntityCentralIndexKey" id="Tc_uWKdFz0WZ0ax-nn1pjBfyw_2_1">0001871321</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="dei:CurrentFiscalYearEndDate" id="Tc_0Z7YmwCM9kSjTWcvnt6GAg_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="dei:DocumentFiscalYearFocus" id="Tc_NRSSu4fZ3kmmtpRtoHQuqA_4_1">2021</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="dei:DocumentFiscalPeriodFocus" id="Tc_HEg5GGjQuUyTT9dC5VfKCA_5_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="dei:AmendmentFlag" id="Tc_rpFEf0If8USZgy6XaJ1ewQ_6_1">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="dei:EntityRegistrantName" id="Tc_eXwkR2xzXUuSkggz-w21Kg_8_1">Alpha Tau Medical Ltd.</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="drts-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="As_Of_4_30_2016_rW7hRh2E3Emvv6ppXNzIxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2016-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_o8AlyFK5_0q1GKpbfc38VQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_DDHUZat3sk6fWEo027gkiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_ajdK4nogIEm72h8iR_gO5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_hKjTfEKuFUCkwF-mupksAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_Jm9aG3RQCE2XotHJYhCprg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_6C1-PLSDy0mfoXDzXtxQwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_gKe2q9eKk0e3gwlR_9b76A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_26q-bJ04nk64a6-bSVGKkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_66Y1DeYIKEiZUIV-AiM0QQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_1CGa6Hpjaku4CPgZdTORGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_56RoFMzD20emutTGyd2S_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_wDZnSvtkgU6z66pKDtkfXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_drts_SeriesConvertiblePreferredSharesMember_2rsemjdtU0aLnNvzSudxpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">drts:SeriesConvertiblePreferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_drts_SeriesBConvertiblePreferredSharesMember_aujqloiYdUqLgyG-IywV-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">drts:SeriesBConvertiblePreferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_drts_SeriesBConvertiblePreferredSharesMember__unz0Gwr4U6xfvew_rt8qg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">drts:SeriesBConvertiblePreferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_7_2022_To_3_7_2022_us-gaap_BusinessAcquisitionAxis_drts_HcccMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_E1MNaT3WY0K3ZcXXAPmtVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">drts:HcccMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-07</xbrli:startDate><xbrli:endDate>2022-03-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_7_2022_To_3_7_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_WEfc-vShRUy3Gx5vSV4mVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-07</xbrli:startDate><xbrli:endDate>2022-03-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_7_2022_To_3_7_2022_zxGQCP-7Fk277229BSbBmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-07</xbrli:startDate><xbrli:endDate>2022-03-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HEnHaE37ekigHo4AetBJFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_MouG0PPKQkmZNUQVCP7aqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_bsiFZBQITkihmHXGW4LWHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ykMIzfofVUuPDoPU0k2Pgg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Az5at6t9sUi2LDLd7cWsbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VMREA2dVCUqalyS79-xuRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_hVc9GNOKXk-_jqzkPdtv8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_6ynx3rWt90GJLYzfoH7j8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4ygP12wMPUWWbr6h1XztVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_7_2022_us-gaap_BusinessAcquisitionAxis_drts_HcccMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_iIVxwLK7kE2b1JwNE4XyzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">drts:HcccMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_2jPIe9FCpk-lk0x3ei7plQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ODoUIImeZUSC5k7f53zukQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_bNVdyxnBY0S_wDAMjuaFkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QBEQ8mAQX0SOz4gXrPGKLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_i1mWmb_nSEecsnGxFg7m_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GocQ7aqoEkCbUnmv9spesw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_aj4GYFUqrka7uJcyVmTHIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4I62Q1RYY0G4dDLq0oH8kA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_kiT9W3vqp0OZhbNgXlCDlw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_N81fmDen3E25LY0nhNqEwg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_H5r7wu2GjkCR2jWr-TITxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_Qp1t4h1WuE20sketeFkQaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_OSPpJbgS_kKHuzfkXV5w1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_lVBebhm2NUeEc6aQ92svqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_kZCpG9oRQUWYe1QTUnt4Mg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_LahhRefsiUeIK16_07ddRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_drts_ShareOptionPlanMember_dFYkG00x2k-k8R6SDAZdBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">drts:ShareOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_-q59_3u_sUqS3xTBriYDrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_u1KsUB5GUkyYW_fz6BxGKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_QL_lHDCdIUaW2VkrmxWUYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zmqejbh0ukqtNgBs60C6XA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Sg0gHG4UoU-lLL3GVY6j-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_jB-0qsL4s0iRjn2iZ1I0eg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_a-Npz0DAckea4fyrLYOJvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_1fUps4YHpUmalFLxoLPtsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_S6irH3nF3kiUBJuvNW1GvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_drts_ShareOptionPlanMember_RIX788L11EWA3ahCtQufmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">drts:ShareOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2019_To_12_31_2019_yCEIW0JlakWqYIDxGbuWtQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_ZaOgQu4r90edkwyq9ZaeAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_drts_LaboratoryEquipmentMember_zGBF3SpbBE-OhZ3qDsbqLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">drts:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_1lJIcyzl2ka-godfGb-vHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_drts_LaboratoryEquipmentMember_DHtJpJcfZ06X41B2GbaKSw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">drts:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_URRNsHmmMUWu9_-B9brINQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_dZomxtzLFkWxB2CX70Casw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AutomobilesMember_MdIVVvN1b0Gj0kdnXqxCvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AutomobilesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_StatementGeographicalAxis_country_US_RZN6ejeNsEmQtCCCNm9spQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_StatementGeographicalAxis_country_JP__8sfu7Pxlk-mMRFbDKhBZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_StatementGeographicalAxis_country_IL_c_kJyhiBYEGoZcGQuB67uA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_srt_StatementGeographicalAxis_country_US_in1yQM0Z10-KwKkqgUSCKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_srt_StatementGeographicalAxis_country_IL_PMTZcbNK3kWZuaPNc0HC8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_BpY3NXZYiUacPgGpq8sVxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_bFz5PWOuYUWTs4rHFVh4Ig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_DR2lnPTSYkOr47Js9w5IFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AutomobilesMember_nSEbQEFkgkqLdoCosAad7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AutomobilesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_drts_LaboratoryEquipmentMember_GAJWzUvUwEyFjKgZHPzslw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">drts:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_JS-1SNXCvUeJpcN2z_gkow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_q_uetuy3B0Wa4ahNzfjYhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_Tsmzg43NZEq8r_rl1YdOkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_kmZMVTkZDk-WlRLrABkDOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AutomobilesMember_50PifpuGVkegwyS9RNi4Cw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AutomobilesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_drts_LaboratoryEquipmentMember_HT92yqEwAU2zKGWsZbh7gA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">drts:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_7_31_2019_srt_CounterpartyNameAxis_drts_HekabioK.k.Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_rNX51eEBuEGWtuOpNs--fw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">drts:HekabioK.k.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_30_2020_us-gaap_StatementClassOfStockAxis_drts_SeriesBConvertiblePreferredSharesMember_30sMLfKYZ0ukHDW9qDg6NQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">drts:SeriesBConvertiblePreferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2018_H4Zwi9gmHkGz2evRAa1_dQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_18_2022_srt_CounterpartyNameAxis_drts_BankLeumiLeIsraelBmMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_BeRyXpDJ5kGTXPHFaRTfqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">drts:BankLeumiLeIsraelBmMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_4_30_2020_us-gaap_StatementClassOfStockAxis_drts_SeriesBConvertiblePreferredSharesMember_bAcjFcmMGEKODAHgmn7SUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">drts:SeriesBConvertiblePreferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_LPp8QInDWUu1wZCHIvnfQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_IbEezU48YkqEkwVicJ4VDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_EKhArHp_YEqXT7Vh3-UQ7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_RAo1T_5iU0emGFXFccTaVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2021_rqAxnV6ZuUS7C0LOKQQJbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_dsprqrhawkyPoi6VXySrYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_Vcye6381VUeQWqckP0fFwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_762hkA1xekWBcZRYtQnetQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_2ghnd2En8UiT0zWguTDZrw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_58F--dymdEiPpkMxGCFxLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_S4dFGjmRIE2hAjthSZNbJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_hb-EpK2zOE6IW_s6W3VP0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_rrpsDYs6x0SIZ6A54vpDQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_s0BI7zNnAEKLzKmtfc-EqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_31_2019_srt_CounterpartyNameAxis_drts_HekabioK.k.Member_WD3hZ8b710aQRjZMhkzTsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">drts:HekabioK.k.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_9X1M-BXfgEWsSJdmFxdJhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_XIXddAY3L0yRBxsPKwvT6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_7_2022_To_3_7_2022_us-gaap_BusinessAcquisitionAxis_drts_HcccMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_wb4aa4hMOk-oUeKQrzX1-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">drts:HcccMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-07</xbrli:startDate><xbrli:endDate>2022-03-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_ugDRsvTNaUmilQmO6qFALQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_CVs6y3ige0mbtcVCtEnhqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_xkz4fyumv021UlW6DLiR0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_MHykc8OPo0iqU-HsSzCVvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_drts_WarrantsToPreferredSharesMember_3xaGNXkiQk215jhKwwMGtA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">drts:WarrantsToPreferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_8q6cV2yAM0a3XAboz3EV0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_ywa_0-bXzkKhuRpBh5X1qg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_Woekbq1Vh0m9LF6giXkjAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_drts_WarrantsToPreferredSharesMember_F-36Oqlx4UWKJm0Pn_tXwg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">drts:WarrantsToPreferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_83Yv-70FokCNwA9HBVo3Ag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_-g979nKaYE-fgpAUV8oCPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_JaC_a1cel0-cR7a1zDVJ8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_drts_WarrantsToPreferredSharesMember_g4e9gxAYuUqhsD456SMaZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">drts:WarrantsToPreferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_o_i3_DfHik6LOoF2B8rb3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember__1I8UfYct0qja66GZyQuYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_jSuYco4A6kWDk0WIg-bOhg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_pPraAX3UkUu0_lMAnsHfJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Y0-0nKnve0qsDthMlv68-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_nhO5-HJ1nk6RNhK67yOGoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_fv33GX4WVUa4CZlwHesWww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_KkiZY-M7yk-YryD1n_upAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_kforSQ4jYUSPrZV_1I2SsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_rhxpidqOe0uEnhSdwKCtbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_drts_SeriesConvertiblePreferredSharesMember_Ciu93EXH3Uu0zKZgtaOVHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">drts:SeriesConvertiblePreferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_HekaBioKKMember_KbAb2SB6LkyHj7B8hsEHXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">drts:HekaBioKKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_STmFVK2iUkKhWvfG-Crldw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iKd2bcgAO0yb8cTymXlliw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OA7LnjwMsEWxaEV_8urPuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xyh47eHvfkKb6vxdvq7wAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_u2IRTL2hREuTiBdvWBPJIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_Bx-4ke71BkK7RwJqTEiSgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_YkvYRoxUekOnNqnvzrP72A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_3YDYP2NS1kWrJTyY6tlLEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_9PHxHzoF8EaVkrgQF_FmYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_drts_SeriesConvertiblePreferredSharesMember_UHBSJ1OmqEK-PEYAzs74DA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">drts:SeriesConvertiblePreferredSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_7_31_2019_srt_CounterpartyNameAxis_drts_HekabioK.k.Member_r5R-uUg6Vk-zl0lhq3yl_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">drts:HekabioK.k.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2018_To_9_30_2018_QkwZ1akbskyCxXcB-8mukw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2016_To_4_30_2016_aEGL3Dhxo0CNZ5ITN3VZQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2016-04-01</xbrli:startDate><xbrli:endDate>2016-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_IsraeliInnovationAuthorityMember_drts_MethodOfPaymentRoyaltiesAxis_drts_FutureSalesOfDevelopedProductMember_srt_RangeAxis_srt_MinimumMember_GIY9mAr40kOVwTeAjK_dRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">drts:IsraeliInnovationAuthorityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="drts:MethodOfPaymentRoyaltiesAxis">drts:FutureSalesOfDevelopedProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_IsraeliInnovationAuthorityMember_drts_MethodOfPaymentRoyaltiesAxis_drts_FutureSalesOfDevelopedProductMember_srt_RangeAxis_srt_MaximumMember_FUMYd9CZyEiec-h-1tOPiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">drts:IsraeliInnovationAuthorityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="drts:MethodOfPaymentRoyaltiesAxis">drts:FutureSalesOfDevelopedProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_RamotMember_drts_MethodOfPaymentRoyaltiesAxis_drts_NetSalesOfAllCompanySProductMember_xoU_wft5E0-hugLOshOmLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">drts:RamotMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="drts:MethodOfPaymentRoyaltiesAxis">drts:NetSalesOfAllCompanySProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_HekaBioKKMember_drts_MethodOfPaymentRoyaltiesAxis_drts_ReimbursementPriceMember_cs_dWcRnWUyl8xd3aQkyBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">drts:HekaBioKKMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="drts:MethodOfPaymentRoyaltiesAxis">drts:ReimbursementPriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_HekaBioKKMember_drts_MethodOfPaymentRoyaltiesAxis_drts_DistributionReceiptsMember_B9pb87J-lk2fbjT-Lab7cw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">drts:HekaBioKKMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="drts:MethodOfPaymentRoyaltiesAxis">drts:DistributionReceiptsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_CambridgeUniversityHospitalsNhsTrustMember_drts_MethodOfPaymentRoyaltiesAxis_drts_RevenueGeneratedFromPatentMember_j1N6BX57fkmmH4t4HBjQrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">drts:CambridgeUniversityHospitalsNhsTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="drts:MethodOfPaymentRoyaltiesAxis">drts:RevenueGeneratedFromPatentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_CambridgeUniversityHospitalsNhsTrustMember_drts_MethodOfPaymentRoyaltiesAxis_drts_NetSalesSquamousCellCarcinomaMember_oyhYZ1hIYEeJctRg2MllLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">drts:CambridgeUniversityHospitalsNhsTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="drts:MethodOfPaymentRoyaltiesAxis">drts:NetSalesSquamousCellCarcinomaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_BgnTechnologiesMember_drts_MethodOfPaymentRoyaltiesAxis_drts_SalesOfProductContainingIntellectualPropertyMember_l6QmPIm-lka3XHyr-5FdgQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">drts:BgnTechnologiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="drts:MethodOfPaymentRoyaltiesAxis">drts:SalesOfProductContainingIntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_BgnTechnologiesMember_drts_MethodOfPaymentRoyaltiesAxis_drts_SalesOfAlphaRadiationProductsMember_fGiGrutCqkW4dBwjPHMKtw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">drts:BgnTechnologiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="drts:MethodOfPaymentRoyaltiesAxis">drts:SalesOfAlphaRadiationProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_BgnTechnologiesMember_drts_MethodOfPaymentRoyaltiesAxis_drts_LicenseRevenueToJointlyDevelopedIntellectualPropertyMember_E5RwUYMMMkKa7VOuc2eEbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">drts:BgnTechnologiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="drts:MethodOfPaymentRoyaltiesAxis">drts:LicenseRevenueToJointlyDevelopedIntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_BgnTechnologiesMember_drts_MethodOfPaymentRoyaltiesAxis_drts_LicenseRevenueRelatedToIntellectualPropertyMember_MPPvAjzvLEWclU5g9v1-PA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">drts:BgnTechnologiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="drts:MethodOfPaymentRoyaltiesAxis">drts:LicenseRevenueRelatedToIntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_AltheraMember_drts_MethodOfPaymentRoyaltiesAxis_drts_FutureGrossRevenuesDerivedFromPurchasedIntellectualPropertyMember_nP72Cyn7NkCYPc6GpcX5BA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">drts:AltheraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="drts:MethodOfPaymentRoyaltiesAxis">drts:FutureGrossRevenuesDerivedFromPurchasedIntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_IsraeliInnovationAuthorityMember_drts_MethodOfPaymentRoyaltiesAxis_drts_FutureSalesOfDevelopedProductMember_JSAQ3iw-VUSQibua7dXDzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">drts:IsraeliInnovationAuthorityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="drts:MethodOfPaymentRoyaltiesAxis">drts:FutureSalesOfDevelopedProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_drts_MethodOfPaymentRoyaltiesAxis_drts_NetSalesOfAllCompanySProductSoldByCompanySLicensesMember_gkrRFhGJnEimcQjvPTPPcQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="drts:MethodOfPaymentRoyaltiesAxis">drts:NetSalesOfAllCompanySProductSoldByCompanySLicensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_AltheraMember_GvfqErhqZEeZc_TxFNeN5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">drts:AltheraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_15_2021_To_7_15_2021_5Bu_BFUidUuMuhyoWEwmhg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-15</xbrli:startDate><xbrli:endDate>2021-07-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2020_To_11_30_2020_AqgH_S771EKQA0UT8K6nCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_4_30_2020_MsmjV8uDakyuT86VtP1xdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_dei_LegalEntityAxis_drts_HekaBioKKMember_k78dGWWtOUezu7C6qI5GDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">drts:HekaBioKKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_drts_AtmIncMember_srt_StatementGeographicalAxis_country_US_at7B-1SAeEur5CA5l3wWEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">drts:AtmIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_drts_AtmKkMember_srt_StatementGeographicalAxis_country_JP_7CxdZ9e-1k-8KSkiHCA2Aw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">drts:AtmKkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2019_To_4_30_2019_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_drts_AtmKkMember_srt_StatementGeographicalAxis_country_JP_zK9sUscq3kOiuunJG2qXkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">drts:AtmKkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_IsraeliInnovationAuthorityMember_xhyc0CWH6kS_-vAND8TX1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">drts:IsraeliInnovationAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_drts_AtmKkMember_rsvutQDxxkWFvd6im8QGtQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">drts:AtmKkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_drts_AtmKkMember_25Jj3jm1eU-OcstYM8wmaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">drts:AtmKkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_1_31_2018_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_drts_AtmKkMember_JbImIrkcuUGQZ_vY9-jX-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">drts:AtmKkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_7_2022_To_3_7_2022_us-gaap_BusinessAcquisitionAxis_drts_HcccMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_pSFCWjg1hEmAKs-87AaDOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">drts:HcccMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-07</xbrli:startDate><xbrli:endDate>2022-03-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zDmmSI986UmJIj-sGT2-Wg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_xeoIhA1uIke-CkfI6GwV9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IJsPnv36fkauy1pWGb0jpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_21_2022_Kx_JzkXasUWXdwjUN5eDyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8z9inUQaDEqLpH7MXNDp2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_atci3uMJzkOMMdtkZKqeBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_fqhSQAsxpUWRPhj9cc-Pog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001871321</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_AGp3CTLP9EiC4gKcttUqYA"><xbrli:measure>drts:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Vote_yl2FdYUkMUizA1ZcpmmCgA"><xbrli:measure>drts:Vote</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_segment_F1A8hT57kUWQPIMNg0d3ZQ"><xbrli:measure>drts:segment</xbrli:measure></xbrli:unit><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_2e32zEawfkeQRIldT_VSig_17_2" toRefs="_3912af17_c1f9_4243_a55a_b4731c1ce7c2" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_Rku296PeK0i4awh1scxZVA_17_5" toRefs="_3912af17_c1f9_4243_a55a_b4731c1ce7c2" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Hidden_G6MlAfQenUC5KMBm8hIoeQ" toRefs="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Hidden_fD_C-mmYfEiNLNqRvC2r7A" toRefs="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_P686uzzh_0240QcKLJnzuw_4_7" toRefs="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_0CdjEUrQ60qc-aWGXE0svw_4_2" toRefs="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_jCQr6Q1pxUqmv6xXVY9RKw_12_7" toRefs="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_u_LKhmMgwEaHCoxpK9whWw_12_2" toRefs="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_kglc91OPek-hdjs6FhlB7A_20_7" toRefs="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_y4vKTxUAcEqA0oTt8NslHA_20_2" toRefs="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_wBe7AwRzvUaMt38Ii5x4Og_27_7" toRefs="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_i3xv8QEPgUKYHXUfXzMJLw_27_2" toRefs="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_8U1wMLEo2UyQSZe3sFuTQQ_4_22" toRefs="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_lyh0_IXKxUC_nS-q0yyDCw_4_13" toRefs="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_1OwVenEu-0eEAuydtTNhTw_4_19" toRefs="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_T3zJEjDNFkGTCGwsdZE6uA_4_16" toRefs="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_0n0znmQK4kiznLwqpz-FmA_4_5" toRefs="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_56XM67-Ms0yj_sPp4AVY9w_12_22" toRefs="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_KJyJAPCCxUepTgIJXxk0WA_12_13" toRefs="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_r7OqZTkDyUiuLQbJGIbpmA_12_16" toRefs="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_7ASbk5JcKEOtWKvUjhU-XQ_12_5" toRefs="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_76XUmnnJH0WBOHwIejBh7Q_20_22" toRefs="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_ZKdYgNzJjUCbyRtM_ftH6w_20_13" toRefs="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_uAsIpfpH1EuGwJuct4F3Xw_20_16" toRefs="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_0eVudmzgAk2o9n9P9JaYrQ_20_5" toRefs="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_pbHeOPec5kCo7burVpgWUw_27_22" toRefs="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_CXgll3kXZkGRtrU7Mm5iuw_27_13" toRefs="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_DPen8g3MI0qtSL9TNu5vTQ_27_16" toRefs="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_ED3uytwyLEemO4jP3bMLrw_27_5" toRefs="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_rVR-ysL_j0WZafYvxyYOJw_18_5" toRefs="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_Zy7HkBmCZU29s2bBPs0NuA_18_8" toRefs="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Hidden_m0PgDCiYQU2PjrsApvCBvw" toRefs="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Hidden_uci48Mn9D0itSoXcTjZpVg" toRefs="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Hidden_pfkY8QG510ql5k4pesQm0w" toRefs="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_IYJZigyOHkyJZpyoc1xRsw_26_5" toRefs="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_XWLpghrsXUO5fpZiFUwglg_26_8" toRefs="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc__vRHrcT0Q0SDmSrSq27f1A_26_11" toRefs="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25" order="1"></ix:relationship></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:35.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:3pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_a5e0a1c2_8a9a_4d56_a311_ddf95aded47e"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:86.67%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="dei:DocumentType" id="Narr_zpJlG1ZVe0aBO7rEBaJxSA"><b style="font-weight:bold;">20-F</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">(Mark One) </b><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="dei:DocumentRegistrationStatement" id="Narr_Nh_b-RjYNkSW3W_7hReedA"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#8195;REGISTRATION STATEMENT PURSUANT TO SECTION&#160;12(b)&#160;OR SECTION&#160;12(g)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><i style="font-style:italic;">OR</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><ix:nonNumeric format="ixt:booleantrue" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="dei:DocumentAnnualReport" id="Narr_CJrC0hNorEiXN7eAxt_XoA"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></ix:nonNumeric>&#8195;ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;">For the fiscal&#160;year ended <ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="dei:DocumentPeriodEndDate" id="Narr_6QjYgtzZqkOhu28iPaJ1ug">December&#160;31, 2021</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><i style="font-style:italic;">OR</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><ix:nonNumeric format="ixt:booleanfalse" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="dei:DocumentTransitionReport" id="Narr_QBC9Ia6XZ0WM9xdO2Ni-Yg"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#8195;TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;">For the transition period from &#8195;&#8195;&#8195;&#8195; to</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><i style="font-style:italic;">OR</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><ix:nonNumeric format="ixt:booleanfalse" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="dei:DocumentShellCompanyReport" id="Narr_I6crHrcQuEye9m5XJZbTpA"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#8195;SHELL COMPANY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;">Date of event requiring this shell company report</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;">Commission file number: &#160;<ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="dei:EntityFileNumber" id="Narr__ICSkj1a90iAgefb6jZGFA">001-41316</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="font-size:12pt;"><img src="drts-20211231x20f002.jpg" alt="Graphic" style="display:inline-block;height:35.15pt;width:143.15pt;" /></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="dei:EntityRegistrantName" id="Narr_g1hqOn2rGkmuZh3jfUH3CA"><b style="font-weight:bold;">Alpha Tau Medical&#160;Ltd.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;">(Exact name of Registrant as specified in its charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Not Applicable</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;">(Translation of Registrant&#8217;s name into English)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">State of </b><ix:nonNumeric format="ixt-sec:edgarprovcountryen" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="dei:EntityIncorporationStateCountryCode" id="Narr_JxCPaXZdLUSJErkswd1NBw"><b style="font-weight:bold;">Israel</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;">(Jurisdiction of incorporation or organization)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="dei:EntityAddressAddressLine1" id="Narr_jTkXV0I9ZUKK25cX0sOL6A"><b style="font-weight:bold;">Kiryat HaMada St. 5</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="dei:EntityAddressCityOrTown" id="Narr_XCnLp460kEWDHXkUPAc89w"><b style="font-weight:bold;">Jerusalem</b></ix:nonNumeric><b style="font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="dei:EntityAddressPostalZipCode" id="Narr_aR2J93RjkECE6JcSsAqOpg"><b style="font-weight:bold;">9777605</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric format="ixt-sec:countrynameen" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="dei:EntityAddressCountry" id="Narr_dFEYQUBTnkKJDhYBB1W33w"><b style="font-weight:bold;">Israel</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;">(Address of principal executive offices)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_fqhSQAsxpUWRPhj9cc-Pog" name="dei:ContactPersonnelName" id="Narr_gVwL4Jts70CMZYDRXe-Kuw"><b style="font-weight:bold;">Uzi Sofer</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Chief Executive Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">E-mail: IR@alphatau.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Telephone: <b style="font-weight:bold;">+</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_fqhSQAsxpUWRPhj9cc-Pog" name="dei:CityAreaCode" id="Narr_rScbBgphakOmMZDMpxRMSw"><b style="font-weight:bold;">972</b></ix:nonNumeric><b style="font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_fqhSQAsxpUWRPhj9cc-Pog" name="dei:LocalPhoneNumber" id="Narr_YgcU3Kcn6E6B3zyG2_UxBA"><b style="font-weight:bold;">(3)&#160;577-4115</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Alpha Tau Medical&#160;Ltd.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_fqhSQAsxpUWRPhj9cc-Pog" name="dei:EntityAddressAddressLine1" id="Narr_lgsHKxJg3UaOuiY1x7KEJw">Kiryat HaMada St. 5</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_fqhSQAsxpUWRPhj9cc-Pog" name="dei:EntityAddressCityOrTown" id="Narr_30FpRhjBaEGUQq0WEYuLuQ">Jerusalem</ix:nonNumeric> <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_fqhSQAsxpUWRPhj9cc-Pog" name="dei:EntityAddressPostalZipCode" id="Narr_PsBxWE130ES9B512c9TXVw">9777605</ix:nonNumeric>, <ix:nonNumeric format="ixt-sec:countrynameen" contextRef="Duration_1_1_2021_To_12_31_2021_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_fqhSQAsxpUWRPhj9cc-Pog" name="dei:EntityAddressCountry" id="Narr_aXdKk36kpEy7MrRmB3HHCw">Israel</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)</p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:86.67%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">Securities registered or to be registered, pursuant to Section&#160;12(b)&#160;of the Act</p><a id="_7aef83a6_0982_4bd1_b851_bee22faa1940"></a><a id="Tc_8wxdOwmjgU-k_mGeqKIIqA_1_0"></a><a id="Tc_nr6OhN5a9U--ez9Tf8ClXw_1_2"></a><a id="Tc_CDYG1bYzPEu5TKjkQ4TAeA_1_4"></a><a id="Tc_xlzckyNvn0Sm0XuvLeT84A_2_0"></a><a id="Tc_fiilv_yWO06TyrC8IYctOg_2_4"></a><a id="Tc_0BiCh4w5o0u8QcKG01kyHw_3_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:35.84%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:35.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class </b></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)&#160;</b></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:35.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name&#160;of&#160;each&#160;exchange&#160;on&#160;which&#160;registered</b></p></td></tr><tr><td style="vertical-align:top;width:35.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IJsPnv36fkauy1pWGb0jpQ" name="dei:Security12bTitle" id="Narr_i7WFL4aV9kalFg18EoBodA">Ordinary shares, no par value </ix:nonNumeric></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IJsPnv36fkauy1pWGb0jpQ" name="dei:TradingSymbol" id="Tc_T3q-rNv2lE2hWb5FYQznPg_2_2">DRTS</ix:nonNumeric></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:35.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IJsPnv36fkauy1pWGb0jpQ" name="dei:SecurityExchangeName" id="Narr_hvJS_LQKDUmLHhdLTKpnEA">Nasdaq</ix:nonNumeric> Stock Market LLC</p></td></tr><tr><td style="vertical-align:top;width:35.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_xeoIhA1uIke-CkfI6GwV9A" name="dei:Security12bTitle" id="Tc_Ju4F53eWD0iVU3ZVW_BiHQ_3_0">Warrants to purchase ordinary shares</ix:nonNumeric></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_xeoIhA1uIke-CkfI6GwV9A" name="dei:TradingSymbol" id="Tc_tla6efP6nE6QGjN69RAcgA_3_2">DRTSW</ix:nonNumeric></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:35.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_xeoIhA1uIke-CkfI6GwV9A" name="dei:SecurityExchangeName" id="Narr_TmW0q46Q3UiRXoJT0gHcNw">Nasdaq</ix:nonNumeric> Stock Market LLC</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">Securities registered or to be registered pursuant to Section&#160;12(g)&#160;of the Act: None</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">Securities for which there is a reporting obligation pursuant to Section&#160;15(d)&#160;of the Act: None</b></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:13.8pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;">Indicate the number of outstanding shares of each of the issuer&#8217;s classes of capital stock or common stock as of the close of the period covered by the annual report. As of December&#160;31, 2021, the registrant had outstanding <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_atci3uMJzkOMMdtkZKqeBw" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="Narr_Enib91DN6Em7Vgng3YlE-Q">40,528,913</ix:nonFraction> ordinary shares, no par value and <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8z9inUQaDEqLpH7MXNDp2Q" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="Narr_IzPDFfenkUeYbeLl94ujWw">13,739,186</ix:nonFraction> preferred shares, no par value. As of March&#160;21, 2022, the registrant had <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_3_21_2022_Kx_JzkXasUWXdwjUN5eDyQ" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="Narr_uepU1uSQ_EeC1lyUpdEgtA">66,529,265</ix:nonFraction> ordinary shares outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;">Yes <span style="font-family:'Segoe UI Symbol';">&#9744;</span> <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_xaUWZNVCPkWcY2MwxiRzDQ">No</ix:nonNumeric> <b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9746;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;">If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;">Yes <b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9744;</b> <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="dei:EntityVoluntaryFilers" id="Narr_49tyxbPUzESeUARqiEGx2A">No</ix:nonNumeric> <b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9746;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;">Note&#8212;Checking the box above will not relieve any registrant required to file reports pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 from their obligations under those Sections.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;">Yes <b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9744;</b><b style="font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="dei:EntityCurrentReportingStatus" id="Narr_tA6c39l5SUKcAUx3hJrHVA">No</ix:nonNumeric> <b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9746;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;">Yes <b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9746;</b><b style="font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="dei:EntityInteractiveDataCurrent" id="Narr_FDB6S5NTZE6aNKJVKjekew">No</ix:nonNumeric> <b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9744;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:24%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:26%;margin:0pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:24%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:26%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9744;</b><b style="font-weight:bold;"> Large accelerated filer </b></p></td><td style="vertical-align:top;width:24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9744;</b><b style="font-weight:bold;"> Accelerated filer</b></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9746;</b><b style="font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="Narr_6W5tMNG5AUSqRCzxKev70A"><b style="font-weight:bold;">Non-accelerated filer</b></ix:nonNumeric><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:top;width:26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany" id="Narr_ut1QwCLf-kyd9FPav3Vxaw"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9746;</b></ix:nonNumeric><b style="font-weight:bold;"> Emerging growth company </b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:86.67%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards&#8201;provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" format="ixt:booleanfalse" name="dei:EntityExTransitionPeriod" id="Narr_OMP25ffIFE6yHtz-Pu4Q5g"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9744;</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section&#160;404(b)&#160;of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.<ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" format="ixt-sec:boolballotbox" name="dei:IcfrAuditorAttestationFlag" id="Narr_96th9629dUOyfsvxElYk_w"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9744;</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;">Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:93.34%;"><tr style="height:1pt;"><td style="vertical-align:top;width:15.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.77%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:8.04%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:15.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9746;</b><b style="font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="dei:DocumentAccountingStandard" id="Narr_LhUhped2eUWEsmfVigHr1A"><b style="font-weight:bold;">U.S. GAAP</b></ix:nonNumeric><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:top;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span> </p></td><td style="vertical-align:top;width:75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> International Financial Reporting Standards as issued by the International Accounting Standards Board </b></p></td><td style="vertical-align:top;width:8.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span><b style="font-weight:bold;"> Other </b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;">If &#8220;Other&#8221; has been checked in response to the previous question indicate by check mark which financial statement item the registrant has elected to follow.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;">Item&#160;17 <b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9744;</b> Item&#160;18 <b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9744;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;">If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;">Yes <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="Narr_8xTYhAt8WECuRFqs9NK9CA"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric> No <b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9746;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_fa47c2f7_d53e_4637_8f27_a98c1c61d0dd"></a><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">CONTENTS</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:95.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#ABOUTTHISANNUALREPORT_713375"><b style="font-style:normal;font-weight:bold;">ABOUT THIS ANNUAL REPORT</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;">i</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:95.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#PRESENTATIONOFFINANCIALANDOTHERINFORMATI"><b style="font-style:normal;font-weight:bold;">PRESENTATION OF FINANCIAL AND OTHER INFORMATION</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;">i</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:95.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#CAUTIONARYSTATEMENTREGARDINGFORWARDLOOKI"><b style="font-style:normal;font-weight:bold;">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;">ii</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:95.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#PARTI_376629"><b style="font-style:normal;font-weight:bold;">PART I</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;">1</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:95.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#Item1IdentityofDirectorsSeniorManagement"><b style="font-style:normal;font-weight:bold;">ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;">1</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:95.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#Item2OfferStatisticsandExpectedTimetable"><b style="font-style:normal;font-weight:bold;">ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;">1</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:95.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#Item3KeyInformation_830317"><b style="font-style:normal;font-weight:bold;">ITEM 3. KEY INFORMATION </b></a><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;">1</p></td></tr><tr><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4.5pt 0pt;"><a href="#AReserved_330517"><b style="font-style:normal;font-weight:bold;">A.</b></a></p></td><td style="vertical-align:top;width:89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#AReserved_330517"><b style="font-style:normal;font-weight:bold;">[Reserved.]</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;">1</p></td></tr><tr><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4.5pt 0pt;"><a href="#BCapitalizationandIndebtedness_9421"><b style="font-style:normal;font-weight:bold;">B.</b></a></p></td><td style="vertical-align:top;width:89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#BCapitalizationandIndebtedness_9421"><b style="font-style:normal;font-weight:bold;">Capitalization and Indebtedness</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;">1</p></td></tr><tr><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4.5pt 0pt;"><a href="#CReasonsfortheOfferandUseofProceeds_9888"><b style="font-style:normal;font-weight:bold;">C.</b></a></p></td><td style="vertical-align:top;width:89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#CReasonsfortheOfferandUseofProceeds_9888"><b style="font-style:normal;font-weight:bold;">Reasons for the Offer and Use of Proceeds</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;">1</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:95.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#Item4InformationontheCompany_88486"><b style="font-style:normal;font-weight:bold;">ITEM 4. INFORMATION ON THE COMPANY</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;"><span style="font-weight:bold;">56</span></p></td></tr><tr><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4.5pt 0pt;"><a href="#AHistoryandDevelopmentoftheCompany_22271"><b style="font-style:normal;font-weight:bold;">A.</b></a></p></td><td style="vertical-align:top;width:89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#AHistoryandDevelopmentoftheCompany_22271"><b style="font-style:normal;font-weight:bold;">History and Development of the Company </b></a><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;">56</p></td></tr><tr><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4.5pt 0pt;"><a href="#BBusinessOverview_943006"><b style="font-style:normal;font-weight:bold;">B.</b></a></p></td><td style="vertical-align:top;width:89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#BBusinessOverview_943006"><b style="font-style:normal;font-weight:bold;">Business Overview</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;">57</p></td></tr><tr><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4.5pt 0pt;"><a href="#AOrganizationalStructure_148506"><b style="font-style:normal;font-weight:bold;">C.</b></a></p></td><td style="vertical-align:top;width:89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#AOrganizationalStructure_148506"><b style="font-style:normal;font-weight:bold;">Organizational Structure</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;">106</p></td></tr><tr><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4.5pt 0pt;"><a href="#BPropertyPlantsandEquipment_788102"><b style="font-style:normal;font-weight:bold;">D.</b></a></p></td><td style="vertical-align:top;width:89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#BPropertyPlantsandEquipment_788102"><b style="font-style:normal;font-weight:bold;">Property, Plants and Equipment</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;">106</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:95.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#Item4AUnresolvedStaffComments_13611"><b style="font-style:normal;font-weight:bold;">ITEM 4A. &#160;UNRESOLVED STAFF COMMENTS</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;"><span style="font-weight:bold;">106</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:95.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#Item5OperatingandFinancialReviewandProsp"><b style="font-style:normal;font-weight:bold;">ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;"><span style="font-weight:bold;">106</span></p></td></tr><tr><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4.5pt 0pt;"><a href="#OperatingResults_304067"><b style="font-style:normal;font-weight:bold;">A.</b></a></p></td><td style="vertical-align:top;width:89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#OperatingResults_304067"><b style="font-style:normal;font-weight:bold;">Operating Results</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;">112</p></td></tr><tr><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4.5pt 0pt;"><a href="#LiquidityandCapitalResources_671200"><b style="font-style:normal;font-weight:bold;">B.</b></a></p></td><td style="vertical-align:top;width:89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#LiquidityandCapitalResources_671200"><b style="font-style:normal;font-weight:bold;">Liquidity and Capital Resources</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;">114</p></td></tr><tr><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4.5pt 0pt;"><a href="#ResearchandDevelopmentPatentsandLicenses"><b style="font-style:normal;font-weight:bold;">C.</b></a></p></td><td style="vertical-align:top;width:89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#ResearchandDevelopmentPatentsandLicenses"><b style="font-style:normal;font-weight:bold;">Research and Development, Patents and Licenses, Etc.</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4.5pt 0pt;"><a href="#TrendInformation_102347"><b style="font-style:normal;font-weight:bold;">D.</b></a></p></td><td style="vertical-align:top;width:89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#TrendInformation_102347"><b style="font-style:normal;font-weight:bold;">Trend Information</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4.5pt 0pt;"><a href="#ECriticalAccountingEstimates_906789"><b style="font-style:normal;font-weight:bold;">E.</b></a></p></td><td style="vertical-align:top;width:89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#ECriticalAccountingEstimates_906789"><b style="font-style:normal;font-weight:bold;">Critical Accounting Estimates</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:95.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#RecentlyIssuedandAdoptedAccountingPronou"><b style="font-style:normal;font-weight:bold;">[Recent Accounting Pronouncements</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:95.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#Item6DirectorsSeniorManagementandEmploye"><b style="font-style:normal;font-weight:bold;">ITEM 6.&#160;&#160;DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;"><span style="font-weight:bold;">122</span></p></td></tr><tr><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4.5pt 0pt;"><a href="#ADirectorsandSeniorManagement_894186"><b style="font-style:normal;font-weight:bold;">A.</b></a></p></td><td style="vertical-align:top;width:89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#ADirectorsandSeniorManagement_894186"><b style="font-style:normal;font-weight:bold;">Directors and Senior Management</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;">122</p></td></tr><tr><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4.5pt 0pt;"><a href="#BCompensation_241263"><b style="font-style:normal;font-weight:bold;">B.</b></a></p></td><td style="vertical-align:top;width:89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#BCompensation_241263"><b style="font-style:normal;font-weight:bold;">Compensation</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;">125</p></td></tr><tr><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4.5pt 0pt;"><a href="#CBoardPractices_69234"><b style="font-style:normal;font-weight:bold;">C.</b></a></p></td><td style="vertical-align:top;width:89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#CBoardPractices_69234"><b style="font-style:normal;font-weight:bold;">Board Practices</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;">133</p></td></tr><tr><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4.5pt 0pt;"><a href="#DEmployees_645610"><b style="font-style:normal;font-weight:bold;">D.</b></a></p></td><td style="vertical-align:top;width:89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#DEmployees_645610"><b style="font-style:normal;font-weight:bold;">Employees</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;">144</p></td></tr><tr><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4.5pt 0pt;"><a href="#EShareOwnership_804574"><b style="font-style:normal;font-weight:bold;">E.</b></a></p></td><td style="vertical-align:top;width:89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#EShareOwnership_804574"><b style="font-style:normal;font-weight:bold;">Share Ownership</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;">144</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:95.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#Item7MajorShareholdersandRelatedPartyTra"><b style="font-style:normal;font-weight:bold;">ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS **</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;"><span style="font-weight:bold;">145</span></p></td></tr><tr><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4.5pt 0pt;"><a href="#AMajorShareholders_70977"><b style="font-style:normal;font-weight:bold;">A.</b></a></p></td><td style="vertical-align:top;width:89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#AMajorShareholders_70977"><b style="font-style:normal;font-weight:bold;">Major Shareholders</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;">145</p></td></tr><tr><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4.5pt 0pt;"><a href="#BRelatedPartyTransactions_55434"><b style="font-style:normal;font-weight:bold;">B.</b></a></p></td><td style="vertical-align:top;width:89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#BRelatedPartyTransactions_55434"><b style="font-style:normal;font-weight:bold;">Related Party Transactions</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;">148</p></td></tr><tr><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4.5pt 0pt;"><a href="#CInterestsofExpertsandCounsel_282760"><b style="font-style:normal;font-weight:bold;">C.</b></a></p></td><td style="vertical-align:top;width:89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#CInterestsofExpertsandCounsel_282760"><b style="font-style:normal;font-weight:bold;">Interests of Experts and Counsel</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;">150</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:95.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#Item8FinancialInformation_714368"><b style="font-style:normal;font-weight:bold;">ITEM 8. FINANCIAL INFORMATION</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;"><span style="font-weight:bold;">150</span></p></td></tr><tr><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4.5pt 0pt;"><a href="#AConsolidatedStatementsandOtherFinancial"><b style="font-style:normal;font-weight:bold;">A.</b></a></p></td><td style="vertical-align:top;width:89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#AConsolidatedStatementsandOtherFinancial"><b style="font-style:normal;font-weight:bold;">Consolidated Statements and Other Financial Information</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;">150</p></td></tr><tr><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4.5pt 0pt;"><a href="#BSignificantChanges_405325"><b style="font-style:normal;font-weight:bold;">B.</b></a></p></td><td style="vertical-align:top;width:89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#BSignificantChanges_405325"><b style="font-style:normal;font-weight:bold;">Significant Changes</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;">150</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:95.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#Item9TheOfferandListing_113549"><b style="font-style:normal;font-weight:bold;">ITEM 9. THE OFFER AND LISTING</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;"><span style="font-weight:bold;">151</span></p></td></tr><tr><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4.5pt 0pt;"><a href="#AOfferandListingDetails_242844"><b style="font-style:normal;font-weight:bold;">A.</b></a></p></td><td style="vertical-align:top;width:89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#AOfferandListingDetails_242844"><b style="font-style:normal;font-weight:bold;">Offer and Listing Details</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;">151</p></td></tr><tr><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4.5pt 0pt;"><a href="#BPlanofDistribution_953078"><b style="font-style:normal;font-weight:bold;">B.</b></a></p></td><td style="vertical-align:top;width:89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#BPlanofDistribution_953078"><b style="font-style:normal;font-weight:bold;">Plan of Distribution</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;">151</p></td></tr><tr><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4.5pt 0pt;"><a href="#CMarkets_449293"><b style="font-style:normal;font-weight:bold;">C.</b></a></p></td><td style="vertical-align:top;width:89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#CMarkets_449293"><b style="font-style:normal;font-weight:bold;">Markets</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;">151</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4.5pt 0pt;"><a href="#DSellingShareholders_610130"><b style="font-style:normal;font-weight:bold;">D.</b></a></p></td><td style="vertical-align:top;width:89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#DSellingShareholders_610130"><b style="font-style:normal;font-weight:bold;">Selling Shareholders</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;">151</p></td></tr><tr><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4.5pt 0pt;"><a href="#EDilution_640293"><b style="font-style:normal;font-weight:bold;">E.</b></a></p></td><td style="vertical-align:top;width:89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#EDilution_640293"><b style="font-style:normal;font-weight:bold;">Dilution</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;">151</p></td></tr><tr><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4.5pt 0pt;"><a href="#FExpensesoftheIssue_39808"><b style="font-style:normal;font-weight:bold;">F.</b></a></p></td><td style="vertical-align:top;width:89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#FExpensesoftheIssue_39808"><b style="font-style:normal;font-weight:bold;">Expenses of the Issue</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;">151</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:95.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#Item10AdditionalInformation_683670"><b style="font-style:normal;font-weight:bold;">ITEM 10. ADDITIONAL INFORMATION</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;"><span style="font-weight:bold;">151</span></p></td></tr><tr><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4.5pt 0pt;"><a href="#AShareCapital_21921"><b style="font-style:normal;font-weight:bold;">A.</b></a></p></td><td style="vertical-align:top;width:89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#AShareCapital_21921"><b style="font-style:normal;font-weight:bold;">Share Capital</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;">151</p></td></tr><tr><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4.5pt 0pt;"><a href="#BMemorandumandArticlesofAssociation_6214"><b style="font-style:normal;font-weight:bold;">B.</b></a></p></td><td style="vertical-align:top;width:89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#BMemorandumandArticlesofAssociation_6214"><b style="font-style:normal;font-weight:bold;">Memorandum and Articles of Association</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;">151</p></td></tr><tr><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4.5pt 0pt;"><a href="#CMaterialContracts_621752"><b style="font-style:normal;font-weight:bold;">C.</b></a></p></td><td style="vertical-align:top;width:89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#CMaterialContracts_621752"><b style="font-style:normal;font-weight:bold;">Material Contracts</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;">151</p></td></tr><tr><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4.5pt 0pt;"><a href="#DExchangeControls_815357"><b style="font-style:normal;font-weight:bold;">D.</b></a></p></td><td style="vertical-align:top;width:89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#DExchangeControls_815357"><b style="font-style:normal;font-weight:bold;">Exchange Controls</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;">151</p></td></tr><tr><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4.5pt 0pt;"><a href="#ETaxation_718918"><b style="font-style:normal;font-weight:bold;">E.</b></a></p></td><td style="vertical-align:top;width:89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#ETaxation_718918"><b style="font-style:normal;font-weight:bold;">Taxation </b></a><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;">152</p></td></tr><tr><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4.5pt 0pt;"><a href="#FDividendsandPayingAgents_415202"><b style="font-style:normal;font-weight:bold;">F.</b></a></p></td><td style="vertical-align:top;width:89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#FDividendsandPayingAgents_415202"><b style="font-style:normal;font-weight:bold;">Dividends and Paying Agents</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;">162</p></td></tr><tr><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4.5pt 0pt;"><a href="#GStatementbyExperts_32755"><b style="font-style:normal;font-weight:bold;">G.</b></a></p></td><td style="vertical-align:top;width:89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#GStatementbyExperts_32755"><b style="font-style:normal;font-weight:bold;">Statement by Experts</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;">162</p></td></tr><tr><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4.5pt 0pt;"><a href="#HDocumentsonDisplay_973841"><b style="font-style:normal;font-weight:bold;">H.</b></a></p></td><td style="vertical-align:top;width:89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#HDocumentsonDisplay_973841"><b style="font-style:normal;font-weight:bold;">Documents on Display</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;">162</p></td></tr><tr><td style="vertical-align:top;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4.5pt 0pt;"><a href="#ISubsidiaryInformation_317881"><b style="font-style:normal;font-weight:bold;">I.</b></a></p></td><td style="vertical-align:top;width:89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#ISubsidiaryInformation_317881"><b style="font-style:normal;font-weight:bold;">Subsidiary Information</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;">162</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:95.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#Item11QuantitativeandQualitativeDisclosu"><b style="font-style:normal;font-weight:bold;">ITEM 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </b></a><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;"><span style="font-weight:bold;">162</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:95.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#Item12DescriptionofSecuritiesOtherthanEq"><b style="font-style:normal;font-weight:bold;">ITEM 12.&#160;&#160;DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;"><span style="font-weight:bold;">163</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:95.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#PARTII_403707"><b style="font-style:normal;font-weight:bold;">PART II</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;"><span style="font-weight:bold;">164</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:95.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#Item13DefaultsDividendArrearagesandDelin"><b style="font-style:normal;font-weight:bold;">ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;"><span style="font-weight:bold;">164</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:95.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#Item14MaterialModificationstotheRightsof"><b style="font-style:normal;font-weight:bold;">ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS </b></a><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;"><span style="font-weight:bold;">164</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:95.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#Item15ControlsandProcedures_26969"><b style="font-style:normal;font-weight:bold;">ITEM 15. CONTROLS AND PROCEDURES</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;"><span style="font-weight:bold;">164</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:95.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#Item16Reserved_405629"><b style="font-style:normal;font-weight:bold;">ITEM 16. [RESERVED]</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;"><span style="font-weight:bold;">164</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:95.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#Item16AAuditCommitteeFinancialExpert_491"><b style="font-style:normal;font-weight:bold;">ITEM 16A. AUDIT COMMITTEE FINANCIAL EXPERT</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;"><span style="font-weight:bold;">164</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:95.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#Item16BCodeofEthics_67423"><b style="font-style:normal;font-weight:bold;">ITEM 16B. CODE OF ETHICS</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;"><span style="font-weight:bold;">164</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:95.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#Item16CPrincipalAccountingFeesandService"><b style="font-style:normal;font-weight:bold;">ITEM 16C. PRINCIPAL ACCOUNTING FEES AND SERVICES</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;"><span style="font-weight:bold;">165</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:95.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#Item16DExemptionsfromtheListingStandards"><b style="font-style:normal;font-weight:bold;">ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;"><span style="font-weight:bold;">166</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:95.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#Item16EPurchasesofEquitySecuritiesbytheI"><b style="font-style:normal;font-weight:bold;">ITEM 16E. PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;"><span style="font-weight:bold;">166</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:95.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#Item16FChangeinRegistrantsCertifyingAcco"><b style="font-style:normal;font-weight:bold;">ITEM 16F. CHANGE IN REGISTRANT&#8217;S CERTIFYING ACCOUNTANT</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;"><span style="font-weight:bold;">166</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:95.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#Item16GCorporateGovernance_106647"><b style="font-style:normal;font-weight:bold;">ITEM 16G. CORPORATE GOVERNANCE</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;"><span style="font-weight:bold;">166</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:95.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#Item16HMineSafetyDisclosure_75226"><b style="font-style:normal;font-weight:bold;">ITEM 16H. MINE SAFETY DISCLOSURE</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;"><span style="font-weight:bold;">166</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:95.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#Item16IDisclosureRegardingForeignJurisdi"><b style="font-style:normal;font-weight:bold;">ITEM 16I. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;"><span style="font-weight:bold;">166</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:95.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#PARTIII_842629"><b style="font-style:normal;font-weight:bold;">PART III</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;"><span style="font-weight:bold;">167</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:95.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#Item17FinancialStatements_223831"><b style="font-style:normal;font-weight:bold;">ITEM 17. FINANCIAL STATEMENTS</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;"><span style="font-weight:bold;">167</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:95.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#Item18FinancialStatements_431468"><b style="font-style:normal;font-weight:bold;">ITEM 18. FINANCIAL STATEMENTS</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;"><span style="font-weight:bold;">167</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:95.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#Item19Exhibits_69009"><b style="font-style:normal;font-weight:bold;">ITEM 19. EXHIBITS.</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;"><span style="font-weight:bold;">167</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:95.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#SIGNATURES_313991"><b style="font-style:normal;font-weight:bold;">SIGNATURES</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;"><span style="font-weight:bold;">170</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:95.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.5pt 0pt;"><a href="#INDEX_160743"><b style="font-style:normal;font-weight:bold;">INDEX</b></a></p></td><td style="vertical-align:top;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;"><b style="font-weight:bold;">F-</b><span style="font-weight:bold;">1</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c071331e_222a_459e_a6d4_25cec919b929"></a><a id="ABOUTTHISANNUALREPORT_713375"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ABOUT THIS ANNUAL REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Except where the context otherwise requires or where otherwise indicated in this Annual Report, the terms &#8220;Alpha Tau Medical&#160;Ltd.,&#8221; &#8220;Alpha Tau,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;our company&#8221; and &#8220;our business&#8221; refer to Alpha Tau Medical&#160;Ltd. and its subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All references in this Annual Report to &#8220;Business Combination&#8221; refer to the transactions effected under the merger agreement, dated as of July&#160;7, 2021 (the &#8220;Merger Agreement&#8221;), by and among Healthcare Capital Corp., a Delaware corporation (&#8220;HCCC&#8221;), Alpha Tau and Archery Merger Sub,&#160;Inc., a Delaware corporation and wholly owned subsidiary of Alpha Tau (&#8220;Merger Sub&#8221;). Pursuant to the Merger Agreement, Merger Sub merged with and into HCCC, with HCCC surviving the merger. Upon consummation of the Business Combination and the other transactions contemplated by the Merger Agreement on March&#160;7, 2022, HCCC became a wholly owned subsidiary of Alpha Tau.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All references in this Annual Report to &#8220;Israeli currency&#8221; and &#8220;NIS&#8221; refer to New Israeli Shekels, the terms &#8220;dollar,&#8221; &#8220;USD&#8221; or &#8220;$&#8221; refer to U.S. dollars and the terms &#8220;&#8364;&#8221; or &#8220;euro&#8221; refer to the currency introduced at the start of the third stage of European economic and monetary union pursuant to the treaty establishing the European Community, as amended.</p><a id="_3e072aa6_b324_4295_b366_b76836d32b75"></a><a id="PRESENTATIONOFFINANCIALANDOTHERINFORMATI"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PRESENTATION OF FINANCIAL AND OTHER INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our financial statements have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;). We present our consolidated financial statements in U.S. dollars.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our fiscal&#160;year ends on December&#160;31 of each&#160;year. References to fiscal 2019 and 2019 are references to the fiscal&#160;year ended December&#160;31, 2019, references to fiscal 2020 and 2020 are references to the fiscal&#160;year ended December&#160;31, 2020, and references to fiscal 2021 and 2021 are references to the fiscal&#160;year ended December&#160;31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Market and Industry Data</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unless otherwise indicated, information contained in this Annual Report concerning our industry and the regions in which we operate, including our general expectations and market position, market opportunity, market share and other management estimates, is based on information obtained from various independent publicly available sources and other industry publications, surveys and forecasts, which we believe to be reliable based upon our management&#8217;s knowledge of the industry. We assume liability for the accuracy and completeness of such information to the extent included in this Annual Report. Such assumptions and estimates of our future performance and growth objectives and the future performance of our industry and the markets in which we operate are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those discussed under the headings &#8220;<i style="font-style:italic;">Cautionary Statement Regarding Forward-Looking Statements&#8221;&#160;</i>Item&#160;3.D.<i style="font-style:italic;">&#160;&#8220;Key Information&#8212;Risk Factors</i>&#8221; and Item&#160;5. &#8220;<i style="font-style:italic;">Operating and Financial Review and Prospects</i>&#8221; in this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Certain monetary amounts,&#160;percentages and other figures included in this Annual Report have been subject to rounding adjustments. Certain other amounts that appear in this Annual Report may not sum due to rounding. Revenue shown throughout this Annual Report is revenue from continuing operations, unless otherwise stated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unless otherwise noted, in this Annual Report we cite a source the first time a statement relying upon that source is made, and do not include citations subsequently when that statement is repeated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Trademarks</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:20pt;margin:0pt 0pt 12pt 5pt;"><span style="font-size:10pt;">This Annual Report contains references to trademarks, trade names and service marks belonging to other entities. Solely for convenience, trademarks, trade names and service marks referred to in this Annual Report may appear without the </span><span style="font-size:7.5pt;">&#174; </span><span style="font-size:10pt;">or TM symbols, but such references are not intended to indicate, in any way, that the applicable licensor will not assert, to the fullest extent under applicable law, its rights to these trademarks and trade names. We do not intend our use or display of other companies&#8217; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">i</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_2b782c79_a9a6_4e85_8e24_c38437f22898"></a><a id="CAUTIONARYSTATEMENTREGARDINGFORWARDLOOKI"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to historical facts, this Annual Report contains forward-looking statements within the meaning of Section&#160;27A of the U.S. Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), Section&#160;21E of the U.S. Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements are principally contained in the sections entitled Item&#160;3.D. &#8220;Key Information&#8212;Risk Factors,&#8221; Item&#160;4. &#8220;Information on the Company,&#8221; and Item&#160;5. &#8220;Operating and Financial Review and Prospects.&#8221; In some cases, these forward-looking statements can be identified by words or phrases such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;seek,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;contemplate,&#8221; &#8220;possible&#8221; or similar words. Statements regarding our future results of operations and financial position, growth strategy and plans and objectives of management for future operations, including, among others, expansion in new and existing markets, are forward-looking statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Forward-looking statements involve a number of risks, uncertainties and assumptions, and actual results or events may differ materially from those projected or implied in those statements. Important factors that could cause such differences include, but are not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Alpha Tau has incurred significant losses since inception, and expects to incur losses over the next several&#160;years and may not be able to achieve or sustain revenues or profitability in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Even though the Business Combination has been consummated, Alpha Tau will need substantial additional funding, and if Alpha Tau is unable to raise capital when needed, Alpha Tau could be forced to delay, reduce or terminate the development of its Alpha DaRT technology or other product discovery and development programs or commercialization efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Alpha Tau&#8217;s limited operating history may make it difficult for you to evaluate the success of Alpha Tau&#8217;s business to date and to assess its future viability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Alpha Tau&#8217;s approach to the development of its proprietary Alpha DaRT technology represents a novel approach to radiation therapy, which creates significant and potentially unpredictable challenges for Alpha Tau;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The commercial success of Alpha Tau&#8217;s Alpha DaRT technology, if authorized or certified for commercial sale, will depend in part upon public perception of radiation therapies, and to a lesser extent, radiopharmaceuticals, and the degree of their market acceptance by physicians, patients, healthcare payors and others in the medical community;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The ongoing COVID-19 pandemic could continue to adversely impact Alpha Tau&#8217;s business, including its clinical trials, supply chain and business development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The market opportunities for Alpha Tau&#8217;s Alpha DaRT technology may be smaller than it anticipated or may be limited to those patients who are ineligible for or have failed prior treatments. If Alpha Tau encounter difficulties enrolling patients in its clinical trials, its clinical development activities could be delayed or otherwise adversely affected;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Alpha Tau currently has no marketing and sales organization and has no experience in marketing products. If Alpha Tau is unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell its Alpha DaRT technology, if approved or certified for commercial sale, Alpha Tau may not be able to generate product revenue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">Alpha Tau currently conducts and in the future intends to continue conducting pre-clinical studies,       clinical trials for its Alpha DaRT technology outside the United States, and the FDA and similar foreign regulatory authorities or notified bodies may not accept data from such trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Alpha Tau&#8217;s Alpha DaRT technology and operations are subject to extensive government regulation and oversight both in the United States and abroad, and our failure to comply with applicable requirements could harm our business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Alpha Tau may not receive, or may be delayed in receiving, the necessary marketing authorizations or certifications for its Alpha DaRT technology or any future products or product candidates, and failure to timely obtain necessary marketing authorizations or certifications for our product candidates would have a material adverse effect on Alpha Tau&#8217;s business;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">ii</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If Alpha Tau does not obtain and maintain international regulatory registrations, marketing authorizations or certifications for any product candidates it develops, Alpha Tau will be unable to market and sell such product candidates outside of the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If in the future Alpha DaRT is approved or certified for commercial sale but Alpha Tau is unable to obtain adequate reimbursement or insurance coverage from third-party payors, it may not be able to generate significant revenue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Alpha Tau may be unable to obtain a sufficient or sufficiently pure supply of radioisotopes to support clinical development or at commercial scale;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If Alpha Tau is unable to obtain and maintain patent or other intellectual property protection for its Alpha DaRT technology and for any other products or product candidates that Alpha Tau develops, or if the scope of the patent or other intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and Alpha Tau&#8217;s ability to commercialize any product candidates that it may develop, and its technology may be adversely affected; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Alpha Tau will incur increased costs as a result of operating as a public company, and its management will devote substantial time to new compliance initiatives.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our estimates and forward-looking statements are mainly based on our current expectations and estimates of future events and trends which affect or may affect our business, operations and industry. Although we believe that these estimates and forward-looking statements are based upon reasonable assumptions, they are subject to numerous risks and uncertainties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These forward-looking statements are subject to a number of known and unknown risks, uncertainties, other factors and assumptions, including the risks described in Item&#160;3.D &#8220;Key Information&#8212;Risk Factors&#8221; and elsewhere in this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">You should not rely on forward-looking statements as predictions of future events. We have based the forward-looking statements contained in this Annual Report primarily on our current expectations and projections about future events and trends that we believe may affect our business, financial condition and operating results. The outcome of the events described in these forward-looking statements is subject to risks, uncertainties and other factors described in the section titled &#8220;<i style="font-style:italic;">Risk factors</i>&#8221; and elsewhere in this Annual Report. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Annual Report. The results, events and circumstances reflected in the forward-looking statements may not be achieved or occur, and actual results, events or circumstances could differ materially from those described in the forward-looking statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this Annual Report. While we believe that information provides a reasonable basis for these statements, that information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements. We qualify all of our estimates and forward-looking statements by these cautionary statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The forward-looking statements made in this Annual Report relate only to events as of the date on which the statements are made. We undertake no obligation to update any forward-looking statements made in this Annual Report to reflect events or circumstances after the date of this Annual Report or to reflect new information or the occurrence of unanticipated events, except as required by law. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">iii</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_131f6c4c_694a_4865_a23c_63fdcda233c3"></a><a id="PARTI_376629"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;I</p><a id="Item1IdentityofDirectorsSeniorManagement"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item&#160;1.</b></span><b style="font-weight:bold;">Identity of Directors, Senior Management and Advisers</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">Not applicable.</p><a id="_870a2480_7bac_4520_b0da_f286564301ba"></a><a id="Item2OfferStatisticsandExpectedTimetable"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;2. Offer Statistics and Expected Timetable</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">Not applicable.</p><a id="_f10feeaf_1c2a_4b81_934c_eeb472161dc2"></a><a id="Item3KeyInformation_830317"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;3. Key Information</b></p><a id="AReserved_330517"></a><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">A.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">[Reserved.]</b></p></td></tr></table><a id="BCapitalizationandIndebtedness_9421"></a><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">B.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Capitalization and Indebtedness</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">Not applicable.</p><a id="CReasonsfortheOfferandUseofProceeds_9888"></a><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">C.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Reasons for the Offer and Use of Proceeds</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">Not applicable.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">D.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Risk Factors</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">You should carefully consider the risks described below before making an investment decision. Additional risks not presently&#160;known to us or that we currently deem immaterial may also impair our business operations. Our business, financial condition or results&#160;of operations could be materially and adversely affected by any of these risks. The trading price and value of our ordinary shares could&#160;decline due to any of these risks, and you may lose all or part of your investment. This Annual Report also contains forward-looking&#160;statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking&#160;statements as a result of certain factors, including the risks faced by us described below and elsewhere in this Annual Report. See &#8220;Cautionary Statement Regarding Forward-Looking Statements&#8221; on page&#160;ii of this Annual Report. </i>Such risks include, but are not limited to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 22pt;"><b style="font-weight:bold;">Risk Factors Summary</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 22pt;"><i style="font-style:italic;">The following is a summary of the principal risks that could materially adversely affect our business, results of operations, and financial condition, all of which are more fully described below. This summary should be read in conjunction with the other information discussed in this Item&#160;3.D, and should not be relied upon as an exhaustive summary of the material risks facing our business. Please carefully consider all of the information discussed in this Item&#160;3.D. &#8220;Risk Factors&#8221; and elsewhere in this Annual Report for a more thorough description of these and other risks. Such risks include, but are not limited to:</i></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have incurred significant losses since inception and have not generated any revenue to date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We expect to incur losses over the next several&#160;years and may not be able to achieve or sustain revenues or profitability in the future;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We will need substantial additional funding, and if we are unable to raise capital when needed, we could be forced to delay, reduce or terminate the development of our Alpha DaRT technology or other product discovery and development programs or commercialization efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess its future viability;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our approach to the development of our proprietary Alpha DaRT technology represents a novel approach to radiation therapy, which creates significant and potentially unpredictable challenges for us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The commercial success of our Alpha DaRT technology, if authorized or certified for commercial sale, will depend in part upon public perception of radiation therapies, and to a lesser extent, radiopharmaceuticals, and the degree of their market acceptance by physicians, patients, healthcare payors and others in the medical community;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The ongoing COVID-19 pandemic could continue to adversely impact our business, including its clinical trials, supply chain and business development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The market opportunities for our Alpha DaRT technology may be smaller than it anticipated or may be limited to those patients who are ineligible for or have failed prior treatments. If we encounter difficulties enrolling patients in its clinical trials, our clinical development activities could be delayed or otherwise adversely affected;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We currently have no commercial marketing and sales organization and has no experience in marketing products. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our Alpha DaRT technology, if approved for commercial sale, we may not be able to generate product revenue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We currently conduct and in the future intend to continue conducting pre-clinical studies, clinical trials for our Alpha DaRT technology outside the United States, and the FDA and similar foreign regulatory authorities or notified bodies may not accept data from such trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our Alpha DaRT technology and operations are subject to extensive government regulation and oversight both in the United States and abroad, and our failure to comply with applicable requirements could harm our business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may not receive, or may be delayed in receiving, the necessary marketing authorizations or certifications for our Alpha DaRT technology or any future products or product candidates, and failure to timely obtain necessary marketing authorizations or certifications for our product candidates would have a material adverse effect on our business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we do not obtain and maintain international regulatory registrations, marketing authorizations or certifications for any product candidates we develop, we will be unable to market and sell such product candidates outside of the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If in the future Alpha DaRT is approved or certified for commercial sale, but we are unable to obtain adequate reimbursement or insurance coverage from third-party payors, we may not be able to generate significant revenue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may be unable to obtain a sufficient or sufficiently pure supply of radioisotopes to support clinical development or at commercial scale;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we are unable to obtain and maintain patent or other intellectual property protection for our Alpha DaRT technology and for any other products or product candidates that we develop, or if the scope of the patent or other intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to our products and technology, and our ability to commercialize any product candidates that we may develop, and our technology may be adversely affected; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We will incur increased costs as a result of operating as a public company, and our management will devote substantial time to new compliance initiatives.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><b style="font-weight:bold;">Risks Related to Our Business and the Alpha DaRT Technology</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our approach to the development of our proprietary Alpha DaRT technology represents a novel approach to radiation therapy, which creates significant and potentially unpredictable challenges for us.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Our future success depends on the successful development of our Alpha DaRT technology, which is designed to treat solid tumors through alpha-irradiation by intratumoral insertion of radium-224 impregnated sources, representing what we believe to be a novel </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">approach to local radiotherapy. Alpha-emitting isotope oncology therapy is relatively new, and only one alpha-emitting isotope therapy has been approved in the United States or the European Union, or EU and only a limited number of clinical trials of products based on alpha-emitting isotope therapies have commenced. In addition, the majority of the clinical trials evaluating alpha-emitting isotope oncology therapy have focused on systemic delivery of drugs like radiopharmaceuticals (including Xofigo or certain antibody-radionuclide conjugates), while our Alpha DaRT technology is designed to be a local therapy. As such, it is difficult to accurately predict the developmental challenges we may incur for our Alpha DaRT technology as it proceeds through preclinical studies and clinical trials. In addition, beyond the limited universe of patients treated with Xofigo, the sole alpha-emitting isotope therapy approved in the United States or the EU, as well as other uses of alpha-emitting isotope therapy outside of oncology, such as in the use in treating ankylosing spondylitis, assessments of the long-term safety of targeted alpha-emitting isotope therapies in humans have been limited, and there may be long-term effects from treatment with our Alpha DaRT technology or any future products or product candidates we develop that we cannot predict at this time. It is difficult for us to predict the time and cost of the regulatory development of our Alpha DaRT technology, and we cannot predict whether the application of our technology, or any similar or competitive technologies, will result in the identification, development, and marketing authorization or certification of any products. There can be no assurance that any development problems we experience in the future related to our technology or any of our research programs will not cause significant delays or unanticipated costs, or that such development problems can be solved at all. Any of these factors may prevent us from completing our preclinical studies and clinical trials that we may initiate or commercializing any product candidates we may develop on a timely or profitable basis, if at all. In addition, the success of our Alpha DaRT technology will depend on several factors, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing manufacturing capabilities and infrastructure to produce and distribute adequate supply of Alpha DaRT sources in compliance with applicable regulations governing the transport of radiological materials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">generating meaningful clinical data to support widespread clinical adoption and reimbursement for the </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Alpha DaRT technology;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">educating medical personnel regarding the potential benefits and correct use of our Alpha DaRT </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">technology;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ensuring appropriate methods of handling and logistics of our products and appropriate capabilities at clinical use points;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">facilitating patient access to the facilities able to administer our Alpha DaRT technology, if authorized for sale or certified;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing sales and marketing capabilities upon obtaining any marketing authorization in the United States and similar authorization or certification in other target jurisdictions to gain market acceptance of a novel therapy; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sourcing clinical and, if successfully authorized or certified for commercial sale, commercial supplies for the materials used to manufacture our Alpha DaRT technology, and especially our Alpha DaRT sources.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The commercial success of our Alpha DaRT technology, if authorized or certified for commercial sale, will depend in part upon public perception of radiation therapies, and to a lesser extent, radiopharmaceuticals, and the degree of their market acceptance by physicians, patients, healthcare payors and others in the medical community.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Adverse events in clinical trials of our Alpha DaRT technology or in clinical trials of others developing similar products and the resulting negative publicity, as well as any other adverse events in the field of radiation therapies or radiopharmaceuticals that may occur in the future, could result in a decrease in demand for our Alpha DaRT technology or any future products or any product candidates that we may develop that rely on radiation therapy. If public perception is influenced by claims that radiation therapies or radiopharmaceuticals or specific therapies within radiation therapies or radiopharmaceuticals are unsafe or if alternative therapies for cancer treatment are developed and proven to be more successful or provide an actual or perceived, preferred course of treatment for cancer(s), our Alpha DaRT technology or any future products or any product candidates we may develop may not be accepted by the general public or the medical community.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In particular, the future commercial success of our Alpha DaRT technology or any future products or any product candidates we may develop, as applicable, depends and will depend upon, among other things, these products and product candidates gaining and maintaining acceptance by physicians, patients, third-party payors and other members of the medical community as efficacious and cost-effective alternatives to competing products and treatments. If any of our products or product candidates do not achieve and maintain an adequate level of acceptance, we may not generate material sales of that product or product candidate or be able to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">successfully commercialize it. The degree of market acceptance of our products and product candidates, if authorized for sale or certified, will depend on a number of factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to provide acceptable evidence of safety and efficacy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of any side effects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">publicity concerning our products and product candidates or competing products and treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">availability, relative cost and relative efficacy of alternative and competing treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to offer our products for sale at competitive prices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the relative convenience and ease of administration of our products and product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of the target patient population to try new products and product candidates and of physicians to prescribe these products and product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the strength of marketing and distribution support; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the sufficiency of coverage or reimbursement by third parties.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20pt;margin:0pt 0pt 12pt 0pt;">If our Alpha DaRT technology or any of our other future products or product candidates, if authorized or certified, do not become widely accepted by potential customers, physicians, patients, third-party payors and other members of the medical community, such a lack of acceptance could have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are exploring development of our Alpha DaRT technology in combination with other therapies, which exposes us to additional risks.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20pt;margin:0pt 0pt 12pt 0pt;">We are conducting a combination trial evaluating our Alpha DaRT technology in combination with pembrolizumab for the treatment of locally advanced or metastatic head and neck squamous cell carcinoma, and in the future we may explore conduct additional combination trials with one or more currently approved or experimental cancer therapies for this or other indications. Even if our Alpha DaRT technology receives marketing authorization or obtains certification for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA or similar foreign regulatory authorities could revoke marketing authorization of the therapy used in combination with our Alpha DaRT technology or that safety, efficacy, manufacturing or supply issues could arise with these other therapies. Combination therapies are commonly used for the treatment of cancer, and we would be subject to similar risks if we develop any of our products or product candidates for use in combination with other drugs or for indications other than cancer. This could result in our own products being removed from the market or being less successful commercially.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20pt;margin:0pt 0pt 12pt 0pt;">We may also evaluate our Alpha DaRT technology in combination with one or more other cancer therapies that have not yet been approved for marketing by the FDA or similar foreign regulatory authorities. We will not be able to market and sell our product candidate we develop in combination with any such unapproved cancer therapies that do not ultimately obtain marketing authorization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20pt;margin:0pt 0pt 12pt 0pt;">If the FDA or similar foreign regulatory authorities do not approve these other drugs or revoke their marketing authorization, or if safety, efficacy, manufacturing, or supply issues arise with, the drugs we choose to evaluate in combination with our product candidate, we may be unable to obtain marketing authorization or certification of or market our product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The ongoing COVID-19 pandemic could continue to adversely impact our business, including our clinical trials, supply chain and business development activities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20pt;margin:0pt;">In connection with the ongoing COVID-19 pandemic, governments have implemented significant measures, including closures of businesses, quarantines, travel restrictions and other social distancing directives, intended to control the spread of the virus. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Companies have also taken precautions, such as requiring employees to work remotely, imposing travel restrictions and temporarily closing businesses. In response to these public health directives and orders, we have implemented certain travel restrictions and work-from-home policies for our employees, and as a result we have experienced limitations on employee resources. The effects of government actions and our own policies and those of third parties to reduce the spread of COVID-19 may negatively impact productivity and slow down or delay our ongoing and future clinical trials, preclinical studies and research and development activities, may cause disruptions to our supply chain, to the administrative functions of clinical trial sites and/or to the operations of our other partners, and as a result may impair our ability to execute our programs and/or business development strategy. In the event that government authorities were to enhance current restrictions, our employees who currently are not telecommuting may no longer be able to access our facilities, including our laboratories and our operations may be further limited or curtailed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20pt;margin:0pt 0pt 12pt 0pt;">Our clinical trials have been, and may in the future be, affected by the ongoing COVID-19 pandemic. In particular, certain of our clinical trial sites, most notably Memorial Sloan Kettering Cancer Center in New York, and Centre hospitalier de l&#8217;Universit&#233; de Montr&#233;al in Montreal, have both seen significantly decreased clinical trial recruitment in general due to the devastating local impact of COVID-19, and therefore have not yet recruited any patients into our clinical trials in these cities. However, in July&#160;2021, the first participant in our U.S. pilot trial for skin cancer was treated with Alpha DaRT at University Cancer Center in Houston, Texas, and we completed recruitment of this trial in October&#160;2021. We may experience other disruptions due to the ongoing COVID-19 pandemic that could severely impact our business, preclinical studies and clinical trials, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays or difficulties in enrolling and maintaining patients in our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays or difficulties in shipping and delivering in a timely manner supplies, samples or products required for our clinical trials due to the impact of the ongoing COVID-19 pandemic on the United States Postal Service, FedEx, United Parcel Service and/or other commercial shipping organizations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays or difficulties in clinical site initiation, including difficulties completing any required contracts, successfully completing institutional review board, or IRB, or other reviewing body reviews in a timely manner, or in recruiting clinical site investigators and clinical site staff;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disruptions in our supply chain that result in shortages of materials to conduct our laboratory experiments and/or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in local regulations as part of a response to the ongoing COVID-19 outbreak which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or cause us to discontinue such clinical trials altogether;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials, which may also increase the cost of the limited available remaining resources available for use in our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties in recruiting and retaining principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interruption of key clinical trial activities, such as clinical trial site monitoring, manufacturing and equipment maintenance due to limitations on travel or access imposed or recommended by federal, state or foreign governments, hospitals, employers and others, or interruption of clinical trial subject visits and study procedures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interruption or delays in the operations of the FDA or other regulatory authorities or bodies, which may impact review timelines;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risk that participants enrolled in our clinical trials will contract COVID-19 while the clinical trial is ongoing, which could result in serious adverse events, potentially including patient deaths, and impact the results of the clinical trial, including by increasing the number of observed adverse events; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal of the FDA or similar foreign authorities or bodies to accept data from clinical trials in affected geographies.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These and other disruptions in our operations and the global economy could negatively impact our business, operating results and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The spread of COVID-19 and actions taken to reduce its spread may also materially affect us economically. While the potential economic impact brought by, and the duration of, the ongoing COVID-19 pandemic may be difficult to assess or predict, there have recently been, and could in the future be, significant disruptions of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity and financial position. In addition, the trading prices for other medical device and other biopharmaceutical companies have been highly volatile as a result of the ongoing COVID-19 pandemic. As a result, we may face difficulties raising capital or such capital raises may be on unfavorable terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">COVID-19 and actions taken to reduce its spread continue to rapidly evolve. The extent to which COVID-19 may impede the development of our product Alpha DaRT technology or any future products or product candidates, reduce the productivity of our employees, disrupt our supply chains, delay our clinical trials, reduce our access to capital or limit our business development activities, will depend on future developments, which are highly uncertain and cannot be predicted with confidence. To the extent the ongoing COVID-19 pandemic adversely affects our business and financial results, it may also have the effect of heightening many of the other risks described in this &#8220;Risk Factors&#8221; section, such as those relating to the timing and results of our clinical trials and our financing needs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The market opportunities for our Alpha DaRT technology may be smaller than we anticipated or may be limited to those patients who are ineligible for or have failed prior treatments. If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our current and future target patient populations are based on our beliefs and estimates regarding the incidence or prevalence of certain types of cancers that may be addressable by our Alpha DaRT technology or any future products or product candidates we develop, which is derived from a variety of sources, including scientific literature, publications by medical societies and non-profit organizations, and surveys of clinics. Our projections may prove to be incorrect and the number of potential patients may turn out to be lower than expected. Even if we obtain significant market share for our Alpha DaRT technology, because the potential target populations could be small, we may never achieve profitability without obtaining marketing authorizations for additional indications in the United States or similar authorizations or certifications in other target jurisdictions, including use of our Alpha DaRT technology for front-line and second-line therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We currently have no commercial marketing and sales organization and have no experience in marketing products. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our Alpha DaRT technology, if approved or certified for commercial sale, we may not be able to generate product revenue.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We currently have no in-house sales or distribution capabilities and have no experience in marketing products. We intend to develop an in-house marketing organization and sales force, which will require significant capital expenditures, management resources and time. We will have to compete with other pharmaceutical, medical device and biotechnology companies to recruit, hire, train and retain marketing and sales personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we are unable or decide not to establish internal sales and marketing capabilities, we will pursue collaborative arrangements regarding the sales and marketing of our products, if licensed, as we have done in Canada and Israel. However, there can be no assurance that we will be able to establish or maintain such collaborative arrangements, or if we are able to do so, that they will have effective sales forces. Any revenue we receive will depend upon the efforts of such third parties, which may not be successful. We may have little or no control over the marketing and sales efforts of such third parties and our revenue from product sales may be lower than if we had commercialized our Alpha DaRT technology ourselves. We also face competition in our search for third parties to assist us with the sales and marketing efforts of our Alpha DaRT technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There can be no assurance that we will be able to develop in-house sales and distribution capabilities or establish or maintain relationships with third-party collaborators to commercialize any product in the United States or overseas for which we are able to obtain marketing authorization or certification.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may expend our resources to pursue a particular indication and forgo the opportunity to capitalize on Alpha DaRT technology in indications that may ultimately be more profitable or for which there is a greater likelihood of success.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have limited financial and personnel resources and are placing significant focus on the development of our Alpha DaRT technology in certain indications, and as such, we may forgo or delay pursuit of opportunities with other future products or product candidates or other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and other future products or product candidates for specific indications may not yield any commercially viable future products or product candidates. If we do not accurately evaluate the commercial potential or target market for a particular future product candidate, we may relinquish valuable rights to those future products or product candidates through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such future products or product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We currently conduct and in the future intend to continue conducting pre-clinical studies, clinical trials for our Alpha DaRT technology outside the United States, and the FDA and similar foreign regulatory authorities may not accept data from such trials.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">We are currently conducting clinical trials in Israel, Canada, the United States, Japan and Europe and may in the future choose to conduct additional clinical trials, including in Asia, Australia, elsewhere in Europe or other foreign jurisdictions. The acceptance of trial data from clinical trials conducted outside the United States by the FDA may be subject to certain conditions. For example, in cases where data from clinical trials conducted outside the United States are intended to serve as the sole basis for marketing authorization in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless such clinical trials were conducted in accordance with good clinical practices, or GCP, and (i) the data are applicable to the United States population and United States medical practice; (ii) the trials were performed by clinical investigators of recognized competence; and (iii) the data may be considered valid without the need for an on-site inspection by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. In addition, even where the foreign study data are not intended to serve as the sole basis for approval, the FDA will not accept the data as support for an application for marketing approval unless the study is well-designed and well-conducted in accordance with GCP requirements and the FDA is able to validate the data from the study through an onsite inspection if deemed necessary.  Many foreign regulatory bodies have similar requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any similar foreign regulatory authority or notified bodies will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA or any similar foreign regulatory authority or other bodies does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in our Alpha DaRT not receiving approval, clearance or certification for commercialization in the applicable jurisdiction.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Government Regulation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our Alpha DaRT technology and operations are subject to extensive government regulation and oversight both in the United States and abroad, and our failure to comply with applicable requirements could harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any products or product candidates which ultimately integrate our Alpha DaRT technology are expected to be regulated as medical devices in the United States. Medical devices and their manufacturers and product developers are subject to extensive regulation in the United States and elsewhere, including by the FDA and its foreign counterparts. The FDA and foreign regulatory agencies regulate, among other things, with respect to medical devices: design, development and manufacturing; testing, labeling, content and language of instructions for use and storage; clinical trials; product safety; establishment registration and device listing; marketing, sales and distribution; premarket clearance, classification and approval or certification; recordkeeping procedures; advertising and promotion; recalls and field safety corrective actions; postmarket surveillance, including reporting of deaths or serious injuries and malfunctions that, if they were to recur, could lead to death or serious injury; post-market studies; and product import and export.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The regulations to which we are subject are complex, burdensome to understand and apply and have tended to become more stringent over time. Regulatory changes could result in restrictions on our ability to carry on or expand our operations, higher than anticipated costs or lower than anticipated sales, if our product candidate receives marketing authorization or certification. The FDA and foreign regulatory authorities enforces their regulatory requirements through, among other means, periodic unannounced inspections. We do not know whether we or any contract manufacturers we may utilize will be found compliant in connection with </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">any future FDA or foreign inspections. Failure to comply with applicable regulations could jeopardize our ability to sell our Alpha DaRT technology or any future products or product candidates, if they obtain marketing authorization or certification, and result in enforcement actions such as: warning letters; fines; injunctions; civil penalties; termination of distribution; recalls or seizures of products; delays in the introduction of products into the market; total or partial suspension of production; refusal to grant future clearances, approvals or certifications; withdrawals or suspensions of clearances, approvals or certifications, resulting in prohibitions on sales of our products; and in the most serious cases, criminal penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not receive, or may be delayed in receiving, the necessary marketing authorizations or certifications for our Alpha DaRT technology or any future products or product candidates, and failure to timely obtain necessary marketing authorizations or certifications for our product candidates would have a material adverse effect on our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the United States, before we can market a new medical device, or a new use of, or other significant modification to an existing, marketed medical device, we must first receive either clearance under Section&#160;510(k)&#160;of the Federal Food, Drug, and Cosmetic Act, or the FDCA, approval of a premarket approval application, or PMA, or grant of a <i style="font-style:italic;">de novo </i>classification request from the FDA, unless an exemption applies. In the 510(k)&#160;clearance process, before a device may be marketed, the FDA must determine that a proposed device is &#8220;substantially equivalent&#8221; to a legally-marketed &#8220;predicate&#8221; device, which includes a device that has been previously cleared through the 510(k)&#160;process, a device that was legally marketed prior to May&#160;28, 1976 (pre-amendments device), a device that was originally on the U.S. market pursuant to an approved PMA and later down-classified, or a 510(k)-exempt device. To be &#8220;substantially equivalent,&#8221; the proposed device must have the same intended use as the predicate device, and either have the same technological characteristics as the predicate device or have different technological characteristics and not raise different questions of safety or effectiveness than the predicate device. Clinical data are sometimes required to support substantial equivalence. In the process of obtaining PMA approval, the FDA must determine that a proposed device is safe and effective for its intended use based, in part, on extensive data, including, but not limited to, technical, pre-clinical, clinical trial, manufacturing and labeling data. The PMA process is typically required for devices that are deemed to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices. In the <i style="font-style:italic;">de novo </i>classification process, a manufacturer whose novel device under the FDCA would otherwise be automatically classified as Class&#160;III and require the submission and approval of a PMA prior to marketing is able to request down-classification of the device to Class&#160;I or Class&#160;II on the basis that the device presents a low or moderate risk. If the FDA grants the <i style="font-style:italic;">de novo </i>classification request, the applicant will receive authorization to market the device. This device type may be used subsequently as a predicate device for future 510(k)&#160;submissions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The PMA approval, 510(k)&#160;clearance and <i style="font-style:italic;">de novo </i>classification processes can be expensive, lengthy and uncertain. The FDA&#8217;s 510(k)&#160;clearance process usually takes from three to 12&#160;months, but can take longer. The process of obtaining a PMA is much more costly and uncertain than the 510(k)&#160;clearance process and generally takes from one to three&#160;years, or even longer, from the time the application is submitted to the FDA. In addition, a PMA generally requires the performance of one or more clinical trials. Clinical data may also be required in connection with an application for 510(k)&#160;clearance or a <i style="font-style:italic;">de novo </i>request. Despite the time, effort and cost, a device may not obtain marketing authorization by the FDA. Any delay or failure to obtain necessary regulatory marketing authorizations could harm our business. Furthermore, even if we are granted such marketing authorizations, they may include significant limitations on the indicated uses for the device, which may limit the potential commercial market for the device.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To date, we have not obtained authorization from the FDA to market any product candidate in the United States, and we expect to pursue the <i style="font-style:italic;">de novo </i>classification process for our Alpha DaRT technology. If the FDA requires us to go through a lengthier, more rigorous examination for our products than we had expected, our product introductions or modifications could be delayed or prevented, which would have a material impact on our business and prospects. For example, if the FDA disagrees with our determination that the <i style="font-style:italic;">de novo </i>classification pathway is the appropriate path to obtain marketing authorization for Alpha DaRT, the FDA may require us to submit a PMA application, which is generally more costly, time-consuming, and uncertain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In the United States, any modification to a product candidate for which we receive marketing authorization may require us to submit a new 510(k)&#160;premarket notification and obtain clearance, to submit a PMA and obtain FDA approval, or to submit a <i style="font-style:italic;">de novo </i>request prior to implementing the change. For example, any modification to a 510(k)-cleared device that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, design or manufacture, generally requires a new 510(k)&#160;clearance or other marketing authorization. The FDA requires every manufacturer to make such determinations in the first instance, but the FDA may review any manufacturer&#8217;s decision. The FDA may not agree with a manufacturer&#8217;s decisions regarding whether new clearances or approvals are necessary. If we obtain marketing authorizations from the FDA, we may make modifications or add additional features in the future that we believe do not require a new 510(k)&#160;clearance, <i style="font-style:italic;">de novo </i>request or approval of a PMA. If the FDA disagrees with our determination and requires us to seek new marketing authorizations for the modifications for which we </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">have concluded that new marketing authorizations are unnecessary, we may be required to cease marketing or to recall the modified product until we obtain such marketing authorization, and we may be subject to significant regulatory fines or penalties. If the FDA requires us to go through a lengthier, more rigorous examination for future products or modifications to existing products than we had expected, product introductions or modifications could be delayed or canceled, which could adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA, applicable foreign regulatory entity or notified body can delay, limit or deny marketing authorization or certification of a device for many reasons, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to demonstrate to the satisfaction of the FDA or the applicable regulatory entity or notified body that our products are substantially equivalent to a predicate device or are safe and effective for their intended uses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the disagreement of the FDA , foreign regulatory authorities or notified body with the design or implementation of our clinical trials or the interpretation of data from preclinical studies or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">serious and unexpected adverse device effects experienced by participants in our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the data from our preclinical studies and clinical trials may be insufficient to support clearance, </span><i style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">de novo </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">classification, approval or certification, where required;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to demonstrate that the clinical and other benefits of the device outweigh the risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the manufacturing process or facilities we use may not meet applicable requirements; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential for marketing authorization or certification policies or regulations of the FDA or applicable foreign regulatory bodies to change significantly in a manner rendering our clinical data or regulatory filings insufficient for marketing authorization or certification.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In order to sell our products in member states of the EU, our products must comply with the general safety and performance requirements of the EU Medical Devices Regulation (Regulation (EU) No 2017/745), which repeals and replaces the EU Medical Devices Directive (Council Directive 93/42/EEC) and the Active Implantable Medical Devices Directive (Council Directive 90/385/EEC). Compliance with these requirements is a prerequisite to be able to affix the European Conformity, or CE, mark to our products, without which they cannot be sold or marketed in the EU. All medical devices placed on the market in the EU must meet the general safety and performance requirements laid down in Annex I to the EU Medical Devices Regulation including the requirement that a medical device must be designed and manufactured in such a way that, during normal conditions of use, it is suitable for its intended purpose. Medical devices must be safe and effective and must not compromise the clinical condition or safety of patients, or the safety and health of users and &#8211; where applicable &#8211; other persons, provided that any risks which may be associated with their use constitute acceptable risks when weighed against the benefits to the patient and are compatible with a high level of protection of health and safety, taking into account the generally acknowledged state of the art. The European Commission has adopted various standards applicable to medical devices. These include standards governing common requirements, such as sterilization and safety of medical electrical equipment and product standards for certain types of medical devices. There are also harmonized standards relating to design and manufacture. While not mandatory, compliance with these standards is viewed as the easiest way to satisfy the general safety and performance requirements as a practical matter, as it creates a rebuttable presumption that the device satisfies the general safety and performance requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">To demonstrate compliance with the general safety and performance requirements we must undergo a conformity assessment procedure, which varies according to the type of medical device and its (risk) classification. As a general rule, demonstration of conformity of medical devices and their manufacturers with the general safety and performance requirements must be based, among other things, on the evaluation of clinical data supporting the safety and performance of the products during normal conditions of use. Specifically, a manufacturer must demonstrate that the device achieves its intended performance during normal conditions of use, that the known and foreseeable risks, and any adverse events, are minimized and acceptable when weighed against the benefits of its intended performance, and that any claims made about the performance and safety of the device are supported by suitable evidence. Except for low-risk medical devices (Class I non-sterile, non-measuring devices), where the manufacturer can self-assess the conformity of its products with the general safety and performance requirements (except for any parts which relate to sterility, metrology or reuse aspects), a conformity assessment procedure requires the intervention of an organization accredited or designated </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">by a member state of the EU to conduct conformity assessments, or a notified body. Depending on the relevant conformity assessment procedure, the notified body would typically audit and examine the technical file and the quality system for the manufacture, design and final inspection of our devices. If satisfied that the relevant product conforms to the general safety and performance requirements, the notified body issues a certificate of conformity, which the manufacturer uses as a basis for its own declaration of conformity. The manufacturer may then apply the CE mark to the device, which allows the device to be placed on the market throughout the EU. If we fail to comply with applicable EU laws and regulations, and corresponding EU member state laws, we would be unable to affix the CE mark to our products, which would prevent us from selling them within the EU.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the EU, we must inform the notified body that carried out the conformity assessment of the devices that we market or sell in the EU and EEA of any planned substantial changes to our quality system or substantial changes to our medical devices that could affect compliance with the general safety and performance requirements laid down in Annex I to the EU Medical Devices Regulation or cause a substantial change to the intended use for which the device has been CE marked. The notified body will then assess the planned changes and verify whether they affect the products&#8217; ongoing conformity with the EU Medical Devices Regulation. If the assessment is favorable, the notified body will issue a new certificate of conformity or an addendum to the existing certificate attesting compliance with the general safety and performance requirements and quality system requirements laid down in the Annexes to the EU Medical Devices Regulation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The aforementioned EU rules&#160;are generally applicable in the European Economic Area, or EEA, which consists of the 27 EU member states plus Norway, Liechtenstein and Iceland. Non-compliance with the above requirements would also prevent us from selling our products in these three countries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From January 1, 2021 onwards, the Medicines and Healthcare Products Regulatory Agency, or MHRA became the sovereign regulatory authority responsible for Great Britain (i.e. England, Wales and Scotland) medical device market according to the requirements provided in the Medical Devices Regulations 2002 (SI 2002 No 618, as amended) that sought to give effect to the three pre-existing EU directives governing active implantable medical devices, general medical devices and in vitro diagnostic medical devices whereas Northern Ireland continues to be governed by EU rules according to the Northern Ireland Protocol. Following the end of the Brexit transitional period on January 1, 2021, new regulations require medical devices to be registered with the MHRA (but manufacturers were given a grace period of four to 12 months to comply with the new registration process) before being placed on Great Britain market. The MHRA will only register devices where the manufacturer or their United Kingdom Responsible Person has a registered place of business in the United Kingdom. Manufacturers based outside the United Kingdom will need to appoint a U.K. Responsible Person that has a registered place of business in the United Kingdom to register devices with the MHRA. By July 1, 2023, in Great Britain, all medical devices will require a UKCA (UK Conformity Assessed) mark but CE marks issued by EU notified bodies will remain valid until this time. Manufacturers may choose to use the UKCA mark on a voluntary basis until June 30, 2023. However, UKCA marking will not be recognized in the EU.. Compliance with this legislation is a prerequisite to be able to affix the UKCA mark to our products, without which they cannot be sold or marketed in Great Britain. The rules for placing medical devices on the market in Northern Ireland, which is part of the United Kingdom, differ from those in the rest of the United Kingdom. Under the terms of the Northern Ireland Protocol, Northern Ireland will follow EU rules on medical devices and devices marketed in Northern Ireland will require assessment according to the EU regulatory regime. Such assessment may be conducted by an EU notified body, in which case a CE mark will be required before placing the device on the market in the EU or Northern Ireland. Alternatively, if a UK notified body conducts such assessment, a &#8216;UKNI&#8217; mark will be applied and the device may only be placed on the market in Northern Ireland and not the EU.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The clinical trial process is lengthy and expensive with uncertain outcomes. Results of earlier studies may not be predictive of future clinical trial results.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Clinical testing is difficult to design and implement, can take many&#160;years, can be expensive and carries uncertain outcomes. The results of preclinical studies and clinical trials of our products conducted to date and ongoing or future studies and trials of our current, planned or future products may not be predictive of the results of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. The data and results from our clinical trials do not ensure that we will achieve similar results in future clinical trials. In addition, preclinical and clinical data are often susceptible to various interpretations and analyses, and many companies that have believed their products performed satisfactorily in preclinical studies and earlier clinical trials have nonetheless failed to replicate results in later clinical trials, or have viewed such data in different ways than regulators do. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy despite having progressed through nonclinical studies and earlier clinical trials. Failure can occur at any stage of clinical testing. Our clinical studies or investigations may produce negative or </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical and nonclinical testing in addition to those we have planned.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The initiation and completion of clinical studies may be prevented, delayed, or halted for numerous reasons. We may experience delays in our clinical trials for a number of reasons, which could adversely affect the costs, timing or successful completion of our clinical trials, including related to the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to submit an IDE to the FDA, which must become effective prior to commencing certain human clinical trials of medical devices, and the FDA may reject our IDE application and notify us that we may not begin clinical trials, or place restrictions on the conduct of such trials; similar requirements may apply in foreign jurisdictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulators and other comparable foreign regulatory authorities may disagree as to the design or implementation of our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulators and/or IRBs, or other bodies may not authorize us or our investigators to commence a clinical trial, or to conduct or continue a clinical trial at a prospective or specific trial site;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not reach agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical trials may produce negative or inconclusive results, and we may decide, or regulators or notified bodies may require us, to conduct additional clinical trials or abandon product development programs;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of subjects or patients required for clinical trials may be larger than we anticipate, enrollment in these clinical trials may be insufficient or slower than we anticipate (including as a result of delays in enrollment caused or resulting from the ongoing COVID-19 pandemic), and the number of clinical trials being conducted at any given time may be high and result in fewer available patients for any given clinical trial, or patients may drop out of these clinical trials at a higher rate than we anticipate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we might have to suspend or terminate clinical trials for various reasons, including occurrence of adverse events or other findings that the subjects in our clinical trials are being exposed to unacceptable health risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may have to amend clinical trial protocols or conduct additional studies to reflect changes in regulatory requirements or guidance, which we may be required to submit to an IRB, or other bodies and/or regulatory authorities for re-examination;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulators, IRBs, other bodies or other parties may require or recommend that we or our investigators suspend or terminate clinical research for various reasons, including safety signals or noncompliance with regulatory requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of clinical trials may be greater than we anticipate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical sites may not adhere to the clinical protocol or may drop out of a clinical trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be unable to recruit a sufficient number of clinical trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulators, IRBs, or other bodies may fail to approve or subsequently find fault with our manufacturing processes or facilities of third-party manufacturers with which we enter into agreement for clinical and commercial supplies, the supply of devices or other materials necessary to conduct clinical trials may be insufficient, inadequate or not available at an acceptable cost, or we may experience interruptions in supply;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">marketing authorization or certification policies or regulations of FDA or applicable foreign regulatory authorities may change in a manner rendering our clinical data insufficient for marketing authorization or certification; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our current or future products may have undesirable side effects or other unexpected characteristics.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any of these occurrences may significantly harm our business, financial condition and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of marketing authorization or similar certification of any product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Patient enrollment in clinical trials and completion of patient follow-up depend on many factors, including the size of the patient population, the nature of the trial protocol, the proximity of patients to clinical sites, the eligibility criteria for the clinical trial, patient compliance, competing clinical trials and clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product being studied in relation to other available therapies, including any new treatments that may be approved for the indications we are investigating. For example, patients may be discouraged from enrolling in our clinical trials if the trial protocol requires them to undergo extensive post-treatment procedures or follow-up to assess the safety and efficacy of a product candidate, or they may be persuaded to participate in contemporaneous clinical trials of a competitor&#8217;s product candidate. In addition, patients participating in our clinical trials may drop out before completion of the trial or experience adverse medical events unrelated to our product candidate. Delays in patient enrollment or failure of patients to continue to participate in a clinical trial may delay commencement or completion of the clinical trial, cause an increase in the costs of the clinical trial and delays, or result in the failure of the clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Clinical trials must be conducted in accordance with the laws and regulations of the FDA and other applicable regulatory authorities&#8217; legal requirements, regulations or guidelines, and are subject to oversight by these governmental agencies and IRBs, or other bodies at the medical institutions where the clinical trials are conducted. In addition, clinical trials must be conducted with supplies of our devices produced under current good manufacturing practice, or cGMP, and other regulations. Furthermore, we rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and while we have agreements governing their committed activities, we have limited influence over their actual performance. We depend on our collaborators and on medical institutions and CROs to conduct our clinical trials in compliance with good clinical practice, or GCP, requirements. To the extent our collaborators or the CROs fail to enroll participants for our clinical trials, fail to conduct the study to GCP standards or are delayed for a significant time in the execution of trials, including achieving full enrollment, we may be affected by increased costs, program delays or both. In addition, conducting clinical trials in various countries may subject us to further delays and expenses as a result of increased shipment costs, additional regulatory requirements and the engagement of non-U.S. CROs and other third party contractors, as well as expose us to risks associated with clinical investigators who are unknown to the FDA, and different standards of diagnosis, screening and medical care.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if our Alpha DaRT technology obtains marketing authorization in the United States, commercialization of our products in foreign countries would require similar authorization or certification by regulatory authorities or notified bodies in those countries. Marketing authorization and certification practices vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies, clinical trials. Any of these occurrences could have an adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Interim, &#8220;top-line&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may publicly disclose interim, top-line or preliminary data from our clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the interim, top-line or preliminary results that we report may differ from future results of the same trial, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Interim, top-line or preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the interim, top-line or preliminary data we previously announced. As a result, interim, top-line and preliminary data should be viewed with caution until the final data are available.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In particular, we may disclose interim data from our preclinical studies and clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in our share price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20pt;margin:0pt 0pt 12pt 0pt;">Further, others, including regulatory agencies or other bodies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, or the approvability or potential for commercialization of the particular product candidate. In addition, the information we choose to publicly disclose regarding a particular study, clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. If the interim, top-line or preliminary data that we report differ from actual results, or if others, including regulatory authorities and other bodies, disagree with the conclusions reached, our ability to obtain marketing authorization or certification for, and commercialize, our Alpha DaRT technology may be harmed, which could harm our business, operating results, prospects or financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if we obtain marketing authorization or certification, we will be subject to ongoing regulatory review and scrutiny. Failure to comply with post-marketing regulatory requirements could subject us to enforcement actions, including substantial penalties, and might require us to recall or withdraw a product from the market.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we obtain marketing authorization or certification for a product candidate, we will remain subject to ongoing and pervasive regulatory requirements governing, among other things, the manufacture, marketing, advertising, medical device reporting, sale, promotion, import, export, registration, and listing of devices. For example, medical device manufacturers must submit periodic reports to the FDA as a condition of obtaining marketing authorization. These reports include information about failures and certain adverse events associated with the device after its marketing authorization. Failure to submit such reports, or failure to submit the reports in a timely manner, could result in enforcement action by the FDA. Following its review of the periodic reports, the FDA might ask for additional information or initiate further investigation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Regulatory changes could result in restrictions on our ability to continue or expand our operations, higher than anticipated costs, or lower than anticipated sales. Even after we have obtained marketing authorization or certification, we have ongoing responsibilities under FDA regulations and applicable foreign laws and regulations. The FDA, state and foreign regulatory authorities have broad enforcement powers. Our failure to comply with applicable regulatory requirements could result in enforcement action by the FDA, state or foreign regulatory authorities, which may include any of the following sanctions:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">untitled letters or warning letters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, injunctions, consent decrees and civil penalties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recalls, termination of distribution, administrative detention, or seizure of our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">customer notifications or repair, replacement or refunds;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">operating restrictions or partial suspension or total shutdown of production;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in or refusal to grant our requests for future clearances, </span><i style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">de novo </i><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">classifications or approvals or comparable foreign marketing authorizations or certifications of new products, new intended uses, or modifications to existing products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawals or suspensions of any granted marketing authorizations or certifications, resulting in prohibitions on sales of our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA refusal to issue certificates to foreign governments needed to export products for sale in other countries; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">criminal prosecution.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any of these sanctions could result in higher than anticipated costs or lower than anticipated sales and have a material adverse effect on our reputation, business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the FDA may change its marketing authorization policies, adopt additional regulations or revise existing regulations, or take other actions, which may prevent or delay marketing authorization of any product candidate under development or impact our ability to modify any products authorized for market on a timely basis. Such changes may also occur in foreign jurisdictions where we intend to market our products. Such policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain marketing authorizations or certifications, increase the costs of compliance or restrict our ability to maintain any marketing authorizations we have obtained. For example, in recent years, the FDA has announced plans to modernize the premarket notification pathway under Section&#160;510(k)&#160;of the FDCA. For more information, see &#8220;<i style="font-style:italic;">Legislative or regulatory reforms in the United States or the EU may make it more difficult and costly for us to obtain marketing authorizations or certifications for any product candidate or to manufacture, market or distribute any product candidates after such marketing authorizations or certifications have been obtained.</i>&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Any product candidates we develop must be manufactured in accordance with applicable laws and regulations, and we could be forced to recall our devices or terminate production if we fail to comply with these regulations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the United States, the methods used in, and the facilities used for, the manufacture of medical devices must comply with the FDA&#8217;s cGMPs for medical devices, known as the Quality System Regulation, or QSR, which is a complex regulatory scheme that covers the procedures and documentation of the design, testing, production, process controls, quality assurance, labeling, packaging, handling, storage, distribution, installation, servicing and shipping of medical devices. Furthermore, we will be required to verify that our suppliers maintain facilities, procedures and operations that comply with our quality standards and applicable regulatory requirements. The FDA enforces the QSR through periodic announced or unannounced inspections of medical device manufacturing facilities, which may include the facilities of subcontractors. Our product candidates are also subject to similar state regulations and various laws and regulations of foreign countries governing manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our third-party manufacturers may not take the necessary steps to comply with applicable regulations, which could cause delays in the delivery of product candidate. In addition, failure to comply with applicable FDA or foreign requirements or later discovery of previously unknown problems with our products or manufacturing processes could result in, among other things: warning letters or untitled letters; fines, injunctions or civil penalties; suspension or withdrawal of marketing authorizations or certifications; seizures or recalls of our products; total or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">partial suspension of production or distribution; administrative or judicially imposed sanctions; the FDA&#8217;s refusal to grant pending or future clearances or approvals for our products or similar decisions by foreign regulatory authorities or notified bodies; clinical holds; refusal to permit the import or export of our products; and criminal prosecution of us, our suppliers, or our employees. Similar requirements may apply in foreign jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any of these actions could significantly and negatively affect supply of our product candidates, if authorized for sale or certified by the FDA, foreign regulatory authorities or notified bodies. If any of these events occurs, our reputation could be harmed, we could be exposed to product liability claims and we could lose customers and experience reduced sales and increased costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Any product candidate we develop may cause or contribute to adverse medical events, which could interrupt, delay, or prevent their continued development. If certain events occur after marketing authorization or certification, we may be required to report them to the FDA or foreign regulatory authorities, and if we fail to do so, we would be subject to sanctions that could harm our reputation, business, financial condition and results of operations. In addition, the discovery of serious safety issues with our products, or a recall of our products either voluntarily or at the direction of the FDA, another governmental authority or foreign regulatory authorities, could have a negative impact on us.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As is the case with cancer therapies generally, it is likely that there may be side effects and adverse events associated with our Alpha DaRT technology or any future product or product candidate&#8217;s use. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Undesirable side effects caused by our product candidates could cause us or regulatory authorities or other bodies to interrupt, delay or halt clinical trials or, may cause us to abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Undesirable side effects could also </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Patients treated with our product candidates may also be undergoing surgical, chemotherapy, immunotherapy or alternative radiation treatments, which can cause side effects or adverse events that are unrelated to our product candidate, but may still impact the success of our clinical trials. The inclusion of critically ill patients in our clinical trials may result in deaths or other adverse medical events due to other therapies or medications that such patients may be using or due to the gravity of such patients&#8217; illnesses. Even if the side effects do not preclude the product candidate from obtaining or maintaining marketing authorization or certification, undesirable side effects may inhibit market acceptance due to its tolerability versus other therapies. Any of these developments could materially harm our business, financial condition and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, if our Alpha DaRT technology or any future product candidate receives marketing authorization from the FDA, the side effects observed in clinical studies could result in a more restrictive label and we will subject to the FDA&#8217;s medical device reporting regulations and similar foreign regulations, which require us to report to the FDA or to foreign regulatory authorities when we receive or become aware of information that reasonably suggests that one or more of our products may have caused or contributed to a death or serious injury or malfunctioned in a way that, if the malfunction were to recur, it could cause or contribute to a death or serious injury. The timing of our obligation to report is triggered by the date we become aware of the event as well as the nature of the event. We may fail to report events of which we become aware within the prescribed timeframe. We may also fail to recognize that we have become aware of a reportable event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of the product. If we fail to comply with our reporting obligations, the FDA or foreign regulatory authorities could take action, including warning letters, untitled letters, administrative actions, criminal prosecution, imposition of civil monetary penalties, revocation of our marketing authorizations or certification, seizure of our products or delay in obtaining marketing authorizations or certification for our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA and foreign regulatory bodies have the authority to require the recall of commercialized products in the event of material deficiencies or defects in design or manufacture of a product or in the event that a product poses an unacceptable risk to health. The FDA&#8217;s authority to require a recall must be based on a finding that there is reasonable probability that the device could cause serious injury or death. We may also choose to voluntarily recall a product if any material deficiency is found. A government-mandated or voluntary recall by us could occur as a result of an unacceptable risk to health, component failures, malfunctions, manufacturing defects, labeling or design deficiencies, packaging defects or other deficiencies or failures to comply with applicable regulations. Product defects or other errors may occur in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Depending on the corrective action we take to redress a product&#8217;s deficiencies or defects, the FDA or foreign regulatory bodies may require, or we may decide, that we will need to obtain new marketing authorizations or certifications for the device before we may market or distribute the corrected device. Seeking such clearances, certifications or approvals may delay our ability to replace the recalled devices in a timely manner. Moreover, if we do not adequately address problems associated with our devices, we may face additional regulatory enforcement action, including FDA warning letters, product seizure, injunctions, administrative penalties or civil or criminal fines or similar actions by the foreign regulatory bodies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Companies are required to maintain certain records of recalls and corrections, even if they are not reportable to the FDA or foreign regulatory authorities. We may initiate voluntary withdrawals or corrections for our products in the future that we determine do not require notification of the FDA or foreign regulatory authorities. If the FDA or foreign regulatory authorities disagrees with our determinations, it could require us to report those actions as recalls and we may be subject to enforcement action. A future recall announcement could harm our reputation with customers, potentially lead to product liability claims against us and negatively affect our sales. Any corrective action, whether voluntary or involuntary, as well as defending ourselves in a lawsuit, will require the dedication of our time and capital, distract management from operating our business and may harm our reputation and financial results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The misuse or off-label use of our product candidates, if authorized or certified for marketing, may harm our reputation in the marketplace, result in injuries that lead to product liability suits or result in costly investigations, fines or sanctions by regulatory bodies if we are deemed to have engaged in the promotion of these uses, any of which could be costly to our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any marketing authorization or certification we may receive for a product candidate will be limited to specified indications for use. We plan to train our sales and marketing personnel, as well as any direct sales force which may be hired in the future, to not promote our devices for uses outside of the FDA (or foreign regulatory authorities)- authorized indications for use, known as &#8220;off-label uses.&#8221; We cannot, however, prevent a physician from using our devices off-label, when in the physician&#8217;s independent professional medical judgment he or she deems it appropriate. There may be increased risk of injury to patients if physicians attempt to use our devices off-label, which could harm our reputation in the marketplace among physicians and patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the FDA or any foreign regulatory body determines that our promotional materials or training constitute promotion of an off-label use, it could request that we modify our training or promotional materials or subject us to regulatory or enforcement actions, including the issuance or imposition of an untitled letter, which is used for violators that do not necessitate a warning letter, injunction, seizure, civil fine or criminal penalties. It is also possible that other federal, state or foreign enforcement authorities might take action under other regulatory authority, such as false claims laws, if they consider our business activities to constitute promotion of an off-label use, which could result in significant penalties, including, but not limited to, criminal, civil and administrative penalties, damages, fines, disgorgement, exclusion from participation in government healthcare programs and the curtailment of our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, physicians may misuse our products or use improper techniques if they are not adequately trained, potentially leading to injury and an increased risk of product liability. If our devices are misused or used with improper technique, we may become subject to costly litigation by our customers or their patients. As described above, product liability claims could divert management&#8217;s attention from our core business, be expensive to defend and result in sizeable damage awards against us that may not be covered by insurance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we do not obtain and maintain international regulatory registrations, marketing authorizations or certifications for any product candidates we develop, we will be unable to market and sell such product candidates outside of the United States.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Sales of our product candidates outside of the United States will remain subject to foreign regulatory requirements that vary widely from country to country. In addition, the FDA regulates exports of medical devices from the United States. While the regulations of some countries may not impose significant barriers to marketing and selling our products or only require notification to regulators or third parties, others require that we obtain affirmative marketing authorization or certification from a notified body. Complying with foreign regulatory requirements, including obtaining registrations, certifications, clearances or approvals, can be expensive and time-consuming, and we may not receive necessary marketing authorizations or certifications in each country in which we plan to market our products or we may be unable to do so on a timely basis. The time required to obtain registrations, certifications and marketing authorizations, if required by other countries, may</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">be longer than that required for FDA marketing authorizations, and requirements for such certifications, registrations or authorizations may significantly differ from FDA requirements. If we modify our products, we may need to apply for additional marketing authorizations or certifications before we are permitted to sell the modified product. In addition, we may not continue to meet the quality and safety standards required to maintain the authorizations or certifications that we have received. If we are unable to maintain our marketing authorizations or certifications in a particular country, we will no longer be able to sell the applicable product in that country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Obtaining marketing authorization from the FDA does not ensure similar marketing authorization or certifications by regulatory authorities or notified bodies in other countries, and registration, marketing authorization or certification by one or more foreign regulatory authorities or notified bodies does not ensure registration, marketing authorization or certification by regulatory authorities or notified bodies in other foreign countries or by the FDA. However, a failure or delay in obtaining registration, marketing authorization or certification in one country may have a negative effect on the regulatory process in others.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Legislative or regulatory reforms in the United States or the EU may make it more difficult and costly for us to obtain marketing authorizations or certifications for any product candidate or to manufacture, market or distribute any product candidates after such authorizations or certifications have been obtained.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time, legislation is drafted and introduced in Congress that could significantly change the statutory provisions governing the regulation of medical devices. In addition, the FDA may change its policies, adopt additional regulations or revise existing regulations, or take other actions, which may prevent or delay marketing authorization of our future products under development or impact our ability to modify any products for which we have already obtained marketing authorizations on a timely basis. Over the last several&#160;years, the FDA has proposed reforms to its 510(k)&#160;clearance process, and such proposals could include increased requirements for clinical data and a longer review period, or could make it more difficult for manufacturers to utilize the 510(k)&#160;clearance process for their products. For example, in November&#160;2018, FDA officials announced steps that the FDA intended to take to modernize the premarket notification pathway under Section&#160;510(k)&#160;of the FDCA. Among other things, the FDA announced that it planned to develop proposals to drive manufacturers utilizing the 510(k)&#160;pathway toward the use of newer predicates. These proposals included plans to potentially sunset certain older devices that were used as predicates under the 510(k)&#160;clearance pathway, and to potentially publish a list of devices that have been cleared on the basis of demonstrated substantial equivalence to predicate devices that are more than 10&#160;years old. These proposals have not yet been finalized or adopted, although the</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">FDA may work with Congress to implement such proposals through legislation. Accordingly, it is unclear the extent to which any proposals, if adopted, could impose additional regulatory requirements on us that could delay our ability to obtain 510(k)&#160;clearances in the future, increase the costs of compliance, or restrict our ability to maintain any marketing authorizations that we may obtain, or otherwise create competition that may negatively affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">More recently, in September&#160;2019, the FDA issued revised final guidance describing an optional &#8220;safety and performance based&#8221; premarket review pathway for manufacturers of &#8220;certain, well-understood device types&#8221; to demonstrate substantial equivalence under the 510(k)&#160;clearance pathway by showing that such device meets objective safety and performance criteria established by the FDA, thereby obviating the need for manufacturers to compare the safety and performance of their medical devices to specific predicate devices in the clearance process. The FDA maintains a list device types appropriate for the &#8220;safety and performance based&#8221; pathway and continues to develop product-specific guidance documents that identify the performance criteria for each such device type, as well as recommended testing methods, where feasible. The FDA may establish performance criteria for classes of devices similar to ours, and it is unclear the extent to which such performance standards, if established, could impact our ability to obtain marketing authorization or otherwise create competition that may negatively affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, FDA regulations and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect our business and our products. Any new statutes, regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of any product candidates or make it more difficult to obtain marketing authorizations for, manufacture, market or distribute any product candidate we are developing. We cannot determine what effect changes in regulations, statutes, legal interpretation or policies, when and if promulgated, enacted or adopted may have on our business in the future. Such changes could, among other things, require: additional testing prior to obtaining clearance or approval; changes to manufacturing methods; recall, replacement or discontinuance of our products; or additional record keeping.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be promulgated that could prevent, limit or delay marketing authorization of any product candidates we develop. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may be subject to enforcement action and we may not achieve or sustain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the EU regulatory landscape concerning medical devices evolved and on May 26, 2021, the EU Medical Devices Regulation (Regulation 2017/745) became applicable, which repeals and replaces the EU Medical Devices Directive and the Active Implantable Medical Devices Directive (See &#8211; Regulation of Medical Devices in the European Union) and these modifications may have an effect on the way we conduct our business in the EU and the EEAFor example, as a result of the transition towards the new regime, notified body review times have lengthened, and product introductions or modifications could be delayed or canceled, which could adversely affect our ability to grow our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The EU-UK Trade and Cooperation Agreement, or TCA, came into effect on January 1, 2021. The TCA does not specifically refer to medical devices. However, as a result of Brexit, the EU Medical Devices Regulation was not implemented in the UK. The regulatory regime for medical devices in Great Britain (England, Scotland and Wales) will continue to be based on the requirements </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">derived from current EU legislation, and the UK may choose to retain regulatory flexibility or align with the EU Medical Devices Regulation going forward. CE markings will continue to be recognized in the UK, and certificates issued by EU-recognized notified bodies will be valid in the UK, until June 30, 2023. For medical devices placed on the market in Great Britain after this period, the UK Conformity Assessment, or UKCA, marking will be mandatory. In contrast, UKCA marking and certificates issued by UK notified bodies will not be recognized on the EU market. The TCA does provide for cooperation and exchange of information in the area of product safety and compliance, including market surveillance, enforcement activities and measures, standardization related activities, exchanges of officials, and coordinated product recalls (or other similar actions). For medical devices that are locally manufactured but use components from other countries, the &#8220;rules of origin&#8221; criteria will need to be reviewed. Depending on which countries products will be ultimately sold in, manufacturers may start seeking alternative sources for components if this would allow them to benefit from no tariffs. The rules for placing medical devices on the Northern Ireland market will differ from those in Great Britain. A public consultation by the MHRA was opened until end of November 2021 on the post-Brexit regulatory framework for medical devices and diagnostics in the UK. The consultation proposes amendments to the Medical Devices Regulations 2002, in particular to create a new access pathways to support innovation, create an innovative framework for regulating software and artificial intelligence  as  medical devices, reform in vitro diagnostic regulation, and foster sustainability through the reuse and remanufacture of medical devices. The regime is expected to come into force in July 2023, coinciding with the end of the acceptance period for EU CE marks in Great Britain, subject to appropriate transitional arrangements. The consultation indicated that the MHRA will publish guidance in relation to the changes to the regulatory framework and may rely more heavily on guidance to add flexibility to the regime. These modifications may have an effect on the way we intend to conduct our business in these countries.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes in funding for, or disruptions caused by global health concerns impacting, the FDA and other agencies or notified bodies could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new medical device products from being developed, authorized, certified or commercialized in a timely manner, which could negatively impact our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The ability of the FDA, foreign regulatory authorities and notified bodies to review and authorize or certify the sale of new products can be affected by a variety of factors, including government budget and funding levels; its ability to hire and retain key personnel and accept the payment of user fees; statutory, regulatory, and policy changes; and other events that may otherwise affect the FDA&#8217;s, foreign regulatory authorities&#8217; and notified bodies&#8217; ability to perform routine functions. Average review times at the FDA, foreign regulatory authorities and notified bodies have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA, other agencies and foreign bodies may also slow the time necessary for new devices to be reviewed and/or authorized or certified for marketing by necessary government agencies or foreign bodies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Separately, in response to the COVID-19 pandemic, in March 2020, the FDA announced its intention to postpone most inspections of foreign manufacturing facilities, and on March 18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. Subsequently, in July 2020, the FDA resumed certain on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA utilized this risk-based assessment system to assist in determining when and where it was safest to conduct prioritized domestic inspections. In May 2021, the FDA outlined a detailed plan to move toward a more consistent state of inspectional operations, and in July 2021, the FDA resumed standard inspectional operations of domestic facilities and was continuing to maintain this level of operation as of September 2021. More recently, the FDA has continued to monitor and implement changes to its inspectional activities to ensure the safety of its employees and those of the firms it regulates as it adapts to the evolving COVID-19 pandemic. Other regulatory authorities may have adopted similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA, other regulatory authorities or notified bodiesfrom conducting business as usual or conducting inspections, reviews or other regulatory activities, it could significantly impact the ability of the FDA, foreign regulatory authorities and notified bodies to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the EU, notified bodies must be officially designated to certify products and services in accordance with the MDR. While several notified bodies have been designated the COVID-19 pandemic has significantly slowed down their designation process and the current designated notified bodies are facing a large amount of requests with the new regulation as a consequence of which review times have lengthened. This situation could significantly impact the ability of notified bodies to timely review and process our regulatory submissions, which could have a material adverse effect on our business in the EU and EEA.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, and customers, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our product candidates, if approved or certified. Such laws include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under U.S. federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. federal civil and criminal false claims laws, including the civil False Claims Act, which, among other things, impose criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. In addition, the government may assert that a </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">claim including items and services resulting from a violation of the U.S. federal Anti- Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal civil monetary penalties laws, which impose civil fines for, among other things, the offering or transfer of remuneration to a Medicare or state healthcare program beneficiary if the person knows </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or should know it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state healthcare program, unless an exception applies;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services; similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. Physician Payments Sunshine Act and its implementing regulations, which require certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid or the Children&#8217;s Health Insurance Program to report annually to the government information related to certain payments and other transfers of value to physicians, as defined by such law, certain non-physician providers such as physician assistants and nurse practitioners, and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">analogous U.S. state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third- party payor, including private insurers; state laws that require medical device and pharmaceutical companies to comply with the industry&#8217;s voluntary compliance guidelines and the relevant </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">made to healthcare providers and other potential referral sources; state laws and regulations that require drug and device manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; and state and local laws that require the registration of sales representatives; and</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">similar healthcare laws and regulations in the EU and other jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices, including our relationships with physicians and other healthcare providers, some of whom are compensated in the form of stock options for consulting services provided, may not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment, which could affect our ability to operate our business. Further, defending against any such actions can be costly, time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business and our ability to sell our products may be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If in the future Alpha DaRT is approved or certified for commercial sale, but we are unable to obtain adequate reimbursement or insurance coverage from third-party payors, we may not be able to generate significant revenue.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because the Alpha DaRT is still in the development stage, it is not yet approved for third-party payor coverage or reimbursement. Coding and coverage determinations as well as reimbursement levels and conditions are important to the commercial success of any product or offering. The future availability of insurance coverage and reimbursement for newly approved medical devices is highly uncertain, and our future business will be greatly impacted by the level of reimbursement provided by third-party payors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the United States, third-party payors decide which cancer treatment products and services they will cover, how much they will pay and whether they will continue reimbursement. Third-party payors may not cover or provide adequate reimbursement for the Alpha DaRT device, the Alpha DaRT sources or the procedures using the system, assuming we are able to fully develop and obtain all marketing authorizations to market it in the United States or similar certifications in other geographies. To date, we have not had any discussions with any third-party payors, including any regulatory agencies administering any government funded healthcare programs, regarding the coding, coverage or reimbursement for imaging services using the Alpha DaRT, which may vary depending on the specific application or indication of our technology. Accordingly, unless government and other third-party payors provide coverage and reimbursement for our products, patients and healthcare providers may choose not to use them, which would adversely impact our future revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No uniform policy of coverage and reimbursement among payors in the United States exists and coverage and reimbursement for procedures can differ significantly from payor to payor. Some third-party payors must approve coverage for new or innovative devices or procedures before they will reimburse healthcare providers who use the products or therapies. Even though a new product may have been cleared for commercial distribution by the FDA, we may find limited demand for the product unless and until reimbursement approval has been obtained from governmental and private third-party payors. We can provide no assurances that we would be successful in obtaining coverage from Medicare or any other governmental or commercial third-party payor. In addition, while we believe that we may be able to rely on certain existing procedure codes for certain elements of the physician&#8217;s treatment efforts, we are not certain of this and as such may be required to seek new billing codes for our products, and regulatory authorities may not approve the creation of separate codes. Additionally, even if we are successful, these billing codes or the payment amounts associated with such codes may change in the future.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to uncertainties surrounding coverage policies, there are periodic changes to reimbursement levels. Third-party payors regularly update reimbursement amounts and also from time to time revise the methodologies used to determine reimbursement amounts. This includes routine updates to payments to physicians, hospitals and ambulatory surgery centers for procedures during which our products are used. These updates could directly impact the demand for our products. By way of example, in the United States, payment rates under the Medicare Physician Fee Schedule are regularly subject to updates to effectuate various policy goals. The Medicare Access and CHIP Reauthorization Act of 2015 repealed the formula by which Medicare made annual payment adjustments to physicians and replaced the former formula with fixed annual updates and a new system of incentive payments that began in 2019 that are based on various performance measures and physicians&#8217; participation in alternative payment models, such as accountable care organizations. The ongoing and future impact of these changes cannot be determined at this time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A primary trend in the United States healthcare industry and elsewhere is cost containment. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular products and services. Reimbursement may not be available, or continue to be available, for the Alpha DaRT or the treatment services using the Alpha DaRT or any other products we may develop in the future, or even if reimbursement is available, such reimbursement may not be adequate. We also will be subject to foreign reimbursement policies in the international markets we expect to enter. Decisions by health insurers or other third-party payors in these markets not to cover, or to discontinue reimbursing, our products could materially and adversely affect our business. If such decisions are made, they could also have a negative impact on our ability to generate revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On September&#160;18, 2020, the Centers for Medicare and Medicaid Services, or CMS, the federal agency responsible for administering the Medicare program, issued a final rule&#160;implementing a new mandatory payment model for radiation oncology services: the Radiation Oncology Alternative Payment Model, or the RO Model. Although the RO Model was originally intended to begin on January&#160;1, 2022, recent legislation delayed its implementation until January&#160;1, 2023. The RO Model significantly alters CMS&#8217; payment methodology from a fee for service, or FFS, paradigm to a prospective payment for all radiotherapy services furnished during a 90-day episode of care for fifteen (15) different cancer types, regardless of the modality used or site of service. Under the RO Model, all providers of radiotherapy services, including physician group practices, hospital outpatient departments and free-standing radiation therapy centers located within a randomly selected Core Based Statistical Area, or CBSA are required to participate. The CBSAs selected for the RO Model will contain approximately 30% of all eligible Medicare FFS radiotherapy episodes in the U.S. Any provider outside of the CBSAs will continue to receive Medicare reimbursement based on a FFS methodology. It is uncertain the impact, if any, of the RO Model, if implemented, on the Medicare reimbursement to our customers when using our Alpha DaRT technology, if authorized for marketing, or our business, financial condition, or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Outside of the United States, reimbursement levels vary significantly by country. For example, in the EU, member states impose controls on whether products are reimbursable by national or regional health service providers and on the prices at which medical devices are reimbursed under state-run healthcare schemes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Healthcare policy changes, including recently enacted legislation reforming the U.S. healthcare system, could harm our business, financial condition and results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. Federal and state lawmakers regularly propose and, at times, enact legislation that would result in significant changes to the healthcare system, some of which are intended to contain or reduce the costs of medical products and services. Current and future legislative proposals to further reform healthcare or reduce healthcare costs may limit coverage of or lower reimbursement for our product candidates and the treatment associated with the use of our products. The cost containment measures that payors and providers are instituting and the effect of any healthcare reform initiative implemented in the future could impact our revenue from the sale of our product candidates, if approved or cleared.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">By way of example, in the United States, the Affordable Care Act, or ACA, made a number of substantial changes in the way healthcare is financed by both governmental and private insurers. Among other ways in which it may affect our business, the ACA</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Established a new Patient-Centered Outcomes Research Institute to oversee and identify priorities in comparative clinical effectiveness research in an effort to coordinate and develop such research;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Implemented payment system reforms including a national pilot program on payment bundling to encourage hospitals, physicians and other providers to improve the coordination, quality and efficiency of certain healthcare services through bundled payment models; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Expanded the eligibility criteria for Medicaid programs.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. On June&#160;17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#8217;s decision, President Biden issued an executive order to initiate a special enrollment period from February&#160;15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules&#160;that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how other healthcare reform measures of the Biden administration will impact our business. Any expansion in the government&#8217;s role in the U.S. healthcare industry may result in decreased profits to us and/or lower reimbursement by payors for our product candidates, any of which may have a material adverse effect on our business, financial condition or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. The Budget Control Act of 2011, among other things, reduced Medicare payments to providers by 2% per fiscal&#160;year, effective on April&#160;1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030, with the exception of a temporary suspension from May&#160;1, 2020, through March&#160;31, 2022 and a 1% reduction from April&#160;1, 2022 through June&#160;30, 2022, unless additional Congressional action is taken. Additionally, the American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five&#160;years. The Medicare Access and CHIP Reauthorization Act of 2015, or MACRA, enacted on April&#160;16, 2015, repealed the formula by which Medicare made annual payment adjustments to physicians and replaced the former formula with fixed annual updates and a new system of incentive payments that are based on various performance measures and physicians&#8217; participation in alternative payment models such as accountable care organizations. It is unclear what effect new quality and payment programs, such as MACRA, may have on our business, financial condition, results of operations or cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18.35pt;margin:0pt 0pt 12pt 0pt;">We expect additional state, federal and foreign healthcare policies and reform measures to be adopted in the future, any of which could limit reimbursement for healthcare products and services or otherwise result in reduced demand for our product candidates or additional pricing pressure and have a material adverse effect on our industry generally and on our customers. We cannot predict what other healthcare programs and regulations will ultimately be implemented at the federal or state level or the effect of any future legislation or regulation in the United States may negatively affect our business, financial condition and results of operations. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare may adversely affect our ability to set a price that we believe is fair for our product candidates, our ability to generate revenue and achieve or maintain profitability or the availability of capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18.35pt;margin:0pt 0pt 12pt 0pt;">For instance, in December 2021, the EU Regulation No 2021/2282 on Health Technology Assessment, or HTA, amending Directive 2011/24/EU, was adopted. This regulation which entered into force in January 2022 intends to boost cooperation among EU member states in assessing health technologies, including some medical devices, and providing the basis for cooperation at the EU level for joint clinical assessments in these areas. The regulation foresees a three-year transitional period and will permit EU member states to use common HTA tools, methodologies, and procedures across the EU, working together in four main areas, including joint clinical assessment of the innovative health technologies with the most potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual EU member states will continue to be responsible for assessing non-clinical (e.g., economic, social, ethical) aspects of health technologies, and making decisions on pricing and reimbursement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18.35pt;margin:0pt 0pt 12pt 0pt;">Any changes of, or uncertainty with respect to, future coverage or reimbursement rates could affect demand for our product candidates, which in turn could impact our ability to successfully commercialize these devices and could have a material adverse effect on our business, financial condition and results of operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, financial condition and prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The global data protection landscape is rapidly evolving, and we are or may become subject to numerous state, federal and foreign laws, requirements and regulations governing the collection, use, disclosure, retention, and security of personal data, such as information that we may collect in connection with clinical trials in the U.S. and abroad. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in our business, affect our ability to operate in certain jurisdictions or to collect, store, transfer use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us to comply with federal, state or foreign laws or regulation, our internal policies and procedures or our contracts governing our processing of personal information could result in negative publicity, government investigations, fines and enforcement actions, claims by third parties and damage to our reputation, any of which could have a material adverse effect on our business, financial condition and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As our operations and business grow, we may become subject to or affected by new or additional data protection laws and regulations and face increased scrutiny or attention from regulatory authorities. For example, the State of Israel has implemented data protection laws and regulations, including the Israeli Protection of Privacy Law of 1981. Further, in the U.S., HIPAA imposes, among other things, certain standards relating to the privacy, security, transmission and breach reporting of individually identifiable health information. Certain states have also adopted comparable privacy and security laws and regulations, some of which may be more stringent than HIPAA. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. In addition, the CCPA went into effect on January&#160;1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability, and many similar laws have been proposed at the federal level and in other states. Further, the CPRA recently passed in California. The CPRA will impose additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It will also create a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. The majority of the provisions will go into effect on January&#160;1, 2023, and additional compliance investment and potential business process changes may be required. In the event that we are subject to or affected by Israeli data protection laws, HIPAA, the CCPA, the CPRA or other domestic or foreign privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">In Europe, the GDPR went into effect in May 2018 and imposes strict requirements for processing the personal data of individuals within the European Economic Area, or EEA. Companies that must comply with the GDPR face increased compliance obligations and risk, including providing detailed disclosures about how personal data is collected and processed (in a concise, intelligible and easily accessible form); demonstrating that an appropriate legal basis is in place or otherwise exists to justify data processing activities; granting rights for data subjects in regard to their personal data (including data access rights, the right to be &#8220;forgotten&#8221; and the right to data portability); introducing the obligation to notify data protection regulators or supervisory authorities (and in certain cases, affected individuals) of significant data breaches; imposing limitations on retention of personal data; maintaining a record of data processing; and complying with the principal of accountability and the obligation to demonstrate compliance through policies, procedures, training and audit. The GDPR also introduces more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the United States. In July  2020, the Court of Justice of the European Union, or CJEU limited how organizations could lawfully transfer personal data from the EU/EEA to the United States by invalidating the Privacy Shield for purposes of international transfers and imposing further restrictions on the use of standard contractual clauses, or SCCs. The European Commission has published revised SCCs for data transfers from the EEA: the revised clauses became mandatory for relevant new data transfers on September 27, 2021; existing SCC arrangements had to be migrated to the revised clauses by December 27, 2022. The new SCCs apply only to the transfer of personal data outside of the EEA and not the UK; the UK&#8217;s Information Commissioner&#8217;s Office launched a public consultation on its draft revised data transfers mechanisms in August 2021 and laid its proposal before Parliament, with the UK SCCs expected to come into force in March 2022, with a two-year grace period. We are now required to implement the revised standard contractual clauses, in relation to relevant existing contracts and certain additional contracts and arrangements. There is some uncertainty around whether the revised clauses can be used for all types </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">of data transfers, particularly whether they can be relied on for data transfers to non-EEA entities subject to the GDPR. These recent developments are likely to require us to review and amend the legal mechanisms by which we make and/or receive personal data transfers to/in the United States. As supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the standard contractual clauses cannot be used, and/or start taking enforcement action, we could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Further, from January 1, 2021, companies have had to comply with the GDPR and also the United Kingdom GDPR, or UK GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law. The UK GDPR mirrors the fines under the GDPR, i.e., fines up to the greater of &#8364;20 million (&#163;17.5 million) or 4% of global turnover. The European Commission has adopted an adequacy decision in favor of the United Kingdom, enabling data transfers from EU member states to the United Kingdom without additional safeguards. However, the United Kingdom adequacy decision will automatically expire in June 2025 unless the European Commission re-assesses and renews/extends that decision, and remains under review by the Commission during this period. The United Kingdom&#8217;s Information Commissioner&#8217;s Office has published new data transfer standard contracts for transfers from the UK under the UK GDPR. This new documentation will be mandatory for relevant data transfers from September 21, 2022; existing standard contractual clauses arrangements must be migrated to the new documentation by March 21, 2024.  In September 2021, the UK government launched a consultation on its proposals for wide-ranging reform of UK data protection laws following Brexit. There is a risk that any material changes which are made to the UK data protection regime could result in the European Commission reviewing the UK adequacy decision, and the UK losing its adequacy decision if the European Commission deems the UK to no longer provide adequate protection for personal data. The relationship between the United Kingdom and the EU in relation to certain aspects of data protection law remains unclear, and it is unclear how UK data protection laws and regulations will develop in the medium to longer term, and how data transfers to and from the United Kingdom will be regulated in the long term. These changes will lead to additional costs and increase our overall risk exposure.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Although we work to comply with applicable laws, regulations and standards, our contractual obligations and other legal obligations, these requirements are evolving and may be modified, interpreted and applied in an inconsistent manner from one jurisdiction to another, and may conflict with one another or other legal obligations with which we must comply. Any failure or perceived failure by us or our employees, representatives, contractors, consultants, collaborators, or other third parties to comply with such requirements or adequately address privacy and security concerns, even if unfounded, could result in additional cost and liability to us, damage our reputation, and adversely affect our business, financial condition and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Reliance on Third Parties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We rely on a limited number of third-party suppliers and, in some cases, sole suppliers, for the majority of our components, subassemblies and materials and may not be able to find replacements or immediately transition to alternative suppliers.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We rely on several sole suppliers for certain components of our Alpha DaRT technology. These sole suppliers, and any of our other suppliers, may be unwilling or unable to supply components of these systems to us reliably and at the levels we anticipate or are required by us. For us to be successful, our suppliers must be able to provide us with products and components in substantial quantities, in compliance with regulatory requirements, in accordance with agreed upon specifications, at acceptable costs and on a timely basis. If we obtain marketing authorization or certification, and we encounter delays or difficulties in securing these components, an interruption in our commercial operations could occur if we cannot then obtain an acceptable substitute. If we are required to transition to new third-party suppliers for certain components of our Alpha DaRT technology or any future product or product candidates, we believe that there are a few other manufacturers that are currently capable of supplying the necessary components. In addition, the use of components or materials furnished by these alternative suppliers could require us to alter our operations. Any such interruption or change in supplier could harm our reputation, business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Furthermore, if we are required to change the manufacturer of a critical component of our product candidates, we will be required to verify that the new manufacturer maintains facilities, procedures and operations that comply with our quality and applicable regulatory requirements, which could further impede our ability to manufacture our implant systems in a timely manner. We currently do not carry inventory for components for more than three&#160;months at any given time. Transitioning to a new supplier could be time- consuming and expensive, may result in interruptions in our operations and product delivery, could affect the performance specifications of our product candidates or could require that we modify their design. If the change in manufacturer results in a </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">significant change to any product after its authorization or certification for marketing, a new 510(k)&#160;clearance from the FDA or similar international regulatory authorization or certification may be necessary before we implement the change, which could cause substantial delays. The occurrence of any of these events could harm our ability to meet the demand for our products in a timely manner or cost-effectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We cannot assure you that we will be able to secure alternative equipment and materials and utilize such equipment and materials without experiencing interruptions in our workflow. If we should encounter delays or difficulties in securing, reconfiguring or revalidating the equipment and components we require for our implant systems, our reputation, business, financial condition and results of operations could be negatively impacted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We currently rely, and plan to rely in the future, on third parties to conduct and support our portions of our preclinical studies and clinical trials. If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain marketing authorization or certification of or commercialize our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have utilized and plan to continue to utilize and depend upon independent investigators and collaborators, such as medical institutions, CROs, contract manufacturing organizations, or CMOs, and strategic partners to conduct and support portions of our preclinical studies and clinical trials under agreements with us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expect to have to negotiate budgets and contracts with CROs, trial sites and CMOs and we may not be able to do so on favorable terms, which may result in delays to our development timelines and increased costs. We will rely heavily on these third parties over the course of our preclinical studies and clinical trials, and we control only certain aspects of their activities. As a result, we will have less direct control over the conduct, timing and completion of these preclinical studies and clinical trials and the management of data developed through preclinical studies and clinical trials than would be the case if we were relying entirely upon our own staff. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. We and these third parties are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for product candidates in clinical development. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, principal investigators and trial sites.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we or any of these third parties fail to comply with applicable GCP regulations, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities or other bodies may require us to perform additional clinical trials before approving our marketing applications or certifications. We cannot assure you that, upon inspection, such regulatory authorities will determine that any of our clinical trials comply with the GCP regulations. In addition, our product candidates must be produced in accordance with cGMP requirements known as the QSR. Our failure or any failure by these third parties to comply with these regulations or to recruit a sufficient number of patients may require us to repeat clinical trials, which would delay the marketing authorization or certification process. Moreover, our business may be implicated if any of these third parties violates federal, state or foreign fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any third parties conducting or supporting portions of our clinical trials will not be our employees and, except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our product candidates. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials, or other product development activities, which could affect their performance on our behalf. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to complete development of, obtain marketing authorizations or certifications for or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates would be adversely affected, our costs could increase and our ability to generate revenue could be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Switching or adding third parties to conduct or support portions of our preclinical studies and clinical trials involves substantial cost and requires extensive management time and focus. In addition, there is a natural transition period when a new third party commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we or third parties, such as CROs or trial sites, use hazardous and biological materials in a manner that causes injury or violates applicable law, we may be liable for damages.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our research and development activities involves the controlled use of potentially hazardous substances, including radiological materials, by us or third parties, such as CROs and CMOs. Our use of radioactive materials is regulated by the United States Nuclear Regulatory Commission and specified agencies of certain states, as well as the Israeli Ministry for Environmental Protection, for the possession, transfer, import, export, use, storage, handling and disposal of radioactive materials. We are also subject to international laws and regulations that apply to manufacturers of radiation-emitting devices and products utilizing radioactive materials. These are often comparable to, if not more stringent than, the equivalent regulations in the United States. The use of Thorium-228 in our manufacturing processes, and Radium-224 in our Alpha DaRT technology, involves the inherent risk of exposure from alpha and beta particle emissions to the patient receiving the sources implanted, the clinicians administering the Alpha DaRT technology, our employees and others who may handle our products, which can alter or harm healthy cells in the body. Additionally, as we continue to develop our Alpha DaRT technology we may experiment with increased amounts of radiation in an attempt to increase the potential efficacy of our technology, which could heighten the potential risk of radiation exposure. We and such third parties are subject to the Israeli and U.S. federal, state, provincial and local laws and regulations governing the use, manufacture, storage, handling, and disposal of radiological, medical and hazardous materials. Although we believe that our and such third-parties&#8217; procedures for using, handling, storing and disposing of these materials comply with legally prescribed standards, we cannot completely eliminate the risk of contamination or injury resulting from radiological, medical or hazardous materials. As a result of any such contamination or injury, we may incur liability or Israeli and U.S. local, city, state, provincial or federal authorities may curtail the use of these materials and interrupt our business operations. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition, or results of operations. We currently maintain insurance coverage for injuries resulting from the hazardous materials we use; however, future claims may exceed the amount of our coverage. Also, we do not have insurance coverage for pollution cleanup and removal. Currently the costs of complying with such Israeli and U.S. federal, state, provincial, local and foreign environmental regulations are not significant, and consist primarily of waste disposal expenses. However, they could become expensive, and current or future environmental laws or regulations may impair our research, development, production and commercialization efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, our manufacture and distribution of devices utilizing radioactive material or emitting radiation also requires us to obtain a number of licenses and certifications for these devices and materials. Handling of these products must also be in accordance with a specific radioactive materials license. Obtaining licenses and certifications may be time consuming, expensive, and uncertain. If we fail to obtain such licenses and registrations or if substantial delays are incurred in obtaining such licenses and registrations, we may be unable to manufacture, distribute and ultimately sell our Alpha DaRT technology, if approved or certified. Additionally, any lapse in our licenses, or the licenses of our facilities, could increase our costs and adversely affect our operations and financial results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be unable to obtain a sufficient or sufficiently pure supply of radioisotopes to support clinical development or at commercial scale.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Thorium-228 is a key component of our Alpha DaRT technology, as it naturally decays into Radium-224 that is collected onto the sources which comprise an integral part of our Alpha DaRT technology. We have entered into a multi-year supply contract with Eckert&#160;&amp; Ziegler AG in Germany, and also acquire Thorium-228 from the Oak Ridge National Laboratory of the United States Department of Energy. We are also aware of or have spoken with other potential suppliers of Thorium-228, such that we anticipate a steady, unrestricted supply of thorium for the production of the Alpha DaRT. We will continually evaluate Thorium-228 manufacturers and suppliers and intend to have redundant suppliers prior to the commercial launch of the Alpha DaRT technology, if approved. While we consider Thorium-228 to be readily available, there can be no guarantee that we will be able to secure another Thorium-228 supplier or obtain on terms that are acceptable to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Our ability to conduct clinical trials to advance our Alpha DaRT technology is dependent on our ability to obtain the radioisotope Thorium-228 and other isotopes we may choose to utilize in the future. Currently, we are dependent on third-party manufacturers and suppliers for our isotopes. These suppliers may not perform their contracted services or may breach or terminate their agreements with us, or may provide a product not of sufficient quality to allow successful use in our manufacturing processes. Our suppliers are subject to regulations and standards that are overseen by regulatory and government agencies and we have no control over our suppliers&#8217; compliance to these standards. Failure to comply with regulations and standards may result in their inability to supply isotope could </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">result in delays in our clinical trials, which could have a negative impact on our business. We have developed intellectual property, know-how and trade secrets related to the manufacturing process of the Alpha DaRT technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may form or seek collaborations or strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such collaborations, alliances or licensing arrangements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may form or seek strategic alliances, create joint ventures or collaborations, or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our Alpha DaRT technology and any future products or product candidates that we may develop. Any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing shareholders or disrupt our management and business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. We may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view our product candidates as having the requisite potential to demonstrate safety, potency and quality and obtain marketing authorization or certification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, collaborations involving our product candidates are subject to numerous risks, which may include the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators have significant discretion in determining the efforts and resources that they will apply to a collaboration;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization of our product candidates based on clinical trial results, changes in their strategic focus due to the acquisition of competitive products, availability of funding or other external factors, such as a business combination that diverts resources or creates competing priorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial, stop a clinical trial, abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a collaborator with marketing and distribution rights to one or more products may not commit sufficient resources to their marketing and distribution;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disputes may arise between us and a collaborator that cause the delay or termination of the research, development or commercialization of our product candidates, or that result in costly litigation or arbitration that diverts management attention and resources;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may own or co-own intellectual property covering our products that results from our collaborating with them, and in such cases, we would not have the exclusive right to commercialize such intellectual property.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As a result, if we enter into collaboration agreements and strategic partnerships or license our product candidates, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture, which could delay our timelines or otherwise adversely affect our business. We also cannot be certain that, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">following a strategic transaction or license, we will achieve the revenue or specific net income that justifies such transaction. Any delays in entering into new collaborations or strategic partnership agreements related to our product candidates could delay the development and commercialization of our product candidates in certain geographies for certain indications, which would harm our business, prospects, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to obtain and maintain patent or other intellectual property protection for our Alpha DaRT technology and for any other products or product candidates that we develop, or if the scope of the patent or other intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to commercialize any product candidates we may develop, and our technology may be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our success depends in large part on our ability to obtain and maintain patents, trademarks and other intellectual property rights in the United States and other countries with respect to our Alpha DaRT technology or other products or product candidates we may develop, their respective components, formulations, combination therapies, methods used to manufacture them and methods of treatment and development that are important to our business, as well as our ability to operate without infringing the proprietary rights of others. We rely on a combination of contractual provisions, patent protection, as well as a combination of trade secret and trademark laws, to protect our core technology and commercial products and prevent others from copying our treatment delivery devices and methods. However, these legal measures afford only limited protection, and competitors or others may gain access to or use of our intellectual property and proprietary information. For example, patent protection and intellectual property laws may not: (i)&#160;prevent competitors from obtaining access to our trade secrets, proprietary information, data, know-how and technology; (ii)&#160;prevent others from copying our systems and methods; or (iii)&#160;provide a sustained competitive advantage. If we do not adequately protect our intellectual property rights, competitors may be able to erode or negate any competitive advantage we may have, which could harm our business and ability to achieve profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To protect our proprietary position, we file patent applications in the United States and abroad related to our novel product candidates that are important to our business. We may in the future also license or purchase patents and patent applications owned or controlled by others. As of December&#160;31, 2021, our patent portfolio included 83 issued patents, and 76 pending patent applications including two allowed patent applications, in the United States, Europe, Canada, Japan, Australia, China, South Korea, Russia, Mexico, India, Hong Kong, Singapore, South Africa and the African Regional Intellectual Property Organization, or the ARIPO. Some of our earlier filed patents are expected to expire between 2024 and 2026, subject to patent term extensions and adjustments that may be available in certain jurisdictions. When key patents covering our core technology expire, competitors and other third parties may be able to make competing products and encroach on our market share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">It is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If we are unable to secure or maintain patent protection with respect to our Alpha DaRT technology and any proprietary products and technology we develop, our business, financial condition, results of operations, and prospects could be materially harmed. Our pending and future patent applications may not result in patents being issued or that issued patents will afford sufficient protection of our product candidates or their intended uses against competitors, nor can there be any assurance that the patents issued will not be infringed, designed around, invalidated by third parties, or effectively prevent others from commercializing competitive technologies, products or product candidates. Further, some of our pending patent applications may be allowed in the future, but we cannot be certain that an allowed patent application will become an issued patent. There may be events that cause withdrawal of the allowance of a patent application. For example, after a patent application has been allowed, but prior to being issued, material that could be relevant to patentability may be identified. In such circumstances, the applicant may pull the application from allowance in order for the USPTO to review the application in view of the new material. We cannot be certain that the USPTO will issue the application in view of the new material. We anticipate additional patent applications will be filed both in the United States and in other countries, as appropriate. However, we cannot predict: (i)&#160;if additional patent applications covering new technologies related to our product candidates will be filed; (ii)&#160;if and when patents will issue; (iii)&#160;the degree and range of protection any issued patents will afford us against competitors, including whether third parties will find ways to invalidate or otherwise circumvent our patents; (iv)&#160;whether any of our intellectual property will provide any competitive advantage; (v)&#160;whether any of our patents that may be issued may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise provide any competitive advantage; (vi)&#160;whether others will obtain patents claiming inventions similar to those covered by our patents and patent applications; or (vii)&#160;whether we will need to initiate or defend litigation or administrative proceedings which may be costly regardless of whether we win or lose. The patent prosecution process is complex, expensive, time-consuming and inconsistent across jurisdictions. We may not </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">be able to file, prosecute, maintain, enforce, or license all necessary or desirable patent rights at a commercially reasonable cost or in a timely manner. In addition, we may not pursue or obtain patent protection in all relevant markets. It is possible that we will fail to identify important patentable aspects of our research and development efforts in time to obtain appropriate or any patent protection. If we delay filing a patent application, and a competitor files a patent application on the same or a similar invention before we do, our ability to secure patent rights may be limited. We may not be able to patent the invention at all. Even if we can patent the invention, we may be able to patent only a limited scope of the invention, and the limited scope may be inadequate to protect our products, or to block competitor products that are similar or adjacent to ours. Our earliest patent filings have been published. A competitor may review our published patents and arrive at the same or similar technology advances for our products as we developed. If the competitor files a patent application on such an advance before we do, then we may no longer be able to protect that aspect of our products and we may require a license from the competitor. If the license is not available on commercially-viable terms, then we may not be able to launch our product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Going forward, the growth of our business may depend in part on our ability to acquire or in-license additional proprietary rights. For example, our programs may involve additional product candidates that may require the use of additional proprietary rights held by third parties. We may be unable to acquire or in-license any relevant third-party intellectual property rights that we identify as necessary or important to our business operations. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all, which would adversely affect our business. We may need to cease use of, and may need to seek to develop alternative approaches that do not infringe on, such intellectual property rights which may entail additional costs and development delays and such alternative approaches may not be feasible. Even if we are able to obtain a license under such intellectual property rights, any such license may be non-exclusive, and may allow our competitors access to the same technologies licensed to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The patent positions of medical device companies may involve complex legal and factual questions and have been the subject of much litigation in recent&#160;years, and therefore, the scope, validity and enforceability of any patent claims that we have or may obtain cannot be predicted with certainty. Our pending and future patent applications may not result in patents being issued in the United States or in other jurisdictions that protect our technology or products or that effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. In addition, the laws of foreign countries may not protect our products and inventions to the same extent as the laws of the United States. While we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development efforts, including for example, our employees, corporate collaborators, external academic scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby endangering our ability to seek patent protection. In addition, publications of discoveries in the scientific and scholarly literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18&#160;months after filing, or in some cases not until issuance as a patent. Consequently, we cannot be certain that we were the first to file for patent protection on the inventions claimed in our patents or pending patent applications. In addition, the USPTO might require that the term of a patent issuing from a pending patent application be disclaimed and limited to the term of another patent that is commonly owned or names a common inventor. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our competitors may be able to circumvent our owned or any future in-licensed patents by developing similar or alternative technologies or products in a non-infringing manner. The issuance of a patent is not conclusive as to its scope, validity or enforceability, and our owned and future in-licensed patents may be challenged in the courts or patent offices in the United States and abroad. For example, we may become involved in opposition, interference, derivation, <i style="font-style:italic;">inter partes </i>review or other proceedings challenging our patent rights, and the outcome of any proceedings are highly uncertain. Such challenges may result in the patent claims of our owned or any future in-licensed patents being narrowed, invalidated or held unenforceable, which could limit our ability to stop or prevent us from stopping others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. Moreover, some of our patents and patent applications are, and may in the future be, co-owned with third parties. If we are unable to obtain an exclusive license to any such third-party co-owners&#8217; interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">competing products and technology. In addition, we or our future licensors may need the cooperation of any such co-owners of our owned and in-licensed patents in order to enforce such patents against third parties, and such cooperation may not be provided to us or our future licensors. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20&#160;years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our products are obtained, once the patent life has expired for a product, we may be open to competition. Given the amount of time required for the development, testing and regulatory review of new products, patents protecting such products might expire before or shortly after such products are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours for a meaningful amount of time, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to the protection afforded by patents, we seek to rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable, processes for which patents are difficult to enforce and any other elements of our product discovery and development processes that involve proprietary know-how, information, or technology that is not covered by our patents. Elements of our products, including processes for their preparation and manufacture, may involve proprietary know-how, information, or technology that is not covered by patents, and thus for these aspects we may consider trade secrets and know-how to be our primary intellectual property. Any disclosure, either intentional or unintentional, by our employees or third-party consultants and vendors that we engage to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in our market. Because we expect to rely on third parties in the development and manufacture of our products, we must, at times, share trade secrets with them. Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Trade secrets and know-how can be difficult to protect. We require all of our employees to enter into written employment agreements containing provisions of confidentiality and obligations to assign any inventions generated in the course of their employment to us. Further, we enter into non-disclosure and confidentiality agreements with our corporate collaborators, outside scientific collaborators, contract research organizations, contract manufacturers, consultants, advisors and any other third parties who have access to our proprietary know-how, information, or technology. With our consultants, contractors, and outside scientific collaborators, these agreements typically include invention assignment obligations. We cannot guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or proprietary technology and processes. We cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may need to share our proprietary information, including trade secrets, with future business partners, collaborators, contractors and others located in countries at heightened risk of theft of trade secrets, including through direct intrusion by private parties or foreign actors, and those affiliated with or controlled by state actors. Further, if any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third-party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third-party, our competitive position would be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In addition, we take other appropriate precautions, such as physical and technological security measures, to guard against misappropriation of our proprietary technology by third parties. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. We have also </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">adopted policies and conduct training that provides guidance on our expectations, and our advice for best practices, in protecting our trade secrets. Despite these undertakings, we may not be able to effectively protect our trade secrets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The intellectual property landscape around our radiopharmaceutical product candidates is crowded, rapidly evolving and interdisciplinary, and it is difficult to conclusively assess our freedom to operate without infringing on third-party rights. We may analyze patents or patent applications of our competitors that we believe are relevant to our activities, and consider that we are free to operate in relation to our product candidates, but our competitors may obtain issued claims, including in patents we consider to be unrelated to our products or activities, which block our efforts or may potentially result in our product candidates or our activities infringing such claims. We cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect. For example, we may incorrectly determine that our products are not covered by a third-party patent or may incorrectly predict whether a third-party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain. Defending against such law suits will be costly and time consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our commercial success depends in part on our ability to avoid infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation involving the infringement of patents and other intellectual property rights in the biotechnology and pharmaceutical industries. We may be exposed to, or threatened with, future litigation by third parties having patent or other intellectual property rights and who allege that our product candidates, uses and/or other proprietary technologies infringe their intellectual property rights. Numerous United States and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk that our product candidates may give rise to claims of infringement of the patent rights of others increases. Moreover, it is not always clear to industry participants, including us, which patents exist which may be found to cover various types of products or their methods of use or manufacture. Thus, because of the large number of patents issued and patent applications currently pending in our fields, there may be a risk that third parties may allege they have patent rights which are infringed by our product candidates, technologies or methods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If a third party alleges that we infringe its intellectual property rights, we may face a number of issues, including, but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">infringement and other intellectual property misappropriation which, regardless of merit, may be expensive and time-consuming to litigate and may divert our management&#8217;s attention from our core business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial damages for infringement or misappropriation, which we may have to pay if a court decides that the product candidate or technology at issue infringes on or violates the third-party&#8217;s rights, and, if </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the court finds we have willfully infringed intellectual property rights, we could be ordered to pay treble damages and the patent owner&#8217;s attorneys&#8217; fees;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an injunction prohibiting us from manufacturing, marketing or selling our product candidates, or from using our proprietary technologies, unless the third party agrees to license its patent rights to us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">even if a license is available from a third party, we may have to pay substantial royalties, upfront fees and other amounts, and/or grant cross-licenses to intellectual property rights protecting our products; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be forced to try to redesign our product candidates or processes so they do not infringe </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">third-party intellectual property rights, an undertaking which may not be possible or which may require substantial monetary expenditures and time.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations or could otherwise have a material adverse effect on our business, results of operations, financial condition and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Third parties may assert that we are employing their proprietary technology without authorization. Generally, conducting preclinical and clinical trials or investigations and other development activities in the United States is not considered an act of infringement. If our product candidate is approved by the FDA, a third party may then seek to enforce its patent by filing a patent infringement lawsuit against us. While we may believe that patent claims or other intellectual property rights of a third party would not have a materially adverse effect on the commercialization of our product candidates, we may be incorrect in this belief, or we may not be able to prove it in litigation. In this regard, patents issued in the United States by law enjoy a presumption of validity that can be rebutted only with evidence that is &#8220;clear and convincing,&#8221; a heightened standard of proof. There may be issued third-party patents of which we are currently unaware with claims to compositions, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Patent applications can take many&#160;years to issue. There may be currently pending patent applications which may later result in issued patents that may be infringed by our product candidates. Moreover, we may fail to identify relevant patents or incorrectly conclude that a patent is invalid, not enforceable, exhausted, or not infringed by our activities. If any third-party patents, held now or obtained in the future by a third party, were found by a court of competent jurisdiction to cover the manufacturing process of our product candidates, constructs or molecules used in or formed during the manufacturing process, or any final product or methods use of the product, the holders of any such patents may be able to block our ability to commercialize the product candidate unless we obtained a license under the applicable patents, or until such patents expire or they are finally determined to be held invalid or unenforceable. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover any aspect of our formulations, any combination therapies or patient selection methods, the holders of any such patent may be able to block our ability to develop and commercialize the product candidate unless we obtained a license or until such patent expires or is finally determined to be held invalid or unenforceable. In either case, such a license may not be available on commercially reasonable terms or at all. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, or at all, our ability to commercialize our product candidates may be impaired or delayed, which could in turn significantly harm our business. Even if we obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize our current or future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Parties making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates. Defense of these claims, regardless of their merit, could involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need or may choose to obtain licenses from third parties to advance our research or allow commercialization of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize our product candidates, which could harm our business significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not be successful in obtaining or maintaining necessary rights through acquisitions and in-licenses to product components and processes that may be required to complete development of and commercialize our Alpha DaRT Technology.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Presently we own various patents and patent applications related to our Alpha DaRT technology and we are not a party to any license agreements with third parties that enable us to utilize third-party technology. Because our Alpha DaRT technology, including the use in connection with other therapies, may require the use of proprietary rights held by third parties in the future, the growth of our business will likely depend in part on our ability to acquire, in-license or use such third-party proprietary rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The licensing and acquisition of third-party intellectual property rights is a competitive practice, and companies that may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive for commercializing our product candidates. More established companies may have </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">a competitive advantage over us due to their larger size and cash resources or greater clinical development and commercialization capabilities. There can be no assurance that we will be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to acquire. We may be unable to acquire or in-license methods of use, processes or other intellectual property rights from third parties that we identify as necessary or important to our business operations. If we fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all, it would harm our business. We may need to cease use of the compositions or methods covered by such third-party intellectual property rights, and/or may need to seek to develop alternative approaches that do not infringe on such intellectual property rights which may entail additional costs and development delays, even if it is possible and we were able to develop such alternatives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies that we have licensed. In that event, we may be required to expend significant time and resources to develop or license replacement technologies. Moreover, we may need to rely on our future licensors to obtain, maintain and enforce patent rights for the licensed intellectual property; however, they may not successfully prosecute, maintain or enforce such licensed intellectual property. We may have limited control over the manner in which our future licensors initiate an infringement proceeding against a third-party infringer of the intellectual property rights, or defend certain of the intellectual property that is licensed to us. It is possible that the future licensors&#8217; infringement proceeding or defense activities may be less vigorous than had we conducted them ourselves. Further, our future licensors may retain certain rights under their agreements with us, including the right to use the underlying technology for noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. It would be difficult to monitor whether our future licensors limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to our licensed technology in the event of misuse. Also, the United States federal government retains certain rights in inventions produced with its financial assistance under the Patent and Trademark Law Amendments Act, or the Bayh-Dole Act. The federal government retains a &#8220;nonexclusive, nontransferable, irrevocable, paid-up license&#8221; for its own benefit. The Bayh-Dole Act also provides federal agencies with &#8220;march-in rights.&#8221; March-in rights allow the government, in specified circumstances, to require the contractor or successors in title to the patent to grant a &#8220;nonexclusive, partially exclusive, or exclusive license&#8221; to a &#8220;responsible applicant or applicants.&#8221; If the patent owner refuses to do so, the government may grant the license itself. We sometimes collaborate with academic institutions to accelerate our preclinical research or development. While it is generally our policy to avoid engaging our university partners in projects in which there is a risk that federal funds may be commingled, we cannot be sure that any co-developed intellectual property will be free from government rights pursuant to the Bayh-Dole Act. If, in the future, we co-own or license in technology which is critical to our business that is developed in whole or in part with federal funds subject to the Bayh-Dole Act, our ability to enforce or otherwise exploit patents covering such technology may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, we have and may continue to collaborate with academic institutions to accelerate our preclinical research or development under written agreements with these institutions. In certain cases, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to others, potentially blocking our ability to pursue our program. If we are unable to successfully obtain rights to required third-party intellectual property or to maintain the existing intellectual property rights we have, we may have to abandon development of such program and our business and financial condition could suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Further, our future intellectual property license agreements may impose on us various development, regulatory and/or commercial diligence obligations, payment of milestones, royalties or other amounts and other obligations. If we fail to comply with our obligations under these agreements (including as a result of COVID-19 impacting our operations), we use the licensed intellectual property in an unauthorized manner or we are subject to bankruptcy-related proceedings, the terms of the licenses may be materially modified, such as by rendering currently exclusive licenses non-exclusive, or it may give our future licensors the right to terminate their respective agreement with us, which could limit our ability to implement our current business plan and materially adversely affect our business, financial condition, results of operations and prospects. In addition, disputes may arise between us and our future licensors regarding intellectual property subject to a license agreement, including: (i)&#160;the scope of rights granted under the license agreement and other interpretation-related issues; <span style="color:#231f20;">(ii)&#160;whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the license agreement; (iii)&#160;our right to sublicense patents and other rights to third parties; (iv)&#160;our diligence obligations with respect to the use of the licensed technology in relation to our development </span>and commercialization of our product candidates, and what activities satisfy those diligence obligations; (v)&#160;our right to transfer or assign the license; and (vi)&#160;the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our future licensors and us and our partners. If disputes over intellectual property that we license in the future prevent or impair our ability </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">to maintain our licensing arrangements on acceptable terms, we may not be able to successfully develop and commercialize the affected product candidates, which would have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, certain of our future agreements with third parties may limit or delay our ability to consummate certain transactions, may impact the value of those transactions, or may limit our ability to pursue certain activities. For example, we may in the future enter into license agreements that are not assignable or transferable, or that require the licensor&#8217;s express consent in order for an assignment or transfer to take place.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be involved in lawsuits or litigation to protect or enforce our patents or other intellectual property, which could result in substantial costs and liability and prevent us from commercializing our potential products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Competitors may infringe our patents, trademarks or other intellectual property. To counter infringement or unauthorized use, we may be required to take legal action to enforce our patents against such infringing activity. Such enforcement proceedings against infringers can be expensive and time-consuming. Any such claims could provoke these parties to assert counterclaims against us, including claims alleging that we infringe their patents or other intellectual property rights. In addition, in an infringement proceeding, a court may decide that one or more of our patents is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In such a case, we could ultimately be forced to cease use of such marks. In any intellectual property litigation, even if we are successful, any award of monetary damages or other remedy we receive may not be commercially valuable. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable, or interpreted narrowly and could put our patent applications at risk of not issuing. Defense against these assertions, non-infringement, invalidity or unenforceability regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may be required to protect our patents through procedures created to attack the validity of a patent at the USPTO. The USPTO hears post-grant proceedings, including post-grant review, <i style="font-style:italic;">inter partes </i>review and derivation proceedings. Post-grant proceedings may be provoked by third parties or brought by the USPTO to determine the validity or priority of inventions with respect to our patents or patent applications. An adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. An unfavorable outcome could result in a loss of our current patent rights and could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if resolved in our favor, litigation or other legal proceedings relating to our intellectual property rights may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In addition, if our product candidates are found to infringe the intellectual property rights of third parties, these third parties may assert infringement claims against our licensees and other parties with whom we have business relationships, and we may be required </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">to indemnify those parties for any damages they suffer as a result of these claims. The claims may require us to initiate or defend protracted and costly litigation on behalf of licensees and other parties regardless of the merits of these claims. If any of these claims succeed, we may be forced to pay damages on behalf of those parties or may be required to obtain licenses for the products they use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18.35pt;margin:0pt 0pt 12pt 0pt;">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and foreign countries may require the payment of maintenance fees or patent annuities during the lifetime of a patent application and/or any subsequent patent that issues from the application. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process and following the issuance of a patent. While an inadvertent lapse, including due to the effect of the COVID-19 pandemic on us or our patent maintenance vendors, can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application. Such noncompliance can result in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. Such an event could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Any issued patents we own covering our product candidates could be narrowed or found invalid or unenforceable if challenged in court or before the administrative bodies in the United States or abroad, including the USPTO.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18.35pt;margin:0pt 0pt 12pt 0pt;">Any of our intellectual property rights could be challenged or invalidated despite measures we take to obtain patent and other intellectual property protection with respect to our product candidates and proprietary technology. For example, if we initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate, as applicable, is invalid and/or unenforceable. In patent litigation in the United States and in some other jurisdictions, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld material information from the USPTO or the applicable foreign counterpart, or made a misleading statement, during prosecution. A litigant or the USPTO itself could challenge our patents on this basis even if we believe that we have conducted our patent prosecution in accordance with the duty of candor and in good faith. The outcome following such a challenge is unpredictable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18.35pt;margin:0pt 0pt 12pt 0pt;">Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, <i style="font-style:italic;">inter partes </i>review, post-grant review and equivalent proceedings in foreign jurisdictions (such as opposition proceedings). Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18.35pt;margin:0pt 0pt 12pt 0pt;">The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, or if we are otherwise unable to adequately protect our rights, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection could have a material adverse impact on our business and our ability to commercialize or license our technology and product candidates. Even if a defendant does not prevail on a legal assertion of invalidity and/or unenforceability, our patent claims may be construed in a manner that would limit our ability to enforce such claims against the defendant and others. The cost of defending such a challenge, particularly in a foreign jurisdiction, and any resulting loss of patent protection could have a material adverse impact on one or more of our product candidates and our business. Any efforts to enforce our intellectual property rights are also likely to be costly and may divert the efforts of our scientific and management personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes to patent law in the United States and in foreign jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18.15pt;margin:0pt;">Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs, and may diminish our ability to protect our inventions, obtain, maintain, and enforce our intellectual property rights and, more </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">generally, could affect the value of our intellectual property or narrow the scope of our owned and licensed patents. Patent reform legislation in the United States and other countries, including the Leahy-Smith America Invents Act (the Leahy-Smith Act), signed into law on September&#160;16, 2011, could increase those uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and cost-effective avenues for competitors to challenge the validity of patents. These include allowing third- party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, <i style="font-style:italic;">inter partes </i>review, and derivation proceedings. Further, because of a lower evidentiary standard in these USPTO post-grant proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Thus, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18.15pt;margin:0pt 0pt 12pt 0pt;">After March&#160;2013, under the Leahy-Smith Act, the United States transitioned to a first inventor to file system in which, assuming that the other statutory requirements are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third-party was the first to invent the claimed invention. A third party that files a patent application in the USPTO after March&#160;2013, but before we file an application covering the same invention, could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we were the first to either (i)&#160;file any patent application related to our product candidates and other proprietary technologies we may develop or (ii)&#160;invent any of the inventions claimed in our or our licensor&#8217;s patents or patent applications. Even where we have a valid and enforceable patent, we may not be able to exclude others from practicing the claimed invention where the other party can show that they used the invention in commerce before our filing date or the other party benefits from a compulsory license. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18.15pt;margin:0pt 0pt 12pt 0pt;">Moreover, recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. We cannot predict how future decisions by the courts, Congress or the USPTO may impact the value of our patents. Changes in the laws and regulations governing patents in other jurisdictions could similarly have an adverse effect on our ability to obtain and effectively enforce our patent rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not be able to protect our intellectual property rights throughout the world, and different jurisdictions may grant patent rights of differing scope.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18.35pt;margin:0pt;">Certain of our key patent families have been filed in the United States; however, we have less robust intellectual property rights outside the United States, and, in particular, we may not be able to pursue patent coverage of our product candidates in certain countries outside of the United States. Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States may be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to certain territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. Most of our </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">patent portfolio is at the very early stage. We will need to decide whether and in which jurisdictions to pursue protection for the various inventions in our portfolio prior to applicable deadlines. We may decide to abandon national and regional patent applications before they are granted. The examination of each national or regional patent application is an independent proceeding. As a result, patent applications in the same family may issue as patents in some jurisdictions, such as in the United States, but may issue as patents with claims of different scope or may be refused in other jurisdictions. It is also quite common that depending on the country, the scope of patent protection may vary for the same product or technology. For example, certain jurisdictions do not allow for patent protection with respect to method of treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18.35pt;margin:0pt 0pt 12pt 0pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protections, particularly those relating to biopharmaceutical products. This difficulty with enforcing patents could make it difficult for us to stop the infringement of our patents or marketing of competing products otherwise generally in violation of our proprietary rights. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, put our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18.35pt;margin:0pt 0pt 12pt 0pt;">Further, many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of its patents. If we are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position in the relevant jurisdiction may be impaired and our business prospects may be materially adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may be subject to claims that former employees, collaborators or other third parties have an interest in our patents or other intellectual property as an inventor or co-inventor. The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing our product candidates or as a result of questions regarding co-ownership of potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our future licensors may have relied on third-party consultants or collaborators or on funds from third parties, such as the U.S. government, such that our future licensors are not the sole and exclusive owners of the patents we in-licensed. If other third parties have ownership rights or other rights to our future in-licensed patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">While it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations, and prospects.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information or alleged trade secrets of third parties or competitors or are in breach of non-competition or non-solicitation agreements with our competitors or their former employers.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have received confidential and proprietary information from third parties. In addition, as is common in the biotechnology, medical device and pharmaceutical industries, we employ individuals and engage the services of consultants who were previously employed or engaged at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although no claims against us are currently pending, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of these third parties or our employees&#8217; former employers or our consultants&#8217; or contractors&#8217; current or former clients or customers. In addition, we may in the future be subject to claims that we caused an employee to breach the terms of his or her non-competition or non-solicitation agreement. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees. If we are not successful, in addition to paying monetary damages, we could lose access or exclusive access to valuable intellectual property rights or lose valuable personnel. Any litigation or the threat thereof may adversely affect our ability to hire employees. A loss of key personnel or their work product could hamper or prevent our ability to commercialize product candidates, which could have an adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our marks of interest and our business may be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We use and will continue to use registered and/or unregistered trademarks or trade names to brand and market ourselves and our products. Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We rely on both registration and common law protection for our trademarks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. During the trademark registration process, we may receive office actions from the USPTO objecting to the registration of our trademark. Although we would be given an opportunity to respond to those objections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and/or to seek the cancellation of registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. Additionally, we may license our trademarks and trade names to third parties, such as distributors. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, any name we have proposed to use with our product candidate in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. Similar requirements exist in Europe. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA (or an equivalent administrative body in a foreign jurisdiction) objects to any of our proposed proprietary product names, it may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA (or the relevant administrative body in a foreign jurisdiction). Furthermore, in many countries, owning and maintaining a trademark registration may not provide an adequate defense against a subsequent infringement claim asserted by the owner of a senior trademark.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Numerous factors may limit any potential competitive advantage provided by our intellectual property rights.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The degree of future protection afforded by our intellectual property rights, whether owned or in-licensed, is uncertain because intellectual property rights have limitations, and may not adequately protect our business, provide a barrier to entry against our competitors or potential competitors, or permit us to maintain our competitive advantage. Moreover, if a third party has intellectual property rights that cover the practice of our technology, we may not be able to fully exercise or extract value from our intellectual property rights. The following examples are illustrative:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pending patent applications that we own or license in the future may not lead to issued patents;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patents, should they issue, that we own or license in the future, may not provide us with any competitive advantages, or may be challenged and held invalid or unenforceable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may be able to develop and/or practice technology that is similar to our technology or aspects of our technology but that is not covered by the claims of any of our owned or future in-licensed patents, should any such patents issue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">third parties may compete with us in jurisdictions where we do not pursue and obtain patent protection;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we (or our future licensors) might not have been the first to make the inventions covered by a pending patent application that we own or license in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we (or our future licensors) might not have been the first to file patent applications covering a particular invention;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may independently develop similar or alternative technologies without infringing our intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not be able to obtain and/or maintain necessary licenses on reasonable terms or at all;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">third parties may assert an ownership interest in our intellectual property and, if successful, such disputes may preclude us from exercising exclusive rights, or any rights at all, over that intellectual property;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not be able to maintain the confidentiality of our trade secrets or other proprietary information;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not develop or in-license additional proprietary technologies that are patentable; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patents of others may have an adverse effect on our business.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">Should any of these events occur, they could materially harm our business and the results of our operation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Employee Matters and Managing Growth</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our ability to compete in the highly competitive biotechnology, medical device and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, scientific and medical personnel, including Uzi Sofer, our Chief Executive Officer. The loss of the services of any of our executive officers, other key employees and other scientific and medical advisors, and an inability to find suitable replacements, could result in delays in product development and harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We conduct the majority of our operations at our facility in Israel. The region is headquarters to many other biopharmaceutical and medical device companies and many academic and research institutions. Competition for skilled personnel in our market is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all. Changes to Israeli or similar immigration and work authorization laws and regulations, including those that restrain the flow of scientific and professional talent, can be significantly affected by political forces and levels of economic activity. Our business may be materially adversely affected if legislative or administrative changes to Israeli or similar foreign immigration or visa laws and regulations, including as a result of the restrictions on international travel due to the global COVID-19 pandemic, impair our hiring processes and goals or projects involving personnel who are not Israeli citizens.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">To encourage valuable employees to remain at our company, in addition to salary and cash incentives, we have provided stock options that vest over time. The value to employees of stock options that vest over time may be significantly affected by movements in our share price that are beyond our control, and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on short notice. Although we have employment agreements with our key employees, these employment agreements provide for at-will employment, which means that any of our employees could leave our employment at any </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">time, with or without notice. Our success also depends on our ability to continue to attract, retain and motivate highly skilled junior, mid-level and senior managers as well as junior, mid-level and senior scientific and medical personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We will need to grow the size of our organization, and we may experience difficulties in managing this growth.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As our development and commercialization plans and strategies develop, and as we transition into operating as a public company, we expect to need additional managerial, operational, sales, marketing, financial and other personnel, as well as additional facilities to expand our operations. Future growth would impose significant added responsibilities on members of management, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">identifying, recruiting, integrating, maintaining and motivating additional employees;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">managing our internal development efforts effectively, including the clinical and FDA review process for our product candidate and the manufacturing infrastructure required to produce our product candidate, while complying with our contractual obligations to contractors and other third parties; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">improving our operational, financial and management controls, reporting systems and procedures.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our future financial performance and our ability to commercialize our product candidates will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services, including certain aspects of regulatory approval, clinical trial management and construction of manufacturing facilities. There can be no assurance that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval or certification of our Alpha DaRT technology or other future products or product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all. If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, or we are not able to effectively build out new facilities to accommodate this expansion, we may not be able to successfully implement the tasks necessary to further develop and commercialize our product candidates and, accordingly, may not achieve our research, development and commercialization goals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Expectations relating to environmental, social and governance (ESG) programs may impose additional costs and expose us to new risks.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There is an increasing focus from certain investors, clients and other key stakeholders concerning corporate responsibility, specifically related to environmental, social and governance, or ESG, factors. As a result, there is an increased emphasis on corporate responsibility ratings and a number of third parties provide reports on companies in order to measure and assess corporate responsibility performance. In addition, the ESG factors by which companies&#8217; corporate responsibility practices are assessed may change, which could result in greater expectations of us and cause us to undertake costly initiatives to satisfy such new criteria. Alternatively, if we are unable to satisfy such new criteria, investors may conclude that our policies with respect to corporate responsibility are inadequate. We risk damage to our brand and reputation if our corporate responsibility procedures or standards do not meet the standards set by various constituencies. We may be required to make investments in matters related to ESG, which could be significant and adversely impact our results of operations. Furthermore, if our competitors&#8217; corporate responsibility performance is perceived to be greater than ours, potential or current investors may elect to invest with our competitors instead. In addition, if we communicate certain initiatives and goals regarding ESG matters, we could fail, or be perceived to fail, in our achievement of such initiatives or goals, or we could be criticized for the scope of such initiatives or goals. If we fail to satisfy the expectations of investors and other key stakeholders or our initiatives are not executed as planned, our reputation and financial results could be materially and adversely affected.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may explore strategic collaborations that may never materialize or we may be required to relinquish important rights to and control over the development and commercialization of our product candidates to any future collaborators.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our business strategy includes broadening our platform by potentially exploring strategic partnerships that maximize the potential of our Alpha DaRT technology. As a result, we intend to periodically explore a variety of possible strategic partnerships in an effort to gain access to additional resources, indications or combination therapy opportunities, or development of supportive or complementary products. These strategic partnerships may include partnerships with large strategic partners. At the current time however, we cannot predict what form such a strategic collaboration might take. We are likely to face significant competition in seeking appropriate strategic collaborators, and strategic collaborations can be complicated and time consuming to negotiate and document. We may not be able to negotiate strategic collaborations on acceptable terms, if at all. If and when we collaborate with a third party for development and commercialization of a product candidate, we can expect to relinquish some or all of the control over the future success of our Alpha DaRT technology to the third party. We are unable to predict when, if ever, we will enter into any strategic partnerships because of the numerous risks and uncertainties associated with establishing them, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenditure of substantial operational, financial and management resources;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">dilutive issuances of our securities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial actual or contingent liabilities; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">termination or expiration of the arrangement, which would delay the development and may increase the cost of developing our Alpha DaRT technology.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Strategic partners may also delay clinical trials, experience financial difficulties, provide insufficient funding, terminate a clinical trial or abandon an indication or combination therapy, which could negatively impact our development efforts. Additionally, strategic partners may not properly maintain, enforce or defend our intellectual property rights or may use our proprietary information in a manner that could jeopardize or invalidate our proprietary information or expose us to potential litigation, any of which could adversely affect our business, financial position and operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our information technology systems, or those of any of our existing or potential future collaborators, trial sites, CROs or other contractors or consultants, may fail or suffer system failures and security breaches, which could result in a material disruption of our product development programs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We collect and maintain information in digital form that is necessary to conduct our business, and we are increasingly dependent on information technology systems and infrastructure to operate our business. In the ordinary course of our business, we collect, store and transmit large amounts of confidential information, including intellectual property, proprietary business information and personal information of our customers, employees and other related third parties. It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such confidential information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Despite the implementation of security measures, our information technology systems and those of our current and any future trial sites, CROs and other contractors, consultants and collaborators are vulnerable to damage from cyberattacks, &#8220;phishing&#8221; attacks and other social engineering schemes, hacking, computer viruses and malware (e.g. ransomware), unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures, employee theft or misuse, human error, fraud, denial or degradation of service attacks, sophisticated nation-state and nation-state-supported actors, or unauthorized access or use by persons inside our organization, or persons with access to systems inside our organization. Attacks upon information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. As a result of the COVID-19 pandemic, we may also face increased cybersecurity risks due to our reliance on internet technology and the number of our employees and collaborators who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. Even if identified, we may be unable to adequately investigate or remediate incidents or breaches due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We and certain of our service providers are from time to time subject to cyberattacks and security incidents. While we do not believe that we have experienced any significant system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs, whether due to a loss of our trade secrets or other similar disruptions. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our efforts to obtain marketing authorization or certification and significantly increase our costs to recover or reproduce the data. In addition, such a breach may require notification to governmental agencies, the media or individuals pursuant to applicable data privacy and security law and regulations. We would also be exposed to a risk of loss, including financial assets or litigation and potential liability, which could materially adversely affect our business, financial condition, results of operations and prospects. We also rely on third parties to manufacture our product candidates, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our product candidates could be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If our security measures are breached or unauthorized access to individually identifiable health information or other personally identifiable information is otherwise obtained, our reputation may be harmed, and we may incur significant liabilities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unauthorized access to, or security breaches of, our systems and databases could result in unauthorized access to data and information and loss, compromise or corruption of such data and information. Present and future trial sites, CROs, contractors and consultants also could experience breaches of security leading to the exposure of confidential and sensitive information. Such breaches of security could be caused by computer hacking, phishing attacks, ransomware, dissemination of computer viruses, worms and other destructive or disruptive software, denial of service attacks, and other malicious activity, which may be heretofore unknown. The number and complexity of these threats continue to increase over time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Most healthcare providers, including research institutions from which we obtain patient health information, are subject to privacy and security regulations promulgated under HIPAA, as amended by the HITECH. We are not currently classified as a covered entity or business associate under HIPAA and thus are not directly subject to its requirements or penalties. However, any person may be prosecuted under HIPAA&#8217;s criminal provisions either directly or under aiding-and-abetting or conspiracy principles. Consequently, depending on the facts and circumstances, we could face substantial criminal penalties if we knowingly receive individually identifiable health information from a HIPAA-covered healthcare provider or research institution that has not satisfied HIPAA&#8217;s requirements for disclosure of individually identifiable health information. In addition, we may in the future maintain sensitive personally identifiable information, including health information, that we receive throughout the clinical trial process, in the course of our research collaborations, and directly from individuals (or their healthcare providers) who enroll in our patient assistance programs. As such, we may be subject to state laws requiring notification of affected individuals and state regulators in the event of a breach of personal information, which is a broader class of information than the health information protected by HIPAA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Furthermore, certain health privacy laws, data breach notification laws, consumer protection laws and genetic testing laws may apply directly to our operations and/or those of our collaborators and may impose restrictions on our collection, use and dissemination of individuals&#8217; health information. Patients about whom we or our collaborators obtain health information, as well as the providers who share this information with us, may have statutory or contractual rights that limit our ability to use and disclose the information. We may be required to expend significant capital and other resources to ensure ongoing compliance with applicable privacy and data security laws. Claims that we have violated individuals&#8217; privacy rights or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event of a security breach, our company could suffer loss of business, severe reputational damage adversely affecting investor confidence, regulatory investigations and orders, litigation, indemnity obligations, damages for contract breach, penalties for violation of applicable laws or regulations, significant costs for remediation and other liabilities. For example, the loss of preclinical study or clinical trial data from completed or future preclinical studies or clinical trials could result in delays in our efforts to obtain marketing authorization or certification and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our product candidates could be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We have incurred and expect to incur significant expenses to prevent security breaches, including costs related to deploying additional personnel and protection technologies, training employees, and engaging third- party solution providers and consultants. Although we expend significant resources to create security protections that shield our data against potential theft and security </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">breaches, such measures cannot provide absolute security. Moreover, given that we have outsourced our information systems to vendors and rely on cloud-based information systems, we face related security risks which require us to expend resources to protect our technology and information systems.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our operations, and those of our CROs, CMOs and other contractors and consultants, could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or man-made disasters or business interruptions, for which we are predominantly self-insured. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. Our ability to obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers are affected by a man-made or natural disaster or other business interruption.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are an international business, and we are exposed to various global risks that could have a material adverse effect on our financial condition and results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As an international business, which operates in multiple jurisdictions, we are exposed to trends and financial risks of international markets, and are also required to comply with varying legal and regulatory requirements in such multiple jurisdictions. Profitability from international operations may be limited by risks and uncertainties related to regional and global economic conditions, regulatory clearances, approvals or certifications and reimbursement approvals, and our ability to implement our overall business strategy in various jurisdictions. We expect these risks will increase as we pursue our strategy to expand operations into new geographic markets. We may not succeed in developing and implementing effective policies and strategies in each location where we conduct business. Any failure to do so may harm our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">International sales and operations are subject to a variety of risks, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">foreign currency exchange rate fluctuations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential adverse changes in laws and regulatory practices, including export license requirements, trade barriers, tariffs and tax laws;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">burdens and costs of compliance with a variety of foreign laws;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">foreign tax laws and potential increased costs associated with overlapping tax structures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">greater difficulty in staffing and managing foreign operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">greater risk of uncollectible accounts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">longer collection cycles;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">logistical and communications challenges;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in labor conditions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">political and economic instability, including, without limitation, due to natural disasters or other catastrophic events, such as the Russian invasion of Ukraine and world sanctions on Russia, Belarus, and related parties, terrorist attacks, pandemic diseases, such as the ongoing COVID-19 pandemic, hurricanes, fire, floods, pollution and earthquakes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">greater difficulty in protecting intellectual property;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the risk of third-party disputes over ownership of intellectual property and infringement of third-party intellectual property by Our Products; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">general economic and political conditions in these foreign markets.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">International markets are also affected by economic pressure to contain reimbursement levels and healthcare costs. Profitability from international operations may be limited by risks and uncertainties related to regional economic conditions, regulatory clearances and approvals and reimbursement approvals, competing products, infrastructure development, intellectual property rights protection and our ability to implement our overall business strategy. We expect these risks will increase as we pursue our strategy to expand operations into new geographic markets. We may not succeed in developing and implementing effective policies and strategies in each location where we conduct business. Any failure to do so may harm our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, as a result of escalating tensions and the subsequent invasion of Ukraine by Russia, the United States and other countries have imposed sanctions on Russia, including its major financial institutions and certain other businesses and individuals. Russia may respond in kind, and the continuation of the conflict may result in additional sanctions being enacted by the United States, other North Atlantic Treaty Organization member states, or other countries. We cannot predict the impact of Russian activities in Ukraine and any heightened military conflict or geopolitical instability that may follow, including heightened operating risks and production disruptions in Russia and Europe, additional sanctions or counter-sanctions, heightened inflation, cyber disruptions or attacks, higher energy costs, higher manufacturing costs, disruptions in raw materials supplies, increased raw material costs and higher supply chain costs. Although we do not presently foresee direct material adverse effects upon our business, financial condition, or results of operations as a result of developments in&#160;Ukraine&#160;and the consequent controls and sanctions, these factors may affect companies in many sectors and could lead to increased market volatility and uncertainty, which could affect us in turn.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We face an inherent risk of product liability as a result of the planned clinical testing of our product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if our Alpha DaRT technology or any future products or product candidates we develop, cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical trials, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product (which may include inherent dangers in the use of radioactive materials), negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decreased demand for our Alpha DaRT technology or any future products or product candidates we develop that we may develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injury to our reputation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of clinical trial participants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiation of investigations by regulators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs to defend the related litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a diversion of management&#8217;s time and our resources;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial monetary awards to trial participants or patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">loss of revenue;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">exhaustion of any available insurance and our capital resources; the inability to commercialize our </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Alpha DaRT technology or any future products or product candidates we develop; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a decline in our share price.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Failure to obtain or retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop, alone or with corporate collaborators. Although we have clinical trial insurance, our insurance policies also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The increasing use of social media platforms presents new risks and challenges.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Social media is increasingly being used to communicate about our clinical development programs for our Alpha DaRT technology and the diseases our technology is being developed to treat, and we intend to utilize appropriate social media in connection with our commercialization efforts following marketing authorization or certification of our Alpha DaRT technology or other future products or product candidates, if any. Social media practices in the medical device, biotechnology and biopharmaceutical industries continue to evolve and regulations and regulatory guidance relating to such use are evolving and not always clear. This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business, resulting in potential regulatory actions against us, along with the potential for litigation related to off-label marketing or other prohibited activities and heightened scrutiny by the FDA, the SEC and other regulators. For example, patients may use social media channels to comment on their experience in a future blinded clinical trial or to report an alleged adverse event. If such disclosures occur, there is a risk that trial enrollment may be adversely impacted, that we may fail to monitor and comply with applicable adverse event reporting obligations or that we may not</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">be able to defend our business or the public&#8217;s legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our Alpha DaRT technology or other future products or product candidates. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. In addition, we may encounter attacks on social media regarding our company, management, our Alpha DaRT technology or other future products or product candidates. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face regulatory actions or incur other harm to our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our business could be disrupted by catastrophic events.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Occurrence of any catastrophic event, including a global pandemic like the ongoing COVID-19 pandemic, earthquake, fire, flood, tsunami or other weather event, power loss, telecommunications failure, software or hardware malfunction, cyber-attack, war or terrorist attack, explosion or pandemic could impact our business. Our insurance coverage may not compensate us for losses that may occur in the event of an earthquake or other significant natural disaster. If any disaster were to occur, our ability to operate our business at our facilities could be impaired and we could incur significant losses, require substantial recovery time and experience significant expenditures in order to resume operations. If we are unable to develop adequate plans to ensure that our business functions continue to operate during and after a disaster and to execute successfully on those plans in the event of a disaster or emergency, our business would be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Being a Public Company</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are incurring increased costs as a result of operating as a newly public company, and our management will devote substantial time to new compliance initiatives.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As a newly public company subject to reporting requirements in the United States, we are incurring significant legal, accounting and other expenses that we did not incur as a private company, and these expenses may increase even more after we are no longer an emerging growth company, as defined in Section&#160;2(a)&#160;of the Securities Act. As a public company, we are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, as well as rules&#160;adopted, and to be adopted, by the SEC and Nasdaq. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules&#160;and regulations have substantially increased our legal and financial compliance costs and to make some activities more time-consuming and costly. The increased costs will increase our net loss. For example, we expect these rules&#160;and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be forced to accept reduced policy limits or incur substantially higher costs to maintain the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">A market for our securities may not develop or be sustained, which would adversely affect the liquidity and price of our securities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The price of our securities may fluctuate significantly due to general market and economic conditions. An active trading market for our securities may never develop or, if developed, it may not be sustained. In addition, the price of our securities can vary due to general economic conditions and forecasts, our general business condition and the release of our financial reports. Additionally, if our securities become delisted from Nasdaq and are quoted on the OTC Bulletin Board (an inter-dealer automated quotation system for equity securities that is not a national securities exchange) or the combined company&#8217;s securities are not listed on Nasdaq and are quoted on the OTC Bulletin Board, the liquidity and price of our securities may be more limited than if we were quoted or listed on the NYSE, Nasdaq or another national securities exchange. You may be unable to sell your securities unless a market can be established or sustained.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our internal controls over financial reporting may not be effective and our independent registered public accounting firm may not be able to certify as to their effectiveness, which could have a significant and adverse effect on our business and reputation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are subject to the reporting requirements of the Securities Act, the Exchange Act, the Sarbanes-Oxley Act and the rules&#160;and regulations of Nasdaq. We expect that the requirements of these rules&#160;and regulations will continue to increase our legal, accounting and financial compliance costs, make some activities more difficult, time-consuming and costly, and place significant strain on our personnel, systems and resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The applicable provisions of the Sarbanes-Oxley Act require, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. We are continuing to develop and refine our disclosure controls, internal control over financial reporting and other procedures that are designed to ensure that information required to be disclosed by us in the reports that we will file with the SEC is recorded, processed, summarized and reported within the time periods specified in SEC rules&#160;and forms, and that information required to be disclosed in reports under the Exchange Act is accumulated and communicated to our principal executive and financial officers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our current controls and any new controls that we develop may become inadequate because of changes in conditions of our business. Further, weaknesses in our internal controls may be discovered in the future. Any failure to develop or maintain effective controls, or any difficulties encountered in their implementation or improvement, could adversely affect our operating results or cause us to fail to meet reporting obligations and may result in a restatement of our financial statements for prior periods. Any failure to implement and maintain effective internal controls also could adversely affect the results of periodic management evaluations and annual independent registered public accounting firm attestation reports regarding the effectiveness of our internal control over financial reporting that is required to include in the periodic reports we will file with the SEC under Section&#160;404 of the Sarbanes-Oxley Act. Ineffective disclosure controls and procedures and internal control over financial reporting could also cause investors to lose confidence in our reported financial and other information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In order to maintain and improve the effectiveness of our disclosure controls and procedures and internal control over financial reporting, we have expended and anticipate that we will continue to expend significant resources, including accounting-related costs, and provide significant management oversight. Any failure to maintain the adequacy of our internal controls, or consequent inability to produce accurate financial statements on a timely basis, could increase our operating costs and could materially and adversely affect our ability to operate our business. In the event that our internal controls are perceived as inadequate or that we are unable to produce timely or accurate financial statements, investors may lose confidence in our operating results and the share price of the combined company could decline. In addition, if we are unable to continue to meet these requirements, we may not be able to maintain listing on Nasdaq.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our independent registered public accounting firm is not required to formally attest to the effectiveness of its internal control over financial reporting until after we are no longer an emerging growth company. At such time, our independent registered public accounting firm may issue a report that is adverse in the event it is not satisfied with the level at which our controls are documented, designed or operating. Any failure to maintain effective disclosure controls and internal control over financial reporting could have a material and adverse effect on our business and operating results.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Ownership of Our Ordinary Shares</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our Articles and Israeli law could prevent a takeover that shareholders consider favorable and could also reduce the market price of our ordinary shares.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Certain provisions of Israeli law and our Articles could have the effect of delaying or preventing a change in control and may make it more difficult for a third party to acquire us or for our shareholders to elect different individuals to its board of directors, even if doing so would be beneficial to its shareholders, and may limit the price that investors may be willing to pay in the future for the our ordinary shares. Among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Israeli corporate law regulates mergers and requires that a tender offer be effected when more than a specified&#160;percentage of shares in a company are purchased;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Israeli corporate law requires special approvals for certain transactions involving directors, officers or significant shareholders and regulates other matters that may be relevant to these types of transactions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Israeli corporate law does not provide for shareholder action by written consent for public companies, thereby requiring all shareholder actions to be taken at a general meeting of shareholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our Articles divide our directors into three classes, each of which is elected once every three&#160;years;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our Articles generally require a vote of the holders of a majority of our outstanding ordinary shares entitled to vote present and voting on the matter at a general meeting of shareholders (referred to as simple majority), and the amendment of a limited number of provisions, such as the provision empowering our board of directors to determine the size of the board, the provision dividing our directors into three classes, the provision that sets forth the procedures and the requirements that must be met in order for a shareholder to require the Company to include a matter on the agenda for a general meeting of the shareholders and the provisions relating to the election and removal of members of our board of directors and empowering our board of directors to fill vacancies on the board, require a vote of the holders of 65% of our outstanding ordinary shares entitled to vote at a general meeting;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our Articles do not permit a director to be removed except by a vote of the holders of at least </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">65% of our outstanding shares entitled to vote at a general meeting of shareholders; and</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our Articles provide that director vacancies may be filled by our board of directors.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Furthermore, under the Encouragement of Research, Development and Technological Innovation in the Industry Law 5744-1984 (formerly known as the Law for the Encouragement of Research and Development in Industry 5744-1984), and the regulations and guidelines promulgated thereunder, or the Innovation Law, to which we are subject due to our receipt of grants from the Israel Innovation Authority, or IIA (formerly known as the Office of the Chief Scientist of the Ministry of Economy and Industry, or the OCS), a recipient of IIA grants such as us must report to the IIA regarding any change of control of the company or regarding any change in the holding of the means of control of the company which results in any non-Israeli citizen or entity becoming an &#8220;interested party&#8221;, as defined in the Innovation Law, in the company, and in the latter event, the non-Israeli citizen or entity will be required to execute an undertaking in favor of IIA, in a form prescribed by IIA, acknowledging the restrictions imposed by such law and agreeing to abide by its terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, Israeli tax considerations may make potential transactions undesirable to us or to some of our shareholders whose country of residence does not have a tax treaty with Israel granting tax relief to such shareholders from Israeli tax. See the section titled &#8220;<i style="font-style:italic;">Certain Material Israeli Tax Considerations&#8212;Taxation of Our shareholders</i>.&#8221;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We do not intend to pay dividends for the foreseeable future. Accordingly, you may not receive any return on investment unless you sell your ordinary shares for a price greater than the price you paid for such shares.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have never declared or paid any cash dividends on our shares. We currently intend to retain all available funds and any future earnings for use in the operation of our business and do not anticipate paying any dividends on our ordinary shares in the foreseeable future. Consequently, you may be unable to realize a gain on your investment except by selling such shares after price appreciation, which may never occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our board of directors has sole discretion whether to pay dividends. If our board of directors decides to pay dividends, the form, frequency, and amount will depend upon its future, operations and earnings, capital requirements and surplus, general financial condition, contractual restrictions and other factors that its directors may deem relevant. The Israeli Companies Law, 1999 (the &#8220;Companies Law&#8221;) imposes restrictions on our ability to declare and pay dividends. See the section titled <i style="font-style:italic;">&quot;Dividend and Liquidation Rights&quot;</i> in Exhibit 2.1 to this Annual Report. Payment of dividends may also be subject to Israeli withholding taxes. See the section titled &#8220;<i style="font-style:italic;">Certain Material Israeli Tax Considerations</i>&#8221; for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The market price and trading volume of our ordinary shares may be volatile and could decline significantly.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The stock markets, including Nasdaq on which we have listed our ordinary shares and our warrants under the symbol &#8220;DRTS,&#8221; and &#8220;DRTSW,&#8221; respectively, have from time to time experienced significant price and volume fluctuations. Even if an active, liquid and orderly trading market develops and is sustained for our ordinary shares and our warrants, the market price of our ordinary shares and our warrants may be volatile and could decline significantly. In addition, the trading volume in our ordinary shares and our warrants may fluctuate and cause significant price variations to occur. If the market price of our ordinary shares and our warrants declines significantly, you may be unable to resell your shares or warrants at or above the market price of the ordinary shares  and warrants as of the date immediately following the date of this Annual Report. We cannot assure you that the market price of our ordinary shares and our warrants will not fluctuate widely or decline significantly in the future in response to a number of factors, including, among others, the following:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the realization of any of the risk factors presented in this Annual Report;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additions and departures of key personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to comply with the requirements of Nasdaq;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to comply with the Sarbanes-Oxley Act or other laws or regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">publication of research reports about us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the performance and market valuations of other similar companies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">new laws, regulations, subsidies, or credits or new interpretations of existing laws applicable to us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">commencement of, or involvement in, litigation involving us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">broad disruptions in the financial markets, including sudden disruptions in the credit markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">speculation in the press or investment community;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">actual, potential or perceived control, accounting or reporting problems;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in accounting principles, policies and guidelines; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other events or factors, including those resulting from infectious diseases, health epidemics and pandemics (including the ongoing COVID-19 public health emergency), natural disasters, war, acts of terrorism or responses to these events.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the past, securities class-action litigation has often been instituted against companies following periods of volatility in the market price of their shares. This type of litigation could result in substantial costs and divert our management&#8217;s attention and resources, which could have a material adverse effect on us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our quarterly operating results may fluctuate significantly and could fall below the expectations of securities analysts and investors due to seasonality and other factors, some of which are beyond our control, resulting in a decline in its stock price.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our quarterly operating results may fluctuate significantly because of several factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">labor availability and costs for hourly and management personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">profitability of our products, especially in new markets and due to seasonal fluctuations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in interest rates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">impairment of long-lived assets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">macroeconomic conditions, both internationally and locally;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in competitive conditions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expansion to new markets; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fluctuations in commodity prices.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If securities or industry analysts do not publish or cease publishing research or reports about us, our business, or our market, or if they change their recommendations regarding our ordinary shares adversely, then the price and trading volume of our ordinary shares could decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The trading market for the ordinary shares will be influenced by the research and reports that industry or financial analysts publish about its business. Alpha Tau does not control these analysts, or the content and opinions included in their reports. As a new public company, Alpha Tau may be slow to attract research coverage and the analysts who publish information about the ordinary shares will have had relatively little experience with Alpha Tau, which could affect their ability to accurately forecast Alpha Tau&#8217;s results and make it more likely that Alpha Tau fails to meet their estimates. In the event Alpha Tau obtains industry or financial analyst coverage, if any of the analysts who cover Alpha Tau issues an inaccurate or unfavorable opinion regarding it, Alpha Tau&#8217;s share price would likely decline. If one or more of these analysts cease coverage of Alpha Tau or fail to publish reports on it regularly, Alpha Tau&#8217;s visibility in the financial markets could decrease, which in turn could cause its share price or trading volume to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our failure to meet the continued listing requirements of Nasdaq could result in a delisting of its</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Securities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we fail to continue to satisfy the continued listing requirements of Nasdaq such as the corporate governance requirements or the minimum closing bid price requirement, Nasdaq may take steps to delist its securities. Such a delisting would likely have a negative effect on the price of the securities and would impair your ability to sell or purchase the securities when you wish to do so. In the event of a delisting, Alpha Tau can provide no assurance that any action taken by it to restore compliance with listing requirements would allow its securities to become listed again, stabilize the market price or improve the liquidity of its securities, prevent its securities from dropping below the Nasdaq minimum bid price requirement or prevent future non-compliance with Nasdaq&#8217;s listing requirements. Additionally, if Alpha Tau&#8217;s securities are not listed on, or become delisted from, Nasdaq for any reason, and are quoted on the OTC Bulletin Board, an inter-dealer automated quotation system for equity securities that is not a national securities exchange, the liquidity and price of Alpha Tau&#8217;s securities may be more limited than if it were quoted or listed on Nasdaq or another national securities exchange. You may be unable to sell your securities unless a market can be established or sustained.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are eligible to be treated as an emerging growth company, as defined in the Securities Act, and we cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make our ordinary shares less attractive to investors because we may rely on these reduced disclosure requirements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We qualify as an emerging growth company within the meaning of the Securities Act, and we take advantage of certain exemptions from disclosure requirements available to emerging growth companies, which could make our securities less attractive to investors and may make it more difficult to compare our performance with other public companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are eligible to be treated as an emerging growth company, as defined in Section&#160;2(a)&#160;of the Securities Act, as modified by the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised financial accounting standards until such time as those standards apply to private companies. Alpha Tau intends to take advantage of this extended transition period under the JOBS Act for adopting new or revised financial accounting standards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For as long as we continue to be an emerging growth company, we may also take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including presenting only limited selected financial data and not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act. As a result, its shareholders may not have access to certain information that they may deem important. Alpha Tau could be an emerging growth company for up to five&#160;years, although circumstances could cause it to lose that status earlier, including if its total annual gross revenue exceeds $1.07 billion, if it issues more than $1.0 billion in non-convertible debt securities during any three-year period, or if before that time it is a &#8220;large accelerated filer&#8221; under U.S. securities laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Alpha Tau cannot predict if investors will find ordinary shares less attractive because it may rely on these exemptions. If some investors find ordinary shares less attractive as a result, there may be a less active trading market for ordinary shares and Alpha Tau&#8217;s share price may be more volatile. Further, there is no guarantee that the exemptions available to Alpha Tau under the JOBS Act will result in significant savings. To the extent that Alpha Tau chooses not to use exemptions from various reporting requirements under the JOBS Act, it will incur additional compliance costs, which may impact Alpha Tau&#8217;s financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are a foreign private issuer and, as a result, we will not be subject to U.S. proxy rules&#160;and will be subject to Exchange Act reporting obligations that, to some extent, are more lenient and less frequent than those of a U.S. domestic public company.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We report under the Exchange Act as a non-U.S. company with foreign private issuer status. We qualify as a foreign private issuer under the Exchange Act, we are exempt from certain provisions of the Exchange Act that are applicable to U.S. domestic public companies, including (1)&#160;the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered under the Exchange Act, (2)&#160;the sections of the Exchange Act requiring insiders to file public reports of their share ownership and trading activities and liability for insiders who profit from trades made in a short period of time and (3)&#160;the rules&#160;under the Exchange Act requiring the filing with the SEC of quarterly reports on Form&#160;10-Q containing unaudited financial and other specified information, although it is subject to Israeli laws and regulations with regard to certain of these matters and intend to furnish comparable quarterly information on Form&#160;6-K. In addition, foreign private issuers are not required to file their annual report on Form&#160;20-F until 120&#160;days after the end of each fiscal&#160;year, while U.S. domestic issuers that are accelerated filers are required to file their annual report on Form&#160;10-K within 75&#160;days after the end of each fiscal&#160;year and U.S. domestic issuers that are large accelerated filers are required to file their annual report on Form&#160;10-K within 60&#160;days after the end of each fiscal&#160;year. Foreign private issuers are also exempt from Regulation FD, which is intended to prevent issuers from making selective disclosures of material information. As a result of all of the above, you may not have the same protections afforded to shareholders of a company that is not a foreign private issuer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may lose our foreign private issuer status in the future, which could result in significant additional costs and expenses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As discussed above, Alpha Tau is a foreign private issuer, and therefore is not required to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act. The determination of foreign private issuer status is made annually on the last business day of an issuer&#8217;s most recently completed second fiscal quarter, and, accordingly, the next determination will be made with respect to Alpha Tau on June&#160;30, 2022. In the future, Alpha Tau would lose its foreign private issuer status if (1)&#160;more than 50% of its outstanding voting securities are owned by U.S. residents and (2)&#160;a majority of its directors or executive officers are U.S. citizens or residents, or it fails to meet additional requirements necessary to avoid loss of foreign private issuer status. If Alpha Tau loses its foreign private issuer status, it will be required to file with the SEC periodic reports and registration statements on U.S. domestic issuer forms, which are more detailed and extensive than the forms available to a foreign private issuer. Alpha Tau would </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">also have to mandatorily comply with U.S. federal proxy requirements, and its officers, directors and principal shareholders will become subject to the short-swing profit disclosure and recovery provisions of Section&#160;16 of the Exchange Act. In addition, it would lose its ability to rely upon exemptions from certain corporate governance requirements under the listing rules&#160;of Nasdaq. As a U.S. listed public company that is not a foreign private issuer, Alpha Tau would incur significant additional legal, accounting and other expenses that it will not incur as a foreign private issuer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">As we are a &#8220;foreign private issuer&#8221; and follow certain home country corporate governance practices, our shareholders may not have the same protections afforded to shareholders of companies that are subject to all Nasdaq corporate governance requirements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a foreign private issuer we have the option to follow certain home country corporate governance practices rather than those of Nasdaq, provided that we disclose the requirements we are not following and describes the home country practices we are following. We intend to rely on this &#8220;foreign private issuer exemption&#8221; with respect to the Nasdaq rules&#160;for shareholder meeting quorums and Nasdaq rules&#160;requiring shareholder approval. We may in the future elect to follow home country practices with regard to other matters. As a result, our shareholders may not have the same protections afforded to shareholders of companies that are subject to all Nasdaq corporate governance requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our Amended and Restated Articles of Association provide that unless we consent to an alternate forum, the federal district courts of the United States shall be the exclusive forum of resolution of any claims arising under the Securities Act.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our Amended and Restated Articles of Association (the &#8220;Articles&#8221;) provide that, unless Alpha Tau consents in writing to the selection of an alternative forum, the federal district courts of the United States shall be the sole and exclusive forum for any claim asserting a cause of action arising under the Securities Act (for the avoidance of any doubt, such provision does not apply to any claim asserting a cause of action arising under the Exchange Act). Section&#160;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both U.S. state and federal courts have jurisdiction to entertain such claims. This choice of forum provision may limit a shareholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with Alpha Tau or our directors, officers or other employees and may increase the costs associated with such lawsuits, which may discourage such lawsuits against Alpha Tau and our directors, officers and employees. Alternatively, if a court were to find these provisions of the Articles inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, Alpha Tau may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect Alpha Tau&#8217;s business and financial condition. Any person or entity purchasing or otherwise acquiring any interest in Alpha Tau&#8217;s share capital shall be deemed to have notice of and to have consented to the choice of forum provisions of the Articles described above. This provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act or any other claim for which the U.S. federal courts have exclusive jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The listing of our securities on Nasdaq did not benefit from the process undertaken in connection with an underwritten initial public offering, which could result in diminished investor demand, inefficiencies in pricing and a more volatile public price for Alpha Tau&#8217;s securities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Alpha Tau&#8217;s ordinary shares and warrants are listed on Nasdaq under the symbols &#8220;DRTS&#8221; and &#8220;DRTSW,&#8221; respectively. Unlike an underwritten initial public offering of the Alpha Tau securities, the initial listing of Alpha Tau&#8217;s securities as a result of the Business Combination did not benefit from the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the book-building process undertaken by underwriters that helps to inform efficient price discovery with respect to opening trades of newly listed securities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">underwriter support to help stabilize, maintain or affect the public price of the new issue immediately after listing; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">underwriter due diligence review of the offering and potential liability for material misstatements or omissions of fact in a prospectus used in connection with the securities being offered or for statements made by its securities analysts or other personnel.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Underwriters have liability under the U.S. securities laws for material misstatements or omissions in a registration statement pursuant to which an issuer sells securities. Section&#160;11 of the Securities Act (&#8220;Section&#160;11&#8221;) imposes liability on parties, including </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">underwriters, involved in a securities offering if the registration statement contains a materially false statement or material omission. To effectively establish a due diligence defense against a cause of action brought pursuant to Section&#160;11, a defendant, including an underwriter, carries the burden of proof to demonstrate that he or she, after reasonable investigation, believed that the statements in the registration statement were true and free of material omissions. In order to meet this burden of proof, underwriters in a registered offering typically conduct extensive due diligence of the registrant and vet the registrant&#8217;s disclosure. Due diligence entails engaging legal, financial and/or other experts to perform an investigation as to the accuracy of an issuer&#8217;s disclosure regarding, among other things, its business, prospects and financial results. In making their investment decision, investors have the benefit of such diligence in underwritten public offerings. HCCC&#8217;s investors must rely on the information in this Annual Report and will not have the benefit of an independent review and investigation of the type normally performed by an independent underwriter in a public securities offering. While sponsors, private investors and management in a business combination undertake a certain level of due diligence, it is not necessarily the same level of due diligence undertaken by an underwriter in a public securities offering and, therefore, there could be a heightened risk of an incorrect valuation of Alpha Tau&#8217;s business or material misstatements or omissions in this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, because there were no underwriters engaged in connection with the Transactions, prior to the opening of trading on the trading day immediately following the Closing Date, there was be no traditional &#8220;roadshow&#8221; or book building process, and no price at which underwriters initially sold shares to the public to help inform efficient and sufficient price discovery with respect to the initial post-closing trades. Therefore, buy and sell orders submitted prior to and at the opening of initial post-closing trading of Alpha Tau&#8217;s securities did not have the benefit of being informed by a published price range or a price at which the underwriters initially sold shares to the public, as would be the case in an underwritten initial public offering. There were be no underwriters assuming risk in connection with an initial resale of Alpha Tau&#8217;s securities or helping to stabilize, maintain or affect the public price of Alpha Tau&#8217;s securities following the closing. Moreover, neither Alpha Tau nor HCCC engaged in, nor will they, directly or indirectly, request financial advisors to engage in, any special selling efforts or stabilization or price support activities in connection with the Alpha Tau&#8217;s securities that will be outstanding immediately following the closing. In addition, since we became public through a merger, securities analysts of major brokerage firms may not provide coverage of Alpha Tau since there is no incentive to brokerage firms to recommend the purchase of its ordinary shares. No assurance can be given that brokerage firms will, in the future, want to conduct any offerings on Alpha Tau&#8217;s behalf. All of these differences from an underwritten public offering of Alpha Tau&#8217;s securities could result in a more volatile price for the Alpha Tau&#8217;s securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20pt;margin:0pt 0pt 12pt 5pt;">Such differences from an underwritten public offering may present material risks to unaffiliated investors that would not exist if we became a publicly listed company through an underwritten initial public offering instead of upon completion of the merger. Further, the lack of such processes in connection with the listing of our securities could result in diminished investor demand, inefficiencies in pricing and a more volatile public price for Alpha Tau&#8217;s securities during the period immediately following the listing than in connection with an underwritten initial public offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Incorporation and Location in Israel</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Conditions in Israel could materially and adversely affect Alpha Tau&#8217;s business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Many of Alpha Tau&#8217;s employees, including certain management members operate from its offices that are located in Jerusalem, Israel. In addition, a number of Alpha Tau&#8217;s officers and directors are residents of Israel. Accordingly, political, economic, and military conditions in Israel and the surrounding region may directly affect Alpha Tau&#8217;s business and operations. Recently, there has been an unprecedented degree of political instability in Israel, with four sets of elections for the Israeli parliament, or Knesset, in a two-year period. While a new government was formed in June&#160;2021, there is no guarantee that it will last for a significant portion of its full four-year term and provide political stability. On the military front, in recent&#160;years, Israel has been engaged in sporadic armed conflicts with Hamas, an Islamist terrorist group that controls the Gaza Strip, with Hezbollah, an Islamist terrorist group that controls large portions of southern Lebanon, and with Iranian-backed military forces in Syria. In addition, Iran has threatened to attack Israel and may be developing nuclear weapons. Some of these hostilities were accompanied by missiles being fired from the Gaza Strip, Lebanon and Syria against civilian targets in various parts of Israel, including areas in which Alpha Tau&#8217;s employees are located, which negatively affected business conditions in Israel. Any hostilities involving Israel, regional political instability or the interruption or curtailment of trade between Israel and its trading partners could materially and adversely affect Alpha Tau&#8217;s operations and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Alpha Tau&#8217;s commercial insurance does not cover losses that may occur as a result of events associated with war and terrorism. Although the Israeli government currently covers the reinstatement value of direct damages that are caused by terrorist attacks or acts of war, Alpha Tau cannot assure you that this government coverage</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">will be maintained or that it will sufficiently cover Alpha Tau&#8217;s potential damages. Any losses or damages incurred by Alpha Tau could have a material adverse effect on its business. Any armed conflicts or political instability in the region would likely negatively affect business conditions and could harm Alpha Tau&#8217;s results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, in the past, the State of Israel and Israeli companies have been subjected to economic boycotts. Several countries still restrict business with the State of Israel and with Israeli companies. These restrictive laws and policies may have an adverse impact on Alpha Tau&#8217;s results of operations, financial condition or the expansion of its business. A campaign of boycotts, divestment, and sanctions has been undertaken against Israel, which could also adversely affect Alpha Tau&#8217;s business. Actual or perceived political instability in Israel or any negative changes in the political environment, may individually or in the aggregate adversely affect the Israeli economy and, in turn, Alpha Tau&#8217;s business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, many Israeli citizens are obligated to perform several weeks of annual military reserve duty each&#160;year until they reach the age of 40 (or older, for reservists who are military officers or who have certain occupations) and, in the event of a military conflict, may be called to active duty. In response to increases in terrorist activity, there have been periods of significant call-ups of military reservists. It is possible that there will be military reserve duty call-ups in the future. Alpha Tau&#8217;s operations could be disrupted by such call-ups, which may include the call-up of members of its management. Such disruption could materially adversely affect its business, prospects, financial condition, and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Alpha Tau may become subject to claims for remuneration or royalties for assigned service invention rights by Alpha Tau&#8217;s employees, which could result in litigation and adversely affect Alpha Tau&#8217;s business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A significant portion of Alpha Tau&#8217;s intellectual property has been developed by its employees in the course of their employment by Alpha Tau. Under the Israeli Patents Law, 5727-1967 (the &#8220;Patents Law&#8221;), inventions conceived by an employee during and as a result of his or her employment with a company are regarded as &#8220;service inventions,&#8221; which belong to the employer, absent an agreement between the employee and employer providing otherwise. The Patents Law also provides that if there is no agreement between an employer and an employee determining whether the employee is entitled to receive consideration for service inventions and on what terms, this will be determined by the Israeli Compensation and Royalties Committee (the &#8220;Committee&#8221;), a body constituted under the Patents Law. Case law clarifies that the right to receive consideration for &#8220;service inventions&#8221; can be waived by the employee and that in certain circumstances, such waiver does not necessarily have to be explicit. The Committee will examine, on a case-by-case basis, the general contractual framework between the parties, using interpretation rules&#160;of the general Israeli contract laws. Further, the Committee has not yet determined one specific formula for calculating this remuneration, but rather uses the criteria specified in the Patents Law. Although Alpha Tau generally enters into agreements with its employees pursuant to which such individuals assign to it all rights to any inventions created during and as a result of their employment with Alpha Tau, Alpha Tau may face claims demanding remuneration in consideration for assigned inventions. As a consequence of such claims, Alpha Tau could be required to pay additional remuneration or royalties to its current and/or former employees, or be forced to litigate such monetary claims (which will not affect Alpha Tau&#8217;s proprietary rights), which could negatively affect its business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Certain tax benefits that may be available to Alpha Tau, if obtained by Alpha Tau, would require it to continue to meet various conditions and may be terminated or reduced in the future, which could increase Alpha Tau&#8217;s costs and taxes.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Alpha Tau may be eligible for certain tax benefits provided to &#8220;Preferred Technological Enterprises&#8221; under the Israeli Law for the Encouragement of Capital Investments, 5719-1959, referred to as the Investment Law. If Alpha Tau obtains tax benefits under the &#8220;Preferred Technological Enterprises&#8221; regime then, in order to remain eligible for such tax benefits, it will need to continue to meet certain conditions stipulated in the Investment Law and its regulations, as amended. If these tax benefits are reduced, cancelled or discontinued, Alpha Tau&#8217;s Israeli taxable income may be subject to Israeli corporate tax rates of 23% in 2018 and thereafter. Additionally, if Alpha Tau increases its activities outside of Israel through acquisitions, for example, its activities might not be eligible for inclusion in future Israeli tax benefit programs. See &#8220;<i style="font-style:italic;">Certain Material Israeli Tax Considerations</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">It may be difficult to enforce a U.S. judgment against Alpha Tau, its officers and directors and the Israeli experts named in this Annual Report in Israel or the United States, or to assert U.S. securities laws claims in Israel or serve process on Alpha Tau&#8217;s officers and directors and these experts.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Most of Alpha Tau&#8217;s directors or officers are not residents of the United States and most of their and Alpha Tau&#8217;s assets are located outside the United States. Service of process upon Alpha Tau or its non-U.S. resident directors and officers and enforcement of judgments obtained in the United States against Alpha Tau or its non-U.S. directors and executive officers may be difficult to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">obtain within the United States. Alpha Tau have been informed by its legal counsel in Israel that it may be difficult to assert claims under U.S. securities laws in original actions instituted in Israel or obtain a judgment based on the civil liability provisions of U.S. federal securities laws. Israeli courts may refuse to hear a claim based on a violation of U.S. securities laws against Alpha Tau or its non-U.S. officers and directors because Israel may not be the most appropriate forum to bring such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proved as a fact, which can be a time-consuming and costly process. Certain matters of procedure will also be governed by Israeli law. There is little binding case law in Israel addressing the matters described above. Israeli courts might not enforce judgments rendered outside Israel, which may make it difficult to collect on judgments rendered against Alpha Tau or its non-U.S. officers and directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, an Israeli court will not enforce a non-Israeli judgment if (among other things) it was given in a state whose laws do not provide for the enforcement of judgments of Israeli courts (subject to exceptional cases), or if its enforcement is likely to prejudice the sovereignty or security of the State of Israel, or if it was obtained by fraud or in absence of due process, or if it is at variance with another valid judgment that was given in the same matter between the same parties, or if a suit in the same matter between the same parties was pending before a court or tribunal in Israel, at the time the foreign action was brought. For more information, see &#8220;<i style="font-style:italic;">Enforceability of Civil Liabilities</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Your rights and responsibilities as a shareholder of Alpha Tau will be governed by Israeli law, which may differ in some respects from the rights and responsibilities of shareholders of U.S. corporations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Alpha Tau is incorporated under Israeli law. The rights and responsibilities of holders of the ordinary shares are governed by the Articles and the Companies Law. These rights and responsibilities differ in some respects from the rights and responsibilities of shareholders in typical U.S. corporations. In particular, pursuant to the Companies Law each shareholder of an Israeli company has to act in good faith and in a customary manner in exercising his or her rights and fulfilling his or her obligations toward the company and other shareholders and to refrain from abusing his or her power in the company, including, among other things, in voting at the general meeting of shareholders and class meetings, on amendments to a company&#8217;s articles of association, increases in a company&#8217;s authorized share capital, mergers, and transactions requiring shareholders&#8217; approval under the Companies Law. In addition, a controlling shareholder of an Israeli company or a shareholder who knows that it possesses the power to determine the outcome of a shareholder vote or who has the power to appoint or prevent the appointment of a director or officer in the Company, or has other powers toward the Company has a duty of fairness toward the Company. However, Israeli law does not define the substance of this duty of fairness. There is limited case law available to assist in understanding the implications of these provisions that govern shareholder behavior.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may issue additional ordinary shares or other equity securities without seeking approval of our shareholders, which would dilute your ownership interests and may depress the market price of the ordinary shares.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March&#160;7, 2022, following the closing of the Business Combination, we had warrants outstanding to purchase up to an aggregate of 3,970,693 ordinary shares as well had granted options to our employees to purchase a total of 6,162,660 ordinary shares and 1,031,250 RSUs. Further, we may choose to seek third party financing to provide additional working capital for our business, in which event we may issue additional equity securities. We may also issue additional ordinary shares or other equity securities of equal or senior rank in the future for any reason or in connection</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If Alpha Tau or any of its subsidiaries are characterized as a Passive Foreign Investment Company (&#8220;PFIC&#8221;) for U.S. federal income tax purposes, U.S. Holders may suffer adverse tax consequences.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A non-U.S. corporation generally will be treated as a PFIC for U.S. federal income tax purposes, in any taxable&#160;year if either (1)&#160;at least 75% of its gross income for such&#160;year is passive income or (2)&#160;at least 50% of the value of its assets (generally based on an average of the quarterly values of the assets) during such&#160;year is attributable to assets that produce or are held for the production of passive income. Alpha Tau believes it was not a PFIC in 2021. Based on the current and anticipated composition of the income, assets and operations of Alpha Tau and its subsidiaries, there is a risk that Alpha Tau may be treated as a PFIC for future taxable&#160;years. Moreover, the application of the PFIC rules&#160;is subject to uncertainty in several respects, and Alpha Tau cannot assure you that the IRS will not take a contrary position or that a court will not sustain such a challenge by the IRS.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Whether Alpha Tau or any of its subsidiaries are a PFIC for any taxable&#160;year is a factual determination that depends on, among other things, the composition of Alpha Tau&#8217;s income and assets, and the market value of its and its subsidiaries&#8217; shares and assets. Changes in the composition of our income or composition of Alpha Tau or any of its subsidiaries assets may cause us to be or become a PFIC for the current or subsequent taxable years. Whether Alpha Tau is treated as a PFIC for U.S. federal income tax purposes is a factual determination that must be made annually at the close of each taxable&#160;year and, thus, is subject to significant uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If Alpha Tau is a PFIC for any taxable&#160;year, a U.S. Holder of Alpha Tau ordinary shares may be subject to adverse tax consequences and may incur certain information reporting obligations. For a further discussion, see &#8220;<i style="font-style:italic;">Certain Material U.S. Federal Income Tax Considerations&#8212;U.S. Holders&#8212;Passive Foreign Investment Company Rules</i>.&#8221; U.S. Holders of Alpha Tau ordinary shares and Alpha Tau warrants are strongly encouraged to consult their own advisors regarding the potential application of these rules&#160;to Alpha Tau and the ownership of Alpha Tau ordinary shares and/or Alpha Tau warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If a U.S. Holder is treated as owning at least 10% of the Alpha Tau stock, such U.S. Holder may be subject to adverse U.S. federal income tax consequences.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For U.S. federal income tax purposes, if a U.S. Holder is treated as owning (directly, indirectly or constructively) at least 10% of the value or voting power of the Alpha Tau stock, such person may be treated as a &#8220;United States shareholder&#8221; with respect to Alpha Tau, or any of its subsidiaries, if Alpha Tau or such subsidiary is a &#8220;controlled foreign corporation.&#8221; If Alpha Tau has one or more U.S. subsidiaries, certain of Alpha Tau&#8217;s non-U.S. subsidiaries could be treated as a controlled foreign corporation regardless of whether Alpha Tau is treated as a controlled foreign corporation (although there are recently promulgated final and currently proposed Treasury regulations that may limit the application of these rules&#160;in certain circumstances).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Certain United States shareholders of a controlled foreign corporation may be required to report annually and include in their U.S. federal taxable income their pro rata share of the controlled foreign corporation&#8217;s &#8220;Subpart F income&#8221; and, in computing their &#8220;global intangible low-taxed income,&#8221; &#8220;tested income&#8221; and a pro rata share of the amount of certain U.S. property (including certain stock in U.S. corporations and certain tangible assets located in the United States) held by the controlled foreign corporation regardless of whether such controlled foreign corporation makes any distributions. The amount includable by a United States shareholder under these rules&#160;is based on a number of factors, including potentially, but not limited to, the controlled foreign corporation&#8217;s current earnings and profits (if any), tax basis in the controlled foreign corporation&#8217;s assets, and foreign taxes paid by the controlled foreign corporation on its underlying income. Failure to comply with these reporting obligations (or related tax payment obligations) may subject such United States shareholder to significant monetary penalties and may extend the statute of limitations with respect to such United States shareholder&#8217;s U.S. federal income tax return for the&#160;year for which reporting (or payment of tax) was due. Alpha Tau cannot provide any assurances that it will assist U.S. Holders in determining whether Alpha Tau or any of its subsidiaries are treated as a controlled foreign corporation for U.S. federal income tax purposes or whether any U.S. Holder is treated as a United States shareholder with respect to any of such controlled foreign corporations or furnish to any holder information that may be necessary to comply with reporting and tax paying obligations if Alpha Tau, or any of its subsidiaries, is treated as a controlled foreign corporation for U.S. federal income tax purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">As a result of the Business Combination, the IRS may not agree that Alpha Tau should be treated as a non-U.S. corporation for U.S. federal income tax purposes.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under current U.S. federal income tax law, a corporation generally will be considered to be a U.S. corporation for U.S. federal income tax purposes if it is created or organized in the United States or under the law of the United States or of any State. Accordingly, under generally applicable U.S. federal income tax rules, Alpha Tau, which is incorporated and tax resident in Israel, would generally be classified as a non-U.S. corporation for U.S. federal income tax purposes. Section 7874 of the Code and the Treasury regulations promulgated thereunder, however, contain specific rules that may cause a non-U.S. corporation to be treated as a U.S. corporation for U.S. federal income tax purposes. If it were determined that Alpha Tau is treated as a U.S. corporation for U.S. federal income tax purposes under Section 7874 of the Code and the Treasury regulations promulgated thereunder, Alpha Tau would be liable for U.S. federal income tax on its income in the same manner as any other U.S. corporation and certain distributions made by Alpha Tau to Non-U.S. Holders (as defined in &#8220;Certain Material U.S. Federal Income Tax Considerations&#8221;) of Alpha Tau may be subject to U.S. withholding tax.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Based on the terms of the Business Combination and certain factual assumptions, Alpha Tau does not currently expect to be treated as a U.S. corporation for U.S. federal income tax purposes under Section 7874 of the Code after the Business Combination. However, the application of Section 7874 of the Code is complex, subject to detailed regulations (the application of which is uncertain in various respects and would be impacted by changes in such U.S. Treasury regulations with possible retroactive effect) and subject to certain factual uncertainties. Accordingly, there can be no assurance that the IRS will not challenge the status of Alpha Tau as a non-U.S. corporation for U.S. federal income tax purposes under Section 7874 of the Code or that such challenge would not be sustained by a court.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the IRS were to successfully challenge under Section 7874 of the Code Alpha Tau&#8217;s status as a non-U.S. corporation for U.S. federal income tax purposes, Alpha Tau and certain Alpha Tau shareholders may be subject to significant adverse tax consequences, including a higher effective corporate income tax rate on Alpha Tau and future withholding taxes on certain Alpha Tau shareholders, depending on the application of any applicable income tax treaty that may apply to reduce such withholding taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">You should consult your own advisors regarding the application of Section 7874 of the Code to the Business Combination and the tax consequences if the classification of Alpha Tau as a non-U.S. corporation is not respected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Articles provide that unless Alpha Tau consents otherwise, the competent courts of Tel Aviv, Israel shall be the sole and exclusive forum for substantially all disputes between Alpha Tau and its shareholders under the Companies Law and the Israeli Securities Law.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The competent courts of Tel Aviv, Israel shall, unless Alpha Tau consents otherwise in writing, be the exclusive forum for (i)&#160;any derivative action or proceeding brought on behalf of Alpha Tau, (ii)&#160;any action asserting a claim of breach of fiduciary duty owed by any director, officer or other employee of Alpha Tau to Alpha Tau or Alpha Tau&#8217;s shareholders, or (iii)&#160;any action asserting a claim arising pursuant to any provision of the Companies Law or the Israeli Securities Law, 5728-1968 (the &#8220;Israeli Securities Law&#8221;). This exclusive forum provision is intended to apply to claims arising under Israeli law and would not apply to claims brought pursuant to the Securities Act or the Exchange Act or any other claim for which federal courts would have exclusive jurisdiction. Such exclusive forum provision in the Articles will not relieve Alpha Tau of its duties to comply with federal securities laws and the rules&#160;and regulations thereunder, and shareholders of Alpha Tau will not be deemed to have waived Alpha Tau&#8217;s compliance with these laws, rules&#160;and regulations. This exclusive forum provision may limit a shareholders ability to bring a claim in a judicial forum of its choosing for disputes with Alpha Tau or its directors or other employees which may discourage lawsuits against Alpha Tau, its directors, officers and employees.</p><a id="_4ae7ee83_a864_4818_8760_37b9facbacea"></a><a id="Item4InformationontheCompany_88486"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 4.</b></span><b style="font-weight:bold;">Information on the Company.</b></p><a id="AHistoryandDevelopmentoftheCompany_22271"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">A.&#160;History and Development of the Company</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We were founded in November&#160;2015 by Uzi Sofer, Alpha Tau&#8217;s Chief Executive Officer and Chairman, along with the inventors of the Alpha DaRT technology including Professor Itzhak Kelson and Professor Yona Keisari of Tel Aviv University, Alpha Tau&#8217;s Chief Physics Officer and Chief Scientific Officer, respectively. Together, they founded Alpha Tau with the goal of bringing this innovative technology out of the laboratory and into patients, in order to bring hope to cancer patients around the world. We are registered with the Israeli Registrar of Companies. Our registration number&#160;is&#160;51-534453-9.&#160;Our&#160;website address is www.alphatau.com.&#160;Information contained on, or that can be accessed through, our website does not constitute a part of this Annual Report and is not incorporated by reference herein. We have included our website address in this Annual Report solely for informational purposes. The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers, such as we, that file electronically, with the SEC at www.sec.gov.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The main address of our principal executive offices is Kiryat HaMada St. 5, Jerusalem, Israel 9777605 and its telephone number is +972 (3)&#160;577-4115. Our agent for service of process in the United States is Alpha Tau Medical,&#160;Inc., 1 Union Street 3<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">rd</sup>&#160;Floor, Lawrence, MA 01840 For a description of our principal capital expenditures and divestitures for the two&#160;years ended December&#160;31, 2021 and for those currently in progress, see Item&#160;5. &#8220;<i style="font-style:italic;">Operating and Financial Review and Prospects</i>.&#8221;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recent Developments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July&#160;7, 2021, we entered into the Merger Agreement with HCCC and Merger Sub. Pursuant to the Merger Agreement, Merger Sub merged with and into HCCC, with HCCC surviving the merger. Upon consummation of the Business Combination and the other transactions contemplated by the Merger Agreement on March&#160;7, 2022, HCCC became a wholly owned subsidiary of Alpha Tau.</p><a id="BBusinessOverview_943006"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">B.&#160;Business Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Company Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Our proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation&#8217;s limited range. We believe that our Alpha DaRT technology has the potential to be broadly applicable across multiple targets and tumor types. We evaluated the feasibility, safety and efficacy of the Alpha DaRT technology in a first-in-human study of locally advanced and recurrent squamous cell carcinoma, or SCC, cancers of the skin and head and neck. Efficacy was evaluated in 28 tumors, and results showed that Alpha DaRT achieved 100% overall response rate and over 78% complete response rate. The Alpha DaRT was generally well-tolerated, with limited local toxicity and no systemic toxicity. On the basis of this clinical trial as well as some of our further clinical trials, we received marketing approval in Israel in August&#160;2020 for the treatment of SCC of the skin or oral cavity using the Alpha DaRT in August&#160;2020. In June&#160;2021, the FDA granted the Alpha DaRT Breakthrough Device Designation for the treatment of patients with SCC of the skin or oral cavity without curative standard of care. In October&#160;2021, the FDA granted the Alpha DaRT a second Breakthrough Device Designation, in treating recurrent Glioblastoma Multiforme, or GBM, as an adjunct to standard medical therapies or as a standalone therapy after standard medical therapies have been exhausted. If approved, we expect to commercialize our Alpha DaRT technology first in the United States before other markets, including Israel, notwithstanding our existing marketing authorization in Israel (under which we have not yet commercialized the product). To support our U.S. strategy, we are conducting a multi-center pilot feasibility trial to explore the feasibility of delivering radiotherapy for malignant skin and superficial soft tissue tumors using Alpha DaRT at Memorial Sloan Kettering Cancer Center and up to five other clinical sites around the United States. All ten patients in this trial were treated in the second half of 2021. The study met its primary feasibility endpoint, as all patients had successful delivery of radiation by Alpha DaRT. At approximately 12 weeks, all ten lesions treated demonstrated a complete response to the treatment, with no product-related serious adverse events observed. We hold exclusive rights to our proprietary Alpha DaRT technology in our core markets, including the United States and Europe.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">While local radiation therapy has been a mainstay of cancer therapy for&#160;years, it has been mostly limited to modalities utilizing beta or gamma emissions, which primarily destroy cells through an indirect mechanism relying on oxygen and the generation of free radicals to cause single-strand DNA breaks. By contrast, alpha radiation has hundreds of times the linear energy transfer rate of beta-emitters. Additionally, alpha particles&#8217; heavier mass and far shorter particle paths (less than 100 &#956;m) relative to beta&#8217;s lighter mass and lengthier (up to 12 mm) path, have been shown to destroy radioresistant cells in clinical studies&#160;&#8211; causing multiple, irreparable, double-strand DNA breaks and other cellular damage upon direct impact&#160;&#8211; within a very short distance. Accordingly, we believe that alpha radiation has several significant potential advantages for use in cancer radiotherapy, including a high relative biological efficiency (potentially enabling it to destroy tumor cells with administration of lower levels of radiation), imperviousness to factors such as hypoxia, and a very well-defined range of travel with limited collateral damage. Nonetheless, its use has also been limited precisely due to alpha&#8217;s extremely short particle range in living tissue, as the range of less than 100 &#956;m is insufficient to provide meaningful clinical utility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Alpha DaRT technology employs a series of radioactive sources that are embedded with Radium-224 to enable a controlled, intratumoral release of alpha-emitting atoms which diffuse and decay throughout the tumor, seeking to kill cancerous cells with localized precision, while penetrating deeper into the tumor than can otherwise be reached by the limited ranges of the alpha particles themselves. Due to the inherent limited range of the alpha particles, we believe that the Alpha DaRT technology has the potential to deliver powerful and localized precise killing impact to the tumor without damage to surrounding healthy tissue. By combining the innate relative biological effectiveness and short range of alpha particles in a single-use disposable form, we believe that the Alpha DaRT could address tumors that have otherwise demonstrated poor response to radiation therapy or other standards of care, with the potential to apply to a wide range of tumors and clinical settings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We evaluated the feasibility, safety and efficacy of the Alpha DaRT technology in a first-in-human study of locally advanced and recurrent SCC cancers of the skin and head and neck, the results of which were subsequently published in the International Journal for </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Radiation Oncology, Biology, Physics and which elicited a positive editorial reaction in the same journal. Efficacy was evaluated in 28 tumors of the skin and head and neck, and results showed that Alpha DaRT achieved a &gt;78% complete response rate. The trial was conducted in an elderly (median age = 80.5&#160;years) and largely pre-treated patient population, with 42% of the target lesions, including non-evaluated lesions, having already received radiation therapy. The Alpha DaRT was generally well-tolerated, with limited local toxicity and no systemic toxicity. Following these initial positive results, we substantially expanded our clinical evaluations in later trials to a much wider patient population. Specifically, we initiated follow-on studies at multiple clinical sites in Israel and around the world, to evaluate Alpha DaRT in cancers of the skin, superficial soft tissue, or oral cavity, regardless of cell type, which includes SCC as well as basal cell carcinoma, melanoma, skin metastases, and others. As of February&#160;28, 2022, across our clinical trials involving superficial lesions, i.e. tumors of the skin, head or neck, Alpha DaRTs have been administered to over 100 lesions, with no treatment-related severe adverse events, and in a pooled analysis evaluating those lesions that reached the evaluation endpoint per the treatment protocol of the applicable clinical trial, we have observed an overall response rate of 98%, including a complete response rate of 74%. The supportive data from these first trials also led to the U.S. Food and Drug Administration, or FDA, granting Breakthrough Device Designation to the Alpha DaRT for the treatment of patients with SCC of the skin or oral cavity without curative standard of care.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In parallel, we are pursuing a similar approach towards seeking FDA marketing authorization for other uses for the Alpha DaRT technology in other indications by conducting feasibility studies and then generating potentially registrational data in other indications, such as breast, pancreas and prostate cancers, or applications such as combinations with immunotherapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have engaged with a number of prestigious medical and educational institutions and, as of March&#160;21, 2022, have nine clinical studies ongoing worldwide across these two parallel strategies, of generating data in superficial tumors as well as conducting studies in other indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, in our pre-clinical studies, we evaluated the Alpha DaRT on 19 tumor models (both human and mouse). Alpha DaRT sources were observed to have killed multiple types of mouse and human tumors <i style="font-style:italic;">in vivo</i>. The intensity of the killing activity varied between tumor types, and was dependent on the ability of the radioactive atoms to diffuse inside the tumor and on the intrinsic sensitivity of the tissue to DNA damage induced by the radiation, but all tumor types showed responsiveness to Alpha DaRT, i.e., there was no observed resistance. We therefore believe that our technology may potentially be relevant for treatment across a broad range of tumors. We are currently focused on developing the Alpha DaRT for use in a number of potential applications, particularly in refractory or unresectable localized tumors which are not being adequately addressed by standard of care, tumor types with a high unmet need (such as pancreatic adenocarcinoma or glioblastoma multiforme), and metastatic tumors in combination with systemic therapies such as checkpoint inhibitors. We are also investigating the potential of the Alpha DaRT to elicit an immune response as observed in previous pre-clinical data, as well as anecdotal evidence of response from untreated tumors, or abscopal effects, which may have the potential to inhibit or even reduce metastases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company was founded in November&#160;2015 by Uzi Sofer, our Chief Executive Officer and Chairman, along with the inventors of the Alpha DaRT technology including Professor Itzhak Kelson and Professor Yona Keisari of Tel Aviv University, our Chief Physics Officer and Chief Scientific Officer, respectively. Together, they founded Alpha Tau with the goal of bringing this innovative technology out of the laboratory and into patients, in order to bring hope to cancer patients around the world.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have also devoted a significant amount of time and resources establishing a robust patent portfolio so as to gain a strong scientific and commercial foothold worldwide. As of December&#160;31, 2021, our patent portfolio included 83 issued patents, and 76 pending patent applications including two allowed patent applications, in the United States, Europe, Canada, Japan, Australia, China, South Korea, Russia, Mexico, India, Hong Kong, Singapore, South Africa and ARIPO.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Our Therapeutic Focus</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">While we believe the Alpha DaRT has the potential to revolutionize the treatment of nearly all solid tumors, we have identified three initial areas of therapeutic focus for the development of our Alpha DaRT technology:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Localized and Unresectable&#160;- </b><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Localized tumors of a type where either current treatment options are inadequate or unavailable for the patient, e.g., refractory or recurring tumors following surgery and/or radiation, unresectable tumors, or tumors in patients who are unable to withstand surgery. Some of these tumor types include SCC, head and neck SCC, and prostate tumors.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:244.8pt;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">High Unmet Need</b><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Tumor types with high unmet need, limited treatment options and generally poor prognosis, such as pancreatic adenocarcinoma and glioblastoma.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Metastatic</b><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. By combining our Alpha DaRT technology with systemic therapies, such as checkpoint inhibitors, we seek to boost the Alpha DaRT&#8217;s potentially immunogenic activity and trigger an immune response to detect and destroy metastatic cancers throughout the body.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Development Pipeline</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have a number of active clinical programs targeting a range of different tumor types. Our global clinical trial strategy involves progressing our lead program in superficial tumors, particularly in the United States, while conducting feasibility studies in order to evaluate the potential of the Alpha DaRT in other tumor areas of high unmet need or metastatic disease. As of February&#160;28, 2022, we have administered Alpha DaRT treatment to over 110 tumors across eight clinical trials. The following table summarizes our development pipeline:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="drts-20211231x20f005.jpg" alt="Graphic" style="display:inline-block;height:244.8pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:539.9pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Potential Advantages of the Alpha DaRT Technology</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">We believe the Alpha DaRT technology may offer the following potential advantages<i style="font-style:italic;">:</i></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Potential to destroy solid tumors and preserve health tissue</b><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Proprietary technology designed to harness alpha radiation in an effort to destroy solid tumors irreparably with localized precision, while sparing surrounding healthy tissue and limiting systemic side effects.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Broad potential utility across multiple tumors types supported by compelling safety data. </b><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Anti-tumor activity in clinical trials and pre-clinical studies has been observed across multiple tumor types, regardless of the size or location of the tumor or prior treatments, and the Alpha DaRT was generally well-tolerated in these studies and trials. We have also not observed any tumor types that demonstrated resistance to treatment with the Alpha DaRT technology. Taken together, we believe these results suggest the potential to treat patients with high unmet need.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Promising preliminary efficacy results</b><i style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">. </i><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In a first-in-human study of 28 tumors of locally advanced and recurrent SCC cancers of the skin and head and neck, results showed that Alpha DaRT achieved 100% overall response rate with over 78% complete response rate.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Potential to treat patients with limited treatment options</b><i style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">. </i><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our Alpha DaRT technology is designed to deliver a powerful but conformal dose of radiation to a very targeted area, which we believe has the potential to address patients who have radio-resistant or recurring tumors, who are ineligible for surgery or for whom surgery would not have a meaningful impact on quality of life, or who otherwise would have limited treatment options.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Potential ease of use for patients and physician</b><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Potential to be convenient and efficient for both physician and patient alike: The Alpha DaRT technology is designed to be administered through a quick, minimally invasive, generally outpatient procedure, with minimal radioactive exposure, and to yield rapid results without the need for hospitalization or protective gear. We believe that, if approved and commercialized, physicians could easily adapt the customizable treatment to a wide patient profile range without the need to purchase special equipment.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Potential stimulatory immune effect</b><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Pre-clinical studies have demonstrated encouraging anti-tumor immune responses, cancer resistance and prolonged survival, with early results suggesting potential systemic cancer immune response when tested in combination with immunotherapies or other systemic therapies:</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Our Strategy</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our mission is to use our proprietary Alpha DaRT technology to transform the treatment of solid tumors and broaden the potential scope of local radiotherapy delivery across multiple clinical settings. Key elements of our strategy include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Complete our ongoing U.S. clinical trial evaluating the feasibility of Alpha DaRT in treating malignant skin and superficial soft tissue tumors. </b><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are conducting a multi-center pilot feasibility trial to explore the delivery of radiotherapy for malignant skin and superficial soft tissue tumors using Alpha DaRT at Memorial Sloan Kettering Cancer Center and up to five other clinical sites around the United States. All ten patients in this trial were treated in the second half of 2021. The study met its primary feasibility endpoint, as all patients had successful delivery of radiation by Alpha DaRT. At approximately 12 weeks, all ten lesions treated demonstrated a complete response to the treatment, with no product-related serious adverse events observed. Pending feedback from the FDA, we anticipate initiating a pivotal trial in 2022.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Advance our global development pipeline by conducting feasibility studies in other tumors of high unmet need or metastatic diseases. </b><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are seeking to develop the Alpha DaRT technology by conducting feasibility studies in other indications and then generating potentially registrational data in other such indications, such as breast, pancreas and prostate cancers, as well as in patients with metastatic cancer. As of March&#160;21, 2022, we have nine clinical trials ongoing worldwide. We are also planning to investigate additional indications in pre-clinical studies, including hepatic cell carcinoma, glioblastoma multiforme, lung cancer and others.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Continue to evaluate the potential systemic immune response generated by the Alpha DaRT, particularly in combination with immunotherapies. </b><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have conducted extensive pre-clinical studies focused on the combination of Alpha DaRT with immunomodulators, which have demonstrated encouraging anti-tumor immune responses. By combining our Alpha DaRT technology with systemic therapies, we seek to harness the Alpha DaRT&#8217;s potential immunogenic activity and trigger an immune response to detect and destroy metastatic cancers. In November&#160;2021 we enrolled the first patient in our feasibility combination study of Alpha DaRT and pembrolizumab (Keytruda) for the treatment of SCC of the head and neck, or HNSCC, in Israel. We are currently constructing our own radioactive pre- clinical laboratory at our headquarters in Jerusalem, Israel to further enhance our capabilities of exploring potential combination therapies with Alpha DaRT.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Expand our independent manufacturing capabilities across strategic geographical regions. </b><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are establishing production sites in key regions around the world to supply sufficient radioactive sources with fast, reliable and cost-efficient delivery to our global clinical trials and core markets where we may seek additional marketing authorizations. We currently operate two manufacturing plants: a first facility located in Jerusalem, Israel and the second facility located in the United States, in Lawrence, Massachusetts. We are in the design phase for a facility in Togane, Japan.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Pursue marketing authorization and, if authorized, third-party payor coverage in multiple geographies, with a focus on the United States. </b><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We anticipate pursuing marketing authorization, third-party payor coverage and reimbursement for the use of our Alpha DaRT technology in multiple geographies, with a focus on the United States. If approved, we expect to </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">commercialize our Alpha DaRT technology first in the United States before other markets, including Israel, notwithstanding our existing marketing authorization in Israel.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Background of Radiation-Based Cancer Treatment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Solid Tumors</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Tumors develop as an accumulation of mutated cells that are unable to regulate their growth, moving through the cell cycle uncontrollably and dividing excessively with properties that enable them to invade and destroy surrounding tissue. Cancer cells are able to co-opt the microenvironment, which enables the tumors to bypass the immune system and promote further growth and spread. Cancer cells can break away from the original tumor via the blood stream or the lymphatic system to form new cells elsewhere, called <i style="font-style:italic;">metastasis</i>, and cause the growth of new blood vessels, a process called <i style="font-style:italic;">angiogenesis</i>, which gives tumor cells a source of oxygen, nutrients and a mechanism to release waste products. In 2020 alone, there were over 19 million new cancer diagnoses and 10 million cancer-related deaths worldwide, of which over 90% related to solid tumors, according to the World Health Organization&#8217;s International Agency for Research on Cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Radioactive Decay</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Radioactive decay, the process by which a source emits energy that can penetrate certain materials, is well known for its extreme potency and capacity to destroy living cells when the radiation generated is at a sufficiently high intensity. Such sources include elements that possess an excess or imbalance of energy and consequently lack internal stability. As a result, such elements, termed <i style="font-style:italic;">radionuclides or radioisotopes</i>, will naturally and spontaneously emit, or <i style="font-style:italic;">radiate</i>, the excess energy in order to stabilize, in a random process which cannot be predicted. However, it is possible to define certain parameters such as the nature of the decay and its likelihood over a specified period of time. Amid the process of radioactive decay, the original element, with the excess energy stripped, will spin off into a new element, or a daughter atom. If this daughter atom is itself unstable, it, too, will shed its excess energy and generate its own daughter atom, setting into motion a decay chain until full stability is ultimately reached. While it remains unknown how long it will take an individual atom to fully stabilize, we can quantify how long it will take, on average, for half of a given quantity of an element to decay: known as a <i style="font-style:italic;">half-life</i>, which can range among different radioisotopes from as little as infinitesimal fractions of a second, to billions of&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Alpha, Beta, and Gamma Radiation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Specific radioactive elements will consistently undergo one or more types of radioactive decay with their own, fixed characteristics, and can result in the release of particles or photons. For example, the element Radium-224 will undergo decay by shedding two protons and two neutrons (alpha particle), generating the element Radon-220, and in so doing, emit energy during the release of the alpha particle. This process is known as <i style="font-style:italic;">alpha radiation </i>or <i style="font-style:italic;">alpha decay</i>, and the alpha particle, bearing the mass-heavy, sloughed-off protons and neutrons, will itself be heavy (with an atomic mass of 4). By comparison, one form of <i style="font-style:italic;">beta decay </i>occurs when an element emits an electron, with a negative charge and a relatively low mass. Alpha particles are far bulkier and slower than beta particle electrons: over 7,000 times heavier with approximately 200 times the linear energy transfer rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Alpha and beta particles, being charged, interact with the charges of every atom they encounter and continually slow down as they travel. Because alpha particles have such a high mass and linear energy transfer rate, they dissipate their energy quickly and are unable to penetrate most surfaces, even as thin as a piece of paper. Alpha particles therefore have no clinical impact when delivered externally, since they cannot penetrate the skin. On the other hand, beta particles are more nimble than their alpha counterparts and can penetrate further into matter; however, because they have equally low mass as the electrons they encounter, beta particles transfer their energy and also fade quickly when encountering a surface of some thickness, such as being stopped by a sheet of aluminum.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Gamma decay</i>, by contrast, does not involve any transfer of charge but rather a reconfiguration of the existing subatomic particles, triggering the emission of high-energy photons in the form of gamma rays that can pass longer distances and are attenuated over lengths, depending on the medium being traversed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Radioactivity involves spontaneity, with high radioactivity corresponding to high likelihood of sporadic emissions towards stabilization. Clinical application of the emitted energy&#160;&#8211; the alpha particles, beta particles and gamma rays&#160;&#8211; from a radioactive source therefore demands the controlled harnessing of a spontaneous phenomenon, but with some predictable, key parameters, towards a specific desired outcome.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Mechanisms of Alpha, Beta, and Gamma Radiotherapy</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Radiation, when aimed towards the destruction of cancerous or other damaged cells in the body, is known as <i style="font-style:italic;">radiotherapy</i>. Depending on the patient&#8217;s particular condition, radiotherapy can be either an alternative or a complement to surgery or systemic therapies for the treatment of cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cell death induced by radiotherapy can occur either through direct or indirect DNA damage. Alpha particles generate direct DNA damage, while beta particles and gamma rays destroy cancer cells primarily when they encounter oxygen: specifically, they rely on the presence of oxygen which, upon impact from the beta or gamma radiation, forcefully ejects electrons in a process known as <i style="font-style:italic;">ionization</i>, wherein these atoms, now excited with unpaired electrons, become free radicals which are highly reactive. While the beta or gamma radiation will have little direct impact on the cells, the highly reactive free radicals will react with cellular machinery, including a strand of DNA should they encounter one, generating a single-strand break in the DNA. This is often a short- lived success, however, as the cancer cell may be able to reconstitute or repair the DNA damage after single- strand breaks, depending on its current position in the cell cycle. By contrast, alpha-emitters, with hundreds of times the linear energy transfer rate of beta-emitters, and alpha particles&#8217; heavier mass and far shorter particle paths (less than 100 &#956;m) relative to beta particles&#8217; lighter mass and lengthier (up to 12 mm) path, have destroyed radioresistant cells more effectively than other forms of radiation such as photons (e.g. X-rays) in pre-clinical studies&#160;&#8211; causing multiple, irreparable, DNA double-strand breaks and other cellular damage upon <i style="font-style:italic;">direct </i>impact&#160;&#8211; within a very short distance. Alpha radiotherapy has approximately 500x more concentrated cytotoxic potency than beta particles, with radioactive potency that attenuates as they travel. Beta and gamma radiation are inherently limited in their use in radiotherapy, as their weaker potency and their reliance on multiple interactions demand significantly higher levels of radiation to destroy cancer cells, and these modalities have shown limited efficacy in hypoxic tumor tissue due to the lack of oxygen to generate free radicals. In addition, the relatively long range of beta and gamma increases the risk of greater imprecision, dissipation of potency, and potential collateral tissue damage. By contrast, we believe that alpha radiotherapy, owing to the nature of its high strength and very tightly controlled range, as well as the <i style="font-style:italic;">direct </i>cellular impact not reliant on oxygen, has the potential to overcome treatment resistance to beta and gamma radiotherapy, and to offer a highly conformal and effective source of radiotherapy with very limited damage to surrounding tissues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe that alpha radiation may also have the potential to generate an immune-modulated systemic effect in the body when being used for localized treatment, given that it possesses several unique properties:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</span></span><span style="color:#231f20;">its high linear energy transfer, (b)&#160;rapid tumor cell destruction while sparing the surrounding lymphatic tissue, nearby tissues and blood vessels, and (c)&#160;the potential to release large amounts of tumor antigens and attract inflammatory and immune cells into the tumor vicinity.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Systemic vs. Local Radiotherapies</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Radiotherapy can be deployed as both a systemic agent and as a localized therapy. <i style="font-style:italic;">Systemic </i>therapies are those which treat the entire body, and in the context of cancer therapies generally utilize pharmaceutical products, such as chemotherapy or immunotherapy drugs, injected into the body to damage (or stimulate the body to damage) cancer cells throughout the body preferentially over other cells. <i style="font-style:italic;">Local </i>therapies, such as surgical excision, are those which address a disease or injury at a specific point, and in the context of cancer therapies will generally target a specific tumor or set of tumors to be treated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Localized radiotherapy is commonly performed by <i style="font-style:italic;">External Beam Radiotherapy</i>, or EBRT, directing external beams of gamma radiation powerful enough to penetrate the body and damage or destroy cancer cells&#8217; DNA if such cells are in the process of division. EBRT remains a widely used form of radiotherapy, but due to the high doses required for tumor control, results in normal tissue toxicity. While toxicity has been reduced due to technologic improvements such as Intensity-modulated radiation therapy, or IMRT, which allow for a more conformal treatment, significant side effects have continued to be observed in the clinic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Developments in the field of nuclear medicine have introduced the use of <i style="font-style:italic;">radiopharmaceuticals </i>or <i style="font-style:italic;">radio- labeled antibodies</i>, drugs containing a radiation-emitting radionuclide that is naturally absorbed into specific organs or binds to specific molecules to target specific organs, tissues or cells within the body. Systemic radiotherapy involves the use of isotopes such as beta emitting Iodine-131, Strontium-89, Samarium-153, and Radium-223, alone or attached to targeting molecules and injected in liquid form into the body intravenously to travel through the bloodstream to kill cancerous cells, and are then ejected from the body via urine, sweat, and saliva.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Limitations of Systemic Radiotherapy</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Systemic radiotherapy is beset by certain significant limitations. Although the radiopharmaceuticals or radio-labeled antibodies are armed with targeting mechanisms, certain amounts of radionuclide may still damage healthy tissue. Additionally, certain tumors may be beyond the reach of intravenously administered radiopharmaceuticals. Given the need for sufficient concentration of radiation at the tumor site to have an effect, systemic therapy has the potential to generate systemic toxicity and collateral damage to healthy tissue, critical organs and blood vessels, without sufficiently addressing the targeted tumor if the local concentration of radiation on site is insufficient.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Limitations of Local Radiotherapy</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In contrast to systemic radiotherapies, local radiotherapies are targeted directly to the cancer and therefore may avoid the shortcomings of systemic treatment. By focusing on the tumor and sparing the healthy cells, there may be fewer debilitating side effects, and the cancerous cells may be destroyed while allowing healthy cells to utilize their superior repair mechanisms to recover from the impact of localized radiation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Local radiotherapy can be performed either externally, by directing one or more beams of EBRT, such as high-energy X-rays or gamma rays, towards the primary tumor and its immediate surroundings, or internally, through the insertion into the body of radiation in solid form, a procedure known as brachytherapy. EBRT and related therapies can be an effective method of destroying the tumor by irradiation but are prone to causing spillover damage in the surrounding healthy tissue and are therefore not practicable in every situation, as certain tumors may be unable to receive a sufficient therapeutic dose due to the surrounding normal tissue tolerance. Recent innovations in the field, such as IMRT, stereotactic radiosurgery and stereotactic body radiation therapy, have focused on improving the precision of gamma rays to concentrate more radiation in a tighter area, but ultimately face similar limitations from the innate characteristics of gamma rays.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In brachytherapy, small capsules containing a therapeutic dose of radiation, or seeds, are placed in or as close as possible to the tumor. By hewing closely to the tumor and utilizing the sharp dose falloff beyond the seed, physicians may more ably navigate around the healthy surrounding tissue. Brachytherapy, in being based on beta or gamma radiation, has similar concerns with respect to spillover damage in the surrounding healthy tissue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A less common form of internal radiotherapy is radioembolization, or selective internal radiation therapy, via tiny radioactive beads. The ability of these radioactive beads to adhere to small blood vessels has led to their use in the treatment of liver cancer. Given the unique differential blood supply of the liver, irradiating the tumor and concurrently blocking the blood supply may deprive the tumor of vital oxygen and nutrients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In any instance of radiotherapy, the total exposure must be carefully calibrated, as the human body has a fixed, maximum level of radiation tolerance before the onset of irreversible toxicity and debilitating side effects, such as impaired brain, spinal cord, kidney and bone marrow function and immune deficiency. With its higher relative biological efficiency enabling lower dose levels for anti-tumor activity, and very limited range, we believe alpha radiotherapy may offer an attractive treatment modality against this backdrop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Uses of Alpha Radiation in Radiotherapy</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe alpha radiation has several significant advantages for use in cancer radiotherapy, including having a high relative biological efficiency (potentially enabling it to destroy tumor cells with administration of lower levels of radiation); it is impervious to factors such as hypoxia, and it has a very well-defined range of travel with limited collateral damage. Nonetheless, its use has also been limited precisely due to alpha&#8217;s extremely short particle range of less than 100 &#956;m in living tissue, well below the threshold of clinical utility. For this reason, traditional attempts to deliver alpha radiation locally have failed to generate a clinically useful killing effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The limited use to date of alpha radiation in radiotherapy has been in systemic therapies using radiopharmaceuticals. For example, Xofigo, a salt of radium that naturally localizes to regions where cancer cells are infiltrating bone, has been approved by the FDA for the treatment of bone metastases associated with prostate cancer. Other experimental systemic alpha applications often rely on the conjugation of an alpha-emitting radioisotope with a targeting mechanism such as an antibody (creating an antibody-radionuclide conjugate), with the aim of preferential attachment to cancer cells throughout the body before the radionuclide decays. No solution has </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:191.04pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">been approved that delivers local alpha particles able to penetrate into the depth of tumors, which we believe has hindered the local radiotherapeutic utility of alpha emitters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Our Solution: Alpha DaRT Technology</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Mechanism of Action of the Alpha DaRT Technology</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Alpha DaRT technology is designed to act through the controlled release of alpha-emitting atoms directly into a tumor, relying on the innate decay chain of Radium-224 to release and propel multiple alpha emitters deeper into the tumor than can be achieved by the limited (less than 100 &#956;m) ranges of the alpha particles themselves. Radium-224, with a decay chain releasing four alpha particles, has a half-life of approximately 3.7&#160;days, while the remaining decay chain has a total half-life of approximately 12 hours, before eventually stabilizing in inert form.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Alpha DaRT utilizes stainless steel sources that are embedded with Radium-224. The Alpha DaRT source is designed to be injected into the tumor using one of the proprietary applicators we have developed. Once injected, the radium remains attached to the source, while its daughter atoms detach, spontaneously decay and recoil in succession, with the goal of emitting potentially cytotoxic alpha particle payloads as they move deeper into the tumor until eventually stabilizing. The sources are designed to be placed a few millimeters apart from each other in the tumor to fully utilize the range of each source, and the Alpha DaRT&#8217;s localized action is designed to kill the cancer cells while sparing the neighboring healthy cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The illustration below depicts the decay chain process of Radium-224, which is affixed to the Alpha DaRT source while its daughter atoms are designed to diffuse inside a tumor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="drts-20211231x20f006.jpg" alt="Graphic" style="display:inline-block;height:99.99pt;left:0%;padding-bottom:0.55pt;position:relative;top:0pt;width:467.94pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The graphics below illustrate the radioactivity seen in a cross-section of a tumor grown in a mouse with a single Alpha DaRT source through the center, as well as the impact on the tumor from an adjacent slice under a histological stain. As illustrated, the Alpha DaRT delivered a high dose of radiation in a very conformal form, with near zero radiation detected outside of the 5mm range surrounding the source. This result is also seen clearly under histological stain, where the corresponding section of the tumor was destroyed while the surrounding environs continued to be unaffected by radiation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="drts-20211231x20f007.jpg" alt="A picture containing text, arthropod&#10;&#10;Description automatically generated" style="display:inline-block;height:191.04pt;width:435.84pt;" /></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:187.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The radioisotopes are designed to disperse in the cancerous medium by diffusion and convection due to the tumor chaotic vascularity, as well as from ongoing recoil during the repeated alpha decays. Moreover, the blood vessels formed in tumors tend to have leaky walls, which we believe increases the chance of the radioactive isotopes staying in the tumor and potentially prolonging killing activity. The net result is that the potential range of cell killing in the tumor is up to five millimeters, which is up to 100 times the range of the alpha particles themselves. By contrast, healthy tissue has a highly organized vascular structure, with numerous, well-ordered blood vessels through which a radioisotope can be easily washed out..</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In our animal studies, the range of the Alpha DaRT was meaningfully more extensive in tumor tissue than it was in healthy tissue, as shown in the two images below comparing radioactivity visible on a radiograph when inserting the Alpha DaRT into SCC tissue and healthy tissue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:51.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="drts-20211231x20f008.jpg" alt="Graphic" style="display:inline-block;height:187.2pt;left:0%;padding-bottom:0.3pt;position:relative;top:0pt;width:262.69pt;" /></p></td><td style="vertical-align:top;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="drts-20211231x20f009.jpg" alt="Graphic" style="display:inline-block;height:187.2pt;left:0%;padding-bottom:0.3pt;position:relative;top:0pt;width:278.22pt;" /></p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Diffusion in SCC</p></td><td style="vertical-align:top;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Diffusion in Healthy Tissue</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Our Programs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Clinical Development Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our development strategy is focused on evaluating the safety and efficacy of the Alpha DaRT technology across multiple solid tumor types through broad-ranging pre-clinical studies and into clinical trials. We have successfully completed a first-in-human trial of Alpha DaRT in patients with superficial and skin tumors and are focused on further developing Alpha DaRT for purposes of seeking FDA marketing authorization in this indication. We are also generating additional clinical evidence regarding the Alpha DaRT technology in superficial and skin tumors from clinical sites around the world, to provide further support for a potential FDA marketing authorization and third-party payor coverage and reimbursement in the United States and around the world. In parallel, we are pursuing a similar approach towards developing the Alpha DaRT technology for other uses by conducting feasibility studies and then generating potentially registrational data in other indications, such as breast, pancreas and prostate cancers, or applications such as combinations with immunotherapies. We have engaged with a number of prestigious medical and educational institutions and, as of March&#160;21, 2022, we have nine clinical studies ongoing worldwide.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Squamous Cell Carcinoma of the Skin, Head and Neck</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">SCCs are cancers which grow out of squamous epithelial cells, commonly found on the skin or in the lining of bodily organs or respiratory and upper digestive tracts. According to the American Cancer Society and the Skin Cancer Foundation, more than one million cases of SCC of the skin are diagnosed every&#160;year in the United States. Over 50,000 cases of SCC of the head and neck are diagnosed every&#160;year in the United States, with SCC making up approximately 90% of head and neck cancers. In the more difficult cutaneous SCC cases, we estimate that approximately 10% are treated by radiotherapy, and nearly 20% of cutaneous SCC will recur within five&#160;years after treatment by superficial radiotherapy. We selected SCC of the skin, head and neck as an initial target for the Alpha DaRT because of the relative simplicity of delineation and delivery to superficial solid tumors, as well as the ability to easily </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">assess the Alpha DaRT&#8217;s effects on the tumors and the surrounding tissue on an ongoing basis and to monitor for any potential serious adverse events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Rabin Medical Center, Israel, and ISRT, Italy (Completed; 2017&#160;&#8211; 2019)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We evaluated the feasibility, safety and efficacy of the Alpha DaRT technology in a first-in-human study of locally advanced and recurrent squamous cell carcinoma cancers of the skin and head and neck, the results of which were subsequently published in the International Journal for Radiation Oncology, Biology, Physics and which elected a positive editorial reaction in the same journal. The trial was conducted in an elderly (median age = 80.5&#160;years) and largely pre-treated patient population, with 42% of the treated lesions having already received radiation therapy. Efficacy was evaluated in 28 tumors of the skin and head and neck, and results showed that Alpha DaRT achieved a &gt;78% complete response rate. The Alpha DaRT was generally well-tolerated, with limited local toxicity and no systemic toxicity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Study Design</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This prospective, first-in-human, multi-center clinical study initially included 31 lesions across 27 patients. Four patients were enrolled at first to evaluate feasibility, which was defined as the ability to implant Alpha DaRT into a tumor without generating Grade 3 toxicity after three&#160;months on treatment. Once feasibility was established, an additional 23 patients were enrolled to further evaluate toxicity and preliminary efficacy, namely, the tumor response and local progression-free survival, or PFS. Eligibility criteria included patients with biopsy- proven squamous cancers of the skin and head and neck with either primary tumors or recurrent/previously treated disease by either surgery or prior external beam radiation therapy; 13 of 31 lesions (42%) received prior radiation therapy. Safety was evaluated according to the Common Terminology Criteria for Adverse Events, or CTCAE, version 4.03. Tumor response was assessed at 30 to 45&#160;days at a follow-up visit using the Response Evaluation Criteria in Solid Tumors, version 1.1, or RECIST. Median follow-up time was 6.7&#160;months when the trial ended in March&#160;2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Eastern Cooperative Oncology Group, or ECOG, Performance Status scale was also evaluated at baseline. Lesions were photographed and measured physically. Additional baseline (pre-insertion) examinations included complete blood test, liver and kidney function tests, urinalysis, and radioactivity measurements in blood and urine. After enrollment, eligible patients underwent a computed tomography, or CT, scan to obtain pretreatment tumor volume. These values were used to determine the appropriate number of Alpha DaRT sources required to encompass tumor volume. Before treatment, an experienced head and neck surgeon evaluated all patients to assess feasibility for further salvage surgery.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Thirty-one lesions in 27 patients were evaluated in this study, including 22 patients from Rabin Medical Center, Israel, and five from Instituto Scientifico Romagnolo per Lo Studio e la Cura dei Tumori, Italy. Of the 31 lesions, efficacy evaluations were conducted on 28 lesions from patients who met the study eligibility criteria, received the protocol-specified Alpha DaRT treatment, and completed the minimum follow-up at 6 weeks after treatment. The average number of Ra-224 DaRT sources inserted into these 31 tumors was 27.7 sources (range, 3-169 sources) of two &#956;Ci each, with an average treatment duration of 16.3&#160;days. The average radioactivity of the sources on the day of insertion was 55.4 &#956;Ci.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Biosafety Evaluation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Radioactivity measurements (at insertion site, at different body areas, and in blood and urine samples), vital signs, and general assessments of the patients&#8217; medical condition were recorded at baseline and during follow-up visits. There was no measurable radioactivity from the treatment in the blood and urine in patients 30&#160;days after treatment. The values of alpha doses were well within the maximum tolerable doses of radiation for the lungs, kidneys, and bone marrow at 1500, 500, and 100 centiGy (a unit of measuring absorbed radiation dose), respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Study follow-up examinations included repeat blood tests and urinalysis, additional blood and urine radiation measurements, and assessment of ECOG Performance Status scale at four, nine, and 30&#160;days post- Alpha DaRT insertion. Tumor size was measured again at 30 to 45&#160;days following Alpha DaRT insertion. Change in tumor size was assessed by physical examination when possible, or in most cases, by radiological imaging, including PET-CT or CT scans. Tumor response was assessed during a 30-to-45 day follow-up visit using RECIST. Only the irradiated tumor was considered a target lesion for response assessment. Response criteria were defined as follows: complete response, disappearance of the irradiated tumor, or CR; partial response, at least a 30% decrease in the longest dimension of the irradiated tumor, or PR; progressive disease, at least a 20% increase in the longest dimension of the irradiated tumor, taking as reference the smallest longest dimension recorded in radiotherapy, or PD; stable disease, neither sufficient shrinkage to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:196.54pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum since the treatment started. Four to six weeks following Alpha DaRT insertion, a biopsy was obtained if there was clinical suspicion of residual disease. Patients were subsequently evaluated every two&#160;months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Efficacy Results</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Twenty-eight target lesions were evaluable to determine tumor response. All evaluable target lesions responded to treatment, with CRs observed in 22 lesions (78.6%), and a PR (tumor reduction between 30% and 100%) was observed in the other six lesions (21.4%). An example of a CR observed in a patient with a newly diagnosed scalp tumor is shown in the figure below.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:86.57%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="drts-20211231x20f010.jpg" alt="Graphic" style="display:inline-block;height:195.94pt;left:0%;padding-bottom:0.6pt;position:relative;top:0pt;width:229.93pt;" /></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="drts-20211231x20f011.jpg" alt="Graphic" style="display:inline-block;height:195.85pt;left:0%;padding-bottom:0.65pt;position:relative;top:0pt;width:175.65pt;" /></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Pre-Treatment</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Alpha DaRT Insertion</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:43.28%;"><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="drts-20211231x20f012.jpg" alt="A close-up of a person's chest&#10;&#10;Description automatically generated with low confidence" style="display:inline-block;height:182.93pt;left:0%;padding-bottom:0.1pt;position:relative;top:0pt;width:227.75pt;" /></p></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">30 Days Post Alpha DaRT Insertion</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Fifteen of the 16 evaluable lesions (94%) that did not receive prior radiotherapy demonstrated a CR and, among the lesions that were previously treated with radiotherapy, 7 of 12 (58%) had a CR. Among the 22 lesions that achieved a CR, 5 developed a local relapse at the site of DaRT implantation at a median of 4.9&#160;months (range, 2.43-5.52&#160;months) after treatment. The Kaplan-Meier estimated local PFS rate for all patients at one&#160;year was 44% (CI, 20.3-64.3%). Among patients with an initial CR to treatment, the Kaplan-Meier estimated local PFS rate at one&#160;year was 60%. Only 32% of the patients had a full&#160;year of follow-up. Patients who </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:312.71pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">achieved an initial CR had significantly higher local PFS and overall survival rates at one&#160;year compared with those who achieved a PR (60.1% and 93% compared with 0% and 0%, respectively) (Fig).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="drts-20211231x20f013.jpg" alt="Graphic" style="display:inline-block;height:312.71pt;width:416.03pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">Local Progression-Free Survival Stratified by Response Status</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Overall survival rates to 12&#160;months post-DaRT implantation were 75% (95% CI, 46.14-89.99%) among all patients and 93% (95% CI, 59.08-98.96%) among complete responders. The median follow-up was 6.7&#160;months (range, 1.45-23.36&#160;months).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">One patient who was treated twice for skin SCC exhibited a unique response, as each time a lesion was treated, a second, non-target lesion responded as well, manifesting as CR to the treatment. The details of this patient&#8217;s unique response were published in a 2019 case report in the <i style="font-style:italic;">Journal of Contemporary Brachytherapy</i>. The publication concluded that DaRT treatment may play a very important role because it could stimulate an anti-tumor immune reactivity with more ease than low-LET radiation that is used with conventional EBRT.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Furthermore, the destruction of the tumor by DaRT maintains an intact vasculature around the tumor, enabling an influx of immune cells to recognize and destroy tumor cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There was no statistically significant difference in local PFS between primary (newly diagnosed) and recurrent lesions at one&#160;year. Median local PFS among patients with recurrent tumors was 5.5&#160;months and was <span style="color:#231f20;">5.09&#160;months for those with primary tumors. There was also no statistically significant difference in local PFS between recurrent or primary lesions. There was no significant difference in initial response rates and toxicity outcomes between patients who received prior radiotherapy and those who did not. Median local PFS among patients with prior radiation was 5.2&#160;months and was 5.1&#160;months for those without previous radiation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Following these initial positive results, we expanded our clinical evaluations to a wider patient population and initiated follow-on trials at multiple clinical sites in Israel and around the world. These trials are designed to evaluate Alpha DaRT in cancers of the skin, superficial soft tissue, or oral cavity, regardless of cell type, which includes SCC as well as basal cell carcinoma, melanoma, skin </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">metastases, and others. We also initiated a trial to evaluate the retreatment of patients who previously were treated with the Alpha DaRT. As of February&#160;28, 2022, across our clinical trials involving superficial lesions, i.e., tumors of the skin, head or neck, Alpha DaRTs have been administered to over 100 lesions, with no treatment-related SAEs, and in a pooled analysis of patients who were treated per the applicable trial protocol, we identified an overall response rate of 98% observed among those lesions that reached the evaluation endpoint, including a complete response rate of 74%. The data from these first trials led to the FDA granting Breakthrough Device Designation to the Alpha DaRT for the treatment of patients with SCC of the skin or oral cavity without curative standard of care.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Safety Results</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Treatment-related adverse events generally included local pain and erythema at the implant site, followed by swelling and mild skin ulceration, and were limited to Grade 1 (mild) or Grade 2 (moderate) adverse events. For pain and Grade 2 skin ulcerations, 90% of patients showed resolution of these adverse events within three to five weeks. In general, these acute toxicities were resolved within a median time of 15&#160;days. In eight patients, the Alpha DaRT sources were inserted adjacent (less than 5 mm) to bone and teeth, and none developed osteoradionecrosis. Two serious adverse events, or SAEs, were reported, both of which were determined to be unrelated to the study treatment. No device-related SAEs were observed during the course of treatment or at follow-up. The incidence rate of device-related SAEs was 0% over time (95% confidence interval, or CI, 0-12.06%) and the incidence rate of unrelated SAEs was 7.14% (95% CI, 1.98-22.65%). Two SAEs were reported, both of which were determined to be unrelated to the protocol therapy. One patient developed pneumonia after therapy and subsequently expired owing to their underlying poor performance status and multiple comorbidities. In a second patient treated with the Alpha DaRT for a SCC confined to the nose, cerebral edema was attributed to a prior course of radiation therapy to the base of skull and posterior orbit. No device- related SAEs were observed during the course of treatment or follow-up. No subsequent toxicities were observed during follow-up visits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Memorial Sloan Kettering Cancer Center, NY / Multi-Center (Ongoing)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have received approval of an investigational device exemption, or IDE, from the FDA to evaluate Alpha DaRT in a clinical study designed to collect preliminary safety and efficacy data that may be required to support an application for marketing authorization. The IDE permits us to conduct a clinical study to evaluate the feasibility of Alpha DaRT in treating malignant skin and superficial soft tissue tumors. This trial was initially opened in 2020 at Memorial Sloan Kettering Cancer Center, New York, but recruitment was delayed due to the impact of COVID-19 in New York City. The FDA recently approved our request to convert the study into a multi-center study via the addition of up to five other clinical sites around the United States. Following completion of this trial, and pending further discussion with the FDA, we plan to conduct a single pivotal trial to support U.S. marketing authorization. All ten patients in this trial were treated in the second half of 2021. The study met its primary feasibility endpoint, as all patients had successful delivery of radiation by Alpha DaRT. At approximately 12 weeks, all ten lesions treated demonstrated a complete response to the treatment, with no product-related serious adverse events observed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18.15pt;"><i style="font-style:italic;">Study Design</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The initial IDE study is a pilot feasibility trial in which 10 subjects will be enrolled, with an interim read-out planned after the first five subjects administered with the Alpha DaRT have been evaluated. The primary objectives are to explore the feasibility of delivering radiotherapy for malignant skin and superficial soft tissue tumors using Alpha DaRT, with a goal of achieving successful delivery in at least 7 of the 10 patients, as well as to determine the frequency and severity of acute adverse events. Secondary objectives will include assessments of radiotherapy-related adverse events, tumor response, radiation safety, stability of device placement, and quality of life measures. Eligible patients will have a malignant skin or superficial soft tissue tumor 1-5 cm in size that is suitable for percutaneous interstitial brachytherapy, a form of radiotherapy. The minimum longest dimension for the tumor is 1 cm. The minimum tumor thickness is 4 mm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">After enrolling in the trial, eligible subjects will undergo a volumetric assessment of the tumor by a CT planning scan. Volumetric images will be used to generate the plan for delivering Alpha DaRT by defining the optimal number, size and location for Alpha DaRT source placement. After radiation planning is completed, the Alpha DaRT source will be inserted using pre-planned radiotherapy parameters (with a specified number and size of Alpha DaRT sources). Immediately after placement of the Alpha DaRT sources, a standard planning CT will be performed to assess source positions within the tumor. A physical dose of 10 Gy will be prescribed, which is equivalent to a weighted radiation dose of 200 CGyE.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:111.73pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Approximately two to three weeks after placement of the Alpha DaRT sources, the placement of the sources will be reassessed by volumetric imaging, and then they will be removed. Tumor response will be assessed periodically three&#160;months after removal of the Alpha DaRT source.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Combination Study: DaRT + Checkpoint Inhibitor (Recruiting)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As part of our clinical development program for the Alpha DaRT in SCC, in November&#160;2021 we initiated a combination study of the Alpha DaRT and pembrolizumab (Keytruda) for the treatment of HNSCC, in Israel. We chose to evaluate the Alpha DaRT in combination with pembrolizumab for the treatment of HNSCC because in our pre-clinical studies (discussed below), the combined use of Alpha DaRT with immunomodulators resulted in decreased metastatic burden and improved survival in treated animals. Further, the results indicated that this activity was modulated by activation of the immune system. Both pembrolizumab, a humanized antibody targeting the PD-1 receptor of lymphocytes, and Alpha DaRT have shown positive results in clinical studies in the treatment of HNSCC. Consequently we are aiming to explore the combination of these interventions as a potential treatment for metastatic or recurrent HNSCC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Study Objectives and Design</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The primary objectives of this study are to evaluate efficacy of Alpha DaRT in combination with pembrolizumab via the Confirmed Best Overall Response as defined by RECIST. Secondary objectives include assessments of the frequency, severity and causality of acute adverse events related to the Alpha DaRT treatment in combination with pembrolizumab. Patients enrolled in the trial will receive pembrolizumab cycles every three weeks both before and after receiving Alpha DaRT treatment. The study uses a two-stage adaptive design and can recruit up to 48 patients, with a planned interim analysis after the first 18 patients have been treated. Adverse events will be assessed and graded according to CTCAE version 5.0. PFS will be defined as the time from embrolizumab treatment start date to progressive disease according to RECIST or death due to any cause, whichever occurs first. Overall Survival is defined as the time from pembrolizumab treatment start date to death due to any cause or lost to follow up. Duration of Response is defined as the interval from the time measurement criteria are first met for CR, PR, or stable disease (whichever is first recorded) until the first date recurrent or progressive disease is objectively documented. Exploratory objectives include the assessment of immunological parameters as a result of Alpha DaRT administration in combination with pembrolizumab. The image below illustrates the trial design for this combination study:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="drts-20211231x20f014.jpg" alt="Graphic" style="display:inline-block;height:111.73pt;width:424.59pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">France Multi-Center&#8211; Skin Cancer (Open)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have initiated a multi-center study at six cancer centers in France to investigate the safety and efficacy of Alpha DaRT for the treatment of malignant cutaneous tumors. The target population will consist of two cohorts: newly diagnosed patients (up to 49 subjects), and patients with recurrent disease or aggressive pathology (i.e., melanoma) (36 subjects). The primary effectiveness endpoint is the assessment of the overall response rate, or ORR, using RECIST criteria, 9 to 11 weeks after Alpha DaRT source insertion. The secondary effectiveness endpoints include assessment of the reduction in tumor volume based on CT / ultrasound / physical examination- measured tumor volume at 9 to 11 weeks, assessment of Alpha DaRT source placement using CT imaging on the day of Alpha DaRT insertion, patient-reported health-related Quality of Life, or QoL, outcomes, and Disease- Free Survival at 12- and 24-months post-Alpha DaRT source insertion. Safety objectives include assessment of acute AEs both related and unrelated to Alpha DaRT administration, according to CTCAE version 5.0, all vital signs, blood and urine tests, and subject external radiation levels, and assessment of chronic AEs related to Alpha DaRT at 12- and 24-months post-source insertion.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Breast Cancer</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We selected breast cancer as the next target for clinical evaluation of the Alpha DaRT given the potential for percutaneous access using similar applicators to those we have used in clinical studies evaluating skin, head&#160;&amp; neck tumors, as well as the high worldwide incidence of the disease. In the United States, the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute estimates there will be over 280,000 new female breast cancer diagnoses in 2021, and the U.S. Centers for Disease Control and Prevention reports that breast cancer is the second most common cancer in US women, after skin cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Japan&#160;&#8211; Head and Neck Cancer and Breast Cancer (Recruiting)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Japanese Cancer Information Service, in 2013 there were approximately 25,000 new diagnoses of skin cancers, 19,000 new diagnoses of cancers of the oral cavity&#160;&amp; pharynx, and 77,000 new diagnoses of female breast cancer in Japan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In Japan, we are conducting a clinical study at three cancer centers, in which we plan to recruit a total of 18 patients: 12 with head or neck cancer and six breast cancer patients. The study is designed as a prospective, single arm open-label study. Patients with a history of radiation therapy with cancer of the head and neck or breast which is recurrent and non-responsive or non-indicative for medical treatment are included in the study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The primary objective and endpoint of this study is to assess the efficacy of Alpha DaRT, and the rate of reduction in tumor size 9 to 11 weeks after the source insertion is evaluated based on RECIST. The secondary objective of this study is to assess the safety of Alpha DaRT, including as measured by the incidence, severity, and frequency of AEs, including during the observation period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January&#160;3, 2022, we announced the completion of patient recruitment for the head and neck tumors section of the trial. If the results from the head and neck tumors section of the trial are positive, we may engage with Japan&#8217;s Pharmaceuticals and Medical Devices Agency regarding potential review later in 2022. We are continuing to recruit breast cancer patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">A. Tsyb Medical Radiological Research Center, Russia (Recruiting)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2019, we initiated a trial at the A. Tsyb Medical Radiological Research Center in Obninsk, Russia, to investigate the safety and efficacy of Alpha DaRT for the treatment of 30 newly diagnosed breast carcinoma patients with distant metastases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The primary efficacy endpoint of the study is the assessment of tumor response using RECIST 9 to 11 weeks after Alpha DaRT source insertion. The primary safety endpoint is to assess the frequency, severity and causality of acute AEs related to Alpha DaRT sources insertion, assessed and graded according to CTCAE version 5.0. Other safety endpoints include all AEs related and unrelated to the study treatment, vital signs, blood and urine tests, and subject and personnel radiation levels.</p><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">The secondary endpoints include: assessment of the reduction in tumor volume and maximum standardized uptake value (SUV</span><span style="font-size:6.5pt;">max</span><span style="font-size:10pt;">) in CT/PET-CT and any pathological remissions, assessment of the Alpha DaRT source placement using CT imaging on the day of placement, patient-reported QoL measures, any abscopal effect on existing distant metastases at the time of Alpha DaRT removal, and PFS for 6&#160;months after Alpha DaRT source insertion.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2021, one patient had been recruited and treated in this trial. We understand from the clinicians treating her that this patient showed a response following treatment as well as a potential abscopal effect, although we do not expect that this patient will be included in the per-protocol population due to insufficient ongoing imaging.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Pancreatic Cancer</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pancreatic cancer is the fourth leading cause of cancer-related mortality, responsible for 7% of all cancer- related deaths in both men and women. It is associated with an extremely poor prognosis, reflected by a median survival of five to eight&#160;months and a five-year survival probability of less than 5% when all stages are combined. Pancreatic cancer is particularly deadly due to the fact that there are no unique symptoms in its early stages, and, since the pancreas is obscured by other organs in the abdomen and is difficult to visualize clearly on imaging tests, it is therefore typically not detected before having already metastasized to regional lymph nodes, the liver, the lungs or other visceral organs such as the stomach or colon. We selected pancreatic cancer as a target for the Alpha DaRT technology in light of the poor prognosis associated with this particular cancer, as well as our pre-clinical research in which the Alpha DaRT showed activity against pancreatic adenocarcinoma cells.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 5pt;"><i style="font-style:italic;">Centre Hospitalier de l&#8217;Universit&#233; de Montr&#233;al, Canada (Recruiting)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have initiated a single-site clinical study at Centre Hospitalier de l&#8217;Universit&#233; de Montr&#233;al, or CHUM, to investigate the feasibility, safety and preliminary efficacy of Alpha DaRT for the treatment of advanced pancreatic cancer. No patients have been recruited as of December&#160;31, 2021 due to COVID-19. Recruitment is open for 30 patients with locally advanced (Stage II or Stage III) or metastatic (Stage IV) pancreatic adenocarcinoma which has been histologically and/or cytologically proven and which is not amenable to surgery, with a tumor lesion of less than four cm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There are two short-term objectives of this study: to evaluate the feasibility and safety of Alpha DaRT as assessed by the incidence of device-related AEs and SAEs, and to evaluate the preliminary efficacy of Alpha DaRT for pancreatic cancer patients, as measured by ORR following the insertion of the sources, and any observable change in CA19-9 as a marker of tissue damage. The long-term objectives include evaluating overall survival following Alpha DaRT sources insertion, stent durability after Alpha DaRT sources insertion, and change in quality of life as measured by patient questionnaires.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The primary endpoints of the study are: feasibility, as measured by the successful placement of the Alpha DaRT sources within the tumor or less than 5 mm from the tumor, to be determined based on CT scan performed immediately following the insertion procedure; and safety, by assessing the frequency, severity and causality of acute AEs and SAEs related to Alpha DaRT sources insertion. AEs and SAEs will be assessed and graded according to CTCAE version 5.0. Other safety endpoints include all AEs and SAEs related and unrelated to the study treatment, vital signs, blood and urine tests, and subject and personnel radiation levels. For the first five patients, only one patient will be recruited on a four-week basis to allow for assessment of AEs and SAEs before the next patient is recruited, and an interim analysis will be conducted after five patients have been enrolled. Secondary endpoints include: preliminary efficacy, measured by assessing the ORR four to six weeks after Alpha DaRT sources insertion as assessed by CT scan, changes in CA19-9, which serves as a marker of tissue damage (elevation during treatment, and reduction as a result of tumor ablation), and assessments of overall survival, local control, regional control, distal metastases following DaRT sources insertion for 24&#160;months, or until patients are lost to follow-up or disease progression, stents durability (assessed by the time elapsed from DaRT insertion to the need for follow up referral for endoscopic retrograde cholangiopancreatograph, or ERCP, for stent change due to tumor ingrowth), and change in patient-reported quality of life measures 35 and 60&#160;days after Alpha DaRT source insertion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are also in advanced stages of drafting a protocol for another trial evaluating the Alpha DaRT technology in the treatment of pancreatic adenocarcinoma, which we expect to open in Israel in the second half of 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Prostate Cancer</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prostate cancer is the second most frequently diagnosed cancer in men worldwide, with approximately <span style="color:#231f20;">1.3 million new cases diagnosed each&#160;year. We believe there are several potential benefits to delivering neoadjuvant radiation therapy specifically with Alpha DaRT in patients with prostate cancer. First, we believe that Alpha DaRT may be able to elicit an immune response, as suggested by previous pre-clinical data that showed immune activity, as well as data from our clinical studies that showed anecdotal evidence of a potential abscopal effect, which we believe would have the potential to inhibit the development of future metastases. Second, while prostate cancer is a heterogeneous disease, it appears that local recurrences emanate from the dominant lesion. Therefore, we believe treating these lesions with Alpha DaRT could decrease the risk of recurrence. Third, these dominant lesions can create hypoxic microenvironments which is associated with worse outcomes for traditional radiation therapy. Alpha radiation cytotoxic activity has been observed to be independent of oxygen levels and therefore we believe may be better suited to treating these lesions. While our first planned study will focus on evaluating neoadjuvant use of Alpha DaRT in treating prostate cancer, we plan to evaluate Alpha DaRT in the future for focal treatment of radiation recurrent tumors or in combination with external beam radiation therapy.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Rambam Health Care Campus, Israel (Planning)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our first planned study will focus on evaluating neoadjuvant use of Alpha DaRT in treating prostate cancer at the Rambam Health Care Campus in Israel. The primary objective of the study is to evaluate the feasibility and the safety of intratumoral insertion of Alpha DaRT sources into prostate adenocarcinoma in the neoadjuvant setting. The secondary objectives are to evaluate the pathological ORR at 35&#160;days (+/-7) following Alpha DaRT source insertion through the examination of the pathology of the tumor after prostatectomy, the radiological ORR based on imaging (change in standard uptake value and T2 weighting) within one week of surgery and the</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 5pt;">change in disease-related QoL. The exploratory objectives are to assess DNA damage and repair and immune infiltration (biomarker analysis: CD34, TILs) from baseline to surgery and within one week of surgery, and the biochemical response evaluation based on PSA levels.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Liver Metastasis&#160;&#8211; Clinical Trial (Planning)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are currently designing a clinical study to evaluate the feasibility and safety of intratumoral Alpha DaRT for the treatment of liver metastases in approximately 10 patients. The liver is the most common site for metastatic disease from the gastrointestinal tract. It is also one of the most commons sites for metastases of other malignancies such as breast cancer, lung cancer, and melanoma. In colorectal cancer, about two thirds of 600,000 annual deaths are related to liver metastases. Liver metastases are diagnosed in more than 50% of colorectal cancer patients during the course of their disease. During the last two decades, treatment paradigms of metastatic disease have changed dramatically. While surgical resection of metastases was once considered futile, today surgical resection of liver metastases is a well-established therapeutic strategy and offers the best chance for long term survival for suitable patients. Colorectal liver metastases are the most common indication for liver resection, but selected patients with neuroendocrine, breast, lung and melanoma also benefit from resection of liver metastases. Other common indications for liver resection include primary liver tumors such as hepatocellular carcinoma and intra-hepatic cholangiocarcinoma.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We plan to test the effect of the Alpha DaRT technology on liver metastases during a two-staged hepatectomy. This unique clinical scenario is designed to allow us to implant Alpha DaRT sources in right-sided liver metastases during the first operation and resect the right liver containing the sources during the second operation. Thus, we believe a complete histopathological evaluation of liver metastases following Alpha DaRT administration can be performed, after which we will be able to evaluate the effect of Alpha DaRT sources on liver metastases with different histopathological growth patterns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The rationale for evaluating Alpha DaRT with this approach is multi-fold. First, we believe Alpha DaRT may elicit an immunological response, thus through treatment of a single liver metastasis, we believe there could be reduction in metastases throughout the remaining liver. We believe a reduction in metastases may also reduce the risk of future metastases from arising. Secondly, during the time between the two stages of the hepatectomy, patients are normally not receiving metastasis-directed therapy, but in this study their remaining lesions will be receiving Alpha DaRT during the period between surgical procedures. Third, we believe there may be synergy between Alpha DaRT and chemotherapy, which could further improve outcomes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expect that this study&#8217;s primary objectives will be to evaluate the safety and feasibility of Alpha DaRT implanted in liver metastases. We expect the secondary objectives will be to evaluate the pathological and radiological response of liver metastases to DaRT and to stratify the differences in response to Alpha DaRT by histopathological growth patterns. We expect that the exploratory objective will be to evaluate the immunological effects of Alpha DaRT treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">SCC of the Vulva&#160;&#8211; Cambridge University Addenbrooke&#8217;s Hospital (Planning)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are currently planning, in collaboration with the Cambridge University Hospital, a study to evaluate the safety and efficacy of the Alpha DaRT technology for the treatment of primary and recurrent SCC of the vulva. We expect that ten patients will be evaluated in this study, with the primary objective being the safety, feasibility and tolerability, and the secondary objective being the effectiveness of the treatment. We also plan to measure the immunological response.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Additional Pipeline Indications</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to the trials and clinical pathways described above, we are currently planning a number of other clinical studies, both to generate additional data from the tumor types we are already exploring in humans, as well as to test the use of Alpha DaRT in additional tumor types, including prostate cancer, glioblastoma multiforme, and lung cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Summary of Our Pre-Clinical Findings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We consider pre-clinical research as a source of strong and ongoing support for our core thesis and for potential expansion into a wide range of proposed indications. To that end, we continue to invest, both internally and with leading universities and academic centers around the world, in conducting robust pre-clinical research with particular focus on potential supra-additive combinations of Alpha DaRT with other therapies such as immunotherapies and chemotherapies. Among other things, we are currently constructing our own pre-clinical laboratory at our headquarters in Jerusalem, Israel to facilitate our own examination of such combinations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:176.16pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The extensive pre-clinical research conducted on Alpha DaRT has generally focused on three core areas: (1)&#160;evaluating the potency of Alpha DaRT in destroying tumors, measured across a broad range of cell lines, (2)&#160;evaluating combinational treatments with standard of care / FDA approved therapies such as chemotherapy and antiangiogenic agents, and (3)&#160;evaluating the immunostimulatory potential of the Alpha DaRT and optimizing the combination of Alpha DaRT and immunotherapy. Pre-clinical research, including both <i style="font-style:italic;">in vitro </i>and <i style="font-style:italic;">in vivo </i>experiments as well as physical, biological and computational modeling of the diffusion or biokinetic properties of Alpha DaRT, have led to the publication of 18 articles in peer-reviewed journals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">DaRT is Designed to Efficiently Destroy a Tumor</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pre-clinical studies were performed <i style="font-style:italic;">in vitro </i>and <i style="font-style:italic;">in vivo </i>with mouse tumor models and human derived tumors, to evaluate the diffusion properties and potential therapeutic activity of Alpha DaRT:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:25.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:32.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Summary of Pre-Clinical Studies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Histology</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Murine Cells in Mice or in Vitro</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Human Cells in Athymic Mice or in Vitro</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Skin SCC</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:bottom;width:37.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Lung SCC</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:bottom;width:37.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">HNSCC</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:bottom;width:37.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Lung Adenocarcinoma</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:bottom;width:37.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Pancreas Adenocarcinoma</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:bottom;width:37.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Prostate Adenocarcinoma</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:bottom;width:37.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Breast Carcinoma</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:bottom;width:37.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Glioblastoma Multiforme</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:bottom;width:37.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Cervical Carcinoma</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:bottom;width:37.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Melanoma</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:bottom;width:37.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Colon Carcinoma</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:bottom;width:37.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Sarcoma</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:32.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">In vitro </i>studies were performed to evaluate the impact of alpha particles on tumor cell viability. Cell lines investigated <i style="font-style:italic;">in vitro </i>included squamous cell, lung, colon, prostate, breast, pancreatic and cervical carcinomas, glioblastoma <span style="color:#0d0d0d;">and melanoma. All cell lines were sensitive to alpha particles (typically dying within&#160;days after exposure), with a mean lethal dose in the range 0.7-1.5 Gy. </span><i style="color:#0d0d0d;font-style:italic;">In vivo </i><span style="color:#0d0d0d;">studies using various tumor types were consistent with the </span><i style="color:#0d0d0d;font-style:italic;">in vitro </i><span style="color:#0d0d0d;">findings, and showed that Alpha DaRT sources destroyed tumors and achieved a high degree of local control.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As shown in the figure below regarding observed tumor growth in mice, in a pre-clinical study using a sealed Alpha DaRT source designed to prevent radon recoil, no ablative effect was observed, suggesting that the ablation was caused primarily by alpha radiation from the recoiling alpha emitters, rather than the low level of gamma/beta radiation emitted from the source, which had a minor effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="drts-20211231x20f015.jpg" alt="Chart, line chart&#10;&#10;Description automatically generated" style="display:inline-block;height:176.16pt;width:265.92pt;" /></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:466.53pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Alpha DaRT sources were observed to have killed multiple types of mouse and human tumors <i style="font-style:italic;">in vivo</i>. The extent of the tumor killing varied between tumor types, and was dependent on the ability of the radioactive atoms to diffuse inside the tumor and on the intrinsic sensitivity of the cancer cells to DNA damage induced by the radiation, but all tumor types showed responsiveness to Alpha DaRT, i.e., there was no observed resistance. The figure below compares the growth of tumors in groups of mice who received a Radium-224-loaded Alpha DaRT vs. an inert wire (control), in athymic mice bearing colonic HCT15 (A), prostatic PC3 (B)&#160;or glioblastoma U87 (C)&#160;tumors, as well as representative mice in the HCT15 group treated with a Radium-224-loaded Alpha DaRT (D)&#160;and an inert source (E).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="drts-20211231x20f016.jpg" alt="Diagram&#10;&#10;Description automatically generated" style="display:inline-block;height:466.08pt;left:0%;padding-bottom:0.45pt;position:relative;top:0pt;width:448.8pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The complex DNA damage induced by alpha radiation, namely clustered double-strand breaks, is nearly impossible to repair and is largely unaffected by the presence of oxygen or by cell cycle phase, which may indicate the potential for alpha particles to kill hypoxic cells which might otherwise be resistant to conventional radiation treatments based on photons or electrons. Consistent with this understanding, mouse and human cells showed lower survival following treatment with alpha radiation compared to x-ray in the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:570.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">same dose. The figure below demonstrates&#160;<i style="font-style:italic;">in&#160;vitro</i>&#160;survival curves for Panc1 (A)&#160;and FaDu (B)&#160;cancer cell lines after exposure to&#160;X-rays&#160;or to alpha particles generated from&#160;Thorium-228.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="drts-20211231x20f017.jpg" alt="Chart, line chart&#10;&#10;Description automatically generated" style="display:inline-block;height:569.52pt;left:0%;padding-bottom:0.5pt;position:relative;top:0pt;width:344.16pt;" /></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:568.52pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Alpha DaRT was evaluated in combination with chemotherapy (e.g., cisplatin), locally and systemically, which extended host survival. The figure below shows the development of tumor growth (A)&#160;and survival curve (B)&#160;for BALB/c mice bearing SQ2 tumors who were each treated with two sources that were either loaded with&#160;Radium-224&#160;or inert, where some received Cisplatin and others did not.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="drts-20211231x20f018.jpg" alt="Chart&#10;&#10;Description automatically generated" style="display:inline-block;height:568.32pt;left:0%;padding-bottom:0.2pt;position:relative;top:0pt;width:414.48pt;" /></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:513.12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The figure below demonstrates the metastatic lung burden using hematoxylin-eosin-stained lung cross- sections from this experiment, comparing representative mice from the Inert group (A)&#160;and Radium-224 + Cisplatin group (B), as well as a graph (C)&#160;of the ratio of total average gray pixel value for each group vs. normal healthy lungs from mice without tumors, when images were analyzed with Image J software.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="drts-20211231x20f019.jpg" alt="A picture containing text&#10;&#10;Description automatically generated" style="display:inline-block;height:513.12pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:263.52pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In human xenografts in nude mice of Glioblastoma Multiforme, or GBM, Alpha DaRT was combined with the chemotherapy drug Temozolomide. As seen in Figure A below, the combination led to significantly increased tumor growth retardation compared to each of the treatments alone. Moreover, as seen in Figure B below, the rate of animals that reached the maximal allowed tumor size </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:223.92pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">before sacrifice was significantly decreased in Alpha DaRT-treated mice and in the combination-treated mice, which may indicate a potential of Alpha DaRT to extend lifespan.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="drts-20211231x20f020.jpg" alt="Graphic" style="display:inline-block;height:161.95pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:264.7pt;" />&#160;&#160;&#160;<img src="drts-20211231x20f021.jpg" alt="Chart, box and whisker chart&#10;&#10;Description automatically generated" style="display:inline-block;height:164.64pt;left:0%;padding-bottom:0.4pt;position:relative;top:0pt;width:263.52pt;" /></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Notably, in our combination pre-clinical experiments only a single Alpha DaRT source was used for the treatment of a tumor, despite that the alpha-emitting atoms released from this single source would not be expected to cover the whole tumor. The purpose of using a single source is to avoid a complete response of the tumor only by virtue of the direct impact of the alpha radiation. Deliberately under-dosing Alpha DaRT enables the investigation of the combination and potential synergy between Alpha DaRT and the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">GBM-bearing mice were also treated with Alpha DART in combination with the anti-angiogenic agent Avastin (bevacizumab), where Avastin was injected 3 times per week for 3 weeks from day 5 after insertion of the Alpha DaRT. The combination treatment prevented tumor regrowth following treatment, and tumor size was stable for a longer period than in either of the treatments alone. Additionally, in the mice treated with the combination or with Alpha DaRT, 2 of 6 or 2 of 7 mice, respectively, saw their tumors disappear completely without late relapse, potentially indicating an ability to prevent GBM recurrence. We are investigating a hypothesis that this effect may be mediated by the Avastin-induced changes in the tumor vasculature that may affect alpha particle dispersion in the tumor or leakage rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="drts-20211231x20f022.jpg" alt="Graphic" style="display:inline-block;height:223.92pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:325.07pt;" /></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:244.8pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Alpha DaRT as a Potential Immunostimulator</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Radiation is traditionally considered to produce damage-associated molecular patterns, or DAMPs, that activate dendritic cells; in the presence of an antigen this may lead to specific T cell responses. During the escape phase, melanoma cells acquire deficient antigen presentation machinery, masking them from the immune system.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A published third-party study recently reported that, apart from the potential to efficiently kill tumor cells relative to other radiation types, alpha-emitting radium significantly enhanced T cell-mediated tumor lysis that was accompanied by augmented protein expression of MHC-I and calreticulin, molecules that are essential for efficient antigen presentation and immune activation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The figure below illustrates the potential effect of irradiation to release antigens from the tumor, which, in turn, may be able to harness the dendritic cells to generate T cell response to detect and target the specific tumor cells for destruction. Tumor antigens released by irradiated tumor cells can be taken up by antigen-presenting cells, or APCs, such as dendritic cells and phagocytic cells. The APCs may then interact with tumor antigens and then migrate to the lymph nodes where they present antigens to T cells, a process that is mediated by the MHC pathway and other co-stimulatory signals, such as CD80 and CD28. After activation by multiple signals, T cells, especially the CD8+ T cells, may be activated and begin to propagate. As a result, activated effector T cells may exit the lymph nodes and home to tumors, including primary tumors and non-irradiated tumor metastases, to exert their effect of killing tumor cells. However, cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) competitively combines with CD80/86 and inhibits the activation of T cells. Following T cell activation, programmed cell death 1 (PD-1) receptors that are expressed on the T cell surface bind primarily to PD-L1 and inhibit immune responses. Hence, we believe the administration of immune checkpoint blockades of CTLA-4, PD-1, and PD-L1 may be able to enhance the anti-tumor immunity induced by radiotherapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="drts-20211231x20f023.jpg" alt="Diagram&#10;&#10;Description automatically generated" style="display:inline-block;height:244.8pt;width:333.49pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 28.3pt;"><i style="font-style:italic;">Source: Journal of Hematology&#160;&amp; Oncology available at: https://pubmed.ncbi.nlm.nih.gov/30115069/</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Previously reported studies have demonstrated that ablation treatments, such as radiotherapy, have the potential to expose the body to large amounts of tumor antigens and danger signals and thus may trigger anti- tumor immunity. Consistent with this thesis, we observed that Alpha DaRT rendered studied animals resistant to a second tumor challenge in two tumor models, colon carcinoma and breast carcinoma. In the immunogenic colon carcinoma tumor model CT26, mice that were treated with Alpha DaRT developed resistance to tumor re-challenge in the opposite lateral side of the back or to experimental metastases in the lungs, suggesting that a systemic immune memory was induced following treatment. The figure below demonstrates the tumor development (A)&#160;and survival (B)&#160;of mice who were challenged with CT26 cancer cells, where those mice were previously treated for CT26 tumors with Alpha DaRT or with inert sources, compared to na&#239;ve mice that did not previously have tumors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:156.72pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="drts-20211231x20f024.jpg" alt="Chart, line chart&#10;&#10;Description automatically generated" style="display:inline-block;height:156.24pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:260.4pt;" />&#160;&#160;&#160;&#160;<img src="drts-20211231x20f025.jpg" alt="Diagram&#10;&#10;Description automatically generated" style="display:inline-block;height:156.48pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:260.4pt;" /></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Inhibition of regulatory T cells by low-dose cyclophosphamide, inhibition of Myeloid-derived Suppressor Cells, or MDSCs, by sildenafil, or immuno-stimulation by CpG further enhanced the tumor retardation induced by Alpha DaRT, providing further evidence of immune response.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As seen in the figure below, mice bearing breast DA3 tumors demonstrated the least tumor development when treated with the Alpha DaRT together with CpG (as compared to phosphate-buffered saline, or PBS).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="drts-20211231x20f026.jpg" alt="Chart, line chart&#10;&#10;Description automatically generated" style="display:inline-block;height:156.48pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:263.76pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, as seen in the figures below, the combination of sildenafil (A)&#160;or cyclophosphamide (B)&#160;with Alpha DaRT, led to greater tumor growth inhibition compared to any of the monotherapy groups.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:49.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="drts-20211231x20f027.jpg" alt="Chart&#10;&#10;Description automatically generated" style="display:inline-block;height:156.72pt;width:264.72pt;" />&#160;&#160;&#160;&#160;<img src="drts-20211231x20f028.jpg" alt="Chart, line chart&#10;&#10;Description automatically generated" style="display:inline-block;height:156.48pt;width:264.48pt;" /></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:159pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As can be seen in the figure below showing survival curves for the different groups, the combination of cyclophosphamide, sildenafil, CpG and Alpha DaRT led to 51% long-term tumor rejection of the CT26 bearing mice, while the combination of cyclophosphamide, sildenafil, CpG and an inert source in lieu of Alpha DaRT mostly led to tumor recurrence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="drts-20211231x20f029.jpg" alt="A picture containing chart&#10;&#10;Description automatically generated" style="display:inline-block;height:157.44pt;left:0%;padding-bottom:0.1pt;position:relative;top:0pt;width:264.96pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, as shown in the figure below, when repeating the previously described challenge tests four&#160;months after a previous treatment, the previous treatment that included Alpha DART and immunomodulation (CpG, cyclophosphamide and sildenafil) led to the most meaningful tumor inhibition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="drts-20211231x20f030.jpg" alt="Chart, line chart&#10;&#10;Description automatically generated" style="display:inline-block;height:158.4pt;left:0%;padding-bottom:0.6pt;position:relative;top:0pt;width:266.16pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">It was observed that the anti-tumor immune memory evidenced following combination treatment (Alpha DaRT and immunomodulators) was specific to CT26 tumor cells and did not provide any protection against other tumor cell lines. In addition, this specific anti-tumor immune memory was transferable to na&#239;ve mice, as splenocytes isolated from treated mice were able to protect na&#239;ve mice from the CT26 tumor cells, yet not from other tumor cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In a range of tumors, including triple negative breast cancer, pancreatic and squamous cell carcinoma, a synergy in tumor/metastases development was observed between Alpha DaRT and the delivery of viral dsRNA into the cytoplasm of tumor cells by intratumoral injection of polyIC complexed with polyethylenimine, or PEI.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:175.82pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As shown in the figure below, under neoadjuvant settings and following long-term follow-up in mice with 4T1 breast tumors, it was observed that metastases were not formed in the lungs of 75% of studied mice which underwent the combined before surgery treatment, while metastases-related death was observed in the other animals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="drts-20211231x20f031.jpg" alt="Graphic" style="display:inline-block;height:158.4pt;left:0%;padding-bottom:0.6pt;position:relative;top:0pt;width:265.92pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20pt;margin:0pt 0pt 12pt 5pt;">In light of the observed potential of Alpha DART to induce antigen-specific immune memory and to demonstrate synergy with immunomodulation, we have investigated the use of the Alpha DART in combination with an inhibitor of programmed cell death protein 1, or PD1. As there are many patients who do not demonstrate a response to such therapies, we wish to understand whether the Alpha DaRT may demonstrate immunostimulatory traits that can potentially enhance response rates or efficacy of response to anti-PD1 therapies, thereby offering a potential mechanism for reducing recurrence rates or enhancing systemic effects in addition to the local therapeutic effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Recent preliminary data supports this hypothesis, shown in the figure below, in mice bearing SCC tumors which were treated with the Alpha DaRT, and then a PD1 inhibitor was injected 4 times from day 2 to day 12 after Alpha DaRT treatment. Alpha DaRT demonstrated the potential to increase the response of tumors otherwise unresponsive to a PD-1 inhibitor, where the tumor growth of SCC tumors in mice was meaningfully inhibited in mice that received both the Alpha DaRT as well as a PD-1 inhibitor, as compared to mice that received either the Alpha DaRT or the PD-1 inhibitor alone. Whereas anti-PD-1 therapy did not affect tumor progression on its own, adding anti-PD-1 therapy to Alpha DART further increased the growth retardation induced by Alpha DaRT, suggesting that Alpha DART may induce responsiveness to anti-PD-1 therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="drts-20211231x20f032.jpg" alt="Graphic" style="display:inline-block;height:175.82pt;width:281.21pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Furthermore, as shown below both graphically and in representative immunohistochemistry cryo-sections, it was observed that the density of tumor-infiltrating lymphocytes (CD3+TILs) in the tumor, which is often used to define a &#8220;hot tumor&#8221; and as a predictor for treatment response, is higher in the combination treatment relative to anti-PD-1 alone, further suggesting that Alpha DART may activate T-cell function when used with anti-PD-1 therapy.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:216pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><img src="drts-20211231x20f033.jpg" alt="Graphic" style="display:inline-block;height:216pt;width:189.2pt;" /></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:49.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="drts-20211231x20f034.jpg" alt="Graphic" style="display:inline-block;height:150.7pt;width:222.08pt;" /></p></td><td style="vertical-align:top;width:49.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="drts-20211231x20f035.jpg" alt="Graphic" style="display:inline-block;height:151.11pt;left:0%;padding-bottom:0.4pt;position:relative;top:0pt;width:222.7pt;" /></p></td></tr><tr><td style="vertical-align:top;width:50.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Alpha DaRT + anti PD-1</p></td><td style="vertical-align:top;width:49.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">DaRT + anti PD-1</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:216.01pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Similar effects were seen with respect to the density of the lymphocyte effector sub population (CD8+TILs) and Granzyme B, a serine protease most commonly found in the granules of natural killer cells and cytotoxic T cells, as seen in the figures below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="drts-20211231x20f036.jpg" alt="Graphic" style="display:inline-block;height:215.96pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:191.15pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="drts-20211231x20f037.jpg" alt="Graphic" style="display:inline-block;height:216pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:181.4pt;" /></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:216pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20pt;margin:0pt 0pt 12pt 5pt;">In the pancreatic tumor model, as seen below in the figure of average tumor volume measured at day 14 after treatment, a similar trend was observed in response to the combination of Alpha DaRT with anti-PD1, which led to better tumor control than either therapy alone or the standard of care chemotherapy gemcitabine.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="drts-20211231x20f038.jpg" alt="Graphic" style="display:inline-block;height:216pt;width:183.18pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Components of the Alpha DaRT Technology</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Alpha DaRT technology is delivered in a kit comprising radioactive 316LVM stainless steel hollow wires or tubes of 5-10 mm length and &lt;1mm diameter, known as &#8220;sources,&#8221; and applicators to administer the sources. Each source is impregnated with Radium-224, which generates the decay chain of alpha emitters that are designed to recoil into the tumor. These proprietary applicators have been specially designed and developed by us for dispensing the sources based upon the tumor&#8217;s location in the body in order to facilitate clinicians&#8217; access to hard-to-reach tumors or tumors which are extremely close to major organs or blood vessels. We believe the applicators are a key component to maximizing the potential advantages of localized alpha radiotherapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our Alpha DaRT kit comprises three main components: the radioactive source, specialized applicators, and accessories. We have developed the applicators and accessories with input from clinicians across a variety of specialties in an effort to optimize the Alpha DaRT technology for clinical use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Our Alpha DaRT Sources</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20pt;margin:0pt 0pt 12pt 0pt;">Our Alpha DaRT sources utilize a 316LVM stainless steel hollow tube or rod to which Radium-224 is affixed. Our Alpha DaRT sources are designed to be customized to multiple sizes (depending on their intended use) and designed as temporary implants (for use in and removal from superficial tumors) or permanent implants (for use in internal organs). Our R&amp;D department is constantly examining enhancements to future versions of the Alpha DaRT sources, including the use of additional materials that we believe could offer advantages in flexibility, biocompatibility or biodegradability, more advanced anchoring and fixation, or enhanced properties of desorption of the alpha-emitting decay chain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Our Applicators and Accessories</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Our Applicators</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Alpha DaRT applicator is composed of a needle or tube (with an attached hub) with the Alpha DaRT sources placed inside for deployment into a tumor, and a stylet (with an attached hub) which functions like a plunger in the needle or tube to eject the source(s)&#160;towards the appropriate location within the tumor. A protective cap is attached to the needle to prevent inadvertent damage or loss of a source, and a safety screw is used to fasten the needle and the stylet firmly together. Additionally, the sources are encapsulated with glycerin, a biocompatible material which is designed to act as a sealant to trap the decay product Radon-220 gas </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">from release until it is ejected into the tumor by the applicator. Each applicator can hold up to six sources for deployment in a single injection.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have developed seven applicators designed to cover a range of potential applications, including the treatment delivery method, the duration of the sources&#8217; implantation, and on the location of the tumor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the temporary implantation of sources into superficial tumors, we have developed the following three categories of applicators:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Alpha DaRT Needle Applicator&#160;&#8211; </b><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a rigid, hypodermic needle designed in various lengths. In this applicator, the sources are affixed to a biocompatible suture and loaded inside the needle;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Alpha DaRT Flex Applicator&#160;&#8211; </b><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">designed for difficult geometry insertions. This applicator is in the form of a flexible (Kapton) tube, wherein the sources are strung upon a biocompatible suture and loaded inside the tube. The Flex Applicator is designed to be used in conjunction with a rigid hypodermic needle, which may be straight or curved, depending upon the specific geometry of the patient&#8217;s tumor and the physician&#8217;s preference; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Alpha DaRT Template Applicator&#160;&#8211; </b><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">designed to be used together with a custom-fitted 3D-printed template molded to the patient&#8217;s tumor. The template is used as a guiding channel for rigid hypodermic needles. The sources are attached to a stainless-steel wire and loaded inside the needle. This applicator is designated for deeper tumors.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All of the foregoing applicators are designed to be supplied preloaded, sealed and ready for immediate use in the procedure room.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have also developed a number of applicators for implantation of sources into tumors inside the body:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Alpha DaRT Plant Applicator&#160;&#8211; </b><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">designed for percutaneous delivery (delivery through the skin) to tumors located in organs such prostate and liver. This applicator is designed to be preloaded with the radioactive sources in accordance with a specific treatment plan.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Alpha DaRT Scope Applicator&#160;&#8211; </b><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">designed to be attached to an existing endoscope or bronchoscope for endoscopic delivery to tumors located in the upper and peripheral lungs. This applicator is also preloaded with the radioactive sources.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Loading Device&#160;&#8211; </b><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">designed to be fitted to existing needles such as standard FNA needles, for the administration of Alpha DaRT to GI organs such as the pancreas. While our other applicators come preloaded and ready for deployment, the Loading Device is designed to allow the clinician to load the radioactive sources into the delivery device, such as the FNA needle, in the procedure room in the course of treatment, to select how many sources to deliver into the treatment area.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Finally, we are developing an applicator to address glioblastoma multiforme, or GBM, which we are designing to be adapted to specific constraints in the brain, including minimizing movement in the brain when deploying Alpha DaRT sources. Our goal is to ensure that such adaptor is appropriately sterilized and does not release any undesired radioactivity into the brain.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:303.04pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 25pt;">Below are images of several applicators within our range:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="drts-20211231x20f039.jpg" alt="Graphic" style="display:inline-block;height:186.5pt;width:393.7pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The Alpha DaRT Needle Applicator and components (18 gauge needle, 140 mm in length)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="drts-20211231x20f040.jpg" alt="Graphic" style="display:inline-block;height:302.64pt;left:0%;padding-bottom:0.4pt;position:relative;top:0pt;width:456pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The Alpha DaRT Flex Applicator</i></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:279.01pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="drts-20211231x20f041.jpg" alt="Graphic" style="display:inline-block;height:278.6pt;left:0%;padding-bottom:0.4pt;position:relative;top:0pt;width:419.77pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The Alpha DaRT Template Applicator</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="drts-20211231x20f042.jpg" alt="Graphic" style="display:inline-block;height:279.01pt;width:420.4pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Loading Device</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">Our Accessories</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to our sources and applicators, we have also developed a number of ancillary accessories specially designed for use with our Alpha DaRT sources, including grids for guiding deployment, surgical buttons and clips. We have also developed and printed personalized bolus templates for use in specific clinical cases, designed to allow the clinician to execute the treatment plan accurately and seamlessly in conjunction with the Alpha DaRT Template Applicator.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 5pt;"><b style="font-weight:bold;">Our Manufacturing and Supply Infrastructure</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Alpha DaRT technology utilizes sources enriched with Radium-224, a radioactive material with a half- life of only 3.7&#160;days. As each treatment requires a different number of sources and applicators tailored for the specific patient, a reliable and timely delivery of the personalized Alpha DaRT kit to the hospital is required. We therefore plan to develop production sites in key regions around the world. We have already built two sites in the United States and Israel, have started the planning process for a site in Japan, and anticipate that we may build another facility in Europe. Our global manufacturing plan is designed to ensure a sufficient supply of radioactive sources with fast and cost-efficient delivery to our core markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our key input for production of the Alpha DaRT is Thorium-228, a readily available radioisotope that can be purchased from licensed vendors around the world. The Thorium-228 naturally decays into the Radium-224 that is collected onto the sources. We have entered into a multi-year supply contract with Eckert&#160;&amp; Ziegler AG in Germany, and also acquire Thorium-228 from the Oak Ridge National Laboratory of the United States Department of Energy. We are also aware of or have spoken with other potential suppliers of Thorium-228, such that we anticipate a steady, unrestricted supply of thorium for the production of the Alpha DaRT.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We currently operate two manufacturing plants. One, located in Jerusalem, Israel, is currently running at a small scale while capacity is being added, and we estimate it will contain sufficient capacity for approximately 400,000 sources when at full capacity. Our second facility, in Lawrence, Massachusetts, was completed in 2020 and began producing Thorium-228 generators at the start of 2021, and we estimate that the facility will have sufficient capacity for production of approximately 125,000 sources per&#160;year when operating near full capacity. We have also entered into a lease for a building in Togane, Japan where we hope to construct a facility of a similar size as our Jerusalem facility at scale. The modular nature of our manufacturing capacity allows us to initiate manufacturing more swiftly and then scale up to full capacity over time. We believe these facilities will enable us to maintain sufficient quantities of Thorium-228 securely, to safely produce and capture radium from thorium&#8217;s alpha decay, to affix the radium onto the sources, and to ship the sources with their suitable applicator(s)&#160;to various destinations efficiently.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In our manufacturing facilities, we employ different methods to produce extractable radium for scalable use. One such method, in a dry setup, utilizes an electrostatic field to attract and isolate radium atoms. Specifically, we use the thorium as a flux-generating surface source to create a collecting unit in which we place the Alpha DaRT sources for charging. The thorium decays into ionized radium atoms, which recoil from the thorium generator and can be attracted or repelled using their inherent charge. The source is placed at a precise distance from the thorium generator and an electrostatic field is placed across it to attract the radium to adhere to the source.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">After the radium is collected, each source is thermally treated or coated with a polymer to embed the radium securely on the outermost layers of the metallic matrix of the source, while allowing the Radon-220 and subsequent daughter atoms to desorb, or detach from the source and enter the tumor. Each Alpha DaRT source is individually measured to determine the overall Radium-224 activity on it and the desorption probability of Radon-220, to calculate how much Radon-220 will diffuse into the tumor. It is then placed in an applicator to fit upon the prescribed treatment profile.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have also recently devised a new method of radium production, which entails the collection of Radium-224 via a liquid solution of Thorium-228, allowing for more efficient production with a higher output by significantly increasing the&#160;percentage yield of Radium-224 which is collected, as well as shortening the time to collect Radium-224 onto each source. This method has the potential of increasing our existing capacity by a factor of 2 to 3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Alpha DaRT sources are prepared upon receiving an order from the clinician and are designed specifically for the treatment of an individual patient; specifically, the number of active sources in each applicator is made to order to match the prescribed treatment plan. Supply of the Alpha DaRT sources is carefully coordinated to account for a usable window up to 24 hours after receipt of the Alpha DaRT sources by the hospital, for the natural decay of the Radium-224 during shipment and intake. Pursuant to the United Nations guidance regarding the transport of radioactive materials, the Alpha DaRT sources do not require special handling or </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">protective gear in transit and can be shipped in Excepted Packages, which are used to transport material with extremely low levels of radioactivity, by standard courier. Prior to shipment, our clinical operations team ensures that all relevant clinicians undergo sufficient training as to proper handling, storage, and disposal of the Alpha DaRT sources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 5pt;"><b style="font-weight:bold;">Our Commercialization Strategies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have yet to commercialize in any geographical market, even though we presently have received marketing approval in Israel for the treatment of squamous cell carcinoma of the skin or oral cavity using the Alpha DaRT, and expect that our existing clinical trials, if completed successfully, may be sufficient to satisfy the regulatory requirements for marketing authorization in Europe and Japan. As we believe that the Alpha DaRT technology has the potential address the majority of solid tumors, including in potential combination with immunotherapies, we are focused on evaluating that potential in these various tumors by conducting clinical trials across multiple indications, to be incorporated into a future plan of commercial launch, sequencing and pricing if we obtain marketing authorization(s)&#160;in the future. We aim to generate clinical and healthcare economic data to support marketing authorization and third-party payor coverage and reimbursement in the United States, which we see as our primary market, and we anticipate seeking to commercialize initially in the United States before other markets, including Israel, notwithstanding our existing marketing approval in Israel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We also believe that our clinical trials being conducted in leading sites around the world will ultimately serve our commercial purposes as well, as we believe those clinical sites may ultimately become lead commercial end-users or centers of excellence in the commercial setting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">While we ultimately envision leading much of the commercialization of the Alpha DaRT in core markets such as the United States, we may choose to enter into distribution agreements in other geographies with parties who have exemplary local sales and marketing capabilities. To that end, we have entered into binding term sheets with Medison Pharma&#160;Ltd., one of the largest commercial partners of leading global biotech companies in international markets, and its affiliates, to lead the potential commercialization of the Alpha DaRT in Canada and Israel. We intend to enter into definitive commercial agreements covering the commercialization, distribution and sales of the Company&#8217;s future products in Canada and Israel. Under these term sheets, effective for a 15-year term following the approval to sell our products, Medison will be responsible for performing regulatory submissions, marketing and distribution directly to clinicians. We remain focused on performing investigational studies to evaluate the potential efficacy of the Alpha DaRT as a monotherapy and an immuno-stimulating combination therapy, and on supplementing our robust patent portfolio across a broad range of tumor applications, as we continue to navigate the regulatory pathways towards commercialization. We believe that these studies will also allow us to better explore the question of which clinicians are ultimately our end customer for commercial purposes, given the involvement of multiple practitioners including the radiation oncologist, medical physicist, and the clinician delivering the Alpha DaRT such as the oncology surgeon or interventional radiologist.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Competition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The biotechnology, medical device and pharmaceutical industries are characterized by the rapid evolution of technologies and understanding of disease etiology, intense competition and a strong emphasis on intellectual property. We face potential competition from many different sources, including major pharmaceutical, medical device, specialty pharmaceutical and biotechnology companies, academic research institutions, governmental agencies and public and private research institutions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the field of local therapy for solid tumors, we face competition from new or continually improving surgical techniques, as well as a number of radiation therapies&#160;&#8211; EBRT, stereotactic body radiation therapy, intensity-modulated radiation therapy, brachytherapy, and others, as well as particle therapies such as proton therapy, neutron therapy and carbon ion therapy. There are several companies developing improved or new forms of local radiation therapy, including Varian Medical Systems,&#160;Inc. (a subsidiary of Siemens Healthineers), Elekta AB, BTG plc (a subsidiary of Boston Scientific Corporation), ViewRay,&#160;Inc., Accuray,&#160;Inc., RefleXion Medical,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, in the field of systemic therapy for cancer, commercial and academic clinical trials are being pursued by a number of parties in the field of radiopharmaceuticals, some of which involve the use of alpha radiation as well. Early results from these trials have fueled continued interest in radiopharmaceuticals, which is being pursued by several biotechnology companies as well as by large pharmaceutical companies.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There are several companies developing targeted alpha-based radiopharmaceuticals for the treatment of cancer, including Bayer AG, or Bayer, Novartis AG, Fusion Pharmaceuticals&#160;Inc., RayzeBio,&#160;Inc., Actinium Pharmaceuticals,&#160;Inc., RadioMedix, Inc, Orano and Telix Pharmaceuticals Limited. These companies are targeting a wide range of solid and hematologic malignancies using various alpha emitting isotopes, including Radium-223, Actinium-225 and Thorium-227. The first and only approved alpha particle-based therapy is Bayer&#8217;s Xofigo, a salt of Radium-223 that cannot easily and robustly be attached to a targeting molecule, but naturally localizes to regions where cancer cells are infiltrating bone. Xofigo was approved in 2013 for the treatment of bone metastases associated with prostate cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Many of our current or potential competitors, either alone or with their collaboration partners, have significantly greater financial resources and expertise in research and development, manufacturing, pre-clinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical, medical device and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient enrollment in clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We could see a reduction or elimination in our commercial opportunity if our competitors develop and commercialize treatments that are safer, more effective, have fewer or less severe side effects, are more convenient to administer, are less expensive or have a more favorable label than our Alpha DaRT technology. Our competitors also may obtain FDA or other regulatory approval for their treatments more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. The key competitive factors affecting the success of all of our product candidates, if approved, are likely to be their efficacy, safety, convenience and ease of use, price, the effectiveness of imaging diagnostics, the level of generic competition and the availability of reimbursement from government and other third-party payors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Our Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2021, our patent portfolio included 83 issued patents, and 76 pending patent applications including two allowed patent applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to an Intellectual Property Purchase Agreement dated February&#160;2, 2016, we acquired from Althera Medical&#160;Ltd. a patent portfolio which now totals 80 patents, including some patent applications whose prosecution was completed following our acquisition. These patents were all assigned to us and are recorded in our name. The patents relate primarily to a device, method of treatment, or method of production of the Alpha DaRT product itself, specifically, to intratumoral diffusing alpha-emitter radiation therapy wherein a probe is loaded with radioisotopes which undergo a process of alpha-emitting radioactive decay solely in proximity to and/or within a tumor. These patents include three U.S. patents, one Canadian patent, three Japanese patents, one Chinese patent, one Hong Kong patent, two European patents each validated in 30 European countries, two Korean patents, three U.K. patents, three French patents, and three German patents. The three issued patents in the United States are expected to expire between 2025 and 2029, without accounting for any potential patent term adjustments or extensions or other forms of exclusivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have two issued patents and 12 pending patent applications, including one allowed patent application, relating to the use of a polymer allowing daughter atoms to escape the source and penetrate the tumor where they emit alpha particles by diffusion. This increases the&#160;percentage of daughter radionuclides that reach the tumor. Of the two issued patents, one is an Australian patent, and the other is a South African patent. The foregoing patent applications are pending in the U.S., Europe, Japan, Canada, China, Korea, Russia, African Regional Intellectual Property Organization (ARIPO), Mexico, India, Hong Kong, and Singapore. These patents or patents issuing from the pending applications will begin to expire in 2038, exclusive of possible patent term adjustments or extensions or other forms of exclusivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have 14 pending patent applications, including one allowed patent application, relating to the potential controlled release of a certain amount of Radium-224 from the Alpha DaRT source into the tumor. One of these patent application has been allowed in Australia and 13 of these patent applications are pending in the U.S., Europe, Japan, Canada, China, Korea, Russia, ARIPO, Mexico, India, Hong Kong, Singapore, and South Africa. Patents issuing from these pending applications will begin to expire in 2039, exclusive of possible patent term adjustments or extensions or other forms of exclusivity.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have one issued patent and 16 pending patent applications, relating to a number of our applicators and other accessories that are used in the Alpha DaRT source itself or in its delivery. The issued patent is an Australian patent, and the 16 patent applications are pending in the U.S., Europe, Japan, Canada, China, Korea, Russia, ARIPO, Mexico, India, Hong Kong, Singapore, South Africa and three pending patent applications in Australia. Patents issuing from these pending applications will begin to expire in 2039, exclusive of possible patent term adjustments or extensions or other forms of exclusivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have 11 pending patent applications relating to a therapeutic substance administered to a tumor as a medicant, which triggers cytoplasmatic sensors to the presence of an intracellular pathogen, followed by intratumoral Alpha DaRT thereafter. The foregoing patent applications are pending in the U.S., Europe, Japan, China, Canada, Australia, India, Korea, Singapore, Russia, and Hong Kong. Patents issuing from these patent applications begin to expire in 2038, exclusive of possible patent term adjustments or extensions or other forms of exclusivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have a total of five PCT applications, 15 U.S. applications, including four provisional applications, and 3 Taiwan applications, which relate to other potential approaches for our products, including other potential approaches for our product candidates. Patents issuing from these applications will begin to expire in 2040, exclusive of possible patent term adjustments or extensions or other forms of exclusivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Grants Under the Innovation Law</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Encouragement of Research, Development and Technological Innovation in the Industry Law 5744-1984, and the provisions of the applicable regulations, rules,&#160;IIA directives and benefit tracks, (collectively, the &#8220;Innovation Law&#8221;), research and development programs that meet specified criteria and are approved by a committee of the IIA are eligible for grants. The grants awarded are typically up to 50% of the project&#8217;s expenditures, as determined by the research committee and subject to the benefit track under which the grant was awarded. A company that receives a grant from the IIA, or a grant recipient, is typically required to pay royalties to the IIA on income generated from products incorporating know-how developed using such grants (including income derived from services associated with such products), until 100% of the U.S. dollars-linked grant plus annual LIBOR interest is repaid. The rate of royalties under the regular benefits tracks varies between 3% to 5% of the income generated from the IIA-supported products. The obligation to pay royalties is contingent on actual income generated from such products and services. In the absence of such income, no payment of such royalties is required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The terms of the grants under the Innovation Law also generally require that the products developed as part of the programs under which the grants were given be manufactured in Israel and that the know-how developed thereunder may not be transferred outside of Israel, unless a prior written approval is received from the IIA (such approval is not required for the transfer of a portion of the manufacturing capacity which does not exceed, in the aggregate, 10% of the portion declared to be manufactured outside of Israel in the applications for funding, in which case only notification is required) and additional payments are required to be made to the IIA. It should be noted, that this does not restrict the export of products that incorporate the funded know-how. With respect to transfer of know how out of Israel, when an approval is received from the IIA, a redemption fee must be paid to the IIA. The Innovation Law provides a formula for the calculation of such redemption fee, based on the value of the transferred know-how, multiplied by the amount of grants received from the IIA (including the accrued interest), and divided by the total amounts expended by the grant recipient on R&amp;D. To the extent any royalties were paid to the IIA on account of the grants, such royalties will be deducted from the calculation. The redemption fee is subject to a cap of six times the total amount of the IIA grants, plus interest accrued thereon, and a floor of equal to the total amounts of the IIA grants, plus the interest accrued. Upon payment of the redemption fee, the know-how and manufacturing rights developed under the IIA funding cease to be subject to the Innovation Law. See &#8220;Risk Factors&#8212;Risks Related to Israeli Law and Our Operations in Israel&#8221; for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since our incorporation, we have received grants from the IIA relating to various projects. No royalties have been paid to the IIA in respect of any grant. Our total outstanding obligation to the IIA at December&#160;31, 2021, including grants received by the Company, grants assumed from Althera Medical&#160;Ltd. and the associated interest accrued on all such grants, including the interest accrued through, amounts to approximately $5.06 million, of royalty-bearing grants. In addition, through December&#160;31, 2021, we received IIA participation payments in the aggregate amount of $975 thousand under non-royalty-bearing programs from the IIA. This includes an advance payment of $242 thousand received in December&#160;2021 toward such a&#160;non-royalty-bearing&#160;grant program, which is effective from December&#160;1, 2021. This amount is presented as an accrued expense at December&#160;31, 2021.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Government Regulation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our products and operations are subject to extensive regulation by the U.S. Food and Drug Administration, or FDA, and other federal and state authorities in the United States, as well as comparable authorities in foreign jurisdictions. Our product candidates are subject to regulation as medical devices in the United States under the Federal Food, Drug, and Cosmetic Act, or FDCA, as implemented and enforced by the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">United States Regulation of Medical Devices</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA regulates the development, design, non-clinical and clinical research, manufacturing, safety, efficacy, labeling, packaging, storage, installation, servicing, recordkeeping, premarket clearance or approval, adverse event reporting, advertising, promotion, marketing and distribution, and import and export of medical devices to ensure that medical devices distributed domestically are safe and effective for their intended uses and otherwise meet the requirements of the FDCA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">FDA Premarket Clearance and Approval Requirements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unless an exemption applies, each medical device commercially distributed in the United States requires either FDA clearance of a 510(k)&#160;premarket notification, or approval of a premarket approval, or PMA, application. Under the FDCA, medical devices are classified into one of three classes&#8212;Class&#160;I, Class&#160;II or Class&#160;III&#8212;depending on the degree of risk associated with each medical device and the extent of manufacturer and regulatory control needed to ensure its safety and effectiveness. Class&#160;I includes devices with the lowest risk to the patient and are those for which safety and effectiveness can be assured by adherence to the FDA&#8217;s General Controls for medical devices, which include compliance with the applicable portions of the Quality System Regulation, or QSR, facility registration and product listing, reporting of adverse medical events, and truthful and non-misleading labeling, advertising, and promotional materials. Class&#160;II devices are subject to the FDA&#8217;s General Controls, and special controls as deemed necessary by the FDA to ensure the safety and effectiveness of the device. These special controls can include performance standards, post-market surveillance, patient registries and FDA guidance documents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">While most Class&#160;I devices are exempt from the 510(k)&#160;premarket notification requirement, manufacturers of most Class&#160;II devices are required to submit to the FDA a premarket notification under Section&#160;510(k)&#160;of the FDCA requesting permission to commercially distribute the device. The FDA&#8217;s permission to commercially distribute a device subject to a 510(k)&#160;premarket notification is generally known as 510(k)&#160;clearance. Devices deemed by the FDA to pose the greatest risks, such as life-sustaining, life-supporting or some implantable devices, or devices that have a new intended use, or use advanced technology that is not substantially equivalent to that of a legally marketed device, are placed in Class&#160;III, requiring approval of a PMA. Some pre-amendment devices are unclassified, but are subject to FDA&#8217;s premarket notification and clearance process in order to be commercially distributed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">510(k)&#160;Clearance Marketing Pathway</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To obtain 510(k)&#160;clearance, a manufacturer must submit to the FDA a premarket notification demonstrating that the proposed device is &#8220;substantially equivalent&#8221; to a predicate device already on the market. A predicate device is a legally marketed device that is not subject to premarket approval, i.e., a device that was legally marketed prior to May&#160;28, 1976 (pre-amendments device) and for which a PMA is not required, a device that has been reclassified from Class&#160;III to Class&#160;II or I, or a device that was found substantially equivalent through the 510(k)&#160;process. The FDA&#8217;s 510(k)&#160;clearance process usually takes from three to twelve&#160;months, but may take longer. The FDA may require additional information, including clinical data, to make a determination regarding substantial equivalence. In addition, FDA collects user fees for certain medical device submissions and annual fees and for medical device establishments. For fiscal&#160;year 2022, the standard user fee for a 510(k)&#160;premarket notification application is $12,745.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the FDA agrees that the device is substantially equivalent to a predicate device currently on the market, it will grant 510(k)&#160;clearance to commercially market the device. If the FDA determines that the device is &#8220;not substantially equivalent&#8221; to a previously cleared device, the device is automatically designated as a Class&#160;III device. The device sponsor must then fulfill more rigorous PMA requirements, or can request a risk-based classification determination for the device in accordance with the &#8220;<i style="font-style:italic;">de novo</i>&#8221; process, which is a route to market for novel medical devices that are low to moderate risk and are not substantially equivalent to a predicate device.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">After a device receives 510(k)&#160;clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change or modification in its intended use, will require a new 510(k)&#160;clearance or, depending on the modification, PMA approval or <i style="font-style:italic;">de novo </i>reclassification. The FDA requires each manufacturer to determine whether the proposed change requires submission of a 510(k), <i style="font-style:italic;">de novo </i>request or a PMA in the first instance, but the FDA can review any such decision and disagree with a manufacturer&#8217;s determination. If the FDA disagrees with a manufacturer&#8217;s determination, the FDA can require the manufacturer to cease marketing and/or request the recall of the modified device until 510(k)&#160;marketing clearance or PMA approval is obtained or a <i style="font-style:italic;">de novo </i>request is granted. Also, in these circumstances, the manufacturer may be subject to significant regulatory fines or penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Over the last several&#160;years, the FDA has proposed reforms to its 510(k)&#160;clearance process, and such proposals could include increased requirements for clinical data and a longer review period, or could make it more difficult for manufacturers to utilize the 510(k)&#160;clearance process for their products. For example, in November&#160;2018, FDA officials announced steps that the FDA intended to take to modernize the premarket notification pathway under Section&#160;510(k)&#160;of the FDCA. Among other things, the FDA announced that it planned to develop proposals to drive manufacturers utilizing the 510(k)&#160;pathway toward the use of newer predicates. These proposals included plans to potentially sunset certain older devices that were used as predicates under the 510(k)&#160;clearance pathway, and to potentially publish a list of devices that have been cleared on the basis of demonstrated substantial equivalence to predicate devices that are more than 10&#160;years old. These proposals have not yet been finalized or adopted, although the FDA may work with Congress to implement such proposals through legislation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">More recently, in September&#160;2019, the FDA issued revised final guidance describing an optional &#8220;safety and performance based&#8221; premarket review pathway for manufacturers of &#8220;certain, well-understood device types&#8221; to demonstrate substantial equivalence under the 510(k)&#160;clearance pathway by showing that such device meets objective safety and performance criteria established by the FDA, thereby obviating the need for manufacturers to compare the safety and performance of their medical devices to specific predicate devices in the clearance process. The FDA has developed and maintains a list device types appropriate for the &#8220;safety and performance based&#8221; pathway and continues to develop product-specific guidance documents that identify the performance criteria for each such device type, as well as recommended testing methods, where feasible.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">PMA Approval Pathway</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Class&#160;III devices require PMA approval before they can be marketed, although some pre-amendment Class&#160;III devices for which FDA has not yet required a PMA are cleared through the 510(k)&#160;process. The PMA process is more demanding than the 510(k)&#160;premarket notification process. In a PMA, the manufacturer must demonstrate that the device is safe and effective, and the PMA must be supported by extensive data, including data from pre-clinical studies and human clinical trials. The PMA must also contain a full description of the device and its components, a full description of the methods, facilities, and controls used for manufacturing, and proposed labeling. Following receipt of a PMA, the FDA determines whether the application is sufficiently complete to permit a substantive review. If FDA accepts the application for review, it has 180&#160;days under the FDCA to complete its review of a PMA, although in practice, the FDA&#8217;s review often takes significantly longer, and can take up to several&#160;years. An advisory panel of experts from outside the FDA may be convened to review and evaluate the application and provide recommendations to the FDA as to the approvability of the device. The FDA may or may not accept the panel&#8217;s recommendation. In addition, the FDA will generally conduct a pre-approval inspection of the applicant or its third-party manufacturers&#8217; or suppliers&#8217; manufacturing facility or facilities to ensure compliance with the QSR. PMA applications are also subject to the payment of user fees, which for fiscal&#160;year 2022 includes a standard application fee of $374,858.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA will approve the new device for commercial distribution if it determines that the data and information in the PMA constitute valid scientific evidence and that there is reasonable assurance that the device is safe and effective for its intended use(s). The FDA may approve a PMA with post-approval conditions intended to ensure the safety and effectiveness of the device, including, among other things, restrictions on labeling, promotion, sale and distribution, and collection of long-term follow-up data from patients in the clinical study that supported PMA approval or requirements to conduct additional clinical studies post-approval. The FDA may condition PMA approval on some form of post-market surveillance when deemed necessary to protect the public health or to provide additional safety and efficacy data for the device in a larger population or for a longer period of use. In such cases, the manufacturer might be required to follow certain patient groups for a number of&#160;years and to make periodic reports to the FDA on the clinical status of those patients. Failure to comply with the conditions of approval can result in material adverse enforcement action, including withdrawal of the approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Certain changes to an approved device, such as changes in manufacturing facilities, methods, or quality control procedures, or changes in the design performance specifications, which affect the safety or effectiveness of the device, require submission of a PMA </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">supplement. PMA supplements often require submission of the same type of information as a PMA, except that the supplement is limited to information needed to support any changes from the device covered by the original PMA and may not require as extensive clinical data or the convening of an advisory panel. Certain other changes to an approved device require the submission of a new PMA, such as when the design change causes a different intended use, mode of operation, and technical basis of operation, or when the design change is so significant that a new generation of the device will be developed, and the data that were submitted with the original PMA are not applicable for the change in demonstrating a reasonable assurance of safety and effectiveness.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 6pt;"><i style="font-style:italic;">De novo classification process</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Medical device types that the FDA has not previously classified as Class&#160;I,&#160;II, or III are automatically classified into Class&#160;III regardless of the level of risk they pose. The Food and Drug Administration Modernization Act of 1997 established a route to market for low-to-moderate risk medical devices that are automatically placed into Class&#160;III due to the absence of a predicate device, called the &#8220;Request for Evaluation of Automatic Class&#160;III Designation,&#8221; or the <i style="font-style:italic;">de novo </i>classification procedure. This procedure allows a manufacturer whose novel device is automatically classified into Class&#160;III to request down-classification of its medical device into Class&#160;I or Class&#160;II on the basis that the device presents low or moderate risk, rather than requiring the submission and approval of a PMA application. Prior to the enactment of the Food and Drug Administration Safety and Innovation Act, or FDASIA, in July&#160;2012, a medical device could only be eligible for <i style="font-style:italic;">de novo </i>classification if the manufacturer first submitted a 510(k)&#160;pre-market notification and received a determination from the FDA that the device was not substantially equivalent. FDASIA streamlined the <i style="font-style:italic;">de novo </i>classification pathway by permitting manufacturers to request <i style="font-style:italic;">de novo </i>classification directly without first submitting a 510(k)&#160;pre-market notification to the FDA and receiving a not-substantially-equivalent determination. <i style="font-style:italic;">De novo </i>classification requests are subject to the payment of user fees, which for fiscal&#160;year 2021, includes a standard fee of $109,697.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under FDASIA, FDA is required to classify the device within 120&#160;days following receipt of the <i style="font-style:italic;">de novo </i>request, although the process may take significantly longer. If the manufacturer seeks reclassification into Class&#160;II, the manufacturer must include a draft proposal for special controls that are necessary to provide a reasonable assurance of the safety and effectiveness of the medical device. If FDA grants the <i style="font-style:italic;">de novo </i>request, the device may be legally marketed in the United States. However, the FDA may reject the request if the FDA identifies a legally marketed predicate device that would be appropriate for a 510(k)&#160;notification, determines that the device is not low-to-moderate risk, or determines that general controls would be inadequate to control the risks and/or special controls cannot be developed. After a device receives <i style="font-style:italic;">de novo </i>classification, any modification that could significantly affect its safety or efficacy, or that would constitute a major change or modification in its intended use, will require a new 510(k)&#160;clearance or, depending on the modification, another <i style="font-style:italic;">de novo </i>request or even PMA approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Clinical Trials</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Clinical trials are almost always required to support a PMA or a <i style="font-style:italic;">de novo </i>request, and are sometimes required to support 510(k)&#160;submissions. All clinical investigations of devices to determine safety and effectiveness must be conducted in accordance with the FDA&#8217;s investigational device exemption, or IDE, regulations which govern investigational device labeling, prohibit promotion of the investigational device, and specify an array of recordkeeping, reporting and monitoring responsibilities of study sponsors and study investigators. If the device presents a &#8220;significant risk&#8221; to human health, as defined by the FDA, the FDA requires the device sponsor to submit an IDE application to the FDA, which must become effective prior to commencing human clinical trials. If the device under evaluation does not present a significant risk to human health, then the device sponsor is not required to submit an IDE application to the FDA before initiating human clinical trials, but must still comply with abbreviated IDE requirements when conducting such trials. A significant risk device is one that presents a potential for serious risk to the health, safety or welfare of a patient and either is implanted, used in supporting or sustaining human life, substantially important in diagnosing, curing, mitigating or treating disease or otherwise preventing impairment of human health, or otherwise presents a potential for serious risk to a subject. An IDE application must be supported by appropriate data, such as animal and laboratory test results, showing that it is safe to test the device in humans and that the testing protocol is scientifically sound. The IDE will automatically become effective 30&#160;days after receipt by the FDA unless the FDA notifies the company that the investigation may not begin. If the FDA determines that there are deficiencies or other concerns with an IDE for which it requires modification, the FDA may permit a clinical trial to proceed under a conditional approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Regardless of the degree of risk presented by the medical device, clinical studies must be approved by, and conducted under the oversight of, an Institutional Review Board, or IRB, for each clinical site. The IRB is responsible for the initial and continuing review of the IDE, and may pose additional requirements for the conduct of the study. If an IDE application is approved by the FDA and one or more IRBs, human clinical trials may begin at a specific number of investigational sites with a specific number of patients, as </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">96</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">approved by the FDA. If the device presents a non-significant risk to the patient, a sponsor may begin the clinical trial after obtaining approval for the trial by one or more IRBs without separate approval from the FDA, but must still follow abbreviated IDE requirements, such as monitoring the investigation, ensuring that the investigators obtain informed consent, and labeling and record-keeping requirements. Acceptance of an IDE application for review does not guarantee that the FDA will allow the IDE to become effective and, if it does become effective, the FDA may or may not determine that the data derived from the trials support the safety and effectiveness of the device or warrant the continuation of clinical trials. An IDE supplement must be submitted to, and approved by, the FDA before a sponsor or investigator may make a change to the investigational plan that may affect its scientific soundness, study plan or the rights, safety or welfare of human subjects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During a study, the sponsor is required to comply with the applicable FDA requirements, including, for example, trial monitoring, selecting clinical investigators and providing them with the investigational plan, ensuring IRB review, adverse event reporting, record keeping and prohibitions on the promotion of investigational devices or on making safety or effectiveness claims for them. The clinical investigators in the clinical study are also subject to FDA&#8217;s regulations and must obtain patient informed consent, rigorously follow the investigational plan and study protocol, control the disposition of the investigational device, and comply with all reporting and recordkeeping requirements. Additionally, after a trial begins, we, the FDA or the IRB could suspend or terminate a clinical trial at any time for various reasons, including a belief that the risks to study subjects outweigh the anticipated benefits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 5pt;"><i style="font-style:italic;">Expedited Development and Review Programs</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following passage of the 21st Century Cures Act, the FDA implemented the Breakthrough Devices Program, which is a voluntary program offered to manufacturers of certain medical devices and device-led combination products that may provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. The goal of the program is to provide patients and health care providers with more timely access to qualifying devices by expediting their development, assessment and review, while preserving the statutory standards for PMA approval, 510(k)&#160;clearance and <i style="font-style:italic;">de novo </i>classification. The program is available to medical devices that meet certain eligibility criteria, including that the device provides more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions, and that the device meets one of the following criteria: (i)&#160;the device represents a breakthrough technology, (ii)&#160;no approved or cleared alternatives exist, (iii)&#160;the device offers significant advantages over existing approved or cleared alternatives, or (iv)&#160;the availability of the device is in the best interest of patients. Breakthrough Device Designation provides certain benefits to device developers, including more interactive and timely communications with FDA staff, use of post-market data collection, when scientifically appropriate, to facilitate expedited and efficient development and review of the device, opportunities for efficient and flexible clinical study design, and prioritized review of premarket submissions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Post-market Regulation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">After a device is cleared or approved for marketing, numerous and pervasive regulatory requirements continue to apply. These include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishment registration and device listing with the FDA;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">QSR requirements, which require manufacturers, including third-party manufacturers, to follow stringent design, testing, control, documentation and other quality assurance procedures during all aspects of the design and manufacturing process;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">labeling regulations and FDA prohibitions against the promotion of investigational products, or the promotion of &#8220;off-label&#8221; uses of cleared or approved products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">requirements related to promotional activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clearance or approval of product modifications to cleared devices or devices authorized through the </span><i style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">de novo </i><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">classification process that could significantly affect safety or effectiveness, or that would constitute a major change in intended use of such devices, or approval of certain modifications to PMA-approved devices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">medical device reporting regulations, which require that a manufacturer report to the FDA if a device it markets may have caused or contributed to a death or serious injury, or has malfunctioned and the device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">97</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">correction, removal and recall reporting regulations, which require that manufacturers report to the </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA field corrections and product recalls or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDCA that may present a risk to health;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA&#8217;s recall authority, whereby the agency can order device manufacturers to recall from the market a product that is in violation of governing laws and regulations; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">post-market surveillance activities and regulations, which apply when deemed by the FDA to be necessary to protect the public health or to provide additional safety and effectiveness data for the device.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Manufacturing processes for medical devices are required to comply with the applicable portions of the QSR, which cover the methods and the facilities and controls for the design, manufacture, testing, production, processes, controls, quality assurance, labeling, packaging, distribution, installation and servicing of finished devices intended for human use. The QSR also requires, among other things, maintenance of a device master file, device history file, and complaint files. As a manufacturer, we are subject to periodic scheduled or unscheduled inspections by the FDA. Failure to maintain compliance with the QSR requirements could result in the shutdown of, or restrictions on, manufacturing operations and the recall or seizure of marketed products. The discovery of previously unknown problems with marketed medical devices, including unanticipated adverse events or adverse events of increasing severity or frequency, whether resulting from the use of the device within the scope of its clearance or off-label by a physician in the practice of medicine, could result in restrictions on the device, including the removal of the product from the market or voluntary or mandatory device recalls.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA has broad regulatory compliance and enforcement powers. If the FDA determines that a manufacturer has failed to comply with applicable regulatory requirements, it can take a variety of compliance or enforcement actions, which may result in any of the following sanctions:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">warning letters, untitled letters, fines, injunctions, consent decrees and civil penalties;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recalls, withdrawals, or administrative detention or product seizures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">operating restrictions or partial suspension or total shutdown of production;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusing or delaying requests for 510(k)&#160;marketing clearance or PMA approvals of new products or modified products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawing 510(k)&#160;clearances or PMA approvals that have already been granted;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to grant export approvals for; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">criminal prosecution.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Regulation of Medical Devices in the European Union</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The European Union, or EU, has adopted specific directives regulating the design, manufacture, clinical investigations, conformity assessment, labeling and adverse event reporting for medical devices. Until May 25, 2021, medical devices were regulated by Council Directive 93/42/EEC, or the EU Medical Devices Directive, or Council Directive 90/385/EEC, or the Active Implantable Medical Devices Directive, which have been repealed and replaced by Regulation (EU) No 2017/745, or thek EU Medical Devices Regulation. Unlike the directives, the EU Medical Devices Regulation is directly applicable in EU member states without the need for member states to implement into national law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In the EU, there is currently no premarket government review of medical devices. However, the EU requires that all medical devices placed on the market in the EU must meet the general safety and performance requirements laid down in Annex I to the EU Medical Devices Regulation including the requirement that a medical device must be designed and manufactured in such a way that, during normal conditions of use, it is suitable for its intended purpose. Medical devices must be safe and effective and must not compromise the clinical condition or safety of patients, or the safety and health of users and &#8211; where applicable &#8211; other persons, provided that any risks which may be associated with their use constitute acceptable risks when weighed against the benefits to the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">98</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">patient and are compatible with a high level of protection of health and safety, taking into account the generally acknowledged state of the art. The European Commission has adopted various standards applicable to medical devices. These include standards governing common requirements, such as sterilization and safety of medical electrical equipment and product standards for certain types of medical devices. There are also harmonized standards relating to design and manufacture. While not mandatory, compliance with these standards is viewed as the easiest way to satisfy the general safety and performance requirements as a practical matter as it creates a rebuttable presumption that the device satisfies that general safety and performance requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Compliance with the general safety and performance requirements of the EU Medical Devices Regulation is a prerequisite for European Conformity Marking, or CE mark, without which medical devices cannot be marketed or sold in the EU. To demonstrate compliance with the general safety and performance requirements, medical device manufacturers must undergo a conformity assessment procedure, which varies according to the type of medical device and its (risk) classification. As a general rule, demonstration of conformity of medical devices and their manufacturers with the general safety and performance requirements must be based, among other things, on the evaluation of clinical data supporting the safety and performance of the products during normal conditions of use. Specifically, a manufacturer must demonstrate that the device achieves its intended performance during normal conditions of use, that the known and foreseeable risks, and any adverse events, are minimized and acceptable when weighed against the benefits of its intended performance, and that any claims made about the performance and safety of the device are supported by suitable evidence. Except for low-risk medical devices (Class I non-sterile, non-measuring devices), where the manufacturer can self-assess the conformity of its products with the general safety and performance requirements (except for any parts which relate to sterility or metrology), a conformity assessment procedure requires the intervention of a notified body. Notified bodies are independent organizations designated by EU member states to assess the conformity of devices before being placed on the market. A notified body would typically audit and examine a product&#8217;s technical dossiers and the manufacturers&#8217; quality system (notified body must presume that quality systems which implement the relevant harmonized standards &#8211; which is ISO 13485:2016 for Medical Devices Quality Management Systems &#8211; conform to these requirements). If satisfied that the relevant product conforms to the relevant general safety and performance requirements, the notified body issues a certificate of conformity, which the manufacturer uses as a basis for its own declaration of conformity. The manufacturer may then apply the CE mark to the device, which allows the device to be placed on the market throughout the EU.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Notified body certificates of conformity are valid for a fixed duration (which shall not exceed five years). Throughout the term of the certificate, the manufacturer will be subject to periodic surveillance audits to verify continued compliance with the applicable requirements. In particular, there will be a new audit by the notified body before it will renew the relevant certificate(s).All manufacturers placing medical devices into the market in the EU must comply with the EU medical device vigilance system which has been reinforced by the EU Medical Devices Regulation. Under this system, incidents and Field Safety Corrective Actions, or FSCAs, must be reported to the relevant authorities of the EU member states. These reports will have to be submitted through Eudamed &#8211; once functional &#8211; and aim to ensure that, in addition to reporting to the relevant authorities of the EU member states, other actors such as the economic operators in the supply chain will also be informed.  Until Eudamed is fully functional, the corresponding provisions of the EU Medical Devices Directive continue to apply. A serious incident is defined as any malfunction or deterioration in the characteristics or performance of a device made available on the market, including use-error due to ergonomic features, as well as any inadequacy in the information supplied by the manufacturer and any undesirable side-effect, which, directly or indirectly, might have led or might lead to the death of a patient or user or of other persons or to a temporary or permanent serious deterioration of a patient&#8217;s, user&#8217;s or other person&#8217;s state of health or  a serious public health threat. Manufacturers are required to take FSCAs defined as any corrective action for technical or medical reasons to prevent or reduce a risk of a serious incident associated with the use of a medical device that is made available on the market. An FSCA may include the recall, modification, exchange, destruction or retrofitting of the device. FSCAs must be communicated by the manufacturer or its legal representative to its customers and/or to the end users of the device through Field Safety Notices. For similar serious incidents that occur with the same device or device type and for which the root cause has been identified or a FSCA implemented or where the incidents are common and well documented, manufacturers may provide periodic summary reports instead of individual serious incident reports.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Manufacturers (and authorized representatives) must also have available within their organization at least one person responsible for regulatory compliance, or PRRC, who possesses the requisite expertise in the field of medical devices. The PRRC is responsible for all aspects of compliance with the requirements of the EU Medical Devices Regulation and in particular compliance with post-market surveillance and vigilance requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The advertising and promotion of medical devices is subject to some general principles set forth by EU legislation. According to the Medical Devices Regulation, only devices that are CE marked may be marketed and advertised in the EU in accordance with their intended purpose. Directive 2006/114/EC concerning misleading and comparative advertising and Directive 2005/29/EC on unfair </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">99</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">commercial practices, while not specific to the advertising of medical devices, also apply to the advertising thereof and contain general rules, for example requiring that advertisements are evidenced, balanced and not misleading. Specific requirements are defined at national level. EU member states&#8217; laws related to the advertising and promotion of medical devices, which vary between jurisdictions, may limit or restrict the advertising and promotion of products to the general public and may impose limitations on promotional activities with healthcare professionals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Many EU member states have adopted specific anti-gift statutes that further limit commercial practices for medical devices, in particular vis-&#224;-vis healthcare professionals and organizations. Additionally, there has been a recent trend of increased regulation of payments and transfers of value provided to healthcare professionals or entities and many EU member states have adopted national &#8220;Sunshine Acts&#8221; which impose reporting and transparency requirements (often on an annual basis), similar to the requirements in the United States, on medical device manufacturers. Certain countries also mandate implementation of commercial compliance programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the EU, regulatory authorities have the power to carry out announced and, if necessary, unannounced inspections of companies, as well as suppliers and/or sub-contractors and, where necessary, the facilities of professional users. Failure to comply with regulatory requirements (as applicable) could require time and resources to respond to the regulatory authorities&#8217; observations and to implement corrective and preventive actions, as appropriate. Regulatory authorities have broad compliance and enforcement powers and if such issues cannot be resolved to their satisfaction can take a variety of actions, including untitled or warning letters, fines, consent decrees, injunctions, or civil or criminal penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The aforementioned EU rules are generally applicable in the European Economic Area, or EEA, which consists of the 27 EU member states plus Norway, Liechtenstein and Iceland.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Brexit and Regulation of Medical Devices in the United Kingdom</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since January 1, 2021, the Medicines and Healthcare Products Regulatory Agency, or MHRA, has become the sovereign regulatory authority responsible for Great Britain (i.e. England, Wales and Scotland) medical device market according to the requirements provided in the&#8239;Medical Devices Regulations 2002&#8239;(SI 2002 No 618, as amended) that sought to give effect to the three pre-existing EU directives governing active implantable medical devices, general medical devices and in vitro diagnostic medical devices whereas Northern Ireland continues to be governed by EU rules according to the Northern Ireland Protocol. Following the end of the Brexit transitional period on January 1, 2021, new regulations require medical devices to be registered with the MHRA (but manufacturers were given a grace period of four to 12 months to comply with the new registration process) before being placed on Great Britain market. The MHRA only registers devices where the manufacturer or their United Kingdom, or UK, Responsible Person has a registered place of business in the UK. Manufacturers based outside the UK need to appoint a UK Responsible Person that has a registered place of business in the UK to register devices with the MHRA in line with the grace periods. Additionally, UK-based notified bodies, which were designated to independently assess the conformity of certain products requiring CE marking before being placed on the EU market, are now no longer established in the EU, and accordingly, the conformity assessments carried out by such UK bodies, including those assessments carried out prior to January 1, 2021, are no longer valid for the EU compliance regime. Manufacturers whose products currently rely on third-party conformity assessments carried out by UK notified bodies now require new conformity assessments to be carried out by EU-based notified bodies in order to ensure continuing compliance with the EU regime and to continue to place those products on the EU market. By July 1, 2023, in Great Britain, all medical devices will require a UKCA, or UK Conformity Assessed, mark but CE marks issued by EU notified bodies will remain valid until this time. Manufacturers may choose to use the UKCA mark on a voluntary basis until June 30, 2023. However, UKCA marking will not be recognized in the EU. The rules for placing medical devices on the market in Northern Ireland, which is part of the UK, differ from those in the rest of the UK. Compliance with this legislation is a prerequisite to be able to affix the UKCA mark to our products, without which they cannot be sold or marketed in Great Britain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">An MHRA public consultation was opened until the end of November 2021 on the post-Brexit regulatory framework for medical devices and diagnostics. MHRA seeks to amend the UK Medical Devices Regulations 2002 (which are based on EU legislation, primarily the EU Medical Devices Directive, the EU Active Implantable Medical Devices Directive and the EU In Vitro Diagnostic Medical Devices Directive), in particular to create a new access pathways to support innovation, create an innovative framework for regulating software and artificial intelligence as  medical devices, reform in vitro diagnostic medical devices regulation, and foster sustainability through the reuse and remanufacture of medical devices. The regime is expected to come into force in July 2023, coinciding with the end of the acceptance period for EU CE marks in Great Britain, subject to appropriate transitional arrangements. The consultation indicated that the MHRA will publish guidance in relation to the changes to the regulatory framework and may rely more heavily on guidance to add flexibility to the regime.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">100</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the trade deal between the UK and the EU generally provides for cooperation and exchange of information between the parties in the areas of product safety and compliance, including market surveillance, enforcement activities and measures, standardization-related activities, exchanges of officials, and coordinated product recalls. As such, processes for compliance and reporting should reflect requirements from regulatory authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Northern Ireland Protocol, Northern Ireland follows EU rules on medical devices and devices marketed in Northern Ireland require assessment according to the EU regulatory regime. Such assessment may be conducted by an EU notified body, in which case a CE mark is required before placing the device on the market in the EU or Northern Ireland. Alternatively, if a UK notified body conducts such assessment, a &#8216;UKNI&#8217; mark applied and the device may only be placed on the market in Northern Ireland and not the EU. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Other EU requirements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the EU, Council Directive 2013/59 lays down basic safety standards for protection against the dangers arising from any planned, existing or emergency exposure situation which involves a risk from exposure to ionizing radiation which cannot be disregarded from a radiation protection point of view or with regard to the environment in view of long-term human health protection. Directive has been implemented at national levels and requirements may vary from one member state to another. These EU rules are generally applicable in the EEA</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Israel&#8217;s Regulations of our Products</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our product candidates require approval by the Israeli Ministry of Health for sale and distribution in Israel. Our manufacturing activities in Israel are also subject to regulation by the Israeli Ministry of Health, in addition to the radioactive aspect of our manufacturing which is subject to regulation by the Israeli Ministry of Environmental Protection. In addition to approvals related to marketing and selling our products, once approved, we or our clinical trial partner sites also must obtain pertinent approvals or permits to perform our clinical trials in the countries in which we perform such trials, such as in compliance with an international guideline for the ethical conduct of clinical research known as the Declaration of Helsinki. In Israel, our clinical trials require a permit for a research plan (protocol) by the Helsinki Committee, operating under the Israeli Public Health Regulations (Clinical Trials in Human Subject Research), 1980.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Japan&#8217;s Regulations of Medical Devices</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Medical devices are defined as &#8220;appliances or instruments, etc. which are intended for use in the diagnosis, treatment or prevention of disease&#8230;,&#8221; which are classified into 85 broad product categories under the implementing Cabinet Order, such as &#8220;physical diagnostic and treatment devices&#8221; or &#8220;radioactive material treatment devices&#8221;, based on product features and functionalities. If a product falls under any of these categories, it will be regulated as a medical device For the regulatory purposes, the medical devices are given classification of Class&#160;I through IV, in light of their potential safety concerns and health risks. For example, a simple device such as blood pressure meter is Class&#160;I, whereas products with potential health risks but for which technology is well established in the form of ISO specifications are Class&#160;II (e.g., a pulse oximeter). More advanced products with significant safety concerns are Class&#160;III (e.g., a heart pacemaker). Finally, the Ministry of Health, Labor and Welfare (&#8220;MHLW&#8221;) designates part of Class&#160;III devices as Class&#160;IV which covers those invasive items with significant safety concerns which may impair human lives (e.g., a balloon cardiovascular catheter). These classifications are compiled in a classification table describing thousands of product subcategories, which is updated from time to time by the MHLW, reflecting introduction of new medical device.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For introduction to the Japanese market, new Class&#160;I medical devices do not require any pre market regulatory action. In contrast, it is mandatory, for both Class&#160;III and Class&#160;IV devices, to obtain pre marketing product approval which the MHLW grants on the basis of safety testing information, as well as clinical trial information, when required. Class&#160;II devices (and part of Class&#160;III devices) are subject to the certification requirement for compliance with the applicable product specifications, which are often developed under the ISO, before introduction into Japan. Certification of these Class&#160;II devices is granted by private sector laboratories accredited in Japan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At present, no mutual recognition agreement is in force with either the United States or the European Union for medical device registration. Foreign registration of a medical device, therefore, does not exempt products registered in these regions from the Japanese registration requirement. However, the MHLW will accept foreign electric or other safety data as well as foreign clinical trial data for the purpose of Japanese registration.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">101</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 5pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Approval and Clinical Trial</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For approval of a new Class III/IV medical device product, the applicant (which can be either a foreign manufacturer or its distributor in Japan) is required to submit a package of information required by the Japanese regulations which are largely consistent with the Global Harmonization Task Force (&#8220;GHTF&#8221;)&#8217;s regulatory recommendations. For example, the manufacturer is required to prepare documentation and test results demonstrating compliance with the Essential Principles of Safety and Performance, which are largely identical to the general safety and performance requirements of the European Union, such as a risk management program and safety and efficacy documentation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unlike the case of pharmaceuticals, not all new medical devices are required to submit clinical trial data to prove safety and efficacy. In particular, new products without &#8220;evident&#8221; improvement from existing products may be approved with clinical information of a limited size, if they do not pose a new, material clinical risk. On the other hand, truly innovative medical devices have to be tested through a clinical trial, but the domestic clinical trial can be limited or waived if the foreign/international pivotal clinical trial data is available. Importantly, the authorities&#8217; guidance document provides that &#8220;clinical significance&#8221;, or operability by Japanese healthcare providers (&#8220;HCPs&#8221;) in the Japanese clinical environment is a most important point of reference for a new medical device. For this reason, even when domestic clinical trial data is required, the scope of the trial is limited to applicability of the new technology to the Japanese clinical environment, the number of subjects is limited, and comparative data is not essential. reason, even when domestic clinical trial data is required, the scope of the trial is limited to applicability of the new technology to the Japanese clinical environment, the number of subjects is limited, and comparative data is not essential.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Separately, in order to expedite introduction of new medical devices from overseas, the authorities accept, in lieu of clinical trial results, a &#8220;clinical evaluation report&#8221; which proves the risks and benefits of the new medical device based on published professional information on the mechanism and operation of the device.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Quality Management Systems</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to the approval requirements, manufacturers of Class&#160;III/IV medical devices, either domestic or foreign, are required to observe the Japanese quality management systems (QMS) requirements and obtain certification of compliance from the authorities. The QMS requirements are largely identical to those under ISO 13485, and cover matters including adequate documentation of manufacturing processes in the form of SOPs, adequate staffing and the PDCA cycle procedure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Post Marketing Surveillance and &#8220;Data Exclusivity&#8221;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In contrast to new pharmaceuticals, which are typically given a post marketing surveillance period for certain&#160;years to assess the safety and efficacy of the new product upon approval, not all newly approved medical devices are subject to the post marketing surveillance requirement. Since 2014, the MHLW requires post marketing surveillance only for &#8220;evidently&#8221; new medical devices in terms of its mechanical structure, usage, operative procedures, or efficacy, and which have not been used either in Japan or abroad. The post marketing surveillance period is, in principle, 3&#160;years, and generally 5&#160;years for embedded products or orphan products which require a long term observation or a larger number of clinical cases to fully assess the product profile. These determinations are made by the MHLW on a case by case basis, and the Ministry may set the period up to 7&#160;years if it finds necessary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Notably, when a new product is assigned a post marketing surveillance period, it is the policy of the MHLW to require similar follow on products to submit the equivalent set of date (in particular clinical trial data) to obtain approval, as the right of reference is not automatically granted to competitors. This operation of the post marketing surveillance to block follow on applications is known as the &#8220;data exclusivity.&#8221; However, the data exclusivity is less important for medical devices than in the case of the pharmaceuticals which are given a much longer post marketing surveillance period (8&#160;years for a new API). Indeed, unlike chemical compounds or biological preparations, medical device manufacturers frequently improve and update device models and software to compete in the market, rather than relying on the patents or data exclusivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Safety Reports</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">After approval, incidents impacting on safety and efficacy of the medical device products marketed in Japan must be reported within 15&#160;days or 30&#160;days of the date when the Japanese distributor becomes aware of the incident. These periods begin counting on the date the relevant information is received by the Japanese distributor, and not the date when the foreign manufacturer has found the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">102</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">incident. In the past, quite a few Japanese distributors sometimes failed to collect overseas information and file a timely report, resulting in regulatory penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the distributor is also required to file a periodic safety report to the authorities collecting information on serious incidents as well as unexpected incidents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reimbursement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Reimbursement for medical devices in Japan is centralized, as it is covered by the Japanese National Health Insurance (NHI). Institutions who purchased the reimbursable medical devices receive monetary compensation either in the form of price reimbursement (for consumable medical devices), or through their professional/ technical fees (for non-consumables such as CT scanners, automated surgical robotics).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">When a new Class&#160;III/IV non consumable device product is granted approval, the manufacturer who wishes to obtain the reimbursement status under the NHI must submit a reimbursement proposal to the MHLW. Upon receipt of the proposal, the Ministry will task the advisory body to evaluate if the new medical device would require a new technical fee for reimbursement, or would be reimbursable under the existing technical fee. If the product is entirely new, a new technical fee will be created, under which the fee will be payable to the institution when the device is used for treatment. On the other hand, the authorities may determine that the existing (generic) technical fee covers the new technology, and simply add the new medical device as being eligible for NHI reimbursement under the technical fee. In the latter case, the new product will have to compete with the existing products for compensation from the same technical fee payable to the institution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance, Promotion and Advertisement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The law was amended in 2020 to strengthen the compliance mechanism inside the corporate structure of the holder of the product approval. Specifically, the approval holder is required to nominate an officer in charge of the medical device matters who shall bear overall responsibilities for compliance, as well as a qualified individual who supervises the operational issues of safety and efficacy of the medical device it distributes. The law also requires the approval holder to organize the compliance structure and allocate and document necessary responsibilities among its staff.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Another major change from the previous law is the introduction of a regulatory surcharge designed to strip the companies of the profits they gain from &#8220;false or excessive&#8221; advertisement or promotion. The amount of the surcharge will be 4.5&#160;percent of the sales volume of the particular product it unlawfully promoted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Promotional incentives to the HCPs are governed by the industry association in the form of a fair competition code. For example, the prices of meals offered to the HCPs may not exceed the ceiling under the code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Advertisement is subject to detailed regulatory guidance of the MHLW. Notably, it is not permitted to distribute academic publication articles to the HCPs when the product is yet to be approved in Japan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Other U.S. Regulatory Requirements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Medical device and pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states in which they conduct their business and may constrain the financial arrangements and relationships through which we research, as well as sell, market and distribute any products for which we obtain marketing authorization. Such laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, data privacy and security, and transparency laws and regulations related to drug pricing and payments and other transfers of value made to physicians and other healthcare providers. If their operations are found to be in violation of any of such laws or any other governmental regulations that apply, they may be subject to penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, disgorgement, the curtailment or restructuring of operations, integrity oversight and reporting obligations, exclusion from participation in federal and state healthcare programs and imprisonment.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">103</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Coverage and Reimbursement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the United States, our commercial success will depend in part on the extent to which governmental authorities, private health insurers and other third-party payors provide coverage for and establish adequate reimbursement levels for our product candidates, if cleared or approved by the FDA. Failure by physicians, hospitals, ambulatory surgery centers and other users of our products to obtain coverage and adequate reimbursement from third-party payors for our product candidates, or adverse changes in government and private third-party payors&#8217; coverage and reimbursement policies, may adversely impact demand for our product candidates if cleared or approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A substantial portion of our revenue will depend on the extent to which the costs of our products purchased by our customers (or services provided with our products) will be reimbursed by third-party payors, including Medicare, Medicaid, other U.S. government sponsored programs and private payors. These third-party payors exercise significant control over patient access and increasingly use their enhanced bargaining power to secure discounted rates and impose other requirements that may reduce demand for our product candidates, if cleared or approved. Our potential customers&#8217; ability to obtain adequate reimbursement for products and services from these third-party payors affects the selection of products they purchase and the prices they are willing to pay. In addition, demand for new products may be limited unless we obtain favorable reimbursement (including coverage, coding and payment) from governmental and private third-party payors at the time of the product&#8217;s introduction, which will depend, in part, on our ability to demonstrate that our products have a positive impact on clinical outcomes. Third-party payors continually review their coverage policies for existing and new products and procedures and can deny coverage for our products or revise payment policies such that payments do not adequately cover the cost of our products. Even if third-party payors make coverage and reimbursement available, that reimbursement may not be adequate, which may have an adverse effect on our business, results of operations, financial condition and cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No uniform policy of coverage and reimbursement among payors in the United States exists and coverage and reimbursement for procedures can differ significantly from payor to payor. Some third-party payors must approve coverage for new or innovative devices or procedures before they will reimburse healthcare providers who use the products or therapies. Even though a new product may have been cleared for commercial distribution by the FDA, we may find limited demand for the product unless and until reimbursement approval has been obtained from governmental and private third-party payors. We can provide no assurances that we will be successful in obtaining coverage from Medicare or any other governmental or commercial third-party payor. Moreover, we may be required to seek new billing codes for the components of the Alpha DaRT, and regulatory authorities may not approve the creation of separate codes. Additionally, even if we are successful, these billing codes or the payment amounts associated with such codes may change in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to uncertainties surrounding coverage policies, there are periodic changes to reimbursement levels. Third-party payors regularly update reimbursement amounts and also from time to time revise the methodologies used to determine reimbursement amounts. This includes routine updates to payments to physicians, hospitals and ambulatory surgery centers for procedures during which our products are used. These updates could directly impact the demand for our products. See &#8220;Risk Factors&#160;&#8212; Risks Related to Government Regulation&#160;&#8212; Healthcare policy changes, including recently enacted legislation reforming the U.S. healthcare system, could harm our business, financial condition and results of operations.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe the overall escalating cost of medical products and services being paid for by the government and private health insurance has led to, and will continue to lead to, increased pressures on the healthcare and medical device industry to reduce the costs of products and services. Third-party payors are developing increasingly sophisticated methods of controlling healthcare costs through prospective reimbursement and capitation programs, group purchasing, redesign of benefits, and exploration of more cost-effective methods of delivering healthcare. In the United States, some insured individuals enroll in managed care programs, which monitor and often require pre-approval of the services that a member will receive. Some managed-care programs pay their providers on a per capita (patient) basis, which puts the providers at financial risk for the services provided to their patients by paying these providers a predetermined payment per member per&#160;month and, consequently, may limit the willingness of these providers to use our products. It is possible that third-party payor coding, coverage and reimbursement policies will affect the need or prices for our products in the future, which could significantly affect our financial performance and our ability to conduct our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific product lines and procedures.  EU member states and UK impose controls on whether products are reimbursable by national or regional health service providers and on the prices at which devices are reimbursed under state-run healthcare schemes. More and more, local, product specific reimbursement law is applied as an overlay to medical device regulation, which has provided an additional layer of clearance requirement.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">104</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 5pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Healthcare Reform</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The United States government has enacted a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our products profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. Current and future legislative proposals to further reform healthcare or reduce healthcare costs may limit coverage of or lower reimbursement for our product candidates, if cleared or approved, and the procedures associated with the use of such products. The cost containment measures that payors and providers are instituting and the effect of any healthcare reform initiative implemented in the future could impact our revenue from the sale of our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The implementation of the Affordable Care Act, or ACA, in the United States, for example, has changed healthcare financing and delivery by both governmental and private insurers substantially, and affected medical device manufacturers significantly. The ACA, among other things, provided incentives to programs that increase the federal government&#8217;s comparative effectiveness research and implemented payment system reforms including   national pilot program on payment bundling to encourage hospitals, physicians and other providers to improve the coordination, quality and efficiency of certain healthcare services through bundled payment models. Additionally, the ACA expanded eligibility criteria for Medicaid programs and created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since its enactment, there have been judicial, executive and political challenges to certain aspects of the ACA. On June&#160;17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#8217;s decision, President Biden issued an executive order to initiate a special enrollment period from February&#160;15, 2021 through August&#160;15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules&#160;that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how other healthcare reform measures of the Biden administration will impact our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. For example, the Budget Control Act of 2011, among other things, reduced Medicare payments to providers by 2% per fiscal&#160;year, effective on April&#160;1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030, with the exception of a temporary suspension from May&#160;1, 2020 through March&#160;31, 2022 and a 1% reduction from April&#160;1, 2022 through June&#160;30, 2022, unless additional Congressional action is taken. Additionally, the American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expect additional state, federal and foreign healthcare reform measures to be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products or additional pricing pressure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For instance, in December 2021, the EU Regulation No 2021/2282 on Health Technology Assessment, or HTA, amending Directive 2011/24/EU, was adopted. This regulation which entered into force in January 2022 intends to boost cooperation among EU member states in assessing health technologies, including some medical devices, and providing the basis for cooperation at the EU level for joint clinical assessments in these areas. The regulation foresees a three-year transitional period and will permit EU member states to use common HTA tools, methodologies, and procedures across the EU, working together in four main areas, including joint clinical assessment of the innovative health technologies with the most potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual EU member states will continue to be responsible for assessing non-clinical (e.g., economic, social, ethical) aspects of health technologies, and making decisions on pricing and reimbursement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Data Privacy and Security Laws</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Numerous state, federal and foreign laws, including consumer protection laws and regulations, govern the collection, dissemination, use, access to, confidentiality, and security of personal information, including health- related information. In the United </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">105</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">States, numerous federal and state laws and regulations, including data breach notification laws, health information privacy and security laws and federal and state consumer protection laws and regulations (e.g., Section 5 of the Federal Trade Commission Act) that govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our partners. In addition, certain state and non-U.S. laws govern the privacy and security of personal information, including health-related information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to make compliance efforts more challenging, and can result in investigations, proceedings, or actions that lead to significant penalties and restrictions on data processing.</p><a id="AOrganizationalStructure_148506"></a><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">C.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Organizational Structure</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Alpha Tau Medical&#160;Ltd. was incorporated in 2015 under the Israel Companies Law of the State of Israel and commenced operations on that date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have four wholly-owned subsidiaries: Alpha Tau Medical,&#160;Inc. and HCCC, each of which is incorporated in the United States, Alpha Tau Medical Canada, which is incorporated under the laws of Canada, and Alpha Tau Medical KK, which is incorporated under the laws of Japan.</p><a id="BPropertyPlantsandEquipment_788102"></a><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">D.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Property, Plants and Equipment</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our principal facilities are located in Jerusalem, Israel and consist of approximately 2,000 square meters (approximately 22,000 square feet) of leased office space and a manufacturing facility. These facilities currently accommodate our principal executive offices, research and development, account management, marketing, design, business development, finance, and other administrative activities. Of our total 88 employees as of December&#160;31, 2021, 82 are located in Israel. The lease for these facilities expires in May&#160;2035.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2021, we also lease offices in Lawrence, MA, USA and Togane, Japan. We believe that our facilities are adequate to meet our needs for the immediate future, and that, should it be needed, suitable additional space will be available to accommodate any such expansion of our operations. We are currently constructing our own radioactive pre-clinical laboratory at our headquarters in Jerusalem, Israel to further enhance our capabilities of exploring potential combination therapies with Alpha DaRT.</p><a id="_4010e03e_6990_49ce_82c4_7df661d7a0c4"></a><a id="Item4AUnresolvedStaffComments_13611"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;4A.&#160;Unresolved Staff Comments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_2d86cc63_0450_45e6_8ad2_05de5cdb8178"></a><a id="Item5OperatingandFinancialReviewandProsp"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;5. &#160;Operating and Financial Review and Prospects</b></p><a id="OperatingResults_304067"></a><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">A.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Operating Results</b></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">You should read the following discussion together with the consolidated financial statements and related notes included elsewhere in this Annual Report. The statements in this discussion regarding industry outlook, our expectations regarding our future performance, planned investments in our expansion into additional geographies, research and development, sales and marketing and general and administrative functions as well as other non-historical statements in this discussion are forward-looking statements. These forward-looking statements are subject to numerous risks and uncertainties, including, but not limited to, the risks and uncertainties described in Item&#160;3.D entitled &#8220;Risk Factors&#8221; and &#8220;Cautionary Statement Regarding Forward-Looking Statements&#8221; included elsewhere in this Annual Report. Our actual results may differ materially from those contained in or implied by any forward-looking statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We are a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Our proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">106</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">benefit, the traditional shortcomings of alpha radiation&#8217;s limited range. We believe that our Alpha DaRT technology has the potential to be broadly applicable across multiple targets and tumor types.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We evaluated the feasibility, safety and efficacy of the Alpha DaRT technology in a&#160;first-in-human&#160;study of locally advanced and recurrent squamous cell carcinoma, or SCC, cancers of the skin and head and neck. Efficacy was evaluated in 28 tumors, and results showed that Alpha DaRT achieved 100% overall response rate and over 78% complete response rate. The Alpha DaRT was generally well-tolerated, with limited local toxicity and no systemic toxicity. On the basis of this clinical trial as well as some of our further clinical trials, we received marketing approval in Israel for the treatment of SCC of the skin or oral cavity using the Alpha DaRT in August&#160;2020. In June&#160;2021, the FDA granted the Alpha DaRT Breakthrough Device Designation for the treatment of patients with SCC of the skin or oral cavity without curative standard of care. In October&#160;2021, the FDA granted the Alpha DaRT a second Breakthrough Device Designation, in treating recurrent Glioblastoma Multiforme, or GBM, as an adjunct to standard medical therapies or as a standalone therapy after standard medical therapies have been exhausted. If approved, we expect to commercialize our Alpha DaRT technology first in the United States before other markets, including Israel, notwithstanding our existing marketing authorization in Israel (under which we have not yet commercialized the product). To support our U.S. strategy, we are conducting a multi-center pilot feasibility trial to explore the feasibility of delivering radiotherapy for malignant skin and superficial soft tissue tumors using Alpha DaRT at Memorial Sloan Kettering Cancer Center and up to five other clinical sites around the United States. All ten patients in this trial were treated in the second half of 2021. The study met its primary feasibility endpoint, as all patients had successful delivery of radiation by Alpha DaRT. At approximately 12 weeks, all ten lesions treated demonstrated a complete response to the treatment, with no product-related serious adverse events observed. We hold exclusive rights to our proprietary Alpha DaRT technology in our core markets, including the United States and Europe.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">While local radiation therapy has been a mainstay of cancer therapy for&#160;years, it has been mostly limited to modalities utilizing beta or gamma emissions, which primarily destroy cells through an indirect mechanism relying on oxygen and the generation of free radicals to cause single-strand DNA breaks. By contrast, alpha radiation has hundreds of times the linear energy transfer rate of beta-emitters. Additionally, alpha particles&#8217; heavier mass and far shorter particle paths (less than 100 &#181;m) relative to beta&#8217;s lighter mass and lengthier (up to 12 mm) path, have been shown to destroy radioresistant cells in clinical studies&#160;&#8211; causing multiple, irreparable, double-strand DNA breaks and other cellular damage upon direct impact&#160;&#8211; within a very short distance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Accordingly, we believe that alpha radiation has several significant potential advantages for use in cancer radiotherapy, including a high relative biological efficiency (potentially enabling it to destroy tumor cells with administration of lower levels of radiation), imperviousness to factors such as hypoxia, and a very well-defined range of travel with limited collateral damage. Nonetheless, its use has also been limited precisely due to alpha&#8217;s extremely short particle range in living tissue, as the range of less than 100 &#181;m is insufficient to provide meaningful clinical utility. The Alpha DaRT technology employs a series of radioactive sources that are embedded with&#160;Radium-224&#160;to enable a controlled, intratumoral, release of alpha-emitting atoms which diffuse and decay throughout the tumor, seeking to kill cancerous cells with localized precision, while penetrating deeper into the tumor than can otherwise be reached by the limited ranges of the alpha particles themselves. Due to the inherent limited range of the alpha particles, we believe that the Alpha DaRT technology has the potential to deliver powerful and localized precise killing impact to the tumor without damage to surrounding healthy tissue. By combining the size and potency of alpha particles in a&#160;single-use&#160;disposable form, we believe that the Alpha DaRT may offer potent local radiation to tumors that have otherwise demonstrated poor response to radiation therapy or other standards of care, with the potential to apply to a wide range of tumors and clinical settings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We were incorporated in Israel in 2015 and our headquarters is located in Jerusalem, Israel. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, developing our technology, acquiring and building our intellectual property portfolio and conducting research and development activities, including pre-clinical studies and clinical trials, for our Alpha DaRT technology. We do not have any products approved for sale in the United States and have not generated any revenue from product sales. To date, we have funded our operations primarily through private placements of ordinary and convertible preferred shares and funding from government contracts. From inception through December 31, 2021, we have raised an aggregate of $77,020 to fund our operations, of which $57,911 were gross proceeds from sales of our convertible preferred shares, $14,069 were gross proceeds from the issuance of ordinary shares and $5,040 were gross proceeds from government grants. In addition, upon consummation of the Business Combination on March 7, 2022 as discussed further below, we raised $90,872 of further gross proceeds from the associated transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We have incurred significant net operating losses in every&#160;year since our inception and expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. Our net losses may fluctuate significantly from quarter to quarter and&#160;year to&#160;year and could be substantial. Our net losses were $8,367, $8,882 and $27,271 for the&#160;year ended December&#160;31, 2019, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">107</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">December&#160;31, 2020 and December&#160;31, 2021, respectively. As of December&#160;31, 2021, we had an accumulated deficit of $52,840. We anticipate that our expenses will increase significantly as we:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">conduct additional clinical trials of our Alpha DaRT technology;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continue to discover and develop additional product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">construct manufacturing facilities and supply chain capabilities in multiple geographies of sufficient capacity to provide commercial quantities of our Alpha DaRT products and any other product candidates for which we may obtain marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek regulatory and marketing approvals for our Alpha DaRT technology and any other product candidates that successfully complete clinical trials, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">develop and execute launch strategies, and establish a sales, marketing and distribution infrastructure to commercialize our Alpha DaRT technology and any other products for which we may obtain regulatory approval in geographies in which we plan to commercialize our products ourselves;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintain, expand and protect our intellectual property portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">hire additional staff, including clinical, scientific, technical, regulatory operational, and financial personnel, to execute our business plan; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">add clinical, scientific, operational, financial and management information systems and personnel to support our product development and potential future commercialization efforts, and to enable us to operate as a public company.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We do not expect to generate revenue from product sales unless and until we successfully complete clinical development and obtain further regulatory approvals for our Alpha DaRT technology. If we obtain regulatory approval for our Alpha DaRT technology or any other product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Furthermore, commencing upon the closing of the Business Combination, we expect to incur additional costs associated with operating as a public company. As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to fund our operations through public or private equity or debt financings or other sources, including strategic collaborations. We may, however, be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our failure to raise capital or enter into such other arrangements as and when needed would have a negative impact on our financial condition and our ability to develop our current product candidates, or any additional product candidates, if developed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because of the numerous risks and uncertainties associated with therapeutics product development, we are unable to accurately predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate revenue from product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2021, we had cash and cash equivalents, restricted cash and short-term deposits totaling $31,934. We believe that the proceeds we received from the Business Combination and PIPE Investment, together with our existing cash and cash equivalents, will enable us to fund our operating expenses and capital expenditure requirements for at least two&#160;years. We have based these estimates on assumptions that may prove to be imprecise, and we may use our available capital resources sooner than we currently expect. See &#8220;Liquidity and Capital Resources.&#8221; Because of the numerous risks and uncertainties associated with the development of our Alpha DaRT technology and any future product candidates, and because the extent to which we may enter into collaborations with third parties for product development is unknown, we are unable to estimate the amounts of increased capital outlays and operating expenses associated with completing the research and development of our Alpha DaRT technology or any future potential product candidates.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">108</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we raise additional funds through collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce, or terminate our product development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Business Combination</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July&#160;7, 2021, the Company entered into the Merger Agreement with HCC and Merger Sub. Pursuant to the Merger Agreement, Merger Sub merged with and into HCC, with HCC surviving the merger. Upon consummation of the Business Combination and the other transactions contemplated by the Merger Agreement on March&#160;7, 2022, HCC became a wholly owned subsidiary of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Business effects of&#160;COVID-19</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The current&#160;COVID-19&#160;pandemic has presented a substantial public health and economic challenge around the world and is affecting our employees, patients, communities and business operations, as well as the U.S. economy and financial markets. To date, our financial conditions and own operations have not been significantly impacted by the&#160;COVID-19&#160;outbreak; however, the full extent to which the&#160;COVID-19&#160;pandemic will directly or indirectly impact our business, results of operations, liquidity and financial condition will depend on future developments, which are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning&#160;COVID-19,&#160;the actions taken to contain it or treat its impact and the economic impact on local, regional, national and international markets.&#160;COVID-19&#160;has resulted in a slowdown in recruitment of patients into certain of our clinical trials, particularly in North America, in part due to local restrictions or changes in practices at clinical sites during the pandemic. In other sites, the restrictions imposed by local&#160;COVID-19&#160;regulations have required us to incur additional costs in treating patients due to the use of additional safety measures or scarcity of available hospital resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To date, our vendors have been able to continue to provide services and supply materials, and products and currently do not anticipate any disruption in services or interruptions in supply. However, we are continuing to assess the potential impact of the&#160;COVID-19&#160;pandemic on our business and operations, including our expenses, and our ability to hire and retain employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The&#160;COVID-19&#160;pandemic has caused us to modify our business practices (including but not limited to curtailing or modifying employee travel, moving to partial remote work, and cancelling physical participation in meetings, events and conferences), and we may take further actions as may be required by government authorities or that we determine are in the best interests of our employees, patients and business partners. The majority of our office-based employees have continued to work from the office without interruption during the pandemic, with certain adjustments as needed, such as division into capsules or installation of office dividers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For additional information on the various risks posed by the&#160;COVID-19&#160;pandemic, please read the section entitled &#8220;Risk Factors&#8221; in this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Basis of presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial statements are prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP. Unless otherwise indicated, all dollar amounts are presented in thousands.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Financial Operations Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Revenue</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products in the foreseeable future. If our development efforts for our Alpha DaRT technology or other product candidates are successful and result in further regulatory approvals and successful commercialization efforts, we may generate revenue in the future from product sales. We cannot predict if, when, or to what extent we will generate revenue from the commercialization and sale of our Alpha DaRT technology or any other product candidates. We may never succeed in obtaining further regulatory approvals for our Alpha DaRT technology or any of our other product candidates that we may develop in the future.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">109</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Operating Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our operating expenses since inception have consisted solely of research and development costs, marketing expenses and general and administrative costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">Research and development, net</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development, net consist primarily of costs incurred for our research activities, including the development of and pursuit of further regulatory approvals of our Alpha DaRT technology, which include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">employee-related expenses, including salaries, benefits and share-based compensation expense for personnel engaged in research and development functions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses incurred in connection with the preclinical and clinical development of our product candidates, including under agreements with CROs, investigative sites and consultants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs of manufacturing our product candidates or other material costs for use in our preclinical studies and clinical trials, including costs of raw materials, components, and other laboratory materials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">consulting and professional fees related to research and development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">facility costs and other allocated expenses, which include expenses for rent and maintenance of our facility, utilities, depreciation, overhead expenses and other supplies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">registration and maintenance of our intellectual property portfolio.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expense research and development costs as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our external research and development expenses consist primarily of costs such as fees paid to consultants, contractors and CROs in connection with our preclinical and clinical development activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because the bulk of our research and development expenses are for internal personnel or for manufacture of our Alpha DaRT for use across our clinical trials and&#160;pre-clinical&#160;studies, and the majority of our clinical trials and&#160;pre-clinical&#160;studies are led internally rather than using external CROs, we are unable to allocate our research and development expenses on a&#160;program-by-program&#160;basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Grants from the Israeli Innovation Authority (IIA) are offset against research and development costs at the later of when grant receipt is assured or the expenses are incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect that our research and development expenses will continue to increase for the foreseeable future as we initiate additional clinical trials of our Alpha DaRT technology, scale our manufacturing processes, continue to discover and develop additional components to the Alpha DaRT platform or other product candidates, and hire additional clinical and scientific personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The successful development of our Alpha DaRT technology and other potential future product candidates is highly uncertain. Accordingly, at this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the development of these product candidates. We are also unable to predict when, if ever, we will generate revenue and material net cash inflows from the commercialization and sale of any of our product candidates for which we have obtained or may obtain marketing approval. We may never succeed in achieving further regulatory approvals for any of our product candidates. The </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">110</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">duration, costs and timing of preclinical studies, clinical trials and development of our product candidates will depend on a variety of factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful completion of clinical trials with safety, tolerability and efficacy profiles for our Alpha DaRT technology and any potential future product candidates that are satisfactory to the FDA or any comparable foreign regulatory authority;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approval of IDEs or comparable applications for Alpha DaRT technology and any potential future product candidate to commence planned or future clinical trials in the United States or foreign countries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant and changing government regulation and regulatory guidance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">timing and receipt of marketing approvals from applicable regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful construction of additional manufacturing facilities, or establishing arrangements with contract manufacturing organizations, or CMOs, for third-party clinical and commercial manufacturing, to obtain sufficient supply of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining patent and other intellectual property protection and regulatory exclusivity for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">commercializing our Alpha DaRT technology and any potential future product candidate, if and when further approved, whether alone or in collaboration with others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance of the product, if and when approved, by patients, the medical community and third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competition with other therapies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintenance of a continued acceptable safety profile of for Alpha DaRT technology and any potential future product candidate following approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A change in the outcome of any of these variables with respect to the development, manufacture or commercialization enabling activities of any of our product candidates would significantly change the costs, timing and viability associated with the development of that product candidate. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we anticipate will be required for the completion of clinical development of our Alpha DaRT technology and any potential future product candidate, or if we experience significant delays in our clinical trials due to patient enrollment or other reasons, we would be required to expend significant additional financial resources and time on the completion of clinical development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">Marketing expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Marketing expenses consist primarily of salaries and other related costs, including share-based compensation, for personnel in marketing functions. Marketing expenses also include direct and allocated facility-related costs as well as costs of participation in conferences and exhibitions, licenses for marketing software, production of videos and marketing materials, and external consulting on product marketing or reimbursement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expect that our marketing expenses will increase in the future to support continued marketing activities and potential commercialization of our Alpha DaRT technology and any potential future product candidate. These increases will likely include increased costs related to the hiring of additional personnel and fees to outside consultants, particularly if and when we initiate the hiring of a commercial team or increase our&#160;pre-launch&#160;commercial activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">General and administrative expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">General and administrative expenses consist primarily of salaries and other related costs, including share- based compensation, for personnel in executive, finance and administrative functions. General and administrative expenses also include direct and allocated </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">111</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">facility-related costs as well as professional fees for legal, consulting, investor and public relations, accounting, auditing, tax services and insurance costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expect that our general and administrative expenses will increase in the future to support continued research and development activities and potential commercialization of our Alpha DaRT technology and any potential future product candidate. These increases will likely include increased costs related to the hiring of additional personnel and fees to outside consultants, attorneys and accountants, among other expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, we expect to incur increased expenses associated with being a public company, including costs of additional personnel, accounting, audit, legal, regulatory and&#160;tax-related&#160;services associated with maintaining compliance with exchange listing and Securities and Exchange Commission, or SEC, requirements, director and officer insurance costs, and investor and public relations costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">Financial (income) expenses, net</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial (income) expenses, net, primarily consists of&#160;non-cash&#160;interest expense incurred on remeasurement of warrants, foreign currency transaction, bank charges and interest, and interest income earned on our cash and cash equivalents.</p><a id="ResultsofOperations_517610"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Results of Operations</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;Ended&#160;December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Operating expenses:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Research and development, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,636</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,544</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,477</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Marketing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 397</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 288</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 482</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 977</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,412</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,861</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,010</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,244</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,790</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Loss from operations:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Financial (income) expense, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 308</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (520)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,474</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Loss before taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,318</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,724</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 27,264</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Tax on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 146</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 158</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,464</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,882</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 27,271</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss attributable to noncontrolling interests</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 97</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net&#160; loss attributable to Alpha Tau Medical Ltd.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,367</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,882</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 27,271</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Comparison of the&#160;Year Ended December&#160;31, 2020 and 2021</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our results of operations for the&#160;years ended December&#160;31, 2020 and 2021:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Ended&#160;December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Operating expenses:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Research and development, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,544</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,447</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,903</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Marketing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 288</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 482</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 194</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,412</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,861</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 449</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,244</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,790</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,546</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Loss from operations:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Financial (income)expense, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (520)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,474</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,994</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Loss before taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,724</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 27,264</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18,540</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Tax on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 158</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (151)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,882</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 27,271</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18,389</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">112</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Research and development, net</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development, net increased by $3,903 from $7,544 for the&#160;year ended December&#160;31, 2020 to $11,447 for the&#160;year ended December&#160;31, 2021. The increase in research and development expense was primarily attributable to increased employee compensation and benefits increased primarily as result of an increase in headcount, and additional payments to clinical sites owing to the use of the Alpha DaRT in a larger number of patients and clinical trials, but was also offset by an increase in government grants from the Israel Innovation Authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Marketing expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Marketing expense increased by $194 from $288 for the&#160;year ended December&#160;31, 2020 to $482 for the&#160;year ended December&#160;31, 2021. The increase in marketing expenses was primarily attributable to increased engagement with third-party advisors and a return of marketing and conference activity that had previously decreased in 2020 due to COVID-19.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">General and administrative</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">General and administrative increased by $449 from $1,412 for the&#160;year ended December&#160;31, 2020 to $1,861 for the&#160;year ended December&#160;31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The increase in general and administrative expenses was primarily attributable to increased employee compensation and benefits, primarily due to an increase in headcount and related expenses, increased office-related expenses resulting primarily from relocation of the Company&#8217;s offices to Jerusalem, and increased audit fees in connection with preparations for public listing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Financial (income) expense, net</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial expense, net increased $13,994 from $(520) for the&#160;year ended December&#160;31, 2020 to $13,474 for the&#160;year ended December&#160;31, 2021. The increase was primarily attributable to a remeasurement of warrants in the amount of $13,257, as well as changes in foreign exchange rates and a decrease in interest received from bank deposits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Comparison of the&#160;Years Ended December&#160;31, 2019 and 2020</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our results of operations for the&#160;years ended December&#160;31, 2019 and 2020:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years&#160;Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dollar&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Operating expenses:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Research and development, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,636</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,544</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 908</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Marketing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 397</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 288</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (109)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 977</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,412</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 435</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,010</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,244</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,234</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Loss from operations:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Financial (income) expense, net </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 308</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (520)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (828)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Loss before taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,318</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,724</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 406</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Tax on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 146</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 158</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 12</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,464</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,882</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 418</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss attributable to noncontrolling interests</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 97</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (97)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss attributable to Alpha Tau Medical Ltd.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,367</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,882</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 515</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Research and development, net</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Research and development, net increased by $908 from $6,636 for the&#160;year ended December&#160;31, 2019 to $7,544 for the&#160;year ended December&#160;31, 2020. The increase in research and development expense was primarily attributable to increased employee compensation and benefits increased primarily as result of an increase in headcount, owing to the use of the Alpha DaRT in a larger </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">113</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">number of patients and clinical trials, but was also offset by a decrease in travel expenses and an increase in government grants from the Israel Innovation Authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Marketing expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Marketing expense decreased by $109 from $397 for the&#160;year ended December&#160;31, 2019 to $288 for the&#160;year ended December&#160;31, 2020. The decrease in marketing expenses was primarily attributable to decreased participation in conferences and exhibitions and related expenses, due to the effects of&#160;COVID-19.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">General and administrative</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">General and administrative increased by $435 from $977 for the&#160;year ended December&#160;31, 2019 to $1,412 for the&#160;year ended December&#160;31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The increase in general and administrative expenses was primarily attributable to increased employee compensation and benefits, including share-based compensation, primarily due to an increase in headcount and related expenses, increased consulting and professional services primarily resulting from the growth in our general business operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Financial (income) expense, net</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial (income) expense, net decreased by $828 from $308 for the&#160;year ended December&#160;31, 2019 to $(520) for the&#160;year ended December&#160;31, 2020. The decrease was primarily attributable to remeasurement of warrants, as well as a reduction in interest rate on our bank deposits and changes in foreign exchange rates.</p><a id="LiquidityandCapitalResources_717244"></a><a id="LiquidityandCapitalResources_671200"></a><a id="LiquidityandCapitalResources_144510"></a><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">B.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Liquidity and Capital Resources</b></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Sources of Liquidity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have funded our operations from inception through December&#160;31, 2021 primarily through gross proceeds of $57,911 from sales of our convertible preferred shares, $14,069 from the issuance of ordinary shares and $5,040 from government grants. The following table provides information regarding our total cash and cash equivalents, restricted cash and short-term deposits for the periods presented:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,831</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 15,598</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 23,236</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 576</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 618</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Short-term deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 26,298</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 30,417</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,080</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 28,139</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 46,591</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 31,934</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash Flows</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table provides information regarding our cash flows for the periods presented:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years&#160;Ended&#160;December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (6,910)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (7,251)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (11,812)</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net cash (used in) provided by investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (10,163)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (7,817)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 19,273</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,323</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 29,317</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 111</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Effect&#160; of exchange rate changes on cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (18)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 84</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 108</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">(Decrease) increase in cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (11,768)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14,333</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,680</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">114</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Net cash used in operating activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The cash used in operating activities resulted primarily from our net losses adjusted for&#160;non-cash&#160;charges and changes in components of working capital. Net cash used in operating activities was $7,251 for the&#160;year ended December&#160;31, 2020, compared to $11,812 for the&#160;year ended December&#160;31, 2021. The increase of $4,561 was primarily attributable to an increase in net loss of $18,389, offset by an increase of $13,054 in the add-back of the change in fair value of warrants to convertible preferred shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash used in operating activities was $6,910 for the&#160;year ended December&#160;31, 2019, compared to $7,251 for the&#160;year ended December&#160;31, 2020. The $341 increase in cash used in operating activities was primarily attributable to an increase in net loss of $418, offset by a decrease of $791 in the financial expenses related to remeasurement of warrants, and an increase of $963 in changes in the components of working capital, including a decrease in prepaid expenses and other receivables as compared to an increase in the&#160;year ended December&#160;31, 2019, and larger increase in other payables and accrued expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Net cash provided from/ used in investing activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash used in investing activities was $7,817 for the&#160;year ended December&#160;31, 2020 compared to net cash provided by investing activities of $19,273 for the&#160;year ended December&#160;31, 2021. The increase in cash provided from investing activities of $27,090 was primarily attributable to a $26,250 decrease in bank deposits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash used in investing activities was $10,163 for the&#160;year ended December&#160;31, 2019 compared to $7,817 for the&#160;year ended December&#160;31, 2020. The decrease in cash used for investing activities of $2,346 was primarily attributable to a $2,474 increase in purchases of property and equipment and a $4,820 decrease in deposits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Net cash provided by financing activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash provided by financing activities was $29,317 for the&#160;year ended December&#160;31, 2020 compared to $111 for the&#160;year ended December&#160;31, 2021. The decrease of $29,206 was primarily attributable to the $28,726 of proceeds from the issuance of Series&#160;B Preferred Shares in the&#160;year ended December&#160;31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash provided by financing activities was $5,323 for the&#160;year ended December&#160;31, 2019 compared to $29,317 for the&#160;year ended December&#160;31, 2020. The increase of $23,994 was primarily attributable to the $28,726 proceeds from the issuance of series B Preferred shares in the&#160;year ended December&#160;31, 2020, as compared to the $5,250 of proceeds from the issuance ordinary shares in the&#160;year ended December&#160;31, 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="color:#231f20;">Effect of exchange rate changes</span><i style="font-style:italic;"> on cash, cash equivalents and restricted cash </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The effect of exchange rate changes on cash, cash equivalents and restricted cash was an increase of $84 for the&#160;year ended December&#160;31, 2020 compared to an increase of $108 for the&#160;year ended December&#160;31, 2021. The increase of $24 was primarily attributable to changes in the exchange rate between the U.S.&#160;Dollar vs. the Israeli NIS.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The effect of exchange rate changes on cash, cash equivalents and restricted cash was a decrease of $18 for the&#160;year ended December&#160;31, 2019 compared to an increase of $84 for the&#160;year ended December&#160;31, 2020. The increase of $102 was primarily attributable to changes in the exchange rate between the U.S. Dollar vs. the Israeli NIS and the Euro.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Funding Requirements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expect our expenses to increase in connection with our ongoing activities, particularly as we continue the research and development for, initiate later stage clinical trials for, and seek further marketing approvals for, our Alpha DaRT technology and other potential future product candidates. In addition, if we obtain further marketing approvals for our Alpha DaRT technology and other potential future product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Furthermore, upon the closing of the Business Combination, we expect to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">115</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expect that the proceeds we received from the Business Combination and the PIPE Investment, together with our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements for at least two&#160;years. We have based this estimate on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of conducting future clinical trials of our Alpha DaRT technology;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of manufacturing additional supply for one or more pivotal clinical trials of our Alpha DaRT technology and potential future clinical studies we might conduct for other future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of scaling up our manufacturing process and supply chain capacity to provide sufficient quantities of Alpha DaRT for the potential commercialization of Alpha DaRT if our clinical development program is successful and we obtain further marketing approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, progress, results and costs of discovery, preclinical development, laboratory testing and clinical trials for other potential product candidates we may develop, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs, timing and outcome of regulatory review of our Alpha DaRT technology and other potential future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish and maintain collaborations on favorable terms, if at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the achievement of milestones or occurrence of other developments that trigger payments under any collaboration agreements we might have at such time;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of future commercialization activities, including product sales, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the amount of revenue, if any, received from commercial sales of our Alpha DaRT technology and other potential future product candidates, should any of our product candidates receive further marketing approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of preparing, filing and prosecuting patent applications, obtaining, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our headcount growth and associated costs as we expand our business operations and our research and development activities; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of operating as a public company.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Identifying potential product candidates and conducting preclinical testing and clinical trials is a time- consuming, expensive and uncertain process that takes&#160;years to complete, and we may never generate the necessary data or results required to obtain further marketing approvals and achieve product sales. In addition, our Alpha DaRT technology and other potential future product candidates, if further approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many&#160;years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interests may be diluted, and the terms of these securities may include liquidation or other preferences that could adversely affect your rights as a shareholder. Any debt financing, if available, may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, that could adversely impact our ability to conduct our business.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">116</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we raise funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Contractual Obligations and Commitments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our significant and&#160;non-cancellable&#160;contractual obligations as of payment due date by period at December&#160;31, 2021:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:32.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:32.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="20" style="vertical-align:bottom;white-space:nowrap;width:65.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Payments&#160;Due&#160;by&#160;Period&#160;Ended&#160;December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:32.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2026</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Thereafter</b></p></td></tr><tr><td style="vertical-align:bottom;width:32.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Operating leases (facilities and motor vehicles)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,364</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 775</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 722</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 724</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 590</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 605</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,948</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,364</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.45%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 775</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 722</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 724</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 590</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 605</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,948</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We occasionally enter into ordinary course agreements with CROs for clinical trials, third party manufacturers of certain components, professional consultants for expert advice and other vendors for other services for operating purposes. We have not included these payments in the table of contractual obligations above since the contracts do not contain any minimum purchase commitments and are cancelable at any time by us, generally upon 30&#160;days prior written notice and therefore we believe that our&#160;non-cancelable&#160;obligations under these agreements are not material.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are also obligated to make royalty payments in certain circumstances. We have received royalty-bearing grants from the IIA to finance our research and development programs in Israel, through which we received IIA participation payments in the aggregate amount of $4,065 through December&#160;31, 2021. In return, we committed to pay IIA royalties at a rate of&#160;3-3.5%&#160;of future sales of the developed products, up to 100% of the amount of grants received plus interest at LIBOR rate. Through December&#160;31, 2021, no royalties have been paid or accrued. In addition, in connection with acquiring certain intellectual property from Althera Medical (&#8220;Althera&#8221;), our predecessor, we assumed all of Althera&#8217;s liabilities towards the IIA totaling $474 of royalty-bearing grants received by Althera (plus accrued interest at LIBOR rate). The Company&#8217;s liability to the IIA at December&#160;31, 2021, including royalty-bearing grants received by the Company, grants assumed from Althera and the associated LIBOR interest accrued on all such grants, totaled $5,061. In addition, through December&#160;31, 2021, we received IIA participation payments in the aggregate amount of $975 under non-royalty-bearing programs from the IIA. This includes an advance payment of $242 received in December&#160;2021 toward such a&#160;non-royalty-bearing&#160;grant program, which is effective from December&#160;1, 2021. This amount is presented as an accrued expense at December&#160;31, 2021. Additionally, we also agreed to pay Althera 2% (subject to certain adjustments), from sales derived from the purchased intellectual property, up to a maximum amount of $1,500 (plus VAT), in the aggregate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with ongoing research and development activities and acquiring certain intellectual property from Ramot at Tel Aviv University&#160;Ltd., the technology transfer company of Tel Aviv University, we agreed to pay a 2.5% royalty on net sales of our alpha radiation products and a 7% royalty on any royalties or revenues from licensing such products. We also agreed to grant to HekaBio K.K. options to acquire 271,588 of Alpha Tau ordinary shares at a price of $4.42 each and to pay HekaBio K.K. a royalty of 3.5% of the reimbursement price and 10% of distribution receipts in Japan if HekaBio K.K. successfully assists us in obtaining regulatory marketing approval of the Alpha DaRT in Japan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As part of our ongoing research and development activities with BGN Technologies, the technology transfer company of Ben Gurion University (&#8220;BGN&#8221;), we agreed to pay BGN a 0.75% royalty on all sales of our alpha radiation products and a 1.5% royalty on sales of any products that contain intellectual property owned by Ben Gurion University, net of certain deductions. We also agreed to pay BGN 4% of certain license revenues that relate to jointly developed intellectual property, and 8% of license revenues that relate to intellectual property developed solely by Ben Gurion University. We will wholly own any intellectual property that is developed jointly with Ben Gurion University.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As part of our clinical trial agreement with Cambridge University Hospitals NHS Trust, we agreed to pay Cambridge 5% of any marginal increase in our net sales generated on account of any patent or patent claim granted from the research performed in such trial and 2% of our net sales received for the treatment of Squamous Cell Carcinoma of the vulva.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">117</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Off-Balance&#160;Sheet Arrangements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We did not have during the periods presented, and we do not currently have, any&#160;off-balance&#160;sheet arrangements, as defined under applicable SEC rules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Quantitative and Qualitative Disclosures About Market Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are exposed to market risk related to changes in interest rates. As of December&#160;31, 2020 and 2021, our cash equivalents consisted of interest-bearing checking accounts and deposits. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. Due to the short-term nature and the low risk profile of our interest-bearing accounts, an immediate 10% change in interest rates would not have a material effect on the fair market value of our cash and cash equivalents or on our financial position or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We operate primarily in Israel and the majority of our expenses are denominated in New Israeli Shekels, or NIS. We are subject to fluctuations in foreign currency rates in connection with these arrangements. With respect to our foreign currency exposures for the&#160;years ended December&#160;31, 2020 and 2021, a 10% unfavorable movement in foreign currency exchange rates would have increased our operating expenses by approximately 8.5% and 7.4%, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We do not currently hedge our foreign currency exchange rate risk. In the future, we may enter into formal currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange rates of our principal operating currencies. These measures, however, may not adequately protect us from the material adverse effects of such fluctuations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Emerging Growth Company Status</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Jumpstart Our Business Startups Act of 2012, or the JOBS Act, permits an &#8220;emerging growth company&#8221; such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are in the process of evaluating the benefits of relying on other exemptions and reduced reporting requirements under the JOBS Act. Subject to certain conditions, as an emerging growth company, or EGC, we intend to rely on certain of these exemptions, including exemptions from the requirement to provide an auditor&#8217;s attestation report on our system of internal controls over financial reporting pursuant to Section&#160;404(b)&#160;of the Sarbanes-Oxley Act and from any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements, known as the auditor discussion and analysis. We will remain an EGC until the earlier of: the last day of the fiscal&#160;year in which we have total annual gross revenues of $1.07&#160;billion or more; the last day of the fiscal&#160;year following the fifth anniversary of the date of the completion of this offering; the date on which we have issued more than $1&#160;billion in nonconvertible debt during the previous three&#160;years; or the date on which we are deemed to be a large accelerated filer under the rules&#160;of the SEC.</p><a id="ResearchandDevelopmentPatentsandLicenses"></a><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">C.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Research and Development, Patents and Licenses, Etc.</b></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For a discussion of our research and development policies, see &#8220;Item 4.B above and the &#8220;<i style="font-style:italic;">Key Information &#8212;Risk Factors &#8212;Risks Related To Our Incorporation and Location In Israel</i>&#8221; in Item 3.D above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For a description of our intellectual property, please see &#8220;Item 4.B&#8221; above under &#8220;&#8212;Intellectual Property.</p><a id="TrendInformation_102347"></a><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">D.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Trend Information</b></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other than as described in Item 3.D. &#8220;<i style="font-style:italic;">Key Information &#8212;Risk Factors</i>&#8221; and in Item 5.A. &#8220;<i style="font-style:italic;">Operating and Financial Review&#8221;</i> of this Annual Report, we are not aware of any trends, uncertainties, demands, commitments or events that are reasonably likely to have a material effect on our results of operations or financial condition, liquidity or capital resources, or that caused the disclosed financial information to be not necessarily indicative of future operating results or financial condition. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">118</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="ECriticalAccountingEstimates_906789"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">E.</b></span><b style="font-weight:bold;">Critical Accounting Estimates</b></p><a id="RecentlyIssuedandAdoptedAccountingPronou"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recently Issued and Adopted Accounting Pronouncements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A description of recently issued accounting pronouncements that may potentially impact our financial position, results of operations or cash flows is disclosed in Note&#160;2 to our audited consolidated financial statements included elsewhere in this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Critical Accounting Policies and Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our management&#8217;s discussion and analysis of financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements during the reporting periods. These items are monitored and analyzed by us for changes in facts and circumstances, and material changes in these estimates could occur in the future. We base our estimates on historical experience, known trends and events, and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Changes in estimates are reflected in reported results for the period in which they become known. Actual results may differ materially from these estimates under different assumptions or conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">While our significant accounting policies are described in more detail in the notes to our consolidated financial statements appearing elsewhere in this Annual Report, we believe the following accounting policies used in the preparation of our consolidated financial statements require the most significant judgments and estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Share-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We apply the fair value recognition provisions of ASC 718,&#160;<i style="font-style:italic;">Compensation&#8212;Stock Compensation</i>, or ASC&#160;718, for share-based awards granted to employees and directors for their services on the board of directors. Determining the amount of share-based compensation to be recorded requires us to develop estimates of the fair value of share options as of their grant date. We estimate the fair value of each share option grant using the Black-Scholes option-pricing model. Calculating the fair value of share-based awards requires that we make subjective assumptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to ASC 718, we measure share-based awards granted to employees and members of the board of directors at fair value on the date of grant and recognize the corresponding share-based compensation expense of those awards on a straight-line basis over the requisite service period, which is generally the vesting period of the respective award. We have historically granted share options with exercise prices equivalent to or higher than the fair value of Alpha Tau ordinary shares as of the date of grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For awards with no performance conditions, the Company recognizes the related share-based compensation expense on a straight-line basis over the requisite service period of the awards, including awards with graded vesting. For awards with performance conditions the share-based compensation expense is recognized if and when the Company concludes that it is probable that the performance condition will be achieved and where the performance condition awards include graded vesting, the share-based compensation expense is recognized based on the accelerated method. The Company reassesses the probability of vesting at each reporting period for awards with performance conditions and adjusts compensation cost based on its probability assessment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We account for share-based awards to&#160;non-employees&#160;in accordance with ASU&#160;No.&#160;2018-07,&#160;<i style="font-style:italic;">Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting</i>, or ASU&#160;No.&#160;2018-07,&#160;which simplifies the accounting for share-based payments granted to nonemployees for goods and services and aligns most of the guidance on such payments to the nonemployees with the requirements for share-based payments granted to employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Black-Scholes option-pricing model uses the following inputs: the fair value of Alpha Tau ordinary shares, the expected volatility of Alpha Tau ordinary shares, the expected term of our share options, the risk-free interest rate for a period that approximates the expected term of our share options and our expected dividend yield. Due to the lack of a public market for Alpha Tau ordinary shares and a lack of company-specific historical and implied volatility data, we have based our computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to us, including stage of product development, life science industry focus, length of trading history and similar vesting provisions. The historical volatility data </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">119</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">is calculated based on a period of time commensurate with the expected term assumption. We will continue to apply this process until a sufficient amount of historical information regarding the volatility of our own share price becomes available or until circumstances change, such that the identified entities are no longer representative companies. In the latter case, more suitable, similar entities whose share prices are publicly available would be utilized in the calculation. We use the simplified method as prescribed by the SEC Staff Accounting Bulletin No.&#160;107,&#160;<i style="font-style:italic;">Share-Based Payment</i>, to calculate the expected term for options granted to employees as we do not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. Under this approach, the weighted-average expected option term is presumed to be the average of the contractual term (ten&#160;years) and the vesting term (generally four&#160;years) of our share options. We utilize this method due to lack of historical exercise data and the &#8220;plain-vanilla&#8221; nature of our share-based awards. The expected term is applied to the share option grant group as a whole, as we do not expect substantially different exercise or post-vesting termination behavior among our employee population. The risk- free interest rate is based on a treasury instrument whose term is consistent with the expected term of the share options. The expected dividend yield is assumed to be zero as we have never paid cash dividends and have no current plans to pay any cash dividends on Alpha Tau ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Valuation of Our Ordinary Shares</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The fair value of the ordinary shares underlying our option awards was determined by our board of directors, with input from management. We believe that our board of directors has the relevant experience and expertise to determine the fair value of our ordinary share as of each respective grant date. The valuations of Alpha Tau ordinary shares were determined in accordance with the guidelines outlined in the American Institute of Certified Public Accountants Practice Aid,&#160;<i style="font-style:italic;">Valuation of Privately-Held-Company Equity Securities Issued as Compensation</i>, or the AICPA Practice Aid. The assumptions used in the valuation model are based on future expectations combined with management judgment. Our board of directors, with input from management, exercised significant judgment and considered numerous objective and subjective factors to determine the fair value of Alpha Tau ordinary shares as of the date of each option grant, including the following factors:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">independent valuations performed at periodic intervals by an independent third-party valuation specialist;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our current business projections;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our stage of development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prices, rights, preferences and privileges of our convertible preferred shares;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">current business conditions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the likelihood of a liquidity event for the ordinary shares underlying these options, such as an initial public offering or sale of our company, given prevailing market conditions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any adjustments necessary due to the lack of marketability of Alpha Tau ordinary shares;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the purchase of our preferred shares by third party investors in arms-length transactions; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the market performance of comparable publicly traded companies.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event of a qualified initial public offering, our preferred shares would convert into ordinary shares (on a&#160;one-for-one&#160;basis for our Preferred B shares, and a&#160;1.07-to-one&#160;basis for our Preferred A shares), and accordingly would receive a pro rata amount of proceeds per share vs. ordinary shares. In the case of a sale or liquidation of the Company, the preferred shares would receive their liquidation preferences and thereafter a fraction in the remaining proceeds with the ordinary shares on a&#160;pro-rata&#160;basis. Accordingly, we determined the fair value of Alpha Tau ordinary shares in a hybrid model method utilizing two scenarios of OPM and public market offering (i.e., initial public offering or SPAC merger), and applying a weighted average of these values based on their relative probabilities in order to calculate the final per share value.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">First, we determined our Company&#8217;s value in an exit scenario due to a liquidity event, such as an initial public offering or SPAC merger, using the market approach and based on preliminary discussions with investment banks or engagement with SPACs. In this scenario, all preferred shares, warrants to purchase preferred shares and options to purchase Alpha Tau ordinary </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">120</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">shares convert into, or are deemed to be exercised for, ordinary shares. The firm value is divided by the resulting number of shares to determine a per share value.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Second, we determined our Company&#8217;s value using a market approach (based on the backsolve method). The backsolve method involves making assumptions for the time to liquidity, volatility, and risk-free rate and then solving for the value of equity such that value for the most recent financing equals the amount paid. In order to estimate the value of our equity value, including both ordinary and preferred shares, we relied upon our Series B preferred share price determined in recent financing rounds of our Series B preferred shares, which we believed to be the most indicative of our value.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We then allocated the value between all elements of our securities (preferred shares, ordinary shares, warrants for preferred shares and options for ordinary shares) using the option pricing model (&#8220;OPM&#8221;), on the assumption that our preferred shares will benefit from their liquidation preference, as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Under the backsolve method we used recent share purchase transactions to solve our implied equity value. This approach takes into account the economic rights of the various classes of shares such as liquidation preferences, redemption rights and dividend rights and then allocates the value accordingly to the rights and privileges of each class of shares. Since the Series B Preferred shares financing rounds involved multiple unrelated investors in a set of arms-length transactions, we determined it was the most appropriate method to determine the fair value of Alpha Tau ordinary shares given the early-stage nature of the company.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Under the OPM, preferred and ordinary shares are treated as a series of call options, with the preferred shares having an exercise price based on the liquidation preference of the respective preferred share. The OPM operates through a series of Black&#8211;Scholes option pricing models, with the strike prices of the options representing the upper and lower bounds of the proceed ranges that a security holder would receive upon a liquidity event. The strike prices occur at break points where the allocation of firm value changes among the various security holders. The ordinary shares are presumed to have value only if funds available for distribution to shareholders exceed the value of the respective liquidation preferences at the time of a liquidity event. The OPM requires an enterprise level input of firm value or a transaction level input of specific security value (typically, a recently issued convertible preferred security) to anchor the allocation of firm value among the various classes of securities.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In making the final determination, we also applied a discount for lack of marketability right, as applicable, to Alpha Tau ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe we applied a reasonable valuation method to determine the share option exercise prices on the respective share option grant dates. A combination of factors led to changes in the fair value of Alpha Tau ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accounting Treatment of the Convertible Preferred Shares</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our preferred shares are considered a &#8220;freestanding financial instrument&#8221; pursuant to ASC 480 &#8220;Distinguishing Liabilities from Equity&#8221; and are redeemable in a deemed liquidation event, which is not under our control; thus, we classified the shares outside permanent equity pursuant to ASC&#160;480-10-S99.&#160;As of December&#160;31, 2019, 2020 and 2021, we did not adjust the carrying values of the shares to the deemed liquidation values of such shares since a deemed liquidation event was not probable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Warrants to Purchase Convertible Preferred Shares</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Warrants to purchase our convertible preferred shares are considered a &#8220;freestanding financial instrument&#8221; pursuant to ASC 480. Our warrants were classified as a liability on the balance sheet initially, and subsequently measured at fair value through earnings, as the underlying shares are contingently redeemable (upon a deemed liquidation event, which is not under our control) and, therefore, embody an obligation that is indexed to an obligation to repurchase our shares by transferring assets. The change in fair value of our warrants is recognized as a component of financial expenses (income), net, in the statements of operation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Our board of directors calculates the fair value of the warrants on the issuance date and on subsequent reporting dates, considering among other things, a third-party valuation. We first calculated the underlying preferred share value by using the income approach and the market approach. Then the equity value was allocated by using the hybrid model method utilizing two scenarios of OPM and initial public offering. Once the preferred shares value was derived from the two scenarios, the Black-Scholes model was utilized to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">121</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">calculate the warrants value in each one of the scenarios. Then, probability for each one of the scenarios was applied by the Company to derive the weighted average fair value of the warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_5be12df7_9a21_410c_b1d9_655c925a2881"></a><a id="Item6DirectorsSeniorManagementandEmploye"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;6. Directors, Senior Management and Employees</b></p><a id="ADirectorsandSeniorManagement_894186"></a><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">A.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Directors and Senior Management</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Management and Board of Directors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth the name, age and position of each of our executive officers and directors as of March&#160;21, 2022:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:4pt;"><td style="vertical-align:bottom;width:46.86%;margin:0pt;padding:0pt;"><div style="height:4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><div style="height:4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:36.6%;margin:0pt;padding:0pt;"><div style="height:4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Age</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:36.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Position</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Executive Officers</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:36.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Uzi Sofer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief&#160;Executive&#160;Officer&#160;and&#160;Chairman</p></td></tr><tr><td style="vertical-align:bottom;width:46.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raphi Levy</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">37</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:36.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr><tr><td style="vertical-align:bottom;width:46.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prof. Itzhak Kelson</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">82</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:36.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Physics Officer</p></td></tr><tr><td style="vertical-align:bottom;width:46.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prof. Yona Keisari</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:36.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Scientific Officer</p></td></tr><tr><td style="vertical-align:bottom;width:46.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Robert Den, M.D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">43</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:36.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Medical Officer</p></td></tr><tr><td style="vertical-align:bottom;width:46.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amnon Gat</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">47</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:36.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Operations Officer</p></td></tr><tr><td style="vertical-align:bottom;width:46.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ronen Segal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:36.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Technology Officer</p></td></tr><tr><td style="vertical-align:bottom;width:46.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Directors</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Michael Avruch</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:36.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:46.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ruth Alon</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:36.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:46.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">S. Morry Blumenfeld, Ph.D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:36.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:46.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Meir Jakobsohn</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:36.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:46.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Alan Adler</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:36.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:46.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gary Leibler</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">56</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:36.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:46.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Peter Melnyk</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:36.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:46.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">David M. Milch, M.D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:36.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Executive Officers</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Uzi Sofer </i>has served as Alpha Tau&#8217;s Chief Executive Officer and as chairman of its board of directors since the company&#8217;s founding in 2015. Prior to that, Mr.&#160;Sofer was the co-founder, Chief Executive Officer and director of Brainsway&#160;Ltd. (NASDAQ: BWAY), an Israeli medical device company, from 2003 until his retirement in 2014, and also served as its acting Chief Financial Officer from its inception until 2010. Mr.&#160;Sofer has served as Chief Executive Officer, Chief Financial Officer, and chairman of various private and public companies for the past two decades. From 2001 until 2010, Mr.&#160;Sofer served as both chairman of the board and Chief Financial Officer of Hofit Kibbutz Kinneret&#160;Ltd. (TASE:HOFI). From 2000 through 2002, he served as director and Chief Financial Officer of Magen David Taasiot&#160;Ltd. Mr.&#160;Sofer has a B.Sc. in Accounting and Information Systems from the Lev Institute (Jerusalem College of Technology). We believe that Mr.&#160;Sofer&#8217;s public company and industry experience qualify him to serve on our board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Raphi Levy </i>has served as Alpha Tau&#8217;s Chief Financial Officer since 2019. Prior to joining Alpha Tau, Mr.&#160;Levy served in the Investment Banking Division at Goldman Sachs from 2006 until 2019 in New York and Tel Aviv, most recently serving as Executive Director in charge of healthcare banking in Israel. Mr.&#160;Levy holds a BS in Economics from the Wharton School of Business, University of Pennsylvania, and a BSE and MSE in Electrical Engineering from the School of Engineering and Applied Science, University of Pennsylvania<i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-indent:18pt;margin:0pt;"><i style="font-size:10pt;font-style:italic;">Professor Itzhak Kelson </i><span style="font-size:10pt;">has served as Alpha Tau&#8217;s Chief Physics Officer since 2016, and, together with Prof. Yona Keisari, co-invented the Alpha DaRT</span><span style="font-size:6.5pt;">TM </span><span style="font-size:10pt;">technology in 2003. In addition to his position with the Company, Prof. Kelson is Professor Emeritus and retired chairman of the Tel Aviv University School of Physics and Astronomy. In addition to his career as a tenured professor at Tel Aviv University, between 1963 and 1999, Prof. Kelson held research and teaching positions at multiple universities and institutions, including the Weizmann Institute, Yale University, University of California, Berkeley, University of Wisconsin, Brookhaven National Laboratory, Goethe University Frankfurt, Michigan State University, the Soreq Nuclear Research Center, University of Rochester, Rutgers University, University of Paris XI at Orsay, Saclay Nuclear Research Centre, the European Organization for Nuclear Research </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">122</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">(CERN) and the University of British Columbia. Prof. Kelson holds an M.Sc. in Physics, Mathematics and Applied Mathematics and a Ph.D. in Physics (Nuclear Theory) from the Hebrew University of Jerusalem.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-size:10pt;font-style:italic;">Professor Yona Keisari </i><span style="font-size:10pt;">co-founded Alpha Tau and, together with Prof. Itzhak Kelson, invented the Alpha DaRT</span><span style="font-size:6.5pt;">TM </span><span style="font-size:10pt;">technology in 2003. Prof. Keisari served as Alpha Tau&#8217;s Chief Biological Officer from 2016 until 2019 and has served as Chief Scientific Officer since 2019. Prof. Keisari was a faculty member at the Department of Clinical Microbiology and Immunology, Faculty of Medicine, Tel Aviv University, Israel from 1979 until 2015, and as Full Professor from 2002 until 2015, at which time he became Professor Emeritus. Prof. Keisari&#8217;s studies focus on the activation of systemic anti-tumor immune reactivity through in-situ destruction of solid cancers with Alpha DaRT</span><span style="font-size:6.5pt;">TM</span><span style="font-size:10pt;">, and developing means to improved eradication of metastases. Prof. Keisari has co-authored 93 peer-reviewed scientific papers and is an editorial board member of eight journals. He co-founded and served as president of the Israeli Society for Cancer Research from 2013 until 2015 and has served as treasurer of The International Cancer Microenvironment Society since 2015. Prof. Keisari holds an M.Sc. in Microbiology and Immunology and a Ph.D. in Immunology from Tel Aviv University, and was a postdoctoral fellow at the National Cancer Institute of the NIH in Bethesda, MD.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Robert Den, MD </i>has served as Alpha Tau&#8217;s Chief Medical Officer since 2019. Dr.&#160;Den specializes in radiation oncology and conducts innovative research across a broad variety of malignancies. From 2011 to 2015 and from 2015 to the present, Dr.&#160;Den has served as an assistant professor and an associate professor, respectively, at Jefferson University, where he has also served as a clinical practitioner since 2007. Dr.&#160;Den holds a B.S. in Chemistry from Yale University and an M.D. from Harvard Medical School.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Amnon Gat </i>has served as Alpha Tau&#8217;s Chief Operations Officer since 2018, after having served as Alpha Tau&#8217;s VP of Marketing and Business Development and then VP of Operations between 2016 and 2018. Mr.&#160;Gat also served as a director of Alpha Tau Medical Canada from 2019 until 2021. Mr.&#160;Gat leads our operations in the United States and has over 20&#160;years of experience in the medical device and healthcare industries. Prior to joining Alpha Tau, Mr.&#160;Gat held managerial positions in public and private companies, such as Brainsway&#160;Ltd. (NASDAQ: BWAY) from 2011 until 2015, OSG Optimal Strategix Group,&#160;Inc. from 2010 until 2011, and Truphatek International&#160;Ltd. from 2007 until 2009, and served as a senior paramedic in the Israeli national emergency services. Mr.&#160;Gat holds a BA from The Open University of Israel and an MBA in International Management and Marketing from the Interdisciplinary Center, Herzliya.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Ronen Segal </i>has served as Alpha Tau&#8217;s Chief Technology Officer since 2019. Mr.&#160;Segal has served in a variety of senior managerial and technological development positions, including at Brainsway Ltd (NASDAQ: BWAY), where he served as Chief Technology Officer, Deputy CEO and Head of Business Development from 2010 until 2018, and co-founder and Vice President at WiTech Communications&#160;Ltd. from 2004 until 2010. Mr.&#160;Segal completed studies in 1994 toward a BSc in Electro-Optical Engineering and Applied Physics at the Jerusalem College of Technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Directors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Michael Avruch </i>has served as a member of Alpha Tau&#8217;s board of directors since 2016. Mr.&#160;Avruch has served as chief executive officer, chief financial officer, and as a member of the board of directors of Sabor LTD (The Sabor Group Europe) since 1998 and Sabor Venture Capital Investments (VCI) LTD since 2017. Mr.&#160;Avruch has also served as chief executive officer and chief financial officer of Sabor Group USA since 2015. Mr.&#160;Avruch has experience in the real estate, services, and trade sectors in multiple countries in Europe and the USA. Mr.&#160;Avruch holds a B.A. in Management Accounting and Information Systems from the Jerusalem College of Technology and an MBA from Bar Ilan University. We believe Mr.&#160;Avruch&#8217;s financial and cross-border experience qualify him to serve on our board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><i style="font-style:italic;">Ruth Alon </i>has served on our Board since March&#160;2022. Ms.&#160;Alon is currently the founder and CEO of Medstrada. From 1997 and until December&#160;24, 2016, Ms.&#160;Alon served as a general partner in Pitango Venture Capital. Prior to her tenure at Pitango, Ms.&#160;Alon held senior positions with Montgomery Securities from 1981 to 1987, Genesis Securities, LLC from 1993 to 1996, and Kidder Peabody&#160;&amp; Co. from 1987 to 1993, and managed her own independent consulting business in San Francisco in the medical devices industry from 1995 to 1996. Ms.&#160;Alon was the founder and Chairperson of Israel Life Science Industry, a not-for-profit organization representing the mutual goals of the then approximately 1,000 Israeli life science companies. She was also the co-founder of the Israeli Advanced Technology Industries (IATI), an umbrella organization of the hi-tech and life sciences industries in Israel, which includes venture capital funds, R&amp;D centers of multinational corporations and others. She currently serves on the boards of Vascular Biogenics Ltd (Nasdaq:VBLT), Moringa Acquisition Corp (NASDAQ:MACA), Treos Bio (privately held), Phoska BioPharma (privately held), Blue Tree Technologies (privately held), and Brainsgate (privately held) (as Chairperson). Ms.&#160;Alon has a B.A. in Economics from the Hebrew University of Jerusalem, Israel, an M.B.A. from Boston University, and an M.S. from the Columbia University School of </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">123</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Physicians and Surgeons. We believe Ms.&#160;Alon&#8217;s financial and capital markets experience with healthcare companies qualify her to serve on our board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">S. Morry Blumenfeld, Ph.D. </i>has served as a member of Alpha Tau&#8217;s of directors since 2016<i style="font-style:italic;">. </i>Dr.&#160;Blumenfeld is President and CEO of Quescon Consultants Ltd, a medical device consulting company, as position he has held since 2012. Dr.&#160;Blumenfeld is also a Venture Partner for MedTech Investments at OurCrowd and is the Founding Partner of Meditech Advisors LLC, a private equity fund specializing in investments in healthcare and medical device companies. In April&#160;2002, Dr.&#160;Blumenfeld retired as Managing Director of GE Medical Systems in Israel after 34&#160;years with the company, where he helped initiate both GE&#8217;s CT and MRI business lines as well as the initial use of MR guided Focused Ultrasound, now being used by Insightec. Currently, Dr.&#160;Blumenfeld serves on the board of directors of a number of private medical device and technology companies. Dr.&#160;Blumenfeld holds a B.A.Sc in Engineering Physics, an M.A. in Molecular Physics and a Ph.D. in Molecular Physics from the University of Toronto. We believe that Dr.&#160;Blumenfeld&#8217;s industry experience qualify him to serve on our board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Meir Jakobsohn </i>has served as a member of Alpha Tau&#8217;s board of directors since 2016. In 1996, Mr.&#160;Jakobsohn founded Medison Pharma Limited, a global pharma company and one of the largest commercialization partners of biopharma companies, and he currently serves as its Chief Executive Officer and chairman of the board of directors. Mr.&#160;Jakobsohn has served on the board of directors of various public and private healthcare and technology companies. Mr.&#160;Jakobsohn holds a BA in Economics from Bar-Ilan University and an Executive MBA from Bradford University in the UK. We believe that Mr.&#160;Jakobsohn&#8217;s financial and industry experience qualify him to serve on our board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Alan Adler </i>has served as a member of Alpha Tau&#8217;s board of directors since 2018. Mr.&#160;Adler served as a chairman of the board of directors and chief executive officer of Israeli-based Oridion Systems Ltd, from 2004 until the company was acquired by Medtronic plc, f/k/a Covidien (NYSE: MDT), in 2012. Prior to that, he gained over 14&#160;years of experience as a principal at McKinsey&#160;&amp; Company and, afterwards, as a senior partner at Evergreen Venture Partners, an Israeli venture capital group. Mr.&#160;Adler currently serves as a member of the board of directors of a number of private technology and life science companies. Mr.&#160;Adler holds a B.Sc. in Mathematics from Rensselaer Polytechnic Institute and an MBA with honors from Stanford University. We believe that Mr.&#160;Adler&#8217;s financial and industry experience qualify him to serve on our board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Gary Leibler </i>has served as a member of Alpha Tau&#8217;s board of directors since 2018. Mr.&#160;Leibler is the founder of Shavit Capital, a private equity practice that specializes in investing in late stage Israeli technology companies, and has been serving as the managing partner of Shavit Capital since 2007. Since 2021, Mr.&#160;Leibler has also served as a director of Growth Capital Acquisition Corp. (NASDAQ: GCAC), a special purpose acquisition vehicle. Mr.&#160;Leibler has served as director of various private hi-tech and investment advisory companies. Mr.&#160;Leibler was also the founder and managing partner of AIG Orion Venture Capital Fund, which was managed in partnership with the international private equity practice of American International Group (NYSE: AIG), and also served as a manager of the private equity practice of AIG Global Emerging Markets. Mr.&#160;Leibler holds a B.Sc. degree in Laws and a B.Sc. degree in Economics from Monash University, Melbourne, Australia. We believe that Mr.&#160;Leibler&#8217;s financial and industry experience qualify him to serve on our board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Peter Melnyk </i>has served as a member of Alpha Tau&#8217;s board of directors since 2020. From 2019 until 2021, Mr.&#160;Melnyk served as the chief executive officer of Fortovia Therapeutics,&#160;Inc., a commercial stage, pharmaceutical company focused on oncology supportive care products. From 2011 until 2017, Mr.&#160;Melnyk was chief commercial officer at NovoCure Limited (NASDAQ: NVCR), a cancer medical device company, where he built a global commercial platform and infrastructure to launch a new modality of anticancer technology. Mr.&#160;Melnyk was previously senior vice president for global sales and marketing at OSI Pharmaceuticals,&#160;Inc., a U.S. pharmaceutical company, where he led the global commercialization efforts for Tarceva, a chemotherapy drug, from 2003 to 2011. Prior to that, Mr.&#160;Melnyk was the executive director of oncology at Pharmacia Oncology from 2001 until 2003, until its acquisition by Pfizer,&#160;Inc. Mr.&#160;Melnyk also served in various capacities at Bristol-Myers Squibb Company from 1991 until 2001. Mr.&#160;Melnyk holds a B.Sc in Animal Science and M.Sc in reproductive endocrinology from McGill University. We believe that Mr.&#160;Melnyk&#8217;s public company and industry experience qualify him to serve on our board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><i style="font-style:italic;">David M. Milch, M.D. </i>has served as a member of our board of directors since March&#160;2022. Dr.&#160;Milch has been a self-employed independent investor in the life sciences and technology areas for the past 30&#160;years. Recently, Dr.&#160;Milch pursued a number of media opportunities, as the lead investor, including Mila-Media, BeTerrific! and others. In 2014, Dr.&#160;Milch invested in the first biopharma spinout from well-known genomics research leader Jackson Laboratories, Cyteir Therapeutics, with co-investors Celgene Corporation, Venrock, Silverlake and others. In 2010, Dr.&#160;Milch established the Dr.&#160;David M. Milch Foundation to serve &#8220;Tikkun Olam&#8221; (healing the world) in two primary areas: Arts for Social Impact which focuses on film, theater, and other modes of creativity, and Youth </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">124</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Mentoring, which helps foster leadership development and civic responsibility. In 2008, Dr.&#160;Milch was part of the small angel group which capitalized Games24X7 in India, currently named RummyCircle. Dr.&#160;Milch received his B.S. in Biology at Stanford University and his M.D. from Harvard Medical School. We believe that Dr.&#160;Milch&#8217;s financial and industry experience qualify him to serve on our board of directors.</p><a id="BCompensation_241263"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">B.</b></span><b style="font-weight:bold;">Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Directors</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Companies Law, the compensation of a public company&#8217;s directors requires the approval of (i)&#160;its compensation committee, (ii)&#160;its board of directors and, unless exempted under regulations promulgated under the Companies Law, (iii)&#160;the approval of its shareholders at a general meeting. In addition, if the compensation of a public company&#8217;s directors is inconsistent with the company&#8217;s compensation policy, then those inconsistent provisions must be separately considered by the compensation committee and board of directors, and approved by the shareholders by a special vote in one of the following two ways:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">at least a majority of the shares held by all shareholders who are not controlling shareholders and do not have a personal interest in such matter, present and voting at such meeting, vote in favor of the inconsistent provisions of the compensation package, excluding abstentions; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the total number of shares of non-controlling shareholders and shareholders who do not have a personal interest in such matter voting against the inconsistent provisions of the compensation package does not exceed two&#160;percent (2%) of the aggregate voting rights in the Company.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Executive Officers other than the Chief Executive Officer</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Companies Law requires the compensation of a public company&#8217;s executive officers (other than the chief executive officer and who do not also serve as a director) be approved in the following order: (i)&#160;the compensation committee, (ii)&#160;the company&#8217;s board of directors, and (iii)&#160;if such compensation arrangement is inconsistent with the company&#8217;s stated compensation policy, the company&#8217;s shareholders (by a special vote as discussed above with respect to the approval of director compensation that is inconsistent with the compensation policy).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">However, there are exceptions to the foregoing approval requirements with respect to such non-director executive officers. If the shareholders of the company do not approve the compensation of such a non-director executive officer, the compensation committee and board of directors may override the shareholders&#8217; disapproval for such non-director executive officer provided that the compensation committee and the board of directors each document the basis for their decision to override the disapproval of the shareholders and approve the compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An amendment to an existing compensation arrangement with a non-director executive officer requires only the approval of the compensation committee, if the compensation committee determines that the amendment is immaterial. However, if such non-director executive officer is subordinate to the chief executive officer, an immaterial amendment to an existing compensation arrangement shall not require the approval of the compensation committee if (i)&#160;such amendment is approved by the chief executive officer, (ii)&#160;the company&#8217;s compensation policy allows for such immaterial amendments to be approved by the chief executive officer and (iii)&#160;the engagement terms are consistent with the company&#8217;s compensation policy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Chief Executive Officer</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Under the Companies Law, the compensation of a public company&#8217;s chief executive officer is required to be approved by: (i)&#160;the company&#8217;s compensation committee, (ii)&#160;the company&#8217;s board of directors and (iii)&#160;the company&#8217;s shareholders (by a special vote as discussed above with respect to the approval of director compensation that is inconsistent with the compensation policy). However, if the shareholders of the company do not approve the compensation arrangement with a chief executive officer who does not serve as a director, the compensation committee and board of directors may override the shareholders&#8217; decision provided that they each document the basis for their decision and the compensation is in accordance with the company&#8217;s compensation policy. The approval of each of the compensation committee and board of directors should be in accordance with the company&#8217;s compensation policy; however, in special circumstances, they may approve compensation terms of a chief executive officer that are inconsistent with such policy provided that they have considered those provisions that must be included in the compensation policy according to the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">125</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Companies Law and that shareholder approval was obtained (by a special majority vote as discussed above with respect to the approval of director compensation that is inconsistent with the compensation policy).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the case of a new chief executive officer, the compensation committee may waive the shareholder approval requirement with regard to the compensation of a candidate for the chief executive officer position if the compensation committee determines that: (i)&#160;the compensation arrangement is consistent with the company&#8217;s compensation policy, (ii)&#160;the chief executive officer candidate did not have, on the date of his appointment or during the two-year period preceding his appointment, an &#8220;affiliation&#8221; (including an employment relationship, a business or professional relationship or control) with the company or a controlling shareholder of the company or a relative thereof and (iii)&#160;subjecting the approval of the engagement to a shareholder vote would impede the company&#8217;s ability to employ the chief executive officer candidate. However, if the chief executive officer candidate will serve as a member of the board of directors, such candidate&#8217;s compensation terms as chief executive officer must be approved in accordance with the rules&#160;applicable to approval of compensation of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Compensation of Executive Officers and Directors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The aggregate cash compensation and benefits in kind, paid by us and our subsidiaries to our executive officers and directors as a group for the&#160;year ended December&#160;31, 2021 was approximately $1.77 million. This amount includes $199,000 of amounts set aside or accrued to provide pension, severance, retirement, health or similar benefits or expenses as well as other benefits commonly reimbursed or paid by companies in Israel. In addition, in 2021 we granted to our executive officers and directors a total of 608,500 restricted share units and 601,859 options to purchase our ordinary shares with an exercise price of $11.50. Both the share options and restricted share units shall commence vesting only upon consummation of the Business Combination, will vest over a 4-year period therefrom and will expire 10&#160;years from the date of grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For 2022, we expect that the aggregate base compensation payable by us and our subsidiaries to our executive officers and directors as a group will be in the aggregate amount of approximately $3.66 million. This amount excludes potential salary raises, bonuses and share-based compensation, which have not yet been determined for 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2021, options to purchase 3,134,875 ordinary shares granted to our executive officers and directors as a group were outstanding under our equity incentive plans at a weighted average exercise price of $4.95 per ordinary share. As of December&#160;31, 2021, 608,500 restricted share units granted to our executive officers and directors were outstanding under our equity incentive plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We currently pay each of our non-employee directors an annual retainer of $26,000, with an additional annual payment for service on board committees as follows: $18,000 (or $21,000 for the chairperson) per membership of the audit committee, or $12,000 (or $14,000 for the chairperson) per membership of the compensation committee, $6,000 (or $7,000 for the chairperson) per membership of the nominating and governance committee and $5,000 (or $6,000 for the chairperson) per any membership on any other standing board committee. In addition, upon election, non- employee directors and each employee director that serves as chairperson of our board of directors, will be granted equity awards under our incentive plan at a value of $100,000, which will vest on a&#160;monthly basis over a period of three&#160;years. In addition, each non-employee director and each employee director that serves as chairperson of our board of directors will be granted annual equity awards under our incentive plan (provided the director is still in office) at a value of $100,000, which will vest on the earlier of the first anniversary of the date on which such options and restricted share units were granted or the date upon which our next annual general meeting of the shareholders is convened, subject to such director&#8217;s continued service through such date. Any unvested equity grants will accelerate and fully vest upon the occurrence of a change in control transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Share Option Plans</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">2016 Share Incentive Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We adopted our 2016 Share Incentive Plan (the &#8220;2016 Plan&#8221;) on September&#160;8, 2016. The 2016 Plan provides for the grant of options to our and our subsidiaries&#8217; and affiliates&#8217; employees, directors, office holders, service providers and consultants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Authorized Shares. </i>As of December&#160;31, 2021, there were 442,439 ordinary shares reserved and available for issuance under the 2016 Plan.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">126</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Administration. </i>Our board of directors, or a duly authorized committee of the board of directors, administers the 2016 Plan. Under the 2016 Plan, the Administrator has the authority, subject to applicable law, to (among other things) interpret the terms of the 2016 Plan and any notices of grant or options granted thereunder, designate recipients of option grants, determine and amend (in certain cases, with the consent of the grantee) the terms of awards, including: the number of shares underlying each award, the class and the exercise price of an option or purchase price per share covered by an award, the fair market value of our ordinary shares, the time of grant and vesting schedule applicable to an award (including the determination to accelerate an award and/or amend the vesting schedule), the method of payment for shares purchased upon the exercise or (if applicable) vesting of an award or for satisfaction of any tax withholding obligation arising in connection with the award or such shares, the time of the expiration of the awards, the effect of the grantee&#8217;s termination of employment, prescribe the forms of agreement under which each award is granted, and take all other actions and make all other determinations necessary or desirable for, or incidental to, the administration of the 2016 Plan and any award under the 2016 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Administrator also has the authority to interpret the 2016 Plan and any award agreement, and to amend or rescind provisions of the 2016 Plan or terminate the 2016 Plan at any time before the date of expiration of its ten&#160;year term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Eligibility. </i>The 2016 Plan provides for granting awards under various tax regimes, including, without limitation, in compliance with Section&#160;102 (&#8220;Section&#160;102&#8221;) of the Israeli Income Tax Ordinance (New Version), 5721-1961 (the &#8220;Ordinance&#8221;), and Section&#160;3(i)&#160;of the Ordinance, and for awards granted to our United States employees or service providers, including those who are deemed to be residents of the United States for tax purposes or are otherwise subject to U.S. Federal income tax (&#8220;U.S. Grantees&#8221;), Section&#160;422 of the Code and Section&#160;409A of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;102 of the Ordinance allows employees, directors and officers who are not controlling shareholders and are considered Israeli residents to receive favorable tax treatment for compensation in the form of shares or options under certain terms and conditions. Our non-employee service providers and controlling shareholders who are considered Israeli residents may only be granted options under section 3(i)&#160;of the Ordinance, which does not provide for similar tax benefits. Section&#160;102 includes two alternatives for tax treatment involving the issuance of options or shares to a trustee for the benefit of the grantees and also includes an additional alternative for the issuance of options or shares directly to the grantee. Section&#160;102(b)(2)&#160;of the Ordinance, the most favorable tax treatment for the grantee, permits the issuance to a trustee under the &#8220;capital gain track&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Grant. </i>All awards granted pursuant to the 2016 Plan are evidenced by a written or electronic agreement between Alpha Tau and the grantee or a written or electronic notice delivered by Alpha Tau (the &#8220;Award Agreement&#8221;). The Award Agreement sets forth the terms and conditions of the award, including the type of award, number of shares subject to such award, manner of exercise, term and vesting schedule (including performance goals or measures) and the exercise price, if applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each award will expire ten&#160;years from the date of the grant thereof (or five&#160;years in case of incentive stock options, within the meaning of Section&#160;422 of the Code, granted to certain significant shareholders), unless such shorter term of expiration is otherwise designated by the Administrator.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Awards. </i>The 2016 Plan provides for the grant of options (including incentive stock options and nonqualified stock options) to acquire ordinary shares or shares of such other class as may be designated by the board of directors, restricted shares, restricted share units and other share-based awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Options granted under the 2016 Plan to U.S. Grantees may qualify as &#8220;incentive stock options&#8221; within the meaning of Section&#160;422 of the Code, or may be non-qualified stock options. The exercise price of a stock option may not be less than 100% of the fair market value of the underlying share on the date of grant (or 110% in the case of incentive stock options granted to certain significant shareholders), unless such award is granted pursuant to an assumption or substitution for another option in a manner qualifying under the provisions of the Code or any successor guidance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Exercise. </i>An award under the 2016 Plan may be exercised by providing Alpha Tau or Alpha Tau&#8217;s Chief Executive Officer with a written notice of exercise and full payment of the exercise price for such shares underlying the award, if applicable, in such form and method as may be determined by the Administrator and permitted by applicable law. An award may not be exercised for a fraction of a share. With regard to tax withholding, exercise price and purchase price obligations arising in connection with awards under the 2016 Plan, the Administrator may, in its discretion, among others, accept cash or otherwise provide for net withholding of shares in a cashless exercise mechanism.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">127</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Transferability. </i>Other than by will, the laws of descent and distribution or as otherwise provided under the 2016 Plan, and unless otherwise determined by the Administrator, neither the awards nor any right in connection with such awards are assignable or transferable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Termination of Employment. </i>In the event of termination of a grantee&#8217;s employment or service with Alpha Tau or any of its affiliates, all vested and exercisable awards held by such grantee as of the date of termination may be exercised within three&#160;months after such date of termination, unless otherwise determined by the Administrator. Any awards which are unvested as of the date of such termination, or which are vested but not exercised within the three-month period following such termination, will terminate and the shares covered by such awards shall again be available for issuance under the 2016 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event of termination of a grantee&#8217;s employment or service with Alpha Tau or any of its affiliates due to such grantee&#8217;s death or &#8220;disability&#8221; (as defined in the 2016 Plan), all vested and exercisable awards held by such grantee as of the date of termination may be exercised by the grantee or the grantee&#8217;s estate or by a person who acquired the legal right to exercise such awards by bequest or inheritance, or by a person who acquired the legal right to exercise such awards in accordance with applicable law in the case of disability of the grantee as applicable, within one&#160;year after such date of termination, unless otherwise provided by the Administrator. Any awards which are unvested as of the date of such termination or which are vested but not exercised within the one-year period following such termination, will terminate and the shares covered by such awards shall again be available for issuance under the 2016 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding any of the foregoing, if a grantee&#8217;s employment or services with Alpha Tau or any of its affiliates is terminated for &#8220;cause&#8221; (as defined in the 2016 Plan), unless otherwise determined by the Administrator, all outstanding awards held by such grantee (whether vested or unvested) will terminate on the date of such termination and the shares covered by such awards shall again be available for issuance under the 2016 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Transactions. </i>In the event of division or subdivision of the outstanding share capital of Alpha Tau, any distribution of bonus shares (share split), consolidation or combination of share capital of Alpha Tau (reverse share split), reclassification with respect to the shares or any similar recapitalization events, a merger, consolidation, amalgamation or like transaction of Alpha Tau with or into another corporation, a reorganization (which may include a combination or exchange of shares, spin-off or other corporate divestiture or division), or other similar occurrences, the administrator shall have the authority to make, without the need for a consent of any holder of an award, such adjustments in order to adjust the number and class of shares reserved and available for grants of awards, the number and class of shares covered by outstanding awards, the exercise price per share covered by any award, the terms and conditions concerning vesting and exercisability and the term and duration of the outstanding awards, and any other terms of the award that in the opinion of the Administrator should be adjusted. Any fractional shares resulting from such adjustment shall be treated as determined by the Administrator, and in the absence of such determination shall be rounded to the nearest whole share, and Alpha Tau shall have no obligation to make any cash or other payment with respect to such fractional shares. No adjustment shall be made by reason of the distribution of subscription rights or rights offering to outstanding shares or other issuance of shares by Alpha Tau, unless the Administrator determines otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event of a merger or consolidation of Alpha Tau, or a sale of all, or substantially all, of Alpha Tau&#8217;s shares or assets or a scheme of arrangement for the purpose of effecting such merger, consolidation, sale or such other transaction having a similar effect on Alpha Tau (as described in the 2016 Plan), or liquidation or dissolution of the Company, or such other transaction or circumstances as determined by our board of directors (&#8220;Merger\Sale&#8221;), then without the consent of the grantee, the Administrator may, but is not required to, among other things, (i)&#160;cause any outstanding award to be assumed or substituted by us, or by the successor corporation in such Merger/Sale, or (ii)&#160;regardless of whether or not awards are assumed or substituted (a)&#160;provide the grantee with the right to exercise the award as to all or part of the shares, and may provide for an acceleration of vesting of unvested awards, or (b)&#160;cancel the award and pay the grantee an amount in cash, shares of Alpha Tau, shares of the acquirer or of other corporation which is a party to such transaction or such other property as determined by the Administrator as fair under the circumstances. Notwithstanding the foregoing: (1)&#160;the</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Administrator may upon such event of Merger/Sale amend, modify or terminate the terms of any award as it shall deem, in good faith, appropriate and (2)&#160;the board of directors may determine, in its discretion, that such transaction should be excluded from the definition of Merger/Sale set forth above.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">128</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">2021 Share Incentive Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon closing of the Business Combination, we adopted the 2021 Share Incentive Plan (the &#8220;2021 Plan&#8221;). The 2021 Plan provides for the grant of equity-based incentive awards to Alpha Tau&#8217;s and its affiliates, employees, directors, office holders, service providers and consultants in order to incentivize them to increase their efforts on behalf of Alpha Tau or its affiliates and to promote the success of Alpha Tau&#8217;s business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Shares Available for Grants. </i>The maximum number ordinary shares available for issuance under the 2021 Plan is equal to the sum of (i)&#160;15,428,386 Shares plus (and without the need to further amend the 2021 Plan), <span style="color:#231f20;">(ii)&#160;any shares subject to awards under the 2016 Plan which have expired, or were cancelled, terminated, forfeited or settled in cash in lieu of issuance of shares or became unexercisable without having been exercised and (iii)&#160;an annual increase on the first day of each&#160;year beginning in 2023 and on January&#160;1st of each calendar&#160;year </span>thereafter and through January&#160;1, 2032, equal to the lesser of (A)&#160;4% of the outstanding ordinary shares of Alpha Tau on the last day of the immediately preceding calendar&#160;year; and (B)&#160;such amount as determined by our board of directors if so determined prior to January&#160;1 of a calendar&#160;year in which the increase will occur, provided that no more than 125,000,000 ordinary shares may be issued upon the exercise of Incentive Stock Options. Any shares (a)&#160;underlying the 2021 Plan or the 2016 Plan that has expired, or was cancelled, terminated, forfeited, or settled in cash in lieu of issuance of Shares, for any reason, without having been exercised; (b)&#160;if permitted by the company, shares tendered to pay the exercise price or other purchase price or withholding tax obligations with respect to an award granted under the 2021 Plan or the 2016 Plan; or (c)&#160;if permitted by the company, subject to an award granted under the 2021 Plan or the 2016 Plan that are not delivered to a grantee because such shares are withheld to pay the exercise price of such award, or withholding tax obligations with respect to such award; shall automatically, and without any further action on the part of the company or any grantee be available for grant of awards and issuance under the 2021 Plan, unless determined otherwise by the board of directors. Our board of directors may also reduce the number of ordinary shares reserved and available for issuance under the 2021 Plan in its discretion (provided that such reduction does not derogate from any issuance of shares in respect of 125,000,000 awards then outstanding). <i style="font-style:italic;">Administration. </i>Our board of directors, or a duly authorized committee of our board of directors (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Administrator</span>&#8221;), will administer the 2021 Plan. Under the 2021 Plan, the Administrator has the authority, subject to applicable law, to interpret the terms of the 2021 Plan and any award agreements or awards granted thereunder, designate recipients of awards, determine and amend the terms of awards, including the exercise price of an option award, the fair market value of an ordinary share, the time and vesting schedule applicable to an award or the method of payment for an award, accelerate or amend the vesting schedule applicable to an award, prescribe the forms of agreement for use under the 2021 Plan and take all other actions and make all other determinations necessary for the administration of the 2021 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Administrator also has the authority to approve the conversion, substitution, cancellation or suspension under and in accordance with the 2021 Plan of any or all option awards or ordinary shares, and the authority to modify option awards to eligible individuals who are foreign nationals or are individuals who are employed outside Israel or the United State of America to recognize differences in local law, tax policy or custom, in order to effectuate the purposes of the 2021 Plan but without amending the 2021 Plan. The Administrator also has the authority to amend and rescind rules&#160;and regulations relating to the 2021 Plan or terminate the 2021 Plan at any time. No termination or amendment of the 2021 Plan shall affect any then outstanding award unless expressly provided by the Administrator.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Eligibility. </i>The 2021 Plan provides for granting awards under various tax regimes, including, without limitation, in compliance with Section&#160;102 of the Ordinance, and Section&#160;3(i)&#160;of the Ordinance and for awards granted to our United States employees or service providers, including those who are deemed to be residents of the United States for tax purposes, Section&#160;422 of the Code and Section&#160;409A of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Grants. </i>All awards granted pursuant to the 2021 Plan will be evidenced by an award agreement, in a form approved, from time to time, by the Administrator in its sole discretion. The award agreement will set forth the terms and conditions of the award, including the type of award, number of shares subject to such award, vesting schedule and conditions (including performance goals or measures) and the exercise price, if applicable. Certain awards under the 2021 Plan may constitute or provide for a deferral of compensation, subject to Section&#160;409A of the Code, which may impose additional requirements on the terms and conditions of such awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unless otherwise determined by the Administrator and stated in the award agreement, and subject to the conditions of the 2021 Plan, awards vest and become exercisable under the following schedule: 25% of the shares covered by the award on the first anniversary of the vesting commencement date determined by the Administrator (and in the absence of such determination, the date on which such award was granted) and 6.25%</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">129</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">of the shares covered by the award at the end of each subsequent three-month period thereafter over the course of the following three&#160;years; provided that the grantee remains continuously as an employee or provides services to Alpha Tau throughout such vesting dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each award will expire ten&#160;years from the date of the grant thereof, unless such shorter term of expiration is otherwise designated by the Administrator.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Awards. </i>The 2021 Plan provides for the grant of stock options (including incentive stock options and nonqualified stock options), ordinary shares, restricted shares, RSUs, stock appreciation rights and other share- based awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Options granted under the 2021 Plan to Alpha Tau employees who are U.S. residents may qualify as &#8220;incentive stock options&#8221; within the meaning of Section&#160;422 of the Code, or may be non-qualified stock options. The exercise price of an option may not be less than the par value of the shares (if the shares bear a par value) for which such option is exercisable, otherwise an exercise price of an award of less than the par value of the shares (if shares bear a par value) shall comply with section 304 of the Companies Law. The exercise price of a non-qualified stock option shall not be less than 100% of the fair market value of a share on the date of grant of such option or such other amount as may be required pursuant to the section 409A of the Code. Notwithstanding the foregoing, a non-qualified stock option may be granted with an exercise price lower than the minimum exercise price set forth above if such Award is granted pursuant to an assumption or substitution for another option in a manner qualifying under the provisions of that complies with section 424(a)&#160;of the Code 1.409A-1(b)(5)(v)(D)&#160;of the U.S. Treasury Regulations or any successor guidance. The exercise price of an Incentive Stock Option may not be less than 100% of the fair market value of the underlying share on the date of grant or such other amount as may be required pursuant to the Code. Notwithstanding the foregoing, an Incentive Stock Option may be granted with an exercise price lower than the minimum exercise price set forth above if such award is granted pursuant to an assumption or substitution for another option in a manner that complies with the provisions of Section&#160;424(a)&#160;of the Code. In the case of Incentive Stock Options granted to a ten&#160;percent shareholder, (i)&#160;the exercise price shall not be less than 110% of the fair market value of the underlying share on the date of grant, and (ii)&#160;the exercise period shall not exceed five (5)&#160;years from the effective date of grant of such grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Exercise. </i>An award under the 2021 Plan may be exercised by providing Alpha Tau with a written or electronic notice of exercise and full payment of the exercise price for such shares underlying the award, if applicable, in such form and method as may be determined by the Administrator and permitted by applicable law. An award may not be exercised for a fraction of a share. With regard to tax withholding, exercise price and purchase price obligations arising in connection with awards under the 2021 Plan, the Administrator may, in its discretion, accept cash, provide for net withholding of shares in a cashless exercise mechanism or direct a securities broker to sell shares and deliver all or a part of the proceeds to Alpha Tau or the trustee. <i style="font-style:italic;">Transferability. </i>Other than by will, the laws of descent and distribution or as otherwise provided under the 2021 Plan or by the Administrator, neither the options nor any right in connection with such options are assignable or transferable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Termination of Employment. </i>In the event of termination of a grantee&#8217;s employment or service with Alpha Tau or any of its affiliates, all vested and exercisable awards held by such grantee as of the date of termination may be exercised within three&#160;months after such date of termination, unless otherwise determined by the Administrator, but in no event later than the date of expiration of the award as set forth in the award agreement. After such three-month period, all such unexercised awards will terminate and the shares covered by such awards shall again be available for issuance under the 2021 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event of termination of a grantee&#8217;s employment or service with Alpha Tau or any of its affiliates due to such grantee&#8217;s death or permanent disability, or in the event of the grantee&#8217;s death within the three&#160;month period (or such longer period as determined by the Administrator) following his or her termination of service, all vested and exercisable awards held by such grantee as of the date of termination may be exercised by the grantee or the grantee&#8217;s legal guardian, estate or by a person who acquired the right to exercise the award by bequest or inheritance, as applicable, within one&#160;year after such date of termination, unless otherwise provided by the Administrator, but in no event later than the date of expiration of the award as set forth in the award agreement. Any awards which are unvested as of the date of such termination or which are vested but not then exercised within the one-year period following such date, will terminate and the shares covered by such awards shall again be available for issuance under the 2021 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event that the employment or service of a grantee shall terminate on account of such grantee&#8217;s retirement, all awards of such grantee that are exercisable at the time of such retirement may, unless earlier terminated in accordance with their terms, be exercised at any time within the three-month period after the date of such retirement (or such different period as the Administrator shall prescribe).</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">130</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding any of the foregoing, if a grantee&#8217;s employment or services with Alpha Tau or any of its affiliates is terminated for &#8220;cause&#8221; (as defined in the 2021 Plan), all outstanding awards held by such grantee (whether vested or unvested) will terminate on the date of such termination and the shares covered by such awards shall again be available for issuance under the 2021 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Voting Rights. </i>Except with respect to restricted share awards, grantees will not have the rights as a shareholder of Alpha Tau with respect to any shares covered by an award until the award has vested and/or the grantee has exercised such award, paid any exercise price for such award and becomes the record holder of the shares. With respect to restricted share awards, grantees will possess all incidents of ownership of the restricted shares, including the right to vote and receive dividends on such shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Dividends. </i>Grantees holding restricted share awards will be entitled to receive dividends and other distributions with respect to the shares underlying the restricted share award. Any share split, share dividend, combination of shares or similar transaction will be subject to the restrictions of the original restricted share award. Grantees holding RSUs will not be eligible to receive dividend but may be eligible to receive dividend equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Transactions. </i>In the event of a share split, reverse share split, share dividend, recapitalization, combination or reclassification of Alpha Tau&#8217;s shares, the Administrator in its sole discretion may, without the need for a consent of any holder of an award, make an appropriate adjustment in order to adjust (i)&#160;the number and class of shares reserved and available for grants of awards, (ii)&#160;the number and class of shares covered by outstanding awards, (iii)&#160;the exercise price per share covered by any award, (iv)&#160;the terms and conditions concerning vesting and exercisability and the term and duration of the outstanding awards, (v)&#160;the type or class of security, asset or right underlying the award (which need not be only that of Alpha Tau, and may be that of the surviving corporation or any affiliate thereof or such other entity party to any of the above transactions), and (vi)&#160;any other terms of the award that in the opinion of the Administrator should be adjusted; provided that any fractional shares resulting from such adjustment shall be rounded to the nearest whole share unless otherwise determined by the Administrator and the company shall have no obligation to make any cash or other payment with respect to such fractional shares. In the event of a distribution of a cash dividend to all shareholders, the Administrator may determine, without the consent of any holder of an award, that the exercise price of an outstanding and unexercised award shall be reduced by an amount equal to the per share gross dividend amount distributed by Alpha Tau, subject to applicable law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event of a merger or consolidation of Alpha Tau or a sale of all, or substantially all, of Alpha Tau&#8217;s shares or assets or other transaction having a similar effect on Alpha Tau, or change in the composition of the board of directors, or liquidation or dissolution, or such other transaction or circumstances that our board of directors determines to be a relevant transaction, then without the consent of the grantee and without any prior notice requirement, (i)&#160;unless otherwise determined by the Administrator, any outstanding award will be assumed or substituted by Alpha Tau, or such successor corporation, or by any parent or affiliate thereof, or (ii)&#160;regardless of whether or not awards are assumed or substituted (a)&#160;provide the grantee with the option to exercise the award as to all or part of the shares, and may provide for an acceleration of vesting of unvested awards, (b)&#160;cancel the award and pay in cash, shares of Alpha Tau, the acquirer or other corporation which is a party to such transaction or other property as determined by the Administrator as fair in the circumstances, or (c)&#160;provide that the terms of any award shall be otherwise amended, modified or terminated, as determined by the Administrator to be fair in the circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">2021 Employee Share Purchase Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon closing of the Business Combination, we adopted the 2021 Employee Share Purchase Plan (the &#8220;ESPP&#8221;).The ESPP is comprised of two distinct components: (1)&#160;the component intended to qualify for favorable U.S. federal tax treatment under Section&#160;423 of the Code (the &#8220;Section&#160;423 Component&#8221;) and (2)&#160;the component not intended to be tax qualified under Section&#160;423 of the Code to facilitate participation for employees who are not eligible to benefit from favorable U.S. federal tax treatment and, to the extent applicable, to provide flexibility to comply with non U.S. law and other considerations (the &#8220;Non Section&#160;423 Component&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Authorized Shares. </i>A total of 1,285,699 ordinary shares will be available for sale under the ESPP, subject to adjustment as provided for in the ESPP. In addition, on the first day of each fiscal&#160;year beginning with Alpha Tau&#8217;s 2023 fiscal&#160;year and through its 2032 fiscal&#160;year, such pool of ordinary shares shall be increased by that number of ordinary shares equal to the lesser of:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1% of the outstanding ordinary shares as of the last day of the immediately preceding fiscal&#160;year; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">such other amount as our board of directors may determine.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In no event will more than 30,000,000 ordinary shares be available for issuance under the Section&#160;423 Component.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">131</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">ESPP Administration. </i>Unless otherwise determined by Alpha Tau&#8217;s board of directors, the compensation committee of Alpha Tau&#8217;s board of directors (the &#8220;Administrator&#8221;); will administer the ESPP and will have the authority to interpret the terms of the ESPP and determine eligibility under the ESPP, to impose a mandatory holding period under which employees may not dispose or transfer shares under the ESPP, prescribe, revoke and amend forms, rules&#160;and procedures relating to the ESPP, and otherwise exercise such powers and to perform such acts as the Administrator deems necessary or expedient to promote the best interests of Alpha Tau and its subsidiaries and to carry out the intent that the ESPP be treated as an &#8220;employee stock purchase plan&#8221; within the meaning of Section&#160;423 of the Code for the Section&#160;423 Component.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Eligibility. </i>Participation in the Section&#160;423 Component may be limited in the terms of any offering to employees of Alpha Tau and any of its designated subsidiaries (a)&#160;who customarily work 20 hours or more per week, (b)&#160;whose customary employment is for more than five&#160;months per calendar&#160;year and (c)&#160;who satisfy the procedural enrollment and other requirements set forth in the ESPP. Under the Section&#160;423 Component, designated subsidiaries include any subsidiary (within the meaning of Section&#160;424(f)&#160;of the Code) of Alpha Tau that has been designated by our board of directors or the compensation committee as eligible to participate in the ESPP (and if an entity does not so qualify within the meaning of Section&#160;424(f)&#160;of the Code, it shall automatically be deemed to be a designated subsidiary in the Non-Section&#160;423 Component). In addition, with respect to the Non-Section&#160;423 Component, designated subsidiaries may include any corporate or noncorporate entity in which Alpha Tau has a direct or indirect equity interest or significant business relationship. Under the Section&#160;423 Component, no employee may be granted a purchase right if, immediately after the purchase right is granted, the employee would own (or, under applicable statutory attribution rules, would be deemed to own) shares possessing 5% or more of the total combined voting power or value of all classes of shares and other securities of Alpha Tau or any of its subsidiaries. In addition, in order to facilitate participation in the ESPP, the compensation committee may provide for such special terms applicable to participants who are citizens or residents of a non-U.S. jurisdiction, or who are employed by a designated subsidiary outside of the U.S., as the compensation committee may consider necessary or appropriate to accommodate differences in local law, tax policy or custom. Except as permitted by Section&#160;423 of the Code, with respect to the Section&#160;423 Component, such special terms may not be more favorable than the terms of rights granted under the Section&#160;423 Component to eligible employees who are residents of the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Offering Periods</i>. The ESPP provides for offering periods, not to exceed 27&#160;months each, during which we will grant rights to purchase ordinary shares to our employees. The timing of the offering periods will be determined by the Administrator. The terms and conditions applicable to each offering period will be set forth in an offering document adopted by the Administrator for the particular offering period. The provisions of offerings during separate offering periods under the ESPP need not be identical.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Contributions. </i>The ESPP will permit participants to purchase ordinary shares through contributions (in the form of payroll deductions, or otherwise, to the extent permitted by the Administrator). The&#160;percentage of compensation designated by an eligible employee as payroll deductions for participation in an offering may not be less than 1% and may not be more than the maximum&#160;percentage specified by the Administrator in the applicable offering document (which maximum&#160;percentage shall be 20% in the absence of any such specification). A participant may increase or decrease the&#160;percentage of compensation designated in his or her subscription agreement, or may suspend his or her payroll deductions, at any time during an offering period; provided, however, that the Administrator may limit the number of changes a participant may make in the applicable offering document. In the absence of any specific designation by the Administrator, a participant may decrease or increase his or her payroll deduction elections one time during each offering period. Amounts contributed and accumulated by the participant will be used to purchase ordinary shares at the end of each offering period. Unless otherwise determined by the Administrator, the purchase price of the shares will be 85% of the lower of the fair market value of ordinary shares on (i)&#160;the first trading day of the offering period or (ii)&#160;the last trading day of the offering period (and may not be lower than such amount with respect to the Section&#160;423 Component).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Participants may end their participation at any time during an offering period and will be paid their accrued contributions and such participant&#8217;s rights for the offering period shall be automatically terminated, and no further payroll deductions for the purchase of shares shall be made for such offering period. Participation ends automatically upon termination of employment with us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Non-Transferability. </i>A participant may not transfer contributions credited to his or her account nor any rights granted under the ESPP other than by will, the laws of descent and distribution or as otherwise provided under the ESPP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><i style="font-style:italic;">Corporate Transactions. </i>In the event of certain transactions or events such as a consolidation, merger or similar transaction, a sale or transfer of all or substantially all of Alpha Tau&#8217;s assets, or a dissolution or liquidation of Alpha Tau, with respect to which the Administrator determines that an adjustment is appropriate in order to prevent dilution or enlargement of the benefits or potential benefits intended by Alpha Tau to be made available under the ESPP or with respect to any outstanding purchase rights under the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">132</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">ESPP, the Administrator shall make equitable adjustments, if any, to reflect such change with respect to (a)&#160;the aggregate number and type of shares that may be issued under the ESPP; (b)&#160;the class(es) and number of shares and price per share subject to outstanding rights; and (c)&#160;the purchase price with respect to any outstanding rights. In addition, in any such situation, the Administrator may, in its discretion, make other adjustments, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">providing for either (i)&#160;termination of any outstanding right in exchange for an amount of cash, or (ii)&#160;the replacement of such outstanding right with other rights or property selected by the Administrator in its sole discretion;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">providing that the outstanding rights under the ESPP shall be assumed by the successor or survivor corporation, or a parent or subsidiary thereof, or shall be substituted for by similar rights covering the shares of the successor or survivor corporation, or a parent or subsidiary thereof, with appropriate adjustments as to the number and kind of shares and prices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">making adjustments in the number and type of shares (or other securities or property) subject to outstanding rights under the ESPP and/or in the terms and conditions of outstanding rights and rights that may be granted in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">d.</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">providing that participants&#8217; accumulated payroll deductions may be used to purchase shares prior to the next occurring purchase date on such date as the Administrator determines in its sole discretion and the participants&#8217; rights under the ongoing offering period(s)&#160;shall be terminated; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">e.</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">providing that all outstanding rights shall terminate without being exercised.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Amendment; Termination. </i>The Administrator will have the authority to amend, suspend or terminate the ESPP. The ESPP is not subject to a specific termination date.</p><a id="CBoardPractices_69234"></a><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">C.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Board Practices</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Corporate Governance Practices</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As an Israeli company, we are subject to various corporate governance requirements under the Companies Law, relating to matters such as external directors, the audit committee, the compensation committee and an internal auditor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are a &#8220;foreign private issuer&#8221;, as such term is defined in Rule&#160;405 under the Securities Act. As a foreign private issuer we will be permitted to comply with Israeli corporate governance practices instead of the certain listing rules&#160;of Nasdaq, provided that we disclose which requirements we are not following and the equivalent Israeli requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We rely on this &#8220;foreign private issuer exemption&#8221; with respect to the quorum requirement for shareholder meetings and with respect to Nasdaq shareholder approval rules. Whereas under the corporate governance rules&#160;of Nasdaq, a quorum requires the presence, in person or by proxy, of holders of at least 33 1/3% of the total issued and outstanding voting power of our shares at each general meeting of shareholders, pursuant to the Articles, and as permitted under the Companies Law, the quorum required for a general meeting of shareholders will consist of at least two shareholders present in person or by proxy in accordance with the Companies Law who hold or represent at least 331/3% of the total outstanding voting power of our shares, except if (i)&#160;any such general meeting of shareholders was initiated by and convened pursuant to a resolution adopted by the board of directors and (ii)&#160;at the time of such general meeting, we qualify as a &#8220;foreign private issuer,&#8221; then in such case, the requisite quorum will consist of two or more shareholders present in person or by proxy who hold or represent at least 25% of the total outstanding voting power of our shares (and if the meeting is adjourned for a lack of quorum, the quorum for such adjourned meeting will be, subject to certain exceptions, any number of shareholders). We otherwise intend to comply with the rules&#160;generally applicable to U.S. domestic companies listed on the Nasdaq. We may, however, in the future decide to rely upon the &#8220;foreign private issuer exemption&#8221; for purposes of opting out of some or all of the other Nasdaq listing rules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For more information regarding our corporate governance practices and foreign private issuer status, see Item&#160;16G. &#8220;Corporate Governance.&#8221;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">133</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Board of Directors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Companies Law and our Articles, our business and affairs are managed under the direction of our board of directors. Our board of directors may exercise all powers and may take all actions that are not specifically granted to our shareholders or to executive management. Our Chief Executive Officer (referred to as a &#8220;general manager&#8221; under the Companies Law) is responsible for our day-to-day management. Our Chief Executive Officer is appointed by, and serves at the discretion of, our board of directors, subject to the employment or consulting agreement that we have entered into with him. All other executive officers are appointed by the Chief Executive Officer, subject to applicable corporate approvals, and are subject to the terms of any applicable employment or consulting agreements that we may enter into with them.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under our Articles, the number of directors on our board of directors will be no less than three and no more than eleven, divided into three classes with staggered three-year terms. Each class of directors consists, as nearly as possible, of one-third of the total number of directors constituting the entire board of directors. At each annual general meeting of our shareholders, the election or re-election of directors following the expiration of the term of office of the directors of that class of directors will be for a term of office that expires on the third annual general meeting following such election or re-election. Therefore, beginning with the annual general meeting of 2022, each&#160;year the term of office of only one class of directors will expire.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our directors are divided among the three classes as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Class&#160;I directors are Alan Adler, S. Morry Blumenfeld and Gary Leibler, and their terms will expire at the annual general meeting of shareholders to be held in 2022;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Class&#160;II directors are David Milch, Peter Melnyk and Ruth Alon, and their terms will expire at our annual meeting of shareholders to be held in 2023; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Class&#160;III directors are Michael Avruch, Meir Jakobsohn and Uzi Sofer, and their term will expire at our annual meeting of shareholders to be held in 2024.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our directors will generally be appointed by a simple majority vote of holders of our ordinary shares, participating and voting (in person or by proxy) at an annual general meeting of our shareholders, provided that (i) <span style="color:#231f20;">in the event of a contested election, the method of calculation of the votes and the manner in which the resolutions will be presented to our shareholders at the general meeting shall be determined by our board of directors in its discretion, and (ii)&#160;in the event that our board of directors does not or is unable to make a determination on such matter, then the directors will be elected by a plurality of the voting power represented at the general meeting in person or by proxy and voting on the election of directors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each director will hold office until the annual general meeting of our shareholders for the&#160;year in which such director&#8217;s term expires, unless the tenure of such director expires earlier pursuant to the Companies Law or unless such director is removed from office as described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Our Articles, generally require a vote of the holders of a majority of our outstanding ordinary shares entitled to vote present and voting on the matter at a general meeting of shareholders (referred to as simple majority), and the amendment of a limited number of provisions, such as the provision empowering our board of directors to determine the size of the board of directors, the provision dividing our directors into three classes, the provision that sets forth the procedures and the requirements that must be met in order for a shareholder to require us to include a matter on the agenda for a general meeting of the shareholders and the provisions relating to the election and removal of members of our board of directors and empowering our board of directors to fill vacancies on the board, require a vote of the holders of 65% of our outstanding ordinary shares entitled to vote at a general meeting. In addition, vacancies on our board of directors may be filled by a vote of a simple majority of the directors then in office. A director so appointed will hold office until the next annual general meeting of our shareholders for the election of the class of directors in respect of which the vacancy was created. In the case of a vacancy due to the number of directors being less than the maximum number of directors stated </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">134</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">in our Articles, the new director filling the vacancy will serve until the next annual general meeting of our shareholders for the election of the class of directors to which such director was assigned by our board of directors.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Board Diversity Matrix (As of March 21, 2022)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Country of Principal Executive Offices:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Israel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign Private Issuer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Yes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Disclosure Prohibited under Home Country Law</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">No</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total Number of Directors</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:6.53%;background:#d9d9d9;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Female</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#d9d9d9;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:6.53%;background:#d9d9d9;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Male</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#d9d9d9;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.53%;background:#d9d9d9;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Non-<br />Binary</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#d9d9d9;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.24%;background:#d9d9d9;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Did Not Disclose<br />Gender</p></td></tr><tr><td style="vertical-align:bottom;width:61.37%;background:#d9d9d9;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Part I: Gender Identity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#d9d9d9;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#d9d9d9;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#d9d9d9;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#d9d9d9;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#d9d9d9;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#d9d9d9;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#d9d9d9;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#d9d9d9;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Directors</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">0</p></td></tr><tr><td style="vertical-align:bottom;width:61.37%;background:#d9d9d9;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Part II: Demographic Background</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#d9d9d9;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#d9d9d9;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#d9d9d9;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#d9d9d9;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#d9d9d9;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#d9d9d9;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#d9d9d9;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#d9d9d9;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Underrepresented Individual in Home Country Jurisdiction</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LGBTQ+</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Did Not Disclose Demographic Background</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Chairperson of the Board</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our Articles provide that the board of directors shall appoint a member of the board to serve as the Chairperson. Under the Companies Law, the chief executive officer of a public company, or a relative of the chief executive officer, may not serve as the chairperson of the board of directors, and the chairperson of the board of directors, or a relative of the chairperson, may not be vested with authorities of the Chief Executive Officer unless approved by a special majority of the company&#8217;s shareholders. We have received such approval from a special majority of our shareholders in December&#160;2021, which is effective for a period of five&#160;years from the closing of the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, a person who is subordinated, directly or indirectly, to the chief executive officer may not serve as the chairperson of the board of directors, the chairperson of the board of directors may not be vested with authorities that are granted to persons who are subordinated to the chief executive officer, and the chairperson of the board of directors may not serve in any other position in the company or in a controlled subsidiary, but may serve as a director or chairperson of a controlled subsidiary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">External Directors</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Companies Law, companies incorporated under the laws of the State of Israel that are &#8220;public companies,&#8221; including companies with shares listed on Nasdaq, are required to appoint at least two external directors. Pursuant to regulations promulgated under the Companies Law, companies with shares traded on certain U.S. stock exchanges, including Nasdaq, which do not have a &#8220;controlling shareholder,&#8221; may, subject to certain conditions, &#8220;opt out&#8221; from the Companies Law requirements to appoint external directors and related Companies Law rules&#160;concerning the composition of the audit committee and compensation committee of the board of directors. In accordance with these regulations, we have elected to &#8220;opt out&#8221; from the Companies Law requirement to appoint external directors and related Companies Law rules&#160;concerning the composition of the audit committee and compensation committee of our board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Audit Committee</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Companies Law Requirements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Companies Law, the board of directors of a public company must appoint an audit committee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Listing Requirements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the listing rules&#160;of the Nasdaq, we are required to maintain an audit committee consisting of at least three independent directors, each of whom is financially literate and one of whom has accounting or related financial management expertise.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">135</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our audit committee consists of Alan Adler, Michael Avruch and Gary Leibler. Michael Avruch serves as the chairperson of the audit committee. All members of our audit committee meet the requirements for financial literacy under the applicable rules&#160;and regulations of the SEC and the listing rules&#160;of the Nasdaq. Our board of directors has determined that each of Michael Avruch and Gary Leibler is an audit committee financial expert as defined by the SEC rules&#160;and has the requisite financial experience as defined by the listing rules&#160;of Nasdaq.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our board of directors has determined that each member of our audit committee is &#8220;independent&#8221;, as such term is defined in Rule&#160;10A-3(b)(1)&#160;under the Exchange Act, which is different from the general test for independence of board and committee members.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Audit Committee Role</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our board of directors has adopted an audit committee charter setting forth the responsibilities of the audit committee, which are consistent with the Companies Law, the SEC rules, and the listing rules&#160;of the Nasdaq. These responsibilities include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">retaining and terminating our independent auditors, subject to ratification by the board of directors, and in the case of retention, subject to ratification by the shareholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pre-approving audit and non-audit services to be provided by the independent auditors and related fees and terms;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">overseeing the accounting and financial reporting processes of our company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">managing audits of our financial statements</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">preparing all reports as may be required of an audit committee under the rules&#160;and regulations promulgated under the Exchange Act;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing with management and our independent auditor our annual and quarterly financial statements prior to publication, filing, or submission to the SEC;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recommending to the board of directors the retention and termination of the internal auditor, and the internal auditor&#8217;s engagement fees and terms, in accordance with the Companies Law, as well as approving the&#160;yearly or periodic work plan proposed by the internal auditor;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing with our general counsel and/or external counsel, as deemed necessary, legal and regulatory matters that may have a material impact on the financial statements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">identifying irregularities in our business administration, inter alia, by consulting with the internal auditor or with the independent auditor, and suggesting corrective measures to the board of directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing policies and procedures with respect to transactions (other than transactions related to compensation or terms of services) between the Company and officers and directors, affiliates of officers or directors, or transactions that are not in the ordinary course of the Company&#8217;s business and deciding whether to approve such acts and transactions if so required under the Companies Law; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing procedures for handling employee complaints relating to the management of our business and the protection to be provided to such employees.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Compensation Committee</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Companies Law Requirements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Companies Law, the board of directors of a public company must appoint a compensation committee.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">136</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Listing Requirements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the listing rules&#160;of the Nasdaq, we are required to maintain a compensation committee consisting of at least two independent directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our compensation committee consists of S. Morry Blumenfeld, Meir Jakobsohn and Peter Melnyk. Peter Melnyk serves as chairperson of the compensation committee. Our board of directors has determined that each member of our compensation committee is independent under the listing rules&#160;of the Nasdaq, including the additional independence requirements applicable to the members of a compensation committee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Compensation Committee Role</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In accordance with the Companies Law, the responsibilities of the compensation committee are, among others, as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">making recommendations to the board of directors with respect to the approval of the compensation policy for office holders and, once every three&#160;years, with respect to any extensions to a compensation policy that was adopted for a period of more than three&#160;years;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing the implementation of the compensation policy and periodically making recommendations to the board of directors with respect to any amendments or updates to the compensation policy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">resolving whether to approve arrangements with respect to the terms of office and employment of office holders, which require the approval of the compensation committee pursuant to the Companies Law; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">exempting, under certain circumstances, a transaction with our Chief Executive Officer from the approval of our shareholders.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our board of directors has adopted a compensation committee charter setting forth the responsibilities of the committee, which are consistent with the listing rules&#160;of the Nasdaq and include among others:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recommending to our board of directors for its approval a compensation policy, in accordance with the requirements of the Companies Law, as well as other compensation policies, incentive-based compensation plans, and equity-based compensation plans, overseeing the development and implementation of such policies, and recommending to our board of directors any amendments or modifications the committee deems appropriate, including as required under the Companies Law;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing and approving the granting of options and other incentive awards to our Chief Executive Officer and other executive officers, including reviewing and approving corporate goals and objectives relevant to the compensation of our Chief Executive Officer and other executive officers, including evaluating their performance in light of such goals and objectives;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approving and exempting certain transactions regarding office holders&#8217; compensation pursuant to the </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Companies Law; and</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">administering our equity-based compensation plans, including without limitation, approving the adoption of such plans, amending and interpreting such plans, and the awards and agreements issued pursuant thereto, and making and determining the terms of awards to eligible persons under the plans.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Compensation Policy under the Companies Law</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In general, under the Companies Law, the board of directors of a public company must approve a compensation policy after receiving and considering the recommendations of the compensation committee. In addition, our compensation policy must be approved at least once every three&#160;years, first, by our board of directors, upon recommendation of our compensation committee, and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">137</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">second, by a simple majority of the ordinary shares present, in person or by proxy, and voting (excluding abstentions) at a general meeting of shareholders, provided that either:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the majority of such ordinary shares is comprised of shares held by shareholders who are not controlling shareholders and shareholders who do not have a personal interest in such compensation policy; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the total number of shares of non-controlling shareholders and shareholders who do not have a personal interest in the compensation policy voting against the policy does not exceed two&#160;percent (2%) of the aggregate voting rights in the company.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under special circumstances, the board of directors may approve the compensation policy despite the objection of the shareholders on the condition that the compensation committee and then the board of directors decide, on the basis of detailed grounds, and after discussing again with the compensation policy, that approval of the compensation policy, despite the objection of shareholders, is for the benefit of the company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If a company adopts a compensation policy in advance of its initial public offering (or in this case, prior to the closing of the Business Combination) and describes such compensation policy in the prospectus for such offering, then such compensation policy shall be deemed a validly adopted policy in accordance with the Companies Law requirements described above. Furthermore, if the compensation policy is established in accordance with the aforementioned relief, then it will remain in effect for a term of five&#160;years from the date such company becomes a public company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The compensation policy must be based on certain considerations include certain provisions and reference certain matters as set forth in the Companies Law. The compensation policy must serve as the basis for decisions concerning the financial terms of employment or engagement of office holders, including exculpation, insurance, indemnification, or any monetary payment or obligation of payment in respect of employment or engagement. The compensation policy must be determined and later reevaluated according to certain factors, including: the advancement of the company&#8217;s objectives, business plan and long-term strategy; the creation of appropriate incentives for office holders, while considering, among other things, the company&#8217;s risk management policy; the size and the nature of the company&#8217;s operations; and with respect to variable compensation, the contribution of the office holder towards the achievement of the company&#8217;s long-term goals and the maximization of its profits, all with a long-term objective and according to the position of the office holder. The compensation policy must furthermore consider the following additional factors:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the education, skills, experience, expertise, and accomplishments of the relevant office holder;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the office holder&#8217;s position and responsibilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prior compensation agreements with the office holder;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ratio between the cost of the terms of employment of an office holder and the cost of the employment of other employees of the company, including employees employed through contractors who provide services to the company; in particular the ratio between such cost to the average and median salary of such employees of the company, as well as possible impacts of compensation disparities between them on the work relationships in the company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if the terms of employment include variable components, the possibility of reducing variable components at the discretion of the board of directors and setting a limit on the value of non-cash variable equity-based components; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if the terms of employment include severance compensation, the term of employment or office of the office holder, the terms of the office holder&#8217;s compensation during such period, the company&#8217;s performance during such period, the office holder&#8217;s individual contribution to the achievement of the company goals and the maximization of its profits, and the circumstances under which the office holder is leaving the company.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The compensation policy must also include, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">with regards to variable components:</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">138</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">with the exception of office holders who report to the chief executive officer, a means of determining the variable components on the basis of long-term performance and measurable criteria; provided that the company may determine that an immaterial part of the variable components of the compensation package of an office holder shall be awarded based on non-measurable criteria, or if such amount is not higher than three&#160;months&#8217; salary per annum, taking into account such office holder&#8217;s contribution to the company; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ratio between variable and fixed components, as well as the limit of the values of variable components at the time of their payment, or in the case of equity-based compensation, at the time of grant.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a condition under which the office holder will refund to the company, according to conditions to be set forth in the compensation policy, any amounts paid as part of the office holder&#8217;s terms of employment, if such amounts were paid based on information later to be discovered to be wrong, and such information was restated in the company&#8217;s financial statements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the minimum holding or vesting period of variable equity-based components to be set in the terms of office or employment, as applicable, while taking into consideration long-term incentives; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a limit to retirement grants.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our compensation policy, which became effective immediately prior to the closing of the Business Combination, is designed to retain and motivate our directors and executive officers, incentivize superior individual excellence, align the interests of our directors and executive officers with our long-term performance, and provide a risk management tool. To that end, a portion of our executive officer compensation package is targeted to reflect our short and long-term goals, as well as the executive officer&#8217;s individual performance. Our compensation policy also includes measures designed to reduce the executive officer&#8217;s incentives to take excessive risks that may harm the Company in the long-term, such as limits on the value of cash bonuses and equity-based compensation, limitations on the ratio between the variable and the total compensation of an executive officer, and minimum vesting periods for equity-based compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our compensation policy also addresses our executive officers&#8217; individual characteristics (such as their respective position, education, scope of responsibilities, and contribution to the attainment of our goals) as the basis for compensation variation among our executive officers and considers the internal ratios between compensation of our executive officers and directors and other employees. Pursuant to our compensation policy, the compensation that may be granted to an executive officer may include: base salary, annual bonuses, and other cash bonuses (such as a signing bonus and special bonuses with respect to any special achievements, such as outstanding personal achievement, outstanding personal effort, or outstanding company performance), equity- based compensation, benefits and retirement and termination of service arrangements. All cash bonuses are limited to a maximum amount linked to the executive officer&#8217;s base salary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An annual cash bonus may be awarded to executive officers upon the attainment of pre-set periodic objectives and individual targets. The annual cash bonus that may be granted to our executive officers, other than our Chief Executive Officer, will be based on performance objectives and a discretionary evaluation of the executive officer&#8217;s overall performance by our Chief Executive Officer and subject to minimum thresholds. The annual cash bonus that may be granted to executive officers, other than our Chief Executive Officer, may alternatively be based entirely on a discretionary evaluation. Furthermore, our Chief Executive Officer will be entitled to approve performance objectives for executive officers who report to him.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The measurable performance objectives of our Chief Executive Officer will be determined annually by our compensation committee and board of directors. A non-material portion of the Chief Executive Officer&#8217;s annual cash bonus, as provided in our compensation policy, may be based on a discretionary evaluation of the Chief Executive Officer&#8217;s overall performance by the compensation committee and the board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Under our compensation policy, our executive officers&#8217; (including members of our board of directors) equity-based compensation is designed in a manner consistent with the underlying objectives in determining the base salary and the annual cash bonus, with its main objectives being to enhance the alignment between the executive officers&#8217; interests with our long-term interests and those of our shareholders and to strengthen the retention and the motivation of executive officers in the long term. Our compensation policy provides for executive officer compensation in the form of share options or other equity-based awards, such as restricted shares and restricted share units, in accordance with our then-current equity incentive plan. All equity-based incentives granted to executive officers shall be subject to vesting periods in order to promote long-term retention of those executive officers. Equity-based </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">139</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">compensation shall be granted from time to time and be individually determined and awarded according to the performance, educational background, prior business experience, qualifications, role, and the personal responsibilities of the executive officer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, our compensation policy contains compensation recovery provisions which allow us, under certain conditions, to recover bonuses paid in excess, as well as provisions which enable our Chief Executive Officer to approve an immaterial change in the terms of employment of an executive officer who reports directly him (provided that such changes are in accordance with our compensation policy), and allow us to exculpate, indemnify, and insure our executive officers and directors to the maximum extent permitted by Israeli law subject to certain limitations set forth therein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our compensation policy also provides for compensation to the members of our board of directors either (i) <span style="color:#231f20;">in accordance with the amounts provided in the Companies Regulations (Rules&#160;Regarding the Compensation and Expenses of an External Director) of 2000, as amended by the Companies Regulations (Relief for Public Companies Traded in Stock Exchange Outside of Israel) of 2000, as such regulations may be amended from time to time, or (ii)&#160;in accordance with the amounts determined in our compensation policy.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our compensation policy became effective immediately prior to the closing of the Business Combination and is filed as an exhibit to this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Nominating and Governance Committee</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our nominating and governance committee consists of S. Morry Blumenfeld, Meir Jakobsohn and Peter Melnyk. Peter Melnyk serves as chairperson of the nominating and governance committee. Our board of directors has adopted a nominating and governance committee charter setting forth the responsibilities of the committee, which include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">overseeing and assisting our board in reviewing and recommending nominees for election of directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">assessing the performance of the members of our board; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing and maintaining effective corporate governance policies and practices, including, but not limited to, developing and recommending to our board a set of corporate governance guidelines applicable to our business.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Internal Auditor</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Companies Law, the board of directors of a public company must appoint an internal auditor based on the recommendation of the audit committee. The role of the internal auditor is, among other things, to review the company&#8217;s compliance with applicable law and orderly business procedure. Under the Companies Law, the internal auditor cannot be an interested party, an office holder, or a relative of an interested party or an office holder. Nor may the internal auditor be the company&#8217;s independent auditor or its representative. An &#8220;interested party&#8221; is defined in the Companies Law as (i)&#160;a holder of 5% or more of the issued share capital or voting power in a company, (ii)&#160;any person or entity who has the right to designate one or more directors or to designate the chief executive officer of the company, or (iii)&#160;any person who serves as a director or as chief executive officer of the company. The company will appoint an internal auditor in accordance with applicable law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Approval of Related Party Transactions under Israeli Law</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Fiduciary Duties of Directors and Executive Officers</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Companies Law codifies the fiduciary duties that office holders owe to a company. An office holder is defined in the Companies Law as a general manager, chief business manager, deputy general manager, vice general manager, any other person assuming the responsibilities of any of these positions regardless of such person&#8217;s title, a director, and any other manager directly subordinate to the general manager. Each person listed in the table under &#8220;Management of Alpha Tau After the Business Combination&#8212;Management and Board of Directors&#8221; is an office holder under the Companies Law.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">140</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An office holder&#8217;s fiduciary duties consist of a duty of care and a duty of loyalty. The duty of care requires an office holder to act with the level of care with which a reasonable office holder in the same position would act under the same circumstances. The duty of care includes, among other things, a duty to use reasonable means, in light of the circumstances, to obtain:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">information on the business advisability of a given action brought for the office holder&#8217;s approval or performed by virtue of the office holder&#8217;s position; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">all other important information pertaining to such action.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The duty of loyalty requires an office holder to act in good faith and in the best interests of the Company, and includes, among other things, the duty to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refrain from any act involving a conflict of interest between the performance of the office holder&#8217;s duties in the company and the office holder&#8217;s other duties or personal affairs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refrain from any activity that is competitive with the business of the company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refrain from exploiting any business opportunity of the company for the purpose of gaining a personal advantage for the office holder or others; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disclose to the company any information or documents relating to the company&#8217;s affairs which the office holder received as a result of the office holder&#8217;s position.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Companies Law, a company may approve an act, specified above, which would otherwise constitute a breach of the office holder&#8217;s duty of loyalty, provided that the office holder acted in good faith, neither the act nor its approval harms the company, and the personal interest of the office holder is disclosed a sufficient time before the approval of such act. Any such approval is subject to the terms of the Companies Law setting forth, among other things, the appropriate bodies of the company required to provide such approval and the methods of obtaining such approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Disclosure of Personal Interests of an Office Holder and Approval of Certain Transactions</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Companies Law requires that an office holder promptly disclose to the board of directors any personal interest and all related material information known to such office holder concerning any existing or proposed transaction with the company. A personal interest includes an interest of any person in an act or transaction of a company, including a personal interest of one&#8217;s relative or of a corporate body in which such person or a relative of such person is a 5% or greater shareholder, director, or general manager or in which such person has the right to appoint at least one director or the general manager, but excluding a personal interest stemming solely from one&#8217;s ownership of shares in the company. A personal interest includes the personal interest of a person for whom the office holder holds a voting proxy or the personal interest of the office holder with respect to the officer holder&#8217;s vote on behalf of a person for whom he or she holds a proxy even if such shareholder has no personal interest in the matter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If it is determined that an office holder has a personal interest in a non-extraordinary transaction (meaning any transaction that is in the ordinary course of business, on market terms or that is not likely to have a material impact on the company&#8217;s profitability, assets or liabilities), approval by the board of directors is required for the transaction unless the company&#8217;s articles of association provide for a different method of approval. Any such transaction that is adverse to the company&#8217;s interests may not be approved by the board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Approval first by the company&#8217;s audit committee and subsequently by the board of directors is required for an extraordinary transaction (meaning any transaction that is not in the ordinary course of business, not on market terms or that is likely to have a material impact on the company&#8217;s profitability, assets or liabilities) in which an office holder has a personal interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">A director and any other office holder who has a personal interest in a transaction which is considered at a meeting of the board of directors or the audit committee may generally (unless it is with respect to a transaction which is not an extraordinary transaction) not be present at such a meeting or vote on that matter unless a majority of the directors or members of the audit committee, as applicable, have a personal interest in the matter. If a majority of the members of the audit committee or the board of directors have a personal </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">141</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">interest in the matter, then all of the directors may participate in deliberations of the audit committee or board of directors, as applicable, with respect to such transaction and vote on the approval thereof and, in such case, shareholder approval is also required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Certain disclosure and approval requirements apply under Israeli law to certain transactions with controlling shareholders, certain transactions in which a controlling shareholder has a personal interest, and certain arrangements regarding the terms of service or employment of a controlling shareholder. For these purposes, a controlling shareholder is any shareholder that has the ability to direct the company&#8217;s actions, including any shareholder holding 25% or more of the voting rights if no other shareholder owns more than 50% of the voting rights in the company. Two or more shareholders with a personal interest in the approval of the same transaction are deemed to be one shareholder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For a description of the approvals required under Israeli law for compensation arrangements of officers and directors, see &#8220;<i style="font-style:italic;">&#8212;Compensation of Directors and Executive Officers.&#8221;</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Shareholder Duties</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Companies Law, a shareholder has a duty to act in good faith and in a customary manner toward the company and other shareholders and to refrain from abusing his or her power with respect to the company, including, among other things, in voting at a general meeting and at shareholder class meetings with respect to the following matters:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an amendment to the company&#8217;s articles of association;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an increase of the company&#8217;s authorized share capital;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a merger; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interested party transactions that require shareholder approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, a shareholder has a general duty to refrain from discriminating against other shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Certain shareholders also have a duty of fairness toward the company. These shareholders include any controlling shareholder, any shareholder who knows that it has the power to determine the outcome of a shareholder vote, and any shareholder who has the power to appoint or to prevent the appointment of an office holder of the company or exercise any other rights available to it under the company&#8217;s articles of association with respect to the company. The Companies Law does not define the substance of this duty of fairness, except to state that the remedies generally available upon a breach of contract will also apply in the event of a breach of the duty of fairness.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 5pt;"><i style="font-style:italic;">Exculpation, Insurance and Indemnification of Office Holders</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20pt;margin:0pt 0pt 12pt 5pt;">Under the Companies Law, a company may not exculpate an office holder from liability for a breach of the duty of loyalty. An Israeli company may exculpate an office holder in advance from liability to the company, in whole or in part, for damages caused to the company as a result of a breach of duty of care, but only if a provision authorizing such exculpation is included in its articles of association. The Articles include such a provision. An Israeli company may not exculpate a director from liability arising out of a prohibited dividend or distribution to shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20pt;margin:0pt 0pt 12pt 5pt;">An Israeli company may indemnify an office holder from the following liabilities and expenses incurred for acts performed as an office holder, either in advance of an event or following an event, provided a provision authorizing such indemnification is contained in its articles of association:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a financial liability imposed on him or her in favor of another person pursuant to a judgment, including a settlement or arbitrator&#8217;s award approved by a court. However, if an undertaking to indemnify an office holder with respect to such liability is provided in advance, then such an undertaking must be limited to events which, in the opinion of the board of directors, can be foreseen based on the company&#8217;s activities when the undertaking to indemnify is given, and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances, and such undertaking shall detail the above mentioned events and amount or criteria;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">142</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reasonable litigation expenses, including legal fees, incurred by the office holder (1)&#160;as a result of an investigation or proceeding instituted against him or her by an authority authorized to conduct such investigation or proceeding, provided that (i)&#160;no indictment was filed against such office holder as a result of such investigation or proceeding; and (ii)&#160;no financial liability, such as a criminal penalty, was imposed upon him or her as a substitute for the criminal proceeding as a result of such investigation or proceeding or, if such financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal intent; and (2)&#160;in connection with a monetary sanction;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reasonable litigation expenses, including legal fees, incurred by the office holder or imposed by a court in proceedings instituted against him or her by the company, on its behalf or by a third-party or in connection with criminal proceedings in which the office holder was acquitted or as a result of a conviction for an offense that does not require proof of criminal intent;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses, including reasonable litigation expenses and legal fees, incurred by an office holder in relation to an administrative proceeding instituted against such office holder, or certain compensation payments made to an injured party imposed on an office holder by an administrative proceeding, pursuant to certain provisions of the Israeli Securities Law; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses, including reasonable litigation expenses and legal fees, incurred by an office holder in relation to an administrative proceeding instituted against such office holder pursuant to certain provisions of the Israeli Economic Competition Law, 5758-1988.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">An Israeli company may insure an office holder against the following liabilities incurred for acts performed as an office holder if and to the extent provided in the company&#8217;s articles of association:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a breach of the duty of loyalty to the company, to the extent that the office holder acted in good faith and had a reasonable basis to believe that the act would not prejudice the company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a breach of the duty of care to the company or to a third-party, including a breach arising out of the negligent conduct of the office holder;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a financial liability imposed on the office holder in favor of a third-party;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a financial liability imposed on the office holder in favor of a third-party harmed by a breach in an administrative proceeding, pursuant to certain provisions of the Israeli Securities Law; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses, including reasonable litigation expenses and legal fees, incurred by the office holder as a result of an administrative proceeding instituted against him or her, pursuant to certain provisions of the Israeli Securities Law.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An Israeli company may not exempt, indemnify or insure an office holder against any of the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a breach of the duty of loyalty, except with respect to insurance coverage or indemnification, to the extent that the office holder acted in good faith and had a reasonable basis to believe that the act would not prejudice the company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a breach of the duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office holder;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an act or omission committed with intent to derive illegal personal benefit; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a fine, monetary sanction, or forfeit levied against the office holder.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Companies Law, exculpation, indemnification, and insurance of office holders must be approved by the compensation committee and the board of directors (and, with respect to directors and the chief executive officer, by the shareholders). However, under regulations promulgated under the Companies Law, the insurance of office holders shall not require shareholder approval and may be approved by only the compensation committee if the engagement terms are determined in accordance with the company&#8217;s compensation policy,</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">143</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">which was approved by the shareholders by the same special majority required to approve a compensation policy, provided that the insurance policy is on market terms and the insurance policy is not likely to materially impact the company&#8217;s profitability, assets, or obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Articles allow us to exculpate, indemnify, and insure our office holders to the maximum extent permitted by law. Our office holders are currently covered by a directors and officers&#8217; liability insurance policy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have entered enter into agreements with each of our directors and executive officers exculpating them in advance, to the fullest extent permitted by law, from liability to us for damages caused to us as a result of a breach of duty of care, and undertaking to indemnify them to the fullest extent permitted by law. This indemnification is limited to events determined as foreseeable by the board of directors based on our activities and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The maximum indemnification amount to be set forth in such agreements is limited to an amount equal to the higher of $100 million, 25% of our total shareholders&#8217; equity as reflected in our most recent consolidated financial statements prior to the date on which the indemnity payment is made and 10% of our total market capitalization calculated based on the average closing price of ordinary shares over the 30 trading&#160;days prior to the actual payment, multiplied by the total number of our issued and outstanding shares as of the date of the payment (other than indemnification for an offering of securities to the public, including by a shareholder in a secondary offering, in which case the maximum indemnification amount is limited to the gross proceeds raised by us and/or any selling shareholder in such public offering). The maximum amount set forth in such agreements is in addition to any amount paid (if paid) under insurance and/or by a third-party pursuant to an indemnification arrangement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the opinion of the SEC, indemnification of directors and office holders for liabilities arising under the Securities Act, however, is against public policy and therefore unenforceable.</p><a id="DEmployees_645610"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">D.</b></span><b style="font-weight:bold;">Employees</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2021, we had 83 FTEs across 3 offices in 3 countries, with 73 FTEs in research and development and related activities. In response to the&#160;COVID-19&#160;pandemic, we implemented changes that we determined were in the best interest of our employees and the communities in which we operate, and which comply with government regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Of our total number of employees, 82 are located in Jerusalem. We apply the law with respect to all aspects of the employment of our employees including with respect to hiring and termination procedures, equal opportunity and&#160;anti-discrimination&#160;laws and other conditions of employment. In many cases, the terms of employment of our employees exceed the minimum required under Israeli labor laws including, but not limited to, with respect to the minimum wage, vacation&#160;days, retirement savings and sick&#160;days. As per the requirements of the law, we make payments to the National Insurance Institute.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">None of our employees work under any collective bargaining agreements. Extension orders issued by the Israeli Ministry of Economy and Industry apply to us and affect matters such as length of working hours and week, recuperation pay, travel expenses and pension rights. We have never experienced labor related work stoppages&#160;or strikes and believe that our relations with our employees are satisfactory.</p><a id="EShareOwnership_804574"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">E.</b></span><b style="font-weight:bold;">Share Ownership</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For information regarding the share ownership of directors and officers, see. &#8220;<i style="font-style:italic;">Major Shareholders</i>&#8221; in Item&#160;7.A below. For information as to our equity incentive plans, see &#8220;<i style="color:#231f20;font-style:italic;">Compensation of Directors and Executive Officers</i><i style="font-style:italic;">&#160;&#8212;Share Option Plans.&#8221;&#8221; </i>in Item&#160;6.B above.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">144</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b0fc094c_bb66_4346_9c65_96319fe8a473"></a><a id="Item7MajorShareholdersandRelatedPartyTra"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;7. Major Shareholders and Related Party Transactions</b></p><a id="AMajorShareholders_70977"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">A.</b></span><b style="font-weight:bold;">Major Shareholders</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth information regarding the beneficial ownership of our ordinary shares as of March&#160;21, 2022 by:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:18pt;margin-top:0pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"><span style="display:inline-block;min-width:12.2pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>each person known by us who is the beneficial owner of 5% or more of our outstanding Ordinary shares;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:18pt;margin-top:0pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"><span style="display:inline-block;min-width:12.2pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>each of our executive officers and directors individually; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:18pt;margin-top:0pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"><span style="display:inline-block;min-width:12.2pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>all of our executive officers and directors as a group.</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Beneficial ownership for the purposes of the following table is determined in accordance with the rules&#160;and regulations of the SEC. A person is a &#8220;beneficial owner&#8221; of a security if that person has or shares &#8220;voting power,&#8221; which includes the power to vote or to direct the voting of the security, or &#8220;investment power,&#8221; which includes the power to dispose of or to direct the disposition of the security or has the right to acquire such powers within 60&#160;days of March&#160;21, 2022. Unless otherwise indicated, we believe that all persons named in the table have sole voting and investment power with respect to all ordinary shares (of the applicable type) beneficially owned by them.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Except as otherwise noted herein, the number and&#160;percentage of our Ordinary shares beneficially owned is determined in accordance with Rule&#160;13d-3&#160;of the Exchange Act, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rule, beneficial ownership includes any of our Ordinary shares as to which the holder has sole or shared voting power or investment power and also any of our Ordinary shares which the holder has the right to acquire within 60&#160;days of through the exercise of any option, warrant or any other right. The column entitled &#8220;Percentage of Voting Power&#8221; reflects the overall voting power of a given shareholder based on the composition of his, her or its share ownership.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A description of any material relationship that our principal shareholders have had with us or any of our affiliates within the past three&#160;years is included under &#8220;Certain Relationships and Related Party Transactions.&#8221;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">145</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:13.8pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For a description of the voting rights attached to our ordinary shares, please see &#8220;<i style="font-style:italic;">Voting Rights</i>.&#8221; Unless otherwise noted below, each shareholder&#8217;s address is Kiryat HaMada St. 5 Jerusalem, Israel 9777605.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:43.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:54.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;Ordinary&#160;Shares</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percentage&#160;of&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount&#160;and&#160;Nature&#160;of&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percentage&#160;of&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Name of Beneficial Owner</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Beneficial&#160;Ownership</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Voting&#160;Power</b></p></td></tr><tr><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:100%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">All 5% or Greater Shareholders Directors and Named Executive Officers</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Uzi Sofer(1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,623,950</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 17.4</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:43.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Raphi Levy(2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 468,489</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:43.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Itzhak Kelson(3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,495,091</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2.2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:43.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Yona Keisari (4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 670,064</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1.0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:43.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Robert Den(5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 203,691</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:43.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Amnon Gat(6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 492,439</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:43.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Ronen Segal(7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 316,852</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:43.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Michael Avruch(8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,134,419</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3.2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:43.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Ruth Alon</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:43.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">S. Morry Blumenfeld(9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 196,280</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:43.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="white-space:pre-wrap;">Meir Jakobsohn(10)   </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,106,483</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:43.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Alan Adler(11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 54,318</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:43.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Gary Leibler(12)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,483,277</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5.2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:43.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Peter Melnyk(13)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 22,632</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:43.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">David Milch(14)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,065,925</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5.9</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:43.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Althera Medical Ltd.(15)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,319,771</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 17.0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">All executive officers and directors as a group (14 persons)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 28,333,910</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 39.5</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Less than one&#160;percent (1%) of our outstanding ordinary shares.</p></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of (i)&#160;11,515,314 Alpha Tau ordinary shares and (ii)&#160;108,636 Alpha Tau ordinary shares subject to options exercisable within 60&#160;days of March&#160;21, 2022.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of 468,489 Alpha Tau ordinary shares subject to options, which are exercisable within 60&#160;days of March&#160;21, 2022.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of (i)&#160;725,365 Alpha Tau ordinary shares held directly by Mr.&#160;Kelson, (ii)&#160;603,151 Alpha Tau ordinary shares held by Mr.&#160;Kelson&#8217;s domestic partner and (iii)&#160;166,575 Alpha Tau ordinary shares subject to options exercisable within 60&#160;days of March&#160;21, 2022.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of (i)&#160;503,489 Alpha Tau ordinary shares and (ii)&#160;166,575 Alpha Tau ordinary shares subject to options exercisable within 60&#160;days of March&#160;21, 2022.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(5)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of 203,691 Alpha Tau ordinary shares subject to options exercisable within 60&#160;days of March&#160;21, 2022.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(6)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of (i)&#160;68,475 Alpha Tau ordinary shares, (ii)&#160;warrants to purchase 7,529 ordinary shares, which are exercisable within 60&#160;days of March&#160;21, 2022 and (iv)&#160;416,435 Alpha Tau ordinary shares subject to options, which are exercisable within 60&#160;days of March&#160;21, 2022.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(7)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of 316,852 Alpha Tau ordinary shares subject to options exercisable within 60&#160;days of March&#160;21, 2022.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(8)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of (i)&#160;789,193 Alpha Tau ordinary shares held directly by Mr.&#160;Avruch, (ii)&#160;68,951 Alpha Tau ordinary shares held by Mr.&#160;Avruch&#8217;s child that is a minor, (iii)&#160;256,356 Alpha Tau ordinary shares held by Mr.&#160;Avruch&#8217;s spouse, (iv)&#160;108,636 Alpha Tau ordinary shares subject to options granted to Mr.&#160;Avruch, which are exercisable within 60&#160;days of March&#160;21, 2022, (v)&#160;96,520 warrants to purchase ordinary shares held by Mr.&#160;Avruch&#8217;s spouse, which are exercisable within 60&#160;days of March&#160;21, 2022 and (vii)&#160;814,763 Alpha Tau ordinary shares held by Sabor Venture Capital Investment Kft. Mr.&#160;Avruch is the general manager and chief financial officer of Sabor Venture Capital Investment Kft.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">146</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(9)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of (i)&#160;80,986 ordinary shares, (ii)&#160;warrants to purchase 6,658 ordinary shares, which are exercisable within 60&#160;days of March&#160;21, 2022, and (iii)&#160;108,636 Alpha Tau ordinary shares subject to options exercisable within 60&#160;days of March&#160;21, 2022.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(10)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of (i)&#160;2,576,959 ordinary shares held by Medison Ventures&#160;Ltd. (&#8220;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Medison Venture</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">s&#8221;), (ii)&#160;warrants to purchase 345,888 ordinary shares held by Medison Ventures, which are exercisable within 60&#160;days of March&#160;21, 2022, (iii)&#160;75,000 ordinary shares held by Tzalir Pharma&#160;Ltd. (&#8220;Tzalir Pharma&#8221;) and (iv)&#160;108,636 Alpha Tau ordinary shares subject to options granted directly to Mr.&#160;Jakobsohn, which are exercisable within 60&#160;days of March&#160;21, 2022. Mr.&#160;Jakobsohn is the sole owner of Medison Pharma Group&#160;Ltd., which is the sole owner of Medison Ventures and as such has voting and investment discretion with respect to the ordinary shares and warrants held of record by the Medison Ventures and may be deemed to have beneficial ownership of the ordinary shares and warrants held directly by Medison Ventures. Mr.&#160;Jakobsohn is the majority controlling owner of Tzalir Pharma and may be deemed to have beneficial ownership of the ordinary shares held directly by Tzalir Pharma.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(11)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of 54,318 Alpha Tau ordinary shares subject to options exercisable within 60&#160;days of March&#160;21, 2022.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(12)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of (i)&#160;90,529 ordinary shares held by Mr.&#160;Leibler directly, (ii)&#160;54,318 Alpha Tau ordinary shares subject to options, which are exercisable within 60&#160;days of March&#160;21, 2022 held by the Shavit Funds (as defined below), (iii)&#160;3,085,004 ordinary shares held by the Shavit Funds, and (iv)&#160;warrants to purchase 253,426 ordinary shares held by the Shavit Funds. Gabriel Capital Management&#160;Ltd. (&#8220;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">GCM</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) is the management company to certain affiliated funds (collectively, the &#8220;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Shavit Funds</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). As such GCM may be deemed to beneficially own such securities held by the Shavit Funds. Mr.&#160;Leibler is the sole shareholder of the sole shareholder of GCM. Decisions regarding the voting and disposition of securities held by the Shavit Funds are subject to approval by certain internal investment committees comprising three or more individuals, of which Mr.&#160;Leibler is a member.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(13)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consists of 22,632 ordinary shares subject to options exercisable within 60&#160;days of March&#160;21, 2022.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(14)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Includes (i)&#160;1,923,525 ordinary shares held by Healthcare Capital Sponsor LLC (the &#8220;Sponsor&#8221;) and (ii)&#160;2,142,000 warrants to purchase ordinary shares held by the Sponsor. David M. Milch is the manager of the Sponsor, and as such has voting and investment discretion with respect to the ordinary shares and warrants held of record by the Sponsor and may be deemed to have beneficial ownership of the ordinary shares and warrants held directly by the Sponsor. However, Dr.&#160;Milch disclaims any beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(15)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Althera Medical&#160;Ltd. (&#8220;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Althera</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) is under voluntary liquidation. Adv. Zvi Chowers of Glusman, Chowers, Lahat&#160;&amp; Co., was appointed by the shareholders of Althera to serve as Althera&#8217;s liquidator. In such capacity, Adv. Chowers holds the signature rights on behalf of Althera. Upon completion of Althera&#8217;s liquidation process, all of its available assets (including its holdings in Alpha Tau), will be distributed to the shareholders of Althera in accordance with the provisions of Althera&#8217;s Articles of Association, and the distribution process and preference detailed therein.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><b style="font-weight:bold;">Significant Changes in Ownership</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To our knowledge, other than as disclosed in the table above, our other filings with the SEC and this Annual Report, there has been no significant change in the&#160;percentage ownership held by any major shareholder during the past three&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">147</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:13.8pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><b style="font-weight:bold;">Voting Rights</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other than the voting undertakings under the Investors&#8217; Rights Agreement and the Shareholder and Sponsor Support Agreement, described below under &#8220;Related Party Transactions&#8212;Rights of Appointment,&#8221; which have been fully performed already and have therefore expired, no major shareholders listed above had or have voting rights with respect to their ordinary shares that are different from the voting rights of other holders of our ordinary shares.]<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><b style="font-weight:bold;">Change in Control Arrangements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are not aware of any arrangement that may at a subsequent date, result in a change of control of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><b style="font-weight:bold;">Registered Holders</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Based on a review of the information provided to us by our transfer agent, as of March&#160;21, 2022, there were 275 registered holders of our ordinary shares, (one of which (Cede&#160;&amp; Co.) is a United States registered holder, holding approximately 1.906% of our outstanding ordinary shares).</p><a id="BRelatedPartyTransactions_55434"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">B.</b></span><b style="font-weight:bold;">Related Party Transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following is a description of related-party transactions we have entered into since January&#160;1, 2021 with any of the members of the board of directors, executive officers or holders of more than 5% of any class of our voting securities at the time of such transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Rights of Appointment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20pt;margin:0pt 0pt 12pt 6pt;">Our board of directors currently consists of nine directors. Pursuant to our articles of association as in effect immediately prior to the Business Combination, certain of our shareholders, including related parties, had rights to appoint directors and observers to its board of directors. All rights to appoint directors and observers terminated upon the closing of the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Agreements with Officers</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Employment Agreements</i>. We have entered into employment or consulting agreements with each of our executive officers, and the terms of each individual&#8217;s employment or service, as applicable, have been approved by our board of directors. These agreements provide for notice periods of varying duration for termination of the agreement by Alpha Tau or by the relevant executive officer, during which time the executive officer will continue to receive base salary and benefits. These agreements also contain customary provisions regarding noncompetition, confidentiality of information and assignment of inventions. However, the enforceability of the noncompetition provisions may be limited under applicable law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Options</i>. Since Alpha Tau&#8217;s inception, Alpha Tau has granted options to purchase ordinary shares to its executive officers and directors. Such ordinary shares issuable under these options are subject to lock-up terms with Alpha Tau.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><i style="font-style:italic;">Exculpation, indemnification, and insurance</i>. The Articles permit us to exculpate, indemnify and insure certain of its officeholders (as such term is defined under the Companies Law) to the fullest extent permitted by the Companies Law. Alpha Tau has entered into agreements with certain officeholders, exculpating them from a breach of their duty of care to Alpha Tau to the fullest extent permitted by law and undertaking to indemnify them to the fullest extent permitted by law, subject to certain exceptions, including with respect to liabilities resulting from the closing of the Business Combination to the extent that these liabilities are not covered by insurance.<span style="font-size:12pt;"> </span></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2 </sup>Meitar to advise of any additional voting rights that should be disclosed here.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">148</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Amended and Restated Investors&#8217; Rights Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July&#160;7, 2021, we amended and restated our existing Investors&#8217; Rights Agreement, dated as of April&#160;16, 2020, and adopted the Amended IRA, which provides, among other things, that certain holders of our ordinary shares, (the &#8220;Investors&#8221;) (the ordinary shares of those holders referred to in the Amended IRA are collectively referred to hereinafter as the &#8220;Registrable Securities&#8221;), have the right to demand that we file a registration statement, or to request that their shares be covered by a registration statement that we are otherwise filing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Form&#160;F-1 Demand Rights</i>. At any time after 180&#160;days following the closing of the Transactions (or earlier upon expiration or waiver of any lockup applicable to the Investors) with respect to an IPO which is not a SPAC Transaction (as defined under the Amended IRA), or following the closing of the Merger Agreement and expiration or waiver of any lockup applicable to the Investors, with respect to an IPO which is a SPAC, and in all cases until the five&#160;years thereafter, the Investors holding a majority of the Registrable Securities then held by the Investors or other holders of a majority of the Registrable Securities (including, prior to an IPO, as defined under the Amended IRA, the lead investor under our Series&#160;A Financing- Shavit Capital), can provide us with written request to file a registration statement on Form&#160;F-1 in respect of the Registrable Securities. Within 14&#160;days of the receipt of a request to effect such registration, we must give written notice of the request to the other holders of the Registrable Securities, and use our best efforts to effect the registration together with all or such portion of the registrable securities of any other holders joining in such request (as specified by notice given by each such other holder to us, within 20&#160;days of the date of our notice to such holders), within 90&#160;days. We are not required to effect more than two registrations on Form&#160;F-1. In addition, we are only required to effect any such registration if the anticipated aggregate proceeds will be at least US $5 million (net of underwriting discounts and commissions) and if such registration could not be effected on Form&#160;F-3. Furthermore, we are not required to effect such registration within the period that is 60&#160;days before its good faith estimate of the date of filing of, and ending on a date that is 180&#160;days after the effective date of, registration on Form&#160;F-1 or F-3, initiated by holders of Registrable Securities, or if the holders of Registrable Securities had an opportunity to participate during such period in any offering initiated by us, provided that we have actively employed in good faith efforts to cause such registration statement to become effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Form&#160;F-3 Demand Rights</i>. At any time when we are eligible to use a Form&#160;F-3 registration statement, the Investors holding a majority of the Registrable Securities can provide us with request to file a registration on Form&#160;F-3 in respect of the Registrable Securities. Within 14&#160;days of the receipt of a request to effect such registration, we must give written notice of the request to the other holders of the Registrable Securities, and use our best efforts to effect the registration together with all or such portion of the registrable securities of any other holders joining in such request (as specified by notice given by each such other holder to us, within 15&#160;days of the date of our notice to such holders), within 45&#160;days. We are only required to effect any such registration if the anticipated aggregate proceeds will be at least US$2 million (net of underwriting discounts and commissions and such other fees specified under the Investor&#8217;s Rights Agreement). Furthermore, we are not required to file such Form&#160;F-3 if it has, within the 12-month period preceding the date of such request, already effected two registrations on a Form&#160;F-3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Piggyback Offerings</i>. Holders of a majority of the Registrable Securities having a value of at least US $1 million, will also have the right to request to participate in any registration initiated by us in connection with the public offering of any of our Ordinary Shares, subject to specified exceptions. Holders of Registrable Securities continue to have the right to participate in subsequent piggyback offerings regardless of whether the holder has opted out of prior offerings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Cutback</i>. In the event that the underwriter advises that marketing factors require a limitation on the number of shares that can be included in a demand registered offering on a Form&#160;F-1 or F-3, the Registrable Securities that are to be included in such the registration statement, to the extent necessary to satisfy such limitation, shall be as follows: first, Preferred Registrable Securities held by the initiating Investors; second, Preferred Registrable Securities held by the non-initiating Investors; and third, Ordinary Registrable Securities; with respect to each of the first, second and third priorities above- on a pro rata basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the case of a piggyback offering, we are required to include in the offering only that number of shares that the underwriters determine in their sole discretion will not jeopardize the success of the offering. If the underwriters determine that less then all Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included shall be allocated as follows: first, all the securities to </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">be included by the Company; second, Preferred Registrable Securities (on a pro rata basis); and third, Ordinary Registrable Securities (on a pro rata basis); Provided, however, that: (i)&#160;the number of Registrable Securities in the offering may be reduced only if all other shareholders&#8217; securities are first entirely excluded from the offering; and (ii)&#160;in no event shall the number of Registrable </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">149</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Securities included in the offering be reduced below 50% of the total number of securities included in the offering (unless such offering is an IPO, in which case the selling holders may be excluded further).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Termination</i>. Rights granted to holders of Registrable Securities pursuant to the Amended IRA terminate upon the earlier of: (i)&#160;the closing of a Deemed Liquidation and payment of the full Series&#160;A Preference and/or Series&#160;B Preference, as applicable (as such terms are defined in the Amended and Restated Articles of Association), (ii)&#160;such time as Rule&#160;144 or another similar exemption under the Securities Act is available for the sale of all of such holder&#8217;s shares without limitation during a three-month period without registration and (iii)&#160;the fifth anniversary of the date that is 180-days following the closing of the Transactions. We have the right to terminate or withdraw any registration or offering which is subject to piggyback rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expenses</i>. We will pay all expenses in carrying out the foregoing registrations or offerings other than any underwriting discounts and commissions (subject to certain exceptions).</p><a id="CInterestsofExpertsandCounsel_282760"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">C.</b></span><b style="font-weight:bold;">Interests of Experts and Counsel</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_027d29b7_fbb5_428a_adb0_609f74e2f5bd"></a><a id="Item8FinancialInformation_714368"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;8. Financial Information</b></p><a id="AConsolidatedStatementsandOtherFinancial"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">A.</b></span><b style="font-weight:bold;">Consolidated Statements and Other Financial Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Consolidated Financial Statements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">See Item&#160;18. &#8220;<i style="font-style:italic;">Financial Statements</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Legal and Arbitration Proceedings</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may be subject to various legal proceedings and claims that arise in the ordinary course of business, as well as governmental and other regulatory investigations and proceedings. Although the outcome of the various legal proceedings and claims cannot be predicted with certainty, we are not currently a party to any legal proceedings that, if determined adversely to us, would, in our opinion, likely have a significant effect on our financial position or profitability. For more information regarding risks related to litigation, see &#8220;<i style="font-style:italic;">Risk Factors&#8212;Risks Related to Our Business and Industry&#8212; </i><i style="color:#231f20;font-style:italic;">Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain. Defending against such law suits will be costly and time consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Dividend Policy</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We do not anticipate paying any dividends in the foreseeable future. We currently intend to retain future earnings, if any, to finance operations and expand our business. Our board of directors has sole discretion whether to pay dividends. If our board of directors decides to pay dividends, the form, frequency and amount will depend upon our future operations and earnings, capital requirements and surplus, general financial condition, contractual restrictions and other factors that our directors may deem relevant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the&#160;years ended December&#160;31, 2021, 2020, 2019 and 2018, we did not pay any dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Companies Law imposes restrictions on our ability to declare and pay dividends. See &#8220;<i style="font-style:italic;">Dividend and Liquidation Rights</i>&#8221; in Exhibit 2.1 to this Annual Report for additional information. See also &#8220;<i style="font-style:italic;">Item&#160;3.D. Risk Factors&#8212;Risks Related to Our Class&#160;A Ordinary Shares&#8212;</i><i style="color:#231f20;font-style:italic;"> We do not intend to pay dividends for the foreseeable future. Accordingly, you may not receive any return on investment unless you sell your ordinary shares for a price greater than the price you paid for such shares.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Payment of dividends may be subject to Israeli withholding taxes. See &#8220;<i style="font-style:italic;">Israeli Tax Considerations</i>&#8221; for additional information.</p><a id="BSignificantChanges_405325"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">B.</b></span><b style="font-weight:bold;">Significant Changes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">None.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">150</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e341630b_1d7d_4fbb_b614_7a13d1ba7c83"></a><a id="Item9TheOfferandListing_113549"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;9. The Offer and Listing</b></p><a id="AOfferandListingDetails_242844"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">A.</b></span><b style="font-weight:bold;">Offer and Listing Details</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our ordinary shares and warrants commenced trading on Nasdaq on March&#160;8, 2022 under the symbol &#8220;DRTS&#8221; and &#8220;DRTSW,&#8221; respectively. Prior to this, no public market existed for our ordinary shares or warrants.</p><a id="BPlanofDistribution_953078"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">B.</b></span><b style="font-weight:bold;">Plan of Distribution</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="CMarkets_449293"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">C.</b></span><b style="font-weight:bold;">Markets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our ordinary shares commenced trading on Nasdaq on March&#160;8, 2022.</p><a id="DSellingShareholders_610130"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">D.</b></span><b style="font-weight:bold;">Selling Shareholders</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="EDilution_640293"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">E.</b></span><b style="font-weight:bold;">Dilution</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="FExpensesoftheIssue_39808"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">F.</b></span><b style="font-weight:bold;">Expenses of the Issue</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_03960f82_57bf_403a_ac84_2686f9c175d9"></a><a id="Item10AdditionalInformation_683670"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;10. Additional Information</b></p><a id="AShareCapital_21921"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">A.</b></span><b style="font-weight:bold;">Share Capital</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="BMemorandumandArticlesofAssociation_6214"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">B.</b></span><b style="font-weight:bold;">Memorandum and Articles of Association</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A copy of our amended and restated articles of association is attached as Exhibit&#160;1.1 to this Annual Report. The information called for by this Item&#160;is set forth in Exhibit&#160;2.1 to this Annual Report and incorporated by reference herein.</p><a id="CMaterialContracts_621752"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">C.</b></span><b style="font-weight:bold;">Material Contracts</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Except as disclosed below or otherwise disclosed in this Annual Report in Item&#160;4.A &#8220;History and Development of the Company,&#8221; Item&#160;4.B &#8220;Business Overview,&#8221; Item&#160;5.B &#8220;Operating and Financial Review and Prospects&#8212;Liquidity and Capital Resources,&#8221; Item&#160;6.C &#8220;Board Practices,&#8221; Item&#160;7.B &#8220;Related Party Transactions&#8221; and Item&#160;19 &#8220;Exhibits,&#8221; we are not currently, nor have we been for the two&#160;years immediately preceding the date of this Annual Report, party to any material contract, other than contracts entered into in the ordinary course of business..</p><a id="DExchangeControls_815357"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">D.</b></span><b style="font-weight:bold;">Exchange Controls</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There are currently no Israeli currency control restrictions on remittances of dividends on our ordinary shares, proceeds from the sale of the ordinary shares or interest or other payments to non-residents of Israel, except for shareholders who are subjects of countries that are, have been, or will be, in a state of war with Israel.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">151</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="ETaxation_718918"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">E.</b></span><b style="font-weight:bold;">Taxation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following description is not intended to constitute a complete analysis of all tax consequences relating to the acquisition, ownership and disposition of our ordinary shares and warrants. You should consult your own tax advisor concerning the tax consequences of your particular situation, as well as any tax consequences that may arise under the laws of any state, local, foreign or other taxing jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Israeli tax considerations and government programs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following is a brief summary of the material Israeli tax laws applicable to us, and certain Israeli Government programs that benefit us. This section also contains a discussion of material Israeli tax consequences concerning the ownership and disposition of our ordinary shares. This summary does not discuss all the aspects of Israeli tax law that may be relevant to a particular investor in light of his or her personal investment circumstances or to some types of investors subject to special treatment under Israeli law. Examples of such investors include residents of Israel or traders in securities who are subject to special tax regimes not covered in this discussion. To the extent that the discussion is based on new tax legislation that has not yet been subject to judicial or administrative interpretation, we cannot assure you that the appropriate tax authorities or the courts will accept the views expressed in this discussion. The discussion below is subject to change, including due to amendments under Israeli law or changes to the applicable judicial or administrative interpretations of Israeli law, which change could affect the tax consequences described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">General corporate tax structure in Israel</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Israeli companies are generally subject to corporate tax. In December&#160;2016, the Israeli Parliament approved the Economic Efficiency Law (Legislative Amendments for Applying the Economic Policy for the 2017 and 2018 Budget&#160;Years) which reduces the corporate income tax rate from 25% to 24% effective from January&#160;1, 2017, and to 23% effective from January&#160;1, 2018. However, the effective tax rate payable by a company that derives income from a Preferred Enterprise, a Special Preferred Enterprise, a Preferred Technology Enterprise or a Special Preferred Technology Enterprise (as discussed below) may be considerably less. Capital gains derived by an Israeli company are generally subject to the corporate tax rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Law for the Encouragement of Industry (Taxes), 5729-1969</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Law for the Encouragement of Industry (Taxes), 5729-1969, generally referred to as the Industry Encouragement Law, provides several tax benefits for &#8220;Industrial Companies.&#8221; We believe that we currently qualify as an Industrial Company within the meaning of the Industry Encouragement Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Industry Encouragement Law defines an &#8220;Industrial Company&#8221; as an Israeli resident-company, of which 90% or more of its income in any tax&#160;year, other than income from certain government loans, is derived from an &#8220;Industrial Enterprise&#8221; owned by it and located in Israel or in the &#8220;Area&#8221;, in accordance with the definition under section 3A of the Israeli Income Tax Ordinance (New Version) 1961, or the Ordinance. An &#8220;Industrial Enterprise&#8221; is defined as an enterprise whose principal activity in a given tax&#160;year is industrial production.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following are the main tax benefits available to Industrial Companies:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Amortization of the cost of purchased patent, rights to use a patent, and know-how, which are used for the development or advancement of the Industrial Enterprise, over an eight-year period, commencing on the&#160;year in which such rights were first exercised;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Under limited conditions, an election to file consolidated tax returns with controlled Israeli Industrial Companies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Expenses related to a public offering are deductible in equal amounts over three&#160;years commencing on the&#160;year of the offering.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Eligibility for benefits under the Industry Encouragement Law is not contingent upon approval of any governmental authority.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">152</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Tax benefits and grants for research and development</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Israeli tax law allows, under certain conditions, a tax deduction for expenditures, including capital expenditures, for the&#160;year in which they are incurred. Expenditures are deemed related to scientific research and development projects, if:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The expenditures are approved by the relevant Israeli government ministry, determined by the field of research;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The research and development must be for the promotion of the company; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The research and development is carried out by or on behalf of the company seeking such tax deduction.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The amount of such deductible expenses is reduced by the sum of any funds received through government grants for the finance of such scientific research and development projects. No deduction under these research and development deduction rules&#160;is allowed if such deduction is related to an expense invested in an asset depreciable under the general depreciation rules&#160;of the Ordinance. Expenditures that are unqualified under the conditions above are deductible in equal amounts over three&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time we may apply to the Israel Innovation Authority for approval to allow a tax deduction for all or most of research and development expenses during the&#160;year incurred. There can be no assurance that such application will be accepted. If we will not be able to deduct research and development expenses during the&#160;year of the payment, we will be able to deduct research and development expenses during a period of three&#160;years commencing in the&#160;year of the payment of such expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Law for the Encouragement of Capital Investments 5719-1959</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Law for the Encouragement of Capital Investments, 5719-1959, generally referred to as the Investment Law, provides certain incentives for capital investments in production facilities (or other eligible assets).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Investment Law was significantly amended effective as of April&#160;1, 2005 (the &#8220;2005 Amendment&#8221;), as of January&#160;1, 2011 (the &#8220;2011 Amendment&#8221;) and as of January&#160;1, 2017 (the &#8220;2017 Amendment&#8221;). Pursuant to the 2005 Amendment, tax benefits granted in accordance with the provisions of the Investment Law prior to its revision by the 2005 Amendment remain in force but any benefits granted subsequently are subject to the provisions of the amended Investment Law. Similarly, the 2011 Amendment introduced new benefits to replace those granted in accordance with the provisions of the Investment Law in effect prior to the 2011 Amendment. However, companies entitled to benefits under the Investment Law as in effect prior to January&#160;1, 2011 were entitled to choose to continue to enjoy such benefits, provided that certain conditions are met, or elect instead, irrevocably, to forego such benefits and have the benefits of the 2011 Amendment apply. The 2017 Amendment introduces new benefits for Technological Enterprises, alongside the existing tax benefits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Tax benefits under the 2011 amendment</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The 2011 Amendment canceled the availability of the benefits granted to Industrial Companies under the Investment Law prior to 2011 and, instead, introduced new benefits for income generated by a &#8220;Preferred Company&#8221; through its &#8220;Preferred Enterprise&#8221; (as such terms are defined in the Investment Law) as of January&#160;1, 2011. The definition of a Preferred Company includes a company incorporated in Israel that is not fully owned by a governmental entity, and that has, among other things, Preferred Enterprise status and is controlled and managed from Israel. Pursuant to the 2011 Amendment, a Preferred Company is entitled to a reduced corporate tax rate of 15% with respect to its income derived by its Preferred Enterprise in 2011 and 2012, unless the Preferred Enterprise is located in a specified development zone, in which case the rate will be 10%. Under the 2011 Amendment, such corporate tax rate was reduced from 15% and 10%, respectively, to 12.5% and 7%, respectively, in 2013, 16% and 9% respectively, in 2014, 2015 and 2016, and 16% and 7.5%, respectively, in 2017 and thereafter. Income derived by a Preferred Company from a &#8220;Special Preferred Enterprise&#8221; (as such term is defined in the Investment Law) would be entitled, during a benefits period of 10&#160;years, to further reduced tax rates of 8%, or 5% if the Special Preferred Enterprise is located in a certain development zone.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Dividends distributed from income which is attributed to a &#8220;Preferred Enterprise&#8221; will be subject to withholding tax at source at the following rates: (i)&#160;Israeli resident&#160;corporations-0%,&#160;(although, if such dividends are subsequently distributed to individuals or a&#160;non-Israeli&#160;company the below rates detailed in sub sections (ii)&#160;and (iii)&#160;shall apply)&#160;(ii)&#160;Israeli resident&#160;individuals-20%&#160;(iii)&#160;non-Israeli&#160;residents (individuals and corporations)- 25% or 30%, and subject to the receipt in advance of a valid certificate from the Israel </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">153</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Tax Authority (&#8220;ITA&#8221;) allowing for a reduced tax rate&#8212;20% or a reduced tax rate under the provisions of any applicable double tax treaty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We currently do not intend to implement the 2011 Amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">New tax benefits under the 2017 amendment that became effective on January&#160;1, 2017</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The 2017 Amendment provides that a technology company satisfying certain conditions will qualify as a &#8220;Preferred Technology Enterprise&#8221; and will thereby enjoy a reduced corporate tax rate of 12% on income that qualifies as &#8220;Preferred Technology Income&#8221;, as defined in the Investment Law. The tax rate is further reduced to 7.5% for a Preferred Technology Enterprise located in development zone &#8220;A&#8221;. In addition, a Preferred Technology Company will enjoy a reduced corporate tax rate of 12% on capital gain derived from the sale of certain &#8220;Benefitted Intangible Assets&#8221; (as defined in the Investment Law) to a related foreign company if the Benefitted Intangible Assets were acquired from a foreign company on or after January&#160;1, 2017 for at least NIS 200&#160;million, and the sale receives prior approval from the Israel Innovation Authority. The 2017 Amendment further provides that a technology company satisfying certain conditions (group consolidated revenues of at least NIS 10 billion) will qualify as a &#8220;Special Preferred Technology Enterprise&#8221; and will thereby enjoy a reduced corporate tax rate of 6% on &#8220;Preferred Technology Income&#8221; regardless of the company&#8217;s geographic location within Israel. In addition, a Special Preferred Technology Enterprise will enjoy a reduced corporate tax rate of 6% on capital gain derived from the sale of certain &#8220;Benefitted Intangible Assets&#8221; to a related foreign company if the Benefitted Intangible Assets were either developed by the Special Preferred Enterprise or acquired from a foreign company on or after January&#160;1, 2017, and the sale received prior approval from the Israel Innovation Authority. A Special Preferred Technology Enterprise that acquires Benefitted Intangible Assets from a foreign company for more than NIS 500&#160;million will be eligible for these benefits for at least ten&#160;years, subject to certain approvals as specified in the Investment Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Dividends distributed to Israeli shareholders by a Preferred Technology Enterprise or a Special Preferred Technology Enterprise, paid out of Preferred Technology Income, are generally subject to withholding tax at source at the rate of 20% (in the case of&#160;non-Israeli&#160;shareholders&#8212;subject to the receipt in advance of a valid certificate from the ITA allowing for a reduced tax rate, 20% or such lower rate as may be provided in an applicable tax treaty). However, if such dividends are paid to an Israeli company, no tax is required to be withheld (although, if such dividends are subsequently distributed to individuals or a&#160;non-Israeli&#160;company, withholding tax at a rate of 20% or such lower rate as may be provided in an applicable tax treaty, will apply). If such dividends are distributed to a foreign company that holds solely or together with other foreign companies 90% or more in the Israeli company and other conditions are met, the withholding tax rate will be 4%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe that we may be eligible to the tax benefits under the 2017 Amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Taxation of our shareholders</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Capital gains taxes applicable to&#160;non-Israeli&#160;resident shareholders</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">A&#160;non-Israeli&#160;resident who derives capital gains from the sale of shares in an Israeli resident company that were purchased after the company was listed for trading on a stock exchange outside of Israel, should be exempt from Israeli tax unless, among others, the shares were held through a permanent establishment that the&#160;non-resident&#160;maintains in Israel. If not exempt, a&#160;non-Israeli&#160;resident shareholder would generally be subject to tax on capital gain at the ordinary corporate tax rate (23% in 2021), if generated by a company, or at the rate of 25%, if generated by an individual, or 30%, if generated by an individual who is a &#8220;substantial shareholder&#8221; (as defined under the Tax Ordinance), at the time of sale or at any time during the preceding&#160;12-month&#160;period (or if the shareholder claims a deduction for interest and linkage differences expenses in connection with the purchase and holding of such shares). A &#8220;substantial shareholder&#8221; is generally a person who alone or together with such person&#8217;s relative or another person who collaborates with such person on a permanent basis, holds, directly or indirectly, at least 10% of any of the &#8220;means of control&#8221; of the corporation. &#8220;Means of control&#8221; generally include, among others, the right to vote, receive profits, nominate a director or an executive officer, receive assets upon liquidation, or order someone who holds any of the aforesaid rights how to act, regardless of the source of such right. Individual and corporate shareholders dealing in securities in Israel are taxed at the tax rates applicable to business income (a corporate tax rate for a corporation (23% in 2021) and a marginal tax rate of up to 47% for an individual in 2021 (excluding excess tax as discussed below)) unless contrary provisions in a relevant tax treaty apply.&#160;Non-Israeli&#160;corporations will not be entitled to the foregoing exemption if Israeli residents: (i)&#160;have a controlling interest more than 25% in such&#160;non-Israeli&#160;corporation or (ii)&#160;are the beneficiaries of, or are entitled to, 25% or more of the revenues or profits of such&#160;non-Israeli&#160;corporation, whether directly or </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">154</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">indirectly. In addition, such exemption is not applicable to a person whose gains from selling or otherwise disposing of the shares are deemed to be business income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, a sale of securities by a&#160;non-Israeli&#160;resident may be exempt from Israeli capital gains tax under the provisions of an applicable tax treaty. For example, under Convention Between the Government of the United States of America and the Government of the State of Israel with respect to Taxes on Income, as amended (the &#8220;United States Israel Tax Treaty&#8221;), the sale, exchange or other disposition of shares by a shareholder who is a United States resident (for purposes of the treaty) holding the shares as a capital asset and is entitled to claim the benefits afforded to such a resident by the U.S. Israel Tax Treaty (a &#8220;Treaty U.S. Resident&#8221;) is generally exempt from Israeli capital gains tax unless: (i)&#160;the capital gain arising from such sale, exchange or disposition is attributed to real estate located in Israel; (ii)&#160;the capital gain arising from such sale, exchange or disposition is attributed to royalties; (iii)&#160;the capital gain arising from the such sale, exchange or disposition is attributed to a permanent establishment in Israel, under certain terms; (iv)&#160;such Treaty U.S. Resident holds, directly or indirectly, shares representing 10% or more of the voting capital during any part of the 12&#160;month period preceding the disposition, subject to certain conditions; or (v)&#160;such Treaty U.S. Resident is an individual and was present in Israel for 183&#160;days or more during the relevant taxable&#160;year. In each case, the sale, exchange or disposition of our ordinary shares would be subject to Israeli tax, to the extent applicable; however, under the United States-Israel Tax Treaty, the taxpayer may be permitted to claim a credit for such taxes against the U.S. federal income tax imposed with respect to such sale, exchange or disposition, subject to the limitations under U.S. law applicable to foreign tax credits. The United States-Israel Tax Treaty does not provide such credit against any U.S. state or local taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In some instances where our shareholders may be liable for Israeli tax on the sale of their ordinary shares, the payment of the consideration may be subject to the withholding of Israeli tax at source. Shareholders may be required to demonstrate that they are exempt from tax on their capital gains in order to avoid withholding at source at the time of sale (i.e., resident certificate or other documentation). Specifically, in transactions involving a sale of all of the shares of an Israeli resident company, in the form of a merger or otherwise, the ITA may require from shareholders who are not liable for Israeli tax to sign declarations in forms specified by this authority or obtain a specific exemption from the ITA to confirm their status as&#160;non-Israeli&#160;tax residents, and, in the absence of such declarations or exemptions, may require the purchaser of the shares to withhold taxes at source.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Taxation of&#160;non-Israeli&#160;shareholders on receipt of dividends</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Non-Israeli&#160;residents (either individuals or corporations) are generally subject to Israeli income tax on the receipt of dividends paid on our ordinary shares at the rate of 25%, which tax will be withheld at source, unless relief is provided in a treaty between Israel and the shareholder&#8217;s country of residence (subject to the receipt in advance of a valid certificate from the ITA allowing for a reduced tax rate). With respect to a person who is a &#8220;substantial shareholder&#8221; at the time of receiving the dividend or on any time during the preceding twelve&#160;months, the applicable tax rate is 30%. Such dividends are generally subject to Israeli withholding tax at a rate of 25% so long as the shares are registered with a nominee company (whether the recipient is a substantial shareholder or not) and, subject to the receipt in advance of a valid certificate from the ITA allowing for a reduced tax rate, 15% if the dividend is distributed from income attributed to an Approved Enterprise or a Beneficiary Enterprise and 20% if the dividend is distributed from income attributed to a Preferred Enterprise or Preferred Technology Enterprise or such lower rate as may be provided in an applicable tax treaty. For example, under the United States Israel Tax Treaty, the maximum rate of tax withheld at source in Israel on dividends paid to a holder of our ordinary shares who is a Treaty U.S. Resident is 25%. However, generally, the maximum rate of withholding tax on dividends, not generated by a Preferred Enterprise or Beneficiary Enterprise, that are paid to a United States corporation holding 10% or more of the outstanding voting capital throughout the tax&#160;year in which the dividend is distributed as well as during the previous tax&#160;year, is 12.5%, provided that not more than 25% of the gross income for such preceding&#160;year consists of certain types of dividends and interest. The aforementioned rates under the United States- Israel Tax Treaty would not apply if the dividend income is derived through a permanent establishment of the U.S. resident in Israel. If the dividend is attributable partly to income derived from an Approved Enterprise, Benefited Enterprise or Preferred Enterprise, and partly to other sources of income, the withholding rate will be a blended rate reflecting the relative portions of the two types of income. We cannot assure you that we will designate the profits that we may distribute in a way that will reduce shareholders&#8217; tax liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A&#160;non-Israeli&#160;resident who receives dividends from which tax was withheld is generally exempt from the obligation to file tax returns in Israel with respect to such income, provided that (i)&#160;such income was not generated from business conducted in Israel by the taxpayer, (ii)&#160;the taxpayer has no other taxable sources of income in Israel with respect to which a tax return is required to be filed, and (iii)&#160;the taxpayer is not obligated to pay excess tax (as further explained below).</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">155</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Surtax</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Subject to the provisions of an applicable tax treaty, individuals who are subject to tax in Israel (whether any such individual is an Israeli resident or&#160;non-Israeli&#160;resident) are also subject to an additional tax at a rate of 3% on annual income (including, but not limited to, dividends, interest and capital gain) exceeding NIS 647,640 for 2021, which amount is linked to the annual change in the Israeli consumer price index.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Estate and Gift Tax</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Israeli law presently does not impose estate or gift taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Certain Material U.S. Federal Income Tax Considerations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following discussion is a summary of the material U.S. federal income tax considerations of the acquisition, ownership and disposition of Alpha Tau ordinary shares and warrants. This discussion addresses only the U.S. federal income tax consequences to U.S. Holders (as defined below) that hold Alpha Tau ordinary shares or warrants as &#8220;capital assets&#8221; within the meaning of Section&#160;1221 of the U.S. Internal Revenue Code of 1986, as amended (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Code</span>&#8221;) (generally, property held for investment).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following does not purport to be a complete analysis of all potential tax considerations of the acquisition, ownership and disposition of Alpha Tau ordinary shares and warrants. The effects and considerations of other U.S. federal tax laws, such as estate and gift tax laws, alternative minimum or Medicare contribution tax consequences and any applicable state, local or&#160;non-U.S.&#160;tax laws are not discussed. This discussion is based on the Code, Treasury regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements of the U.S. Internal Revenue Service (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">IRS</span>&#8221;), in each case in effect as of the date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect the tax consequences discussed below. Alpha Tau has not sought and will not seek any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS will not take or a court will not sustain a contrary position to that discussed below regarding the tax consequences discussed below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This discussion does not address all U.S. federal income tax consequences relevant to a holder&#8217;s particular circumstances. In addition, it does not address consequences relevant to holders subject to special rules, including, without limitation:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">banks, insurance companies, and certain other financial institutions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulated investment companies and real estate investment trusts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">brokers, dealers or traders in securities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">traders in securities that elect to mark to market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">tax-exempt&#160;organizations or governmental organizations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">U.S. expatriates and former citizens or long-term residents of the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">persons holding Alpha Tau ordinary shares and/or Alpha Tau warrants, as the case may be, as part of a hedge, straddle, constructive sale, or other risk reduction strategy or as part of a conversion transaction or other integrated investment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">persons subject to special tax accounting rules as a result of any item of gross income with respect to Alpha Tau ordinary shares and/or Alpha Tau warrants, as the case may be, being taken into account in an applicable financial statement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">persons that actually or constructively own 5% or more (by vote or value) of outstanding and issued Alpha Tau stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;controlled foreign corporations,&#8221; &#8220;passive foreign investment companies,&#8221; and corporations that accumulate earnings to avoid U.S. federal income tax;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">S corporations, partnerships or other entities or arrangements treated as partnerships or other flow-through entities for U.S. federal income tax purposes (and investors therein);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">U.S. Holders having a functional currency other than the U.S. dollar;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">156</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">persons who hold or received Alpha Tau ordinary shares and/or Alpha Tau warrants, as the case may be, pursuant to the exercise of any employee stock option or otherwise as compensation; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">tax-qualified&#160;retirement plans.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For purposes of this discussion, a &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">U.S. Holder</span>&#8221; is any beneficial owner of shares of Alpha Tau ordinary shares and/or Alpha Tau warrants, as the case may be, that is for U.S. federal income tax purposes:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an individual who is a citizen or resident of the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a corporation (or other entity taxable as a corporation) created or organized under the laws of the United States, any state thereof, or the District of Columbia;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a trust that (1)&#160;is subject to the primary supervision of a U.S. court and the control of one or more &#8220;United States persons&#8221; (within the meaning of Section&#160;7701(a)(30) of the Code), or (2)&#160;has a valid election in effect to be treated as a &#8220;United States person&#8221; (within the meaning of Section&#160;7701(a)(30) of the Code) for U.S. federal income tax purposes.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If an entity or arrangement treated as a partnership for U.S. federal income tax purposes holds Alpha Tau ordinary shares and/or Alpha Tau warrants, the tax treatment of an owner of such entity will depend on the status of the owners, the activities of the entity or arrangement and certain determinations made at the owner level. Accordingly, entities or arrangements treated as partnerships for U.S. federal income tax purposes and the partners in such partnerships should consult their tax advisors regarding the U.S. federal income tax consequences to them.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Distribution on Alpha Tau ordinary shares</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Subject to the discussion below under &#8220;&#8212; Passive Foreign Investment Company Rules&#8221;, if Alpha Tau makes distributions of cash or property on the Alpha Tau ordinary shares, such distributions will be treated for U.S. federal income tax purposes first as a dividend to the extent of Alpha Tau&#8217;s current and accumulated earnings and profits (as determined for U.S. federal income tax purposes), and then as a&#160;tax-free&#160;return of capital to the extent of the U.S. Holder&#8217;s tax basis, with any excess treated as capital gain from the sale or exchange of the shares. If Alpha Tau does not provide calculations of its earnings and profits under U.S. federal income tax principles, a U.S. Holder should expect all cash distributions to be reported as dividends for U.S. federal income tax purposes. Any dividend will not be eligible for the dividends received deduction allowed to corporations in respect of dividends received from U.S. corporations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Subject to the discussions below under &#8220;&#8212;Passive Foreign Investment Company Rules,&#8221; dividends received by certain&#160;non-corporate&#160;U.S. Holders (including individuals) may be &#8220;qualified dividend income,&#8221; which is taxed at the lower applicable capital gains rate, provided that:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">either (a)&#160;the Alpha Tau ordinary shares are readily tradable on an established securities market in the United States, or (b)&#160;Alpha Tau is eligible for the benefits of a qualifying income tax treaty with the United States that includes an exchange of information program;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Alpha Tau is neither a PFIC (as discussed below under below under &#8220;&#8212;</span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Passive Foreign Investment Company Rules</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) nor treated as such with respect to the U.S. Holder for Alpha Tau&#8217;s in any taxable year in which the dividend is paid or the preceding taxable year;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. Holder satisfies certain holding period requirements; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. Holder is not under an obligation to make related payments with respect to positions in substantially similar or related property.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There can be no assurances that Alpha Tau will be eligible for benefits of an applicable comprehensive income tax treaty between the United States and Israel (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Treaty</span>&#8221;). In addition, there also can be no assurance that Alpha Tau ordinary shares will be considered &#8220;readily tradable&#8221; on an established securities market in the United States in accordance with applicable legal authorities. Furthermore, Alpha Tau will not constitute a &#8220;qualified foreign corporation&#8221; for purposes of these rules if it is a PFIC for the taxable year in which it pays a dividend or for the preceding taxable year. See &#8220;&#8212;<i style="font-style:italic;">Passive Foreign Investment Company Rules.</i>&#8221; U.S. Holders should consult their own tax advisors regarding the availability of the lower rate for dividends paid with respect to Alpha Tau ordinary shares.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">157</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Subject to certain exceptions, dividends on Alpha Tau ordinary shares will constitute foreign source income for foreign tax credit limitation purposes. If such dividends are qualified dividend income (as discussed above), the amount of the dividend taken into account for purposes of calculating the foreign tax credit limitation will be limited to the gross amount of the dividend, multiplied by a fraction, the numerator of which is the reduced rate applicable to qualified dividend income and the denominator of which is the highest rate of tax normally applicable to dividends. The limitation on foreign taxes eligible for credit is calculated separately with respect to specific classes of income. For this purpose, dividends distributed by Alpha Tau with respect to the Alpha Tau ordinary shares generally will constitute &#8220;passive category income&#8221; but could, in the case of certain U.S. Holders, constitute &#8220;general category income.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Sale, Exchange, Redemption or Other Taxable Disposition of Alpha Tau ordinary shares and Alpha Tau Warrants.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Subject to the discussion below under &#8220;&#8212;<i style="font-style:italic;">Passive Foreign Investment Company Rules</i>,&#8221; a U.S. Holder generally will recognize gain or loss on any sale, exchange, redemption or other taxable disposition of Alpha Tau ordinary shares or Alpha Tau warrants in an amount equal to the difference between (i)&#160;the amount realized on the disposition and (ii)&#160;such U.S. Holder&#8217;s adjusted tax basis in such Alpha Tau ordinary shares and/or Alpha Tau warrants. Any gain or loss recognized by a U.S. Holder on a taxable disposition of Alpha Tau ordinary shares or Alpha Tau warrants generally will be capital gain or loss. A&#160;non-corporate&#160;U.S. Holder, including an individual, who has held the Alpha Tau ordinary shares and/or Alpha Tau warrants for more than one year generally will be eligible for reduced tax rates for such long-term capital gains. The deductibility of capital losses is subject to limitations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any such gain or loss recognized generally will be treated as U.S. source gain or loss. Accordingly, in the event any Israeli tax (including withholding tax) is imposed upon such sale or other disposition, a U.S. Holder may not be able to utilize foreign tax credits unless such U.S. Holder has foreign source income or gain in the same category from other sources. Moreover, there are special rules under the Treaty, which may impact a U.S. Holder&#8217;s ability to claim a foreign tax credit. U.S. Holders are urged to consult their own tax advisor regarding the ability to claim a foreign tax credit and the application of the Treaty to such U.S. Holder&#8217;s particular circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Exercise or Lapse of an Alpha Tau Warrant</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Except as discussed below with respect to the cashless exercise of an Alpha Tau warrant, a U.S. Holder generally will not recognize gain or loss upon the acquisition of an Alpha Tau ordinary share on the exercise of an Alpha Tau warrant for cash. A U.S. Holder&#8217;s tax basis in an Alpha Tau ordinary shares received upon exercise of the Alpha Tau warrant generally should be an amount equal to the sum of the U.S. Holder&#8217;s tax basis in the Alpha Tau warrant received therefore and the exercise price. The U.S. Holder&#8217;s holding period for an Alpha Tau ordinary share received upon exercise of the Alpha Tau warrant will begin on the date following the date of exercise (or possibly the date of exercise) of the Alpha Tau warrant and will not include the period during which the U.S. Holder held the Alpha Tau warrant. If an Alpha Tau warrant is allowed to lapse unexercised, a U.S. Holder that has otherwise received no proceeds with respect to such Alpha Tau warrant generally will recognize a capital loss equal to such U.S. Holder&#8217;s tax basis in the Alpha Tau warrant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The tax consequences of a cashless exercise of an Alpha Tau warrant are not clear under current U.S. federal income tax law. A cashless exercise may&#160;be&#160;tax-deferred,&#160;either&#160;because the exercise is not a realization event or because the exercise is treated as a recapitalization for U.S. federal income tax purposes. In either&#160;situation, a U.S. Holder&#8217;s basis in the Alpha Tau ordinary shares received would equal the U.S. Holder&#8217;s basis in the Alpha Tau warrants exercised therefore. If the cashless exercise is not treated as a realization event, a U.S. Holder&#8217;s holding period in the Alpha Tau ordinary shares would be treated as commencing on the date following the date of exercise (or possibly the date of exercise) of the Alpha Tau warrants. If the cashless exercise were treated as a recapitalization, the holding period of the Alpha Tau ordinary shares would include the holding period of the Alpha Tau warrants exercised therefore.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">It is also possible that a cashless exercise of an Alpha Tau warrant could be treated in part as a taxable exchange in which gain or loss would be recognized in the manner set forth above under <i style="font-style:italic;">&#8220;&#8212;Sale, Exchange,&#160;Redemption or Other Taxable Disposition of Alpha Tau ordinary shares and Alpha Tau Warrants</i>.&#8221; In such event, a U.S. Holder could be deemed to have surrendered warrants equal to the number of Alpha Tau ordinary shares having an aggregate fair market value equal to the exercise price for the total number of warrants to be exercised. The U.S. Holder would recognize capital gain or loss in an amount generally equal to the difference between (i)&#160;the fair market value of the Alpha Tau warrants deemed surrendered and (ii)&#160;the U.S. Holder&#8217;s tax basis in such Alpha Tau warrants deemed surrendered. In this case, a U.S. Holder&#8217;s tax basis in the Alpha Tau ordinary shares received would equal the sum of (i)&#160;U.S. Holder&#8217;s tax basis in the Alpha Tau warrants deemed exercised and (ii)&#160;the exercise price of such Alpha Tau warrants. A U.S. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">158</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Holder&#8217;s holding period for the Alpha Tau ordinary shares received in such case generally would commence on the date following the date of exercise (or possibly the date of exercise) of the Alpha Tau warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Due to the absence of authority on the U.S. federal income tax treatment of a cashless exercise of warrants, there can be no assurance which, if any, of the alternative tax consequences and holding periods described above would be adopted by the IRS or a court of law. Accordingly, U.S. Holders should consult their own tax advisors regarding the tax consequences of a cashless exercise of Alpha Tau warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Possible Constructive Distributions</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The terms of each Alpha Tau warrant provide for an adjustment to the number of Alpha Tau ordinary shares for which the Alpha Tau warrant may be exercised or to the exercise price of the Alpha Tau warrant in certain events, as discussed under &#8220;<i style="font-style:italic;">Description of Alpha Tau warrants</i>.&#8221; An adjustment which has the effect of preventing dilution generally is not taxable. A U.S. Holder of an Alpha Tau warrant would, however, be treated as receiving a constructive distribution from Alpha Tau if, for example, the adjustment increases the holder&#8217;s proportionate interest in Alpha Tau&#8217;s assets or earnings and profits (for instance, through an increase in the number of Alpha Tau ordinary shares that would be obtained upon exercise of such warrant) as a result of a distribution of cash or other property such as other securities to the holders of the Alpha Tau ordinary shares which is taxable to the U.S. Holders of such shares as described under &#8220;&#8212;<i style="font-style:italic;">Distributions on Alpha Tau ordinary shares</i>&#8221; above. Such constructive distribution would be subject to tax as described under that section in the same manner as if the U.S. Holder of such Alpha Tau warrant received a cash distribution from Alpha Tau equal to the fair market value of such increase interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Passive Foreign Investment Company Rules</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The treatment of U.S. Holders of the Alpha Tau ordinary shares could be materially different from that described above, if Alpha Tau is treated as a PFIC for U.S. federal income tax purposes. A&#160;non-U.S.&#160;entity treated as a corporation for U.S. federal income tax purposes generally will be a PFIC for U.S. federal income tax purposes for any taxable year if either:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">at least 75% of its gross income for such year is passive income; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">at least 50% of the value of its assets (generally based on an average of the quarterly values of the assets) during such year is attributable to assets that produce passive income or are held for the production of passive income.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For this purpose, Alpha Tau will be treated as owning its proportionate share of the assets and earning its proportionate share of the income of any other entity treated as a corporation for U.S. federal income tax purposes in which Alpha Tau owns, directly or indirectly, 25% or more (by value) of the stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Alpha Tau believes it was not a PFIC in 2021. Based on the current and anticipated composition of the income, assets and operations of Alpha Tau and its subsidiaries, there is a risk Alpha Tau may be treated as a PFIC for future taxable years. However, there can be no assurances in this regard, nor can there be any assurances that Alpha Tau will not be treated as a PFIC in any future taxable year. Moreover, the application of the PFIC rules is subject to uncertainty in several respects, and Alpha Tau can make no assurances that the IRS will not take a contrary position or that a court will not sustain such a challenge by the IRS.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Whether Alpha Tau or any of its subsidiaries is treated as a PFIC is determined on an annual basis. The determination of whether Alpha Tau or any of its subsidiaries is a PFIC is a factual determination that depends on, among other things, the composition of Alpha Tau&#8217;s income and assets, and the market value of its and its subsidiaries&#8217; shares and assets. Changes in the composition of Alpha Tau&#8217;s or any of its subsidiaries&#8217; income or composition of Alpha Tau&#8217;s or any of its subsidiaries&#8217; assets may cause it to be or become a PFIC for the current or subsequent taxable years. Under the PFIC rules, if Alpha Tau were considered a PFIC at any time that a U.S. Holder owns Alpha Tau ordinary shares or Alpha Tau warrants, Alpha Tau would continue to be treated as a PFIC with respect to such investment unless (i)&#160;it ceased to be a PFIC and (ii)&#160;the U.S. Holder made a &#8220;deemed sale&#8221; election under the PFIC rules. If such election is made, a U.S. Holder will be deemed to have sold its Alpha Tau ordinary shares or Alpha Tau warrants at their fair market value on the last day of the last taxable year in which Alpha Tau is classified as a PFIC, and any gain from such deemed sale would be subject to the consequences described below. After the deemed sale election, the Alpha Tau ordinary shares or Alpha Tau warrants with respect to which the deemed sale election was made will not be treated as shares in a PFIC unless Alpha Tau subsequently becomes a PFIC.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">159</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For each taxable year that Alpha Tau is treated as a PFIC with respect to a U.S. Holder&#8217;s Alpha Tau ordinary shares or Alpha Tau warrants, the U.S. Holder will be subject to special tax rules with respect to any &#8220;excess distribution&#8221; (as defined below) received and any gain realized from a sale or disposition (including a pledge) of its Alpha Tau ordinary shares (collectively the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Excess Distribution Rules</span>&#8221;), unless the U.S. Holder makes a valid QEF election or&#160;mark-to-market&#160;election as discussed below. Distributions received by a U.S. Holder in a taxable year that are greater than 125% of the average annual distributions received during the shorter of the three preceding taxable years or the U.S. Holder&#8217;s holding period for the Alpha Tau ordinary shares will be treated as excess distributions. Under these special tax rules:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the excess distribution or gain will be allocated ratably over the U.S. Holder&#8217;s holding period for the Alpha Tau ordinary shares;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the amount allocated to the current taxable year, and any taxable years in the U.S. Holder&#8217;s holding period prior to the first taxable year in which Alpha Tau is a PFIC, will be treated as ordinary income; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the amount allocated to each other taxable year will be subject to the highest tax rate in effect for individuals or corporations, as applicable, for each such year and</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">the interest charge generally applicable to underpayments of tax will be imposed on the resulting tax attributable to each such year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Excess Distribution Rules, the tax liability for amounts allocated to taxable years prior to the year of disposition or excess distribution cannot be offset by any net operating losses, and gains (but not losses) realized on the sale of the Alpha Tau ordinary shares or Alpha Tau warrants cannot be treated as capital gains, even though the U.S. Holder holds the Alpha Tau ordinary shares or Alpha Tau warrants as capital assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Certain of the PFIC rules may impact U.S. Holders with respect to equity interests in subsidiaries and other entities which Alpha Tau may hold, directly or indirectly, that are PFICs (collectively, &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Lower-Tier</span>&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PFICs</span>&#8221;). There can be no assurance, however, that Alpha Tau does not own, or will not in the future acquire, an interest in a subsidiary or other entity that is or would be treated as a Lower-Tier PFIC. U.S. Holders should consult their own tax advisors regarding the application of the PFIC rules to any of Alpha Tau&#8217;s subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If Alpha Tau is a PFIC, a U.S. Holder of Alpha Tau ordinary shares (but not Alpha Tau warrants) may avoid taxation under the Excess Distribution Rules described above by making a &#8220;qualified electing fund&#8221; (&#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">QEF</span>&#8221;) election. However, a U.S. Holder may make a QEF election with respect to its Alpha Tau ordinary shares only if Alpha Tau provides U.S. Holders on an annual basis with certain financial information specified under applicable U.S. Treasury regulations. Alpha Tau will endeavor to provide U.S. Holders with the required information on an annual basis to allow U.S. Holders to make a QEF election with respect to the Alpha Tau ordinary shares in the event Alpha Tau is treated as a PFIC for any taxable year. There can be no assurance, however, that Alpha Tau will timely provide such information for the current year or subsequent years. The failure to provide such information on an annual basis could prevent a U.S. Holder from making a QEF election or result in the invalidation or termination of a U.S. Holder&#8217;s prior QEF election. In addition, U.S. Holders of Alpha Tau warrants will not be able to make a QEF election with respect to their warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event Alpha Tau is a PFIC, a U.S. Holder that makes a QEF election with respect to its Alpha Tau ordinary shares would generally be required to include in income for each year that Alpha Tau is treated as a PFIC the U.S. Holder&#8217;s pro rata share of Alpha Tau&#8217;s ordinary earnings for the year (which would be subject to tax as ordinary income) and net capital gains for the year (which would be subject to tax at the rates applicable to long-term capital gains), without regard to the amount of any distributions made in respect of the Alpha Tau ordinary shares. Any net deficits or net capital losses of Alpha Tau for a taxable year would not be passed through and included on the tax return of the U.S. Holder, however. A U.S. Holder&#8217;s basis in the Alpha Tau ordinary shares would be increased by the amount of income inclusions under the qualified electing fund rules. Dividends actually paid on the Alpha Tau ordinary shares generally would not be subject to U.S. federal income tax to the extent of prior income inclusions and would reduce the U.S. Holder&#8217;s basis in the Alpha Tau ordinary shares by a corresponding amount.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If Alpha Tau owns any interests in a Lower-Tier PFIC, a U.S. Holder generally must make a separate QEF election for each Lower-Tier PFIC, subject to Alpha Tau&#8217;s providing the relevant tax information for each Lower-Tier PFIC on an annual basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">If a U.S. Holder does not make a QEF election (or a&#160;mark-to-market&#160;election, as discussed below) effective from the first taxable year of a U.S. Holder&#8217;s holding period for the Alpha Tau ordinary shares in which Alpha Tau is a PFIC, then the Alpha Tau ordinary shares will generally continue to be treated as an interest in a PFIC, and the U.S. Holder generally will remain subject to the Excess Distribution Rules. A U.S. Holder that first makes a QEF election in a later year may avoid the continued application of the Excess </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">160</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Distribution Rules to its Alpha Tau ordinary shares by making a &#8220;deemed sale&#8221; election. In that case, the U.S. Holder will be deemed to have sold the Alpha Tau ordinary shares at their fair market value on the first day of the taxable year in which the QEF election becomes effective, and any gain from such deemed sale would be subject to the Excess Distribution Rules described above. A U.S. Holder that is eligible to make a QEF election with respect to its Alpha Tau ordinary shares generally may do so by providing the appropriate information to the IRS in the U.S. Holder&#8217;s timely filed tax return for the year in which the election becomes effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">U.S. Holders should consult their own tax advisors as to the availability and desirability of a QEF election.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Alternatively, a U.S. Holder of &#8220;marketable stock&#8221; (as defined below) may make a&#160;mark-to-market&#160;election for its Alpha Tau ordinary shares to elect out of the Excess Distribution Rules discussed above if Alpha Tau is treated as a PFIC. If a U.S. Holder makes a&#160;mark-to-market&#160;election with respect to its Alpha Tau ordinary shares, such U.S. Holder will include in income for each year that Alpha Tau is treated as a PFIC with respect to such Alpha Tau ordinary shares an amount equal to the excess, if any, of the fair market value of the Alpha Tau ordinary shares as of the close of the U.S. Holder&#8217;s taxable year over the adjusted basis in the Alpha Tau ordinary shares. A U.S. Holder will be allowed a deduction for the excess, if any, of the adjusted basis of the Alpha Tau ordinary shares over their fair market value as of the close of the taxable year. However, deductions will be allowed only to the extent of any net&#160;mark-to-market&#160;gains on the Alpha Tau ordinary shares included in the U.S. Holder&#8217;s income for prior taxable years. Amounts included in income under a&#160;mark-to-market&#160;election, as well as gain on the actual sale or other disposition of the Alpha Tau ordinary shares, will be treated as ordinary income. Ordinary loss treatment will also apply to the deductible portion of any&#160;mark-to-market&#160;loss on the Alpha Tau ordinary shares, as well as to any loss realized on the actual sale or disposition of the Alpha Tau ordinary shares, to the extent the amount of such loss does not exceed the net&#160;mark-to-market&#160;gains for such Alpha Tau ordinary shares previously included in income. A U.S. Holder&#8217;s basis in the Alpha Tau ordinary shares will be adjusted to reflect any&#160;mark-to-market&#160;income or loss. If a U.S. Holder makes a&#160;mark-to-market&#160;election, any distributions Alpha Tau makes would generally be subject to the rules discussed above under &#8220;<i style="font-style:italic;">&#160;&#8212;Distributions on Alpha Tau</i>&#160;<i style="font-style:italic;">ordinary shares</i>,&#8221; except the lower rates applicable to qualified dividend income would not apply. U.S. Holders of Alpha Tau warrants will not be able to make&#160;a&#160;mark-to-market&#160;election&#160;with respect to their Alpha Tau warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The&#160;mark-to-market&#160;election is available only for &#8220;marketable stock,&#8221; which is stock that is regularly traded on a qualified exchange or other market, as defined in applicable U.S. Treasury regulations. The Alpha Tau ordinary shares, which are expected to be listed on Nasdaq, are expected to qualify as marketable stock for purposes of the PFIC rules, but there can be no assurance that Alpha Tau ordinary shares will be &#8220;regularly traded&#8221; for purposes of these rules. Because a&#160;mark-to-market&#160;election cannot be made for equity interests in any Lower-Tier PFICs, a U.S. Holder that does not make the applicable QEF elections generally will continue to be subject to the Excess Distribution Rules with respect to its indirect interest in any Lower-Tier PFICs as described above, even if a&#160;mark-to-market&#160;election is made for Alpha Tau.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If a U.S. Holder does not make a&#160;mark-to-market&#160;election (or a QEF election, as discussed above) effective from the first taxable year of a U.S. Holder&#8217;s holding period for the Alpha Tau ordinary shares in which Alpha Tau is a PFIC, then the U.S. Holder generally will remain subject to the Excess Distribution Rules. A U.S. Holder that first makes a&#160;mark-to-market&#160;election with respect to the Alpha Tau ordinary shares in a later year will continue to be subject to the Excess Distribution Rules during the taxable year for which the&#160;mark-to-market&#160;election becomes effective, including with respect to any&#160;mark-to-market&#160;gain recognized at the end of that year. In subsequent years for which a valid&#160;mark-to-mark&#160;election remains in effect, the Excess Distribution Rules generally will not apply. A U.S. Holder that is eligible to make a&#160;mark-to-market&#160;with respect to its Alpha Tau ordinary shares may do so by providing the appropriate information on IRS Form 8621 and timely filing that form with the U.S. Holder&#8217;s tax return for the year in which the election becomes effective. U.S. Holders should consult their own tax advisors as to the availability and desirability of a&#160;mark-to-market&#160;election, as well as the impact of such election on interests in any Lower-Tier PFICs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A U.S. Holder of a PFIC may be required to file an IRS Form 8621 on an annual basis. U.S. Holders should consult their own tax advisors regarding any reporting requirements that may apply to them if Alpha Tau is a PFIC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">U.S. Holders are strongly encouraged to consult their tax advisors regarding the application of the PFIC rules to their particular circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Information Reporting and Backup Withholding</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Information reporting requirements may apply to dividends received by U.S. Holders of Alpha Tau ordinary shares and the proceeds received on sale or other taxable the disposition of Alpha Tau ordinary shares or Alpha Tau warrants effected within the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">161</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">United States (and, in certain cases, outside the United States), in each case other than U.S. Holders that are exempt recipients (such as corporations). Backup withholding (currently at a rate of 24%) may apply to such amounts if the U.S. Holder fails to provide an accurate taxpayer identification number (generally on an IRS Form&#160;W-9&#160;provided to the paying agent of the U.S. Holder&#8217;s broker) or is otherwise subject to backup withholding. U.S. Holders should consult their own tax advisors regarding the application of the U.S. information reporting and backup withholding rules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Backup withholding is not an additional tax. Amounts withheld as backup withholding generally may be credited against the taxpayer&#8217;s U.S. federal income tax liability, and a taxpayer may obtain a refund of any excess amounts withheld under the backup withholding rules by timely filing the appropriate claim for a refund with the IRS and furnishing any required information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Foreign asset reporting</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Certain U.S. Holders are required to report their holdings of certain foreign financial assets, including equity of foreign entities, if the aggregate value of all of these assets exceeds certain threshold amounts, by filing IRS Form 8938 with their federal income tax return. Alpha Tau ordinary shares and Alpha Tau warrants are expected to constitute foreign financial assets subject to these requirements unless they are held in an account at certain financial institutions. U.S. Holders are urged to consult their tax advisors regarding their information reporting obligations, if any, with respect to their ownership and disposition of Alpha Tau ordinary shares and/or Alpha Tau warrants and the significant penalties for&#160;non-compliance.</p><a id="FDividendsandPayingAgents_415202"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">F.</b></span><b style="font-weight:bold;">Dividends and Paying Agents</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Not applicable.</p><a id="GStatementbyExperts_32755"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">G.</b></span><b style="font-weight:bold;">Statement by Experts</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 18pt;">Not applicable.</p><a id="HDocumentsonDisplay_973841"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">H.</b></span><b style="font-weight:bold;">Documents on Display</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are subject to the informational requirements of the Exchange Act. Accordingly, we are required to file reports and other information with the SEC, including annual reports on Form&#160;20-F and reports on Form&#160;6-K. Our filings with the SEC are also available to the public through the SEC&#8217;s website at http://www.sec.gov. This site contains reports and other information about issuers, like us, that file electronically with the SEC. The address of that website is <span style="color:#0000ff;text-decoration-color:#0000ff;text-decoration-line:underline;text-decoration-style:solid;">www.sec.gov</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a foreign private issuer, we are exempt under the Exchange Act from, among other things, the rules&#160;prescribing the furnishing and content of proxy statements, and our officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section&#160;16 of the Exchange Act. In addition, we will not be required under the Exchange Act to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act. However, we will file with the SEC, within 120&#160;days after the end of each subsequent fiscal&#160;year, or such applicable time as required by the SEC, an annual report on Form&#160;20-F containing financial statements audited by an independent registered public accounting firm. We also intend to furnish certain other material information to the SEC under cover of Form&#160;6-K.</p><a id="ISubsidiaryInformation_317881"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">I.</b></span><b style="font-weight:bold;">Subsidiary Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_b3599e5f_cba9_430d_8c9e_1751c2321373"></a><a id="Item11QuantitativeandQualitativeDisclosu"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;11. Quantitative and Qualitative Disclosures about Market Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are exposed to market risk in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily a result of foreign currency exchange rates and interest rates, which are discussed in detail below.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">162</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Foreign currency risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our financial results are reported in U.S. dollars, changes in exchange rate between the USD and local currencies in those countries in which we operate (primarily the ILS) may affect the results of our operations. The USD cost of our operations in countries other than the United States, is negatively influenced by revaluation of the USD against other currencies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During 2021, the value of the U.S. dollar devaluated against the ILS by approximately 3.3%. Our most significant foreign currency exposures are related to our operations in Israel.</p><a id="_73b6c155_626c_4d2e_9653_8f811e895947"></a><a id="Item12DescriptionofSecuritiesOtherthanEq"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;12. Description of Securities Other than Equity Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">163</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_2b3e6536_b22d_465a_b179_4f804c1fb3b7"></a><a id="PARTII_403707"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;II</p><a id="Item13DefaultsDividendArrearagesandDelin"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;13. Defaults, Dividend Arrearages and Delinquencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_b8a4e49f_fd55_4348_b816_f65d3e6f2c3c"></a><a id="Item14MaterialModificationstotheRightsof"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;14. Material Modifications to the Rights of Security Holders and Use of Proceeds</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_7ceaa50c_5726_4816_a4cc_a94d9dfc2b08"></a><a id="Item15ControlsandProcedures_26969"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;15. Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Evaluation of Disclosure Controls and Procedures</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We maintain disclosure controls and procedures (as that term is defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Securities Exchange Act of 1934, as amended (&#8220;Exchange Act&#8221;)) that are designed to ensure that information required to be disclosed in the Company&#8217;s reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules&#160;and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures. Any controls and procedures, no matter how well-designed and operated, can provide only reasonable assurance of achieving the desired control objectives. Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of December&#160;31, 2021. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of December&#160;31, 2021, our disclosure controls and procedures were effective to accomplish their objectives at the reasonable assurance level.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Management&#8217;s Annual Report on Internal Control over Financial Reporting and Attestation Report of the Registered Public Accounting Firm</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This Annual Report does not include a report of management&#8217;s assessment regarding internal control over financial reporting (as such term is defined in Rules&#160;13a-15(f)&#160;and 15d-15(f)&#160;<span style="white-space:pre-wrap;">under the Securities Exchange Act) or an attestation report of the company&#8217;s registered public accounting firm due to a transition period established by SEC guidance relating to transactions involving special purpose acquisition companies.  Additionally, our independent registered public accounting firm will not be required to opine on the effectiveness of our internal control over financial reporting until we are no longer an emerging growth company</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes in Internal Control over Financial Reporting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There were no changes in our internal controls over financial reporting (as such term is defined in Rules&#160;13a-15(f)&#160;and 15d-15(f)&#160;under the Securities Exchange Act) that occurred during the period covered by this Annual Report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><a id="_c90ea386_45da_4a65_9ee1_85820577dec8"></a><a id="Item16Reserved_405629"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;16. [Reserved]</b></p><a id="_a123b1b0_1761_4a4e_ae51_21d253f517e7"></a><a id="Item16AAuditCommitteeFinancialExpert_491"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;16A. Audit Committee Financial Expert</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our board of directors has determined that each of Michael Avruch and Gary Leibler is an audit committee financial expert as defined by the SEC rules&#160;and has the requisite financial experience as defined by the listing rules&#160;of Nasdaq.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our board of directors has determined that each member of our audit committee is &#8220;independent&#8221; as such term is defined in Rule&#160;10A-3(b)(1)&#160;under the Exchange Act, which is different from the general test for independence of board and committee members.</p><a id="_0c151bc1_200e_4590_9ff8_ce0eca713313"></a><a id="Item16BCodeofEthics_67423"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;16B. Code of Ethics</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We have adopted a Code of Business Conduct and Ethics that applies to all our employees, officers and directors. Our Code of Business Conduct and Ethics addresses, among other things, competition and fair dealing, gifts and entertainment, conflicts of interest, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">164</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">international business laws, financial matters and external reporting, company assets, confidentiality and corporate opportunity requirements and the process for reporting violations of the Code of Business Conduct and Ethics. Our Code of Business Conduct and Ethics is intended to meet the definition of &#8220;code of ethics&#8221; under Item&#160;16B. of Form&#160;20-F under the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We will disclose on our website any amendment to, or waiver from, a provision of our Code of Business Conduct and Ethics that applies to our directors or executive officers to the extent required under the rules&#160;of the SEC or Nasdaq. Our Code of Business Conduct and Ethics is available on our website at https://www.alphatau.com/corporate-governance. The information contained on or through our website, or any other website referred to herein, is not incorporated by reference in this Annual Report. We granted no waivers under our Code of Business Conduct and Ethics.</p><a id="_ee842317_c777_4a31_902f_5eccac0d3fe4"></a><a id="Item16CPrincipalAccountingFeesandService"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;16C. Principal Accounting Fees and Services</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements of Alpha Tau Medical&#160;Ltd. at December&#160;31, 2020 and 2021, and for each of the two&#160;years in the period ended December&#160;31, 2021, appearing in this Annual Report have been audited <span style="color:#231f20;">Kost, Forer, Gabbay&#160;&amp; Kasierer, a member of Ernst&#160;&amp; Young Global, independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. The current address of Kost, Forer, Gabbay&#160;&amp; Kasierer is 144 Menachem Begin Road, Building A, Tel Aviv 6492102, Israel.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The table below sets out the total amount of services rendered to us by <span style="color:#231f20;">Kost, Forer, Gabbay&#160;&amp; Kasierer, a member of Ernst&#160;&amp; Young Global</span>, for services performed in the&#160;years ended December&#160;31, 2020 and 2021, and breaks down these amounts by category of service:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;2020&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(in&#160;thousands)</p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Audit Fees</p></td><td style="vertical-align:bottom;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 20</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 160</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Audit Related Fees</p></td><td style="vertical-align:bottom;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 80</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax Fees</p></td><td style="vertical-align:bottom;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 33</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 26</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 53</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 266</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Audit Fees</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Audit fees for the&#160;years ended December&#160;31, 2021 and 2020 include fees for the audit of our annual financial statements. This category also includes services that the independent accountant generally provides, such as consents and assistance with and review of documents filed with the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Audit Related Fees</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Audit related fees for the&#160;year ended December&#160;31, 2021 relate to services in connection with the Business Combination which we consummated on March&#160;7, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Tax Fees</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Tax fees for the&#160;years ended December&#160;31, 2021 and 2020 were related to ongoing tax and grant-related advisory, tax compliance and tax planning services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">All Other Fees</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All other fees in the&#160;years ended December&#160;31, 2021 and 2020 related to services in connection with non-audit compliance and review work.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Pre-Approval Policies and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The advance approval of the Audit Committee or members thereof, to whom approval authority has been delegated, is required for all audit and non-audit services provided by our auditors.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">165</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All services provided by our auditors are approved in advance by either the Audit Committee or members thereof, to whom authority has been delegated, in accordance with the Audit Committee&#8217;s pre-approval policy.</p><a id="_0ac74f79_d0f0_40fd_87bf_bc26cada2980"></a><a id="Item16DExemptionsfromtheListingStandards"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;16D. Exemptions from the Listing Standards for Audit Committees</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_29c9e90e_fa80_4859_9fc1_60362fd7818f"></a><a id="Item16EPurchasesofEquitySecuritiesbytheI"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;16E. Purchases of Equity Securities by the Issuer and Affiliated Purchasers</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_87e2c65a_8df9_4a80_8c7d_ef4eb7652667"></a><a id="Item16FChangeinRegistrantsCertifyingAcco"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;16F. Change in Registrant&#8217;s Certifying Accountant</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_e5a6d875_972e_4881_a2fd_b54ba464d742"></a><a id="Item16GCorporateGovernance_106647"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;16G. Corporate Governance</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As an Israeli company, we are subject to various corporate governance requirements under the Companies Law, relating to matters such as external directors, the audit committee, the compensation committee and an internal auditor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are a &#8220;foreign private issuer&#8221;, as such term is defined in Rule&#160;405 under the Securities Act. As a foreign private issuer we will be permitted to comply with Israeli corporate governance practices instead of the certain listing rules&#160;of Nasdaq, provided that we disclose which requirements we are not following and the equivalent Israeli requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We intend to rely on this &#8220;foreign private issuer exemption&#8221; with respect to the quorum requirement for shareholder meetings and with respect to Nasdaq shareholder approval rules. Whereas under the corporate governance rules&#160;of Nasdaq, a quorum requires the presence, in person or by proxy, of holders of at least 33 1/3% of the total issued and outstanding voting power of our shares at each general meeting of shareholders, pursuant to the Articles, and as permitted under the Companies Law, the quorum required for a general meeting of shareholders will consist of at least two shareholders present in person or by proxy in accordance with the Companies Law who hold or represent at least 33 1/3% of the total outstanding voting power of our shares, except if (i)&#160;any such general meeting of shareholders was initiated by and convened pursuant to a resolution adopted by the board of directors and (ii)&#160;at the time of such general meeting, we qualify as a &#8220;foreign private issuer,&#8221; then in such case, the requisite quorum will consist of two or more shareholders present in person or by proxy who hold or represent at least 25% of the total outstanding voting power of our shares (and if the meeting is adjourned for a lack of quorum, the quorum for such adjourned meeting will be, subject to certain exceptions, any number of shareholders). We otherwise intend to comply with the rules&#160;generally applicable to U.S. domestic companies listed on the Nasdaq. We may, however, in the future decide to rely upon the &#8220;foreign private issuer exemption&#8221; for purposes of opting out of some or all of the other Nasdaq listing rules.</p><a id="_cc229302_4348_474e_8112_22b4eb151beb"></a><a id="Item16HMineSafetyDisclosure_75226"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;16H. Mine Safety Disclosure</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_9de58eb4_d8d0_4ec1_aa00_284de13523b7"></a><a id="Item16IDisclosureRegardingForeignJurisdi"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;16I. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">166</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_36cc58d7_670e_443e_b75c_5e8ce0f1c6a1"></a><a id="PARTIII_842629"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;III</p><a id="Item17FinancialStatements_223831"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;17. Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have provided financial statements pursuant to Item&#160;18.</p><a id="_b12991da_61fe_4ad0_8477_99a4302659cb"></a><a id="Item18FinancialStatements_431468"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;18. Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The audited consolidated financial statements as required under Item&#160;18 are attached hereto starting on page&#160;F-1 of this Annual Report. The audit report of <span style="color:#231f20;">Kost, Forer, Gabbay&#160;&amp; Kasierer, a member of Ernst&#160;&amp; Young Global</span>, an independent registered public accounting firm, is included herein preceding the audited consolidated financial statements.</p><a id="_6f631cb8_c80f_4e6a_be1d_ff3a83848cb6"></a><a id="Item19Exhibits_69009"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;19.</b> <b style="font-weight:bold;">Exhibits</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">List all exhibits filed as part of the registration statement or annual report, including exhibits incorporated by reference.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:14.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:34.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:14.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:34.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th colspan="9" style="font-weight:normal;text-align:left;vertical-align:bottom;width:48.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporation by Reference</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:14.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:10pt;margin:0pt;"><b style="font-weight:bold;">Exhibit No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:34.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:14.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing Date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed /</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Furnished</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:14.87%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:34.87%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.87%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.86%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:5.87%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:14.87%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">1.1</p></td><td style="vertical-align:top;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="drts-20211231xex1d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Articles of Association of Alpha Tau Medical Ltd.</span></a></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">*</p></td></tr><tr><td style="vertical-align:top;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">2.1</p></td><td style="vertical-align:top;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="drts-20211231xex2d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of Securities.</span></a></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">*</p></td></tr><tr><td style="vertical-align:top;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">4.1&#8224;&#8224;</p></td><td style="vertical-align:top;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1871321/000119312521345535/d199994dex1010.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Director and Officer Indemnification Agreement.</span></a></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">F-4</p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">333-258915</p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">10.10</p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">December 1, 2021</p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">4.2&#8224;&#8224;</p></td><td style="vertical-align:top;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1871321/000119312521345535/d199994dex1011.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Compensation Policy for Directors and Officers.</span></a></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">F-4</p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">333-258915</p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">10.11</p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">December 1, 2021</p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">4.3&#8224;&#8224;</p></td><td style="vertical-align:top;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1871321/000119312521250728/d199994dex107.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2016 Share Incentive Plan of Alpha Tau Medical Ltd.</span></a></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">F-4</p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">333-258915</p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">10.7</p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">August 18, 2021</p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">4.4&#8224;&#8224;</p></td><td style="vertical-align:top;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1871321/000119312521345535/d199994dex108.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2021 Share Incentive Plan of Alpha Tau Medical Ltd.</span></a></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">F-4</p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">333-258915</p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">10.8</p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">December 1, 2021</p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">4.5&#8224;&#8224;</p></td><td style="vertical-align:bottom;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:34.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1871321/000119312521345535/d199994dex109.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2021 Employee Share Purchase Plan of Alpha Tau Medical</span></a></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">F-4</p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">333-258915</p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">10.9</p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;">December  1, 2021</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">4.6</p></td><td style="vertical-align:bottom;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:34.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1871321/000119312521300521/d199994dex103.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Sponsor Letter Agreement, dated as of July&#160; 7, 2021, by and among Healthcare Capital Sponsor LLC, Healthcare Capital Corp., Alpha Tau Medical Ltd. and the investors named on the signature pages thereto..</span></a></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">F-4</p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">333-258915</p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">10.3</p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">October 18, 2021</p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">4.7</p></td><td style="vertical-align:bottom;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1871321/000119312521300521/d199994dex104.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;white-space:pre-wrap;">Support Agreement, dated as of July  7, 2021, by and among Alpha Tau Medical Ltd., Healthcare Capital Corp., and the shareholders of Alpha Tau Medical Ltd. named on the signature pages thereto.</span></a></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">F-4</p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">333-258915</p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">10.4</p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">October 18, 2021</p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">4.8</p></td><td style="vertical-align:bottom;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="drts-20211231xex4d8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Sponsor Support Agreement, dated as of February 17, 2022, by and among Healthcare Capital Sponsor LLC, Healthcare Capital Corp., Alpha Tau Medical Ltd. and the individuals named on the signature pages thereto.</span></a></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">*</p></td></tr><tr><td style="vertical-align:top;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">167</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:13.8pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:14.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:34.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:14.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:34.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th colspan="9" style="font-weight:normal;text-align:left;vertical-align:bottom;width:48.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporation by Reference</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:14.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:10pt;margin:0pt;"><b style="font-weight:bold;">Exhibit No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:34.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:14.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing Date</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed /</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Furnished</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:14.87%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:34.87%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.87%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.86%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:5.87%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:14.87%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">4.9</p></td><td style="vertical-align:bottom;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:34.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="drts-20211231xex4d9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Warrant Agreement, dated as of March 7, 2022, between, Alpha Tau Medical, Continental Stock Transfer&#160; &amp; Trust Company and Healthcare Capital Corporation.</span></a></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">*</p></td></tr><tr><td style="vertical-align:top;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">4.10</p></td><td style="vertical-align:bottom;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:34.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1871321/000119312521345535/d199994dex48.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Investor Rights Agreement dated as of July 7, 2021 by and among Alpha Tau Medical Ltd. and certain shareholders of Alpha Tau Medical Ltd.</span></a></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">F-4</p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">333-258915</p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">August 18, 2021</p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">8.1</p></td><td style="vertical-align:bottom;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:34.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="drts-20211231xex8d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">List of Subsidiaries.</span></a></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">*</p></td></tr><tr><td style="vertical-align:top;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">12.1</p></td><td style="vertical-align:bottom;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:34.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="drts-20211231xex12d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Principal Executive Officer Certification Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">*</p></td></tr><tr><td style="vertical-align:top;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">12.2</p></td><td style="vertical-align:bottom;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:34.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="drts-20211231xex12d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Principal Financial Officer Certification Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">*</p></td></tr><tr><td style="vertical-align:top;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">13.1</p></td><td style="vertical-align:bottom;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:34.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="drts-20211231xex13d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Principal Executive Officer Certification Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">**</p></td></tr><tr><td style="vertical-align:top;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">13.2</p></td><td style="vertical-align:bottom;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:34.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="drts-20211231xex13d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Principal Financial Officer Certification Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">**</p></td></tr><tr><td style="vertical-align:top;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:top;width:84.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">101.INS</p></td><td style="vertical-align:bottom;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="10" style="vertical-align:top;width:76.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">Inline XBRL Instance Document.</p></td><td style="vertical-align:top;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">*</p></td></tr><tr><td style="vertical-align:top;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:top;width:84.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">101.SCH</p></td><td style="vertical-align:bottom;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="10" style="vertical-align:top;width:76.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Schema Document.</p></td><td style="vertical-align:top;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">*</p></td></tr><tr><td style="vertical-align:top;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:top;width:84.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">101.CAL</p></td><td style="vertical-align:bottom;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="10" style="vertical-align:top;width:76.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</p></td><td style="vertical-align:top;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">*</p></td></tr><tr><td style="vertical-align:top;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:top;width:84.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">101.DEF</p></td><td style="vertical-align:bottom;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="10" style="vertical-align:top;width:76.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">Inline XBRL Taxonomy Definition Linkbase Document.</p></td><td style="vertical-align:top;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">*</p></td></tr><tr><td style="vertical-align:top;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:top;width:84.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">101.LAB</p></td><td style="vertical-align:bottom;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="10" style="vertical-align:top;width:76.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Label Linkbase Document.</p></td><td style="vertical-align:top;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">*</p></td></tr><tr><td style="vertical-align:top;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:top;width:84.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">101.PRE</p></td><td style="vertical-align:bottom;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="10" style="vertical-align:top;width:76.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</p></td><td style="vertical-align:top;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;">*</p></td></tr><tr><td style="vertical-align:top;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:top;width:84.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:top;width:84.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:10pt;margin:0pt;"><span style="font-size:10pt;">Inline XBRL for the cover page of this Annual Report on Form 20-F</span>(embedded within the Inline XBRL document)</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Filed herewith.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">**</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Furnished herewith.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">&#8224;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Schedules and exhibits to this Exhibit&#160;omitted pursuant to Instructions as to Exhibits to Form&#160;20-F. The Registrant agrees to furnish supplementally a copy of any omitted schedule or exhibit to the SEC upon request.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">&#8224;&#8224;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Indicates management contract or compensatory plan or arrangement.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">Certain agreements filed as exhibits to this Annual Report contain representations and warranties that the parties thereto made to each other. These representations and warranties have been made solely for the benefit of the other parties to such agreements and may have been qualified by certain information that has been disclosed to the other parties to such agreements and that may not be reflected in such agreements. In addition, these representations and warranties may be intended as a way of allocating risks among parties if the statements contained therein prove to be incorrect, rather than as actual statements of fact. Accordingly, there can be no </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">168</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 2pt;">reliance on any such representations and warranties as characterizations of the actual state of facts. Moreover, information concerning the subject matter of any such representations and warranties may have changed since the date of such agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">169</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d66a8be8_f313_4076_8fb6_f4fa57144552"></a><a id="SIGNATURES_313991"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The registrant hereby certifies that it meets all of the requirements for filing on Form&#160;20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ALPHA TAU MEDICAL&#160;LTD.</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:4.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:41.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March 28, 2022</p></td><td style="vertical-align:bottom;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:41.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Uzi Sofer</p></td></tr><tr><td style="vertical-align:bottom;width:53.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:41.35%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Uzi Sofer</p></td></tr><tr><td style="vertical-align:bottom;width:53.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:41.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td></tr><tr><td style="vertical-align:bottom;width:53.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:41.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">170</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_11231f63_1664_4594_8263_7eb363fc84c3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">ALPHA TAU MEDICAL&#160;LTD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">AS OF DECEMBER&#160;31, 2021</p><a id="INDEX_160743"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">INDEX</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:88.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:11.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:88.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:bottom;width:88.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.7pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.58%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:88.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.7pt;margin:0pt;"><a href="#REPORTOFINDEPENDENTAUDITORS_992763"><b style="font-style:normal;font-weight:bold;">Reports of Independent Registered Public Accounting Firm</b></a><b style="font-weight:bold;"> (PCAOB ID: </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="dei:AuditorFirmId" id="Narr_pmulj8W3_k6MzZgAt8z05Q"><b style="font-weight:bold;">1281</b></ix:nonNumeric><b style="font-weight:bold;">)</b></p></td><td style="vertical-align:bottom;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">F-</b><span style="font-weight:bold;">2</span></p></td></tr><tr><td style="vertical-align:bottom;width:88.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.7pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:88.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.7pt;margin:0pt;"><a href="#CONSOLIDATEDBALANCESHEETS_931922"><b style="font-style:normal;font-weight:bold;">Consolidated Balance Sheets</b></a></p></td><td style="vertical-align:bottom;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">F-</b><span style="font-weight:bold;">3</span><b style="font-weight:bold;"> - F-</b><span style="font-weight:bold;">3</span></p></td></tr><tr><td style="vertical-align:bottom;width:88.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.7pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:88.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.7pt;margin:0pt;"><a href="#CONSOLIDATEDSTATEMENTSOFOPERATIONS_54585"><b style="font-style:normal;font-weight:bold;">Consolidated Statements of Operations</b></a></p></td><td style="vertical-align:bottom;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">F-</b><span style="font-weight:bold;">5</span></p></td></tr><tr><td style="vertical-align:bottom;width:88.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.7pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:88.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:11.35pt;text-indent:-11.35pt;margin:0pt;"><a href="#CONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFE"><b style="font-style:normal;font-weight:bold;">Consolidated Statements of Convertible Preferred Shares and Shareholders&#8217; Deficiency</b></a></p></td><td style="vertical-align:bottom;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">F-</b><span style="font-weight:bold;">6</span></p></td></tr><tr><td style="vertical-align:bottom;width:88.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.7pt;margin:0pt;"><span style="direction:rtl;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:88.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.7pt;margin:0pt;"><a href="#CONSOLIDATEDSTATEMENTSOFCASHFLOWS_636405"><b style="font-style:normal;font-weight:bold;">Consolidated Statements of Cash Flows</b></a></p></td><td style="vertical-align:bottom;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">F-</b><span style="font-weight:bold;">7</span></p></td></tr><tr><td style="vertical-align:bottom;width:88.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.7pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:88.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0.7pt;margin:0pt;"><a href="#NOTE1GENERAL_632360"><b style="font-style:normal;font-weight:bold;">Notes&#160;to Consolidated Financial Statements</b></a></p></td><td style="vertical-align:bottom;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">F-</b><span style="font-weight:bold;">8</span><b style="font-weight:bold;"> - F-</b><span style="font-weight:bold;">32</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="direction:rtl;font-weight:bold;">-&#160;-&#160;-&#160;-&#160;-&#160;-&#160;-&#160;-&#160;-&#160;-&#160;-&#160;-&#160;-&#160;-&#160;-&#160;-&#160;-&#160;-&#160;-</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:81.03pt;"><a id="_a6accebd_5793_4d91_921f_e54c601228e9"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:84.7pt;"><td style="vertical-align:top;width:16.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <img src="drts-20211231x20f046.jpg" alt="Graphic" style="display:inline-block;height:80.98pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:70.49pt;" /></p></td><td style="vertical-align:bottom;width:26.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="color:#666666;font-weight:bold;">Kost Forer Gabbay&#160;&amp; Kasierer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#666666;">144A Menachem Begin Road</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#666666;">Tel-Aviv 6492102, Israel</span></p></td><td style="vertical-align:bottom;width:56.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#666666;">Tel: +972-3-6232525</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#666666;">Fax: +972-3-5622555</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#666666;">ey.com</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="REPORTOFINDEPENDENTAUDITORS_992763"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">REPORT OF INDEPENDENT AUDITORS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">To the Shareholders&#8217; and Board of Directors of</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">ALPHA TAU MEDICAL&#160;LTD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Opinion on the Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have audited the accompanying consolidated balance sheets of Alpha Tau Medical&#160;Ltd. (the &#8220;Company&#8221;) as of December&#160;31, 2020 and 2021, the related consolidated statements of operations, convertible preferred shares and shareholders&#8217; deficiency and cash flows for each of the three&#160;years in the period ended December&#160;31, 2021 and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2020 and 2021, and the results of its operations and its cash flows for each of the three&#160;years in the period ended December&#160;31, 2021, in conformity with U.S. generally accepted accounting principles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Basis for Opinion</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules&#160;and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.</p><div style="padding-left:18pt;"><a id="_c33e53b5_cb4f_471b_8529_659409ba3e41"></a><a id="Tc_jFieFYLDm0eSoRRt0xNFXw_1_0"></a><a id="Tc_7vUZZM3Z9E6eYYgC2p02ig_2_0"></a><a id="Tc_A_0mBnFsyk6kCNxXCd2bSw_3_0"></a><a id="Tc_uhc5ke77IEmwqNQcafv_QA_5_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="dei:AuditorName" id="Narr_CAxMvmoA30i3li56ez09nQ">KOST FORER GABBAY&#160;&amp; KASIERER</ix:nonNumeric></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">A Member of Ernst&#160;&amp; Young Global</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have served as the Company&#8217;s auditor since 2016.</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="dei:AuditorLocation" id="Tc__JU6wYcJaEKwqBY_33hTKg_4_0">Tel-Aviv, Israel</ix:nonNumeric></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March&#160;28, 2022</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="text-transform:uppercase;">f-</span><span style="text-transform:uppercase;">2</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e7ec96f3_5123_48b5_be0c_e48a0ea66956"></a><a id="BalanceSheets_End"></a><a id="CONSOLIDATEDBALANCESHEETS_931922"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:1pt;border-bottom:1.5pt solid #000000;margin:0pt;">CONSOLIDATED BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">U.S.&#160;dollars in thousands (except share and per share data)</p><a id="_307e5081_548b_4d09_b838_b0b16852ea72"></a><a id="Tc_cPjJGcdTbUWvJexOIm-5bg_1_4"></a><a id="Tc_-DdDG6kRrUOIowXtqe6kUA_2_2"></a><a id="Tc_3TcaJncBJ0yNWcss1MAYyQ_2_4"></a><a id="Tc_h6uq86T1xkqHNHgQFaEMBQ_2_7"></a><a id="Tc_UxovqBAAX06dcEoDy-SytA_3_0"></a><a id="Tc_7_O8AuuxOUeDPGsABeOJ6w_5_0"></a><a id="Tc_TcIx77tSUkOVPudPyaC0rg_6_0"></a><a id="Tc_qWWB1yVIokaHB1yxr_jd0Q_6_4"></a><a id="Tc_tu_g_0z560mGFBfUZFgOag_6_7"></a><a id="Tc_S5TLfXRmuU-O70EnNfMIvg_7_0"></a><a id="Tc_iT0DiYL1QkejRVGWBB48ig_8_0"></a><a id="Tc_bzlkiKi1N0eNPF2Dh-pZRA_9_0"></a><a id="Tc_saGKX-_9RkidDWwnGzOUAg_9_2"></a><a id="Tc_jVaJSaR18kGTbMQrpBnK9g_11_0"></a><a id="Tc_6APYrkCNY0aGXsbfm856VQ_13_0"></a><a id="Tc_Xn2R73AnREeJM4btU0LWOw_14_0"></a><a id="Tc_12JhhOvPGE6anteBgAgxhg_15_0"></a><a id="Tc_iiYqwID_qkW_YA8c2IsWkw_15_2"></a><a id="Tc_nKWrQWqT5kW6GUPGRlMFDA_17_0"></a><a id="Tc_zAhioVdRmEKQ4wmWdrc80g_19_0"></a><a id="Tc_GtmHdFfYrEyvD57_IVinog_19_4"></a><a id="Tc_1QinG-vxrkqOyK-8hjbl6Q_19_7"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Note</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">ASSETS</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:61.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">CURRENT ASSETS:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:61.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_gQZjw0dxZ0uuZt2NCpew0A_6_5">15,598</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_5JrrrgdAVkSMzUEgrIhjog_6_8">23,236</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_-R6Jt0ngRk6Tk57L9ejqZw_7_5">576</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_yGZ81pROfU6sguFz0DUZJw_7_8">618</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Short-term deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedInvestmentsCurrent" scale="3" id="Tc_5RcL1GiaJE2nOurvQAWg5A_8_5">30,417</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedInvestmentsCurrent" scale="3" id="Tc_T3ST138dUkeren0cHV4T0A_8_8">8,080</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Prepaid expenses and other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_Mj_0pyaBAkC7pdA4PPKGTg_9_5">864</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_R0190MJSpk-PJGOzM2svpg_9_8">707</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Total</span> current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_5x-xrxgPXEmZLf5kA6jWbQ_11_5">47,455</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_Hn1wy7J6kkWt-Zvu4kNkwQ_11_8">32,641</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Long-term assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:61.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Long term prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseNoncurrent" scale="3" id="Tc_knGeAXaOtUiTJlCq4kCKOw_14_5">139</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseNoncurrent" scale="3" id="Tc_KTLbOC0LxEupc4K8sZkDtw_14_8">2,028</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_dowEYBUw4EyP0V-TumCY8w_15_5">5,395</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_l3Vtu5gFB0qroPa0UWHw5A_15_8">7,546</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Total</span> long-term assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsNoncurrent" scale="3" id="Tc_afvEDEGgh0aZOWlXUcmSzg_17_5">5,534</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsNoncurrent" scale="3" id="Tc_WSdcYYqUVUCW_smjL5ypOg_17_8">9,574</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_PccGda70d0W0dtJIrfOSQg_19_5">52,989</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_NMIq64kpXEOvMch7H7eEcg_19_8">42,215</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="text-transform:uppercase;">f-</span><span style="text-transform:uppercase;">3</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:1pt;border-bottom:1.5pt solid #000000;margin:0pt;">CONSOLIDATED BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">U.S.&#160;dollars in thousands (except share and per share data)</p><a id="_5184e22e_d5e3_425a_b96b_396bf45e849e"></a><a id="Tc_eEeRa1X_PEyNhyBML23pjA_1_4"></a><a id="Tc_lkmVZ8GT40CU26S4O_pkGw_2_2"></a><a id="Tc_92XNDcXYiEeiMz7hosWE_A_2_4"></a><a id="Tc_d2ciEg7TJkCAcIxewMdRLw_2_7"></a><a id="Tc_cNQDSaA8G0y5J0tuTNLPmQ_3_0"></a><a id="Tc_7LTf7ipkxUSVM7yaZ1mp0A_5_0"></a><a id="Tc_8fYRkfbrUUOaSYTw4UUxQA_6_0"></a><a id="Tc_hkDdu3LIWEqqC8aapc9t2Q_6_4"></a><a id="Tc_D90jyAFTkkeEM8fRpiUBKg_6_7"></a><a id="Tc_iGIYDRRhuEmhNY7yi6ZKjg_7_0"></a><a id="Tc_Y2gCS2jKoE-zEdhLPpKFxg_7_2"></a><a id="Tc__vinlQMeXU-41rNKQDzYZg_9_0"></a><a id="Tc_RJQM95G7GESZc-L44SEB9g_11_0"></a><a id="Tc_PUweBuB3JEWqI_ErPI6yXA_12_0"></a><a id="Tc_wvrgZHAzzEez0OEQN8FNmA_12_2"></a><a id="Tc_vPkE6Gy7UEiAByjc-hdVRQ_14_0"></a><a id="Tc_-gKQvr3No023eb_0bTusBg_16_0"></a><a id="Tc_l9cqnSS5aUOuwNW-ScAlEA_16_2"></a><a id="Tc_r1A5riGxgESfjohFABrSPw_18_0"></a><a id="Narr_0GhNeRX2zke6uUAJeTLgKQ"></a><a id="Narr_7aJUOFY1VESoM9crM0z5GA"></a><a id="Tc_CUg1rISxDEyUao9aCFM2Pg_18_2"></a><a id="Tc_M7ufSMsCz0G9VHNpoYtCyw_20_0"></a><a id="Tc_PCSl7GughEm6R1sbS1WleA_21_0"></a><a id="Tc_seQrlXNZmke5gpkvgubn2w_21_2"></a><a id="Tc_8r5dDnvUKEaCNAzz16eL9g_22_0"></a><a id="Tc__yjlwTDPj0OCJibDlraO3w_23_0"></a><a id="Tc_gZPRrO1k10Owr1Nl7tz2EA_25_0"></a><a id="Tc_p713ssCEUEaz7XJJB20rog_27_0"></a><a id="Tc_EDa9pngE2kC_zRzKNuBMIg_27_4"></a><a id="Tc_k03M-Ny9JE-het6OP5ybcA_27_7"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Note</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">LIABILITIES, CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS&#39; DEFICIENCY</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">CURRENT LIABILITIES:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Trade payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_WfsExRii4UO-5fcM6L6N5Q_6_5">964</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_uj9HesGyhUuxFhu65fsJzw_6_8">1,203</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Other payables and accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_PRlmHprLlE6VyLx2oqYckQ_7_5">1,124</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_kHJlFr6ZuUOz3kEti9Tuzg_7_8">3,202</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Total</span> current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_ywJizeNb0U-i_kAA4R5ZZg_9_5">2,088</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_WUnSMBQU_EaUxL3ujivOyQ_9_8">4,405</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">LONG-TERM LIABILITIES:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Warrants to convertible preferred shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="-3" format="ixt:numdotdecimal" name="drts:Warrantliability" scale="3" id="Tc_HK11ZElTV0SekkZJwdCtCg_12_5">5,366</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="drts:Warrantliability" scale="3" id="Tc_XFhR_5XJ3UiazYt4ZsHdUA_12_8">18,623</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Total</span> liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_LqIGRbNkwEqtMy7XoV5m7g_14_5">7,454</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_pEc1RikvVk-pFEEERxKGlQ_14_8">23,028</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Commitments and Contingencies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Convertible Preferred shares of <ix:nonFraction unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_enq6-sH080WLkDUjoz87iA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_CIwFY4V8F0maEioOxd-0eA">no</ix:nonFraction></ix:nonFraction>-par value per share &#8211; Authorized: <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_xhMOyMBhy0mDzcUr8bOn7g"><ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_4NNlRPZH8EizBWb6ap4mqQ">25,348,176</ix:nonFraction></ix:nonFraction> shares as of December 31, 2020 and 2021; Issued and outstanding: <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="Narr_aIgjH2LQUk-Ex3rhfQ1N_w"><ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="Narr_BrYEmWaffEOK0FhOlfpHxQ">13,739,186</ix:nonFraction></ix:nonFraction> shares as of December 31, 2020 and 2021; *)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_rVR-ysL_j0WZafYvxyYOJw_18_5">53,964</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_Zy7HkBmCZU29s2bBPs0NuA_18_8">53,964</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Shareholders&#39; deficiency:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Ordinary shares of <ix:nonFraction unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_Nob06mhTXUGE7tVb1HQ4OQ"><ix:nonFraction unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_Q0IlGIwcHEex_9B4XTKiAA">no</ix:nonFraction></ix:nonFraction>-par value per share &#8211; Authorized: <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_DAtP0J6IBUy36M_KvKKBnw"><ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_Aebv0_3UMUykFpbQG4r9Mg">72,423,360</ix:nonFraction></ix:nonFraction> shares as of December 31, 2020 and 2021; <span style="-sec-ix-hidden:Hidden_4TC6wvDOF0Gs_JaCVjlbqw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Issued</span></span> and <span style="-sec-ix-hidden:Hidden_FM5Dlv3n_Uq5VkWGqLzMYg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span>: <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_xChUhHR8C0SytmWJPcNnSA">40,433,578</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_20u3YKi7jkekiITBdrRxbQ">40,528,913</ix:nonFraction> shares as of December 31, 2020 and 2021, respectively; *)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_G6MlAfQenUC5KMBm8hIoeQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_fD_C-mmYfEiNLNqRvC2r7A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:67.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_xJYc4aPF40-MrdZEKMZgjQ_22_5">17,140</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_x_S53JucXEGWKOfL7QDaNw_22_8">18,063</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_JHdyj_-BwEOTe9tA3-pYUg_23_5">25,569</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_xUdjV9eF10-aVv1LLnRwVw_23_8">52,840</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Total</span> shareholders&#39; deficiency</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_JRAYKoKlEkuEOtDS03KdMw_25_5">8,429</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_oU4m9JnwpUCEZbKg3K53jQ_25_8">34,777</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total liabilities, convertible preferred shares and shareholders&#39; deficiency</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_uCsnxKV_A0-oRzXKxiFnTw_27_5">52,989</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_rfzthGoaaECcMEXUBYuWOA_27_8">42,215</ix:nonFraction></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-left:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">*)</span></span><ix:footnote xml:lang="en-US" id="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25">Prior period results have been retroactively adjusted to reflect the 1: <ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_3_7_2022_To_3_7_2022_zxGQCP-7Fk277229BSbBmw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="Narr_PF6LO7Z_pkWCYhrPAyClcQ">0.905292</ix:nonFraction> stock split effected on March&#160;7, 2022. See also note 10, Shareholders&#8217; Deficiency, for details.</ix:footnote></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="text-transform:uppercase;">f-</span><span style="text-transform:uppercase;">4</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><a id="_9f1a677f_0df4_4f97_b218_6bba37f5dbaf"></a><a id="CONSOLIDATEDSTATEMENTSOFOPERATIONS_54585"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:1pt;border-bottom:1.5pt solid #000000;margin:0pt;">CONSOLIDATED STATEMENTS OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">U.S.&#160;dollars in thousands (except share and per share data)</p><a id="_bff488b7_2673_4737_b1e6_62439089976d"></a><a id="Tc_LmNiZdGMJUKkPZ9t8wsfrw_1_4"></a><a id="Tc_ROJJGSJ2EU2URZOyamEQWQ_2_4"></a><a id="Tc_N9BOpw2b80iy7-E2pnVeew_3_2"></a><a id="Tc_kzV_ylVYEE2GusEcetfqsw_3_4"></a><a id="Tc_XB3WtBwMA02DSuOe-DFcaQ_3_7"></a><a id="Tc_1YsGsbOGZEWeSCy6NBcrzg_3_10"></a><a id="Tc_5TD6LgFG7Ua7gm6vxKx2dg_4_0"></a><a id="Tc_pBK1NMJRm0C29g3w5Ec2GQ_4_4"></a><a id="Tc_eUYvuJkHakWKzwP22v93Lg_4_7"></a><a id="Tc_-3IjKoXYik2hEDMHwoIBWg_4_10"></a><a id="Tc_CV85d_zRq0SsfWRZzsbmxw_6_0"></a><a id="Tc_ykFnI7nY4U2eDLkely5CjA_8_0"></a><a id="Tc_nnBtG1uNeEu39-EH_2KqZw_10_0"></a><a id="Tc_DjZqbWYt0UqWJfhcnicfwg_12_0"></a><a id="Tc_mgem_N8SK0WUv_AY4oZDPw_12_2"></a><a id="Tc_RO2Mjg7gcE2IRFqsPehG3w_14_0"></a><a id="Tc_5z4bHV6nXkSC9bTFvapIlQ_16_0"></a><a id="Tc_N0kH8eD4JE6fMvjV3Em0bQ_18_0"></a><a id="Tc_5FThM2ePs0mN7aVwpSyuzQ_18_4"></a><a id="Tc_pe-jRE7mFkuIgXqLfdJbBA_18_7"></a><a id="Tc_BO2Mf7zvk0OPJpQcGWjCqg_18_10"></a><a id="Tc_JALZyltLK06V9iwaz8HmvQ_20_0"></a><a id="Tc_ldu_gGhxWU-L794_g2IPIA_20_4"></a><a id="Tc_GIgrLbbZx0KYJtsKFLkXHQ_20_7"></a><a id="Tc_iSWcuDpJL0G-AglZoh3wMw_20_8"></a><a id="Tc_81Ksv8R3t0KF10flPPgbSw_20_10"></a><a id="Tc_CKcrsp5y30OcZYlz2WNI4g_20_11"></a><a id="Tc_lHyx3-Wn3Umj4IYlGm3rtA_22_0"></a><a id="Tc_FqObXietSkeLpiXRylSoMw_22_4"></a><a id="Tc_RWqCtiKWpkiszXg-EQEPKg_22_7"></a><a id="Tc_bod1wozF0kaEax12TlJfWg_22_10"></a><a id="Tc_9Z3pKQcn6ky4uAxcCbuKOg_24_0"></a><a id="Tc_DL4ctQYkI0W1YKX1l7s7WA_26_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:58.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:33.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Note</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Research and development, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.49%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_RF5G6OXG40aYfNZDVa6kpA_4_5">6,636</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_DA5ZE1AfDkyHwbpTNNiQ7A_4_8">7,544</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_Iz8LbHALzkik2zG1eUkoMw_4_11">11,447</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Marketing expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketingExpense" scale="3" id="Tc_oNBllAbV9kmqqB2mZF9d_A_6_5">397</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketingExpense" scale="3" id="Tc_Kx7_ZWtHrke6K6Vc_rlObQ_6_8">288</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.75pt 0.05pt 0pt;"><span style="font-size:11pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketingExpense" scale="3" id="Tc_5sXHPIW0HUWEhlNNJoBzCw_6_11">482</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:58.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_ZyT76Y4DqUqXRtd3whrpKQ_8_5">977</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_eDvtcyf_BkK-MRFl2-Lmfg_8_8">1,412</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_LPfg7Bwj80ugh2FZaVyFbA_8_11">1,861</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total operating loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="Tc_klcSi4s1NUWn52ulE8STFQ_10_5">8,010</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="Tc_MSnA3TPAH0OGU5C1g9mebg_10_8">9,244</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.75pt 0.05pt 0pt;"><span style="font-size:11pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="Tc_Z65DdLC-hUSaNGpwDXiGTg_10_11">13,790</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:58.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Financial (income) expenses, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">11</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingGainsLosses" scale="3" id="Tc_uFMx797t_0uc3Izs_UncZg_12_5">308</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingGainsLosses" sign="-" scale="3" id="Tc_cazKacp_QEGcUBkJOdBKpg_12_8">520</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingGainsLosses" scale="3" id="Tc_CCqxNzyk6EmGCfYdtThBCA_12_11">13,474</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Loss before taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="Tc_ZaKNdHkgKEGL2w8FmxcfuA_14_5">8,318</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="Tc_URVAllYEM0GXxcJg1Nn4SQ_14_8">8,724</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="Tc_CYnohwC1SEO9WSo5eyIkDA_14_11">27,264</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Tax on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_KYHlN55T10Kk_dEcdVB6LQ_16_5">146</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_aJy43ATrXUe1Rad7RsqnGA_16_8">158</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_J0n159Ei_0S7cvW56mGoag_16_11">7</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_K42sKET04k6I_Hm9OAsGwQ_18_5">8,464</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_2TsEVpsr8kKn6zVqzbki-A_18_8">8,882</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_C7CWLNyW4UyoQ0EpjFFZ6w_18_11">27,271</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Less: net loss attributable to noncontrolling interests</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc__PcInAM6Sk6t49uyU_9n8A_20_5">97</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to Alpha Tau Medical Ltd.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_xrb3rNpHzUiiyZeRIvOYdQ_22_5">8,367</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_UA726Ubn3Umfr8Ja6e-ASw_22_8">8,882</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_MV9aSFdvQEKrCuBGTZsRig_22_11">27,271</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss per share attributable to ordinary shareholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_p7kyJw94cEWVBTjg-IZiLg_24_5">0.25</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_3qbWUsuMRUOthLWbkBcpjg_24_8">0.22</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_6ghBKrnvMEi0P-AORPDxOg_24_11">0.67</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted&#160;*)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_IYJZigyOHkyJZpyoc1xRsw_26_5">33,815,448</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_XWLpghrsXUO5fpZiFUwglg_26_8">40,274,935</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc__vRHrcT0Q0SDmSrSq27f1A_26_11">40,534,697</ix:nonFraction></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-left:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">*)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Prior period results have been retroactively adjusted to reflect the 1: <ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_3_7_2022_To_3_7_2022_zxGQCP-7Fk277229BSbBmw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="Narr_kX1p4qCW3UmRxPXf4o0zBA">0.905292</ix:nonFraction> stock split effected on March&#160;7, 2022. See also note 10, Shareholders&#8217; Deficiency, for details.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="text-transform:uppercase;">f-</span><span style="text-transform:uppercase;">5</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:4.55%;padding-right:4.55%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><a id="_9ed579f9_47e6_459a_8f6f_1aab696416a6"></a><a id="CONSOLIDATEDSTATEMENTSOFCONVERTIBLEPREFE"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:1pt;text-align:justify;border-bottom:1.5pt solid #000000;margin:0pt;">CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS&#8217; DEFICIENCY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">U.S.&#160;dollars in thousands (except share data)</p><a id="_746f2b30_d596_4eb5_824a_102d65a317e2"></a><a id="Tc_7Xr1OEXetky6yAAW6ig-5Q_1_2"></a><a id="Tc_Kvt5imF5pkGzavBuTE68Iw_1_12"></a><a id="Tc_A19UmAj2pEKV0Z91oKJ7RQ_2_2"></a><a id="Tc_paJ_A-4wWEC_PcpuXi2WuQ_2_7"></a><a id="Tc_64bBrNZHxEejJ-kjA44UVA_2_12"></a><a id="Tc_wC8T_vmBdkOG6tQMdoh6jg_2_15"></a><a id="Tc_GOSt11R7d0aulxPNdvzcHw_2_18"></a><a id="Tc_5JvkeMjj-UO4hCUbtNZxoA_2_21"></a><a id="Tc_ZsY2kU1dsEOT8RWTpoOAsg_3_2"></a><a id="Tc_gB6p3ewZYUiFo-7ZAfW4Iw_3_4"></a><a id="Tc_ddwc0GGHU0WXyd4YyztBrQ_3_7"></a><a id="Tc_xD4HyxEsj0aaYGnGXe-U1g_3_9"></a><a id="Tc_LhAEfPkuR0CFmBx0NxT0LA_3_12"></a><a id="Tc_lfapNWR1mEiUUgfsI9XsCw_3_15"></a><a id="Tc_Tq5wcJultkqxrPdXka1UcA_3_18"></a><a id="Tc_WcQSKsH0Jky9WHSI_x5eVg_3_21"></a><a id="Tc_93t0Kz_khkmA-14a_qJQRw_4_0"></a><a id="Tc_4r-EqkE9cUC0D2I9yjgmyA_4_4"></a><a id="Tc_B0w_EWusakWJU_XAnGilzg_4_9"></a><a id="Tc_uXC87n-cVUe3gR6OA-T-Pg_4_10"></a><a id="Tc_b0iu0cRX20GCVYMfgS9AWg_4_12"></a><a id="Tc_ahdceJfS-EaTauLvVTFW3Q_4_15"></a><a id="Tc__zrs1pF_M02y4Q19I22beA_4_18"></a><a id="Tc_5jeuCMv9GEedmn_IiZuvDg_4_21"></a><a id="Tc_3YE5SMf98k-gtKQjnxnHbA_6_0"></a><a id="Tc_oCTgQ1ClyEqiLwJgmtgFGQ_6_2"></a><a id="Tc_mcVSOPMGpEOtk6q5tfJ2CQ_6_5"></a><a id="Tc_viXIRj2nq0iqhGwiRKVHNA_6_7"></a><a id="Tc_ZzWGV3LSLkyhOb3pKsdtCg_6_10"></a><a id="Tc_mdeBtNgW3k6A1c4KST6L1g_6_16"></a><a id="Tc_qJlx9Wwuy0WYphbCdeGUuw_6_19"></a><a id="Tc_o_QDxwp7h0a-PkCevgXLmA_7_0"></a><a id="Tc_UtR9iqj_7Uq94EMxM7fDog_7_2"></a><a id="Tc_nmQ7jmfZskqn_VSfsPaQkA_7_5"></a><a id="Tc_WRKGXmt0VkGRH-sM238GoQ_7_10"></a><a id="Tc_lGuHU3O-X0ukBuFKNDZbFA_7_16"></a><a id="Tc_vQTqww2IkUiAZuBFDZl6GA_7_19"></a><a id="Tc_O2oyvXHUFU-iBy8_2d1-qg_8_0"></a><a id="Tc_AYPRh8nTIke3_xtyFNATQw_8_2"></a><a id="Tc_RxStL32VDUq1TqjVMibzvw_8_5"></a><a id="Tc_R6HcgiSP9kW-8liNC9-pxQ_8_10"></a><a id="Tc_Slvk_XBz0k-qvavUFmkUEQ_8_16"></a><a id="Tc_w5bguXVikUGpN5VpiW6ECg_8_19"></a><a id="Tc_cABzFo1Vf0SNVL3M2us83w_9_0"></a><a id="Tc_96J0fQY6PEWpAKii33tfEQ_9_2"></a><a id="Tc_tymkEP4rOkqm50aToGKP9w_9_5"></a><a id="Tc_CUhI8gCkuEOxcN87cuob7w_9_7"></a><a id="Tc_l6s7LRqpuUak4H_4JSn68g_9_10"></a><a id="Tc_HfBa9LS-YEa_Eo8PgbWxyA_9_13"></a><a id="Tc_WrBdlR_UI02oxVBcRqgwog_10_0"></a><a id="Tc_JK_cpgCVCUyZ_rpvnxtj0w_10_2"></a><a id="Tc__pwp4RIHukKv0rSowSZuKw_10_5"></a><a id="Tc_9N6PAu64Y0GoST7J95IDTg_10_7"></a><a id="Tc_ICcbwMtnFECOzAtZfhJR9Q_10_10"></a><a id="Tc_3T6vI3kJ1k26N8RXXy6dgg_10_16"></a><a id="Tc__2DhY6ezJEuWwZBnnxO-gw_12_0"></a><a id="Tc_TUbqLnk7kUa-0I6k4mq-jw_12_10"></a><a id="Tc_0O7bBTOjqUWj5-PilzufVg_12_19"></a><a id="Tc_JmK_8-r3SU6se1KG5XX7FA_14_0"></a><a id="Tc_b8uJKytHH0mYeWeOkiOYCQ_14_2"></a><a id="Tc_enbe-S4z6EKNMxwQDEEiyw_14_5"></a><a id="Tc_xk3SpgX8dE66wgGiOF7OpA_14_10"></a><a id="Tc_J-BbR3F72USa-HANvYkrTg_14_16"></a><a id="Tc_YWdnv70QZk63K4Elz-MJVQ_14_19"></a><a id="Tc_DShEGfgbkEeS9Yha1bQBxA_15_0"></a><a id="Tc_gAf-37JpMkePvGivFsJY2Q_15_2"></a><a id="Tc_7mA5evdP30mV61eLbyeFRQ_15_5"></a><a id="Tc_a5ttyebz7U-Lfh4uZC3vQA_15_10"></a><a id="Tc_xkUH4lORiUSDQo2ij3_dbg_15_16"></a><a id="Tc_ZNF-HAjdsE2oPO0RBXw6pg_15_19"></a><a id="Tc_U2_4D0zELkmws9z46IALrg_16_0"></a><a id="Tc_ANqLYWSSo0ivK_7Gd_9gFw_16_2"></a><a id="Tc_CjOkZI9pU0OdNihbR4yefw_16_5"></a><a id="Tc_22oRlcUd0EmAyhLFBZRj4g_16_7"></a><a id="Tc_gCEdVPtC_UCPQoIxnbwGFA_16_10"></a><a id="Tc_omLfw6zzDUmkbBL3A0npqQ_16_16"></a><a id="Tc_ukqwgbq9LkuzU_XWCc0tEw_16_19"></a><a id="Tc_ciS2wDN8YkiPaBNvxpj1mg_17_0"></a><a id="Tc_xUwDoMzRMk2oSyt3TOXHvQ_17_7"></a><a id="Tc_ikp7ANXEpU-AthNLrm6aIg_17_10"></a><a id="Tc_FZ472RC2B0Kk07JpU0dlSg_17_13"></a><a id="Tc_ztLDKdC1s069vIDMTYIF7g_17_16"></a><a id="Tc_ZaHJcBEt90mwqxr7kh6TIQ_17_19"></a><a id="Tc_28USzP1EI0myni5rnUpGoA_17_22"></a><a id="Tc_MGaklnyE0kyGSagOjBfsLQ_18_0"></a><a id="Tc_iRQATx9QtU-l-m7qGHsGlw_18_2"></a><a id="Tc_ABP0Y0Kn6kaxIiVSIZHhVQ_18_5"></a><a id="Tc_7jtxLD5yO02O604LHNh-Lg_18_7"></a><a id="Tc_FjbO2e4jmkGO3E0PFV4sFQ_18_10"></a><a id="Tc_SEJxSqSyckCvj6m0V1oppA_18_13"></a><a id="Tc_ocGhBRg5W0-f57XWhX8WtQ_18_19"></a><a id="Tc_PbrvqHUfr0Wn4mb7pfDSbQ_20_0"></a><a id="Tc_ZtD3hnQJMEamGUe6rm28JA_20_10"></a><a id="Tc_dEQ92Kcg-kOKhw4wdz1bNw_20_19"></a><a id="Tc_JuLS2MFN9UmccIYCbEmbvw_22_0"></a><a id="Tc_JRTy2VBcgUeS5Cq00OJsTA_22_2"></a><a id="Tc_cZQxzJqMMkWvWQkoIJoBXg_22_5"></a><a id="Tc_Mp06WBqjBESSiPsy8qp9zw_22_10"></a><a id="Tc_kLaEZ6LM0kOJsdtKlKTD-w_22_13"></a><a id="Tc_KI2qM1MyDEGZap-lXyNIhQ_22_16"></a><a id="Tc_AYmdrr_d2UKCivQ6cohzUQ_22_19"></a><a id="Tc_i1ArFTvp7EiWrcLsHV3V7g_22_22"></a><a id="Tc_cQ5BU4haTEuF1arEDK1d0A_23_0"></a><a id="Tc_x-MyfLNQ6UqNfi-Rx4SW7A_23_2"></a><a id="Tc_Am8Q4mHQyEGVFjfflo87pA_23_5"></a><a id="Tc_4BIQGdiookaeSRPDOHsSZQ_23_10"></a><a id="Tc_PGhvu0KCWkuuQWeOZA7uxA_23_16"></a><a id="Tc_I7I7wOPsxkagfFw63JjukA_23_19"></a><a id="Tc_V0AkU9wpsk6psfMX6ZcGBA_24_0"></a><a id="Tc_3zR--D5K6UOkRG-swJJ14Q_24_2"></a><a id="Tc_XAE7iDyilEO50OSZ5GATPQ_24_5"></a><a id="Tc_iqnmGll2iU6I4CILxkuybw_24_7"></a><a id="Tc_CtAv_3i6K0CwKBizn38lqA_24_10"></a><a id="Tc_hhsalbkwYU2NlJSwd0F18A_24_16"></a><a id="Tc_eptRlMxizkyoyfOM0HsJXg_24_19"></a><a id="Tc_6FrX-APx8EC-mUpZ-R_wDQ_25_0"></a><a id="Tc_X1izFfVwyUKqsZbQDZl1Qg_25_2"></a><a id="Tc_AYAgCKKJG0-nyfCPJYRqww_25_5"></a><a id="Tc_VZ_xSZamu0m2qsZrafTf5w_25_7"></a><a id="Tc_tXuVGx8kT0Wzm0pW9LQX4Q_25_10"></a><a id="Tc_omfzpgUTYkqNjXMGGNzQlw_25_13"></a><a id="Tc_jlxpQebx-UOiPo6xUuSnNg_25_19"></a><a id="Tc_DTMyw8hTQkyp64xfnfF8Fw_27_0"></a><a id="Tc_ueuy2T3lfkyQ9Qm1bvNzqw_27_4"></a><a id="Tc_XQ413wlNIk6QMgTBGrGTVw_27_9"></a><a id="Tc_r8ZrJwm2O0-yhYcbAchtWQ_27_10"></a><a id="Tc_O5zmSK_FNUaArG_ilPdoCQ_27_12"></a><a id="Tc_R5peC22A7Eear3reG3XxYQ_27_15"></a><a id="Tc_AykQ56ZKW0-GIuEqI4RSvQ_27_18"></a><a id="Tc_p8YPaLVHhUqFCQVPPTSouQ_27_19"></a><a id="Tc_xCKLJfjD2kevDme_O5wsyQ_27_21"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Convertible&#160;Preferred</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:14.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:14.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Ordinary&#160;Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">paid-in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nom&#160;controlling</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Balances as of January 1, 2019 *)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_aj4GYFUqrka7uJcyVmTHIQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_0CdjEUrQ60qc-aWGXE0svw_4_2">7,229,885</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_aj4GYFUqrka7uJcyVmTHIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_0n0znmQK4kiznLwqpz-FmA_4_5">25,238</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4I62Q1RYY0G4dDLq0oH8kA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_P686uzzh_0240QcKLJnzuw_4_7">33,185,538</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4ygP12wMPUWWbr6h1XztVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_lyh0_IXKxUC_nS-q0yyDCw_4_13">9,330</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_hVc9GNOKXk-_jqzkPdtv8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_T3zJEjDNFkGTCGwsdZE6uA_4_16">8,320</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_6ynx3rWt90GJLYzfoH7j8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_1OwVenEu-0eEAuydtTNhTw_4_19">851</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2018_XIXddAY3L0yRBxsPKwvT6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_8U1wMLEo2UyQSZe3sFuTQQ_4_22">1,861</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:35.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OA7LnjwMsEWxaEV_8urPuA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_HLrYnSWMTUebuGylxQr1GQ_6_13">546</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_RDFpsZIcN0Whay5dSHdfBw_6_22">546</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:35.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of ordinary shares and warrants to ordinary shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zDmmSI986UmJIj-sGT2-Wg" decimals="INF" format="ixt:numdotdecimal" name="drts:AdjustmentsToAdditionalPaidInCapitalWarrantSharesIssued" scale="0" id="Tc_6ayeoxB6Tk2byLwQI5jrCA_7_7">1,302,132</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OA7LnjwMsEWxaEV_8urPuA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="Tc_zfv5uC0Xb0Omrqonhw5Svg_7_13">5,250</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="Tc_bEyvMPzQxUWOfmgBVhT40w_7_22">5,250</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:35.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of warrants to ordinary shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zDmmSI986UmJIj-sGT2-Wg" decimals="INF" format="ixt:numdotdecimal" name="drts:StockIssuedDuringPeriodSharesExerciseOfWarrants" scale="0" id="Tc_N4dcXpQi2EWIR8_33Hbcqg_8_7">5,316,493</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OA7LnjwMsEWxaEV_8urPuA" decimals="-3" format="ixt:numdotdecimal" name="drts:StockIssuedDuringPeriodValueExerciseOfWarrants" scale="3" id="Tc_9rmSyec0Jk2svKg-cvJglA_8_13">1,560</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="drts:StockIssuedDuringPeriodValueExerciseOfWarrants" scale="3" id="Tc_UYhuJLC31EuCWlO-rjPvyQ_8_22">1,560</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:35.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_RAo1T_5iU0emGFXFccTaVQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_XIMNv7HkHUON4puP8yly3g_9_16">8,367</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_LPp8QInDWUu1wZCHIvnfQw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_BACguXWQ3km7rKVNkBYAaw_9_19">97</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_Po7KSpw1O0uMwNw6XOxkvA_9_22">8,464</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:35.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Acquisition of non-controlling interests</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OA7LnjwMsEWxaEV_8urPuA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromPaymentsToMinorityShareholders" sign="-" scale="3" id="Tc_X6cTyF74QEyoYZLQew4iyw_10_13">192</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_LPp8QInDWUu1wZCHIvnfQw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromPaymentsToMinorityShareholders" sign="-" scale="3" id="Tc_B1jkZZ9YQkK2VBEVvdqLkw_10_19">754</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromPaymentsToMinorityShareholders" sign="-" scale="3" id="Tc_VF9sGYTew0yCLtCLPKP2UA_10_22">946</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:35.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.56%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.63%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Balances as of January 1, 2020 *)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_i1mWmb_nSEecsnGxFg7m_g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_u_LKhmMgwEaHCoxpK9whWw_12_2">7,229,885</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_i1mWmb_nSEecsnGxFg7m_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_7ASbk5JcKEOtWKvUjhU-XQ_12_5">25,238</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GocQ7aqoEkCbUnmv9spesw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_jCQr6Q1pxUqmv6xXVY9RKw_12_7">39,804,163</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VMREA2dVCUqalyS79-xuRg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_KJyJAPCCxUepTgIJXxk0WA_12_13">16,494</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Az5at6t9sUi2LDLd7cWsbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_r7OqZTkDyUiuLQbJGIbpmA_12_16">16,687</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2019_9X1M-BXfgEWsSJdmFxdJhA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_56XM67-Ms0yj_sPp4AVY9w_12_22">193</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:35.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of Warrants to ordinary shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_u2IRTL2hREuTiBdvWBPJIA" decimals="INF" format="ixt:numdotdecimal" name="drts:StockIssuedDuringPeriodSharesExerciseOfWarrants" scale="0" id="Tc_q1cgtjuXVEGG9Yq3b3T2lQ_14_7">624,445</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iKd2bcgAO0yb8cTymXlliw" decimals="-3" format="ixt:numdotdecimal" name="drts:StockIssuedDuringPeriodValueExerciseOfWarrants" scale="3" id="Tc_KaqDe1STCUqERLc8tUor8Q_14_13">30</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="drts:StockIssuedDuringPeriodValueExerciseOfWarrants" scale="3" id="Tc_-cjFs9p_y0qxcgojcOH3cg_14_22">30</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:35.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of ordinary shares upon exercise of share options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_u2IRTL2hREuTiBdvWBPJIA" decimals="INF" format="ixt:numdotdecimal" name="drts:StockIssuedDuringPeriodSharesOrdinarySharesUponExerciseOfShareOptions" scale="0" id="Tc_lw-A74uNxkeBg8FkIefx-w_15_7">4,970</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iKd2bcgAO0yb8cTymXlliw" decimals="-3" format="ixt:numdotdecimal" name="drts:StockIssuedDuringPeriodValueOrdinarySharesUponExerciseOfShareOptions" scale="3" id="Tc_1Xf3YopFlEKWxgjqU_1b8Q_15_13">20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="drts:StockIssuedDuringPeriodValueOrdinarySharesUponExerciseOfShareOptions" scale="3" id="Tc_0PFDai-W9kye6VhE1Sm9Eg_15_22">20</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:35.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iKd2bcgAO0yb8cTymXlliw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_Ee4be-8NDUeXyW9iAnMvow_16_13">596</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_0Yz9nD3F3Eu7t_m-tLKtBQ_16_22">596</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:35.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of series B Preferred shares, net **)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_rhxpidqOe0uEnhSdwKCtbg" decimals="INF" format="ixt:numdotdecimal" name="drts:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_2e32zEawfkeQRIldT_VSig_17_2">6,509,301</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_rhxpidqOe0uEnhSdwKCtbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_Rku296PeK0i4awh1scxZVA_17_5">28,726</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:35.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_EKhArHp_YEqXT7Vh3-UQ7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_Z-rzjQGOFUGvUZ7jp59gyg_18_16">8,882</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_g52TISVmvEKFneKfeUaokw_18_22">8,882</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:35.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.56%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.63%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Balances as of December 31, 2020 *)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_bNVdyxnBY0S_wDAMjuaFkg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_y4vKTxUAcEqA0oTt8NslHA_20_2">13,739,186</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_bNVdyxnBY0S_wDAMjuaFkg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_0eVudmzgAk2o9n9P9JaYrQ_20_5">53,964</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QBEQ8mAQX0SOz4gXrPGKLQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_kglc91OPek-hdjs6FhlB7A_20_7">40,433,578</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ykMIzfofVUuPDoPU0k2Pgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_ZKdYgNzJjUCbyRtM_ftH6w_20_13">17,140</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_bsiFZBQITkihmHXGW4LWHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_uAsIpfpH1EuGwJuct4F3Xw_20_16">25,569</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_76XUmnnJH0WBOHwIejBh7Q_20_22">8,429</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:35.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of Warrants to ordinary shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xyh47eHvfkKb6vxdvq7wAw" decimals="INF" format="ixt:numdotdecimal" name="drts:StockIssuedDuringPeriodSharesExerciseOfWarrants" scale="0" id="Tc_nL9XyQV4CkG4-B7KmDLi8A_22_7">9,053</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:35.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of ordinary shares upon exercise of share options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xyh47eHvfkKb6vxdvq7wAw" decimals="INF" format="ixt:numdotdecimal" name="drts:StockIssuedDuringPeriodSharesOrdinarySharesUponExerciseOfShareOptions" scale="0" id="Tc_wzpMCVn4Dk-3K4XSHfKwuw_23_7">86,282</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.75pt 0.05pt 0pt;"><span style="font-size:11pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_STmFVK2iUkKhWvfG-Crldw" decimals="-3" format="ixt:numdotdecimal" name="drts:StockIssuedDuringPeriodValueOrdinarySharesUponExerciseOfShareOptions" scale="3" id="Tc_Uopa-ljNLEucGVKiVdAnQQ_23_13">111</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="drts:StockIssuedDuringPeriodValueOrdinarySharesUponExerciseOfShareOptions" scale="3" id="Tc_wc3v0gWttEKQrnR1r1pm9g_23_22">111</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:35.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.75pt 0.05pt 0pt;"><span style="font-size:11pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_STmFVK2iUkKhWvfG-Crldw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_CKDlYRWLtUa99HS6TucCag_24_13">812</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_2NhmfzWUYUGWNeva5tORGg_24_22">812</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:35.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_IbEezU48YkqEkwVicJ4VDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_GUCgKC778kGFzhox86mpfw_25_16">27,271</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_YEdIdRItVUGVDXJXE_GnCQ_25_22">27,271</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:35.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.56%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.63%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Balances as of December 31, 2021 *)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_2jPIe9FCpk-lk0x3ei7plQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_i3xv8QEPgUKYHXUfXzMJLw_27_2">13,739,186</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_2jPIe9FCpk-lk0x3ei7plQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_ED3uytwyLEemO4jP3bMLrw_27_5">53,964</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ODoUIImeZUSC5k7f53zukQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_wBe7AwRzvUaMt38Ii5x4Og_27_7">40,528,913</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_MouG0PPKQkmZNUQVCP7aqg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_CXgll3kXZkGRtrU7Mm5iuw_27_13">18,063</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HEnHaE37ekigHo4AetBJFg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_DPen8g3MI0qtSL9TNu5vTQ_27_16">52,840</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_pbHeOPec5kCo7burVpgWUw_27_22">34,777</ix:nonFraction>)</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-left:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">*)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Prior period results have been retroactively adjusted to reflect the 1: <ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_3_7_2022_To_3_7_2022_zxGQCP-7Fk277229BSbBmw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="Narr_9kKryNpo8kWGGsrzUAJiGA">0.905292</ix:nonFraction> stock split effected on March&#160;7, 2022. See also note 10, Shareholders&#8217; Deficiency, for details.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">**)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><ix:footnote xml:lang="en-US" id="_3912af17_c1f9_4243_a55a_b4731c1ce7c2">Net of issuance costs of $<span style="direction:rtl;"><ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="Narr_cQ2WWPXAXE2VTqtKN9rJkQ">35</ix:nonFraction></span>.</ix:footnote></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The accompanying notes are an integral part of the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="text-transform:uppercase;">f-</span><span style="text-transform:uppercase;">6</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:90.91%;border:0;margin:30pt 4.55% 30pt 4.55%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e62c22c5_2fc7_4d4f_aa4c_fe1da0b60688"></a><a id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS_636405"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:1pt;border-bottom:1.5pt solid #000000;margin:0pt;">CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">U.S.&#160;dollars in thousands</p><a id="_c87be863_befc_447d_b979_798349812f0f"></a><a id="Tc__PBjjrTdsEKJ4PEBdyqXEw_1_2"></a><a id="Tc_9d3bqylElESdtCGnFmBB_w_2_2"></a><a id="Tc_LfXHEWBk5Ey3cWKGvYQteA_2_5"></a><a id="Tc_pwH3yNkTSUGtNlARTQ_8Jw_2_8"></a><a id="Tc_VrJOK142lUqzkdIzs1BDWA_3_0"></a><a id="Tc_TqQPU2RbjkqK1C73-zy3kg_4_0"></a><a id="Tc_OA1nj8LX7EyqBp22HIRi9g_4_2"></a><a id="Tc_le1X6ZzREEeSo_W-4vlqyA_4_5"></a><a id="Tc_OuboIK3JFESwLCoTa_LUgg_4_8"></a><a id="Tc_XF_GQExF4EiyVtMkh_q-9Q_5_0"></a><a id="Tc_hfXZS2Cv1ESzapVi6KG0Ow_7_0"></a><a id="Tc_DmymRZhpJ0ymPwuslddimg_8_0"></a><a id="Tc_tHzZaFxhV0Oxc20LOr5_Sg_9_0"></a><a id="Tc_sibIsaJ440WnctybzY9DXg_10_0"></a><a id="Tc_AHzMta-U-UyRmjSJXTfXOA_11_0"></a><a id="Tc_e0wzr7Ob10-xFEO4vNOkWw_12_0"></a><a id="Tc_H30mHnGkWkiXlofISzXZdw_13_0"></a><a id="Tc_UdxLnIKzgky5HJP-1HF-Aw_14_0"></a><a id="Tc_SfeDFNOurkmqEvTdVQovOg_16_0"></a><a id="Tc_niTQzEsU4kCbybkUHzP9IQ_18_0"></a><a id="Tc_etqvSsjESEWw9FRNV7gRRw_19_0"></a><a id="Tc_6OlklNCAJkW3c9LwN5bsyA_20_0"></a><a id="Tc_8xj61s18SEyFUzq7pdpgqg_21_0"></a><a id="Tc_484cdq3lMUOyEgbUGFbspg_23_0"></a><a id="Tc_8FVT05CSekSU0O8ARgEo8A_25_0"></a><a id="Tc_BW5NT9EEoUaX7RQ78RwpKQ_26_0"></a><a id="Tc_2i88EDC5_kKmgxjGInhLUg_26_6"></a><a id="Tc_O9NIlamcaECOVhZjDWBLUg_26_9"></a><a id="Tc_cbVGeoblEkeknCHTGtdnMA_27_0"></a><a id="Tc_f56x42CK_USee6BpLxa_Iw_27_3"></a><a id="Tc_M1M_nfjSBkC-82bEnE0JCg_27_9"></a><a id="Tc_Ke63azAlfUelIyPlJ2umWA_28_0"></a><a id="Tc_PVEmHB6TPUi-t0O1WoA7RA_28_9"></a><a id="Tc_cXQJK2uCykGZEMTMLvx5IQ_29_0"></a><a id="Tc_GMcfkllrO0qpK-AUGzs0Aw_29_3"></a><a id="Tc_4lq46fPFXE-aGkmNFWiwuA_30_0"></a><a id="Tc_xhW4-Z6d4UStmPG5_phOvg_30_6"></a><a id="Tc_t8nBi2FHuUaKHDXA96f65A_30_9"></a><a id="Tc_Gx2OuqOwPkiTo31_9YmwbA_32_0"></a><a id="Tc_T9xGy69X-Eea-FOS-S2nlQ_34_0"></a><a id="Tc_aUkG5k5JPkO9FHlb8f4nQg_36_0"></a><a id="Tc_HfNZiJoBD0-QI6TrKM2iag_37_0"></a><a id="Tc_i4-LIxAcukS6lwGSHI1Ekw_39_0"></a><a id="Tc_IH6VRRyxmkio1dVTN4y1tg_39_2"></a><a id="Tc_NdUAm205iECc7Ir8Yr-Wig_39_5"></a><a id="Tc_ERp8XQYzZ0G7T4Gg5UklIg_39_8"></a><a id="Tc_966Rhr2RA02n2hgJ6DB4VQ_41_0"></a><a id="Tc_3_xX_0U09U6NVlEV-DCy4A_42_0"></a><a id="Tc_Fjt_RwwJhUKYqOvLpiqnRw_42_2"></a><a id="Tc_HIDFpZWv40KqMNOFW7Xk7g_42_5"></a><a id="Tc_cU47zVMeYECsD1y5S7XZqw_42_6"></a><a id="Tc_mLJ9KfSH4Eqwz6duNv2Mrw_42_8"></a><a id="Tc_EeLvA6SFA0aRoDeF5K443g_42_9"></a><a id="Tc_DLm1vQCzr0GuvPYjJ8bTHQ_44_0"></a><a id="Tc_w1D3N_hwsUCvhzCtXRC72g_45_0"></a><a id="Tc_pJV_fcVQR0SUxoB6G8mM0g_45_2"></a><a id="Tc_njVnGFBwe02u5BdDUENiuw_45_3"></a><a id="Tc_jutiEj-gDUGuIXxiPikriQ_45_5"></a><a id="Tc_U6QKjLF1C0-Pwch9GqkY_g_45_8"></a><a id="Tc_EUx7CjICbE6IV-oJe8rxzg_46_0"></a><a id="Tc_ZgcOCS6fbEqmPY-pXCEFYg_46_2"></a><a id="Tc_50vOLAwrA0WvysnT0zPOog_46_5"></a><a id="Tc_m8ksgMg5XUG3GuPG9vvEtw_46_8"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;ended&#160;December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cash flows from operating activities:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="Tc_7fRSOt8Bs0mL4WwMCiBf7A_4_3">8,464</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="Tc_ZridnnB7IESlv8fawEkW9A_4_6">8,882</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="Tc_kaisS3YwC0KzFfE6-Ex2vQ_4_9">27,271</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_PRLmokmeBkywWGZNEoueHQ_7_3">66</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_giC1P3_kjkmnq3jaxUu3rQ_7_6">86</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_s4XWLE_b0USkMbfvM-3CRw_7_9">776</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_TNqtztJoqkWkRTe-jPPJ4g_8_3">546</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_nRyCMYbqI0-gz6k51TtTcw_8_6">596</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_EBWtlHEA-E2kTUGRRm-Y7A_8_9">812</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">(Increase) decrease in prepaid expenses and other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_DNAEAoKAAE-QK-Db7e-ZRw_9_3">509</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_GPqwnMdNHUaPBdbRjCj-Jw_9_6">283</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_6i6yQvXZSkeZqvAjBs37Kw_9_9">157</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Increase in long term prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" scale="3" id="Tc_rdN0JDCSMkKaqEW8nIMkWw_10_3">16</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" scale="3" id="Tc_q9gh7BGJMUyfQ13ZSaTbrA_10_6">123</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" scale="3" id="Tc__8jQM7SbP0mfOdE03Ht9bw_10_9">1,889</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Change in the fair value of warrants to convertible preferred shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="drts:IncreaseDecreaseInFairValueOfWarrantsConvertiblePreferredShares" scale="3" id="Tc_ZREPghhen0y_Cvc0HaHqWA_11_3">994</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="drts:IncreaseDecreaseInFairValueOfWarrantsConvertiblePreferredShares" scale="3" id="Tc_hgxvQVTPlkmig_NRJ33xOw_11_6">203</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="drts:IncreaseDecreaseInFairValueOfWarrantsConvertiblePreferredShares" scale="3" id="Tc_gkfJeRkAEk2lm7wB-w-Tbg_11_9">13,257</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Non-cash financial (income) expenses, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="drts:IncreaseDecreaseInNonCashFinancialIncomeExpenses" sign="-" scale="3" id="Tc_phr66QqvyEyIqFl_ovU0dw_12_3">12</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="drts:IncreaseDecreaseInNonCashFinancialIncomeExpenses" scale="3" id="Tc_hf0mbRdj20mODCER-27IVg_12_6">153</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="drts:IncreaseDecreaseInNonCashFinancialIncomeExpenses" sign="-" scale="3" id="Tc_CNgTXQORlkmVWpPPHZuCMQ_12_9">29</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Increase in trade payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" id="Tc_PeZ0HkP2UEyh8UEeqdXQVQ_13_3">148</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" id="Tc_h94-g7naBkipUgBuyLhFWA_13_6">114</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" id="Tc_bSd7awKAlUS6NOVwvNR-lQ_13_9">239</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Increase in other payables and accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" scale="3" id="Tc_R9yZGFzLvkeTDQ9X6ddC5Q_14_3">313</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" scale="3" id="Tc_5adSUDCDsE67h8bq25W3_Q_14_6">625</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" scale="3" id="Tc_PPTc8tf1PUSpBUobgJntmQ_14_9">2,078</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_wMXhguSTB0qS5y_Q8zOLpA_16_3">6,910</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_k2iHpiNliUeSyEUtLn7xng_16_6">7,251</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_ovNsaNt5ckqqp7_g7PciFw_16_9">11,812</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cash flows from investing activities:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Investment in short-term deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseOfRestrictedInvestments" scale="3" id="Tc_C1plAPderEmm1Po5Wau9PA_19_3">54,270</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseOfRestrictedInvestments" scale="3" id="Tc_PdyFdzbjwE-wtuy6BvjRVQ_19_6">70,200</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseOfRestrictedInvestments" scale="3" id="Tc_PWAsWa-ocE6pX20fff7ctg_19_9">8,082</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Redemption of short-term deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfRestrictedInvestments" scale="3" id="Tc_8eOuVYshcUWzo5BnJFnTUg_20_3">45,400</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfRestrictedInvestments" scale="3" id="Tc_NPP1OpBmtUm9fRcxQ5eiug_20_6">66,150</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfRestrictedInvestments" scale="3" id="Tc_Fd9bDjwds0GQLfzVP8SZrA_20_9">30,282</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Purchase of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_rIZJaFsKNUG96kzLe3agGA_21_3">1,293</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_a7FifNB0dESKhvuBup83JA_21_6">3,767</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_Mo1shavlbkSS-cuVnaDFjg_21_9">2,927</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Net cash (used in) provided by investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_b4ituS2vk02jLT7X83FXUw_23_3">10,163</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_Hw9bCSy1_E-fGgyLLgsyIQ_23_6">7,817</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="Tc_PNtoe-phikel1QWCLbbbKg_23_9">19,273</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cash flows from financing activities:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Proceeds from issuance of ordinary shares and warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" scale="3" id="Tc_SQhTU8ZbLUm3AqNwDfQwHw_26_3">5,250</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:67.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Proceeds from issuance of series B Preferred shares, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" scale="3" id="Tc_2b-i139OcU6LDrughcXyjA_27_6">28,726</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:67.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Proceeds from exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="Tc_PrTxfwLclEGLaCbBKLKmcg_28_3">1,019</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="Tc_QNkeB4uX8Ue2v78sKB3Trg_28_6">571</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:67.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Proceeds from exercise of options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_ukvq07Fk80CQOK6H-wNT_A_29_6">20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_0ovylxA-t0i9uxaEuMurlA_29_9">111</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Acquisition of non-controlling interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromPaymentsToMinorityShareholders" sign="-" scale="3" id="Tc_KEg8zmxGTkGQm9V0tcRPFQ_30_3">946</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:67.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_jEbgfhepaUGYQFw1A6CBsw_32_3">5,323</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_139r1et5V0qO-QJVWMuQsg_32_6">29,317</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_WTx2FkXKv0qWO2k-VQxrpA_32_9">111</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Effect of exchange rate changes on cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" sign="-" scale="3" id="Tc_LZYSwuiBck2CEMO0dJbKdg_34_3">18</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_RM78oJ72G0Gf7SIVPX_y9A_34_6">84</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_NlTkUIq60kmpgxnZvuZRdA_34_9">108</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">(Decrease) increase in cash and cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_h32YjfuCGUebwknwjL0kNQ_36_3">11,768</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_fMFfYRM_TU20DaAVswX0WQ_36_6">14,333</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_g44W-u2sREi08SwOPjtamw_36_9">7,680</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Cash, cash equivalents and restricted cash at the beginning of the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2018_XIXddAY3L0yRBxsPKwvT6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_ftOhcksQ4EiYnfwgluHehw_37_3">13,609</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2019_9X1M-BXfgEWsSJdmFxdJhA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_teOLd2WFQ0SR1_Xw8HZ9LQ_37_6">1,841</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_05g_ALlGxUyGHL3HDZqRYA_37_9">16,174</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Cash, cash equivalents and restricted cash at the end of the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2019_9X1M-BXfgEWsSJdmFxdJhA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_xKcglKBYZkulxhHobj1yLQ_39_3">1,841</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_eNutqQg4gUyaOU1hn5caiA_39_6">16,174</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_Rg9-mgbPYUKxmfY7MXFOtQ_39_9">23,854</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Non-cash transactions:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Receivables from exercise of warrants to ordinary shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1" scale="3" id="Tc_ypVZ9n8u5UqDx7xr6AW-BQ_42_3">541</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:67.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Supplemental disclosures of cash flow information:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Income tax payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaid" scale="3" id="Tc_styyz4QYuUmKOTRQlx_MOQ_45_6">218</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaid" scale="3" id="Tc_O273s4jbQU6hHyXD4uSG3w_45_9">103</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="color:#231f20;">Interest received</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_kO-7yCedfEKgLpANNOZsOw_46_3">780</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_j2gCwgtXvEWoMhGL7kSTUQ_46_6">541</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_5KNi06n9sEuHBHe-Yaw3Pw_46_9">351</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The accompanying notes are an integral part of the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="text-transform:uppercase;">f-</span><span style="text-transform:uppercase;">7</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;padding-bottom:1pt;text-align:justify;border-bottom:1.5pt solid #000000;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">U.S.&#160;dollars in thousands (except share and per share data)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:justify;margin:0pt;"><span style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="NOTE1GENERAL_632360"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="us-gaap:NatureOfOperations" id="Tb_SOnb38JKQkqblrjO5Qs8HQ" continuedAt="Tb_SOnb38JKQkqblrjO5Qs8HQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;1:-</b></span>GENERAL</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Company description:</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Alpha Tau Medical&#160;Ltd. (&#8220;the Company&#8221;) is an Israeli clinical-stage oncology therapeutics company that focuses on research, development and commercialization of Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) for the treatment of solid cancer. The Company was established in November&#160;2015 and began its operations in January&#160;2016, and shortly thereafter acquired the full rights to the Alpha DaRT technology from Althera Medical&#160;Ltd., (&#8220;Althera&#8221;), developed in 2003 at Tel Aviv University.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">In August&#160;2017 the Company established a fully owned subsidiary in the United States&#160;- &#8220;Alpha Tau Medical&#160;Inc.&#8221; (hereafter: ATM Inc). ATM Inc began its activity in August&#160;2018.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">In January&#160;2018 the Company established a subsidiary in Japan &#8220;Alpha Tau Medical KK&#8221; (hereafter: ATM KK). ATM KK began its activity in January&#160;2018, initially as a JV that was jointly owned by the Company (holding more than <ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_1_1_2018_To_1_31_2018_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_drts_AtmKkMember_JbImIrkcuUGQZ_vY9-jX-g" decimals="2" format="ixt:numdotdecimal" name="drts:DisposalGroupIncludingDiscontinuedOperationOwnershipDisposed" scale="-2" id="Narr_y86pt6bBaUCCnvgpBnfHhA">90</ix:nonFraction>% of ATM KK) and HekaBio K.K. In July&#160;2019, the Company acquired full ownership of ATM KK by virtue of a transaction in which the Company invested additional funds into ATM KK, and ATM KK repurchased its own shares that were held by HekaBio K.K. As of December&#160;31, 2021 and 2020, the Company holds <ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_1_1_2020_To_12_31_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_drts_AtmKkMember_25Jj3jm1eU-OcstYM8wmaw" decimals="2" format="ixt:numdotdecimal" name="drts:DisposalGroupIncludingDiscontinuedOperationOwnershipDisposed" scale="-2" id="Narr_EJun68ZrJESEVRWDCW9ZRg"><ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_drts_AtmKkMember_rsvutQDxxkWFvd6im8QGtQ" decimals="2" format="ixt:numdotdecimal" name="drts:DisposalGroupIncludingDiscontinuedOperationOwnershipDisposed" scale="-2" id="Narr_6d8TGPNnZEKHHVeGvPiXlg">100</ix:nonFraction></ix:nonFraction>%of ATM KK. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">In July&#160;2019, the Company established a fully owned subsidiary in Canada &#8220;Alpha Tau Medical Canada&#160;Inc.&#8221; (hereafter: ATM Canada Inc). ATM Canada Inc began its activity in March&#160;2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">On July&#160;7, 2021, the Company entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) with Healthcare Capital Corp., a Delaware corporation (&#8220;HCCC&#8221;), and Archery Merger Sub&#160;Inc., a Delaware corporation and wholly-owned subsidiary of the Company (&#8220;Merger Sub&#8221;). As part of the completion of business combination on March&#160;7, 2022 (the &#8220;closing date&#8221;), the Merger Sub was merged with and into HCCC (the &#8220;Merger&#8221;), with HCCC survived the merger as a wholly owned subsidiary of the Company (for further information see note 14b).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The novel coronavirus&#160;(&#8220;COVID-19&#8221;)&#160;pandemic has created and may continue to create significant uncertainty in macroeconomic conditions, and the extent of its impact on the Company&#8217;s operational and financial performance will depend on certain developments. The Company considered the impact of&#160;COVID-19&#160;on the estimates and assumptions and determined that there were no material adverse impacts on the consolidated financial statements for the period ended December&#160;31, 2021. As events continue to evolve and additional information becomes available, the Company&#8217;s estimates and assumptions may change materially in future periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="text-transform:uppercase;">f-</span><span style="text-transform:uppercase;">8</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;padding-bottom:1pt;text-align:justify;border-bottom:1.5pt solid #000000;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">U.S.&#160;dollars in thousands (except share and per share data)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:justify;margin:0pt;"><span style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_SOnb38JKQkqblrjO5Qs8HQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;1:-</b></span>GENERAL (Cont.)</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company&#8217;s activities since inception have consisted of performing research and development activities. Successful completion of the Company&#8217;s development programs and, ultimately, the attainment of profitable operations are dependent on future events, including, among other things, its ability to secure financing; obtain further marketing approvals from regulatory authorities; access potential markets; and build a sustainable customer base; attract, retain and motivate qualified personnel; and develop strategic alliances. The Company&#8217;s operations are funded by its shareholders and research and development grants and the Company intends to seek further private or public financing as well as make applications for further research and development grants for continuing its operations. Although management believes that the Company will be able to successfully fund its operations, there can be no assurance that the Company will be able to do so or that the Company will ever operate profitably.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company expects to continue to incur substantial losses over the next several&#160;years during its clinical development phase. To fully execute its business plan, the Company will need to complete registrational clinical studies and certain development activities as well as manufacture the required clinical and commercial products in its manufacturing plants. Further, the Company will seek further regulatory approvals prior to commercialization and the Company will need to establish sales, marketing and logistic infrastructures. These activities may span many&#160;years and require substantial expenditures to complete and may ultimately be unsuccessful. Any delays in completing these activities could adversely impact the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;">As of December&#160;31, 2021, the Company had cash, cash equivalents, short-term deposits and restricted cash of $<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="drts:CashCashEquivalentsShortTermDepositsAndRestrictedCash" scale="3" id="Narr_UU3Rycg8OEeqC8q7jDVbJQ">31,934</ix:nonFraction>. During the&#160;year ended December&#160;31, 2021, the Company incurred a net loss of $<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Narr_IDSpsarAMUqypnld_SZaZA">27,271</ix:nonFraction> and had negative cash flows from operating activities of $<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Narr_qgBv4vKPNUCW04gQViflXA">11,812</ix:nonFraction>. In addition, the Company had an accumulated deficit of $<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Narr_zUNXQ7wAc02OlZtWKkJ_Cw">52,840</ix:nonFraction> on December&#160;31, 2021. The Company believes that its existing capital resources will be adequate to satisfy its expected liquidity requirements for at least <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" format="ixt-sec:durwordsen" name="drts:CurrentResourcesCoverageOfLiquidityRequirements" id="Narr_E62Oh_NQUUWMYIW5MtcxlA">two&#160;years</ix:nonNumeric> (for further information see note 13b).</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_s8O6byrZ2E6Dt-PJymgCnQ" continuedAt="Tb_s8O6byrZ2E6Dt-PJymgCnQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;2:-</b></span>SIGNIFICANT ACCOUNTING POLICIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The consolidated financial statements are prepared according to United States generally accepted accounting principles (&#8220;U.S. GAAP&#8221;). The significant accounting policies are applied in the preparation of the financial statements on a consistent basis, as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="us-gaap:UseOfEstimates" id="Tb_OU-7vyttZ02jDyGf5HN94w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">a.&#160;&#160;&#160;&#160;&#160;Use of estimates for the preparation of financial statements:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The preparation of the consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, the Company&#8217;s management evaluates estimates, including those related to fair values of convertible preferred shares warrants, fair values of share-based awards, deferred taxes, and contingent liabilities. Such estimates are based on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="text-transform:uppercase;">f-</span><span style="text-transform:uppercase;">9</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;padding-bottom:1pt;text-align:justify;border-bottom:1.5pt solid #000000;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">U.S.&#160;dollars in thousands (except share and per share data)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:justify;margin:0pt;"><span style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_s8O6byrZ2E6Dt-PJymgCnQ_cont1" continuedAt="Tb_s8O6byrZ2E6Dt-PJymgCnQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;2:-</b></span>SIGNIFICANT ACCOUNTING POLICIES (Cont.)</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="Tb_nJ5GUYwZEUyK6RVMVFTJMA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">b.&#160;&#160;&#160;&#160;&#160;Consolidated financial statements in U.S.&#160;dollars:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The accompanying consolidated financial statements have been prepared in U.S.&#160;dollars.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">A substantial portion of the Company&#8217;s expenses are incurred in New Israeli Shekels. However, the Company finances its operations mainly in U.S. dollars, a substantial portion of its expenses are incurred in U.S. dollars and revenues from its primary markets are anticipated to be generated in U.S. dollars. As such, the Company&#8217;s management believes that the U.S. dollar is the currency of the primary economic environment in which the Company operates. Thus, the functional and reporting currency of the Company is the U.S.&#160;dollar.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">A subsidiary&#8217;s functional currency is the currency of the primary economic environment in which the subsidiary operates; normally, that is the currency of the environment in which a subsidiary primarily generates and expends cash. In making the determination of the appropriate functional currency for a subsidiary, the Company considers cash flow indicators, local market indicators, financing indicators and the subsidiary&#8217;s relationship with both the parent company and other subsidiaries. For subsidiaries that are primarily a direct and integral component or extension of the parent entity&#8217;s operations, the U.S. dollar is the functional currency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company has determined the functional currency of its foreign subsidiaries is the U.S.&#160;Dollar. The foreign operations are considered a direct and integral part or extension of the Company&#8217;s operations. The&#160;day-to-day&#160;operations of the foreign subsidiaries are dependent on the economic environment of the U.S.&#160;Dollar.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Transactions and balances denominated in U.S. dollars are presented at their original amounts. Monetary accounts maintained in currencies other than the dollar are&#160;re-measured&#160;into dollars in accordance with Accounting Standards Codification No.&#160;830, &#8220;Foreign Currency Matters&#8221; (&#8220;ASC 830&#8221;). All transaction gains and losses of the&#160;re-measurement&#160;of monetary balance sheet items are reflected in the statements of operations as financial income or expenses, as appropriate.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="us-gaap:ConsolidationPolicyTextBlock" id="Tb_nW-SXvKtN0iwVAY1j6HSXQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">c.&#160;&#160;&#160;&#160;&#160;Principles of consolidation:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany balances have been eliminated upon consolidation.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_9ZdiZnMUzUmP8yQ1FAICSg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">d.&#160;&#160;&#160;&#160;&#160;Cash equivalents:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Cash equivalents are short-term, highly liquid investments that are readily convertible into cash with an original maturity of three&#160;months or less, at the date acquired.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="text-transform:uppercase;">f-</span><span style="text-transform:uppercase;">10</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;padding-bottom:1pt;text-align:justify;border-bottom:1.5pt solid #000000;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">U.S.&#160;dollars in thousands (except share and per share data)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:justify;margin:0pt;"><span style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_0CuusZXNwEuXvNW7lmqFcQ_1_2"></a><a id="Tc_uZ0c-jwMUEOqvqGpkXbI8Q_2_2"></a><a id="Tc_Ro7ygEyiiEy1Q_S-U8nk0w_2_5"></a><a id="Tc_71JrDrtzCEavG0HcNuoq9Q_3_0"></a><a id="Tc_KMpOAavGd0KIPPP_7nIimA_3_2"></a><a id="Tc_tcATaa4u2UC8rH55CKs2XA_3_5"></a><a id="Tc_gBDxQ7CvgEeCY_J_di3fFQ_4_0"></a><a id="Tc_DXZWVE2g0E-O36Zr8yycBQ_5_0"></a><a id="Tc_LRcZEYdpbkCVywDHO1SLDg_5_2"></a><a id="Tc_8L-Uw8S0yU2lRmCckV020w_5_5"></a><a id="Tc_Cnjyahk_2ke46UJ5dwbLWQ_1_2"></a><a id="Tc_L__8OAODEEacXZpw-Ksu1A_2_0"></a><a id="Tc_B0ybnxI1SESPbbgfk_Hkbw_3_0"></a><a id="Tc_ElOB_wzSGEyLBogdhuToRw_3_2"></a><a id="Tc_xl7dT17TkUqtVDXSf9p4Dg_4_0"></a><a id="Tc_yJrb-aMKoUywIUfFTMOa7A_4_2"></a><a id="Tc_82UBLWdkpkS3xdO8Zpj8kA_5_0"></a><a id="Tc_g1QrCHeIk0KRKvF5qd20Ig_6_0"></a><a id="Tc_jbpT1_xHD06Yyu4aivFG3w_7_0"></a><a id="Tc_0KZlotzlmkuaKP-zC6LJTw_7_2"></a><ix:continuation id="Tb_s8O6byrZ2E6Dt-PJymgCnQ_cont2" continuedAt="Tb_s8O6byrZ2E6Dt-PJymgCnQ_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;2:-</b></span>SIGNIFICANT ACCOUNTING POLICIES (Cont.)</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="Tb_-mPpOeE_wEiVWHOnAn5JAg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">e.&#160;&#160;&#160;&#160;&#160;Restricted cash:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Restricted cash is primarily invested in bank deposits and is used as security for the Company&#8217;s lease commitments. The following table provides a reconciliation of the cash and cash equivalents balances reported on the balance sheets and the cash, cash equivalents and restricted cash balances reported in the statements of cash flows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="Tb_5eYoK2dcJ0qw6e2Ef3eQDA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Cash and cash equivalents, as reported on the balance sheets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_F1-fmF33C0GJ9DacBjFOPA_3_3">15,598</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_aRO_Sd8j802fgSeI0t7GWA_3_6">23,236</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Restricted cash, as reported on the balance sheets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_iPrFL4hvAki0RZO9zdfyWA_4_3">576</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.75pt 0pt 0pt;"><span style="font-size:11pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_WLES_ZhBBUStRbd3BOTUSw_4_6">618</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Cash, cash equivalents, and restricted cash, as reported in the statements of cash flows</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_gBPS8yVbDkW0koX7-61cRQ_5_3">16,174</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_a8DJH4crn0mZhDPKkvPe7A_5_6">23,854</ix:nonFraction></p></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="drts:ShortTermDepositsPolicyTextBlock" id="Tb_pyoMcyi1lUmTOySgJQCKlg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">f.&#160;&#160;&#160;&#160;&#160;Short-term deposits:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">A short-term bank deposit is a deposit with a maturity of more than three&#160;months but less than one&#160;year. Deposits in U.S. dollars bear interest at rates ranging from.<ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_3YDYP2NS1kWrJTyY6tlLEw" decimals="4" format="ixt:numdotdecimal" name="drts:ShortTernBankDepositInterestRate" scale="-2" id="Narr_cG0fp660GUmeD71jaOOpaw">0.05</ix:nonFraction>%-<ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_9PHxHzoF8EaVkrgQF_FmYw" decimals="4" format="ixt:numdotdecimal" name="drts:ShortTernBankDepositInterestRate" scale="-2" id="Narr_UUr3_n1XMUCjnQQ78hrsBQ">1.65</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_Bx-4ke71BkK7RwJqTEiSgw" decimals="4" format="ixt:numdotdecimal" name="drts:ShortTernBankDepositInterestRate" scale="-2" id="Narr_aAuuSEov5U6BOGRUjlDIxA">0.01</ix:nonFraction>%-<ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_YkvYRoxUekOnNqnvzrP72A" decimals="4" format="ixt:numdotdecimal" name="drts:ShortTernBankDepositInterestRate" scale="-2" id="Narr_DeqmAms2tEKjHP3Xo2QgnQ">0.62</ix:nonFraction>%, per annum, as of December&#160;31, 2020 and 2021, respectively. Short-term deposits are presented at cost, which approximates market value due to their short maturities.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Tb_eBO7DxuVcU6y-bEMaKUzbw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">g.&#160;&#160;&#160;&#160;&#160;Property and equipment, net:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following rates:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="drts:PropertyPlantAndEquipmentUsefulLivesTableTextBlock" id="Tb_lzOUEedwak6CK5Blc_bV8w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:24.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">%</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Computers and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.91%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_dZomxtzLFkWxB2CX70Casw" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_tP_Y4NkSokal7U8hZx_cWA_2_2">33</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_drts_LaboratoryEquipmentMember_zGBF3SpbBE-OhZ3qDsbqLA" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_wbkCsKDQOk6DREtqCd6HXw">10</ix:nonNumeric> - <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_drts_LaboratoryEquipmentMember_DHtJpJcfZ06X41B2GbaKSw" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_kazxDVrZYUad9AUouV-1yg">15</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Furniture and office equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_ZaOgQu4r90edkwyq9ZaeAQ" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_ZrwYb7h8pUmEtI5OxJTT2w">7</ix:nonNumeric> - <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_1lJIcyzl2ka-godfGb-vHA" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_P1hCQEDLa0GJFlev6-LnPQ">15</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Car</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AutomobilesMember_MdIVVvN1b0Gj0kdnXqxCvQ" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_cySrHd-5MUu4KdzyWSHMPg_5_2">20</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Manufacturing equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_URRNsHmmMUWu9_-B9brINQ" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_SIc0yoRMjUCHKGpB4xvBYg_6_2">10</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:24.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Over the shorter of the term of the lease or its useful life</p></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="Tb_iEfIis4_PE6T2c9Tg3vnWQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">h.&#160;&#160;&#160;&#160;&#160;Impairment of long-lived assets:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company&#8217;s long-lived assets are reviewed for impairment in accordance with ASC 360, &#8220;Property, Plant and Equipment&#8221; (&#8220;ASC 360&#8221;), whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">For the&#160;years ended December&#160;31, 2019, 2020 and 2021 there were <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="3" id="Narr_fOrO6godREWblz6WH8HG6A"><ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="3" id="Narr_ZSyz0M_-VU-wmadw5fDb3Q"><ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="3" id="Narr_eUG3J583qUuAX3I0q1gtlw">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment losses identified.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="text-transform:uppercase;">f-</span><span style="text-transform:uppercase;">11</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;padding-bottom:1pt;text-align:justify;border-bottom:1.5pt solid #000000;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">U.S.&#160;dollars in thousands (except share and per share data)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:justify;margin:0pt;"><span style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_s8O6byrZ2E6Dt-PJymgCnQ_cont3" continuedAt="Tb_s8O6byrZ2E6Dt-PJymgCnQ_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;2:-</b></span>SIGNIFICANT ACCOUNTING POLICIES (Cont.)</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_1pkYGgj1mUedcOQ1y9Ud5Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">i.&#160;&#160;&#160;&#160;&#160;Research and development expenses, net:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Research and development expenses consist of personnel costs (including salaries, benefits and share-based compensation), materials, consulting fees and payments to subcontractors, costs associated with obtaining regulatory approvals, executing pre-clinical and clinical studies and maintenance and prosecution of the Company&#8217;s intellectual property rights. In addition, research and development expenses include overhead allocations consisting of various administrative and facilities related costs. The Company charges research and development expenses as expenses when incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Grants from the Israeli Innovation Authority (IIA) are offset against research and development costs at the later of when grant receipt is assured or the expenses are incurred.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_0vdcuDyeXku1bL4lDdDxTg" continuedAt="Tb_0vdcuDyeXku1bL4lDdDxTg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">j.&#160;&#160;&#160;&#160;&#160;Accounting for share-based payments:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company accounts for share based compensation in accordance with ASC No.&#160;718, &#8220;Compensation&#160;- Stock Compensation&#8221; that requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The Company recognizes compensation expenses for the value of its awards granted based on the straight-line attribution method over the requisite service period of each of the awards. The Company recognizes forfeitures of awards as they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">For awards with no performance conditions, the Company recognizes the related share-based compensation expense on a straight-line basis over the requisite service period of the awards, including awards with graded vesting. For awards with performance conditions the share-based compensation expense is recognized if and when the Company concludes that it is probable that the performance condition will be achieved and where the performance condition awards include graded vesting, the share-based compensation expense is recognized based on the accelerated method. The Company reassesses the probability of vesting at each reporting period for awards with performance conditions and adjust compensation cost based on its probability assessment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company selected the Black-Scholes option-pricing model as the most appropriate fair value method for its option awards. The option-pricing model requires a number of assumptions, of which the most significant are the share price, volatility and the expected option term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The fair value of ordinary share underlying the options has historically been determined by management and the board of directors. Because there has been no public market for the Company&#8217;s ordinary shares, the board of directors has determined fair value of an ordinary share at the time of grant of the option by considering a number of objective and subjective factors including financing investment rounds, operating and financial performance, the lack of liquidity of share capital and general and industry specific economic outlook, amongst other factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The fair value of the underlying ordinary shares will be determined by the board of directors until such time as the Company&#8217;s ordinary shares are listed on an established stock exchange.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="text-transform:uppercase;">f-</span><span style="text-transform:uppercase;">12</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;padding-bottom:1pt;text-align:justify;border-bottom:1.5pt solid #000000;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">U.S.&#160;dollars in thousands (except share and per share data)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:justify;margin:0pt;"><span style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_-TFv37GRqEW_63UqDHzZaA_1_2"></a><a id="Tc_N6Fr7oAbXU2x-3FqxCi4Og_2_2"></a><a id="Tc_bSKbSIC-80eW1m1kBX5TfQ_2_4"></a><a id="Tc_Hb303hIXxEWGgWAoz93bdQ_2_6"></a><a id="Tc_vJNNk9AVSEKkbOKbnyk12w_3_0"></a><a id="Tc_A9jijYil9k2BixbQyvThlw_3_2"></a><a id="Tc_C1PQAyurVkmhpzzSoxAF8w_3_4"></a><a id="Tc_K_3VZZRzWki0x5sYbMcOeQ_3_6"></a><a id="Tc_wobqV2yDRU-4Ngk99T6fQg_4_0"></a><a id="Tc_A46sAgutlkGN3qUYmKp4tQ_4_2"></a><a id="Tc_PLDeKStnIUug4XYgv_H_cg_4_3"></a><a id="Tc_bYzX9uQ5qEqQHT_QnZsS2g_4_4"></a><a id="Tc_MQX0nIczCkmQsMwcLbYDtQ_4_5"></a><a id="Tc_pA_kvX-BwEqO7vA_zwvueg_4_6"></a><a id="Tc_wj34VwzgbkqoDhcqQ6HdaA_4_7"></a><a id="Tc_bMYUoRK-FU6PZrK-mBBb1g_5_0"></a><a id="Tc_cy1ZGhv6Y06KlcTl1vLmOQ_5_2"></a><a id="Tc_XV1FIFb4bE6LN2CRASg4pA_5_3"></a><a id="Tc_8KPRd69k70OgR4xBqd9FAg_5_4"></a><a id="Tc_aNClGgjrykqyM_IUTnLT3w_5_5"></a><a id="Tc_XZyGts3uGU-_tde3bQedzQ_5_6"></a><a id="Tc_G1_ajvQBMkqlu2RqlhCaqQ_5_7"></a><a id="Tc_goXHQBP6HkKgCAppHYGw9Q_6_0"></a><a id="Tc_mrW4LbIKJ06mfLa3YGK1LA_6_3"></a><a id="Tc_-S1bIjj-pUKJonLfFbIqZA_6_5"></a><a id="Tc_LXrohu1520OAXdFIFdCOlw_6_7"></a><ix:continuation id="Tb_s8O6byrZ2E6Dt-PJymgCnQ_cont4" continuedAt="Tb_s8O6byrZ2E6Dt-PJymgCnQ_cont5"><ix:continuation id="Tb_0vdcuDyeXku1bL4lDdDxTg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;2:-</b></span>SIGNIFICANT ACCOUNTING POLICIES (Cont.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The computation of expected volatility is based on actual historical share price volatility of comparable companies. For option grants that are considered to be &#8220;plain vanilla,&#8221; the Company determines the expected term using the simplified method. The simplified method deems the term to be the average of the&#160;time-to-vesting&#160;and the contractual life of the options. The Company has historically not paid dividends and has no foreseeable plans to pay dividends and, therefore, uses an expected dividend yield of zero in the option pricing model. The risk-free interest rate is based on the yield of U.S. treasury bonds with equivalent terms as the expected term of the options.</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_SEWHMmhP_0WnhelwXhYi3Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:56.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Sg0gHG4UoU-lLL3GVY6j-w" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_fbLtjuI9tECpemDgDhDKUA">5.4</ix:nonNumeric>-<ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_jB-0qsL4s0iRjn2iZ1I0eg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr__9yYJbisi0K_efchof4Xjw">7.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_QL_lHDCdIUaW2VkrmxWUYA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_1ISHeGM59Ee3pG08g1KReA">2.0</ix:nonNumeric>-<ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zmqejbh0ukqtNgBs60C6XA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_O1x2OQSSMEGGMfW_96KpRw">6.2</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_-q59_3u_sUqS3xTBriYDrg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_NJhHSey_p0G6WP4EZcUmdQ">5.0</ix:nonNumeric>-<ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_u1KsUB5GUkyYW_fz6BxGKQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_u835W4ZK0EC5D_S58p5qyw">6.3</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_S6irH3nF3kiUBJuvNW1GvQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_lyNCTSzIAkaCDjiAfji6eA">85.3</ix:nonFraction>%-<ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_S6irH3nF3kiUBJuvNW1GvQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_K0AQzijj3ECCpzxipoxpUA">88.6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_1fUps4YHpUmalFLxoLPtsg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_yvFw76v1T02WCbQBbMg3DA">90.8</ix:nonFraction>%-<ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_1fUps4YHpUmalFLxoLPtsg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_Ul4M9JuP90SMRl4z5ZzJDQ">102.1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_a-Npz0DAckea4fyrLYOJvQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_sGaSRpmyFE2XPyrLeANx9g">85.5</ix:nonFraction>%-<ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_a-Npz0DAckea4fyrLYOJvQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_YakaxR28mEyxwrp2tnN-AQ">89.2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_S6irH3nF3kiUBJuvNW1GvQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_8gyQ0_PebEuoI5wY9GJJFA">1.9</ix:nonFraction>%-<ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_S6irH3nF3kiUBJuvNW1GvQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_c-Avej1PY0yw497dVEQ76g">2.6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_1fUps4YHpUmalFLxoLPtsg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_GPas6o_v_UKODpdt11-4Dw">0.1</ix:nonFraction>%-<ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_1fUps4YHpUmalFLxoLPtsg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_DZcByEjzlUaThktUWnNg4Q">0.5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_a-Npz0DAckea4fyrLYOJvQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_y-MYWuMPp0aeB7N4aJge2A">0.8</ix:nonFraction>%-<ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_a-Npz0DAckea4fyrLYOJvQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_Bsi-MnKl406P40nXT2j6Gg">1.4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_S6irH3nF3kiUBJuvNW1GvQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_VYloemMCWkOKr6zaXdOs-g_6_2">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_1fUps4YHpUmalFLxoLPtsg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_hGpU85qCXUa13k2TdnktTw_6_4">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_a-Npz0DAckea4fyrLYOJvQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_VyIipC9G90W3hTMnvgONfA_6_6">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></div></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Total share-based compensation expenses related to employees, consultants and other service providers for the&#160;years ended December&#160;31, 2019, 2020 and 2021, amounted to $<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Narr_IcFayP0VlkGDZHAYfbNu-Q">546</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Narr_x7gl9hp4PE2wY_I1GM8wTw">596</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Narr_t2P4v29nd0mWvjNFOF63Gw">812</ix:nonFraction>, respectively.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="drts:GrantsAndParticipationsPolicyTextBlock" id="Tb_kF_JJnsSm0eCMUZmaKWB6A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">k.&#160;&#160;&#160;&#160;&#160;Grants and participations:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Royalty-bearing grants from the Israeli Innovation Authority (&#8220;IIA&#8221;) (previously known as Office of the Chief Scientist) of the Ministry of Economy and Industry in Israel for funding of approved research and development projects are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred, and are presented as a deduction from research and development expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Since the payment of royalties is not probable when the grants are received, the Company does not record a liability for amounts received from IIA until the related revenues are recognized.&#160;In the event of failure of a project that was partly financed by IIA, the Company will not be obligated to pay any royalties or repay the amounts received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company recognized participations in research and development as a reduction from research and development expenses in the amount of $ <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" scale="3" id="Narr_L6yMbRbVlEuNTY9XKy6vkA">571</ix:nonFraction>, $ <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" scale="3" id="Narr_QTZBdE5PCE6FjvMsJHJCpw">878</ix:nonFraction> and $ <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" scale="3" id="Narr_aw7-kYL160-NeI3xMyoFYg">2,459</ix:nonFraction> for the&#160;years ended December&#160;31,2019, 2020 and 2021, respectively.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="drts:ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock" id="Tb_kDjeNN4kQkW7s99wOBbRcg" continuedAt="Tb_kDjeNN4kQkW7s99wOBbRcg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">l.&#160;&#160;&#160;&#160;&#160;Convertible preferred shares and convertible preferred shares warrant liability:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company&#8217;s preferred shares are considered a &#8220;freestanding financial instrument&#8221; pursuant to ASC 480 &#8220;Distinguishing Liabilities from Equity&#8221; and are redeemable in a deemed liquidation event, which is not under the control of the Company; thus, the Company classified the shares outside permanent equity pursuant to ASC&#160;480-10-S99.&#160;As of December&#160;31, 2021, and 2020, the Company did not adjust the carrying values of the shares to the deemed liquidation values of such shares since a deemed liquidation event was not probable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="text-transform:uppercase;">f-</span><span style="text-transform:uppercase;">13</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;padding-bottom:1pt;text-align:justify;border-bottom:1.5pt solid #000000;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">U.S.&#160;dollars in thousands (except share and per share data)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:justify;margin:0pt;"><span style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_s8O6byrZ2E6Dt-PJymgCnQ_cont5" continuedAt="Tb_s8O6byrZ2E6Dt-PJymgCnQ_cont6"><ix:continuation id="Tb_kDjeNN4kQkW7s99wOBbRcg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;2:-</b></span>SIGNIFICANT ACCOUNTING POLICIES (Cont.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company&#8217;s warrants to purchase the Company&#8217;s convertible preferred shares are considered a &#8220;freestanding financial instrument&#8221; pursuant to ASC 480. The warrants were classified as a liability on the balance sheet, initially and subsequently measured at fair value through earnings, as the underlying shares are contingently redeemable (upon a deemed liquidation event, which is not under the Company&#8217;s control) and, therefore, embody an obligation that is indexed to an obligation to repurchase the Company&#8217;s shares by transferring assets. The change in fair value of the warrants is recognized as a component of financial expenses, net, in the statements of operation (see note 9).</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="Tb_3AJCHzQhnkKNUO54wuagmg" continuedAt="Tb_3AJCHzQhnkKNUO54wuagmg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">m.&#160;&#160;&#160;&#160;&#160;Fair value of financial instruments:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company applies ASC 820, &#8220;Fair Value Measurements and Disclosures&#8221; (&#8220;ASC 820&#8221;), pursuant to which fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the &#8220;exit price&#8221;) in an orderly transaction between market participants at the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Fair value is an exit price, representing the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;1-&#160;Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2&#160;- Other than quoted prices included in Level&#160;1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3&#160;- Unobservable inputs which are supported by little or no market activity.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The carrying amounts of cash and cash equivalents, short-term deposits, prepaid expenses, other receivables, trade payables, other accounts payable and accrued expenses approximate their fair value due to the short-term maturity of such instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="text-transform:uppercase;">f-</span><span style="text-transform:uppercase;">14</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;padding-bottom:1pt;text-align:justify;border-bottom:1.5pt solid #000000;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">U.S.&#160;dollars in thousands (except share and per share data)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:justify;margin:0pt;"><span style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_s8O6byrZ2E6Dt-PJymgCnQ_cont6" continuedAt="Tb_s8O6byrZ2E6Dt-PJymgCnQ_cont7"><ix:continuation id="Tb_3AJCHzQhnkKNUO54wuagmg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;2:-</b></span>SIGNIFICANT ACCOUNTING POLICIES (Cont.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The financial instruments carried at fair value on the Company&#8217;s consolidated balance sheets as of December&#160;31, 2019, 2020 and 2021 are warrants to convertible preferred shares classified as a liability (see note&#160;7).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The following methods and assumptions were used by the Company in estimating their fair value disclosures for financial instruments:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The fair value measurement of warrants to convertible preferred shares are measured using unobservable inputs that require a high level of judgment to determine fair value, and thus are classified as Level&#160;3 financial instruments. To calculate the fair value of the warrants, the Company first calculated the underlying preferred share value by using the income approach and the market approach. Then the equity value was allocated by using the hybrid model method utilizing two scenarios of OPM and IPO. Once the preferred shares value was derived from the two scenarios, the Black-Scholes model was utilized to calculate the warrants value in each one of the scenarios. Then, probability for each one of the scenarios was applied by the Company to derive the weighted average fair value of the warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Fair value estimates are made at a specific point in time, based on relevant market information and information about the financial instruments. These estimates are subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. Changes in assumptions could significantly affect these estimates.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="drts:OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock" id="Tb_6CmUMnvlbEasnwz24bFTKw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">n.&#160;&#160;&#160;&#160;&#160;Ordinary share warrants classification and measurement:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance. The assessment considers whether the warrants are freestanding financial instruments, meet the definition of a liability under ASC 480, are indexed to the Company&#8217;s own stock and whether the warrants are eligible for equity classification under ASC 815-40. This assessment is conducted at the time of warrant issuance and as of each subsequent reporting period end date while the warrants are outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Warrants that meet all the criteria for equity classification, are required to be recorded as a component of additional paid-in capital. Warrants that do not meet all the criteria for equity classification, are required to be recorded as liabilities at their initial fair value on the date of issuance and remeasured to fair value through earnings at each balance sheet date thereafter.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">As of December 31, 2020, and 2021, the Company had <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_eobfj0sETkCP8yULVX8rpw">728,017</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_t-3oJjmADk-TJ4M_vb0iAw">718,964</ix:nonFraction> outstanding ordinary share warrants, respectively. The warrants were classified as equity (see notes 10d and 10e).</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_GZA_XK571k-tUXoxISwglg" continuedAt="Tb_GZA_XK571k-tUXoxISwglg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">o.&#160;&#160;&#160;&#160;&#160;Income taxes:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company accounts for income taxes in accordance with ASC 740, &#8220;Income Taxes&#8221; (&#8220;ASC 740&#8221;). ASC 740 prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, to reduce deferred tax assets to their estimated realizable value, if needed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="text-transform:uppercase;">f-</span><span style="text-transform:uppercase;">15</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;padding-bottom:1pt;text-align:justify;border-bottom:1.5pt solid #000000;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">U.S.&#160;dollars in thousands (except share and per share data)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:justify;margin:0pt;"><span style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_s8O6byrZ2E6Dt-PJymgCnQ_cont7" continuedAt="Tb_s8O6byrZ2E6Dt-PJymgCnQ_cont8"><ix:continuation id="Tb_GZA_XK571k-tUXoxISwglg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;2:-</b></span>SIGNIFICANT ACCOUNTING POLICIES (Cont.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">ASC 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. As of December&#160;31, 2021, and 2020 no liability for unrecognized tax benefits was recorded as a result of ASC 740.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_0tbQ_0v-d0WSuwslbFSiIA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">p.&#160;&#160;&#160;&#160;&#160;Concentration of credit risks:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents, restricted cash and short-term deposits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Cash, cash equivalents, restricted cash and short-term deposits are deposited in major banks in Israel, United States and Japan. Such investments in Israel and abroad may be in excess of insured limits and are not insured in other jurisdictions. Generally, cash and cash equivalents may be redeemed upon demand and, therefore, bear minimal risk.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="drts:SeverancePayPolicyTextBlock" id="Tb_zjquw4NmPUm6eAIkcHEdpg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">q.&#160;&#160;&#160;&#160;&#160;Severance pay:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">All the Company&#8217;s employees who are Israeli citizens have subscribed to Section&#160;14 of Israel&#8217;s Severance Pay Law, 5723-1963 (&#8220;Section&#160;14&#8221;). Pursuant to Section&#160;14, employees covered by this section are entitled to&#160;monthly deposits at a rate of <ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="4" format="ixt:numdotdecimal" name="drts:SeverancePayDepositRate" scale="-2" id="Narr_qjW5jzHybU2LJokkcDdhqQ">8.33</ix:nonFraction>% of their&#160;monthly salary, made on their behalf by the Company. Payments in accordance with Section&#160;14 release the Company from any future severance liabilities in respect of those employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Neither severance pay liability nor severance pay fund under Section&#160;14 for such employees is recorded on the Company&#8217;s consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Severance pay expense for the&#160;years ended December&#160;31, 2019, 2020 and 2021 amounted to $ <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="drts:SeverancePayExpense" scale="3" id="Narr_tphtKFdt7ECTvYNRUHP8dw">117</ix:nonFraction>, $ <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="drts:SeverancePayExpense" scale="3" id="Narr_vkaAz87th0eRgX_eQWrGAg">194</ix:nonFraction> and $ <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="drts:SeverancePayExpense" scale="3" id="Narr_KBumdKZ6YEqVn4qbYk7nMw">318</ix:nonFraction>, respectively.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="Tb_TljenB4zLEG3Slpel20Vaw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">r.&#160;&#160;&#160;&#160;&#160;Contingent liabilities:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company accounts for its contingent liabilities in accordance with ASC 450, &#8220;Contingencies&#8221; (&#8220;ASC 450&#8221;). A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">As of December&#160;31, 2019, 2020 and 2021, <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2019_9X1M-BXfgEWsSJdmFxdJhA" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="0" id="Narr_omGZiTtCSE25E6roMS6fUg"><ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="0" id="Narr_Z6VxYV6S-UqZWlP55Ipzig"><ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="0" id="Narr_E2RehG1BGEWUD68MZUcKew">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> provision is recorded.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="text-transform:uppercase;">f-</span><span style="text-transform:uppercase;">16</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;padding-bottom:1pt;text-align:justify;border-bottom:1.5pt solid #000000;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">U.S.&#160;dollars in thousands (except share and per share data)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:justify;margin:0pt;"><span style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_s8O6byrZ2E6Dt-PJymgCnQ_cont8" continuedAt="Tb_s8O6byrZ2E6Dt-PJymgCnQ_cont9"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;2:-</b></span>SIGNIFICANT ACCOUNTING POLICIES (Cont.)</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_8OjorD-sVEeHzdb7WxzxEg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">s.&#160;&#160;&#160;&#160;&#160;Basic and diluted net loss per share:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company computes net loss per share using the two-class method required for participating securities. The two-class method requires income available to ordinary shareholders for the period to be allocated between ordinary shares and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. The Company considers its convertible preferred shares to be participating securities as the holders of the convertible preferred shares would be entitled to dividends that would be distributed to the holders of ordinary shares, on a pro-rata basis, on an as-converted basis. These participating securities do not contractually require the holders of such shares to participate in the Company&#8217;s losses. As such, net loss for the periods presented was not allocated to the Company&#8217;s participating securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company&#8217;s basic net loss per share is calculated by dividing net loss attributable to ordinary shareholders by the weighted-average number of shares of ordinary shares outstanding for the period, without consideration of potentially dilutive securities. The diluted net loss per share is calculated by giving effect to all potentially dilutive securities outstanding for the period using the treasury share method or the if-converted method based on the nature of such securities. Diluted net loss per share is the same as basic net loss per share in periods when the effects of potentially dilutive shares of ordinary shares are anti-dilutive.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="drts:DeferredTransactionCostsPolicyTextBlock" id="Tb_TzicNbfVwkCb7L9moS2H1g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">t.&#160;&#160;&#160;&#160;&#160;Deferred Transaction costs:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Deferred transactions costs consist primarily of accounting, legal, and other fees related to the Company&#8217;s transaction. Upon consummation of the transaction, the deferred transaction costs will be reclassified to shareholders&#8217; deficit and recorded against the proceeds from the transaction. The Company capitalized $<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_S4dFGjmRIE2hAjthSZNbJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredOfferingCosts" scale="3" id="Narr_PovQzXGzI0KSimsYzxOI8A">1,700</ix:nonFraction> of deferred offering costs within other assets, noncurrent in the consolidated balance sheets as of December&#160;31, 2021. <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_hb-EpK2zOE6IW_s6W3VP0A" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:DeferredOfferingCosts" scale="3" id="Narr_tWDEehQUrUK6jP1uL2M33w">No</ix:nonFraction> transaction costs were capitalized as of December&#160;31, 2020.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="drts:NonControllingInterestPolicyTextBlock" id="Tb_nMH1HYsD3ECaUF0xZjUzAQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">u.&#160;&#160;&#160;&#160;&#160;Non-controlling interest:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The consolidated financial statements included the Company&#8217;s accounts and the accounts of the Company&#8217;s wholly- and majority-owned subsidiaries.&#160;Non-controlling&#160;interest positions of our consolidated entities are reported as a separate component of consolidated equity from the equity attributable to the Company&#8217;s shareholders.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_3r1iD-AOY0yEF8emC9LHpw" continuedAt="Tb_3r1iD-AOY0yEF8emC9LHpw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">v.&#160;&#160;&#160;&#160;&#160;Recently Issued Accounting Pronouncements and not yet adopted</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">As an &#8220;emerging growth company&#8221;, the Jumpstart Our Business Startups Act (JOBS Act) allows the Company to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. The Company has elected to use this extended transition period under the JOBS Act. The adoption dates discussed below reflect this election.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="text-transform:uppercase;">f-</span><span style="text-transform:uppercase;">17</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;padding-bottom:1pt;text-align:justify;border-bottom:1.5pt solid #000000;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">U.S.&#160;dollars in thousands (except share and per share data)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:justify;margin:0pt;"><span style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_s8O6byrZ2E6Dt-PJymgCnQ_cont9"><ix:continuation id="Tb_3r1iD-AOY0yEF8emC9LHpw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;2:-</b></span>SIGNIFICANT ACCOUNTING POLICIES (Cont.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">In February&#160;2016, the FASB issued ASU No.&#160;2016-02, Leases, which would require lessees to recognize assets and liabilities on the balance sheet for most leases, whether operating or financing, while continuing to recognize the expenses on their income statements in a manner similar to current practice. Under the new guidance, the Company would also require to provide enhanced disclosures. The guidance states that a lessee would recognize a lease liability for the obligation to make lease payments and a right-to-use asset for the right to use the underlying asset for the lease term. The guidance will be effective for the Company as of January&#160;1, 2022, and interim periods in fiscal&#160;years beginning January&#160;1, 2023. The Company is in the initial stage of its assessment of the new standard and is currently evaluating the timing of adoption, the quantitative impact of adoption, and the related disclosure requirements. The Company anticipates the adoption of this standard will result in an increase in its noncurrent assets, and current and noncurrent liabilities recorded on the consolidated balance sheets. The Company is currently evaluating the effect that ASU No.&#160;2016-02 will have on its consolidated financial statements and related disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">In August&#160;2020, the FASB issued ASU&#160;2020-06,&#160;Debt&#160;- Debt with Conversion and Other Options (Subtopic&#160;470-20)&#160;and Derivatives and Hedging&#160;- Contracts in Entity&#8217;s Own Equity (Subtopic&#160;815-40):&#160;Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity (&#8220;ASU&#160;2020-06&#8221;).&#160;The final guidance issued by the FASB for convertible instruments eliminates two of the three models in ASC&#160;470-20&#160;that require separate accounting for embedded conversion features. Separate accounting is still required in certain cases. Additionally, among other changes, the guidance eliminates some of the conditions for equity classification in ASC&#160;815-40-25&#160;for contracts in an entity&#8217;s own equity. The guidance also requires entities to use the&#160;if-converted&#160;method for all convertible instruments in the diluted earnings per share calculation and include the effect of share settlement for instruments that may be settled in cash or shares, except for certain liability-classified share-based payment awards. ASU&#160;2020-06&#160;is effective for fiscal&#160;years beginning after December&#160;15, 2023, and interim periods within those fiscal&#160;years. The Company is currently evaluating the potential impact of this guidance on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;">In November&#160;2021, the FASB issued ASU No.&#160;2021-10, &#8220;Government Assistance (Topic 832): Disclosure by Business Entities about Government Assistance.&#8221; The new standard improves the transparency of government assistance received by most business entities by requiring the disclosure of: (1)&#160;the types of government assistance received; (2)&#160;the accounting for such assistance; and (3)&#160;the effect of the assistance on a business entity&#8217;s financial statements. This guidance is effective for financial statements issued for annual periods beginning after December&#160;15, 2021. Early adoption is permitted. The Company does not expect the adoption of the standard will have a material impact on its consolidated financial statements.</p></ix:continuation></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Tc_ymLAL6H1-k6zU1w4gJz19Q_1_2"></a><a id="Tc_1ZGAUhzLDU-s0eDr2A6LDg_2_2"></a><a id="Tc_ScdQguEwmU-8QrK7USV-kw_2_5"></a><a id="Tc_dC5f0bO9E06oE0eLRJCAtw_3_0"></a><a id="Tc_vn_DyNPLs02Yf1N7R1ZcHA_3_2"></a><a id="Tc_2Hz0d0wp1UijIRGzCoa3Ww_3_5"></a><a id="Tc_ycBD4fgoqkGiOZ7WxCSxUw_4_0"></a><a id="Tc_XOCRHPU1MEmEoqZSl0kRYA_5_0"></a><a id="Tc_2iJBnLhLx0GrkgXqH1aZkg_6_2"></a><a id="Tc_HWfw3VP45EuI4Ftxa6DYIQ_6_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="drts:PrepaidExpensesAndOtherReceivablesTextBlock" id="Tb_oVx9mW7qFUyCxhpadinY6g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;3:-</b></span>PREPAID EXPENSES AND OTHER RECEIVABLES</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="Tb_A8bJVpjvxkiVn5zGoVqDFw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Government authorities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="-3" format="ixt:numdotdecimal" name="drts:GovernmentAuthoritiesReceivable" scale="3" id="Tc_GyBy6dafM0K-RftMHxD2hA_3_3">472</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="drts:GovernmentAuthoritiesReceivable" scale="3" id="Tc_sED1PXDBiE6muKbiR-KqZA_3_6">458</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" scale="3" id="Tc_VE8pUbYQF0CydoTh-R7xtg_4_3">387</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" scale="3" id="Tc_sjRJraIkfUaoAbns2L1Eqg_4_6">227</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherReceivables" scale="3" id="Tc_bBxWUwQ99kqHfO4aKqxsQA_5_3">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherReceivables" scale="3" id="Tc_3ix18_2mHkWt_QziiY-vaQ_5_6">22</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssets" scale="3" id="Tc_AuD70tTRBk2opoNUIH6f1A_6_3">864</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssets" scale="3" id="Tc_-tvmRLhgwEWd1MQJq-okAw_6_6">707</ix:nonFraction></p></td></tr></table></div></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="text-transform:uppercase;">f-</span><span style="text-transform:uppercase;">18</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;padding-bottom:1pt;text-align:justify;border-bottom:1.5pt solid #000000;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">U.S.&#160;dollars in thousands (except share and per share data)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:justify;margin:0pt;"><span style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_na2W6eFOakWPINr5BQJDxg_1_2"></a><a id="Tc_LkICrXhd-k66RU7yg1gZ6g_2_2"></a><a id="Tc_tYXPufH16UGg1JePp-0kzQ_2_5"></a><a id="Tc_pywrxANAfUqlFT72rfn7YQ_3_0"></a><a id="Tc_yA9VkeH2UkKzoIhjHG-dgg_5_0"></a><a id="Tc_JtpljUE-b06Jc3c0yUcS8Q_5_2"></a><a id="Tc_1a5woIX3k0qW89y6A1ogUA_5_5"></a><a id="Tc_nt6XZVq8VkK6dTjdgX3b3g_6_0"></a><a id="Tc_enAeWDeT9UmI4Se3eCputA_7_0"></a><a id="Tc_5a14tJt8mkmAW9GoJFXHVg_8_0"></a><a id="Tc_J70EmdIcr0Gt7rC6CzVqXQ_9_0"></a><a id="Tc_Dztauj0GwkCSf4AsoZP_jA_10_0"></a><a id="Tc_0hI7u7XvnUK2DbsbiTRFgQ_10_6"></a><a id="Tc_IYmU_2uwF0SSKddTouKwGw_14_0"></a><a id="Tc_Sear3qr-90K9kMrBT4yBow_15_0"></a><a id="Tc_5NCG074nA02GZsPA-iM0Cg_15_2"></a><a id="Tc_fnM2JhAvIkqZqUwmwVR4jA_15_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Tb_Nwjfq-c0NkqdJpjXGUSf7g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;4:-</b></span>PROPERTY AND EQUIPMENT, NET</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_2bQftDLW1kuyoZ8U1hpr_g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Manufacturing equipment *)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_Tsmzg43NZEq8r_rl1YdOkQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_QAZyN1g0OUOt-TfwL8XRIw_5_3">5,058</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_bFz5PWOuYUWTs4rHFVh4Ig" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_-H7D3yS4PECq3OT2aL3UCA_5_6">7,238</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Computers and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_kmZMVTkZDk-WlRLrABkDOA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_fIUEfgFaSkO3CSk1OMKi_A_6_3">128</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_DR2lnPTSYkOr47Js9w5IFQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_s8I2EXdeyEeRIH2GLWx2Xw_6_6">394</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_drts_LaboratoryEquipmentMember_HT92yqEwAU2zKGWsZbh7gA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_ev7fLVz-60ah-F3OLbN_bQ_7_3">251</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_drts_LaboratoryEquipmentMember_GAJWzUvUwEyFjKgZHPzslw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_m28JFWrN7EG3Luy1scLgzA_7_6">719</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Furniture and office equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_q_uetuy3B0Wa4ahNzfjYhA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_swQbsozngUWjtsTIpG5WiA_8_3">37</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_BpY3NXZYiUacPgGpq8sVxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_NAf_vAAoC0eHDSA2LijDUg_8_6">50</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Cars</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AutomobilesMember_50PifpuGVkegwyS9RNi4Cw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_arpLIw1q2kas0XxGr8MCyQ_9_3">57</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AutomobilesMember_nSEbQEFkgkqLdoCosAad7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_h9kOZIz-GUWujj8tRG44Sw_9_6">57</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_JS-1SNXCvUeJpcN2z_gkow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_iz6mJiCjM0OrsPC0VWNoeg_10_3">34</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_uSnbjcPGjkGnfjRbjkrJ_g_12_3">5,565</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_NNMJbjXiYUydIdM-7n9Cbw_12_6">8,458</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_XFdJajl2lUqTbXqKzem7BA_14_3">170</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_Tqf5ZBHHukm46szhICQycw_14_6">912</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Depreciated cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_fgsuIuIagU25EJ3Tk_EjEQ_15_3">5,395</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_R9WbglXQukWoEE9OAyL4kQ_15_6">7,546</ix:nonFraction></p></td></tr></table></div></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Depreciation expenses amounted to $ <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Narr_fzIyElhJ1UmUou5i9UTV7w">66</ix:nonFraction>, $ <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Narr_0x7yMYgYj0q8Oj4GBBj9Dg">86</ix:nonFraction> and $ <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Narr_MRQ19UQtuU6qxkbENG2P1g">776</ix:nonFraction> for the&#160;years ended December&#160;31, 2019, 2020 and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;">During 2021 total cost of $ <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" scale="3" id="Narr_teaz7oUEyEawfEzFhm11JQ">34</ix:nonFraction> and total accumulated depreciation of $ <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" scale="3" id="Narr_Bdw5VXojXUqQyr03zUYv4w">34</ix:nonFraction> were disposed from the consolidated balance sheets.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Tc_QbuzZsvWRk6BbO7XhIRE-g_1_2"></a><a id="Tc_0YpEizmnxU6ZbHvgEyJyHQ_2_2"></a><a id="Tc_oOPrUUkGJ0SvfsMqTm7Z0A_2_5"></a><a id="Tc_nzKM723l6Uu220-AJYvUgw_3_0"></a><a id="Tc_xbRpLYBPXEGsOyn8-dEfOA_3_2"></a><a id="Tc_j-af-0s5zEe8ZDWvGo5ypw_3_5"></a><a id="Tc_uDJrCZm_lkS_9zEbNsUo5Q_4_0"></a><a id="Tc_-gNX4ks_IE25-nF8ZSwIEA_5_0"></a><a id="Tc_fsWtycc2z0O1CyY1yvlRPA_6_2"></a><a id="Tc_jQMu5YHuj0yaASZ3IPfLqA_6_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="drts:OtherPayablesAndAccruedExpensesDisclosureTextBlock" id="Tb_K7jVViZ4U0Welyk3WPHuBg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;5:-</b></span>OTHER PAYABLES AND ACCRUED EXPENSES</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="drts:ScheduleOfOtherPayablesAndAccruedExpensesTableTextBlock" id="Tb_Gmwd40FptEiUGD3PF2PGmg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Employees and payroll accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedSalariesCurrent" scale="3" id="Tc_dwrU8slzm0m24Oo4N4r1Gg_3_3">525</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedSalariesCurrent" scale="3" id="Tc_5yPEaAYSXEGRNLj1IerwGg_3_6">788</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_MDvyY-k2jEu0D02FvL2heQ_4_3">551</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_GMD-tWIKcEq-Ha-3b_gDEA_4_6">2,366</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableRelatedPartiesCurrent" scale="3" id="Tc_TqS1g_q8p0GsGx_H35hAwA_5_3">48</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableRelatedPartiesCurrent" scale="3" id="Tc_9IqpkyUGD0-GChfEvdOcmQ_5_6">48</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" scale="3" id="Tc_J34WQswSoEuSV9IQFhhimg_6_3">1,124</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" scale="3" id="Tc_-3WF0pZ3bkqHeK-toAZuZw_6_6">3,202</ix:nonFraction></p></td></tr></table></div></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_qnqHWrHTCE-Sb69GnVPO7w" continuedAt="Tb_qnqHWrHTCE-Sb69GnVPO7w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;6:-</b></span>COMMITMENTS AND CONTINGENT LIABILITIES</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company&#8217;s facilities are leased under operating lease agreements for periods ending no later than 2035. The Company also leases motor vehicles under various operating leases, the latest of which expires in 2024.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Certain motor vehicles of the Company are rented under non-cancellable operating lease agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="text-transform:uppercase;">f-</span><span style="text-transform:uppercase;">19</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;padding-bottom:1pt;text-align:justify;border-bottom:1.5pt solid #000000;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">U.S.&#160;dollars in thousands (except share and per share data)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:justify;margin:0pt;"><span style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_W6fkZWs0JUax-LAPrR0AGQ_1_0"></a><a id="Tc_E3ZdEXe4XUW0pD5tX3-fXw_2_0"></a><a id="Tc_uSCJ5CEIKUGFVX19oAz_Yg_2_2"></a><a id="Tc_6cDOb96Rr0GrSnxPEgfNtA_3_0"></a><a id="Tc_rNa6YaRwuEOa1GKvpgDemg_4_0"></a><a id="Tc_cbSszUFZdkaNiZppBUyVIA_5_0"></a><a id="Tc_AqeK7ayhIkqsqaVjqMFdAw_6_0"></a><a id="Tc_EaFgtjcgkEmBbaa32dm7TA_7_0"></a><a id="Tc_BznvHmaCyk6NKOoS503nJw_8_2"></a><ix:continuation id="Tb_qnqHWrHTCE-Sb69GnVPO7w_cont1" continuedAt="Tb_qnqHWrHTCE-Sb69GnVPO7w_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;6:-</b></span>COMMITMENTS AND CONTINGENT LIABILITIES (Cont.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Future minimum lease payments under operating leases as of December&#160;31, 2021 are as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_MXnlhY92N0KtM5lbtJgNrQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">As of December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_v_2-A0ENw0qZs-lM4mpf2w_2_3">775</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_h2NevaM4SEio0tfy8qmJXA_3_3">722</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_axap3N1jlEKgQQx82eWLXQ_4_3">724</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="Tc_Q_-uF4hanE6p-FmRyzmpVA_5_3">590</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="Tc_04vZbE8EsUqoTX2gttY2cA_6_3">605</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="Tc__5gW6V76kUechUuVjESEqQ_7_3">4,948</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_d9bIYswFNUy-_hkiQY4jtA_8_3">8,364</ix:nonFraction></p></td></tr></table></div></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Rental and lease expenses for the&#160;years ended December&#160;31, 2019, 2020 and 2021 were $ <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="3" id="Narr_XNJ3aOPQdk-paUWZsq4MmQ">158</ix:nonFraction>, $ <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="3" id="Narr_V4y47tk9bkigRr6L8tqZfg">408</ix:nonFraction> and $ <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="3" id="Narr_IB5FFgibvEqwMp45adD3eA">803</ix:nonFraction> respectively.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Guarantee in the amount of $&#160;<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermBankLoansAndNotesPayable" scale="3" id="Narr_7VeVTuaLqEqf4o89tTvauw">618</ix:nonFraction> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">was issued by a bank to secure rent payments.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company has received royalty-bearing grants from the IIA to finance its research and development programs in Israel, through which the Company received IIA participation payments in the aggregate amount of $ <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_IsraeliInnovationAuthorityMember_xhyc0CWH6kS_-vAND8TX1Q" decimals="-3" format="ixt:numdotdecimal" name="drts:GrantIncome" scale="3" id="Narr_StBjmQqxj06fn54ybNHsgQ">4,065</ix:nonFraction> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">through December&#160;31, 2021. In return, the Company is committed to pay IIA royalties at a rate of <ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_IsraeliInnovationAuthorityMember_drts_MethodOfPaymentRoyaltiesAxis_drts_FutureSalesOfDevelopedProductMember_srt_RangeAxis_srt_MinimumMember_GIY9mAr40kOVwTeAjK_dRA" decimals="INF" format="ixt:numdotdecimal" name="drts:RoyaltyRate" scale="-2" id="Narr_wynE00lxQEi0JL2zEUsMGg">3</ix:nonFraction>-<ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_IsraeliInnovationAuthorityMember_drts_MethodOfPaymentRoyaltiesAxis_drts_FutureSalesOfDevelopedProductMember_srt_RangeAxis_srt_MaximumMember_FUMYd9CZyEiec-h-1tOPiQ" decimals="3" format="ixt:numdotdecimal" name="drts:RoyaltyRate" scale="-2" id="Narr_GtDbNlfsrEyZkcGnfgEZBw">3.5</ix:nonFraction>% of future sales of the developed products, up to <ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_IsraeliInnovationAuthorityMember_drts_MethodOfPaymentRoyaltiesAxis_drts_FutureSalesOfDevelopedProductMember_JSAQ3iw-VUSQibua7dXDzw" decimals="INF" format="ixt:numdotdecimal" name="drts:RoyaltyPaymentAsPercentageOfGrants" scale="-2" id="Narr_bLvwG19yjkOfG8wBh9cSgw">100</ix:nonFraction>% of the amount of grants received plus interest at LIBOR rate. Through December&#160;31, 2021, <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_IsraeliInnovationAuthorityMember_xhyc0CWH6kS_-vAND8TX1Q" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:RoyaltyExpense" scale="0" id="Narr_ISMNpUAgn0qBo9UrEBWETA">no</ix:nonFraction> royalties have been paid or accrued. In addition, under the intellectual property purchase agreement with Althera, the Company assumed all of Althera&#8217;s liabilities towards the IIA totaling $ <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_AltheraMember_GvfqErhqZEeZc_TxFNeN5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAssumed1" scale="3" id="Narr_y3FbNTMxBUmjC-9d-cilqA">474</ix:nonFraction> of royalty-bearing grants received by Althera (plus accrued interest at LIBOR rate). The Company&#8217;s liability to the IIA at December&#160;31, 2021, including royalty-bearing grants received by the Company, grants assumed from Althera and the associated LIBOR interest accrued on all such grants, totaled $ <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_IsraeliInnovationAuthorityMember_xhyc0CWH6kS_-vAND8TX1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAssumed1" scale="3" id="Narr_DXEfAwkXjUmUtdQvqjGujA">5,061</ix:nonFraction>.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">d.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Under the February&#160;2, 2016 intellectual property purchase agreement with Althera, the Company is obligated to pay Althera a fixed rate of <ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_AltheraMember_drts_MethodOfPaymentRoyaltiesAxis_drts_FutureGrossRevenuesDerivedFromPurchasedIntellectualPropertyMember_nP72Cyn7NkCYPc6GpcX5BA" decimals="INF" format="ixt:numdotdecimal" name="drts:RoyaltyRate" scale="-2" id="Narr_MsvETEHWXUiqi1RWvb6X_Q">2</ix:nonFraction>% (plus VAT) of Company&#8217;s future gross revenues (as defined in the agreement) that are derived from the purchased intellectual property, up to a maximum amount of $ <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_AltheraMember_GvfqErhqZEeZc_TxFNeN5g" decimals="-3" format="ixt:numdotdecimal" name="drts:PotentialPayment" scale="3" id="Narr_HknZo7dJwkKb2lYgl6KuRg">1,500</ix:nonFraction> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(plus VAT), in the aggregate, with the potential to set off against certain payments made by the Company to the IIA.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">e.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company also entered into intellectual property agreements with Ramot at Tel Aviv University&#160;Ltd., the technology transfer company of Tel Aviv University (&#8220;Ramot&#8221;) on April&#160;21, 2016 and July&#160;14, 2016, all as amended on May&#160;5, 2019, pursuant to which the Company is obligated to pay Ramot a fixed royalty of <ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_RamotMember_drts_MethodOfPaymentRoyaltiesAxis_drts_NetSalesOfAllCompanySProductMember_xoU_wft5E0-hugLOshOmLg" decimals="3" format="ixt:numdotdecimal" name="drts:RoyaltyRate" scale="-2" id="Narr_ul90UdyqQUm-4A59mXkepw">2.5</ix:nonFraction>% on net sales of all of the Company&#8217;s products (as defined in the agreement) by the Company and its affiliates, with no set maximum. The royalty will be payable as of the first commercial sale (as defined in the agreement), until the later of: 15&#160;years; or until the last to expire of the patents or patent applications from research developed at Tel Aviv University and assigned to the Company, on a country-by-country, product-by-product basis. The Company is also obligated to pay a <ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="INF" format="ixt:numdotdecimal" name="drts:RoyaltyRate" scale="-2" id="Narr_kAtkdQ6VQkOy5smrUo6BVA">7</ix:nonFraction>% royalty (and in no event less than <ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_1_1_2021_To_12_31_2021_drts_MethodOfPaymentRoyaltiesAxis_drts_NetSalesOfAllCompanySProductSoldByCompanySLicensesMember_gkrRFhGJnEimcQjvPTPPcQ" decimals="4" format="ixt:numdotdecimal" name="drts:RoyaltyPaymentAsPercentageOfGrants" scale="-2" id="Narr_0AMeebIZf0KiEMfaAaVk0g">0.65</ix:nonFraction>% of the net sales of Company products sold by the Company&#8217;s licensees in a given&#160;year) on any royalties or revenues received by the Company from its licensees.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="text-transform:uppercase;">f-</span><span style="text-transform:uppercase;">20</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;padding-bottom:1pt;text-align:justify;border-bottom:1.5pt solid #000000;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">U.S.&#160;dollars in thousands (except share and per share data)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:justify;margin:0pt;"><span style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_qnqHWrHTCE-Sb69GnVPO7w_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;6:-</b></span>COMMITMENTS AND CONTINGENT LIABILITIES (Cont.)</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">f.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Under an Operations Partner Agreement between the Company and services provider HekaBio K.K. of May&#160;21, 2019, the Company makes certain payments to HekaBio K.K. in exchange for consulting and administrative services in Japan, as well as payments upon the achievement of certain clinical and regulatory milestones. In addition, if HekaBio K.K. successfully assists the Company in obtaining regulatory marketing approval of the Company&#8217;s products in Japan, then the Company is to grant to HekaBio K.K. options to acquire <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_drts_HekaBioKKMember_k78dGWWtOUezu7C6qI5GDg" decimals="INF" format="ixt:numdotdecimal" name="drts:MilestoneNumberOfOrdinaryStockOptions" scale="0" id="Narr_xPxDsEuKwE6FyYTcYxl8-g">271,588</ix:nonFraction> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of the Company&#8217;s ordinary shares at a price of $<ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_HekaBioKKMember_KbAb2SB6LkyHj7B8hsEHXQ" decimals="4" format="ixt:numdotdecimal" name="drts:StockOptionExercisePrice" scale="-2" id="Narr_rO2i-7IAx0G039l39H2aPQ">4.42</ix:nonFraction> each, and to pay HekaBio K.K. a royalty of <ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_HekaBioKKMember_drts_MethodOfPaymentRoyaltiesAxis_drts_ReimbursementPriceMember_cs_dWcRnWUyl8xd3aQkyBQ" decimals="3" format="ixt:numdotdecimal" name="drts:RoyaltyRate" scale="-2" id="Narr_XM3U9BwtS0WTK89xc-eMjg">3.5</ix:nonFraction>% of the reimbursement price (as defined in the agreement) of such products in Japan and <ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_HekaBioKKMember_drts_MethodOfPaymentRoyaltiesAxis_drts_DistributionReceiptsMember_B9pb87J-lk2fbjT-Lab7cw" decimals="INF" format="ixt:numdotdecimal" name="drts:RoyaltyRate" scale="-2" id="Narr_6YV7E_eQ70q48p-kOfdMKQ">10</ix:nonFraction>% of revenues received by the Company from distribution receipts (as defined in the agreement) for such products in Japan.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">g.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">On November&#160;18, 2018 and July&#160;29, 2019, the Company entered into research and license agreements with BGN Technologies, the technology transfer company of Ben Gurion University (&#8220;BGN&#8221;), further amended on May&#160;12, 2021, wherein the Company will wholly own any intellectual property that is developed jointly by Ben Gurion University and others (including the Company), and BGN will receive <ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_BgnTechnologiesMember_drts_MethodOfPaymentRoyaltiesAxis_drts_SalesOfAlphaRadiationProductsMember_fGiGrutCqkW4dBwjPHMKtw" decimals="4" format="ixt:numdotdecimal" name="drts:RoyaltyRate" scale="-2" id="Narr_AwFoqWuYbUeq1nj1M8EtWg">0.75</ix:nonFraction>% royalties on all sales of the Company&#8217;s alpha radiation products, net of certain deductions and irrespective of the intellectual property underlying such sales, or <ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_BgnTechnologiesMember_drts_MethodOfPaymentRoyaltiesAxis_drts_SalesOfProductContainingIntellectualPropertyMember_l6QmPIm-lka3XHyr-5FdgQ" decimals="3" format="ixt:numdotdecimal" name="drts:RoyaltyRate" scale="-2" id="Narr_qH6Hfdf5gECNuSLaOmR76A">1.5</ix:nonFraction>% royalties on sales of products that contain intellectual property owned by Ben Gurion University, net of certain deductions. BGN will receive <ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_BgnTechnologiesMember_drts_MethodOfPaymentRoyaltiesAxis_drts_LicenseRevenueToJointlyDevelopedIntellectualPropertyMember_E5RwUYMMMkKa7VOuc2eEbA" decimals="INF" format="ixt:numdotdecimal" name="drts:RoyaltyRate" scale="-2" id="Narr_xlZmf6qgS0iTVy3NAl5q-w">4</ix:nonFraction>% of license revenues (as defined in the agreements) that relate to jointly developed intellectual property, and <ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_BgnTechnologiesMember_drts_MethodOfPaymentRoyaltiesAxis_drts_LicenseRevenueRelatedToIntellectualPropertyMember_MPPvAjzvLEWclU5g9v1-PA" decimals="INF" format="ixt:numdotdecimal" name="drts:RoyaltyRate" scale="-2" id="Narr_ss8UXautmUCvpYZtVyFp5w">8</ix:nonFraction>% of license revenues that relate to intellectual property developed solely by Ben Gurion University. The parties also agreed that the Company will continue to conduct research at Ben Gurion University for as long as the researchers wish to and the parties have agreed on a research budget in good faith.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">h.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">On December&#160;1, 2020, the Company entered into a clinical trial agreement with Cambridge University Hospitals NHS Trust, wherein Cambridge will receive <ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_CambridgeUniversityHospitalsNhsTrustMember_drts_MethodOfPaymentRoyaltiesAxis_drts_RevenueGeneratedFromPatentMember_j1N6BX57fkmmH4t4HBjQrg" decimals="INF" format="ixt:numdotdecimal" name="drts:RoyaltyRate" scale="-2" id="Narr_39hD0WdMuUmQ3c7ZlXA-Pg">5</ix:nonFraction>% of any marginal increase in the Company&#8217;s net sales (all as defined in the agreement) generated on account of any patent or patent claim granted from the research performed in such trial, and <ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_CambridgeUniversityHospitalsNhsTrustMember_drts_MethodOfPaymentRoyaltiesAxis_drts_NetSalesSquamousCellCarcinomaMember_oyhYZ1hIYEeJctRg2MllLA" decimals="INF" format="ixt:numdotdecimal" name="drts:RoyaltyRate" scale="-2" id="Narr_iHnyEg4tBEWmPOkO8MR7uA">2</ix:nonFraction>% of the Company&#8217;s net sales (minus the aforementioned marginal increase payment) received for the treatment of Squamous Cell Carcinoma of the vulva, for three&#160;years from the date of first sale, world-wide.</span></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_xuzMFPceAUKIZ9-gUijzRA" continuedAt="Tb_xuzMFPceAUKIZ9-gUijzRA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;7:-</b></span>FAIR VALUE MEASUREMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Financial instruments measured at fair value on a recurring basis include warrants to convertible preferred shares (see note 9). The warrants are classified as a liability in accordance with ASC 480-10-25. These warrants were classified as level 3 in the fair value hierarchy since some of the inputs used in the valuation (the share price) were determined based on management&#8217;s assumptions. To calculate the fair value of the warrants, the Company first calculated the underlying preferred share value by using the income approach and the market approach. Then the equity value was allocated by using the hybrid model method utilizing <ix:nonFraction unitRef="Unit_Standard_item_AGp3CTLP9EiC4gKcttUqYA" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="INF" format="ixt-sec:numwordsen" name="drts:NumberOfScenariosInAllocatingValueToWarrants" scale="0" id="Narr_pl6hBlaTXEeJvdMnKew2wA">two</ix:nonFraction> scenarios of OPM and IPO. Once the preferred shares value was derived from the two scenarios, the <span style="-sec-ix-hidden:Hidden_L9Ato0C33E2LNSpyydoKvQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Black-Scholes model</span></span> was utilized to calculate the warrants value in each one of the scenarios. Then, probability for each one of the scenarios was applied by the Company to derive the weighted average fair value of the warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="text-transform:uppercase;">f-</span><span style="text-transform:uppercase;">21</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;padding-bottom:1pt;text-align:justify;border-bottom:1.5pt solid #000000;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">U.S.&#160;dollars in thousands (except share and per share data)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:justify;margin:0pt;"><span style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_wsbU_tgwSE-qu9ooXn7byA_1_2"></a><a id="Tc_cfT12BmZvkqEdPfK3HDsuA_2_2"></a><a id="Tc_l5C6X4TajE6uufTLDST5Cw_2_4"></a><a id="Tc_BUuW9fvDzk2LzfQnJtRh2w_2_6"></a><a id="Tc_4X8OAbY8Okqvl887ZZ9oVw_3_0"></a><a id="Tc_-TK2mdjH40ehdnGrECgcgA_4_0"></a><a id="Tc_M0cgRSq0f0CQmLyv34fbug_4_3"></a><a id="Tc_EQSemJlaH0mjrnlwfNXKQA_4_5"></a><a id="Tc_ZBh4Za2mwkWn6Zy7cdXOXA_4_7"></a><a id="Tc_k-WW9i2x_0C4hyCxRizZGQ_5_0"></a><a id="Tc_iRo7fBfYVUCJkh15wmlSfg_5_3"></a><a id="Tc_SJFmtaFIKkSetImUXyADMg_5_5"></a><a id="Tc_CYEHwX8mXkO9av8Fn3HtFQ_5_7"></a><a id="Tc_tNJMJcUIIE6uGqh2u1d0cQ_6_0"></a><a id="Tc_Wf9qH1AJWUqNGoGETnaDHQ_6_3"></a><a id="Tc_meAs0nuGaEeIoDOuk1_pSA_6_5"></a><a id="Tc_FE75rOaMcEyfs8TqSx84kQ_6_7"></a><a id="Tc_IqKplQRdB0uXIX2bwlNulw_1_2"></a><a id="Tc_p8N3zQadAEyJlsiOwIobBw_1_5"></a><a id="Tc_qmK48BADiEOqtaybEGF0lA_2_0"></a><a id="Tc_Zzo5uX4eqE-e4iSayI36JQ_2_2"></a><a id="Tc_PkeTLTU1D0mxZXbAqZ6C1w_2_5"></a><a id="Tc_stoQHSPDM0eKXRTKPwbsXw_3_0"></a><a id="Tc_722OggtftUKalRS8lCo-uw_4_0"></a><a id="Tc_7rRRewM5MEOx0waQJ4j40A_4_2"></a><a id="Tc_urXwwW_oikKTyo2RF2Q9VQ_4_5"></a><ix:continuation id="Tb_xuzMFPceAUKIZ9-gUijzRA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;7:-</b></span>FAIR VALUE MEASUREMENTS (Cont.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The following table summarizes the assumptions used by the Company in the Black-Scholes model:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="Tb_9GeJDP6220utYp6sGeRjCA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:60.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="As_Of_12_31_2019_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_56RoFMzD20emutTGyd2S_g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Tc_tR4WPj4lY0SD0aE6STZBjQ_3_2">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="As_Of_12_31_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_gKe2q9eKk0e3gwlR_9b76A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Tc_-5N4LpejskmGljYiUm6ZFw_3_4">2.25</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="As_Of_12_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_ajdK4nogIEm72h8iR_gO5g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Tc_Tgx-Q50_UUategiaMMor9g_3_6">1.25</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="As_Of_12_31_2019_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_wDZnSvtkgU6z66pKDtkfXQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Tc_H37tOyHy-ES98QEWfTZV1A_4_2">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="As_Of_12_31_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_26q-bJ04nk64a6-bSVGKkA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Tc_V4JQ4JmBuUSl24t4-N-RpA_4_4">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="As_Of_12_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_hKjTfEKuFUCkwF-mupksAw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Tc_coMB9NQ7rEmvjeUgjEVPEw_4_6">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:60.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="As_Of_12_31_2019_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_1CGa6Hpjaku4CPgZdTORGw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Tc_GfyNTtjVxU2ggk8HdSIWuw_5_2">78.11</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="As_Of_12_31_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_6C1-PLSDy0mfoXDzXtxQwA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Tc_CT3Oh7-fDEmi-Y3rrYxltw_5_4">96.83</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="As_Of_12_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_DDHUZat3sk6fWEo027gkiw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Tc_IIAy7K9qUEmYhJsxEM5p2Q_5_6">83.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:60.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="As_Of_12_31_2019_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_66Y1DeYIKEiZUIV-AiM0QQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Tc_nMawejZue0iJft-bNoWtbA_6_2">1.91</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="As_Of_12_31_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_Jm9aG3RQCE2XotHJYhCprg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Tc_6lD1eGQPWkO983kzmJJXew_6_4">0.42</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="As_Of_12_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_o8AlyFK5_0q1GKpbfc38VQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Tc_Jic2gs-Nw0u2shbHdr_uDQ_6_6">0.75</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></div></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The change in the fair value of the preferred share warrants liability is summarized below:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="Tb_Nu4NqvJ9JUOjHenGYgB65w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2019_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_762hkA1xekWBcZRYtQnetQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_wN9DsGgmVUqsoXXMqJJyoQ_2_3">5,163</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_Vcye6381VUeQWqckP0fFwQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_q5TPX_Usm0G-hrBMR5B0lQ_2_6">5,366</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Change in fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_58F--dymdEiPpkMxGCFxLg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" scale="3" id="Tc_PyseJCEAaEW_VqR16KtKeQ_3_3">203</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_2ghnd2En8UiT0zWguTDZrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" scale="3" id="Tc_8XVSXLw6aES0eRA_QKc5eg_3_6">13,257</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">End of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_Vcye6381VUeQWqckP0fFwQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_9umelgUPZUORcE8gROXnEg_4_3">5,366</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_dsprqrhawkyPoi6VXySrYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="Tc_SVJNtq9Fck284daUd4x9mQ_4_6">18,623</ix:nonFraction></p></td></tr></table></div></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_SB6YFDBvvkiYSJVseZCksw" continuedAt="Tb_SB6YFDBvvkiYSJVseZCksw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;8:-</b></span>INCOME TAXES</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Tax rate applicable to Company:</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The corporate tax rate in Israel in 2019, 2020 and 2021 was <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2021_rqAxnV6ZuUS7C0LOKQQJbw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="0" id="Narr_r7XoOBpyu0K2law5Jce99w">23</ix:nonFraction>%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company has the status of an &#8220;Preferred Company&#8221; and &#8220;Preferred Technological Enterprise&#8221;, as defined in the Law for the Encouragement of Capital Investments, 5719-1959 and is subject to a reduced tax rate. The reduced tax rates at development area A in which the Company&#8217;s offices are located is <ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="3" format="ixt:numdotdecimal" name="drts:IncomeTaxRateReconciliationPreferredCompanyPercent" scale="-2" id="Narr_pi66g6xS5EaYhwhtcSk9kA">7.5</ix:nonFraction>%, subject to various conditions.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Income taxes on non-Israeli subsidiaries:</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company&#8217;s subsidiaries are separately taxed under the domestic tax laws of the jurisdiction of incorporation of each entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Tax rate applicable to ATM Inc:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">On December&#160;22, 2017, the United States enacted the Tax Cuts and Jobs Act (the &#8220;U.S. Tax Reform&#8221;); a comprehensive tax legislation that includes significant changes to the taxation of business entities. These changes, most of which are effective for tax&#160;years beginning after December&#160;31, 2017, include several key tax provisions that might impact the Company, among others: (i)&#160;a permanent reduction to the statutory federal corporate income tax rate from <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_drts_AtmIncMember_srt_StatementGeographicalAxis_country_US_at7B-1SAeEur5CA5l3wWEA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="0" id="Narr_tV2GeW5EREa2Fj2RvHdHKA">35</ix:nonFraction>% (top rate) to <ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_drts_AtmIncMember_srt_StatementGeographicalAxis_country_US_at7B-1SAeEur5CA5l3wWEA" decimals="INF" format="ixt:numdotdecimal" name="drts:IncomeTaxRateReconciliationPreferredCompanyPercent" scale="-2" id="Narr_5M1N8MMFW0ewEW15U55tTw">21</ix:nonFraction>% (flat rate) effective for tax&#160;years beginning after December&#160;31, 2017 ((ii)&#160;stricter limitation on the tax deductibility of business interest expense; (iii)&#160;a shift of the U.S. taxation of multinational corporations from a tax on worldwide income to a territorial system (along with certain rules&#160;designed to prevent erosion of the U.S. income tax base)&#160;(iv)&#160;a&#160;one-time&#160;deemed repatriation tax on accumulated offshore earnings held in cash and illiquid assets, with the latter taxed at a lower rate and (v)&#160;an expansion of the U.S. controlled foreign corporation (&#8220;CFC&#8221;) anti deferral starting with the CFC&#8217;s first tax&#160;year beginning in 2018 intended to tax in the U.S. &#8220;global intangible&#160;low-taxed&#160;income&#8221; (&#8220;GILTI&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="text-transform:uppercase;">f-</span><span style="text-transform:uppercase;">22</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;padding-bottom:1pt;text-align:justify;border-bottom:1.5pt solid #000000;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">U.S.&#160;dollars in thousands (except share and per share data)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:justify;margin:0pt;"><span style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_oRCp0nBo4E6rZrlCz2fDQw_1_2"></a><a id="Tc_2u81mV1HFUWrjY-fVZqgXQ_2_2"></a><a id="Tc_VV-cCUGCc0mwsZKOIQGV_w_2_5"></a><a id="Tc_CVXQ4eixtkmJZ40KwLexFQ_2_8"></a><a id="Tc_w0pizn22OEKepmYrUAbplw_3_0"></a><a id="Tc_qjV9asYdUUes06LKhkdQVw_3_2"></a><a id="Tc_wOmZTGs1B0GgyC-DM1QCDA_3_5"></a><a id="Tc_eE4cyMhyxUKZNBrK5YVGMA_3_8"></a><a id="Tc_eL246qHoVkCj0bOtW8Xh0A_4_0"></a><a id="Tc_hGFy1ttvcUuYsybKKE8nvw_5_0"></a><a id="Tc_nd1feN47fEeDNW3ffUivzw_5_2"></a><a id="Tc_5UaSYgsDuUiuSQA9zpoVIg_5_5"></a><a id="Tc_X3bzZZWQAEOIwohWW7aFMQ_5_8"></a><a id="Tc_jSEjVKa6j0yh4yGrxWpwbA_1_2"></a><a id="Tc_GqhxZhkvh0Od-o6Jpf0swA_2_2"></a><a id="Tc_rk0mlIrTBk6RB_Bp6DcbfQ_2_5"></a><a id="Tc_vZAcbmO_wUmqGYZYC8B5hQ_2_8"></a><a id="Tc_U1V3VmsAfU-mwzcwryCzSA_3_0"></a><a id="Tc_DgwHTyGi5kaepimP0_YV2Q_4_0"></a><a id="Tc_5A3NJer5G06rYawtw6EY9w_4_2"></a><a id="Tc_26y_5mspmUWYJzr75v65nA_4_3"></a><a id="Tc_H8k-GeqjZEGCNghFKLu1eQ_4_5"></a><a id="Tc_3WGmjkjvtkm6OwjoXelxVA_4_6"></a><a id="Tc_jp8-HUT_ik25vXTmCCDABw_4_8"></a><a id="Tc_FkBwEpVRc0GpYF5E7xJrxA_4_9"></a><a id="Tc_uxJpO3n6R0OZYOIu-IUgWg_5_0"></a><a id="Tc_Hbg02QUJpE2eLEqRK4rgOg_7_0"></a><a id="Tc_mJO5LHrmH0m75KnRRtoZOA_9_0"></a><a id="Tc_zAkW2O4lF0a2Gm_au6hrQg_10_0"></a><a id="Tc_oBkRWvNAiEuyMJUQL-8qTg_10_3"></a><a id="Tc__O-TeqhRSkSvPsn6q5ZVYQ_10_6"></a><a id="Tc_zUGRMO6tbkWoxBxU-Wi0vA_10_9"></a><a id="Tc_ooeUQUp-10aZqbx3bwdhtg_11_0"></a><a id="Tc_aLyn5AFBj06bBgPjrmM9XA_11_3"></a><a id="Tc_XADWh_9vHUyAq7TAWxF2qw_11_6"></a><a id="Tc_LkhqYgsNekWaGofheC-9mA_11_9"></a><a id="Tc__NgjTZSUiECKe2gf4jO8vg_13_0"></a><a id="Tc_V2-Bh2kSE06KaOhXa81bSA_13_3"></a><a id="Tc_B5ib-OXABEG9_rCOOEn_jA_13_6"></a><a id="Tc_TAKSDq_5nUi539x9eizWiw_13_9"></a><a id="Tc_RoxBKgv7Tkif61bM_bKCWA_14_0"></a><a id="Tc_adJA-v9E1kOmS1pp_kuT0Q_14_2"></a><a id="Tc_lMcKLCpmpk-f_AOckZ8Epg_14_5"></a><a id="Tc_KvelP8l7ekKbp0i15yhtXQ_14_8"></a><ix:continuation id="Tb_SB6YFDBvvkiYSJVseZCksw_cont1" continuedAt="Tb_SB6YFDBvvkiYSJVseZCksw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;8:-</b></span>INCOME TAXES (Cont.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Tax rate applicable to ATM KK (Japan-Tokyo):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The General Corporation tax (national tax in Japan) rate is <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_drts_AtmKkMember_srt_StatementGeographicalAxis_country_JP_7CxdZ9e-1k-8KSkiHCA2Aw" decimals="1" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="0" id="Narr_RSnI7amxGEaDY2ZxY4i0WQ">23.2</ix:nonFraction>% for fiscal&#160;years beginning after April&#160;2018. Local taxes are also applicable in different rates and may result in a higher effective tax rate (for example, for Tokyo-based companies the effective statutory tax rate would generally be <ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_drts_AtmKkMember_srt_StatementGeographicalAxis_country_JP_7CxdZ9e-1k-8KSkiHCA2Aw" decimals="4" format="ixt:numdotdecimal" name="drts:IncomeTaxRateReconciliationLargeCompaniesPercent" scale="-2" id="Narr_0JrhebRaaUunQX1NcuoZKw">30.62</ix:nonFraction>% for large companies, and <ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_drts_AtmKkMember_srt_StatementGeographicalAxis_country_JP_7CxdZ9e-1k-8KSkiHCA2Aw" decimals="3" format="ixt:numdotdecimal" name="drts:IncomeTaxRateReconciliationSmallCompaniesPercent" scale="-2" id="Narr_xQHFf-YpbEe8Hl0dmcEJbw">33.6</ix:nonFraction>% for small companies). Special rate of <ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_drts_AtmKkMember_srt_StatementGeographicalAxis_country_JP_7CxdZ9e-1k-8KSkiHCA2Aw" decimals="INF" format="ixt:numdotdecimal" name="drts:IncomeTaxRateReconciliationMediumCompaniesSpecialRatePercent" scale="-2" id="Narr_QVjue2-xnk-MzO4eMAJW3g">15</ix:nonFraction>% is applicable on the first JPY <span style="-sec-ix-hidden:Hidden_Z-DGe3jtHEK1rvKDxu5T2w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8M</span></span> for small and medium companies (<ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_4_1_2019_To_4_30_2019_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_drts_AtmKkMember_srt_StatementGeographicalAxis_country_JP_zK9sUscq3kOiuunJG2qXkg" decimals="INF" format="ixt:numdotdecimal" name="drts:IncomeTaxRateReconciliationLargeCompaniesPercent" scale="-2" id="Narr_DxAX7LXl5k2iC40uLUf-Pg">19</ix:nonFraction>% for larger companies for fiscal&#160;years from April&#160;2019).</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The components of the net loss (income) before tax on income were as follows:</span></td></tr></table><div style="margin-top:12pt;"></div><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="Tb_RmZcztoMLk2G-547xDrnWg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;width:32.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;ended</b>&#160;<br /><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Domestic (Israel)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" id="Tc_82jhlFwlN0ilFF6EgHMsnQ_3_3">8,898</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" id="Tc_PqCjG_6otUiK9XgjqBDK-A_3_6">9,322</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" id="Tc_Ul88YUe98kCrtHRlxq0k6A_3_9">27,089</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" sign="-" scale="3" id="Tc_a1ftvA6ZnEexKIiNLdn05A_4_3">580</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" sign="-" scale="3" id="Tc_mVvNxI1CdES1X2NSxYgjag_4_6">598</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="Tc_TScSmAeCOEGQnhNn5YAR_w_4_9">175</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="Tc_BMh12ZMip0S_Uqx2MY9EUQ_5_3">8,318</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="Tc_IUQuviWWOkyajM91qGVNpg_5_6">8,724</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="Tc_twyZPX_Vz0-NEhKnJNRqzg_5_9">27,264</ix:nonFraction></p></td></tr></table></div></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Income tax expense was as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="Tb_RGOEuEvVwkKyzkkb7TZgAQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;width:32.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;ended</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Israel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="Tc_t-VWuBQYLk-MQbcPq4GPZA_5_3">146</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="Tc_SSHABaoEwkumsaIMPMxYcA_5_6">158</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="Tc_OMu2rfJLbEqNQVVbot4Zhg_5_9">7</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total current income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="Tc_KVJ6-dFfV0eCE65m1wkSPg_7_3">146</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="Tc_q8loNIHJKk-w9C2Af8JSpQ_7_6">158</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="Tc_vehROasGl0-S8cQ-6hZFnQ_7_9">7</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Domestic (Israel)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_GBCUVHbZzUmbJTtRfMOoYQ_14_3">146</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_QZpMUrVfu0OG03CIlRc6Hw_14_6">158</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_cK4sYLfTREWNX2gKmJYHTw_14_9">7</ix:nonFraction></p></td></tr></table></div></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">d.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Net operating losses carry forward:</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company has accumulated losses for tax purposes as of December&#160;31, 2021 in the amount of approximately $ <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="3" id="Narr_Wyhlk2VorEWca38qnxR9tw">39,585</ix:nonFraction> which may be carried forward and offset against taxable income in the future for an indefinite period.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">e.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Deferred taxes:</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company&#8217;s deferred tax assets are comprised of operating loss carryforwards and other temporary differences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="text-transform:uppercase;">f-</span><span style="text-transform:uppercase;">23</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;padding-bottom:1pt;text-align:justify;border-bottom:1.5pt solid #000000;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">U.S.&#160;dollars in thousands (except share and per share data)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:justify;margin:0pt;"><span style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><a id="Tc_6D77NJ-vok6oFTNc6_XAJw_1_2"></a><a id="Tc_OjNbeTxzX0-JNlckzioVhw_2_2"></a><a id="Tc_Dzqd8Ffzb0qz04t8bnZyIw_2_5"></a><a id="Tc_M-WjV2FO1U-0mfJ0XpxcwA_3_0"></a><a id="Tc_QwnnJyIwGECITboGJr-wBw_3_2"></a><a id="Tc_W7ZT4viLZESeP-LdiIDRhw_3_5"></a><a id="Tc_kWnvx9Y6cU2XGCuf-uqWTA_4_0"></a><a id="Tc_46at8NybGkyqGJQ8DsOw-w_5_0"></a><a id="Tc_wUg0oLh8tES8ivaXtJaqaA_6_0"></a><a id="Tc_XXwb5oo72Uq6Nl72fq1LRw_7_0"></a><a id="Tc_2ZpIDN5FK0ef-WzuS60gFg_9_0"></a><a id="Tc_MFmaj6cE30S-nB89Jaw6hw_10_0"></a><a id="Tc_NART78MzSk6RV4I6Rm4qFg_11_0"></a><a id="Tc_w_D5ZCSfUEOjYX_0XJ5OXA_11_2"></a><a id="Tc_puzbvLKmJU6gb8kVspnR1g_11_3"></a><a id="Tc_u5oEZnMzNEqM8GBha2H5BA_11_5"></a><a id="Tc_9V7FoE_JiUeo8U2vZxLCJA_11_6"></a><ix:continuation id="Tb_SB6YFDBvvkiYSJVseZCksw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;8:-</b></span>INCOME TAXES (Cont.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Significant components of the Company&#8217;s deferred tax assets are as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_XJa80iGBA0ad2_pRKI3qlQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reserves and allowances</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances" scale="3" id="Tc__QyktVYOEU6613hmlE4hDg_3_3">22</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances" scale="3" id="Tc_jKcckGqXZ02MnpCirkMtdQ_3_6">18</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">R&amp;D expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" id="Tc_XaXQtB50SUmhAN7ja2c17A_4_3">482</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" id="Tc_QNsm05hnaUGdpf_a6GxptQ_4_6">399</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" id="Tc_wdGIYcY5V0yV0XHWsVjqKg_5_3">44</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" id="Tc_FuTKtMp86E6GrGaeYoPY7g_5_6">31</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_kUCIXnxx_EyX6OusFUGD0g_6_3">134</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_PBm0XASeVE-c87EZFwPIDw_6_6">33</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss carryforward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_tQpCjMUEXkaGyub7eSxyXQ_7_3">1,551</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_cgsyP96e_06lEv2cF67yqw_7_6">3,322</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets before valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_MkgBxPQksUqmtkU8q3Jw-Q_9_3">2,233</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_DqA0ROPFVkm2FLu1xZ2jAA_9_6">3,803</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less - valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_at_Cs4tjoEuGzVXa4DAQhA_10_3">2,233</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_68Ig5nK_7Eqwqgz9wfOhaA_10_6">3,803</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table></div></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Management currently believes that since the Company has a history of losses, and there is uncertainty with respect to future taxable income of the Company, it is more likely than not that the deferred tax assets will not be utilized in the foreseeable future. Thus, a full valuation allowance was provided to reduce deferred tax assets to their realizable value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">In 2020 and 2021 the main reconciling item for the Company&#8217;s tax rate is tax loss carryforwards and temporary differences, for which a full valuation allowance was provided.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">f.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Tax assessment:</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;">The Company has not received assessments since its inception.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_243be612_3ae4_4b96_9f40_a8e5f836623d"></a><a id="Tc_dAkn3Q68-kam7-3t1eS1Ng_1_2"></a><a id="Tc_Rd0BmDuJtkGmYgWdckAc8w_1_6"></a><a id="Tc_5tjt8jb2AUaJa2pDMKJLsw_2_2"></a><a id="Tc_sPWU8k-Sk0CqeQEii0YIVg_2_4"></a><a id="Tc_j8XMT6iMPUqtqlFlu69Q5w_2_6"></a><a id="Tc_J9QXnKG8E0mdWsbtPFEL2g_2_8"></a><a id="Tc_OZ-cVpahGk-CR6d92R8_Jg_2_10"></a><a id="Tc_edcOO0xVh0C0cBoHm8sOtg_2_13"></a><a id="Tc_x1_YUyog1UCn_k6uZ2fpPA_3_2"></a><a id="Tc_hyU_8-fvokuxD4tELISJhA_4_0"></a><a id="Tc_lgMh4Pai5UqWrnFtdNlSaw_4_10"></a><a id="Tc_2eNYUW8vNU27-1FvLT7fWQ_4_13"></a><a id="Tc_a0jag01mJ0mnKKppyBWwIw_5_0"></a><a id="Tc_XqdHZQZzhkqqtIiKYJAVSg_6_0"></a><a id="Tc_Ma1j966YykCr6GDYjimwbg_6_10"></a><a id="Tc_GVVbiaUSmEKrWxeBIWlZYQ_6_13"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="drts:TemporaryEquityTextBlock" id="Tb_OehYXXtojkirkpWRddg-nw" continuedAt="Tb_OehYXXtojkirkpWRddg-nw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;9:-</b></span>CONVERTIBLE PREFERRED SHARES AND WARRANTS</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Composition of the Company&#8217;s Convertible Preferred shares is as follows:</span></td></tr></table><div style="margin-top:12pt;"></div><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="us-gaap:TemporaryEquityTableTextBlock" id="Tb_pEsUQIlbUkeNb4EHT-4aIA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Authorized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issued&#160;and&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Authorized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issued&#160;and&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#231f20;font-weight:bold;">Carrying&#160;</b><b style="color:#231f20;font-weight:bold;"><br /></b><b style="color:#231f20;font-weight:bold;">amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#231f20;font-weight:bold;">Liquidation&#160;</b><b style="color:#231f20;font-weight:bold;"><br /></b><b style="color:#231f20;font-weight:bold;">preference</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="15" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:33.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:42.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of&#160;shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series A Convertible Preferred shares of no-par value *)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_drts_SeriesConvertiblePreferredSharesMember_2rsemjdtU0aLnNvzSudxpQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Tc_Mncq1zZ_106u-MgL5ZmYfQ_4_2">16,295,256</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_drts_SeriesConvertiblePreferredSharesMember_2rsemjdtU0aLnNvzSudxpQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="Tc_bCFVg1ZD4UWurK2A3yEBXQ_4_4">7,229,885</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_drts_SeriesConvertiblePreferredSharesMember_Ciu93EXH3Uu0zKZgtaOVHQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Tc_YjDSifYJrUG3oVqkq2SgEg_4_6">16,295,256</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_drts_SeriesConvertiblePreferredSharesMember_Ciu93EXH3Uu0zKZgtaOVHQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="Tc_uacO1YxwIEStYz3NeSAvXQ_4_8">7,229,885</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_drts_SeriesConvertiblePreferredSharesMember_Ciu93EXH3Uu0zKZgtaOVHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" scale="3" id="Tc_p6GIQdGwoEisxTFa-q58vg_4_11">25,238</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_drts_SeriesConvertiblePreferredSharesMember_Ciu93EXH3Uu0zKZgtaOVHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="Tc_X_rrXXIzakKcLMdS4ztcVg_4_14">36,437</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:33.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series B Convertible Preferred shares of no- par value *)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_drts_SeriesBConvertiblePreferredSharesMember_aujqloiYdUqLgyG-IywV-g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Tc_LqVqclq_JEi4L6OmBJTt8w_5_2">9,052,920</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_drts_SeriesBConvertiblePreferredSharesMember_aujqloiYdUqLgyG-IywV-g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="Tc_3J9rSQXAI0qEFZmNbnG8ng_5_4">6,509,301</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_drts_SeriesBConvertiblePreferredSharesMember__unz0Gwr4U6xfvew_rt8qg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Tc_mvSDijtwoESZ6AUjwl0KAw_5_6">9,052,920</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_drts_SeriesBConvertiblePreferredSharesMember__unz0Gwr4U6xfvew_rt8qg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="Tc_YRSWubzyjk6Q31pHq_tmag_5_8">6,509,301</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_drts_SeriesBConvertiblePreferredSharesMember__unz0Gwr4U6xfvew_rt8qg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" scale="3" id="Tc_JCJQUF7-VEWmPYo0qwYwow_5_11">28,726</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_drts_SeriesBConvertiblePreferredSharesMember__unz0Gwr4U6xfvew_rt8qg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="Tc_xatdXIyTzkqqVA0Car8XsQ_5_14">28,761</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:33.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Tc_qy4RGCextUKB6JD27IY9xA_6_2">25,348,176</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="Tc_i4HTP7aEu0am-IfZNSg7og_6_4">13,739,186</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Tc_QibM1fnmy0WkhOK_v-RK7w_6_6">25,348,176</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="Tc_7GHgS0kYdU2JjfO4iSgghw_6_8">13,739,186</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" scale="3" id="Tc_49WtNRt7Q0We0O-nLKHS7Q_6_11">53,964</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="Tc_QTZcMLBNu0KGD0V9RCwmlg_6_14">65,198</ix:nonFraction></p></td></tr></table></div><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-left:72pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">*)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Prior period results have been retroactively adjusted to reflect the 1: <ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_3_7_2022_To_3_7_2022_zxGQCP-7Fk277229BSbBmw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="Narr_oAPQ6utGekaS6k0maftYUg">0.905292</ix:nonFraction> stock split effected on March&#160;7, 2022. See also note 10, Shareholders&#8217; Deficiency, for details.</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company issued Series&#160;A convertible preferred shares in 2018 and Series&#160;B convertible preferred shares in 2020. The Company classifies the convertible preferred shares outside of shareholders&#8217; deficiency as required by ASC 480-10-S99, since these convertible preferred shares are entitled to liquidation preferences which may trigger a deemed liquidation event that is not solely within the Company&#8217;s control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="text-transform:uppercase;">f-</span><span style="text-transform:uppercase;">24</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;padding-bottom:1pt;text-align:justify;border-bottom:1.5pt solid #000000;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">U.S.&#160;dollars in thousands (except share and per share data)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:justify;margin:0pt;"><span style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_OehYXXtojkirkpWRddg-nw_cont1" continuedAt="Tb_OehYXXtojkirkpWRddg-nw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;9:-</b></span>CONVERTIBLE PREFERRED SHARES AND WARRANTS (Cont.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Pursuant to the Company&#8217;s Amended and Restated Articles of Incorporation (the &#8220;AoA&#8221;), a deemed liquidation event would occur, inter alia, upon the closing of the transfer of the Company&#8217;s securities to a person or a group of affiliated persons, in one or a series of related transactions, if immediately after such transaction, such person or group of affiliated persons would hold <ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="Narr__qFR1toVP0CoQQB9LeL1sQ"><ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="Narr_JODvJIInYEK6Dg4fKVSNCw">50</ix:nonFraction></ix:nonFraction>%or more of the outstanding voting shares of the Company and upon the occurrence of the events listed in the AoA. For the&#160;years ended December&#160;31, 2021 and 2020, the Company did not adjust the carrying values of the convertible preferred shares to the deemed liquidation values of such shares since a deemed liquidation event was not probable at each balance sheet date. Subsequent adjustments to increase the carrying values to the ultimate liquidation values will be made only when it becomes probable that such a deemed liquidation event will occur. </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Preferred shares rights:</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Preferred A and the Preferred B shares (collectively, the &#8220;Preferred Shares&#8221;) confer upon their holders all the rights conferred by Ordinary shares, in addition to certain rights stipulated in the Company&#8217;s AoA, inter alia, the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><i style="font-style:italic;">Dividend rights&#160;- </i>the convertible Preferred B shares shall be entitled to receive, prior and in preference to the declaration or payment of any dividend to the holders of any other class of shares, including the Preferred A shares, for each Preferred B share, cumulative dividends (whether paid in cash or otherwise) if and when declared by the Company&#8217;s board of directors, in an amount equal to the Preferred B share original issue price (the &#8220;Series&#160;B Dividend Preference&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Following the payment in full of all of the Series&#160;B Dividend Preference, the convertible Preferred A shares shall be entitled to receive, prior and in preference to the declaration or payment of any dividend to the holders of any other class of shares, including the ordinary shares, for each Preferred A share, cumulative dividends (whether paid in cash or otherwise) if and when declared by the Company&#8217;s board of directors, in an amount equal to <ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_drts_SeriesConvertiblePreferredSharesMember_Ciu93EXH3Uu0zKZgtaOVHQ" decimals="4" format="ixt:numdotdecimal" name="drts:TemporaryEquityDistributionRateFromProceedsOfSaleAnotherClassOfShares" scale="-2" id="Narr_m4XlLY6KgEC7nwIXpe1sww">1.25</ix:nonFraction>x the Preferred A share original issue price (the &#8220;Series&#160;A Dividend Preference&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Following the payment in full of all of the Series&#160;A Dividend Preference, the holders of the Preferred Shares and the ordinary shares shall be entitled to receive, on a pro-rata, as-converted basis, any and all other dividends distributed by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><i style="font-style:italic;">Liquidation rights&#160;-</i> In the event of any event of liquidation or deemed liquidation event, the Company shall distribute all distributable proceeds first to the holders of the Preferred B shares, on a pro-rata basis among themselves, prior to and in preference to any payments to any of the holders of any other classes of shares, for each Preferred B share, the greater of: (a)&#160;the Preferred B share original issue price, plus an amount equal to the declared but unpaid dividends, less any Series&#160;B Dividend Preference amount previously declared and actually paid, and (b)&#160;the pro rata portion of the distributable proceeds the Preferred B shares would receive if all the distributable proceeds were distributed to all shareholders, on a pro-rata and as-converted-to-ordinary shares basis (the &#8220;Series&#160;B Preference&#8221;). In the event of insufficient distributable proceeds, distribution shall be done ratably among the holders of the Preferred B shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="text-transform:uppercase;">f-</span><span style="text-transform:uppercase;">25</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;padding-bottom:1pt;text-align:justify;border-bottom:1.5pt solid #000000;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">U.S.&#160;dollars in thousands (except share and per share data)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:justify;margin:0pt;"><span style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_OehYXXtojkirkpWRddg-nw_cont2" continuedAt="Tb_OehYXXtojkirkpWRddg-nw_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;9:-</b></span>CONVERTIBLE PREFERRED SHARES AND WARRANTS (Cont.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Following payment in full of the Series&#160;B Preference, the Company shall distribute the remaining distributable proceeds to the holders of Preferred A shares, on a pro-rata basis among themselves, prior to and in preference to any payments to any of the holders of any other classes of shares, for each Preferred A share, the greater of: (a)&#160;<ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_drts_SeriesConvertiblePreferredSharesMember_Ciu93EXH3Uu0zKZgtaOVHQ" decimals="4" format="ixt:numdotdecimal" name="drts:TemporaryEquityDistributionRateFromProceedsOfSaleAnotherClassOfShares" scale="-2" id="Narr_ffmnsAWgnEO-_EJzfjqcYg">1.25</ix:nonFraction>x the Preferred A share original issue price, plus an amount equal to the declared but unpaid dividends, less any Series&#160;A Dividend Preference amount previously declared and actually paid, and (b)the pro rata portion of the distributable proceeds the Preferred A shares would receive if all the distributable proceeds were distributed to all shareholders, on a pro-rata and as-converted-to-ordinary shares basis (the &#8220;Series&#160;A Preference&#8221;). In the event of insufficient distributable proceeds, distribution shall be done ratably among the holders of the Preferred A shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Following the payment in full of the Series&#160;A Preference, the holders of the ordinary shares shall be entitled to receive, on a pro rata basis among themselves, any and all remaining distributable proceeds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><i style="font-style:italic;">Voting rights</i>&#160;- each holder of Preferred Shares is entitled to <ix:nonFraction unitRef="Unit_Standard_Vote_yl2FdYUkMUizA1ZcpmmCgA" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="INF" format="ixt-sec:numwordsen" name="drts:TemporaryEquityNumberOfVotes" scale="0" id="Narr_pPjEV6TrW0q9DYrx1tbviA">one</ix:nonFraction>&#160;vote per each share held by it (on an as-converted-to-ordinary share basis).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><i style="font-style:italic;">Conversion</i>&#160;- each Preferred Share is automatically convertible into ordinary shares, at the respective holder&#8217;s option, or automatically upon a qualified IPO of the Company or upon written demand of the Investor Majority (each as defined in the AoA) for each respective class of shares. The initial conversion ratio for each Preferred Share is <ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_rPUd7br4qEWZUqZEcN3zyw">1</ix:nonFraction>:1.The conversion price per Preferred Share will be adjusted in the event of recapitalizations, share splits, ordinary share dividends, subdivisions and combinations of ordinary shares, as well in the event of certain anti-dilution events.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Financing rounds:</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">In September&#160;2018, the Company entered into a Share Purchase Agreement (as amended, the &#8220;2018 SPA&#8221;) with new and existing investors, pursuant to which <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_9_1_2018_To_9_30_2018_QkwZ1akbskyCxXcB-8mukw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="Narr_XI0atcvbekS4Sctp4orEVw">7,229,885</ix:nonFraction> Preferred A shares and <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_9_1_2018_To_9_30_2018_QkwZ1akbskyCxXcB-8mukw" decimals="INF" format="ixt:numdotdecimal" name="drts:SaleOfStockNumberOfWarrantsIssuedInTransaction" scale="0" id="Narr_EohPg9P4BUG2e7giWu9fRg">3,614,960</ix:nonFraction> warrants to Preferred A share were issued in consideration of approximately $ <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_9_1_2018_To_9_30_2018_QkwZ1akbskyCxXcB-8mukw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" scale="3" id="Narr_dXqc0ptR80Scme8GVDapvg">29,150</ix:nonFraction>, reflecting a price per share of $ <ix:nonFraction unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw" contextRef="As_Of_9_30_2018_H4Zwi9gmHkGz2evRAa1_dQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="Narr_ANzwCVgKmE-HgdLzqzETJg">4.03</ix:nonFraction>. Total issuance expenses were amounted to $ <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_9_1_2018_To_9_30_2018_QkwZ1akbskyCxXcB-8mukw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="Narr_kSSzQfJ1Ak2v6P1a3iCyeA">91</ix:nonFraction>. The warrants to Preferred A Shares were recorded at fair value in the amount of $ <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_9_1_2018_To_9_30_2018_QkwZ1akbskyCxXcB-8mukw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="3" id="Narr_nNOvcxL_b06iVD3bL_SA_A">3,821</ix:nonFraction> and the residual amount was allocated to the Preferred A Shares. The Preferred A shares can be converted into ordinary shares at a conversion ratio of <ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="As_Of_9_30_2018_H4Zwi9gmHkGz2evRAa1_dQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_4EDFPy4VXkmaaMCpPHdxYg">1</ix:nonFraction>:1, however such ratio is subject to amendment in certain situations and was adjusted in the context of the 2020 SPA, as more fully described above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">In April&#160;2020, the Company entered into a Preferred B Share Purchase Agreement (as amended, the &#8220;2020 SPA&#8221;) with new and existing investors, pursuant to which <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_StatementClassOfStockAxis_drts_SeriesBConvertiblePreferredSharesMember_bAcjFcmMGEKODAHgmn7SUA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="Narr_oocvvah-HkmykP4mLWOSKA">6,509,301</ix:nonFraction> Preferred B shares were issued in consideration of approximately $ <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_StatementClassOfStockAxis_drts_SeriesBConvertiblePreferredSharesMember_bAcjFcmMGEKODAHgmn7SUA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" scale="3" id="Narr_Yg4ukkgUpkaBFnYqsnnO0A">28,761</ix:nonFraction>, reflecting a price per share of $ <ix:nonFraction unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw" contextRef="As_Of_4_30_2020_us-gaap_StatementClassOfStockAxis_drts_SeriesBConvertiblePreferredSharesMember_30sMLfKYZ0ukHDW9qDg6NQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="Narr_UFo83V0a90-XqrlrGDT9xA">4.42</ix:nonFraction>. Total issuance expenses amounted to $ <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_StatementClassOfStockAxis_drts_SeriesBConvertiblePreferredSharesMember_bAcjFcmMGEKODAHgmn7SUA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="Narr_nNa_uukQvEyGffjqFEGhsA">35</ix:nonFraction>. The Preferred B shares can be converted into ordinary shares at a conversion ratio of <ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="As_Of_4_30_2020_us-gaap_StatementClassOfStockAxis_drts_SeriesBConvertiblePreferredSharesMember_30sMLfKYZ0ukHDW9qDg6NQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_X7-Y9bB82E-PGizGj4cXyQ">1</ix:nonFraction>:1, subject to adjustment in certain situations, more fully described above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">In conjunction with the 2020 SPA, the Company and the holders of the Preferred A shares agreed on a modified adjustment to the conversion ratio of Preferred A shares into ordinary shares as compared to the AoA in effect at that time. The conversion ratio of the Preferred A shares was adjusted to approximately <ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_drts_SeriesConvertiblePreferredSharesMember_Ciu93EXH3Uu0zKZgtaOVHQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_6R79zSJYtE2C5EYq4zIDPQ">1.07</ix:nonFraction>:1, such that <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_drts_SeriesConvertiblePreferredSharesMember_UHBSJ1OmqEK-PEYAzs74DA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="Narr_MRbhfyKbz0qb0n2PWmDNbA">7,229,885</ix:nonFraction> Preferred A shares can be converted into <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_rrpsDYs6x0SIZ6A54vpDQw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" id="Narr_Zs6enMC1K0KOyjMQjmE_vg">7,761,495</ix:nonFraction> ordinary shares of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="text-transform:uppercase;">f-</span><span style="text-transform:uppercase;">26</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;padding-bottom:1pt;text-align:justify;border-bottom:1.5pt solid #000000;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">U.S.&#160;dollars in thousands (except share and per share data)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:justify;margin:0pt;"><span style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><ix:continuation id="Tb_OehYXXtojkirkpWRddg-nw_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;9:-</b></span>CONVERTIBLE PREFERRED SHARES AND WARRANTS (Cont.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The revised Preferred A share conversion ratio, along with other amendments in the new agreement, did not result a substantial change in the fair value of the Preferred A shares. Therefore, the amendment to the agreement was accounted for as a modification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">On July&#160;6, 2021, the Company&#8217;s board of directors approved a 1: <ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_3_7_2022_To_3_7_2022_zxGQCP-7Fk277229BSbBmw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="Narr_P_VOaLJT0USFNNTMe7WY_Q">0.905292</ix:nonFraction> stock split which was effected on March&#160;7, 2022. As a result, all Ordinary shares, Convertible preferred shares, options for Ordinary Shares, warrants to Preferred Shares, exercise price and net loss per share amounts were adjusted retroactively for all periods presented in these consolidated financial statements as if the stock split and change in par value had been in effect as of the date of these consolidated financial statements.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">d.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Warrants to purchase Preferred A shares:</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Under the 2018 SPA, the Company had initially granted the Preferred A share investors an aggregate number of <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_drts_SeriesConvertiblePreferredSharesMember_UHBSJ1OmqEK-PEYAzs74DA" decimals="INF" format="ixt:numdotdecimal" name="drts:SaleOfStockNumberOfWarrantsIssuedInTransaction" scale="0" id="Narr_0IXW6XAstkqpJZNpxNfzpw">3,614,960</ix:nonFraction> warrants convertible into Preferred A shares of the Company (&#8220;Preferred A Warrants&#8221;), with an exercise price of $ <ix:nonFraction unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_drts_SeriesConvertiblePreferredSharesMember_Ciu93EXH3Uu0zKZgtaOVHQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_QR9O0lSeuEqqhPN61XD3-A">5.04</ix:nonFraction>. The number of warrants issued is subject to similar adjustments as the conversion ratio of the Preferred A shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">In connection with the 2020 SPA, the Warrants agreement was modified, and the Company subsequently granted the Preferred A share investors approximately <ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_drts_SeriesConvertiblePreferredSharesMember_UHBSJ1OmqEK-PEYAzs74DA" decimals="2" format="ixt:numdotdecimal" name="drts:WarrantsGrantedIncreaseFromNewFinancing" scale="-2" id="Narr_vbgV-UjjXkiAWHahA-tXkA">7</ix:nonFraction>% additional Preferred A Warrants, increasing the aggregate number of Preferred A Warrants to <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="INF" format="ixt:numdotdecimal" name="drts:SaleOfStockNumberOfWarrantsIssuedInTransaction" scale="0" id="Narr_5XXxqhoQFkO0oUTyw6CPEA">3,880,777</ix:nonFraction>, and reducing the exercise price to $ <ix:nonFraction unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_0MF5f0pXUE2YMmgysr1i4w">3.87</ix:nonFraction> per share. Since the Warrants were classified as a liability and subsequently measured at fair value through earnings, the effect of The Preferred A Warrants modification was reflected in the fair value of the warrants and recognized in earnings. The warrants may be converted at any time until September&#160;16, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">All outstanding Preferred A Warrants are classi&#64257;ed as a long-term liability and are re-measured at each reporting date, as the underlying shares may be redeemed upon an event which is not solely in the control of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;">As of December&#160;31, 2020 and <span style="direction:rtl;">2021</span>, <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="0" id="Narr_yrhOHL5fiEqwlUI8LYylbw">3,880,777</ix:nonFraction> Preferred A Warrants are outstanding.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_860856af_da21_4730_ab0e_5f46e621332e"></a><a id="Tc_Zvw6GusBu0a0l3_aYAz0-g_1_2"></a><a id="Tc_7UOWawli7E6HnqqlE1HFdw_1_6"></a><a id="Tc_joLicwmjUU6kFy1PwapYNg_2_2"></a><a id="Tc_inskg_1tFECQABFN9PM1rQ_2_4"></a><a id="Tc_pcL-jiabXkCpOIwkVq-7MQ_2_6"></a><a id="Tc_qV45NviaRkOv2WN2sqjiEA_2_8"></a><a id="Tc_bgkHGr1Akk2Sre-fG1FnnA_3_2"></a><a id="Tc_8fm0WmBIHUWcQewqIOSpgg_4_0"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" id="Tb_ft7E9GxXDUSQtRIA6Exygg" continuedAt="Tb_ft7E9GxXDUSQtRIA6Exygg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;10:-</b></span>SHAREHOLDERS&#8217; DEFICIENCY</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Ordinary share capital is composed as follows:</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">On July&#160;6, 2021, the Company&#8217;s board of directors approved a 1: <ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_3_7_2022_To_3_7_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_WEfc-vShRUy3Gx5vSV4mVw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="Narr_J9CqV8wJmEyicrz56kgtGA">0.905292</ix:nonFraction> stock split which was effected on March&#160;7, 2022. As a result, all Ordinary shares, Convertible preferred shares, options for Ordinary Shares, warrants to Preferred Shares, exercise price and net loss per share amounts were adjusted retroactively for all periods presented in these consolidated financial statements as if the stock split and change in par value had been in effect as of the date of these consolidated financial statements.</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="us-gaap:ScheduleOfStockByClassTextBlock" id="Tb_izIkX3MpjUeGvXEX8BV-HQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:12.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:12.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Authorized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:12.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issued&#160;and&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Authorized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issued&#160;and&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">outstanding</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:54.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of&#160;shares</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Ordinary shares of no-par value *)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_s0BI7zNnAEKLzKmtfc-EqQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Tc_zKoLrJaILEqOC7k0hRBBZw_4_2">72,423,360</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_0jQ1wpuXQEOGP5y5qmv7Cw_4_4">40,433,578</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Tc_eXulsXfku0q8PNlUW21_FQ_4_6">72,423,360</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_pY41TZxAwEWSUj_VLG2PNA_4_8">40,528,913</ix:nonFraction></p></td></tr></table></div><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-left:72pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">*)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Prior period results have been retroactively adjusted to reflect the 1: <ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_3_7_2022_To_3_7_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_WEfc-vShRUy3Gx5vSV4mVw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="Narr_35U6l95TOUK19U6yQj2MPw">0.905292</ix:nonFraction> stock split effected on March&#160;7, 2022. See also note 10, Shareholders&#8217; Deficiency, for details.</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="text-transform:uppercase;">f-</span><span style="text-transform:uppercase;">27</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;padding-bottom:1pt;text-align:justify;border-bottom:1.5pt solid #000000;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">U.S.&#160;dollars in thousands (except share and per share data)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:justify;margin:0pt;"><span style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b331f849_2654_47c1_9eb1_118d414c8512"></a><a id="Tc_XKgyurYm00uYrCJoI7b3nQ_1_0"></a><a id="Tc_cySL3Y0wHke3u7c4rn4T0Q_1_2"></a><a id="Tc_CyombppatkiEJHWUyFTDlw_2_10"></a><a id="Tc_yAqs447cTUmBsMEobP5TDA_3_4"></a><a id="Tc_ycCFOjTPN0uhXOgG06lLzw_3_10"></a><a id="Tc_JmIfgDPwMkiNmjlIj2ZoHA_4_4"></a><a id="Tc_yWdscJVEhkOsNHFqdEkjSA_4_7"></a><a id="Tc_1dti9zTilk-zxJP9K0qaWA_4_10"></a><a id="Tc_6u6TF-AG002JDYTA2lW4Pw_5_2"></a><a id="Tc_89vOzURgaEmtxOmuBCJQ2w_5_4"></a><a id="Tc_jm2CoGQsm0izmhYMd07W-Q_5_7"></a><a id="Tc_wD5QVKIgIkqiurJvp70RTw_5_10"></a><a id="Tc_yyOedbFg6EyNFR4zYJXAFg_6_2"></a><a id="Tc_1LYD8ist60-5mCABcvHr0g_6_4"></a><a id="Tc_cf79Tgjg7kuVL-g2lW1n-A_6_7"></a><a id="Tc_vxLERI8OhUWz2s4bZBYxfw_6_10"></a><a id="Tc_RRgB91xv-0Sj1Zx-BtiL1w_7_0"></a><a id="Tc_JsyAQKhhW0mqy3G7qPdjYg_7_4"></a><a id="Tc_cn9OgR2GOEGcbuGj6JF1fQ_7_7"></a><a id="Tc_xPrJpOSxSUuueQ-FZwkspw_8_0"></a><a id="Tc_uGLjML6lKkCzGmzE0PGAbQ_8_4"></a><a id="Tc_A_GbWH-H7UKYA0hSX0wUEg_9_0"></a><a id="Tc_aTTVsfDm_U6ABIvxKVapHQ_9_4"></a><a id="Tc_n66USPmP7EWI-fOxdtNTMA_10_0"></a><a id="Tc_yXF_wSYE_0u7V290D8Z9LA_10_4"></a><a id="Tc_HlKMhZ4zTUm1jkvtow9nbQ_12_0"></a><a id="Tc_S3mLhKdxR0ujoEHxNqpv2w_12_4"></a><a id="Tc_Pax82ZMzaEOXAi3kUJamog_12_7"></a><a id="Tc_dbN-ocTTtUO35Dorap2wLA_13_0"></a><a id="Tc_g5djSNSBlUKxotE9grM-5A_13_4"></a><a id="Tc_nsa9-8KNwkKZL4nOLMrvVg_13_7"></a><a id="_ce92f603_7f3d_4f07_9c34_39c3a8fc72e4"></a><a id="Tc_HGL6G4mUQ0GDW2JX_hF5pQ_1_0"></a><a id="Tc_KcLZ2HsgW0yH23OKaL6udw_1_2"></a><a id="Tc_x4aqC9PPkka67xwWIlS2Qw_2_10"></a><a id="Tc_L43oYu0rxEOis8wu2oVBog_3_4"></a><a id="Tc_9DBxONQlBU-N8jRoI91NFg_3_10"></a><a id="Tc_zXG7Jwi6k0iIHqQ1TU0Qrg_4_4"></a><a id="Tc_Q6u1H5PEFkudKfVsGFAk7Q_4_7"></a><a id="Tc_e7YmQOhS5UCJmaagUDjSlw_4_10"></a><a id="Tc_vNtc5Z_1IUWMXrZHD2mk3A_5_2"></a><a id="Tc_giOnCDEqkUWX57B6kpbRIg_5_4"></a><a id="Tc_hxanWohc7E-i_pkM2yrkBQ_5_7"></a><a id="Tc_WxaSFOhHMki_i4JWfAaFHQ_5_10"></a><a id="Tc_XOYkGfAGzE2mqszwr1cfZA_6_2"></a><a id="Tc_EC1V5wK4DUGlMkpASxFWOA_6_4"></a><a id="Tc_SBA_Bx6_bEi2uhbfGjMnYw_6_7"></a><a id="Tc_-HyUFyY_4U66v2NaBfzaPA_6_10"></a><a id="Tc_Nu4_3PCrokmivZyr4Qv_yg_7_0"></a><a id="Tc_G7ZcyM94zEaI15RF4gR1jw_7_4"></a><a id="Tc_8p9-ea711UGh66mSPXJH0A_7_7"></a><a id="Tc_pUg26xnWb0Gch1apdLnHuA_8_0"></a><a id="Tc_XDsBDHAZAkqEINMVBWkG5Q_8_4"></a><a id="Tc_rgqDBYt3WUSACqDqsA_DEw_9_0"></a><a id="Tc_eiKhdpgkukKT1gIsEiFdhg_9_4"></a><a id="Tc_xW24cz61yESEl4tPp4rnsw_10_0"></a><a id="Tc_QvojztE-J0i7CjbuT2PHKQ_10_2"></a><a id="Tc_Y85rEug3pEeykrEMwqFwmg_12_0"></a><a id="Tc_AeD5kgwJREmdfKYCqCKIJg_12_4"></a><a id="Tc_r8QedFkmQ0mysrYiwjVDEQ_12_7"></a><a id="Tc_9lhpzimSHE2nfGQvQxtriA_13_0"></a><a id="Tc_6nd2k2s8gEGswUwhWS7ziA_13_4"></a><a id="Tc_MgBntAOLbEqH4c00k4NLeQ_13_7"></a><ix:continuation id="Tb_ft7E9GxXDUSQtRIA6Exygg_cont1" continuedAt="Tb_ft7E9GxXDUSQtRIA6Exygg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;10:-</b></span>SHAREHOLDERS&#8217; DEFICIENCY (Cont.)</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Ordinary shares rights:</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Ordinary shares confer upon their holders the right to participate in the general meetings of the Company, to vote at such meetings (each share represents <ix:nonFraction unitRef="Unit_Standard_Vote_yl2FdYUkMUizA1ZcpmmCgA" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="INF" format="ixt-sec:numwordsen" name="drts:SharesNumberOfVotes" scale="0" id="Narr_nQQJRJYOrkijyiiImm8x4w">one</ix:nonFraction> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">vote), and to participate in any distribution of dividends or any other distribution of the Company&#8217;s property, including the distribution of surplus assets upon liquidation.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In July&#160;2019, HekaBio K.K. invested an amount of $ <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_7_1_2019_To_7_31_2019_srt_CounterpartyNameAxis_drts_HekabioK.k.Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_rNX51eEBuEGWtuOpNs--fw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" scale="3" id="Narr_kZSUfCIw0Uyyj0q5en9Fvw">5,250</ix:nonFraction> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">into the Company, in exchange for <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_7_1_2019_To_7_31_2019_srt_CounterpartyNameAxis_drts_HekabioK.k.Member_r5R-uUg6Vk-zl0lhq3yl_w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="Narr_t5aB1KaUqUqnKkcuCFVNCA">1,302,132</ix:nonFraction> Ordinary shares and <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_7_1_2019_To_7_31_2019_srt_CounterpartyNameAxis_drts_HekabioK.k.Member_r5R-uUg6Vk-zl0lhq3yl_w" decimals="INF" format="ixt:numdotdecimal" name="drts:SaleOfStockNumberOfWarrantsIssuedInTransaction" scale="0" id="Narr_UNx1-Y4JzUqCMwxTl6t6Tg">651,067</ix:nonFraction> warrants to ordinary shares of the Company.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Share option plans:</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company has authorized through its 2016 Share Option Plan (the &#8220;Plan&#8221;), an available pool of Ordinary shares of the Company from which to grant options to officers, directors, advisors, management and other key employees of up to <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_drts_ShareOptionPlanMember_dFYkG00x2k-k8R6SDAZdBQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_ipfJnnSvOE2W2_IVd9sFQg">7,611,725</ix:nonFraction> Ordinary shares. The options granted generally have a <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_drts_ShareOptionPlanMember_RIX788L11EWA3ahCtQufmA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_0vPTXw6Rv0eJ7VP53jD9kw">four-year</ix:nonNumeric> vesting period and expire <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_drts_ShareOptionPlanMember_RIX788L11EWA3ahCtQufmA" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr__IgNa9Yj-kikjkYu4atVzQ">ten&#160;years</ix:nonNumeric> after the date of grant, subject to the terms set forth in the Plan. Options granted under the Plan that are cancelled or forfeited before expiration become available for future grant. As of December&#160;31, 2021, <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_drts_ShareOptionPlanMember_dFYkG00x2k-k8R6SDAZdBQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr__fmt8u7zNEif70oinv_BWQ">442,439</ix:nonFraction> of the Company&#8217;s options are available for future grants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">A summary of the status of options under the Plan as of December&#160;31, 2021 and changes during the relevant period ended on that date is presented below:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_y5q9dcuUQ06NsMFlOcL2BA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Employees</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:47.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;ended&#160;December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">intrinsic</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">contractual</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of&#160;options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">life&#160;(years)</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_Qp1t4h1WuE20sketeFkQaQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_xZNRT1IrpES7dTMsojuYaQ_7_2">4,062,408</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw" contextRef="As_Of_12_31_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_Qp1t4h1WuE20sketeFkQaQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_QEj3xNnmmkSMxPnAD4qnMg_7_5">3.40</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_Qp1t4h1WuE20sketeFkQaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_Lc9CMt6mU0K9rYA-gz4jqA_7_8">944,820</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_N81fmDen3E25LY0nhNqEwg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_985cgyof8UKvR0ZLkS30MQ_7_10"> 7.78</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:50.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_lVBebhm2NUeEc6aQ92svqw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_uBubnrqsa0KIiskDrFlYTg_8_2">1,321,211</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_lVBebhm2NUeEc6aQ92svqw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_kezqcKxF1k23Y-LC3Mnnvg_8_5">9.81</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_lVBebhm2NUeEc6aQ92svqw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_pi_qzLtGjkKTY-4qw_S7GA_9_2">4,809</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_lVBebhm2NUeEc6aQ92svqw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_fpFV8wG5D0m5H-PFa_2Utw_9_5">4.42</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited and cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_lVBebhm2NUeEc6aQ92svqw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="Tc_CoCfE2okrUWscO_RoZtcPQ_10_2">53,238</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_lVBebhm2NUeEc6aQ92svqw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_9vILTUPZtEekFR3s-o22tA_10_5">5.16</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_LahhRefsiUeIK16_07ddRQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_zZV_xzMg50mVEGa0iYMlJw_12_2">5,325,572</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw" contextRef="As_Of_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_LahhRefsiUeIK16_07ddRQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_yUo2yMYEokaAw2o1CbPhlw_12_5">4.97</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_LahhRefsiUeIK16_07ddRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_rE2COmFbDESUsTTA37mxXg_12_8">17,854,046</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_lVBebhm2NUeEc6aQ92svqw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_36jdlp28-0u4Uxpx8CIm0w_12_10"> 7.42</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:50.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_LahhRefsiUeIK16_07ddRQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_BuxewycFxUKygx9i-bxSag_13_2">3,233,657</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw" contextRef="As_Of_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_LahhRefsiUeIK16_07ddRQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_MsQx1UFJW0u8FhF9AxJUKA_13_5">3.23</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_LahhRefsiUeIK16_07ddRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="Tc_onyd-N69kEq1vor0Q26lBQ_13_8">14,184,527</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_lVBebhm2NUeEc6aQ92svqw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_0tiMAveKcEy8vvwBJpE0Nw_13_10"> 6.56</ix:nonNumeric></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Service Providers</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:47.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;ended&#160;December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">intrinsic</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">contractual&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of&#160;options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">life&#160;(years)</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_H5r7wu2GjkCR2jWr-TITxg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_ZKuhT48880SUledeu5J8VQ_7_2">662,006</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw" contextRef="As_Of_12_31_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_H5r7wu2GjkCR2jWr-TITxg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_CeIFaqiAkEuLa7fY9EQstg_7_5">2.79</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_H5r7wu2GjkCR2jWr-TITxg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_bb79aRXpuE2Fs15E6PbDMQ_7_8">313,200</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_kiT9W3vqp0OZhbNgXlCDlw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_smHW4DCVeUuH509uZbs9xQ_7_10"> 6.91</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:50.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_OSPpJbgS_kKHuzfkXV5w1Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_uakGZB61p0G9l0p0U5X78w_8_2">140,667</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_OSPpJbgS_kKHuzfkXV5w1Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_YtGPJFoEjkmas3ef_VLZLw_8_5">9.79</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_OSPpJbgS_kKHuzfkXV5w1Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_--05Jpl3UkOKtv8cKUG1mw_9_2">81,476</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_OSPpJbgS_kKHuzfkXV5w1Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_Y8Q-qf5AFEGh6FefHCnC9g_9_5">1.10</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited and cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_kZCpG9oRQUWYe1QTUnt4Mg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_d8B1fAijy0SHGFToFHwBfw_12_2">721,197</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw" contextRef="As_Of_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_kZCpG9oRQUWYe1QTUnt4Mg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_swK_RPx4yEaeJGvh69qOIw_12_5">4.34</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_kZCpG9oRQUWYe1QTUnt4Mg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_MSwRpDql7UaytiTE3QfypQ_12_8">2,695,213</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_OSPpJbgS_kKHuzfkXV5w1Q" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_vIAesrghPEqqBiICcyjVyA_12_10"> 6.61</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:50.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_kZCpG9oRQUWYe1QTUnt4Mg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_EwgIHaPZL0ePiE0uerieQg_13_2">580,745</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw" contextRef="As_Of_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_kZCpG9oRQUWYe1QTUnt4Mg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_08NojENtzU6jbUvSXqILcw_13_5">3.05</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_kZCpG9oRQUWYe1QTUnt4Mg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="Tc_hu8Gd8Zt80e5sojgyewndQ_13_8">2,649,873</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_OSPpJbgS_kKHuzfkXV5w1Q" format="ixt-sec:durhour" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_qcbzWDcT5UOf-YelIQc-zQ_13_10"> 5.89</ix:nonNumeric></p></td></tr></table></div></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="text-transform:uppercase;">f-</span><span style="text-transform:uppercase;">28</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;padding-bottom:1pt;text-align:justify;border-bottom:1.5pt solid #000000;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">U.S.&#160;dollars in thousands (except share and per share data)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:justify;margin:0pt;"><span style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_3d5f069e_a872_4634_8130_3502ba75f294"></a><a id="Tc_UhmRB7t9A0uXLpD7dJtZIQ_1_2"></a><a id="Tc_JCPvAZd8VkuNrtD6xQsxsg_2_0"></a><a id="Tc_-071k3RU6UOBrwm9lDb8aA_2_2"></a><a id="Tc_I1CDHOH-VUOJN5tfvSv1cg_3_0"></a><a id="Tc_Lc1btio5mEivTasLLlMDNQ_4_0"></a><a id="Tc_xjYgYZ-cXUuBQwc3wcm4kw_5_0"></a><a id="Tc_70U5of8dbk2TwkX9AN5Jpw_1_2"></a><a id="Tc_6QaiW-9YAEe7FQt4AmBDjQ_2_2"></a><a id="Tc_ydcX0JGEZkGsmDyaLZEXrw_2_5"></a><a id="Tc_vx-qQyukLk-dklzm-CBAxQ_2_8"></a><a id="Tc_gYHkW8DL_UW4QPLyOla9ww_3_0"></a><a id="Tc_Ujt90_UJZk-SZ3IJHheKeA_3_2"></a><a id="Tc_zapXWN0F9kCQ15OOGBHMJA_3_5"></a><a id="Tc_wQigt0clYE-ZzjktT0OZLQ_3_8"></a><a id="Tc_dFvzuo1hnEii9ZcYLkj1Ng_4_0"></a><a id="Tc_aATOitQRak6bTAoSqzIORg_5_0"></a><a id="Tc_dpKHJKkOM0ac0zzD8gBD_A_6_0"></a><a id="Tc_j-xjlhQ6qE-IfdfY9uzdUw_6_2"></a><a id="Tc_sVsoooUWTESJqMTDMGfFaQ_6_5"></a><a id="Tc_ujVlNmBBbUSHCg-Wy2rU0Q_6_8"></a><ix:continuation id="Tb_ft7E9GxXDUSQtRIA6Exygg_cont2" continuedAt="Tb_ft7E9GxXDUSQtRIA6Exygg_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE 10:-</b></span>SHAREHOLDERS&#8217; DEFICIENCY (Cont.)</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="Tb_Z7pK-xJ2NUmLeKz7RTetlQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">A summary of the status of RSUs under the Plan as of December&#160;31, 2021 and changes during the relevant period ended on that date is presented below:</p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;RSU</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:83.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" scale="0" id="Tc_BSBuRfFfZ0i1XtOgzD6riA_3_2">1,036,850</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited and cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" scale="0" id="Tc_alJfpMyA9UG8dFEwgbX9TQ_4_2">5,600</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:83.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding on December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" id="Tc_fUEESHwZlkm5Eor8CBALuA_5_2">1,031,250</ix:nonFraction></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The total equity-based compensation expense related to all of the Company&#8217;s equity-based awards recognized for the&#160;year ended December&#160;31, 2020 and 2021, was comprised as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="drts:ScheduleOfShareBasedCompensationCostsByIncomeStatementLocationTableTextBlock" id="Tb_DWEU8jPVGU2Bq3UPhqcFpA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;width:32.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;ended&#160;</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_KkiZY-M7yk-YryD1n_upAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_TcDtSzk_10mdhFiRTnYygA_3_3">380</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Y0-0nKnve0qsDthMlv68-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_eolCbYrwvEC-PZ8ydrex6g_3_6">372</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember__1I8UfYct0qja66GZyQuYw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_aHl-oGHzy065cc98CjmMqA_3_9">654</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketing expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_fv33GX4WVUa4CZlwHesWww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_atiol8ijQEqED5USLmWsZg_4_3">18</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_pPraAX3UkUu0_lMAnsHfJQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_-dFMToaoh0u7xw5Az9Hl0g_4_6">20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_o_i3_DfHik6LOoF2B8rb3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_U41muGu2kkagBVQbEc4vTA_4_9">7</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_kforSQ4jYUSPrZV_1I2SsQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_uu3F-6vSP02BPKOWpAwS-A_5_3">148</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_nhO5-HJ1nk6RNhK67yOGoA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_95VEcwAVHUmVRWubbXm7jw_5_6">204</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_jSuYco4A6kWDk0WIg-bOhg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_PyDE67GpjEW6J7HBRr8Kwg_5_9">151</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total share-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_MUEO4AYH5UOq5VEkn4X34A_6_3">546</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_9pKfTLxc60GCpxrOsDTZKw_6_6">596</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_IDEKCWyVwE68J83iJHs87w_6_9">812</ix:nonFraction></p></td></tr></table></div></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">As of December&#160;31, 2021, there were unrecognized compensation costs of $ <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="3" id="Narr_QUvWeq5EOU29pcQTVlu-JA">2,280</ix:nonFraction>, which are expected to be recognized over a weighted average period of approximately <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_o-bnOZNr2UWSkmKwcJ9Mow">3.28</ix:nonNumeric>&#160;years. The weighted average exercise price of the Company&#8217;s options granted during the&#160;year ended December&#160;31, 2019, 2020 and 2021 was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_uOEmurDClEGUrmXBNJVwqw">4.06</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_Dm47Ye4vKkaT_4NV3GcuIA">4.42</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_6o95YS9by0ScaxKUMaqpww">9.81</ix:nonFraction>, respectively. The weighted-average grant date fair value of options granted during the&#160;years ended December&#160;31, 2021, 2020 and 2019, was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_z7XKoEaGD0SlUZfhfNwZYg">4.45</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_fPp2DXf3dkKZ5rmH3GyxlQ">0.76</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_wY_sOa33_0uqZpbbf1L1kg">0.6</ix:nonFraction>, respectively.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">d.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Warrants to investors:</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">As part of 2016 investment round, the Company granted the investors <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="INF" format="ixt:numdotdecimal" name="drts:SaleOfStockNumberOfWarrantsIssuedInTransaction" scale="0" id="Narr_vACNhudlwU6_3weOVYC-hg">6,789,694</ix:nonFraction> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">warrants. In December&#160;2019, these warrants were exercised into <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_12_1_2019_To_12_31_2019_yCEIW0JlakWqYIDxGbuWtQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="Narr_NEKZZ3E_5EWEmlEPx9APNw">5,316,493</ix:nonFraction> Ordinary shares of no-par value, of them <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="INF" format="ixt:numdotdecimal" name="drts:WarrantsExercisedCashBasis" scale="0" id="Narr_DUopFt4EokCk6Pb6gY9nRQ">1,412,520</ix:nonFraction> were exercised on a cash basis in consideration of approximately $ <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="drts:StockIssuedDuringPeriodValueExerciseOfWarrants" scale="3" id="Narr_JRAI5CN26kO3iJZz0r8YaQ">1,560</ix:nonFraction>, and <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="INF" format="ixt:numdotdecimal" name="drts:WarrantsExercisedCashlessBasis" scale="0" id="Narr_cz3IqLgqBUOTjoXG7mxrmA">5,377,174</ix:nonFraction> were exercised on a cashless basis at a ratio of approximately <ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="INF" format="ixt:numdotdecimal" name="drts:WarrantsToOrdinaryShareRatioCashlessExercise" scale="0" id="Narr_R41yAhPuKky1tQfUWEzo2A">0.73</ix:nonFraction> Ordinary share per exercised warrant</span><span style="direction:rtl;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">As part of the 2018 SPA, the Company granted <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_7_15_2021_To_7_15_2021_5Bu_BFUidUuMuhyoWEwmhg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="Narr_qJaQBHDhdESG6dgW-9igpg">9,053</ix:nonFraction> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">warrants to ordinary shares to a public service foundation in Israel. The warrants were exercised on July&#160;15, 2021 into <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_7_15_2021_To_7_15_2021_5Bu_BFUidUuMuhyoWEwmhg" decimals="INF" format="ixt:numdotdecimal" name="drts:NumberOfWarrantsExercised" scale="0" id="Narr_owDOoPTumkKM3d3VcSVMoA">9,053</ix:nonFraction> Ordinary shares of no-par value with <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_7_15_2021_To_7_15_2021_5Bu_BFUidUuMuhyoWEwmhg" decimals="-3" format="ixt-sec:numwordsen" name="drts:StockIssuedDuringPeriodValueExerciseOfWarrants" scale="3" id="Narr_T-cW9avO9Ee98eGjF6jxgA">no</ix:nonFraction> consideration.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(iii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In July&#160;2019, as part of the investment round of HekaBio K.K, the investors received <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_7_1_2019_To_7_31_2019_srt_CounterpartyNameAxis_drts_HekabioK.k.Member_r5R-uUg6Vk-zl0lhq3yl_w" decimals="INF" format="ixt:numdotdecimal" name="drts:SaleOfStockNumberOfWarrantsIssuedInTransaction" scale="0" id="Narr_69nRuO8bjUu5trIc5hbgKg">651,067</ix:nonFraction> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">warrants to Ordinary shares with an exercise price of $ <ix:nonFraction unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw" contextRef="As_Of_7_31_2019_srt_CounterpartyNameAxis_drts_HekabioK.k.Member_WD3hZ8b710aQRjZMhkzTsg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_mo3Od4hsU0yk9FSIoEl0sw">5.04</ix:nonFraction> to be exercise within </span><ix:nonNumeric contextRef="As_Of_7_31_2019_srt_CounterpartyNameAxis_drts_HekabioK.k.Member_WD3hZ8b710aQRjZMhkzTsg" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_woQf_2bin02kPM4NbUr_ew"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4&#160;years</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> from grant date.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">e.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Warrants to consultants:</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In April&#160;2016, <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_4_1_2016_To_4_30_2016_aEGL3Dhxo0CNZ5ITN3VZQg" decimals="INF" format="ixt:numdotdecimal" name="drts:SaleOfStockNumberOfWarrantsIssuedInTransaction" scale="0" id="Narr_LiotR57YmEW0cZ5inBsAIA">67,897</ix:nonFraction> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">warrants to Ordinary shares were issued to a consultant for services received to be exercised within </span><ix:nonNumeric contextRef="As_Of_4_30_2016_rW7hRh2E3Emvv6ppXNzIxA" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_YCeWpVCZm0S9QgNE18-OlQ"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7&#160;years</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> from grant date.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="text-transform:uppercase;">f-</span><span style="text-transform:uppercase;">29</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;padding-bottom:1pt;text-align:justify;border-bottom:1.5pt solid #000000;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">U.S.&#160;dollars in thousands (except share and per share data)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:justify;margin:0pt;"><span style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_ft7E9GxXDUSQtRIA6Exygg_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE 10:-</b></span>SHAREHOLDERS&#8217; DEFICIENCY (Cont.)</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In April&#160;2020 <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_4_1_2020_To_4_30_2020_MsmjV8uDakyuT86VtP1xdQ" decimals="INF" format="ixt:numdotdecimal" name="drts:NumberOfWarrantsExercised" scale="0" id="Narr_mmc1dABeBEewR29_Ytz9jA">879,609</ix:nonFraction> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">warrants were exercised into <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_4_1_2020_To_4_30_2020_MsmjV8uDakyuT86VtP1xdQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="Narr_hVy-Gx5mDkudWjnHtobY-Q">556,548</ix:nonFraction> Ordinary shares of no-par value, for $ <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_4_1_2020_To_4_30_2020_MsmjV8uDakyuT86VtP1xdQ" decimals="-3" format="ixt:numdotdecimal" name="drts:StockIssuedDuringPeriodValueExerciseOfWarrants" scale="3" id="Narr_3VA7ZuUAv0WkFFYuB7jgkQ">30</ix:nonFraction> received in cash and the rest exercised on a cashless basis. In addition, in November&#160;2020, <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_11_1_2020_To_11_30_2020_AqgH_S771EKQA0UT8K6nCw" decimals="INF" format="ixt:numdotdecimal" name="drts:NumberOfWarrantsExercised" scale="0" id="Narr_DO7ic--CmUON9AkN7glJbw">90,529</ix:nonFraction> warrants were exercised into <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_11_1_2020_To_11_30_2020_AqgH_S771EKQA0UT8K6nCw" decimals="INF" format="ixt:numdotdecimal" name="drts:WarrantsExercisedCashlessBasis" scale="0" id="Narr_1CPbU9MWFE2SFdALm25OHg">67,897</ix:nonFraction> Ordinary shares of no-par value, all on a cashless basis</span><span style="direction:rtl;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Tc_WPJz9PKsFEqh-WsR3HVk-g_1_2"></a><a id="Tc_Ntx6BwhYxEuQy4t1HKsjEg_2_2"></a><a id="Tc_p1D0Y30tVUGgbg_1dzAuIw_2_5"></a><a id="Tc_cd6d8uGg-kuwyQB1MvQZpA_2_8"></a><a id="Tc_s9Pe6A4fM0u-m7AMQ0EGhQ_3_0"></a><a id="Tc_GdRffqUV40Cck7ehQp_2-A_5_0"></a><a id="Tc_QOurbsAuHkeH2l82UFuNXQ_5_2"></a><a id="Tc_kKE3Zi1nG0-8F2yd8Bl6qg_5_5"></a><a id="Tc_0Eda1hyxGEanbM7mjhhpgw_5_6"></a><a id="Tc_U5O_AvmWcEuklZioXbwH1g_5_8"></a><a id="Tc_2qajUxMuKk-3rgaccAp5jA_6_0"></a><a id="Tc_tHTbh_uY40uh00qKLuWgMQ_7_0"></a><a id="Tc__zIhnlFrBkSxFIZRFfXE5A_9_0"></a><a id="Tc_qo4d9vDJXUe6dRocPw5zyg_11_0"></a><a id="Tc_hMTmZInXKkanonbD_sGCwA_13_0"></a><a id="Tc_jZb6TTp5u0KrkaoQE-ltgQ_13_3"></a><a id="Tc_1h6V8nYtqEOLBk1JYDamTQ_13_9"></a><a id="Tc_0QEGM0QC00S__b-nvhghZA_14_0"></a><a id="Tc_2aMZ67YRuEOnfEcTquloSQ_15_0"></a><a id="Tc_Z7_8oqszo0-X4wIyKZzTNA_15_3"></a><a id="Tc_iDJO_xKpBUCBysEC-V4kxQ_15_9"></a><a id="Tc_z98oU5FgU0S1fsUoB8uhew_17_0"></a><a id="Tc_Md1wIhr18Eyd8RNeK10PuA_18_0"></a><a id="Tc_STIAXhnWh0eZ0aiMCVJhXA_18_2"></a><a id="Tc_4kXeyf9zmUmjD_oP7dE_rw_18_5"></a><a id="Tc_hX2To6Ot5UG6o0pq_O5mkA_18_8"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock" id="Tb_wkyLmlJSaEm2s3yygG26Pg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;11:-</b></span>FINANCIAL EXPENSES, NET</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="Tb_zsJtNPWJDUKanDrYVvttQw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;ended&#160;December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Financial expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign currency transaction loss, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionLossBeforeTax" scale="3" id="Tc_wbgYSizneUSuBTZcwsUuDw_5_3">79</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionLossBeforeTax" scale="3" id="Tc_30_IRSuprEOaEPJ4TViFPw_5_9">412</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Remeasurement of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="Tc_F-XRcUqwrE6lh1ZiO4HmaA_6_3">994</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="Tc_HPigw7LqVEmwnUI-X0JrvQ_6_6">203</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="Tc_cDafO42M5kiRqoj-ujVRLw_6_9">13,257</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Others</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_-8LeYxmzrUS8HGZFwlt1kg_7_3">11</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_r8sUiWxqG0mtxpfPMAnxqQ_7_6">14</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_8BTXerDu60iEM46rYitr9Q_7_9">16</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total financial expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="drts:FinancialExpensesTotal" scale="3" id="Tc_PWs6mMlF8kClEFmKgMb53g_9_3">1,084</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="drts:FinancialExpensesTotal" scale="3" id="Tc_4bf8rg6RkUOxG3w7xUZfBw_9_6">217</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="drts:FinancialExpensesTotal" scale="3" id="Tc_6UcKUCYdf0qSoB3CbRq5EQ_9_9">13,685</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Financial income:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign currency transaction profit, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="Tc_apbjFTVNAkCjNECUt5ApqQ_13_6">101</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest from deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeDepositsWithFinancialInstitutions" scale="3" id="Tc_NaL8lodqB0eePHPHBAkUqA_14_3">776</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeDepositsWithFinancialInstitutions" scale="3" id="Tc_SCgQihGSzkK3ARtZ3cdyTg_14_6">613</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeDepositsWithFinancialInstitutions" scale="3" id="Tc_LiwZ9Z5VE06VnybwdEWe_A_14_9">211</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Others</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_FbRk1X5g00CthWlS4wGYsg_15_6">23</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total financial income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="drts:FinancialIncomeTotal" scale="3" id="Tc_hZfF2yQ0dkuUepAxJR46OA_17_3">776</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="drts:FinancialIncomeTotal" scale="3" id="Tc_i8zK64bw3UqrcIsawT2u2g_17_6">737</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="drts:FinancialIncomeTotal" scale="3" id="Tc_Ofe2ZHE4SUuPMrBjCzYpZQ_17_9">211</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Financial expenses (income), net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingGainsLosses" scale="3" id="Tc_j4E_cEt9PUa56Ut_SbLA3w_18_3">308</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingGainsLosses" sign="-" scale="3" id="Tc_tL1w_hK9f0KSFnnoM5EduA_18_6">520</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingGainsLosses" scale="3" id="Tc_1M7WT8ulvUeRTuNgL8yGWA_18_9">13,474</ix:nonFraction></p></td></tr></table></div></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Tc_LZ024TG-iUCtfeuliizLWA_1_2"></a><a id="Tc_m_JQlIRnHU2eZgEfi7sw3w_2_2"></a><a id="Tc_UYA1w5mggEaceO4GRc4zPg_2_5"></a><a id="Tc_dD2KiFhDgk-LLhgLkKuN6A_2_8"></a><a id="Tc_UkViuOeYOkudkwVwPTEEXA_3_0"></a><a id="Tc_34pT2haYLkmat3o-wuifqg_4_0"></a><a id="Tc_K72FYfpAzE6CyLyK2UZtyw_4_2"></a><a id="Tc_GxEJyOUEvEudUK4RohQZ_A_4_5"></a><a id="Tc_K7phUM3qTkm6SugEHCvjsw_4_8"></a><a id="Tc_FIUB6l-Um0i1oI_YtrXiSw_6_0"></a><a id="Tc_6BGtEs2xYU2XbWeWp12Rag_7_0"></a><a id="Tc_Q7RDfu3HN0WYbuAPdGnS0g_8_0"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="us-gaap:EarningsPerShareTextBlock" id="Tb_rA_JbpENtk2mmHOh9XjiCw" continuedAt="Tb_rA_JbpENtk2mmHOh9XjiCw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;12:-</b></span>BASIC AND DILUTED NET LOSS PER SHARE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The following table sets forth the computation of the Company&#8217;s basic and diluted net loss per Ordinary share:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Tb_3XbxPe__ykK1MJZkV2ZrRA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:42.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;ended&#160;December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss attributable to Ordinary shareholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperations" sign="-" scale="3" id="Tc_0VZFjQS9sUGKvFibWmr92g_4_3">8,367</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperations" sign="-" scale="3" id="Tc_jxpA9vyEm02nLmqx-x-h0Q_4_6">8,882</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperations" sign="-" scale="3" id="Tc_wTx_Xu-CJUWTD1XyKuqAGw_4_9">27,271</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:55.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:55.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Weighted-average shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_iJnG7V0VvUWdLsomyegb9g_7_3">33,815,448</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_OOtWiDlpP0qiYHaI9Xbo3Q_7_6">40,274,935</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_gVe36pH3V02RnpMqbGPopw_7_9">40,534,697</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss per share attributable to ordinary shareholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" sign="-" scale="0" id="Tc_nmXJ6TLx9Equ4seVjk4ytA_8_3">0.25</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" sign="-" scale="0" id="Tc_YKLY_poxI0CGrTwjcpvrRw_8_6">0.22</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" sign="-" scale="0" id="Tc_fQ9RUCqPi0OSGbt7J0WVbw_8_9">0.67</ix:nonFraction>)</p></td></tr></table></div></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="text-transform:uppercase;">f-</span><span style="text-transform:uppercase;">30</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;padding-bottom:1pt;text-align:justify;border-bottom:1.5pt solid #000000;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">U.S.&#160;dollars in thousands (except share and per share data)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:justify;margin:0pt;"><span style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_VKuteuD9AEqLF5D_k43fPw_1_2"></a><a id="Tc_fJIfSxVaNU-5xpOYTbWNkw_2_2"></a><a id="Tc_RvtoZH7dDU6w5Sod0olBfA_2_4"></a><a id="Tc_uPdamlsmc06nVhPvujSE1A_2_6"></a><a id="Tc_xz0DSRuUXkmerzD0zVBzGQ_3_0"></a><a id="Tc_sV-Izt5_TEyvc9v4h8skCA_4_0"></a><a id="Tc_L-O-q6CAgUSzqP9WGmuowg_5_0"></a><a id="Tc_PWa59OgiX0y2II8RxKN2Zg_5_2"></a><a id="Tc_NONuDfZ4PUyk-OllFsSX5A_5_4"></a><a id="Tc_u2kRAfpicECW8ZwKyccekw_6_0"></a><a id="Tc_bx5rsMuDI0SnaLltFmIFPQ_7_0"></a><ix:continuation id="Tb_rA_JbpENtk2mmHOh9XjiCw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;12:-</b></span>BASIC AND DILUTED NET LOSS PER SHARE (Cont.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The potential shares of ordinary shares that were excluded from the computation of diluted net loss per share attributable to ordinary shareholders for the periods presented because including them would have been anti-dilutive are as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_9jg2zIvlwkWGr_JPoGggDg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;ended&#160;December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Convertible preferred shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_JaC_a1cel0-cR7a1zDVJ8Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_6CeKLGvvHkybTgRkzZ2pqw_3_2">7,229,885</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_Woekbq1Vh0m9LF6giXkjAQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_w-Ty5g2LcUutMZQbTkncXQ_3_4">13,739,186</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_MHykc8OPo0iqU-HsSzCVvw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_xEHbcl6SMkKsLtPcq3BVzQ_3_6">13,739,186</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding share options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_-g979nKaYE-fgpAUV8oCPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_vAWN4DUme0ytQGQQTEaBTA_4_2">4,371,668</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_ywa_0-bXzkKhuRpBh5X1qg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_z2Bv7dzDW0WzqKVGtYnJ1Q_4_4">4,724,414</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_CVs6y3ige0mbtcVCtEnhqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_ycps9gner0uDv7NBU26kUA_4_6">6,046,769</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RSU</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_xkz4fyumv021UlW6DLiR0Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_20cjkc-3LUi96foz8dJNXg_5_6">1,031,250</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant to Preferred A shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_drts_WarrantsToPreferredSharesMember_g4e9gxAYuUqhsD456SMaZw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_zZsgayPo9UCJRa2fYUQA-w_6_2">3,614,960</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_drts_WarrantsToPreferredSharesMember_F-36Oqlx4UWKJm0Pn_tXwg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_FkAek7faBkKOCNW7WGNLGQ_6_4">3,880,777</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_drts_WarrantsToPreferredSharesMember_3xaGNXkiQk215jhKwwMGtA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_2hsYy2KH5UO21hGSt21Z6A_6_6">3,880,777</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_83Yv-70FokCNwA9HBVo3Ag" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_bRRAaotaAkmb10hJ8keamA_7_2">8,436,578</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_8q6cV2yAM0a3XAboz3EV0g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_Z6_g74XQb0iuP44B9NbW8g_7_4">651,067</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_ugDRsvTNaUmilQmO6qFALQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_FGjf8BJdNkOSMNASASF6VQ_7_6">651,067</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_8RVCcqwZ30GdIqNqsQHGLg_8_2">23,653,091</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_ZAaf2Zqv3kmfMDSFWWhFPg_8_4">22,995,444</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_ulYUG4NEEESRNkC7adFKkw_8_6">25,349,049</ix:nonFraction></p></td></tr></table></div></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Tc_F6LjEd7NSEaYkRiffbNqAw_1_2"></a><a id="Tc_bMHtlD1x0Uqln4PYl4Po1A_2_2"></a><a id="Tc_1ULiZ9yLVE2FjYuXa4OJgA_2_5"></a><a id="Tc_cIXPJh5vuEaJJMuC0q5Pvw_3_0"></a><a id="Tc_0tpA67WdnUuL6knpDFjRQg_3_2"></a><a id="Tc_EBKaqi3MH0mH1op5w5xMQA_3_5"></a><a id="Tc_SjEMtI2Z1U6J3cx6ArqPPg_4_0"></a><a id="Tc_L1rpV-mOnUKC36eMKeEbCQ_5_0"></a><a id="Tc_IDKy6zFdQE-1QRU-MfBKjQ_5_3"></a><a id="Tc_NXm5lUXQqk2zJDgvioB-Sg_6_0"></a><a id="Tc_Ff60_sUqkka_SUpZBbNcKA_6_2"></a><a id="Tc_7QDvo5lCS02zSGaXqyku8g_6_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="us-gaap:SegmentReportingDisclosureTextBlock" id="Tb_Xm5y_OTwFkOcIImKKWp3Nw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;13:-GEOGRAPHIC INFORMATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Financial information is available for evaluation by the chief operating decision maker, the Company&#8217;s Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in <ix:nonFraction unitRef="Unit_Standard_segment_F1A8hT57kUWQPIMNg0d3ZQ" contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="Narr_Yncpk2ub00avA4GHGku73w">one</ix:nonFraction> operating segment. Operating segments are defined as components of an enterprise in which separate financial information is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and assessing performance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Property and equipment, net by geographic location are as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="Tb_i0TAqorfr0mzGXPFmZogRw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Israel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_srt_StatementGeographicalAxis_country_IL_PMTZcbNK3kWZuaPNc0HC8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_il3SoFr7Y0SyOvnPE5KGqA_3_3">3,540</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_srt_StatementGeographicalAxis_country_IL_c_kJyhiBYEGoZcGQuB67uA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_tX4pkiUD4UWvPUhKbycc6g_3_6">5,842</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_srt_StatementGeographicalAxis_country_US_in1yQM0Z10-KwKkqgUSCKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_crVAUoMPLkSp0LRMRwFxcQ_4_3">1,855</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_srt_StatementGeographicalAxis_country_US_RZN6ejeNsEmQtCCCNm9spQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_DYSpr-6fV0-y4prewE5sAw_4_6">1,699</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Japan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_srt_StatementGeographicalAxis_country_JP__8sfu7Pxlk-mMRFbDKhBZw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_NFf6ChuO20qGMCKgydvxow_5_6">5</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_VbrO8sa3Q062oABjLtMM2w_6_3">5,395</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_haedi-v5gU2UPVM9idpvhg_6_6">7,546</ix:nonFraction></p></td></tr></table></div></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;">Property and equipment, net is attributed to the geographic location in which it is located.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA" name="us-gaap:SubsequentEventsTextBlock" id="Tb_G0xaic_J8UKqS9wWsPUiqQ" continuedAt="Tb_G0xaic_J8UKqS9wWsPUiqQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;14:-SUBSEQUENT EVENTS</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">On January&#160;18, 2022, the Company instituted a floating pledge on its assets in favor of Bank Leumi Le-Israel BM, to support a $ <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="As_Of_1_18_2022_srt_CounterpartyNameAxis_drts_BankLeumiLeIsraelBmMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_BeRyXpDJ5kGTXPHFaRTfqA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PledgedFinancialInstrumentsNotSeparatelyReportedSecuritiesForLetterOfCreditFacilities" scale="3" id="Narr_e4JAPs4gD0izZ44PCxaOmQ">225</ix:nonFraction> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">standby letter of credit in favor of the Massachusetts Department of Public Health. The letter of credit was provided in connection with an application by ATM&#160;Inc. for an expansion of the maximum possession limit in its radioactive license for use in the Lawrence, MA site, pursuant to decommissioning financial assurance regulations of the Massachusetts Department of Public Health&#8217;s Radiation Control Program.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Business Combination</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Pursuant to the Merger Agreement described in Note&#160;1a, on March&#160;7, 2022 (the &#8220;Closing Date&#8221;), Archery Merger Sub,&#160;Inc., a Delaware corporation and wholly owned subsidiary of the Company was merged with and into HCCC, with HCCC surviving as a wholly-owned subsidiary of the Company (the &#8220;Business Combination&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="text-transform:uppercase;">f-</span><span style="text-transform:uppercase;">31</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;padding-bottom:1pt;text-align:justify;border-bottom:1.5pt solid #000000;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">U.S.&#160;dollars in thousands (except share and per share data)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.31;text-align:justify;margin:0pt;"><span style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_G0xaic_J8UKqS9wWsPUiqQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;14:-SUBSEQUENT EVENTS (Cont.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Pursuant to the Merger Agreement, and immediately prior to the consummation of the Merger (the time of such consummation, the &#8220;Effective Time&#8221;), the Company effected a recapitalization whereby (i)&#160;the Company adopted amended and restated articles of association, (i)&#160;each preferred share of the Company was automatically converted into such number of the Company&#8217;s ordinary shares as determined in accordance with the Company&#8217;s existing articles of association; (ii)&#160;each of the Company&#8217;s ordinary shares that was issued and outstanding immediately prior to the Effective Time was split into <ix:nonFraction unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg" contextRef="Duration_3_7_2022_To_3_7_2022_us-gaap_BusinessAcquisitionAxis_drts_HcccMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_E1MNaT3WY0K3ZcXXAPmtVQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="Narr_sLtTUA3kJkmLJJ_S2VyAVQ">0.905292</ix:nonFraction> ordinary shares of the Company (rounded to the nearest whole number), such that the value of each of the Company&#8217;s ordinary shares at the time of execution of the Merger Agreement equaled $<ix:nonFraction unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw" contextRef="As_Of_3_7_2022_us-gaap_BusinessAcquisitionAxis_drts_HcccMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_iIVxwLK7kE2b1JwNE4XyzA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_0Y-LHuwe90OIhZ9p2WUB0g">10.00</ix:nonFraction> per share, based upon the agreed pre-money equity value of the Company (the &#8220;Share Split&#8221;); and (iii)&#160;outstanding securities convertible into securities of the Company were adjusted to give effect to the foregoing transactions and remain outstanding. As a result, all ordinary shares, convertible preferred shares, options and warrants for ordinary shares, exercise prices and net loss per share amounts were adjusted retroactively for all periods presented in these financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Additionally, concurrently with the closing of the Merger, Alpha Tau issued securities pursuant to the Subscription Agreements executed with certain investors under a PIPE (Private Investment in Public Equity) transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Following the recapitalization, (a)&#160;immediately prior to the Merger, each share of Class&#160;B common stock of HCCC was cancelled automatically and converted into <ix:nonFraction unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw" contextRef="Duration_3_7_2022_To_3_7_2022_us-gaap_BusinessAcquisitionAxis_drts_HcccMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_pSFCWjg1hEmAKs-87AaDOg" decimals="INF" format="ixt-sec:numwordsen" name="drts:CommonStockCancelledAndConvertedInToShares" scale="0" id="Narr_GTOgqSsSyU6NrFCVASkQMA">one</ix:nonFraction> share of Class&#160;A common stock of HCCC, (b)&#160;after giving effect to the foregoing and in connection with the Merger, each share of Class&#160;A common stock of HCCC issued and outstanding was converted automatically into one Company ordinary share, and (c)&#160;each outstanding warrant of HCCC was converted into a warrant of the Company and convertible into the Company&#8217;s ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">An amount of $ <ix:nonFraction unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg" contextRef="Duration_3_7_2022_To_3_7_2022_us-gaap_BusinessAcquisitionAxis_drts_HcccMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_wb4aa4hMOk-oUeKQrzX1-g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAcquiredFromAcquisition" scale="3" id="Narr_2E7RwSkJnU-yQjcxvKT1Jg">90,872</ix:nonFraction> of gross cash proceeds were raised by the Company in the aforementioned transactions.</p></ix:continuation><a id="Notes_END"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">-&#160;-</b><b style="direction:rtl;font-weight:bold;">&#160;-&#160;-&#160;-&#160;-&#160;-&#160;-&#160;-&#160;-&#160;-&#160;-&#160;-</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="text-transform:uppercase;">f-</span><span style="text-transform:uppercase;">32</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>drts-20211231xex1d1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/28/2022 08:45:56 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Exhibit 1.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">THE COMPANIES LAW, 1999</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">A LIMITED LIABILITY COMPANY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1.5" style="background-color:#000000;color:#000000;height:1.5pt;position:relative;top:0.6em;width:100%;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AMENDED AND RESTATED</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ARTICLES OF ASSOCIATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OF</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ALPHA TAU MEDICAL LTD.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 18pt 0pt;">As Adopted on March 7, 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PRELIMINARY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">DEFINITIONS; INTERPRETATION</b>.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">(a) In these Articles, the following terms (whether or not capitalized) shall bear the meanings set forth opposite them, respectively, unless the subject or context requires otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:65%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24pt;margin:0pt;">&#8220;Articles&#8221;</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">shall mean these Amended and Restated Articles of Association, as amended from time to time.</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24pt;margin:0pt;">&#8220;Board of Directors&#8221;</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">shall mean the Board of Directors of the Company.</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24pt;margin:0pt;">&#8220;Chairperson&#8221;</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">shall mean the Chairperson of the Board of Directors, or the Chairperson of the General Meeting, as the context implies;</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24pt;margin:0pt;">&#8220;Companies Law&#8221;</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">shall mean the Israeli Companies Law, 5759-1999 and the regulations promulgated thereunder. The Companies Law shall include reference to the Companies Ordinance (New Version), 5743-1983, of the State of Israel, to the extent in effect according to the provisions thereof.</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24pt;margin:0pt;">&#8220;Company&#8221;</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">shall mean Alpha TAU Medical Ltd.</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24pt;margin:0pt;">&#8220;Director(s)&#8221;</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">shall mean the member(s) of the Board of Directors holding office at a given time.</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24pt;margin:0pt;">&#8220;Economic Competition Law&#8221;</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">shall mean the Israeli Economic Competition Law, 5758-1988 and the regulations promulgated thereunder.</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24pt;margin:0pt;">&#8220;External Director(s)&#8221;</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">shall have the meaning provided for such term in the Companies Law.</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24pt;margin:0pt;">&#8220;General Meeting&#8221;</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">shall mean an Annual General Meeting or Special General Meeting of the Shareholders (each as defined in Article 23 of these Articles), as the case may be.</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24pt;margin:0pt;">&#8220;NIS&#8221;</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">shall mean New Israeli Shekels.</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24pt;margin:0pt;">&#8220;Office&#8221;</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">shall mean the registered office of the Company at any given time.</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24pt;margin:0pt;">&#8220;Office Holder&#8221; or &#8220;Officer&#8221;</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">shall have the meaning provided for such term in the Companies Law.</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24pt;margin:0pt;">&#8220;Securities Law&#8221;</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">shall mean the Israeli Securities Law, 5728-1968, and the regulations promulgated thereunder.</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24pt;margin:0pt;">&#8220;Shareholder(s)&#8221;</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">shall mean the shareholder(s) of the Company, at any given time.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">(b) Unless the context shall otherwise require: words in the singular shall also include the plural, and vice versa; any pronoun shall include the corresponding masculine, feminine and neuter forms; the words &#8220;include&#8221;, &#8220;includes&#8221; and &#8220;including&#8221; shall be deemed to be followed by the phrase &#8220;without limitation&#8221;; the words &#8220;herein&#8221;, &#8220;hereof&#8221; and &#8220;hereunder&#8221; and words of similar import refer to these Articles in their entirety and not to any part hereof; all references herein to Articles or clauses shall be deemed references to Articles or clauses of these Articles; any references to any agreement or other instrument or law, statute or regulation are to it as amended, supplemented or restated, from time to time (and, in the case of any law, to any successor provisions or&#160;re-enactment&#160;or modification thereof being in force at the time); any reference to &#8220;law&#8221; shall include any law (&#8216;<i style="font-style:italic;">din</i>&#8217;) as defined in the Interpretation Law, 5741-1981 and any applicable supranational, national, federal, state, local, or foreign statute or law and shall be deemed also to refer to all rules and regulations promulgated thereunder; any reference to a &#8220;day&#8221; or a number of &#8220;days&#8221; (without any explicit reference otherwise, such as to business days) shall be interpreted as a reference to a calendar day or number of calendar days; any reference to a business day shall mean each calendar day other than any calendar day on which commercial banks in New York, New York or&#160;Tel-Aviv,&#160;Israel are authorized or required by applicable law to close; reference to a month<b style="font-weight:bold;">&#160;</b>or<b style="font-weight:bold;">&#160;</b>year means </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">according to the Gregorian calendar; any reference to a &#8220;Person&#8221; shall mean any individual, partnership, corporation, limited liability company, association, estate, any political, governmental, regulatory or similar agency or body, or other legal entity; and reference to &#8220;written&#8221; or &#8220;in writing&#8221; shall include written, printed, photocopied, typed, any electronic communication (including email, facsimile, signed electronically (in Adobe PDF, DocuSign or any other format)) or produced by any visible substitute for writing, or partly one and partly another, and signed shall be construed accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(c) The captions in these Articles are for convenience only and shall not be deemed a part hereof or affect the construction or interpretation of any provision hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 18pt 24.5pt;">(d) The specific provisions of these Articles shall supersede the provisions of the Companies Law to the extent permitted thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">LIMITED&#160;LIABILITY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:18pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:18pt;margin-top:0pt;">The Company is a limited liability company and each Shareholder&#8217;s liability for the Company&#8217;s debts is therefore limited (in addition to any liabilities under any contract) to the payment of the full amount (par value (if any) and premium) such Shareholder was required to pay the Company for such Shareholder&#8217;s Shares (as defined below) and which amount has not yet been paid by such Shareholder.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">COMPANY&#8217;S&#160;OBJECTIVES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">OBJECTIVES</b>.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">The Company&#8217;s objectives are to carry on any business, and do any act, which is not prohibited by law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">DONATIONS</b>.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 18pt 24.5pt;">The Company may donate a reasonable amount of money (in cash or in kind, including the Company&#8217;s securities) to worthy purposes such as the Board of Directors may determine in its discretion, even if such donations are not made on the basis or within the scope of business considerations of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SHARE&#160;CAPITAL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">5.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">AUTHORIZED SHARE CAPITAL</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(a) The authorized share capital of the Company shall consist of 275,000,000 Ordinary Shares without par value (the &#8220;<b style="font-weight:bold;">Shares</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(b) The Shares shall rank&#160;<i style="font-style:italic;">pari passu</i>&#160;in all respects. The Shares may be redeemable to the extent set forth in Article 18.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">6.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">INCREASE OF AUTHORIZED SHARE CAPITAL</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(a) The Company may, from time to time, by a Shareholders&#8217; resolution, whether or not all of the shares then authorized have been issued, and whether or not all of the shares theretofore issued have been called up for payment, increase its authorized share capital by increasing the number of shares it is authorized to issue by such amount, and such additional shares shall confer such rights and preferences, and shall be subject to such restrictions, as such resolution shall provide.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">(b) Except to the extent otherwise provided in such resolution, any new shares included in the authorized share capital increase as aforesaid shall be subject to all of the provisions of these Articles that are applicable to shares that are included in the existing share capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">7.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">SPECIAL OR CLASS RIGHTS; MODIFICATION OF RIGHTS</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(a) The Company may, from time to time, by a Shareholders&#8217; resolution, provide for shares with such preferred or deferred rights or other special rights and/or such restrictions, whether in regard to dividends, voting, repayment of share capital or otherwise, as may be stipulated in such resolution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(b) If at any time the share capital of the Company is divided into different classes of shares, the rights attached to any class, unless otherwise provided by these Articles, may be modified or cancelled by the Company by a resolution of the General Meeting of the holders of all shares as one class, without any required separate resolution of any class of shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(c) The provisions of these Articles relating to General Meetings shall apply,&#160;<i style="font-style:italic;">mutatis mutandis</i>, to any separate General Meeting of the holders of the shares of a particular class, it being clarified that the requisite quorum at any such separate General Meeting shall be two or more Shareholders present in person or by proxy and holding not less than thirty-three and&#160;one-third&#160;percent (33<sup style="font-size:7.5pt;vertical-align:top;">1</sup>&#8260;<sub style="font-size:7.5pt;vertical-align:sub;">3</sub>%) of the issued shares of such class, provided, however, that if (i)&#160;such separate General Meeting of the holders of the particular class was initiated by and convened pursuant to a resolution adopted by the Board of Directors and (ii)&#160;at the time of such meeting the Company is qualified to use the forms of a &#8220;foreign private issuer&#8221; under US securities laws, then the requisite quorum at any such separate General Meeting shall be two or more Shareholders (not in default in payment of any sum referred to in Article 13 hereof) present in person or by proxy and holding not less than twenty-five percent (25%) of the issued shares of such class. For the purpose of determining the quorum present at such General Meeting, a proxy may be deemed to be two (2)&#160;or more Shareholders pursuant to the number of Shareholders represented by the proxy holder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">(d) Unless otherwise provided by these Articles, an increase in the authorized share capital, the creation of a new class of shares, an increase in the authorized share capital of a class of shares, or the issuance of additional shares thereof out of the authorized and unissued share capital, shall not be deemed, for purposes of this Article 7, to modify or derogate or cancel the rights attached to previously issued shares of such class or of any other class.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">8.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">CONSOLIDATION, DIVISION, CANCELLATION AND REDUCTION OF SHARE CAPITAL</b>.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(a) The Company may, from time to time, by or pursuant to an authorization of a Shareholders&#8217; resolution, and subject to applicable law:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 55.1pt;">(i) consolidate all or any part of its issued or unissued authorized share capital;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 55.1pt;">(ii) divide or&#160;sub-divide&#160;its shares (issued or unissued) or any of them and the resolution whereby any share is divided may determine that, as among the holders of the shares resulting from such subdivision, one or more of the shares may, in contrast to others, have any such preferred or deferred rights or rights of redemption or other special rights, or be subject to any such restrictions, as the Company may attach to unissued or new shares;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 55.1pt;">(iii) cancel any authorized shares which, at the date of the adoption of such resolution, have not been issued to any person nor has the Company made any commitment, including a conditional</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 55.1pt;">commitment, to issue such shares, and reduce the amount of its share capital by the amount of the shares so canceled; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 55.1pt;">(iv) reduce its share capital in any manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(b) With respect to any consolidation of issued shares and with respect to any other action which may result in fractional shares, the Board of Directors may settle any difficulty which may arise with regard thereto, as it deems fit, and, in connection with any such consolidation or other action which could result in fractional shares, may, without limiting its aforesaid power:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 55.1pt;">(i) determine, as to the holder of shares so consolidated, which issued shares shall be consolidated;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 55.1pt;">(ii) issue, in contemplation of or subsequent to such consolidation or other action, shares sufficient to preclude or remove fractional share holdings;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 55.1pt;">(iii) redeem such shares or fractional shares sufficient to preclude or remove fractional share holdings;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 55.1pt;">(iv) round up, round down or round to the nearest whole number, any fractional shares resulting from the consolidation or from any other action which may result in fractional shares; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 55.1pt;">(v) cause the transfer of fractional shares by certain Shareholders of the Company to other Shareholders thereof so as to most expediently preclude or remove any fractional shareholdings, and cause the transferees of such fractional shares to pay the transferors thereof the fair value thereof, and the Board of Directors is hereby authorized to act in connection with such transfer, as agent for the transferors and transferees of any such fractional shares, with full power of substitution, for the purposes of implementing the provisions of this&#160;sub-Article&#160;8(b)(v).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">9.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">ISSUANCE OF SHARE CERTIFICATES, REPLACEMENT OF LOST CERTIFICATES</b>.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(a) To the extent that the Board of Directors determines that all shares shall be certificated or, if the Board of Directors does not so determine, to the extent that any Shareholder requests a share certificate or the Company&#8217;s transfer agent so requires, share certificates shall be issued under the corporate seal of the Company or its written, typed or stamped name and shall bear the signature of one Director, the Company&#8217;s Chief Executive Officer, or any person or persons authorized therefor by the Board of Directors. Signatures may be affixed in any mechanical or electronic form, as the Board of Directors may prescribe.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(b) Subject to the provisions of Article 9(a), each Shareholder shall be entitled to one numbered certificate for all of the shares of any class registered in his or her name. Each certificate shall specify the serial numbers of the shares represented thereby and may also specify the amount paid up thereon. The Company (as determined by an officer of the Company to be designated by the Chief Executive Officer) shall not refuse a request by a Shareholder to obtain several certificates in place of one certificate, unless such request is, in the opinion of such officer, unreasonable. Where a Shareholder has sold or transferred a portion of such Shareholder&#8217;s shares, such Shareholder shall be entitled to receive a certificate in respect of such Shareholder&#8217;s remaining shares, provided that the previous certificate is delivered to the Company before the issuance of a new certificate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(c) A share certificate registered in the names of two or more persons shall be delivered to the person first named in the Register of Shareholders in respect of such&#160;co-ownership.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">(d) A share certificate which has been defaced, lost or destroyed, may be replaced, and the Company shall issue a new certificate to replace such defaced, lost or destroyed certificate upon payment of such fee, and upon the furnishing of such evidence of ownership and such indemnity, as the Board of Directors in its discretion deems fit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.25pt;text-indent:-14.25pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:13.9pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">10.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">REGISTERED HOLDER</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">Except as otherwise provided in these Articles or the Companies Law, the Company shall be entitled to treat the registered holder of each share as the absolute owner thereof, and accordingly, shall not, except as ordered by a court of competent jurisdiction, or as required by the Companies Law, be obligated to recognize any equitable or other claim to, or interest in, such share on the part of any other person.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">11.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">ISSUANCE AND REPURCHASE OF SHARES</b>.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(a) The unissued shares from time to time shall be under the control of the Board of Directors (and, to the extent permitted by law, any Committee thereof), which shall have the power to issue or otherwise dispose of shares and of securities convertible or exercisable into or other rights to acquire from the Company to such persons, on such terms and conditions (including, inter alia, price, with or without premium, discount or commission, and terms relating to calls set forth in Article 13(f) hereof), and at such times, as the Board of Directors (or the Committee, as the case may be) deems fit, and the power to give to any person the option to acquire from the Company any shares or securities convertible or exercisable into or other rights to acquire from the Company on such terms and conditions (including, inter alia, price, with or without premium, discount or commission), during such time as the Board of Directors (or the Committee, as the case may be) deems fit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">(b) The Company may at any time and from time to time, subject to the Companies Law, repurchase or finance the purchase of any shares or other securities issued by the Company, in such manner and under such terms as the Board of Directors shall determine, whether from any one or more Shareholders. Such purchase shall not be deemed as payment of dividends and as such, no Shareholder will have the right to require the Company to purchase his or her shares or offer to purchase shares from any other Shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">12.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">PAYMENT IN INSTALLMENT</b>.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">If pursuant to the terms of issuance of any share, all or any portion of the price thereof shall be payable in installments, every such installment shall be paid to the Company on the due date thereof by the then registered holder(s) of the share or the person(s) then entitled thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">13.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">CALLS ON SHARES</b>.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(a) The Board of Directors may, from time to time, as it, in its discretion, deems fit, make calls for payment upon Shareholders in respect of any sum (including premium) which has not been paid up in respect of shares held by such Shareholders and which is not, pursuant to the terms of issuance of such shares or otherwise, payable at a fixed time, and each Shareholder shall pay the amount of every call so made upon him or her (and of each installment thereof if the same is payable in installments), to the person(s) and at the time(s) and place(s) designated by the Board of Directors, as any such times may be thereafter extended and/or such person(s) or place(s) changed. Unless otherwise stipulated in the resolution of the Board of Directors (and in the notice hereafter referred to), each payment in response to a call shall be deemed to constitute a pro rata payment on account of all the shares in respect of which such call was made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(b) Notice of any call for payment by a shareholder shall be given in writing to such shareholder not less than fourteen (14)&#160;days prior to the time of payment fixed in such notice, and shall specify the time and place of payment, and the person to whom such payment is to be made. Prior to the time for any such payment fixed in a notice of a call given to a shareholder, the Board of Directors may in its absolute discretion, by notice in writing to such shareholder, revoke such call in whole or in part, extend the time fixed for payment thereof, or designate a different place of payment or person to whom payment is to be made. In the event of a call payable in installments, only one notice thereof need be given.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(c) If pursuant to the terms of issuance of a share or otherwise, an amount is made payable at a fixed time, such amount shall be payable at such time as if it were payable by virtue of a call made by the Board of Directors and for which notice was given in accordance with paragraphs (a)&#160;and (b) of this Article 13, and the provision of these Articles with regard to calls (and the&#160;non-payment&#160;thereof) shall be applicable to such amount or such installment (and the&#160;non-payment&#160;thereof).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">(d) Joint holders of a share shall be jointly and severally liable to pay all calls for payment in respect of such share and all interest payable thereon.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(e) Any amount called for payment which is not paid when due shall bear interest from the date fixed for payment until actual payment thereof, at such rate (not exceeding the then prevailing debitory rate charged by leading commercial banks in Israel), and payable at such time(s) as the Board of Directors may prescribe.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">(f) Upon the issuance of shares, the Board of Directors may provide for differences among the holders of such shares as to the amounts and times for payment of calls for payment in respect of such shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">14.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">PREPAYMENT</b>.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">With the approval of the Board of Directors, any Shareholder may pay to the Company any amount not yet payable in respect of his or her shares, and the Board of Directors may approve the payment by the Company of interest on any such amount until the same would be payable if it had not been paid in advance, at such rate and time(s) as may be approved by the Board of Directors. The Board of Directors may at any time cause the Company to repay all or any part of the money so advanced, without premium or penalty. Nothing in this Article 14 shall derogate from the right of the Board of Directors to make any call for payment before or after receipt by the Company of any such advance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">15.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">FORFEITURE AND SURRENDER</b>.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(a) If any Shareholder fails to pay an amount payable by virtue of a call, installment or interest thereon as provided for in accordance herewith, on or before the day fixed for payment of the same, the Board of Directors may at any time after the day fixed for such payment, so long as such amount (or any portion thereof) or interest thereon (or any portion thereof) remains unpaid, forfeit all or any of the shares in respect of which such payment was called for. All expenses incurred by the Company in attempting to collect any such amount or interest thereon, including, without limitation, attorneys&#8217; fees and costs of legal proceedings, shall be added to, and shall, for all purposes (including the accrual of interest thereon) constitute a part of, the amount payable to the Company in respect of such call.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(b) Upon the adoption of a resolution as to the forfeiture of a Shareholder&#8217;s share, the Board of Directors shall cause notice thereof to be given to such Shareholder, which notice shall state that, in the event of the failure to pay the entire amount so payable by a date specified in the notice (which date shall be not less than fourteen (14)&#160;days after the date such notice is given and which may be extended by the Board of Directors), such shares shall be ipso facto forfeited, provided, however, that, prior to such date, the Board </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">of Directors may cancel such resolution of forfeiture, but no such cancellation shall stop the Board of Directors from adopting a further resolution of forfeiture in respect of the&#160;non-payment&#160;of the same amount.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(c) Without derogating from Articles 51 and 55 hereof, whenever shares are forfeited as herein provided, all dividends, if any, theretofore declared in respect thereof and not actually paid shall be deemed to have been forfeited at the same time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(d) The Company, by resolution of the Board of Directors, may accept the voluntary surrender of any share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(e) Any share forfeited or surrendered as provided herein, shall become the property of the Company as a dormant share, and the same, subject to the provisions of these Articles, may be sold,&#160;re-issued&#160;or otherwise disposed of as the Board of Directors deems fit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(f) Any person whose shares have been forfeited or surrendered shall cease to be a shareholder in respect of the forfeited or surrendered shares, but shall, notwithstanding, be liable to pay, and shall forthwith pay, to the Company, all calls, interest and expenses owing upon or in respect of such shares at the time of forfeiture or surrender, together with interest thereon from the time of forfeiture or surrender until actual payment, at the rate prescribed in Article 13(e) above, and the Board of Directors, in its discretion, may, but shall not be obligated to, enforce or collect the payment of such amounts, or any part thereof, as it shall deem fit. In the event of such forfeiture or surrender, the Company, by resolution of the Board of Directors, may accelerate the date(s) of payment of any or all amounts then owing to the Company by the person in question (but not yet due) in respect of all shares owned by such Shareholder, solely or jointly with another.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">(g) The Board of Directors may at any time, before any share so forfeited or surrendered shall have been sold,&#160;re-issued&#160;or otherwise disposed of, nullify the forfeiture or surrender on such conditions as it deems fit, but no such nullification shall stop the Board of Directors from&#160;re-exercising&#160;its powers of forfeiture pursuant to this Article 15.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">16.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">LIEN</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(a) Except to the extent the same may be waived or subordinated in writing, the Company shall have a first and paramount lien upon all the shares registered in the name of each Shareholder (without regard to any equitable or other claim or interest in such shares on the part of any other person), and upon the proceeds of the sale thereof, for his or her debts, liabilities and engagements to the Company arising from any amount payable by such Shareholder in respect of any unpaid or partly paid share, whether or not such debt, liability or engagement has matured. Such lien shall extend to all dividends from time to time declared or paid in respect of such share. Unless otherwise provided, the registration by the Company of a transfer of shares shall be deemed to be a waiver on the part of the Company of the lien (if any) existing on such shares immediately prior to such transfer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(b) The Board of Directors may cause the Company to sell a share subject to such a lien when the debt, liability or engagement giving rise to such lien has matured, in such manner as the Board of Directors deems fit, but no such sale shall be made unless such debt, liability or engagement has not been satisfied within fourteen (14)&#160;days after written notice of the intention to sell shall have been served on such Shareholder, his or her executors or administrators.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">(c) The net proceeds of any such sale, after payment of the costs and expenses thereof or ancillary thereto, shall be applied in or toward satisfaction of the debts, liabilities or engagements of such Shareholder in respect of such share (whether or not the same have matured), and the remaining proceeds (if any) shall be paid to the shareholder, his or her executors, administrators or assigns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">17.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">SALE AFTER FORFEITURE OR SURRENDER OR FOR ENFORCEMENT OF LIEN</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">Upon any sale of a share after forfeiture or surrender or for enforcing a lien, the Board of Directors may appoint any person to execute an instrument of transfer of the share so sold and cause the purchaser&#8217;s name to be entered in the Register of Shareholders in respect of such share. The purchaser shall be registered as the shareholder and shall not be bound to see to the regularity of the sale proceedings, or to the application of the proceeds of such sale, and after his or her name has been entered in the Register of Shareholders in respect of such share, the validity of the sale shall not be impeached by any person, and the remedy of any person aggrieved by the sale shall be in damages only and against the Company exclusively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">18.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">REDEEMABLE SHARES</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 18pt 24.5pt;">The Company may, subject to applicable law, issue redeemable shares or other securities and redeem the same upon terms and conditions to be set forth in a written agreement between the Company and the holder of such shares or in their terms of issuance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TRANSFER&#160;OF&#160;SHARES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">19.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">REGISTRATION OF TRANSFER</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">No transfer of shares shall be registered unless a proper writing or instrument of transfer (in any customary form or any other form satisfactory to the Board of Directors or an officer of the Company to be designated by the Chief Executive Officer) has been submitted to the Company (or its transfer agent), together with any share certificate(s) and such other evidence of title as the Board of Directors or an officer of the Company to be designated by the Chief Executive Officer may require. Notwithstanding anything to the contrary herein, shares registered in the name of The Depository Trust Company or its nominee shall be transferrable in accordance with the policies and procedures of The Depository Trust Company. Until the transferee has been registered in the Register of Shareholders in respect of the shares so transferred, the Company may continue to regard the transferor as the owner thereof. The Board of Directors, may, from time to time, prescribe a fee for the registration of a transfer, and may approve other methods of recognizing the transfer of shares in order to facilitate the trading of the Company&#8217;s shares on the Nasdaq Stock Market or on any other stock exchange on which the Company&#8217;s shares are then listed for trading.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">20.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">SUSPENSION OF REGISTRATION</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 18pt 24.5pt;">The Board of Directors may, in its discretion to the extent it deems necessary, close the Register of Shareholders of registration of transfers of shares for a period determined by the Board of Directors, and no registrations of transfers of shares shall be made by the Company during any such period during which the Register of Shareholders is so closed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TRANSMISSION&#160;OF&#160;SHARES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">21.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">DECEDENTS&#8217; SHARES</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">Upon the death of a Shareholder, the Company shall recognize the custodian or administrator of the estate or executor of the will, and in the absence of such, the lawful heirs of the Shareholder, as the only holders of the right for the shares of the deceased Shareholder, after receipt of evidence to the entitlement thereto, as determined by the Board of Directors or an officer of the Company to be designated by the Chief Executive Officer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.8pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">22.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">RECEIVERS AND LIQUIDATORS</b>.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(a) The Company may recognize any receiver, liquidator or similar official appointed to&#160;wind-up,&#160;dissolve or otherwise liquidate a corporate Shareholder, and a trustee, manager, receiver, liquidator or similar official appointed in bankruptcy or in connection with the reorganization of, or similar proceeding with respect to a Shareholder or its properties, as being entitled to the shares registered in the name of such Shareholder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">(b) Such receiver, liquidator or similar official appointed to&#160;wind-up,&#160;dissolve or otherwise liquidate a corporate Shareholder and such trustee, manager, receiver, liquidator or similar official appointed in bankruptcy or in connection with the reorganization of, or similar proceedings with respect to a Shareholder or its properties, upon producing such evidence as the Board of Directors (or an officer of the Company to be designated by the Chief Executive Officer) may deem sufficient as to his or her authority to act in such capacity or under this Article, shall with the consent of the Board of Directors or an officer of the Company to be designated by the Chief Executive Officer (which the Board of Directors or such officer may grant or refuse in its absolute discretion), be registered as a Shareholder in respect of such shares, or may, subject to the regulations as to transfer herein contained, transfer such shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">GENERAL&#160;MEETINGS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">23.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">GENERAL MEETINGS</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(a) An annual General Meeting (&#8220;<b style="font-weight:bold;">Annual General Meeting</b>&#8221;) shall be held at such time and at such place, either within or outside of the State of Israel, as may be determined by the Board of Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(b) All General Meetings other than Annual General Meetings shall be called &#8220;<b style="font-weight:bold;">Special General Meetings</b>&#8221;. The Board of Directors may, at its discretion, convene a Special General Meeting at such time and place, within or outside of the State of Israel, as may be determined by the Board of Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">(c) If so determined by the Board of Directors, an Annual General Meeting or a Special General Meeting may be held through the use of any means of communication approved by the Board of Directors, provided all of the participating Shareholders can hear each other simultaneously. A resolution approved by use of means of communications as aforesaid, shall be deemed to be a resolution lawfully adopted at such general meeting and a Shareholder shall be deemed present in person at such general meeting if attending such meeting through the means of communication used at such meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">24.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">RECORD DATE FOR GENERAL MEETING</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">Notwithstanding any provision of these Articles to the contrary, and to allow the Company to determine the Shareholders entitled to notice of or to vote at any General Meeting or any adjournment thereof, or entitled to receive payment of any dividend or other distribution or grant of any rights, or entitled to exercise any rights in respect of or to take or be the subject of any other action, the Board of Directors may fix a record date for the General Meeting, which shall not be more than the maximum period and not less than the minimum period permitted by law. A determination of Shareholders of record entitled to notice of or to vote at a General Meeting shall apply to any adjournment of the meeting;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>,&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">however</u>, that the Board of Directors may fix a new record date for the adjourned meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">25.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">SHAREHOLDER PROPOSAL REQUEST</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">(a) Any Shareholder or Shareholders of the Company holding at least the required percentage under the Companies Law of the voting rights of the Company which entitles such Shareholder(s) to require the Company to include a matter on the agenda of a General Meeting (the &#8220;<b style="font-weight:bold;">Proposing Shareholder(s)</b>&#8221;) may request, subject to the Companies Law, that the Board of Directors include a matter on the agenda of a General Meeting to be held in the future, provided that the Board of Directors determines that the matter is appropriate to be considered at a General Meeting (a &#8220;<b style="font-weight:bold;">Proposal Request</b>&#8221;). In order for the Board of Directors to consider a Proposal Request and whether to include the matter stated therein in the agenda of a General Meeting, notice of the Proposal Request must be timely delivered in accordance with applicable law, and the Proposal Request must comply with the requirements of these Articles (including this Article 25) and any applicable law and stock exchange rules and regulations. The Proposal Request must be in writing, signed by all of the Proposing Shareholder(s) making such request, delivered, either in person or by registered mail, postage prepaid, and received by the Secretary (or, in the absence thereof, by the Chief Executive Officer of the Company). To be considered timely, a Proposal Request must be received within the time periods prescribed by applicable law. The announcement of an adjournment or postponement of a General Meeting shall not commence a new time period (or extend any time period) for the delivery of a Proposal Request as described above. In addition to any information required to be included in accordance with applicable law, a Proposal Request must include the following: (i)&#160;the name, address, telephone number, fax number and email address of the Proposing Shareholder (or each Proposing Shareholder, as the case may be) and, if an entity, the name(s) of the person(s) that controls or manages such entity; (ii)&#160;the number of Shares held by the Proposing Shareholder(s), directly or indirectly (and, if any of such Shares are held indirectly, an explanation of how they are held and by whom), which shall be in such number no less than as is required to qualify as a Proposing Shareholder, accompanied by evidence satisfactory to the Company of the record holding of such Shares by the Proposing Shareholder(s) as of the date of the Proposal Request; (iii)&#160;the matter requested to be included on the agenda of a General Meeting, all information related to such matter, the reason that such matter is proposed to be brought before the General Meeting, the complete text of the resolution that the Proposing Shareholder proposes to be voted upon at the General Meeting, and a representation that the Proposing Shareholder(s) intend to appear in person or by proxy at the meeting; (iv)&#160;a description of all arrangements or understandings between the Proposing Shareholders and any other Person(s) (naming such Person or Persons) in connection with the matter that is requested to be included on the agenda and a declaration signed by all </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">Proposing Shareholder(s) of whether any of them has a personal interest in the matter and, if so, a description in reasonable detail of such personal interest; (v)&#160;a description of all Derivative Transactions (as defined below) by each Proposing Shareholder(s) during the previous twelve (12)&#160;month period, including the date of the transactions and the class, series and number of securities involved in, and the material economic terms of, such Derivative Transactions; and (vi)&#160;a declaration that all of the information that is required under the Companies Law and any other applicable law and stock exchange rules and regulations to be provided to the Company in connection with such matter, if any, has been provided to the Company. The Board of Directors, may, in its discretion, to the extent it deems necessary, request that the Proposing Shareholder(s) provide additional information necessary so as to include a matter in the agenda of a General Meeting, as the Board of Directors may reasonably require.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">A &#8220;<b style="font-weight:bold;">Derivative Transaction</b>&#8221; means any agreement, arrangement, interest or understanding entered into by, or on behalf or for the benefit of, any Proposing Shareholder or any of its affiliates or associates, whether of record or beneficial: (1)&#160;the value of which is derived in whole or in part from the value of any class or series of shares or other securities of the Company, (2)&#160;which otherwise provides any direct or indirect opportunity to gain or share in any gain derived from a change in the value of securities of the Company, (3)&#160;the effect or intent of which is to mitigate loss, manage risk or benefit of security value or price changes, or (4)&#160;which provides the right to vote or increase or decrease the voting power of, such Proposing Shareholder, or any of its affiliates or associates, with respect to any shares or other securities of the Company, which agreement, arrangement, interest or understanding may include, without limitation, any option, warrant, debt position, note, bond, convertible security, swap, stock appreciation right, short position, profit interest, hedge, right to dividends, voting agreement, performance-related fee or arrangement to borrow or lend shares (whether or not subject to payment, settlement, exercise or conversion in any such class or series), and any proportionate interest of such Proposing Shareholder in the securities of the Company held by any general or limited partnership, or any limited liability company, of which such Proposing Shareholder is, directly or indirectly, a general partner or managing member.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(b) The information required pursuant to this Article shall be updated as of (i)&#160;the record date of the General Meeting, (ii)&#160;five business days before the General Meeting, and (iii)&#160;as of the General Meeting, and any adjournment or postponement thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(c) The provisions of Articles 25(a) and 25(b) shall apply,&#160;<i style="font-style:italic;">mutatis mutandis,</i>&#160;to any matter to be included on the agenda of a Special General Meeting which is convened pursuant to a request of a Shareholder duly delivered to the Company in accordance with the Companies Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 24.5pt;">(d) Notwithstanding anything to the contrary herein, this Article 25&#160;may only be amended, replaced or suspended by a resolution adopted at a General Meeting by a supermajority of at least 65% of the total voting power of the Shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">26.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">NOTICE OF GENERAL MEETINGS; OMISSION TO GIVE NOTICE</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(a) The Company is not required to give notice of a General Meeting, subject to any mandatory provision of the Companies Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(b) The accidental omission to give notice of a General Meeting to any Shareholder, or the&#160;non-receipt&#160;of notice sent to such Shareholder, shall not invalidate the proceedings at such meeting or any resolution adopted thereat.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(c) No Shareholder present, in person or by proxy, at any time during a General Meeting shall be entitled to seek the cancellation or invalidation of any proceedings or resolutions adopted at such General Meeting on account of any defect in the notice of such meeting relating to the time or the place thereof, or any item acted upon at such meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(d) In addition to any places at which the Company may make available for review by Shareholders the full text of the proposed resolutions to be adopted at a General Meeting, as required by the Companies Law, the Company may add additional places for Shareholders to review such proposed resolutions, including an internet site.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PROCEEDINGS&#160;AT&#160;GENERAL&#160;MEETINGS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">27.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">QUORUM</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(a) No business shall be transacted at a General Meeting, or at any adjournment thereof, unless the quorum required under these Articles for such General Meeting or such adjourned meeting, as the case may be, is present when the meeting proceeds to business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(b) In the absence of contrary provisions in these Articles, the requisite quorum for any General Meeting shall be two or more Shareholders (not in default in payment of any sum referred to in Article 13 hereof) present in person or by proxy and holding shares conferring in the aggregate at least thirty-three and&#160;one-third&#160;percent (33<sup style="font-size:7.5pt;vertical-align:top;">1</sup>&#8260;<sub style="font-size:7.5pt;vertical-align:sub;">3</sub>%) of the voting power of the Company, provided, however, that if (i)&#160;such General Meeting was initiated by and convened pursuant to a resolution adopted by the Board of Directors and (ii)&#160;at the time of such General Meeting the Company is qualified to use the forms of a &#8220;foreign private issuer&#8221; under US securities laws, then the requisite quorum shall be two or more Shareholders (not in default in payment of any sum referred to in Article 13 hereof) present in person or by proxy and holding shares conferring in the aggregate at least twenty-five percent (25%) of the voting power of the Company. For the purpose of determining the quorum present at a certain General Meeting, a proxy may be deemed to be two (2)&#160;or more Shareholders pursuant to the number of Shareholders represented by the proxy holder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">(c) If within half an hour from the time appointed for the meeting a quorum is not present, then without any further notice the meeting shall be adjourned either (i)&#160;to the same day in the next week, at the same time and place, (ii)&#160;to such day and at such time and place as indicated in the notice of such meeting, or (iii)&#160;to such day and at such time and place as the Chairperson of the General Meeting shall determine (which may be earlier or later than the date pursuant to clause (i)&#160;above). No business shall be transacted at any adjourned meeting except business which might lawfully have been transacted at the meeting as originally called. At such adjourned meeting, if the original meeting was convened pursuant to a request under Section&#160;63 of the Companies Law, one or more shareholders, present in person or by proxy, and holding the number of shares required for making such request, shall constitute a quorum, but in any other case any shareholder (not in default as aforesaid) present in person or by proxy, shall constitute a quorum.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">28.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">CHAIRPERSON OF GENERAL MEETING</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">The Chairperson of the Board of Directors shall preside as Chairperson of every General Meeting of the Company. If at any meeting the Chairperson is not present within fifteen (15)&#160;minutes after the time fixed for holding the meeting or is unwilling or unable to act as Chairperson, any of the following may preside as Chairperson of the meeting (and in the following order): a Director designated by the Board of Directors, the Chief Executive Officer, the Chief Financial Officer, the General Counsel, the Secretary or any person designated by any of the foregoing. If at any such meeting none of the foregoing persons is present or all are unwilling or unable to act as Chairperson, the Shareholders present (in person or by proxy) shall choose a Shareholder or its proxy present at the meeting to be Chairperson. The office of Chairperson shall not, by itself, entitle the holder thereof to vote at any General Meeting nor shall it entitle such holder to a second or casting vote (without derogating, however, from the rights of such Chairperson to vote as a Shareholder or proxy of a Shareholder if, in fact, the Chairperson is also a Shareholder or such proxy).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">29.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">ADOPTION OF RESOLUTIONS AT GENERAL MEETINGS</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">(a) Except as required by the Companies Law or these Articles, including, without limitation, Article 39 below, a resolution of the Shareholders shall be adopted if approved by the holders of a simple majority of the voting power represented at the General Meeting in person or by proxy and voting thereon, as one class, and disregarding abstentions from the count of the voting power present and voting. Without limiting the generality of the foregoing, a resolution with respect to a matter or action for which the Companies Law prescribes a higher majority or pursuant to which a provision requiring a higher majority would have been deemed to have been incorporated into these Articles, but for which the Companies Law allows these Articles to provide otherwise (including, Sections 327 and 24 of the Companies Law), shall be adopted by a simple majority of the voting power represented at the General Meeting in person or by proxy and voting thereon, as one class, and disregarding abstentions from the count of the voting power present and voting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(b) Every question submitted to a General Meeting shall be decided by a show of hands, but the Chairperson of the General Meeting may determine that a resolution shall be decided by a written ballot. A written ballot may be implemented before the proposed resolution is voted upon or immediately after the declaration by the Chairperson of the results of the vote by a show of hands. If a vote by written ballot is taken after such declaration, the results of the vote by a show of hands shall be of no effect, and the proposed resolution shall be decided by such written ballot.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(c) A defect in convening or conducting a General Meeting, including a defect resulting from the&#160;non-fulfillment&#160;of any provision or condition set forth in the Companies Law or these Articles, including with regard to the manner of convening or conducting the General Meeting, shall not disqualify any resolution passed at the General Meeting and shall not affect the discussions or decisions which took place thereat.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">(d) A declaration by the Chairperson of the General Meeting that a resolution has been carried unanimously, or carried by a particular majority, or rejected, and an entry to that effect in the minute book of the Company, shall be prima facie evidence of the fact without proof of the number or proportion of the votes recorded in favor of or against such resolution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">30.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">POWER TO ADJOURN</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">A General Meeting, the consideration of any matter on its agenda, or the resolution on any matter on its agenda, may be postponed or adjourned, from time to time and from place to place: (i)&#160;by the Chairperson of a General Meeting at which a quorum is present (and he shall do so if directed by the General Meeting, with the consent of the holders of a majority of the voting power represented in person or by proxy and voting on the question of adjournment), but no business shall be transacted at any such adjourned meeting except business which might lawfully have been transacted at the meeting as originally called, or a matter on its agenda with respect to which no resolution was adopted at the meeting originally called; or (ii)&#160;by the Board of Directors (whether prior to or at a General Meeting).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">31.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">VOTING POWER</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">Subject to the provisions of Article 32(a) and to any provision hereof conferring special rights as to voting, or restricting the right to vote, every Shareholder shall have one vote for each share held by the Shareholder of record, on every resolution, without regard to whether the vote thereon is conducted by a show of hands, by written ballot, or by any other means.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">32.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">VOTING RIGHTS.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(a) No Shareholder shall be entitled to vote at any General Meeting (or be counted as a part of the quorum thereat), unless all calls then payable by him or her in respect of his or her shares in the Company have been paid.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(b) A company or other corporate body being a Shareholder of the Company may duly authorize any person to be its representative at any meeting of the Company or to execute or deliver a proxy on its behalf. Any person so authorized shall be entitled to exercise on behalf of such Shareholder all the power, which the Shareholder could have exercised if it were an individual. Upon the request of the Chairperson of the General Meeting, written evidence of such authorization (in form acceptable to the Chairperson) shall be delivered to him or her.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(c) Any Shareholder entitled to vote may vote either in person or by proxy (who need not be a Shareholder of the Company), or, if the Shareholder is a company or other corporate body, by representative authorized pursuant to Article (b)&#160;above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(d) If two or more persons are registered as joint holders of any share, the vote of the senior who tenders a vote, in person or by proxy, shall be accepted to the exclusion of the vote(s) of the other joint holder(s). For the purpose of this Article 32(d), seniority shall be determined by the order of registration of the joint holders in the Register of Shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">(e) If a Shareholder is a minor, under protection, bankrupt or legally incompetent, or in the case of a corporation, is in receivership or liquidation, it may, subject to all other provisions of these Articles and any documents or records required to be provided under these Articles, vote through his, her or its trustees, receiver, liquidator, natural guardian or another legal guardian, as the case may be, and the persons listed above may vote in person or by proxy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PROXIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">33.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">INSTRUMENT OF APPOINTMENT</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">(a) An instrument appointing a proxy shall be in writing and shall be substantially in the following form:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><div style="padding-left:24.5pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:90%;"><tr><td style="vertical-align:middle;width:6.54%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:44.68%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.68%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:1.71%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.02%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:42.66%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24pt;margin:0pt;">&#8220;I</p></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:44.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u></p></td><td style="vertical-align:bottom;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">of</p></td><td style="vertical-align:bottom;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:42.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u></p></td></tr><tr><td style="vertical-align:top;width:6.54%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:44.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(Name of Shareholder)</i></p></td><td style="vertical-align:bottom;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:1.71%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:42.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(Address of Shareholder)</i></p></td></tr><tr style="height:6pt;"><td colspan="7" style="vertical-align:middle;width:100%;margin:0pt;padding:0pt;"></td></tr><tr><td colspan="7" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Being a shareholder of Alpha TAU Medical Ltd. hereby appoints</p></td></tr><tr><td style="vertical-align:top;width:6.54%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:44.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u></p></td><td style="vertical-align:bottom;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">of</p></td><td style="vertical-align:bottom;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:42.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u></p></td></tr><tr><td style="vertical-align:top;width:6.54%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:44.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(Name of Proxy)</i></p></td><td style="vertical-align:bottom;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:1.71%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:42.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(Address of Proxy)</i></p></td></tr><tr style="height:6pt;"><td colspan="7" style="vertical-align:middle;width:100%;margin:0pt;padding:0pt;"></td></tr><tr><td colspan="7" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">as my proxy to vote for me and on my behalf at the General Meeting of the Company to be held on the ___ day of _______, _______ and at any adjournment(s) thereof.</p></td></tr><tr style="height:6pt;"><td colspan="7" style="vertical-align:middle;width:100%;margin:0pt;padding:0pt;"></td></tr><tr><td colspan="7" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Signed this ____ day of ___________, ______.</p></td></tr><tr><td colspan="7" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(Signature of Appointor)&#8221;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;"><font style="font-size:6pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">or in any usual or common form or in such other form as may be approved by the Board of Directors. Such proxy shall be duly signed by the appointor of such person&#8217;s duly authorized attorney, or, if such appointor is company or other corporate body, in the manner in which it signs documents which binds it together with a certificate of an attorney with regard to the authority of the signatories.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">(b) Subject to the Companies Law, the original instrument appointing a proxy or a copy thereof certified by an attorney (and the power of attorney or other authority, if any, under which such instrument has been signed) shall be delivered to the Company (at its Office, at its principal place of business, or at the offices of its registrar or transfer agent, or at such place as notice of the meeting may specify) not less than forty eight (48)&#160;hours (or such shorter period as the notice shall specify) before the time fixed for such meeting. Notwithstanding the above, the Chairperson shall have the right to waive the time requirement provided above with respect to all instruments of proxies and to accept instruments of proxy until the beginning of a General Meeting. A document appointing a proxy shall be valid for every adjourned meeting of the General Meeting to which the document relates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">34.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">EFFECT OF DEATH OF APPOINTER OF TRANSFER OF SHARE AND OR REVOCATION OF APPOINTMENT</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(a) A vote cast in accordance with an instrument appointing a proxy shall be valid notwithstanding the prior death or bankruptcy of the appointing Shareholder (or of his or her&#160;attorney-in-fact,&#160;if any, who signed such instrument), or the transfer of the share in respect of which the vote is cast, unless written notice of such matters shall have been received by the Company or by the Chairperson of such meeting prior to such vote being cast.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">(b) Subject to the Companies Law, an instrument appointing a proxy shall be deemed revoked (i)&#160;upon receipt by the Company or the Chairperson, subsequent to receipt by the Company of such instrument, of written notice signed by the person signing such instrument or by the Shareholder appointing such proxy canceling the appointment thereunder (or the authority pursuant to which such instrument was signed) or of an instrument appointing a different proxy (and such other documents, if any, required under Article 33(b) for such new appointment), provided such notice of cancellation or instrument appointing a different proxy were so received at the place and within the time for delivery of the instrument revoked thereby as referred to in Article 33(b) hereof, or (ii)&#160;if the appointing Shareholder is present in person at the meeting for which such instrument of proxy was delivered, upon receipt by the Chairperson of such meeting of written notice from such Shareholder of the revocation of such appointment, or if and when such Shareholder votes at such meeting. A vote cast in accordance with an instrument appointing a proxy shall be valid notwithstanding the revocation or purported cancellation of the appointment, or the presence in person or vote of the appointing Shareholder at a meeting for which it was rendered, unless such instrument of appointment was deemed revoked in accordance with the foregoing provisions of this Article 34(b) at or prior to the time such vote was cast.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">BOARD&#160;OF&#160;DIRECTORS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">35.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">POWERS OF THE BOARD OF DIRECTORS</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(a) The Board of Directors may exercise all such powers and do all such acts and things as the Board of Directors is authorized by law or as the Company is authorized to exercise and do and are not hereby or by law required to be exercised or done by the General Meeting. The authority conferred on the Board of Directors by this Article 35 shall be subject to the provisions of the Companies Law, these Articles and any regulation or resolution consistent with these Articles adopted from time to time at a General Meeting, provided, however, that no such regulation or resolution shall invalidate any prior act done by or pursuant to a decision of the Board of Directors which would have been valid if such regulation or resolution had not been adopted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">(b) Without limiting the generality of the foregoing, the Board of Directors may, from time to time, set aside any amount(s) out of the profits of the Company as a reserve or reserves for any purpose(s) which the Board of Directors, in its absolute discretion, shall deem fit, including without limitation, capitalization and distribution of bonus shares, and may invest any sum so set aside in any manner and from time to time deal with and vary such investments and dispose of all or any part thereof, and employ any such reserve or any part thereof in the business of the Company without being bound to keep the same separate from other assets of the Company, and may subdivide or&#160;re-designate&#160;any reserve or cancel the same or apply the funds therein for another purpose, all as the Board of Directors may from time to time think fit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">36.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">EXERCISE OF POWERS OF THE BOARD OF DIRECTORS</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(a) A meeting of the Board of Directors at which a quorum is present in accordance with Article 45 shall be competent to exercise all the authorities, powers and discretion vested in or exercisable by the Board of Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(b) A resolution proposed at any meeting of the Board of Directors shall be deemed adopted if approved by a majority of the Directors present, entitled to vote and voting thereon when such resolution is put to a vote.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">(c) The Board of Directors may adopt resolutions, without convening a meeting of the Board of Directors, in writing or in any other manner permitted by the Companies Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">37.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">DELEGATION OF POWERS</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(a) The Board of Directors may, subject to the provisions of the Companies Law, delegate any or all of its powers to committees (in these Articles referred to as a &#8220;<b style="font-weight:bold;">Committee of the Board of Directors</b>&#8221;, or &#8220;<b style="font-weight:bold;">Committee</b>&#8221;), each consisting of one or more persons (who may or may not be Directors), and it may from time to time revoke such delegation or alter the composition of any such Committee. Any Committee so formed shall, in the exercise of the powers so delegated, conform to any regulations imposed on it by the Board of Directors, subject to applicable law. No regulation imposed by the Board of Directors on any Committee and no resolution of the Board of Directors shall invalidate any prior act done or pursuant to a resolution by the Committee which would have been valid if such regulation or resolution of the Board of Directors had not been adopted. The meetings and proceedings of any such Committee of the Board of Directors shall, mutatis mutandis, be governed by the provisions herein contained for regulating the meetings of the Board of Directors, to the extent not superseded by any regulations adopted by the Board of Directors. Unless otherwise expressly prohibited by the Board of Directors, in delegating powers to a Committee of the Board of Directors, such Committee shall be empowered to further delegate such powers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(b) The Board of Directors may from time to time appoint a Secretary to the Company, as well as Officers, agents, employees and independent contractors, as the Board of Directors deems fit, and may terminate the service of any such person. The Board of Directors may, subject to the provisions of the Companies Law, determine the powers and duties, as well as the salaries and compensation, of all such persons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">(c) The Board of Directors may from time to time, by power of attorney or otherwise, appoint any person, company, firm or body of persons to be the attorney or attorneys of the Company at law or in fact for such purposes(s) and with such powers, authorities and discretions, and for such period and subject to such conditions, as it deems fit, and any such power of attorney or other appointment may contain such</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">provisions for the protection and convenience of persons dealing with any such attorney as the Board of Directors deems fit, and may also authorize any such attorney to delegate all or any of the powers, authorities and discretions vested in him or her.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">38.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">NUMBER OF DIRECTORS</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(a) The Board of Directors shall consist of such number of Directors (not less than three (3)&#160;nor more than eleven (11), including the External Directors, if any were elected) as may be fixed from time to time by resolution of the Board of Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">(b) Notwithstanding anything to the contrary herein, this Article 38 may only be amended or replaced by a resolution adopted at a General Meeting by a majority of at least 65% of the total voting power of the Company&#8217;s shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">39.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">ELECTION AND REMOVAL OF DIRECTORS</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(a) The Directors (excluding the External Directors if any were elected), shall be classified, with respect to the term for which they each severally hold office, into three classes, as nearly equal in number as practicable, hereby designated as Class&#160;I, Class&#160;II and Class&#160;III. The Board of Directors may assign members of the Board of Directors already in office to such classes at the time such classification becomes effective</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 55.1pt;">(i) The term of office of the initial Class&#160;I directors shall expire at the Annual General Meeting to be held in 2022 and when their successors are elected and qualified,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 55.1pt;">(ii) The term of office of the initial Class&#160;II directors shall expire at the first Annual General Meeting following the Annual General Meeting referred to in clause (i)&#160;above and when their successors are elected and qualified, and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 55.1pt;">(iii) The term of office of the initial Class&#160;III directors shall expire at the first Annual General Meeting following the Annual General Meeting referred to in clause (ii)&#160;above and when their successors are elected and qualified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(b) At each Annual General Meeting, commencing with the Annual General Meeting to be held in 2022, each Nominee or Alternate Nominee (each as defined below) elected at such Annual General Meeting to serve as a Director in a Class&#160;whose term shall have expired at such Annual General Meeting shall be elected to hold office until the third Annual General Meeting next succeeding his or her election and until his or her respective successor shall have been elected and qualified. Notwithstanding anything to the contrary, each Director shall serve until his or her successor is elected and qualified or until such earlier time as such Director&#8217;s office is vacated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">(c) If the number of Directors (excluding External Directors, if any were elected) that comprises the Board of Directors is hereafter changed by the Board of Directors, any newly created directorships or decrease in</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">directorships shall be so apportioned by the Board of Directors among the classes as to make all classes as nearly equal in number as is practicable, provided that no decrease in the number of Directors constituting the Board of Directors shall shorten the term of any incumbent Director.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(d) Prior to every General Meeting of the Company at which Directors are to be elected, and subject to clauses (a)&#160;and (h) of this Article, the Board of Directors (or a Committee thereof) shall select, by a resolution adopted by a majority of the Board of Directors (or such Committee), a number of Persons to be proposed to the Shareholders for election as Directors at such General Meeting (the &#8220;<b style="font-weight:bold;">Nominees</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">(e) Any Proposing Shareholder requesting to include on the agenda of a General Meeting a nomination of a Person to be proposed to the Shareholders for election as Director (such person, an &#8220;<b style="font-weight:bold;">Alternate Nominee</b>&#8221;), may so request provided that it complies with this Article 39(e), Article 25 and applicable law. Unless otherwise determined by the Board of Directors, a Proposal Request relating to an Alternate Nominee is deemed to be a matter that is appropriate to be considered only at an Annual General Meeting. In addition to any information required to be included in accordance with applicable law, such a Proposal Request shall include information required pursuant to Article 25, and shall also set forth: (i)&#160;the name, address, telephone number, fax number and email address of the Alternate Nominee and all citizenships and residencies of the Alternate Nominee; (ii)&#160;a description of all arrangements, relations or understandings during the past three (3)&#160;years, and any other material relationships, between the Proposing Shareholder(s) or any of its affiliates and each Alternate Nominee; (iii)&#160;a declaration signed by the Alternate Nominee that he or she consents to be named in the Company&#8217;s notices and proxy materials and on the Company&#8217;s proxy card relating to the General Meeting, if provided or published, and that he or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">she, if elected, consents to serve on the Board of Directors and to be named in the Company&#8217;s disclosures and filings; (iv)&#160;a declaration signed by each Alternate Nominee as required under the Companies Law and any other applicable law and stock exchange rules and regulations for the appointment of such an Alternate Nominee and an undertaking that all of the information that is required under law and stock exchange rules and regulations to be provided to the Company in connection with such an appointment has been provided (including, information in respect of the Alternate Nominee as would be provided in response to the applicable disclosure requirements under Form&#160;20-F&#160;(or Form&#160;10-K,&#160;if applicable) or any other applicable form prescribed by the U.S. Securities and Exchange Commission (the&#160;&#8220;<b style="font-weight:bold;">SEC</b>&#8221;)); (v) a declaration made by the Alternate Nominee of whether he or she meets the criteria for an independent director and, if applicable, External Director of the Company under the Companies Law and/or under any applicable law, regulation or stock exchange rules, and if not, then an explanation of why not; and (vi)&#160;any other information required at the time of submission of the Proposal Request by applicable law, regulations or stock exchange rules. In addition, the Proposing Shareholder(s) and each Alternate Nominee shall promptly provide any other information reasonably requested by the Company, including a duly completed director and officer questionnaire, in such form as may be provided by the Company, with respect to each Alternate Nominee. The Board of Directors may refuse to acknowledge the nomination of any person not made in compliance with the foregoing. The Company shall be entitled to publish any information provided by a Proposing Shareholder or Alternate Nominee pursuant to this Article 39(e) and Article 25, and the Proposing Shareholder and Alternate Nominee shall be responsible for the accuracy and completeness thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(f) The Nominees or Alternate Nominees shall be elected by a resolution adopted at the General Meeting at which they are subject to election. Notwithstanding Articles 25(a) and 25(c), in the event of a Contested Election, the method of calculation of the votes and the manner in which the resolutions will be presented to the General Meeting shall be determined by the Board of Directors in its discretion. In the event that the Board of Directors does not or is unable to make a determination on such matter, then the method described in clause (ii)&#160;below shall apply. The Board of Directors may consider, among other things, the following methods: (i)&#160;election of competing slates of Director nominees (determined in a manner approved by the Board of Directors) by a majority of the voting power represented at the General Meeting in person or by proxy and voting on such competing slates, (ii)&#160;election of individual Directors by a plurality of the voting power represented at the General Meeting in person or by proxy and voting on the election of Directors (which shall mean that the nominees receiving the largest number of &#8220;for&#8221; votes will be elected in such Contested Election), (iii) election of each nominee by a majority of the voting power represented at the General Meeting in person or by proxy and voting on the election of Directors, provided that if the number of such nominees exceeds the number of Directors to be elected, then as among such nominees the election shall be by plurality of the voting power as described above, and (iv)&#160;such other method of voting as the Board of Directors deems appropriate, including use of a &#8220;universal proxy card&#8221; listing all Nominees and Alternate Nominees by the Company. For the purposes of these Articles, election of Directors at a General Meeting shall be considered a &#8220;Contested Election&#8221; if the aggregate number of Nominees and Alternate Nominees at such meeting exceeds the total number of Directors to be elected at such meeting, with the determination thereof being made by the Secretary (or, in the absence thereof, by the Chief Executive Officer of the Company) as of the close of the applicable notice of nomination period under Article 25 or under applicable law, based on whether one or more notice(s) of nomination were timely filed in accordance with Article 25, this Article 39 and applicable law;&#160;<u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>,<u style="text-decoration:underline;text-decoration-color:#000000;">&#160;however</u>, that the determination that an election is a Contested Election shall not be determinative as to the validity of any such notice of nomination; and provided, further, that, if, prior to the time the Company mails its initial proxy statement in connection with such election of Directors, one or more notices of nomination of an Alternate Nominee are withdrawn such that the number of candidates for election as Director no longer exceeds the number of Directors to be elected, the election shall not be considered a Contested Election. Shareholders shall not be entitled to cumulative voting in the election of Directors, except to the extent specifically set forth in this clause (f).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(g) Notwithstanding anything to the contrary herein, this Article 39 and Article 42(e) may only be amended, replaced or suspended by a resolution adopted at a General Meeting by a majority of at least 65% of the total voting power of the Company&#8217;s shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(h) Notwithstanding anything to the contrary in these Articles, the election, qualification, removal or dismissal of External Directors, if so elected, shall be only in accordance with the applicable provisions set forth in the Companies Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">40.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">COMMENCEMENT OF DIRECTORSHIP</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">Without derogating from Article 39, the term of office of a Director shall commence as of the date of his or her appointment or election, or on a later date if so specified in his or her appointment or election.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">41.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">CONTINUING DIRECTORS IN THE EVENT OF VACANCIES</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">The Board of Directors (and, if so determined by the Board of Directors, the General Meeting) may at any time and from time to time appoint any person as a Director to fill a vacancy (whether such vacancy is due to a Director no longer serving or due to the number of Directors serving being less than the maximum number stated in Article 38 hereof). In the event of one or more such vacancies in the Board of Directors, the continuing Directors may continue to act in every matter, provided, however, that if the number of Directors serving is less than the minimum number provided for pursuant to Article 38 hereof, they may only act in an emergency or to fill the office of a Director which has become vacant up to a number equal to the minimum number provided for pursuant to Article 38 hereof, or in order to call a General Meeting of the Company for the purpose of electing Directors to fill any or all vacancies. The office of a Director that was appointed by the Board of Directors to fill any vacancy shall only be for the remaining period of time during which the Director whose service has ended was filled would have held office, or in case of a vacancy due to the number of Directors serving being less than the maximum number stated in Article 38 hereof the Board of Directors shall determine at the time of appointment the class pursuant to Article 39 to which the additional Director shall be assigned. Notwithstanding anything to the contrary herein, this Article 41 may only be amended, replaced or suspended by a resolution adopted at a General Meeting by a majority of at least 65% of the total voting power of the Company&#8217;s shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">42.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">VACATION OF OFFICE</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">The office of a Director shall be vacated and he shall be dismissed or removed:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(a) ipso facto, upon his or her death;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(b) if he or she is prevented by applicable law from serving as a Director;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(c) if the Board of Directors determines that due to his or her mental or physical state he or she is unable to serve as a director;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(d) if his or her directorship expires pursuant to these Articles and/or applicable law;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(e) by a resolution adopted at a General Meeting by a majority of at least 65% of the total voting power of the Company&#8217;s Shareholders (with such removal becoming effective on the date fixed in such resolution);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(f) by his or her written resignation, such resignation becoming effective on the date fixed therein, or upon the delivery thereof to the Company, whichever is later; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">(g) with respect to an External Director, if so elected, and notwithstanding anything to the contrary herein, only pursuant to applicable law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">43.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">CONFLICT OF INTERESTS; APPROVAL OF RELATED PARTY TRANSACTIONS</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(a) Subject to the provisions of applicable law and these Articles, no Director shall be disqualified by virtue of his or her office from holding any office or place of profit in the Company or in any company in which the Company shall be a shareholder or otherwise interested, or from contracting with the Company as vendor, purchaser or otherwise, nor shall any such contract, or any contract or arrangement entered into by or on behalf of the Company in which any Director shall be in any way interested, be avoided, nor, other than as required under the Companies Law, shall any Director be liable to account to the Company for any profit arising from any such office or place of profit or realized by any such contract or arrangement by reason only of such Director&#8217;s holding that office or of the fiduciary relations thereby established, but the nature of his or her interest, as well as any material fact or document, must be disclosed by him or her at the meeting of the Board of Directors at which the contract or arrangement is first considered, if his or her interest then exists, or, in any other case, at no later than the first meeting of the Board of Directors after the acquisition of his or her interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">(b) Subject to the Companies Law&#160;and these Articles, a transaction between the Company and an Office Holder, and a transaction between the Company and another entity in which an Office Holder of the Company has a personal interest, in each case, which is not an Extraordinary Transaction (as defined by the Companies Law), shall require only approval by the Board of Directors or a Committee of the Board</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 18pt 24.5pt;">of Directors. Such authorization, as well as the actual approval, may be for a particular transaction or more generally for specific type of transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PROCEEDINGS&#160;OF&#160;THE&#160;BOARD&#160;OF&#160;DIRECTORS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">44.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">MEETINGS</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(a) The Board of Directors may meet and adjourn its meetings and otherwise regulate such meetings and proceedings as the Board of Directors thinks fit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(b) A meeting of the Board of Directors shall be convened by the Secretary upon instruction of the Chairperson or upon a request of at least two Directors which is submitted to the Chairperson or in any event that such meeting is required by the provisions of the Companies Law. In the event that the Chairperson does not instruct the Secretary to convene a meeting upon a request of at least two (2)&#160;Directors within seven (7)&#160;days of such request, then such two Directors may convene a meeting of the Board of Directors. Any meeting of the Board of Directors shall be convened upon not less than two (2)&#160;days&#8217; notice, unless such notice is waived in writing by all of the Directors as to a particular meeting or by their attendance at such meeting or unless the matters to be discussed at such meeting are of such urgency and importance that notice is reasonably determined by the Chairperson as ought to be waived or shortened under the circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(c) Notice of any such meeting shall be given orally, by telephone, in writing or by mail, facsimile, email or such other means of delivery of notices as the Company may apply, from time to time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">(d) Notwithstanding anything to the contrary herein, failure to deliver notice to a Director of any such meeting in the manner required hereby may be waived by such Director, and a meeting shall be deemed to have been duly convened notwithstanding such defective notice if such failure or defect is waived prior to action being taken at such meeting, by all Directors entitled to participate at such meeting to whom notice was not duly given as aforesaid. Without derogating from the foregoing, no Director present at any time during a meeting of the Board of Directors shall be entitled to seek the cancellation or invalidation of any proceedings or resolutions adopted at such meeting on account of any defect in the notice of such meeting relating to the date, time or the place thereof or the convening of the meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">45.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">QUORUM</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">Until otherwise unanimously decided by the Board of Directors, a quorum at a meeting of the Board of Directors shall be constituted by the presence in person or by any means of communication of a majority of the Directors then in office who are lawfully entitled to participate and vote in the meeting. No business shall be transacted at a meeting of the Board of Directors unless the requisite quorum is present (in person or by any means of communication on the condition that all participating Directors can hear each other simultaneously) when the meeting proceeds to business. If within thirty (30)&#160;minutes from the time appointed for a meeting of the Board of Directors a quorum is not present, the meeting shall stand adjourned at the same place and time 48 hours thereafter unless the Chairperson has determined that there is such urgency and importance that a shorter period is required under the circumstances. If an adjourned meeting is convened in accordance with the foregoing and a quorum is not present within 30 minutes of the announced time, the requisite quorum at such adjourned meeting shall be, any two (2)&#160;Directors, if the number of Directors then serving is up to five (5), and any three (3)&#160;Directors, if the number of Directors then serving is more than five (5), in each case who are lawfully entitled to participate in the meeting and who are present at such adjourned meeting. At an adjourned meeting of the Board of Directors the only matters to be considered shall be those matters which might have been lawfully considered at the meeting of the Board of Directors originally called if a requisite quorum had been present, and the only resolutions to be adopted are such types of resolutions which could have been adopted at the meeting of the Board of Directors originally called.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">46.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">CHAIRPERSON OF THE BOARD OF DIRECTORS</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">The Board of Directors shall, from time to time, elect one of its members to be the Chairperson of the Board of Directors, remove such Chairperson from office and appoint in his or her place. The Chairperson of the Board of Directors shall preside at every meeting of the Board of Directors, but if there is no such Chairperson, or if at any meeting he is not present within fifteen (15)&#160;minutes of the time fixed for the meeting or if he is unwilling to take the chair, the Directors present shall choose one of the Directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">present at the meeting to be the Chairperson of such meeting. The office of Chairperson of the Board of Directors shall not, by itself, entitle the holder to a second or casting vote.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">47.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">VALIDITY OF ACTS DESPITE DEFECTS</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">All acts done or transacted at any meeting of the Board of Directors, or of a Committee of the Board of Directors, or by any person(s) acting as Director(s), shall, notwithstanding that it may afterwards be discovered that there was some defect in the appointment of the participants in such meeting or any of them or any person(s) acting as aforesaid, or that they or any of them were disqualified, be as valid as if there were no such defect or disqualification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CHIEF&#160;EXECUTIVE&#160;OFFICER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">48.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">CHIEF EXECUTIVE OFFICER</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 18pt 24.5pt;">The Board of Directors shall from time to time appoint one or more persons, whether or not Directors, as Chief Executive Officer of the Company who shall have the powers and authorities set forth in the Companies Law, and may confer upon such person(s), and from time to time modify or revoke, such titles and such duties and authorities of the Board of Directors as the Board of Directors may deem fit, subject to such limitations and restrictions as the Board of Directors may from time to time prescribe. Such appointment(s) may be either for a fixed term or without any limitation of time, and the Board of Directors may from time to time (subject to any additional approvals required under, and the provisions of, the Companies Law and of any contract between any such person and the Company) fix their salaries and compensation, remove or dismiss them from office and appoint another or others in his, her or their place or places.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">MINUTES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">49.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">MINUTES.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 18pt 24.5pt;">Any minutes of the General Meeting or the Board of Directors or any Committee thereof, if purporting to be signed by the Chairperson of the General Meeting, the Board of Directors or a Committee thereof, as the case may be, or by the Chairperson of the next succeeding General Meeting, meeting of the Board of Directors or meeting of a Committee, as the case may be, shall constitute prima facie evidence of the matters recorded therein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">DIVIDENDS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">50.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">DECLARATION OF DIVIDENDS</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">The Board of Directors may, from time to time, declare, and cause the Company to pay dividends as permitted by the Companies Law. The Board of Directors shall determine the time for payment of such dividends and the record date for determining the shareholders entitled thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">51.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">AMOUNT PAYABLE BY WAY OF DIVIDENDS</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">Subject to the provisions of these Articles and subject to the rights or conditions attached at that time to any share in the capital of the Company granting preferential, special or deferred rights or not granting any rights with respect to dividends, any dividend paid by the Company shall be allocated among the Shareholders (not in default in payment of any sum referred to in Article 13 hereof) entitled thereto on a&#160;<i style="font-style:italic;">pari passu</i>&#160;basis in proportion to their respective holdings of the issued and outstanding Shares in respect of which such dividends are being paid.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">52.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">INTEREST</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">No dividend shall carry interest as against the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">53.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">PAYMENT IN SPECIE</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">If so declared by the Board of Directors, a dividend declared in accordance with Article 50 may be paid, in whole or in part, by the distribution of specific assets of the Company or by distribution of paid up shares, debentures or other securities of the Company or of any other companies, or in any combination thereof, in each case, the fair value of which shall be determined by the Board of Directors in good faith.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">54.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">IMPLEMENTATION OF POWERS</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">The Board of Directors may settle, as it deems fit, any difficulty arising with regard to the distribution of dividends, bonus shares or otherwise, and in particular, to issue certificates for fractions of shares and sell such fractions of shares in order to pay their consideration to those entitled thereto, or to set the value for the distribution of certain assets and to determine that cash payments shall be paid to the Shareholders on the basis of such value, or that fractions whose value is less than NIS 0.01 shall not be taken into account. The Board of Directors may instruct to pay cash or convey these certain assets to a trustee in favor of those people who are entitled to a dividend, as the Board of Directors shall deem appropriate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">55.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">DEDUCTIONS FROM DIVIDENDS</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">The Board of Directors may deduct from any dividend or other moneys payable to any Shareholder in respect of a share any and all sums of money then payable by him or her to the Company on account of calls or otherwise in respect of shares of the Company and/or on account of any other matter of transaction whatsoever.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">56.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">RETENTION OF DIVIDENDS</b><u style="text-decoration:underline;text-decoration-color:#000000;">.</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(a) The Board of Directors may retain any dividend or other moneys payable or property distributable in respect of a share on which the Company has a lien, and may apply the same in or toward satisfaction of the debts, liabilities, or engagements in respect of which the lien exists.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">(b) The Board of Directors may retain any dividend or other moneys payable or property distributable in respect of a share in respect of which any person is, under Articles 21 or 22, entitled to become a Shareholder, or which any person is, under said Articles, entitled to transfer, until such person shall become a Shareholder in respect of such share or shall transfer the same.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">57.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">UNCLAIMED DIVIDENDS</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">All unclaimed dividends or other moneys payable in respect of a share may be invested or otherwise made use of by the Board of Directors for the benefit of the Company until claimed. The payment of any unclaimed dividend or such other moneys into a separate account shall not constitute the Company a trustee in respect thereof, and any dividend unclaimed after a period of one (1)&#160;year (or such other period determined by the Board of Directors) from the date of declaration of such dividend, and any such other moneys unclaimed after a like period from the date the same were payable, shall be forfeited and shall revert to the Company, provided, however, that the Board of Directors may, at its discretion, cause the Company to pay any such dividend or such other moneys, or any part thereof, to a person who would have been entitled thereto had the same not reverted to the Company. The principal (and only the principal) of any unclaimed dividend of such other moneys shall be if claimed, paid to a person entitled thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">58.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">MECHANICS OF PAYMENT</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">Any dividend or other moneys payable in cash in respect of a share, less the tax required to be withheld pursuant to applicable law, may, as determined by the Board of Directors in its sole discretion, be paid by check or warrant sent through the post to, or left at, the registered address of the person entitled thereto or by transfer to a bank account specified by such person (or, if two or more persons are registered as joint holders of such share or are entitled jointly thereto in consequence of the death or bankruptcy of the holder or otherwise, to any one of such Persons or his or her bank account or the person who the Company may then recognize as the owner thereof or entitled thereto under Article 21 or 22 hereof, as applicable, or such person&#8217;s bank account), or to such person and at such other address as the person entitled thereto may by writing direct, or in any other manner the Board of Directors deems appropriate. Every such check or warrant or other method of payment shall be made payable to the order of the person to whom it is sent, or to such person as the person entitled thereto as aforesaid may direct, and payment of the check or warrant by the banker upon whom it is drawn shall be a good discharge to the Company. Every such check shall be sent at the risk of the Person entitled to the money represented thereby.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ACCOUNTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">59.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">BOOKS OF ACCOUNT</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">The Company&#8217;s books of account shall be kept at the Office of the Company, or at such other place or places as the Board of Directors may think fit, and they shall always be open to inspection by all Directors. No shareholder, not being a Director, shall have any right to inspect any account or book or other similar document of the Company, except as explicitly conferred by law or authorized by the Board of Directors. The Company shall make copies of its annual financial statements available for inspection by the Shareholders at the principal offices of the Company. The Company shall not be required to send copies of its annual financial statements to the Shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">60.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">AUDITORS</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">The appointment, authorities, rights and duties of the auditor(s) of the Company, shall be regulated by applicable law, provided, however, that in exercising its authority to fix the remuneration of the auditor(s), the Shareholders in General Meeting may act (and in the absence of any action in connection therewith shall be deemed to have so acted) to authorize the Board of Directors (with right of delegation to a Committee thereof or to management) to fix such remuneration subject to such criteria or standards, and if no such criteria or standards are so provided, such remuneration shall be fixed in an amount commensurate with the volume and nature of the services rendered by such auditor(s). The General Meeting may, if so recommended by the Board of Directors, appoint the auditors for a period that may extend until the third Annual General Meeting after the Annual General Meeting in which the auditors were appointed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">61.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">FISCAL YEAR</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 18pt 24.5pt;">The fiscal year of the Company shall be the 12 months period ending on December&#160;31 of each calendar year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SUPPLEMENTARY&#160;REGISTERS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">62.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">SUPPLEMENTARY REGISTERS</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 18pt 24.5pt;">Subject to and in accordance with the provisions of Sections 138 and 139 of the Companies Law, the Company may cause supplementary registers to be kept in any place outside Israel as the Board of Directors may think fit, and, subject to all applicable requirements of law, the Board of Directors may from time to time adopt such rules and procedures as it may think fit in connection with the keeping of such branch registers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EXEMPTION, INDEMNITY&#160;AND&#160;INSURANCE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">63.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">INSURANCE</b><b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">Subject to the provisions of the Companies Law with regard to such matters, the Company may enter into a contract for the insurance of the liability, in whole or in part, of any of its Office Holders imposed on such Office Holder due to an act performed by or an omission of the Office Holder in the Office Holder&#8217;s capacity as an Office Holder of the Company arising from any matter permitted by law, including the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(a) a breach of duty of care to the Company or to any other person;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">(b) a breach of his or her duty of loyalty to the Company, provided that the Office Holder acted in good faith and had reasonable grounds to assume that act that resulted in such breach would not prejudice the interests of the Company;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(c) a financial liability imposed on such Office Holder in favor of any other person; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">(d) any other event, occurrence, matters or circumstances under any law with respect to which the Company may, or will be able to, insure an Office Holder, and to the extent such law requires the inclusion of a provision permitting such insurance in these Articles, then such provision is deemed to be</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">included and incorporated herein by reference (including, without limitation, in accordance with Section&#160;56h(b)(1) of the Securities Law, if and to the extent applicable, and Section&#160;50P of the Economic Competition Law).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">64.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">INDEMNITY</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(a) Subject to the provisions of the Companies Law, the Company may retroactively indemnify an Office Holder of the Company to the maximum extent permitted under applicable law, including with respect to the following liabilities and expenses, provided that such liabilities or expenses were imposed on such Office Holder or incurred by such Office Holder due to an act performed by or an omission of the Office Holder in such Office Holder&#8217;s capacity as an Office Holder of the Company:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 55.1pt;">(i) a financial liability imposed on an Office Holder in favor of another person by any court judgment, including a judgment given as a result of a settlement or an arbitrator&#8217;s award which has been confirmed by a court;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 55.1pt;">(ii) reasonable litigation expenses, including legal fees, expended by the Office Holder as a result of an investigation or proceeding instituted against him or her by an authority authorized to conduct such investigation or proceeding, or in connection with a financial sanction, provided that (1)&#160;no indictment (as defined in the Companies Law) was filed against such Office Holder as a result of such investigation or proceeding; and (2)&#160;no financial liability in lieu of a criminal proceeding (as defined in the Companies Law) was imposed upon him or her as a result of such investigation or proceeding or if such financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal intent;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 55.1pt;">(iii) reasonable litigation costs, including legal fees, expended by an Office Holder or which were imposed on an Office Holder by a court in proceedings filed against the Office Holder by the Company or in its name or by any other person or in a criminal charge in respect of which the Office Holder was acquitted or in a criminal charge in respect of which the Office Holder was convicted for an offence which did not require proof of criminal intent; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 55.1pt;">(iv) any other event, occurrence, matter or circumstance under any law with respect to which the Company may, or will be able to, indemnify an Office Holder, and to the extent such law requires the inclusion of a provision permitting such indemnity in these Articles, then such provision is deemed to be included and incorporated herein by reference (including, without limitation, in accordance with Section&#160;56h(b)(1) of the Israeli Securities Law, if and to the extent applicable, and Section&#160;50P(b)(2) of the RTP Law).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(b) Subject to the provisions of the Companies Law, the Company may undertake to indemnify an Office Holder, in advance, with respect to those liabilities and expenses described in the following Articles:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 55.1pt;">(i)&#160;Sub-Article&#160;6464(a)(i)(a)(ii) to 64(a)(iv); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 55.1pt;">(ii)&#160;Sub-Article&#160;64(a)(i), provided that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 79.55pt;">(1) the undertaking to indemnify is limited to such events which the Directors shall deem to be foreseeable in light of the operations of the Company at the time that the undertaking to indemnify is made and for such amounts or criterion which the Directors may, at the time of the giving of such undertaking to indemnify, deem to be reasonable under the circumstances; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 79.55pt;">(2) the undertaking to indemnify shall set forth such events which the Directors shall deem to be foreseeable in light of the operations of the Company at the time that the undertaking to indemnify is made, and the amounts and/or criterion which the Directors may, at the time of the giving of such undertaking to indemnify, deem to be reasonable under the circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">65.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">EXEMPTION</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">Subject to the provisions of the Companies Law, the Company may, to the maximum extent permitted by law, exempt and release, in advance, any Office Holder from any liability for damages arising out of a breach of a duty of care.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">66.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">GENERAL</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(a) Any amendment to the Companies Law or any other applicable law adversely affecting the right of any Office Holder to be indemnified, insured or exempt pursuant to Articles 63 to 65 and any amendments to Articles 63 to 65 shall be prospective in effect, and shall not affect the Company&#8217;s obligation or ability to indemnify, insure or exempt an Office Holder for any act or omission occurring prior to such amendment, unless otherwise provided by applicable law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 18pt 24.5pt;">(b) The provisions of Articles 63 to 65 (i) shall apply to the maximum extent permitted by law (including, the Companies Law, the Securities Law and the Economic Competition Law); and (ii)&#160;are not intended, and shall not be interpreted so as to restrict the Company, in any manner, in respect of the procurement of insurance and/or in respect of indemnification (whether in advance or retroactively) and/or exemption, in favor of any person who is not an Office Holder, including, without limitation, any employee, agent, consultant or contractor of the Company who is not an Office Holder; and/or any Office Holder to the extent that such insurance and/or indemnification is not specifically prohibited under law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">LOCK-UP</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">67.&#160;<b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">LOCK-UP</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">Notwithstanding anything to the contrary herein, and subject only to the exceptions set forth in Article 68, other than with the written consent of the Company, each Shareholder as of immediately prior to the time these Articles have become effective (but after giving effect to the stock split as contemplated pursuant to the Agreement and Plan of Merger (the &#8220;<b style="font-weight:bold;">Merger Agreement</b>&#8221;), dated as of July&#160;7, 2021, by and among the Company, Archery Merger Sub Inc. and Healthcare Capital Corp. (such time, the &#8220;<b style="font-weight:bold;">Lock-Up&#160;Effective Time</b>,&#8221; and each such Shareholder, a &#8220;<b style="font-weight:bold;">Locked-Up&#160;Shareholder</b>&#8221;) shall not be entitled to Transfer any Shares held by such&#160;Locked-Up&#160;Shareholder (&#8220;<b style="font-weight:bold;">Locked-Up&#160;Shares</b>&#8221;) or any instruments exercisable or exchangeable for, or convertible into, such&#160;Locked-Up&#160;Shares, in each case until a date that is one hundred and eighty (180)&#160;days following the&#160;Lock-Up&#160;Effective Time (the &#8220;<b style="font-weight:bold;">Lock-Up&#160;Period</b>&#8221;). Notwithstanding the foregoing, if, subsequent to the&#160;Lock-Up&#160;Effective Time, (a)&#160;the volume-weighted average price of the Shares on the Nasdaq Stock Market (or the U.S. exchange on which the Shares are then listed) exceeds $12.00 per share (as adjusted for share&#160;sub-divisions,&#160;share capitalizations, reorganizations, recapitalizations and the like recapitalization) for any 20 trading days within any&#160;30-trading&#160;day period commencing at least 150 days after the closing date of the Merger Agreement, the&#160;Locked-Up&#160;Shares shall be released from the foregoing&#160;lock-up&#160;mechanism, and (b)&#160;the payment of a tax bill issued by the applicable governing authority with respect to dissolution proceedings requires the sale of&#160;Locked-Up&#160;Shares by a Shareholder, such&#160;Locked-Up&#160;Shares shall be, upon receipt of the prior written consent of the Company, released from the foregoing&#160;lock-up&#160;mechanism. &#8220;<b style="font-weight:bold;">Transfer</b>&#8221; shall mean, directly or indirectly, the (x)&#160;sale or assignment of, offer to sell, contract or agreement to sell, hypothecate, pledge, grant of any option to purchase or otherwise dispose of or agreement to dispose of or establishment or increase of a put equivalent position or liquidation with respect to or decrease of a call equivalent position within the meaning of Section&#160;16 of the Exchange Act of 1934, as amended, with respect to the&#160;Locked-Up&#160;Shares, (y)&#160;entry into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of, or any other derivative transaction with respect to, the&#160;Locked-Up&#160;Shares, whether any such transaction is to be settled by delivery of such&#160;Locked-Up&#160;Shares, in cash or otherwise, or (z)&#160;public announcement of any intention to effect any transaction specified in clause (x)&#160;or (y).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">68.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">PERMITTED TRANSFERS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 18pt 24.5pt;">Notwithstanding the provisions set forth in<u style="text-decoration:underline;text-decoration-color:#000000;">&#160;Article 67</u>, transfers of the&#160;Locked-Up&#160;Shares that are held by a Shareholder or any of his, her or its permitted transferees (that have complied with this<u style="text-decoration:underline;text-decoration-color:#000000;">&#160;Article 68</u>), are permitted (i)&#160;in the case of an entity, to any officer, director or affiliate of Shareholder; (ii)&#160;in the case of an individual, by gift to a member of such individual&#8217;s immediate family or to a trust, the beneficiary of which is a member of such individual&#8217;s immediate family, an affiliate of such individual or to a charitable organization; or (iii)&#160;in the case of an individual, by virtue of laws of descent and distribution upon death of such individual.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WINDING&#160;UP</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">69.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">WINDING UP</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 18pt 24.5pt;">If the Company is wound up, then, subject to applicable law and to the rights of the holders of shares with special rights upon winding up, the assets of the Company available for distribution among the Shareholders shall be distributed to them in proportion to the number of issued and outstanding shares held by each Shareholder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTICES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">70.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">NOTICES</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(a) Any written notice or other document may be served by the Company upon any Shareholder either personally, by facsimile, email or other electronic transmission, or by sending it by prepaid mail (airmail if sent internationally) addressed to such Shareholder at his or her address as described in the Register of Shareholders or such other address as the Shareholder may have designated in writing for the receipt of notices and other documents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(b) Any written notice or other document may be served by any Shareholder upon the Company by tendering the same in person to the Secretary or the Chief Executive Officer of the Company at the principal office of the Company, by facsimile transmission, or by sending it by prepaid registered mail (airmail if posted outside Israel) to the Company at its Office.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(c) Any such notice or other document shall be deemed to have been served:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 55.1pt;">(i) in the case of mailing, forty-eight (48)&#160;hours after it has been posted, or when actually received by the addressee if sooner than forty-eight hours after it has been posted, or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 55.1pt;">(ii) in the case of overnight air courier, on the next business day following the day sent, with receipt confirmed by the courier, or when actually received by the addressee if sooner than three business days after it has been sent;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 55.1pt;">(iii) in the case of personal delivery, when actually tendered in person, to such addressee;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 55.1pt;">(iv) in the case of facsimile, email or other electronic transmission, on the first business day (during normal business hours in place of addressee) on which the sender receives automatic electronic confirmation by the addressee&#8217;s facsimile machine that such notice was received by the addressee or delivery confirmation from the addressee&#8217;s email or other communication server.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(d) If a notice is, in fact, received by the addressee, it shall be deemed to have been duly served, when received, notwithstanding that it was defectively addressed or failed, in some other respect, to comply with the provisions of this Article 7070.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.5pt;">(e) All notices to be given to the Shareholders shall, with respect to any share to which persons are jointly entitled, be given to whichever of such persons is named first in the Register of Shareholders, and any notice so given shall be sufficient notice to the holders of such share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(f) Any Shareholder whose address is not described in the Register of Shareholders, and who shall not have designated in writing an address for the receipt of notices, shall not be entitled to receive any notice from the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(g) Notwithstanding anything to the contrary contained herein, notice by the Company of a General Meeting, containing the information required by applicable law and these Articles to be set forth therein, which is published, within the time otherwise required for giving notice of such meeting, in either or several of the following manners (as applicable) shall be deemed to be notice of such meeting duly given, for the purposes of these Articles, to any Shareholder whose address as registered in the Register of Shareholders (or as designated in writing for the receipt of notices and other documents) is located either inside or outside the State of Israel:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 55.1pt;">(i) if the Company&#8217;s shares are then listed for trading on a national securities exchange in the United States or quoted in an&#160;over-the-counter&#160;market in the United States, publication of notice of a General Meeting pursuant to a report or a schedule filed with, or furnished to, the SEC pursuant to the Securities Exchange Act of 1934, as amended; and/or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 55.1pt;">(ii) on the Company&#8217;s internet site.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 18pt 24.5pt;">(h) The mailing or publication date and the record date and/or date of the meeting (as applicable) shall be counted among the days comprising any notice period under the Companies Law and the regulations thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AMENDMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">71.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">AMENDMENT</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 18pt 24.5pt;">Any amendment of these Articles shall require, in addition to the approval of the General Meeting of shareholders in accordance with these Articles, also the approval of the Board of Directors with the affirmative vote of a majority of the then serving Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORUM&#160;FOR&#160;ADJUDICATION&#160;OF&#160;DISPUTES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.9pt;text-indent:-21.9pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:21.6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">72.</font></font><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">FORUM FOR ADJUDICATION OF DISPUTES</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(a) Unless the Company consents in writing to the selection of an alternative forum, the federal district courts of the United States of America, shall be the exclusive forum for the resolution of any complaint asserting a cause or causes of action arising under the U.S. Securities Act of 1933, as amended, including all causes of action asserted against any defendant to such complaint. For the avoidance of doubt, this provision is intended to benefit and may be enforced by the Company, its officers and directors, the underwriters to any offering giving rise to such complaint, and any other professional or entity whose profession gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents underlying the offering. The foregoing provisions of this Article 72 shall not apply to causes of action arising under the U.S. Securities Exchange Act of 1934, as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(b) Unless the Company consents in writing to the selection of an alternative forum, the competent courts in Tel Aviv, Israel shall be the exclusive forum for (i)&#160;any derivative action or proceeding brought on behalf of the Company, (ii)&#160;any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the Company to the Company or the Company&#8217;s shareholders, or (iii)&#160;any action asserting a claim arising pursuant to any provision of the Companies Law or the Securities Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 24.5pt;">(c) Any person or entity purchasing or otherwise acquiring or holding any interest in shares of the Company shall be deemed to have notice of and consented to the provisions of this Article 72.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">* * *</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>3
<FILENAME>drts-20211231xex2d1.htm
<DESCRIPTION>EXHIBIT 2.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/28/2022 08:45:59 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 2.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">DESCRIPTION OF THE REGISTRANT&#8217;S SECURITIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">REGISTERED PURSUANT TO SECTION 12 OF THE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 18pt 0pt;">Alpha Tau Medical Ltd. has two classes of securities registered under Section&#160;12 of the Securities Exchange Act of 1934, as amended: ordinary shares and warrants to purchase ordinary shares. References herein to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and the &#8220;Company&#8221; refer to Alpha Tau Medical Ltd. and not to any of its subsidiaries. The following description may not contain all of the information that is important to you, and we therefore refer you to our amended and restated articles of association (our &#8220;Articles&#8221;), a copy of which is filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) as an exhibit to this annual report on Form&#160;20-F (&#8220;Annual Report&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">ORDINARY SHARES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Share Capital</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Our authorized share capital consists of 275,000,000 ordinary shares, no par value.&#160;All of our outstanding ordinary shares are validly issued, fully paid and&#160;non-assessable. Ourordinary shares are not redeemable and do not have any preemptive rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Our board of directors may determine the issue prices and terms for such shares or other securities, and may further determine any other provision relating to such issue of shares or securities. We may also issue and redeem redeemable securities on such terms and in such manner as our board of directors shall determine.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Registration Number and Purposes of the Company</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">We are registered with the Israeli Registrar of Companies. Our registration number is&#160;51-534453-9.&#160;Our affairs are governed by our Articles of Association (the Articles&#8221;), applicable Israeli law and specifically, the Companies Law. Our purpose as set forth in the Articles is to carry on any business and to engage in any lawful act or activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Voting Rights</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">All ordinary shares have identical voting and other rights in all respects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Transfer of Shares</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Our fully paid ordinary shares are issued in registered form and may be freely transferred under the Articles, unless the transfer is restricted or prohibited by another instrument, applicable law or the rules of the Nasdaq. The ownership or voting of ordinary shares by&#160;non-residents&#160;of Israel is not restricted in any way by the Articles or the laws of the State of Israel, except for ownership by nationals of some countries that are, have been, or will be, in a state of war with Israel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Election of Directors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Under the Articles, our board of directors must consist of not less than three but no more than eleven directors. Pursuant to the Articles, each of our directors are appointed by a simple majority vote of holders of ordinary shares, participating and voting at an annual general meeting of our shareholders, provided that (i)&#160;in the event of a contested election, the method of calculation of the votes and the manner in which the resolutions will be presented to our shareholders at the general meeting shall be determined by our board of directors in its discretion, and (ii)&#160;in the event that our board of directors does not or is unable to make a determination on such matter, then the directors will be elected by a plurality of the voting power represented at the general meeting in person or by proxy and voting on the election of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">In addition, our directors are divided into three classes, one class being elected each year at the annual general meeting of our shareholders, and serve on our board of directors until the third annual general meeting following such election or&#160;re-election&#160;or until they are removed by a vote of 65% of the total voting power of our shareholders at a general meeting of our shareholders or upon the occurrence of certain events in accordance with the Companies Law and the Articles. In addition, the Articles provide that vacancies on our board of directors may be filled by a vote of a simple majority of the directors then in office. A director so appointed will</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">hold office until the next annual general meeting of our shareholders for the election of the class of directors in respect of which the vacancy was created, or in the case of a vacancy due to the number of directors being less than the maximum number of directors stated in the Articles, until the next annual general meeting of our shareholders for the election of the class of directors to which such director was assigned by our board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Dividend and Liquidation Rights</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">We may declare a dividend to be paid to the holders of ordinary shares in proportion to their respective shareholdings. Under the Companies Law, dividend distributions are determined by the board of directors and do not require the approval of the shareholders of a company unless the company&#8217;s articles of association provide otherwise. The Articles do not require shareholder approval of a dividend distribution and provide that dividend distributions may be determined by our board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Pursuant to the Companies Law, the distribution amount is limited to the greater of retained earnings or earnings generated over the previous two years, according to the Company&#8217;s most recently reviewed or audited financial statements (less the amount of previously distributed dividends, if not reduced from the earnings), provided that the end of the period to which the financial statements relate is not more than six months prior to the date of the distribution. If we do not meet such criteria, then we may distribute dividends only with court approval. In each case, we are only permitted to distribute a dividend if our board of directors and, if applicable, the court determines that there is no reasonable concern that payment of the dividend will prevent us from satisfying our existing and foreseeable obligations as they become due.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">In the event of the Company&#8217;s liquidation, after satisfaction of liabilities to creditors, its assets will be distributed to the holders of ordinary shares in proportion to their shareholdings. This right, as well as the right to receive dividends, may be affected by the grant of preferential dividend or distribution rights to the holders of a class of shares with preferential rights which may be authorized in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="color:#231f20;font-weight:bold;">Registration</b><b style="color:#231f20;font-weight:bold;letter-spacing:0.1pt;"> </b><b style="color:#231f20;font-weight:bold;">Rights</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><font style="color:#231f20;">Certain</font><font style="color:#231f20;letter-spacing:0.1pt;"> </font><font style="color:#231f20;">of our shareholders</font><font style="color:#231f20;letter-spacing:0.1pt;"> </font><font style="color:#231f20;">are entitled</font><font style="color:#231f20;letter-spacing:0.1pt;"> </font><font style="color:#231f20;">to certain</font><font style="color:#231f20;letter-spacing:0.1pt;"> </font><font style="color:#231f20;">registration rights</font><font style="color:#231f20;letter-spacing:0.05pt;"> </font><font style="color:#231f20;">under</font><font style="color:#231f20;letter-spacing:0.05pt;"> </font><font style="color:#231f20;">the</font><font style="color:#231f20;letter-spacing:0.05pt;"> </font><font style="color:#231f20;">terms</font><font style="color:#231f20;letter-spacing:0.1pt;"> </font><font style="color:#231f20;">of our Shareholders</font><font style="color:#231f20;letter-spacing:0.1pt;"> </font><font style="color:#231f20;">Rights</font><font style="color:#231f20;letter-spacing:0.05pt;"> </font><font style="color:#231f20;">Agreement.</font><font style="color:#231f20;letter-spacing:0.05pt;"> </font><font style="color:#231f20;">For a discussion</font><font style="color:#231f20;letter-spacing:0.1pt;"> </font><font style="color:#231f20;">of such rights,</font><font style="color:#231f20;letter-spacing:0.05pt;"> </font><font style="color:#231f20;">see</font><font style="color:#231f20;letter-spacing:0.05pt;"> </font><font style="color:#231f20;">&#8220;</font><i style="color:#231f20;font-style:italic;">Related Party Transactions &#8212;Amended</i><i style="color:#231f20;font-style:italic;letter-spacing:0.05pt;"> </i><i style="color:#231f20;font-style:italic;">Investors&#8217;</i><i style="color:#231f20;font-style:italic;letter-spacing:0.1pt;"> </i><i style="color:#231f20;font-style:italic;">Rights</i><i style="color:#231f20;font-style:italic;letter-spacing:0.05pt;"> </i><i style="color:#231f20;font-style:italic;">Agreemen</i><i style="color:#231f20;font-style:italic;letter-spacing:0.05pt;">t</i><font style="color:#231f20;">&#8221; in our Annual Report.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Exchange Controls</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">There are currently no Israeli currency control restrictions on remittances of dividends on ordinary shares, proceeds from the sale of the ordinary shares or interest or other payments to&#160;non-residents&#160;of Israel, except for shareholders who are subjects of countries that at the time are, or have been, in a state of war with Israel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Shareholder Meetings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Under Israeli law, we are required to hold an annual general meeting of shareholders once every calendar year and no later than 15 months after the date of the previous annual general meeting. All meetings other than the annual general meeting of shareholders are referred to in the Articles as special&#160;&#160;&#160;&#160;general meetings. Our board of directors may call special general meetings of our shareholders whenever it sees fit, at such time and place, within or outside of Israel, as it may determine. In addition, the Companies Law provides that our board of directors is required to convene a special general meeting of our shareholders upon the written request of (i)&#160;any two or more of our directors,&#160;(ii)&#160;one-quarter&#160;or more of the serving members of our board of directors or (ii)&#160;one or more shareholders holding, in the aggregate, either (a) 5% or more of our issued and outstanding shares and 1% or more of our outstanding voting power or (b) 5% or more of our outstanding voting power.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">Under Israeli law, one or more shareholders holding at least 1% of the voting rights at the general meeting of shareholders may request that the board of directors include a matter in the agenda of a general meeting of shareholders to be convened in the future, provided that it is appropriate to discuss such a matter at the general meeting. The Articles contain procedural guidelines and disclosure items with respect to the submission of shareholder proposals for general meetings. Subject to the provisions of the Companies Law and the regulations promulgated thereunder, shareholders entitled to participate and vote at general meetings of shareholders are the shareholders of record on a date to be decided by the board of directors, which, as a company listed on an exchange outside Israel, may be between four and 40 days prior to the date of the meeting. Furthermore, the Companies Law requires that resolutions regarding the following matters must be passed at a general meeting of shareholders:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">amendments to the articles of association;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 24.5pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">appointment, terms of service and termination of services of auditors;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">appointment of directors, including external directors (if applicable);</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 24.5pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">approval of certain related party transactions;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 24.5pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">increases or reductions of authorized share capital;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 24.5pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">a merger; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 24.5pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:24.5pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the exercise of the board of director&#8217;s powers by a general meeting, if the board of directors is unable to exercise its powers and the exercise of any of its powers is required for proper management of the company.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The Companies Law requires that a notice of any annual general meeting or special general meeting be provided to shareholders at least 21 days prior to the meeting and, if the agenda of the meeting includes (among other things) the appointment or removal of directors, the approval of transactions with office holders or interested or related parties, or an approval of a merger, notice must be provided at least 35 days prior to the meeting. Under the Companies Law and the Articles, shareholders are not permitted to take action by way of written consent in lieu of a meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-style:italic;font-weight:bold;">Quorum</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Articles, holders of our ordinary shares have one vote for each ordinary share held on all matters submitted to a vote of the shareholders at a general meeting of shareholders. The quorum required for a general meetings of shareholders consists of at least two shareholders present in person or by proxy who hold or represent at least 331/3% of the total outstanding voting power of our shares, except that if (i)&#160;any such general meeting was initiated by and convened pursuant to a resolution adopted by the board of directors and (ii)&#160;at the time of such general meeting we qualify as a &#8220;foreign private issuer,&#8221; the requisite quorum will consist of two or more shareholders present in person or by proxy who hold or represent at least 25% of the total outstanding voting power of our shares. The requisite quorum may be present within half an hour of the time fixed for the commencement of the general meeting. A general meeting adjourned for lack of a quorum shall be adjourned to the same day in the next week, at the same time and place, to such day and at such time and place as indicated in the notice to such meeting, or to such day and at such time and place as the chairperson of the meeting shall determine. At the reconvened meeting, any number of shareholders present in person or by proxy shall constitute a quorum, unless a meeting was called pursuant to a request by our shareholders, in which case the quorum required is one or more shareholders, present in person or by proxy and holding the number of shares required to call the meeting as described under &#8220;<i style="font-style:italic;">&#8212;Shareholder Meetings.&#8221;</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-style:italic;font-weight:bold;">Vote Requirements</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The Articles provide that all resolutions of our shareholders require a simple majority vote, unless otherwise required by the Companies Law or by our Articles. Under the Companies Law, certain actions require the approval of a special majority, including: (i)&#160;an extraordinary transaction with a controlling shareholder or in which the controlling shareholder has a personal interest, (ii)&#160;the terms of employment or other engagement of a controlling shareholder of the company or a controlling shareholder&#8217;s relative (even if such terms are not extraordinary) and (iii)&#160;certain compensation-related matters. Under the Articles, if at any time our share capital is divided into different classes of shares, the rights attached to any class, unless otherwise provided by the Articles, may be modified or cancelled by us by a resolution of the shareholders of the holders of all shares as one class, without any required separate resolution of any class of shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">Under the Articles, the approval of the holders of at least 65% of the total voting power of our shareholders is generally required to remove any of our directors from office, to amend the provision requiring the approval of at least 65% of the total voting power of our shareholders to remove any of our directors from office, or certain other provisions regarding our staggered board, shareholder proposals, the size of our board and plurality voting in contested elections. Another exception to the simple majority vote requirement is a resolution for the voluntary winding up, or an approval of a scheme of arrangement or reorganization, of the company pursuant to Section&#160;350 of the Companies Law, which requires the approval of a majority of the shareholders present and represented at the meeting, and holding at least 75% of the voting rights represented at the meeting and voting on the resolution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Access to Corporate Records</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">Under the Companies Law, all shareholders generally have the right to review minutes of our general meetings, our shareholder register (including with respect to material shareholders), our Articles,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">our financial statements, other documents as provided in the Companies Law, and any document we are required by law to file publicly with the Israeli Registrar of Companies or the Israeli Securities Authority. Any shareholder who specifies the purpose of its request may request to review any document in our possession that relates to any action or transaction with a related party which requires shareholder approval under the Companies Law. We may deny a request to review a document if it determines that the request was not made in good faith, that the document contains a commercial secret or a patent or that the document&#8217;s disclosure may otherwise impair its interests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Anti-Takeover Provisions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-style:italic;font-weight:bold;">Acquisitions under Israeli Law</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Full Tender Offer</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">A person wishing to acquire shares of a public Israeli company who would, as a result, hold over 90% of the target company&#8217;s voting rights or the target company&#8217;s issued and outstanding share capital (or of a class thereof), is required by the Companies Law to make a tender offer to all of the company&#8217;s shareholders for the purchase of all of the issued and outstanding shares of the company (or the applicable class). If (a)&#160;the shareholders who do not accept the offer hold less than 5% of the issued and outstanding share capital of the company (or the applicable class) and the shareholders who accept the offer constitute a majority of the offerees that do not have a personal interest in the acceptance of the tender offer or (b)&#160;the shareholders who did not accept the tender offer hold less than 2% of the issued and outstanding share capital of the company (or of the applicable class), all of the shares that the acquirer offered to purchase will be transferred to the acquirer by operation of law. A shareholder who had its shares so transferred may petition an Israeli court within six months from the date of acceptance of the full tender offer, regardless of whether such shareholder agreed to the offer, to determine whether the tender offer was for less than fair value and whether the fair value should be paid as determined by the court. However, an offeror may provide in the offer that a shareholder who accepted the offer will not be entitled to petition the court for appraisal rights as described in the preceding sentence, as long as the offeror and the company disclosed the information required by law in connection with the full tender offer. If the full tender offer was not accepted in accordance with any of the above alternatives, the acquirer may not acquire shares of the company that will increase its holdings to more than 90% of the company&#8217;s voting rights or the company&#8217;s issued and outstanding share capital (or of the applicable class) from shareholders who accepted the tender offer. Shares purchased in contradiction to the full tender offer rules under the Companies Law will have no rights and will become dormant shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Special Tender Offer</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Companies Law provides that an acquisition of shares of an Israeli public company must be made by means of a special tender offer if as a result of the acquisition the purchaser would become a holder of 25% or more of the voting rights in the company. This requirement does not apply if there is already another holder of 25% or more of the voting rights in the company. Similarly, the Companies Law provides that an acquisition of shares of an Israeli public company must be made by means of a special tender offer if as a result of the acquisition the purchaser would become a holder of more than 45% of the voting rights in the company, if there is no other shareholder of the company who holds more than 45% of the voting rights in the company. These requirements do not apply if (i)&#160;the acquisition occurs in the context of a private placement by the company that received shareholder approval as a private placement whose purpose is to give the purchaser 25% or more of the voting rights in the company, if there is no person who holds 25% or more of the voting rights in the company or as a private placement whose purpose is to give the purchaser 45% of the voting rights in the company, if there is no person who holds 45% of the voting rights in the company, (ii)&#160;the acquisition was from a shareholder holding 25% or more of the voting rights in the company and resulted in the purchaser becoming a holder of 25% or more of the voting rights in the company, or (iii)&#160;the acquisition was from a shareholder holding more than 45% of the voting rights in the company and resulted in the purchaser becoming a holder of more than 45% of the voting rights in the company. A special tender offer must be extended to all shareholders of a company. A special tender offer may be consummated only if (i)&#160;at least 5% of the voting power attached to the company&#8217;s outstanding shares will be acquired by the offeror and (ii)&#160;the number of shares tendered in the offer exceeds the number of shares whose holders objected to the offer (excluding the purchaser, its controlling shareholders, holders of 25% or more of the voting rights in the company and any person having a personal interest in the acceptance of the tender offer, or anyone on their behalf, including any such person&#8217;s relatives and entities under their control).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">In the event that a special tender offer is made, a company&#8217;s board of directors is required to express its opinion on the advisability of the offer, or shall abstain from expressing any opinion if it is unable to do so, provided that it gives the reasons for its abstention. The board of directors shall also disclose any personal interest that any of the directors has with respect to the special tender offer or in connection therewith. An office holder in a target company who, in his or her capacity as an office holder, performs an action the purpose of which is to cause the failure of an existing or foreseeable special tender offer or is to impair the chances of its acceptance, is liable to the potential purchaser and shareholders for damages, unless such office holder acted in good faith and had reasonable grounds to believe he or she was acting for the benefit of the company. However, office holders of the target company may negotiate with the potential purchaser in order to improve the terms of the special tender offer, and may further negotiate with third parties in order to obtain a competing offer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">If a special tender offer is accepted, then shareholders who did not respond to or that had objected the offer may accept the offer within four days of the last day set for the acceptance of the offer and they will be considered to have accepted the offer from the first day it was made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">In the event that a special tender offer is accepted, then the purchaser or any person or entity controlling it or under common control with the purchaser or such controlling person or entity at the time of the offer may not make a subsequent tender offer for the purchase of shares of the target company and may not enter into a merger with the target company for a period of one year from the date of the offer, unless the purchaser or such person or entity undertook to effect such an offer or merger in the initial special tender offer. Shares purchased in contradiction to the special tender offer rules under the Companies Law will have no rights and will become dormant shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Merger</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The Companies Law permits merger transactions if approved by each party&#8217;s board of directors and, unless certain conditions described under the Companies Law are met, a simple majority of the outstanding shares of each party to the merger that are represented and voting on the merger. The board of directors of a merging company is required pursuant to the Companies Law to discuss and determine whether in its opinion there exists a reasonable concern that as a result of a proposed merger, the surviving company will not be able to satisfy its obligations towards its creditors, such determination taking into account the financial status of the merging companies. If the board of directors determines that such a concern exists, it may not approve a proposed merger. Following the approval of the board of directors of each of the merging companies, the boards of directors must jointly prepare a merger proposal for submission to the Israeli Registrar of Companies. For purposes of the shareholder vote of a merging company whose shares are held by the other merging company, or by a person or entity holding 25% or more of the voting rights at the general meeting of shareholders of the other merging company, or by a person or entity holding the right to appoint 25% or more of the directors of the other merging company, unless a court rules otherwise, the merger will not be deemed approved if a majority of the shares voted on the matter at the general meeting of shareholders (excluding abstentions) that are held by shareholders other than the other party to the merger, or by any person or entity who holds 25% or more of the voting rights of the other party or the right to appoint 25% or more of the directors of the other party, or any one on their behalf including their relatives or corporations controlled by any of them, vote against the merger. In addition, if the&#160;non-surviving&#160;entity of the merger has more than one class of shares, the merger must be approved by each class of shareholders. If the transaction would have been approved but for the separate approval of each class or the exclusion of the votes of certain shareholders as provided above, a court may still approve the merger upon the request of holders of at least 25% of the voting rights of a company, if the court holds that the merger is fair and reasonable, taking into account the valuation of the merging companies and the consideration offered to the shareholders. If a merger is with a company&#8217;s controlling shareholder or if the controlling shareholder has a personal interest in the merger, then the merger is instead subject to the same special majority approval that governs all extraordinary transactions with controlling shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">Under the Companies Law, each merging company must deliver to its secured creditors the merger proposal and inform its unsecured creditors of the merger proposal and its content. Upon the request of a creditor of either party to the proposed merger, the court may delay or prevent the merger if it concludes that there exists a reasonable concern that, as a result of the merger, the surviving company will be unable to satisfy the obligations of a merging company, and may further give instructions to secure the rights of creditors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">In addition, a merger may not be completed unless at least 50 days have passed from the date that a proposal for approval of the merger is filed with the Israeli Registrar of Companies and 30 days from the date that shareholder approval of both merging companies is obtained.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-style:italic;font-weight:bold;">Anti-Takeover Measures</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The Companies Law allows us to create and issue shares having rights different from those attached to the ordinary shares, including shares providing certain preferred rights with respect to voting, distributions or other matters and shares having preemptive rights. No preferred shares are authorized under the Articles. In the future, if we do authorize, create and issue a specific class of preferred shares, such class of shares, depending on the specific rights that may be attached to it, may have the ability to frustrate or prevent a takeover or otherwise prevent our shareholders from realizing a potential premium over the market value of the ordinary shares. The authorization and designation of a class of preferred shares will require an amendment to the Articles, which requires the prior approval of the holders of a majority of the voting power attached to our issued and outstanding shares at a general meeting of our shareholders. The convening of the meeting, the shareholders entitled to participate and the vote required to be obtained at such a meeting will be subject to the requirements set forth in the Companies Law and the Articles, as described above in &#8220;&#8212;Shareholder Meetings.&#8221; In addition, as disclosed under &#8220;&#8212;Election of Directors,&#8221; we have a classified board structure, which effectively limits the ability of any investor or potential investor or group of investors or potential investors to gain control of our board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Borrowing Powers</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Companies Law and the Articles, our board of directors may exercise all powers and take all actions that are not required under law or under the Articles to be exercised or taken by our shareholders, including the power to borrow money for company purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Changes in Capital</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">The Articles enable us to increase or reduce our share capital. Any such changes are subject to Israeli law and must be approved by a resolution duly passed by our shareholders at a general meeting of shareholders. In addition, transactions that have the effect of reducing capital, such as the declaration and payment of dividends in the absence of sufficient retained earnings or profits, require the approval of both our board of directors and an Israeli court.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Exclusive Forum</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The Articles provide that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act; and, for the avoidance of any doubt, such provision does not apply to any claim asserting a cause of action arising under the Exchange Act. The Articles also provide that unless we consent in writing to the selection of an alternative forum, the competent courts in Tel Aviv, Israel shall be the exclusive forum for any derivative action or proceeding brought on behalf of the Company, any action asserting a breach of a fiduciary duty owed by any of our directors, officers or other employees to the Company or our shareholders or any action asserting a claim arising pursuant to any provision of the Companies Law or the Israeli Securities Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Transfer Agent and Registrar</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The transfer agent and registrar for our ordinary shares is Continental Stock Transfer &amp; Trust Company. Its address is 1 State Street, 30th Floor, New York, New York 10004.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Exchange Listing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Our ordinary shares are listed on the Nasdaq Capital Market under the symbol &#8220;DRTS.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">WARRANTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">In connection with our business combination that closed on March 7, 2022, we issued 15,642,000 warrants (consisting of 13,500,000 public warrants and 2,142,000 private warrants), each entitling its holder to purchase one ordinary share at an initial exercise price equal to $11.50 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">Public Warrants</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Warrant Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Our warrants were issued in registered form pursuant to the Warrant Agreement dated January 21, 2021, by and between Healthcare Capital Corp. (&#8220;HCCC&#8221;) and Continental Stock Transfer&#160;&amp; Trust Company (&#8220;CST&#8221;), as amended by the Amended and Restated Warrant Agreement, dated March 7, 2022, by and among CST, HCCC and us (the &#8220;Warrant Agreement&#8221;).&#160;You should review a copy of the Warrant Agreement and the form of warrant, as publicly disclosed, for a complete description of the terms and conditions of the warrants and the Warrant Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Duration and Exercise Price Adjustments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The warrants become exercisable on April 6, 2022 and will expire at 5:00 p.m., New York City time on March 7, 2027, unless redeemed by us or we are liquidated prior to that date. The exercise price and number of ordinary shares issuable upon exercise is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our ordinary shares and the exercise price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Exercisability</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The warrants may be exercised upon surrender of the warrant certificate on or prior to the expiration date at the offices of the warrant agent, with the exercise form on the reverse side of the warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price (or on a cashless basis, if applicable), by certified or official bank check payable to us, for the number of warrants being exercised. The warrantholders do not have the rights or privileges of holders of our ordinary shares and any voting rights until they exercise their warrants and receive ordinary shares. After the issuance of ordinary shares upon exercise of the warrants, each holder will be entitled to one (1)&#160;vote for each share held of record on all matters to be voted on by shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Cashless Exercise</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">If, at the time a holder exercises its warrants, a registration statement registering the issuance of the ordinary shares underlying the warrants under the Securities Act is not then effective or available for the issuance of such shares, then in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of ordinary shares determined according to a formula set forth in the warrant agreement (as defined below).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Redemption</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">We may call the warrants for redemption:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:27pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:16.2pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;">in whole and not in part;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:27pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:16.2pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;">at a price of $0.01 per warrant;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:27pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:16.2pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;">upon not less than 30 days<font style="font-family:'Symbol';">&#8217;</font> prior written notice of redemption (the <font style="font-family:'Symbol';">&#8220;</font>30 day redemption period<font style="font-family:'Symbol';">&#8221;</font>) to each warrantholder; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:27pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:16.2pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:6pt;">if, and only if, the reported last sale price of our ordinary shares equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period commencing on March 7, 2022 and ending three business days before the Company sends the notice of redemption to its warrantholders.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Notice of redemption will be mailed by first class mail, postage prepaid, by the Company not less than thirty (30)&#160;days prior to the redemption date to the registered holders of the warrants to be redeemed at their last addresses as they appear on the registration books of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Fractional Shares</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">No fractional shares will be issued upon exercise of the warrants. If, upon exercise of the warrants, a holder would be entitled to receive a fractional interest in a share, we will, upon exercise, round down to the nearest whole number of our ordinary shares to be issued to the warrantholder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Transferability</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Subject to applicable laws, each warrant may be transferred at the option of the holder upon surrender of the warrant to us together with the appropriate instruments of transfer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Warrant Agent</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The warrant agent for our warrants is Continental Stock Transfer &amp; Trust Company.&#160;Its address is 6201 15th Avenue, Brooklyn, New York 11219, and its telephone number is&#160;(718)-921-8200.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Exchange Listing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">Our warrants are listed on the Nasdaq Capital Market under the symbol &#8220;DRTSW.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-style:italic;font-weight:bold;">Private Placement Warrants</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Except as described below, the private placement warrants have terms and provisions that are identical to those of the public warrants.&#160;The private placement warrants (including the ordinary shares underlying the private placement warrants) will not be transferable, assignable or salable until April 7, 2022, except among certain limited exceptions to the combined company&#8217;s officers and directors and to persons or entities affiliated with Healthcare Capital Sponsor, LLC (the &#8220;Sponsor&#8221;)<font style="white-space:pre-wrap;">.  In addition, the Sponsor has agreed not to sell or transfer the private placement warrants without our permission for 180 days following the closing of our Business Combination with HCCC.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The private placement warrants will not be redeemable by the combined company so long as they are held by the Sponsor or its permitted transferees. The Sponsor, or its permitted transferees, has the option to exercise the private placement warrants on a cashless basis. Except as described below, the private placement warrants have terms and provisions that are identical to those of the public warrants, including as to exercise price, exercisability and exercise period. If the private warrants are held by someone other than the Sponsor or its permitted transferees, the private warrants will be redeemable by the combined company and exercisable by such holders on the same basis as the public warrants. If holders of the private warrants elect to exercise them on a cashless basis, they would pay the exercise price by surrendering their warrants for that number of ordinary shares equal to the quotient obtained by dividing (x)&#160;the product of the number of shares of ordinary shares underlying the warrants, multiplied by the difference between the exercise price of the warrants and the &#8220;fair market value&#8221; (defined below) by (y)&#160;the fair market value. The &#8220;fair market value&#8221; means the average reported last sale price of the ordinary shares for the 10 trading days ending on the third trading day prior to the date on which the notice our warrant exercise is sent to the warrant agent.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.8
<SEQUENCE>4
<FILENAME>drts-20211231xex4d8.htm
<DESCRIPTION>EX-4.8
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/28/2022 08:46:02 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Exhibit 4.8</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 6pt 0pt;"><font style="font-style:italic;font-weight:bold;">Execution Version</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">HEALTHCARE CAPITAL SPONSOR LLC</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">301 North Market Street</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Suite 1414</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Wilmington, DE 19801</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">February 17, 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">wjohns@healthccc.com </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Healthcare Capital Corp.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">301 North Market Street</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Suite 1414</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Wilmington, DE 19801</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Attention: William Johns, CEO</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Email: wjohns@healthccc.com </p></td><td style="vertical-align:top;width:51%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Alpha Tau Medical Ltd.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Kiryat HaMada St 5</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jerusalem, 9777605, Israel</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Attention: Uzi Sofer, CEO</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Email: uzi@alphataumedical.com </p></td><td style="vertical-align:top;width:51%;margin:0pt;padding:0pt;"></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Re: </b><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Amendment to Sponsor Support Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Ladies and Gentlemen:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">Reference is made to that certain letter agreement, dated July 17, 2021 (the &#8220;<font style="font-style:italic;font-weight:bold;">Sponsor Support Agreement</font>&#8221;), by and among, Healthcare Capital Corp., a Delaware corporation (&#8220;<font style="font-style:italic;font-weight:bold;">SPAC</font>&#8221;), Alpha Tau Medical Ltd., a company organized under the laws of the State of Israel (the &#8220;<font style="font-style:italic;font-weight:bold;">Company</font>&#8221;), Healthcare Capital Sponsor LLC, a Delaware limited liability company (the &#8220;<font style="font-style:italic;font-weight:bold;">Sponsor</font>&#8221;) and the undersigned individuals, each of whom is a member of SPAC&#8217;s board of directors or management team (each, an &#8220;<font style="font-style:italic;font-weight:bold;">Insider</font>&#8221; and collectively, the &#8220;<font style="font-style:italic;font-weight:bold;">Insiders</font>&#8221;). Any term used but not defined in this letter agreement (this &#8220;<font style="font-style:italic;font-weight:bold;">Amendment</font>&#8221;) will have the meaning ascribed to such term in the Sponsor Support Agreement or, if such term is not defined in the Sponsor Support Agreement, in the Merger Agreement defined therein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">Section 13 of the Sponsor Support Agreement provides that it may only be changed, amended, modified or waived by a written instrument executed by SPAC, the Company and the other parties charged with such change, amendment, modification or waiver.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, SPAC, the Company and the other parties charged with such change, amendment, modification or waiver hereby agree as follows:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Amendments to Sponsor Support Agreement</u>. The Sponsor Support Agreement shall be amended as follows:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Section 9 of the Sponsor Support Agreement is hereby amended by deleting it in its entirety and replacing it with the following:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 36pt;">&#8220;The Sponsor hereby agrees that immediately prior to the Effective Time, the Sponsor shall automatically be deemed to irrevocably transfer to SPAC, surrender and forfeit (and the Sponsor shall take all actions necessary to effect such transfer, surrender and forfeiture) for no consideration, the Sponsor Equity set forth on Schedule B.&#8221;</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Schedule B of the Sponsor Support Agreement is hereby amended by deleting it in its entirety and replacing it the new Schedule B attached to this Amendment</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Miscellaneous.</u></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Except as expressly provided in this Amendment, all of the terms and provisions in the Sponsor Support Agreement are and shall remain unmodified and in full force and effect, on the terms and subject to the conditions set forth therein. This Amendment does not constitute, directly or by implication, an amendment or waiver of any provision of the Sponsor Support Agreement, or any other right, remedy, power or privilege of any party thereto, except as expressly set forth herein.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Any reference to the Sponsor Support Agreement in the Sponsor Support Agreement or any other agreement, document, instrument or certificate entered into or issued in connection therewith shall hereinafter mean the Sponsor Support Agreement, as amended by this Amendment (or as the Sponsor Support Agreement may be further amended or modified in accordance with the terms thereof).</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Each of the parties hereto acknowledges and agrees that such party has full power and authority to enter into this Amendment and has been duly authorized to do so. The execution, delivery and performance of this Amendment will not conflict with or breach any other agreement to which any of the parties or their respective assets are bound.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">The terms of this Amendment shall be governed by, enforced and construed and interpreted in a manner consistent with the provisions of the Sponsor Support Agreement, including Sections 13-19 thereof.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="font-style:italic;font-weight:bold;">{Remainder of Page Intentionally Left Blank; Signature page follows}</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Please indicate your agreement to the foregoing by signing in the space provided below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:60%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">HEALTHCARE CAPITAL SPONSOR LLC </b></p></td></tr><tr><td style="vertical-align:top;width:60%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:35%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:60%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:35%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ William Johns</p></td></tr><tr><td style="vertical-align:top;width:60%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: </p></td><td style="vertical-align:top;width:35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">William Johns</p></td></tr><tr><td style="vertical-align:top;width:60%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Title: </p></td><td style="vertical-align:top;width:35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CFO</p></td></tr><tr><td style="vertical-align:top;width:60%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:35%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:60%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">INSIDERS </b></p></td></tr><tr><td style="vertical-align:top;width:60%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:35%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:60%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:top;width:40%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ David Milch</p></td></tr><tr><td style="vertical-align:top;width:60%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">David Milch </p></td></tr><tr><td style="vertical-align:top;width:60%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:35%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:60%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:top;width:40%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ William Johns</p></td></tr><tr><td style="vertical-align:top;width:60%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">William Johns</p></td></tr><tr><td style="vertical-align:top;width:60%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:35%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:60%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:top;width:40%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Philip Baseil</p></td></tr><tr><td style="vertical-align:top;width:60%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Philip A. Baseil</p></td></tr><tr><td style="vertical-align:top;width:60%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:35%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:60%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:top;width:40%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Peter Kash</p></td></tr><tr><td style="vertical-align:top;width:60%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Peter Kash</p></td></tr><tr><td style="vertical-align:top;width:60%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:35%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:60%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:top;width:40%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Bruce Roberts</p></td></tr><tr><td style="vertical-align:top;width:60%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Bruce E. Roberts</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td colspan="2" style="vertical-align:top;width:40.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Acknowledged and Agreed:</p></td><td style="vertical-align:top;width:59.65%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:5.7%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:34.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:59.65%;margin:0pt;padding:0pt;"></td></tr><tr><td colspan="2" style="vertical-align:top;width:40.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">HEALTHCARE CAPITAL CORP.</b></p></td><td style="vertical-align:top;width:59.65%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:5.7%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:34.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:59.65%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:5.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:34.63%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ William Johns</p></td><td style="vertical-align:top;width:59.65%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:5.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: </p></td><td style="vertical-align:top;width:34.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">William Johns</p></td><td style="vertical-align:top;width:59.65%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:5.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: </p></td><td style="vertical-align:top;width:34.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">CEO</p></td><td style="vertical-align:top;width:59.65%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:5.7%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:34.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:59.65%;margin:0pt;padding:0pt;"></td></tr><tr><td colspan="2" style="vertical-align:top;width:40.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Acknowledged and Agreed:</p></td><td style="vertical-align:top;width:59.65%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:5.7%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:34.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:59.65%;margin:0pt;padding:0pt;"></td></tr><tr><td colspan="2" style="vertical-align:top;width:40.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">ALPHA TAU MEDICAL LTD.</b></p></td><td style="vertical-align:top;width:59.65%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:5.7%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:34.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:59.65%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:5.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:34.63%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Uzi Sofer</p></td><td style="vertical-align:top;width:59.65%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:5.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: </p></td><td style="vertical-align:top;width:34.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Uzi Sofer</p></td><td style="vertical-align:top;width:59.65%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:5.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: </p></td><td style="vertical-align:top;width:34.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CEO</p></td><td style="vertical-align:top;width:59.65%;margin:0pt;padding:0pt;"></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="font-style:italic;font-weight:bold;">[Signature Page to Amendment to Sponsor Support Agreement]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Schedule B</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Forfeited Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:48.58%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt 0pt 1.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Founder Shares</b></p></td><td style="vertical-align:bottom;width:1.86%;border-bottom:1.5pt solid transparent;margin:0pt;padding:0pt 0pt 1.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:49.55%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt 0pt 1.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Private Placement Warrants</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:48.58%;border-top:1.5pt solid #000000;margin:0pt;padding:0pt 0pt 1.75pt 5.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4,709,375</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt 0pt 1.75pt 0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;width:49.55%;border-top:1.5pt solid #000000;margin:0pt;padding:0pt 0pt 1.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4,658,000</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.9
<SEQUENCE>5
<FILENAME>drts-20211231xex4d9.htm
<DESCRIPTION>EX-4.9
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/28/2022 08:46:06 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 4.9</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AMENDED &amp; RESTATED WARRANT AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">THIS AMENDED &amp; RESTATED WARRANT AGREEMENT (this &#8220;<font style="font-style:italic;font-weight:bold;">Agreement</font>&#8221;), dated as of March 7, 2022, is by and between Alpha Tau Medical Ltd., a company organized under the laws of the State of Israel (the &#8220;<font style="font-style:italic;font-weight:bold;">Company</font>&#8221;), Healthcare Capital Corp., a Delaware corporation (&#8220;<font style="font-style:italic;font-weight:bold;">HCCC</font>&#8221;), and Continental Stock Transfer &amp; Trust Company, a New York corporation, as warrant agent (in such capacity, the &#8220;<font style="font-style:italic;font-weight:bold;">Warrant Agent</font>,&#8221; and also referred to herein as the &#8220;<font style="font-style:italic;font-weight:bold;">Transfer Agent</font>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, HCCC and the Warrant Agent are parties to that certain Warrant Agreement, dated as of January 14, 2021 (the &#8220;<font style="font-style:italic;font-weight:bold;">Existing Warrant Agreement</font>&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, in accordance with Section 9.8(ii) of the Existing Warrant Agreement, HCCC and the Warrant Agent agree to amend and restate the Existing Warrant Agreement in its entirety as contemplated hereunder;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, HCCC issued 19,530,000 warrants as part of its initial public offering, including (i) 13,750,000 warrants sold by HCCC to the public (the &#8220;<font style="font-style:italic;font-weight:bold;">Public Warrants</font>&#8221;) and (ii) 6,800,000 warrants (the &#8220;<font style="font-style:italic;font-weight:bold;">Private Placement Warrants</font>&#8221; and, together with the Public Warrants, the &#8220;<font style="font-style:italic;font-weight:bold;">Warrants</font>&#8221;) sold by HCCC to Healthcare Capital Sponsor LLC, a Delaware limited liability company (&#8220;<font style="font-style:italic;font-weight:bold;">Sponsor</font>&#8221;) in each case, on the terms and conditions set forth in the Existing Warrant Agreement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, on July 7, 2021, the Company, Archery Merger Sub Inc., a Delaware corporation and a direct, wholly-owned subsidiary of the Company (&#8220;<font style="font-style:italic;font-weight:bold;">Merger Sub</font>&#8221;), and HCCC entered into that certain Agreement and Plan of Merger (the &#8220;<font style="font-style:italic;font-weight:bold;">Merger Agreement</font>&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, upon the terms and subject to the conditions of the Merger Agreement, Merger Sub will merge with and into HCCC (the &#8220;<font style="font-style:italic;font-weight:bold;">Merger</font>&#8221;), with HCCC continuing as the surviving company after the Merger and a direct, wholly-owned subsidiary of the Company;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, upon the consummation of the Merger, in accordance with <u style="text-decoration:underline;text-decoration-color:#000000;">Section 4.4</u> of the Existing Warrant Agreement, the Company shall effect an Alternative Issuance (as defined in the Existing Warrant Agreement) pursuant to which (i) the Public Warrants and the Private Placement Warrants issued thereunder will no longer be exercisable for shares of Class A common stock, par value $0.0001 per share, of HCCC (the &#8220;<font style="font-style:italic;font-weight:bold;">HCCC Class A Shares</font>&#8221;) but instead will be exercisable (subject to the terms and conditions of this Agreement) for a number of ordinary shares of no par value of the Company (the &#8220;<font style="font-style:italic;font-weight:bold;">Ordinary Shares</font>&#8221;) equal to the number of HCCC Class A Shares for which such warrants were exercisable immediately prior to the Merger subject to adjustment as described herein (such warrants as so adjusted and amended, the &#8220;<font style="font-style:italic;font-weight:bold;">Warrants</font>&#8221;) and (ii) the Warrants shall be assumed by the Company;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, the Company desires the Warrant Agent to act on behalf of the Company, and the Warrant Agent is willing to so act, in connection with the issuance, registration, transfer, exchange, redemption and exercise of the Warrants;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, the Company desires to provide for the form and provisions of the Warrants, the terms upon which they shall be issued and exercised, and the respective rights, limitation of rights, and immunities of the Company, the Warrant Agent, and the holders of the Warrants; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, all acts and things have been done and performed that are necessary to make the Warrants, when executed on behalf of the Company and countersigned by or on behalf of the Warrant Agent, as provided herein, the valid, binding and legal obligations of the Company, and to authorize the execution and delivery of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">NOW, THEREFORE</b>, in consideration of the mutual agreements herein contained, the parties hereto agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">1. <u style="text-decoration:underline;text-decoration-color:#000000;">Assignment and Assumption</u>. HCCC hereby assigns to the Company all of HCCC&#8217;s right, title and interest in and to the Existing Warrant Agreement and the Warrants (each as amended hereby) as of the effective time of the Merger (the &#8220;<font style="font-style:italic;font-weight:bold;">Effective Time</font>&#8221;). The Company hereby assumes, and agrees to pay, perform, satisfy and discharge in full, as the same become due, all of HCCC&#8217;s liabilities and obligations under the Existing Warrant Agreement and the Warrants (each as amended hereby) arising from and after the Effective Time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">2. <u style="text-decoration:underline;text-decoration-color:#000000;">Consent</u>. The Warrant Agent hereby consents to the assignment of the Existing Warrant Agreement and the Warrants by HCCC to the Company pursuant to <u style="text-decoration:underline;text-decoration-color:#000000;">Section 1</u> hereof, effective as of the Effective Time, the assumption of the Warrants by the Company from HCCC pursuant to <u style="text-decoration:underline;text-decoration-color:#000000;">Section 1</u> hereof, effective as of the Effective Time, and the continuation of the Warrants in full force and effect from and after the Effective Time, subject at all times to this Agreement (each as amended hereby) and to all of the provisions, covenants, agreements, terms and conditions of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">3. <u style="text-decoration:underline;text-decoration-color:#000000;">Warrants</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">3.1 <u style="text-decoration:underline;text-decoration-color:#000000;">Form of Warran</u>t. Each Warrant shall be issued in registered form only, and, if a physical certificate is issued, shall be in substantially the form of <u style="text-decoration:underline;text-decoration-color:#000000;">Exhibit A</u> hereto, the provisions of which are incorporated herein and shall be signed by, or bear the electronic signature of, the Chairman of the Company&#8217;s board of directors (the &#8220;<font style="font-style:italic;font-weight:bold;">Board</font>&#8221;), Chief Executive Officer, Chief Financial Officer or other principal officer of the Company. In the event the person whose electronic signature has been placed upon any Warrant shall have ceased to serve in the capacity in which such person signed the Warrant before such Warrant is issued, it may be issued with the same effect as if he or she had not ceased to be such at the date of issuance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">3.2 <u style="text-decoration:underline;text-decoration-color:#000000;">Effect of Countersignature</u>. If a physical certificate is issued, unless and until countersigned by the Warrant Agent pursuant to this Agreement, a Warrant certificate shall be invalid and of no effect and may not be exercised by the holder thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">3.3 <u style="text-decoration:underline;text-decoration-color:#000000;">Registration</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">3.3.1 <u style="text-decoration:underline;text-decoration-color:#000000;">Warrant Register</u>. The Warrant Agent shall maintain books (the &#8220;<font style="font-style:italic;font-weight:bold;">Warrant Register</font>&#8221;) for the registration of original issuance and the registration of transfer of the Warrants. Upon the initial issuance of the Warrants, the Warrant Agent shall issue and register the Warrants in the names of the respective holders thereof in such denominations and otherwise in accordance with instructions delivered to the Warrant Agent by the Company. All of the Public Warrants shall initially be represented by one or more book-entry certificates (each, a &#8220;<font style="font-style:italic;font-weight:bold;">Book-Entry Warrant Certificate</font>&#8221;) deposited with The Depository Trust Company (the &#8220;<font style="font-style:italic;font-weight:bold;">Depositary</font>&#8221;) and registered in the name of Cede &amp; Co., a nominee of the Depositary. Ownership of beneficial interests in the Public Warrants shall be shown on, and the transfer of such ownership shall be effected through, records maintained by (i) the Depositary or its nominee for each Book-Entry Warrant Certificate, or (ii) institutions that have accounts with the Depositary (each such institution, with respect to a Warrant in its account, a &#8220;<font style="font-style:italic;font-weight:bold;">Participant</font>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If the Depositary subsequently ceases to make its book-entry settlement system available for the Public Warrants, the Company may instruct the Warrant Agent regarding making other arrangements for book-entry settlement. In the event that the Public Warrants are not eligible for, or it is no longer necessary to have the Public Warrants available in, book-entry form, the Warrant Agent shall provide written instructions to the Depositary to deliver to the Warrant Agent for cancellation each Book-Entry Warrant Certificate, and the Company shall instruct the Warrant Agent to deliver to the Depositary definitive certificates in physical form evidencing such Warrants (&#8220;<font style="font-style:italic;font-weight:bold;">Definitive Warrant Certificate</font>&#8221;). Such Definitive Warrant Certificate shall be in the form annexed hereto as <u style="text-decoration:underline;text-decoration-color:#000000;">Exhibit A</u>, with appropriate insertions, modifications and omissions, as provided above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.3.2 <u style="text-decoration:underline;text-decoration-color:#000000;">Registered Holder</u>. Prior to due presentment for registration of transfer of any Warrant, the Company and the Warrant Agent may deem and treat the person in whose name such Warrant is registered in the Warrant Register (the &#8220;<font style="font-style:italic;font-weight:bold;">Registered Holder</font>&#8221;) as the absolute owner of such Warrant and of each Warrant represented thereby (notwithstanding any notation of ownership or other writing on a Definitive Warrant Certificate made by anyone other than the Company or the Warrant Agent), for the purpose of any exercise thereof, and for all other purposes, and neither the Company nor the Warrant Agent shall be affected by any notice to the contrary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">3.4 [Reserved]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">3.5 <u style="text-decoration:underline;text-decoration-color:#000000;">No Fractional Warrants</u>. The Company shall not issue fractional Warrants. If a holder of Warrants would be entitled to receive a fractional Warrant, the Company shall round down to the nearest whole number the number of Warrants to be issued to such holder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">3.6 <u style="text-decoration:underline;text-decoration-color:#000000;">Private Placement Warrants</u>. The Private Placement Warrants are identical to the Public Warrants, except that so long as they are held by the Sponsor or any of its Permitted Transferees (as defined below), as applicable, the Private Placement Warrants: (i) may be exercised for cash or on a cashless basis, pursuant to subsection 4.3.1(c) hereof, (ii) may not be transferred, assigned or sold until thirty (30) days after the date hereof, and (iii) shall not be redeemable by the Company; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>, <u style="text-decoration:underline;text-decoration-color:#000000;">however</u>, that in the case of (ii), the Private Placement Warrants and any Ordinary Shares held by the Sponsor or any of its Permitted Transferees, as applicable, and issued upon exercise of the Private Placement Warrants may be transferred by the holders thereof:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(a) to the Company&#8217;s officers or directors, any affiliate or family member of any of the Company&#8217;s officers or directors, any members of the Sponsor or their affiliates, any affiliates of the Sponsor, or any employees of such affiliates;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(b) in the case of an individual, by gift to a member of such individual&#8217;s immediate family or to a trust, the beneficiary of which is a member of such individual&#8217;s immediate family, an affiliate of such individual or to a charitable organization;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(c) in the case of an individual, by virtue of the laws of descent and distribution upon death of such person;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(d) in the case of an individual, pursuant to a qualified domestic relations order;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(e) by private sales or transfers made in connection with any forward purchase agreement or similar arrangement at prices no greater than the price at which the Ordinary Shares or Warrants were originally purchased; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(f) by virtue of the laws of the State of Delaware or the limited liability company agreement of the Sponsor upon termination and winding-up of the Sponsor; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>, <u style="text-decoration:underline;text-decoration-color:#000000;">however</u>, that, in the case of clauses (a) through (e), these transferees (the &#8220;<font style="font-style:italic;font-weight:bold;">Permitted Transferees</font>&#8221;) enter into a written agreement with the Company agreeing to be bound by the transfer restrictions in this Agreement and the other restrictions contained in the letter agreement, dated as of the date hereof, by and among the Company, the Sponsor and the Company&#8217;s officers and directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">4. <u style="text-decoration:underline;text-decoration-color:#000000;">Terms and Exercise of Warrants</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">4.1 <u style="text-decoration:underline;text-decoration-color:#000000;">Warrant Price</u>. Each whole Warrant shall entitle the Registered Holder thereof, subject to the provisions of such Warrant and of this Agreement, to purchase from the Company the number of Ordinary Shares stated therein, at the price of $11.50 per share, subject to the adjustments provided in <u style="text-decoration:underline;text-decoration-color:#000000;">Section 5</u> hereof and in the last sentence of this <u style="text-decoration:underline;text-decoration-color:#000000;">Section 4.1</u>. The term &#8220;Warrant Price&#8221; as used in this Agreement shall mean the price per share at which Ordinary Shares may be purchased at the time a Warrant is exercised. The Company in its sole discretion may lower the Warrant Price at any time prior to the Expiration Date (as defined below) for a period of not less than twenty (20) days on which banks in New York City are generally open for normal business (a &#8220;<font style="font-style:italic;font-weight:bold;">Business Day</font>&#8221;); provided, that the Company shall provide at least twenty (20) days&#8217; prior written notice of such reduction to Registered Holders of the Warrants; and provided further, that any such reduction shall be identical among all of the Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.2 <u style="text-decoration:underline;text-decoration-color:#000000;">Duration of Warrants</u>. A Warrant may be exercised only during the period (the &#8220;<font style="font-style:italic;font-weight:bold;">Exercise Period</font>&#8221;) commencing on the date that is thirty (30) days after the date hereof, and terminating at 5:00 p.m., New York City time on the earlier to occur of: (x) the date that is five (5) years after the date hereof, (y) the liquidation of the Company, or (z) other than with respect to the Private Placement Warrants to the extent then held by the original purchasers thereof or their Permitted Transferees, the Redemption Date (as defined below) as provided in <u style="text-decoration:underline;text-decoration-color:#000000;">Section 7.2</u> hereof (the &#8220;<font style="font-style:italic;font-weight:bold;">Expiration Date</font>&#8221;); <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>, <u style="text-decoration:underline;text-decoration-color:#000000;">however</u>, that the exercise of any Warrant shall be subject to the satisfaction of any applicable conditions, as set forth in <u style="text-decoration:underline;text-decoration-color:#000000;">subsection 4.3.2</u> below, with respect to an effective registration statement. Except with respect to the right to receive the Redemption Price (as defined below) (other than with respect to a Private Placement Warrant) then held by the original purchasers thereof or their Permitted Transferees in the event of a redemption (as set forth in <u style="text-decoration:underline;text-decoration-color:#000000;">Section 7</u> hereof), each outstanding Warrant (other than a Private Placement Warrant) to the extent then held by the Sponsor or its Permitted Transferees in the event of a redemption not exercised on or before the Expiration Date shall become void, and all rights thereunder and all rights in respect</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">thereof under this Agreement shall cease at 5:00 p.m. New York City time on the Expiration Date. The Company in its sole discretion may extend the duration of the Warrants by delaying the Expiration Date; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>, that the Company shall provide at least twenty (20) days prior written notice of any such extension to Registered Holders of the Warrants and, provided further that any such extension shall be identical in duration among all the Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">4.3 <u style="text-decoration:underline;text-decoration-color:#000000;">Exercise of Warrants</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">4.3.1 <u style="text-decoration:underline;text-decoration-color:#000000;">Payment</u>. Subject to the provisions of the Warrant and this Agreement, a Warrant may be exercised by the Registered Holder thereof by delivering to the Warrant Agent at its corporate trust department (i) the Definitive Warrant Certificate evidencing the Warrants to be exercised, or, in the case of a Book-Entry Warrant Certificate, the Warrants to be exercised on the records of the Depositary to an account of the Warrant Agent at the Depositary designated for such purposes in writing by the Warrant Agent to the Depositary from time to time, (ii) an election to purchase (&#8220;<font style="font-style:italic;font-weight:bold;">Election to Purchase</font>&#8221;) Ordinary Shares pursuant to the exercise of a Warrant, properly completed and executed by the Registered Holder on the reverse of the Definitive Warrant Certificate or, in the case of a Book-Entry Warrant Certificate, properly delivered by the Participant in accordance with the Depositary&#8217;s procedures, and (iii) payment in full of the Warrant Price for each Ordinary Share as to which the Warrant is exercised and any and all applicable taxes due in connection with the exercise of the Warrant, the exchange of the Warrant for the Ordinary Shares and the issuance of such Ordinary Shares, as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(a) by certified check payable to the order of the Warrant Agent or by wire transfer;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(b) in the event of a redemption pursuant to <u style="text-decoration:underline;text-decoration-color:#000000;">Section 7</u> hereof in which the Board has elected to require all holders of the Warrants to exercise such Warrants on a &#8220;cashless basis,&#8221; by surrendering the Warrants for that number of Ordinary Shares equal to the quotient obtained by dividing (x) the product of the number of Ordinary Shares underlying the Warrants, multiplied by the difference between the Warrant Price and the &#8220;Fair Market Value,&#8221; as defined in this<u style="text-decoration:underline;text-decoration-color:#000000;"> subsection 4.3.1(b)</u>, by (y) the Fair Market Value. Solely for purposes of this <u style="text-decoration:underline;text-decoration-color:#000000;">subsection 4.3.1(b)</u> and <u style="text-decoration:underline;text-decoration-color:#000000;">Section 7.3</u>, the &#8220;Fair Market Value&#8221; shall mean the average last sale price of the Ordinary Shares for the ten (10) trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of the Warrants, pursuant to <u style="text-decoration:underline;text-decoration-color:#000000;">Section 7</u> hereof;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(c) with respect to any Private Placement Warrant, so long as such Private Placement Warrant is held by the Sponsor or a Permitted Transferee, as applicable, by surrendering the Warrants for that number of Ordinary Shares equal to the quotient obtained by dividing (x) the product of the number of Ordinary Shares underlying the Warrants, multiplied by the difference between the Warrant Price and the &#8220;Fair Market Value,&#8221; as defined in this <u style="text-decoration:underline;text-decoration-color:#000000;">subsection 4.3.1(c)</u> by (y) the Fair Market Value. Solely for purposes of this<u style="text-decoration:underline;text-decoration-color:#000000;"> subsection 4.3.1(c)</u>, the &#8220;<font style="font-style:italic;font-weight:bold;">Fair Market Value</font>&#8221; shall mean the average reported last sale price of the Ordinary Shares for the ten (10) trading days ending on the third trading day prior to the date on which notice of exercise of the Warrant is sent to the Warrant Agent; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(d) as provided in <u style="text-decoration:underline;text-decoration-color:#000000;">Section 8.4</u> hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">4.3.2 </b><u style="text-decoration:underline;text-decoration-color:#000000;">Issuance of Ordinary Shares on Exercise</u>. As soon as practicable after the exercise of any Warrant and the clearance of the funds in payment of the Warrant Price (if payment is pursuant to <u style="text-decoration:underline;text-decoration-color:#000000;">subsection 4.3.1(a))</u>, the Company shall issue to the Registered Holder of such Warrant a book-entry position or certificate, as applicable, for the number of Ordinary Shares to which he, she or it is entitled, registered in such name or names as may be directed by him, her or it, and if such Warrant shall not have been exercised in full, a new book-entry position or countersigned Warrant, as applicable, for the number of Ordinary Shares as to which such Warrant shall not have been exercised. If fewer than all the Warrants evidenced by a Book-Entry Warrant Certificate are exercised, a notation shall be made to the records maintained by the Depositary, its nominee for each Book-Entry Warrant Certificate, or a Participant, as appropriate, evidencing the balance of the Warrants remaining after such exercise. Notwithstanding the foregoing, the Company shall not be obligated to deliver any Ordinary Shares pursuant to the exercise of a Warrant and shall have no obligation to settle such Warrant exercise unless a registration statement under the Securities Act with respect to the Ordinary Shares underlying the Public Warrants is then effective and a prospectus relating thereto is current, subject to the Company&#8217;s satisfying its obligations under <u style="text-decoration:underline;text-decoration-color:#000000;">Section 8.4</u>. No Warrant shall be exercisable and the Company shall not be obligated to issue Ordinary Shares upon exercise of a Warrant unless the Ordinary Shares issuable upon such Warrant exercise have been registered, qualified or deemed to be exempt from registration or qualification under the securities laws of the state of residence of the Registered Holder of the Warrants, except pursuant to <u style="text-decoration:underline;text-decoration-color:#000000;">Section 8.4</u>. In the event that the conditions in the two immediately preceding sentences are not satisfied</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">with respect to a Warrant, the holder of such Warrant shall not be entitled to exercise such Warrant and such Warrant may have no value and expire worthless. In no event will the Company be required to net cash settle the Warrant exercise. The Company may require holders of Public Warrants to settle the Warrant on a &#8220;cashless basis&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">pursuant to <u style="text-decoration:underline;text-decoration-color:#000000;">subsection 4.3.1(b)</u> and <u style="text-decoration:underline;text-decoration-color:#000000;">Section 8.4</u>. If, by reason of any exercise of Warrants on a &#8220;cashless basis,&#8221; the holder of any Warrant would be entitled, upon the exercise of such Warrant, to receive a fractional interest in an Ordinary Share, the Company shall round down to the nearest whole number, the number of Ordinary Shares to be issued to such holder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">4.3.3 <u style="text-decoration:underline;text-decoration-color:#000000;">Valid Issuance</u>. All Ordinary Shares issued upon the proper exercise of a Warrant in conformity with this Agreement shall be validly issued, fully paid and non-assessable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">4.3.4 <u style="text-decoration:underline;text-decoration-color:#000000;">Date of Issuance</u>. Each person in whose name any book-entry position or certificate, as applicable, for Ordinary Shares is issued shall for all purposes be deemed to have become the holder of record of such Ordinary Shares on the date on which the Warrant, or book-entry position representing such Warrant, was surrendered and payment of the Warrant Price was made, irrespective of the date of delivery of such certificate in the case of a certificated Warrant, except that, if the date of such surrender and payment is a date when the share transfer books of the Company or book-entry system of the Warrant Agent are closed, such person shall be deemed to have become the holder of such Ordinary Shares at the close of business on the next succeeding date on which the share transfer books or book-entry system are open.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">4.3.5 <u style="text-decoration:underline;text-decoration-color:#000000;">Maximum Percentage</u>. A holder of a Warrant may notify the Company in writing in the event it elects to be subject to the provisions contained in this <u style="text-decoration:underline;text-decoration-color:#000000;">subsection 4.3.5</u>; <u style="text-decoration:underline;text-decoration-color:#000000;">however</u>, no holder of a Warrant shall be subject to this <u style="text-decoration:underline;text-decoration-color:#000000;">subsection 4.3.5</u> unless he, she or it makes such election. If the election is made by a holder, the Warrant Agent shall not effect the exercise of the holder&#8217;s Warrant, and such holder shall not have the right to exercise such Warrant, to the extent that after giving effect to such exercise, such person (together with such person&#8217;s affiliates), to the Warrant Agent&#8217;s actual knowledge, would beneficially own in excess of 4.9% or 9.8% (or such other amount as a holder may specify)(the &#8220;<font style="font-style:italic;font-weight:bold;">Maximum Percentage</font>&#8221;) of the Ordinary Shares outstanding immediately after giving effect to such exercise. For purposes of the foregoing sentence, the aggregate number of Ordinary Shares beneficially owned by such person and its affiliates shall include the number of Ordinary Shares issuable upon exercise of the Warrant with respect to which the determination of such sentence is being made, but shall exclude Ordinary Shares that would be issuable upon (x) exercise of the remaining, unexercised portion of the Warrant beneficially owned by such person and its affiliates and (y) exercise or conversion of the unexercised or unconverted portion of any other securities of the Company beneficially owned by such person and its affiliates (including, without limitation, any convertible notes or convertible preferred shares or warrants) subject to a limitation on conversion or exercise analogous to the limitation contained herein. Except as set forth in the preceding sentence, for purposes of this paragraph, beneficial ownership shall be calculated in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended (the &#8220;<font style="font-style:italic;font-weight:bold;">Exchange </font><b style="font-weight:bold;">Act</b>&#8221;). For purposes of the Warrant, in determining the number of outstanding Ordinary Shares, the holder may rely on the number of outstanding Ordinary Shares as reflected in (1) the Company&#8217;s most recent annual report on Form 20-F, current report on Form 6-K or other public filing with the Securities and Exchange Commission (the &#8220;<font style="font-style:italic;font-weight:bold;">Commission</font>&#8221;) as the case may be, (2) a more recent public announcement by the Company or (3) any other notice by the Company or the Transfer Agent setting forth the number of Ordinary Shares outstanding. For any reason at any time, upon the written request of the holder of the Warrant, the Company shall, within two (2) Business Days, confirm orally and in writing to such holder the number of Ordinary Shares then outstanding. In any case, the number of outstanding Ordinary Shares shall be determined after giving effect to the conversion or exercise of equity securities of the Company by the holder and its affiliates since the date as of which such number of outstanding Ordinary Shares was reported. By written notice to the Company, the holder of a Warrant may from time to time increase or decrease the Maximum Percentage applicable to such holder to any other percentage specified in such notice; <u style="text-decoration:underline;text-decoration-color:#000000;">provided, however</u>, that any such increase shall not be effective until the sixty-first (61st) day after such notice is delivered to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">5. <u style="text-decoration:underline;text-decoration-color:#000000;">Adjustments</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">5.1 <u style="text-decoration:underline;text-decoration-color:#000000;">Share Capitalizations.</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">5.1.1 <u style="text-decoration:underline;text-decoration-color:#000000;">Increase of Shares</u>. If after the date hereof, and subject to the provisions of <u style="text-decoration:underline;text-decoration-color:#000000;">Section 5.6</u> below, the number of outstanding Ordinary Shares is increased by a share capitalization payable in Ordinary Shares, or by a sub-division of Ordinary Shares or other similar event, then, on the effective date of such share capitalization, sub-division or similar event, the number of Ordinary Shares issuable on exercise of each Warrant shall be increased in proportion to such increase in the outstanding Ordinary Shares. A rights offering made to all or substantially all holders of the Ordinary Shares entitling holders to purchase Ordinary Shares at a price less than the &#8220;Historical Fair Market Value&#8221; (as defined below) shall be deemed a share capitalization of a number of Ordinary Shares equal to the product of (i) the number of Ordinary Shares actually sold in such rights offering (or issuable under any other equity securities sold in such rights offering that are convertible into or exercisable for Ordinary Shares) and (ii) one (1) minus the quotient of (x) the price per Ordinary Share paid in such rights offering divided by (y) the Historical Fair Market Value. For purposes of this <u style="text-decoration:underline;text-decoration-color:#000000;">subsection 5.1.1</u>, (i) if the rights offering is for securities convertible into or exercisable for Ordinary Shares, in determining the price payable for Ordinary Shares, there shall be taken into account any consideration received for such rights, as well as any additional amount payable upon exercise or conversion and (ii) &#8220;Historical Fair Market Value&#8221; means the volume weighted average price of the Ordinary Shares as reported during the ten (10) trading day period ending on the trading day prior to the first date on which the Ordinary Shares trade on the applicable exchange or in the applicable market, regular way, without the right to receive such rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">5.1.2 <u style="text-decoration:underline;text-decoration-color:#000000;">Extraordinary Dividends</u>. If the Company, at any time while the Warrants are outstanding and unexpired, shall pay a dividend or make a distribution in cash, securities or other assets to the holders of Ordinary Shares on account of such Ordinary Shares (or other of the Company&#8217;s share capital into which the Warrants are convertible), other than (a) as described in <u style="text-decoration:underline;text-decoration-color:#000000;">subsection 5.1.1</u> above, (b) Ordinary Cash Dividends (as defined below) or (c) to satisfy the redemption rights of the holders of Ordinary Shares in connection with a shareholder vote to amend the Company&#8217;s articles of association with respect to any material provisions relating to shareholders&#8217; rights (any such non-excluded event being referred to herein as an &#8220;<font style="font-style:italic;font-weight:bold;">Extraordinary Dividend</font>&#8221;), then the Warrant Price shall be decreased, effective immediately after the effective date of such Extraordinary Dividend, by the amount of cash and/or the fair market value (as determined by the Board, in good faith) of any securities or other assets paid on each Ordinary Share in respect of such Extraordinary Dividend. For purposes of this <u style="text-decoration:underline;text-decoration-color:#000000;">subsection 5.1.2</u>, &#8220;<font style="font-style:italic;font-weight:bold;">Ordinary Cash Dividends</font>&#8221; means any cash dividend or cash distribution which, when combined on a per share basis, with the per share amounts of all other cash dividends and cash distributions paid on the Ordinary Shares during the 365-day period ending on the date of declaration of such dividend or distribution (as adjusted to appropriately reflect any of the events referred to in other subsections of this <u style="text-decoration:underline;text-decoration-color:#000000;">Section 5</u> and excluding cash dividends or cash distributions that resulted in an adjustment to the Warrant Price or to the number of Ordinary Shares issuable on exercise of each Warrant) does not exceed $0.50.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">5.2 <u style="text-decoration:underline;text-decoration-color:#000000;">Aggregation of Shares</u>. If after the date hereof, and subject to the provisions of <u style="text-decoration:underline;text-decoration-color:#000000;">Section 5.6</u> hereof, the number of outstanding Ordinary Shares is decreased by a consolidation, combination, reverse stock split or reclassification of Ordinary Shares or other similar event, then, on the effective date of such consolidation, combination, reverse stock split, reclassification or similar event, the number of Ordinary Shares issuable on exercise of each Warrant shall be decreased in proportion to such decrease in outstanding Ordinary Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">5.3 <u style="text-decoration:underline;text-decoration-color:#000000;">Adjustments in Warrant Price</u>. Whenever the number of Ordinary Shares purchasable upon the exercise of the Warrants is adjusted, as provided in <u style="text-decoration:underline;text-decoration-color:#000000;">subsection 5.1.1</u> or<u style="text-decoration:underline;text-decoration-color:#000000;"> Section 5.2</u> above, the Warrant Price shall be adjusted (to the nearest cent) by multiplying such Warrant Price immediately prior to such adjustment by a fraction (x) the numerator of which shall be the number of Ordinary Shares purchasable upon the exercise of the Warrants immediately prior to such adjustment, and (y) the denominator of which shall be the number of Ordinary Shares so purchasable immediately thereafter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">5.4 <u style="text-decoration:underline;text-decoration-color:#000000;">Replacement of Securities upon Reorganization, etc</u>. In case of any reclassification or reorganization of the outstanding Ordinary Shares (other than a change under <u style="text-decoration:underline;text-decoration-color:#000000;">subsections 5.1.1</u> or <u style="text-decoration:underline;text-decoration-color:#000000;">5.1.2</u> or <u style="text-decoration:underline;text-decoration-color:#000000;">Section 5.2</u> hereof or that solely affects the par value of such Ordinary Shares), or in the case of any merger or consolidation of the Company with or into another entity or conversion of the Company as another entity (other than a consolidation or merger in which the Company is the continuing corporation and that does not result in any reclassification or reorganization of the outstanding Ordinary Shares), or in the case of any sale or conveyance to another entity of the assets or other property of the Company as an entirety or substantially as an entirety in connection with which the Company is dissolved, the holders of the Warrants shall thereafter have the right to purchase and receive, upon the basis and upon the terms and conditions specified in the Warrants and in lieu of the Ordinary Shares of the Company</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">immediately theretofore purchasable and receivable upon the exercise of the rights represented thereby, the kind and amount of shares or other securities or property (including cash) receivable upon such reclassification, reorganization, merger or consolidation, or upon a dissolution following any such sale or transfer, that the holder of the Warrants would have received if such holder had exercised his, her or its Warrant(s) immediately prior to such event (the &#8220;<font style="font-style:italic;font-weight:bold;">Alternative Issuance</font>&#8221;); <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>, <u style="text-decoration:underline;text-decoration-color:#000000;">however</u>, that in connection with the closing of any such consolidation, merger, sale or conveyance, the successor or purchasing entity shall execute an amendment hereto with the Warrant Agent providing for delivery of such Alternative Issuance; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>, <u style="text-decoration:underline;text-decoration-color:#000000;">further</u>, that (i) if the holders of the Ordinary Shares were entitled to exercise a right of election as to the kind or amount of securities, cash or other assets receivable upon such consolidation or merger, then the kind and amount of securities, cash or other assets constituting the Alternative Issuance for which each Warrant shall become exercisable shall be deemed to be the weighted average of the kind and amount received per share by the holders of the Ordinary Shares in such consolidation or merger that affirmatively make such election, and (ii) if a tender, exchange or redemption offer shall have been made to and accepted by the holders of the Ordinary Shares under circumstances in which, upon completion of such tender or exchange offer, the maker thereof, together with members of any group (within the meaning of Rule 13d-5(b)(1) under the Exchange Act (or any successor rule)) of which such maker is a part, and together with any affiliate or associate of such maker (within the meaning of Rule 12b-2 under the Exchange Act (or any successor rule)) and any members of any such group of which any such affiliate or associate is a part, own beneficially (within the meaning of Rule 13d-3 under the Exchange Act (or any successor rule)) more than 50% of the outstanding Ordinary Shares, the holder of a Warrant shall be entitled to receive as the Alternative Issuance, the highest amount of cash, securities or other property to which such holder would actually have been entitled as a shareholder if such Warrant holder had exercised the Warrant prior to the expiration of such tender or exchange offer, accepted such offer and all of the Ordinary Shares held by such holder had been purchased pursuant to such tender or exchange offer, subject to adjustments (from and after the consummation of such tender or exchange offer) as nearly equivalent as possible to the adjustments provided for in this <u style="text-decoration:underline;text-decoration-color:#000000;">Section 5</u>; <u style="text-decoration:underline;text-decoration-color:#000000;">provided further</u> that if less than 70% of the consideration receivable by the holders of the Ordinary Shares in the applicable event is payable in the form of capital stock or shares in the successor entity that is listed for trading on a national securities exchange or is quoted in an established over-the-counter market, or is to be so listed for trading or quoted immediately following such event, and if the Registered Holder properly exercises the Warrant within thirty (30) days following the public disclosure of the consummation of such applicable event by the Company pursuant to a Current Report on Form 6-K filed with the Commission, the Warrant Price shall be reduced by an amount (in dollars) (but in no event less than zero) equal to the difference of (i) the Warrant Price in effect prior to such reduction minus (ii) (A) the Per Share Consideration (as defined below) minus (B) the Black-Scholes Warrant Value (as defined below). The &#8220;<font style="font-style:italic;font-weight:bold;">Black-Scholes Warrant Value</font>&#8221; means the value of a Warrant immediately prior to the consummation of the applicable event based on the Black-Scholes Warrant Model for a Capped American Call on Bloomberg Financial Markets (&#8220;<font style="font-style:italic;font-weight:bold;">Bloomberg</font>&#8221;). For purposes of calculating such amount,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(1) <u style="text-decoration:underline;text-decoration-color:#000000;">Section 7</u> of this Agreement shall be taken into account, (2) the price of each Ordinary Share shall be the volume weighted average price of the Ordinary Shares as reported during the ten (10) trading day period ending on the trading day prior to the effective date of the applicable event, (3) the assumed volatility shall be the 90 day volatility obtained from the HVT function on Bloomberg determined as of the trading day immediately prior to the day of the announcement of the applicable event, and (4) the assumed risk-free interest rate shall correspond to the U.S. Treasury rate for a period equal to the remaining term of the Warrant. &#8220;<font style="font-style:italic;font-weight:bold;">Per Share Consideration</font>&#8221; means (i) if the consideration paid to holders of the Ordinary Shares consists exclusively of cash, the amount of such cash per Ordinary Share, and (ii) in all other cases, the volume weighted average price of the Ordinary Shares as reported during the ten (10) trading day period ending on the trading day prior to the effective date of the applicable event. If any reclassification or reorganization also results in a change in Ordinary Shares covered by <u style="text-decoration:underline;text-decoration-color:#000000;">subsection 5.1.1</u>, then such adjustment shall be made pursuant to <u style="text-decoration:underline;text-decoration-color:#000000;">subsection 5.1.1</u> or <u style="text-decoration:underline;text-decoration-color:#000000;">Sections 5.2</u>, <u style="text-decoration:underline;text-decoration-color:#000000;">5.3</u> and this <u style="text-decoration:underline;text-decoration-color:#000000;">Section 5.4</u>. The provisions of this <u style="text-decoration:underline;text-decoration-color:#000000;">Section 5.4</u> shall similarly apply to successive reclassifications, reorganizations, mergers or consolidations, sales or other transfers. In no event will the Warrant Price be reduced to less than the par value per share issuable upon exercise of the Warrant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">5.5<u style="text-decoration:underline;text-decoration-color:#000000;"> Notices of Changes in Warran</u>t. Upon every adjustment of the Warrant Price or the number of Ordinary Shares issuable upon exercise of a Warrant, the Company shall give written notice thereof to the Warrant Agent, which notice shall state the Warrant Price resulting from such adjustment and the increase or decrease, if any, in the number of Ordinary Shares purchasable at such price upon the exercise of a Warrant, setting forth in reasonable detail the method of calculation and the facts upon which such calculation is based. Upon the occurrence of any</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">event specified in <u style="text-decoration:underline;text-decoration-color:#000000;">Sections 5.1</u>, <u style="text-decoration:underline;text-decoration-color:#000000;">5.2</u>, <u style="text-decoration:underline;text-decoration-color:#000000;">5.3</u> or <u style="text-decoration:underline;text-decoration-color:#000000;">5.4</u>, the Company shall give written notice of the occurrence of such event to each holder of a Warrant, at the last address set forth for such holder in the Warrant Register, of the record date or the effective date of the event. Failure to give such notice, or any defect therein, shall not affect the legality or validity of such event.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">5.6 <u style="text-decoration:underline;text-decoration-color:#000000;">No Fractional Shares</u>. Notwithstanding any provision contained in this Agreement to the contrary, the Company shall not issue fractional Ordinary Shares upon the exercise of Warrants. If, by reason of any adjustment made pursuant to this <u style="text-decoration:underline;text-decoration-color:#000000;">Section 5</u>, the holder of any Warrant would be entitled, upon the exercise of such Warrant, to receive a fractional interest in a share, the Company shall, upon such exercise, round down to the nearest whole number the number of Ordinary Shares to be issued to such holder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">5.7 <u style="text-decoration:underline;text-decoration-color:#000000;">Form of Warran</u>t. The form of Warrant need not be changed because of any adjustment pursuant to this <u style="text-decoration:underline;text-decoration-color:#000000;">Section 5</u>, and Warrants issued after such adjustment may state the same Warrant Price and the same number of Ordinary Shares as is stated in the Warrants initially issued pursuant to this Agreement; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>, <u style="text-decoration:underline;text-decoration-color:#000000;">however</u>, that the Company may at any time in its sole discretion make any change in the form of Warrant that the Company may deem appropriate and that does not affect the substance thereof, and any Warrant thereafter issued or countersigned, whether in exchange or substitution for an outstanding Warrant or otherwise, may be in the form as so changed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">5.8 <u style="text-decoration:underline;text-decoration-color:#000000;">Other Events</u>. In case any event shall occur affecting the Company as to which none of the provisions of preceding subsections of this <u style="text-decoration:underline;text-decoration-color:#000000;">Section 5</u> are strictly applicable, but which would require an adjustment to the terms of the Warrants in order to (i) avoid an adverse impact on the Warrants and (ii) effectuate the intent and purpose of this <u style="text-decoration:underline;text-decoration-color:#000000;">Section 5</u>, then, in each such case, the Company shall appoint a firm of independent public accountants, investment banking or other appraisal firm of recognized national standing, which shall give its opinion as to whether or not any adjustment to the rights represented by the Warrants is necessary to effectuate the intent and purpose of this <u style="text-decoration:underline;text-decoration-color:#000000;">Section 5</u> and, if they determine that an adjustment is necessary, the terms of such adjustment. The Company shall adjust the terms of the Warrants in a manner that is consistent with any adjustment recommended in such opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">6. <u style="text-decoration:underline;text-decoration-color:#000000;">Transfer and Exchange of Warrants</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">6.1 <u style="text-decoration:underline;text-decoration-color:#000000;">Registration of Transfer</u>. The Warrant Agent shall register the transfer, from time to time, of any outstanding Warrant upon the Warrant Register, upon surrender of such Warrant for transfer, in the case of a certificated Warrant, properly endorsed with signatures properly guaranteed and accompanied by appropriate instructions for transfer. Upon any such transfer, a new Warrant representing an equal aggregate number of Warrants shall be issued and the old Warrant shall be cancelled by the Warrant Agent. In the case of certificated Warrants, the Warrants so cancelled shall be delivered by the Warrant Agent to the Company from time to time upon request.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">6.2 <u style="text-decoration:underline;text-decoration-color:#000000;">Procedure for Surrender of Warrants</u>. Warrants may be surrendered to the Warrant Agent, together with a written request for exchange or transfer, and thereupon the Warrant Agent shall issue in exchange therefor one or more new Warrants as requested by the Registered Holder of the Warrants so surrendered, representing an equal aggregate number of Warrants; <u style="text-decoration:underline;text-decoration-color:#000000;">provided</u>, <u style="text-decoration:underline;text-decoration-color:#000000;">however,</u> that except as otherwise provided herein or in any Book-Entry Warrant Certificate or Definitive Warrant Certificate, each Book-Entry Warrant Certificate and Definitive Warrant Certificate may be transferred only in whole and only to the Depositary, to another nominee of the Depositary, to a successor depository, or to a nominee of a successor depository; <u style="text-decoration:underline;text-decoration-color:#000000;">provided further</u>, <u style="text-decoration:underline;text-decoration-color:#000000;">however</u>, that in the event that a Warrant surrendered for transfer bears a restrictive legend (as in the case of the Private Placement Warrants), the Warrant Agent shall not cancel such Warrant and issue new Warrants in exchange thereof until the Warrant Agent has received an opinion of counsel for the Company stating that such transfer may be made and indicating whether the new Warrants must also bear a restrictive legend.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">6.3 <u style="text-decoration:underline;text-decoration-color:#000000;">Fractional Warrants</u>. The Warrant Agent shall not be required to effect any registration of transfer or exchange which shall result in the issuance of a warrant certificate or book-entry position for a fraction of a warrant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">6.4 <u style="text-decoration:underline;text-decoration-color:#000000;">Service Charges</u>. No service charge shall be made for any exchange or registration of transfer of Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">6.5 <u style="text-decoration:underline;text-decoration-color:#000000;">Warrant Execution and Countersignature</u>. The Warrant Agent is hereby authorized to countersign and to deliver, in accordance with the terms of this Agreement, the Warrants required to be issued pursuant to the provisions of this</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">Section 6</u>, and the Company, whenever required by the Warrant Agent, shall supply the Warrant Agent with Warrants duly executed on behalf of the Company for such purpose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">7. <u style="text-decoration:underline;text-decoration-color:#000000;">Redemption</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">7.1 <u style="text-decoration:underline;text-decoration-color:#000000;">Redemption</u>. Subject to<u style="text-decoration:underline;text-decoration-color:#000000;"> Section 7.4</u> hereof, not less than all of the outstanding Warrants may be redeemed, at the option of the Company, at any time while they are exercisable and prior to their expiration, at the office of the Warrant Agent, upon notice to the Registered Holders of the Warrants, as described in <u style="text-decoration:underline;text-decoration-color:#000000;">Section 7.2</u> below, at the price of $0.01 per Warrant (the &#8220;<font style="font-style:italic;font-weight:bold;">Redemption Price</font>&#8221;), provided that the last sales price of the Ordinary Shares reported has been at least $18.00 per share (subject to adjustment in compliance with <u style="text-decoration:underline;text-decoration-color:#000000;">Section 5</u> hereof), on each of twenty (20) trading days within the thirty (30) trading-day period ending on the third trading day prior to the date on which notice of the redemption is given and provided that there is an effective registration statement covering the Ordinary Shares issuable upon exercise of the Warrants, and a current prospectus relating thereto, available throughout the 30-day Redemption Period (as defined in <u style="text-decoration:underline;text-decoration-color:#000000;">Section 7.2</u> below) or the Company has elected to require the exercise of the Warrants on a &#8220;cashless basis&#8221; pursuant to <u style="text-decoration:underline;text-decoration-color:#000000;">subsection 4.3.1</u>; provided, however, that if and when the Public Warrants become redeemable by the Company, the Company may not exercise such redemption right if the issuance of Ordinary Shares upon exercise of the Public Warrants is not exempt from registration or qualification under applicable state blue sky laws or the Company is unable to effect such registration or qualification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">7.2 <u style="text-decoration:underline;text-decoration-color:#000000;">Date Fixed for, and Notice of, Redemption; Redemption Price; Reference Value</u>. In the event that the Company elects to redeem all of the Warrants, the Company shall fix a date for the redemption (the &#8220;<font style="font-style:italic;font-weight:bold;">Redemption Date</font>&#8221;). Notice of redemption shall be mailed by first class mail, postage prepaid, by the Company not less than thirty (30) days prior to the Redemption Date (the &#8220;<font style="font-style:italic;font-weight:bold;">30-day Redemption Period</font>&#8221;) to the Registered Holders of the Warrants to be redeemed at their last addresses as they shall appear on the registration books. Any notice mailed in the manner herein provided shall be conclusively presumed to have been duly given whether or not the Registered Holder received such notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">7.3 <u style="text-decoration:underline;text-decoration-color:#000000;">Exercise After Notice of Redemption</u>. The Warrants may be exercised, for cash (or on a &#8220;cashless basis&#8221; in accordance with <u style="text-decoration:underline;text-decoration-color:#000000;">subsection 4.3.1(b)</u> of this Agreement) at any time after notice of redemption shall have been given by the Company pursuant to <u style="text-decoration:underline;text-decoration-color:#000000;">Section 7.2</u> hereof and prior to the Redemption Date. In the event that the Company determines to require all holders of Warrants to exercise their Warrants on a &#8220;cashless basis&#8221; pursuant to <u style="text-decoration:underline;text-decoration-color:#000000;">subsection 4.3.1</u>, the notice of redemption shall contain the information necessary to calculate the number of Ordinary Shares to be received upon exercise of the Warrants, including the &#8220;Fair Market Value&#8221; (as such term is defined in <u style="text-decoration:underline;text-decoration-color:#000000;">subsection 4.3.1(b)</u> hereof) in such case. On and after the Redemption Date, the record holder of the Warrants shall have no further rights except to receive, upon surrender of the Warrants, the Redemption Price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">7.4 <u style="text-decoration:underline;text-decoration-color:#000000;">Exclusion of Private Placement Warrants</u>. The Company agrees that the redemption rights provided in this <u style="text-decoration:underline;text-decoration-color:#000000;">Section 7</u> shall not apply to the Private Placement Warrants if at the time of the redemption such Private Placement Warrants continue to be held by the Sponsor or any of its Permitted Transferees, as applicable. However, once such Private Placement Warrants are transferred (other than to Permitted Transferees under <u style="text-decoration:underline;text-decoration-color:#000000;">Section 3.6)</u>, the Company may redeem the Private Placement Warrants, provided that the criteria for redemption are met, including the opportunity of the holder of such Private Placement Warrants to exercise the Private Placement Warrants prior to redemption pursuant to <u style="text-decoration:underline;text-decoration-color:#000000;">Section 7.4</u>. Private Placement Warrants that are transferred to persons other than Permitted Transferees shall upon such transfer cease to be Private Placement Warrants and shall become Public Warrants under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">8. <u style="text-decoration:underline;text-decoration-color:#000000;">Other Provisions Relating to Rights of Holders of Warrants</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">8.1 <u style="text-decoration:underline;text-decoration-color:#000000;">No Rights as Shareholder</u>. A Warrant does not entitle the Registered Holder thereof to any of the rights of a shareholder of the Company, including, without limitation, the right to receive dividends, or other distributions, exercise any preemptive rights to vote or to consent or to receive notice as shareholders in respect of the meetings of shareholders or the election of directors of the Company or any other matter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">8.2 <u style="text-decoration:underline;text-decoration-color:#000000;">Lost, Stolen, Mutilated, or Destroyed Warrants</u>. If any Warrant is lost, stolen, mutilated, or destroyed, the Company and the Warrant Agent may on such terms as to indemnity or otherwise as they may in their discretion</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">impose (which shall, in the case of a mutilated Warrant, include the surrender thereof), issue a new Warrant of like denomination, tenor, and date as the Warrant so lost, stolen, mutilated, or destroyed. Any such new Warrant shall constitute a substitute contractual obligation of the Company, whether or not the allegedly lost, stolen, mutilated, or destroyed Warrant shall be at any time enforceable by anyone.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">8.3 <u style="text-decoration:underline;text-decoration-color:#000000;">Reservation of Ordinary Shares</u>. The Company shall at all times reserve and keep available a number of its authorized but unissued Ordinary Shares that shall be sufficient to permit the exercise in full of all outstanding Warrants issued pursuant to this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">8.4 <u style="text-decoration:underline;text-decoration-color:#000000;">Registration of Ordinary Shares; Cashless Exercise at Company&#8217;s Option</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">8.4.1 <u style="text-decoration:underline;text-decoration-color:#000000;">Registration of the Ordinary Shares</u>. On January 12, 2022, the registration statement on Form F-4 (Commission File No. 333-258915) registering the Ordinary Shares issuable upon exercise of the Warrants was declared effective by the Commission. The Company shall use its best efforts to maintain the effectiveness of such registration statement until the expiration of the Warrants in accordance with the provisions of this Agreement and to take such action as is necessary to register or qualify for sale, in those states in which the Warrants were initially offered by the Company and in those states where holders of Warrants then reside, the Ordinary Shares issuable upon exercise of the Warrants, to the extent an exemption is not available. During any period when the Company shall fail to have maintained an effective registration statement covering the Ordinary Shares issuable upon exercise of the Warrants, the holders of the Warrants shall have the right to exercise such Warrants on a &#8220;cashless basis,&#8221; by exchanging the Warrants (in accordance with Section 3(a)(9) of the Securities Act (or any successor rule) or another exemption) for that number of Ordinary Shares equal to the quotient obtained by dividing (x) the product of the number of Ordinary Shares underlying the Warrants, multiplied by the difference between the Warrant Price and the &#8220;Fair Market Value&#8221; (as defined below) by (y) the Fair Market Value. Solely for purposes of this <u style="text-decoration:underline;text-decoration-color:#000000;">subsection 8.4.1</u>, &#8220;Fair Market Value&#8221; shall mean the volume weighted average price of the Ordinary Shares as reported during the ten (10) trading day period ending on the trading day prior to the date that notice of exercise is received by the Warrant Agent from the holder of such Warrants or its securities broker or intermediary. The date that notice of cashless exercise is received by the Warrant Agent shall be conclusively determined by the Warrant Agent. In connection with the &#8220;cashless exercise&#8221; of a Public Warrant, the Company shall, upon request, provide the Warrant Agent with an opinion of counsel for the Company (which shall be an outside law firm with securities law experience) stating that (i) the exercise of the Warrants on a cashless basis in accordance with this <u style="text-decoration:underline;text-decoration-color:#000000;">subsection 8.4.1</u> is not required to be registered under the Securities Act and (ii) the Ordinary Shares issued upon such exercise shall be freely tradable under United States federal securities laws by anyone who is not an affiliate (as such term is defined in Rule 144 under the Securities Act (or any successor rule)) of the Company and, accordingly, shall not be required to bear a restrictive legend. Except as provided in <u style="text-decoration:underline;text-decoration-color:#000000;">subsection 8.4.2</u>, for the avoidance of any doubt, unless and until all of the Warrants have been exercised or have expired, the Company shall continue to be obligated to comply with its registration obligations under the first two sentences of this <u style="text-decoration:underline;text-decoration-color:#000000;">subsection 8.4.1</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">8.4.2 <u style="text-decoration:underline;text-decoration-color:#000000;">Cashless Exercise at Company&#8217;s Option</u>. If the Ordinary Shares are at the time of any exercise of a Warrant not listed on a national securities exchange such that they satisfy the definition of &#8220;covered securities&#8221; under Section 18(b)(1) of the Securities Act (or any successor statute), the Company may, at its option, (i) require holders of Public Warrants who exercise Public Warrants to exercise such Public Warrants on a &#8220;cashless basis&#8221; in accordance with Section 3(a)(9) of the Securities Act (or any successor statute) as described in <u style="text-decoration:underline;text-decoration-color:#000000;">subsection 8.4.1</u> and (ii) in the event the Company so elects, the Company shall not be required to file or maintain in effect a registration statement for the registration, under the Securities Act, of the Ordinary Shares issuable upon exercise of the Warrants, notwithstanding anything in this Agreement to the contrary. If the Company does not elect at the time of exercise to require a holder of Public Warrants who exercises Public Warrants to exercise such Public Warrants on a &#8220;cashless basis,&#8221; it agrees to use its best efforts to register or qualify for sale the Ordinary Shares issuable upon exercise of the Public Warrants under the blue sky laws of the state of residence of the exercising Public Warrant holder to the extent an exemption is not available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">9. <u style="text-decoration:underline;text-decoration-color:#000000;">Concerning the Warrant Agent and Other Matters</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">9.1 <u style="text-decoration:underline;text-decoration-color:#000000;">Payment of Taxes</u>. The Company shall from time to time promptly pay all taxes and charges that may be imposed upon the Company or the Warrant Agent in respect of the issuance or delivery of Ordinary Shares upon the</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">exercise of the Warrants, but the Company shall not be obligated to pay any transfer taxes in respect of the Warrants or such Ordinary Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">9.2 <u style="text-decoration:underline;text-decoration-color:#000000;">Resignation, Consolidation, or Merger of Warrant Agent</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">9.2.1 <u style="text-decoration:underline;text-decoration-color:#000000;">Appointment of Successor Warrant Agent</u>. The Warrant Agent, or any successor to it hereafter appointed, may resign its duties and be discharged from all further duties and liabilities hereunder after giving sixty (60) days&#8217; notice in writing to the Company. If the office of the Warrant Agent becomes vacant by resignation or incapacity to act or otherwise, the Company shall appoint in writing a successor Warrant Agent in place of the Warrant Agent. If the Company shall fail to make such appointment within a period of thirty (30) days after it has been notified in writing of such resignation or incapacity by the Warrant Agent or by the holder of a Warrant (who shall, with such notice, submit his, her or its Warrant for inspection by the Company), then the holder of any Warrant may apply to the Supreme Court of the State of New York for the County of New York for the appointment of a successor Warrant Agent at the Company&#8217;s cost. Any successor Warrant Agent, whether appointed by the Company or by such court, shall be a corporation or other entity organized and existing under the laws of the State of New York, in good standing and having its principal office in the United States of America, and authorized under such laws to exercise corporate trust powers and subject to supervision or examination by federal or state authority. After appointment, any successor Warrant Agent shall be vested with all the authority, powers, rights, immunities, duties, and obligations of its predecessor Warrant Agent with like effect as if originally named as Warrant Agent hereunder, without any further act or deed; but if for any reason it becomes necessary or appropriate, the predecessor Warrant Agent shall execute and deliver, at the expense of the Company, an instrument transferring to such successor Warrant Agent all the authority, powers, and rights of such predecessor Warrant Agent hereunder; and upon request of any successor Warrant Agent the Company shall make, execute, acknowledge, and deliver any and all instruments in writing for more fully and effectually vesting in and confirming to such successor Warrant Agent all such authority, powers, rights, immunities, duties, and obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">9.2.2 <u style="text-decoration:underline;text-decoration-color:#000000;">Notice of Successor Warrant Agent</u>. In the event a successor Warrant Agent shall be appointed, the Company shall give notice thereof to the predecessor Warrant Agent and the Transfer Agent for the Ordinary Shares not later than the effective date of any such appointment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">9.2.3 <u style="text-decoration:underline;text-decoration-color:#000000;">Merger or Consolidation of Warrant Agent</u>. Any entity into which the Warrant Agent may be merged or with which it may be consolidated or any entity resulting from any merger or consolidation to which the Warrant Agent shall be a party shall be the successor Warrant Agent under this Agreement without any further act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">9.3 <u style="text-decoration:underline;text-decoration-color:#000000;">Fees and Expenses of Warrant Agent</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">9.3.1 <u style="text-decoration:underline;text-decoration-color:#000000;">Remuneration</u>. The Company agrees to pay the Warrant Agent reasonable remuneration for its services as such Warrant Agent hereunder and shall, pursuant to its obligations under this Agreement, reimburse the Warrant Agent upon demand for all expenditures that the Warrant Agent may reasonably incur in the execution of its duties hereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">9.3.2 <u style="text-decoration:underline;text-decoration-color:#000000;">Further Assurances</u>. The Company agrees to perform, execute, acknowledge, and deliver or cause to be performed, executed, acknowledged, and delivered all such further and other acts, instruments, and assurances as may reasonably be required by the Warrant Agent for the carrying out or performing of the provisions of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">9.4 <u style="text-decoration:underline;text-decoration-color:#000000;">Liability of Warrant Agent</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">9.4.1 <u style="text-decoration:underline;text-decoration-color:#000000;">Reliance on Company Statement</u>. Whenever in the performance of its duties under this Agreement, the Warrant Agent shall deem it necessary or desirable that any fact or matter be proved or established by the Company prior to taking or suffering any action hereunder, such fact or matter (unless other evidence in respect thereof be herein specifically prescribed) may be deemed to be conclusively proved and established by a statement signed by the Chief Executive Officer, Chief Financial Officer, any Executive Vice President, any Vice President, or the Chairman of the Board of the Company and delivered to the Warrant Agent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Warrant Agent may rely upon such statement for any action taken or suffered in good faith by it pursuant to the provisions of this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">9.4.2 <u style="text-decoration:underline;text-decoration-color:#000000;">Indemnity</u>. The Warrant Agent shall be liable hereunder only for its own gross negligence, willful misconduct or bad faith. The Company agrees to indemnify the Warrant Agent and save it harmless against any and all liabilities, including judgments, costs and reasonable counsel fees, for anything done or omitted by the Warrant Agent in the execution of this Agreement, except as a result of the Warrant Agent&#8217;s gross negligence, willful misconduct or bad faith.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">9.4.3 <u style="text-decoration:underline;text-decoration-color:#000000;">Exclusions</u>. The Warrant Agent shall have no responsibility with respect to the validity of this Agreement or with respect to the validity or execution of any Warrant (except its countersignature thereof). The Warrant Agent shall not be responsible for any breach by the Company of any covenant or condition contained in this Agreement or in any Warrant. The Warrant Agent shall not be responsible to make any adjustments required under the provisions of <u style="text-decoration:underline;text-decoration-color:#000000;">Section 5</u> hereof or responsible for the manner, method, or amount of any such adjustment or the ascertaining of the existence of facts that would require any such adjustment; nor shall it by any act hereunder be deemed to make any representation or warranty as to the authorization or reservation of any Ordinary Shares to be issued pursuant to this Agreement or any Warrant or as to whether any Ordinary Shares shall, when issued, be valid and fully paid and non-assessable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">9.5 <u style="text-decoration:underline;text-decoration-color:#000000;">Acceptance of Agency</u>. The Warrant Agent hereby accepts the agency established by this Agreement and agrees to perform the same upon the terms and conditions herein set forth and among other things, shall account promptly to the Company with respect to Warrants exercised and concurrently account for, and pay to the Company, all monies received by the Warrant Agent for the purchase of Ordinary Shares through the exercise of the Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">10. <u style="text-decoration:underline;text-decoration-color:#000000;">Miscellaneous Provisions</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">10.1 <u style="text-decoration:underline;text-decoration-color:#000000;">Successors</u>. All the covenants and provisions of this Agreement by or for the benefit of the Company or the Warrant Agent shall bind and inure to the benefit of their respective successors and assigns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">10.2 <u style="text-decoration:underline;text-decoration-color:#000000;">Notices</u>. Any notice, statement or demand authorized by this Agreement to be given or made by the Warrant Agent or by the holder of any Warrant to or on the Company shall be sufficiently given when so delivered if by hand or overnight delivery or if sent by certified mail or private courier service within five (5) days after deposit of such notice, postage prepaid, addressed (until another address is filed in writing by the Company with the Warrant Agent), as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Alpha Tau Medical Ltd.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Kiryat HaMada St. 5</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Jerusalem, Israel 9777605</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:16.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:0.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:82.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:16.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.8pt;">Attention:</p></td><td style="vertical-align:top;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;width:82.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raphi Levy</p></td></tr><tr><td style="vertical-align:bottom;width:16.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:82.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Rebecca Becker</p></td></tr><tr><td style="vertical-align:bottom;width:16.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.8pt;">E-mail:</p></td><td style="vertical-align:top;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:82.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RaphiL@alphatau.com</p></td></tr><tr><td style="vertical-align:bottom;width:16.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:82.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RebeccaB@alphatau.com</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">in each case, with copies to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Latham &amp; Watkins LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1271 Avenue of the Americas</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">New York, NY 10020</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:16.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:0.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:82.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:16.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.8pt;">Attention:</p></td><td style="vertical-align:top;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:82.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nathan Ajiashvili</p></td></tr><tr><td style="vertical-align:bottom;width:16.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:82.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Orgad</p></td></tr><tr><td style="vertical-align:bottom;width:16.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.8pt;">E-mail:</p></td><td style="vertical-align:top;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:82.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nathan.Ajiashvili@lw.com</p></td></tr><tr><td style="vertical-align:bottom;width:16.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:82.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal.Orgad@lw.com</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Latham &amp; Watkins LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">99 Bishopsgate</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">London EC2M 3XF</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">United Kingdom</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:16.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:0.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:82.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:16.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.8pt;">Attention:</p></td><td style="vertical-align:top;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:82.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Joshua Kiernan</p></td></tr><tr><td style="vertical-align:bottom;width:16.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:82.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Michael J. Rosenberg</p></td></tr><tr><td style="vertical-align:bottom;width:16.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:82.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:16.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.8pt;">E-mail:</p></td><td style="vertical-align:top;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:82.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">joshua.kiernan@lw.com</p></td></tr><tr><td style="vertical-align:bottom;width:16.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:82.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Michael.Rosenberg@lw.com</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Meitar | Law Offices</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">16 Abba Hillel Silver Rd.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Ramat Gan 5250608, Israel</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:16.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:0.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:82.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:16.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.8pt;">Attention:</p></td><td style="vertical-align:top;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:82.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shachar Hadar</p></td></tr><tr><td style="vertical-align:bottom;width:16.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 46.8pt;">E-mail:</p></td><td style="vertical-align:top;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:82.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">shacharh@meitar.com</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Any notice, statement or demand authorized by this Agreement to be given or made by the holder of any Warrant or by the Company to or on the Warrant Agent shall be sufficiently given when so delivered if by hand or overnight delivery or if sent by certified mail or private courier service within five (5) days after deposit of such notice, postage prepaid, addressed (until another address is filed in writing by the Warrant Agent with the Company), as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Continental Stock Transfer &amp; Trust Company</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1 State Street, 30th Floor</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">New York, New York 10004</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Attention: Compliance Department</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">10.3 <u style="text-decoration:underline;text-decoration-color:#000000;">Applicable Law</u>. The validity, interpretation, and performance of this Agreement and of the Warrants shall be governed in all respects by the laws of the State of New York, without giving effect to conflicts of law principles that would result in the application of the substantive laws of another jurisdiction. The Company hereby agrees that any action, proceeding or claim against it arising out of or relating in any way to this Agreement shall be brought and enforced in the courts of the State of New York or the United States District Court for the Southern District of New York, and irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive . The Company hereby waives any objection to such exclusive jurisdiction and that such courts represent an inconvenient forum.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">10.4 <u style="text-decoration:underline;text-decoration-color:#000000;">Persons Having Rights under this Agreement</u>. Nothing in this Agreement shall be construed to confer upon, or give to, any person, corporation or other entity other than the parties hereto and the Registered Holders of the Warrants any right, remedy, or claim under or by reason of this Agreement or of any covenant, condition, stipulation, promise, or agreement hereof. All covenants, conditions, stipulations, promises, and agreements contained in this Agreement shall be for the sole and exclusive benefit of the parties hereto, and their successors and assigns and of the Registered Holders of the Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">10.5 <u style="text-decoration:underline;text-decoration-color:#000000;">Examination of the Warrant Agreement</u>. A copy of this Agreement shall be available at all reasonable times at the office of the Warrant Agent in the United States of America, for inspection by the Registered Holder of any Warrant. The Warrant Agent may require any such holder to submit such holder&#8217;s Warrant for inspection by the Warrant Agent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">10.6 <u style="text-decoration:underline;text-decoration-color:#000000;">Counterparts</u>. This Agreement may be executed in any number of original or electronic copy counterparts and each of such counterparts shall for all purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">10.7 <u style="text-decoration:underline;text-decoration-color:#000000;">Effect of Headings</u>. The section headings herein are for convenience only and are not part of this Agreement and shall not affect the interpretation thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.8 <u style="text-decoration:underline;text-decoration-color:#000000;">Amendments</u>. This Agreement may be amended by the parties hereto without the consent of any Registered Holder (i) for the purpose of curing any ambiguity or correcting any mistake, curing, correcting or supplementing any defective provision contained herein or adding or changing any other provisions with respect to matters or questions arising under this Agreement as the parties may deem necessary or desirable and that the parties deem</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">shall not adversely affect the interest of the Registered Holders, and (ii) to provide for the delivery of an Alternative Issuance pursuant to <u style="text-decoration:underline;text-decoration-color:#000000;">Section 5.4</u>. All other modifications or amendments, including any amendment to increase the Warrant Price or shorten the Exercise Period, shall require the vote or written consent of the Registered Holders of a majority of the then outstanding Public Warrants. Any amendment solely to the Private Placement Warrants shall require the vote or written consent of a majority of the holders of the then outstanding Private Placement Warrants. Notwithstanding the foregoing, the Company may lower the Warrant Price or extend the duration of the Exercise Period pursuant to <u style="text-decoration:underline;text-decoration-color:#000000;">Sections 4.1</u> and <u style="text-decoration:underline;text-decoration-color:#000000;">4.2</u>, respectively, without the consent of the Registered Holders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">10.9 <u style="text-decoration:underline;text-decoration-color:#000000;">Severability</u>. This Agreement shall be deemed severable, and the invalidity or unenforceability of any term or provision hereof shall not affect the validity or enforceability of this Agreement or of any other term or provision hereof. Furthermore, in lieu of any such invalid or unenforceable term or provision, the parties hereto intend that there shall be added as a part of this Agreement a provision as similar in terms to such invalid or unenforceable provision as may be possible and be valid and enforceable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[<i style="font-style:italic;">Signature Page Follows</i>]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the date first above written.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:45.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ALPHA TAU MEDICAL LTD.</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">By: </p></td><td style="vertical-align:bottom;width:45.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Uzi Sofer</p></td></tr><tr><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.82%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Uzi Sofer</p></td></tr><tr><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: Chief Executive Officer</p></td></tr><tr><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CONTINENTAL STOCK TRANSFER &amp;<br>TRUST COMPANY</b>, as Warrant Agent</p></td></tr><tr><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:45.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Douglas C. Reed</p></td></tr><tr><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.82%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Douglas C. Reed</p></td></tr><tr><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: Vice President</p></td></tr><tr><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">HEALTHCARE CAPITAL CORP.</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:45.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ William Johns</p></td></tr><tr><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: William Johns</p></td></tr><tr><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: Chief Executive Officer</p></td></tr><tr><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 19pt;"><font style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 19pt;"><font style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="white-space:pre-wrap;"> [</font><i style="font-style:italic;">Signature Page to Warrant Agreement</i>]</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.1
<SEQUENCE>6
<FILENAME>drts-20211231xex8d1.htm
<DESCRIPTION>EXHIBIT 8.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/28/2022 08:46:10 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 8.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SUBSIDIARIES OF ALPHA TAU MEDICAL LTD.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:middle;width:50.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:middle;width:47.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:50.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:47.94%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:50.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Name of Subsidiary</b></p></td><td style="vertical-align:bottom;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:47.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Jurisdiction of Organization</b></p></td></tr><tr><td style="vertical-align:top;width:50.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Alpha Tau Medical, Inc.</p></td><td style="vertical-align:bottom;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:47.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Delaware (USA)</p></td></tr><tr><td style="vertical-align:top;width:50.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Alpha Tau Medical Canada Inc.</p></td><td style="vertical-align:bottom;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:47.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Quebec</p></td></tr><tr><td style="vertical-align:top;width:50.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Alpha Tau Medical KK</p></td><td style="vertical-align:bottom;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:47.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Japan</p></td></tr><tr><td style="vertical-align:top;width:50.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Healthcare Capital Corp</p></td><td style="vertical-align:bottom;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:47.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Delaware (USA)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>7
<FILENAME>drts-20211231xex12d1.htm
<DESCRIPTION>EXHIBIT 12.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/28/2022 08:46:13 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Exhibit 12.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Certification by the Chief Executive Officer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">I,</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Uzi Sofer, certify that:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">I have reviewed this annual report on Form 20-F of Alpha Tau Medical Ltd.;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">The company&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the company and have:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:22.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:22.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">[reserved]</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:22.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Evaluated the effectiveness of the company&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:22.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Disclosed in this report any change in the company&#8217;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&#8217;s internal control over financial reporting; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">The company&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&#8217;s auditors and the audit committee of the company&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:22.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:22.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company&#8217;s internal control over financial reporting.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:22.3pt;text-indent:-22.3pt;margin:0pt 0pt 0pt 18pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March 28, 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><i style="font-style:italic;">/s/ Uzi Sofer</i></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Uzi Sofer</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: Chief Executive Officer (principal<br>executive officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>8
<FILENAME>drts-20211231xex12d2.htm
<DESCRIPTION>EXHIBIT 12.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/28/2022 08:46:17 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Exhibit 12.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Certification by the Chief Financial Officer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">I,</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Raphi Levy, certify that:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">I have reviewed this annual report on Form 20-F of Alpha Tau Medical Ltd.;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">The company&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the company and have:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:22.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:22.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">[reserved]</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:22.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Evaluated the effectiveness of the company&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:22.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Disclosed in this report any change in the company&#8217;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&#8217;s internal control over financial reporting; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">The company&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&#8217;s auditors and the audit committee of the company&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:22.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:22.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company&#8217;s internal control over financial reporting.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:22.3pt;text-indent:-22.3pt;margin:0pt 0pt 0pt 18pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March 28, 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><i style="font-style:italic;">/s/ Raphi Levy</i></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Raphi Levy</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: Chief Financial Officer (principal<br>financial officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>9
<FILENAME>drts-20211231xex13d1.htm
<DESCRIPTION>EXHIBIT 13.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/28/2022 08:46:20 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 18pt 0pt;"><b style="font-weight:bold;">Exhibit 13.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Certification by the Chief Executive Officer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In connection with the annual report of Alpha Tau Medical Ltd. (the &#8220;Company&#8221;) on Form&#160;20-F&#160;for the year ended December&#160;31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Uzi Sofer, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:18pt;white-space:nowrap;">(1)</font>The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:18pt;white-space:nowrap;">(2)</font>The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Date: March 28, 2022</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:5.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:44.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><i style="font-style:italic;">/s/ Uzi Sofer</i></p></td><td style="vertical-align:top;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:44.46%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Uzi Sofer</p></td><td style="vertical-align:top;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:44.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer (principal </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">executive officer)</p></td><td style="vertical-align:top;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>10
<FILENAME>drts-20211231xex13d2.htm
<DESCRIPTION>EXHIBIT 13.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/28/2022 08:46:24 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 18pt 0pt;"><b style="font-weight:bold;">Exhibit 13.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Certification by the Chief Financial Officer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In connection with the annual report of Alpha Tau Medical Ltd. (the &#8220;Company&#8221;) on Form&#160;20-F&#160;for the year ended December&#160;31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Raphi Levy, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">(1)</font></font>The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">(2)</font></font>The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Date: March 28, 2022</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:44.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><i style="font-style:italic;">/s/ Raphi Levy</i></p></td><td style="vertical-align:top;width:50.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:44.44%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raphi Levy</p></td><td style="vertical-align:top;width:50.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:44.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer (principal<br>financial officer)</p></td><td style="vertical-align:top;width:50.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>drts-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/28/2022 8:47:09 PM-->
<!--Modified on: 3/28/2022 8:47:09 PM-->
<xsd:schema targetNamespace="http://www.alphatau.com/20211231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2021-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:attributeFormDefault="unqualified" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:drts="http://www.alphatau.com/20211231">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.alphatau.com/role/StatementConsolidatedBalanceSheetss" id="StatementConsolidatedBalanceSheetss">
        <link:definition>00100 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureConsolidatedStatementsOfOperations" id="DisclosureConsolidatedStatementsOfOperations">
        <link:definition>00200 - Disclosure - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesRestrictedCashDetailss" id="DisclosureSignificantAccountingPoliciesRestrictedCashDetailss">
        <link:definition>40201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Restricted cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosurePrepaidExpensesAndOtherReceivablesDetails" id="DisclosurePrepaidExpensesAndOtherReceivablesDetails">
        <link:definition>40301 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" id="DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
        <link:definition>40401 - Disclosure - PROPERTY AND EQUIPMENT, NET - Schedule of property and equipment, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureOtherPayablesAndAccruedExpensesDetails" id="DisclosureOtherPayablesAndAccruedExpensesDetails">
        <link:definition>40501 - Disclosure - OTHER PAYABLES AND ACCRUED EXPENSES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesDetails" id="DisclosureCommitmentsAndContingentLiabilitiesDetails">
        <link:definition>40601 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureFinancialExpensesNetDetails" id="DisclosureFinancialExpensesNetDetails">
        <link:definition>41101 - Disclosure - FINANCIAL EXPENSES, NET (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/StatementConsolidatedStatementsOfConvertiblePreferredSharesAndShareholdersDeficiency" id="StatementConsolidatedStatementsOfConvertiblePreferredSharesAndShareholdersDeficiency">
        <link:definition>00300 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS' DEFICIENCY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureGeneralDetails" id="DisclosureGeneralDetails">
        <link:definition>40101 - Disclosure - GENERAL (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesShortTermDepositsDetails" id="DisclosureSignificantAccountingPoliciesShortTermDepositsDetails">
        <link:definition>40202 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Short-term deposits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentAndImpairmentDetails" id="DisclosureSignificantAccountingPoliciesPropertyAndEquipmentAndImpairmentDetails">
        <link:definition>40203 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Property and equipment and impairment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesShareBasedPaymentsDetails" id="DisclosureSignificantAccountingPoliciesShareBasedPaymentsDetails">
        <link:definition>40204 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Share-based payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesDeferredTransactionCostsDetails" id="DisclosureSignificantAccountingPoliciesDeferredTransactionCostsDetails">
        <link:definition>40208 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Deferred Transaction costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesAdditionalDetails" id="DisclosureCommitmentsAndContingentLiabilitiesAdditionalDetails">
        <link:definition>40602 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES - Additional (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureFairValueMeasurementsValuationAssumptionsDetails" id="DisclosureFairValueMeasurementsValuationAssumptionsDetails">
        <link:definition>40701 - Disclosure - FAIR VALUE MEASUREMENTS - Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureFairValueMeasurementsChangesInFairValueDetails" id="DisclosureFairValueMeasurementsChangesInFairValueDetails">
        <link:definition>40702 - Disclosure - FAIR VALUE MEASUREMENTS - Changes in fair value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureIncomeTaxesTaxRatesDetails" id="DisclosureIncomeTaxesTaxRatesDetails">
        <link:definition>40801 - Disclosure - INCOME TAXES - Tax rates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsCompositionOfConvertiblePreferredSharesDetails" id="DisclosureConvertiblePreferredSharesAndWarrantsCompositionOfConvertiblePreferredSharesDetails">
        <link:definition>40901 - Disclosure - CONVERTIBLE PREFERRED SHARES AND WARRANTS - Composition of Convertible Preferred shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsPreferredSharesRightsDetails" id="DisclosureConvertiblePreferredSharesAndWarrantsPreferredSharesRightsDetails">
        <link:definition>40902 - Disclosure - CONVERTIBLE PREFERRED SHARES AND WARRANTS - Preferred shares rights (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsFinancingRoundsDetails" id="DisclosureConvertiblePreferredSharesAndWarrantsFinancingRoundsDetails">
        <link:definition>40903 - Disclosure - CONVERTIBLE PREFERRED SHARES AND WARRANTS - Financing rounds (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsPreferredSharesWarrantsDetails" id="DisclosureConvertiblePreferredSharesAndWarrantsPreferredSharesWarrantsDetails">
        <link:definition>40904 - Disclosure - CONVERTIBLE PREFERRED SHARES AND WARRANTS - Preferred A shares warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOrdinaryShareCapitalDetails" id="DisclosureShareholdersDeficiencyOrdinaryShareCapitalDetails">
        <link:definition>41001 - Disclosure - SHAREHOLDERS' DEFICIENCY - Ordinary share capital (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureShareholdersDeficiencyShareOptionPlanDetails" id="DisclosureShareholdersDeficiencyShareOptionPlanDetails">
        <link:definition>41002 - Disclosure - SHAREHOLDERS' DEFICIENCY - Share option plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOptionsChangesDetails" id="DisclosureShareholdersDeficiencyOptionsChangesDetails">
        <link:definition>41003 - Disclosure - SHAREHOLDERS' DEFICIENCY - Options changes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureShareholdersDeficiencyRsusDetails" id="DisclosureShareholdersDeficiencyRsusDetails">
        <link:definition>41004 - Disclosure - SHAREHOLDERS' DEFICIENCY - RSUs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureShareholdersDeficiencyEquityBasedCompensationExpenseDetails" id="DisclosureShareholdersDeficiencyEquityBasedCompensationExpenseDetails">
        <link:definition>41005 - Disclosure - SHAREHOLDERS' DEFICIENCY - Equity-based compensation expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureShareholdersDeficiencyWarrantsDetails" id="DisclosureShareholdersDeficiencyWarrantsDetails">
        <link:definition>41006 - Disclosure - SHAREHOLDERS' DEFICIENCY - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureBasicAndDilutedNetLossPerShareDetails" id="DisclosureBasicAndDilutedNetLossPerShareDetails">
        <link:definition>41201 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureGeographicInformationDetails" id="DisclosureGeographicInformationDetails">
        <link:definition>41301 - Disclosure - GEOGRAPHIC INFORMATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>41401 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/StatementConsolidatedStatementOfOperations" id="StatementConsolidatedStatementOfOperations">
        <link:definition>00200 - Statement - CONSOLIDATED STATEMENT OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/StatementConsolidatedStatementsOfOperationsParenthetical" id="StatementConsolidatedStatementsOfOperationsParenthetical">
        <link:definition>00205 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/StatementConsolidatedStatementsOfConvertiblePreferredSharesAndShareholdersDeficiencyParenthetical" id="StatementConsolidatedStatementsOfConvertiblePreferredSharesAndShareholdersDeficiencyParenthetical">
        <link:definition>00305 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS' DEFICIENCY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureGeneral" id="DisclosureGeneral">
        <link:definition>10101 - Disclosure - GENERAL</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureSignificantAccountingPolicies" id="DisclosureSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosurePrepaidExpensesAndOtherReceivables" id="DisclosurePrepaidExpensesAndOtherReceivables">
        <link:definition>10301 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosurePropertyAndEquipmentNet" id="DisclosurePropertyAndEquipmentNet">
        <link:definition>10401 - Disclosure - PROPERTY AND EQUIPMENT, NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureOtherPayablesAndAccruedExpenses" id="DisclosureOtherPayablesAndAccruedExpenses">
        <link:definition>10501 - Disclosure - OTHER PAYABLES AND ACCRUED EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilities" id="DisclosureCommitmentsAndContingentLiabilities">
        <link:definition>10601 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>10701 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>10801 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrants" id="DisclosureConvertiblePreferredSharesAndWarrants">
        <link:definition>10901 - Disclosure - CONVERTIBLE PREFERRED SHARES AND WARRANTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureShareholdersDeficiency" id="DisclosureShareholdersDeficiency">
        <link:definition>11001 - Disclosure - SHAREHOLDERS' DEFICIENCY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureFinancialExpensesNet" id="DisclosureFinancialExpensesNet">
        <link:definition>11101 - Disclosure - FINANCIAL EXPENSES, NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureBasicAndDilutedNetLossPerShare" id="DisclosureBasicAndDilutedNetLossPerShare">
        <link:definition>11201 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureGeographicInformation" id="DisclosureGeographicInformation">
        <link:definition>11301 - Disclosure - GEOGRAPHIC INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>11401 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesPolicies" id="DisclosureSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesTables" id="DisclosureSignificantAccountingPoliciesTables">
        <link:definition>30203 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosurePrepaidExpensesAndOtherReceivablesTables" id="DisclosurePrepaidExpensesAndOtherReceivablesTables">
        <link:definition>30303 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosurePropertyAndEquipmentNetTables" id="DisclosurePropertyAndEquipmentNetTables">
        <link:definition>30403 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureOtherPayablesAndAccruedExpensesTables" id="DisclosureOtherPayablesAndAccruedExpensesTables">
        <link:definition>30503 - Disclosure - OTHER PAYABLES AND ACCRUED EXPENSES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesTables" id="DisclosureCommitmentsAndContingentLiabilitiesTables">
        <link:definition>30603 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>30703 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>30803 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsTables" id="DisclosureConvertiblePreferredSharesAndWarrantsTables">
        <link:definition>30903 - Disclosure - CONVERTIBLE PREFERRED SHARES AND WARRANTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureShareholdersDeficiencyTables" id="DisclosureShareholdersDeficiencyTables">
        <link:definition>31003 - Disclosure - SHAREHOLDERS' DEFICIENCY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureFinancialExpensesNetTables" id="DisclosureFinancialExpensesNetTables">
        <link:definition>31103 - Disclosure - FINANCIAL EXPENSES, NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureBasicAndDilutedNetLossPerShareTables" id="DisclosureBasicAndDilutedNetLossPerShareTables">
        <link:definition>31203 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureGeographicInformationTables" id="DisclosureGeographicInformationTables">
        <link:definition>31303 - Disclosure - GEOGRAPHIC INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesRestrictedCashDetails" id="DisclosureSignificantAccountingPoliciesRestrictedCashDetails">
        <link:definition>40201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Restricted cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesGrantsAndParticipationsOrdinaryShareWarrantsClassificationAndMeasurementDetails" id="DisclosureSignificantAccountingPoliciesGrantsAndParticipationsOrdinaryShareWarrantsClassificationAndMeasurementDetails">
        <link:definition>40205 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Grants and participations &amp; Ordinary share warrants classification and measurement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesSeverancePayDetails" id="DisclosureSignificantAccountingPoliciesSeverancePayDetails">
        <link:definition>40206 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Severance pay (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesContingentLiabilitiesDetails" id="DisclosureSignificantAccountingPoliciesContingentLiabilitiesDetails">
        <link:definition>40207 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Contingent liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureIncomeTaxesNetLossIncomeBeforeTaxDetails" id="DisclosureIncomeTaxesNetLossIncomeBeforeTaxDetails">
        <link:definition>40802 - Disclosure - INCOME TAXES - Net loss (income) before tax (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails" id="DisclosureIncomeTaxesIncomeTaxExpenseDetails">
        <link:definition>40803 - Disclosure - INCOME TAXES - Income tax expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureIncomeTaxesNetOperatingLossesCarryDetails" id="DisclosureIncomeTaxesNetOperatingLossesCarryDetails">
        <link:definition>40804 - Disclosure - INCOME TAXES - Net operating losses carry (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureIncomeTaxesDeferredTaxesDetails" id="DisclosureIncomeTaxesDeferredTaxesDetails">
        <link:definition>40805 - Disclosure - INCOME TAXES - Deferred taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="drts-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="drts-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="drts-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="drts-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://www.alphatau.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xsd:element name="NumberOfScenariosInAllocatingValueToWarrants" id="drts_NumberOfScenariosInAllocatingValueToWarrants" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="TemporaryEquityTextBlock" id="drts_TemporaryEquityTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="SeriesConvertiblePreferredSharesMember" id="drts_SeriesConvertiblePreferredSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SeriesBConvertiblePreferredSharesMember" id="drts_SeriesBConvertiblePreferredSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TemporaryEquityDistributionRateFromProceedsOfSaleAnotherClassOfShares" id="drts_TemporaryEquityDistributionRateFromProceedsOfSaleAnotherClassOfShares" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="TemporaryEquityNumberOfVotes" id="drts_TemporaryEquityNumberOfVotes" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="SaleOfStockNumberOfWarrantsIssuedInTransaction" id="drts_SaleOfStockNumberOfWarrantsIssuedInTransaction" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="WarrantsGrantedIncreaseFromNewFinancing" id="drts_WarrantsGrantedIncreaseFromNewFinancing" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="IncomeTaxDisclosureLineItems" id="drts_IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AtmIncMember" id="drts_AtmIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AtmKkMember" id="drts_AtmKkMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IncomeTaxRateReconciliationPreferredCompanyPercent" id="drts_IncomeTaxRateReconciliationPreferredCompanyPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="IncomeTaxRateReconciliationLargeCompaniesPercent" id="drts_IncomeTaxRateReconciliationLargeCompaniesPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="IncomeTaxRateReconciliationSmallCompaniesPercent" id="drts_IncomeTaxRateReconciliationSmallCompaniesPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="IncomeTaxRateReconciliationSmallCompaniesSpecialRatePercent" id="drts_IncomeTaxRateReconciliationSmallCompaniesSpecialRatePercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="IncomeTaxRateReconciliationMediumCompaniesSpecialRatePercent" id="drts_IncomeTaxRateReconciliationMediumCompaniesSpecialRatePercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="IncomeTaxDisclosureTable" id="drts_IncomeTaxDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ScheduleOfShareBasedCompensationCostsByIncomeStatementLocationTableTextBlock" id="drts_ScheduleOfShareBasedCompensationCostsByIncomeStatementLocationTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="SharesNumberOfVotes" id="drts_SharesNumberOfVotes" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ShareOptionPlanMember" id="drts_ShareOptionPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WarrantsExercisedCashBasis" id="drts_WarrantsExercisedCashBasis" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="WarrantsExercisedCashlessBasis" id="drts_WarrantsExercisedCashlessBasis" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="WarrantsToOrdinaryShareRatioCashlessExercise" id="drts_WarrantsToOrdinaryShareRatioCashlessExercise" type="xbrli:pureItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="NumberOfWarrantsExercised" id="drts_NumberOfWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="HekabioK.k.Member" id="drts_HekabioK.k.Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FinancialExpensesAbstract" id="drts_FinancialExpensesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="GeographicInformationAbstract" id="drts_GeographicInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NonOperatingFinancialExpensesAbstract" id="drts_NonOperatingFinancialExpensesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FinancialExpensesTotal" id="drts_FinancialExpensesTotal" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="NonOperatingFinancialIncomeAbstract" id="drts_NonOperatingFinancialIncomeAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FinancialIncomeTotal" id="drts_FinancialIncomeTotal" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="WarrantsToPreferredSharesMember" id="drts_WarrantsToPreferredSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NumeratorAbstract" id="drts_NumeratorAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DenominatorAbstract" id="drts_DenominatorAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="BankLeumiLeIsraelBmMember" id="drts_BankLeumiLeIsraelBmMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="HcccMember" id="drts_HcccMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PrepaidExpensesAndOtherReceivablesTextBlock" id="drts_PrepaidExpensesAndOtherReceivablesTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="OtherPayablesAndAccruedExpensesAbstract" id="drts_OtherPayablesAndAccruedExpensesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OtherPayablesAndAccruedExpensesDisclosureTextBlock" id="drts_OtherPayablesAndAccruedExpensesDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ScheduleOfOtherPayablesAndAccruedExpensesTableTextBlock" id="drts_ScheduleOfOtherPayablesAndAccruedExpensesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="GovernmentAuthoritiesReceivable" id="drts_GovernmentAuthoritiesReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="LaboratoryEquipmentMember" id="drts_LaboratoryEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ScheduleOfCommitmentsAndContingenciesTable" id="drts_ScheduleOfCommitmentsAndContingenciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CommitmentsAndContingenciesLineItems" id="drts_CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IsraeliInnovationAuthorityMember" id="drts_IsraeliInnovationAuthorityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AltheraMember" id="drts_AltheraMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RamotMember" id="drts_RamotMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="HekaBioKKMember" id="drts_HekaBioKKMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="BgnTechnologiesMember" id="drts_BgnTechnologiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CambridgeUniversityHospitalsNhsTrustMember" id="drts_CambridgeUniversityHospitalsNhsTrustMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MethodOfPaymentRoyaltiesAxis" id="drts_MethodOfPaymentRoyaltiesAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="BasisOfPaymentRoyaltiesDomain" id="drts_BasisOfPaymentRoyaltiesDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FutureSalesOfDevelopedProductMember" id="drts_FutureSalesOfDevelopedProductMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FutureGrossRevenuesDerivedFromPurchasedIntellectualPropertyMember" id="drts_FutureGrossRevenuesDerivedFromPurchasedIntellectualPropertyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NetSalesOfAllCompanySProductMember" id="drts_NetSalesOfAllCompanySProductMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NetSalesOfAllCompanySProductSoldByCompanySLicensesMember" id="drts_NetSalesOfAllCompanySProductSoldByCompanySLicensesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ReimbursementPriceMember" id="drts_ReimbursementPriceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DistributionReceiptsMember" id="drts_DistributionReceiptsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SalesOfAlphaRadiationProductsMember" id="drts_SalesOfAlphaRadiationProductsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SalesOfProductContainingIntellectualPropertyMember" id="drts_SalesOfProductContainingIntellectualPropertyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LicenseRevenueToJointlyDevelopedIntellectualPropertyMember" id="drts_LicenseRevenueToJointlyDevelopedIntellectualPropertyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LicenseRevenueRelatedToIntellectualPropertyMember" id="drts_LicenseRevenueRelatedToIntellectualPropertyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RevenueGeneratedFromPatentMember" id="drts_RevenueGeneratedFromPatentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NetSalesSquamousCellCarcinomaMember" id="drts_NetSalesSquamousCellCarcinomaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="GrantIncome" id="drts_GrantIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="RoyaltyRate" id="drts_RoyaltyRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="RoyaltyPaymentAsPercentageOfGrants" id="drts_RoyaltyPaymentAsPercentageOfGrants" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PotentialPayment" id="drts_PotentialPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="MilestoneNumberOfOrdinaryStockOptions" id="drts_MilestoneNumberOfOrdinaryStockOptions" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="StockOptionExercisePrice" id="drts_StockOptionExercisePrice" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="Warrantliability" id="drts_Warrantliability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CommonStockCancelledAndConvertedInToShares" id="drts_CommonStockCancelledAndConvertedInToShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CashCashEquivalentsShortTermDepositsAndRestrictedCash" id="drts_CashCashEquivalentsShortTermDepositsAndRestrictedCash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CurrentResourcesCoverageOfLiquidityRequirements" id="drts_CurrentResourcesCoverageOfLiquidityRequirements" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PropertyPlantAndEquipmentUsefulLivesTableTextBlock" id="drts_PropertyPlantAndEquipmentUsefulLivesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ShortTernBankDepositInterestRate" id="drts_ShortTernBankDepositInterestRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="SeverancePayDepositRate" id="drts_SeverancePayDepositRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="SeverancePayExpense" id="drts_SeverancePayExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ShortTermDepositsPolicyTextBlock" id="drts_ShortTermDepositsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="GrantsAndParticipationsPolicyTextBlock" id="drts_GrantsAndParticipationsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock" id="drts_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock" id="drts_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="SeverancePayPolicyTextBlock" id="drts_SeverancePayPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DeferredTransactionCostsPolicyTextBlock" id="drts_DeferredTransactionCostsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="NonControllingInterestPolicyTextBlock" id="drts_NonControllingInterestPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="StockIssuedDuringPeriodValueExerciseOfWarrants" id="drts_StockIssuedDuringPeriodValueExerciseOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="StockIssuedDuringPeriodSharesExerciseOfWarrants" id="drts_StockIssuedDuringPeriodSharesExerciseOfWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" id="drts_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="LongTermAssetsAbstract" id="drts_LongTermAssetsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LongTermLiabilitiesAbstract" id="drts_LongTermLiabilitiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="StockIssuedDuringPeriodValueOrdinarySharesUponExerciseOfShareOptions" id="drts_StockIssuedDuringPeriodValueOrdinarySharesUponExerciseOfShareOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="StockIssuedDuringPeriodSharesOrdinarySharesUponExerciseOfShareOptions" id="drts_StockIssuedDuringPeriodSharesOrdinarySharesUponExerciseOfShareOptions" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AdjustmentsToAdditionalPaidInCapitalWarrantSharesIssued" id="drts_AdjustmentsToAdditionalPaidInCapitalWarrantSharesIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DisposalGroupIncludingDiscontinuedOperationOwnershipDisposed" id="drts_DisposalGroupIncludingDiscontinuedOperationOwnershipDisposed" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="IncreaseDecreaseInFairValueOfWarrantsConvertiblePreferredShares" id="drts_IncreaseDecreaseInFairValueOfWarrantsConvertiblePreferredShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="IncreaseDecreaseInNonCashFinancialIncomeExpenses" id="drts_IncreaseDecreaseInNonCashFinancialIncomeExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>drts-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/28/2022 8:47:09 PM-->
<!--Modified on: 3/28/2022 8:47:09 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#StatementConsolidatedBalanceSheetss" roleURI="http://www.alphatau.com/role/StatementConsolidatedBalanceSheetss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureConsolidatedStatementsOfOperations" roleURI="http://www.alphatau.com/role/DisclosureConsolidatedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureSignificantAccountingPoliciesRestrictedCashDetailss" roleURI="http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesRestrictedCashDetailss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosurePrepaidExpensesAndOtherReceivablesDetails" roleURI="http://www.alphatau.com/role/DisclosurePrepaidExpensesAndOtherReceivablesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" roleURI="http://www.alphatau.com/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureOtherPayablesAndAccruedExpensesDetails" roleURI="http://www.alphatau.com/role/DisclosureOtherPayablesAndAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureCommitmentsAndContingentLiabilitiesDetails" roleURI="http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureFinancialExpensesNetDetails" roleURI="http://www.alphatau.com/role/DisclosureFinancialExpensesNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <calculationLink xlink:role="http://www.alphatau.com/role/StatementConsolidatedBalanceSheetss" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637840972285018414" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_637840972285018414" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637840972285018414" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637840972285018414" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637840972285018414" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_637840972285018414" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637840972285018414" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_637840972285018414" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedInvestmentsCurrent" xlink:label="us-gaap_RestrictedInvestmentsCurrent_637840972285018414" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637840972285018414" xlink:to="us-gaap_RestrictedInvestmentsCurrent_637840972285018414" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637840972285018414" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637840972285018414" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637840972285018414" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent_637840972285018414" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent_637840972285018414" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637840972285028130" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_637840972285018414" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637840972285028130" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent_637840972285028130" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent_637840972285018414" xlink:to="us-gaap_PrepaidExpenseNoncurrent_637840972285028130" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637840972285028130" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_637840972285028130" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637840972285028130" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637840972285028130" xlink:to="us-gaap_LiabilitiesCurrent_637840972285028130" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_637840972285028130" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637840972285028130" xlink:to="us-gaap_OtherLiabilitiesCurrent_637840972285028130" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637840972285028130" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637840972285028130" xlink:to="us-gaap_AccountsPayableCurrent_637840972285028130" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_Warrantliability" xlink:label="drts_Warrantliability_637840972285028130" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637840972285028130" xlink:to="drts_Warrantliability_637840972285028130" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_637840972285038135" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies_637840972285038135" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637840972285038135" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637840972285038135" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637840972285038135" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_637840972285038135" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValueOutstanding" xlink:label="us-gaap_CommonStockValueOutstanding_637840972285038135" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637840972285038135" xlink:to="us-gaap_CommonStockValueOutstanding_637840972285038135" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637840972285038135" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637840972285038135" xlink:to="us-gaap_AdditionalPaidInCapital_637840972285038135" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637840972285038135" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637840972285038135" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637840972285038135" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.alphatau.com/role/DisclosureConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Disclosure - CONSOLIDATED STATEMENTS OF OPERATIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_637840972285048115" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_637840972285048115" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_637840972285048115" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_637840972285048115" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637840972285048115" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_637840972285048115" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637840972285048115" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637840972285048115" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637840972285048115" xlink:to="us-gaap_OperatingIncomeLoss_637840972285048115" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketingExpense" xlink:label="us-gaap_MarketingExpense_637840972285048115" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637840972285048115" xlink:to="us-gaap_MarketingExpense_637840972285048115" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637840972285048115" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637840972285048115" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637840972285048115" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637840972285048115" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637840972285048115" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637840972285048115" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingGainsLosses" xlink:label="us-gaap_NonoperatingGainsLosses_637840972285048115" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637840972285048115" xlink:to="us-gaap_NonoperatingGainsLosses_637840972285048115" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637840972285058578" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_637840972285048115" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637840972285058578" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637840972285058578" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637840972285058578" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637840972285058578" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637840972285058578" xlink:to="us-gaap_ProfitLoss_637840972285058578" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637840972285058578" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637840972285058578" xlink:to="us-gaap_Depreciation_637840972285058578" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637840972285058578" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637840972285058578" xlink:to="us-gaap_ShareBasedCompensation_637840972285058578" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637840972285058578" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637840972285058578" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637840972285058578" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_637840972285058578" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637840972285058578" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_637840972285058578" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_IncreaseDecreaseInNonCashFinancialIncomeExpenses" xlink:label="drts_IncreaseDecreaseInNonCashFinancialIncomeExpenses_637840972285068676" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637840972285058578" xlink:to="drts_IncreaseDecreaseInNonCashFinancialIncomeExpenses_637840972285068676" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_IncreaseDecreaseInFairValueOfWarrantsConvertiblePreferredShares" xlink:label="drts_IncreaseDecreaseInFairValueOfWarrantsConvertiblePreferredShares_637840972285068676" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637840972285058578" xlink:to="drts_IncreaseDecreaseInFairValueOfWarrantsConvertiblePreferredShares_637840972285068676" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_637840972285068676" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637840972285058578" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_637840972285068676" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_637840972285068676" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637840972285058578" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_637840972285068676" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637840972285068676" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637840972285068676" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseOfRestrictedInvestments" xlink:label="us-gaap_IncreaseDecreaseOfRestrictedInvestments_637840972285068676" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637840972285068676" xlink:to="us-gaap_IncreaseDecreaseOfRestrictedInvestments_637840972285068676" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:label="us-gaap_ProceedsFromSaleOfRestrictedInvestments_637840972285068676" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637840972285068676" xlink:to="us-gaap_ProceedsFromSaleOfRestrictedInvestments_637840972285068676" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637840972285078506" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637840972285068676" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637840972285078506" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637840972285078506" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637840972285078506" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_637840972285078506" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637840972285078506" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_637840972285078506" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_637840972285078506" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637840972285078506" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_637840972285078506" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_637840972285078506" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637840972285078506" xlink:to="us-gaap_ProceedsFromWarrantExercises_637840972285078506" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637840972285078506" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637840972285078506" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637840972285078506" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:label="us-gaap_ProceedsFromPaymentsToMinorityShareholders_637840972285078506" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637840972285078506" xlink:to="us-gaap_ProceedsFromPaymentsToMinorityShareholders_637840972285078506" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637840972285088485" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637840972285088485" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesRestrictedCashDetailss" xlink:type="extended" xlink:title="40201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Restricted cash (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637840972285088485" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637840972285088485" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_637840972285088485" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_637840972285088485" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.alphatau.com/role/DisclosurePrepaidExpensesAndOtherReceivablesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_GovernmentAuthoritiesReceivable" xlink:label="drts_GovernmentAuthoritiesReceivable_637840972285088485" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="drts_GovernmentAuthoritiesReceivable_637840972285088485" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent_637840972285088485" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent_637840972285088485" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables_637840972285088485" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_OtherReceivables_637840972285088485" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.alphatau.com/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40401 - Disclosure - PROPERTY AND EQUIPMENT, NET - Schedule of property and equipment, net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_637840972285098495" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_637840972285098495" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637840972285098495" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637840972285098495" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.alphatau.com/role/DisclosureOtherPayablesAndAccruedExpensesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - OTHER PAYABLES AND ACCRUED EXPENSES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent_637840972285098495" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedSalariesCurrent_637840972285098495" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637840972285098495" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637840972285098495" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent_637840972285098495" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent_637840972285098495" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesDetails" xlink:type="extended" xlink:title="40601 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637840972285108499" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637840972285108499" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637840972285108499" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637840972285108499" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637840972285108499" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637840972285108499" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637840972285108499" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637840972285108499" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_637840972285108499" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_637840972285108499" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_637840972285108499" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_637840972285108499" order="6" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.alphatau.com/role/DisclosureFinancialExpensesNetDetails" xlink:type="extended" xlink:title="41101 - Disclosure - FINANCIAL EXPENSES, NET (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingGainsLosses" xlink:label="us-gaap_NonoperatingGainsLosses" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_FinancialIncomeTotal" xlink:label="drts_FinancialIncomeTotal_637840972285108499" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingGainsLosses" xlink:to="drts_FinancialIncomeTotal_637840972285108499" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_637840972285108499" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="drts_FinancialIncomeTotal_637840972285108499" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_637840972285108499" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions_637840972285118508" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="drts_FinancialIncomeTotal_637840972285108499" xlink:to="us-gaap_InterestIncomeDepositsWithFinancialInstitutions_637840972285118508" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_637840972285118508" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="drts_FinancialIncomeTotal_637840972285108499" xlink:to="us-gaap_OtherNonoperatingIncome_637840972285118508" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_FinancialExpensesTotal" xlink:label="drts_FinancialExpensesTotal_637840972285118508" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingGainsLosses" xlink:to="drts_FinancialExpensesTotal_637840972285118508" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionLossBeforeTax_637840972285118508" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="drts_FinancialExpensesTotal_637840972285118508" xlink:to="us-gaap_ForeignCurrencyTransactionLossBeforeTax_637840972285118508" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_637840972285118508" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="drts_FinancialExpensesTotal_637840972285118508" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_637840972285118508" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_637840972285118508" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="drts_FinancialExpensesTotal_637840972285118508" xlink:to="us-gaap_OtherNonoperatingExpense_637840972285118508" order="3" use="optional" weight="1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>drts-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/28/2022 8:47:09 PM-->
<!--Modified on: 3/28/2022 8:47:09 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.alphatau.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredSharesAndShareholdersDeficiency" roleURI="http://www.alphatau.com/role/StatementConsolidatedStatementsOfConvertiblePreferredSharesAndShareholdersDeficiency" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureGeneralDetails" roleURI="http://www.alphatau.com/role/DisclosureGeneralDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureSignificantAccountingPoliciesShortTermDepositsDetails" roleURI="http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesShortTermDepositsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureSignificantAccountingPoliciesPropertyAndEquipmentAndImpairmentDetails" roleURI="http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentAndImpairmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureSignificantAccountingPoliciesShareBasedPaymentsDetails" roleURI="http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesShareBasedPaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureSignificantAccountingPoliciesDeferredTransactionCostsDetails" roleURI="http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesDeferredTransactionCostsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureCommitmentsAndContingentLiabilitiesAdditionalDetails" roleURI="http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesAdditionalDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureFairValueMeasurementsValuationAssumptionsDetails" roleURI="http://www.alphatau.com/role/DisclosureFairValueMeasurementsValuationAssumptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureFairValueMeasurementsChangesInFairValueDetails" roleURI="http://www.alphatau.com/role/DisclosureFairValueMeasurementsChangesInFairValueDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureIncomeTaxesTaxRatesDetails" roleURI="http://www.alphatau.com/role/DisclosureIncomeTaxesTaxRatesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureConvertiblePreferredSharesAndWarrantsCompositionOfConvertiblePreferredSharesDetails" roleURI="http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsCompositionOfConvertiblePreferredSharesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureConvertiblePreferredSharesAndWarrantsPreferredSharesRightsDetails" roleURI="http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsPreferredSharesRightsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureConvertiblePreferredSharesAndWarrantsFinancingRoundsDetails" roleURI="http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsFinancingRoundsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureConvertiblePreferredSharesAndWarrantsPreferredSharesWarrantsDetails" roleURI="http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsPreferredSharesWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureShareholdersDeficiencyOrdinaryShareCapitalDetails" roleURI="http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOrdinaryShareCapitalDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureShareholdersDeficiencyShareOptionPlanDetails" roleURI="http://www.alphatau.com/role/DisclosureShareholdersDeficiencyShareOptionPlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureShareholdersDeficiencyOptionsChangesDetails" roleURI="http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOptionsChangesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureShareholdersDeficiencyEquityBasedCompensationExpenseDetails" roleURI="http://www.alphatau.com/role/DisclosureShareholdersDeficiencyEquityBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureShareholdersDeficiencyWarrantsDetails" roleURI="http://www.alphatau.com/role/DisclosureShareholdersDeficiencyWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureBasicAndDilutedNetLossPerShareDetails" roleURI="http://www.alphatau.com/role/DisclosureBasicAndDilutedNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureGeographicInformationDetails" roleURI="http://www.alphatau.com/role/DisclosureGeographicInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.alphatau.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.alphatau.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="drts-20211231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:definitionLink xlink:role="http://www.alphatau.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1" xlink:title="us-gaap_MeasurementInputTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1" xlink:title="us-gaap_MeasurementInputTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_MeasurementInputTypeAxis_1" xlink:to="us-gaap_MeasurementInputTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_MeasurementInputTypeAxis_1 To us-gaap_MeasurementInputTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis_1" xlink:title="us-gaap_FairValueByLiabilityClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" xlink:title="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByLiabilityClassAxis_1" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByLiabilityClassAxis_1 To us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1" xlink:title="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain_1" xlink:title="srt_EquityMethodInvesteeNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1" xlink:to="srt_EquityMethodInvesteeNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1 To srt_EquityMethodInvesteeNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_1" xlink:title="srt_StatementGeographicalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_1" xlink:title="srt_SegmentGeographicalDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementGeographicalAxis_1" xlink:to="srt_SegmentGeographicalDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementGeographicalAxis_1 To srt_SegmentGeographicalDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_1" xlink:title="us-gaap_GranteeStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_1" xlink:title="us-gaap_GranteeStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GranteeStatusAxis_1" xlink:to="us-gaap_GranteeStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GranteeStatusAxis_1 To us-gaap_GranteeStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_1" xlink:title="us-gaap_BusinessAcquisitionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_1" xlink:title="us-gaap_BusinessAcquisitionAcquireeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BusinessAcquisitionAxis_1" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BusinessAcquisitionAxis_1 To us-gaap_BusinessAcquisitionAcquireeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GuaranteeObligationsByNatureAxis" xlink:label="us-gaap_GuaranteeObligationsByNatureAxis_1" xlink:title="us-gaap_GuaranteeObligationsByNatureAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="us-gaap_GuaranteeObligationsNatureDomain_1" xlink:title="us-gaap_GuaranteeObligationsNatureDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GuaranteeObligationsByNatureAxis_1" xlink:to="us-gaap_GuaranteeObligationsNatureDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GuaranteeObligationsByNatureAxis_1 To us-gaap_GuaranteeObligationsNatureDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_MethodOfPaymentRoyaltiesAxis" xlink:label="drts_MethodOfPaymentRoyaltiesAxis_1" xlink:title="drts_MethodOfPaymentRoyaltiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_BasisOfPaymentRoyaltiesDomain" xlink:label="drts_BasisOfPaymentRoyaltiesDomain_1" xlink:title="drts_BasisOfPaymentRoyaltiesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="drts_MethodOfPaymentRoyaltiesAxis_1" xlink:to="drts_BasisOfPaymentRoyaltiesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:drts_MethodOfPaymentRoyaltiesAxis_1 To drts_BasisOfPaymentRoyaltiesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_1" xlink:title="us-gaap_BalanceSheetLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_1" xlink:title="us-gaap_BalanceSheetLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BalanceSheetLocationAxis_1" xlink:to="us-gaap_BalanceSheetLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BalanceSheetLocationAxis_1 To us-gaap_BalanceSheetLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis_1" xlink:title="dei_EntityAddressesAddressTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain_1" xlink:title="dei_AddressTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_EntityAddressesAddressTypeAxis_1" xlink:to="dei_AddressTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_EntityAddressesAddressTypeAxis_1 To dei_AddressTypeDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.alphatau.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="dei_EntityAddressesAddressTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_BusinessContactMember" xlink:label="dei_BusinessContactMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_AddressTypeDomain" xlink:to="dei_BusinessContactMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentType" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentRegistrationStatement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentAnnualReport" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentTransitionReport" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentShellCompanyReport" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentPeriodEndDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityFileNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityRegistrantName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelName" xlink:label="dei_ContactPersonnelName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_ContactPersonnelName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityAddressAddressLine1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityAddressCityOrTown" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityAddressCountry" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityAddressPostalZipCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_CityAreaCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_LocalPhoneNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_Security12bTitle" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_TradingSymbol" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_SecurityExchangeName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityVoluntaryFilers" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCurrentReportingStatus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityInteractiveDataCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityFilerCategory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityEmergingGrowthCompany" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityExTransitionPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentAccountingStandard" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="29" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="30" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityShellCompany" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="31" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="32" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCentralIndexKey" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="33" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_CurrentFiscalYearEndDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="34" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentFiscalYearFocus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="35" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="36" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_AmendmentFlag" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="37" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_AuditorName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="38" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_AuditorLocation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="39" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_AuditorFirmId" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.alphatau.com/role/StatementConsolidatedStatementsOfConvertiblePreferredSharesAndShareholdersDeficiency" xlink:type="extended" xlink:title="00300 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS' DEFICIENCY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_SharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_AdjustmentsToAdditionalPaidInCapitalWarrantSharesIssued" xlink:label="drts_AdjustmentsToAdditionalPaidInCapitalWarrantSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="drts_AdjustmentsToAdditionalPaidInCapitalWarrantSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_StockIssuedDuringPeriodValueOrdinarySharesUponExerciseOfShareOptions" xlink:label="drts_StockIssuedDuringPeriodValueOrdinarySharesUponExerciseOfShareOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="drts_StockIssuedDuringPeriodValueOrdinarySharesUponExerciseOfShareOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_StockIssuedDuringPeriodSharesOrdinarySharesUponExerciseOfShareOptions" xlink:label="drts_StockIssuedDuringPeriodSharesOrdinarySharesUponExerciseOfShareOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="drts_StockIssuedDuringPeriodSharesOrdinarySharesUponExerciseOfShareOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="drts_StockIssuedDuringPeriodValueExerciseOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="drts_StockIssuedDuringPeriodValueExerciseOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="drts_StockIssuedDuringPeriodSharesExerciseOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="drts_StockIssuedDuringPeriodSharesExerciseOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="drts_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="drts_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:label="us-gaap_ProceedsFromPaymentsToMinorityShareholders" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_ProceedsFromPaymentsToMinorityShareholders" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.alphatau.com/role/DisclosureGeneralDetails" xlink:type="extended" xlink:title="40101 - Disclosure - GENERAL (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_AtmKkMember" xlink:label="drts_AtmKkMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="drts_AtmKkMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_DisposalGroupIncludingDiscontinuedOperationOwnershipDisposed" xlink:label="drts_DisposalGroupIncludingDiscontinuedOperationOwnershipDisposed" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="drts_DisposalGroupIncludingDiscontinuedOperationOwnershipDisposed" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_CashCashEquivalentsShortTermDepositsAndRestrictedCash" xlink:label="drts_CashCashEquivalentsShortTermDepositsAndRestrictedCash" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="drts_CashCashEquivalentsShortTermDepositsAndRestrictedCash" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_CurrentResourcesCoverageOfLiquidityRequirements" xlink:label="drts_CurrentResourcesCoverageOfLiquidityRequirements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="drts_CurrentResourcesCoverageOfLiquidityRequirements" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesShortTermDepositsDetails" xlink:type="extended" xlink:title="40202 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Short-term deposits (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="us-gaap_CashAndCashEquivalentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_ShortTernBankDepositInterestRate" xlink:label="drts_ShortTernBankDepositInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="drts_ShortTernBankDepositInterestRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentAndImpairmentDetails" xlink:type="extended" xlink:title="40203 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Property and equipment and impairment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_LaboratoryEquipmentMember" xlink:label="drts_LaboratoryEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="drts_LaboratoryEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AutomobilesMember" xlink:label="us-gaap_AutomobilesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_AutomobilesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesShareBasedPaymentsDetails" xlink:type="extended" xlink:title="40204 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Share-based payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesDeferredTransactionCostsDetails" xlink:type="extended" xlink:title="40208 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Deferred Transaction costs (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentAssetsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredOfferingCosts" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesAdditionalDetails" xlink:type="extended" xlink:title="40602 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES - Additional (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_ScheduleOfCommitmentsAndContingenciesTable" xlink:label="drts_ScheduleOfCommitmentsAndContingenciesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="drts_ScheduleOfCommitmentsAndContingenciesTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_IsraeliInnovationAuthorityMember" xlink:label="drts_IsraeliInnovationAuthorityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="drts_IsraeliInnovationAuthorityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_AltheraMember" xlink:label="drts_AltheraMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="dei_EntityDomain" xlink:to="drts_AltheraMember" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_RamotMember" xlink:label="drts_RamotMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="dei_EntityDomain" xlink:to="drts_RamotMember" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_HekaBioKKMember" xlink:label="drts_HekaBioKKMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="dei_EntityDomain" xlink:to="drts_HekaBioKKMember" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_BgnTechnologiesMember" xlink:label="drts_BgnTechnologiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="dei_EntityDomain" xlink:to="drts_BgnTechnologiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_CambridgeUniversityHospitalsNhsTrustMember" xlink:label="drts_CambridgeUniversityHospitalsNhsTrustMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="dei_EntityDomain" xlink:to="drts_CambridgeUniversityHospitalsNhsTrustMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="drts_ScheduleOfCommitmentsAndContingenciesTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_MethodOfPaymentRoyaltiesAxis" xlink:label="drts_MethodOfPaymentRoyaltiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="drts_ScheduleOfCommitmentsAndContingenciesTable" xlink:to="drts_MethodOfPaymentRoyaltiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_BasisOfPaymentRoyaltiesDomain" xlink:label="drts_BasisOfPaymentRoyaltiesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="drts_MethodOfPaymentRoyaltiesAxis" xlink:to="drts_BasisOfPaymentRoyaltiesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_FutureSalesOfDevelopedProductMember" xlink:label="drts_FutureSalesOfDevelopedProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="drts_BasisOfPaymentRoyaltiesDomain" xlink:to="drts_FutureSalesOfDevelopedProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_FutureGrossRevenuesDerivedFromPurchasedIntellectualPropertyMember" xlink:label="drts_FutureGrossRevenuesDerivedFromPurchasedIntellectualPropertyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="drts_BasisOfPaymentRoyaltiesDomain" xlink:to="drts_FutureGrossRevenuesDerivedFromPurchasedIntellectualPropertyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_NetSalesOfAllCompanySProductMember" xlink:label="drts_NetSalesOfAllCompanySProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="drts_BasisOfPaymentRoyaltiesDomain" xlink:to="drts_NetSalesOfAllCompanySProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_NetSalesOfAllCompanySProductSoldByCompanySLicensesMember" xlink:label="drts_NetSalesOfAllCompanySProductSoldByCompanySLicensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="drts_BasisOfPaymentRoyaltiesDomain" xlink:to="drts_NetSalesOfAllCompanySProductSoldByCompanySLicensesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_ReimbursementPriceMember" xlink:label="drts_ReimbursementPriceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="drts_BasisOfPaymentRoyaltiesDomain" xlink:to="drts_ReimbursementPriceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_DistributionReceiptsMember" xlink:label="drts_DistributionReceiptsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="drts_BasisOfPaymentRoyaltiesDomain" xlink:to="drts_DistributionReceiptsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_SalesOfAlphaRadiationProductsMember" xlink:label="drts_SalesOfAlphaRadiationProductsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="drts_BasisOfPaymentRoyaltiesDomain" xlink:to="drts_SalesOfAlphaRadiationProductsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_SalesOfProductContainingIntellectualPropertyMember" xlink:label="drts_SalesOfProductContainingIntellectualPropertyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="drts_BasisOfPaymentRoyaltiesDomain" xlink:to="drts_SalesOfProductContainingIntellectualPropertyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_LicenseRevenueToJointlyDevelopedIntellectualPropertyMember" xlink:label="drts_LicenseRevenueToJointlyDevelopedIntellectualPropertyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="drts_BasisOfPaymentRoyaltiesDomain" xlink:to="drts_LicenseRevenueToJointlyDevelopedIntellectualPropertyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_LicenseRevenueRelatedToIntellectualPropertyMember" xlink:label="drts_LicenseRevenueRelatedToIntellectualPropertyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="drts_BasisOfPaymentRoyaltiesDomain" xlink:to="drts_LicenseRevenueRelatedToIntellectualPropertyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_RevenueGeneratedFromPatentMember" xlink:label="drts_RevenueGeneratedFromPatentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="drts_BasisOfPaymentRoyaltiesDomain" xlink:to="drts_RevenueGeneratedFromPatentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_NetSalesSquamousCellCarcinomaMember" xlink:label="drts_NetSalesSquamousCellCarcinomaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="drts_BasisOfPaymentRoyaltiesDomain" xlink:to="drts_NetSalesSquamousCellCarcinomaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_CommitmentsAndContingenciesLineItems" xlink:label="drts_CommitmentsAndContingenciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="drts_CommitmentsAndContingenciesLineItems" xlink:to="drts_ScheduleOfCommitmentsAndContingenciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBankLoansAndNotesPayable" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="drts_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_GrantIncome" xlink:label="drts_GrantIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="drts_CommitmentsAndContingenciesLineItems" xlink:to="drts_GrantIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_RoyaltyRate" xlink:label="drts_RoyaltyRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="drts_CommitmentsAndContingenciesLineItems" xlink:to="drts_RoyaltyRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_RoyaltyPaymentAsPercentageOfGrants" xlink:label="drts_RoyaltyPaymentAsPercentageOfGrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="drts_CommitmentsAndContingenciesLineItems" xlink:to="drts_RoyaltyPaymentAsPercentageOfGrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="drts_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_RoyaltyExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="us-gaap_LiabilitiesAssumed1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="drts_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LiabilitiesAssumed1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_PotentialPayment" xlink:label="drts_PotentialPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="drts_CommitmentsAndContingenciesLineItems" xlink:to="drts_PotentialPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_MilestoneNumberOfOrdinaryStockOptions" xlink:label="drts_MilestoneNumberOfOrdinaryStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="drts_CommitmentsAndContingenciesLineItems" xlink:to="drts_MilestoneNumberOfOrdinaryStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_StockOptionExercisePrice" xlink:label="drts_StockOptionExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="drts_CommitmentsAndContingenciesLineItems" xlink:to="drts_StockOptionExercisePrice" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.alphatau.com/role/DisclosureFairValueMeasurementsValuationAssumptionsDetails" xlink:type="extended" xlink:title="40701 - Disclosure - FAIR VALUE MEASUREMENTS - Valuation Assumptions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_NumberOfScenariosInAllocatingValueToWarrants" xlink:label="drts_NumberOfScenariosInAllocatingValueToWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="drts_NumberOfScenariosInAllocatingValueToWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingValuationTechniqueExtensibleList" xlink:label="us-gaap_WarrantsAndRightsOutstandingValuationTechniqueExtensibleList" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingValuationTechniqueExtensibleList" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.alphatau.com/role/DisclosureFairValueMeasurementsChangesInFairValueDetails" xlink:type="extended" xlink:title="40702 - Disclosure - FAIR VALUE MEASUREMENTS - Changes in fair value (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.alphatau.com/role/DisclosureIncomeTaxesTaxRatesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - INCOME TAXES - Tax rates (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_IncomeTaxDisclosureTable" xlink:label="drts_IncomeTaxDisclosureTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="drts_IncomeTaxDisclosureTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_AtmIncMember" xlink:label="drts_AtmIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="drts_AtmIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_AtmKkMember" xlink:label="drts_AtmKkMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="drts_AtmKkMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="drts_IncomeTaxDisclosureTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="country_US" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP" xlink:label="country_JP" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_JP" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_IncomeTaxDisclosureLineItems" xlink:label="drts_IncomeTaxDisclosureLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="drts_IncomeTaxDisclosureLineItems" xlink:to="drts_IncomeTaxDisclosureTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="drts_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_IncomeTaxRateReconciliationPreferredCompanyPercent" xlink:label="drts_IncomeTaxRateReconciliationPreferredCompanyPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="drts_IncomeTaxDisclosureLineItems" xlink:to="drts_IncomeTaxRateReconciliationPreferredCompanyPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_IncomeTaxRateReconciliationLargeCompaniesPercent" xlink:label="drts_IncomeTaxRateReconciliationLargeCompaniesPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="drts_IncomeTaxDisclosureLineItems" xlink:to="drts_IncomeTaxRateReconciliationLargeCompaniesPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_IncomeTaxRateReconciliationSmallCompaniesPercent" xlink:label="drts_IncomeTaxRateReconciliationSmallCompaniesPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="drts_IncomeTaxDisclosureLineItems" xlink:to="drts_IncomeTaxRateReconciliationSmallCompaniesPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_IncomeTaxRateReconciliationSmallCompaniesSpecialRatePercent" xlink:label="drts_IncomeTaxRateReconciliationSmallCompaniesSpecialRatePercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="drts_IncomeTaxDisclosureLineItems" xlink:to="drts_IncomeTaxRateReconciliationSmallCompaniesSpecialRatePercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_IncomeTaxRateReconciliationMediumCompaniesSpecialRatePercent" xlink:label="drts_IncomeTaxRateReconciliationMediumCompaniesSpecialRatePercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="drts_IncomeTaxDisclosureLineItems" xlink:to="drts_IncomeTaxRateReconciliationMediumCompaniesSpecialRatePercent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsCompositionOfConvertiblePreferredSharesDetails" xlink:type="extended" xlink:title="40901 - Disclosure - CONVERTIBLE PREFERRED SHARES AND WARRANTS - Composition of Convertible Preferred shares (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_SeriesConvertiblePreferredSharesMember" xlink:label="drts_SeriesConvertiblePreferredSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="drts_SeriesConvertiblePreferredSharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_SeriesBConvertiblePreferredSharesMember" xlink:label="drts_SeriesBConvertiblePreferredSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="drts_SeriesBConvertiblePreferredSharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsPreferredSharesRightsDetails" xlink:type="extended" xlink:title="40902 - Disclosure - CONVERTIBLE PREFERRED SHARES AND WARRANTS - Preferred shares rights (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_SeriesConvertiblePreferredSharesMember" xlink:label="drts_SeriesConvertiblePreferredSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="drts_SeriesConvertiblePreferredSharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_TemporaryEquityDistributionRateFromProceedsOfSaleAnotherClassOfShares" xlink:label="drts_TemporaryEquityDistributionRateFromProceedsOfSaleAnotherClassOfShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="drts_TemporaryEquityDistributionRateFromProceedsOfSaleAnotherClassOfShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_TemporaryEquityNumberOfVotes" xlink:label="drts_TemporaryEquityNumberOfVotes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="drts_TemporaryEquityNumberOfVotes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsFinancingRoundsDetails" xlink:type="extended" xlink:title="40903 - Disclosure - CONVERTIBLE PREFERRED SHARES AND WARRANTS - Financing rounds (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_SeriesConvertiblePreferredSharesMember" xlink:label="drts_SeriesConvertiblePreferredSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="drts_SeriesConvertiblePreferredSharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_SeriesBConvertiblePreferredSharesMember" xlink:label="drts_SeriesBConvertiblePreferredSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="drts_SeriesBConvertiblePreferredSharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_SaleOfStockNumberOfWarrantsIssuedInTransaction" xlink:label="drts_SaleOfStockNumberOfWarrantsIssuedInTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="drts_SaleOfStockNumberOfWarrantsIssuedInTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsPreferredSharesWarrantsDetails" xlink:type="extended" xlink:title="40904 - Disclosure - CONVERTIBLE PREFERRED SHARES AND WARRANTS - Preferred A shares warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_SeriesConvertiblePreferredSharesMember" xlink:label="drts_SeriesConvertiblePreferredSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="drts_SeriesConvertiblePreferredSharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_SaleOfStockNumberOfWarrantsIssuedInTransaction" xlink:label="drts_SaleOfStockNumberOfWarrantsIssuedInTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="drts_SaleOfStockNumberOfWarrantsIssuedInTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_WarrantsGrantedIncreaseFromNewFinancing" xlink:label="drts_WarrantsGrantedIncreaseFromNewFinancing" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="drts_WarrantsGrantedIncreaseFromNewFinancing" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOrdinaryShareCapitalDetails" xlink:type="extended" xlink:title="41001 - Disclosure - SHAREHOLDERS' DEFICIENCY - Ordinary share capital (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_HekabioK.k.Member" xlink:label="drts_HekabioK.k.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="drts_HekabioK.k.Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_SharesNumberOfVotes" xlink:label="drts_SharesNumberOfVotes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="drts_SharesNumberOfVotes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_SaleOfStockNumberOfWarrantsIssuedInTransaction" xlink:label="drts_SaleOfStockNumberOfWarrantsIssuedInTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="drts_SaleOfStockNumberOfWarrantsIssuedInTransaction" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.alphatau.com/role/DisclosureShareholdersDeficiencyShareOptionPlanDetails" xlink:type="extended" xlink:title="41002 - Disclosure - SHAREHOLDERS' DEFICIENCY - Share option plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_ShareOptionPlanMember" xlink:label="drts_ShareOptionPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="drts_ShareOptionPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOptionsChangesDetails" xlink:type="extended" xlink:title="41003 - Disclosure - SHAREHOLDERS' DEFICIENCY - Options changes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.alphatau.com/role/DisclosureShareholdersDeficiencyEquityBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="41005 - Disclosure - SHAREHOLDERS' DEFICIENCY - Equity-based compensation expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="us-gaap_SellingAndMarketingExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingAndMarketingExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.alphatau.com/role/DisclosureShareholdersDeficiencyWarrantsDetails" xlink:type="extended" xlink:title="41006 - Disclosure - SHAREHOLDERS' DEFICIENCY - Warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_HekabioK.k.Member" xlink:label="drts_HekabioK.k.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="drts_HekabioK.k.Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_SaleOfStockNumberOfWarrantsIssuedInTransaction" xlink:label="drts_SaleOfStockNumberOfWarrantsIssuedInTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="drts_SaleOfStockNumberOfWarrantsIssuedInTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_WarrantsExercisedCashBasis" xlink:label="drts_WarrantsExercisedCashBasis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="drts_WarrantsExercisedCashBasis" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_WarrantsExercisedCashlessBasis" xlink:label="drts_WarrantsExercisedCashlessBasis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="drts_WarrantsExercisedCashlessBasis" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="drts_StockIssuedDuringPeriodValueExerciseOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="drts_StockIssuedDuringPeriodValueExerciseOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_WarrantsToOrdinaryShareRatioCashlessExercise" xlink:label="drts_WarrantsToOrdinaryShareRatioCashlessExercise" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="drts_WarrantsToOrdinaryShareRatioCashlessExercise" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_NumberOfWarrantsExercised" xlink:label="drts_NumberOfWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="drts_NumberOfWarrantsExercised" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.alphatau.com/role/DisclosureBasicAndDilutedNetLossPerShareDetails" xlink:type="extended" xlink:title="41201 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_WarrantsToPreferredSharesMember" xlink:label="drts_WarrantsToPreferredSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="drts_WarrantsToPreferredSharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_NumeratorAbstract" xlink:label="drts_NumeratorAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="drts_NumeratorAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="us-gaap_IncomeLossFromContinuingOperations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="drts_NumeratorAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_DenominatorAbstract" xlink:label="drts_DenominatorAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="drts_DenominatorAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="drts_DenominatorAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="drts_DenominatorAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.alphatau.com/role/DisclosureGeographicInformationDetails" xlink:type="extended" xlink:title="41301 - Disclosure - GEOGRAPHIC INFORMATION (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IL" xlink:label="country_IL" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_IL" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="country_US" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP" xlink:label="country_JP" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_JP" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:label="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.alphatau.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41401 - Disclosure - SUBSEQUENT EVENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_BankLeumiLeIsraelBmMember" xlink:label="drts_BankLeumiLeIsraelBmMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="drts_BankLeumiLeIsraelBmMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_HcccMember" xlink:label="drts_HcccMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="drts_HcccMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PledgedFinancialInstrumentsNotSeparatelyReportedSecuritiesForLetterOfCreditFacilities" xlink:label="us-gaap_PledgedFinancialInstrumentsNotSeparatelyReportedSecuritiesForLetterOfCreditFacilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PledgedFinancialInstrumentsNotSeparatelyReportedSecuritiesForLetterOfCreditFacilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_CommonStockCancelledAndConvertedInToShares" xlink:label="drts_CommonStockCancelledAndConvertedInToShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="drts_CommonStockCancelledAndConvertedInToShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAcquiredFromAcquisition" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>drts-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/28/2022 8:47:09 PM-->
<!--Modified on: 3/28/2022 8:47:09 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ordinary shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ordinary Common Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Addresses, Address Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AddressTypeDomain" xlink:to="dei_AddressTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AddressTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Address Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_BusinessContactMember" xlink:label="dei_BusinessContactMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Contact Member</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Registration Statement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Shell Company Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelName" xlink:label="dei_ContactPersonnelName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contact Personnel Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Country</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Accounting Standard</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CURRENT ASSETS:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents, as reported on the balance sheets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash and Cash Equivalents, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash, as reported on the balance sheets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedInvestmentsCurrent" xlink:label="us-gaap_RestrictedInvestmentsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedInvestmentsCurrent" xlink:to="us-gaap_RestrictedInvestmentsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedInvestmentsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Investments, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedInvestmentsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term deposits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_LongTermAssetsAbstract" xlink:label="drts_LongTermAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_LongTermAssetsAbstract" xlink:to="drts_LongTermAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_LongTermAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_LongTermAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long Term Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_LongTermAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseNoncurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long term prepaid expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total long-term assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, convertible preferred shares and shareholders' deficiency</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CURRENT LIABILITIES:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade payables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other payables and accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_LongTermLiabilitiesAbstract" xlink:label="drts_LongTermLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_LongTermLiabilitiesAbstract" xlink:to="drts_LongTermLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_LongTermLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_LongTermLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long Term Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_LongTermLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LONG-TERM LIABILITIES:</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_Warrantliability" xlink:label="drts_Warrantliability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_Warrantliability" xlink:to="drts_Warrantliability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_Warrantliability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of warrant liability classified as noncurrent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_Warrantliability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_Warrantliability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to convertible preferred shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Carrying Amount, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred shares of no-par value per share - Authorized: 25,348,176 shares as of December 31, 2020 and 2021; Issued and outstanding: 13,739,186 shares as of December 31, 2020 and 2021; *)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shareholders' deficiency:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValueOutstanding" xlink:label="us-gaap_CommonStockValueOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValueOutstanding" xlink:to="us-gaap_CommonStockValueOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValueOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValueOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ordinary shares of no-par value per share - Authorized: 72,423,360 shares as of December 31, 2020 and 2021; Issued and outstanding: 40,433,578 and 40,528,913 shares as of December 31, 2020 and 2021, respectively; *)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance, beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance, beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total shareholders' deficiency</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities, convertible preferred shares and shareholders' deficiency</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Par value (per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Authorized (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ordinary shares par value (per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ordinary shares, authorized (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ordinary shares, issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ordinary shares, outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note, Stock Split, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock split ratio</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENT OF OPERATIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketingExpense" xlink:label="us-gaap_MarketingExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketingExpense" xlink:to="us-gaap_MarketingExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketing Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketing expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingGainsLosses" xlink:label="us-gaap_NonoperatingGainsLosses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingGainsLosses" xlink:to="us-gaap_NonoperatingGainsLosses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingGainsLosses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonoperating Gains (Losses)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingGainsLosses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial (income) expenses, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingGainsLosses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial expenses (income), net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss before taxes on income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax on income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: net loss attributable to noncontrolling interests</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: net loss attributable to noncontrolling interests</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss attributable to Alpha Tau Medical Ltd.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share attributable to ordinary shareholders, basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share attributable to ordinary shareholders, diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average shares used in computing net loss per share attributable to ordinary shareholders, basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average shares used in computing net loss per share attributable to ordinary shareholders, diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS' DEFICIENCY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncontrolling Interest [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-Controlling Interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redeemable Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonClassAMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Class A [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonClassAMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class A Common Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Shareholders' Deficiency</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance, beginning of period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance, beginning of period (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Warrant Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of ordinary shares and warrants to ordinary shares</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_AdjustmentsToAdditionalPaidInCapitalWarrantSharesIssued" xlink:label="drts_AdjustmentsToAdditionalPaidInCapitalWarrantSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_AdjustmentsToAdditionalPaidInCapitalWarrantSharesIssued" xlink:to="drts_AdjustmentsToAdditionalPaidInCapitalWarrantSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_AdjustmentsToAdditionalPaidInCapitalWarrantSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of  Adjustments To Additional Paid In Capital Warrant Shares Issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_AdjustmentsToAdditionalPaidInCapitalWarrantSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments To Additional Paid In Capital Warrant Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_AdjustmentsToAdditionalPaidInCapitalWarrantSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of ordinary shares and warrants to ordinary shares (in shares)</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_StockIssuedDuringPeriodValueOrdinarySharesUponExerciseOfShareOptions" xlink:label="drts_StockIssuedDuringPeriodValueOrdinarySharesUponExerciseOfShareOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_StockIssuedDuringPeriodValueOrdinarySharesUponExerciseOfShareOptions" xlink:to="drts_StockIssuedDuringPeriodValueOrdinarySharesUponExerciseOfShareOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_StockIssuedDuringPeriodValueOrdinarySharesUponExerciseOfShareOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity impact of the value of stock issued during the period. ordinary shares upon exercise of share options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_StockIssuedDuringPeriodValueOrdinarySharesUponExerciseOfShareOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Ordinary Shares Upon Exercise Of Share Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_StockIssuedDuringPeriodValueOrdinarySharesUponExerciseOfShareOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of ordinary shares upon exercise of share options</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_StockIssuedDuringPeriodSharesOrdinarySharesUponExerciseOfShareOptions" xlink:label="drts_StockIssuedDuringPeriodSharesOrdinarySharesUponExerciseOfShareOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_StockIssuedDuringPeriodSharesOrdinarySharesUponExerciseOfShareOptions" xlink:to="drts_StockIssuedDuringPeriodSharesOrdinarySharesUponExerciseOfShareOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_StockIssuedDuringPeriodSharesOrdinarySharesUponExerciseOfShareOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of ordinary shares upon exercise of share options issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_StockIssuedDuringPeriodSharesOrdinarySharesUponExerciseOfShareOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Ordinary Shares Upon Exercise Of Share Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_StockIssuedDuringPeriodSharesOrdinarySharesUponExerciseOfShareOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of ordinary shares upon exercise of share options (in shares)</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="drts_StockIssuedDuringPeriodValueExerciseOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:to="drts_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of stock issued as a result of the exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Exercise of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of warrants to ordinary shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="drts_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant exercise consideration</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="drts_StockIssuedDuringPeriodSharesExerciseOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:to="drts_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants exercised during the current period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Exercise of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of warrants to ordinary shares (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of series B Preferred shares, net</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="drts_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="drts_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New stock classified as temporary equity issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of series B Preferred shares, net (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:label="us-gaap_ProceedsFromPaymentsToMinorityShareholders" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:to="us-gaap_ProceedsFromPaymentsToMinorityShareholders_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromPaymentsToMinorityShareholders_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from (Payments to) Noncontrolling Interests</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromPaymentsToMinorityShareholders_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquisition of non-controlling interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromPaymentsToMinorityShareholders_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquisition of non-controlling interests</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">(Increase) decrease in prepaid expenses and other receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expenses, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in long term prepaid expenses</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_IncreaseDecreaseInFairValueOfWarrantsConvertiblePreferredShares" xlink:label="drts_IncreaseDecreaseInFairValueOfWarrantsConvertiblePreferredShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_IncreaseDecreaseInFairValueOfWarrantsConvertiblePreferredShares" xlink:to="drts_IncreaseDecreaseInFairValueOfWarrantsConvertiblePreferredShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_IncreaseDecreaseInFairValueOfWarrantsConvertiblePreferredShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase (decrease) in the fair value of warrants to convertible preferred shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_IncreaseDecreaseInFairValueOfWarrantsConvertiblePreferredShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) In Fair Value Of Warrants Convertible Preferred Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_IncreaseDecreaseInFairValueOfWarrantsConvertiblePreferredShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in the fair value of warrants to convertible preferred shares</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_IncreaseDecreaseInNonCashFinancialIncomeExpenses" xlink:label="drts_IncreaseDecreaseInNonCashFinancialIncomeExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_IncreaseDecreaseInNonCashFinancialIncomeExpenses" xlink:to="drts_IncreaseDecreaseInNonCashFinancialIncomeExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_IncreaseDecreaseInNonCashFinancialIncomeExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase (decrease) in non-cash financial (income) expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_IncreaseDecreaseInNonCashFinancialIncomeExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) In Non Cash Financial (Income) Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="drts_IncreaseDecreaseInNonCashFinancialIncomeExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash financial (income) expenses, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable, Trade</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in trade payables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Other Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in other payables and accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from investing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseOfRestrictedInvestments" xlink:label="us-gaap_IncreaseDecreaseOfRestrictedInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseOfRestrictedInvestments" xlink:to="us-gaap_IncreaseDecreaseOfRestrictedInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseOfRestrictedInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) of Restricted Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseOfRestrictedInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment in short-term deposits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:label="us-gaap_ProceedsFromSaleOfRestrictedInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:to="us-gaap_ProceedsFromSaleOfRestrictedInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfRestrictedInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Sale of Restricted Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfRestrictedInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redemption of short-term deposits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash (used in) provided by investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of ordinary shares and warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Preferred Stock and Preference Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of series B Preferred shares, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from exercise of options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of exchange rate changes on cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">(Decrease) increase in cash and cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash at the end of the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash at the beginning of the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents, and restricted cash, as reported in the statements of cash flows</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash transactions:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Warrants Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivables from exercise of warrants to ordinary shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Cash Flow Elements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosures of cash flow information:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest received</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">GENERAL</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Operations [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">GENERAL</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PREPAID EXPENSES AND OTHER RECEIVABLES</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_PrepaidExpensesAndOtherReceivablesTextBlock" xlink:label="drts_PrepaidExpensesAndOtherReceivablesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_PrepaidExpensesAndOtherReceivablesTextBlock" xlink:to="drts_PrepaidExpensesAndOtherReceivablesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_PrepaidExpensesAndOtherReceivablesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for prepaid expenses and other receivables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_PrepaidExpensesAndOtherReceivablesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expenses And Other Receivables [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_PrepaidExpensesAndOtherReceivablesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PREPAID EXPENSES AND OTHER RECEIVABLES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PROPERTY AND EQUIPMENT, NET</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PROPERTY AND EQUIPMENT, NET</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_OtherPayablesAndAccruedExpensesAbstract" xlink:label="drts_OtherPayablesAndAccruedExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_OtherPayablesAndAccruedExpensesAbstract" xlink:to="drts_OtherPayablesAndAccruedExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_OtherPayablesAndAccruedExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_OtherPayablesAndAccruedExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OTHER PAYABLES AND ACCRUED EXPENSES</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_OtherPayablesAndAccruedExpensesDisclosureTextBlock" xlink:label="drts_OtherPayablesAndAccruedExpensesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_OtherPayablesAndAccruedExpensesDisclosureTextBlock" xlink:to="drts_OtherPayablesAndAccruedExpensesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_OtherPayablesAndAccruedExpensesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for other payables and accrued expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_OtherPayablesAndAccruedExpensesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Payables And Accrued Expenses Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_OtherPayablesAndAccruedExpensesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OTHER PAYABLES AND ACCRUED EXPENSES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">COMMITMENTS AND CONTINGENT LIABILITIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">COMMITMENTS AND CONTINGENT LIABILITIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FAIR VALUE MEASUREMENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">INCOME TAXES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity Disclosure [Abstract]</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_TemporaryEquityTextBlock" xlink:label="drts_TemporaryEquityTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_TemporaryEquityTextBlock" xlink:to="drts_TemporaryEquityTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_TemporaryEquityTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_TemporaryEquityTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_TemporaryEquityTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONVERTIBLE PREFERRED SHARES AND WARRANTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SHAREHOLDERS' DEFICIENCY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shareholders' Equity and Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SHAREHOLDERS' DEFICIENCY</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_FinancialExpensesAbstract" xlink:label="drts_FinancialExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_FinancialExpensesAbstract" xlink:to="drts_FinancialExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_FinancialExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_FinancialExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FINANCIAL EXPENSES, NET</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:label="us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:to="us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Income and Other Expense Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FINANCIAL EXPENSES, NET</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BASIC AND DILUTED NET LOSS PER SHARE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BASIC AND DILUTED NET LOSS PER SHARE</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_GeographicInformationAbstract" xlink:label="drts_GeographicInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_GeographicInformationAbstract" xlink:to="drts_GeographicInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_GeographicInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_GeographicInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">GEOGRAPHIC INFORMATION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">GEOGRAPHIC INFORMATION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUBSEQUENT EVENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUBSEQUENT EVENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of estimates for the preparation of financial statements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated financial statements in U.S. dollars</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidation, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principles of consolidation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_ShortTermDepositsPolicyTextBlock" xlink:label="drts_ShortTermDepositsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_ShortTermDepositsPolicyTextBlock" xlink:to="drts_ShortTermDepositsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_ShortTermDepositsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for short-term deposits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_ShortTermDepositsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short term Deposits [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_ShortTermDepositsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term deposits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of long-lived assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expenses, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting for share-based payments</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_GrantsAndParticipationsPolicyTextBlock" xlink:label="drts_GrantsAndParticipationsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_GrantsAndParticipationsPolicyTextBlock" xlink:to="drts_GrantsAndParticipationsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_GrantsAndParticipationsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for grants and participations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_GrantsAndParticipationsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grants and Participations [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_GrantsAndParticipationsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grants and participations</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock" xlink:label="drts_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock" xlink:to="drts_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for convertible preferred shares and convertible preferred shares warrant liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Shares And Convertible Preferred Shares Warrant Liability [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred shares and convertible preferred shares warrant liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of financial instruments</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock" xlink:label="drts_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock" xlink:to="drts_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for ordinary share warrants classification and measurement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ordinary Share Warrants Classification and Measurement [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ordinary share warrants classification and measurement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration of credit risks</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_SeverancePayPolicyTextBlock" xlink:label="drts_SeverancePayPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_SeverancePayPolicyTextBlock" xlink:to="drts_SeverancePayPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_SeverancePayPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for severance pay.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_SeverancePayPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Severance Pay [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_SeverancePayPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Severance pay</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic and diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_DeferredTransactionCostsPolicyTextBlock" xlink:label="drts_DeferredTransactionCostsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_DeferredTransactionCostsPolicyTextBlock" xlink:to="drts_DeferredTransactionCostsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_DeferredTransactionCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for deferred transaction costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_DeferredTransactionCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Transaction Costs [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_DeferredTransactionCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Transaction costs</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_NonControllingInterestPolicyTextBlock" xlink:label="drts_NonControllingInterestPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_NonControllingInterestPolicyTextBlock" xlink:to="drts_NonControllingInterestPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_NonControllingInterestPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for non-controlling interest.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_NonControllingInterestPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-controlling Interest [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_NonControllingInterestPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-controlling interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recently Issued Accounting Pronouncements and not yet adopted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Cash and Cash Equivalents [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of reconciliation of the cash and cash equivalents balances reported on the balance sheets and the cash, cash equivalents and restricted cash balances reported in the statements of cash flows</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_PropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:label="drts_PropertyPlantAndEquipmentUsefulLivesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_PropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:to="drts_PropertyPlantAndEquipmentUsefulLivesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_PropertyPlantAndEquipmentUsefulLivesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of the useful lives of property, plant and equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_PropertyPlantAndEquipmentUsefulLivesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Useful Lives [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_PropertyPlantAndEquipmentUsefulLivesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of useful lives of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of assumptions in the valuation of options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of prepaid expenses and other receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_ScheduleOfOtherPayablesAndAccruedExpensesTableTextBlock" xlink:label="drts_ScheduleOfOtherPayablesAndAccruedExpensesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_ScheduleOfOtherPayablesAndAccruedExpensesTableTextBlock" xlink:to="drts_ScheduleOfOtherPayablesAndAccruedExpensesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_ScheduleOfOtherPayablesAndAccruedExpensesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of accrued liabilities and other current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_ScheduleOfOtherPayablesAndAccruedExpensesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Other Payables And Accrued Expenses [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_ScheduleOfOtherPayablesAndAccruedExpensesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of other payables and accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of future minimum operating lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of assumptions in the Black-Scholes model in calculating fair value of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of change in the fair value of the preferred share warrants liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of components of the net loss (income) before tax on income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of income tax expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of significant components of the deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="us-gaap_TemporaryEquityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityTableTextBlock" xlink:to="us-gaap_TemporaryEquityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of composition of Convertible Preferred shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="us-gaap_ScheduleOfStockByClassTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stock by Class [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of composition of ordinary share capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of the status of options and changes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of the status of RSUs and changes</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_ScheduleOfShareBasedCompensationCostsByIncomeStatementLocationTableTextBlock" xlink:label="drts_ScheduleOfShareBasedCompensationCostsByIncomeStatementLocationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_ScheduleOfShareBasedCompensationCostsByIncomeStatementLocationTableTextBlock" xlink:to="drts_ScheduleOfShareBasedCompensationCostsByIncomeStatementLocationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_ScheduleOfShareBasedCompensationCostsByIncomeStatementLocationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of share-based compensation costs incurred by location in the income statement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_ScheduleOfShareBasedCompensationCostsByIncomeStatementLocationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Costs By Income Statement Location [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_ScheduleOfShareBasedCompensationCostsByIncomeStatementLocationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule equity-based compensation expense related</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Financial Expenses, Net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of basic and diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of antidilutive securities excluded from net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Segment Reporting Information, by Segment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Geographical Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment, Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_AtmKkMember" xlink:label="drts_AtmKkMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_AtmKkMember" xlink:to="drts_AtmKkMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_AtmKkMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents ATM KK.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_AtmKkMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ATM KK [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_AtmKkMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ATM KK</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_DisposalGroupIncludingDiscontinuedOperationOwnershipDisposed" xlink:label="drts_DisposalGroupIncludingDiscontinuedOperationOwnershipDisposed" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_DisposalGroupIncludingDiscontinuedOperationOwnershipDisposed" xlink:to="drts_DisposalGroupIncludingDiscontinuedOperationOwnershipDisposed_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_DisposalGroupIncludingDiscontinuedOperationOwnershipDisposed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of disposal group including discontinued operation ownership disposed.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_DisposalGroupIncludingDiscontinuedOperationOwnershipDisposed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disposal Group Including Discontinued Operation Ownership Disposed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_DisposalGroupIncludingDiscontinuedOperationOwnershipDisposed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ownership hold (as a percent)</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_CashCashEquivalentsShortTermDepositsAndRestrictedCash" xlink:label="drts_CashCashEquivalentsShortTermDepositsAndRestrictedCash" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_CashCashEquivalentsShortTermDepositsAndRestrictedCash" xlink:to="drts_CashCashEquivalentsShortTermDepositsAndRestrictedCash_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_CashCashEquivalentsShortTermDepositsAndRestrictedCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of cash, cash equivalents, short-term deposits and restricted cash.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_CashCashEquivalentsShortTermDepositsAndRestrictedCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash equivalents, Short-term Deposits and Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_CashCashEquivalentsShortTermDepositsAndRestrictedCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents, short-term deposits and restricted cash</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_CurrentResourcesCoverageOfLiquidityRequirements" xlink:label="drts_CurrentResourcesCoverageOfLiquidityRequirements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_CurrentResourcesCoverageOfLiquidityRequirements" xlink:to="drts_CurrentResourcesCoverageOfLiquidityRequirements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_CurrentResourcesCoverageOfLiquidityRequirements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum period to satisfy expected liquidity requirements with existing capital resources, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_CurrentResourcesCoverageOfLiquidityRequirements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Resources Coverage of Liquidity Requirements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_CurrentResourcesCoverageOfLiquidityRequirements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liquidity period to satisfy with current resources</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Cash and Cash Equivalents [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="us-gaap_CashAndCashEquivalentsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term deposits</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_ShortTernBankDepositInterestRate" xlink:label="drts_ShortTernBankDepositInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_ShortTernBankDepositInterestRate" xlink:to="drts_ShortTernBankDepositInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_ShortTernBankDepositInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest rates on short-term deposits with banks.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_ShortTernBankDepositInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short Tern Bank Deposit, Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_ShortTernBankDepositInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deposits in U.S. dollars bear interest rates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computer Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computers and software</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_LaboratoryEquipmentMember" xlink:label="drts_LaboratoryEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_LaboratoryEquipmentMember" xlink:to="drts_LaboratoryEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_LaboratoryEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to equipment used in a laboratory.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_LaboratoryEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Laboratory Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_LaboratoryEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Laboratory equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Furniture and Fixtures [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Furniture and office equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AutomobilesMember" xlink:label="us-gaap_AutomobilesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AutomobilesMember" xlink:to="us-gaap_AutomobilesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AutomobilesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Automobiles [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AutomobilesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cars</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Manufacturing equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated useful lives</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment, Long-Lived Asset, Held-for-Use</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment losses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share option plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in RSUs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term (years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility - lower range</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility - upper range</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate - lower range</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate - upper range</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected dividend yield</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" xlink:label="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" xlink:to="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Arrangement with Federal Government, Customer Funding to Offset Costs Incurred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recognized participations in research and development as a reduction from research and development expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding ordinary share warrants</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_SeverancePayDepositRate" xlink:label="drts_SeverancePayDepositRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_SeverancePayDepositRate" xlink:to="drts_SeverancePayDepositRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_SeverancePayDepositRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The monthly deposits at a rate of employees monthly salary deposited  as severance pay, as required by law.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_SeverancePayDepositRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Severance Pay, Deposit Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_SeverancePayDepositRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Severance pay monthly deposit rate</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_SeverancePayExpense" xlink:label="drts_SeverancePayExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_SeverancePayExpense" xlink:to="drts_SeverancePayExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_SeverancePayExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of monthly severance recognized during the period based on the rate prescribed by law.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_SeverancePayExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Severance Pay Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_SeverancePayExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Severance pay expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingency Accrual</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent liability provision</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentAssetsMember" xlink:to="us-gaap_OtherNoncurrentAssetsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncurrentAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Noncurrent Assets [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNoncurrentAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets, noncurrent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Offering Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized deferred offering costs</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_GovernmentAuthoritiesReceivable" xlink:label="drts_GovernmentAuthoritiesReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_GovernmentAuthoritiesReceivable" xlink:to="drts_GovernmentAuthoritiesReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_GovernmentAuthoritiesReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying amount as of the balance sheet date of government authority receivables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_GovernmentAuthoritiesReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government Authorities Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_GovernmentAuthoritiesReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government authorities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total prepaid expenses and other receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VehiclesMember" xlink:label="us-gaap_VehiclesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VehiclesMember" xlink:to="us-gaap_VehiclesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VehiclesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vehicles [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VehiclesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vehicles [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold Improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold improvements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, gross</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Depreciation, Depletion and Amortization, Sale or Disposal of Property, Plant and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disposed accumulated depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Salaries, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employees and payroll accruals</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Related Parties, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related parties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities and Other Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total other payables and accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, after Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Thereafter</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total future minimum lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rental and lease expenses</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_ScheduleOfCommitmentsAndContingenciesTable" xlink:label="drts_ScheduleOfCommitmentsAndContingenciesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_ScheduleOfCommitmentsAndContingenciesTable" xlink:to="drts_ScheduleOfCommitmentsAndContingenciesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_ScheduleOfCommitmentsAndContingenciesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Table providing entire disclosure related to commitments and contingencies of the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_ScheduleOfCommitmentsAndContingenciesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Commitments And Contingencies [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_IsraeliInnovationAuthorityMember" xlink:label="drts_IsraeliInnovationAuthorityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_IsraeliInnovationAuthorityMember" xlink:to="drts_IsraeliInnovationAuthorityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_IsraeliInnovationAuthorityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the Israeli Innovation Authority (IIA)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_IsraeliInnovationAuthorityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Israeli Innovation Authority [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_IsraeliInnovationAuthorityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Israeli Innovation Authority (IIA)</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_AltheraMember" xlink:label="drts_AltheraMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_AltheraMember" xlink:to="drts_AltheraMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_AltheraMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Althera.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_AltheraMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Althera [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_AltheraMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Althera</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_RamotMember" xlink:label="drts_RamotMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_RamotMember" xlink:to="drts_RamotMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_RamotMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Ramot.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_RamotMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ramot [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_RamotMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ramot</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_HekaBioKKMember" xlink:label="drts_HekaBioKKMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_HekaBioKKMember" xlink:to="drts_HekaBioKKMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_HekaBioKKMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to HekaBio K.K.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_HekaBioKKMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Heka Bio K K [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_HekaBioKKMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">HekaBio K.K.</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_BgnTechnologiesMember" xlink:label="drts_BgnTechnologiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_BgnTechnologiesMember" xlink:to="drts_BgnTechnologiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_BgnTechnologiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to BGN Technologies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_BgnTechnologiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BGN Technologies [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_BgnTechnologiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BGN Technologies</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_CambridgeUniversityHospitalsNhsTrustMember" xlink:label="drts_CambridgeUniversityHospitalsNhsTrustMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_CambridgeUniversityHospitalsNhsTrustMember" xlink:to="drts_CambridgeUniversityHospitalsNhsTrustMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_CambridgeUniversityHospitalsNhsTrustMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the Cambridge University Hospitals NHS Trust.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_CambridgeUniversityHospitalsNhsTrustMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cambridge University Hospitals NHS Trust [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_CambridgeUniversityHospitalsNhsTrustMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cambridge University Hospitals NHS Trust</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_MethodOfPaymentRoyaltiesAxis" xlink:label="drts_MethodOfPaymentRoyaltiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_MethodOfPaymentRoyaltiesAxis" xlink:to="drts_MethodOfPaymentRoyaltiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_MethodOfPaymentRoyaltiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information about the basis of payment used in determining the amount of royalties paid.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_MethodOfPaymentRoyaltiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Method Of Payment Royalties [Axis]</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_BasisOfPaymentRoyaltiesDomain" xlink:label="drts_BasisOfPaymentRoyaltiesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_BasisOfPaymentRoyaltiesDomain" xlink:to="drts_BasisOfPaymentRoyaltiesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_BasisOfPaymentRoyaltiesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The basis of payment used in determining the amount of royalties paid.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_BasisOfPaymentRoyaltiesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis Of Payment, Royalties [Domain]</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_FutureSalesOfDevelopedProductMember" xlink:label="drts_FutureSalesOfDevelopedProductMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_FutureSalesOfDevelopedProductMember" xlink:to="drts_FutureSalesOfDevelopedProductMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_FutureSalesOfDevelopedProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to future sales of a developed product.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_FutureSalesOfDevelopedProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Future Sales Of Developed Product [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_FutureSalesOfDevelopedProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Future sales of developed product</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_FutureGrossRevenuesDerivedFromPurchasedIntellectualPropertyMember" xlink:label="drts_FutureGrossRevenuesDerivedFromPurchasedIntellectualPropertyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_FutureGrossRevenuesDerivedFromPurchasedIntellectualPropertyMember" xlink:to="drts_FutureGrossRevenuesDerivedFromPurchasedIntellectualPropertyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_FutureGrossRevenuesDerivedFromPurchasedIntellectualPropertyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to future gross revenues derived from purchased intellectual property.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_FutureGrossRevenuesDerivedFromPurchasedIntellectualPropertyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Future Gross Revenues Derived From Purchased Intellectual Property [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_FutureGrossRevenuesDerivedFromPurchasedIntellectualPropertyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Future gross revenues derived from purchased intellectual property</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_NetSalesOfAllCompanySProductMember" xlink:label="drts_NetSalesOfAllCompanySProductMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_NetSalesOfAllCompanySProductMember" xlink:to="drts_NetSalesOfAllCompanySProductMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_NetSalesOfAllCompanySProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to net sales of all of the Company's products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_NetSalesOfAllCompanySProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Sales Of All Company's Product [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_NetSalesOfAllCompanySProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net sales of all of the Company's products</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_NetSalesOfAllCompanySProductSoldByCompanySLicensesMember" xlink:label="drts_NetSalesOfAllCompanySProductSoldByCompanySLicensesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_NetSalesOfAllCompanySProductSoldByCompanySLicensesMember" xlink:to="drts_NetSalesOfAllCompanySProductSoldByCompanySLicensesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_NetSalesOfAllCompanySProductSoldByCompanySLicensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to net sales of Company products sold by Company's licensees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_NetSalesOfAllCompanySProductSoldByCompanySLicensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Sales Of All Company's Product Sold By Company's Licenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_NetSalesOfAllCompanySProductSoldByCompanySLicensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net sales of Company products sold by Company's licensees</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_ReimbursementPriceMember" xlink:label="drts_ReimbursementPriceMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_ReimbursementPriceMember" xlink:to="drts_ReimbursementPriceMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_ReimbursementPriceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the reimbursement price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_ReimbursementPriceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reimbursement Price [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_ReimbursementPriceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reimbursement Price</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_DistributionReceiptsMember" xlink:label="drts_DistributionReceiptsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_DistributionReceiptsMember" xlink:to="drts_DistributionReceiptsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_DistributionReceiptsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to revenue from distribution receipts.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_DistributionReceiptsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Distribution Receipts [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_DistributionReceiptsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from distribution receipts</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_SalesOfAlphaRadiationProductsMember" xlink:label="drts_SalesOfAlphaRadiationProductsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_SalesOfAlphaRadiationProductsMember" xlink:to="drts_SalesOfAlphaRadiationProductsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_SalesOfAlphaRadiationProductsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to sales of alpha radiation products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_SalesOfAlphaRadiationProductsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales Of Alpha Radiation Products [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_SalesOfAlphaRadiationProductsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales of alpha radiation products</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_SalesOfProductContainingIntellectualPropertyMember" xlink:label="drts_SalesOfProductContainingIntellectualPropertyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_SalesOfProductContainingIntellectualPropertyMember" xlink:to="drts_SalesOfProductContainingIntellectualPropertyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_SalesOfProductContainingIntellectualPropertyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to sales of product containing intellectual property.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_SalesOfProductContainingIntellectualPropertyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales Of Product Containing Intellectual Property [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_SalesOfProductContainingIntellectualPropertyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales of product containing intellectual property</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_LicenseRevenueToJointlyDevelopedIntellectualPropertyMember" xlink:label="drts_LicenseRevenueToJointlyDevelopedIntellectualPropertyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_LicenseRevenueToJointlyDevelopedIntellectualPropertyMember" xlink:to="drts_LicenseRevenueToJointlyDevelopedIntellectualPropertyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_LicenseRevenueToJointlyDevelopedIntellectualPropertyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to sales of alpha radiation products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_LicenseRevenueToJointlyDevelopedIntellectualPropertyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Revenue To Jointly Developed Intellectual Property [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_LicenseRevenueToJointlyDevelopedIntellectualPropertyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License revenue related to jointly developed intellectual property</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_LicenseRevenueRelatedToIntellectualPropertyMember" xlink:label="drts_LicenseRevenueRelatedToIntellectualPropertyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_LicenseRevenueRelatedToIntellectualPropertyMember" xlink:to="drts_LicenseRevenueRelatedToIntellectualPropertyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_LicenseRevenueRelatedToIntellectualPropertyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to license revenue related to intellectual property.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_LicenseRevenueRelatedToIntellectualPropertyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Revenue Related To Intellectual Property [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_LicenseRevenueRelatedToIntellectualPropertyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License revenue related to intellectual property</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_RevenueGeneratedFromPatentMember" xlink:label="drts_RevenueGeneratedFromPatentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_RevenueGeneratedFromPatentMember" xlink:to="drts_RevenueGeneratedFromPatentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_RevenueGeneratedFromPatentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to revenue generated from patent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_RevenueGeneratedFromPatentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Generated From Patent [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_RevenueGeneratedFromPatentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue generated from patent</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_NetSalesSquamousCellCarcinomaMember" xlink:label="drts_NetSalesSquamousCellCarcinomaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_NetSalesSquamousCellCarcinomaMember" xlink:to="drts_NetSalesSquamousCellCarcinomaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_NetSalesSquamousCellCarcinomaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to net sales of treatment for Squamous Cell Carcinoma.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_NetSalesSquamousCellCarcinomaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Sales Squamous Cell Carcinoma [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_NetSalesSquamousCellCarcinomaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net sales of treatment for Squamous Cell Carcinoma</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_CommitmentsAndContingenciesLineItems" xlink:label="drts_CommitmentsAndContingenciesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_CommitmentsAndContingenciesLineItems" xlink:to="drts_CommitmentsAndContingenciesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_CommitmentsAndContingenciesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_CommitmentsAndContingenciesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments And Contingencies Line Items</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBankLoansAndNotesPayable" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBankLoansAndNotesPayable" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term Bank Loans and Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bank guarantee</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_GrantIncome" xlink:label="drts_GrantIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_GrantIncome" xlink:to="drts_GrantIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_GrantIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_GrantIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_GrantIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant income</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_RoyaltyRate" xlink:label="drts_RoyaltyRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_RoyaltyRate" xlink:to="drts_RoyaltyRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_RoyaltyRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage at which royalty payments will be paid out on.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_RoyaltyRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_RoyaltyRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty rate</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_RoyaltyPaymentAsPercentageOfGrants" xlink:label="drts_RoyaltyPaymentAsPercentageOfGrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_RoyaltyPaymentAsPercentageOfGrants" xlink:to="drts_RoyaltyPaymentAsPercentageOfGrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_RoyaltyPaymentAsPercentageOfGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage at which royalty payments will be paid out on relative to the amount of grants received plus interest at LIBOR rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_RoyaltyPaymentAsPercentageOfGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty Payment As A Percentage Of Grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_RoyaltyPaymentAsPercentageOfGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty payment as a percentage of grants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="us-gaap_LiabilitiesAssumed1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAssumed1" xlink:to="us-gaap_LiabilitiesAssumed1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAssumed1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities Assumed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAssumed1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities assumed</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_PotentialPayment" xlink:label="drts_PotentialPayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_PotentialPayment" xlink:to="drts_PotentialPayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_PotentialPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The maximum potential amount of payment based on a agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_PotentialPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potential Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_PotentialPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potential payment</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_MilestoneNumberOfOrdinaryStockOptions" xlink:label="drts_MilestoneNumberOfOrdinaryStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_MilestoneNumberOfOrdinaryStockOptions" xlink:to="drts_MilestoneNumberOfOrdinaryStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_MilestoneNumberOfOrdinaryStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of shares purchasable through stock options dependent on the achievement of various milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_MilestoneNumberOfOrdinaryStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone Number Of Ordinary Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_MilestoneNumberOfOrdinaryStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone number of ordinary stock options</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_StockOptionExercisePrice" xlink:label="drts_StockOptionExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_StockOptionExercisePrice" xlink:to="drts_StockOptionExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_StockOptionExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The per share exercise price of option.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_StockOptionExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Option Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_StockOptionExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock option exercise price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected dividend yield</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation assumptions</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_NumberOfScenariosInAllocatingValueToWarrants" xlink:label="drts_NumberOfScenariosInAllocatingValueToWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_NumberOfScenariosInAllocatingValueToWarrants" xlink:to="drts_NumberOfScenariosInAllocatingValueToWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_NumberOfScenariosInAllocatingValueToWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of scenarios used in allocating value of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_NumberOfScenariosInAllocatingValueToWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Scenarios In Allocating Value to Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_NumberOfScenariosInAllocatingValueToWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of scenarios to allocate equity value to warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingValuationTechniqueExtensibleList" xlink:label="us-gaap_WarrantsAndRightsOutstandingValuationTechniqueExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingValuationTechniqueExtensibleList" xlink:to="us-gaap_WarrantsAndRightsOutstandingValuationTechniqueExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingValuationTechniqueExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Outstanding, Valuation Technique [Extensible Enumeration]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingValuationTechniqueExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation technique</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Outstanding, Measurement Input</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation assumptions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liability Class [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value by Liability Class [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">End of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning of year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_IncomeTaxDisclosureTable" xlink:label="drts_IncomeTaxDisclosureTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_IncomeTaxDisclosureTable" xlink:to="drts_IncomeTaxDisclosureTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_IncomeTaxDisclosureTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of information pertaining to income taxes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_IncomeTaxDisclosureTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_IncomeTaxDisclosureTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Table]</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_AtmIncMember" xlink:label="drts_AtmIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_AtmIncMember" xlink:to="drts_AtmIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_AtmIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents ATM Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_AtmIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ATM Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_AtmIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ATM Inc</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="country_US" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">United States</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP" xlink:label="country_JP" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_JP" xlink:to="country_JP_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_JP_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Japan</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_IncomeTaxDisclosureLineItems" xlink:label="drts_IncomeTaxDisclosureLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_IncomeTaxDisclosureLineItems" xlink:to="drts_IncomeTaxDisclosureLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_IncomeTaxDisclosureLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_IncomeTaxDisclosureLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_IncomeTaxDisclosureLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">INCOME TAXES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate tax rate</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_IncomeTaxRateReconciliationPreferredCompanyPercent" xlink:label="drts_IncomeTaxRateReconciliationPreferredCompanyPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_IncomeTaxRateReconciliationPreferredCompanyPercent" xlink:to="drts_IncomeTaxRateReconciliationPreferredCompanyPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_IncomeTaxRateReconciliationPreferredCompanyPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of statutory tax rate applicable to pretax income (loss) for preferred company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_IncomeTaxRateReconciliationPreferredCompanyPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Rate Reconciliation, Preferred Company, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_IncomeTaxRateReconciliationPreferredCompanyPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred company tax rate</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_IncomeTaxRateReconciliationLargeCompaniesPercent" xlink:label="drts_IncomeTaxRateReconciliationLargeCompaniesPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_IncomeTaxRateReconciliationLargeCompaniesPercent" xlink:to="drts_IncomeTaxRateReconciliationLargeCompaniesPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_IncomeTaxRateReconciliationLargeCompaniesPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of statutory tax rate applicable to pretax income (loss) for large companies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_IncomeTaxRateReconciliationLargeCompaniesPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Rate Reconciliation, Large Companies, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_IncomeTaxRateReconciliationLargeCompaniesPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective statutory tax rate, large companies</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_IncomeTaxRateReconciliationSmallCompaniesPercent" xlink:label="drts_IncomeTaxRateReconciliationSmallCompaniesPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_IncomeTaxRateReconciliationSmallCompaniesPercent" xlink:to="drts_IncomeTaxRateReconciliationSmallCompaniesPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_IncomeTaxRateReconciliationSmallCompaniesPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of statutory tax rate applicable to pretax income (loss) for small companies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_IncomeTaxRateReconciliationSmallCompaniesPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Rate Reconciliation, Small Companies, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_IncomeTaxRateReconciliationSmallCompaniesPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective statutory tax rate, small companies</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_IncomeTaxRateReconciliationSmallCompaniesSpecialRatePercent" xlink:label="drts_IncomeTaxRateReconciliationSmallCompaniesSpecialRatePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_IncomeTaxRateReconciliationSmallCompaniesSpecialRatePercent" xlink:to="drts_IncomeTaxRateReconciliationSmallCompaniesSpecialRatePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_IncomeTaxRateReconciliationSmallCompaniesSpecialRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of special statutory tax rate applicable to pretax income (loss) for small companies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_IncomeTaxRateReconciliationSmallCompaniesSpecialRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Rate Reconciliation, Small Companies, Special Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_IncomeTaxRateReconciliationSmallCompaniesSpecialRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective statutory special tax rate, small companies</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_IncomeTaxRateReconciliationMediumCompaniesSpecialRatePercent" xlink:label="drts_IncomeTaxRateReconciliationMediumCompaniesSpecialRatePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_IncomeTaxRateReconciliationMediumCompaniesSpecialRatePercent" xlink:to="drts_IncomeTaxRateReconciliationMediumCompaniesSpecialRatePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_IncomeTaxRateReconciliationMediumCompaniesSpecialRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of special statutory tax rate applicable to pretax income (loss) for medium companies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_IncomeTaxRateReconciliationMediumCompaniesSpecialRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Rate Reconciliation, Medium Companies, Special Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_IncomeTaxRateReconciliationMediumCompaniesSpecialRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective statutory special tax rate, medium companies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of the net loss (income) before tax on income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Domestic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Domestic (Israel)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Foreign</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Foreign Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current income tax expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated losses for tax purposes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Deferred Tax Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant components of deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Returns and Allowances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reserves and allowances</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, in Process Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">R&amp;D expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Goodwill and Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss carryforward</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets before valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less - valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, by Class of Stock [Table]</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_SeriesConvertiblePreferredSharesMember" xlink:label="drts_SeriesConvertiblePreferredSharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_SeriesConvertiblePreferredSharesMember" xlink:to="drts_SeriesConvertiblePreferredSharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_SeriesConvertiblePreferredSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents Series A Convertible Preferred shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_SeriesConvertiblePreferredSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A Convertible Preferred Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_SeriesConvertiblePreferredSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A Convertible Preferred shares</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_SeriesBConvertiblePreferredSharesMember" xlink:label="drts_SeriesBConvertiblePreferredSharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_SeriesBConvertiblePreferredSharesMember" xlink:to="drts_SeriesBConvertiblePreferredSharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_SeriesBConvertiblePreferredSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents Series B Convertible Preferred shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_SeriesBConvertiblePreferredSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B Convertible Preferred Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_SeriesBConvertiblePreferredSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B Convertible Preferred shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Liquidation Preference</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liquidation preference</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Dividend Rate, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividend rate, as a percent of original issue price</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_TemporaryEquityDistributionRateFromProceedsOfSaleAnotherClassOfShares" xlink:label="drts_TemporaryEquityDistributionRateFromProceedsOfSaleAnotherClassOfShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_TemporaryEquityDistributionRateFromProceedsOfSaleAnotherClassOfShares" xlink:to="drts_TemporaryEquityDistributionRateFromProceedsOfSaleAnotherClassOfShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_TemporaryEquityDistributionRateFromProceedsOfSaleAnotherClassOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The minimum distribution rate from the proceeds of full payment of another class of temporary equity, as percentage of the original issuance price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_TemporaryEquityDistributionRateFromProceedsOfSaleAnotherClassOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Distribution Rate from Proceeds of Sale Another Class of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_TemporaryEquityDistributionRateFromProceedsOfSaleAnotherClassOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Distribution rate from proceeds of the full payment of Series B Preference, as percent of issue price</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_TemporaryEquityNumberOfVotes" xlink:label="drts_TemporaryEquityNumberOfVotes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_TemporaryEquityNumberOfVotes" xlink:to="drts_TemporaryEquityNumberOfVotes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_TemporaryEquityNumberOfVotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of votes each temporary equity is entitled to.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_TemporaryEquityNumberOfVotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Number of Votes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_TemporaryEquityNumberOfVotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of vote entitle to</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionRatio" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Convertible, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion ratio</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Number of Shares Issued in Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_SaleOfStockNumberOfWarrantsIssuedInTransaction" xlink:label="drts_SaleOfStockNumberOfWarrantsIssuedInTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_SaleOfStockNumberOfWarrantsIssuedInTransaction" xlink:to="drts_SaleOfStockNumberOfWarrantsIssuedInTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_SaleOfStockNumberOfWarrantsIssuedInTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of warrants issued in relation to the issuance of shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_SaleOfStockNumberOfWarrantsIssuedInTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Number of Warrants Issued in Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_SaleOfStockNumberOfWarrantsIssuedInTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Redeemable Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consideration for issuance of shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Price per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Stock, Shares Converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred shares that can be converted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares can be issued for conversion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price of warrants (in dollar per share)</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_WarrantsGrantedIncreaseFromNewFinancing" xlink:label="drts_WarrantsGrantedIncreaseFromNewFinancing" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_WarrantsGrantedIncreaseFromNewFinancing" xlink:to="drts_WarrantsGrantedIncreaseFromNewFinancing_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_WarrantsGrantedIncreaseFromNewFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage increase in the number of warrants granted due to fresh financing agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_WarrantsGrantedIncreaseFromNewFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Granted, Increase From New Financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_WarrantsGrantedIncreaseFromNewFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional warrants granted (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stock by Class [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_HekabioK.k.Member" xlink:label="drts_HekabioK.k.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_HekabioK.k.Member" xlink:to="drts_HekabioK.k.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_HekabioK.k.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents HekaBio K.K.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_HekabioK.k.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">HekaBio K.K. [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SHAREHOLDERS' DEFICIENCY</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_SharesNumberOfVotes" xlink:label="drts_SharesNumberOfVotes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_SharesNumberOfVotes" xlink:to="drts_SharesNumberOfVotes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_SharesNumberOfVotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of votes each share is entitled to.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_SharesNumberOfVotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Number of Votes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_SharesNumberOfVotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of vote entitled to</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_ShareOptionPlanMember" xlink:label="drts_ShareOptionPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_ShareOptionPlanMember" xlink:to="drts_ShareOptionPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_ShareOptionPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents Share Option Plan (the "Plan").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_ShareOptionPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Option Plan [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Authorized awards (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expiration period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available for future grants (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grantee Status [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grantee Status [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Employee [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonemployee [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at end of year (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at beginning of year (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited and cancelled (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable options (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at end of year (in dollar per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at beginning of year (in dollar per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in dollar per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price of the options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised (in dollar per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited and cancelled (in dollar per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable options (in dollar per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate intrinsic value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at year end</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at year end</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of RSU</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding on December 31, 2021</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at beginning of year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited and cancelled</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="us-gaap_SellingAndMarketingExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpenseMember" xlink:to="us-gaap_SellingAndMarketingExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling and Marketing Expense [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">unrecognized compensation costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average period of recognition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average grant date fair value of options granted</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_WarrantsExercisedCashBasis" xlink:label="drts_WarrantsExercisedCashBasis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_WarrantsExercisedCashBasis" xlink:to="drts_WarrantsExercisedCashBasis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_WarrantsExercisedCashBasis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number warrants exercised on a cash basis.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_WarrantsExercisedCashBasis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Exercised, Cash Basis</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_WarrantsExercisedCashBasis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants exercised on cash basis (in shares)</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_WarrantsExercisedCashlessBasis" xlink:label="drts_WarrantsExercisedCashlessBasis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_WarrantsExercisedCashlessBasis" xlink:to="drts_WarrantsExercisedCashlessBasis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_WarrantsExercisedCashlessBasis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number warrants exercised on a cashless basis.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_WarrantsExercisedCashlessBasis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Exercised, Cashless Basis</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_WarrantsExercisedCashlessBasis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants exercised on cashless basis</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_WarrantsToOrdinaryShareRatioCashlessExercise" xlink:label="drts_WarrantsToOrdinaryShareRatioCashlessExercise" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_WarrantsToOrdinaryShareRatioCashlessExercise" xlink:to="drts_WarrantsToOrdinaryShareRatioCashlessExercise_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_WarrantsToOrdinaryShareRatioCashlessExercise_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The ratio of warrant to ordinary shares in a cashless exercise of warrant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_WarrantsToOrdinaryShareRatioCashlessExercise_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Ordinary Share Ratio, Cashless Exercise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_WarrantsToOrdinaryShareRatioCashlessExercise_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants exercise on cashless basis to ordinary shares ratio</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Outstanding, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant term</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_NumberOfWarrantsExercised" xlink:label="drts_NumberOfWarrantsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_NumberOfWarrantsExercised" xlink:to="drts_NumberOfWarrantsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_NumberOfWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of warrants exercised in the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_NumberOfWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_NumberOfWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non Operating Income (Expense)</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_NonOperatingFinancialExpensesAbstract" xlink:label="drts_NonOperatingFinancialExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_NonOperatingFinancialExpensesAbstract" xlink:to="drts_NonOperatingFinancialExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_NonOperatingFinancialExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_NonOperatingFinancialExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non Operating Financial Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_NonOperatingFinancialExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionLossBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionLossBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Transaction Loss, before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency transaction loss, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Adjustment of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remeasurement of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Others</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_FinancialExpensesTotal" xlink:label="drts_FinancialExpensesTotal" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_FinancialExpensesTotal" xlink:to="drts_FinancialExpensesTotal_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_FinancialExpensesTotal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total expense included in Net Financial Expense (Income).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_FinancialExpensesTotal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Expenses Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="drts_FinancialExpensesTotal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total financial expenses</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_NonOperatingFinancialIncomeAbstract" xlink:label="drts_NonOperatingFinancialIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_NonOperatingFinancialIncomeAbstract" xlink:to="drts_NonOperatingFinancialIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_NonOperatingFinancialIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_NonOperatingFinancialIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non Operating Financial Income [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_NonOperatingFinancialIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial income:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Transaction Gain (Loss), before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency transaction profit, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:to="us-gaap_InterestIncomeDepositsWithFinancialInstitutions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Income, Deposits with Financial Institutions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest from deposits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Others</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_FinancialIncomeTotal" xlink:label="drts_FinancialIncomeTotal" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_FinancialIncomeTotal" xlink:to="drts_FinancialIncomeTotal_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_FinancialIncomeTotal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total income included in Net Financial Expense (Income).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_FinancialIncomeTotal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Income Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="drts_FinancialIncomeTotal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total financial income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding share options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockCompensationPlanMember" xlink:to="us-gaap_StockCompensationPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RSU</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_WarrantsToPreferredSharesMember" xlink:label="drts_WarrantsToPreferredSharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_WarrantsToPreferredSharesMember" xlink:to="drts_WarrantsToPreferredSharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_WarrantsToPreferredSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security that gives the holder the right to purchase shares of Preferred A stock in accordance with the terms of the instrument.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_WarrantsToPreferredSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants To Preferred A Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_WarrantsToPreferredSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant to Preferred A shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_NumeratorAbstract" xlink:label="drts_NumeratorAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_NumeratorAbstract" xlink:to="drts_NumeratorAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_NumeratorAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_NumeratorAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Numerator [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_NumeratorAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Numerator:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="us-gaap_IncomeLossFromContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperations" xlink:to="us-gaap_IncomeLossFromContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss attributable to Ordinary shareholders</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_DenominatorAbstract" xlink:label="drts_DenominatorAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_DenominatorAbstract" xlink:to="drts_DenominatorAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_DenominatorAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_DenominatorAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Denominator [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_DenominatorAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Denominator:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations, Per Basic Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share attributable to ordinary shareholders, basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations, Per Diluted Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share attributable to ordinary shareholders, diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive securities excluded from calculation of net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IL" xlink:label="country_IL" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_IL" xlink:to="country_IL_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_IL_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Israel</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:label="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:to="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting Items</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of operating segment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_BankLeumiLeIsraelBmMember" xlink:label="drts_BankLeumiLeIsraelBmMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_BankLeumiLeIsraelBmMember" xlink:to="drts_BankLeumiLeIsraelBmMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_BankLeumiLeIsraelBmMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Bank Leumi Le-Israel BM.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_BankLeumiLeIsraelBmMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bank Leumi Le-Israel BM [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_BankLeumiLeIsraelBmMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bank Leumi Le-Israel BM</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition, Acquiree [Domain]</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_HcccMember" xlink:label="drts_HcccMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_HcccMember" xlink:to="drts_HcccMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_HcccMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This members stands for the merger with HCCC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_HcccMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">HCCC [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_HcccMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">HCCC</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PledgedFinancialInstrumentsNotSeparatelyReportedSecuritiesForLetterOfCreditFacilities" xlink:label="us-gaap_PledgedFinancialInstrumentsNotSeparatelyReportedSecuritiesForLetterOfCreditFacilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PledgedFinancialInstrumentsNotSeparatelyReportedSecuritiesForLetterOfCreditFacilities" xlink:to="us-gaap_PledgedFinancialInstrumentsNotSeparatelyReportedSecuritiesForLetterOfCreditFacilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PledgedFinancialInstrumentsNotSeparatelyReportedSecuritiesForLetterOfCreditFacilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pledged Financial Instruments, Not Separately Reported, Securities for Letter of Credit Facilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PledgedFinancialInstrumentsNotSeparatelyReportedSecuritiesForLetterOfCreditFacilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Standby letter of credit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ordinary share price</label>
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_CommonStockCancelledAndConvertedInToShares" xlink:label="drts_CommonStockCancelledAndConvertedInToShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="drts_CommonStockCancelledAndConvertedInToShares" xlink:to="drts_CommonStockCancelledAndConvertedInToShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="drts_CommonStockCancelledAndConvertedInToShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The common stock cancelled automatically and converted into one share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="drts_CommonStockCancelledAndConvertedInToShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Cancelled And Converted in to Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="drts_CommonStockCancelledAndConvertedInToShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock cancelled and converted into share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAcquiredFromAcquisition" xlink:to="us-gaap_CashAcquiredFromAcquisition_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Acquired from Acquisition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash proceeds in connection with merger</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>drts-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/28/2022 8:47:09 PM-->
<!--Modified on: 3/28/2022 8:47:09 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.alphatau.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.alphatau.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.alphatau.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#StatementConsolidatedStatementOfOperations" roleURI="http://www.alphatau.com/role/StatementConsolidatedStatementOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#StatementConsolidatedStatementsOfOperationsParenthetical" roleURI="http://www.alphatau.com/role/StatementConsolidatedStatementsOfOperationsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredSharesAndShareholdersDeficiency" roleURI="http://www.alphatau.com/role/StatementConsolidatedStatementsOfConvertiblePreferredSharesAndShareholdersDeficiency" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredSharesAndShareholdersDeficiencyParenthetical" roleURI="http://www.alphatau.com/role/StatementConsolidatedStatementsOfConvertiblePreferredSharesAndShareholdersDeficiencyParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureGeneral" roleURI="http://www.alphatau.com/role/DisclosureGeneral" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureSignificantAccountingPolicies" roleURI="http://www.alphatau.com/role/DisclosureSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosurePrepaidExpensesAndOtherReceivables" roleURI="http://www.alphatau.com/role/DisclosurePrepaidExpensesAndOtherReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosurePropertyAndEquipmentNet" roleURI="http://www.alphatau.com/role/DisclosurePropertyAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureOtherPayablesAndAccruedExpenses" roleURI="http://www.alphatau.com/role/DisclosureOtherPayablesAndAccruedExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureCommitmentsAndContingentLiabilities" roleURI="http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureFairValueMeasurements" roleURI="http://www.alphatau.com/role/DisclosureFairValueMeasurements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureIncomeTaxes" roleURI="http://www.alphatau.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureConvertiblePreferredSharesAndWarrants" roleURI="http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureShareholdersDeficiency" roleURI="http://www.alphatau.com/role/DisclosureShareholdersDeficiency" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureFinancialExpensesNet" roleURI="http://www.alphatau.com/role/DisclosureFinancialExpensesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureBasicAndDilutedNetLossPerShare" roleURI="http://www.alphatau.com/role/DisclosureBasicAndDilutedNetLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureGeographicInformation" roleURI="http://www.alphatau.com/role/DisclosureGeographicInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureSubsequentEvents" roleURI="http://www.alphatau.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureSignificantAccountingPoliciesPolicies" roleURI="http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureSignificantAccountingPoliciesTables" roleURI="http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosurePrepaidExpensesAndOtherReceivablesTables" roleURI="http://www.alphatau.com/role/DisclosurePrepaidExpensesAndOtherReceivablesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosurePropertyAndEquipmentNetTables" roleURI="http://www.alphatau.com/role/DisclosurePropertyAndEquipmentNetTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureOtherPayablesAndAccruedExpensesTables" roleURI="http://www.alphatau.com/role/DisclosureOtherPayablesAndAccruedExpensesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureCommitmentsAndContingentLiabilitiesTables" roleURI="http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureFairValueMeasurementsTables" roleURI="http://www.alphatau.com/role/DisclosureFairValueMeasurementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.alphatau.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureConvertiblePreferredSharesAndWarrantsTables" roleURI="http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureShareholdersDeficiencyTables" roleURI="http://www.alphatau.com/role/DisclosureShareholdersDeficiencyTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureFinancialExpensesNetTables" roleURI="http://www.alphatau.com/role/DisclosureFinancialExpensesNetTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureBasicAndDilutedNetLossPerShareTables" roleURI="http://www.alphatau.com/role/DisclosureBasicAndDilutedNetLossPerShareTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureGeographicInformationTables" roleURI="http://www.alphatau.com/role/DisclosureGeographicInformationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureGeneralDetails" roleURI="http://www.alphatau.com/role/DisclosureGeneralDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureSignificantAccountingPoliciesRestrictedCashDetails" roleURI="http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesRestrictedCashDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureSignificantAccountingPoliciesShortTermDepositsDetails" roleURI="http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesShortTermDepositsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureSignificantAccountingPoliciesPropertyAndEquipmentAndImpairmentDetails" roleURI="http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentAndImpairmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureSignificantAccountingPoliciesShareBasedPaymentsDetails" roleURI="http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesShareBasedPaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureSignificantAccountingPoliciesGrantsAndParticipationsOrdinaryShareWarrantsClassificationAndMeasurementDetails" roleURI="http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesGrantsAndParticipationsOrdinaryShareWarrantsClassificationAndMeasurementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureSignificantAccountingPoliciesSeverancePayDetails" roleURI="http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesSeverancePayDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureSignificantAccountingPoliciesContingentLiabilitiesDetails" roleURI="http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesContingentLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureSignificantAccountingPoliciesDeferredTransactionCostsDetails" roleURI="http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesDeferredTransactionCostsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosurePrepaidExpensesAndOtherReceivablesDetails" roleURI="http://www.alphatau.com/role/DisclosurePrepaidExpensesAndOtherReceivablesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" roleURI="http://www.alphatau.com/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureOtherPayablesAndAccruedExpensesDetails" roleURI="http://www.alphatau.com/role/DisclosureOtherPayablesAndAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureCommitmentsAndContingentLiabilitiesDetails" roleURI="http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureCommitmentsAndContingentLiabilitiesAdditionalDetails" roleURI="http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesAdditionalDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureFairValueMeasurementsValuationAssumptionsDetails" roleURI="http://www.alphatau.com/role/DisclosureFairValueMeasurementsValuationAssumptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureFairValueMeasurementsChangesInFairValueDetails" roleURI="http://www.alphatau.com/role/DisclosureFairValueMeasurementsChangesInFairValueDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureIncomeTaxesTaxRatesDetails" roleURI="http://www.alphatau.com/role/DisclosureIncomeTaxesTaxRatesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureIncomeTaxesNetLossIncomeBeforeTaxDetails" roleURI="http://www.alphatau.com/role/DisclosureIncomeTaxesNetLossIncomeBeforeTaxDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureIncomeTaxesIncomeTaxExpenseDetails" roleURI="http://www.alphatau.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureIncomeTaxesNetOperatingLossesCarryDetails" roleURI="http://www.alphatau.com/role/DisclosureIncomeTaxesNetOperatingLossesCarryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureIncomeTaxesDeferredTaxesDetails" roleURI="http://www.alphatau.com/role/DisclosureIncomeTaxesDeferredTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureConvertiblePreferredSharesAndWarrantsCompositionOfConvertiblePreferredSharesDetails" roleURI="http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsCompositionOfConvertiblePreferredSharesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureConvertiblePreferredSharesAndWarrantsPreferredSharesRightsDetails" roleURI="http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsPreferredSharesRightsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureConvertiblePreferredSharesAndWarrantsFinancingRoundsDetails" roleURI="http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsFinancingRoundsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureConvertiblePreferredSharesAndWarrantsPreferredSharesWarrantsDetails" roleURI="http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsPreferredSharesWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureShareholdersDeficiencyOrdinaryShareCapitalDetails" roleURI="http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOrdinaryShareCapitalDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureShareholdersDeficiencyShareOptionPlanDetails" roleURI="http://www.alphatau.com/role/DisclosureShareholdersDeficiencyShareOptionPlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureShareholdersDeficiencyOptionsChangesDetails" roleURI="http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOptionsChangesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureShareholdersDeficiencyRsusDetails" roleURI="http://www.alphatau.com/role/DisclosureShareholdersDeficiencyRsusDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureShareholdersDeficiencyEquityBasedCompensationExpenseDetails" roleURI="http://www.alphatau.com/role/DisclosureShareholdersDeficiencyEquityBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureShareholdersDeficiencyWarrantsDetails" roleURI="http://www.alphatau.com/role/DisclosureShareholdersDeficiencyWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureFinancialExpensesNetDetails" roleURI="http://www.alphatau.com/role/DisclosureFinancialExpensesNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureBasicAndDilutedNetLossPerShareDetails" roleURI="http://www.alphatau.com/role/DisclosureBasicAndDilutedNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureGeographicInformationDetails" roleURI="http://www.alphatau.com/role/DisclosureGeographicInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="drts-20211231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.alphatau.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.alphatau.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637840972285798512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="us-gaap_StatementTable_637840972285798512" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637840972285798512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637840972285798512" xlink:to="us-gaap_StatementEquityComponentsAxis_637840972285798512" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637840972285798512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637840972285798512" xlink:to="us-gaap_EquityComponentDomain_637840972285798512" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637840972285798512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637840972285798512" xlink:to="us-gaap_CommonStockMember_637840972285798512" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember_637840972285798512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637840972285798512" xlink:to="us-gaap_PreferredStockMember_637840972285798512" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_637840972285798512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637840972285798512" xlink:to="us-gaap_WarrantMember_637840972285798512" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis_637840972285798512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637840972285798512" xlink:to="dei_EntityAddressesAddressTypeAxis_637840972285798512" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain_637840972285798512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis_637840972285798512" xlink:to="dei_AddressTypeDomain_637840972285798512" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_BusinessContactMember" xlink:label="dei_BusinessContactMember_637840972285808533" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_AddressTypeDomain_637840972285798512" xlink:to="dei_BusinessContactMember_637840972285808533" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637840972285808533" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637840972285798512" xlink:to="us-gaap_StatementLineItems_637840972285808533" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637840972285808533" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637840972285808533" xlink:to="dei_DocumentType_637840972285808533" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement_637840972285808533" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637840972285808533" xlink:to="dei_DocumentRegistrationStatement_637840972285808533" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_637840972285808533" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637840972285808533" xlink:to="dei_DocumentAnnualReport_637840972285808533" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_637840972285808533" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637840972285808533" xlink:to="dei_DocumentTransitionReport_637840972285808533" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport_637840972285808533" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637840972285808533" xlink:to="dei_DocumentShellCompanyReport_637840972285808533" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637840972285808533" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637840972285808533" xlink:to="dei_DocumentPeriodEndDate_637840972285808533" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637840972285808533" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637840972285808533" xlink:to="dei_EntityFileNumber_637840972285808533" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637840972285808533" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637840972285808533" xlink:to="dei_EntityRegistrantName_637840972285808533" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637840972285818524" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637840972285808533" xlink:to="dei_EntityIncorporationStateCountryCode_637840972285818524" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelName" xlink:label="dei_ContactPersonnelName_637840972285818524" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637840972285808533" xlink:to="dei_ContactPersonnelName_637840972285818524" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637840972285818524" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637840972285808533" xlink:to="dei_EntityAddressAddressLine1_637840972285818524" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637840972285818524" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637840972285808533" xlink:to="dei_EntityAddressCityOrTown_637840972285818524" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry_637840972285818524" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637840972285808533" xlink:to="dei_EntityAddressCountry_637840972285818524" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637840972285818524" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637840972285808533" xlink:to="dei_EntityAddressPostalZipCode_637840972285818524" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637840972285818524" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637840972285808533" xlink:to="dei_CityAreaCode_637840972285818524" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637840972285818524" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637840972285808533" xlink:to="dei_LocalPhoneNumber_637840972285818524" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637840972285828496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637840972285808533" xlink:to="dei_Security12bTitle_637840972285828496" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637840972285828496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637840972285808533" xlink:to="dei_TradingSymbol_637840972285828496" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637840972285828496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637840972285808533" xlink:to="dei_SecurityExchangeName_637840972285828496" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_637840972285828496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637840972285808533" xlink:to="dei_EntityWellKnownSeasonedIssuer_637840972285828496" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_637840972285828496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637840972285808533" xlink:to="dei_EntityVoluntaryFilers_637840972285828496" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_637840972285828496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637840972285808533" xlink:to="dei_EntityCurrentReportingStatus_637840972285828496" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_637840972285828496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637840972285808533" xlink:to="dei_EntityInteractiveDataCurrent_637840972285828496" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_637840972285838499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637840972285808533" xlink:to="dei_EntityFilerCategory_637840972285838499" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637840972285838499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637840972285808533" xlink:to="dei_EntityEmergingGrowthCompany_637840972285838499" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_637840972285838499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637840972285808533" xlink:to="dei_EntityExTransitionPeriod_637840972285838499" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard_637840972285838499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637840972285808533" xlink:to="dei_DocumentAccountingStandard_637840972285838499" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_637840972285838499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637840972285808533" xlink:to="dei_IcfrAuditorAttestationFlag_637840972285838499" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_637840972285838499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637840972285808533" xlink:to="dei_EntityShellCompany_637840972285838499" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_637840972285848172" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637840972285808533" xlink:to="dei_EntityCommonStockSharesOutstanding_637840972285848172" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637840972285848172" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637840972285808533" xlink:to="dei_EntityCentralIndexKey_637840972285848172" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_637840972285848172" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637840972285808533" xlink:to="dei_CurrentFiscalYearEndDate_637840972285848172" order="32" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_637840972285848172" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637840972285808533" xlink:to="dei_DocumentFiscalYearFocus_637840972285848172" order="33" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_637840972285848172" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637840972285808533" xlink:to="dei_DocumentFiscalPeriodFocus_637840972285848172" order="34" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637840972285858541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637840972285808533" xlink:to="dei_AmendmentFlag_637840972285858541" order="35" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName_637840972285858541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637840972285808533" xlink:to="dei_AuditorName_637840972285858541" order="36" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_637840972285858541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637840972285808533" xlink:to="dei_AuditorLocation_637840972285858541" order="37" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_637840972285858541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637840972285808533" xlink:to="dei_AuditorFirmId_637840972285858541" order="38" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_637840972285868586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_637840972285868586" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_637840972285868586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637840972285868586" xlink:to="us-gaap_AssetsCurrentAbstract_637840972285868586" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637840972285868586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637840972285868586" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637840972285868586" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_637840972285868586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637840972285868586" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_637840972285868586" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedInvestmentsCurrent" xlink:label="us-gaap_RestrictedInvestmentsCurrent_637840972285868586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637840972285868586" xlink:to="us-gaap_RestrictedInvestmentsCurrent_637840972285868586" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637840972285868586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637840972285868586" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637840972285868586" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637840972285868586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637840972285868586" xlink:to="us-gaap_AssetsCurrent_637840972285868586" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_LongTermAssetsAbstract" xlink:label="drts_LongTermAssetsAbstract_637840972285868586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637840972285868586" xlink:to="drts_LongTermAssetsAbstract_637840972285868586" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent_637840972285868586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_LongTermAssetsAbstract_637840972285868586" xlink:to="us-gaap_PrepaidExpenseNoncurrent_637840972285868586" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637840972285868586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_LongTermAssetsAbstract_637840972285868586" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637840972285868586" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent_637840972285868586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_LongTermAssetsAbstract_637840972285868586" xlink:to="us-gaap_AssetsNoncurrent_637840972285868586" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637840972285878410" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637840972285868586" xlink:to="us-gaap_Assets_637840972285878410" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637840972285878410" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637840972285878410" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_637840972285878410" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637840972285878410" xlink:to="us-gaap_LiabilitiesCurrentAbstract_637840972285878410" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637840972285878410" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637840972285878410" xlink:to="us-gaap_AccountsPayableCurrent_637840972285878410" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_637840972285878410" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637840972285878410" xlink:to="us-gaap_OtherLiabilitiesCurrent_637840972285878410" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637840972285878410" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637840972285878410" xlink:to="us-gaap_LiabilitiesCurrent_637840972285878410" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_LongTermLiabilitiesAbstract" xlink:label="drts_LongTermLiabilitiesAbstract_637840972285878410" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637840972285878410" xlink:to="drts_LongTermLiabilitiesAbstract_637840972285878410" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_Warrantliability" xlink:label="drts_Warrantliability_637840972285878410" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_LongTermLiabilitiesAbstract_637840972285878410" xlink:to="drts_Warrantliability_637840972285878410" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637840972285878410" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637840972285878410" xlink:to="us-gaap_Liabilities_637840972285878410" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_637840972285878410" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637840972285878410" xlink:to="us-gaap_CommitmentsAndContingencies_637840972285878410" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637840972285878410" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637840972285878410" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637840972285878410" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_637840972285888417" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637840972285878410" xlink:to="us-gaap_StockholdersEquityAbstract_637840972285888417" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValueOutstanding" xlink:label="us-gaap_CommonStockValueOutstanding_637840972285888417" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637840972285888417" xlink:to="us-gaap_CommonStockValueOutstanding_637840972285888417" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637840972285888417" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637840972285888417" xlink:to="us-gaap_AdditionalPaidInCapital_637840972285888417" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637840972285888417" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637840972285888417" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637840972285888417" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637840972285888417" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637840972285888417" xlink:to="us-gaap_StockholdersEquity_637840972285888417" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637840972285888417" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637840972285878410" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_637840972285888417" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_637840972285888417" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_637840972285888417" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_637840972285898414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_637840972285898414" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued_637840972285898414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_TemporaryEquitySharesIssued_637840972285898414" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_637840972285898414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_637840972285898414" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637840972285898414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637840972285898414" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637840972285898414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_CommonStockSharesAuthorized_637840972285898414" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637840972285898414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_CommonStockSharesIssued_637840972285898414" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637840972285898414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_CommonStockSharesOutstanding_637840972285898414" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_637840972285898414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_637840972285898414" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/StatementConsolidatedStatementOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENT OF OPERATIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637840972285898414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637840972285898414" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketingExpense" xlink:label="us-gaap_MarketingExpense_637840972285898414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_MarketingExpense_637840972285898414" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637840972285898414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637840972285898414" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637840972285898414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss_637840972285898414" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingGainsLosses" xlink:label="us-gaap_NonoperatingGainsLosses_637840972285908401" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingGainsLosses_637840972285908401" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637840972285908401" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637840972285908401" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637840972285908401" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637840972285908401" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_637840972285908401" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_637840972285908401" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_637840972286008095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_637840972286008095" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637840972286008095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_637840972286008095" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_637840972286008095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic_637840972286008095" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_637840972286008095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted_637840972286008095" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637840972286008095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637840972286008095" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637840972286008095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637840972286008095" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/StatementConsolidatedStatementsOfOperationsParenthetical" xlink:type="extended" xlink:title="00205 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_637840972286018419" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_637840972286018419" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/StatementConsolidatedStatementsOfConvertiblePreferredSharesAndShareholdersDeficiency" xlink:type="extended" xlink:title="00300 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS' DEFICIENCY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637840972286018419" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_637840972286018419" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637840972286018419" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637840972286018419" xlink:to="us-gaap_StatementEquityComponentsAxis_637840972286018419" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637840972286018419" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637840972286018419" xlink:to="us-gaap_EquityComponentDomain_637840972286018419" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember_637840972286018419" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637840972286018419" xlink:to="us-gaap_PreferredStockMember_637840972286018419" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637840972286018419" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637840972286018419" xlink:to="us-gaap_CommonStockMember_637840972286018419" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_637840972286018419" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637840972286018419" xlink:to="us-gaap_AdditionalPaidInCapitalMember_637840972286018419" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_637840972286018419" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637840972286018419" xlink:to="us-gaap_RetainedEarningsMember_637840972286018419" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember_637840972286018419" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637840972286018419" xlink:to="us-gaap_NoncontrollingInterestMember_637840972286018419" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637840972286018419" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637840972286018419" xlink:to="us-gaap_StatementClassOfStockAxis_637840972286018419" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637840972286028426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637840972286018419" xlink:to="us-gaap_ClassOfStockDomain_637840972286028426" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_637840972286028426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637840972286028426" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_637840972286028426" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_637840972286028426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637840972286028426" xlink:to="us-gaap_CommonClassAMember_637840972286028426" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637840972286028426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637840972286018419" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637840972286028426" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637840972286028426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637840972286028426" xlink:to="us-gaap_StockholdersEquity_637840972286028426" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_637840972286028426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637840972286028426" xlink:to="us-gaap_SharesIssued_637840972286028426" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_637840972286028426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637840972286028426" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_637840972286028426" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_AdjustmentsToAdditionalPaidInCapitalWarrantSharesIssued" xlink:label="drts_AdjustmentsToAdditionalPaidInCapitalWarrantSharesIssued_637840972286028426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637840972286028426" xlink:to="drts_AdjustmentsToAdditionalPaidInCapitalWarrantSharesIssued_637840972286028426" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_StockIssuedDuringPeriodValueOrdinarySharesUponExerciseOfShareOptions" xlink:label="drts_StockIssuedDuringPeriodValueOrdinarySharesUponExerciseOfShareOptions_637840972286028426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637840972286028426" xlink:to="drts_StockIssuedDuringPeriodValueOrdinarySharesUponExerciseOfShareOptions_637840972286028426" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_StockIssuedDuringPeriodSharesOrdinarySharesUponExerciseOfShareOptions" xlink:label="drts_StockIssuedDuringPeriodSharesOrdinarySharesUponExerciseOfShareOptions_637840972286028426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637840972286028426" xlink:to="drts_StockIssuedDuringPeriodSharesOrdinarySharesUponExerciseOfShareOptions_637840972286028426" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="drts_StockIssuedDuringPeriodValueExerciseOfWarrants_637840972286028426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637840972286028426" xlink:to="drts_StockIssuedDuringPeriodValueExerciseOfWarrants_637840972286028426" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="drts_StockIssuedDuringPeriodSharesExerciseOfWarrants_637840972286028426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637840972286028426" xlink:to="drts_StockIssuedDuringPeriodSharesExerciseOfWarrants_637840972286028426" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637840972286038405" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637840972286028426" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637840972286038405" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_637840972286038405" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637840972286028426" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_637840972286038405" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="drts_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_637840972286038405" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637840972286028426" xlink:to="drts_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_637840972286038405" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637840972286038405" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637840972286028426" xlink:to="us-gaap_NetIncomeLoss_637840972286038405" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_637840972286038405" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637840972286028426" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_637840972286038405" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_637840972286038405" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637840972286028426" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_637840972286038405" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:label="us-gaap_ProceedsFromPaymentsToMinorityShareholders_637840972286038405" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637840972286028426" xlink:to="us-gaap_ProceedsFromPaymentsToMinorityShareholders_637840972286038405" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637840972286038405" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637840972286028426" xlink:to="us-gaap_StockholdersEquity_637840972286038405" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_637840972286038405" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637840972286028426" xlink:to="us-gaap_SharesIssued_637840972286038405" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/StatementConsolidatedStatementsOfConvertiblePreferredSharesAndShareholdersDeficiencyParenthetical" xlink:type="extended" xlink:title="00305 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS' DEFICIENCY (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_637840972286048391" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract_1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_637840972286048391" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_637840972286048391" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract_1" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_637840972286048391" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637840972286048391" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_1" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637840972286048391" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637840972286048391" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637840972286048391" xlink:to="us-gaap_ProfitLoss_637840972286048391" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637840972286048391" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_1" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637840972286048391" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637840972286048391" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637840972286048391" xlink:to="us-gaap_Depreciation_637840972286048391" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637840972286058490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637840972286048391" xlink:to="us-gaap_ShareBasedCompensation_637840972286058490" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637840972286058490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637840972286048391" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637840972286058490" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_637840972286058490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637840972286048391" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_637840972286058490" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_IncreaseDecreaseInFairValueOfWarrantsConvertiblePreferredShares" xlink:label="drts_IncreaseDecreaseInFairValueOfWarrantsConvertiblePreferredShares_637840972286058490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637840972286048391" xlink:to="drts_IncreaseDecreaseInFairValueOfWarrantsConvertiblePreferredShares_637840972286058490" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_IncreaseDecreaseInNonCashFinancialIncomeExpenses" xlink:label="drts_IncreaseDecreaseInNonCashFinancialIncomeExpenses_637840972286058490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637840972286048391" xlink:to="drts_IncreaseDecreaseInNonCashFinancialIncomeExpenses_637840972286058490" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_637840972286058490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637840972286048391" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_637840972286058490" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_637840972286058490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637840972286048391" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_637840972286058490" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637840972286058490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637840972286048391" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637840972286058490" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637840972286058490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_1" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637840972286058490" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseOfRestrictedInvestments" xlink:label="us-gaap_IncreaseDecreaseOfRestrictedInvestments_637840972286058490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637840972286058490" xlink:to="us-gaap_IncreaseDecreaseOfRestrictedInvestments_637840972286058490" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:label="us-gaap_ProceedsFromSaleOfRestrictedInvestments_637840972286058490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637840972286058490" xlink:to="us-gaap_ProceedsFromSaleOfRestrictedInvestments_637840972286058490" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637840972286058490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637840972286058490" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637840972286058490" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637840972286058490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637840972286058490" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637840972286058490" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637840972286068408" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_1" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637840972286068408" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_637840972286068408" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637840972286068408" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_637840972286068408" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_637840972286068408" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637840972286068408" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_637840972286068408" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_637840972286068408" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637840972286068408" xlink:to="us-gaap_ProceedsFromWarrantExercises_637840972286068408" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637840972286068408" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637840972286068408" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637840972286068408" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:label="us-gaap_ProceedsFromPaymentsToMinorityShareholders_637840972286068408" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637840972286068408" xlink:to="us-gaap_ProceedsFromPaymentsToMinorityShareholders_637840972286068408" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637840972286068408" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637840972286068408" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637840972286068408" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637840972286068408" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_1" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637840972286068408" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637840972286068408" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_1" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637840972286068408" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637840972286068408" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_1" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637840972286068408" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637840972286078550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_1" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637840972286078550" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_637840972286078550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_637840972286078550" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1_637840972286078550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_637840972286078550" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1_637840972286078550" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_637840972286078550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_1" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract_637840972286078550" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid_637840972286078550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract_637840972286078550" xlink:to="us-gaap_IncomeTaxesPaid_637840972286078550" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_637840972286078550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract_637840972286078550" xlink:to="us-gaap_InterestPaidNet_637840972286078550" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureGeneral" xlink:type="extended" xlink:title="10101 - Disclosure - GENERAL" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations_637840972286088133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations_637840972286088133" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_637840972286088133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_637840972286088133" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosurePrepaidExpensesAndOtherReceivables" xlink:type="extended" xlink:title="10301 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_PrepaidExpensesAndOtherReceivablesTextBlock" xlink:label="drts_PrepaidExpensesAndOtherReceivablesTextBlock_637840972286088133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="drts_PrepaidExpensesAndOtherReceivablesTextBlock_637840972286088133" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosurePropertyAndEquipmentNet" xlink:type="extended" xlink:title="10401 - Disclosure - PROPERTY AND EQUIPMENT, NET" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_637840972286088133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_637840972286088133" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureOtherPayablesAndAccruedExpenses" xlink:type="extended" xlink:title="10501 - Disclosure - OTHER PAYABLES AND ACCRUED EXPENSES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_OtherPayablesAndAccruedExpensesAbstract" xlink:label="drts_OtherPayablesAndAccruedExpensesAbstract" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_OtherPayablesAndAccruedExpensesDisclosureTextBlock" xlink:label="drts_OtherPayablesAndAccruedExpensesDisclosureTextBlock_637840972286098461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_OtherPayablesAndAccruedExpensesAbstract" xlink:to="drts_OtherPayablesAndAccruedExpensesDisclosureTextBlock_637840972286098461" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilities" xlink:type="extended" xlink:title="10601 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637840972286098461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637840972286098461" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureFairValueMeasurements" xlink:type="extended" xlink:title="10701 - Disclosure - FAIR VALUE MEASUREMENTS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_637840972286098461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_637840972286098461" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="10801 - Disclosure - INCOME TAXES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_637840972286098461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_637840972286098461" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrants" xlink:type="extended" xlink:title="10901 - Disclosure - CONVERTIBLE PREFERRED SHARES AND WARRANTS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_TemporaryEquityTextBlock" xlink:label="drts_TemporaryEquityTextBlock_637840972286108471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="drts_TemporaryEquityTextBlock_637840972286108471" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureShareholdersDeficiency" xlink:type="extended" xlink:title="11001 - Disclosure - SHAREHOLDERS' DEFICIENCY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_637840972286108471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_637840972286108471" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureFinancialExpensesNet" xlink:type="extended" xlink:title="11101 - Disclosure - FINANCIAL EXPENSES, NET" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_FinancialExpensesAbstract" xlink:label="drts_FinancialExpensesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:label="us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_637840972286108471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_FinancialExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_637840972286108471" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureBasicAndDilutedNetLossPerShare" xlink:type="extended" xlink:title="11201 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_637840972286108471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_637840972286108471" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureGeographicInformation" xlink:type="extended" xlink:title="11301 - Disclosure - GEOGRAPHIC INFORMATION" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_GeographicInformationAbstract" xlink:label="drts_GeographicInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_637840972286118450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_GeographicInformationAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_637840972286118450" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="11401 - Disclosure - SUBSEQUENT EVENTS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_637840972286118450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_637840972286118450" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_637840972286118450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_637840972286118450" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_637840972286118450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_637840972286118450" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock_637840972286118450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock_637840972286118450" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637840972286118450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637840972286118450" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_637840972286118450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_637840972286118450" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_ShortTermDepositsPolicyTextBlock" xlink:label="drts_ShortTermDepositsPolicyTextBlock_637840972286128494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="drts_ShortTermDepositsPolicyTextBlock_637840972286128494" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_637840972286128494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_637840972286128494" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_637840972286128494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_637840972286128494" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_637840972286128494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_637840972286128494" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_637840972286128494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_637840972286128494" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_GrantsAndParticipationsPolicyTextBlock" xlink:label="drts_GrantsAndParticipationsPolicyTextBlock_637840972286128494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="drts_GrantsAndParticipationsPolicyTextBlock_637840972286128494" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock" xlink:label="drts_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock_637840972286128494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="drts_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock_637840972286128494" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_637840972286128494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_637840972286128494" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock" xlink:label="drts_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock_637840972286128494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="drts_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock_637840972286128494" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_637840972286128494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_637840972286128494" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_637840972286128494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_637840972286128494" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_SeverancePayPolicyTextBlock" xlink:label="drts_SeverancePayPolicyTextBlock_637840972286128494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="drts_SeverancePayPolicyTextBlock_637840972286128494" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_637840972286138480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_637840972286138480" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_637840972286138480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_637840972286138480" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_DeferredTransactionCostsPolicyTextBlock" xlink:label="drts_DeferredTransactionCostsPolicyTextBlock_637840972286138480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="drts_DeferredTransactionCostsPolicyTextBlock_637840972286138480" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_NonControllingInterestPolicyTextBlock" xlink:label="drts_NonControllingInterestPolicyTextBlock_637840972286138480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="drts_NonControllingInterestPolicyTextBlock_637840972286138480" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637840972286138480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637840972286138480" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30203 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_637840972286148133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_637840972286148133" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_PropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:label="drts_PropertyPlantAndEquipmentUsefulLivesTableTextBlock_637840972286148133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="drts_PropertyPlantAndEquipmentUsefulLivesTableTextBlock_637840972286148133" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637840972286148133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637840972286148133" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosurePrepaidExpensesAndOtherReceivablesTables" xlink:type="extended" xlink:title="30303 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_637840972286148133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_1" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_637840972286148133" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosurePropertyAndEquipmentNetTables" xlink:type="extended" xlink:title="30403 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_637840972286158494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_637840972286158494" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureOtherPayablesAndAccruedExpensesTables" xlink:type="extended" xlink:title="30503 - Disclosure - OTHER PAYABLES AND ACCRUED EXPENSES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_OtherPayablesAndAccruedExpensesAbstract" xlink:label="drts_OtherPayablesAndAccruedExpensesAbstract_1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_ScheduleOfOtherPayablesAndAccruedExpensesTableTextBlock" xlink:label="drts_ScheduleOfOtherPayablesAndAccruedExpensesTableTextBlock_637840972286158494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_OtherPayablesAndAccruedExpensesAbstract_1" xlink:to="drts_ScheduleOfOtherPayablesAndAccruedExpensesTableTextBlock_637840972286158494" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesTables" xlink:type="extended" xlink:title="30603 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_637840972286158494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_637840972286158494" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureFairValueMeasurementsTables" xlink:type="extended" xlink:title="30703 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_637840972286158494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_1" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_637840972286158494" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_637840972286158494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_1" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_637840972286158494" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="30803 - Disclosure - INCOME TAXES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_637840972286168407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_1" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_637840972286168407" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_637840972286168407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_1" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_637840972286168407" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_637840972286168407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_1" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_637840972286168407" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsTables" xlink:type="extended" xlink:title="30903 - Disclosure - CONVERTIBLE PREFERRED SHARES AND WARRANTS (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="us-gaap_TemporaryEquityTableTextBlock_637840972286168407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract_1" xlink:to="us-gaap_TemporaryEquityTableTextBlock_637840972286168407" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureShareholdersDeficiencyTables" xlink:type="extended" xlink:title="31003 - Disclosure - SHAREHOLDERS' DEFICIENCY (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock_637840972286168407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_1" xlink:to="us-gaap_ScheduleOfStockByClassTextBlock_637840972286168407" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637840972286168407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_1" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637840972286168407" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_637840972286168407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_1" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_637840972286168407" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_ScheduleOfShareBasedCompensationCostsByIncomeStatementLocationTableTextBlock" xlink:label="drts_ScheduleOfShareBasedCompensationCostsByIncomeStatementLocationTableTextBlock_637840972286168407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_1" xlink:to="drts_ScheduleOfShareBasedCompensationCostsByIncomeStatementLocationTableTextBlock_637840972286168407" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureFinancialExpensesNetTables" xlink:type="extended" xlink:title="31103 - Disclosure - FINANCIAL EXPENSES, NET (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_FinancialExpensesAbstract" xlink:label="drts_FinancialExpensesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_637840972286178404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_FinancialExpensesAbstract_1" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_637840972286178404" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureBasicAndDilutedNetLossPerShareTables" xlink:type="extended" xlink:title="31203 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_637840972286178404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_1" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_637840972286178404" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_637840972286178404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_1" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_637840972286178404" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureGeographicInformationTables" xlink:type="extended" xlink:title="31303 - Disclosure - GEOGRAPHIC INFORMATION (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_GeographicInformationAbstract" xlink:label="drts_GeographicInformationAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_637840972286178404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_GeographicInformationAbstract_1" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_637840972286178404" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureGeneralDetails" xlink:type="extended" xlink:title="40101 - Disclosure - GENERAL (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637840972286188416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1" xlink:to="us-gaap_StatementTable_637840972286188416" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_637840972286188416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637840972286188416" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_637840972286188416" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain_637840972286188416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_637840972286188416" xlink:to="srt_EquityMethodInvesteeNameDomain_637840972286188416" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_AtmKkMember" xlink:label="drts_AtmKkMember_637840972286188416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain_637840972286188416" xlink:to="drts_AtmKkMember_637840972286188416" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637840972286188416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637840972286188416" xlink:to="us-gaap_StatementLineItems_637840972286188416" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_DisposalGroupIncludingDiscontinuedOperationOwnershipDisposed" xlink:label="drts_DisposalGroupIncludingDiscontinuedOperationOwnershipDisposed_637840972286188416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637840972286188416" xlink:to="drts_DisposalGroupIncludingDiscontinuedOperationOwnershipDisposed_637840972286188416" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_CashCashEquivalentsShortTermDepositsAndRestrictedCash" xlink:label="drts_CashCashEquivalentsShortTermDepositsAndRestrictedCash_637840972286188416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637840972286188416" xlink:to="drts_CashCashEquivalentsShortTermDepositsAndRestrictedCash_637840972286188416" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_637840972286188416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637840972286188416" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_637840972286188416" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637840972286188416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637840972286188416" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637840972286188416" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637840972286188416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637840972286188416" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637840972286188416" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_CurrentResourcesCoverageOfLiquidityRequirements" xlink:label="drts_CurrentResourcesCoverageOfLiquidityRequirements_637840972286188416" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637840972286188416" xlink:to="drts_CurrentResourcesCoverageOfLiquidityRequirements_637840972286188416" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesRestrictedCashDetails" xlink:type="extended" xlink:title="40201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Restricted cash (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637840972286198448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637840972286198448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_637840972286198448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_637840972286198448" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637840972286198448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637840972286198448" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesShortTermDepositsDetails" xlink:type="extended" xlink:title="40202 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Short-term deposits (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable_637840972286198448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_3" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable_637840972286198448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637840972286198448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable_637840972286198448" xlink:to="srt_RangeAxis_637840972286198448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637840972286198448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637840972286198448" xlink:to="srt_RangeMember_637840972286198448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637840972286198448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637840972286198448" xlink:to="srt_MinimumMember_637840972286198448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637840972286198448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637840972286198448" xlink:to="srt_MaximumMember_637840972286198448" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="us-gaap_CashAndCashEquivalentsLineItems_637840972286198448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable_637840972286198448" xlink:to="us-gaap_CashAndCashEquivalentsLineItems_637840972286198448" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_ShortTernBankDepositInterestRate" xlink:label="drts_ShortTernBankDepositInterestRate_637840972286198448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems_637840972286198448" xlink:to="drts_ShortTernBankDepositInterestRate_637840972286198448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentAndImpairmentDetails" xlink:type="extended" xlink:title="40203 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Property and equipment and impairment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637840972286208474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_4" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637840972286208474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637840972286208474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637840972286208474" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637840972286208474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637840972286208474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637840972286208474" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637840972286208474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember_637840972286208474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637840972286208474" xlink:to="us-gaap_ComputerEquipmentMember_637840972286208474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_LaboratoryEquipmentMember" xlink:label="drts_LaboratoryEquipmentMember_637840972286208474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637840972286208474" xlink:to="drts_LaboratoryEquipmentMember_637840972286208474" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_637840972286208474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637840972286208474" xlink:to="us-gaap_FurnitureAndFixturesMember_637840972286208474" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AutomobilesMember" xlink:label="us-gaap_AutomobilesMember_637840972286208474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637840972286208474" xlink:to="us-gaap_AutomobilesMember_637840972286208474" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember_637840972286208474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637840972286208474" xlink:to="us-gaap_EquipmentMember_637840972286208474" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637840972286208474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637840972286208474" xlink:to="srt_RangeAxis_637840972286208474" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637840972286208474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637840972286208474" xlink:to="srt_RangeMember_637840972286208474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637840972286208474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637840972286208474" xlink:to="srt_MinimumMember_637840972286208474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637840972286208474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637840972286208474" xlink:to="srt_MaximumMember_637840972286208474" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_637840972286208474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637840972286208474" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_637840972286208474" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_637840972286218137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637840972286208474" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_637840972286218137" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_637840972286218137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637840972286208474" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_637840972286218137" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesShareBasedPaymentsDetails" xlink:type="extended" xlink:title="40204 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Share-based payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637840972286218137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_5" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637840972286218137" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637840972286218137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637840972286218137" xlink:to="us-gaap_AwardTypeAxis_637840972286218137" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637840972286218137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637840972286218137" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637840972286218137" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637840972286218137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637840972286218137" xlink:to="us-gaap_EmployeeStockOptionMember_637840972286218137" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637840972286218137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637840972286218137" xlink:to="srt_RangeAxis_637840972286218137" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637840972286218137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637840972286218137" xlink:to="srt_RangeMember_637840972286218137" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637840972286218137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637840972286218137" xlink:to="srt_MinimumMember_637840972286218137" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637840972286228477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637840972286218137" xlink:to="srt_MaximumMember_637840972286228477" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637840972286228477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637840972286218137" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637840972286228477" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637840972286228477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637840972286228477" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637840972286228477" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_637840972286228477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637840972286228477" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_637840972286228477" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_637840972286228477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637840972286228477" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_637840972286228477" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_637840972286228477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637840972286228477" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_637840972286228477" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_637840972286228477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637840972286228477" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_637840972286228477" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637840972286228477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637840972286228477" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637840972286228477" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637840972286228477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637840972286228477" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637840972286228477" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesGrantsAndParticipationsOrdinaryShareWarrantsClassificationAndMeasurementDetails" xlink:type="extended" xlink:title="40205 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Grants and participations &amp; Ordinary share warrants classification and measurement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" xlink:label="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_637840972286238389" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_6" xlink:to="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_637840972286238389" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_637840972286238389" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_6" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_637840972286238389" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesSeverancePayDetails" xlink:type="extended" xlink:title="40206 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Severance pay (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_7" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_SeverancePayDepositRate" xlink:label="drts_SeverancePayDepositRate_637840972286238389" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_7" xlink:to="drts_SeverancePayDepositRate_637840972286238389" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_SeverancePayExpense" xlink:label="drts_SeverancePayExpense_637840972286238389" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_7" xlink:to="drts_SeverancePayExpense_637840972286238389" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesContingentLiabilitiesDetails" xlink:type="extended" xlink:title="40207 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Contingent liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_637840972286238389" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_8" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue_637840972286238389" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesDeferredTransactionCostsDetails" xlink:type="extended" xlink:title="40208 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Deferred Transaction costs (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637840972286248411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_9" xlink:to="us-gaap_StatementTable_637840972286248411" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_637840972286248411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637840972286248411" xlink:to="us-gaap_BalanceSheetLocationAxis_637840972286248411" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_637840972286248411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis_637840972286248411" xlink:to="us-gaap_BalanceSheetLocationDomain_637840972286248411" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember_637840972286248411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain_637840972286248411" xlink:to="us-gaap_OtherNoncurrentAssetsMember_637840972286248411" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637840972286248411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637840972286248411" xlink:to="us-gaap_StatementLineItems_637840972286248411" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts_637840972286248411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637840972286248411" xlink:to="us-gaap_DeferredOfferingCosts_637840972286248411" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosurePrepaidExpensesAndOtherReceivablesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_2" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_GovernmentAuthoritiesReceivable" xlink:label="drts_GovernmentAuthoritiesReceivable_637840972286248411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_2" xlink:to="drts_GovernmentAuthoritiesReceivable_637840972286248411" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent_637840972286248411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_2" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent_637840972286248411" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables_637840972286248411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_2" xlink:to="us-gaap_OtherReceivables_637840972286248411" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_637840972286248411" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_2" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets_637840972286248411" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40401 - Disclosure - PROPERTY AND EQUIPMENT, NET - Schedule of property and equipment, net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637840972286258582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_3" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637840972286258582" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637840972286258582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637840972286258582" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637840972286258582" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637840972286258582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637840972286258582" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637840972286258582" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember_637840972286258582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637840972286258582" xlink:to="us-gaap_EquipmentMember_637840972286258582" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember_637840972286258582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637840972286258582" xlink:to="us-gaap_ComputerEquipmentMember_637840972286258582" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_LaboratoryEquipmentMember" xlink:label="drts_LaboratoryEquipmentMember_637840972286258582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637840972286258582" xlink:to="drts_LaboratoryEquipmentMember_637840972286258582" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_637840972286258582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637840972286258582" xlink:to="us-gaap_FurnitureAndFixturesMember_637840972286258582" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VehiclesMember" xlink:label="us-gaap_VehiclesMember_637840972286258582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637840972286258582" xlink:to="us-gaap_VehiclesMember_637840972286258582" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AutomobilesMember" xlink:label="us-gaap_AutomobilesMember_637840972286258582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VehiclesMember_637840972286258582" xlink:to="us-gaap_AutomobilesMember_637840972286258582" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_637840972286258582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637840972286258582" xlink:to="us-gaap_LeaseholdImprovementsMember_637840972286258582" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_637840972286258582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637840972286258582" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_637840972286258582" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_637840972286258582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637840972286258582" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_637840972286258582" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637840972286268428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637840972286258582" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637840972286268428" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637840972286268428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637840972286258582" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637840972286268428" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637840972286268428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637840972286258582" xlink:to="us-gaap_Depreciation_637840972286268428" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_637840972286268428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637840972286258582" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_637840972286268428" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureOtherPayablesAndAccruedExpensesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - OTHER PAYABLES AND ACCRUED EXPENSES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_OtherPayablesAndAccruedExpensesAbstract" xlink:label="drts_OtherPayablesAndAccruedExpensesAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent_637840972286268428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_OtherPayablesAndAccruedExpensesAbstract_2" xlink:to="us-gaap_AccruedSalariesCurrent_637840972286268428" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637840972286268428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_OtherPayablesAndAccruedExpensesAbstract_2" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637840972286268428" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent_637840972286268428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_OtherPayablesAndAccruedExpensesAbstract_2" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent_637840972286268428" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_637840972286268428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_OtherPayablesAndAccruedExpensesAbstract_2" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_637840972286268428" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesDetails" xlink:type="extended" xlink:title="40601 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637840972286268428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637840972286268428" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637840972286268428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637840972286268428" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637840972286268428" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637840972286268428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637840972286268428" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637840972286268428" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637840972286278446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637840972286268428" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637840972286278446" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637840972286278446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637840972286268428" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637840972286278446" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_637840972286278446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637840972286268428" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_637840972286278446" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_637840972286278446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637840972286268428" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_637840972286278446" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637840972286278446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637840972286268428" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637840972286278446" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense_637840972286278446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637840972286268428" xlink:to="us-gaap_OperatingLeaseExpense_637840972286278446" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesAdditionalDetails" xlink:type="extended" xlink:title="40602 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES - Additional (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_ScheduleOfCommitmentsAndContingenciesTable" xlink:label="drts_ScheduleOfCommitmentsAndContingenciesTable_637840972286278446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3" xlink:to="drts_ScheduleOfCommitmentsAndContingenciesTable_637840972286278446" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_637840972286278446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_ScheduleOfCommitmentsAndContingenciesTable_637840972286278446" xlink:to="dei_LegalEntityAxis_637840972286278446" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_637840972286278446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_637840972286278446" xlink:to="dei_EntityDomain_637840972286278446" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_IsraeliInnovationAuthorityMember" xlink:label="drts_IsraeliInnovationAuthorityMember_637840972286278446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_637840972286278446" xlink:to="drts_IsraeliInnovationAuthorityMember_637840972286278446" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_AltheraMember" xlink:label="drts_AltheraMember_637840972286278446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_637840972286278446" xlink:to="drts_AltheraMember_637840972286278446" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_RamotMember" xlink:label="drts_RamotMember_637840972286278446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_637840972286278446" xlink:to="drts_RamotMember_637840972286278446" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_HekaBioKKMember" xlink:label="drts_HekaBioKKMember_637840972286288130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_637840972286278446" xlink:to="drts_HekaBioKKMember_637840972286288130" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_BgnTechnologiesMember" xlink:label="drts_BgnTechnologiesMember_637840972286288130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_637840972286278446" xlink:to="drts_BgnTechnologiesMember_637840972286288130" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_CambridgeUniversityHospitalsNhsTrustMember" xlink:label="drts_CambridgeUniversityHospitalsNhsTrustMember_637840972286288130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_637840972286278446" xlink:to="drts_CambridgeUniversityHospitalsNhsTrustMember_637840972286288130" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637840972286288130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_ScheduleOfCommitmentsAndContingenciesTable_637840972286278446" xlink:to="srt_RangeAxis_637840972286288130" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637840972286288130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637840972286288130" xlink:to="srt_RangeMember_637840972286288130" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637840972286288130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637840972286288130" xlink:to="srt_MinimumMember_637840972286288130" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637840972286288130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637840972286288130" xlink:to="srt_MaximumMember_637840972286288130" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_MethodOfPaymentRoyaltiesAxis" xlink:label="drts_MethodOfPaymentRoyaltiesAxis_637840972286288130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_ScheduleOfCommitmentsAndContingenciesTable_637840972286278446" xlink:to="drts_MethodOfPaymentRoyaltiesAxis_637840972286288130" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_BasisOfPaymentRoyaltiesDomain" xlink:label="drts_BasisOfPaymentRoyaltiesDomain_637840972286288130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_MethodOfPaymentRoyaltiesAxis_637840972286288130" xlink:to="drts_BasisOfPaymentRoyaltiesDomain_637840972286288130" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_FutureSalesOfDevelopedProductMember" xlink:label="drts_FutureSalesOfDevelopedProductMember_637840972286288130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_BasisOfPaymentRoyaltiesDomain_637840972286288130" xlink:to="drts_FutureSalesOfDevelopedProductMember_637840972286288130" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_FutureGrossRevenuesDerivedFromPurchasedIntellectualPropertyMember" xlink:label="drts_FutureGrossRevenuesDerivedFromPurchasedIntellectualPropertyMember_637840972286288130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_BasisOfPaymentRoyaltiesDomain_637840972286288130" xlink:to="drts_FutureGrossRevenuesDerivedFromPurchasedIntellectualPropertyMember_637840972286288130" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_NetSalesOfAllCompanySProductMember" xlink:label="drts_NetSalesOfAllCompanySProductMember_637840972286288130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_BasisOfPaymentRoyaltiesDomain_637840972286288130" xlink:to="drts_NetSalesOfAllCompanySProductMember_637840972286288130" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_NetSalesOfAllCompanySProductSoldByCompanySLicensesMember" xlink:label="drts_NetSalesOfAllCompanySProductSoldByCompanySLicensesMember_637840972286288130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_BasisOfPaymentRoyaltiesDomain_637840972286288130" xlink:to="drts_NetSalesOfAllCompanySProductSoldByCompanySLicensesMember_637840972286288130" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_ReimbursementPriceMember" xlink:label="drts_ReimbursementPriceMember_637840972286298474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_BasisOfPaymentRoyaltiesDomain_637840972286288130" xlink:to="drts_ReimbursementPriceMember_637840972286298474" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_DistributionReceiptsMember" xlink:label="drts_DistributionReceiptsMember_637840972286298474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_BasisOfPaymentRoyaltiesDomain_637840972286288130" xlink:to="drts_DistributionReceiptsMember_637840972286298474" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_SalesOfAlphaRadiationProductsMember" xlink:label="drts_SalesOfAlphaRadiationProductsMember_637840972286298474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_BasisOfPaymentRoyaltiesDomain_637840972286288130" xlink:to="drts_SalesOfAlphaRadiationProductsMember_637840972286298474" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_SalesOfProductContainingIntellectualPropertyMember" xlink:label="drts_SalesOfProductContainingIntellectualPropertyMember_637840972286298474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_BasisOfPaymentRoyaltiesDomain_637840972286288130" xlink:to="drts_SalesOfProductContainingIntellectualPropertyMember_637840972286298474" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_LicenseRevenueToJointlyDevelopedIntellectualPropertyMember" xlink:label="drts_LicenseRevenueToJointlyDevelopedIntellectualPropertyMember_637840972286298474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_BasisOfPaymentRoyaltiesDomain_637840972286288130" xlink:to="drts_LicenseRevenueToJointlyDevelopedIntellectualPropertyMember_637840972286298474" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_LicenseRevenueRelatedToIntellectualPropertyMember" xlink:label="drts_LicenseRevenueRelatedToIntellectualPropertyMember_637840972286298474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_BasisOfPaymentRoyaltiesDomain_637840972286288130" xlink:to="drts_LicenseRevenueRelatedToIntellectualPropertyMember_637840972286298474" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_RevenueGeneratedFromPatentMember" xlink:label="drts_RevenueGeneratedFromPatentMember_637840972286298474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_BasisOfPaymentRoyaltiesDomain_637840972286288130" xlink:to="drts_RevenueGeneratedFromPatentMember_637840972286298474" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_NetSalesSquamousCellCarcinomaMember" xlink:label="drts_NetSalesSquamousCellCarcinomaMember_637840972286298474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_BasisOfPaymentRoyaltiesDomain_637840972286288130" xlink:to="drts_NetSalesSquamousCellCarcinomaMember_637840972286298474" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_CommitmentsAndContingenciesLineItems" xlink:label="drts_CommitmentsAndContingenciesLineItems_637840972286298474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_ScheduleOfCommitmentsAndContingenciesTable_637840972286278446" xlink:to="drts_CommitmentsAndContingenciesLineItems_637840972286298474" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBankLoansAndNotesPayable" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable_637840972286308529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_CommitmentsAndContingenciesLineItems_637840972286298474" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable_637840972286308529" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_GrantIncome" xlink:label="drts_GrantIncome_637840972286308529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_CommitmentsAndContingenciesLineItems_637840972286298474" xlink:to="drts_GrantIncome_637840972286308529" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_RoyaltyRate" xlink:label="drts_RoyaltyRate_637840972286308529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_CommitmentsAndContingenciesLineItems_637840972286298474" xlink:to="drts_RoyaltyRate_637840972286308529" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_RoyaltyPaymentAsPercentageOfGrants" xlink:label="drts_RoyaltyPaymentAsPercentageOfGrants_637840972286308529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_CommitmentsAndContingenciesLineItems_637840972286298474" xlink:to="drts_RoyaltyPaymentAsPercentageOfGrants_637840972286308529" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense_637840972286308529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_CommitmentsAndContingenciesLineItems_637840972286298474" xlink:to="us-gaap_RoyaltyExpense_637840972286308529" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="us-gaap_LiabilitiesAssumed1_637840972286308529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_CommitmentsAndContingenciesLineItems_637840972286298474" xlink:to="us-gaap_LiabilitiesAssumed1_637840972286308529" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_PotentialPayment" xlink:label="drts_PotentialPayment_637840972286308529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_CommitmentsAndContingenciesLineItems_637840972286298474" xlink:to="drts_PotentialPayment_637840972286308529" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_MilestoneNumberOfOrdinaryStockOptions" xlink:label="drts_MilestoneNumberOfOrdinaryStockOptions_637840972286308529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_CommitmentsAndContingenciesLineItems_637840972286298474" xlink:to="drts_MilestoneNumberOfOrdinaryStockOptions_637840972286308529" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_StockOptionExercisePrice" xlink:label="drts_StockOptionExercisePrice_637840972286318529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_CommitmentsAndContingenciesLineItems_637840972286298474" xlink:to="drts_StockOptionExercisePrice_637840972286318529" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureFairValueMeasurementsValuationAssumptionsDetails" xlink:type="extended" xlink:title="40701 - Disclosure - FAIR VALUE MEASUREMENTS - Valuation Assumptions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637840972286318529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_2" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637840972286318529" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_637840972286318529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637840972286318529" xlink:to="us-gaap_MeasurementInputTypeAxis_637840972286318529" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_637840972286318529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_637840972286318529" xlink:to="us-gaap_MeasurementInputTypeDomain_637840972286318529" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_637840972286318529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637840972286318529" xlink:to="us-gaap_MeasurementInputExpectedTermMember_637840972286318529" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_637840972286318529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637840972286318529" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_637840972286318529" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_637840972286318529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637840972286318529" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_637840972286318529" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_637840972286318529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637840972286318529" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_637840972286318529" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_637840972286318529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637840972286318529" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_637840972286318529" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_NumberOfScenariosInAllocatingValueToWarrants" xlink:label="drts_NumberOfScenariosInAllocatingValueToWarrants_637840972286318529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_637840972286318529" xlink:to="drts_NumberOfScenariosInAllocatingValueToWarrants_637840972286318529" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingValuationTechniqueExtensibleList" xlink:label="us-gaap_WarrantsAndRightsOutstandingValuationTechniqueExtensibleList_637840972286318529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_637840972286318529" xlink:to="us-gaap_WarrantsAndRightsOutstandingValuationTechniqueExtensibleList_637840972286318529" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_637840972286328643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_637840972286318529" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_637840972286328643" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureFairValueMeasurementsChangesInFairValueDetails" xlink:type="extended" xlink:title="40702 - Disclosure - FAIR VALUE MEASUREMENTS - Changes in fair value (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_637840972286328643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_3" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_637840972286328643" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis_637840972286328643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_637840972286328643" xlink:to="us-gaap_FairValueByLiabilityClassAxis_637840972286328643" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_637840972286328643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis_637840972286328643" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_637840972286328643" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_637840972286328643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_637840972286328643" xlink:to="us-gaap_WarrantMember_637840972286328643" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_637840972286328643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_637840972286328643" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_637840972286328643" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_637840972286328643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_637840972286328643" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_637840972286328643" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_637840972286328643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_637840972286328643" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_637840972286328643" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6378409722863286431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_637840972286328643" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6378409722863286431" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureIncomeTaxesTaxRatesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - INCOME TAXES - Tax rates (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_IncomeTaxDisclosureTable" xlink:label="drts_IncomeTaxDisclosureTable_637840972286338460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="drts_IncomeTaxDisclosureTable_637840972286338460" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_637840972286338460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_IncomeTaxDisclosureTable_637840972286338460" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_637840972286338460" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain_637840972286338460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_637840972286338460" xlink:to="srt_EquityMethodInvesteeNameDomain_637840972286338460" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_AtmIncMember" xlink:label="drts_AtmIncMember_637840972286338460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain_637840972286338460" xlink:to="drts_AtmIncMember_637840972286338460" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_AtmKkMember" xlink:label="drts_AtmKkMember_637840972286338460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain_637840972286338460" xlink:to="drts_AtmKkMember_637840972286338460" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_637840972286338460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_IncomeTaxDisclosureTable_637840972286338460" xlink:to="srt_StatementGeographicalAxis_637840972286338460" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637840972286338460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_637840972286338460" xlink:to="srt_SegmentGeographicalDomain_637840972286338460" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="country_US_637840972286338460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637840972286338460" xlink:to="country_US_637840972286338460" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP" xlink:label="country_JP_637840972286338460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637840972286338460" xlink:to="country_JP_637840972286338460" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_IncomeTaxDisclosureLineItems" xlink:label="drts_IncomeTaxDisclosureLineItems_637840972286338460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_IncomeTaxDisclosureTable_637840972286338460" xlink:to="drts_IncomeTaxDisclosureLineItems_637840972286338460" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_637840972286338460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_IncomeTaxDisclosureLineItems_637840972286338460" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_637840972286338460" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_IncomeTaxRateReconciliationPreferredCompanyPercent" xlink:label="drts_IncomeTaxRateReconciliationPreferredCompanyPercent_637840972286338460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_IncomeTaxDisclosureLineItems_637840972286338460" xlink:to="drts_IncomeTaxRateReconciliationPreferredCompanyPercent_637840972286338460" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_IncomeTaxRateReconciliationLargeCompaniesPercent" xlink:label="drts_IncomeTaxRateReconciliationLargeCompaniesPercent_637840972286338460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_IncomeTaxDisclosureLineItems_637840972286338460" xlink:to="drts_IncomeTaxRateReconciliationLargeCompaniesPercent_637840972286338460" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_IncomeTaxRateReconciliationSmallCompaniesPercent" xlink:label="drts_IncomeTaxRateReconciliationSmallCompaniesPercent_637840972286338460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_IncomeTaxDisclosureLineItems_637840972286338460" xlink:to="drts_IncomeTaxRateReconciliationSmallCompaniesPercent_637840972286338460" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_IncomeTaxRateReconciliationSmallCompaniesSpecialRatePercent" xlink:label="drts_IncomeTaxRateReconciliationSmallCompaniesSpecialRatePercent_637840972286348441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_IncomeTaxDisclosureLineItems_637840972286338460" xlink:to="drts_IncomeTaxRateReconciliationSmallCompaniesSpecialRatePercent_637840972286348441" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_IncomeTaxRateReconciliationMediumCompaniesSpecialRatePercent" xlink:label="drts_IncomeTaxRateReconciliationMediumCompaniesSpecialRatePercent_637840972286348441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_IncomeTaxDisclosureLineItems_637840972286338460" xlink:to="drts_IncomeTaxRateReconciliationMediumCompaniesSpecialRatePercent_637840972286348441" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureIncomeTaxesNetLossIncomeBeforeTaxDetails" xlink:type="extended" xlink:title="40802 - Disclosure - INCOME TAXES - Net loss (income) before tax (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_637840972286348441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_3" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_637840972286348441" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_637840972286348441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_637840972286348441" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_637840972286348441" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_637840972286348441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_637840972286348441" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_637840972286348441" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637840972286348441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_637840972286348441" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637840972286348441" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails" xlink:type="extended" xlink:title="40803 - Disclosure - INCOME TAXES - Income tax expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_637840972286358513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_637840972286358513" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_637840972286358513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_637840972286358513" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_637840972286358513" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_637840972286358513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_637840972286358513" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_637840972286358513" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637840972286358513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637840972286358513" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureIncomeTaxesNetOperatingLossesCarryDetails" xlink:type="extended" xlink:title="40804 - Disclosure - INCOME TAXES - Net operating losses carry (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_637840972286358513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="us-gaap_OperatingLossCarryforwards_637840972286358513" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureIncomeTaxesDeferredTaxesDetails" xlink:type="extended" xlink:title="40805 - Disclosure - INCOME TAXES - Deferred taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637840972286368670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_1" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637840972286368670" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances_637840972286368670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637840972286368670" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances_637840972286368670" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_637840972286368670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637840972286368670" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_637840972286368670" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_637840972286368670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637840972286368670" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_637840972286368670" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637840972286368670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637840972286368670" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637840972286368670" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637840972286368670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637840972286368670" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637840972286368670" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_637840972286368670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637840972286368670" xlink:to="us-gaap_DeferredTaxAssetsGross_637840972286368670" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637840972286368670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637840972286368670" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637840972286368670" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsCompositionOfConvertiblePreferredSharesDetails" xlink:type="extended" xlink:title="40901 - Disclosure - CONVERTIBLE PREFERRED SHARES AND WARRANTS - Composition of Convertible Preferred shares (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_637840972286368670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract_2" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_637840972286368670" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637840972286368670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_637840972286368670" xlink:to="us-gaap_StatementClassOfStockAxis_637840972286368670" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637840972286368670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637840972286368670" xlink:to="us-gaap_ClassOfStockDomain_637840972286368670" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_SeriesConvertiblePreferredSharesMember" xlink:label="drts_SeriesConvertiblePreferredSharesMember_637840972286378482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637840972286368670" xlink:to="drts_SeriesConvertiblePreferredSharesMember_637840972286378482" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_SeriesBConvertiblePreferredSharesMember" xlink:label="drts_SeriesBConvertiblePreferredSharesMember_637840972286378482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637840972286368670" xlink:to="drts_SeriesBConvertiblePreferredSharesMember_637840972286378482" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems_637840972286378482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_637840972286368670" xlink:to="us-gaap_TemporaryEquityLineItems_637840972286378482" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_637840972286378482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637840972286378482" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_637840972286378482" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued_637840972286378482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637840972286378482" xlink:to="us-gaap_TemporaryEquitySharesIssued_637840972286378482" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_637840972286378482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637840972286378482" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_637840972286378482" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_637840972286378482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637840972286378482" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_637840972286378482" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_637840972286378482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637840972286378482" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_637840972286378482" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_637840972286378482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637840972286378482" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_637840972286378482" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsPreferredSharesRightsDetails" xlink:type="extended" xlink:title="40902 - Disclosure - CONVERTIBLE PREFERRED SHARES AND WARRANTS - Preferred shares rights (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_637840972286378482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract_3" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_637840972286378482" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637840972286378482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_637840972286378482" xlink:to="us-gaap_StatementClassOfStockAxis_637840972286378482" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637840972286388808" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637840972286378482" xlink:to="us-gaap_ClassOfStockDomain_637840972286388808" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember_637840972286388808" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637840972286388808" xlink:to="us-gaap_ConvertiblePreferredStockMember_637840972286388808" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_SeriesConvertiblePreferredSharesMember" xlink:label="drts_SeriesConvertiblePreferredSharesMember_637840972286388808" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConvertiblePreferredStockMember_637840972286388808" xlink:to="drts_SeriesConvertiblePreferredSharesMember_637840972286388808" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems_637840972286388808" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_637840972286378482" xlink:to="us-gaap_TemporaryEquityLineItems_637840972286388808" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage_637840972286388808" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637840972286388808" xlink:to="us-gaap_PreferredStockDividendRatePercentage_637840972286388808" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_TemporaryEquityDistributionRateFromProceedsOfSaleAnotherClassOfShares" xlink:label="drts_TemporaryEquityDistributionRateFromProceedsOfSaleAnotherClassOfShares_637840972286388808" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637840972286388808" xlink:to="drts_TemporaryEquityDistributionRateFromProceedsOfSaleAnotherClassOfShares_637840972286388808" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_TemporaryEquityNumberOfVotes" xlink:label="drts_TemporaryEquityNumberOfVotes_637840972286388808" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637840972286388808" xlink:to="drts_TemporaryEquityNumberOfVotes_637840972286388808" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio_637840972286388808" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637840972286388808" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio_637840972286388808" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsFinancingRoundsDetails" xlink:type="extended" xlink:title="40903 - Disclosure - CONVERTIBLE PREFERRED SHARES AND WARRANTS - Financing rounds (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_637840972286388808" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract_4" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_637840972286388808" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637840972286398456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_637840972286388808" xlink:to="us-gaap_StatementClassOfStockAxis_637840972286398456" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637840972286398456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637840972286398456" xlink:to="us-gaap_ClassOfStockDomain_637840972286398456" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_SeriesConvertiblePreferredSharesMember" xlink:label="drts_SeriesConvertiblePreferredSharesMember_637840972286398456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637840972286398456" xlink:to="drts_SeriesConvertiblePreferredSharesMember_637840972286398456" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_SeriesBConvertiblePreferredSharesMember" xlink:label="drts_SeriesBConvertiblePreferredSharesMember_637840972286398456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637840972286398456" xlink:to="drts_SeriesBConvertiblePreferredSharesMember_637840972286398456" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637840972286398456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637840972286398456" xlink:to="us-gaap_CommonStockMember_637840972286398456" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems_637840972286398456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_637840972286388808" xlink:to="us-gaap_TemporaryEquityLineItems_637840972286398456" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_637840972286398456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637840972286398456" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_637840972286398456" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_SaleOfStockNumberOfWarrantsIssuedInTransaction" xlink:label="drts_SaleOfStockNumberOfWarrantsIssuedInTransaction_637840972286398456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637840972286398456" xlink:to="drts_SaleOfStockNumberOfWarrantsIssuedInTransaction_637840972286398456" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_637840972286398456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637840972286398456" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_637840972286398456" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare_637840972286398456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637840972286398456" xlink:to="us-gaap_SaleOfStockPricePerShare_637840972286398456" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_637840972286398456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637840972286398456" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_637840972286398456" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_637840972286398456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637840972286398456" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_637840972286398456" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio_637840972286398456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637840972286398456" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio_637840972286398456" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1_637840972286408474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637840972286398456" xlink:to="us-gaap_ConversionOfStockSharesConverted1_637840972286408474" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1_637840972286408474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637840972286398456" xlink:to="us-gaap_ConversionOfStockSharesIssued1_637840972286408474" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_637840972286408474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637840972286398456" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_637840972286408474" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsPreferredSharesWarrantsDetails" xlink:type="extended" xlink:title="40904 - Disclosure - CONVERTIBLE PREFERRED SHARES AND WARRANTS - Preferred A shares warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_637840972286408474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract_5" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_637840972286408474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637840972286408474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_637840972286408474" xlink:to="us-gaap_StatementClassOfStockAxis_637840972286408474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637840972286408474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637840972286408474" xlink:to="us-gaap_ClassOfStockDomain_637840972286408474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_SeriesConvertiblePreferredSharesMember" xlink:label="drts_SeriesConvertiblePreferredSharesMember_637840972286408474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637840972286408474" xlink:to="drts_SeriesConvertiblePreferredSharesMember_637840972286408474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems_637840972286408474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_637840972286408474" xlink:to="us-gaap_TemporaryEquityLineItems_637840972286408474" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_SaleOfStockNumberOfWarrantsIssuedInTransaction" xlink:label="drts_SaleOfStockNumberOfWarrantsIssuedInTransaction_637840972286408474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637840972286408474" xlink:to="drts_SaleOfStockNumberOfWarrantsIssuedInTransaction_637840972286408474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637840972286408474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637840972286408474" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637840972286408474" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_WarrantsGrantedIncreaseFromNewFinancing" xlink:label="drts_WarrantsGrantedIncreaseFromNewFinancing_637840972286418474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637840972286408474" xlink:to="drts_WarrantsGrantedIncreaseFromNewFinancing_637840972286418474" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding_637840972286418474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637840972286408474" xlink:to="us-gaap_WarrantsAndRightsOutstanding_637840972286418474" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOrdinaryShareCapitalDetails" xlink:type="extended" xlink:title="41001 - Disclosure - SHAREHOLDERS' DEFICIENCY - Ordinary share capital (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_637840972286418474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_2" xlink:to="us-gaap_ScheduleOfStockByClassTable_637840972286418474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637840972286418474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637840972286418474" xlink:to="us-gaap_StatementClassOfStockAxis_637840972286418474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637840972286418474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637840972286418474" xlink:to="us-gaap_ClassOfStockDomain_637840972286418474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637840972286418474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637840972286418474" xlink:to="us-gaap_CommonStockMember_637840972286418474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637840972286418474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637840972286418474" xlink:to="srt_CounterpartyNameAxis_637840972286418474" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637840972286418474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637840972286418474" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637840972286418474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_HekabioK.k.Member" xlink:label="drts_HekabioK.k.Member_637840972286418474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637840972286418474" xlink:to="drts_HekabioK.k.Member_637840972286418474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_637840972286418474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637840972286418474" xlink:to="us-gaap_ClassOfStockLineItems_637840972286418474" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637840972286418474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637840972286418474" xlink:to="us-gaap_CommonStockSharesAuthorized_637840972286418474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637840972286428468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637840972286418474" xlink:to="us-gaap_CommonStockSharesIssued_637840972286428468" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637840972286428468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637840972286418474" xlink:to="us-gaap_CommonStockSharesOutstanding_637840972286428468" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_637840972286428468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637840972286418474" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_637840972286428468" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_SharesNumberOfVotes" xlink:label="drts_SharesNumberOfVotes_637840972286428468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637840972286418474" xlink:to="drts_SharesNumberOfVotes_637840972286428468" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_637840972286428468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637840972286418474" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_637840972286428468" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_637840972286428468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637840972286418474" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_637840972286428468" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_SaleOfStockNumberOfWarrantsIssuedInTransaction" xlink:label="drts_SaleOfStockNumberOfWarrantsIssuedInTransaction_637840972286428468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637840972286418474" xlink:to="drts_SaleOfStockNumberOfWarrantsIssuedInTransaction_637840972286428468" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureShareholdersDeficiencyShareOptionPlanDetails" xlink:type="extended" xlink:title="41002 - Disclosure - SHAREHOLDERS' DEFICIENCY - Share option plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637840972286428468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_3" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637840972286428468" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637840972286428468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637840972286428468" xlink:to="us-gaap_PlanNameAxis_637840972286428468" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637840972286428468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637840972286428468" xlink:to="us-gaap_PlanNameDomain_637840972286428468" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_ShareOptionPlanMember" xlink:label="drts_ShareOptionPlanMember_637840972286438466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637840972286428468" xlink:to="drts_ShareOptionPlanMember_637840972286438466" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637840972286438466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637840972286428468" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637840972286438466" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_637840972286438466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637840972286438466" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_637840972286438466" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637840972286438466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637840972286438466" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637840972286438466" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637840972286438466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637840972286438466" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637840972286438466" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_637840972286488467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637840972286438466" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_637840972286488467" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOptionsChangesDetails" xlink:type="extended" xlink:title="41003 - Disclosure - SHAREHOLDERS' DEFICIENCY - Options changes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637840972286488467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_4" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637840972286488467" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_637840972286488467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637840972286488467" xlink:to="us-gaap_GranteeStatusAxis_637840972286488467" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_637840972286488467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis_637840972286488467" xlink:to="us-gaap_GranteeStatusDomain_637840972286488467" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_637840972286488467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_637840972286488467" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_637840972286488467" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_637840972286488467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_637840972286488467" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_637840972286488467" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637840972286488467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637840972286488467" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637840972286488467" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637840972286488467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637840972286488467" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637840972286488467" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637840972286488467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637840972286488467" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637840972286488467" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637840972286498473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637840972286488467" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637840972286498473" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637840972286498473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637840972286488467" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637840972286498473" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_637840972286498473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637840972286488467" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_637840972286498473" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637840972286498473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637840972286488467" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637840972286498473" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637840972286498473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637840972286488467" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637840972286498473" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637840972286498473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637840972286488467" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637840972286498473" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637840972286498473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637840972286498473" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637840972286498473" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637840972286498473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637840972286498473" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637840972286498473" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637840972286498473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637840972286498473" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637840972286498473" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_637840972286498473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637840972286498473" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_637840972286498473" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6378409722864984731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637840972286498473" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6378409722864984731" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637840972286498473" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637840972286498473" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637840972286498473" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637840972286508283" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637840972286488467" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637840972286508283" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637840972286508283" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637840972286508283" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637840972286508283" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_637840972286508283" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637840972286508283" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_637840972286508283" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637840972286508283" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637840972286508283" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637840972286508283" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637840972286508283" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637840972286508283" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637840972286508283" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureShareholdersDeficiencyRsusDetails" xlink:type="extended" xlink:title="41004 - Disclosure - SHAREHOLDERS' DEFICIENCY - RSUs (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_637840972286508283" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_5" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_637840972286508283" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_637840972286508283" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_637840972286508283" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_637840972286508283" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_637840972286518455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_637840972286508283" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_637840972286518455" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_637840972286518455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_637840972286508283" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_637840972286518455" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_637840972286518455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_637840972286508283" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_637840972286518455" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureShareholdersDeficiencyEquityBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="41005 - Disclosure - SHAREHOLDERS' DEFICIENCY - Equity-based compensation expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637840972286518455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_6" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637840972286518455" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637840972286518455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637840972286518455" xlink:to="us-gaap_IncomeStatementLocationAxis_637840972286518455" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637840972286518455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637840972286518455" xlink:to="us-gaap_IncomeStatementLocationDomain_637840972286518455" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_637840972286518455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637840972286518455" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_637840972286518455" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="us-gaap_SellingAndMarketingExpenseMember_637840972286518455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637840972286518455" xlink:to="us-gaap_SellingAndMarketingExpenseMember_637840972286518455" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_637840972286518455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637840972286518455" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_637840972286518455" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637840972286518455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637840972286518455" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637840972286518455" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637840972286518455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637840972286518455" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637840972286518455" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_637840972286518455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637840972286518455" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_637840972286518455" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637840972286528458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637840972286518455" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637840972286528458" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637840972286528458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637840972286518455" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637840972286528458" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637840972286528458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637840972286518455" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637840972286528458" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureShareholdersDeficiencyWarrantsDetails" xlink:type="extended" xlink:title="41006 - Disclosure - SHAREHOLDERS' DEFICIENCY - Warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_637840972286528458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_7" xlink:to="us-gaap_ScheduleOfStockByClassTable_637840972286528458" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637840972286528458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637840972286528458" xlink:to="srt_CounterpartyNameAxis_637840972286528458" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637840972286528458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637840972286528458" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637840972286528458" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_HekabioK.k.Member" xlink:label="drts_HekabioK.k.Member_637840972286528458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637840972286528458" xlink:to="drts_HekabioK.k.Member_637840972286528458" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_637840972286528458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637840972286528458" xlink:to="us-gaap_ClassOfStockLineItems_637840972286528458" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_SaleOfStockNumberOfWarrantsIssuedInTransaction" xlink:label="drts_SaleOfStockNumberOfWarrantsIssuedInTransaction_637840972286528458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637840972286528458" xlink:to="drts_SaleOfStockNumberOfWarrantsIssuedInTransaction_637840972286528458" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_637840972286528458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637840972286528458" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_637840972286528458" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_WarrantsExercisedCashBasis" xlink:label="drts_WarrantsExercisedCashBasis_637840972286538131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637840972286528458" xlink:to="drts_WarrantsExercisedCashBasis_637840972286538131" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_WarrantsExercisedCashlessBasis" xlink:label="drts_WarrantsExercisedCashlessBasis_637840972286538131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637840972286528458" xlink:to="drts_WarrantsExercisedCashlessBasis_637840972286538131" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="drts_StockIssuedDuringPeriodValueExerciseOfWarrants_637840972286538131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637840972286528458" xlink:to="drts_StockIssuedDuringPeriodValueExerciseOfWarrants_637840972286538131" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_WarrantsToOrdinaryShareRatioCashlessExercise" xlink:label="drts_WarrantsToOrdinaryShareRatioCashlessExercise_637840972286538131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637840972286528458" xlink:to="drts_WarrantsToOrdinaryShareRatioCashlessExercise_637840972286538131" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637840972286538131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637840972286528458" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637840972286538131" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_637840972286538131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637840972286528458" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_637840972286538131" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_NumberOfWarrantsExercised" xlink:label="drts_NumberOfWarrantsExercised_637840972286538131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637840972286528458" xlink:to="drts_NumberOfWarrantsExercised_637840972286538131" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureFinancialExpensesNetDetails" xlink:type="extended" xlink:title="41101 - Disclosure - FINANCIAL EXPENSES, NET (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_FinancialExpensesAbstract" xlink:label="drts_FinancialExpensesAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637840972286538131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_FinancialExpensesAbstract_2" xlink:to="us-gaap_StatementTable_637840972286538131" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_637840972286548679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637840972286538131" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_637840972286548679" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_NonOperatingFinancialExpensesAbstract" xlink:label="drts_NonOperatingFinancialExpensesAbstract_637840972286548679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_637840972286548679" xlink:to="drts_NonOperatingFinancialExpensesAbstract_637840972286548679" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionLossBeforeTax_637840972286548679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_NonOperatingFinancialExpensesAbstract_637840972286548679" xlink:to="us-gaap_ForeignCurrencyTransactionLossBeforeTax_637840972286548679" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_637840972286548679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_NonOperatingFinancialExpensesAbstract_637840972286548679" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_637840972286548679" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_637840972286548679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_NonOperatingFinancialExpensesAbstract_637840972286548679" xlink:to="us-gaap_OtherNonoperatingExpense_637840972286548679" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_FinancialExpensesTotal" xlink:label="drts_FinancialExpensesTotal_637840972286548679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_NonOperatingFinancialExpensesAbstract_637840972286548679" xlink:to="drts_FinancialExpensesTotal_637840972286548679" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_NonOperatingFinancialIncomeAbstract" xlink:label="drts_NonOperatingFinancialIncomeAbstract_637840972286548679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_637840972286548679" xlink:to="drts_NonOperatingFinancialIncomeAbstract_637840972286548679" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_637840972286548679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_NonOperatingFinancialIncomeAbstract_637840972286548679" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_637840972286548679" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions_637840972286548679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_NonOperatingFinancialIncomeAbstract_637840972286548679" xlink:to="us-gaap_InterestIncomeDepositsWithFinancialInstitutions_637840972286548679" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_637840972286548679" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_NonOperatingFinancialIncomeAbstract_637840972286548679" xlink:to="us-gaap_OtherNonoperatingIncome_637840972286548679" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_FinancialIncomeTotal" xlink:label="drts_FinancialIncomeTotal_637840972286558644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_NonOperatingFinancialIncomeAbstract_637840972286548679" xlink:to="drts_FinancialIncomeTotal_637840972286558644" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingGainsLosses" xlink:label="us-gaap_NonoperatingGainsLosses_637840972286558644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_637840972286548679" xlink:to="us-gaap_NonoperatingGainsLosses_637840972286558644" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureBasicAndDilutedNetLossPerShareDetails" xlink:type="extended" xlink:title="41201 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637840972286558644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_2" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637840972286558644" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637840972286558644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637840972286558644" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637840972286558644" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_637840972286558644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637840972286558644" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_637840972286558644" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember_637840972286558644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637840972286558644" xlink:to="us-gaap_ConvertiblePreferredStockMember_637840972286558644" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember_637840972286558644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637840972286558644" xlink:to="us-gaap_StockOptionMember_637840972286558644" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember_637840972286558644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637840972286558644" xlink:to="us-gaap_StockCompensationPlanMember_637840972286558644" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_WarrantsToPreferredSharesMember" xlink:label="drts_WarrantsToPreferredSharesMember_637840972286558644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637840972286558644" xlink:to="drts_WarrantsToPreferredSharesMember_637840972286558644" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_637840972286558644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637840972286558644" xlink:to="us-gaap_WarrantMember_637840972286558644" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637840972286558644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637840972286558644" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637840972286558644" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_NumeratorAbstract" xlink:label="drts_NumeratorAbstract_637840972286558644" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637840972286558644" xlink:to="drts_NumeratorAbstract_637840972286558644" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="us-gaap_IncomeLossFromContinuingOperations_637840972286569996" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_NumeratorAbstract_637840972286558644" xlink:to="us-gaap_IncomeLossFromContinuingOperations_637840972286569996" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_DenominatorAbstract" xlink:label="drts_DenominatorAbstract_637840972286569996" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637840972286558644" xlink:to="drts_DenominatorAbstract_637840972286569996" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637840972286569996" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_DenominatorAbstract_637840972286569996" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637840972286569996" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637840972286569996" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_DenominatorAbstract_637840972286569996" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637840972286569996" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_637840972286569996" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637840972286558644" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_637840972286569996" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_637840972286569996" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637840972286558644" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_637840972286569996" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637840972286569996" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637840972286558644" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637840972286569996" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureGeographicInformationDetails" xlink:type="extended" xlink:title="41301 - Disclosure - GEOGRAPHIC INFORMATION (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_GeographicInformationAbstract" xlink:label="drts_GeographicInformationAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637840972286578478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="drts_GeographicInformationAbstract_2" xlink:to="us-gaap_StatementTable_637840972286578478" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_637840972286578478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637840972286578478" xlink:to="srt_StatementGeographicalAxis_637840972286578478" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637840972286578478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_637840972286578478" xlink:to="srt_SegmentGeographicalDomain_637840972286578478" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IL" xlink:label="country_IL_637840972286578478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637840972286578478" xlink:to="country_IL_637840972286578478" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="country_US_637840972286578478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637840972286578478" xlink:to="country_US_637840972286578478" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP" xlink:label="country_JP_637840972286578478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637840972286578478" xlink:to="country_JP_637840972286578478" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:label="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_637840972286578478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637840972286578478" xlink:to="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_637840972286578478" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_637840972286578478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_637840972286578478" xlink:to="us-gaap_NumberOfOperatingSegments_637840972286578478" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637840972286578478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_637840972286578478" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637840972286578478" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.alphatau.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41401 - Disclosure - SUBSEQUENT EVENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_637840972286588126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract_1" xlink:to="us-gaap_SubsequentEventTable_637840972286588126" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_637840972286588126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637840972286588126" xlink:to="us-gaap_SubsequentEventTypeAxis_637840972286588126" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637840972286588126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_637840972286588126" xlink:to="us-gaap_SubsequentEventTypeDomain_637840972286588126" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_637840972286588126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_637840972286588126" xlink:to="us-gaap_SubsequentEventMember_637840972286588126" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637840972286588126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637840972286588126" xlink:to="srt_CounterpartyNameAxis_637840972286588126" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637840972286588126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637840972286588126" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637840972286588126" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_BankLeumiLeIsraelBmMember" xlink:label="drts_BankLeumiLeIsraelBmMember_637840972286588126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637840972286588126" xlink:to="drts_BankLeumiLeIsraelBmMember_637840972286588126" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637840972286588126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637840972286588126" xlink:to="us-gaap_StatementClassOfStockAxis_637840972286588126" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637840972286588126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637840972286588126" xlink:to="us-gaap_ClassOfStockDomain_637840972286588126" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_637840972286588126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637840972286588126" xlink:to="us-gaap_CommonClassAMember_637840972286588126" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637840972286588126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637840972286588126" xlink:to="us-gaap_CommonStockMember_637840972286588126" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_637840972286588126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637840972286588126" xlink:to="us-gaap_BusinessAcquisitionAxis_637840972286588126" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_637840972286588126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_637840972286588126" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_637840972286588126" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_HcccMember" xlink:label="drts_HcccMember_637840972286598476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_637840972286588126" xlink:to="drts_HcccMember_637840972286598476" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637840972286598476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637840972286588126" xlink:to="us-gaap_StatementLineItems_637840972286598476" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PledgedFinancialInstrumentsNotSeparatelyReportedSecuritiesForLetterOfCreditFacilities" xlink:label="us-gaap_PledgedFinancialInstrumentsNotSeparatelyReportedSecuritiesForLetterOfCreditFacilities_637840972286598476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637840972286598476" xlink:to="us-gaap_PledgedFinancialInstrumentsNotSeparatelyReportedSecuritiesForLetterOfCreditFacilities_637840972286598476" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_637840972286598476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637840972286598476" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_637840972286598476" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_637840972286598476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637840972286598476" xlink:to="us-gaap_SharesIssuedPricePerShare_637840972286598476" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="drts-20211231.xsd#drts_CommonStockCancelledAndConvertedInToShares" xlink:label="drts_CommonStockCancelledAndConvertedInToShares_637840972286598476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637840972286598476" xlink:to="drts_CommonStockCancelledAndConvertedInToShares_637840972286598476" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition_637840972286598476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637840972286598476" xlink:to="us-gaap_CashAcquiredFromAcquisition_637840972286598476" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>drts-20211231x20f002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 drts-20211231x20f002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  Q ,@# 2(  A$! Q$!_\0
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MFWQ5U[5M(UG3XM.U">UC>!F<1-C)W8S70_"_4[W5?"LMQJ%U)<S"Z=!)(<G
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,% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>drts-20211231x20f005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 drts-20211231x20f005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'J!#@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P \6>+-?L_%
M>IV]OJUU%#'.RHBO@ 5C?\)KXE_Z#5Y_WW1XU_Y'35_^OEJP:]:$(\JT/%J5
M)\[U-[_A-?$O_0:O/^_E'_":^)?^@U>?]_*P:*ODCV(]I/N;W_":^)?^@U>?
M]_*/^$U\2_\ 0:O/^_E8-%')'L'M)]S>_P"$U\2_]!J\_P"_E'_":^)?^@U>
M?]_*P:*.2/8/:3[F]_PFOB7_ *#5Y_W\H_X37Q+_ -!J\_[^5@T4N2/8/:3[
MF]_PFOB7_H-7G_?RC_A-?$O_ $&KS_OY6#13Y(]@]I/N;W_":^)?^@U>?]_*
M/^$U\2_]!J\_[^5@T4<D>P>TGW-[_A-?$O\ T&KS_OY1_P )KXE_Z#5Y_P!_
M*P:*.2/8/:3[F]_PFOB7_H-7G_?RC_A-?$O_ $&KS_OY6#11R1[![2?<WO\
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MUYKESI5]9Q02V\*R,T;E@Q)[>U=#0 54LB3+>9).)R!GL-JU;JG8_P"MO?\
MKX/_ *"M %RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YH\:_P#(
MZ:O_ -?+5@UO>-?^1TU?_KY:L&O8A\*/"J?&PHHHJR HHHH [J*UTOPYH>D/
M-HJ:MJNJIYRK*QVHA.%  ZDU4U30!J^OV5OI&CW6F/=)F2*Z&V-& RS*3SM
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M;G[&KEG"#U(& ?:BQ\#RW>FZ??3ZM86D5_N6$3,0Q8'&,8[UT=IXYT.TBC6
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M$PP7B0*P(.0?P-9MMX7OWO;675-9EO(+-]\,0C"<CH6(ZUO76IV%BRK=WMO
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MY9:,;36YM1,P8RV\<.S;C&WO5ZTU"SOM_P!DNX+C8<-Y4@;:??%6: "JR_\
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M5W0M.NI27<:,Q"NC ?*2.0>*DM_"U\NDZB@M]/AGNBN(3ND3:O9F)Z\\'M2
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MY=) 8%N9A$>-@<[?RJ"O4_\ A3T/_0QP?]^1_P#%4?\ "GH?^AC@_P"_(_\
MBJ/;T^X?5JO8\LI[2R.BHSL43[JDY"_2O4/^%/0_]#'!_P!^1_\ %4?\*>A_
MZ&.#_OR/_BJ/K%/N'U:KV/+*DAGEMW+0RO&Q&"48@X_"O3_^%/0_]#'!_P!^
M1_\ %4?\*>A_Z&.#_OR/_BJ/K%/N'U:KV/+.O)-%>I_\*>A_Z&.#_OR/_BJ/
M^%/0_P#0QP?]^1_\51]8I]P^JU>QY917J?\ PIZ'_H8X/^_(_P#BJ/\ A3T/
M_0QP?]^1_P#%4?6*?</JU7L>65[Q\(O^1+/_ %\O_(5S7_"GH?\ H8X/^_(_
M^*KN?">D#PIHYTU));X>:TGFQ1@#G''7VK'$583A9'1AJ,X3O)'4T53^WG_G
MSNO^^!_C2_;S_P ^=U_WP/\ &N$] MT54^WG_GSNO^^!_C1]O/\ SYW7_? _
MQH MT54^WG_GSNO^^!_C1]O/_/G=?]\#_&@"W153[>?^?.Z_[X'^-'V\_P#/
MG=?]\#_&@"W153[>?^?.Z_[X'^-'V\_\^=U_WP/\: +=%5/MY_Y\[K_O@?XT
M?;S_ ,^=U_WP/\: +=%5/MY_Y\[K_O@?XT?;S_SYW7_? _QH MT54^WG_GSN
MO^^!_C1]O/\ SYW7_? _QH -3_Y!\G_ ?_0A5NLG4;TM8R#[)<CIR4'J/>K?
MV\_\^=U_WP/\: +=9'BF-YO"^HQQ(SNT+!549)_"KGV\_P#/G=?]\#_&D^W'
M_GSNO^^!_C0!P,OAZ33++1M4$%S?0JL9N;.5F;82!\RK['L<T[6+:7^V-9>X
MBN&CO(T,!2S\TNNW&T'^ C\*[S[<?^?.Z_[X'^-'VX_\^=U_WP/\: .%U73Y
M;>>V<&]AG2Q2/S);07$<N/X2!G:W.*;<6^I,VA7UY9_98(X71TBMO,6)B3@F
M/MD8KO/MQ_Y\[K_O@?XT?;C_ ,^=U_WP/\: .%6">RT"W"V,LD$U^9"US:;C
M N/OK&"<#KC/Y52EL;J32/$4:P74@EN+=H]UOY9D&>6"@<?_ *J]'^W'_GSN
MO^^!_C1]N/\ SYW7_? _QH Y?6].2QU#1+H6!DTV#<)HH8MVUBH 8J!S_P#6
MJAJ=LE_IMJ;/1)K6W;5%8H4/[Q>[E?X17;_;C_SYW7_? _QH^W'_ )\[K_O@
M?XT 86FV;6OCW46BMC%;/:)AE3:A;(_#-=35/[<?^?.Z_P"^!_C1]O/_ #YW
M7_? _P : +E5U/\ IS#_ *9C^9IGV\_\^=U_WP/\:K+>G[>Y^R77^K QL'J?
M>@#4HJI]N/\ SYW7_? _QH^WG_GSNO\ O@?XT 6Z*J?;S_SYW7_? _QH^WG_
M )\[K_O@?XT 6ZY'1+:>/Q!XH=X9%25E\MBI ;ANGK71?;C_ ,^=U_WP/\:/
MMQ_Y\[K_ +X'^- '"KHQB^&,FRQ87\N[>/+_ 'A_>]/7H!4FMBXFO+NV:R,7
M^AHL4L=GYKW!V_=+8(4 Y%=M]N/_ #YW7_? _P :/MQ_Y\[K_O@?XT <AH=K
M<IJ7AIW@F"Q6$B.60C8<]#Z5W=4_MQ_Y\[K_ +X'^-'V\_\ /G=?]\#_ !H
MN454^WG_ )\[K_O@?XT?;S_SYW7_ 'P/\: +=(>AJK]O/_/G=?\ ? _QI#?'
M!_T.Z_[X'^- $UH<VL7^Z*FK-M+TK:1#['='Y1_ /\:G^WG_ )\[K_O@?XT
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MNI6+V_VA;N PYQY@D&W/IFE74+-[5KI;J$VZ\&4.-H_&@"S154ZE8BU%R;N
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M;F 2",S1B1B0%W#)(Z\4]Y$C0N[JJ 9+,< 5R=]I3/I^K3BT+7AO4>*0)\^
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M27F<=170ZCX=6#2- N+3SIKG4T<F/&?F#8 6J^J>%-;T:W6>^L'BB9@N_<&
M/H<'@_6J4XOJ2Z<ET,:BNLTWX>ZY=:C:P7=JUI!-*$,K$''R[L@9YXJPG@2:
M2SUQ8TF>^L+E(H8P5PR,?O,>WR\]:3JP74I49OH<715[5-(OM%N_LNH6[0R[
M0P!(((/<$<&M_P %^%;37UNY]2N9+:TB*1(Z8^:5S@#G_/--S2CS$QA*4N7J
M<E16H/#VI/K=SI,%L\MW;EPT:]<+U(J\/ OB,O$HTU_W@RK;UV]<8SG&<]NM
M'/%=05.3V1SM%:]GX8UF^O+FTAL7\ZU.)PY"B,^A).*6#PMK=SJ%Q81:?*UU
M;@&6+@%03P?UI\\>XN278QZ*WKSP]/8:/*]S:72WL5Z+9B"AB&5SMX.=WZ4R
M_P#"6N:98F]N]/DC@&-QR"4STW '(_&DIQ[C=.2Z&)16Y-X/UZWTYKZ73W6!
M$$C?,NY5/0E<Y _"L.FI)[$N+6X44450@HHHH *]X^$7_(EG_KY?^0KP>O>/
MA%_R)9_Z^7_D*YL5_#.O!_Q#IM=@-Q'"DNG"]M=Q,JK_ *Q#V9>1^G-8YTV_
MGMI(8!>PVAN;=H!.^Z2/#9=ADG '! /I77T5YIZIRD.G7D:Z;:FU;%E=2;IA
MC$BF-P'^I+ 'WJ;2M+FM;+P\#;>7);J1/C *Y0YS^.*Z6B@#&OH[BTUR'4HK
M=[B$P-!*L>"Z_,&# 'KW%4]0DU2_MV?^S]EN+B,QJZ!I54<L^W.,YQ@5TM%
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M&/2I    .@I:* "BBB@ HHHH SX]#TZ*\%TEN!('+CYCM5CU(7. ??%%:%%
M'S1XU_Y'35_^OEJUM-\2KHW@W3_LEPG]H6^J&<P^L>P@Y]CTK)\:_P#(Z:O_
M -?+5@UZRBI029XDIN,Y-'JNH>+?#T.O^&+^T<&TMQ*TT2@DPE_;V)/Y5BW$
MVFZ'X>U>U77(=3FU22-HEAR0@5]Q=\]&/3'6N$HJ512ZE.NWT._N_$-B_P 5
M+/4S>!]/B,*B49*J!& ?R8G]:9J%[86>A^++&/4K>>6[O(I8?);(D7=N.#[9
MYK@Z*?LEH+V[U.I\9:E9ZA'H7V6X65H--BBFV_PN!R#6O#XDT+0?"NEZ8EBF
MIS,WVNX*7#1^7+_#R <D# _"O/Z*?LDTHOH+VS3<ENSU)/$.B3>,(?$*7<5O
M]LTZ1;B(L<Q3;<8)QSGC!]JP+36;6/PWX<M7O )+?53/,A)^1-P(8_K7&44O
M8HIUWV/5Y?$.BZG-K^G+<:>3<WJW,,M[N$,JA5!!*D$$8XS5&X\46DUWXA9M
M0MF9M+%I!)!$T:RD'H Q)[D9KS:BDJ$1O$R['9Z/K=C8>#[6*:4/<0ZW'=-!
M_$8PF"?Z5/XC729)=6U:'Q+YHU!P\5I;EMS9.<2#L!VS7"T57LM;W)]L[6:/
M57U+P_8Q:J+74-/,-WIQC@8%WN'; XD8YP>#@<5Y5113A3Y":E1SL%%%%:&8
M4444 %>Y?"B2>+P:!';F0-<.<AP/0=_I7AM>]?"7_D24_P"N\G\ZY<7\!UX+
M^(=C]HNO^?%O^_BT?:+K_GQ;_OXM.N[^TL%5KNZA@5CA3*X4$_C3K:[MKR/S
M+6>*>/.-T;AAG\*\X]4C^T77_/BW_?Q:/M%U_P ^+?\ ?Q:M44 5?M%U_P ^
M+?\ ?Q:/M%U_SXM_W\6K5% %7[1=?\^+?]_%H^T77_/BW_?Q:M5$;F$.B&5
M\C%47<,L0,D#Z &@"+[1=?\ /BW_ '\6C[1=?\^+?]_%JU5>[O[2P0/>7,,"
M$X!E<*#^= #?M%U_SXM_W\6C[1=?\^+?]_%J>&:.XB66&19(V&5=#D$>QI]
M%7[1=?\ /BW_ '\6C[1=?\^+?]_%JU10!5^T77_/BW_?Q:/M%U_SXM_W\6K5
M% &5J,]R;&0&S8#CGS%]15O[1=?\^+?]_%I-3_Y!\G_ ?_0A3;[5K+3F5;J<
M1LPR!@DXH2N)NVX_[1=?\^+?]_%H^T77_/DW_?Q:H_\ "4:/_P _8_[Y/^%'
M_"4:/_S^#_OD_P"%5R2["YH]R]]HNO\ GR;_ +^+1]HNO^?)O^_BU1_X2C1_
M^?P?]\G_  H_X2C1_P#G\'_?)_PHY)=@YEW+WVBZ_P"?)O\ OXM'VBZ_Y\F_
M[^+5'_A*-'_Y_!_WR?\ "C_A*-'_ .?P?]\G_"CDEV#F7<O?:+K_ )\F_P"_
MBT?:+K_GQ;_OXM4?^$HT?_G\'_?)_P */^$HT?\ Y^Q_WR?\*.278.9=R]]H
MNO\ GQ;_ +^+1]HNO^?%O^_BU1_X2C1_^?P?]\G_  H_X2C1_P#G\'_?)_PH
MY)=@YEW+WVBZ_P"?%O\ OXM'VBZ_Y\6_[^+5'_A*-'_Y_!_WR?\ "C_A*-'_
M .?P?]\G_"CDEV#F7<O?:+K_ )\6_P"_BU +BY^VM_H1SY8_Y:+ZFH/^$HT?
M_G\'_?)_PJ >)=)^VL_VL;3&!]T^IHY)=@YEW-7[1=?\^3?]_%H^T77_ #Y-
M_P!_%JC_ ,)1H_\ S^#_ +Y/^%'_  E&C_\ /X/^^3_A1R2[!S+N7OM%U_SY
M-_W\6C[1=?\ /DW_ '\6J/\ PE&C_P#/X/\ OD_X4?\ "4:/_P _@_[Y/^%'
M)+L',NY>^T77_/DW_?Q:/M%U_P ^+?\ ?Q:H_P#"4:/_ ,_@_P"^3_A1_P )
M1H__ #]C_OD_X4<DNP<T>Y>^T77_ #XM_P!_%H^T77_/BW_?Q:?:7D%] )K:
M021GC(J>I**OVBZ_Y\6_[^+1]HNO^?%O^_BU:HH J_:+K_GQ;_OXM'VBZ_Y\
M6_[^+5JB@"K]HNO^?%O^_BTAN+K!_P!";_OXM6Z0]#0!0M;BY^S1XLCC:.DB
MU-]HNO\ GQ;_ +^+3[/_ (\X?]P5/0!5^T77_/BW_?Q:/M%U_P ^+?\ ?Q:M
M44 5?M%U_P ^+?\ ?Q:/M%U_SXM_W\6K5% %7[1=?\^+?]_%H^T77_/BW_?Q
M:M44 5?M%U_SXM_W\6C[1=?\^+?]_%JU10!5^T77_/BW_?Q:/M%U_P ^+?\
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M&_VB6X -22Z':PSW>^:;RH8$G7;M).>WI^-;O_"/ZN;B69]1MY#*H1U>+<I
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M?9&S]I\._P#0,U#_ ,#5_P#C='VGP[_T#-0_\#5_^-UC44<H<[[&S]I\._\
M0,U#_P #5_\ C='VGP[_ - S4/\ P-7_ .-UC44<H<[[(V?M/AW_ *!FH?\
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M^+JUJ?\ R#Y/^ _^A"J>NZRVD1Q&.(2/(3C<< 8I2DHJ[!NP[[/KO_01L?\
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M1L?_  $;_P"+K!_X3.Z_Y]8?S-'_  F=U_SZP_F:/;P#G1O?9]=_Z"-C_P"
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M9^S0_*V>I]#4G_"9W7_/K#^9H]O .=&]]GUW_H(V/_@(W_Q='V?7?^@C8_\
M@(W_ ,76#_PF=U_SZP_F:/\ A,[K_GUA_,T>W@'.C>^SZ[_T$;'_ ,!&_P#B
MZ/L^N_\ 01L?_ 1O_BZP?^$SNO\ GUA_,T?\)G=?\^L/YFCV\ YT;WV?7?\
MH(V/_@(W_P 71]GUW_H(V/\ X"-_\76#_P )G=?\^L/YFC_A,[K_ )]8?S-'
MMX!SHWOL^N_]!&Q_\!&_^+H^SZ[_ -!&Q_\  1O_ (NL'_A,[K_GUA_,T?\
M"9W7_/K#^9H]O .=&]]GUW_H(V/_ ("-_P#%T?9]=_Z"-C_X"-_\76#_ ,)G
M=?\ /K#^9H_X3.Z_Y]8?S-'MX!SHWOL^N_\ 01L?_ 1O_BZ/L^N_]!&Q_P#
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MHH ROL^N_P#01L?_  $;_P"+H^SZ[_T$;'_P$;_XNM6B@#*^SZ[_ -!&Q_\
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M_"*Z5_SR?_OX:/\ A%=*_P">3_\ ?PT?5YAR,X&BN^_X172O^>3_ /?PT?\
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MO#&EK- !$^&<@_O#Z&IO^$5TK_GD_P#W\-'U>8<C.!HKOO\ A%=*_P">3_\
M?PT?\(KI7_/)_P#OX:/J\PY&<#17??\ "*Z5_P \G_[^&C_A%=*_YY/_ -_#
M1]7F'(S@:*[[_A%=*_YY/_W\-'_"*Z5_SR?_ +^&CZO,.1G T5WW_"*Z5_SR
M?_OX:/\ A%=*_P">3_\ ?PT?5YAR,X&BN^_X172O^>3_ /?PT?\ "*Z5_P \
MG_[^&CZO,.1G T5WW_"*Z5_SR?\ [^&C_A%=*_YY/_W\-'U>8<C.!KM_!O\
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M>F?\_L/_ 'U1_;>F?\_L/_?5'-'N%T._LR'_ )[7?_@5)_C1_9D/_/:[_P#
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M_P "I/\ &KM%4,I?V9#_ ,]KO_P*D_QH_LR'_GM=_P#@5)_C5VB@"E_9D/\
MSVN__ J3_&C^S(?^>UW_ .!4G^-7:* *7]F0_P#/:[_\"I/\:/[,A_Y[7?\
MX%2?XU=HH RYM,B\Z#]_=_?/_+U)_=/^U4_]F0_\]KO_ ,"I/\:GE.)8>/XC
M_(U-0!2_LR'_ )[7?_@5)_C1_9D/_/:[_P# J3_&KM% %+^S(?\ GM=_^!4G
M^-']F0_\]KO_ ,"I/\:NT4 4O[,A_P">UW_X%2?XT?V9#_SVN_\ P*D_QJ[1
M0!2_LR'_ )[7?_@5)_C1_9D/_/:[_P# J3_&KM% %+^S(?\ GM=_^!4G^-']
MF0_\]KO_ ,"I/\:NT4 4O[,A_P">UW_X%2?XT?V9#_SVN_\ P*D_QJ[10!2_
MLR'_ )[7?_@5)_C52RTV$RWG[Z[XG(XN9/[J^];%4['_ %M[_P!?!_\ 05H
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M /SWMOS;_"C_ (0V_P#^>]M_WTW^%<GLI]C/E9SM%=%_PAM__P ][;_OIO\
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MZ4ZM^'P??-$C">WP1ZM_A3_^$.O_ /GO;?\ ?3?X4>RGV#E9SM%=%_PAM_\
M\][;_OIO\*/^$-O_ /GO;?\ ?3?X4>RGV#E9SM26_P#Q\Q?[X_G6]_PAU_\
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M#N8E']*7^S-/_P"?&V_[\K_A0!;HJI_9>G_\^-M_WY7_  H_LO3_ /GQMO\
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M_"C^R]/_ .?&V_[\K_A0!;HJI_9>G_\ /C;?]^5_PH_LO3_^?&V_[\K_ (4
M6Z*J?V7I_P#SXVW_ 'Y7_"C^R]/_ .?&V_[\K_A0!;HJI_9>G_\ /C;?]^5_
MPH_LO3_^?&V_[\K_ (4 2S?ZZ#_?/\C4U9L^F:>)[?\ T&V^^?\ EDO]T^U3
M_P!EZ?\ \^-M_P!^5_PH MT54_LO3_\ GQMO^_*_X4?V7I__ #XVW_?E?\*
M+=%5/[+T_P#Y\;;_ +\K_A1_9>G_ //C;?\ ?E?\* +=%5/[+T__ )\;;_OR
MO^%']EZ?_P ^-M_WY7_"@"W153^R]/\ ^?&V_P"_*_X4?V7I_P#SXVW_ 'Y7
M_"@"W153^R]/_P"?&V_[\K_A1_9>G_\ /C;?]^5_PH MT54_LO3_ /GQMO\
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M_P ^-M_WY7_"C^R]/_Y\;;_ORO\ A0!;HJI_9>G_ //C;?\ ?E?\*/[+T_\
MY\;;_ORO^% %NBJ8TW3B3BRM3@X.(E_PH&FZ<V<65J<'!Q$O^% %RBJG]EZ?
M_P ^-M_WY7_"@Z9IX_Y<;7_OTO\ A0!;HJFNFZ<ZAELK4@]"(E_PI?[+T_\
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MFRLFD:&'YY1AW=B[,/0DDG'M45OH&FVT\<T5OAHB3&&=BJ?[H)P/PH CU/\
M?:GIEJQ/E-(TKCLVQ<@?F0?PJI::C?7$;ZBUU#';K<21?9F0#(5BOWNN\X^G
M-:E_9M<M;31.%GMY1(A/0CHP/U4G\<4T:/8B[^U"'$F_S,;CMW_WMN<9]\4
M8Z:MJ,4&G7DL\4L>H<>4(\>42A8;3U/3G-,L[W6;D:6&OXE_M"V:5B(!F(J%
M/R^N=W.:VH=$T^WF$D=N 0&"@L2$SUV@G"Y]JGBT^VA^S>7$%^S(8X>?NJ0
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M\L(C?YBPQ@=N/8UNU3M-+M+*:2:",B60 .[,69L=,DGFKE !1110!\T>-?\
MD=-7_P"OEJP:WO&O_(Z:O_U\M6#7L0^%'A5/C844459 4444 %%%% !1110
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M ._J_P"-']HV/_/[;_\ ?U?\: +-%5O[1L?^?VW_ ._J_P"-']HV/_/[;_\
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MA9&: _;;?AS_ ,M5_NGWJ?\ M&Q_Y_;?_OZO^- %FBJW]HV/_/[;_P#?U?\
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M['&T+P(T[S1Q02F-XXV+YZAAG(P>G7BK$MGH\TDSM?KB8*647"@!UQAQW##
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M].M3R0Z1)!=PM>Q;;N(128F7. NWC\* *ESKE^T%_>64=O\ 9;-O+*RYWNP
M+'C@ ;A]<=JT=7F$5K:L4#;KN!<9(QF11GBL#4K-+F:YA@GMDAN-H,B7H52
M ,NG=ACMP>,UT%S+IMW%%'+>P8CD25<3*/F4@C]10!G1:QJ3E+EH[;[(;PVI
M49WXWE0V>G7'%5+75]1M;7RY)(YIY[V:-7,;L(U4G)P,D]  *UEBTA;80"]B
MV"X^T?ZY<[MV[\LU ;+2#YA74RC-,9T9+E08G.<[?8Y.0<T 0+K>J3M:6T5O
M%'<S321EYD=4(5=P8 X.".U.M]0O"\=K9Q0+)-/<!GD+$+L;[V,Y.?3/>K4%
MOI$$EO(+]7D@9W#O<!BS,,$G_P"MBGPQZ3!.DR7L6Y'D<9F7JYRU %/3]:U&
MX-C+<16ZPW,SVY5,[E9=WS9]"5/%7;Z]OEUB"RM%@"-"TTCRY) # 8 '?FF0
MPZ1!';QI>Q;;>9IDS,OWFW9S[?,:L&;3&OEO#>P>:L1B'[Y<;20?Z4 9.G>(
M[N]DMIA;%K:Y8A46%]T8YVL6QM.<#/IFF1^)+Q5N?/%NDJ6LLPMV5DD1E&0.
M?OCKR/2KMO9Z/;3*T>HCR8R3';FY7RXR>N!U[GJ<4Q-/T42 S:B+A%1HXXYK
MD%8U88('?IQR30!%K.IS/I,L0 7SM,EN"RD@A@%Z?]]5$M]JEM/JLB$7"QO"
MJ($9B@*C)P#R "20.IJ==+T81/&^J-*&@:VS)<J2L9QP/IBII;3299YI1J?E
MF4+D)<J &7&UA[C ]O:@"QH>I/J,$S226\ACDV;H<C/ ZJ>5/7@UJUDV TO3
M_-9-0CEEF8-+++.I9R!@9Z#IZ"KO]HV/_/[;_P#?U?\ &@"S14$=[:2N$CNH
M7<]%60$FB@#YO\:_\CIJ_P#U\M6#6]XU_P"1TU?_ *^6K!KV(?"CPJGQL***
M*L@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KW?X3PQ/X+0O&C
M'SWY*Y[UX17O?PE_Y$E/^N\G\ZY<7\!V8+^(=K]G@_YXQ_\ ?(H^SP?\\8_^
M^16)XDO6M+C38SJ36$$TCB690O0(2!\P(ZU'IFK3K]MVS3:K;Q^7Y$J1J&=F
MSE<@!2!QSVS7G'J'0?9X/^>,?_?(H^SP?\\8_P#OD5ACQ2@CE#V4OVB*9(6A
M1T<DO]W!!Q4P\08@<26,RWBS" 6H9268C(PV<8QSGV- &M]G@_YXQ_\ ?(H^
MSP?\\8_^^16/+XAEB-O"=*NC=S.Z"#<HY4 YW9P1@]:3_A)X!=^6T#K;^=Y!
MG+K@/G'W<YQGC.* -C[/!_SQC_[Y%'V>#_GC'_WR*RVU_P N_CMY+&:.*6;R
M8Y7906;G^'.<<=:H66O7,QLY+U'MP]S<)\I4JRHKGGOQM[=2/2@#I/L\'_/&
M/_OD4GV>#_GC'_WR*H:=J\E](F[3[B"*5/,AE?:0R\=<'Y3R#@U7F:[U/5[J
MS@O9+.&T";FB52SLPSU8'  QTH U_L\'_/&/_OD4OV>#_GC'_P!\BLXW5]IU
ME&EQ$U]<%RJM%A 5'(9R<!>/UZ54C\4)/';"WL9I9YWEC$0=?E:/&<MG&.>M
M &Y]G@_YXQ_]\BC[/!_SQC_[Y%9(\0>;!!]FL9IKJ4N#;[E!38<,22<8!X]\
MTR;Q*B&...RG:<Q^;)$[+&8UR1SN(!.0< =<4 ;/V>#_ )XQ_P#?(H^SP?\
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MIS0!U?V>#_GC'_WR*9(EI$4#I"I<[5! ^8X)P/P!KC8[_53_ &E8B\>-XIH
MBS3H9/FSN0.!@$XX]*T+*]G9;2&26Y\U+]HI5N-K,O[IFV[EX8=.>M '0H+.
M2 3HL+1%=P< 8(]<U$MSI;XVR6IR$(P1R'^Y^?;UKEM.EN+&PT@P7\MPMU;2
M"2)B"J!8R0RX'&" /Q]:BL;J8O%-YA\R6'2P[8'.YN?YF@#M4CM9-VQ(6VG:
MV #@^A]Z=]G@_P">,?\ WR*X_3FETQ+F]6[E,,6J2K<H[ CRR<;C[@D&MZQ:
M>]T"2>=Y%:Z1Y%[-&K9V@?08H T$BMI$#I'"RD9#* 0:2)+2>)98DA=&Y#*
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M1]G@_P">,?\ WR*DHH C6")6W+$@([A114E% 'S1XU_Y'35_^OEJP:WO&O\
MR.FK_P#7RU8->Q#X4>%4^-A1115D!1110 4444 %%%% !1110 4444 %%%%
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M\HU-]N7_ )][G_OT: +5%5?MR_\ /O<_]^C1]N7_ )][G_OT: +5%5?MR_\
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MFC"HK=\CPM_S^ZI_X#I_\51Y'A;_ )_=4_\  =/_ (JCG\@]GYHPJ]Z^$O\
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MR[AR1.8_X5@O_03/_?K_ .O1_P *P7_H)G_OU_\ 7KI_.\3?\^FF_P#?Y_\
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M_/IIO_?Y_P#"CSO$W_/IIO\ W^?_  H VZ*Q/.\3?\^FF_\ ?Y_\*/.\3?\
M/IIO_?Y_\* -NBL3SO$W_/IIO_?Y_P#"CSO$W_/IIO\ W^?_  H VZ*Q/.\3
M?\^FF_\ ?Y_\*/.\3?\ /IIO_?Y_\* -N@]#6)YWB;_GTTW_ +_/_A2&;Q-@
M_P"B:;_W^?\ PH U[;_CVC[?**EKG[:;Q)]FCV6FG;=HQF9\_P JE\[Q-_SZ
M:;_W^?\ PH VZ*Q/.\3?\^FF_P#?Y_\ "CSO$W_/IIO_ '^?_"@#;HK$\[Q-
M_P ^FF_]_G_PH\[Q-_SZ:;_W^?\ PH VZ*Q/.\3?\^FF_P#?Y_\ "CSO$W_/
MIIO_ '^?_"@#;HK$\[Q-_P ^FF_]_G_PH\[Q-_SZ:;_W^?\ PH VZ*Q/.\3?
M\^FF_P#?Y_\ "CSO$W_/IIO_ '^?_"@#;HK$\[Q-_P ^FF_]_G_PH\[Q-_SZ
M:;_W^?\ PH U9?\ 70\?Q_T-35STLWB3S8=UIIV=WRXF?K@]>*F\[Q-_SZ:;
M_P!_G_PH VZ*Q/.\3?\ /IIO_?Y_\*/.\3?\^FF_]_G_ ,* -NBL3SO$W_/I
MIO\ W^?_  H\[Q-_SZ:;_P!_G_PH VZ*Q/.\3?\ /IIO_?Y_\*/.\3?\^FF_
M]_G_ ,* -NBL3SO$W_/IIO\ W^?_  H\[Q-_SZ:;_P!_G_PH VZ*Q/.\3?\
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M>^5%N(]ZHP<#<0,CU //T/%6*Q/.\3?\^FF_]_G_ ,*/.\3?\^FF_P#?Y_\
M"@#;HK$\[Q-_SZ:;_P!_G_PH\[Q-_P ^FF_]_G_PH VZ*Q/.\3?\^FF_]_G_
M ,*/.\3?\^FF_P#?Y_\ "@#;HK$\[Q-_SZ:;_P!_G_PH\[Q-_P ^FF_]_G_P
MH VZ*Q/.\3?\^FF_]_G_ ,*/.\3?\^FF_P#?Y_\ "@#;HK$\[Q-_SZ:;_P!_
MG_PH\[Q-_P ^FF_]_G_PH VZ*Q/.\3?\^FF_]_G_ ,*/.\3?\^FF_P#?Y_\
M"@#;HK$\[Q-_SZ:;_P!_G_PH\[Q-_P ^FF_]_G_PH VZ*Q/.\3?\^FF_]_G_
M ,*/.\3?\^FF_P#?Y_\ "@#;HK$\[Q-_SZ:;_P!_G_PH\[Q-_P ^FF_]_G_P
MH VZ*Q/.\3?\^FF_]_G_ ,*/.\3?\^FF_P#?Y_\ "@#;HK*M)==:Y07=O8I!
M_$8Y6+#Z9%% 'S[XU_Y'35_^OEJP:WO&O_(Z:O\ ]?+5@U[$/A1X53XV%%%%
M60%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5[Q\(O^1+/_ %\O
M_(5X/7O'PB_Y$L_]?+_R%<V*_AG7@_XAVES?VUG-;Q7$RQO</LB!_B;TIXNX
M3>&T#_OP@D*X_A)QG\ZQM?LHM0U'2[68'8[3<CJIV$@CW!P:P)[[4HKS5 X9
M+^UL$C:51]X>9_K%_P" G/L<UYIZIWU%<8UU/!!>?9;P&(11E_*N'F* R ,X
M8C@[2QQ[ XHN[Y+.>\ALKNXELC!%ETFW>7*TF/\ 6-G:".OH.: .SJJ^HVJ7
M#P&3]ZC(K*%)P7X6N22\F0W\*7!2V5K?S&BN6E$:LQ#D.>1P!GTI \4&LW7V
M&Z=XC=6*;O-+\%R"N[/(_P : .XHKD;346\BVMI+LFZ_M5T>,O\ -LWMP?;&
M/TIT-S=&Z:PEEG4:699964DM*N/W0SWX;\UH ZRFNZQHSNP55&23T KBK"]D
M-Y:F.X8B:TE9_P#2S,S$*"I8=%;KT]ZD:*2.WM$\^XD%YIDK3!Y6;<P52#UX
M/)Z4 =A#+'/"DT3AXW4,K#H0>AI]8N@,5\*6!LPLSBW3 :0XS@9&><=ZNP2Z
MBTJB>T@CC[LLY8C\-HH =>:E:V+1I/(?,DSLC12[MCKA1S3[.]M[^$RVTHD4
M,5;L5(Z@@\@^U93SPV'BF>:]D6-)K9%@E<X7@G<N?7D'_P#563=2-<7=_<6<
MSI;7-W9PB:)L;CNPY4]^"!GVH [.H8KJ&:XF@C?,D! D&/NY&17'ZY<"V:_A
M@FF5K.!?+,MXRD';D%5'+^Y-:^@2-+JFJRL<E_(8GUS&* -34_\ D'R?5?\
MT(5F:YK[Z5<1PQPB1F3>2QQWQ_2M/4_^0?)_P'_T(5RGC'_D*P_]<1_,UE6D
MXQNB9.R)/^$SN/\ GTB_[Z-'_"9W'_/I%_WT:YFBN3VT^YGS,Z;_ (3.X_Y]
M(O\ OHT?\)G<?\^D7_?1KF:*/;3[AS,Z;_A,[C_GTB_[Z-'_  F=Q_SZ1?\
M?1KF:*/;3[AS,Z;_ (3.X_Y](O\ OHT?\)G<?\^D7_?1KF:*/;3[AS,Z?_A,
M[C_GTB_[Z-)_PF=Q_P ^D7_?1KF:*/;3[AS,Z;_A,[C_ )](O^^C1_PF=Q_S
MZ1?]]&N9HH]M/N',SJ$\93%U#6D>W/.&.:Z:-MU\S#H8E/ZFO,E^\/K7IL '
MG#_KDO\ 6NBA.4KW+@V]RU111706%%%% !1110 4444 %%%% !1110 4AZ&E
MI#T- $-G_P ></\ NBIZBMN+:/\ W14M !1110 4444 %%%% !1110 4444
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M=_E'_P#$T?8)_P#H)W?Y1_\ Q- %MXTD7:ZJP]&&:-B!0H4!1T&.!53[!/\
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MO\H__B:/L$__ $$[O\H__B: +M%4OL$__03N_P H_P#XFC[!/_T$[O\ */\
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M#8HJC]@G_P"@G=_E'_\ $TOV"?\ Z"=W^4?_ ,30!=HJC]@G_P"@G=_E'_\
M$TOV"?\ Z"=W^4?_ ,30!=HJE]@G_P"@G=_E'_\ $T?8)_\ H)W?Y1__ !-
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M +M%4OL$_P#T$[O\H_\ XFC[!/\ ]!.[_*/_ .)H NTA4,,, 0>H-4_L$_\
MT$[O\H__ (FC[!/_ -!.[_*/_P")H N@8Z452^P3_P#03N_RC_\ B:/L$_\
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M?9?\^EO_ -^Q_A0!/N7^\/SHW+_>'YU7_L^R_P"?2W_[]C_"C^S[+_GTM_\
MOV/\* )]R_WA^=+N7^\/SJO_ &?9?\^D'_?H?X4O]GV7_/I;_P#?L?X4 3[E
M_O#\Z-R_WA^=0?V?9?\ /I;_ /?L?X4?V?9?\^EO_P!^Q_A0!-N7^\/SI=R_
MWA^=0?V?9?\ /I;_ /?L?X4?V?9?\^EO_P!^Q_A0!/O7^\/SHWK_ 'A^=0?V
M?9?\^EO_ -^Q_A1_9]E_SZ6__?L?X4 3[U_O#\Z-Z_WA^=0?V?9?\^EO_P!^
MQ_A1_9]E_P ^EO\ ]^Q_A0!'J3+_ &?)\P_A[^XJUN7^\/SK.U&QM%L9"MK
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M_P!^Q_A18"?<O]X?G1O7^\/SJ#^S[+_GTM_^_8_PH_L^R_Y]+?\ []C_  H
MGWK_ 'A^=&]?[P_.H/[/LO\ GTM_^_8_PH_L^R_Y]+?_ +]C_"@"?>O]X?G1
MO7^\/SJ#^S[+_GTM_P#OV/\ "C^S[+_GTM_^_8_PH GWK_>'YT;U_O#\Z@_L
M^R_Y]+?_ +]C_"C^S[+_ )]+?_OV/\* $G8>=;X8??/?_9-6-Z_WA^=4I=/M
M/-AQ9P8W<XC'H?:IO[/LO^?2W_[]C_"@"?>O]X?G1O7^\/SJ#^S[+_GTM_\
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MW_/:P_\  Z'_ .*K&HHM+N%X]C9_X1F^_P">UA_X'0__ !5'_",WW_/:P_\
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MOO\ P"E_^)H_X2&S_P">5]_X!2__ !-:M% &5_PD-G_SROO_  "E_P#B:/\
MA(+/_GE??^ 4O_Q-:M% &5_PD%G_ ,\K[_P"E_\ B:@&OVGVMF\F]QL S]CE
M]3_LUN57'_'\X[^6/YF@"E_PD-G_ ,\K[_P"E_\ B:/^$AL_^>5]_P" 4O\
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M2_\ Q-5+/7K1);LF*]^:<D8LY3_"O^S7053L1^]O?^O@_P#H*T 5O^$@L_\
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M #ROO_ *7_XFM7(%&10!E?\ "06?_/*^_P# *7_XFC_A(+/_ )Y7W_@%+_\
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MZC& Z@$K\K<\\50FBOK35+M+B>:YO&M)/[-F( &<99=H &[(!SW'TKKJ* .
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MUW"3(L=W-:!4#!56104(!.0-VW'L:L1K<VT%_"XN9(M(@DB38Y#OYAR#N]D
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MEY(+"=)UP?D<1 ;6]\@\5W6!G-&,4 >?Q06Z>86=X)9]'@*R1J2Q /S' ZC
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M +X%'V6W_P">$7_? J+[=_TZW/\ W[_^O1]N_P"G6Y_[]_\ UZ+("7[+;_\
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M^_?_ ->C[=_TZW/_ '[_ /KT60$OV6W_ .>$7_? H^RV_P#SPB_[X%1?;O\
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M +^?_6H_X3Q?^@>?^_G_ -:N+HHL@]K/N=I_PGB_] \_]_/_ *U'_">+_P!
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M[3_A/%_Z!Y_[^?\ UJ/^$\7_ *!Y_P"_G_UJXNBBR#VL^YVG_">+_P! \_\
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MB29',49<@L%QD#GL:SM,TUIY]--Y9,42.Y8K-'PK-*",@]\$T =.\\2(':1
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M510** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ^:/&O\ R.FK_P#7RU8-=QXK_P"$8_X2O4_M3:OY_GMO\I8]N?;)SBL;
M'A'^]K?_ 'S%_C7K0E[JT/%J0]]ZF!16_CPC_>UO_OF+_&C'A'^]K?\ WS%_
MC5<_D1R>9@45OX\(_P![6_\ OF+_ !HQX1_O:W_WS%_C1S^0<GFC HK?QX1_
MO:W_ -\Q?XT8\(_WM;_[YB_QHY_(.3S,"BM_'A'^]K?_ 'S%_C1CPC_>UO\
M[YB_QHY_(.3S1@45OX\(_P![6_\ OF+_ !HQX1_O:W_WS%_C1S^0<GF8%%;^
M/"/][6_^^8O\:,>$?[VM_P#?,7^-'/Y!R>:,"BM_'A'^]K?_ 'S%_C1CPC_>
MUO\ [YB_QHY_(.3S,"BM_'A'^]K?_?,7^-&/"/\ >UO_ +YB_P :.?R#D\T8
M%%;^/"/][6_^^8O\:,>$?[VM_P#?,7^-'/Y!R>9@5[U\)?\ D24_Z[R?SKR3
M'A'^]K?_ 'S%_C7J7@%KP^' /#WD&Q$S#_B89$F[J?N<8Y%<V)E>&QUX.-I[
MG<7VF6FHF(W,;,8B60K(R%21@\J1VID6BZ? FU(.LBRDL[,Q93E223DXJG_Q
M5'IH_P"<M'_%4>FC_G+7 >D7;G1[&\F:6:$EW4*^V1E#@= P! /XTR?0M.N6
MF,L!(F_UBB1E5N,9*@XSCO[55_XJCTT?\Y:/^*H]-'_.6@"V^B:>\QE: Y)5
MF D8*Q7&"5S@G@=1VJQ;V-O:2S20(5:9M[_.2"WJ 3@?A69_Q5'IH_YRT?\
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ME_XJCTT?\Y:/^*H]-'_.6B[#DCV$_P"$1T;_ )]W_P"_C?XT?\(AHW_/N_\
MW\;_ !I?^*H]-'_.6C_BJ/31_P Y:+L.2/83_A$-&_Y]W_[^-_C1_P (AHW_
M #[O_P!_&_QI?^*H]-'_ #EH_P"*H]-'_.6B[#DCV$_X1#1O^?=_^_C?XT?\
M(CHW_/N__?QO\:7_ (JCTT?\Y:/^*H]-'_.6B[#DCV$_X1'1O^?=_P#OXW^-
M'_"(:-_S[O\ ]_&_QI?^*H]-'_.6C_BJ/31_SEHNPY(]A/\ A$=&_P"?=_\
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MV$_X1'1O^?=_^_C?XT^'PKI$,R2K;'<IR,R,1G\Z;_Q5'IH_YRT?\51Z:/\
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MIH_YRU5M#XE\R[V#2<^<=VXR==J]/;I0!TM%8G_%4>FC_G+1_P 51Z:/^<M
M&W16)_Q5'IH_YRT?\51Z:/\ G+0!MT5B?\51Z:/^<M'_ !5'IH_YRT ;=%8G
M_%4>FC_G+1_Q5'IH_P"<M &W16)_Q5'IH_YRT?\ %4>FC_G+0!MT5B?\51Z:
M/^<M'_%4>FC_ )RT ;=5X[&WCO)+M8_W\@VLY)/'H,]/PK,_XJCTT?\ .6C_
M (JCTT?\Y: -NBL3_BJ/31_SEH_XJCTT?\Y: -NBL3_BJ/31_P Y:/\ BJ/3
M1_SEH VZ*Q/^*H]-'_.6C_BJ/31_SEH VZ*Q/^*H]-'_ #EH_P"*H]-'_.6@
M#;HK$_XJCTT?\Y:/^*H]-'_.6@#;HK$_XJCTT?\ .6C_ (JCTT?\Y: -NBL3
M_BJ/31_SEH_XJCTT?\Y: -NBL3_BJ/31_P Y:/\ BJ/31_SEH VZ*Q/^*H]-
M'_.6C_BJ/31_SEH VZ*Q/^*H]-'_ #EH_P"*H]-'_.6@#;HK$_XJCTT?\Y:/
M^*H]-'_.6@#;HK*M/[?^TI]L&F^1_%Y/F;OPSQ10!\^^-?\ D=-7_P"OEJ;X
M5\./XEU1K7[0+:&.(RRSL,A /_KFG>-?^1TU?_KY:NBT271M$\!2-JIG9]8F
MV[;1E$@C3UST&?YUZCDU35MSQE%2JOFV..U72I]+UJXTR12TT,IC  Y;T('O
MQ5]?"UXFA:GJ%XDUJ]D8L0RQ$%PY(SSZ8KO);S1;KQ5X9\4I(JVT^Z"?SF!=
M9%#*C/COTY]A5:\&I67@_7H-=U.*[D:YADCC%P)&V;^2.> <<#MBI]K+1&BH
M1U9QFB>%;[5;N*.:*>UMY8I)$G>$[6VJ6P.G7%/L?"LVJ#2H[&5WN+XON62%
ME2(+WW8PP^E>E++>-XJN=135[?\ L"XLF6VA^TKAOW?W0F>"""<UCZ+J,5G;
M^!&-TL8$DZ2X?& QP WMG'6I]K)[#5&"W_K8X:;P^]K:ZHUR\\4]E*J",V[8
M<$]2W1>.1GKFJ)TG418_;C8W/V3_ )[>4=GYUWEX)K;0_%\6ISB6=[J!P#,'
M+IN)&#D_PX^E;WVF=?$;ZS)JMNWA(VI @\\;2OEX$?EY^]NJO:R1/L8L\GM]
M&U.[6-K?3[J59%+(4B8A@.I''.,BH[73+^^G>"TLYYY4^^D<98K]?2O0DU>6
MTT#P3%9WK0(]X_G(DF/E\P8#8[8)ZU>2!'UCQ3<6EY+(XO%/V.WO5M@Z]2Y<
M\X'/0^M'MFN@O81[G!Z/X8FU(:NL[O:2Z=:M<-&\9RV/X2#C%4]&LM-O9Y%U
M/5/[/C5<H_DM)N.>F!7J&H7-NVO^)I5FA*S:"-C+(&#G;C@]Z\=JH3<T^A,X
M1@UU.M\2>$K#0I'LXM9:[U,%-MHMLP+;L$8/(Z&N:.GW@>=3:S!K<9F'EG,8
M_P!KT_&NV\57EO'\5K>Z,R&!'MF9PP( "KGFMG4;$V4_C6]FN;7R[ZW+6RI.
MK-(N<YP#D>G-2JCBE<MTHR;MT/-AHNJ&)I1IUUY:()&;R6P%/0].E17.G7ME
M'%)=6D\*2C,;21E0X]L]:]<M-7>/QEX9MEO]MG_97[R,2X0ML;[PZ9X'6L&T
MUB.[\(:=<ZU<FY\K70TGFON81X!/![=:%5EV!T8]SA+C2=1M;5+FXL;F*!\;
M9'B(4YZ<FAM*U!;9KEK&X$"J',AC.T*>ASZ&O3=2DOK5?$MYJ^K07.D7EO(M
MC$)PX=V.8]BY^7 _SWKF_&>KW/\ 96A:=#=M]D.F1-+$C_*7W'[P]1M%5&K*
M5D3.E&*;N<51116YSA7O'PA_Y$L_]?+_ ,A7@]>\?"+_ )$L_P#7R_\ (5S8
MK^&=>#_B';37D$%S;V\CXDN&98A@_,0"Q_0&@7<!O39A_P!^(Q(5Q_"3C/YU
MB^((IIM9T)()V@D,TN)50-M_=-V/'M6/J:ZA8:M=L;V2=C:Q;Y=@C*1^;\V-
MH],\X)KS3U3N:*X6YNO++*NH%+3S[<.8+EY F2V?G/3(QD?C4\MXL=W-;Q32
M26!G40NUT4CW;"74R<G'3@=Z .MENH89(XY) KR9V+W; R<?A3X9DGA25,[7
M4,,@@X/L>E<!;2F6]L9IYF,<-Y=1QOYS$*/+!0!CR>>GK5K3[J-[9GU:^NHW
M2T@:WVRE6;*<E1_$Q;(YS^M '<45AZS*1=Z;'/*\6GR%_.?>4^;:-BDCH#\W
MY"L22[5KN1!=R?84@)MY+BZ:/<=S;BI ^;& !GMCUH ZMM4LTO#:-+B<.J;=
MIZL"1^@-7*X.R:>36+9YV,DIEM2SE2NX^5)S@]*[R@ HHHH **** "BBB@"I
MJ?\ R#Y/^ _^A"H[_6++3'1+J7:S#( 4DX_"I-3_ .0?)_P'_P!"%<CXT_Y"
ML'_7 ?\ H34 ;_\ PE>D?\]W_P"_;?X4?\)7I'_/=_\ OVW^%>>44Q'H?_"5
MZ1_SW?\ []M_A1_PE>D?\]W_ ._;?X5YY10!Z'_PE>D?\]W_ ._;?X4?\)7I
M'_/=_P#OVW^%>>44 >EV6O:?J%QY%O,3(1D!E(S^=:5><^&/^1@MO^!?^@FO
M1J0PHHHH **** "H 1]M89Y\L<?B:GJNI/V]QV\L<?B: +%%%% !1110 444
M4 %%%% !1110 4444 %(>AI:0]#0!':G-M&0<_**EJ&TYM(B>NT5-0 4444
M%%%% !1110 4444 %%%% !1110!#,<2P<XRY_D:FJ"?/G6_^^?\ T$U/0 44
M44 %%%% !1110 4444 %%%% !1110 53L?\ 6WO_ %\'_P!!6KE4['_6WO\
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ML*BTC0KJQ\GSFC.S35M3M.?G#,?RYH T?[8M5,TS7"FW2&.480YPY.#GOG'
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MP^GZ3NNB9Y=2DBD&>60-+P?;A?TJE9WNI6VCZ9J1OKBYFNH9-\4F"I(C9EP
M.N5'UYH ZS4_^0?)]5_]"%9^M>'DU>>.;[08G1=OW<@C.?7WK&EFFBO=/A75
M9;N.YMWEE1V4@,"F",#@<GCVKM* .2_X0A?^?\_]^O\ Z]'_  A"_P#/^?\
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M[BNJTVT^PZ=!;$[FC0!F_O-U)_/- %NBBB@ P#VHHHH **** "BBB@ HHHH
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M>(YC9E!*'U![5+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
+!1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>drts-20211231x20f006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 drts-20211231x20f006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #( Z@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME!\LE9A1113("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?:</B);^"CH-DVDJ$BV& !PVW>) W7L/KS7 ^+V)\5ZM/$JJB7#+Y2H%V*O
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MDG0HQ#G+@]0?6NFA056/-S!7ISHSY)K4^H]-\9^'M6OC9V.J033YPJ@D;_\
M=)X/X5O9KY"TN]O+>6!XXWC>-U<.1@*0<YS71:E\2/$]V$BGU:9$E8LXB CQ
M[#'.*G%0A1:Y7>YIAZ$ZUWL?3=%>5_"?Q7?ZM=W>F74\ES%%")4DD.YDYQC/
MH:]4KGC+F5Q5Z+HS<&[A1115&05Y?\7O&USX?M;;2=.D,5W>*6DE'5(^F![G
M^5>H5X1\>M(N5U/3M81&-NT7D,V.%8$D9^H/Z5,MC6@DYJYYMI.F"_\ &&G6
ML@/V6]ND5F7LI;YAGMWKV<ZAI]W\25\'2:#9'2H"$C3[. Z.JAPX;KC^GK7A
M:7TL5BSPR,CK(A!4X(QD@_F!7?Q?%G5)O*NO[/TU=3"+&^H+%^]=1U'H,]Z[
MZ495X*Z_X?N372I5&H,H>)W8^)-4N8U"I]I<>6$"[ #@<#C' K5^&$LUUX_L
M?)SA%=I#Z+M/_P!:N<U/6SJFJSWSQ)&]Q*7>./.T9Z@9KWCP!X%L?"&G&6-F
MFO;E 99G&"!UV@=A_.N?%X*-*<91ZG73S.<J#I2]#LZ***R.$**** "BL+Q=
MXHMO".@R:G<QM+AA''&IP7<]!GM7E=Y\6]?N[??:16=J=K<!2Y/'')/!H33D
MHWW-H8>I4BYQ5TCV[SH_,\OS$\S^[N&?RK"'C?PVVIG3AJ]L;D-L(!^7=Z;N
MF?QKY@M-=N#.]S)=3F]8DM,9#OW'KSUJO92W4:&/RG)Z9 R#[YKT(X.'VI=#
MEYF]D?8P.:6OF>\^(_BA+$6XU:1(QMA_=J!A0.N<9R<=:ZOX9>,=2N/$L&F3
M7<UW!<JV5E8L4(&=P)Z5YCJ)2L>C]1G[-S;6A[;1115G$%%%% '-^.?$P\)^
M%KG4E4-/Q'"IZ%STS].M?+FMWE[K,QU6YE:>Y8_OG/4^A^G:OHCXPZ/<:MX$
MF-LC.]K(LY5>I49!_+-?.%A<M'(0"0P5B/RHA-PJ)HZJ=.$Z3ON>N7=_;>"/
M!OAF"STJTN)-1A%Q=R7$ D\W@93)Z?>Q[57^)5E;66K:?8:;:I:P0689(0@&
M=Q)Z]2>,<UR_AWXCWMAH=OI5UI]AJ45H^^U:\C+- ?;UIVO>+[OQ)]FEOUC-
MQ!%Y9E08,@SG)[?E7I+!JM\:[ZW^XY:>)G0DI0,^RN99M2M880QF:954#KG(
MKZNC#"-0QRV!GZUY-\+/ ]C+'#XLNBTMQ*28(F'RQD<%O<\5ZW7EJE[)N)V8
MS%O$M,****HXPHHJCK.JV^B:/=ZG=DB"VC,CXZG'8?6@"]3&FC1PC2(K-T4L
M 37BT_QAU>_C)L;2TM%+94OF1L>AZ"O,[OQ)>:AKMU?:C<2/=-(6R6(V\\!?
M0>F*VP])5]I6-*]&I0MSK<^FK_QIX>TO4?L%YJL$=R/O)DG9_O$=/QK;CE26
M-9(W5T895E.01ZBOCY+N[:_N)G$LS2N7,A^8MGUKJH?'_B72='CL[;4&AB@C
MPBJH)&X\Y)';-5B*4*4%).[%0ISK2:6ECZ:HKYW\&^.M7AUZQ5]0N+I;B98Y
M(I7+A@QQWZ&OHBN2$U(UQ&'E0:3=[A1115G.%%%% !114"WUH]RULES"TZ]8
MA("P_#K0!/1110 4444 %%%% !11FJTFHV4,CQR7<"2(I9U:0 J!R21GTH L
MT5B:/XOT'7KE[?3-1BN)4!.T C('<9'(^E;61G&>:;36C 6BBBD!4U/3;75]
M/FL;V(202KAE_J/0UYZOP6TAM06:YU"YGM5.?LY55R/0L.<?@*[S6=>TKP_9
MF[U:_@M(>QD;!8^BCJQ]A7+_ -O^*?%'R^'-+_LJP;_F)ZM&0[#UC@ZGV+$#
MVK2%6<$U%VN)Q3W.GO\ 4])\-Z6LU]=VUA9PJ%4R,$4 = !W^@KF!XG\1>)L
M+X5TC[)9-P=5U=&C4CUCA^\_U.!5[2? .EV=ZFIZG+/K6K+R+W46$A3_ *YI
M]U!]!^-:6L^([71IH+4V]U>WTZEH[2TC\R1E'5CT 49')/>LQF5I_P /].6Z
M74-=N)]?U(<B?4,,D?\ USB'R(/PS[UI^&?"FD^$;"6STFW$4<LS3.3R68GU
M] . .P%5[OQIIEEX>@UF>*\CBG?R8X9+=ED\WG"$'H21@$\9(YK!DU/Q!KWB
M*/P]J/F^&RUL]VDEE<++). 0H0,5PI7)+ =>,'% 'H-?+?Q&L;K3O'FJ37EH
MT*27!DA=4PCQMCD=C[^]>_\ @S5KN^L+G3]4??JNESM:W3XQYF.4DQ_M*0?K
MFIO%GA/3O%NE&TOH_P!XFYH)@?FB<C&?<>H[U4)<LE(J+W3ZGR]-NF@B:S7[
MC9*#C/'6H;IR6(GA4W")D<\C\NM:NK:!>>%]>FT>_FB\Y0K[H&R"IZ?RZ50U
M$^<$(@61HVP2/O%:]/VDKKEC[K_,%"$J<I2E[RZ>1+9ZM);-%>V3&.YMB)5D
M &01]:GU*^BUN=]2OI/-OY,,\W0M@ <CIT JFES'))GR?F"8"@8R.U3_ &:.
M, 0E5=CAE9>U98A_OH.+^26YMAH<U&?,EZOH06+W]DR-!+L=#NCD1\$'L>.E
M=MI'B/QOXCO;72'U*6X$S@-"-F"@^\78 $KCJ,US$-M=7=V(=+TZ>YN.C1P1
MEOH3CI]:][\#> ++PQ&FH.LCZI- %EWN"L1."RJ![]_:LZ]7GBF_NZHAPA1D
MX[M=>C.TC18T5%4*J@  #  ]J)(TEC:.15=&!5E89!![$4ZN+BU76_%FHW/]
MA7L>FZ-:N8?MQ@$SW4H.&V!N @/&[N>E<9D03^&=5\(SO?>#=LMB27GT&9\1
M-ZF!C_JV_P!G[I]JW_#OBO3?$L,GV5I(;N [;FRN%V3V[>CJ?Y]#3/"&LW.M
MZ*TUVL9N(+B:UDDB&(Y3&Y7>H[ XZ?6H_$7@^TUR:._@FET[68!^XU*UXD3_
M &6[.GJI_2@#7U73;?6-+N=.NUW07$9C<?7N*^;->^%_B/P[JN8+*6^LM^4F
MMUW97W Y!KVK3_%]YH]]%H_C.&*RN9&V6VI1?\>EV>PR?]6_^RWX&NTZTFKF
MD*CAL?%<J3Z7?36UQ&T;QN0RL,$?A5M+X%<!CSVKZA\1?#WPYXHNENM1LC]I
M P98FV,P]\=:@T+X8^%O#UV+JTL#).O*O</YFWZ9XKT(8WE6ASN%R#X5:1<:
M5X)@-TACFN7:?8W!"GIG\!FNWH'%%<4Y.<G)EI6"BBD+ $ D9/3WJ1BT444
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MWODFFXOV;FNAOAZ:G5C&6S.[\4_%G7;N:VAMG&FP99F:W8EG] 6/3\*Y._\
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M($B0 1@C*JS8QO(YQTZ5M[>T;/2Z^X48J]V8G@GQ)/X.N2Z2)-%<,HN49>6
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M).2 !D4 ='16)X?O]6N([N/6+>W5X' BNK5OW-RA&=RY)((Z$5E>'_&4NO\
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M5M48M^[D7>7+?-O//.2"&/TKI1\0;!RUS'8:@^CK+Y+:J(QY&[.,CG<4SQN
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MY4L>ZXC"G[W QCWK/,/9/EYFS;+%6O+V=EZE>59+AP)8"Z$<CK3;>TA;/EQ
M*0596)Y%684:W,DN_?R<Y';VJ.(7^HWRIIMC<7,D@ Q#&6R>V?2KC-RE[&K&
MT;:,SG3A""KPES2OJA]A:027L5C:0,;BXE6$#.YB3QBOI[PQX=M/"^APZ99E
MV5,L\C_>D<]6-9'@OP1I^@:997%Q80?VR(0)[C&6#'J >WID>E=?7%.5TH[V
MOJ95*G.VTK)] HHHJ#,R]0BC:Y>2Q-@-<6V(@>X&2J%AG(!W;<^G>N>\ &:"
MX\0V%^JG5HM0,MY+&?W<ID4,K(/X1M &#R,=36UK7AFVUB\M[Y;FZL=0MU9(
M[NT<*^P]4.00R]\$=:BM?"-G9Z->:?!=W\<MY)YMQ?"?_2)'R/F+X] !P,8X
MH @\<ZC=6FBPV&GR&._U6X2Q@D!YCWYW./\ =4,:H:W;-I<?ACPGI-Q-I]I=
MS- \\)Q((XXV<@-V9B.O7K727FB6U_JFF7\[2F73F=X5##:69=I+#'/&<?6F
MZYH-IK]G'!<M-$\,JS03P/LDAD'1E/KU'H<T <KH>EOI/Q3O(&U"ZO(SHT;1
MFZD\R1!YQ^7=U(SR,^M=]7/Z/X2MM(UB;5C?7]Y?SP""6:ZE#;E#;AP  ,>@
MXKH* "J>IZ99ZQITUA?P+/;3+M=&[_X&KE% 'S!X[\ 7OA+47N%4_P!E/+LM
MIE;=P<D*_<$>O>N=M;A9+8!H_-!;[N.!7UKJ>F66KV,EEJ%M'<6TF-T;CCV/
ML:^5_$%NGA_QCJFG?9S;Q0W#>5&2>$ZJ<GKD=Z[<-)R3I-VN-R2DIM7L5=3M
MQY4=U#(J&,!2AZ8]OQJM#8AHFF+A7)SL5OE-322PW;M&V0'4;N>GH159X9+6
M1HEG#LB[ER,#%;48NA"U5W5[)EXF4:]3FHJVEVOS+4UI-(4GB.'VXX[@4Y%9
MML4DY$A.<;?YU)9@M^^\P[@H !I?MD4TQ>1?F48Z<CZUE*G-XAN,;-[,Z(3I
M+#KGFVD]8CVC:.4"=E*GE6''3^M;.A^&];\1WT4&GVDC6KR /=8Q&H!^8D^H
M].M;.A_"?6O$=K;WDU_#96,JB6)\>8[*>VWC'%>W>'/#]KX9T.WTNS+-'$"2
M[_>=CU8_6LYU;QC*2]]=3*=10E*%%^XR]8V-MIME%9VD*0P1+M1$& !5BBBN
M4P"FNVU&;!.!G &2?I3J* /'[S3_  Q9_#XZUX?O[Q-2B)-G+)=-]H,Y?_5&
M/..6)!7'?\:T+/1K*^\=>)X/$-W+"95M[J&V6Z:!&!B"M("I!8J5*]<#\:[T
M>'-%75?[4&DV0O\ .[[2(%WY]<XZ^]/U/0M)UH1C4]-M;SRSE//B#[?IF@#S
M&'SM7T/P^9]6MGNX+Z[33&U6(RP7\*DJI<_WMO*MU/)&:ZKP#<1>;K=B-+L[
M&ZMKI3<_8)C);RNR Y3/W3C&5[&NGN](TV_L%L;NPMI[1<;89(@47'3 Z#%/
ML--LM*M1:Z?:06L .1'"@1<^N!0!:HHHH CFACN(7AF17CD4JR,,A@>H-?/?
MQ(^&4N@3S:KI,&W1E =@K;F@8G!!!ZK[]J^B*BN+>*ZMY()XUDAD4JZ.,A@>
MH---Q=T4G;?8^0;2X"B5"/,QP5 ^]S5F\M4GL 8F6%XB7"]O>MSXD:3;>%_'
M4MM9V8M;*6))(0"2']3D^_:N>DNXIW7KE@5QG@CO7H3A4K*-2$M5T-*%:E3C
M*%2-[]2K;V8N=TTD@1L<;&^]]:L/:2301%2 \9P".E5WM3:R)''.660$HI'?
MT)JU9 S%6>3YD!SZ9K6JU.$J<8WEV,J*Y9QG-VB^HB+($*3RLK-P!MYJR\,D
M87S&5HB-N<8Q227D<DRI,HRA..,UU'A[X=ZQXPM!=6MS#:Z>[E1,_P Q!4\C
M;WY]ZY:;J4X1E9*&S1V5W0;FFVYK9F/8Z5J^L3^1H]G+=DX1F0<*3_>;L._-
M?1_A;0XO#WA^TL$CC654!G=!C?)CYF/KS5/P5X-M?!NDO:0SO<33/OGG<8WG
M&!@=@*Z6N>I*-VH;7N<LZLZEG/<*#THHK,@X&RU>P\)>*/$\6M7*VB7EPE];
M/(#B9#&JL%/=@RD;>O(JYX,N(]#\)Z5'JA:UN=3NI6BA=#G?*[R*IP.#M]:[
M!XTDV[T5MIR,C.#ZTI /44 <C\0P6TK2< G_ (G%GT'_ $T%)XGF\.0>)=-;
MQ%I<3(89!!J%R T$39&8V!X!(Y!([5UY /49I'19$*.H93U!&0: /)%M=*DT
MOQ1<PQ7L'AJ34+:2SEL8_P#4R+CS)XU/_+,/M)P,<&MOPIJES<>,GM?[1L?$
M$(L23JT-L(Y8OF&(G9?E.<DX&.G2O00   !@#@ 4B1I$NV-%49SA1@4 .HHH
MH \3^)GPM+2/K'A^T58FW27D*-RI'.] ?QR!7DEE<;)=I8M\N>!R01FOL8@$
M<U\]_&/P_8^'=;T^[T[3UM;:Z5_-DCSM,F<XQT''.*ZL+4<9<M]&$VFM3C#;
MQ7=D\046[M@@>_;-9EO:FZD'FR*NSC>C<FK;WT<D:'G@@ @XYJO+:K 1,DY6
M.1L%0,X/UKHI4I4.9S=XFN(JPK\JIQM(G^R-);/%D?(VX,/6B-9H 1<2E%''
M"]?I26H:1O*D?!5\G:>.E6[BZ4$02@%000?7Z5%>+E5C*,-'U\S7#N,:,U*=
MFNG<002Q0*^\/&/O9&#BK=I:7MW(D&EVTMW,!DQQ+N8#U^E:GAWP=JOC$S?V
M4\45O$1'-)(V-A(Z@=^.U>Q> OAW;^"Q//)>->WTZA&E*;%5<YPHYK.I-\KA
M7UDGHT*56%.:EAM$UJGW+'P[\+OX;\-QK>PQKJ4^7N&4 D<_*A/? KKZ**Y9
M2<FVSF.4^)/_ "3[5_\ KFG_ *&M0>*I8],\3^%]<NG\NPMFGMIY3]V+S4&U
MF/897&?<5V#HLB%74,IZ@C(-#QI+&T<B*R,,%6&01]*0'$:7?6FH>/-9\06]
MQ$^E66FQVCW2G,;.&:1\,."%&,D>M9WB:+1[_P 9^'];U22.7P]=6,D0F<_N
M&D+!X_,/3:1DC/&0*]&CMX88!!%$B1 8"*H"@?3I0\$,D!@>)&B(P4905(],
M=* /*[73+S48O$NG^#9+9=#FN8%0-(R0M\I^T+$P!P#\H)''+8JWH"Z[!\4I
M(+BQTNW2/2H8Y([:9RL<(=]NS*CG/&.!BO2HHHX8EBB14C4855& ![ 4OEIY
MA?:N\C!;'./K0!Y3!9VR_ S6W$$>Z5KV5SM^\XG<!C[C:,?2O4K0EK.!B228
MU))[\"G^3'Y9C\M/+.<KM&#GVIX&!@4 %>9_%SP=8:EH%WKZ0S'4K*$$>2?]
M8H8?>'? )->F4C*&4A@"",$'O3B[.X'R!#?Q>2IC;#9!+*.M0$36K82961\N
MH)Y^AKZ8UWX:>%M=MY$DTR*UF886>U'ELISG.!P?Q%8]I\%O#,.F/:W+7EU,
MS[Q<M)M=>,8&.,>M=?UF*O*"M(=W*T9NZ1X;;R_N#+)L>, 83'2KNBZ==ZS>
MK8Z/%YUU+N?RRP *CKR:]8T#X)V&E:O]IOM2?4+-,^7:O"%!R,?.<\X]J[/P
M]X(\/>%[B6?2=.6":4;6D+LY"_W02>!45949-NS=^_<VABJL8I1TM^7F<I\/
M_AE-X?GEOM=DM+N=E"PPHF](N<YRW\7;BO3***PG.4W>1@C#O/%>F:;XAAT:
M_:6UEN$#6\\R;89F_N*_3>/0^M3:YH<>MPV^+F:TN[6436US#C?$^".A&"""
M00>H-6=5TFPUO3Y;#4[2*ZM91\T4JY!]_8^XYKCL>(/ '*_:M?\ #:]OOWMD
MOM_SU0?]]#WJ0*/BCP\^F:>9[S5[BZO-8NH-/O-1E"QBWM6;YE0+PBGH3ZM6
MAXCDM]4%GX&T(1[) GVTP\I:6BD94D=&; 4#ZFNILK_2/%.BB>UEM]0TZY7:
M> RL.ZL#T/L:KQ:,-$AMH/#=AIMG UPK72^64S'SDKMZMTQF@"UK&M6&@6'V
MO4)O+CW!$55+/(QZ*JCEF/H*K:-XFLM:GEMHXKJUO(E$C6MY 8I-AZ, >J]L
MBN7N=)?Q5\0-3EN]2N[&/0TCBM$MW5&!D3<TQ)!ZYVCC^$U3TSQ)8VFG6/B?
M6II[N_6>;2+26%?^/R+S?]:$'7A<DCT..HH ].HJCI>L:?K5JUQI]TD\:N4;
M&058=0P."#[$5>H **** "BC-% !1110 44C,%4LQ 4#))/ K L?&NA:EJ<=
MA;7;-)-D0.T+K'.1U$;D;7Q[&@#?=UC1G=@JJ,DDX %9.H^(+:V\/7^KV#1:
MBEG"\I2WF4[BHR5R,@&L?XD97PJLTBE[&&\MY+Z,='MQ(-X/J.A/L#6=XATV
MR\.ZE8:YIL$4.G7LBV&IP0*%CEBE^5),#C*L1SW!H O:%K]P]]%+KVOZ-!)>
MPJUKI=NXRH;!#%F.YF(] !6-=7'BGQ1%XA6SU-])OM(=K>.QMU5EG;;N#,S#
M.&4@#&,=>:IW5KX+TCPWJ?A;[)-/J42-$BSVI-S<R%?D>-L<@' !!P,5U>A^
M'-0L]3TW5[BZ5;E]+CM=3B(R9I5 *OGID$L">^: .<AAT_3M*\-^,_#M@(85
M5+>_A@C^9X'(5MP'+,C\Y//6O3ZYC6=0TOX>^&KS5(M.N'LQ<&>>.U^8AI&^
M9\,< 9/./6L7P?\ %K2_&NM?V;I>E:F&5#)+-*B!(E'=B&/4\"@"[X^\ 6GB
M^Q::)4CU:)-L$S'AAG.UO;K],U\]?8Y],U&YTZ[E59[25HY C94L/?O7US7F
M_BGX/Z7X@U6YU6VO9[&[N/F=5 :-G_O$=>>^#6U&<8WC/9E*<HM2B]4>"7CY
MNTN#;*PZ.5Y.>V<5)'+%.SCR<ER R@=*[RW^#/BE=5>RDFM!IS,0;L29.T^B
M=<UFZE\,/&.C7T206 U!'&T2VK @$<?-G&*ZXU8)*E%Z6W"4N:;JR6M]CG!;
MQI(J0[&CZLI7]*NZ3I=_K>IQVFE:=/*LKA'=8SLCR>26Z#CFN\C^!^HS3VDT
MNLQ0I(BF[C$99D;^((>A^IKV>QLH-/LXK6WC"11J%  QG QD^IKF514[.+N[
M6?;[C6K7YTXJ*2O==U\S%\)>#=-\'VDT-B99))V#2S3-EFQT'L!Z5T5%%<]S
M%N^H4444""BBB@ K@/B7\.V\:6]M<V5PD&HVH*H9/NNIYVGTYKOZ*<6XNZ ^
M6M=^'GBS0+:62XL6GA2/>TUL=Z 9YSW_ $K'TE+S791IFGV\D]S," B#D<=3
MZ"OKP@$<BJ]MIUE9N[VUI!"[_>:.,*6^N*Z5BY\KB];BY5=-=#Y!NX;S39HT
MO[26WD4E'$L94Y'UZULZ3I>H>*I)K+2H!-<0PF;:#@<=L^_ZU]/:OH6EZ_:?
M9=5LH;N$'<%D'0^H/45'HOAS1_#L#PZ3I\-HCG+>6.6^I/)HCB>6E[.URI-N
M?.M&?/?A/P+XGU77+>"[TNXM+6.4-<37"[5"@Y(&>I/I7T?9:?9Z="8K*UAM
MHR<E8D"@G\*LT5E5K2J6YNA*5@HHHK(84444 %%%% !1110 4444 %%%% !6
M/K'A70M?=7U32[:ZD5=JR2)\P'UZUL44 >/^(/@7:7,\<^A:D]D0,/'< R@^
MX/6K+? S2GTN"(ZI="_0,)+D*-KY[;>P'UKU>BK<Y-<M] 3L[H\ TWX)^(TU
M9(+R\LET]7&Z>-B690>RXX)]Z[V;X,^$I]6-]Y%RB%MS6R38C8_SQ[9KT*BJ
ME6J2W8K(9##';PQPPHJ1QJ%1%& H'  I]%%9#"BBB@ HHHH **** "BBB@ H
MHHH **** ,[5M!TK784BU33[>[1#E1,@;:?8]J\[\2?!'2-13S=$N7TVX#E@
MKYDBP>P'45ZK151DXNZ \EL?@;IZZ08M0U2>74"X=;B%=JQX_A"GJ/K7,3_!
M#Q';ZLT-E>V<E@S?+/(Q5E4^JXZ_2OH&BKC6G&3DGJP>JLSSB?X+>&+I;5I3
M=)-%$L<KPR;?/('4CG!/M7>:9IEGH^G06%A L-M NU$7M_\ 7JW14.<I;L+!
M1114@%%%% !1110 4444 %%%% !1110 54U'3+'5K1K34+2&ZMVY,<JAAGU^
MM6Z* /-_$7P9\/:M;RG30^F7)P4,7S1@C_8]_8UD:-\"[6.TN$UO5)+J21=L
M7V==@B.?O<YR:]?HJ_:2Y7&^@=;G@6K_  0UVUU$-HM];W5LX&3<-Y;J>^0,
M@UUUO\%=#FT.SMM3EF?4(LF2ZMVV;B3G;@]AV[UZ?15>VGRJ-]A65[F3X=\-
MZ9X7TM=/TN QQ [F9CN9V]6/<UK445DW<84444 %%%% !1110 4444 %%%%
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M#IN@Z4BE[>QL+6,(I9@D<:C@#)KEG\;WVNNT'@S26OQG!U.\S#9K[J?O2?\
M 1CWH [&XG@M87N;B6.&*,9>61@JJ/<GI7'2>.Y]8E:U\&Z4^KL#M:_E)ALH
MS_UT(R_T0'ZT^#P"-1N$O?%VHRZY< [EMG'EV<1_V81P<>K9-=C%%'#$L44:
MI&@PJ*,!1Z =J .)_P"%?RZZ#+XSU:;5G8'%E!F"TB)_NH#EB.Q8GZ5H>!/
MVG^!-#-A9L9II'+SW++AI3V^@ X ^OK74T4 %%%% !1BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "@T44 ?/\ \5O&ES?^
M)9M AE9-/M?DF53_ *U\<D^N.PK'^#^E1O\ $)4O(5E$$$DL ;E6<8P1Z\9-
M5OBMHEUHOCN\N'1O(O&\^)^Q!ZCZ@US-OK-YIEUIU]97#PS0,SHZG[K9Q_+M
M6F'E)R<.YU5H0]DI+='M/A/Q)J^N1^*+C48FEFL897MW= 'MG(8&-2!QP!Q[
M5Y3*S6B!@Y:,\;CU!]ZW_P#A:/B.XE61KBV52&#QQVZJDA88)<?Q'%9_A[3D
M\3^(+71Y&:..Z;:S(.5 YR/RKKK8&,Z<I-6[:F>%QT\/4TV>YZ3\$5FECU:Z
M(/D$H@/8L,DUZY6=H>B6/A[2H=.T^+RX(A^+'N2>YK1KSH1Y58*]5U:CF^I'
M.AD@D0(CEE(VR#Y3QT/M7@%G\)?'7ASQC#XCTR3299(YS*8+>4PH4)^:,*1@
M*02,=J^@Z*HQ&H244LI4D9*D]/:O-_B%:7OBA19Q7^FV>B6L@%Q/>/MWW /"
M ^V?S/M7I5?.]KH^O^+O$VJ65W=O;:-:WDLUX9'_ '-N=Q/R@\;B"3^.350?
MO(J*T;[&1>^"=>LM:@T.2VAGN[EU:%HVRDB_W@?0<YSTQ6EKG@:ZTG3I[^2Y
ML+NU@81736<A+0OZ/Z<X%=EX>UZVUSXN6<=C"W]F:?I[VMK,3DN1C)/ID=/I
M6/X5<W/@OX@[XP<^8=K 8+_/V]<XK6K&51\Z=FDC:C7='W6KI_B<[IOP\U>_
MAM;\ZEIEC]M&+.&[FVR3@="H [US6H:7>6FI7^F7DBQW-O)M<#D!A7JZ2:+8
MZ;X(@\6VTUQJ2HDMJ\"E5A0D; _/S<XZ>E9NM6WA/3_%VJQ>+H+ZZU2>Y\T3
M6C%(S&57:,;N"!P:[*=:=[2U1QS2;NM#S*W GA*3RC?N '.,$5NZ+XFN_#>K
M)<V^V,P]%QQ*O<'U!KT#Q1X<^&_A.XM_[0TW4-]S&9E:&9CP.N?FZ\UCZ5X?
MT+5/ VO>(([:1Y+2>3[$9)#E$X*@CH3@]ZF<J4DZSC=_F;4ISLJ7-9,]TL+M
M;^PM[M,!9HU? .<9&<5F>(KGQ'&MO!X>L+.:68D27-Y-MCMP,8)4?,Y.>@].
M:YGX1VVI1>'KBXO!LM;B4/:H3GY<<L/0$_RKT*O-5^HZD5";C%W1QEI\/X+J
MY6^\4WTWB"\4[D2Y 6VA/_3.$?*/JV378JBHBHBA548  P *=13(,'Q=XIM?
M"&A2:E<QM*=P2*%#@R.>@SV'')KS'1/CO--K,-MK6DPVUG,X3SH9"3'D\$@]
M1Z]*[;XG^';KQ#X<B%G&99K6;SO*7JXP0<>_.:\97PYJ?BBXM-%L]!AMV1U$
MMTMNT;*HX)=B<?XFNVC1IRI.3>I#DT['TV"",@Y'K2U%;PK;6\<"DE8T" GK
M@#%2UQ%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 9FN:!I?B*Q-GJEHEQ%U&>"I]0>H->7>)O@;9OI+_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %&*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
)BB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>drts-20211231x20f007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 drts-20211231x20f007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %_ V@# 2(  A$! Q$!_\0
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MS_<O?^_7_P!>C_A<_AG^Y>_]^O\ Z]'U:K_*',CT:BO.?^%T>&?[E[_WZ_\
MKT?\+G\,_P!R]_[]?_7H^K5?Y0YD>C45YS_PN?PS_<O?^_7_ ->C_A='AG^Y
M>_\ ?K_Z]'U:K_*',CT:BO.?^%S^&?[E[_WZ_P#KT?\ "Y_#/]R]_P"_7_UZ
M/JU7^4.9'HU%><_\+G\,_P!R]_[]?_7H_P"%T>&?[E[_ -^O_KT?5JO\H<R/
M1J*\Y_X7/X9_N7O_ 'Z_^O1_PNCPS_<O?^_7_P!>CZM5_E#F1Z-17G/_  N?
MPS_<O/\ OU_]>C_A<_AG^Y>_]^O_ *]'U:K_ "AS(]&HKSG_ (71X9_N7O\
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MQ]*RK[QW=-K%YIWA_P .76LFQ.VZFCF2)$;^Z"WWC["J7PA4)X,E5%  O)\
M?[YI?A'E_#5],_\ KI-2N&D/?=NIB-W3/&FE:CX7GUYF>VM[8,+F.88>%EZJ
M1Z^GKD5@K\2KN&V@U/4/"FH6>A3,H6_:5&*JQP&:,<JO3FN%U[,5EX[MX\BV
M?6X X'0!F&[^E>H^.8HO^%:ZQ&0HC%BV!VX Q_2@"?Q)XN@T%+&*"TFU*_OV
MQ:VEN0&DP,EB3P% [U7T/QE+?ZVVB:QHMQH^IF+SHHI95E65,X)5UX./2N.\
M-N]Q\1O#8NB<Q>&T>(-_>.-QK9\9@Q_$OP/)#Q*TEPC$==FT?XF@#T.BBB@
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M;QD4<Y4DX]C5"6-K24.&(?H,=Z?//::5:26T1,DLH&YB>E'VR"YTZ,O\DBG
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M:< 2=P8#-$BG:"%S[XJD$K)$6,C.!59Y'$H!QMJTIWIEA3#$I&>]6F8-%65
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MGN*4'-(I &.M&3Z4R!2?>BCO13 ^1M0_Y"5U_P!=G_F:K58U#_D)77_79_\
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MC)F:R_,<4PJ<U(Y^8TPMBOH:+G96/*FHW&.:C.,TK$DT"OI,#AI:-GFUZJU
M#KGI6)K=HTT9V+Z=ZVFD /'-5[@>:F!7U&'BX:,\JI42?,MT>77]IF8K(O()
M[UF2VJ1YQ_.NCU:+9>R G^(UA76W)^;GTKN1[U&;E%,SCUHH[T5#.H****0!
M1110 4,2?RHHQD@4= /6OB?_ ,B+X9_W!_Z"*\EKUGXL?NO"GAJ'T3./^ BO
M)JYL)_#^\J6Y/8?\A&V_ZZI_,5]=V_\ QYQ?[@_E7R)8_P#(1MO^NJ?S%?7=
MO_QYQ?[@_E7+F/V2H'DNEQEK-CC_ ):R?^A&KODGTJ/1HP;#.?\ EK)_Z$:T
M?+%?E&,JVQ$UYL^MH5/W<?0I>4?2CRO:KOEBCRQ7+[8U]H4_)]J/*]A5SRQ1
MY8]:/;![0L>"%V^)-5'_ $PB_K7?5PW@]0OB?5!_TPA_K6_XBU'6=.M$;1M%
M_M.9LY!N%B$?H3GK^%?H.6.^$@_(^9Q;O6DS:HKB/A;JFHZOX3>ZU.>2:Z-U
M*&+MG;AONCV%96FQ:O\ $"_U2_\ ^$AU#2]-MKE[:RAL&"9*<%W)'S<]J[CG
M/3**\NM?'FI:5X,U\:BRW.LZ-<&S60J )F)Q&Q ^O/KBDU32/$_AOPPWB<>*
M=0NM2MT6XNK68J;>1>-R!,?+@$X/M0!ZE1573;U-2TNUO8QA+B)90/8C-6J
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M;)-,M[O]V1(0IKNHP1&-QR:S;6R9%"XX'O6F/E7;7%C)QC#4\2-5UJET@Y)
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M>%B'>;+J+Q@FI,>AJ$%<8# _2GC@8W?K3.8>:*0,OUHH ^2]0_Y"5U_UV?\
MF:K59U#_ )"5U_UV?^9JM7TZV,6%%%%, HHHH *Z?P%X97Q3XECM)21;1+YL
M^.Z@]/Q-<Q7KGPK@31_"FN^))_E 0I&2.H09./Q(%8XB;A3=MRHK4Q_BAXM7
M4;U?#^FX33;$[7V=)''&/HO3ZUY_#&9' ILDKS3/,YR\A+M]2<U/:9+CTK2C
M34(J*)F^IJP)M"CTKK],EQ'\JGKVKD$.#72:!=OAD)^7=Z5KU/*QL7*FV=7:
M2,<@@U< R]4;:=B2#C%7E/SUXF<IJDVC@R]KF2)XUYK4@7]T5-9\:YP16E;,
M!P:_*LRFYGV.#7*[E2:'.>*R;H;6(-=)(A.<#BL6]MF+,V.M<&%JVE:1]%AZ
MJ;U,;<3(!BH+D9/(K32W8')%-FM]W)%>K&K%,]"-1)G/RH-WW:<D)P,5K&T#
M'E:GBL5P./UK:6)BD:O$)(HQ(R=C69J<A'KS79"P/EYV_K7*:Q;E6;([FIPM
M>-2H+#5HSJ',3.=V,FJY)/K5N9#GD57*FO?@U8]Z#5@5"1UJ];1X8'-5H>HK
M4M80S#BLJL[(RJSLC9TSH*Z[3E+%<'%<WIUK@ @<5U5G%Y46\]J^8S":;LCY
MG'U%9D=XP+D=Q68?O5:N9,S,<]ZJ$Y-?3Y#2E22N?!9A-3;L9&L[$A)*C)S7
M$7A*N=IQ]*[?73$+8%R>]<-<NDC?+FOTBD[Q1YF"5KE)F;=RQI2PQR:5E!/-
M12)\AQ6IZ)F2X+MCIFHZ4]3]:2H9TH***.* "BBD)QW%(8OO7KWPYA.A_#_6
MM=F&PRJPB9N,@# Q^)KE_!/P[N?$P:]OG>STM/O2D8:3_=SV]ZU/B'XJTMM)
MM?#.@3>996V!*Z?=;'10>_UKDK3522I1^945;4\V9B[LQZDDFDHHKK()['_D
M(VW_ %U3^8KZZM_^/.+_ '!_*OD:P_Y"-M_UU3^8KZZM_P#CSB_W!_*O,S#[
M)I \GT>TB6'SP9-_FR'_ %K8^\>V<5K9-9.E74!MC%YT9D\R0; XS]X]JT]U
M?"XBBY56V8\Z3'YI=QJ/=1NK'ZOY![0DS4<L:S1M&Y;:W7:Q4_F*3=2/*D8W
M.ZHHZEC@"A4+/0/:&AX)MX[?Q#JBQ[\&"(_.Y;U[FN]K@O!4T4WB+4VBD20>
M1$,JP/KZ5WM?3X5-48W-Z;O$****W+"BBB@ HHHH **** ,C5;N]@G46T6Y-
MN2V,X-9;:KJ[L!'!MYZ[:ZHJ#VI-B^@JU)+H92@V[IG*_P!N:G"Q62 $@9SM
M-1Q^(M2GXCM@WN!76^4A_A'Y4U;>)/NHH^@I\\>PO9R[G))K^H"Z6.6-L'L5
MJG?Z[JD0E1XU"$'#,O:NTEC4'<%7CVKA_&>HP[UL<\??DQZTG./8WHTG*5CA
M7FF::=G'S2#EO0UCS7#VCH]TZD+]U0.2*TM3OPL#&$;6<_+]*PO+-[EIW/''
M-:1DNQ[$*4FKW,:\U&\OY68LVS)VJHP!4T?GFT DR7)ZGL*W(4\M#'!&FT=6
M(JM*J+GS#@#T%4FNQI&#ON5+8SQ@DD;?6I6\YU+%"%/3-3QX>-9(QD9P,U?F
M>#:L4CX<CH!WI\ROL$KIZ,Y65?WVUGVMGBK18QH,L..Y[U/=6!:X#)T6F"W<
ML5F.47J0*TG)+2PJ2;UN0B2=OF5=QQQ4L,-WC)5B3W':HD'ES#RV)4\<UIP7
M #$!S@'D"LN==C=1ET973[1&03&PQW-;MM<W/V=3L)%9EI<W$CMN*^6#QFMR
MSNBZ[74 ]AZTG-=C"M"36HP7%T<8 ^E,N%E9&VQG/M6DN"<XJCJ%Y)"P2(C<
M>^,T>U78PITIRE[K.<N))02K H<\5FW$TP)4$D5TTUA--'YTSC+<X-94UJH/
M3..]'.GT/3A'F7Q&%YDRL>M.$LQ7DUI21(5' X[U')&NW(7 J;H?LI+J45:5
M%'!/O2L9#@@'BK2$,#\N1ZT\1?A0I&?LF^I3)DQN YIT4LV\<8'>KR* <=:F
M$ *Y(.*?,@=)KJ50TN3Z4SS9$ );&3TJ^J?*<<U3N?DR%3+=J?,3.FTMRK<7
M.T<GFJ:E[@$K4T\;$_..<=*LV<4<0!.,U<7H<DXN329CM&^X@BH\%:TK@J9R
M5&/:HOL[N>%J&S.5!WT*>6/%2(CG'&:O0Z>S_>X%:]KIJ( 2N?J*5[%0PTGN
MS*M;.:1P=IP.E:/DW0.67'IFMN&!8U)VC..PJ,Q/YF2"351J)+8W5*VS(+*&
MX.",X[BK#K.TRX))' %:L**D()&&(J?2+(WNI1@ 8!R<TI5E;8B2:3DV;6EG
M5UMXDPQ ]>U;1;75'"EAVQVK<L[=80NS!4CD5IHJJ, <^]8^T6]CQ)J[W.,2
M7Q$6+$2@CM@"IEF\0J!D.1GD$ UV:A?[M/"(R\*,_2G[;R,?9ON<Q#<ZPZ@&
M+"GN.#172B,#^ 45+EY#Y/,^4M0_Y"=U_P!=G_F:K59U#_D)77_79_YFJU?1
MK8D****8!1110!9TVPFU34K:PMUS+<2+&OXGK7J7Q.U&'P]X>T_P;IK;%$8:
M?'=1TS_O')JA\'M(C?4KW7[D@0V$95<]F(R3^ 'ZUQ'B;6I/$/B*]U.0G$TA
M\L'^%!PH_+^=<K_>5K=(_F7LC*[U-;L1( .]0U-;G]\H]Z[%N1+8VHC\O3/%
M;.C7PM\KY&[)[5C1*2!5^TF%L^3GKF@X*T5.+BSMK"Z$V3Y)'%:9ZUS>DZDD
MA;&> .U=$KJXXZUP8^DZD&D>32:I5'%Z%A'&!S5J*95_BK-Y!IP>OA<9E#EN
M>[1QEC8CNQNY/ZU8)2X3& #6$)#GK5J&X8'K7SV+RB5-<T3T\/CKLO-9_(>!
MD>U5GM3MY'Z582Z;>.14XE#G##BO'E&I3W/5IXNYG168923C\JD6 1GD?I5Y
M4C4XYYI7@#=*B52;W-OK%V-5E5,%17)Z[$&R0 ,DUU$_R+S7/ZD/,X]ZZ,O=
MJG,=.#TGS'%SVY]/TJI);MQ@?I76#3O-/'\Z0Z(3V&?]ZOHXXR$=&SWHXR,=
M&SF(+9B1\OZ5MZ?:,Q V_I6A!H[ C('_ 'U6Y8:44() P/\ :KFQ6/BEHSFQ
M..C8-/L6\L#'Z5HW#".+8*5Y!;IL08/>J%Q,7SDUYN'H5,154GL?*8[&7N5I
M&RY-1BE)R::S;4+5^E99A&H(^.Q5979D:XH:U;/8&N"?KQ78:O/(T$H'3!KC
MR37U45RJPL!=P;*5SYGF+MSC/-13&3MFKC<FJER90#C%6CTD9Y!!YI*=)N)^
M8<TJPNR!ATJ;:F]QE%.*,O6FTFK F* 6(51DG@ #)->J?#CPS#I=C?>)M?LM
MD4"'R4N(_3JV#^0K+^$_AZ/4=<DU>[4?9-/&[+="_P#]8<U7\;_$34O$,]UI
MT,J1Z7YF%1%^:0 \%C7'5E*I+V4/FRU9*[$\5_$W4_$=L]A;Q1V-@3RD9)9Q
MV!/8>PKA^]%%=$*<::M%$MW"BBBK$6+#_D(VW_75/YBOKJ#_ (\XO]P?RKY$
ML?\ D(VW_75/YBOKNW_X\XO]P?RKS,P^R:0/)M+CB%L6\M-_FR?-M&?O'O6A
MFJ&F?\>;?]=9/_0C5W-?-5*-Y-GFRG:3'9]J,TVBH]@+V@[-(P5P0RJP[@C(
MI,T4>P#VAJ>"41/$.IA$5!Y$7"@#UKO:X/P7_P C'J?_ %PA_K7>5Z5)6@D>
ME0=Z:"BBBM#4**** "BBB@ HHHH **** "@]**:[87-)@4[R=8(G9F"C'4]J
M\:U'48)_$%P7EWHYP&[5V?Q#U<6&CB-)0)+A]@Y[=Z\J:/SMSX(_NC'6M:5/
MFNV>CA*7NN3ZFI/IXGF,C?,H^[CI6=>VJ[DVX7KT-4&U"X@9EWL"..M5CJ#R
M?ZP\YSFK]FT=\8R74OL92C)&"6 X-5KC3IOLHF<L7)^[ZUG&]N 2P<KD\5:@
MU:5L0R-O#< GM5<C"3[$UI>K9?NY@&].>E6)(TNE,H)X&=U4)]/=9D:0?NSS
ME:LS3&!@5!V 8Q32,VG:Z+%G.OE[)'4D]S27R>5!N256!/05B%VGF!7J6Z#T
MJ8SF'Y6'(/2JJ)7%030@&.4)YZT^U:02E&[]&JLT^\],5-&2"&SSFL#K6NAJ
M0IY,6PMN.<D]*LVUZP)QSC]*SHXF="Q8@'WJ,S-$^(S18T23T9T_VY9X6+Y7
M:/SJO!'YD@E8\=!FLV&02J%Z9ZBK]N[>44QPO0U-B)TN38TY8U= #D@5E7FF
M>:?D8CVK7C#>4N::RD]!4WL<T9<K.4N+22#"GI52X!* +FNPGA252&4?6N>O
M82DA ' ]!5)W.NG4YM#+'RD @BK(3=TI70,54#!I\<9CE4%Z#7S&K&<<9J50
MRG&>*FGA$1 # AAFJK$KP#R:9-KZ@\JHVT?>]:<$5ANW9/M48MV>3)Z&KL-O
M@#/0=J&3UU*=Q;X3S"N?48JB" 2WKTK9NV)1D'?TK+AAWR;#G .:VC?D=C"<
M?>3%-JK .0 :FCMCQ5U(-PP:LK: #@FLRVTBI%;8QQFK\,61FI8H0" :LI#D
M],"I;,W(B"8]S4RQJV#@U*D?/2K5K;O)( JYSZ5+=C&4[(A^RRW$\<42GG@G
M%=AH>@0V4@D!9I",$FC3[()L 7![G%=);0B, <FLFVSSZU=M61;MHP% 9<5=
M1% Z#FH$)R.*E1P\C)W%(XF2;5##'6C9SG/-.QQ]*09[\"@0NWC!HI<$#C%%
M,#Y*U#_D)77_ %V?^9JM5G4/^0G=?]=G_F:K5].MC$****8!1110!ZWX2/\
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M34%H=5##-M3FR&Z?S!D&KWAJS.IZO9V0R3)*,CV[UFSG:F0/K7I^E26/P_\
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MA3U@CW(N\4T9<@RV2>*B/7C\JL2IAN#QGO4:KR=J$G&:=D3)D+-M&2I%6[:
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M(5JC1];@?]WB>??!Y%@\$/&@.U+N< >P8TOPGQ<Z/JNIR &YO-2F:5SU.&P
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M*R.$85$K'91G?1FP@+'@587&T;N:CAXC&"*GCC9VSUI)=3=S%12Q'R\5>AA
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M13$?)>H?\A*Z_P"NS_S-5JLZA_R$KK_KL_\ ,U6KZ=;&04444P"BBB@ KH_
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M444 -<$BJ5RF_P"49QWJ\:AD!QTZU('EOC'1?LLS7R &-SAU _6N2%O%(F<
MIV/H:]GU.QCO(C%(@96[&O+]:T9M&N203Y3M\O%:0E;0]3#5^:/(SBM0M#"Y
M.,C.1[5E2*#U&#7:26\=PX,B98\<5BZK8/"/E3@>U=$9=#H6NC.;/!ST-0.G
MRFM!X<DY4\#K5>2/(["M#*<#. ^;M5A-H;YAN/I3 B[R!UJ7+)R!BE)V.>"(
M7;)(QQ35'>GGGK1T&!4#$ [U'.\D<1DC7<1V]JE4$]!2.&QD T@:NAL!29!+
M')R1Z=*EVC&#T%4&C>SD\]!F-C\Z^GO5Y#O4,I#*><BICV8H:Z/<54YP.*O1
M1 %/F+,>WI55!TK6T^W+2+(1D+5,ZZ439M9/L[Q(5ZCFNRTNT,V&'"X_.N7L
M+.2ZNU&TG)KTW2].\J) ,  <X-83D3C*J2LBWIUH% &SGZ=*WHX0HZ<TRVA5
M%!./PJZJJ>U9'DRDV-1,#.*E5><D4T*Q?'1<5(!BD0! ],&E!XHX Y%)D4Q$
M%YDVLN#@XZUS?AZ626YD&Y JGG Y-=%>@RVLB*>HQ7,^';22UOIA(O4X%:Q^
M%F<OB1U@/'&#2Y';DTG XQBC;\W4CZ5D:"Y_O<4H.1Q28 'K]:">.>*0A<_2
MD.<4O:CKVH 3M2YI.:3G-  ,#CK1CG(HQMYHSD\=J % !R<4'C'%!/'!I""0
M/2F I*GCBBF;<#CFB@#Y/U#_ )"5U_UV?^9JM5G4/^0E=?\ 79_YFJU?3K8R
M"BBBF 4444 %%%% !5K3;U],U.UOHUW-;RK(%SC.#G%5:#0U=68'LGC/1K?Q
M_P"'X/%6@L9;J*/;+;CJ0.2N/[P_6O&\$':1R#T]*Z/P=XRO?".I^="#+:2D
M">W)X<>H]&KO_$7A+3?&5D/$_A5E:9N9[88&\]^.S_SKDA)T)<D_AZ,MZJZ/
M'=K'^$_E16WM*DHZ%64X*L,$'T-9E[Q/^%=MM#*,[NQ7HHHJ2@HHHH ***GL
M[26_NX[:"-I)9&"HJ]230!!UI0*]=B\%>#?!VGP7/BVY:>\D7/V<,2,^@5>3
M]34?]M?"(\?V/,/^W=_\:YOK*;]V+:*Y3RIH&ZK3H[.:5Q'&ADD/1$&6/X"O
M5A>_"&7GR)HL<X*2C-$WQ2\-Z%"8/#&@*2.!+(HC']6-4\0W\,'?S$HOJS/\
M-?"QO)&J>*)5L;*/YS S ,P_VC_"/UJ+QQ\1([JT_L'PTHMM+C&QI8QM\P>B
M^@_G7*^(_&&L>*9]^H7&(0?DMXOEC7\._P"-8'ZU,:,I2YZN_;H5>VB"EHHK
MI("BBB@"U%IM_/&)(;*YDC/1DA9@?Q J&:WFMI/+GADB?&=LB%3^1KUJ6U\1
M6FBZ%;:5XCL]'@^QJ?+FNQ&TKL<],$UY[XKAUZ#6VC\12RRWBJ,2.P8,G8J1
MU%84ZKF[:%-6,.BND\(^'+7Q%+?K=WC6B6UN9A(!D#![ULV7A7PGK&EW=[8:
MQJ,$>GX:Z>ZA7YT]4 [GL#52K1B[,23."HKKM3\/Z'-X7EUS0+J_9+:813Q7
MJJ#ST8;:O7?A;PMHJZ<^K:GJ+&^@218;6-"R$]2Q/&/;K1[:(<IP=%>@WOA'
MPIHFLQZ9J>KZC-/<E3";6%0(U;[I?/4_2N1\0:0^@Z]>:8\GF&!]H?&-P[&G
M"K&;L@::,RBBBM!!1110 4444 %%%% $]C_R$;;_ *ZI_,5]=V__ !YQ?[@_
ME7R)8_\ (1MO^NJ?S%?7=O\ \><7^X/Y5YF8?9-('R]=2-_:EXNPX^T2<_\
M C1GWIUW_P A&\_Z^)/_ $(U'FO3I? O0XY_$QV:,^],S2YJR;#L^]-9BJD@
M9/I29HS0!Z3\&&+:CK)*D?+%P?QKV&O'_@S_ ,A+6?\ =B_K7L%?/XO^-([Z
M?PH****YRPHHHH **** "BBB@ HI"0#S2T %%%% %&:UN7U.*=;DK;HI#1 ?
M>/KFK;KN7&:?0:3 SS:%9&9F+9]3TKF_$>D_VA9NG =?F3CJ:[%ER*ISPJ1R
M.*149.+NCQ&1!#,R2L$D'!4]JHW5O,S F8R1GMGD5Z-XF\+)>2BXAP)?XAZU
MPMQ;+;2- 6=)0<<KD"MHR3/5A5C42[F1/;V\BM'%)LD;C:XQ63=:/<Q1M\O'
MM741P3E]KQI(@YSCD5++]TKMX]S5QDT[(N3>QYXMG*)!E#726>CPFV6210Q8
M=^U6(X0UR=R+]34^Z(YC\SKT4&MJJ,H6L<IJUC%!<XMR6'<8Z522VD8\1%J[
M9K2(IG8 ?6HQ:HQRJ 5E<T4(LY>VL9'),B%<5#<1%9" I45U-S"?E0#'O4MG
MI22L=R9 ZDU',:2A%1N<8(]X(QGUJF(WTZ8DAC:.>O\ <->IPZ%:\$0@_A5Y
MO"]O=PF-DPCC# #J*ES1QSE"^CU//;73RP#L1M/(QSFNFTO1KBXP$C*K_>(J
M*PL5\(Z]%I>JAGTNZ;%C=-SL;^X]>L:?I<<1' QCI2<V#Q:4?=6IF:+H7V=%
M &2>IQ786MHJ*!L%%O;F(8PH%7HT/:LCAG4<G=CHX<+TQ4JQ@4HSBEZ"@SN&
M*3\*4<GK0>M @V^])@4<Y[8I,F@"&Z;R[:1L9P*Y[1;A)KEP969B<X]*W[]2
MUE* <94UR7A='BU";<,CINK6*7*S*7Q([-<*,=?K2J<TT87G)P:</:LF:ASZ
M4'!I:0FD 4=.,4GS#DX I-Q(XH =QBFD>]&"0,GGVI F&[T"%.<4F3GJ*"K%
MO:EPH/K3 3<.YI?,4=Z,KT IHQW!H #)G..:*:V<<+BBF!\HZA_R$KK_ *[/
M_P"A&JU6=0_Y"5U_UV?^9JM7TRV,@HHHI@%%%% !1110 4444 %;?ACQ5J/A
M74?M5E)E&P)8&^Y(/?W]ZQ*/:E**DK,:/;C!X7^)MNUS82BPUL+EXV^\3_M#
M^(>XYKR_Q1X9U?0+XIJ-FR1YPDZ_-&_T/]#6+;SSVLZ3V\KQ2H<HZ-@J?8UZ
M5X?^+#/;C3?%EHM_9L-K3[ 6Q_M+T;Z]:YN6I1^#6/;J.R;OU/-#&0,YIA]*
M]=U7X=:7KNGMJO@R[CFC89-J7^7Z GE3[&O+I=*U"/4'L#97'VM#AH1&2P_
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MKNW_ ./.+_<'\J^1+'_D)6W_ %U3^8KZ[M_^/.+_ '!_*O,S#[)I ^7[L_\
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M_A(=;_Z#.H_^!3_XT?\ "0ZW_P!!G4?_  *?_&C]]W0:%_\ X0/Q9_T+M_\
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M2YC$7[B,I%%&.=J@DD\]S71N,\T"9Y;/\1;:#PM'96]E=?V]%$L+64MJX$;
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ME**ZO_A6OB__ * TO_?:_P"-'_"M?%__ $!I?^^E_P :/:T_YD%F<I175_\
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MHHH ,#THP*** # ]*,"BB@ P*,444 &!1@>E%% !@48'I110 F!Z4N!Z444
M&!1@444 )@4M%% ";11@>E+10 FT48%+10 FT48%+10 @&*6BB@#!C\,11^-
M9O$OVES++:"V,&T;0 <YSUK>HHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>drts-20211231x20f008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 drts-20211231x20f008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #@ 3H# 2(  A$! Q$!_\0
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M_B:7_A9O@W_H.P_]^W_^)KYCHH_L^'=ASL^G/^%F^#?^@[#_ -^W_P#B:/\
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M3Q_;KN7F6ZNP))'/X\*/0# %:X      X %+10!'/_Q[R_[A_E7Q[+_KI/\
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M2\TFTN(Y/,62%6#_ -[CK5NFQHL4:QH,(H"J/0"G4 %<#::E?2ZU_:%U]K2
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AB@!**7%&* $HI<48H 2BEQ1B@!**7%&* $HI<48H __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>drts-20211231x20f009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 drts-20211231x20f009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #: 40# 2(  A$! Q$!_\0
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MG P,$C .1CI7%?\ "][S'_("@_[_ )_PK6G1G4^!";2/;LT9KQ+_ (7M>?\
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M24M% "4Y49\D#.!SS244 %%%% "44M% !1110 4444 %)2T4 %%%% !1110
M4444 %=O\)/^2C:?_P!<YO\ T6U<17;_  D_Y*/I_P#USF_]%M6.(_A2]!QW
M.X^+XSJ6E?\ 7&3_ -"6O-60[3C@X[BO4OBM'YFI:9[0R?\ H0KSU[8E" <'
M'45\1BII5FC]&R6HE@(+U_-GT'H7_(O:9_UZ1?\ H K0JAH?_(OZ;_UZQ?\
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M5]C76NZ?1F31117I&84444 )2T' /!S10 4444 %)2TE "UV_P )/^2C:?\
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- %**2E% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>drts-20211231x20f010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 drts-20211231x20f010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &( <P# 2(  A$! Q$!_\0
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M:IC&B93E6.*;*FZ(,6.[O5HE>G:H\8QQ0%]2)' 3:W^--8Y*M&X!'!%3&'#
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M/L,F@I(E?>^<-^E4V4K)N>3-609$!/X<CK5:0,Y0( 23GGN*&BT*Y^T%=BA
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MD FF@J & (..QJ-6>8 $KM'.*JRSY;:#A0?SH;!(F:Z/F*P7J><5I0,)",$
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MAFK$:A>Y(I[%UQCH?2@.8J/:K#@A0,^M/A7"D>8IY[9JSY?F\,/S-3PVK*I
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M_P :HAH4$0DY)V\<^U,,R2C,8Y/.%&<4Z>PN"AE:0*HQP>I/H:S@)S*P@W<
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MUO%Q3L,6^^V2_P#'LP=CUW9!^A[TUKU4E&_Y$'&U!D&K\]LS3#RGS&AVY7@
M>U59+#S@XC5TV@G*GG../UHN1:)=MDM[XF58C+&  ZMR%]_8U1=SYWEARR)P
MHSP!4NG27EO=26D+/@J!*K\[N?4?6K4^F$EGB;")UYW#/UIK4R:Y):D*R97:
M%!W=^XJ81\\#&>V:K1%0P# C'&15O: 2PS@GBLF@;%A/JO(JT,!>2,^E5B2(
MMW;ZTU)#D$"IL267!8^U'##D@*.^,U'O8$=.O(J-F'/8'MF@5BPJJ4R%/'Z4
MWS,#;P!UY%5!.@)'FCCL>]64*D@GD#OBDF#5@P#)D$[N-O%*P9/E. <U(Z*
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MIQC)!<#CVJ5U,JF51C&._6D4X4@GKVJ;%7*V[)')&/QIH9EE4;L#UI[JK.6
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M:=S-K4JR3%B"2,YYQ5Y4+V96 +(YYW[L8'IBH)XA,5DC.PY *'D$=\4LB2"
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M/7\*Q)Y%O+J&"-A&W.=HR:JS236NIQVOE$29Z$Y_6BPVEU)M8O9HI5&0I/\
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M('MVJ>'&[ --021@_,=GH#5B*1!C(!-!#8\1 D_Q>Y/-2BV*J"I&/0T*,ME
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MZ=Z2'!X-3F(;0?T]:"Y63(;=C&0-V16@C IZ9J@D>W)SWJU"2YQV%-(YZC+
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M/"G;FK8A!3)'%-,>#P.*")E-A@<569\GG-7W56R!UQ5/R>O-!FC,NW:0-G(
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MMO\ "KGV6<C_ (]YO^_;?X4452BC&4W<;]FN.@MY?^_9_P *8]G<8_X]YO\
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BQ$T^_5\"SNB3W$+?X5=@T[4MAS97?7_GBW^%%%"1+D?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>drts-20211231x20f011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 drts-20211231x20f011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &( 6 # 2(  A$! Q$!_\0
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M69H^O%-E0Y8+WBW&%V!6/&. *@EM=FTX 5SSGM5T6Z1QQKSG'-23Q+.1L&%
MP33,N?70BME(8QQ@G' -6)( DJHK;V'5O6FVZF-."#VS4@0PY=EW,WW,]J+"
MW8V8)$ZKM&0.A[U0\@J6#/M9N@QVJ64.TR\G.<9-"@^>0W7/)J1WT+,=LOE
M;<\4IM5()([\"K,9!4<\TK, &QV%.QDY,H7*80,>W&!5.0,8]H4#U(J_,2T6
M">*IR+D Y)&*"DRB4D+@(N,\Y-1M'S^\);GBM")5.[)_"HKA<+@$**+#YBJT
M<:N6&![=:8@;.0P&>,;:>D/F''/6KBP!4Y%%BDRS:.?,VDGCWK8C<-A2<@]*
MRH8E50RMECU%7X@0N15(F3+YD_AY([FHYR"<JW ' JLTX$6%)^IJ%[Q 5'7U
MH9%B7+ %M@!QZU'Y^X(I!(7WZ57>[&6 ?OTH1TEWDD* .M(M(?/,A'#'(Z?6
MF?:Y4(.X8(YJD[(W[L-R#4?V:YN6PIVK_?-(NR1J-.1AU<$JO/?%4Y]02).6
M9RW)XQ1Y$D-F 95)/WB:S3927#9\S@=A3)5A$UA)&+LK-M., <T^2[4*I9C\
MW3/.*E32K6*%1YC^86P3BI4LK6WC8J?,X[G-58=T(DXB* 'YFX&>AHW;';=@
MXZXJ/RP9!(N2.@#=JEB53)(3@G' S4L+C&FBF8@# %1>8B3L(U)R.*9.Z(IX
M ]0*RWN5CN\%V#;?E"GO2*2-F)2LHD+GS5Z+VYI+:9L2"5OG5N*QY)9$GA0.
MWS#)8FM%Y4B&78$=>.:?*-V1+<N9",,,GM6=)#;E=J_>/7/3-6A.%<,(\^A-
M,60;C+(BX3G':E9[%QE97*,]M&D#.@+'/(-2P6-_<6J_9[1B=WW@.,?6K7A5
M8-2N[S4+T%K6V8+'$.A8^OTK3U3Q1&JF*'YCTPO 6JJ1Y)6%3K\ZT.9UF*^T
MVR9KBVV/*0BL#D5EVUX+14BV\(.01SFKE[J;W^KVT,C'9#\X'7YJZ>;PU#KM
MD9$G47F,AL8S[&K<E&"CW(YO?=3MH9.F6UUKK>7;81$YD9N%4>M;<.@Z.[;&
MU=FE7J00!2:?IMU%X/N8;<^7>1R[V5?XPO\ #^-<?<7T"EENM-DBE'!*/@YK
M+E)EB&]C:UG2'35K/3[&Z,[R_-@  @?6K)B$09'C;S1D$/D5SNG:U#::PEY
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MA)Q3&F;<Y&#CI3'= J!Y% )QR>IJE'/#-,T+<=P&[TT5RW+\B-,JNV V.<5
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M.3+=,[KM7=@@'/XU?+RF%5\RL:OA#1(M9U"2VG5V<Q$QD'"K_M-]/3O7HO\
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M=W([5?B#>6=W3&:25%5U.W&3TJPV0JA<#ZU(-E4*"/K2%-A!)S4DA\O+X_\
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M%01\/CJ*FE3*\#GWK8<6^70@4\_C5R.0  J2".]43][BK$2DBAA!M,TX[O\
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M#1C=NR&'0TBLT:%1SBHFD,IV[2/PJD!8BD3!'4CTJP'#*I^4+T]Q6<BJ#C&
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M 0*&4JIP>M1 L#TX]Z %F5<CIQWI8]I&,'-1@Y8J3FG*"I.>E,0;N2N.*<B
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ABC;<_P V-HQT)ZDU% S*OGLQ(4;L?WCV'Y\T44!T/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>drts-20211231x20f012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 drts-20211231x20f012.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %N <@# 2(  A$! Q$!_\0
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M-R/:L_<4'I0;@&,@?>Z4^A+C<FDF25 RG-+'M*GUJC&_8<8XJS$0'Y/)JDM
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MW2[P67BBMT<S5F=PA('6IB=RXSC%0J34BG->6CZ!D;1[B.<BK42 +\O-,^4
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M4PQBF=QGBG$G/M0B&Q^_;P1D4Z-B6/'%0G)/6A6ZC)%5L(F) 7]X< G\J#*
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M-,'IFE''2E:Q%R7.3QP:>P&.#4<;#.",TYB2,$' I!<E'"#C.:8WK^E1%SG
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M@Y$4:*#M<=..M:4**CKL  [8JJ@5I02@;-6@QC 8#!H42)S;T)$E&_YR!L7
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M'>E7E\G[O>FP&DG:P(S3X93&FPKN3.<>E/503QQ4$AVX85%D/=$]N/M$\[3
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MB;E.:3YJBW429WG-,!K@JZO4Z8$@-+FHP:<#6%C0?2BF TX&@8_-%-S12 P
MN#QR?6I@6JL93QCH*G60[>><U5CM8;B6P#@U,APN":B"Y.:<#CBBXFP/#G%(
M5R,YHV]3G)I@')W&@&,8>@HV@XR*5@>QXIR2*!M:J1+*LXY4 XP:<A8@[CNS
MSFG2J&8D=JA;/ '%,DG*@'FD.YCR>*;N9$W-BD,N"!ZU5T2/<!>E1[BS8["D
M?<S@#I3CE%P!57$*@ ;/>AY#NP6I4?'!]*K&5!+[]*5A#I&/3UJNW&>*LNZ
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M(L=14F53^(5GJ;JR)HXCC%3K!ZBJ_P!NA@7).35=M<)R%2A18-M[&JD"@9;
MH(3'!%8GV^:9N3@>E:MA"[X+'BMH0<G9&-67(KR-:RR(\5=!XJ"%0JX J<=.
ME>M3BXQL>#6FI3;1#,.]5FZU<DY%4W&,BFT*+%C:K2-D51!P<U-')R*DT+)
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A4TO7\:12*TJU&#Q[U-(*AQS]:AFB'*<'ZT4@/%%(9__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>drts-20211231x20f013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 drts-20211231x20f013.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )R T$# 2(  A$! Q$!_\0
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M %JVJ*/90[!RHQ?^$7T[_IM_WW_]:C_A%]._Z;?]]_\ UJVJ*/90[!RHQ?\
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M^FW_ 'W_ /6H_P"$7T[_ *;?]_/_ *U;5%'LX=@Y48O_  BVG?\ 3;_OY_\
M6H_X1?3O^FW_ '\_^M6U11[.'8.5&+_PB^G?]-O^_G_UJ/\ A%]._P"FW_??
M_P!:MJBCV4.P<J,7_A%M._Z;?]_/_K4?\(OIW_3;_OO_ .M6U11[*'8.5&+_
M ,(OIW_3;_OO_P"M1_PB^G?]-O\ OO\ ^M6U11[*'8.5&+_PB^G?]-O^^_\
MZU'_  B^G?\ 3;_OO_ZU;5%'LH=@Y48O_"+:=_TV_P"^_P#ZU'_"+:=_TV_[
M[_\ K5M44>SAV#E1B?\ "+:=_P!-O^^__K4O_"+Z=_TV_P"^_P#ZU;5%'LH=
M@Y48O_"+Z=_TV_[^?_6H_P"$7T__ *;?]_/_ *U;5%'LX=@Y48O_  BVG?\
M3;_OO_ZU'_"+Z=_TV_[[_P#K5M44>SAV#E1B_P#"+Z=ZS?\ ?S_ZU'_"+Z=_
MTV_[[_\ K5M44>SAV#E1B_\ "+:=_P!-O^^__K4?\(OIW_3;_OY_]:MJBCV<
M.P<J,7_A%]._Z;?]]_\ UJ/^$6T[_IM_WW_]:MJBCV4.P<J,7_A%M._Z;?\
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M** "BBB@ HHHH **** "BBB@ HHHH **** "L7Q)_P >UO\ ]=EK:K%\2?\
M'M;?]=EJ*GPL4MC3HHHI 9GA?_D$?]M6_I6U6+X7_P"01_VU;^E;5.E\"".P
M44458PHHHH **** "BBB@ HHJ.::.W@DFFD6.*-2SNQP% &230!)16!!XT\,
MW2;X/$&FR*#@E;A2,U-_PEGA_P#Z#5A_X$+0!LT5C_\ "6>'_P#H-6'_ ($+
M2?\ "6>'_P#H-6'_ ($+0!LT5C_\)9X?_P"@U8?^!"T?\)9X?_Z#5A_X$+0!
ML45C_P#"6>'_ /H-6'_@0M)_PEGA_P#Z#5A_W_6@#9HK&_X2SP__ -!O3_\
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MH_X2SP__ -!JP_\  A: -BBL?_A+/#__ $&K#_P(6D_X2SP__P!!JP_\"%H
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M_A+/#_\ T&K#_O\ K0!LT5C?\)9X?_Z#6G_]_P!?\:7_ (2SP_\ ]!JP_P#
MA: -BBL?_A+/#_\ T&K#_P "%H_X2SP__P!!JP_\"%H V**Q_P#A+/#_ /T&
MK#_P(6D_X2SP_P#]!JP_\"%H V:*QO\ A+/#_P#T&K#_ +_K1_PEGA__ *#5
MA_W_ %H V:*Q_P#A+/#_ /T&K#_P(6C_ (2SP_\ ]!JP_P# A: -BBL?_A+/
M#_\ T&K#_P "%H_X2SP__P!!JP_\"%H V**Q_P#A+/#_ /T&K#_P(6C_ (2S
MP_\ ]!JP_P# A: -BBL?_A+/#_\ T&K#_P "%H_X2SP__P!!JP_\"%H V**Q
M_P#A+/#_ /T&K#_P(6C_ (2SP_\ ]!JP_P# A: -BBL?_A+/#_\ T&K#_P "
M%H_X2SP__P!!JP_\"%H V**Q_P#A+/#_ /T&K#_P(6C_ (2SP_\ ]!JP_P#
MA: -BBL;_A+/#_\ T&M/_P# A:/^$L\/_P#0:L/^_P"M &S16-_PEGA__H-6
M'_?]:7_A+/#_ /T&K#_P(6@#8HK'_P"$L\/_ /0:L/\ P(6C_A+/#_\ T&K#
M_P "%H V**Q_^$L\/_\ 0:L/_ A:/^$L\/\ _0:L/_ A: -BBL?_ (2SP_\
M]!JP_P# A:/^$L\/_P#0:L/_  (6@#8HK&_X2SP__P!!JP_\"%H_X2SP_P#]
M!JP_[_K0!LT5C?\ "6>'_P#H-6'_ ($+1_PEGA__ *#5A_X$+0!LT5C_ /"6
M>'_^@U8?^!"T?\)9X?\ ^@U8?^!"T ;%%8__  EGA_\ Z#5A_P"!"U')XP\.
M1@;]=T]<G:,W"\D]J -RL7Q)_P >UM_UV6M=6W8(.0>:R/$G_'M;?]=EJ*GP
ML4MC3HHHH S/"_\ R"/^VK?TK:K%\+_\@C_MJW]*VJ*7P(([!1115C"BBB@
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M^^!4U% B'[);_P#/O%_WP*/LEO\ \^\7_? J:B@"'[);_P#/O%_WP*/LEO\
M\^\7_? J:B@"'[);_P#/O%_WP*/LEO\ \^\7_? J:B@"'[);_P#/O%_WP*/L
MEM_S[Q?]\"IJ* (?LEO_ ,^\7_? H^R6W_/O%_WP*FHH A^R6_\ S[Q?]\"C
M[);_ //O%_WP*FHH A^R6_\ S[Q?]\"C[);_ //O%_WP*FHH A^R6_\ S[Q?
M]\"C[);_ //O%_WP*FHH A^R6_\ S[Q?]\"C[);_ //O%_WP*FHH A^R6_\
MS[Q?]\"C[);_ //O%_WP*FHH A^R6_\ S[Q?]\"C[);_ //O%_WP*FHH A^R
M6_\ S[Q?]\"C[);_ //O%_WP*FHH A^R6W_/O%_WP*/LEO\ \^\7_? J:B@"
M'[);?\^\7_? H^R6_P#S[Q?]\"IJ* (?LEO_ ,^\7_? H^R6_P#S[Q?]\"IJ
M* (?LEO_ ,^\7_? H^R6_P#S[Q?]\"IJ* (?LEO_ ,^\7_? H^R6_P#S[Q?]
M\"IJ* (?LEO_ ,^\7_? H^R6_P#S[Q?]\"IJ* (?LEO_ ,^\7_? H^R6_P#S
M[Q?]\"IJ* (?LEO_ ,^\7_? H^R6_P#S[Q?]\"IJ* (?LEO_ ,^\7_? H^R6
M_P#S[Q?]\"IJ* (?LEO_ ,^\7_? H^R6_P#S[Q?]\"IJ* (?LEO_ ,^\7_?
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M8QA"8Q\OTJV0 M*%+EO<JK7<[6T.6\#JJ65^JJ HNV  [5U0KE?!7_'IJ/\
MU]O5R\\5Z=8W$EO*9"\;!6"KW-.$DH*XJL7*H[&]135.X YZC-.K4P"BBB@
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M12!@P!!!!Z$=Z6I*"BBN?UCQ-)8ZM'I&FZ9-J>HM";AXHY4C6*/. S,W R>
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M^P75L+6^TX_9IXE3:N0.&7_9(YXKGI=?TS0?BIJ\FI,85DL( L_ELRCEOE)
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M32MNDDM%=CC&25!-<CXX_P"1 L?^NT?_ *%75H"O@Z$$$$629!_W17)^./\
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M,:G>0QF* E$B2)3U(5>I/KFM[^P],_Y\X_UH_L/3/^?./]:/?\@U)?[3L?\
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M* "BBB@ HHHH **** "BBB@ HHHH *R/$_\ R+=]_P!<C6O6/XG_ .1<O_\
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M?0U)6AB%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M45FC7]'Q_P A.S_[_+2_V_H__04L_P#O\M/F7<GDEV-&BL[^W]'_ .@I9_\
M?Y:/[?T?_H*6?_?Y:?,NX<DNQHT5G?V_H_\ T%+/_O\ +1_;^C_]!2S_ ._R
MT<R[AR2[&C16=_;^C_\ 04L_^_RT?V_H_P#T%+/_ +_+2YEW#EEV-&BL[^W]
M'_Z"EG_W^6C^W]'_ .@I9_\ ?Y:.9=PY9=C1HK._M_1_^@I9_P#?Y:/[?T?_
M *"EG_W^6CF7<.678T:*SO[?T?\ Z"EG_P!_EH_M_1_^@I9_]_EI\R[AR2[&
MC16=_;^C_P#04L_^_P M']OZ/_T%+/\ [_+1S+N'++L:-%9W_"0:/_T%+/\
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M*R_$8QX9U7_KSE_] - 'F?[/ "^!=0'8:B__ * E>P5Y#^SP,^!]0_["3_\
MH"5Z]0 4444 %%%% !1110 4444 <_XB_P"/W3?^NPKH*Y_Q%_Q^Z;_UV%=!
M6%/^)+Y%/9!1116Y(4444 %%%% !1110 4444 %%%% !2'I2T4 9-YX>TJ_N
M&GNK&.64]6;.:B_X1'0?^@9#^O\ C6UBEJ>2/8M5)K9F)_PB.@_] R']?\:/
M^$1T'_H&0_K_ (UMT4<D>P>TGW9B?\(CH/\ T#(?U_QH_P"$1T'_ *!D/Z_X
MUMT4<D>P>TGW9B?\(CH/_0,A_7_&C_A$=!_Z!D/Z_P"-;=%')'L'M)]V8G_"
M(Z#_ - R']?\:/\ A$=!_P"@9#^O^-;=%')'L'M)]V8G_"(Z#_T#(?U_QH_X
M1'0?^@9#^O\ C6W11R1[![2?=F)_PB.@_P#0,A_7_&C_ (1'0?\ H&0_K_C6
MW11R1[![2?=F)_PB.@_] R']?\:/^$1T'_H&0_K_ (UMT4<D>P>TGW9B?\(C
MH/\ T#(?U_QH_P"$1T'_ *!D/Z_XUMT4<D>P>TGW9B?\(CH/_0,A_7_&C_A$
M=!_Z!D/Z_P"-;=%')'L'M)]V8G_"(Z#_ - R']?\:/\ A$=!_P"@9#^O^-;=
M%')'L'M)]V8G_"(Z#_T#(?U_QH_X1'0?^@9#^O\ C6W11R1[![2?=GFOC#1M
M/T[4--CM+5(DE)WA<_-R*Z[_ (1'0?\ H&0_K_C6C=Z997TD<EU;1S/']PN,
M[?I5K%1&DDV[&DJ\G%)-Z'!WV@Z7%XPTVS2RC6WEC8N@SAB*Z+_A$=!_Z!D/
MZ_XUIR6-M+=QW3PHT\8(20CE0?2K%-4TKZ"E6DTK-F)_PB.@_P#0,A_7_&C_
M (1'0?\ H&0_K_C6W15<D>Q'M)]V8G_"(Z#_ - R']?\:Y[3M!TN7Q/?6LEE
M&T$:@JAS@5WE5X[&VBN7N(X469QAG Y-3*FFUH7&M))W;,P>$=!Q_P @R']?
M\:/^$1T'_H&0_K_C6WTHJN2/8CVD^[,3_A$=!_Z!D/Z_XT?\(CH/_0,A_7_&
MMNBCDCV#VD^[,3_A$=!_Z!D/Z_XT?\(CH/\ T#(?U_QK;HHY(]@]I/NS$_X1
M'0?^@9#^O^-'_"(Z#_T#(?U_QK;HHY(]@]I/NS$_X1'0?^@9#^O^-'_"(Z#_
M - R']?\:VZ*.2/8/:3[LQ/^$1T'_H&0_K_C1_PB.@_] R']?\:VZ*.2/8/:
M3[LQ/^$1T'_H&0_K_C1_PB.@_P#0,A_7_&MNBCDCV#VD^[,3_A$=!_Z!D/Z_
MXT?\(CH/_0,A_7_&MNBCDCV#VD^[,3_A$=!_Z!D/Z_XT?\(CH/\ T#(?U_QK
M;HHY(]@]I/NS$_X1'0?^@9#^O^-9/B7PWI%EH%U<6]C%'*BY5AG(_6NQJ*YM
MH;N!H+B-9(FX9&&0:3IQ:M8J-62:;;.<TKPOHD^DVDLNG1-(\2LS'/)Q]:N_
M\(CH/_0,A_7_ !K7BACAB6*)0B(,*HZ 5)0H1ML)U9MWNS$_X1'0?^@9#^O^
M-'_"(Z#_ - R']?\:VZ*?)'L+VD^[,3_ (1'0?\ H&0_K_C1_P (CH/_ $#(
M?U_QK;HHY(]@]I/NS$_X1'0?^@9#^O\ C1_PB.@_] R']?\ &MNBCDCV#VD^
M[,3_ (1'0?\ H&0_K_C7->(]"TRSU/2XK>SCC2:8+(%S\P]*] JM<:?:W<D<
MEQ DCQ'<A89VGVJ94TU9(N%:47=MF?#X9T6VG2:'3XDE0Y5AG(/YU@?$_P#Y
M%>/_ *^8_P"==OBN)^*(_P"*7C_Z^8_YU:26QDY-[L[2'_41_P"Z/Y5D>)/^
M/:W_ .NRUKP_ZB/_ '1_*LCQ'_Q[6_\ UV6IJ?"R7L:=%%%(#+\+?\@?_MJW
M]*VZQ/"W_((_[:M_2MNBG\"".Q4N]2L[&2WBN;A(GN'\N(-_&WH*\[$6@WUT
MTWB/Q;]M8.?]'1V2->>G _PKT:YL;6[DADN+>.5X&WQ,ZY*-ZCT->?&ZT_3+
MAH_$?@Z*W!<XNH(!)&1GJ?\ ]==M"VMKW^1A6Z7V^9V^A/I#Z8HT7R?L:L5'
MDC W=_QK3K,T*329=-5]%$ M&8G$*[1N[\>M:=82^)FT=D%%%9.L^)=)T!H4
MU&Z\N2;)CB2-I'8#J0J@G ]:DHUJ*JZ=J-GJUA%?6%PEQ;3#<DB'@C_/:J&M
M>*M%\/30PZI>B"2=2T:B-G+ 8R<*#ZB@#9K,\1_\BQJO_7G+_P"@&I=)UBQU
MNR%YI\YF@+% Q1DY'7A@#4/B/_D6-5_Z\Y?_ $ T >:_L\?\B/J'_82?_P!
M2O7J\A_9X_Y$?4/^PD__ * E>O4 %%%% !1110 4444 %%%% '/^(?\ C\TW
M_KL*Z"N?\1?\?FF_]=A705A3^.7R*>R"BBBMR0HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XCXH
M_P#(L1_]?,?\Z[>N(^*/_(L1_P#7S'_.@#M(?]1'_NC^59'B/_CVM_\ KLM:
M\/\ J(_]T?RK(\1_\>UO_P!=EJ*GPL3V-.BBBD!F>%_^01_VU;^E;58OA?\
MY!'_ &U;^E;5.E\"".PC' SV%>?:7I=]XTMVO=2UZ5K$R,GV6U4QKP>A/?\
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MX8U7K_QYR_\ H!H \S_9X/\ Q0U^2.?[2?C_ ( E>P5Y#^SQSX'U#_L)/_Z
ME>O4 %%%% !1110 4444 %%%% &#XAMKJ9[26U@\TQ2;B,XI/[5UC_H#_P#D
M45OXI"*Q=)\SDG:Y7-I:QD:5J\U]>SVT]KY$D*@D;L]:V*P--_Y&O5/]Q?Z5
MOTZ+;CKYA+?0****U)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M****V)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<R02Z@"\;%6VHS $=>0*ZH3FURI7,IP@GS-V)O".BSZ'H@@NG5KJ65IYBIR
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M_<7^E;]8T/A?JRI;A1116Q(4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *XCXH_\ (L1_]?,?\Z[>N(^*/_(L1_\ 7S'_ #H [2'_
M %$?^Z/Y5D>)/^/:V_Z[+6O#_J(_]T?RK(\2?\>UO_UV6HJ?"Q/8TZ***0&7
MX6_Y _\ VU;^E;=8GA;_ ) __;5OZ5MT4_@01V,K7M?LO#UB+J]9L,VU$099
MSZ"N%T#0_!_B::=8HK^&Z3+O#-+@X)ZCUZUK_$*=+2XT&ZEA>6*&[,CHBY)
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M9U%__0$KV"O(/V>1GP/J'_82?_T!*]?H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *0]#2TAZ'Z4 8/AW_CZU'_KK6_6!X=_X^M1_P"N
MM;]8X?\ AHJ6X4445L2%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS/$?_(L:K_UYR_\ H!H \S_9Y&? ^H?]A)__ $!*]?KR']GC_D1]0_["3_\
MH"5Z]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<1\
M4?\ D6(_^OF/^==O7$?%'_D6(_\ KYC_ )T =I#_ *B/_='\JR/$?_'M;_\
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M &$G_P#0$KUZF(*@N+RVM%#7,\4*DX!D<+G\ZGK(O[/3;:YFU;4&1@L00><
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M61XD_P"/:V_Z[+6O#_J(_P#='\JR/$G_ ![6W_79:BI\+$]C3HHHI 9GA?\
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MUBQZ9*6@2YOA-;V[!HX]@!)'3<<\XK65QG[P_.HIIIMVL-DE%)N7^\/SIGF
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M2V-.BBBD!F>%_P#D$?\ ;5OZ5M5B^%_^01_VU;^E;5.E\"".P44458PHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** &3$K!(0<$*<'\*Y7X?:A>:EH<\U[<R7$BW+*&D.2!@<5U,_-O)C
M^Z?Y5YGX.\1Q^'M+FM+O3M2:1IV<&*V)&#C_  K>G#FIRLM=#&I+EFK[:G=Z
MYX@L= MDEO&<M(VV.*-=SN?856T7Q98:U<R6B)/;7<:[C!<Q[&(]17-Z]=R7
ME[H7B>"PNY+*VD82Q-%^\3G[VW\*6!I/%7C6WU.QMKB&SM(&1IYHRAD8@@ 9
M^O\ .J5*/+K_ %Y$.K+FT-6Y^(&DV]S*BPWDT$+;);F*',2GZU>U/Q;I^FBU
M55GO);I-\,=JF]F7U^E<=HFL/X8T:[T6[TFYN-0$[&.(PEDFSC'/IQ6AKVJZ
ME#JFFPW?VK2]/DM]TC64>]Q)_<W <8XZ"J=&/-:WX[B567+=O_@&C>>*8=6\
M)ZM<Z<UQ;7-JA5E==CQM6OX7GFNO#&GSSR-+*\(+.QR6/O7 Z9;S+HOBZ,P7
M@:4!XQ<(WF.IS@GCD\BN[\)HT?A334=65A",JPP1UJ:L(QBTN_Z#I2E*5WV_
M4Y,?VCJ_C+6+,^(;RP@ML,@C<8[<<U/X9\17=I=:W:ZA>OJ-MIZ>8MRH!8@=
M1[__ %JKVGANTUKQWK@U.TE>!<-&260$\#@CK71ZCH=CI'A/4[;3+,1!X'RJ
M LS''KR35SE#2#ZV)A&?Q>HW3?&^FZI*XBBNHX4A,KSRQ[8U Z@GUJ"'XAZ1
M+<(K17D5O(VQ+J2$B(GZU4M=+NKWX5)801LMP\!PC#:2=Q./QK%O-5;5O"-M
MX;MM+O/[2&R-D>$JJ%3RV:2I4VW9=;;_ (C=2:2OV_I':ZSXKL=&N8;5H[BZ
MNIAN6&V3>VWUJ*P\9Z;J)O1!'<_Z'#YLN^/:<=QCUKG;B&Z\+^++34KBTN+N
MU:R6W:2WC+E& P>/P_6JFE327NM>+)C:R0/+:$B%A\XR.,CU/I0J,.6_X_,'
M5ES6.HT[QUI>I2D11721+$97GDCPB #)!/K26/CO2[V\A@\F\@2X;;!/-%MC
MD/L:R[#2[F\^$XL88F6Y>)B(R-I)#$XP?6L"TCBU.#3=-=]?GN$=0]L55(X"
M.^2O2FJ5-W\OZN+VE16\SM[_ ,96=E?SV<5G?7CVXS.UM#N6/ZFIKCQ?I<&C
MV^I!I9([AMD421YD9O3'K7&Z_':0>(;V;=J^CWAP4G@4R1W''7"]/SJ:Z^UW
MW@NQE\0:??3N)B1/;_++"G9RN.>_Z4O8PM%C]K.[1UNE>)[75;J6R-M=V=W&
MF\Q7,6TX]16=X?URTM]%U"^NM2NIX(+A@SW2@%?]E0"<CTK(\)W&HGQ ]O:W
M][?Z0(26ENX2I1NP!/)-946C7][X,U!(;:0RQ:B9O**D&11Z#O3]E&[7307M
M9-)^IV6G^.]+O[V*V>&[M3/Q"]S%M63Z&I+WQII]EJ-SIYM[R:Z@Q^[ABW%\
MC/&/3OFN9U743XO.E:?INGW4<T,JR3/+$46$ 8(S6MI%O(/B/KDS1.$,"A7*
MD _=Z&I=."U:Z;%*I-Z)_,Z#0M>L_$%D;JSW@*VQTD7#*?0UA?$._N[#2K1[
M2[EM6>Y",\;8.,&L_P ,:5=7FF:[:I<7&GR27I*S*A# 9/3I5;Q5H-Y8:!:V
MTU[=:HSWRL6="2JX(QU/%$(0C5W%*<G3V-;2K!6U&W:/QO<WK*VXV_FH=X')
M! [5;'CS36U V,5K>RSK/Y+!(L@<XSG/3-:5CX;T;3YTN;33;>&=1PZ+@C(Y
MK"\%6TB7WB,O$Z%[L[692,CYNGK2;A*\GT^15I1LEU^9;N_'NEVMY-"(;N>.
M!MLUQ#%NCC/N:O:IXJT[2[6VF9I+AKH9@CMUW-(/4"O.8(7TF'4=,U"76HIG
ME;;;VB QW /N0:OZOI,^ER:!>8U&"S@A,;O$ \T&3GG QW]*MT:=TOZ9"K3L
MW_2.\T3Q#9ZZDOV<2Q30G;+!,FUT^HK&\?:I?:9IMM]DF>VBEF"3W$:Y:-?:
MH/!EO#-J]_J4/]J2*ZB/[3>[0)>G08!XQ6CXNO=2L+6":TL8[RSWXNX3'O8I
M["LU%1JI(T<G*E=F'HBW2ZM;2:)XG_M2T)_TF"ZE^<#U /-=9:Z]:W6MW>E1
MI*)[50SL0-I!]/SKSN2*PU?Q#IK^&-)NK.:.4//*8C&BC\\5L->G0/B!J5Q=
MVMRT5W"!"T4)?<>../I6E2FI/SM\S.$W%>5S?'C/3CIE]?\ E7'E64OE2#:,
MDYQQSTJH/B#IIA>X^QW_ -F1E4S&(!?FZ'KTKDX;:[/@KQ$LEI.DLEV&$90[
MNOZUW3:4FI^"8M/D3:7M% !&-K;>#^=3*%.._<J,ZDMNQ9O_ !#9V%W8VK+)
M+->MB)8@#QZGVYK!M/$=OIKZ[=3W.H7<5O<JCHR#$.<_=YY%9O@FSU'4-9^W
M:I$Z_P!G0"UAWJ1EN>1GV[_2K?A_3/MMUXLM;F%Q%<3[074@'@\C/6APA"Z?
M3_,.><K-?UH=%J'B6QT^"QD822_;658%B ).1UJEJ7C:PT^^GM%M;VZ>W&9V
MMXMRQ_4US/A'3M2O/$$$>IQN(-&1HXBRD!F)X(SU_P#K4FI:C?7.J:M9ZC-J
MD+#*VEI91$+,.Q+ <_G35&"ER[B=67+?8U?%'B!Y]*T:^TJ[EBBN;I02IVDC
MN#7;CI7E#VT[>"O#\8MYC)'>_.OEG*\GJ,5Z%%KL<GB*31OLTRR)%YOFD#8P
M]JBK"R2CTN53G=MRZV,GX@WMY8>'TDLKB2"4SJN^-L'![5A0^);]?A_<>9<R
M_P!IQS_9A(3\^XG@Y^F:VOB+#+-X?B6*-Y&^TH<(I)Z^U<S-HUVWCN*T\J3[
M#-)'=-\AVY"^OY_G6M%1=-7]?N,ZKDJCMZ&[X,UJ6'P]J%WK-])(+:<JTDK9
M( '05>LO'VE7EW% \-Y;+,<0S7$6U'/L:Y:'2+Z^\':S#!;R&87YE$94@N <
M\9ZU+JFI'Q3INFZ-I^G7:W4;H93)$56':,'FB5.$I-_T@C4E&*7],ZN_\9Z?
MI^ISZ<\%W+=1*"$ABWE\^F*IWGC>WF\+W>I:='-Y\1\LQO%DQL>A8>E5]+M9
M8_B5J#O&^P6JJ)"IP3@=ZR[.SN6T_P 9HMO+NDD.P;"-W7IZU"A35OD4YS_,
M34/%-[<>#+"[2>[@N%N$2:4KL\SJ3CU%=/IWC/3[W4XM.,-W!+*,Q//$567Z
M5Q]Y<?VEX#TNV@M[DR6MQ''*K0MUYZ>HK?U^"5O&?AMTA=D3.XA20O3J>U7*
M$'HUW)C*:U3[%Z[\<V%M<W$<=E?W,5LVV>>"'<B'W-=%:7<-]:174#;HI5#*
M<8XKRS5%@M-4U"6U?6='U R%EBC0RQSGU&/6O1/#<NH3:!:2:HNV[*?.",'V
MR/7%95:<8Q31K2J2E)IFK1117.;A1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !6+XD_P"/:V_Z[+6U6+XD_P"/:W_Z[+45/A8I;&G1112
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M8I:* $Q2T44 &**** "BBB@ HHHH **** "BBB@ HI,T9H 6B@'-% !1110
M4444 %%%% !1110 5B^(_P#CVM_^NRUM5B^(_P#CVM_^NRU%3X6)[&G1112
MR_"W_('_ .VK?TK;K$\+?\@?_MJW]*VZ=+X$$=@HHHJQA1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% %34;E[.PFN$4,8UR >AK,BU'6I(E
MD33X2C#<#O[?G5[7/^0+=?[E.L/^0=;?]<E_E64KN5KBZE'[=KG_ $#H?^^_
M_KT?;M=_Z!T/_??_ ->M:EHY7W"QD?;M=_Z!T/\ WW_]>C[=KG_0.A_[[_\
MKUK4&BS[A8R?MVN?] Z'_OO_ .O1]NUW_H'0_P#??_UZUN_2CGTHL^X6,G[=
MKG_0.A_[[_\ KT?;M<_Z!T/_ 'W_ /7K7Q[48]J+/N%C(^W:[_T#H?\ OO\
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MSH_M;3_^?R'_ +ZHYEW'=%VLG6=#BUDQ&6XN(?*SCR7QG/K5G^U]/_Y_(?\
MOJD.K:=_S^P_]]4-Q:U&I<KNF88\#VG_ $$=1_[^TO\ P@UI_P!!+4?^_M;?
M]K:?G_C]B_.E_M?3O^?R'\ZCEIFGMY]S#_X0>T_Z".H_]_:/^$'M/^@CJ/\
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M\H_X1.V_Y_KW_OY6G_:VG_\ /Y#_ -]4?VMIW_/Y#^='LJ0>T?<S/^$3MO\
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MX]Z1]3TR0;7NH&'HW(HYUW"Z/-$M])'AJ>_FOM9^SS:H)H]56W2/RI ,><%
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MCA>^.]-\._\ (&A^I_G3;C5;!K:55NXB2IP :=X>/_$FA_'^=)-.>@NIJT4
MYHK484444 %%%% !1110 4444 %8OB/_ (]K?_KLM;58OB/_ (]K?_KLM14^
M%B>QIT444@,OPM_R"/\ MJW]*VZYC0-4LK/3?*GN%C?S&."#6K_;VF?\_D?Y
M'_"E3G%06HHM6-*BL[^WM+_Y_(_R/^%']O:7_P _B?D?\*OGCW'=&C16=_;V
ME_\ /XGY'_"C^WM+_P"?Q/R/^%'/'N%T:-%9W]O:7_S^)^1_PH_M[2_^?Q/R
M/^%'/'N%T:-%9W]O:7_S^)^1_P */[>TO_G\3\C_ (4<\>X71HT5G?V]I?\
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M^^!47]O:7_S^)^1_PH_M[2_^?Q/R/^%%X>0:$O\ 9.G_ //E!_WP*/[)T_\
MY\H/^^!47]O:7_S^)^1_PH_M[2_^?Q/R/^%%X>0:$O\ 96G_ //E!_WP*/[)
MT_\ Y\H/^^!47]O:7_S^)^1_PH_M[2_^?Q/R/^%%X>0:$O\ 9.G_ //E!_WP
M*/[*T_\ Y\H/^^!47]O:7_S^)^1_PH_M[2_^?Q/R-%Z?D&A+_9.G_P#/E!_W
MP*/[)T__ )\H/^^!47]O:7_S^)^1_P */[>TO_G\3\C_ (47AY!H2_V3I_\
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M^%%X>0:$O]DZ?_SY0?\ ? H_LG3_ /GR@_[X%1?V]I?_ #^)^1_PH_M[2_\
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M*2BJ @^P6?\ SZ0?]^Q1]@L_^?2#_OV***Q)$^PV?_/K!_W[%'V&S_Y]8/\
MOV*** #[#9_\^L'_ '[%'V&S_P"?6#_OV*** #[#9_\ /K!_W[%'V&S_ .?6
M#_OV*** #[#9_P#/K!_W[%'V&S_Y]8/^_8HHH /L-G_SZ0?]^Q1]@L_^?2#_
M +]BBB@ ^PV?_/K!_P!^Q1]AL_\ GU@_[]BBB@ ^PV?_ #ZP?]^Q1]AL_P#G
MU@_[]BBB@ ^PV?\ SZP?]^Q1]AL_^?6#_OV*** #[#9_\^L'_?L4?8;/_GU@
M_P"_8HHH /L-G_SZP?\ ?L4?8;/_ )]8/^_8HHH /L-G_P ^L'_?L4?8;/\
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M]^Q1]AL_^?6#_OV*** #[#9_\^L'_?L4?8;/_GU@_P"_8HHH /L-G_SZP?\
M?L4?8;/_ )]8/^_8HHH /L-G_P ^L'_?L4?8;/\ Y]8/^_8HHH /L-G_ ,^L
M'_?L4?8;/_GU@_[]BBB@ ^PV?_/K!_W[%'V&S_Y]8/\ OV*** #[#9_\^L'_
M '[%'V&S_P"?6#_OV*** #[#9_\ /K!_W[%'V"S_ .?2#_OV*** #[#9_P#/
MK!_W[%'V&S_Y]8/^_8HHH /L-G_SZP?]^Q1]AL_^?6#_ +]BBB@ ^PV?_/K!
M_P!^Q1]AL_\ GU@_[]BBB@ ^PV?_ #ZP?]^Q1]AL_P#GU@_[]BBB@ ^PV?\
MSZP?]^Q2_8;/_GT@_P"_8HHH /L%G_SZ0?\ ?L4?8+/_ )](/^_8HHH&!L;/
M_GT@_P"_8I/L-G_SZP?]^Q110(/L-G_SZP?]^Q1]AL_^?6#_ +]BBB@ ^PV?
B_/K!_P!^Q3A8V@((M8 <_P#/,444=0+FT>@HHHKH-#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>drts-20211231x20f014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 drts-20211231x20f014.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #@ U(# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBB@ HI&944LQPH&2:Q-2\200Z1:WNFF&]-[*L-J1+MC9FSR6YP!@D\9XQUH
MW**YGPSXI?66>"\BMX9RS_9W@D+QW4:X#.F0#M!.,GKVR*Z:@ HHHH ****
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M.?\ A(M.SZ^:*^2MC?W6_(T;&_NM^1H ^MO^%B>#_P#H8]._[_"C_A8G@_\
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MQ]P)8%LC((V[:S-.TQ;6Y\->(-%&H)#=D0MI\CF:.*&098ACRH!4-UV\<=:
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MWAP:9<+=7-_<7]RD7D0O,J((HN/E54  S@9/4X%;M%% !1110 4444 %%%%
M!1110 4444 %%%% '"?$KX?0^,M*\ZV"QZO;J?(D/ <?W&]CV]#73Z'8+;Z!
MIT,]LB31VL:.K(,A@H!!_&M2B@"+[-!_SQC_ .^!1]F@_P">,?\ WP*EHH B
M^S0?\\8_^^!1]F@_YXQ_]\"I:* (OLT'_/&/_O@4?9H/^>,?_? J6B@"+[-!
M_P \8_\ O@4?9H/^>,?_ 'P*EHH B^S0?\\8_P#O@4?9H/\ GC'_ -\"I:*
M(OLT'_/&/_O@4?9H/^>,?_? J6B@"+[-!_SQC_[X%'V:#_GC'_WP*EHH B^S
M0?\ /&/_ +X%'V:#_GC'_P!\"I:* (OLT'_/&/\ [X%'V:#_ )XQ_P#? J6B
M@"+[-!_SQC_[X%'V:#_GC'_WP*EHH \TF^&R:U\3[S7M3A7^S8%B\B# Q,X7
MJ1_='ZFO2@ !@=*6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ^<M+W(P.AQ[@'JU%9/AUM1.E*-1FCN&!_<W* J9X\ JS*0-K<\CU&?:M:@
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M##"&0LIC<-N(!P#G.1D\4FF>(M:BN/+U6[N(+N6VE<6]Q9J(G=5W P2I\K*
M,X8DD<T >AT5Y_!KNN:78:)JE]?I?IJ4!:6W6%4"-Y1D!0CG'RX.<]>U3P:K
MK=E#H&HW>I1W<6KNJ26P@55BWH74QD<G&,'.<]>* .YHKSS2]=U]K'P_JUSJ
M4<R:E=?9Y+7[.JHJG> P8?-N^49YQ[4NG>)-7MM1C_MFXN8GD\W_ $=[13;S
M8#%1!,F>< <,<GGB@#T*BO/=!\0>(KN;2+R:.[E@OW'GQR6T<<,2,"5,;[MQ
MQQUSGG@5Z%0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYUO)%8R.8IHFVL\<=PR;5E 0'CWH GLGT_Q!J]XNKW7G+J3AM'U"%F14"?\
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M[@MG#0LSP1O,[1PL>I1"=JGD]!WK=HHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KD?%VO7]C)):6+6T CMOM$LUS"TH
MD+-L2)%4C+,W'7C(X.:J^)_%$5Y!=:?HUU]I:UD0ZF+.4_:(K<D;VBQ]XCD'
M'(Y[U"GAZ>]6SBTS4Y[G0)G6\L[M;@236,JC*E2^?,C;D;6R03Z= #-T2SDU
M2&ZTS3[.RMH-ZQ:OH=[N:.UDX)D@9>S#G&0,X/!SGT+2M'L-$M3;:?!Y4;,7
M8EV=G8]V9B23P.I[4NEZ9#I-D+:)I)"69Y)93EY'8Y9F/J3_ ("KM !1110
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M<&@"EX0TGSI/[6-S=,T,LEO#<L<-?6H^X901\Q4D@-P2!GH:[6@<44 %%%%
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MM>*-%E\/R^'+JRN[@".YN)F0VT*Y!+HX.7/'R@ '/7&* +G@1X)+2]>X\_\
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M],]*YW_A8?A7_H++_P!^9/\ XFC_ (6'X5_Z"R_]^9/_ (F@#IE4*H50 H&
M .E+7,?\+#\*_P#067_OS)_\31_PL/PK_P!!9?\ OS)_\30!T]%<Q_PL/PK_
M -!9?^_,G_Q-'_"P_"O_ $%E_P"_,G_Q- '3T5S'_"P_"O\ T%E_[\R?_$T?
M\+#\*_\ 067_ +\R?_$T =/17,?\+#\*_P#067_OS)_\31_PL/PK_P!!9?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXCSR: .LHKSSPAXEO=>N+!YO%FF233)YSZ=%: /MZ[0^[DCC.!7H= !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2K1O&,(R$="/QJ;2?#MOI5W->-=7=[>S((VN;N0,^P'(48  &>>!0!L4444
+%%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>drts-20211231x20f015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 drts-20211231x20f015.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %A A0# 2(  A$! Q$!_\0
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MT,08$ GKG SFO0V^Z?Z5X1<#1X;^W7PJFL6WBK^UOWEM<.Y;:6^<L/N;".]
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M<GMHIO[5MAO16Q]BZ9&?[] %S^Q-+_Y\(/\ OBC^Q-+_ .?"#_OBH/L>M_\
M06MO_ +_ .SH^QZW_P!!:V_\ O\ [.@"?^Q-+_Y\(/\ OBC^Q-+_ .?"#_OB
MH/L>M_\ 06MO_ +_ .SH^QZW_P!!:V_\ O\ [.@"?^Q-+_Y\(/\ OBC^Q-+_
M .?"#_OBH/L>M_\ 06MO_ +_ .SH^QZW_P!!:V_\ O\ [.@"?^Q-+_Y\(/\
MOBC^Q-+_ .?"#_OBH/L>M_\ 06MO_ +_ .SH^QZW_P!!>V_\ O\ [.@"?^Q-
M+_Y\(/\ OBC^Q-+_ .?"#_OBH/L>M_\ 06MO_ +_ .SH^QZW_P!!:V_\ O\
M[.@"?^Q-+_Y\(/\ OBC^Q-+_ .?"#_OBH/L>M_\ 06MO_ +_ .SH^QZW_P!!
M:V_\ O\ [.@"?^Q-+_Y\(/\ OBC^Q-+_ .?"#_OBH/L>M_\ 07MO_ +_ .SH
M^QZW_P!!:V_\ O\ [.@"?^Q-+_Y\(/\ OBC^Q-+_ .?"#_OBH/L>M_\ 07MO
M_ +_ .SH^QZW_P!!>V_\ O\ [.@"?^Q-+_Y\(/\ OBC^Q-+_ .?"#_OBH/L>
MM_\ 07MO_ +_ .SH^QZW_P!!:V_\ O\ [.@"?^Q-+_Y\(/\ OBC^Q-+_ .?"
M#_OBH/L>M_\ 06MO_ +_ .SH^QZW_P!!:V_\ O\ [.@"?^Q-+_Y\(/\ OBC^
MQ-+_ .?"#_OBH/L>M_\ 06MO_ +_ .SH^QZW_P!!:V_\ O\ [.@"?^Q-+_Y\
M(/\ OBC^Q-+_ .?"#_OBH/L>M_\ 06MO_ +_ .SH^QZW_P!!:V_\ O\ [.@"
M?^Q-+_Y\(/\ OBC^Q-+_ .?"#_OBH/L>M_\ 06MO_ +_ .SH^QZW_P!!:V_\
M O\ [.@"?^Q-+_Y\(/\ OBC^Q-+_ .?"#_OBH/L>M_\ 06MO_ +_ .SH^QZW
M_P!!:V_\ O\ [.@"?^Q-+_Y\(/\ OBC^Q-+_ .?"#_OBH/L>M_\ 06MO_ +_
M .SH^QZW_P!!:V_\ O\ [.@"?^Q-+_Y\(/\ OBC^Q-+_ .?"#_OBH/L>M_\
M06MO_ +_ .SH^QZW_P!!:V_\ O\ [.@"?^Q-+_Y\(/\ OBC^Q-+_ .?"#_OB
MH/L>M_\ 06MO_ +_ .SH^QZW_P!!:V_\ O\ [.@"?^Q-+_Y\(/\ OBC^Q-+_
M .?"#_OBH/L>M_\ 06MO_ +_ .SH^QZW_P!!:V_\ O\ [.@"?^Q-+_Y\(/\
MOBC^Q-+_ .?"#_OBH/L>M_\ 06MO_ +_ .SH^QZW_P!!:V_\ O\ [.@"?^Q-
M+_Y\(/\ OBC^Q-+_ .?"#_OBH/L>M_\ 06MO_ +_ .SH^QZW_P!!:V_\ O\
M[.@"?^Q-+_Y\(/\ OBC^Q-+_ .?"#_OBH/L>M_\ 06MO_ +_ .SH^QZW_P!!
M:V_\ O\ [.@"?^Q-+_Y\(/\ OBC^Q-+_ .?"#_OBH/L>M_\ 06MO_ +_ .SH
M^QZW_P!!:V_\ O\ [.@"?^Q-+_Y\(/\ OBC^Q-+_ .?"#_OBH/L>M_\ 06MO
M_ +_ .SH^QZW_P!!:V_\ O\ [.@"?^Q-+_Y\(/\ OBC^Q-+_ .?"#_OBH/L>
MM_\ 06MO_ +_ .SH^QZW_P!!:V_\ O\ [.@"?^Q-+_Y\(/\ OBC^Q-+_ .?"
M#_OBH/L>M_\ 06MO_ +_ .SH^QZW_P!!:V_\ O\ [.@"?^Q-+_Y\(/\ OBC^
MQ-+_ .?"#_OBH/L>M_\ 06MO_ +_ .SH^QZW_P!!:V_\ O\ [.@"?^Q-+_Y\
M(/\ OBC^Q-+_ .?"#_OBH/L>M_\ 06MO_ +_ .SH^QZW_P!!:V_\ O\ [.@#
MF=>M+>VU1HX84C3:#M48%%-UN*ZCU)EN;F.:3:/F2+8,?3)HIB.NT/\ Y =E
M_P!<5K0K/T/_ ) =E_UQ6M"D,**** "DVC.<#/3-+10!4M--MK*:ZFA5O-NI
M/,E=F+%CC Z]  , 5:"A1@  >@I:* $"@9P ,\\4!0"2!R>OO2T4 4M8_P"0
M->?]<6_E4FG_ /(-M?\ KBG_ *"*CUC_ ) UY_UQ;^52:?\ \@VU_P"N*?\
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M*>)T*G/\2G!K G\;>+='M]*U#4QH-S9WTL<?D6A<3 /W )YQ68/"NOS:7XP
MTO40^H0Q_9A>7"22R$==S X!]JMR?#Z7PW/H>O\ A_18I+N)42_LBJL6R.74
ML>&'L: -#Q+XD\<:)K%A;1_V&T.I7!BMMT<FY!U&_G^5=]HXU0:;&-9:U:^Y
MWFT#"/VQNYKE/&ND:CJ^L>%KFSLY)([6[\V?D#RUQWR?Y5W(Z4 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M EO TDCMW&P#.1[UC:[X^27PO%JF@3?/]OBM95N("&3+892IZ&@#OJ*Y6_\
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M6MKFZBR6C1N>.#CU_"@"]K'_ "!KS_KBW\JDT_\ Y!MK_P!<4_\ 014>L?\
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M%=-7F_A'PCJEKKMK>ZGI%K:"SA,:R_VA+<O(W3*@G"+[$5Z10 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%(30!QOQ \47/A_3TALX7\^YRHG*_+'_P#95Q_P\\5WMKJ*:1*DES;W#DKM
M&6C8]3]/6M;QGJ,OB76E\/6 =[>V_>W;Q)N/'8#OCT]:T?AGIUC#IMQ<16LR
MW)D9&FFCQE03@*?PY]Z]%>SIX9J2U?\ 2/.?M*F)O%Z+^F=X****\X]$****
M "N1\)ZM8WWB/Q+!;7"R21W2EE'^Z!_/BF_$7QC;>$_#D[^<GV^="EM%GDD\
M9^@KY_\  GBD^&?%]KJ#S!H9F\NZR?O*QY/X'F@#ZPHIL;K+&LB,&1@"I'0@
MTZ@#B?$O_(8;_<%%'B7_ )##?[@HJA'3:'_R [+_ *XK6)\0M+O=;\*2VNF6
MD=W>I/%)'&\@50RL&R<\'Z'KFMO1/^0'9?\ 7%:P]<\#0ZEJ,FJ:;JVHZ-J4
MH EFLY?EEP,#>AX) [\5(S'TN^\>MJ-HE]X,T>"W,BB:>*X!9%SRP'K7H8(.
M0#G!P?:O/X_ /B65MFH?$+59;?NEO"L+$?[V378:)HECX?TY;&P1Q$&+LTDA
M=W<]69CR2: -&BBB@ HHHH **** *6L?\@:\_P"N+?RJ33_^0;:_]<4_]!%1
MZQ_R!KS_ *XM_*I-/_Y!MK_UQ3_T$4 6:*** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *YCQKXD_L#2-L!S?7/[N!>O/][\*Z"\NX;&S
MENKAPD,2EF8]@*\]\,VDWC#Q-+XFOT(L[=MEI$W3CI^77ZUO1@M9RV7]6,*T
MWI".[-[P9X;.A:*\UR-U_=#S)V/)&>0O^/O4W@7_ )%L?]?$W_H9KHW_ -4W
MT-<YX%_Y%P?]?$W_ *&:4IN<92?=?J.,%"48KL_T.EHHHK$V"N4\:^.++PC8
M@$>?J,PQ;VJGECZGT%0>./'EMX6MQ:VRBZU><8@MEY()Z,WM[=ZR?!7@.Y%\
M?$WBEC<ZS.=Z1OR(/3CU]NU %?PGX#N=8OCXF\:(MU>S?-#:3*"D2]LJ>/PK
M;T'PUH3ZUKJMHFFL(KI1&#:1G8-H/''%=K7/>'O^0WXA_P"OM?\ T 4 = JA
M5"J  !@ =J6BB@#B?$O_ "&&_P!P44>)?^0PW^X**H1TVA_\@.R_ZXK5'Q?X
MA?PUH$E]#;"YN6D2""(MM#2.VU<GL,FKVA_\@.R_ZXK65X\;0E\(7O\ PD9<
M:<0H8Q@^8'S\NS'\6<8J1G,6'CCQ)9/;IKEE8OG6?[-NFMB0(MR*4VY^]R3F
MO3*\"\*2^#E\56+M<^*M0F:Z5K=+V#$2RG"AVYY(XY/I7OM !1110 4444 %
M%%% %+6/^0->?]<6_E4FG_\ (-M?^N*?^@BH]8_Y UY_UQ;^52:?_P @VU_Z
MXI_Z"* +-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445S7
MC/Q(/#VCDQ8:]G_=VZ>_K^%5"+G)11,YJ$7)G.^+KZ?Q1K\/A737/E*P>\E7
MH,=OP_GBN^T^Q@TVPAL[9 D,*A5']?K7.>!O#;:)I9N;L%M0N_WDS-U7/(7^
MI]ZZRM:TUI3CLOQ\S*C!ZU);L;)_JV^AKG/ O_(N#_KXF_\ 0S6]>)-):2I;
MRB*5E(1RNX*?7'>N<\!VMW;:&_VBZ6:-II-BB/;M(=@WUR1GVJ%;D:N6T^=.
MQU5<-XZ\?)X>"Z7ID?VO7+CY8H$&[R\]"0/T%0^.?'S:5.NA:#']LUVX^140
M;A#GN??V_.I? W@%=!+:MJTGVS7;CYI)G.[R\]0I]?4UF:$'@;P%)IUPVO\
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ML?\ (&O/^N+?RJ33_P#D&VO_ %Q3_P!!%1ZQ_P @:\_ZXM_*I-/_ .0;:_\
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MCY/^OG_]&M6VWW3]*Q?"7_(OQ_\ 7>?_ -&M0!MT444 %%%% !1110 4444
M<3XE_P"0PW^X**/$O_(8;_<%%4(Z;0_^0'9?]<5K&^(&B7&O^%9;2SDA2[26
M.:!9CA)'1MP0_7I6SH?_ " [+_KBM9?CI?#[>%KC_A)I&CTT,A9D+!@^?EV[
M><YJ1G(L/&/C75M'M]5\-IHUGI]VEW/</.'+LG14'H?\FO4J\8\&77BUM>MX
M_#KZM=>%1( \FMQJI"9Y\LD[CQT_E7L] !1110 4444 %%%% %+6/^0->?\
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MW&HO>1H&N(Y0(5)Y<9)&1UYKW*J*:QI<DBQQZC9M(QP%6="2?3&:O4 %%%%
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MCT#XAWNHZKID6I:,ME8ZPKMITZS[V;;V=<?*2* .SUC_ ) UY_UQ;^52:?\
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M6/\ D#7G_7%OY5+I_P#R#;7_ *XI_P"@BH]8_P"0->?]<6_E4FG_ /(-M?\
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M\A;6O^OA?_0:!W-NBBB@1Q/B7_D,-_N"BCQ+_P AAO\ <%%4(Z;1/^0'9?\
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MF$A4VIDV<$;R0>1VQ^-=XAR@.<\=:"H)Y I:J4DXI=B8Q:;?<****@L****
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M1&*_+D]J?\,F\^?Q1=Q,'M9M6D,+KRK8')![\T =GK'_ "!KS_KBW\JDT_\
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M ,\[#_OM_P#"C=K/_/.P_P"^W_PH T:*SMVL_P#/.P_[[?\ PHW:S_SSL/\
MOM_\* -&BL[=K/\ SSL/^^W_ ,*-VL_\\[#_ +[?_"@#FO$O_(8;_<%%0ZZ;
MHZFWVA81)M'^K+$?J**8CK-#_P"0'9?]<5K0K/T/_D!V7_7%:T*0PHHHH **
M** "BBB@"M?Z?9ZI:M:W]K#<V[?>CF0,I_ TZSLK;3[6.UL[>*W@C&$CB0*J
M_0"IZ* "BBB@ J&ZNK>RMI+FZFCA@C&YY)&"JH]234U<#\6CGPS9Q,?W$E_
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MZ;0_^0'9?]<5K0K/T/\ Y =E_P!<5K0J1A1110 4444 %%%% !1110 4444
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MK3/=1WMFBHKQ7!02*IR X'WA_.HU\ Z"OAF]T +/]AO)C/*//.[<2#P>W(H
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C%% !1110 4444 %%%% !1110 4444 %%%% #3UHHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>drts-20211231x20f016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 drts-20211231x20f016.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .E X(# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO=6TD,ABGM[J/8\;@ X(_'K6W2!0"2 ,GJ?6EH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *K:A_R#KG_KDW\JLU7O\ G3[C_KDW\J /C0'YC]36IH^A:KKDLD>EV,UV
M\8W.(P/E%8[/AV_WC_.O7O@(V[6M6'_3NO\ Z%6*U8[=3DA\/O%V/^1?O/R'
M^-8NH:9?Z3<>1J%G/:RGHLJ%<_3UKW+QE\59?"?B=M)&E)<1K&KF3S2IY]L>
MU;6IVNG?$7P#]I6/_71&2 L/FBD'O]>*KE07/FH')IZ\TS:5=E8?,IP?K3U'
M-0,F4<4\8Q3%QZT\'B@ W"G=5J(G!IZMF@8JC'-2!SFF9%+GGI0!.&IV['.:
MA5J>&H&65DRO6E5AFJP)[4X-@TPL6W?*XJJP(.:7?DTA;WI,:1:MF!89KHK1
M\V[#_9KF(6PU;-M<XB('I3CH3(SF?RY)/J:KP?O+@'MFDN)/WK^]+:_+\U(:
MV+]W/A%C4U=MCY-D6/<5C(3+<_C6C=R[+=4!HN%B_I$HY8]36Q#_ *PR&N:T
MV0A@N:W)YQ#!@'DU47H0]R?S//N<#H*O*X:0(.@K*MW\B RM]X]*NVQQ 96Z
MM2O<1TMJRF(<\4&3S)@HZ"L^WG*69;-36+ERSL:T$;0^[BJ\J>8I3/-/A?=F
MHY&VS#ZTVA%>&W:)OF)Q6C"X%,;!Q32=E"2 N,JRH5/-<5XHT8>6\B+[UUL<
MF>]+=VRW=NRLHR14S@F@3U/#W!5R#U%/5PJUM>(M)^QS%PN!FN<,E<$TX,Z(
MZDKS>E-#EJ@+\TX2@=*GF*)3P,U"9#GUI6E)%0ALMQ1S"L2KECSTJ95^6H-Q
MI_F<4F.UBTA('%3*YS56-O4U,AW,*+V$;%H<BK@'S54M5VIFK"/\_6G<5B^H
MQ'3K.,RSX%1L<0U:T'Y[HY]:+BL:XM3@<&BM<1+CI15"N=Y2$ ]0#CGFEHKT
MC,\FU;Q9XYUCQCJVE^$--L_)TMA#--.J[F)YZL0.N< >F:TO#,OQ1;Q!:CQ#
M;Z>FE_-YQB\O<.#C&&)ZXKE[M/&&L_%#Q'-X/-OIILVCM[IW8!9R!\K,"#EC
MS@@= *ZOPW9?$V+7[9]?U/3IM,&[SHX0NX\'&,(.^.] 'HE%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !4%]_QX7'_7-OY5/4%Y_QY3_]<V_E0!\728\Q\C^(_P Z
M]=^ /_(<U?\ Z]E_]"KR&4?OI/\ ?/\ .O1/A)XITGPKJNH3ZM<-#'-"J(5C
M+9(;/:L5\1;V#XS<_$27!_Y=HOZUZ]\.+>73?AI9_:U\LF-Y2&XPI)(S^%4)
MOB=\/YYO.FE267^^]D6;\R*Y'QS\6K?5]-ETK0(IDBF&R6YE&TE>X4>_J:O1
M:D'E]PPDO)Y%^Z\C,/H232#I3%Z4\<&LQCQP*-WO4;'!HW9H&B0'-*IQ40?G
M%.WB@9*&-/!/6H-] D.* )MW/6I-XJN']:0R8H&6@].WBJ8DQ3Q(,]:!EK>*
M,^]5B_O3Q)[T#+*/@U>@GPG6LD2<U(L^T8H%8)Y<S-4\3[8?>LNYE(E!]35L
M2[HN* +]FV92:DN9-[CG@54M'VH2:7?E^30-&I9,$.XG&*N),;RY5<_**R ^
M(^*T[+$%L9#UI$M%^20RW"0KT'6M.:0*(X5K$L7^9IF//6K-A*;K4,YR!33(
M:.A>01P(GK5N"01Q  ]:QKZ79.HSP*LQS;T&#6B8CH[)P5SFDN6 D'UJI8RX
MC%)<3>9.BCUJKZ$FJQ_<*PZT]5$D>3UJ/.(!4EL<Q'Z4("$@QMQTJU"V<9-1
M<,<'K2J"IXHN!0U[2$OK5F"Y..PKQ_6+.6PNF5E(7M7NZ.'7!KE?%/AR.^@=
MT4;L5G5I*:+A*S/'#-GH:;YY%&HVDMA=M'(#UXXJGOKCY+'1>Y?$V[O2K)@U
M1$F*D5\FDX@7A)GO3U)JO%R*LHA/:LV%R2,G(K7LX=Q!(K/MX#N!K=MP%04@
M+"X2/%0))^^Z]Z61_EQ5>-@9>M438V'D_<]:T?#9#3,?>L65P(?PK6\,'D_6
MIOJ-G:#&**B#'%%:7(L=]1117IF1Y'XA\#^.)?&>H:[I'B*QT]+G")F5D8Q@
M<*P"$''/7-7_  KH7C^S\1VL^M>++.^T]=WFV\<VYG^4XP-@[X/6N:U;PQ:^
M)?B9KUOXLUV?3A'L;3HS(J++"1U4MQQCD#G)-='X4^''AC0O$EIJ6G^();JZ
MAW;(6N(V#94@\#GH: /3BP49) 'O2YKSCXA^'=/GN7U[Q+JM\VBVT CBT^T#
M*PE)^]E3R3[CT[5R2:_K.E_ !KDZ@[3W%S]FMIA-NDBA9L %@>&P#[C- 'N8
M8'H<XXH+ $#/)Z>]>,VNFCX??$3PK:Z;<W3V^L0&*\BEF+AWQ]_GH<D&L>33
MW\7V'C;Q3>WMVMYID[I8>7.RK (^< #\/YT >_9&,T @C(Y!KQ#4M:OO&-I\
M/]%N[F:.#5E,E^8G*--L.WDCUVD_4U=\.3W'AG6_'/AJUNIWL+"S:[LQ(Y9H
M3MS@$_4?E0!['17*> O&EMXVT,WMO!-"T+"*59<?>V@\8[5U= !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>A2PA5M[8*LL4OJ2>2/\?:N/MOAOKEY\-=;MKB&.WU/4+[[?!9;QMB(/"YZ
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MJ9ZY.<$^U4]%^(>IS6/BBPEU&PU&\TNR:ZM=0M4PDJX_B7ID'% 'K#,%!)(
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MYZ4!*=QC .:>%IVT4[:*38B/;2A*?THH&-"\T[I2$XI%!9J0%B _.*Z732I
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M .,@@T >4?  _P#$CUP>E\/_ $&O7Z\>_9_ &BZZHZ"^ _\ '*]AH!A1110
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M&&NVKBOAA_R+-W[:G=?^C#7:T %%%% !1110 5%<<VTO^X?Y5+4<_P#J)/\
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M6E7&ERLLJX'8USTDA!/-<O(T[,Z%)6)_-]S15/S#13Y N?9-%%%>D<YXA?\
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M?#&COJ1TZYO8HS^\6 J"B]V.3TI_AW6[C7;$W5QI%WIO(V)<E274C(8;2>*
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ME64)(T@MV"DJR,>A(R".>*K:GXD^#VL:G<:C?6=]+=7#;Y'VR#)QCH&]JW?
M>M_#-/$D-IX:L9HM2N%9$DEB8D #) 9B<<#M0!ZU1110 4444 %-D_U;?0TZ
MFO\ ZMOH: /(?@+_ ,>GB0?]/X_D:]@KQ_X#?\>WB8?]/X_DU>P4 %%%% !1
M110 4444 )@$YP,^M! (P>E+10 W8O8#\JYGP?X.C\*6VH0&[^UB[O&NLM$%
MV$]NI_.NHHH 0J#U&?K1@$YQS2T4 -\M-Y?:NXC!..32@ # &![4M% #2BD\
MJ/RIV*** &B- 6(106ZG'7ZTNU>.!Q[4M% "%0W4 _6@J#U /UI:* "BBB@
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M*=6AO?%.H7-OI5RD0B=(PLP9-WS8'')[5Z*.E<9X0_Y&_P 9?]?L/_HH5VE
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MFE-?ZCXRU/4X_*\U([8,YE&,@+N;O]*WO"'@[PY=ZYXIBN-%L98[?41'$KQ
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MBMX(X(4$<4:A41> H'  H X_X<:Q'J7A\I- ]KJ0FDDN;:8%9 78L&P<$C!
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M@:I>%?!%IX9O+S4&OKO4=3O %FO+M]SE1T4>W^% 'B2:?\3/"VN:O_8NEWT
MO9S)(T$"S*PR2,-@_P!X]*@N%^,-WGS4\28/9?D'Z8KZ=HQ0!\G3^%OB3=9,
M^FZ_+GKO=C_[-7IGP]\<W^@^'X=%\0>'-=0VF8X9X=/D<,N?ND8ZCU[U[)@>
ME+CZT > ^.]1U[Q_J$,-CX+U:?3+($JMQ$\#.[?Q=N,#&*Y=/!6OKU^&TK?[
MT\G_ ,77U+@5Y;\5O$UYI>LZ#I=IKIT6*X\R6ZN\9VH, 9&.><\>M 7//-)T
MCQ[X?UR#5-"\&3:>Z(4DB7+K,IZAMSD_E71>*M:^*/B;1Y-,3PA-803+MG:(
M[F<=QDG@&N_^'33W&FW5W)XN'B.&5U$<GE[/)(!R".N3D=?2NTP/2@#Y/3P%
M\045%71=3548.JA@ "#D'&[M7IUOXN^*\6E"VD\&^==!=HNF(!/N5!P37L6!
M2X'I0!\HWW@+XA:E>SWEWHM_)//(9)&+*,L>IQNK=\&Z5\3/!5W)+IWAR:2&
M;'G03%=KXZ'[V0?<5[AXLUG4](L85T;2)-2O[F3RHE'"1G&=SGLHKF/AOXAU
M&X\ :IJNL74EW<6MS<%F<YX10=H]LYQ0!QOBB7XF>+$CMK[P>!8(=QM5DPKM
MV+,'!./3I6):>%_&^G2I<:9X$@LKR-@T5U$[&1"/3=(1]1CFMT>)/%UCX4L/
M'T^O2S17-[LDTPH!"(BQ&![\5[I#(D\$<J?==0P^A&: /'+_ ,1?%Z]TQK1/
M"T=M(Z[6N(B-^.^ 7P#69:_\+)LX(X8/ 6DJL:A0QM4+''<DMDGWKWK%% 'S
MVUI\6DGEDL-(FTZ.8EI(+214C+'J0I8[3_NXK4TN[^+6D6GV:Q\+V<:%BS%@
M&9V/5F8OEB?4UUOQ-\2Z_I>GW5GH6GRKMM#<3ZF3A($R1A?5SC\,T^^\07NG
M_!1=:-T_V\Z:C"<G+>8P #?7)H YS^W/C.?^9?L?^^5_^+J&YOOB_?0&&Z\-
M:9-$>J2Q1L#^!:K/P_U"]U?6K)G^(XU*1$\RXTSRL$Y7E0W&<$]O2O8* /$K
M.7XMZ>A2Q\,Z3:HW)6&*)0?KAJGFO?C+<Q-%-HFFO&PPRND; CW!:O9J,4 >
M%177Q0T:3;%I&@6#R]E6WB+_ /CPS5]]2^-*1F1[+38T R68Q  ?4M5OQKX0
M\-:/;:[XA\3W;ZC=7N19I)\K1-@[4C //;GL!6#J$6I2^%OA[X8UAI0M_<9N
M4=B&,88;%/?[K?H* -&#4_C/=1>;;V^ERQG@/&T+ _B&J3[3\;_^?/3_ ,H?
M_BJO^$K:#PS\8M:\/:8AATR6R2Y6W#$JCC;R,_4UZK0!XW]H^-Y_Y==._*+_
M !IPF^-Y_P"7?31_WZ_QKV*B@#Q:XU'XR6I7[3+HT&XX7S9(%S],FI'G^-21
M>:[:4D>,[V:$#'UK7\7^$/#=G<ZQXI\6WCWT4L>RWMY?E\DXX6/!Y)_Q-<Q/
M::XOP$L["6SO+B:[NU$<*H7=8"VX9'8<=_44 78KSXRSOLAN]&=L9VI)"3^E
M3[?C>?X],_\ (7^%+\/X/#6E^,A8GPQ?Z#K9MV,(NI_,$R=\8.,\?H:]@H \
M=\KXW_\ /;3?SB_PH,/QO/\ R\Z:/QB_PKV*J]];->6%Q;)/);M+&4$L>-R9
M&,C/>@#QV*;XR33M;Q:KHSS)]Z-9("R_48S1<O\ &6T"FYU72( QPIDDA7)]
M!D50U;P[I7ACQ=X;TO2DN+*]ANE:XUJZ)1+C/.S=T9CTQQ6O)I5CXX^+/B.U
MUF(W%MIEFL=O$6(5&(!+#'?DT -%K\;F (O]-P>008O_ (FG?8OC=_T$=.'_
M 'Z_^)K?^#-_/>>!C!<2-)]BNI+>-F.3L&"!^&37H= 'CPL/C:1SJFFC_OU_
M\11_9OQK[ZQIH_[]_P#Q%>PUGZYIAUG1;O3A=S6OVB,QF:'&]0>N,T >26B_
M%V_:1+3Q-I$S1G#B-XR5/O\ )Q3IH/B[;R>7/XHTB%\9VN\8/_H%0VVD:5H7
MQ4T#3=%@FTHVNY+F[NB4&H' ^5,\,3G_ #BJOC"PEU3XCZS>ZEX2U/6-/M;=
M(HO)8PJH R6W?Q=6X% &K#I?QDN(Q)%XDTQT/1D9"#^4=/\ ["^-!Z^(]/'X
MK_\ &Z[GX?3Z'<>#K-_#T4D.GY;$4I):-LY8'/O744 >/?\ "/?&8_\ ,S:>
M/^!+_P#&Z3_A'/C,?^9HL/\ OH?_ !JO8J* .%\$Z7X\T_4+AO%6L6M]:M'B
M-8CEE;/7A%[5W5%% !1110 4C?=-+2-TH ^6=7MB^NZFV.#>3?\ H9JNMCGM
M7175L'U746QUO)O_ $,TJ6H'857)<Q<M3"2P).,5833@3]VMM(4':I%0+VHY
M!7,E-,7TJ5=+7TK4&T<T%AGBGRI!<H#3D'_ZJ>+",=0/RJR[_-U%1M/MHL@(
M_L,1[#\J:=.AP>!^5#W8 ZU"]\%'6EH/49)I43=A^549]%1LX_E4\NI '[U5
M9-5 Z-4M1*5T4)]'9"2HS3;>)XHGC)Z<U<;5%)JN9UEFRO?K6;BMS6F]=3+D
MB)N<@=.M:\2XC ]J6.U3)8D9-.P0V./SI1.F3N*0 G%0D9)S3RXP14:G(/-5
M<0UDR  H_*J\D(5@V*N*WS<T.@8<\T"N4R3QBID9CUIPC4#D4\(!WIIC;'QR
M,,9J96/4U!T%/4GTJB"P0& QUIG*'%*A&.:5CQR*DM,>IP1@U;AG8.!GIZ5G
M;L$58AF P"1UIFEKF_!/QCI[FM%'<1\UA0S$$!3_ %K6B)$8&<YK2)#B-N)0
MD;N>,"N-ED,DA)[DFNCUJ?RK$K_>.*Y?<-W'>JL8R8[.*F4Y J)L8ZTX. *"
M&R1?F;CI5A!Q5,/CG-/%QZ4A%HBF.^T5&@GF_P!7$Y_"K,6CZC<#B' /<F@+
MV*4LN1C-4V!9N:Z6+P??R#+2HOX5-_PA%SC/GC\J:%S(Y8*14JCN:W+SPK=V
MD!D5]Y';%<-?:S<VT[P&$(ZG!S2N5%W.D1L=*L&8QJ"ZLH[$BN;\/Z^8]4C^
MU .A( '85[/!#8ZG9(WEJ5([ &A:DRO$\V:_#<!J:9LCCK7H9\+Z63GR0#["
MIHM"T^+[L"Y'M3(]H>;Q1R2/A$8_136M;Z/>2 GR648S\U=ZMK!$/DB4'Z5(
M(P3DX%%@]H>,Z]=ZG82F)K=DC_OXK!CF,Q+,<D]:]YO=.M;Z,QRQAA]*YJ]\
M V4A9H3Y9/I5 JG<\T&W%%=B? 5P"<2\?2BD5S(^FJ\N^.<H@\+Z7*<X34HV
M./0*QKU&N(^)OAC4O%.C:?:Z;'$\D%\D\@D<*-@!S]>O2L2CG?\ A?\ X:_Z
M!VI_E'_\76MX;^,&A^)]?MM'M+.^CGN-VUI0FT8!/.&)[5W/]F6'_/E;?]^5
M_P *='8VD,@DBM8$<=&6, C\<4 6**** "BBB@ HHHH **** "BBB@ K@_&6
MO:?H'B?3;G6?#BW%BT3*-56'S6MVY^3;@D _7O7>4A4$8(R/>@#R_P"%MG+/
MX@\3Z];6<MGHVH3K]DCD39OP3E@O8?X^U>HT 8HH **** $;[I^E>7?#/3YK
MOX;:[8E&22YN[N-0ZE?O# /->I44 ?.;W=UJ?P]TSX?)IUXNO0WX22-H&"H@
M8G<6Z8Y_2OH>VA^SVL4.<^6BIGUP,5)M&<XY]:6@ HHHH Y?XC(S_#W7%169
MC:M@*,D_A6,))+3X.:;(=!76!%90F2QD'WE &3C!R1UQBO0*7% 'BC7EEXU\
M=^%)O"^FS6PTYO-O9OLQA6)./D)P,]"/QKVL4@4#H /I2T %!HHH \7UCP]X
M^O\ QY)KTN@6.H06[%;"WNKM?+B4'AMH/WN_/<^PK>\2^'O%'B/0]#UA[*S@
M\2:7<F?[(LO[MUW?=#9ZD!3U]:](=TC0N[!5')). *565U#*05(R"#D&@#@/
M!WA[7)?&&J>+O$-I#97-U"MO!:1R>8408R21]*] I*6@ HHHH \<\5>'?'.L
M^.O[4.AV>H:;9L196MS= 1_[[*#R2>>?:NIO/^%@7_A.*XMTL]-UR&XW-:1L
MKQS1#HNXYP37=44 >;Z/H/B/7O'MKXH\1:?!I<=A 8K>VCF$K.QSEB1T')_2
MO2*8DL<A8(ZL5.&VG.#Z&GT %5-3@NKG3+F&RNC:W3QD13!0=C8X.#UYJW10
M!X_?Z!\0?%EGI_A[7;.TAMK:X66XU03AFF"DX*J.AY]/RK2UKP]XHT+QM?:_
MX9L+?48M2M1!-#),(VC<  -SU' _6O3J* .5^'GA>;PGX3BL+MT>\DD:>X*'
M(#MV![X  KJJ** "LSQ!:ZE>:'=0:1>BSOV3]Q.5!"M[Y!X[5IT4 >2R:!XV
M\8:KH4?B+3[73[72I1-+<QSAWN&&/N@=,X_7\*V=7D^(FFZWJ TZUM=8TV[7
M_1=\BQ&T;W_O#_ZU>@T4 <M\/O"\WA+PG#IMS*DERSM-,4^Z&;L/I74T44 %
M%%% !1110 4444 %(W2EI#TH ^?I\#4-0_Z_)O\ T,TPMZ$?G65J^J/;ZYJD
M"1DE;R;G_@9J@;J^GSM&T>N*T3,6M3H/,",06 _&HY-0@CZR+GZU@#3K^<Y,
MWZT]/#TSG,CD_C0W)BLC0EURVB'WP:IR^)8P/D6G)X<3.6)(J0>'X.#M)J6I
M,I)(SIO$KD_*G/TJNVN7,@.$.:WO^$?M\C"FKD.@0X!$=+E95TCC_ME]+G 8
M#Z4PK>ODG?\ E7H46D0@ !13Y-)C"\!?RI<C#F/,Y!<=V.:@+2KUR:[ZZT!6
M!*J*YN]TR2%RNWBLY0:*4KF)]I(&"*DCN0I!W5))9XSQ5-[5UY%1J4K,TQ?'
M:,&F?;)=^0:RM[IQ4B7)'6G<KF:-)+LACN[U)Y^#P>*SA(C\FI,@]*=Q\_<O
M&X 88;-1MJ! .,G%5QM[]:!MS2N'.13WURP(0$"IM.CNY&R[MC/>A5W2!?4U
MT>GV@VC IHUA*Z&P6K$#.:)76 A3@5IS-':6Y=L BN1N+IYYF<GJ>*N]D9RD
MKFJUQ&&^\#3XYUE.TFN3N[F6-\JY%5QJ=VO27'X4)W&CM98ROS8R*(#E@,<5
MD^'M6DN[@V=TV_<,H3ZUM[0DF!TH-82N:5I&6.,]/:MB$,$]JS=-&Z11W-=&
MEMMM"Q';-:1V%.1POB;4XUNDMMXRHRP]ZQ4GR<CI63K-S]IU>YEW9S(0.>PX
MI(+HHF"<U#J-&<XHV_,+<=*D0$_>?CVK(6\YY-2"\P/O5/M696-Z(P@?,<_6
MKT-Q;KC"+7+"\ST:GB](_BI<["QV]OJ,4?"[0*T(=91>"PKSP7Y_OXJ0:BW]
M^J50EQ/38]80@#?5I-3C./FKRQ=4D'\=3QZQ*O\ %Q]:KVHN0]3:\ADC.2"3
M7E/BSPQ=3ZA+>V^TH>2M64UV<'[PQ]:DEU^1XRK'((IN::'&-CSSYD?!!5@:
M])\!^)G#BRN''^R37GM^RM>R,HP"<TVSNY;2X6:)BK*:29LTFK'TDLBD9# Y
MYI2Q)XKQ2W\<ZA%UPWXUM:5X_GDF"7(P#Z5:FNIA["1ZD' H:3=WQ7(CQ=!M
MSFA?%MN_!-5S(RY&=;Y@!H+@]37+#Q5;#C-2)XFM"<EZ.9!RLZ3*T5S_ /PD
MEE_?HIW0:GN5%%%8FX4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?>G<"'Y/^>;45+D>U% 'L-%%%<QTA1110 5Q'Q=_Y)EJ_P!(_P#T8M=O7/\
MC;0)O%'A.]T>WGCAEN N)) 2HPP/./I0!Y!X(^&-WXB\(V>J1>*;ZQ2;?BWB
M5MJ8<CC##KC/2G^$A<_#7XJCPY<?9KY-1*)]K$>)0&R5.>2.1R.?6M6Q^%OC
MW2[-+.P\;"VMDSLBB,BJN3DX'U-;/A'X43:3XF'B#7]8;5+^/YHN&P&QC<Q8
MY.!T% 'IU%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MD.*$95B=QZ]*E0*,$DBNR'PZM1_S&M6_[[C_ /B*:/AM9 Y_MG5\_P#75/\
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M** "BBB@ HHHH ***Y34/B)X?TS7QHES+=+?%Q&%6U=@2<="!@]: .KHHHH
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MJ/S3\XJG&^35E<MBI:L!94Y YJ9&/ J #TJ]:0%F!-0P+=G$2035V9MJXI4
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MT728-"T>VTRU>5X;==JM,^]VY)))[DDFK] !1110 4UUW(5R1D8R#@TZ@]*
M/"_@@H3QKXI0$G'&2<D_O6KW2O#/@K_R/GBL?7_T:U>YT %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5YQXNX^+G@G_MX_]!%>CUYSXO'_ !=KP0?>X_\ 0: /
M1ATHH[5YO\1OB=!X80Z5I6VYUR7Y51?F$.>A8=SZ+0!;^(?Q&M?"-K]DM0MU
MK,XQ#;CG9GHS?T'>O(-?^''B>;P[=^,=?OHQ<%?.EMY03+@D #T'7IVKT7X<
M_#6>VNO^$G\4[KC69V\Q(I?F\HG^)O\ :]NU=+\5/^2::W_UP_\ 9A0!QGPV
M^&NN^&=3L]<BU>T>TN85,UN$;+HP!QZ9%>RCI69X=Y\-:5_UZ1?^@"M.@ HH
MHH **** "BBB@ H[44=J /F?Q;"TGC;6]O3[6W\A6<EKM[BMCQ7*(_&6MC_I
M[/\ Z"*PGG;/!J&!*T80\'FD<] <57=R>]1.Y=<'KV-3<"V8F[-Q30I4\G-5
M2[ 8#&FB:0<9I7'8TA)MJ83C;FLQ;B3O@U(UPP'(%%PL:B3ACZ5:BF'K6+'=
M+D BKJ7"?PT[A8V(IESBKD3+UK%AF7UJW',OK3$:P;/>K-O+AQS66LR[1S4D
M<X!SFF!NW(\VV(]JXJXB,=RV3751W2M%C/:N>U-1]KR#UHGL$=#0TBYVN!1X
MBB(PXZ-@YK+M)7BD&1WK>OD-[I>!RP&14;H;T8NE3@V@!["J=_,/-" ]:9I;
ME(2K<8ZU5\P7&H#'0&GT&EU.A@D$%FO8D58\X-;#<:Q[N?9LCS5F:39:I5(D
MW[,Y@6K8(VFLW3)1);*,U>9@J'-,""1%F#JPR"*\Y\:^'5@A-S;)\W4@"O14
M?$3O[TC017=J1(NX5#28T['SNY=3AP5/H>*5&YYKU3Q3X4AN+%Y+6']X.1@5
MY9-:S6\QCF0JP[$5%BTR1W^7BHMQIZIG"U86UW"HND6E<I>813=Y)JW)8MSB
MG6]@Q<;@:.:-A%7)Q2;CZ5OG34*<"JQTL\\<4O:(=C&+&G!C6G_91)J"33W0
M\']*:G%A9E96J5032&!DZU-'@"AL:'Q5H0C*U4B3<:O0QD&L)L9:CAR,UH6Q
MV$#%5HAA<584XQ65T(NLV5K.G;YOQJRS_)5*4Y-2,TK*3;$:C1]U^N?6HH&Q
M$:;;-F_3ZT7N.QZ%:MBV'/:JMQ)@GFGQR8MQ6==SXSS5*22"Q%-/UYJA+-D]
M:9//QUJA+/[TN8?*7/-]Z*S//]Z*=V%SZDHHI&SM.!D]J]<Y#.O_ !!I&EW$
M5O?ZG:6T\I CBEE =LG P.M78;F"Y\SR)HY?+<QOL8':PZJ<="/2OFA#I%QI
M\^KZK=?\56->C$Z3R$&.(2#.%/4#!R>V.U>B>!;BS?XN^)QH-TUSI$]N)YW#
MED^T%QG:>_5O\B@#UBBBB@ HHHH *0TM!H \-^"_'Q \6#_>_P#1IKW*O#?@
MUQ\1O%@_W_\ T<:]RH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **0G S7)^'O'UGXB\07>C
MP:;J-O/:@F1[B(*HP>._?J/6@#K:*** "O.?&/'Q6\$'_;G_ /017HI.!FOF
M;XJ>.I]2\<+_ &5<-%'I6Z&&:,\ESPY!_3\* .]^(_Q5>PN&\.^&?W^J.?+D
MGC&[RB?X5'=_Y5:^&WPN&BN-=\0?Z3K,O[Q5D.[R">Y/=_?M1\)/ ND:?HUK
MXB\Y+_4+M-XF/(ASU5<]_4GFO4Z "N.^*?\ R376_P#KA_45V-<?\4AGX:ZW
M_P!</ZB@#<\-G/A?2?\ KSB_] %:E9?AK_D5M)_Z\XO_ $ 5J4 %%%% !111
M0 4444 %':BB@#YA\;OM\<ZV,_\ +R?_ $$5S_FG/6MKQ]D>/=:_Z^/_ &45
MSN2:R>Y1>68!>@-0RS$GI4)DP.M0O(<U-QI%@28J0.-N35(/S4RMD>U)!8L*
MP/(J8-O3IS5#=M-2).5:F%B=9/FQWJTDV*H,<N&]:>7XZT7'8UHYAZU927 K
M#2;I5R.;(ZTTPL;<4P(Q4BS#I6-'/COS4PN:=R>4WH[@!.N*IWIWH"#\U5!<
M_)UI'N 4/-#V"P^VN"& ;G%=18RJ\)';%<6D@,G6NBTR?'&?:B(-$32B$S]L
M&J>E2>9<,_J:CUJ?R6E&<$U7TF8)'NS@XJ>;6Q26AIW%QYFHJF>AK2OYL1(,
M]JYNUG\[4BV<\U?U2YPR*#5*745M3H]&NL!<FM>ZG 08/6N.TZYVA><5LFZ\
MW:H-.^A#1K%L6>,]:=92DQ,/2JGG H5SP!2Z;)N\S!Z4@-.)0T1W#OTK'U'P
MS8:D&:2%=Q[UI12C=M!JY']T@U5@/+=6\#?90TUKG ZK7."/RW*,,,.,5[;<
MQKC!&0:P+_PS:7)\Q4 )[BN>I3OL:1G8\Y6(.,FG",(W2MK4M(DTV0\$IV.*
MSD7S'KF::=B[IBH"V*E,7RU86$*.E#$ <U1-RF(P#44T0/.!^56&/-& :R9H
M8MU#GHOZ536(@]*Z)X%;FJLMH#T%6IV0%&!<-5]2,56\O8>E3QG(J7J.Y91N
ME2[L"JH)%/))'6DA$XE..M5I&RU.4&F..:!%B-\1T6CYO5/O4.[Y:+9MMP#4
M]"^IV@N?W/7BLVZN."<U ;K$8 -4)Y\@U"9837!]:HR3'UJ.:?GK5227WK51
M);+/G>]%4?-HJ^0BY]AT44C8*G/3'->H<QX'XP\4?#75M>N7N- OKNX1RDEW
M:/Y0E(XSPPSTZD5V7PM\2^&=0DN=(\.Z'/IJPQB>1I<$R<[>6R23SWKB/"WC
MV#PF^J:7I/AZ?6-,%[(\%S&A#[3V;Y3G&./:O2?!'CI_%>I7-JWANYTH0P^9
MYDO1_FQ@?*/K0!W-%%<G\3-0N-,^'FL7-K(T<WDB-74X*[F"DC\": -JV\0Z
M->Z@^GVNJ6<UXF=T$<RLXQUX!I=1U[2-(EBBU'4[2T>7[BSS*A;Z9KQ/P\FA
M6">$;C4O"UUI\#R)]EUF*<!IICWD4<[2>F>WM6GI^DV7B[QO\09M9MTN6M4-
MO;^8,^4 & *^A^4?K0![)/=V]M:M=3SQ16Z+N:5W 4#USTQ4&G:OIVL6YGTV
M]M[N(':7@D#@'T.*\ &HW&K_  Y\!Z/=.7M;O4VAF!/WDC<!5/M\WZ"NTTFU
MM_#GQUN],TFV2WL[O2Q*]O'\J;UZ$#H.GZF@#%^#G'Q*\6C_ '__ $<:]RKP
MOX-EC\2_%9==C%7)7.<'SNF:]TH **** "BBB@ HHHH **** "BBB@ HHHH
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MXAD'/\(K6K/T31;+P_I46FZ=$8K6+.Q"Q;&3D\GW-:% !1110 4444 %%%%
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M#?A)Q\6?%H_Z[?\ HZO<J\-^$XQ\7/%H_P"NW_HZO<J "BBB@ HHHH ****
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M7TY-;U !1110 5Y_X:/_ !=SQE_URM?_ $"N_(R*X;P_X)U?2/&VH:_<Z_\
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MBZ@B8F-I\;E!YV\=JW*** "LF]\,:'J5Y]KO=(LKBX( \V6$,W'3DUK44 (
M ,#I2T44 %%%% !1110 4444 %0R7=M"^R2XB1O[K. :FKR7XF>&=)N_&OA>
MXGMMTE_>BWN3O8;T X'7C\* /6NHR**:BK$@1>%48 K@/'7Q6TGPBKVEOMOM
M4QQ C?+&?]L]OIUH [35-6L-%L9+W4;J*VMXQEGD; ^@]3[5ROP^UBP\2OK6
MMVSF226\,2LXPRPJJ[!CL#\Q_&O,-,\(>,/BI?QZKXCN9;/2\YC#+CY?2-/_
M &8_K7HNL^$M/\'^$;J^\.--IMY8VK,)86!,V!G$@((;G\NU &WXJ6..]T2X
MBP+X7\<<)'WF5N)%^FW)/TKI1TKD?!-@=0T?3/$6I74][J5Q;*XDF(VPAAR$
M4 !<^O7WKKZ "BBB@ HHHH **** "BBB@#YG^)L._P"(>K'WC_\ 0!7)B D8
MQ7<?$1 ?B!JV?[T?_H KFA"!S46U&F9HM>^*?]F!'2KK*!0N#044FMP.,5"\
M&*TV S567 J6(RKB.L^3@UJ7+@ YK+D.X\5/4I$1IN*6GQQ/,X5%))]*L30^
M!?E=NP%;NG'RX\$]:R98Q;QK#G<['+8[5JVN<<4EN:M>Z6YCA>O:L2XD)<CD
MUKR\I@UC7 "N:J3)@AD+'?@UHV8#3;FZ"LH,5;<*V;9#Y0.WK4FR6IL12 #U
MJRA&W)ZU1MEXY-601NQFK*Y2P&ST-31@$9)Y%5XB 2.U#/L)(/7K5CY31MW'
MF#%:270^[FN>AN,2<&KJR\Y-.YG*)L+)CO0)!DU263Y1S5;4M22QMRY(WD?*
M/4TF18O7VJQVD.UFRYZ 5AOJ,L^2.*Y[[;->W!GD)R>@]*T8W'3/:@+%^*3=
MRQS[YJ42!6STK/0E>_%2>:> >:LB2- 3>AI\;<YS5 .0<YJ59PHZ\T$.)H>:
M/NYH:4Y&.@JBLNXYIZNQ.X'VH#E+XN#CFE66L\R8/!IPE+$ <4T%C3$IV<TG
MGY&!UJGN^3!;-212 51)<25TZ'!JS'*VW[U4"Q;CD>]*K''6@3-$2.5X:A9&
M(YJG'<;6V'G-668;1@4 @+9;FI1*HXJJ3SQ3@P'UH&6<A^>@II /2H?,(0TL
M<GYT 5KVVW1L/45YYKUHT%QN"\&O3I,LE<SK]@D\1P.:F2NAIV//0A<$9YJ$
M1-Z5I&'9(5Z$<5-%;JQZ5BC3S,K[/)C[O%6;2SF>0  BM^"R5A@J*UK33D3G
M:,^M:*(<Z1E+8OM'!Z>M%;_E+13Y1^T/IRD8!E(/0C%+2,<*3Z5F8GA^F:QX
M@^$LU]HL_AV?4M-DN7FM+F'(R&]2 >P'!P171_#VPUO6/%VJ^-=:T\Z=]K@6
MVMK9@0VP$')!Y_A')QG)K!T_7/BAXS%UJFA7%E9Z<+AX8XI @(VGH<@DGU/K
M7:>";7Q[!J5RWBV]M9[4PXA6';D/D<G ';- '<444$9&* /*?%NMR>(]3N?
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M+9;&<<#TH V:*S=$UW3_ !#IB:CIEP)[5RRJ^TKR#@\&JFI^,O#>CY%_K=C
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M_P !U_\ BZ0_'WPEVMM4_P"_"_\ Q5 'J=%>5'X_>%.UIJG_ 'Z3_P"*IO\
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M#_T+<O\ X$C_ .)H_P"&AH^WAJ;_ ,"1_P#$T >W45XA_P -"CMX9E_\"/\
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M_BZ#H:W* ,3_ (0[PU_T+^F?^ J?X5<OM$TO4[-+2^T^UN+>/&R*6(,JXX&
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M?E7+>72%<4&L:\T:NN:P=3F79N6-1TS6/C-.Q[4!?>F9-W=QHIP&#2[<<YH
MH$2Q.4.:U(=4FP!O( K(I0Q%)H:9T"W\C $RM^=7(;LL!\Q_.N769EZ58CO9
M$[TM1)(ZX2Y7=FD^TO\ PUSJ:LP&"*GCU;GGBE<=CHXKF;;P>:N0W,O\3'\Z
MYN/5U]JMIJRXZTU*PK'502EB"6)K2BD7H:XZ+6%7'-6X];7J6JE)$M'61RX;
M&:O1W.WY:XU-<C##+8JY%K4(/7/XU7,'*=2"N<GH:9<11SH8V 9#QBL9-8C8
M?ZP#\:L1:K 3]\'\:JY/*SE_$/@>)HFN-/&V3DE,\&N&C+V=PT<J[64X(->S
M?;K=O^6B_2N+\7Z,ET4NK(+O_B4=ZEV-Z<VM&9FGWYMIDFAD((]*]#T?5TU"
M'YV D'7WKR*,RP$0NI5O>NATBYEAD'[P@T(UJ4E)71Z@) _%*2J>]95EJ220
M_/@-CK5@7*==XP/6KN<;C8L+EFP>G6I"X7A><U76YA8<.!2F:-!]\4Q$W%%5
MOM:^H_.B@+'N-%%%8FH4444 %%%-=UCC9W8*J@DD] !0 ZBO%IOB!XR\;:Y=
M67@:VB@L;8X:ZF49(SPQ+<+G!P "<4VT^(/C+P=XFM-+\;PQ36MR0%GC5<@$
MXW*5X8 GD$9H ]KHI <@$<@TM !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 5KFQM+HAKBU@F8# ,D88@?B*\@^#=E:W.L>+%GM8)0EV H>-6V_
M,_3(XKV=NAKR[X2Z)JFDZMXGDU'3[FU2XN0T+31E1(-S\CUZB@";4-<N[7XW
M:1H<45FMD]H&/^C)Y@^63@/C('RC@5EVGBKQSK_C/Q#X?TB[T^%+25MEQ<0_
MZE V, #[Q/ YK0U71=4E^/.D:K'I]PVGQV@1[D(?+4[9>"?Q'YTG@31=4L?B
M;XMOKO3[F"UN6)AFD0A9/GS\I[\4 8_AOQ;\0O%46H:39SZ;!>Z<[">_DCY;
M!("!0,9R#SCI6MX6^)MW/\/=8UG68HY;S2Y#&?+&P3$_=X['/'%/^%^BZGI>
MK^+9+_3[BV2YNBT+2QE1(-S\KZ]17/\ A3P-K%]\/O%6D7=C/975U<B2V%PI
M0.5Y'X$C&?>@ _X3?QW::#'XKGU/19K-V#MI2A1(L9.![Y_'->QZ1J<.LZ/:
M:E;Y$5S$LJ@]1D=#7@UEI<T&DVVE?\*K,^OQL$DNKF%O)<9^\6!')'?.._M7
MO&BV0T[1K.S%O!;^5$JF*WSY:'N%SSC- 'G'B"9M;^.6@Z3+S:Z=";K8>A?!
M.?T6I_%7B[Q'>>.H?!WA1K>WN5C$MQ=3KN"\9P!SP!CMGFJ^J1-I?[0.DWDH
MQ#J-FT2-C@L%88^O3\ZA\4:;K?A;XGIXQTW2)]5LKF+R[B*W7+H=NT\#Z @_
MA0!AJ=='QST*'Q";9[V&,()[8$),F'(;!Z'J"/:NL\1WWCUM9O#;ZCI'A_28
M!_H\MXZ,;CWSSCZ<8XK"BMO$VN_%W1O$-WX=O+"Q";4\Q=QC0!N9"/NDD]/I
M6?#I.H6?C769?$G@V_\ $5W/*383[=\*KDXY/R@8V_3'2@#<T;QWXFU_X::S
MJ-O);IK&E2<R1PAEF0#)^4\9QGIZ"KU]\2+A/@_!XC@DB&J3!;=?D!439P3M
M^@)Q3?A!HFIZ3IVNV.LZ7-:/)=;PLD>$=2I!VGH1Q^6*\_TOPU=R_$M/!4DF
M_2K+4'OM@Z!-H/ZC:/QH [/Q/XZ\2:#I?AK3YKJUL]1U*+S;K4;B',</(X"C
MCC(S6UX,U3Q=<ZT8;W5-'UW2&CW?;;.1%>-NPV#G\QWZU)\1UU1OL03PO:Z_
MHV[_ $J$1EKA#ZI@\<=Q7$^$?"]R_P 1K#5- \/ZKH>DP FY-^Q'F=<JH/)!
MZ8Y]: .AOI!X>^/=B\7RQ:U:>7, >"XR ?S5:]5KRK7(?[8^/6AV\9RNFVAG
MF(_AZD9_\=_.O51TH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH ^:OC-<2P?$.;R\X-O'G]:X$:K, !VKTWXLP++X]N"1D_9XOZUY[/IR
M@$E>M%F)LA756[9IW]JMGG-5FM,' '%1F#MWJ6V(OG50!P32?VQQWK.\@G^$
MTPQ;3R*7,RK(U!JY!SDFD_ML^XK,,8^E)Y/'3-/F861KC7B!@G-/&O(1SD&L
M3R<GI2&(CM1SL+&\NMQ,><_C2'4893PQ!^M8'ED4@4BCF861M2W*8^\*S9SY
MA(SD57+'UI"QQ4W':VPQEVFF$T_><5$V2>E4BN84FC-,YHP:H5R3-&::,T4A
MW'=J4-3:2@39)D4TXIO-(118D4XIO%*!1BF AQ13B.*;0 4M*!2XH ;BG4H&
M3BG8Q2N.PP9IZD^E.6,GH.*D6#<"=PR*5QI# QSCO3PY'535B.#<HR/F]:MI
M;< /UI6N#=BBLN.N:D6X&>2<5I"R3;C :GK8*QP(A2Y!W**S\_>J5;D@9W9_
M&K8TE23\I^E/&CH1\J'!I\K(NBLEX2.&_6IA.P(_>8/UJ3^PE !#,I]JD&@%
MN?-?ZFGRL+D9N91T8_G3_MDJJNYR/QJ4>'[K.%N#CW%(WAR_/RB=#]>*.5CN
MBEJ0\^+>N"RCK6;;WTJ/PU;$GAG5F&%=#[9JF?"FL*<^0#[AJ:YC>G445:YO
MZ7?BY386 XZYJR4F#;E<E?K7,V^@:U#.,6[KZG/%=-8Z9?(O[Q9<^PS5:E2=
M-ZCT=G^0,RO437$R'!8G'7-7K>&=;G:\9*XYR*L/I*F3?N(![4TFS"KRK8R_
MMQ_VJ*V?[*C]1^=%5RLQN?1=%%%9EA1110 5@>.'GC\"ZZ]MGSA8R[<?[IK?
MJ.:&.X@DAE4-'(I5E/<$8(H \K^ :PCP??E,>8;XA_7&Q<5Z9=RZ='<VXNWM
M5G8D0><5#'IG;G\.E>-1^%_''PSUJ[E\+6HU72+DY\DC<0!T#+D$,.F1P120
M^$?&7Q%\56FH^+K0:=IMH1B#[N1G)5%R3DD#+'M0![E12* H    X %+0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!SOBSPI%XGALF6Z:TO;&X6XMKE%W%"#R,=P:Z%00!DY/?%+10 4444 9^MZ
M?<:IH]Q96FH3:?/*N$NH1\T9SG(KGO!GP_MO"5S>7\E_/J.I7G^MNIQ@XSD@
M=>IZ\]A78T4 %%%% '.:%X3CT?7M7UJ:Y-U?:E("7*;?*C'1!STZ<^U='110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X+\39(X_'MS
MO=5S;18S_P "KCGFMY#AIDQ]:^I9+2WE??)!$[>K(":3[%:_\^T/_?L?X528
MFKGRK)'9N/ED3\ZJ264&21,A_&OK46=L.EO"/^V8I?LEO_SPB_[X%2]0L?(3
M6:9XD3\ZC:V"GC::^PA;0#I#'_WP*7R(?^>4?_?(H&?'#6F[L/PH^QG' ./I
M7V/Y$/\ SR3_ +Y%'DQ?\\T_[Y%*R ^.!8L!D*Q]MIIILI>T3_\ ?)K[*\F/
M_GFG_?(H\J/^XO\ WR*+(#XS.GSXXAD/_ #36TV<C_42_A&?\*^S_+3^XOY4
M;%_NK^5%D!\7?V5<D_\ 'M-_W[;_  I#HUWG_CVGQ_US;_"OM/:O]T?E1M'H
M/RHL@/BS^Q+O&?LMP?\ MDW^%1'1=0S\MC<D?]<6_P *^V-H]!1@>E*P[GQ*
M=$U+/_'A='_MBW^%+_8>J?\ 0.N_^_#?X5]M44[!<^)/[!U;_H&7G_?AO\*4
M>']8/32[S_OPW^%?;5%%@N?$W_".ZS_T"KT_]N[?X4O_  CFM?\ 0)OO_ =O
M\*^V**+!<^)_^$:UP_\ ,(O_ /P'?_"E_P"$8UWMHU__ . [_P"%?:]%,+GQ
M.WAO6TP&TB_&?^G9_P#"E_X1S6NHTB__ / 9_P#"OM>BE81\4CPSK;<?V1?C
M_MV?_"@>%=<SQI-_^-L_^%?:U%,=SXN'A37"N?[)OOI]F?\ PJ2+PGK9.7TB
M_ _Z]G_PK[-HH%<^.%\'ZN#G^R[_ /\  5_\*F;PAK&T%-*OPW?-H_\ A7V#
M10!\A1>$M9V;6T>^^OV1_P#"GCPAJZDYT;4&_P"W23_"OKJB@#Y,_P"$4UD-
MF/2-1 _Z])#_ $JPOAG6< MI&ID]/^/-_P#"OJNBF!\KQ^'M;0\:)J6.V;-_
M\*L1Z#K2G<=$U3/M9O\ X5]0447%8^94T360,G0]4S_UYO\ X5.FDZT!@^']
M2/\ VZ/_ (5])T47"Q\Y)I6KXPV@:I_X"/\ X5872]3QQH&J'_MT>OH6BFI-
M!8^?UTS5,@_V#JH^EHU3?V=J;8SH6JY]?LC5[UBC%'.PY3PC[!JO;0-6^OV1
MJ1=/UCH=!U;'_7J:]XP**.9ARH\*.FZMCC0-6/M]D-']G:UD;= U=?I:G_&O
M=<48HYF%D>%C3-9).?#^K_\ @-_]>D.F:X&PN@:J5][?_P"O7NF!2X'I3YV+
ME1X5_9.M_P#0OZK_ -^/_KT5[K11SL?*@HHK$\3^*]*\):<MYJDK*)&V111J
M6>5NNU1ZU S;HKRF7X@>/=3;S-"\"RI:G[CWF0S#UQE0/UIT'Q"\;Z8V_P 0
M>!;@VP^_+998J/7&2#^8H ]4HK$T+Q3I_B;19-2T=VG";E:)U*.L@&=C ]#T
M_.O-+*Y\43?&7P_)XC,=O)<6LTD5C!(2D";6&&[,V>2: /9J*\5\>Z];:C\1
MGT'6+_4;?1K&V5VM].W>;<3, 0,+R< _H:2]\02Z'\&Y9-&\2SZE]IO1:VUS
M(I2:V5N2AR<[@ >??B@#VO-%>/Z=9S> OB1X>TRUU&^N;+6+9A<Q7,QD_>@$
M[QGISC]:P9(KWQ3H_B[QC+J^H07>F7+KIZ0SE8XE3G&T=<B@#WZBO,T^+>GZ
M7X>\/3ZK!<RW>HVRNWD*,!LA23G'4\\5Z6#D ^HH 6BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "N.\;:O>V&H:'9:;;Z:;Z\FD$-QJ(/EQE5SM7'.]N@KL:CF
MMX;@)YT,<GEN'3>H.UAT(ST(]: . T[Q)XH@\3:/!K:V*1ZP7"Z9&A^T6:JI
M(=FS\PXP3TY&*]" XKR;7/'7B&;QIJ%EX4\*V]_-IH%O-=R(6<9Y*Y!&%SVS
MSC-:?ACQ)\0[_P 0VMMK?AF&STY]WFSJIRORDC^(]\4 >AQ6\,+2-%%&AD;<
MY50-Q]3CJ:X36M)U";XR^'=3BLYGL8+*5);A5^1&.[ )]>17?T4 >6^(M.U7
MPS\3QXPLM%N=6L[JU\B>.T ,D3@ 9QZ$ ?K6#_PK_7=5\!:_.]D;74+_ %(:
MC:Z>[ % N>#V#$,>/85[A10!Y-I4&M^,?B#HFL7V@WFDV>C6S*YNQM,LQ!&%
M'<<_I6+/I?B7P[I_BCPG:^'+R^CU>X9[.\A ,2JYYWGM@>M>YXHP* /G3XIZ
M.WA_3/ ^E.^][6!D=AT+;D)Q^)-?12?<7Z"O#?C]QJGAH^\G_H25[C'_ *M?
MH*!CJ***!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.*]#CM;>&U%M%!&D 7:(E4!0/3 [5YKJ]O#:_'+PG!;Q)%"FG3!4C4*JCY^
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >?>,?BM8^&-1F
MTVTTZXU2]MX_,N%A.$@&,_,V#VQVXS6GI?C^PO\ Q+;Z#-!+;WEQ9Q7<1;E'
MW)O*@^H'YXKSCQI;:YX4U;Q;LTB2_P!-\21_)=0J2T#8(P< ^IX[\5=\('6_
M&/BOPYJ$VC2:=I>@VQB$TP(:9]FW R!GUP.GK0![15&;1M.N-7@U66SB>_MT
M,<5P1\R*>H!_$U>I,C(&1DT 8&H^!_#&K7TM[?Z)9W%S*07ED3); P,_@*M:
M?X8T/2]/N+"RTNUAM+DYFA6/Y9.,<@]>*UB0.M% &-HOA/0/#TLLND:5;6DD
MHP[QKR1Z9/;VJ/4/!?AO5=374K[1K.XO%P?->/DXZ9['\:W,@T9'KUH \2_:
M& %OX= & ))NGT2O9[+_ (\;?_KFO\A7BO[0[';X>&?EW3'_ - KVJR_X\;?
M_KDO\A0,GHHHH$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!R?Q+&?AWK7_ %[F
MHOA6<_#?1_:(_P#H1J?XC7-G;^ M7-Z^V-H"H]V/0?G63\&KP7/P\M(S*KO
M[QLHZKSP#0!Z!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG[XNZ$GAWPKX0T[Y6F@B>.20 99@%SSZ9)KZ T[_ )!MK_UQ3_T$4#+-%%%
M@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *1F"J2Q  ZDTIXKQ;XM^/+F>Z'@[P^S274
M[".Y>$Y;GI$,=SWH Y7XN>.3XJU+^R=)\R73;(DR.@)$KC^+C^$>M5_@[XEO
M/#_B);>6&=M*OV$<CK&2J/\ PMG'X'ZUZ7HW@6#P9\+]8214?4KBRD>YE Z'
M:<(/8?SJW\$P#\-+//\ SVE_G0!Z+1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% 'D'B?P&=3\7WNK#Q]#I\[MM6+S KPK@?)D.#
MCOCWJWX2\(W.F>)K2[D^(/\ :JQ[LV?GEO,RI'3>>G7IVJYKWPU\#ZOKMYJ&
MI7CI>3R;Y5%ZJ8; '0].E<SI7A[PMX4^+FA0Z-=_;A<Q2C:+@2-;.%."2O!!
M&1@_6@#VZC%%% !BBL_5->TG150ZIJ5K9B3[GGRA-WTSUJRE[:R60O4N86M2
MGF"<."FWUW=,>] $^*,5F:5XAT;7#*-+U.UO#%]\0RABOU%17OBO0--U---O
M=8LK>\?&(9)0&YZ9],^] 'E'[1 _T?0#_P!-)OY+7LNF'.E6A]8$_P#017C?
M[1'_ !YZ 1T\R;_T%:]CTO\ Y!-G_P!<(_\ T$4#+=%%% @HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHKGO&/BVQ\'Z#-J-VP9_NPPYPTK]@/ZF@# ^*/C]/"&C_9K-E;5K
ML%8%Z^6.A<_T]ZQ?A+\/7TV/_A)=;1GU6Z!>%9.3$K<EC_M-G\!6'\./"U[X
MW\12^-O$JF6'S,VT3CY9&'3 _N+V]37NH&!0!C>+1_Q1VL#_ *<Y?_037*?!
M'_DFEI_UVE_G76^+/^10UC_KSE_]!-<C\$/^2:6O_7>7^= 'HU%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M44 %%%% &5XF_P"17U7_ *])?_037%_ T_\ %MX?^OF7^E=/XS\+?\)?H?\
M9G]H3V(,BN981DD#MU'!S5#P%X!C\"P7D,6I3WB7#*V)$"A,9Z $]<T =C11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'F>O?\
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MM8(X(8UCBC4*B*,!0.@%24 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** /!KZS\%_P#"T?$J^,[P2>8Z/:N)7"(,?,C;>0PXP#QBNJ\*
M6?PMB\26C^'9X6U4;O("S2L?NG/#<=,U@>+O$'@"U\6:E!JG@R[O;Y)L37"8
MQ(V!R/G'M4W@77_ =_XPL[?1?"%S97_S;+EL$1_*<YPYQD9'2@#VBBBB@!DL
MT<*[I9$1>F68 ?K3@01D'@]Z\^\5^"M+O];N_$7BO4VET:WMML5F6:-82.K9
M!^8DYX]2*\]_M/5--^!=QMFN8[:^U3[/9/(QWK;'GKZ':P_$T >_PW$-P&,,
MT<@4X)1@V#^%-DO+:*=()+B))G^Y&S@,WT'4UY%%I-GX"^*'A>WT99(;75;5
MH;J+S"RR,!PW/?.*Y^+1K3Q5X7\;^*=06235;>ZD-K-YA!@5.0%YXXXH Z+]
MH7_D5]+/_3VW_H!KTWPR<^%-'_Z\8?\ T 5X3\2=>DUKX7>%GNFW7<D:RNV#
M\V Z$Y^J_K7NOA<Y\):,?^G&'_T 4#-:BBB@04444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4457O;^TTZUDNKRXB@@C&6DD8*H_$T >=?%
M/QGXH\'/9W&EVUD=.E_=M+,"S>;UQC(P,#K6]>>.;/PWX9M+[Q//;V^H2P*[
M6MNV]G8CH@Z_CT'K7D7Q>^(ND^*;:VTG1R\T4$_G/<E=JL0" %!Y/7K5KX=?
M#6/QC#'XD\0:FUY"[E1;K(6=BO&'8]!_LB@93O\ 5?%7QEUG[#I\#VFBQMD@
MG]V@_O2-_$WH!_\ 7KVKP?X*TKP;I@M;"/=*P!FN7'SRGW]!Z"MNRL+33;2.
MULK:*WMXQA8XD"J/P%6:!!BO,Y_@IH=QKDFK-J&H"9[@W&T,NT-NW8Z=*],H
MH 0# I:** "BBB@ HHHH **** "BF22QPIND=47U8@"DBN(9\^5-')CKL8''
MY4 24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117F7
MQLO);'PUI<T4\L0&I1[S&Q4E=K$CCKTH EU[XOZ'H.NWFE7.F7\LUK)L=XXT
M*L< \9/O6!HGBP^-/BKI%]H6DW-I!;P2QW\SJ!YD9' ;''! QGG)K=;XS^!F
M8LSW1)ZDV9K3T#XH>%M?U>#2=,DN/M,^=BM;%%X!)Y^@H [>BBB@#R#XBZ5X
MQ\1>*[>&WT$WV@V15UMVN%CCN7QDEN<XYQCV/K6IJFA>(_&OP]O=+U/1[31[
MZ"5&L88Y0T9" 8Y&<=Q7I=% 'ENC:'XH\0^-M'UKQ%I46F0:-;F-$6<.9Y",
M;ACH._\ C67>^#_&.DIXCT'1M.M;O2M<G,J73SA#;!OO J>3Q_GM7LU% 'A7
MQ?T./P_\-/#VFQMO-K(L+/\ WB$8D_F37KOA0Y\(:+_UXP_^@"O._P!H#_D4
M; _]/?\ [*:]#\)_\BAH_P#UYQ?^@B@#9HHHH **** "BC.*3- "T444 %%%
M&: "BC-% !1110 444UG"J22, 9)H =17GNB_%OP[J6HZK;W5Y#91VDI$$DS
M8$\8ZL/QSQZ8JIK/QQ\*:<"MDUQJ,G_3%-B?]]-B@#TVJ.IZSIVC6K7.I7L-
MK".=TKA?R]:\/D^)'Q!\;2-;^%])-I >/,B3<0/>1OE'X5=TOX):KJ]RE[XO
MUV65SRT43F1_IO;@?@* -#Q!\=K*.4VGAJPEU"X8[4EE4JA/LOWF_2L*+P+X
M\^(MP+_Q1=/968!:*W?Y3[!4'"_5N:]@\/\ @W0/#$032].AB?',Q&Z1OJQY
MK>Q0!\E>+_ASJO@ZTCNM1N+$K-)L2.*8L_UP0.!ZUZ]\)O"'B7PH\INKBQFT
MF]C$H6*4LROCAAQCD<&NL\4?#WP]XOO8KO5K>5YXD\M7BE*?+G.#BM_2M,M=
M&TV#3K*/R[:W0)&F2<#ZF@"Y1110 44'BL:\\5Z%I]V;6[U2VBG'WD+Y*_7'
M3\: -FBF0S1SQ++$ZO&XRK(<@CU!I^: "BC-5Y[ZTM03<74,('_/20+_ #-
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MLHD!4?CG%2PS17$2RPR))&W1D8$'\10 ^BJYOK470MC<PB<](C(-WY9S5B@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>/?#/\
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M7!A..I7<O^)_.O6*\NUJW_X27XV:1:Q'=!HEO]IN#V5F.5'U.%KU&@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH @O;*UU"TDM+RWBN+>08>*50RL/<&
MI(HD@B2*) D:*%55&  . !110 ^BBB@"*XMX;NWDM[B))89%*O&ZY5@>H(]*
MK:;H^F:1&T>FV%M:(YRP@B";OKCK110!>HHHH JVVG65G<W%Q;6D,4URP::1
M$ :0CH6/>K5%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
64444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>drts-20211231x20f017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 drts-20211231x20f017.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 1T K$# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ=(I!"L#\JYP,D9KT&-%BC6-%"HH 51T '04 .JO?70LK"XNF4LL,;2%1U.
M3C]*L5GZ]_R+VI?]>LO_ * : //-&\<?$'Q%I4.K:3X2TV2PN-QA:2_VL5#$
M<CUXJ_\ V[\4?^A.TG_P9"J?P(CLD^'\36^I2W,[N3<0/+N6V;) 55_AR,-C
MOG->H4 >=_V[\4?^A.TG_P &0H_MWXH_]"=I/_@R%>B44 >=_P!N_%'_ *$[
M2?\ P9"C^W?BC_T)VD_^#(5Z)10!YW_;OQ1_Z$[2?_!D*/[=^*/_ $)VD_\
M@R%>B44 >=_V[\4?^A.TG_P9"LR'QY\09_$=QH*>$]+.H6\"W$B?;^ C' .>
MG6O5ZR8?#UA!XFN/$"+)]ON+=;:0E_EV*<C ]<T <C_;OQ1_Z$[2?_!D*/[=
M^*/_ $)VD_\ @R%>B44 >=_V[\4?^A.TG_P9"C^W?BC_ -"=I/\ X,A7HE%
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M/_T%;'_P)3_&@#CO[:^)_P#T*>C?^#&C^VOB?_T*>C?^#&NQ_M[2/^@K8_\
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M /B:/^$0\,_]"[I'_@%'_P#$ULT4 8W_  B'AG_H7=(_\ H__B:/^$0\,_\
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M (FMFB@#&_X1#PS_ -"[I'_@%'_\31_PB'AG_H7=(_\  */_ .)K9HH QO\
MA$/#/_0NZ1_X!1__ !-'_"(>&?\ H7=(_P# */\ ^)K9HH Q?^$0\,_]"[I'
M_@%'_P#$T?\ "'^&/^A<TC_P!B_^)K:HH Q?^$/\,?\ 0N:1_P" ,?\ \31_
MPA_AC_H7-(_\ 8__ (FMJB@#%_X0_P ,?]"YI'_@#'_\31_PA_AC_H7-(_\
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MAVG=5P9"'8 L>^  *]"H \PN]$3Q]\2-1^VM>1Z9HD"V\#02-"6G<Y<AAR<
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MJ>IZQX.T^_U9-MY*A+';MWC) ;';(YH Z.BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "N43_DJC?\ 8';_ -&K75UR
MB?\ )5&_[ [?^C5H Z:YN(;6W>>XE2*&,%GD<X51ZD]J\W^$4\5S<>+9X)$E
MBDU5F1T.0P.<$&O1[JV@O+:2VN8DF@E4J\;C*L#U!%><?"&WAM)_%EO;Q)%#
M'JK*D:#"J!G  H ]-HHHH **** "BBB@ HHHH **** "L_7O^1?U+_KUE_\
M0#6A6?KW_(OZE_UZR_\ H!H X?X'KJ8^&UB;UK8VA+?8Q$#O";FW;\\9W9QC
MM7I%<)\&_P#DE&A?[DG_ *->N[H **** "BBB@ HHHH **** "BBB@ HHHH
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M-NK@7%QI]I-,.DDD*LP_$C-6P !@=*6B@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KE$_Y*HW_8';_T:M=77*)_
MR51O^P.W_HU: .AU%;Q].N%T^2*.\*$0O,I**W8D#M7G'P;6[4^*5OGBDNQJ
MC"9HAA"V#D@>E>HGI7FWPI_X_P#QA_V%W_K0!Z31110 4444 %%%% !1110
M4444 %9^O?\ (O:E_P!>LO\ Z :T*S]>_P"1?U+_ *]9?_0#0!P_P/MKV'X;
M6,MS??:+>8LUM#Y87R%#,"N?XLG)_&O2*X3X-_\ )*-"_P!R3_T:]=W0 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!R7A_P#Y'[Q;_P!N
M?_HMJZVN2\/_ /(_>+?^W/\ ]%M76T %%%% "9&:-P]1^=<3XNTVSU?QMX6L
MM0MTN+9Q=EHG^Z2(QCBJFN>%M#T+6O"]SI>F06DSZLD;/$""5,<AQ].!0!Z%
M10.@HH *XWXF:YJ6@>%5N]*N!;W+7447F% ^ S8/!KLJ\[^,X8^!T",%8WL&
M"1G!W4 69M!^($,#RP^-+::15RL<FFH%8^A(/%:/@SQ>GB#P>FL:AY-H\3/%
M=$MMC5T."03T'2LR3PUX]O(FM[GQM;Q0N,,UMIJJ^.^"3Q57Q%HOASPOX.TK
M0I[2^OT^UI]GM(' >\FR6^?L03R<\4 =5IOC/PWK%Y]CT[6[&YN>T4<P+'Z#
MO^%6;_Q)HNF/.E]JMI;/ BR2K+*%**QP"1[GI7EOC)M6D.@W5[X9T_18XM4M
MUA>.Y5Y^6Z?(H &.O-;L6EV6H_'+4GO+:.?[/I<+QB10P5BQ&<'OB@#NM*UO
M3-<M3<Z7?V]Y"#@O#(& /H?2J5YXR\-Z?J(T^[URPANR<>4\X# ^A]/QKCH(
MUTCXA^+_ .SH4A_XE$<XCB7:#)\W.!WJYX!T#1KSX9VAN[2"7^T(&EO)70%I
M&8G<2QYR/TQ0!T_B+Q):>'M-2ZECGN7F81V\%M&9'F<C( Q].O2L/X=^(=8\
M0)K3ZRBPS6]^85MU _<KM!VY'4\]:W_#<.G0>'K*#2KLWEC"FR&=I/,) ./O
M=\=*YKX=?\A/QA_V&I/_ $%: .\K%E\7^'8=6&ERZU8I?$[?(,Z[L^GU]JLZ
M]<3VOA_4+BV&9XK:1XQ_M!217#> ]#TB\^$\#W5K!*;V&26YE= 69\MEB>N1
MB@#T&TU"SOS,+2YBG,$ABE\ML[''53Z&K->7?#VYU#2_AUITNBZ0=8DN9II+
M@_:TA*MN(R2W7H*Z+_A(O&'_ $(C?^#6"@#>O]>TG2Y'CO\ 4K6V=(C,RS2A
M2$SC=SVS1I.O:5KT#3:5J%M>1J<,89 VT^X[5P<]I'K7Q9T636M/2&=-*>;[
M)(ZRA) _'(X;'6K6IQ6^D_%W19;$+"U_9SK>I&  Z( 59@.X/>@#IM3\9^&]
M&N_LNHZW8VUQWCDF 8?4=OQK0DUC3H=.749+ZW6R?&V<R#8<G P>G6O-M#G^
MTV5[_P (MX-6^LKF>1I-2U:Y1?/8DY/0LR^E<XBG_A0^IPG:JIJK(%C)*J/-
M7A?;TH ]"\4_$?1M*T+4)],U33KK4;8^6L'G _/Z8'7')_"K2Z\-4AT"ZT_Q
M#81Q33A)TX;[2=OS1IZ-FL3Q[H.DZ7\+=0%EIUK RP1@,D2AC@CDG&<\GGWI
MOB&&*"]^'ZPQI&OVU"0B@#)CY/% ';:OXDT70%0ZMJEK9[_N":0*6^@ZFL'Q
MGXH>U\&#5]!OX9 T\2I/$5D4AG /MT-9GA&UM]5\=>+K_48(YKRWN4MHO-0-
MY46W(QGIGK69XVTK0])\,:U#H\P$DFH6TMU;+("L+EUQA1]W(YH ]*U'6-.T
M:R^U:G?6]I!P/,GD"@G\>M-TK7-+UVV-QI5_;WD0."T,@;!]#Z5YMKSZG>_%
MI8[;2+75C8Z>LEO;7=R(D0L<%P""">U6]*T_7%^(L&HW>E:9HR3VLD=S%;7Z
MNTPQE7V8&<'O0!V-UXS\-66H_P!GW.NZ?%=YP8GG (/H?0_6MQ65U#*05(R"
M#D&O'K?3-8\/:->64GAS3O$^@7$DLC7=G,OGLK$DEL_>(]0>U>C>$+S3;[PI
MITVD+*ECY06))22Z <;223TQ0!N4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5RB?\E4;_ + [?^C5KJZY1/\ DJK?]@=O_1JT =#J-O/=
MZ=/;VUTUI/(A5)U4,8SV8 ]<5YQ\&X)K8^*8+BY:ZFCU1E>=E"F0@'+$#IFO
M43TKS;X4_P#'_P",/^PN_P#6@#TFBBB@ HHHH **** "BBB@ HHHH *S]>_Y
M%_4O^O67_P! -:%9^O?\B]J7_7K+_P"@&@#C?@I?6MS\,-+MX+B.2:V#I,BM
MDQDNQ 8=N"#7H5>??!6SMK?X7:3/#;Q1RW =IG1 &D(D8 L>Y &.:]!H ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y+P_P#\C]XM_P"W
M/_T6U=;7)>'_ /D?_%O_ &Y_^BVKK: "BBB@#$UWPO8^()K2:ZEO(9K4L8I;
M2Y:%EW##<KZBJ-MX#TRWU"TO7O=7N9+67S8ENM0DE17P1G:QQT)KJ:* "BBB
M@ K$\4^&;;Q7I2Z?=3S0QK,DVZ+&<J<@<@\5MT4  &*P_$WA>U\3VD$<UQ<6
MMQ;2B>VN;=@'B<=",\'Z5N44 </>_#A-7$$NLZ_J=_=V\JR02OL18B#GA%7;
MSC!)R?I6_;^'+>W\6W7B)9Y3<7-JELT9QL"J<Y'&<ULT4 8T'ARVA\3WNN^;
M(TUW;);/$V-@53G(XSGFL!OAPL27%GIWB'5;#2+ABTMA"R%1G[P1B-R ^@-=
MQ10!5T[3K72=.M["RB$5M;H(XT'8"J&A^';?0;C5)H)I9#J%VUU(),85B ,#
M Z<5LT4 (RAU*L,@C!%<.OPUA@$]G::]JEKHMPY>738F79SU56(W*I[@&NYH
MH Q?#7AJU\+64]E8RRM;27#3I&^,1;OX5QVXK:HHH \S\2Z.=9^+FG1+=W5E
M+'I;R17-LV&C</QU!!'/(/6NGT3P=!IE_<:G>WUUJFIW$?E/=76W*Q_W550
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M_D7]2_Z]9?\ T T <K\&_P#DE&A?[DG_ *->NZKA/@V?^+4:%_N2?^C7KNZ
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8D*2!D@=*\9>Y\;3?$ZV\3GP%=+%%9FR,7VV,Y!8G?NQ[],?C7L]% !1110
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M@P/XBMHSC+8\ZOA:M!^^M._1_,FHHHJSG"BBB@ HHHH **** "BBB@ HHHH
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M[4?^O67_ - - '+?!O\ Y)1H7^Y)_P"C7KNJX3X-_P#)*-"_W)/_ $:]=W0
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MTFBN1#+&K,6V.&ZX)ZBO1STKRKPSX4'C.PGUG6]=UHW\EU-');V]XT*6^UR
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MVW.<$=1R.]=50 4444 %%%% !6?KW_(O:E_UZR_^@&M"L_7O^1?U+_KUE_\
M0#0!Q/P1NYI_AII\$EC-!'!O6.9R-LX+L25QV!XY[BO1JX/X-,K?"G1 &!(2
M3(!Z?O&ZUWE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6(48>RYM;[&W1115F 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0DXR5F@HHHIDA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MUCW"UD23<TJ[V+%AV(;(KTBN%^#?_)*-"_W)/_1KUW5 !1110 4444 %%%%
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M"ZIO^^5SG'MUKMK>>.Y@CGA</'(H96'0@U,'>^IMB*?);2Q+1116AS!1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** *&L:+IVO:;+I^IVD=S;2#YDD'Z@]C[BN \)_#?6
M?!/B\MI.N,WAF8,\MG-\S!NRCM_P(8/'.:].HH **** "BBB@ HHHH ****
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M#GAZ_P#"]AJS^'VBU6S<XOI58"5LMAD.<$ <=.HKV6@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MTQ+O8,&/\66R:](H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/@D01A_$UANVC.7/7'TH [*BN0_X6EX'_P"AFL/^^S_A1_PM+P/_ -#-8?\
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M6EX'_P"AFL/^^S_A1_PM+P/_ -#-8?\ ?9_PH Z^BN0_X6EX'_Z&:P_[[/\
MA7'>+/B;HS^*_"K:5XGB^P+=,;_R92$V<8W^HZT >P45R'_"TO ^/^1FL/\
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MVNYS(88OX<D_Q$<FN\H R/\ A%/#G_0 TK_P#C_PH_X13PY_T -*_P# ./\
MPK7HH R/^$4\.?\ 0 TK_P  X_\ "C_A%/#G_0 TK_P#C_PK7HH R/\ A%/#
MG_0 TK_P#C_PH_X13PY_T -*_P# ./\ PK7HH R/^$4\.?\ 0 TK_P  X_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\"I: /0J*\^^W_%?_H#^&/\ P*EH^W_%?_H#^&/_  *EH ]!HKS[[?\ %?\
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MRH@#;>5#N!E@,#CVKNQP*** "L_7O^1>U+_KUE_] -:%9^O?\B]J7_7K+_Z
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M(_\ "@ _X2;0?^@WIO\ X%Q_XT?\)-H/_0;TW_P+C_QH_P"$8T'_ * FF_\
M@)'_ (4?\(QH'_0$TW_P$C_PH AN]<\.7MI-:SZUIK13(4<"\09!&#WJOH^H
M>%="TFVTRPUC3H[6W79&K7J,0,YZELGK5[_A&- _Z FF_P#@)'_A1_PC.@_]
M 33?_ 2/_"@ _P"$FT'_ *#>F_\ @7'_ (T?\)-H'_0<TS_P+C_QH_X1C0?^
M@)IO_@)'_A1_PC&@?] 33?\ P$C_ ,* #_A)M _Z#FF_^!<?^-'_  DV@_\
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M%% !1110 4444 %%%% !1110 4444 %<YX__ .2>^(?^P?-_Z :Z.N<\?_\
M)/?$/_8/F_\ 0#0!K:/_ ,@2P_Z]H_\ T$5=JEH__($L/^O:/_T$5=H ****
M $S2UYAXS\4W^FZO;*D5P(A.LJ1SH$P4R,@J<LASGGTKNM NI[O2XVN5N?-
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M!7TF]CT[P)IUY,LC1PZ=$[")"[$",= .2:XWX.7<=^WBF[B$BQS:HSJ)%*L
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MSQ__ ,D]\0_]@^;_ - - &MH_P#R!+#_ *]H_P#T$5=JEH__ "!+#_KVC_\
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M=O\ 4KO9;P:I<EY96)VJ"..?Y5:A^)6F.UO)=:9J]C8W#!(;ZZM-D+$].<Y
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M&"ZUIT=X(#;F+>S#;E3GH1Z"O7*HVNC:?9:C>:A;6J1W=YM^T2C.9-O3/TH
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MWMSX*D8Q1+&2-3@YP /Z5/\ \)!XL_Z$B3_P:04 =717*?\ "0>+/^A(D_\
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MY-Q>IJD\<C;B5!&!A?11V% ';T5YKI-OJ/Q!GU359=>U/3K&&[DM=/@L)?*
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M/]P?^A"MU/N+]!5NW+>Q/4=1114%!1110 4444 %%%% !1110 4444 %%%%
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MKIZXGPU<ZUH_BJ?POK&I'5(FM/MEG>2*%EV!MK(^."<D8-=M0 4444 %%%%
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M]/QKLXY$EC62-E=&&593D$>QK*=.4':2*4D]A]%%%0,**,BB@ HHHH ****
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M:DB2HKHP=& *LIR"#T(IU !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !65KOA[3?$5G]FU" .!RC@X9#Z@UJT4TW%W0-7/+7MO$OPZD62
MVDDU70@?FB(.Z)?_ &7ZCBJ=]\1%N]7L)K51<!)3)"K1E#&60IL<<[L$YR.H
MKUT@,,$9%>8>-? EM-J=I)I ^SWM[*X92?W;$(6Z=LXQZ<UV4JE.<OWBU[_Y
MF,HR2]T]"TBYDNM.C>8R&91MD:2W:'<W<A6Y J]7G7AKQNVF/#H'B6W>PNH5
M$:3RD[7 X&2?Y]*]#1U=0R,&4C((.017-4IN#U-(R30ZBBBLR@HHHH ****
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M<5W!(YZ*DBD_D#2L!9HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MAFO53$TD*;49O4#L*N5F:'KMIK]E)<VBSHL4SP2)/$8W5UZ@@_6M.@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I&574JP!!&"#WI:*
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M&5]'N6J***R*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH :[*B%F("CJ2< 5YO\)V#7OB]E((.KN00<@]:]!U"PMM3L)[&\
MB$MM.ACD0DC<IZC(YKSCX.65OI[>*K.TC\NW@U1HXT!)VJ 0!D\T >H4444
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MKW^,EHU)ZD UX-H^C>)/$/B7Q[I22Z3%)<30K>.?-('&1Y?_ ->O>4&U%![
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M[L=,$B+_ &O<EL%]RC,<>1\Q*\%S]T>_3K-75!X:U Q',9M)-N#P!Y9QCVH
MYKX-_P#)*-"_W)/_ $:]=U7G?P<U&R7X9:%:F\MQ<%9!Y7FKOSYC_P .<UZ)
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MFVJN^DZL@MM7M_D*-QYN!R?KZBNK$4793C]QE3GT9VE%%%<1L%%%% !1110
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M *JN>#?%T7B6Q*RA8=1AXG@Z?B >W\J=2"DO:0VZ^01;3Y6=11116!84444
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MTC:S.S#D]>".E>CT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME.HX/R)E&YF:#KUEXBTU+VR?*$[71N&1O0UJ5Y=JUA>?#W7VUO2HFET>X/\
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M4 %%%% !1110 4444 %%%% !6?KW_(OZE_UZR_\ H!K0K/U[_D7M2_Z]9?\
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M+=>$KH-*WGOS >P _O=/8CKTH ]8HHHH **** "BBB@ HHHH **** "BBB@
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MHH **** "L_7O^1?U+_KUE_] -:%9^O?\B_J7_7K+_Z : .4^#?_ "2C0O\
M<D_]&O7=UPGP;_Y)1H7^Y)_Z->N[H **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** ,?Q'X=M/$FE265R,-UCE R8V]17FXU?5=&QX3UP-(RSPF
MTN,<% XXSW&/RZ5[!7+>-M-M+K3[6ZF@1Y[>ZB\MR.1EP"/I[5O1J)>[+5$2
MCU1U(HH%%8%A1110 4444 %%%% "&O-_A3_Q_P#C#_L+O_6O237FWPI_X_\
MQA_V%W_K0!Z31110 4444 %%%% !1110 4444 %9^O?\B_J7_7K+_P"@&M"L
M_7O^1?U+_KUE_P#0#0!Q'P0M[V+X:V$ES>B>WEW&VB$07R%#L""?XLG)S[UZ
M/7"_!O\ Y)1H7^Y)_P"C7KNJ "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!6KKISX?U+_KUE_] - '+?!O_DE&A?[DG_HUZ[JN%^#?_)*-"_W)/_1KUW5
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M?F_=J3GWXI?[-L?^?.W_ ._2_P"% '(_\+A\ _\ 0Q0_]^9/_B:/^%P^ ?\
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M:/\ A</@'_H8H?\ OS)_\377?V=8_P#/G;_]^E_PH_LVQ_Y\[?\ []+_ (4
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MM^S[+:[\9V^6N?RQ3O[.L?\ GSM_^_2_X4 <B/C!X!)Q_P )%!^,4G_Q-/\
M^%N> _\ H9+;_OA__B:ZLZ98D$&RMB/^N2_X4S^R--_Z!]I_WX7_  H Y?\
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M /"W/ 7_ $,EM_WP_P#\31_PMSP%_P!#);?]\/\ _$UU']D:;_T#[3_OPO\
MA1_9&F_] ^T_[\+_ (4 <O\ \+<\!?\ 0R6W_?#_ /Q-'_"W? 7_ $,EM_WP
M_P#\374?V1IO_0/M/^_"_P"%']CZ;_T#[3_OPO\ A0!RQ^+G@+_H9+;_ +X?
M_P")K'^#]S%?'Q1>VS>9;7&J,\4@! =3GD9KT'^R--_Z!]I_WX7_  J>WCMX
MD,=LL2(IY2,  'Z"@":BBB@ HHHH **** "BBB@ HHHH *XWXE:G>6/AN"TL
M)F@NM3O(K%9E.&C#GYF'O@&NRKAOBE#(GA^PU2-&==*U*"\F"]1&&PQ_ '-
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MNKHW-POK'$,X/X_RH ?\,/"YT71Y-3G66*YU+$HMVE9Q!%U1.3UQR37>4@
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M+J[T33YYY#EY)(%9F/N34VG>&]$TBX:XT[2;.TF9=A>"%4)'ID5J44 %%%%
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M:\B1H7=U51U+' KCM5\57F@^.-.LKWR'T355\NWF48:*8=B<X(/% '9T444
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MJW4<$2P01PI]R-0J_0#%24 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $-U;
M07EK+;7,*302J5>-QD,#U!%,L+&UTVRBL[.%8;>(;8XTZ*/0444 6:JZCIUG
MJMC)9W]K%<VT@^>*5=RM^%%% #=,TNPTBR6TTZTAM;=22(XE"C/K34TC3TU:
M35%LXA?R1B-KC;\Y7TSZ444 7J*** "BBB@ HHHH **** "BBB@ HHHH ***
L* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>drts-20211231x20f018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 drts-20211231x20f018.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 1Q ST# 2(  A$! Q$!_\0
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M_P#/)/RH^SP_\\D_*I*0D*,D@#U- #/L\/\ SR3\J/L\/_/)/RJ0$$9!R**
M(_L\/_/)/RH^SP_\\D_*GLRJ,L0![FEH C^SP_\ /)/RH^SP_P#/)/RJ2B@"
M/[/#_P \D_*C[/#_ ,\D_*I** (_L\/_ #R3\J/L\/\ SR3\JDHH C^SP_\
M/)/RH^SP_P#/)/RJ2B@"/[/#_P \D_*C[/#_ ,\D_*I** (_L\/_ #R3\J/L
M\/\ SR3\JDHH C^SP_\ /)/RH^SP_P#/)/RJ2B@"/[/#_P \D_*C[/#_ ,\D
M_*I** (_L\/_ #R3\J/L\/\ SR3\JDHH C^SP_\ /)/RH^SP_P#/)/RJ2B@"
M/[/#_P \D_*C[/#_ ,\D_*I** (_L\/_ #R3\J/L\/\ SR3\JDHH C^SP_\
M/)/RH^SP_P#/)/RJ2B@"/[/#_P \D_*C[/#_ ,\D_*I** (_L\/_ #R3\J/L
M\/\ SR3\JDHH C^SP_\ /)/RH^SP_P#/)/RJ2B@"/[/#_P \D_*C[/#_ ,\D
M_*I** (_L\/_ #R3\J/L\/\ SR3\JDHH C^SP_\ /)/RH^SP_P#/)/RJ2B@"
M/[/#_P \D_*C[/#_ ,\D_*I** (_L\/_ #R3\J/L\/\ SR3\JDHH C^SP_\
M/)/RH^SP_P#/)/RJ2B@"/[/#_P \D_*C[/#_ ,\D_*I** (_L\/_ #R3\J/L
M\/\ SR3\JDHH C^SP_\ /)/RH^SP_P#/)/RJ2B@"/[/#_P \D_*C[/#_ ,\D
M_*I** (_L\/_ #R3\J/L\/\ SR3\JDHH C^SP_\ /)/RH^SP_P#/)/RJ2B@"
M/[/#_P \D_*C[/#_ ,\D_*I** (_L\/_ #R3\J/L\/\ SR3\JDHH C^SP_\
M/)/RH^SP_P#/)/RJ2B@"/[/#_P \D_*C[/#_ ,\D_*I** (_L\/_ #R3\J/L
M\/\ SR3\JDHH C^SP_\ /)/RH^SP_P#/)/RJ2B@"/[/#_P \D_*C[/#_ ,\D
M_*I** (_L\/_ #R3\J/L\/\ SR3\JDHH C^SP_\ /)/RH^SP_P#/)/RJ2B@"
M/[/#_P \D_*C[/#_ ,\D_*I** (_L\/_ #R3\J/L\/\ SR3\JDHH C^SP_\
M/)/RJG>Q1ILVHHSGH*T*IW__ "S_ !_I0!8M_P#CVC_W14E1V_\ Q[1_[HJ2
M@ HHHH **** "BBB@#(\3>(;3POH-QJMX&9(@ D:_>D<\*H]R:H^"/%T?C30
MGU2.R>T"SM#Y;N'.0!SD#WK@?%?BS1[CXC/:Z[=&WT_0XR;> QL_VBZ9?OD
M8PH/&>]6?@/JMG)X9N]*64F]BN'N'CVGA&P <].H- '<^,O%47@_1$U&2TEN
MR\Z0)#$P#,S9QC/TK+T/QOJNK:S!8W/@S6-/BDSNN;C&Q, GGZ]*C^).@7OB
M*VTBTL=3L+&:&]6X!NWP6*C VC'S$$YQ7/6VK^)_"'Q+TKP_JNN'6K+54R&D
MA5&C;)&1CI@CZ8- &GJ?Q6,.J:E;:/X=O=6MM,)%Y=0L%2/'7'!SC!_(UJ:A
M\2M&LO!-KXG19IH;LA(+=0!(TG.5/IC!S7'_  CV?\(QXO\ .QYGVN7S<]<;
M#U_6N TWS/\ A#_!WG9^R_\ "02_>Z8_=8_7=^M 'L_A_P"([:EXBBT'6-!O
M-&O[B,RVZSL&$J]>N!@X!_*N[KRGX@?\E:\">3_KO.;=C^YN&?ZUZL.E !11
M3(Y/,WX&-K%: 'UY%\1K^7Q1XYT?P%:NRVS2+/J!4XR/O;?P4$_4BO7#T->(
M^&BTW[1NLM,/F03!,]@%0#]* /8;NYM-#T6:Y<+%:64!?:O 5%'0?@,5\NV7
MB'7;/6[7QE-/<FUDU)B<RL58C#.F,XQM;'_ZJ]A^.&O?V9X-33(V FU*781G
MGRU^9OUVC\:\JO?%_AVX^%EIX6BM+H7]O(L_GL$V&7)+?Q9P02.GI0!]#>)M
M&MO%WA"[L,JZ74&^"3T;&Y&'XXKF/@_XIGUSPS)IM^[-J&E.()"QY9/X3]1@
MK^%3?![7O[9\!6T,C9GT]C:OSR0.4/\ WR0/PKCOA.6C^*WBR"/_ %/[XD#I
MD3\?S- 'N%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8H ^;]#./@?XO/\ T_)_-*M^+O!^F:1\*M'\1V_G_P!LN;=GNFE8L=RYQUX
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M:<4 N"OFW)'>5N3^7 _"@#IJ*** "BBB@ HHHH **** "BBB@ JG?_\ +/\
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M_:K*[D.97M)-@D/J00>?I0!>B\6Z'J^MZMH]@&FOK.W<SS+$-@&,8W]SDX_
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MK^(S^E6H/$7Q#\:GR=+TA/#]B_WKVYRSA?\ 9! R?H/QKU0^7O&=N_WZTX4
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M-K+.WB;4[*[@:-?(6WCVE3WSP.V*W]4T?3];M1:ZE9Q74 <.(Y5R-PZ&KH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-_BW4^BX'>@#;^%?A>[FFN/&VOYDU74<M ''^KC/?';(P!Z*/>O4J15"J%4
M < #M2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 53O\ _EG^
M/]*N53O_ /EG^/\ 2@"Q;_\ 'M'_ +HJ2H[?_CVC_P!T5)0 5@>-7T>/PCJ#
M:^DCZ6%7SUCSN(W#&,<]<5OUE>)+O2;'0+JYUQ$?344><KQ^8",C&5[\XH \
M0^V_!G_GQU'\I/\ &O2_AG-X3FTR^/A.&>*W%P!.)MV2^P8QGVQ7.R>+OA$T
M; V5DP(/ TYLG_QVK'P2N1<:1K2V]OY>G)J#?9"4 8H1G:3WP,=>F<4 >IT4
M44 <#XC\>:G;^+/^$8\-:.FI:C'#YTYEE\M(P>0,_0C\Q5[P-XW/BO[?9WEB
MUAJNGR>7<VY;<!R1D'Z@BJ/C'Q5I_AC5EM](TB*^\57Z;8TBC&[;V,C#G''3
MV[4[X?>$[GPU'J6LZY=QOJ^IOYMT58;(ADG;GIU)R>G04 :OCOQ3-X2T*&]M
MK1;NXFNH[:.%GV[BV>_X52T/7?&MYK$$&J^%8K*R;/F7"W:N4X..!UYP*I_$
M?3['Q#!H=HWB.WTMC>"6!C\QF8?*-G/4$_GBN=B?5O!/Q7T;18M<OM3L-4C_
M 'L=X^]D)+#(].1G\Z -&\^)>N7NI:P/#7A^._T_2&*W-Q)/M+8SG:/P/Y5?
MO_BG90> ;'Q':VC3SWT@@AM-_(ER05)]!C\<CUKG?A+)'#X9\81SD"2*ZE:4
M'L-AZ_D:X'3TDA\&^#[J;*VH\02MD] /W0_FK?K0!Z_HGCW65\6VOAWQ3HD>
MFW-[$9+62*;>K8S\I]^#^->AUY3X^_>_%OP+%#S,LK.V.R;A_@:]6'2@ J"V
MZS?]=6_I4]06W6;_ *ZM_2@">BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHKD/B'XSB\&^'FG3:^H7&8[2+U;^\1Z#K^0[T <G\3-?O/$.L
M6_@#P^VZYN6'VZ53Q&O7:?;'+?@.]>B^&_#]GX8T*VTJQ7$4*_,QZR,?O,?<
MFN3^%O@R70M-EUG5MSZWJ7[R9Y.6C4G.T^YZG\NU>A4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %4[_ /Y9_C_2KE4[_P#Y9_C_ $H
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M8&\.;N&TE"I-ZY&.];-]X$T&_P#"4/AJ2V9;" #R=C8>-A_$#Z\G/KFNEHH
MXOPU\-M+\.ZN-5:[OM0OU0QQ37DN[RUQC"CZ<5VE%% !4%MUF_ZZM_2IZ@MN
MLW_75OZ4 3T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5=1U"
MUTK3KB_O95BMH$,DCGL!7D7@_3[GXE>-9O&6KPD:59OY>GVS\@D'C\NI]6^E
M+XUU*Z^(GC*'P3HTK#3K9]^HW"=,J>1[A>@]6^E>MZ9IMIH^FV^GV,0BMK=
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% &;K7B#2O#UG]JU:^BM82< R'ECZ =3^%>=>,/BWIDV@&T\*W37
M>JWC^1$$C8&//&[D=>P]S[5YO\9-0N[OXBWEO<%A%:(D<"'H%*AB1]237#6M
MW/8W<-W;.R7$#B2-EZA@<B@#ZG^'/@M/!WA]4F ?4KK$EW+U.[L@/H/U.378
MU!92R3V-O-*FR22)69/[I(!(J>@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *IW_P#RS_'^E7*IW_\ RS_'^E %BW_X]H_]T5)4
M=O\ \>T?^Z*DH #7EGB7XJZC:>(;SP_H'AV:^O[>3RS(V2N< \*HSW[D5ZG4
M:0PPL[QQ(C.<NRJ 6/J?6@#QJ?PM\2/'D6SQ!=6>EV)Y$/E*6_(9/YL*]!\$
M>"+3P1IDUI:W,URT\@EEDD &6"A> .@P/>NH'2B@ HHHH \]\2^.=:C\7?\
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M5O0?U/:F>+_&&F^#M(:]OWW2-D06ZGYY6]!Z#U/:O/?"GA'4_'6LCQ?XR4F
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M>>^37044 <?X;^'&B^&M4.IPR7=W>A/+2:[EWF->F%]..*["BB@ J"VZS?\
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MC;:-8M%,HDB=H5!VGD$9;.,5Z%X&N?%ES8W;>+;:*"X$P$ C  *;1D\$]\T
M=71110 4444 %%%% !1110 4444 %06W6;_KJW]*GJ"VZS?]=6_I0!/1110
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M;'1?Y]!7/>!/ -Y<ZA_PEWC!FN-7F/F0P2=(!V)'8^@[?6@!O@;P'?:AJO\
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M=W=U+YL\V, G&  #_/OF@#KJ*** ,_6]&M/$&C7.E7ZNUK<*%D"-M. 0>OU
MK/OO#MG%X(ET"&TFN;1;;R$MUE =P.@W'@?6N@HH XBR^'6G7/@'3/#NM0B1
MK1"RR0MAHG)).UOQQ[XJWX9^'FA^%KZ2^M1<W%ZZ[/M%W+YCJOH/2NLHH X;
M6?A1X;UK5I]0D%Y;R7!W7$=M-L24]RPQWK<O_!VAZCX:C\/SV2C3HE BC0D&
M,CH0?7KS[UNT4 <CX:^'&A>%]1.HVOVJYO-FQ)KN7>47T7@8XKKJ** "H+;K
M-_UU;^E3U!;=9O\ KJW]* )Z*** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HKS_XE:_J>B/IHTZZ: 2B3?@ YQC'7ZUP7_">>)?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=ZC9V*[KJZAA'^VX%>8>(?&+S>*K>\T^3?;67$?.!)G[WX'I^% 'K!8*,D@
M=2:YC6/'6EZ:QA@)O+D''EP\@'W-8<.G^)/&,:7%]=BRTV3YECCZLOT[_C75
M:/X5TK154VUN&F YFD^9O_K?A0,Y<6?BOQ80UW+_ &98-R$&0S#Z=3^.*Z31
MO"&DZ*%>* 2SC_EM*,G\.PK>HH$%%%% !1110 4444 %%%% !1110 5S.O>.
M-+\.Z@ME>)<&4QB0>6F1@Y]_:MF^U;3]-CWWMY# O7YW KQ3Q[K-EKOB(75A
M(9(5A6/<5(R03TS]:Z\)A_:SM):')B\1[*%XO4[_ /X6KH/_ #RO/^_?_P!>
MK5Y\1M"MM.BN5D>669 Z6Z#YQG^]V%>'5[/X#\+:1'H-CJC6JRW<T?F%Y?FV
MD^@Z"NK$X6A0BI.YRX;$UZTG%6,W[5XQ\9'%M'_9.FO_ ,M#D,P^O4_ABMW0
M_A]H^E,)YU-]=]3).,C/J%_QS778Q17#+$2:Y8Z+R.Z.'BGS2U?F(JA5
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MH44JE>I55INXZ6'ITG>"L%%%%8FP4444 %%%% !1110 4444 %%%% !1110
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MSC/L*\^L_#^@76LV]SJEPT-G"J[X(H]QFQT&>W'4UZ__ ,+'L@BQV6EW4BJ
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MI2Q,H+W;G%C,PC!)QA=^:/=-/T?3=++M86<5N9 -QC&-V.E7Z\UT6^\:2:5
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M4J84;+4PPF6*G&U1MOR;1P__  K^>7_CYUZ[DSU S_4T]/AMIO\ RUN[I_\
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M_H"]8)6^LIK%U[X<M/<K+H\D,$2Q8,,A)WMD\Y[<8KO/)F_Y^&_[Y%'DS?\
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M"H6\/Z._WM,M3_VR%6_)F_Y^#_WP*/)F_P"?@_\ ? I<J$Z<'ND43X9T0_\
M,+M?^^*Y[Q-X&MKNS\[2H4@N8Q_JUX$@]/K77^3-_P _!_[X%'DS?\_!_P"^
M14N$6K6,JF%HU(N+BCSSPAX(:9A?ZO"1&#^[MW&"WNP]/:NV7PYHJ]-,M?\
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M^?@_]\"CR9O^?@_]\"@">BH/)F_Y^#_WP*/)F_Y^#_WP* )Z*@\F;_GX/_?
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M8XL;BS9QC/TK'T'XA3ZWK5OI[^&-7LUFSF>XAVHF 3R?PQ0!W%%%% !1110
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M 4444 %%%% !7,^+U\-V,-KK_B!4_P"):^^V=B<AS@@*HZG(%=-7&>// /\
MPG'V /JDEG':%F"+$'#,<<]>V/UH Y;0;36/&OCE/&]Q9/8:=9V[QZ?')_K)
MOE8 GV^8G\A53X8+$WP@\2>;C+277FYZ_P"J'6NMT/P)K&DZQ:WEQXQU&]@A
M8EK:1 $<8(P>??/X5DWWPFNA=ZA%H_B.?3])U)R]U9B+=UZA3Z4 7_@N9#\,
MM.\S.!)+MSZ;S_\ 7KT&L_0]'M?#^BVFE68(M[:,(N[J?4GW)R:T* "BBB@
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M%OQ/YT >A^'2Y\,Z49,[S9P[L^NP5ITV-%BC5$4*J@  =@*=0 4444 %%%%
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J=__P L_P ?Z5<JG?\
M_+/\?Z4 6+?_ (]H_P#=%25';_\ 'M'_ +HJ2@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQ;X5?\E4\9?[
M\G_H\U[37$>$_ 4GAKQ9K6M-?K.NHLQ$0C(*9<MU[]<4 <I\3@/^%K>"./\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M=:J:?I=CI,+PV%K%;1NYD9(EP"QZG%6Z* "BBB@ K(O?"^B:CJD>I7FF6\]Y
M&%"2R+DC'3\JUZ* "BBB@"G>Z58ZC-;2WEI%.]L_F0F1<[&]1[U<HHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)3U;_OHT>2GJW_?1J2B@"/R4]6_[Z-'DIZM_WT:DHH C\E/5O^^C1Y*>K?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !13/.C_OK^='G1_P!]?SH ?13/.C_O
MK^='G1_WU_.@!]%,\Z/^^OYT>='_ 'U_.@!]%,\Z/^^OYT>='_?7\Z 'T4SS
MH_[Z_G1YT?\ ?7\Z 'T4SSH_[Z_G1YT?]]?SH ?13/.C_OK^='G1_P!]?SH
M?13/.C_OK^='G1_WU_.@!]%,\Z/^^OYT>='_ 'U_.@!]%,\Z/^^OYT>='_?7
M\Z 'T4SSH_[Z_G1YT?\ ?7\Z 'T4SSH_[Z_G1YT?]]?SH ?13/.C_OK^='G1
M_P!]?SH ?13/.C_OK^='G1_WU_.@!]%,\Z/^^OYT>='_ 'U_.@!]%,\Z/^^O
MYT>='_?7\Z 'T4SSH_[Z_G1YT?\ ?7\Z 'T4SSH_[Z_G1YT?]]?SH ?13/.C
M_OK^='G1_P!]?SH ?13/.C_OK^='G1_WU_.@!]%,\Z/^^OYT>='_ 'U_.@!]
M%,\Z/^^OYT>='_?7\Z 'T4SSH_[Z_G1YT?\ ?7\Z 'T4SSH_[Z_G1YT?]]?S
MH ?13/.C_OK^='G1_P!]?SH ?13/.C_OK^='G1_WU_.@!]%,\Z/^^OYT>='_
M 'U_.@!]%,\Z/^^OYT>='_?7\Z 'T4SSH_[Z_G1YT?\ ?7\Z 'T4SSH_[Z_G
M1YT?]]?SH ?13/.C_OK^='G1_P!]?SH ?13/.C_OK^='G1_WU_.@!]%,\Z/^
M^OYT>='_ 'U_.@!]%,\Z/^^OYT>='_?7\Z 'T4SSH_[Z_G1YT?\ ?7\Z 'T4
MSSH_[Z_G1YT?]]?SH ?13/.C_OK^='G1_P!]?SH ?13/.C_OK^='G1_WU_.@
M!]%,\Z/^^OYT>='_ 'U_.@!]%,\Z/^^OYT>='_?7\Z 'T4SSH_[Z_G1YT?\
M?7\Z 'T4SSH_[Z_G1YT?]]?SH ?13/.C_OK^='G1_P!]?SH ?13/.C_OK^='
MG1_WU_.@!]%,\Z/^^OYT>='_ 'U_.@!]%,\Z/^^OYT>='_?7\Z 'T4SSH_[Z
M_G1YT?\ ?7\Z 'T4SSH_[Z_G1YT?]]?SH ?13/.C_OK^='G1_P!]?SH ?13/
M.C_OK^='G1_WU_.@!]%,\Z/^^OYT>='_ 'U_.@!]%,\Z/^^OYT>=%_ST7\Z
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M%$F<F-RN?[I=L5VE !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MF\-^#](\*VDT&G0L3.<SRRMO>4_[1_/B@#RV*^M?^&9W0R(6V&+;GG?YV?\
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MO6T=D>E1_AQ]$%%%%,T"BBB@ KB_$O@R\\0:J;LW\<<2H$CC*D[1W_,UVE%
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M,$,=M!'!$@2*-0B*.@ & *DH \FTOX>^*M"O-9LM-OM-73]3=V:[E0M.@;/
M'KS_ %J6V^&&HK\*KKPG+=VPNGNOM$<JY*'D'!XR.AKU2B@#S#6/ GB/7] \
M.VM]=V NM+NQ([)N"M&-H4#CK@5NCPE>?\+6;Q5YT/V0V/V;R^=^[U],5V5%
M '%Z1X0O-/\ B;K7B:2>%K6^@$4<:YWJ1LZ_]\FNTHHH **** "BBB@ HHHH
M **** "BBB@ JG?_ /+/\?Z5<JG?_P#+/\?Z4 6+?_CVC_W14E1V_P#Q[1_[
MHJ2@#*\1Z==:MX>O;"QNS:74T>V*<$C8V0<\<]J\Q;5?B5X(3.HI::S81\F3
MS 'V_7@_F*]&\3S7-QX>U.VT>^A@U,18C<R >6<CDYZ5YMI_POL;V5;GQ7XL
M;493RT27'RY^I/\ (4 =YX&\;VOC?3KBYMK:6W>W<1R)(0>2,\$5U58OAO1]
M#T6R>WT*&".$L#)Y3;BS8ZD^N*VJ "BBB@ HHHH **** "BBB@ ILG^J?_=-
M.ILG^J?_ '30 RV_X]8?]Q?Y5+45M_QZP_[B_P JEH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *\Y^+?B?2++PCJ6BS7:?VC=P@1P+R
MWW@<GT''>O1J^./%-U=7GBO5I[TL;AKN0/NZC#$ ?@ !0!]#_";Q%I>H>#=-
MTJWNT:^L[<+- >&7D\X[CWKT"OCKPIJ&IZ9XHL+K2(S+?))B.(9_>9!RI]B*
M^DOAKXQNO&F@7-]>6T<$L%T8,1L2"-JMGG_>H T_&_\ R)NH_P"XO_H:U-X1
M_P"13TS_ *X+7.?$G6A!91:3$W[R?YY?9 >!^)_E61X=\<76GZ5%8+IS71MU
M.&5NBYXR,=J0[:'JE%8WAK7E\0Z6;P0&$K(8RI.>1C_&MFF(**** "BBB@#S
MOQ]_R-WA?_KO_P"SK7HE>=^/O^1N\+_]=_\ V=:]$KIK?PX>C_,YJ/\ $GZK
M\@HHHKF.D**** "BBB@ HHHH *YSQW_R*%[_ , _]"%='7.>._\ D4+W_@'_
M *$*F?PLY\5_ GZ,N^%_^18T[_K@M:U9'A?_ )%C3?\ K@M:]..R+H_PX^B"
MBBBF:A112,=JD^@SQ0 M0O=V\;E'GC5AU!8 BN'?XHVJNR_V/?G!(SM'^->9
M^)-3&K>(;R_2.2%9G!$;GE<*!S^5=M#!3J2M+1'%7QL*<;QU/H,7ELS!5N(B
M3P ''-3U\UZ7=FSU:SNF#N(9DD*J>3@YP*]4_P"%IVH_Y@U_^0_QIU\#.FTH
MZBH8Z$TW+0[\D $G@"N9\.^/M!\4:G<:?IER\D\"EV#(5!4-@D$]>:J?$'Q*
M-'^'5YJ46Z.:YA$4 88(:08_, D_A7DFEQ6O@36?!.L07,3+=0^5J(20-M+G
M)R.V%9?^^*X3N6I[IJGBC3-'U?3=+O)62ZU%]ENH0D,<@<GMU%;->4_$8Y^)
M_@$@_P#+R?\ T-*J+?\ B[Q#\1_$N@:=KGV*SMB&\QHPQB7C"K[DGOZ4 >KZ
MC?P:7IUQ?W3%8+>-I9& SA0,FHM%UBSU_2+?4[!R]K."8V*D$X)'0^XKR2R\
M1:X^D>.?"FOW"W=SIMC*\=P!@LN,<_F#^-9&FQ>+=.^$=MXCL=?^RVMDN8;-
M(P0R>9@EB>IR2<>E 'T#17E_B#Q)K=WX*\.7]OJUEHZ7T227MU*P#*"HX13U
MZD_E69X$\7:E)\1/[ .NOK.F2VS2)/+#L8,!GCV[4 >K:MJEMHNDW.I7C,MO
M;(9)"HR0![5Q:?&;P>[#-U<*I_B:W; _2MGXC_\ ).M>_P"O1OZ5E_#G2=.O
MOA?HZ75E;RB6W97+Q@E@68=: .QTW4[/5["*^L+A)[:4921#D&K=>$?#R_U3
M3?!GC"WT>>!#:7H%K-<R!8XP20S9/'10?J:JGQMJ^AZKH\EMXO\ [:-Q.J7D
M'DCRUR1D*V.>IZ4 >I^(?B1X?\,ZL=,U&6=;D1K)M2%F&#TY%+H'Q)\->(]0
M6PLKUA=/]R*6,H6^F>M>>>+=4&C?'07C:9+J073@OV:) S'(/.#Z55&HP^,?
MBUX=":7_ &$]G^]*S*$DFP=P  ^A'YT =[>_%[PK87MQ:SSW*RP2-$_^CMC<
M#@\X]JO>'_B1X?\ $VJIING2SM<.C. \+*,#KR:Y_P"-UI;1?#Z::.WB20W4
M675 "<DYYKLO"5G;1^%]'F2WA64V,.75 #R@SS0!NT444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !5.__ .6?X_TJY5.__P"6?X_TH L6_P#Q[1_[
MHJ2H[?\ X]H_]T5)0!YYXC\&:%IL/B?Q!?W=VL6HV^R[V8.Q=RG*C\!7)Z-\
M,_ 7B!-^F>([B<XR4$BAA]0>:]>UZ?3;;0[R;6!&=.2,F<2+N7;[CO7SYX@G
M\$7]T5\(Z1JQO\_))9DJH/T/- 'MW@WP58^"[2ZM[&>>9;B02,92"00,<8KI
MJX+X5VOBFTT&X3Q,TY8R VRSL"ZIMYSWZ^M=[0 4444 9>M>(])\.P)-JM]#
M:HY(3S&Y8^PI=&\0Z5XAMFN-*OH;J-#AC&V=I]QVKS#XG3P6?Q*\-WAM!JTB
M0NITM5W,1DX<#IU_]!K$\.:@(;KXA:O;0_V5="Q8III!5H^/OD=.#_.@#U<_
M$'PJNI_V>=:M?M._9MW\;NF,]*T-9\2Z/X?2)M5U""U\T_()&P6^@KQN+P[I
MK?LZ27_V6+[9@W'GE1OW"7'7KTXK3@TS6[R/P[XJAT:'74ET5+62VG< QO\
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M_#O_ )$?3_\ MI_Z&U<TJDIT'S.^OZ'3&$85[15M#J****Y3J"BBB@ HHHH
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M(Y_A4#)-1:3JMGK>F0:CI\PFM9@3'(!C.#C^8KR:U\4ZW>:'XW\,>(6CEO\
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M"\"VAF<*B[B0S9)Q@!<_C43>/O$&A:MI!D\3V.M"ZF5+JUAC&(<D C</K^E
M'J.N?$#PWX=U(Z?JFH""Y"!RFQCP>G04[1/'WAKQ%>BSTW4XI;@C(C(*L?H#
MUKS/QAJ=GI'QR%W?Z?)?VZZ<%,"1"0DD'!P?2JD=[IWB[XL>'O['TTZ,;0^;
M+YJ")I0#NP%'4XR/Q- 'I-U\5/!]E=S6MQJH2:&1HW7RFX8'!'3U%7-$^(/A
MKQ%J2Z?IFH>?<LI<)Y;#@=>HKDOC7I=A;> IKJ"RMX[AKN,M*D8#').>>M=E
MX0TK3[?PWH]U#8V\=PUE$3*D8#'*#//7F@#HJ*S-:\0Z5X>@BFU6]BM8Y7V(
MTAP"<9Q7GOA+XIV,VI:\NN:U;);I>;; D;=T7/(]>U 'JM<MKWQ$\,^'+TV=
M_J*BY'WHHU+LOUQTK?OKHP:7<W47S&.!I%]\*2*\G^"VC6.K:+J6O:E!%>7]
MU=LCR3J'(& 3U]230!Z7I/B?1]<TV74--OH[BWB!,A7JF!GD=1Q4FA>(--\2
M:=]OTNX\^VWF/?M(^8=>OUKG+7P5IWAC4M;UK2YWB^U6S[[, >4"!D$#Z@_F
M:XG2/&^KZ?\ !2?6[>"!KTWS0*8X0J1@X^8JO'']10![917COA;Q-X@O=;TW
M[)XHL-;MYR/MEJZK#)$.Y4'DXS^E3#7?&>N_$'Q%X=TG4;>V@M6#+-+%GR5X
MX'J23^E 'JM[>0:?8SWERX2""-I)'/\ "H&2:KZ/K%CKVF1:CITXFM9<[) ,
M9P<']17EFG>*M;O-%\;^&?$+1RZAIMC,PG08WKM(Z?B"#[TWPYJ6M:=\$M(?
M0VMHIWE=9+BY<*L*;VRW)Y- 'LE4[?5;"ZOKBR@NX9+FWQYT2L"T?U':O(M!
M\;ZS;^/=-T23Q%::[9WP*O+#%M\IL'&#WY%,\ V6MK\7?$:R:G"SP2*;YA%C
M[0.P']WM0!ZMH?B32_$<5Q)I=SYZV\IAE.TC:XYQS6M7C7A?Q3J8^'GC+4T:
MWCNK&Y<0M% J 8 Y('4U3O/$7CZ/P#:>,CJ]K'  H^RB'EP6V[F/N>P[4 >X
MT5GZ%J#:MH&GZBZ!&NK:.8J.@+*"16A0 53O_P#EG^/]*N53O_\ EG^/]* +
M%O\ \>T?^Z*DJ.W_ ./:/_=%24 9VO'2QH=V=:\K^S?+_P!(\T_+MSW_ $KS
MF27X.M&P8Z3C'.USG^==%XL\6>'AJD'@_4(Y+R?4F2&6&/HBL1@L>WK7G7C#
M_A7_ (9UYM'M_"TFH742AIO+F8!,C..O)QS^- '3?!2>U>V\16^GQ?Z!#?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQWQ7_P"11C_Z^D_DU=CI_P#R#K;_ *Y)_P"@BE+^#'U?Z!#^-+T19HHHK Z
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M^XO\JEJ*V_X]8?\ <7^52T %%%% !1110 4444 %%%% !1110 4444 %%%%
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M..#6%-5$CR<%3QE.F[M)>9?TS5+75[075G)OB+%<XQR*NUR'PW_Y%7_MN_\
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M.?Q.: .TILG^J?\ W33J;)_JG_W30 RV_P"/6'_<7^52U%;?\>L/^XO\JEH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y
M:\??#_5O#VOW4D-G+/IT\K2031J6 #'.TXZ$5!\.](D?XE:%;WT$L/[W[0JN
MI4MM#,#SVROZ5]5D ]:\EUW_ ).,\/\ _7A_2:@#UNL/Q9J,^G:#.UK&[W,O
M[J/8I.">I_ 9K<HH ^?O[-OO^?.X_P"_9K9EMK>.QT*5;-K>[^U>7/N!&_!7
M!Y^M>T5PGQ$_X_-!_P"OG^JT#N=W1110(**** "LWQ#_ ,BWJ?\ UZR?^@FM
M*J6KVTEYHU[;1 &26!T4$]R"!51TDB9_"SYK X'TK9\+:M%H7B&WU&6)Y$B#
MY5.IRI%;(^&7B/ _<P?]_12GP-K.C6MY?7D40@CM9=Q5P3RN!Q7T,Z]&<7'F
MW/GX4*T)*5MCU_1M5@UO2;?4+<,L4P)"N.1@X(_2K]<O\//^1'T[Z/\ ^AFN
MHKY^I%1FXKHSWZ4G*";"BBBH+"BBB@ HHHH *JZE_P @R[_ZXO\ R-6JJZE_
MR#+O_KB_\C2>Q,_A9S7PV_Y%7_MN_P#(5U]<A\-O^15_[;O_ "%=?4T_@1A@
M_P"!#T"BBBK.D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JG?_ /+/\?Z5<JG?
M_P#+/\?Z4 6+?_CVC_W14E1V_P#Q[1_[HJ2@#S3XC_#J_P#%$L^I6.J2I*ML
M(TLMVV.0@D\G.!U].U<M;?"Z%;6%;CQV]O,(U\R%9LB-L<J/GZ#I7IGQ%^V_
M\*^UK^SRPN?LYQL.#MR-V/?&:\U\-?"?PGK/AVQU"76IGFGA5Y=DB@*Q&2N#
MSP>* /0/AYX6T_POI]['9:I_:4MQ,))Y\@\XP!U-=E7+>"?!^E>#[2[@TNZD
MG2XD#N7<-@@8[5U- !1110 4444 %%%% !1110 4V3_5/_NFG4V3_5/_ +IH
M 9;?\>L/^XO\JEJ*V_X]8?\ <7^52T %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5Y)KO_ "<9X?\ ^O#^DU=QXW\51>#_
M  S/JCQ^;+D1P1YQOD/0?3J?PKYHNO'>NW?BN'Q))<1C4(!LB(C^55Y^7'I\
MQ_.@#ZZHKDOA[XR7QIX=^VM$(KN%_*N(UZ!L9!'L0:ZV@ KA/B)_Q^:#_P!?
M/]5KNZ\^^(MS"NI:)$7 >.7S'']U=R\_H: 1Z#12 @C(.12T %%%% !1110
M5A^,?^1.U7_KW:MRL/QE_P B=JO_ %[M5T_C7J14^!^A4^'O_(CZ=]'_ /0S
M73US'P]_Y$?3O]U__0S73U5?^)+U9-#^''T"BBBLC4**** "BBB@ JKJ7_(,
MN_\ KB_\C5JN#\<>+6L_,TFRR)V7$TA'W01T'O4SDHJ[.?$UH4:3E,N_#?\
MY%4?]=W_ *5U]>1>#_%G]A,;2Z!:R=MV5'*-Z^XKT?1O$-AKOG"RD9C%C<&4
MC&>G\JSI33BD<V7XJG.E&">O8UJ***V/1"BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "J=_P#\L_Q_I5RJ=_\ \L_Q_I0!8M_^/:/_ '14
ME1V__'M'_NBI* ,_7=5M=#T.\U.]R;>VB+N ,DCT_'I7DNDZ#H'BKPEJGBD^
M$!#<1/(UM:1R,!<!5!!P/4DCCTKTKQOH<OB/P;J>E6[!9YXL1Y.!N!# 'ZXQ
M7EVE_$GQ/X8TNWT.]\)S27%G&($=05!"C XQ_*@#T#X<>(M*U[PZ8],L!I_V
M-_*FL\?ZMNOXYYYKL:\Y^%.B:O:)K6N:U;_9KK6+D3"#&-HY.<=LEOTKT:@
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M HHHH **** "BBB@ HHHH **** "J=__ ,L_Q_I5RJ=__P L_P ?Z4 6+?\
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M\ ?\A7Q#_P!?/_LSUW5<#\/YXFUC7T#J6>;>HSU7<W/ZBN^H&PHHHH$%%%%
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MW_'K#_N+_*I:BMO^/6'_ '%_E4M !1110 4444 %%%% !1110 4444 %%%%
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MIIU-D_U3_P"Z: &6W_'K#_N+_*I:BMO^/6'_ '%_E4M !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!D^*/\
MD4=:_P"O&?\ ]%M7'_!#_DFUO_U\S?\ H5=5XQO+:S\(:L;F>.(/9S(F]L;F
M*' 'O7'_  /N[=O ,5J)XS<)/*S1;OF )X.* /3**** "BBB@#A(?^2NS_\
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M@,@TG0_L QE+?S=_X9Q7JE3B*4Z<WS+<K#U8U(+EZ!11FBL#<**,T4 %%%%
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J=__P L_P ?Z5<JG?\
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MR <G_&O2(I4FB62-@R,,AAT(K.#3;.'"3C*I4L^OZ#Z***T.X**** "BBB@
MHHHH **@O+R"QM7N;B18XD&68USN@^-K+6;^2T*&!]W[G<?]8/\ 'VJ7))V9
ME.M3A)0D]6=31115&H4444 %%%% !1110 4444 %%%% !1110 53O_\ EG^/
M]*N53O\ _EG^/]* +%O_ ,>T?^Z*DJ.W_P"/:/\ W14E ' ^/_'>AZ,5T"\M
M&U*XNPJO:IT"L1C<?UQ5;Q?H'@SPEH1U:;PQ#<1I,D;I'G(#'&>O:N;T:XT^
MP^//B Z\8TEE_P"/)Y_N@G;C!/?;T_&O6-2U#1X]-F?4+FT-H%)D\QE*D?2@
M"EX-O]!U'P[!/X=CBBLLD>5&NTHW<,/6N@KR'X'[7F\436:LFEO>C[,K=A\W
M_LI6O7J "BBB@#.U^SEU#P]J5E  9KBUDB0$X&YE(%<QX*\(W.F_#7_A&]81
M!)*L\<H1MP"N3W^AKN** /$O^$,\>+X2;P0(+,Z89O\ C^\WGR]^[&WZ\UZU
M9V7]A>'(;*RB,YL[81Q)G!D*K@#VR:TZ* /-]8\":E?^!/LXDBDUN6]34KGS
M#\DTH.3&3_= PH^E6O!WAW68_%NH^)-7L[73WGMDMH[2V(((!SN..,UWU% !
M39/]4_\ NFG4V3_5/_NF@!EM_P >L/\ N+_*I:BMO^/6'_<7^52T %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% 'SK\7_ !QJ5YXEN] M;B2"PM,1R*AP97P"<GTYQBN2\&>-M3\(:K!+;SNU
MB7'GVQ/R.I/.!V/O7H/Q5^&>J7>OS:]HMNUU'=8:>%/OHX&,@=P<"N9\(?"C
M7M9UB#^TK*6RT]'#3/,,%@#]U1ZGI0![&/B]X+_Z"P_[]FC_ (6]X+_Z"P_[
M]FM?_A _"O\ T K+_OW1_P ('X5_Z 5E_P!^Z *-A\4/"6I7\%E;:HK3SN(X
MU*$98]!FNPKQ/X@Z'I>B>/O!:Z;8PVJRW8+B)<;L2)C->V4 %5K^]BTZPGO)
MSB.%"[?X59K@OB+=7DT4&F6EO,Z-^]F9%)!]%_K^5 &7X$\16.G3:DM]*L N
M'$JLQX[Y'ZUVG_"9>'_^@G#^=>00:;?Q3QR-ITTBJP)0QG##TKUNU\+^'KJU
MBG72HU$B!@K9!&>QYH&R3_A,M _Z"<'YT?\ "9:!_P!!.#\Z=_PB&@?] R+\
MS_C1_P (AH'_ $#(OS/^- #?^$R\/_\ 03@_.MBVN8;RWCN+>19(I!N5UZ$5
MR/BGPSHUEX9O[FVL(XYHX\JXSD'(K5\&?\BAIO\ UR/_ *$:!&]1110 4444
M %>*>*_"VMWGBK4KFWTV>2&28LCJ.","O:Z*WP^(E0DY11A7H1K146SY\/@W
MQ%C_ )!-S_WS7ML'A[2?(CW:;;;MHSF,=<5K45=?%SK6OI8BAA(4;VUN<[KF
MA:5%H.H21Z=;*ZVTA5A&,@[36=\+_P#D2XO^N\G\ZZ+Q!_R+NI?]>LG_ *":
MYWX7_P#(EQ?]=Y/YTE)N@[]T-I*NK=F=G1117,=(4444 %%%% !6;KMG=7^D
M7%M9W!@G=<*X_E[9K2HI-75B914HN+ZGS]<65S:WC6DT3+.K;2F.2?ZUWNE^
M$/$(TZ'_ (G$EH",B$$G9[5V\NE64]_%?26\;7,0PDA'(J[6,**3U/+P^51I
M2;D[]NAP_P#PB/B'_H8I/UH_X1'Q#_T,<GZUW%%:>S1U_4J7G][.'_X1'Q#_
M -#')^M'_"(^(?\ H8Y/UKN**/9H/J5+S^]G#_\ "(^(?^ACD_6C_A$?$/\
MT,<GZUW%%'LT'U*EY_>SA_\ A$?$/_0QR?K1_P (CXA_Z&.3]:[BBCV:#ZE2
M\_O9YCX@\*:]%IC2R:E)?QQG<T63D#UQWKD])TZ\U348[>Q5O-SG<.-GN3VK
MWDC-5++2K+3Y)I+6W2)IFW.5'4UG*@F[G'6RJ,ZJFGIU);.*6"SABGE,TJ(
MTA&-Q]:GHHK<]9*RL%%%% PHHHH **** "BBB@ HHHH **** "J=_P#\L_Q_
MI5RJ=_\ \L_Q_I0!8M_^/:/_ '14E1V__'M'_NBI* .2\8_#W1O&:H]XKPW<
M:[4N8OO >A]17&1? :R,P%UKMY+ #GRPN,C\Z]@HH SM$T33_#VEQ:=IL AM
MX^0!R2>Y)[FM&BB@ HHHH **** "BBB@ HHHH *;)_JG_P!TTZFR?ZI_]TT
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MT!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 53O\ _EG^/]*N53O_ /EG^/\ 2@"Q;_\
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M*@^RC_GK+_WU1]E'_/67_OJ@">BH/LH_YZR_]]4?91_SUE_[ZH GHJ#[*/\
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MIX<$GAV";RVG,F'*YQG'XBO5-.OX-4TVVO[9MT%Q$LJ'V(S0!9HHHH ****
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M::.W@DFF=4CC4L[,<  =37G?@_XF3>*_&ESI"6"PV:PO/!*2=SH"H4D>X.:
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M??.GERRVK[?,7&.:W/#/AK3_  IHZ:;IR,(@2[LQRSL>K$T ;%%%% !1110
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M_$OQ$TSPSJFGV-Q;W$YOHC+$\ # CH!CJ2>,?6H/#/Q(M=?\02:'<Z;=Z=J
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M'YT;E]1^= "T4FY?4?G1N7U'YT +12;E]1^=&Y?4?G0 M%)N7U'YT;E]1^=
M"T4FY?4?G1N7U'YT +12;E]1^=&Y?4?G0 M%)N7U'YT;E]1^= "T4FY?4?G1
MN7U'YT +12;E]1^=&Y?4?G0 M%)N7U'YT;E]1^= "T4FY?4?G1N7U'YT +12
M;E]1^=&Y?4?G0 M%)N7U'YT;E]1^= "T4FY?4?G1N7U'YT +12;E]1^=&Y?4
M?G0 M%)N7U'YT;E]1^= "T4FY?4?G1N7U'YT +12;E]1^=&Y?4?G0 M%)N7U
M'YT;E]1^= "T4FY?4?G1N7U'YT +12;E]1^=&Y?4?G0 M%)N7U'YT;E]1^=
M"T4FY?4?G1N7U'YT +12;E]1^=&Y?4?G0 M%)N7U'YT;E]1^= "T4FY?4?G1
MN7U'YT +12;E]1^=&Y?4?G0 M%)N7U'YT;E]1^= "T4FY?4?G1N7U'YT +12
M;E]1^=&Y?4?G0 M%)N7U'YT;E]1^= "T4FY?4?G1N7U'YT +12;E]1^=&Y?4
M?G0 M%)N7U'YT;E]1^= "T4FY?4?G1N7U'YT +12;E]1^=&Y?4?G0 M%)N7U
M'YT;E]1^= "T4FY?4?G1N7U'YT +12;E]1^=&Y?4?G0 M%)N7U'YT;E]1^=
M"T4FY?4?G1N7U'YT +12;E]1^=&Y?4?G0 M%)N7U'YT;E]1^= "U3O\ _EG^
M/]*M[E_O#\ZIW[ ^7R._]* *2]!3J**8@HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
(F/U%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>drts-20211231x20f019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 drts-20211231x20f019.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0# A # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#WZBBB@ HH
MHH *9+*D,+RR,%1%+,Q[ #)I]<%\7]?&B> KJ-)"MQ?D6L>#S@\N?^^0?SH
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M] *-PL5;W4[6Q4F>4+CG!->0>,?$L.J7K6[3,(2>,=*9XQU.ZN=58AV\I&Y
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M;3[@^E>"_#[3HK;7+::>5!([_*F>:][7[H^E:II['G8Z2E),6BBBF<(4444
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MKSG6K)K4ID/\Q.":=IEQ':O\CLW<C%>CK;:=XST$B/:L]NO>D_W$N9ZIF/\
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MHS\K4_3[#:TLJLKA?>M.57O(5XWL=+\//,O/'5H\Q88?CGCK7TPGW!]*^;_
M"+:>+;%V;]Y(_"?C7TBOW1]*3=SRL8[S%HHHH.0**** "BBB@ HHHH ****
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MIYS]!GFO5E^Z/I3C-2O8\_%N\DQ:***LY HHHH **** "BBB@ HHHH ****
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MFC5E(P>*\EUSPK-I.KM=VZ$H#E2.U:T:\:J<)D64WYG7:CXUM1I$S9VSA?\
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MT'39SU6L_9S[$^UAW*1QCV]:P?$/A^WUJS==@\T#*MCO75G3)R,%::NE3(I
M7K3C&I%W2&JT5U/G%K:_T'Q"MO<,VUVV@'N*M>*/#EU:E-2&3'PRBO3?&W@G
M4=5N+6YLH 98V&3CM3/$?AC7M3T:"SAMOF51N;TXKT%4FW%V]355H/=GF5F\
MVIQ_:'8Q2Q?='2NP\(:_<:D[V-Q)A@"H-58/ASXG$#!H=IYQ5SP_\.?$%C?_
M &F9-I!SUZT5(<T7^!LZU*UKF/XGT^<7)M&N#MR>6]ZPK6Q&DM@RI(6.5P:[
MSQ+X/\4:Q, EJ%4'D^HK%M_A5X@CO$D9"0/4]*=.ZA9D^VI[IG*:G>+>[XI6
MV,".*QHK-?-;S"53/7VKTFX^$NL3WQF>,\]ZIW/PI\2M*WEP_)VK>,E:R9DZ
MM.]VRO;ZQH]KI(LQ%ORO+8K#N)K=+A/(MOD)^\173V'PL\012[9K8E2>:Z&/
MX6WW]E.'7,V?D'I6=HQ8G5AW.&.K)):RV)A"%P KXK#EQ!=Q13J'&<9'>NUD
M^&GBACC[-P#Q2'X9^)F*NUH&=#E:M))%*M"VYS.K11VT]NZ1#&T'&*R=05;F
MY'E(=Y'.*]7U#X?:S>Z1%']DVW0ZMCI6);_"[Q1'=Y\D;1W]:(2[C]M3M:YP
M46Q 8ADN!@T\2S,\4%J2L@YQ78R?"GQ/'/(ZVV=QR,4^Q^%WB>*83/:G>#5N
M2W,W6A:R9PWE3M*\D[?/_=-5Y\!QO'0=*] OOA;XFN[CS?LK+GT[55F^$OBE
M2P6U+Y[T*2W9E*I#N<7I]_+:R^6APKG%&IRR/<&,G('.:ZT?"7Q9G/V(C%68
M_A+XFEN$,]LP7^(TDU>YESKN<MI<Z)H=Y$RC?)@+GZBH+)5$/V>=,%FKM9?A
M+XC,C(MNWE#[M.LOA7XFC9O,MB1_"30K=RN:%MSG+6ZTVS1YFP[@%54]JG\(
MZ1<ZQXA\V$80/O)K67X1>(S,6:V)7.<5Z+X"\$7^B0S-=0['8\ UG4ERQ;CJ
MRXU(K=F?XX\-)?Z;%-_% !N-4/"WA^SNIHIU >&)?UKT76=$N[O2KB"),NZ$
M 5F^$?"U[I&D"":/$FXDUP1=3V5NIHJT>YYC\1;3^R]226R387Y.*?X9DFU*
M>""5MS\$_2NH\:>#=<US4 8+<F)>,TO@;P+J^D7[37L)'IFNA)^QUW*CB(I;
MG:6UN+>!(Q_",5.!5L:=<?W:7^SI_P"[7![.;=VC)U8MWN4P,T8JY_9T_P#=
MH.G3^E"IS[#]K#N<CK_A\ZC,ES"^R>/D$5PNHW6LS22V$\S*J<9]:]F.G7!_
MAKSKQ;X1\1W^J&2PAPA')%=-!3O:2*C5I]69?A32Q'"Z7DF^)N@S1!$!XQ@2
MW^9%].W6M"P\)>)K6W$;0\GJ<U/X9\'Z_8:XT]Q#^Z)SN-:\LKMLN=6E;1G<
M#..1@T_O5@:?/_=I?[/N/[M</LY]C#VD;;C;/_CY2M\=*R+:SFBF5B.E:PZ5
MV8:+C&S.2O)2EH+111728!1110 4444 %%%% !2$@=32UXI\8[B^;QMX=T^U
MU">TCNH_+9HW*@9E R?IF@#VK(]12UX/XE\$ZIX8T&ZUB#QO/+):KO6,RX+\
M]!SUKT_X=:U>Z_X&T[4-1&;EU96?&-^UB WXXH ZF@]**:_W#]*3T B::)#\
MTB@^YH\^$<F11WZUYQXJMKQ\S0W3H$.< UCRP7EUIJ3K?R@JOS8:L%B(O<[X
MX%N/-<]@6XA8X$J$_P"]3C(F?OCVYKYWTJ?7%U.2>*[FEB@/*YKMO#VNW6MZ
MB[LSI'%\I&>]5.KRWL2\$UNSU(NO]X?G33<Q#@RH/^!5SC2R%2#(?2O-O&<>
MH1ZS##:7LJ&8C@&HIXA2=GH)82[M<]K^U0?\]D_[ZH^UV_3SX_\ OJO!M0TC
M7[&V\S[=*X YPQKF_P"T-4&%-[,'+8.6K:-2,MC1X%]SZ@6>)_N2*WT-.WKZ
MC\Z\=\(IK%@ZRWL\CQ.."37=QS22'(<X^M8SQ$8NR(>#:ZG3[U]12%@3]X5S
MS2R ??/YTWSI,_ZPU'UM=B/JK[G1;E!Z@4%A_> KFGN)%&3(1]:JS:DL:[FN
M,#ZT?6D]D5]4?<ZYI$7EG 'N::+J ])D_.O'/&GBO-@L-G>,),X.TUP]CJ>N
MRR*D5U.Y8\8)KHC-RAS6L.&#ONSZ<$\1Y\U/SIV]&&0P(]0:^?K?4]8MIOLU
MY-,N\\,:[_POJ4L]DT3SLSQ-@D]Q4RJ\JN.>"Y=F>A-(BC+.![DTU)HI,[9%
M/T-<?JL;W5E(OVEHSMZ@]*YCPO=FSN)X7U!I6!. 36:Q*DKI"6#TO<]9,J*,
MLZ@#KS2++&PR)%/T-<-<K<:E;,!*\8;@8/-<1?7&N^%)#/\ :GFMW..3TJJ=
M=3T$\(TKW/<=P]1^=+N4?Q?K7G7AK6-0U"U\ZZ;"N,K6\LTI/+GZU$L3RNS0
MEA7W.GW+_>%(&'K^M<Z)G_YZ&D\Z3_GH:7UM=@^JON=)N7^\*-P_O"N<$LA_
MY:&J.KZP-,LI+F64C:.*:Q5W9(3PK74Z]IHD&7D4#W--%S >DR'_ (%7B>GW
MNJ>,[ARMX\,,9.-IKHX?#,\,)3^T)BV.#NK25>,-'N5'"-[L]*^TPD[?-3/U
MI^]<9W _C7@VL0ZOX?U"*X>\F>W)Y.37H6B:M_:.GQS1REN.>:4JZ24EJ-X-
MKJ=MN'3-+N'J*YSS9<?>/YU#=33BW<QN=^..:A8I=B?JK[G4;Q@'</SIOG1D
M[=ZY'O7E,/C2XAD>SF1VN 2% K5T&&]+37EW)(&D;*H3TJW7Y5=H;PC74]!:
M6-1\SJ ?4TX,,=1^=<-KY<V#2B9E,?S<&KNFW;SZ=!)YC$%0>3[5'UKW;V%]
M5?<ZT$>H_.C</45S@FD_OFE\Z0])&I?6U>U@^JON=&&&.HI=R^HKF_/E_P">
MAIWG28_UAI_6UV%]5\SHMZ^HHW+ZBN<\Z3O(://D_P">AI?6UV#ZJ^YT3,,=
M13=P]:Y_SI/^>AI#-(<X<T?6UV#ZJ^YT.Y?[P_.F^=$3CS%SZ9KD=8U0Z=IT
MURSM\JG@5PN@)J^O-)?K?2( QVKFM(UTTVQ_5>ESVO<O]X8H61#P'!_&O/&U
M?4=-LV^U([%1C<*F\.W-Q<VINY)7/FG(&>E2\2DF[#>$:ZG>F6,'EP/QI]<;
MJ"33B/;,P*N.AKL(_P#5K]!6M*I[17,*M/D'4445J9!1110 4444 %%%% !7
MAGQGM4OO'_A>TD=D2=/+9E."H:4#(KW.N*\:?#BQ\::A:7EU>W%O);1F-?)
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M[#6M1?61;7<+(C@XS6*IO4BQUW!I,8-(ORCF@M4"'T8IJR*PX(/TI21@Y.*
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M+!X-LYU>YG7;+*<D>E87B;P2%MO,@QM09.*T(6UME>XD+"-.U*-1U+5E>T7
M0C!8T+GO?F+46O-'G^@VJIXALE53\LHY_&OJ:'_4I_NBOG"WM9-$\5VMO)AM
MT@.?QKZ0A_U*?[HKMAKJ>?CYJ3C8?1115GG!1110 4444 %%%% !1110 444
M4 %1S_ZB3']TU)45Q_Q[2?[IH''<^6-0O)+C6;N-]S$RL,^G)I;6-[99 R.5
MDX!Q6U:Z;)_;5Q(UMD&=B7;TR:[BSM=&8,7:(D<G/8URSJ<KT1]#[2/(D<GI
M.DP6-C)/>PMLE'RG'2HE\0VVEV[PV:DY'6NE\0ZQICZ<UK$Z]/X:\KE(W.L>
M3SQ3I1YTW(UHKFU9K06=SK5T9%'?)-=9!>VFBV(BAD!N.G'K7-&>YTWPVDB-
MY<LAQ^%,M-'N;BP&H.S_ "\D^M4TFKMZ%RGS/EZ(VH;.]UK4%6Z0[6/)]J[_
M $OP_8V%N$2)3]13/#D$/]FQ,HW$CJ>M;FWCCK7'4FWHCEJSO[IQ?B#3]0MY
ME_LV1E1CR.U4K?PKJUP3)->,I/->@^6K]1G%.VC' Q0JTTK(SYE:QR.E^$UM
M99)+R3SF<8YK,8#PYXF2*&']U/CI7?D #)%8+6\&I:X)3AA;CCZT1FV_>%>Z
ML;H)V BH7O(8Y1$[ ,>@-3J?E Q^%<;XLLKZXU"UDM%)"=<5$8J3M>Q.I-XK
M7[;$+&! \K_I7 FRU'POJ"RO&1&2,L*]&TC2KO[6U[>M\Q "KZ5JZEI-OJ5J
M\$Z Y'6MXU53?*MBM#DY]8:_2V:S<$\%C6U+%]I,4H8AE'('>N+O?"-[HK27
M5O,QA3)VBJ>F>-C:3&*Y)8'M5NES*],N+T.];4HW21)EV%<@$UE^#[E'U2ZC
M*\G."*YCQ#XIMM0BBCMGV_WC74?#^WC>U>X!R^<9I2I\E.\D#9VQ0%?PK*UF
M+9;"Z4 21?-GV%; XY_.L7Q+=+%I4L></(-HS7+%:F:N]"*Q\46-Y:&7S0A4
M?,#6=#J>H:Y),MEA(!P)/6N-O](6PTL.LQ#R<E0:Z;P)<71L$B6'$0ZM71*$
M8Q<HFCIN*NSI=$TZZL%8W,_FLQ_*KM]!/-%M@?:PJV!G&?2D8[5)]JYW)MW>
MYE<S+?2%4;[IO.<^O:B^T2ROHRLD*@XXP*=9:DET\BD@%3C%+J>JP:=:O+*X
MW <#/6F^>X]3RN_U&\\-ZQ+96LA*9X&:[3POJNHWDJ"[B.QA]ZN%FADU[4WN
M<[26S^%>B>&)@EOY+8RAZUU56N3;4TE3=KLZ55X'-/IF<C/:G"N+R,0KD_'%
MNCV,4A )5JZT>M<[XNL+B_T]8K=<ONS6E-^]<J.Y:T%8SI,1C ''(%7[F-9K
M=XW7Y2.17&:1!K>AP$R*)( .5STKHH-:@N+$3*<O_=]_2G.#O=:@]696G/?1
MPR6<"8",0&-,FT6]CN!?2W&YX_FVU9M_M=K+)-Y?R.<@>E%]JDLEM(GE'+#%
M5S.^@XK4O:1K$6H0D[@&7@C--\07<4.CS9<988'-<[HWAZ<!IVF>-6.<"L'Q
M=%?6,Z(TC21GI3C3BZEDP:U.Y\)ZI#=Z8D0($B<$5T>1ZUXKH2ZX+L36D3+Q
MT/2O0])&I7]LWVFYV2+P5':G5I).]R'OH=,",]12YK,T_3I;5V:6X,N3QFM+
MH,U@_( S6;=:HD4IB S(>E:#$ $UR2:A;W/BTVX()0=*<(\S*C;=DL'AS[=>
MO>:A\[$_*OI6_:Z?;VBXCC _"K2C'3M2.0B$L?E R30Y.3L#D^AB:_?+9VC1
M1H-TO%0Z!I9MK<W$O5N:AB>#Q!JCL&!C@..OI6Z]U;0+Y3.N0,$"F[Q5NI;J
M*,+(RI/#MIJFMV]\[ ;&R!7I4?\ JU^E>.66H--XP2R29TA+YQ7L:?<7Z5VX
M>,HQU/-Q?Q(=11170<@4444 %%%% !1110 4444 %%%% !3)?]4WTI],F&87
M ]*3&MSYXUW5+A]4EAAD 4.P*K]:QVBNK=#()&4'KN/6NZLO!#'4+JZN"<N[
M,H/UIEGX?2?7)8+W+I&H*+V[US^UBGH>]"4(16FIP*022J77>WT%+%83).CK
M;.5SELBO:H=#L+="L=M&!]*LK86R@ 0QCU^6L_K7D5*NVK(\;NK6YU\ED7RX
M(!RGTKLO#EU8R^'6MI652JD,#UH\3Z,(+B$V),;3MM8+TJ]9>"[2.(%W;<1\
MV#1.<915R.;3<YK3/&?]FP36R1%]K'8U=QX<UE]7L!)*NU\UQ.L^&X]$N8IM
MV;9WYS72C7--T>P46X#$@<+4U%&7P+<<HQY;G5@FE).!7*Z?XTMKN[6!HVC9
M^F>]=0K*PZ]:YY1<79F-CB?%]UK6GJ\UHVZ$CYO85<\$.\VCB:4'S78Y)KHK
MVV2ZM9(9 "&&.:P-'U:SMA)8,ZQ/&Q4=JU4N:#26H_0Z*:>.VB:21@JCUI()
MH[J,2I@J1P:YCQ3.DFB$_:0"&!R#U'I6UH+1G2+?RSD%16;C[MP9JC&#VS2-
M@#<3Q0!22!?+.XX%0O(6A#<I%<6K*^"C@@BO/=4^'%O.))[:0AN2*[U[JSBB
MVM*FWW-5[O4[.ULI)1(I"J2 #6L)3C\)2E8\(U'1S: PEL3*W->G^!M0M+72
M=KR!6')R:RO#UA%XJU.\N;F+]RIXJEXI\-W&EW*)9[_)D8 8/2NR<U4_=R=B
M^:+B>G+JUM<6TDD,JL%'K7FLVIW_ (FUUK)7"A6XK3M_!^H0:23!=LLCC)7-
M<S96NH^'-8CO)T(7=AB16=*$%?E=V9ZI71UMSX-OY8-[W(8H.%J[X'EFMH9K
M&Z3;+&W'N*ZJRN$O+..9>0Z@UF:QI[*1>V@VSIR<?Q5@JC:<)%2DY;FYG.,=
M.]*<=SP17(6WC>U!,=PI6=3AJV=.UZSU+B*0 ^AJ'3E'=$6.>\96$]F@OM/D
M,;Y^91WKF'T77-;EA\R1_+X))KL_$^J6RO!:,P9W<9&:Z2UB1+9 B@+M%;*K
M*$%IN.ZL<!#X0O=/E,J/E /F%06'FWOB 6T,S0+WSWQ7I97@@C(KFM?T<1 Z
MC9(%N(LMQZ4HUKM\W4?.WH=# AAA",V2!R3WJ8'/3FN$N_%5V=/VO"49A@-B
MM#PAJD]^91*3L7IFI=&25V#B[7.N!R#3&&?_ *]**BN?-,#^5C?CC/K67F04
M-;O8+&PD:4CD8 ]:X'PSJ2_VQ(LZ%87;*YZ5U$6@76HS^;JLI8 _*@Z"KM[H
M5F;8A(E0KRK"MHRC!<N]RDKK4U(PDL8Z$5&]K!GYE%<YI6KWEQFVCC_U9QNJ
MU=ZG<Q3>04RS< UG[-K0%<U&N[>!"BD#;VKFKZ2WUC5(80F0.35#5EU&UC>?
M)QW%8V@WUV-4$H!89YXK6G3T<DRDCTZ"WBL[?Y%55 YP*Y"T\2"P\1RPMS%.
MV ?2M^;6[1+1A.P5B.>:YZ*ULKK3;FY10SJV4/<5-..K<D-Q[GH"LKH&'0\T
MM<UX6\00:A;"W>0><AVX)Y-=+QBHE%Q;N9;%/4UG>QD6W.)"N :\SD\.ZMIF
MN0W<<N^>0Y)->K2$JA*\D"N,.JSS>*$CNH_*A0\$\ UI0E);#=NIU=FTYM$:
MYQYF/FQ56^NX;A)+*.4"1QBI[Z[CAL)9@PVA217.:)IS31G4Y9"222![5"C]
MIE14;:DNE>$Y=+>1HKH_O3EJW+?2+>-M[YD?N2:?8:A#>+B-AN7@BKJD<TI2
MDWJ9O2YCW6BQ?VA;7MO&%F1N2!UKT"/_ %:_05S .'7ZUTZ?<7Z5UX23<7<X
M\5NAU%%%=9R!1110 4444 %%%% !1110 4444 %(WW3]*6D;[I^E)[ CEY/]
M8WU-906,:XQP _EC\:UI>9&^IKS_ %W6FL?&=OM)\HJ%8XXZUYD(WDTCU5LC
MO133SQ21N'B5P>&&:<.>:S9HCA=9UECXCM[5HCL1\[L>U=HIRH/6H9K"UEEW
MO"I;/7'-9GB/68M(L64';(R82M-)V444[%/Q);C7)8K&%LX;+D=JO:=X;LK&
M (8Q(W=G&:D\/VJQV"3D9>4;BQZUL#O2E)_"GH*[.0\8:7#;Z8;ZVB5)H?F!
M48JAX6\=17D'E7QV2*, UTWB((^D3K)]TBO.]%LK)(;II57.#M%;4^65)J70
MI4Y25T=G>:[<:B6@TE=YQR_I6+H6@O/>W)U $S Y-7O!,T-O8R<8)>L?Q/XM
M_LC7";5@V1A@.:$G=P@."U,7QW:/I=Q&BSR&-N=F:W? <5[<P)*MTQC3^$GI
M7$:SKD^KWPDN59AT4 =*['X?Z@J3F)F6-,<@\9K><91HV>X.SU/3MV .:Y[Q
M//--"EC;2,LLAY(["K5UK,*2>5!^]E/0+VHTJPE>=KV\&96^ZI[5Q17+JS-F
M$G@MGE4RW,I4KS\W>N5U_0M1TN]6(32/!*<#)KU\@@Y'2N1\;REK-((<-.#E
M?45K2K3<AQTV-+POHZZ7IJ# #. 6K5N;6&[*B5 P4Y&:YG0O$@BLHX-1/ER*
M.2:F_MUM2UF.&Q;?"O+$5G*$G)LIIWU.F"   < "L+Q3H[:MIICA4;\CFM\,
M!PQH"Y'7FLXMQ=T3<YG0K'5-,M%BE?>JC&*36M>N;:V=([9C)C@XKJ<56N[1
M+JW="!DC&:M3O*\D"9P_A?1+75$>]N4!G9SN4U=U_2(+)([BTS"^=N%XIEJL
MWA6[<2_-;2MNW>E3ZM>_VT8(;$%_F!+#H*UN^:Z>A3(;3P@EU<P7UQ*SN,-@
MUVJJ$0*H^7&!45I&8[6-6^\J@&K K&<G+<AVN(1@5E>(+HV>B7,JH6;80 *U
M2.*BG1'A99%#+CD&I32LV!Y78:M_:5FL,T?*L>,=*WM*U6#2'S+M2$G;GWK,
MDLX5U"XDC*QJ#T'%9=Y:IJ!\E)LMN^[FNQI-G<TO9V/7+6>.YA$L;;E89R*L
M#@5C>'+-K#2HX6)/?FMBN227-9' ]QIYK+U>ZC@MBA<*S\#)JOXA\0)HZH@4
MM*_  KCM:M];U=$O/+95'W5 ]*N%-NS>B+@KL[/3+"&SAWQD?-\S'-96JWL"
MZM"P<$9P:XL>)KVQ7[-<LZG[O-=)I-O83VAGGG#MC)R>E6Z7*^9FMDGJS:UB
M>%M+D.]6^7UK#\+VT4%M-=R%<#)Q6%>6-_?M*UF[M"#Z\8JOI]S>07 TDYS*
M<9JXTERV3)YK;&[:Z.?$FH32F1E@ST%/O=+E\..HMF9[>3AU/:NRT?3$T^S6
M)1SC)/K3/$-NLNCS$ ;P.,UG[5N5N@G,\XT'39)?%#M;S%5#;N*]8C?@*2"P
M'2O.(;:YT.Q_M(KEF'.*/#NO7LFJM/<!_*DXYZ5K4BZBNGL)QOL>EGZ]*K3Z
M?;7.3)"I;L>]2QR+)$&4C!I2P'3G%<EVC,YS7-(B33GV3NHP3RU.\,RN=)6!
MD.%R"3W%8&MZK)?^)%L')2!3SV!KK9;ZSTS3@Q=%"IQBMFFH*.]S6UEL8<C0
M:!X@1UEQ',0"">E=C%*DRAT8,IZ$5Y+K&JPZZKA6PZG@UI^#K'5+B+>+US".
MV:N=/W>:3LT14@UJCTQ3^\7/3-=.GW!]*\[-AJ$-Y;M#.TB;ANSS7HB?<7/7
M%:8563L>?BMT.HHHKK.4**** "BBB@ HHHH **** "BBB@ I&^Z?I2TC_</T
MI/8$<Q.RJY)( R>M<EXKBLI[,*NPW!.05ZUTFHV_VN&2'<5R3R*Q--\.1V<Q
MEG<RMGY2W:O,349-WV/7AHE<T='CECTV%9<DA>]7@<<4X8P!@#VJCJ\[VMA+
M.GWE4FH?O%7N6VQGI[UYY\1+E;66WF==R"NCT+Q';:G;C=,JS#@@US'CZ_LI
M94M)&!)')K:C&4:EFA[FYX2\4V>I621F1$=1C:36[<:K:P+EYT'XUX?I]NZW
M7^@AR>Q6DG.L2WAMIM^\G S6\\+&4M&:.'*['I^NZI'J>G/;6.Z61NZ<UR6C
M:1JEO?*MS"Y0GG([5W/A/2?[,TM!(H$K#))KHQ''C)49^E<_M.1.$42I..S/
M.=3L[S3+M;:P!"W/Z5RVO>&M0TTK?3_O"QY[UZ-XM62%H+N($B(\US6O:V-3
MMX8A\J_Q9[FMJ4Y731I!<R+'@OPS#=VPO;E%<N.A'2M34_ \,LOFV9,+>J\5
MI>#X&@TE!G@\BNC/-83JSYW),SEH[&1HVBPZ;;J"-\N.7/6M3:=V[O3\&@GB
MLI-R=V21W$Z6T+.[ *!DY-<;8M#J&IW-]+(&BC.%R>*V?$>EW.J6ODP2;.#Q
MGK7FNFIJ-IJ<VBYYD/7TK>E!.+U*A9&WXBU"QE1@FUF[$5S?A?7Y]+U1UAC,
MJL3E5&:[5_"%M;Z8_GOF0CDDUF^$=,M;.^N9& .S.":TA4@H-;F\US+W2OJ/
MCB\N;Z."")XP&^;(KTK3+I;NQBE!!)7D^]<;:Z;9W>M-*-K!FZ"MOSAHEVH;
M(M). ?0UG4<)625C&I'E.A:5(TW.P '<FL>Y\4Z3:RB)KI-Q/8UQGCC4+S[=
M"EK<'R'7^$]:Y_2]%?4]8B$B.J C);O3A0CR\TV3[-N/,=EK>N0:S?0:7:E6
M$G+.>E=9IFFP:?:)%&@! Y(K+D\+V44 >",+*GS*P[TP>*;>&V"NCFX3@H!4
MR7,K0)OT.F%*,"L+3_$ N_FD@DB'8L*OG4[09!G3CL363BT/E9=WJ<C<,^E1
MR#?&R]R#7%W=Y=W6L@Z7*9"I^;'2M@W6KJFUK?YF& 15.GYB>AY7K=[/9:[<
M0!R5)Z"MKP1H<E[J)O9')"'I74P^![6:8W5X"TS\G/:M_2=&M])1E@'!KHGB
M%R\JW+YM+&FBA0 !C IU ZTIXKDU,C*U'1X;^XBF=02G3-7%C4(%QD =*=.Y
MCB9_05Q[:MJE]<20V6-RDC-4HN:MV-$FXW,OQO9VC:C!N" D<URL^HI:I]DL
MSN=S@@5U6M>%-4OVCN99AO0989K/\-Z-9IKF;K!E!X!]:[*<HJ&KO8TBY<MT
M:^@V&KOIX@8&*-AU]JDU#PR^FR1:BA+R1L"P]J[B,*$&T#'M3F17&&&5/7-<
MOM7S<QFYNUBOI]Q]JM(Y2I4L,X/:JFOV,U_I[QP.5?J,=ZU%4(N%  [ 4C=.
M:B^MR4>7:E?7L5M'872,%7 ;(ZBM-IM.71U2&15EQ^.:ZZ_TFWU!#YB#/8XZ
M5Y[JGA6ZM=2#1JS19[&NB$XRM?0TYQT&N:OIUNTK*SP]C2:9XEU._O=J$MG^
M'TKM(M+BFT9()% &WGBN>L]-.B7S2^3\I/! HYX.^FH1C=W.+\23ZD-68E65
M\]:=-<7TEB!-O?Y:N^)M2>750\,63GN*DA-[=Q!EML#'/%;I^ZG8Z$[:,RK2
M>UBM2'3]]Z=Z]0\#VSP:&AD&"_./2O+AH]V^I!Q&7.[(%>AZ5XOL[8I878\J
M5!@C%17O)6B<]:-D=S!_K4],]JZ5?NBN4T^[@NG4PRJP//6NK7[H^E+";.YY
MF*W0M%%%=ARA1110 4444 %%%% !1110 4444 %(WW#]*6D?[A^E)[#1S++^
M\)]S32!GBGN<LP]S40.#R:\B6YZL=AK?*0:Q_$T_EZ/*H."P(Q6G<W"1(78@
M!1U->7:_K%WK5Y)#;$^2K8^6M*4.:7H;4X\S15\*1VD.M.DSC:W3GH:[C5_"
M>GZO;,0N)=ORM7EUBT5IKUN\SD+NP:]RM"CVT;QD,I&016U9RA)2N564>;0P
M?#'AJWTFS >-3,#U(J/4+6TDU^ ?*&4Y)([UU.."!QCO6'K.E12P23K)Y<H&
MX-GO6,97EJ]R+FUM&,#'2D.>U<OX?\407:?9;AP)HSC)[UU2%2N5.0:B<'%V
M9)1U'3OMME)$?XAQ]:\_U+P/>+"623(4Y(KU!6W=J9)&K=?_ -=5"HX;%*3V
M,GPT@AT6"/G<HYS6L<G('![4R...)0JX6I<@ 5$G=W9+.;M->G77I-.N]BC^
M$UTO!'7BO,]2@.I^-',<QC,8P"/:NF^TZC8P>8K"XB0<^M;3@M+%<CM<Z-B
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MWKU=.4'TKA[S38KB2)RH5U<'<!S7;Q#$:_05U8:?,F>;B]T/HHHKI.0****
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MIY4+=7]JNV_A>RM8B50>;C._OFLGPYK36]L(KJ)XU[,16W>:U;B >1,KR'@
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MKD;:>ISNZ8N.](T@!QS0Q.*R-9U$:=923GG XJ=6[ :^\-U%5KVZ6SMGE8@
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MBBB@ I&^Z?I2TC?=/TI/8$<M.&+M@=S_ #IJDD<BI)&_>,/<TE>1+<]:/PC
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M=)!(VX!?:M%O$SW2*@CVQ?Q<=2*T[*1;BV+3::NP#[P6N>O;V-II(8(54 X
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M^3_C1BX_OQ_]\G_&IJ* (<7']^/_ +Y/^-&+C^_'_P!\G_&IJ* (<7']^/\
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M5)4<W1/]\4 24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !45Q_Q[2_[IJ6HKC_CVE_W30 EI_QZ1?[M
M35#:?\>D7^[4I.%) S@=* .&^(,?@2273_\ A,GC5PLGV7>T@XRN[[G_  'K
M7F>K+\.[;7?#LW@]%O+[^T8EDMU,A5D)Z_-T8'&,>^:ZC5/%^H:PT9U+X47U
MX8LB,SIOVYQG&4XS@4NB:[);:Q:FV^$\]@[RJANEA ,0)P6SL[ T >NT444
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M2[.;PUI?FHTEM+>LY= <D;3ZCL17L^F:)I>BP^5IMA;VBGKY484GZGJ:T.*
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M^#/_ "3'3?\ KI/_ .C6KOJ!!1110 4444 %%%% !7R!XY_Y'W7_ /L(3?\
MH1KZ_KY \<_\C[K_ /V$)O\ T(T 8%%%% P[U]6_"K_DF.A_]<F_]#:OE+O7
MU;\*O^28Z'_UR;_T-J .QHHHH$%%%% !1110 4444 ?&?B+_ )&?5_\ K^G_
M /1C5FUI>(O^1GU?_K^G_P#1C5FT#"BBB@#Z\\!?\B#H/_7C%_Z#715SO@+_
M )$'0?\ KQB_]!KHJ!!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %17'_'M+_NFI:BN/^/:7_=- "6G_'I%_NU-4-I_QZ1?[M34 >>^/M5O[/4]
M&\.^';>SBU/57?%Q-$I6)%ZG&.O^%<QI_BC7-*T#P_J]Z;:]@;59K"_+0H&;
M+[49< 8QAJ[#Q_H=EK=WI")K"Z5KT3O)ITY_B(QN7WZBN/L? 4V@WFF-XP\3
M6\EA#>^=:V,6?WUPS<'H,\G/?\* /::*** .;\=Z3K&N>%+G3=$N(H+FX*H\
MDCE1Y>?F (!//3\37!Z!X.^)'AJP2QTN\T""W!RV$)9^>K';R:]@HH \[UK0
M/&UAXIFUOPWJ,%S#=1A);&]D;9&V!RHZ=1GMU-7?A_X,N_#9U+4M7N([C6-3
ME\RX:+[BC).T?B37;T4 %1S=$_WQ4E1S=$_WQ0!)1110 4'I10>E 'R;\3O^
M2DZ[_P!? _\ 05KDZZSXG?\ )2==_P"O@?\ H*UR= PHHHH ^H/@S_R3'3?^
MND__ *-:N^K@?@S_ ,DQTW_KI/\ ^C6KOJ!!1110 4444 %%%% !7R!XY_Y'
MW7_^PA-_Z$:^OZ^0/'/_ "/NO_\ 80F_]"- &!1110,.]?5OPJ_Y)CH?_7)O
M_0VKY2[U]6_"K_DF.A_]<F_]#:@#L:***!!1110 4444 %%%% 'QGXB_Y&?5
M_P#K^G_]&-6;6EXB_P"1GU?_ *_I_P#T8U9M PHHHH ^O/ 7_(@Z#_UXQ?\
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MK/B=_P E)UW_ *^!_P"@K7)T#"BBB@#Z@^#/_),=-_ZZ3_\ HUJ[ZN!^#/\
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M'P9_Y)CIO_72?_T:U=]7 _!G_DF.F_\ 72?_ -&M7?4""BBB@ HHHH ****
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M"- &!1110,.]?5OPJ_Y)CH?_ %R;_P!#:OE+O7U;\*O^28Z'_P!<F_\ 0VH
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M%%%% !1110 4444 ?&?B+_D9]7_Z_I__ $8U9M:7B+_D9]7_ .OZ?_T8U9M
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MU]G>'_\ D6M*_P"O.'_T 5\8,?D;GL:^SO#_ /R+6E?]></_ * *!&E1110
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MG_?5344 0_9Q_P ])/\ OJC[./\ GI)_WU4U% $/V<?\])/^^J/LX_YZ2?\
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M344 0_9Q_P ])/\ OJGI'Y9.&8Y_O&GT4 %17'_'M+_NFI:BN/\ CVE_W30
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M]TMM&/ZU'9+ OQ"U$:<%%M]D;S!']W.T?UH N^'?&L']D>;K5X@N&E8* O\
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M44 'VF?_ )Z-1]IG_P">C444 'VF?_GHU'VF?_GHU%% !]IG_P">C4?:9_\
MGHU%% !]IG_YZ-1]IG_YZ-110 ?:9_\ GHU'VF?_ )Z-110 ?:9_^>C4?:9_
M^>C444 'VF?_ )Z-1]IG_P">C444 'VF?_GHU'VF?_GHU%% !]IG_P">C4?:
<9_\ GHU%% !]IG_YZ-2-<3,I!D)!X-%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>drts-20211231x20f020.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 drts-20211231x20f020.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #8 6$# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W=FMX+7SI
MS%'$B;G=\ * .22>E(TUFDL,3R0+)-DQ(6 :3 R=H[_A7,^/R6\-64#$BVN-
M1LX;H_\ 3)I5R#['@?C7#>+7UC6/%.IZ_IFD3W2>'GCBL[A9%18WB.^X^4G+
M[@=G'I0![#$]M,9!$T3F-MCA<':W7!]#R/SJCJ^N:+H*Q-JMY;6@ER(S+QNQ
MUQ^=<[X;OTOO'NK7-ES8WNEV5VQ_Z:-O S[E ,_05L>+;"[U728=.M8RT=U=
M117;*0"EOG,F/J!MX_O4 31^(M EOK2RCU&S:YNXQ+;QAAF1",@CZ@$CUQ4N
MG:SHVK7%S;Z?>6MS+;-MF2(@E#DC^8(S[5Q6J>&M5D\82QVVGG[%<ZA8WB7B
M,H2".!-K(1G(/&  ,8;M4G@3P_J^G:Q;O?V#6D>GZ6=/+LZD7#F8ON7!/RX[
MG!RQH ]"\M/[B_E1Y:?W%_*A&+%\]FQ3J &^6G]Q?RH\M/[B_E69K_B+3?#-
M@M[JDKQ0-((P4B:0[CD]%!]#7 -\== 'B(6(L[HZ?G:;[!R#C_GGC=C/'K[4
M >I>6G]Q?RH\N/\ N+^5<G=^,[35/ NMZUX?N7+V=O*4DD@9=LBIN'# 9[54
MA\?2I?1VLVELT"7D%A-=^> ?-EB5PP3'3YL'G\Z .W\M/[B_E1Y<?]Q?RKS^
M+XI)+IEWJ"Z+<&!(/M%N1)_K5\P1X8E<(WS @9/'?BM?0->UG4?%VKZ;J%A!
M:P6EO;NJQS>84=]Q()P,YQ[8QWS0!U/EI_<7\J/+3^XOY4ZB@!OEI_<7\J/+
M3^XOY4ZB@!OEI_<7\J/+3^XOY4ZB@!OEI_<7\J/+3^XOY4ZB@!OEI_<7\J/+
M3^XOY4ZB@!OEI_<7\J/+3^XOY4ZB@!OEI_<7\J/+3^XOY4ZB@!OEI_<7\J/+
M3^XOY4ZB@!OEI_<7\J/+3^XOY4ZB@!OEI_<7\J/+3^XOY4ZB@!OEI_<7\J/+
M3^XOY4ZB@!OEI_<7\J/+3^XOY4ZB@!OEI_<7\J/+3^XOY4ZB@!OEI_<7\J/+
M3^XOY4ZB@!OEI_<7\J/+3^XOY4ZB@#+VK_='Y44M%,1-?Z;;:OI$EA>(7MYX
MPK@'!]00>Q! (/M5Q1M4#)..Y[TD?^J3_=%.I#*=IIEK97=[=0H?/O'5YG9L
MD[5"J!Z  <#W/K5RBJ>I:KI^CVOVG4KV"T@W!1),X4$GMS0!<HJ@=;TH:A!8
M'4;7[9<)YD,/FKND7KD#N*=8ZQINI3W$-C?V]S+;-LF2*0,8SZ''3H?RH LQ
M=9/]\_R%25'%UD_WS_(5)0 =:R3X7T)M=&N'2K4ZF!@7.SY^F,_7'&>M7KN.
MYDA"VLZPR9Y9DW<>E<F8?%W_  E(D!_T';Y/F_)MV]=^S/K^.* .MO+*WU"Q
MGLKJ)9;:=#'+&>C*1@BN=1?!K6=_J"/9M;V-XLUU,KDB*XA 4%N>J@ 5HZBV
ML67AZ_>V'V_4A&WV9$4)ER,+U..#S7FS>!O$NC:+JNEPPV][%J6D^2QM5\O%
MQ&?E9][<LX9LD?W1TH ]#C\'^'4@N0FFQ>3=*/-7>Q4KNWX SA1NYP,#-6=.
MMM'O[L>)-/6.6:[@$?VJ-CB6,'(XZ'![XS7GUI9ZI?\ C&^>SM[XR6VM@->?
M:OW,=N(4\R(IN[YZ;>^<C%1:9X7\1:-HL"VFG7#32:')#=0->%0T_FJ5 P_!
M"%\;<>F1F@#UB65((7EE8+&BEF8] !R365I'BK0M>F:'2]4M[F54\PHC?-M_
MO 'J/<5SWA72=6M/#&OV-W;W">=+*;*.9AGRVB4  ;VV_-NX+<5C6>E>([JR
MT0C0);.?0])F@_?W*(UU*T00(A1B57(SN)':@#T/5M:TW0K5+G5+N.UA=Q&K
M/GECD@#'?@UFR>.?#$5C'?/K5L+9W:,29. RXR#QP1D=?6N"M/"OB*:*& V]
M]:P#5[2ZC8NNZ!!$XD90SOC#8X).<YQ6C)X8UI? ?BS29+.2YU:ZG+K>&1?]
M/!V[7QG"$* I7@<<=: /0M-U.SU>R2\L)UGMW)"R*" <'!ZU;IL0*Q(#P0H!
MIU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !152XC5K^
MT8YR"W1B!T].]6Z "BBB@ HHHH S****8C1C_P!4G^Z*YS4?&*VMW+;6&AZQ
MJLD3%)&M+;$:L.HWN5!/TS71Q_ZI/]T5PFJLOA[Q)9R1KKFK:C*TUSY%KEP(
M<XVD,X55!=>@YVKT[H9TNC>(K?67DA^R7UE=1J&>WO;<QL!TR#]UA]":Y_X@
M:7?W=YHM]:0WTT-H;A95L0AF!DCVJ0&X(R,'V/IFNLTN^DU'3HKN6RN;)Y,Y
MM[D 2)@D<X)'OUJY0!Y+%X>\0'6+2&ZTLK<3W&G7;7<"H(8!!%MD7@_*<@@*
M!@[N*TO .AZI8:U UWILMFEAI9L99)-N+B4S%]R8/S+CG/JWUKTBB@".+K)_
MOG^0J2HXNLG^^?Y"I* *]Y?6MA$);N>.&,G:&<X&?2L<^--"_M'[']N3.W=Y
MO_+//]W/K6Y+!%.NV:))%SG#J"/UJC_PC^D_;_MO]GP>?LV9V#&/ITS[U$N>
M^AE4533DM\^PYKTZGIT[Z+>6K3CY4D=3(BM_M $$\>XKSJ7QSXM@\)/K.W29
MY6U%K&*!+>1>4=U8D[SU"<>F>]>HQ00VZE88DC4G.$4 ?I7.Q>'?#T.DK;K.
M#9V6H-?,QN 0DVXLP8^F6/!JE>VIJO,YZS\=WVK:[K$&GRZ99Z9!8K=07MQ&
MS#(*>87PPR!N(XQR*Z'P3JFN:SI#ZAK,=LD4TF;+R86B9X>SLK,2-W4#TQ5%
M_AAX:;2UL%2ZBMEB,6([@C*F7S>3W^;] *W]#TV#3[9WM]3O;^*;#*]S<^<
M!_=/84P-6BD9E1&=V"JHR23@ 57M-2L;_?\ 8KVVN=GWO)E5]OUP>* +-%07
M5[:6,8DO+J&WC)P&FD" GTR:@;6M*2&.9]3LEBER(W-PH5\=<'/.* +U%16]
MS;WD"SVL\4\+?=DB<,I^A%.FFBMX7FGE2*)!EG=@JJ/4D]* 'T5GKKVCNK,N
MK6#!<%B+E#C)P,\U/+J5C \B37MM&\2>9(KRJ"B?WCD\#WH LT56M-0LK\,;
M.\M[D)C=Y,JOMSTS@U9H **** "B@G S45O<1747FPL63)&=I'3ZT 2T444
M%%%% !1110 4444 %%%% %:?_C]M?J_\JLU6G_X_;7ZO_*K- !1110 4444
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M\?VIJ@,, ]U7[SUDZ[\)KK7K9;WQ%XFOKW5 P :"!1%&A/*I'C@=\Y[5ZP
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MRFR1I*A21%=3U5AD&E)QENK>G],V<)=)'EVH_$Z\AN+=8X[<*A$DFP[Q(O\
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MW+D=#BO*?#=E8Z;X&\&WUK8VBW5]J\$<\QB!9P)),'/J.Q[4 >Q45Y/INO\
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M )X[%V?ETHHH D5;965E$095V*1@$+Z#VIL<%E$VZ.*W1MQ;*JH.3U/U-%%
M");V,8E"0VZB8YD 51O^OK^-2*+=7WJ(@^T+N&,X'0?2BB@"E'I5A%J5_>@@
MM?HBW$;$%'* @''K@X/L!5@VFGM%Y1M[4QY!V%%QD=#CVHHH S=0\.Z=J6I:
M?=SSRB.QE\Z*T20+"91G#LH'+#)QS6HT%FURMRT5NTZC"RE06 ]CUHHH KZ5
MIUGH]J\%O(6\R:2>221P6D=V+,Q/X_D!5[S$_OK^=%% !YB?WU_.CS$_OK^=
<%% !YB?WU_.CS$_OK^=%% &;N'J/SHHHIB/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>drts-20211231x20f021.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 drts-20211231x20f021.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %* A # 2(  A$! Q$!_\0
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MI)'I4GDQ?\\U_*B'_4I]*YV^\1SCQUIWANQ2)BT#W=[(X),<0X4#'=F]>PH
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MKRS_ (7WX7_Y\]4_[])_\51_POKPO_SY:I_WZ3_XJ@#U,]*Y#P7_ ,?FL?\
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M_P!2W*3Y>\8CC7T).6Y[#WH ZV;_ %$G^Z?Y4L?^K3_=%)-_J)/]T_RI8_\
M5I_NB@!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW!R((@?]P5+THHI7"R"F2_ZI_P#=-/IDO^J?_=- PA_U"?2GTR'_ %"?2GT
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MH3Z4^F0_ZA/I3Z "BLW6_$&E>'+1+O5[Z*S@=Q&KR9P6QG''T-8/_"U/ _\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MKHP*L/4$=: )!1145Q<P6D#3W,T<,*?>DD8*H^I- $M%4[35M.OW*6=_:W#
M9(AF5R/R-7* "BJ-UK.EV,WDW>HV=O+@'9+.J-CUP33FU73DM!=O?VJVQ.T3
M&90F?3=G&: +E%9T.OZ-<3)##JUA+*YVJB7"%F/H #S6C0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5Y++_ ,G(VW_8._\ 9'KUJO)9
M?^3D;;_L'?\ LCT >M4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MF21(D+R.J(.K,< 4DDL<*%Y'5%'\3$ 4 5AI5DNDG2X[=(K(Q&'R8OD 0C!
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M>J:C9:5^T-#=W]U#:VZZ> TLSA5!*N!R: /9**Y[_A//"?\ T,>E_P#@2O\
MC1_PGGA/_H8]+_\  E?\: .AHKGO^$\\)_\ 0QZ7_P"!*_XT?\)YX3_Z&/2_
M_ E?\: .AHKGO^$\\)_]#'I?_@2O^-'_  GGA/\ Z&/2_P#P)7_&@#H:*Y[_
M (3SPG_T,>E_^!*_XT?\)YX3_P"ACTO_ ,"5_P : .AHKGO^$\\)_P#0QZ7_
M .!*_P"-'_">>$_^ACTO_P "5_QH Z&BN>_X3SPG_P!#'I?_ ($K_C1_PGGA
M/_H8]+_\"5_QH Z&BN>_X3SPG_T,>E_^!*_XT?\ ">>$_P#H8]+_ / E?\:
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MM7JENL2V\:P!!"J@($QM '3&.U $E%%% !1110 4444 %%%% !1110 4444
M%<UKW@'PUXEOUOM5TT3W(01^8)&0E1T!P1GJ:Z6B@#AO^%/^!_\ H#?^3$G_
M ,51_P *?\#_ /0&_P#)B3_XJNYHH X;_A3_ ('_ .@-_P"3$G_Q5'_"G_ _
M_0&_\F)/_BJ[FB@#AO\ A3_@?_H#?^3$G_Q5'_"G_ __ $!O_)B3_P"*KN:*
M .&_X4_X'_Z W_DQ)_\ %4?\*?\  _\ T!O_ "8D_P#BJ[FB@#AO^%/^!_\
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M %%%% !3)?\ 5/\ [II],E_U3_[IH (?]0GTI],A_P!0GTI] !1110 4444
M%>;>)O!?B&;7-<N="EL/L^O6J6]W]I9E:$J-N]< [OE[5Z310!S=YH]_I_@>
M+0]#9?M"6\=FDSMM\M<!6D]R!D@>N*Y/5_AY?'6[4:7#;FRCALH;>YDEQ)8B
M"0LY48R2X]".<YKU"B@!" 00>AJ+[+;_ //%/RKE/B/KE_HVA6<6F3_9[O4+
MZ*S6?:&,0<\L >,X%5O!&JZDGB3Q#X9U/4)-1.F/$\%S,JB1D=<X;  .#WH
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M[)!K7V#^R_+7RC &"GG&=W.<YH ]B^R6_P#SQ3\J/LEO_P \4_*I0<C(Z4M
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MK+PX_P#;VFS+'-ITERH!!/W@_MS7'P:%JFM_$3QNND:[=Z7=PM&4\AL+*2O
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MGU[5<KA_A'YG_"N=/WYV[Y?+S_=WG%=Q0 4444 %%%% !3)?]4_^Z:?3)?\
M5/\ [IH (?\ 4I_NBGUEK(X4 .V,>M.\V3_GHWYT :5%9OFR?\]&_.CS9/\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>drts-20211231x20f022.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 drts-20211231x20f022.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $# 7@# 2(  A$! Q$!_\0
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M)C_YYI_WR*/)C_YYI_WR*\3D\<:KJ.OWL4U]?6%O?26,8@\F2 V,#SLCY9E
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M-="=7\A]D9\H1DJN<9R,X(QVXQF@#T:'7-%N+R2UAN8'EB=XY,+PC(5#!CC
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MYI_WR*/)C_YYI_WR*?10 SR8_P#GFG_?(H\F/_GFG_?(I]% #/)C_P">:?\
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M>G'4\'/'45TGBW5/%&M>';'0=4T":WU+4+IWEM=,NE9S;1*#NWD@*2[(,$]
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M)J5]JGA=)M2F,UU'<7%NTI0*9!'*R*Q P,D*,XKI*** &3?ZF3_=/\J*)O\
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M4&>TU%;?\>T?TJ4=*BMO^/:/Z4 2T444 %%%% !1110 4444 %%%% !1110
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MHHHI#"HK;_CVC^E2U%;?\>T?TH EHHHH **** "BBB@ HHHH **** "BBB@
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MG/ KT^BL'J;',:SX1@\5>"X]%UJ&!)A" K0LSI#*%*AU^[NQD\'%5M5\% >
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M?45K#.!G&>^*6BM$DE9%)65@HHHIC();R"&YBMW9A++]P!&(/X@8%3U1NO\
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M"6_/^==Y79BYP?+",;-+7\#DPU*<7*4I73>GD%%%%<9UA1110 4444 %%%%
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MA=?\A2P_[:?^@U>JC=?\A2P_[:?^@U>H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@!DW^ID_W3_*BB;_4R?[I_E10 0_ZF/_='\JQ=9\)Z;KVM
MZ9J6HQ+<"P294MY8U>-_,"@E@P/(V\5M0_ZF/_='\J?0!2L-&TO2C(=.TVSL
MS)C>;>!8]V.F=H&>IJXRAE*L 5(P0>]+10!S-Q\/O#$]Q<7"Z5#;S31QIOMA
MY1C*,75D*XVL&.<CDX&>E)/\/_#UQ96MJ]O.$@61"RW#AIED;=(LK Y<,PR0
M>IKIZ* $50BA5 "@8 '85';?\>T?TJ6HK;_CVC^E $M%%% !1110 4444 %%
M%% !1110 445G:[J(TO1KBZ!^<+MC'JQX%*4E%-L3=E=F78?\3?Q==WQYM[!
M?L\/H7/WC72UE^'M..F:)! _^M8>9*?5VY/^'X5J5G2BU&[W>I,%9:A2$A5+
M,0 !DD]J4D 9)P*XWQ1K<U[;)H>GQR1WM_*;?+%3M0??;Y2>,?UKHIP<Y*(Y
M2Y5<S8A!XBU>Z\0WD2R644J6EBKQ[PRAP7?&#QU_,UZ!!'%#"D<$:1Q ?*J+
MM 'L*H+ -"T>VMK&&-HX=D05W*]2!G@'G)R:OR3)! TLS*B*,LQ/ JJM3GEI
MLMA0ARK7<2YN(K2VDN)W"11J6=CV KEM"\5)>:4@LM.NIY%9@RJ!A3DD9/T(
MJ:6T?Q?N%SYL.D _(BG:TQ]3[58\*Z%9:1:/-:><#.3O5Y"P^4D X]:R+.8U
M;QC?VWBJR2:T,,%LV)D4%R0PYY]ASQ7HRL'4,IRI&0?6J=U_R%+#_MI_Z#5V
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &3?ZF3_=/\J*)O\
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MWK1-<QH$=HL[3CC(R!7$=A;5510J@!0, #H*I:1_R#(OJW_H1JZQ(4D+N('
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M?_ESLCNN77T9_P"'_/%:P^%/A/3M$-E9^'K:\E9U9I;MMTC$'))<\^O P.:
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MT $W^ID_W3_*BB;_ %,G^Z?Y44 $/^IC_P!T?RI],A_U,?\ NC^5/H ****
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M]_\ 0444 'VJ;^_^@H^U3?W_ -!110 ?:IO[_P"@H^U3?W_T%%% !]JF_O\
MZ"C[5-_?_0444 'VJ;^_^@H^U3?W_P!!110 ?:IO[_Z"C[5-_?\ T%%% !]J
MF_O_ *"C[5-_?_0444 'VJ;^_P#H*/M4W]_]!110 ?:IO[_Z"C[5-_?_ $%%
M% !]JF_O_H*/M4W]_P#0444 'VJ;^_\ H*/M4W]_]!110 ?:IO[_ .@H^U3?
MW_T%%% !]JF_O_H*/M4W]_\ 0444 'VJ;^_^@H^U3?W_ -!110 ?:IO[_P"@
MH^U3?W_T%%% !]JF_O\ Z"C[5-_?_0444 'VJ;^_^@H^U3?W_P!!110 ?:IO
L[_Z"C[5-_?\ T%%% !]JF_O_ *"C[5-_?_0444 (]S,48%^"/04444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>drts-20211231x20f023.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 drts-20211231x20f023.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'J IL# 2(  A$! Q$!_\0
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M[D#%M=E8I\= W16_I7F91G-6IB'"N]);>1OB,+%0O!;'?T4@I:^R/,"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** ,[5=&M=7MO)ND.0<QR(=KQGU4]JX^]M[W0GVZ@
M1-:EL)=J,8]-X['WZ5Z#6;J]_8Z=9/+J#J(&^3##=O)X"X[D^E>?CLOHXN%J
MBU[FU&M*F]#E5;< 0001D$=ZI:G)$8DM)(6F-VWDJ@XR3ZGM3+"%DO)I+:%K
M33F'[JUD.2ISU']T?[-7+FVCN[=H90=K=U."#V(/8U^?RA3PV*Y6^9)[H]E.
M4Z>BLSK= CO8='MHM197NT3:[*<YQT_'&,UIURWAW7)7D_LO4) ;Q%S'(?\
MENGK_O#N/QKJ%Y7)K]*P]6%6FIP=T>%.+C)IGG]EXAN=)@UF0127DLGB"6UB
MC:3&W.W !/0"MH>(=6.NPZ0-)B-P+6.ZN&\_Y8U9W7 XY/RYJ!/"$X:8_:8_
MWFM'4NAX4X^7Z\5L'29/^$DNM4$VU9K&.U 'WE*N[;O_ !\?E6Q)AS^-;BSN
MK<7EE;PP3SB$1FY!G7)P"4JMKGB:_O=$UF;3K M8VS/;FY$NURR\,RCT!]ZK
MQ^ KZ.RMK1/[+A\BX2:2Z2$^=<[6W?.W4'\35^Y\*ZM'8ZGI6G7MM'I]],\P
M,BDO#O.64=B"<X],T /L=7\C4]=\FUN)[FVM;-F4S95RRMC /"].3W_"J\OC
M*\<ZCIPBM%ODL)+J%[:Y$BC;@$-QP1D&I;_P5<79UHI=QK]OBM$"D''[G.5;
MU5LXIL'@VZ.IFZD_L^T@^P2V:VME#M5-^#NSQD\>E %73?$+0#1+K5UD\\Z3
M-<O(LQ*E5*9)7H6.1].:UX/%%['-ITFI:8MM9ZA((H)%EW,K,,J'&.,^U4H/
M!5U/%81:E<0NEMITU@PB4C<KE=K<]\+5F/PYJUX^E6^JW5LUEILJS+Y*D/,Z
M#";L\ #J?6@"M!XUOY;!-4?2%731<_9WD\[YQ^\V!@N.F<5VU<JOA68>#SHO
MVA/,-QYWF8.,>;YF/RXKJJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***3(]
M: %HHR/6C(]: "BC(HR* "BC-)D>M '-^*)I8M6\,K'(Z+)J6UPK$!AY3\'U
M%7]9UD:/)8-+%N@N;A8'DS_JRWW2?;/'XU7\2Z1>ZH^F3Z?-!'/8W7V@><"5
M;Y&7''^]65X@>^3PU?1:]):%I5"V@M4<L91RO7OD#% $U_XPFMI;L6VG&X2&
M^CL8V\S'F2,,M^"Y JN?%^KB75;;^Q(OM.EA7N?](^38R[AM..3BI[#PS<+X
M9T>TEG7[5!<I>7#L/OODLWZFK9\.R_;_ !'<^>F-6CC1!C[FV/9S0!7'BN^O
MM06STK2UG+64=YOEEVJ Y/RGCKQQ^-9LWB2ZU/5?#=UIEJ[R3I>1O;/)M577
M8#N/L0?SIEEIFLZ?XJD@TZ:WS!I-M!)YZG8Y!?# CN,=/>MC2O"ATNXTB1;D
M2&S6X,S$<R/*5)(].0: "'Q1=2Z3-,--_P!-@NOLDL7F@(C==Q<]%QCGWK#U
MCQG?S^&M?6T6"+4+!(R9;:X$B;7/4-CKP>*NZEX*N+R.;$]O*KZI]N-M,I,4
MR[=NQQWYY[]*8W@F\GM-=CDGLX/[2MXXHHK>+;'!L)P,=QS0!.?$<>E3:G=W
MT,HGM[&U9U64LKL[,JJH/0YZGW]JVM,U'59KTV^HZ6+96B\Q)8Y-Z]?NGT:L
M>Y\(3ZG#J OKF)9;NTMX@T0.$DA9F#<]LD<>QK7TRUUO^T/M.IWD'E)#Y:P6
MX.UFSR[$]^.GO0 Y]<6WUNZT^Z01)%:_:DE+<.@.&^F./SK#/CII%LXH;6WB
MN+B#[21=7 B5(R2%Y/4GTJ[XN\+/XC%F8+O[,\3-',P'^L@<8D3\>*;J?AEV
MUB+4=/BL),6XMWM[N+<FU?NE3@X(S0!4;Q]#)I]E-!% LMS-) QGG"Q1NG4%
M^ASV]:FO/&$UE86+SV4,$]W,T2M-< 0C SNWCL>U./AW4X]+M[<3V%R=[M<V
MTUNH@E#=  !QM[&JUIX2OM.TI;:UDL&C>X>6:PDBS;,C#[B@YP!U_I0!8NO&
M366FVDES:11WEW,T,*M<+Y38&2^_^[C\:Q];\4OJ6AW$",D-Y;7EJ':UGWHR
MM(.0P_$$5/%\/VM[.&2)[-+J"\:YBMC&3;(&7:8PIZ#'.?6K<_A.]OM/N(YI
M;&!Y;B&5(K:$*B*C!L9QDDXZT =G129'K2YH **,T9H **3(]:7- !11FB@
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MVX;/R2(TC+['!'-6B*R- &T7ZKPHNGP*U^LU.7<R^KPN7_MWB?\ Y_=,_P#
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M4]*N]&BD2XWWVFMD>;MS)&I[/CJ/<?C7S%7*ZF!K+$875+=>1WQKQJQY*AZ
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MAB!Z9!%=7^%(1Q5>QA:U@]K.][G+?\(_JV.-6@_\!?\ [*D_X1_6/^@O;_\
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M,-KJ.F]K*^EC7_=)W#^==0PR*YO1$6'Q5XAC P&DAD_$IS0!TM%%% !1110
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MS!<N /13R/YFNOJSVX2YHJ04444%!1110 4444 %%%% !1110 4444 %%%%
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MV>/\?W[/^35WU9TW[I>)^,3:/2EZ4459SA1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/2:*IZ=J$&IV45W;.&BD4,"*N5V'GM-.S"BBB@04444 %%%% !1110 4444
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M@#6HHHH **** "N<UC_D</#W_;?_ - %='7.:Q_R./A[_MO_ .@"@#HZ***
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MJ3 )S0*24E9GBTJNEPUG=QM;7L?)C;@X]1ZCWJ:*YNHEP!N [BO5-4T:PU>
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M6SEOL-<F0AD VD\8Y/'!S5I_#^K0:@UY#%!(UOJ3WD*-)@2JZ%6!X^4C/!H
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M)3^E+%96\)RD2@^O6IZ*=V+E6X8Q1112&%%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3L/^?ZV_[^K_ (USG]@Z/_T";#_P&3_"C^P='_Z!-A_X#)_A0!T?]IV'_/\
M6W_?U?\ &C^T[#_G^MO^_J_XUSG]@Z/_ - FP_\  9/\*/[!T?\ Z!-A_P"
MR?X4 ='_ &G8?\_UM_W]7_&C^T[#_G^MO^_J_P"-<Y_8.C_] FP_\!D_PH_L
M'1_^@38?^ R?X4 ='_:=A_S_ %M_W]7_ !H_M.P_Y_K;_OZO^-<Y_8.C_P#0
M)L/_  &3_"C^P='_ .@38?\ @,G^% '1_P!IV'_/];?]_5_QH_M*P_Y_;;_O
MZO\ C7.?V#H__0)L/_ 9/\*/[!T?_H$V'_@,G^% '1_VG8?\_P!;?]_5_P :
M/[3L/^?ZV_[^K_C7.?V#H_\ T";#_P !D_PH_L'1_P#H$V'_ (#)_A0!T?\
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66WT^TAD"G#QPJI'X@4 =!1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>drts-20211231x20f024.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 drts-20211231x20f024.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $Y @D# 2(  A$! Q$!_\0
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M_P#UR7^535#9_P#'C;_]<E_E4U '*_$'0-4\3>&&TC2YX83/*GGM*Q'[H')
MP#SP*Y[7O@UX<N/#UQ!HVGQ6VJ;!Y-R\TA&X8Z\D<\]N]>ET4 9V@6]_:Z!8
M6^IO&][%"J3/&<JS 8SFM&BB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO%&% I:!16!N%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!&?3-<+XE\/0:2/[?-W<O</-#-%IX"[9KT+Y<9SC=C)Y&>U,\->(9]$U&VT
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M1110 4444 %%%% !1110 4444 %%%% !6?:_\AF__P!V/^M:%9]K_P AF_\
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MY7(+9/3BN7G\/_$R<RI_PEVG)"Y8?+9?,%/X=<4 =5X.>UE\(:7)96 L+5X
MT5J)-_EJ>0-W?U_&MRLGPQHB^'/#=AI"SM.+6+89&&-QR23CMR:UJ "BO/=4
M\?7 ^(^E>'M-1&LFG:"\N&7.9 N[RU/8@8)^N*S-1^(/B"*XU76+2&Q_L'2;
MY;.6%U;SIN0&<-G P3P,4 >JT5YQ<^-]2C\<+8I+:_8Q>PVWV,Q_O7C>,N9M
MV>@^F.*ZCPOJEYK<%WJ4NU;&6<K8J%P3$O&\GON.2/;% &BG_(:E_P"N"_\
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M "BBB@ HHHH **** "BBB@ HHHH *S[7_D,W_P#NQ_UK0K/M?^0S?_[L?]:
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ML<:#"H@P /0"@#C?"GPST7PU(+R4-J.J,=SWEU\QW=RH/3Z]:[6BB@ HHHH
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M#<3A6.YESSC.<"O9K09L+<?],E_E7G3> /%>G+=Z9X?\516NAW,CN(9K??+
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MC9:3R+'>2[P"D Y8 =RV-OXUS,/@S5(?'J7Z6UNMJE[]I6^$H#B$1;!;[>N
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M_P!8T[6+BR:PU 2K%"JE96Q_'D$D8["@#W&D9E12S$!0,DGL*\G\3>(M2O9
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MD02R11"%22PR@Z*0#\P'OFM:RTVST_38].M8!':1)Y:1 D@+Z<\U8C+F)#(
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MK.XM)F.#+.@X'M[UR(ZSTBBO+] ^(5["LD6I0S7W='B0;A]?:MS_ (6);_\
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M4_Y]+W_P':@"_15#^U4_Y]+W_P !VH_M5/\ GTO?_ =J +]%4/[53_GTO?\
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M1_:J?\^E[_X#M7.=!YQHO@;7;*'P;'<6\(_LF]N)+DK,"-C9VE?7KTZU?L?
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MX1TKPS-+<VKW!)B$*F>;>(8@2P1?10370UF^(8Y9?#FI1P F9K:0(!USM.*
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M:RMEBENVGDGDR2SMCN367XF^QV&L>)=:T[QE<66KP*A:SV*@)'W4.X9<'VH
M];MYX[JVCGB),<BAER"#@^U2UGZ'=W%]H5C=72>7/- KR+C&"1S6A0 4444
M-=UC1G=@JJ,DD\ 5RVG?$7PWJ>JQZ?;7<OF3,4ADD@=(IF'4(Y&#73W!A%M*
M;C9Y.P^9O^[MQSGVQ7DFFZII'B_Q7IZVUQIVFZ'I$[?8;42*DES-TR$'1?3U
MH [?_A8/AS^WO['^V/\ :/-\CS/);RO,_N;\8W>U=17SX)5_X0\:4LJ#5_\
MA)<^3G]YG>3G'7&.]?0$8(B4-U YH ?1110 5!>WEMIUE->7<RPV\*%Y)'/"
M@=ZGK/UN;38-%O)M76%M/2,M.LRAE*CL0>OTH R="\>:#XAU#[#93SK<%/,C
M2>W>+S4_O)N'S"H;#XC^&]2U9-,M;FXDN'E,2XM9-A89S\V,=JY+PUJ=IXK\
M0OXBGO[2QBMK26#3-.AD5IDCQ\TCJ.<X'"UGZ%<)X<NO"\7ASQ7-JUIJ%TT4
MUBZH $.2S[ -R$'DYH ]IHHHH **** *&LZS8:!I<VHZE<""UBQN<@GDG
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MD%K',ES(48Q.3C9N48(QSB@#T.BBB@ HHHH JZAJ%KI6GSWU[,L5O A>1V[
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M/>/_ '1_*I* .JHKE:* .JHKE:* .JHKE:* .JHKE:* .JHKE:* .JHKE:*
M.JJCJFCZ?K=LMMJ5I'<PJX<)(#@,.AK#HH V]2T;3]7M$M=0M([B!&5U1P<
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MFP7-[<16<:37W_'RX!S+QCFL^Y\$>&KO2X=,GT:W>S@8M%%@C83UP0<U5HH
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>drts-20211231x20f025.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 drts-20211231x20f025.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $Y @D# 2(  A$! Q$!_\0
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MS_A'-&_Z!=I_WZ%'_".:-_T"[3_OT*TZ* ,S_A'-&_Z!=I_WZ%'_  CFC?\
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M^_0K3HH S/\ A'-&_P"@7:?]^A1_PCFC?] NT_[]"M.B@#,_X1S1O^@7:?\
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MT_[]"M.B@#)E\.Z,(G(TNTR%/_+(5Y3]GA_YY)_WS7M,O^ID_P!T_P J\:I
M>J^'/^1<T[_KW3^5:=9GAS_D7-._Z]T_E6G3 **** /GTVOAB\\=>-X_$FO3
MZ8AN\1K%=&(2\'.5 .[''!]:[[X-7E]=>"2ESEK6"Y>*RD,80O",8.![YYKM
M)="TB>=IYM*L9)F.YI'MT+$^I)%7D18T"(H55& JC  H =1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 ,E_U,G^Z?Y5XU7LLO^ID_P!T_P J\:I >J^'/^1<
MT[_KW3^5:=9GAS_D7-._Z]T_E6G3 *9+*D,3RR'"(I9CZ <FGT4 <1X6\>2>
M)_%>I:?'8/;6%O:QSP23H4EE#'&XJ>BD=.]96G_$O4;F]T^^GTRVC\/:CJ#6
M%O,LK&8,"0KL.F"1VK6T[2[U?BOK]]):S+97&G011SE?D=AU /J*X;3?#FNO
M;:#X1GT:\B73-9-Y-?LH\AH58LI5L\DYQB@#H]0^)>HVM]J-Y#IEK)X?TW4%
ML+F9I6$S,2 64=, FK\OCJ]3QH-,6WM/L U%-.(+'SRS0^9YH[;.W3WS7':K
MX=UT0:_X3BT:\E&JZRM[#?*H\A82RLQ9L\$8Z5WOB[3(VBMK;3;!!J^H$62Z
M@L&7MX<?O'+XXPF0.>I% &IX;UJ?7H;R_P#+C33S<-'9, =TL:_*7/L6!Q[#
MWIFJ>--#T?48[&[N\3,<.%4L(O=CVKD--CURP\>PZ?;KJ,=E!=&)8 A^QK8"
M !"#C&_S/?.?:N3\0>&]:_X2.\"Z=?2K-=.()'0$S?Q9&#Z9].E=.&I4ZDK3
M=CFQ-2=.-X*Y[Q'(DL:R1L&1@"K+R"#WI]><:+X"OI]&LY)M=U>QD:(%K;.W
MRC_=QGM5[_A7MU_T->K?]]__ %ZETZ5_C_!C52K_ "?BCN:Y[4/&NA:9JJ:=
M<W@6<G#D*2L9_P!H]JQ_^%>W7_0UZM_WW_\ 7KR_5M U2VUV6R-G>2RRS.+<
MRJ-]R ?O#GO6U##TIR:<S*MB*L(W4#Z'1E= RD,I&01R"*=7EMK\,+^]LK>X
M?Q;KUB\D2%K57VB(XY7&>U3?\*FO?^A[\0?]_?\ Z]<<DD[([(MM79Z917F?
M_"IKW_H>_$'_ ']_^O1_PJ:]_P"A[\0?]_?_ *](9Z917F?_  J:]_Z'OQ!_
MW]_^O1_PJ:]_Z'OQ!_W]_P#KT >F45YG_P *FO?^A[\0?]_?_KTG_"IKW_H>
M_$'_ ']_^O0!VNN>*-(\.1J^J7BP[NBX+$\XS@=JAO\ QEH.FZ8FHW&HQBVD
M!*,H+$XZ\#FO$/'?PT\41:G';Z:^L:[ 8@TD\[ A6R<*.>?7\:YC7/"/BG3/
M#R7>H66IQQ)G[3YY'EQC< N.3G- 'U3I^I6FJVBW5E.LT+=&7U]".QJEJOB?
M2=&G2"]N@DK#.Q5+$#U..E>;?#CPEK%WX;#:C<ZCI<@(V*I $R%05?@^G'X5
M-K_@?68=1W6PFU&.0#]\Q&_/HV3^M SU:WN8;NW2XMY%EBD&Y70Y!%9%UXNT
M2RU#[#/?*LP.&^4E5/H3T%<_I?@.]CTZ%9]:O+67&6A@;Y4/H.:X_5/"VI6O
MB(::!YTMPQ,,A8?O!ZGT/K0![6K!E#*001D$=Z6LJPTB2UT^WMWO[HM%&J$J
MXQD#MQ5G[ W_ #_7?_?8_P *!%RBJ?V!O^?Z[_[['^%'V!O^?Z[_ .^Q_A0!
M<HJG]@;_ )_KO_OL?X4?8&_Y_KO_ +['^% %RBJ?V!O^?Z[_ .^Q_A1]@;_G
M^N_^^Q_A0!<HJG]@;_G^N_\ OL?X4?8&_P"?Z[_[['^% %RBJ?V!O^?Z[_[[
M'^%'V!O^?Z[_ .^Q_A0!<HJG]@;_ )_KO_OL?X4?8&_Y_KO_ +['^% %RBJ?
MV!O^?Z[_ .^Q_A1]@;_G^N_^^Q_A0!<HJG]@;_G^N_\ OL?X4?8&_P"?Z[_[
M['^% %RBJ?V!O^?Z[_[['^%'V!O^?Z[_ .^Q_A0!<HJG]@;_ )_KO_OL?X4?
M8&_Y_KO_ +['^% %RBJ?V!O^?Z[_ .^Q_A1]@;_G^N_^^Q_A0!<HJG]@;_G^
MN_\ OL?X4?8&_P"?Z[_[['^% %RBJ?V!O^?Z[_[['^%'V!O^?Z[_ .^Q_A0!
M<HJG]@;_ )_KO_OL?X4?8&_Y_KO_ +['^% %RBJ?V!O^?Z[_ .^Q_A1]@;_G
M^N_^^Q_A0!<HJG]@;_G^N_\ OL?X4?8&_P"?V\_[Z'^% %RBJ%IYD>H7$#3R
M2HJ(R^802"<Y[>U7Z &2_P"ID_W3_*O&J]EE_P!3)_NG^5>-4@/5?#G_ "+F
MG?\ 7NG\JTZS/#G_ "+FG?\ 7NG\JTZ8!1110 45SOCG7KCPSX-U'5K2)9+B
M!!Y8894$L%R?89S7)6/C'6-!\07>E:UJ=MJZ?V2VI0SPQ",J5!)0A>"".AH
M]/HKRGPYXO\ $J:IX:DUB]M[JU\1V\LD4"0"/[,ZC<JAA]X'@<U'H/C[6(H;
MZZU&62\\NP61[<VXC,%ZTI1;=< 9S\O7)[T >LUF:B!_:VD?]=Y/_135+HL=
M[#H]M'J5T+F^"#SY0  7/)  Z 9P/85%J/\ R%]'_P"N\G_HIJ -2BBB@ K@
M_$P_XN3X8^CUWE<)XF_Y*5X9^CUOA_B?H_R,,1\*]5^9W8Z44=J*P-PHHHH
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ME,N6D^_(Q_0#TKU:B@#RWPUX-\1KK'AL:W;V<-GX<@DCAEAGWM<LPPIVX^4
M#O75ZMI-]K'B>T+IY6FZ?$UQ$Y8'S;I@54D=<(,G/J1Z5T]% 'GOP[\,ZOH=
M]/)?VHM(S9102CSQ)]IN%9BT_!XR"!SS77:C_P A?1_^N\G_ **:M2LO4?\
MD+Z/_P!=Y/\ T4U &I1110 5PGB;_DI7AGZ/7=UPGB;_ )*5X9^CUOA_B?H_
MR,,1\*]5^9W?:BCM16!N%%%% !1110 4444 %<+\8?\ DF.K?2/_ -#6NZKR
M;XVW>L7>DVV@:3IM[<K<'S;F2"!G4*I^5<@=2>?PH ](T#_D7=,_Z](O_0!5
MNXN[>T$9N)DB\R18TWMC<YX"CW->)>#/#GCS7M%WR>+M6TA[=O)^RW%LPPH
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M[?5UFLG2"WM;;#^9^ &?I5?2= OO^$S\*SW6ES?9[;0_*E>2'*QR;?NG/1J
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MD_W3_*O&J]EE_P!3)_NG^5>-4@/5?#G_ "+FG?\ 7NG\JTZS/#G_ "+FG?\
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M-_R4KPS]'KNZX3Q-_P E*\,_1ZWP_P 3]'^1AB/A7JOS.[[44=J*P-PHHHH
M**** "BBB@ HHHH *\T^,'_'IX<_["\7]:]+KS3XP?\ 'IX<_P"PO%_6@#TJ
MEHHH **** .-?_DJ<7_7F?Y&NRKC7_Y*G%_UYG^1KLJ "BBB@ HHHH ****
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M]'KNZX3Q-_R4GPQ]'K?#_$_1_D88CX5ZK\SN^U% HK W"BBB@ HHHH ****
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M%4  < #H*6E[2C_)^(_9U?Y_P.#_ .%FQ_\ 0O:K_P!^Q1_PLV/_ *%[5?\
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MM%87_"9^'?\ H*P_DW^%'_"9^'?^@K#^3?X4 ;M%87_"9^'?^@K#^3?X4?\
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M=F41OG^(;>U=)J/_ "%]'_Z[R?\ HIJ -2BBB@ HHHH **** "BBB@ HHHH
M**** .+^*'_(H-_UWC_G74V\\5OI<$DTB1QK$I9G; ' [FO+/BI+K']IQ1W
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M0   !T I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME?F&!M;(Z<]: .KT_1M,TEIFT^PMK4SMOE,,83>?4XJ'4?\ D+Z/_P!=Y/\
MT4U2Z->7.H:/:WEW:_9)IXQ(8-VXH#R 3ZXQGWJ+4?\ D+Z/_P!=Y/\ T4U
M&I1110 4444 %%%% !1110 4444 %%%% $%U9VU]"8;JWCGB)!*2*&&1TX-$
M]G;75J;:X@CE@( ,;J"N.W%3T4[L5D-1$C1410JJ,!0, #TJ&YLK6\\O[3;Q
M3>6P=/,0-M8=QGO5BBE=[A9!BN#U\#_A:/A[C_EF_P#6N\K@]?\ ^2I>'O\
MKF_]:WP_Q/T?Y&.(^%>J_,[L4M%%8&X5YKK'_)>_#_\ V#I?_9J]*/ KYR\:
M_$66U^+:ZEI"6TO]FQFS0S$E')R&)P1P"<?A0!]&T5YC'KGQ;DC5T\.:"R,
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M -$^'_@6* /3**\S_P"$S^(O_1/A_P"!8H_X3/XB_P#1/A_X%B@#TRBO,_\
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M_P#(7T?_ *[R?^BFK4K+U'_D+Z/_ -=Y/_134 :E%%% !1110 4444 %%%%
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M:(QS/!+%,NUXY$.&5AZBDU02+>:=<)!+*D,K%Q&N2 48#CZD4 :E%9_]J_\
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>"O)** /6)IXO)D_>I]T_Q"O'=Z_WE_.K5-I!8__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>drts-20211231x20f026.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 drts-20211231x20f026.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $Y A # 2(  A$! Q$!_\0
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M6KV$5]I]S'<VLHRDL;9!I;_4+32[*6]O[F*VMHAEY96VJHH I_\ "-:+_P!
MRV_[XJIJGAW1XM(O9(].MU=('96"<@A3S3]$\9>'_$5R]MI>I1SSHN\Q%61]
MO]X!@"1[BM#6/^0)?_\ 7M)_Z": (-"_X][O_K]G_P#0S6I67H7_ ![W?_7[
M/_Z&:U* "BBB@#@?$_AOQAJQU;3;;5-/ET;5 %(NT/F6BXPP0*,,.XS5?5/
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MUJT@:*1@S")I T?(X/!QD>E>V9MEN]N8A<NN<<;V4?J13FMH'9F:&-F;!)*
MDXZ?E6IWGB6M:W+%<>+I1XFU&'6++4]NEV*7!VOG;A1'_&#R,=JF\017@O\
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M_P#U[2?^@FIX+6WMMWD011;NOEH%S^50:Q_R!+__ *]I/_030!!H7_'O=_\
M7[/_ .AFM2LO0O\ CWN_^OV?_P!#-:E !1110 4444 %9VO_ /(N:G_UZ2_^
M@FM&L[7_ /D7-3_Z])?_ $$T 78/^/>/_<'\JDJ.#_CWC_W!_*I* "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HJE>RW<=Q;+;F#9*^QO,4DC@GC!]J
MNT %%%% !1110 4444 %%%5-3FN8-/FEM%1I47< _3 Z]Q0!;HJKITMQ/I\,
MMTJK,Z[F"]!Z=_2K5 !114<D\,1 DE1">@9@,T 24444 %%%% !0<X..M%%
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MO\C5RJ=_]^S_ .OA?Y&@"Y1110 4444 %%%5-2U"'2].GO;C/E0KN;;U/L*
M&:9_J[G_ *^I?_0JO5R/A/Q9::Q=7%FL4D,S.\ZAR"&4G)Y'<9KKJ "BBB@
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M5]1NY6REM'P-[$GAL=%'L:A>QM(?B!K5G>F.>&V\+I';M, <J!AB,_2NQO\
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M "G JW;_ /'M%_N#^5$ZKE/F6G8(4E&'*]>YYY;WVJ_#VZ2SU(R7N@NVV&Y
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M?.-2+%RVT=-Q/&,5V=</\-M2N+ZVUF&?6I-9%K?&*.\( 5TV*1MQ]3GWKN*
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M?1,_9;S;C/VR?&?]\UYWK</BZY=;S6_#'@V0J-BS7=R>!V&6%>BZ%_Q[W?\
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M?0<5V.G_ .IEY_Y;R_\ H9JV1E2.1D8XK!+?8-&NS&\CR23R1H'<MR7(&,T
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M!<HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *I:Q_R!+_ /Z]I/\ T$U=JEK'_($O_P#KVD_]!- $&A?\>]W_
M -?L_P#Z&:X?QY%>:-XHM_$=GXBTC1FDM/LC?;$+-, V[&!G(''2NXT+_CWN
M_P#K]G_]#-<;XNL[S3O&\'B!O#LNOV+6/V40Q*KO;.&)+!3U# ]?:@#H_!ES
MJ=[HQNM2U;3M3$KYAGL%*ILQT.>^<UT=<7\.M+O;*SU6\NM._LN/4+YKB#3\
MC]PFT#D#@$D9Q7:4 <1XC\?_ -E>)M.T2RLWGDFO(K>ZG="(XMXR%#=WQSCT
MI/$WC#5[/Q#-HV@:=;W<]I9&^NVN)2@"9P%7'5CBIO'NG7=[/X9-G:RS"#68
M9IC&N=B '+'V]ZQ/$T.IZ'XYU/6(-'O-1M=4TG[&GV1-Y28$X##L#GK0!<F^
M(5[JD>@0>&].AFO]7M7NPMW(52)$X()'4[LBM+3?$B^*_AS>:F(#!*;:>.:$
MG/ER*"&&>_-<98:%J_@F7PCJLVEW5\EEIDMI=Q6:^8\3NQ<<=QDXS70^$=%O
MM$^%E_%J,)@NKA+JZ>$]8]^2%/OB@#O8/^/>/_<'\JDJ.#_CWC_W!_*I* "B
MBB@ HHHH :[K&C.Y"JHR2>PKSW1D;QKXPDUN92=*TYO+M$8<._\ >_K^57/'
M>J7%U);>%],.;V_($I'_ "SB[Y^O/X UU6CZ7;Z-I5O86PQ'"N,]V/<GW)KH
MC^[I\W5_D<\OWD^7HOS+U9NO:K%HVC7%[-&9%0!0@.-Q/ &>U:58%_&OB-I-
M/49L <3R?WB.R_XUSG08'A#Q=:RB>UDLGBDW&0>43(&!/3GIC-97B_S?B#J%
MOHFGW0_LZTD$NHP1G,KX. IQPHZ]>_TI-?O;+X?^'I3I$;R:[J<KVEHI.Y_O
M$9 ]!Q]3BNH^'WA%?"7AU89B)-2N3YU[,>2\A[9]!T_,]Z ,?QB=6@T"VM[.
MQ>RT^+]VZ0MG"@84''1:N^!]5N;?21#J[S(&?-O).#RF!QD^]=7JO_((O?\
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MX\;?_KDO\A4] !6=J<KK+:A+:>7;*')C3( &1S^=:-% !1110 4444 %%%%
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MUE,WB6TL[:Y$F(UM'+*4P.3[YS6Y0 445S$'Q"\,W.L+I4.I![QIS;B,1/\
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M% !1110 4444 %4M8_Y E_\ ]>TG_H)J[5+6/^0)?_\ 7M)_Z": *^A@&VO
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MLB@58HHJSI22T04AS@XZTM% REIUO<VZS"X:([Y&D'EYXR<GK5J5S'&S[&?
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M9B#+%&Y'0LH.*DHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'0#O6MX7DF\1>.]"U"&QN[>#2-&-M<M<0M&!,V!L&>N,4 >E?V/IG_0.L_\
MOPO^%']CZ9_T#K/_ +\+_A5VB@"E_8^F?] ZS_[\+_A1_8^F?] ZS_[\+_A5
MVB@"E_8^F?\ 0.L_^_"_X4?V/IG_ $#K/_OPO^%7:* *7]CZ9_T#K3_OPO\
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M (-"_P"/>[_Z_9__ $,UJ5EZ%_Q[W?\ U^S_ /H9K4H **** "BBB@ HHHH
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MK^>\GGR0C<IP#_$>X!]:@\.WE^/&N@6R7NIBRUBSF:475^)9)1LR)-J\1GT
M/\J /;J,UXSH^L:QJ%_HW@R?4+H7VG:C.VHSAR'>WBY3<WHVX#WQ5.PU74M,
MUJRO]6O[ZZAGU'RAJ.GZBLL,N6($;0'[HZ#CD8H ]CT_5[/4YKV&W<F6RG,$
MZ,I!5L _D000>]7ZX;3R8?C/K4<?$<^DP2R@=-ZN5!/OBNYH **** "BBB@
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#1__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>drts-20211231x20f027.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 drts-20211231x20f027.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $Z A(# 2(  A$! Q$!_\0
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MN?'&L&^NTGT,0C33%.RK$ H?( .#GOFO7]#O7U#0--O)L"6XMHY6'3YBH)H
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M.]K>P&*3:?X@.X]Q6AJ.L6FFZ3>:B[^;#:1M)*(2&;"C)'7K0 S_ (1S1O\
MH%VG_?H4?\(YHW_0+M/^_0K L?B1IMU<V,5QIFL6"WS!+::[M-L<A(RH# GK
M44WQ+M8=5.F'P[XA-WM9UB%F,L@."P&[E?>@#I/^$<T;_H%VG_?H4?\ ".:-
M_P! NT_[]"K_ )R+;^?)F--N]M_&T8SS3;6Z@OK6*ZM9DF@E4.DB'*L#W!H
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M(YHW_0+M/^_0H_X1S1O^@7:?]^A6G10!F?\ ".:-_P! NT_[]"C_ (1S1O\
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MCS<'.2&8DGGI[9JSJ?P[N-3N+R"3Q+?C1+V<3W&GLBN2<@[5D/*KD=,5W5%
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MKEMJZVC',>H2OAN,HQ^5A['!KMZ "BBB@ HHHH **** "BBB@ HHHH ****
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MJW\JP=%\?>'M?U3^SK"\=YR&:+?"R+,%^\48C#8]JW9O^/NV^K?RH LT444
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M **** "BBB@ HHHH **** "BBB@#R#4/^0E=?]=G_F:*-0_Y"5U_UV?^9HI
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M_![2+-M$E\1R7/VW5]0D;[3,_P!Z,@_<_D3^%>F4 %-<,R,%;:Q'!QG!IU%
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MA*Z_Z[/_ #-%&H?\A*Z_Z[/_ #-%(#T?PYN_L%-N-WF38SZ^8U<C]K^+6?\
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MT>7Z;\/=5;481J$$:VA;]Z4G!./:NG/PXT<?ZN>]C_W91_A74_:&_P"?6?\
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M/M#?\^L_Y+_C1]H;_GUG_)?\: )Z*@^T-_SZS_DO^-'VAO\ GUG_ "7_ !H
MGHJ#[0W_ #ZS_DO^-'VAO^?6?\E_QH GHJ#[0W_/K/\ DO\ C1]H;_GUG_)?
M\: )Z*@^T-_SZS_DO^-'VAO^?6?\E_QH GHJ#[0W_/K/^2_XT?:&_P"?6?\
M)?\ &@">BH/M#?\ /K/^2_XT?:&_Y]9_R7_&@">BH/M#?\^L_P"2_P"-'VAO
M^?6?\E_QH GHJ#[0W_/K/^2_XT?:&_Y]9_R7_&@">BFHQ=02C+[-UIU 'D&H
M?\A*Z_Z[/_,T4:A_R$KK_KL_\S12 ](\-?\ ($C_ .NLO_HQJUZR/#7_ "!(
M_P#KK+_Z,:M>F 4444 %%%% !63KWAK2?$MJEOJMH)TC;?&P8HR-ZJRD$5K4
M4 4]+TJQT73HM/TZV2WM8AA(TZ#N>O)/O6%KWQ T+P[J?V"]:Y>5$62=H(&D
M6W0G :0C[HKJ>U>)>(+NWTS7OB7%J,T<4MY80FU61L&5=I&%SUY(&!0![5%*
MDT22QL'C=0RL.A!Y!I]8WA*&>W\'Z-#<Y\Y+*(.#U!VCBMF@ HHHH **** "
MBBB@ IDDB11-)(ZHBC+,QP /4FGU3U33+/6=.EL-0@$]K+CS(R2 P!!P<=N*
M ,S2/&.C:WI^H:A:7!^QV,C1RSNN%.T9+*>ZX[U7\.^.]%\37SV=F;F*<1^=
M&ES 8O.CSC>F?O+7 V%H3\/_ (AVME$!MOKA8XXAC "C@ >PJ?0[VTU;QYX+
M;2YXYUM-%8W)B(/E@J  V.ASVH ]>HHHH **** "BBB@ HHHH R]?\0:=X:T
MQK_4IC'"&"*JJ69V/154=2?2LS3O'FA:AIM_>M+/:#3QF[ANX3%)$,9!*GU[
M8J3QKKVD^&] ;4M5MXK@1N/(A=02\O\ "%ST/OVKRO4HUU7P%XIUIM3LK[6;
MX0RW5O92!Q;0JPVIQUP,Y/M0!ZKX;\9Z3XGEF@LA<PW$2B1H;J Q.4/1P#U4
M^M=%7F'AZ[M]5^*\=UIEQ'/:PZ'&DKQ,"H)/"DCO[5Z?0 4444 %%%% !111
M0 5D>(?$FG>&K-+B_:4F5Q'###&9))7/\*J.IK7K!\3:QI>E16RZC<BT>YD\
MJWNFB#+#(1PQ)X7ZF@"O!X\T";P[<:V;EXK:V;RYXY8BLL;_ -PIUW>U6?#G
MBS3/$Z3_ &+[1%-;D":WNH3%*F>02I[&O&YRJ>%=;C21;V"SUR"6?5%Y^T@D
M;F;M\O3CBN[\+7,&I_%CQ%?Z?*D]D+.&(S1'<A?KC(X)Q0!Z-1110 4444 %
M%%% !1110!!>7<%A9RW5S(L4$2EW=NB@5SJ>/]#;PJOB(R3K8NYCC!B/F2-G
M "J.I/:L3XE/J]U-9:=!H=_J&CG,UY]D*@R8^ZAR1\N>3]*\\T^[E/@KP[+<
M6,UKI]CK:M)-(1Y;*6/(QT"G@YH ]O\ #WB73O$UI+/8F96A?RYH9XS')$WH
MRGI6Q7GG@&1;SQEXPOK659;*2YC5)$.59@O.#WKT.@ HHHH **** "BBB@ K
M \2>,-*\*FV&H_:"]R2(T@@,C' R>!6_7GGC:TT>[\6Z:;_Q+=Z-=Q6TI@,)
M$8;U(D/ /MUH VIO'^BP:#!J[B\$5Q)Y4,'V9O.D?T5.M:N@^(-/\2::+[3I
M&:/<4=)$*/&PZJRGH:\CM-:N[M_!VJZU=^9:V^I30B^FPJR(.$=CTY]:Z_X8
M,)Y_$]["0UI<:FQA=?NO@8)![T 8.H?\A*Z_Z[/_ #-%&H?\A*Z_Z[/_ #-%
M(#TCPU_R!(_^NLO_ *,:M>LCPU_R!(_^NLO_ *,:M>F 4444 %%%% !1110
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MK/'%<3+<,RW#[UD7HRMG(-:-QXLTJW\2V_A\R2/J$X)"QQEE7C/S-T' K<H
MY-?"EOX<2^U+0K*2]U6XA$;K=7K?O^>K,V>?>J7@OP'#I/A:]L-8M+=Y=2E>
M2ZAC)* 'H@/M7<T4 <MIO@?2M#N1?VJWEU=P1-';?:[MI1"I'W4W'"BI_!FA
MSZ'HKI>;?MMU/)=7 4Y"LYSC/? P*Z*B@ HHHH **** "BBB@ HHHH ****
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M_P#06L/_  )3_&@#0HK/_M[1_P#H+6'_ ($I_C1_;VC_ /06L/\ P)3_ !H
MT**S_P"WM'_Z"UA_X$I_C1_;VC_]!:P_\"4_QH P_&NCZOK]DVF6MEI-S93Q
MD,]X[J\,G9U !SC\#FL*\^'VK7%O>P&]@F\VRL[".65CN,<;;I2W'4]A7<_V
M]H__ $%K#_P)3_&C^WM'_P"@M8?^!*?XT <+<^!M=GU.]B$FG_V9=:K#?22%
MF\YXTVXCQC QM]:GTKP3J-EJ]Y+=6]G=(;N:]@N7NY<B1L[#Y.-@8<#=SP*[
M+^WM&_Z"UA_X$I_C2_V]H_\ T%K#_P "4_QH X>V^'NHPV&EVPGM(VM--NHG
MD0G)N9A@MTY'7GK61?:+K>A::;B^BMC<#2/[)T^VTY9)&\QNK$[>,@9SP!7I
M_P#;VC_]!:P_\"4_QI/[>T?_ *"UA_X$I_C0!Q.H> ]4N;62&VEMH471HM,@
M#,<KE@92<#C(&!6SXE\/:E<7&A7FC"T>72I&*P7+LB,"FP'(!P1UZ5O?V]HW
M_06L/_ E/\:/[>T?_H+6'_@2G^- '/Z)H?B#P_8FTMWTVX\U)KF>68N"]T[9
M  '2/MGKQ63I'@[6M-O=5U6&QT6TENH%A73(9'^SR_-EGD;'WB,@8'UKMEUW
M2&.%U2Q)]!<)_C3_ .U]-_Z"%I_W_7_&@#SRV^'.I_8+Z!ETZR@U"]MY);"U
M9C##%&<MMR.7;'H!5ZX\"7UQ-?2NUH#>:O#<O@GBVBQM7I][CITKM?[7TW_H
M(6G_ '_7_&C^U],_Z"%I_P!_U_QH \AM4U :\EJL'VJPLM5N-4N'AM9?,8C)
M4-N4#.< !<YZ]*ZR+POJM_X*U0RF.+7-=^>Y,I($2'@1\ _=3CZYKLO[7TW_
M *"-I_W_ %_QH_M?3?\ H(VG_?\ 7_&@#B=3\ 7=R-;%H;2/[3:6]C9;B1Y<
M*_?SQP3[>E=#X<T"?2=4UF\G:(_;)8Q"J$G;%&@50>.O6M7^U]-_Z"%I_P!_
MU_QH_M?3?^@A:?\ ?]?\: +M%4O[7TW_ *"%I_W_ %_QH_M?3?\ H(6G_?\
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MGBAO;F.-9I,*DK #YCV!H_MC4_\ H(W?_?\ ;_&F,]<HKR/^V-3_ .@C=_\
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M_P BW:?^/?XT?\*J\#?]"Y:?F_\ C7*?VQJ?_01N_P#O^W^-']L:G_T$;O\
M[_M_C0!U?_"JO W_ $+EI^;_ .-'_"JO W_0N6GYO_C7*?VQJ?\ T$;O_O\
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M_P#0MVGYM_C7*?VQJ?\ T$;O_O\ M_C1_;&I_P#01N_^_P"W^- '5_\ "J?
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)22QYYHH&?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>drts-20211231x20f028.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 drts-20211231x20f028.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $Y A$# 2(  A$! Q$!_\0
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M1_8FE?\ 0.M?^_0JY&_F*3C&&(_(T^@"A_8FE?\ 0.M?^_0H_L32O^@=:_\
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M)H^K3:9<M>/=0HKR+!:22A0PR"2H-177Q%\.6NE6NJ&YGDLKE799H;9W5=I
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M0_L32O\ H'6O_?H4?V)I7_0.M?\ OT*OT4 4/[$TK_H'6O\ WZ%']B:5_P!
MZU_[]"K]% %#^Q-*_P"@=:_]^A1_8FE?] ZU_P"_0J_10!0_L32O^@=:_P#?
MH4?V)I7_ $#K7_OT*OT4 4/[$TK_ *!UK_WZ%']B:5_T#K7_ +]"K]% %#^Q
M-*_Z!UK_ -^A1_8FE?\ 0.M?^_0J_10!0_L32O\ H'6O_?H4?V)I7_0.M?\
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M=.>PL=2NK:74%FT[Q(EM9?OY2(82ZY503R#DYSFO<Z* /&-6EO6CU[[1+?\
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M/^0%8?\ 7!/Y5B_$#4;_ $OPL]QI_P!F20SQ1O/=1[X[=&;!D8=P,BMK1/\
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M"VB&%1>_J2>Y/K5Z@ HHHH @M_OS_P#73^@J>H+<.&E+(5W/N&2/0#M]*GH
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M<$_E5#Q3.W]D21VVB0Z[.KH6L'=!P?XCNXXH).5\)>(]9U#Q%;VUYXR\-:E
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MV]$;MLTC^9O?=M<J.,=*+J\M[&!I[J9(8EZLYP*\JT_QGXDN;R.VMY('EF?
M4Q  D^]=5:^#)K^<7GB2]>]FZB!6(C7V_P#U8J%4YOA1R4L=[=?N(M^NB.*\
M9ZQ::UK8N+,LT21B/<RXW$$\CVK4^'FC6&HW-U<7<"S-;[=BMRHSGDCOTKT*
MXL+&#3Y$6VMT5(R%&P#'%7((8(US#'&H/4HH&?RJ52][F;,H9<_;^VJ._E8;
M<#;;.JH3E< *,U*I##< 1GU&*=16YZH4C?=/TI:1ONGZ4 >54444%'H^B?\
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MXH1Z,W)_#K0W84I**NV7:*XZ;QU]KE,&AZ9<W\G0/M*H/\_A4?\ 9'BS6_\
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M3\MGV';^=0:!X.TS1[HW:03F=21&T[JVT>P'?WKIZ;;>K'HM$%1F%3*),MN
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M[O4_K0!ZY??&3P59-L34I+MQVM8&?]3@5GGXN7-^O_$A\&:U?Y^Z[Q^6A_$
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M8Q=O&A+M[J#@#W!K'O?%_B(PZKXLAU5X[#3]7%BFF^6IC>(,%8L<9W'.<YH
M]B\N?_GNO_?O_P"O1Y<__/=?^_?_ ->I5(8 @Y!Y!I: (?+G_P">Z_\ ?O\
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MN);3[5E[L0X 8@CD$=O6KGAGQDNMOJ-IJ-BVE:EII'VNVFE#*JD9#A^A7WH
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MJ,UQJ9GN!'&8K:4('B)3)8A57AGSCKP*ZB74=%U*:;1I;RRN)I4>.2T,JEF
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>drts-20211231x20f029.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 drts-20211231x20f029.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $[ A(# 2(  A$! Q$!_\0
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MWZ%'_".:-_T"[3_OT*TZ* ,S_A'-&_Z!=I_WZ%'_  CFC?\ 0+M/^_0K3HH
MS/\ A'-&_P"@7:?]^A1_PCFC?] NT_[]"M.B@#,_X1S1O^@7:?\ ?H4?\(YH
MW_0+M/\ OT*TZ* ,S_A'-&_Z!=I_WZ%'_".:-_T"[3_OT*TZ* ,S_A'-&_Z!
M=I_WZ%'_  CFC?\ 0+M/^_0K3HH S/\ A'-&_P"@7:?]^A1_PCFC?] NT_[]
M"M.B@#,_X1S1O^@7:?\ ?H4?\(YHW_0+M/\ OT*TZ* ,S_A'-&_Z!=I_WZ%'
M_".:-_T"[3_OT*TZ* ,S_A'-&_Z!=I_WZ%'_  CFC?\ 0+M/^_0K3HH S/\
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M_P"@7:?]^A1_PCFC?] NT_[]"M.B@#,_X1S1O^@7:?\ ?H4?\(YHW_0+M/\
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MU96#*&!!!Y!'>L^?7=+MKB:":^@26"/S)$9N57U-<NOPPTX(H;5=5R  =LP
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MJ?\ :-OHENMSN9@6+,H)Z_*21W]*OZGX1\/ZO9-:7ND6CPL02%C"'(Z<K@T
M<);?';P_)-9K/:7,$<L9:X?!;R'[+@#Y@?45=_X75X9GU73[.R,TT=S+Y<L[
MH8UAST)R.>:U8?A1X)@G2:/0H]Z,&7,TA&1[%L&N1^(7AG16^(/A)?[.A5;Z
MX,=RJ#8)%&, @?7M0![".113418T5%&%48 ]!3J "LCQ-X@M?#&@76K70W)
MN0@."[=E'U-:]<=\4+"UOOA_JIN81(;>$S19)&UU'!H QH/CAX2>P26:2YBN
MC'N:W\EF(;^[NQ@_6DL/CCX3GLHI;Z2XL[AA\\'E-)M_X$!@U9\%>#?#U_\
M#C3K>ZTFWD2[A668D'<SGONZCH.AKH])\$>&M#ADBL-'MD21MS;U\PD_5LT
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M:V26XG8D%9'Y2,#UV\GTR* ->Y_U#?4?SJ:H;G_CW;ZC^=34 %%%% !1110
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M%4F25%[#G'X5Z'0!Q.LVL^K_ !/T2VEAD;3M.MI+[=L.QIR=B9/3(&3BN?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)NWC\.E6?^%B>'?^?F7_ +\F@#JJ*Y7_ (6)X=_Y^9?^_)H_X6)X=_Y^9?\
MOR: .JHKC)OB5HJ3QI&EQ+&WWY F-GX'DT7'Q*T6-XQ"MQ.&/SLJ;=H]>>M
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MC:F--U#5[>"[.,QMD[,]-Q PN??%2:UXQ\/^'I8(M5U2"V>==T:G+$K_ 'N
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MNM7$/FWFI@M,F[#*+=>%0>IYZ4 >E7WQ-\-Z?J5U8327C3VK[)O*LY'"GKU
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M$>G116^H36%W;RK/!<1\[7'J,\CVK'TWP7JTGB--=\0ZW%?W<$#P6Z06PB1
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M^'[VC^'?,OUD72;>2!P(R/-W9Y'/'6NR^TK_ ,\YO^_9H^TK_P \YO\ OV:
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M 25&6('3-9'_  EFM_\ /[_Y"3_"C_A+-;_Y_?\ R$G^% &G=?#8:A=QB_\
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15D2WMP\SNTF69B2<"BD,_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>drts-20211231x20f030.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 drts-20211231x20f030.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $] A4# 2(  A$! Q$!_\0
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MBB@ HHJO?6BW]C/:/))&LR%"\;89<]P?6A R/4]3M-(L);V]E$<,8R2>I/8
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MJ*QRN0.1GBNN\$Z1)8S:K?7%EJ5M<7LB&1K^YCE>7:N V(Q@>GOB@#KJ***
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MMQ)IA1112&%%%% !1110 4444 %%%% !1110!5O/X/Q_I11>?P?C_2BF(FB
M:W4'H5Q7&2^$?$>GLRZ!XNN(;8GBWOX1<;/97/S8^M=I#_J4^E>??$'Q7K&E
M:@=.TFYM+-H;![^2:X7<TH5MOEQCIGN:0S6TWPIJ[7T-YK_B:[OVA8/';P(+
M>'(Z%@.6^A.*ZZN8\*Z_=:OJ6OV=PUO*NGW@CBGMSE71EW '_:7.#73T %%%
M% !1110 5#/_ ,LO^NBU-4,__++_ *Z+0!-1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)_K77S_\LO\ KHM $U%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV-=S/_RR_P"NBUPGAK1->O?&,.OZ[8Q6 LM-%A#$LHD,C9RS\=!7=S_\LO\
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M/^0I9?23^0J[5*X_Y"EE])/Y"KM !1110 4444 %%%% !1110 4444 %%%%
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MF8?SKNPH48 P!V%+1[:,?ABOGJ'L9/XI/\CA1\/);UP^L:_?79[JC;5K8LO
MWAVPPT>FQR,/XI27/Z\5T5%*6(J/2XXT*:UL<5_PB.BKXV%T+*0#R_,$6S]U
MOS][_P"MTS7:UF&=_P#A(!']GEV^01YF!MZ@YJY=WEM86SW-W/'##&,M)(V
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !112,RHI+$ #J30
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MG2*+%%<1JOQ8\):9E%U#[9*.!':J9"?Q'%8K?$?Q/K0 \->#[IT;I/=_(O\
MG\: /4<U4O-4L-/C+WEY! OK)(%_G7G)\.?$K7F!U/Q%;:3 3S%9+EA^/_UZ
M;=_!33;C3[HRZG>WNIO&1%<7<A*JW8D4 <KJOQCO;?X@W5QIR+=Z6B&UA@X
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M,ZFBBB@04444 5;S^#\?Z447G\'X_P!**8B>'_4I]*?3(?\ 4I]*?2&%%%%
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MD]>]=/K &O\ Q/TW1)?FL=+MCJ4\?9Y2VV//L.30!U\\BS0PRKD*Z[AD8."
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MK;^Z* +=%5/M;?W11]K;^Z* +=%5/M;?W11]K;^Z* +=%5/M;?W11]K;^Z*
3%O/X/Q_I14,TQDVY &,T4P/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>drts-20211231x20f031.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 drts-20211231x20f031.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $] A0# 2(  A$! Q$!_\0
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M6-X8O[_5=$BU'4(EA:Z9I880I!2$GY WJVW!/UK9H **,CUHS0 449%&1ZT
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MT@T/QT'8GQ%;E3T&WI_X[7<T55]RG%.WD<,^A^.B,+XAMP<]=O\ ]C2G1?'
M!/\ PD%O@>W_ -C7<4U_N-]*5] Y;2YC@M#N/$VN^'IA!JJ1W<5X5,KH.4 Z
M<#U]JLQR:[X>N8;S7]<BDL6;RS&D98LQZ?PC'KFI/AU_R"K[_K\?^E6?'6G7
MFIZ3;Q64#S.MPK,J]0.>:F,G)79CA)N=&,I;LT='>Z^V:C'=:G;796;,<40
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MLT:/#*LDCR"2)EQM&YCC!P?PJ"RKI'BZ1-*TNU>ROM1U&:Q%RQB"\J#@DL2
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M#I;&4H# WG /D[2<XP">N,U7B\*ZKIC03:7?VGG?8UM)Q<Q,5(7HRX((/L:
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M:]I8::VIW5Y)):!F2TDD5HXG)/(P,G@\9) H H>&M<U73K#2DN;.W.FW-Q+
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M:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!1NO\ 7?A11=?Z[\**8BW#_J$^E/ID/^H3Z4^D,**** .#^)EA
M=WUOHY-A<:AH\-Z)-2M+8;I)(P." .2 >2!7&'PSK5QX,U)M/TJ[AT^#68K_
M $S39EQ-Y*GYP%/(SG(!YXKV^B@#SKPKILFO>+?$GB*^TJ>WT[4(8;6&WOX=
MK2JH^8E#VSQ6=J%C>);:IJ^C64UE;6,B6%E':P[7CA\Q3<S(N/O-R <9POO7
MJU% '+>#;C4;GPM-)J#7+CSYQ;/=+ME>W#'RRX(!SCU&:ZA?NCZ4R?\ X]Y/
M]T_RIZ_='TH 6BBB@ HHHH **** .+\>_P#'QHG_ %]C^E=I7#?$41$:2)SB
M(W!WG)'RXYY%5O[,^'7_ #W7_P #[C_XNLDTI.YPTZD(5ZG,TMOR/0JY[Q!K
MUQI.JZ3:PPQNMY-L<OG(&0./?FN?_LSX<_\ /=?_  /N/_BZC_X1GP;J=Y;I
MINHI'M?]Y#]ID<S#^Z"S9!^E6I1>S.J-:G)V4D_F>BT5RG@*(0:3?VZ,YB@U
M*XBC#NSE5#<#))-=75&@4444 %%%% !1110 4444 %%%% !1110 4444 %8N
MJK =9THR:N]I()#LME; N#CH1WK:K$UF>*VU+3Y)M*^T1JS%KPXQ:C'WB35T
M]R)[&W16:GB#29-.;4$U"W-HK;6FW_*#Z5.=4L5NX;4W4(GG7?%'NY=?44N6
M78?-'N6Z*H#6M-:&ZE%[ 8[4[9VW\1GWIQU;3U^RYO(1]J_U'S?ZSZ4<LNP^
M9=R[15-=5L6EN8ENXC):C,Z[N8Q[TPZWI@M;>Y-] (+A@L4F_ASZ"CE?87-'
MN7Z*JC4K(WLEF+J+[3&F]XMWS*OJ14']O:5]A^W?VA;_ &7?Y?F[_EW9QBCE
MEV#FCW-&BJAU.R%['9FZB^TR)O2+=\S+ZBHAK>F&UGN1?0&"W;9+)OX0^AHY
M9=A\R[FA15,ZK8++;1&[A#W0S N[F0>WK2+JVGL;H+>0DVO^OPW^K^OI2Y7V
M#F7<NT51.LZ:(;:8WL CNCM@;=Q(?:GC4[)KJ:U%U%Y\"[Y8]W*#U-'*^P<R
M[ENBLXZ[I0L4O3?V_P!FD?8LN_Y2W3%3_P!I67V[[%]JB^U%/,\K=\VWUI\L
MNPN:/<M45GC7=*-G+>"_M_LT3['DW_*K>AJ4ZI8K<P6YNHA-<+NB3=RX]11R
MR[!S1[ENBBBI*"BBB@ HHHH **** "BBB@"C=?Z[\**+K_7?A13$6X?]0GTI
M],A_U"?2GTAA1110!B>(M2UK3HX&T;0_[59V(D7[2L/EC'!YZYKE;;XG3GPI
M?:Y>:$T/E72V=K$EP'%S*3M(#8Q@'OSWK?\ B!<WUKX'U1M-AFEO)(O)B6%"
MS9<A<@#T!)KGO&OAB>U^&^E6.E6C3?V1/;3F")<LZQGYL#N>2: +"_$6XM].
MUQ=3T<6NKZ3Y0>T6X#HXE("$/CIDC/%68?'-S)IDJMI\1UA=3.EQVR3$QR2#
M!+!L9"A<D\=JR_"]@OBCQ?XHUVZTV=-(OX(;2.*]@*&8*/F.T]L\5G:C:2VE
MOJNJ^'K-K2TTIQ967E0EF5F=?M-P%.2Q"_*#S]TT >K39^S29_N'I]*D7[H^
ME<MX-OK^_P##-U)?333JMS/':W$T>QYH <(Y&!U'? S74K]T?2@!:*** "BB
MB@ HHHH J7^F66IQK'>VT<Z*<J'&<&J/_")Z!_T"K;_OFMFBDXI[D2I0D[R2
M9C?\(GH'_0*MO^^:\ZU&SAM/B+#;6D CB2YAVH@X'0UZ]7FMSJDFE_$Z4QQ(
M_P!H:.!MW8''(]ZB44FK(YZE.,)P<8K?]&=%X(_X\M6_["UU_P"AUU%<OX(_
MX\M6_P"PM=?^AUU%:'6%%%% !1110 4444 %%%% !1110 4444 %%%% !3)8
MDFC:.5%=&&&5AD$>]/HH H)HFEQV)L4T^V6U)W&$1C:3ZXJ8Z?9M<Q7)M83/
M"NV.38-R#T!["K-%/F?<7*NQ3&E:>(KB(65OLN3F9?+&)#_M>M*=,L6^SYM(
M#]F_U'R#]W_N^E6Z*.9]PY5V*HTZR62>1;6$/<#$S;!F0?[7K3#I&G&VAMS8
MVYA@8-$GEC"$=P.U7:*.9]PY5V*PL+07;W7V:+[0Z['EV#<R^A/I47]C:;]C
M^Q_8+;[-NW^5Y0V[LYSCUJ]11S/N'*NQ6-A:&[2Z-M#]H1=BR[!N5?0'TJ,:
M1IPMYK<6-N(9VW2IY8PY]2.]7:*.9]PY453IMDTEO(;2$O;C$+;!F/\ W?2@
M:98J;@BT@!N?]=\@_>?[WK5JBB[[ARKL4SI5@8K>(V<!CMSF%?+&(S[>E/&G
MV:W,MP+:(33+MDDV#<X]">]6:*.9]PY5V*)T?33:):&PMOLZ-O6+RQM5NN0/
M6I?L%I]K^U_9H?M(79YNP;MOIGTJS11S/N'*NQ2&CZ:+62U^PVWV>1M[Q>6-
MK'U(]:D.GV;3PSFUA,L VQ/L&4'H#VJS11S/N'*@HHHI#"BBB@ HHHH ****
M "BBB@"C=?Z[\**+K_7?A13$6X?]0GTKD]<^(=CH.K2Z=-H^MW$D84F2ULFD
MC.1GAAUKK(?]0GTKE/B)J%]8:%:?8K]]/%Q?P6\]XB;C!&Q(+8^N!^-(8OA_
MQ_9>(=46P@TG6;9RC/YEW9-$G';<>]=;7D/@G5=27QM9Z;?^*+W4KG9=QW=B
MX %N\;85FP.58<CW(KUZ@ HKG_%?B<>&[6T$5F][?WTZVUI:JX3S'/JQZ =S
M61-X^N=-\,7FI:QH-S:7MO<+;1VN\,MP['"F.3&"I]<<8H [>BN!'Q&GM].U
MA=1T8VNL:8\*/:"X#H_FD+&P<#IDC/'%68/',\NED'3X_P"V/[3.F+:K*2CR
MJ?F8-C.T+ECQVH [&?\ X]Y/]T_RIZ_='TJ.?_CVD_W#_*I%^Z/I0 M%%% !
M1110 4444 %%%% !7FT^FIJ/Q/F#W*P^2T<PSU<C'RCWKTFO(O%$C67Q ^UR
M0R,B312 *O+ 8Z5$MT<];XH>OZ,ZBRTKQAH\M]'IPT*6UGO);E#<23*XWG."
M%7%6]WCW_GAX;_[_ %Q_\36GX?\ $%OXAM))[>*6(1OL99,9SU[5KU9T'*[O
M'O\ SP\-_P#?ZX_^)HW>/?\ GAX;_P"_UQ_\37544 <5?:UXNT5K2;4K70WM
MIKF*!_L\TQ<;V"Y&Y0.]=K7*>//^07IW_82MO_1@KJZ "BBB@ HHHH ****
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M1]* %HHHH **** "BBB@ HHHH *X?QL/^)]X>_Z^/_9EKN*X?QO_ ,A[P_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@"C=?Z[\**+K_7?A13$6X?]0GTK \:
M"W.@XN?#DNOQ^<G^AQJ&.>?FP>./ZUO0_P"H3Z5Y1XI\6ZAI?B+Q3='5V@72
MK2."PTX$ 3RS*,2$=6(/UI#)O">F/)X[M-0T_P #2>';.&UECN9+A54REL;0
MH'<$'GT)KU6O)_"<>I^'O'6DZ5-KEYJ3ZCIKW&H07,N_[/*,$$?W<YQBO6*
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M!MT5RG_""Q_]#+XG_P#!H]'_  @L?_0R^)__  :/0!U=%<I_P@L?_0R^)_\
MP:/1_P (+'_T,OB?_P &CT =717*?\(+'_T,OB?_ ,&CT?\ ""Q_]#+XG_\
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M ,'"_P#QNNJHH Y7^VO&7_0GVG_@X7_XW1_;7C+_ *$^T_\ !PO_ ,;KJJ*
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MO^_3?X5K_P!AZ3_T#+/_ +\K_A1_8>D_] RS_P"_*_X5-JG=&?+BOYH_<_\
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MQ7\T?N?^9D?\)]X=_P"?UO\ OTW^%'_"?>'?^?UO^_3?X5K_ -AZ3_T#+/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MF""4F.5G^Z03R!0!Z+17'^%?%6J:CK-WHNN6-M:W\$*7"FUD9T=&^O.1784
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0?A14,]QOESMQQZT4Q'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>drts-20211231x20f032.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 drts-20211231x20f032.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %@ C,# 2(  A$! Q$!_\0
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M8#$>F>N* /%_%EXEW;ZYX@TM]5>6TOO+34;G4Q'Y3A@/+BA7JOUK=ODUV_\
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MLDGZ9-'P^T6]\/\ @C3],U&-8[J$/O57# 9<D<CV- &M<_\ 'P_X?RHHN?\
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M@ HHHH **** "BBB@ HHHH JVFFV-C-<S6EI#!)=/YD[QH%,K?WF/<U:HHH
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M[N/$^H_-/<L1 #_"O0D?R'L*[RMZS44J2Z;^IE!7?.PHHHKG-0HHHH ****
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MHHH *IV^G);7DMRLT[/+]X/)E?;CVJY10 4444 %%%% !1110 4444 %%%%
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MY%M4\@8!]>:UO#OAVT\-6,UI9R3/'-<27#&5@2&<Y(X XK7H **** "BBB@
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MVD5A#93L@8N7YG;I@JI//TZT >U Y&115>PMVM=/MK=WWM%$B%O[Q  S5B@
M->(:SXLN;GQIKL5QXNU71=/MKE;:$VUGYL2D+AF=L87YJ]OKS3Q)IWCK4K36
M?#PT_3KJQU&3$&H"01>1$2,AX^K,,=10!Z-;?\>T7[[SOD7]Y_?XZ_CUI/\
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M*<>;<YZ..IU9<JT/6F944LS!0.Y.*YGQ5XI?2-)DDTI(+N\S@!Y,)&.[,1U
M]!R37-?VE;:B0UQX@@4GUCDD(_/ JIK%KX>72I&?Q-=//@E5:,;'(Z ( /YU
MPW7-R]3I=6"5VRYX?\<:K=&:VN6MI9Y#BW^4JVXY.,9^8>@Z\4_4/!6H^)Y
M^MS7=U&#D0S3>7"/I&G]<US/@VXT:#5X[W4;_P N:W8-#&(2P<X()SVZUZ/)
MXZTA/N?:)/\ =CQ_,TIS5/2>GJ3#$4ZD>:+T*.D_#RRTO_CV2WM21@F"+YC_
M ,"/-;L/AK3XN71Y3_MM_A62?'D#'$&G74A_#^F:0^+M3D_U&@3GTW;O\*R^
MLT^C*]K =K/@6QU6[%P]U+;HB!1'&JA1[\UH^'/#L?AR&:&&[FFCE8-MD &T
M^V/7^E>;>,?&6JW4S:7<6PM43#21JQR^1D9]O:K'A_Q7K.HVK6[ZO;6D=N%
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MSDF&2:W)Z!)@0/P.:X;QOX5B\.VUK+#J#7*2R,NU@ 5P,]C7M?E1_P#/-/\
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M)_WT*/*C_P">:?\ ?(H\J/\ YYI_WR* #SHO^>B?]]"CS8O^>B?]]"CRH_\
MGFG_ 'R*/*C_ .>:?]\B@ \Z+_GHG_?0H\Z+_GHG_?0H\J/_ )YI_P!\BCRH
M_P#GFG_?(H /.B_YZ)_WT*/.B_YZ)_WT*/*C_P">:?\ ?(H\J/\ YYI_WR*
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M4-K>W-J(9)X6/&Y",9['%>F^'=.U'3=/9-4U>;4[B5_,,DD:ILR!\J@=@<T
M2ZMXATG0FMEU2_AM3<OY<(D.-[>@_,5+J>L:?HT,4VHW26\<LJPQL^?F=NB_
M4XKP_P ?ZMI/B+QKK-MJ5Q,L&FV+6MCY43./M1P2QV],'BM'6/$/_"2?"KPO
M>2/NNHM8M8+C/42)N!S]1@_C0![;FJ-_K.G:9<V=O>W<<,U[+Y-LC9S(_H*\
M[6X\2^(O''BO2+;Q+-IUII[1-"(HD9P2@(&2.%SDGN:YF^US5/%.G> ;F>>.
M+4O[9>W-RL8*EU( ?;T]\=* />*,UYAI6N:MHWB#Q7HFI>(/M$&GV:W4-]>P
MKF$L.=P7&0,]/:LK0O$NN6WB_P .PMK&K:C8ZKO65[^R6"*0A<AH1C<!]>U
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M !1110 4444 %%%% !1110 4444 9US_ ,?#_A_*BBY_X^'_  _E13$78/\
M41_[HJ2H8)(Q!&"ZCY1WI_FQ_P#/1/\ OH4ACZ*9YL?_ #T3_OH4>;'_ ,]$
M_P"^A0 ^BF>;'_ST3_OH4>;'_P ]$_[Z% #Z*9YL?_/1/^^A1YL?_/1/^^A0
M ^BF>;'_ ,]$_P"^A1YL?_/1/^^A0 ^BF>;'_P ]$_[Z%'FQ_P#/1/\ OH4
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MN%' #@=:+?X?Z+:VVB01FZ,>C3-/:9EZ,QR0W'(KI_-C_P">B?\ ?0H\V/\
MYZ)_WT* ,74O">FZGX@T_7)/.BU"QR(Y87V[E_NMQR.O'N:DN_#.GWOB:P\0
M3>=]ML8VCAVOA,-G.1WZUK>;'_ST3_OH4>;'_P ]$_[Z% "NH=&0]",&N4B^
M'.A0Z38::AN_L]C>&]AS-\WF9SR<<CVKJO-C_P">B?\ ?0H\V/\ YZ)_WT*
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B/-C_ .>B?]]"@"C<_P#'P_X?RHI+AU,[$,".._M13$?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>drts-20211231x20f033.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 drts-20211231x20f033.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &P 7L# 2(  A$! Q$!_\0
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MHH **** "BBB@ HHHH **** "BBB@ Q1110 8HQ110 F!Z48'H*6B@ HHHH
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MP^#/_'KXA_["<E>H5Y?\&?\ CU\0_P#83DKU"@ HHHH **** "BBB@ HHHH
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MZD[*1W%>J5Y9\%8TAL->AC7:D>HNJ@=  !7J= !1110 4444 %%%% !1110
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M2[[=2WG'&UP#CBJVM_%#2=&U2?3TMKJ]EMQFX-NFX1?6@#O:*YG_ (3;1O\
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M7\*Z9X6MI(],WB&<AR&;(_"NBK@_A7XE?7_"4*7.[[7:?NI-PP2!T/Y5WF:
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M(4D/11W_ )UZ4* %HHHH **** "BBB@ HHHH *3%+10 A% '-+10 F*,4M%
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MO"<TKRR63L[L6),AY-=[29H PO#OA/3/"T4T6EQ-&DS!F4MD9K>HHH ****
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MM!_WW7J(I: /+?\ A*_B/_T*T'_?='_"5_$?_H5H/^^Z]2HH \M_X2KXC_\
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MK0]7*B_BMO\ 6(1U4]Q6QX6O'\%>)K_0?%:"6+46'EWT@RL@Q@ D]N:ZK0?
M-QX>\8R:AI-\JZ)<KNEM3R">V/:@#+\(6]WKOC"SU2UTZ?3-!TRW,5O#)\OF
M,1C)'X]:]86-57   ]!2JBJ %4 >@IU !1110 4UC6#XI\5V/A733>7CY).V
M.%>6D/H!7"6WQC:.]C36]$N=/M9SA)F!X]Z -_Q1\2?#VA7K:;=K)=-C$ZQ)
MN5 ?[U>7^*_"=O8I!XCT(O>^&+B59KFUC<X7G)X].M7M0TY-(V:1=7D$B^)+
MTRO?$?=@],^^*UOA[H]_;^)=5M-)G2Y\*>:8F$QW G'.W\R* .SM].\,>/\
MP=;+%;(; J @4;6B8=A_*NIT[3[?3+"&RM4V00J$1?84:=IMII=FMI90)! G
M1$&!5O%   !2T44 (QQ6=JNM:?HUM]HU&\BMXR< N<9/M5RZD:*UEE1"[(A8
M(.K$#I7ANC2VOQ \:7[>+IS;FS!$&FN=B@#J?J* )?'1F;Q%8>,H9$UK086
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M9Z8KE_(CP6]3WK9'2@!0,# HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** $Q1MI:* $ Q2T44 %%%% !2
M$9I:* *UW8V]]:R6UU$LL,@PZ,,AA572/#^F:#;M!IEG%;1L=S"-<9-:=% "
M8I:** "BBB@""ZMDNK2:W?[DJ%&^A&*\1\-:[/\ "O7+KP]KD4G]E32F2WN%
M&0 >_P#*O=:SM3T6PUBW,%_:13Q]A(N<4 >1^-->LO'VNZ%I7AXO<2PW(FEG
M4$+&M>TQQ[8U4\D <UFZ3X:TG0U(TVQAM\]2B\G\:UJ "BBB@ HHHH ****
+"BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>drts-20211231x20f034.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 drts-20211231x20f034.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $N ;T# 2(  A$! Q$!_\0
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M8SWSTQ5U;9<Y5B4;KP>:S>@RS]E!3. <]:J21,KY7=TJTD_D(R@[@>%7N/\
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MW!#4^;2P6**R2M<@KL,2@AU7K^?I5RW<7,X5E ; +'&>*JR683:R*X"Y& 0
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MV:5"'^[CC%9UZ%5B7DPO7.!_G%4H+D95TC(D3(P.3G@FKYA6\M_.C?!=>&[
M]#46Y7J/<S8VCNXM\<BRHQ(&T^A[$]:T+0.=L9CV]0<C^M4&A,._?P0<*W3I
M[?YZU8M'N0WRL.!G.>#FJ=["ZF^B+)$R#(..>]95[9E2-@R#P26.5]Q5][K9
M#N7&XC)X-5#=JQ'F-EASM(K*-UJ446C<?-OZCC/)H\Q80%RH[JJGG/OCI_\
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M&XJ.<XX_"K5II:AA(<?3 I7E\Q\I(H0=5[U>A@?(Y(!Z\4.4NH61-!"J@D9
M'0XK)U0#?\AR6.3D?RK9EE2WAX(XK#DD6\)<\ MC'&<>M3"][C94=6D<!Y6/
M. Q;_/'2E2.2!CC!!QDGOV[>U:8M][\(N"1R3G _QJ.X2**X\M9=K?>VD\X]
MJTY^@6*CK"Z$,<%1LVCK]#QS5BTC>)/+<8CR=H[CZ4IMYC)RH^89SMZGU(IE
MS'=)^\22<,HVX(&#SG< .<]J3=] +I8S;0>6'3(Q3#:[AMDCW#.01W_"J<-T
MZN$R6&W[Q/3\ZAEUR/2Y(Y;B67;)(L8C";BS,<# %)KE5Q+5EV:V0*5V.OR%
M=H/3/ID&LL%X+QDEE.V,C&Y^3QZ5J7MQ%(^X"1N!@IQS5.ZM?WN!(KRM@G(Y
MX_\ UU4?,3+^GW!*&-R</D_,._I2-&40@!=P[  54MTEBNE#.=F<.N.#_A5B
MYD=I)%C ##L.M)K490%LS?/+"D[ D81>>O ZGGWJ_;6Z^6R290R=F;G/I5>'
MSH<[3C(QZ<]^:D)ED=GQDG&#NIOL(C,!MI3'&28\8QU)_P ^M59)X=)2?4+C
MS)6?'RAF8*!G[J_C5QW&6 .=I"["W4_YSTIMQ<0QW&P J5'SY.%/?K2:OH4G
M8ETFR3R7U":\N9TNG$Z)<$?NP1]U>.![5<N+EU9?)7=QS@U1#R.-GG!0%! )
MQC_&LVY*W14B>6)UR&VA>?S6DH#;NSH<QO&2S!202,CH:HJA\LOY@4]&5CP?
M2IT$FP^8H CRN?[U4+FXBB \]TCC) ^8\9[?J:$3N6@L4D'S!=Q..>01]*KR
M::NQ+D L[#TP >],4L')(VAQVXY]JT;60_9Q$XX!QS_C5.ZV R)XF)(D12,@
M*4]*1KAG<"-&9E;!VD\_6NAN[53%N2,*=N>*RX%$8"JV6!Z8XQW--330FAS)
M)MWB-"0"#NS^?UXJK+'*TH4Q%452SG</RP>IK<AB$P<,B[L_*.X'J*@N;3<W
MEA. ,9Q4J0[&5&L4<KN@9_GXVC.?0'TK2TF.*VLA;QIM4#H[DD=^IY/6K-AI
MB0V_)RQ))]!]/:I9[;;RHR:F4DV"NC*DB,S&6:([P3\GF!N,X!_$<X[5<TZ!
M&S_HZ(>^#S5GR$*AGX]1G.#4D4EN@9D*Y7@XI.6E@*UQ;N[83Y1TSFJ?E)'D
MRRCS 1G Z_2HM9UY=/2-1#)/+,X5(X@"0,\L>?NCO67=ZFHN$VAG5FX8*3MX
M_P \U4$WH-HT'D4GY%S[=?\ ZU0RQK<-^\C8(I&,'O\ TJK&X<DC(3/(SPW3
M-7]S"%0'Z-U'0UHU8DB>W:)B4'R8')Z=>QJ))&D9-KHT>XY&W'>KADS R%MS
M;N"&Z>N,5#$ K%$&X$_*<<C(R:$P(T,H+.Y.%8@+C&:L+,P;(4#GZU#(Q4X4
M$8')7D_B<4SS7#H/,B?=D[CRW3_ZU/<#8@FCEC!G&3CL>,U5O([:9.=A8]/:
MLW[4<%MI(!_A!.?<4^WE9ER.23D'_/X4N2VH7+<5J5WE5!ZDLA[_ $%(X(^<
MNV%R?[W'?CK0\DBJ 58@\#;P :6.[W.L?RD*IR?Y4M0)DD=$^7.2/EQ_/FFS
MSO(!A=O.#VS36D)4!, ?>QC./I[U%YEQ+>QR1/$;/80Z/&=^_L00<8]1BD]-
M1K4T[&X8KME+*JCJQ_K1/%&6!5N^<*:K'>5P"P7&<CDD]A1 DGF/@@.".H-3
M;6X$@B9GP,#],U:C147YP#W/U]JD.4C)10&(RQ.>:I/G?N?CG@"EN,&DC&X,
MQ9>H;!&*ADOU;!3)!&!NXY/\J)C( 9(T#8/4\X%9TD,GF.@8L?NE%P 1U_R*
MN,4R6Q;RZFA8>9\F_C .<^QQ_GI52.61"\C^<Q<\E7  'T_&KEO:I&S22A_G
M^567U]#5.:,;0BR83)#(%(SV_P :T5MA$XF+L\9&Q"N078X _GZ&K.[S0RS,
M"JC.X8Z>A/\ A5:)"SME@VT8#'OQ@#G^?M3P1$K?:(F.W@-TX[?6A@3&<9W%
MU*]0OKQTJTNL%'4N<)T^\"362CC9(\?*CD#!Q^50QLK0F1PCS,PP1D[3GVZ4
M.">X7-F[NR8!F7 )Z8_'BJENQG'S^9P>,G/;KGI5>\MY'MU2%ANW;6\P C\!
M_6I;6YD,>U61EDR.&^48ZTK)+09J6EQ$K;#O(/5LC ]A67>>'],G\0VVM%KC
M[= N$/FMC'T_&DMY6NL&W+[#D?,N#N!(/7D#@UIK$5CPS%B1CJ>:RE",MRXR
M<=BU!<!?F\LOV.9!A?7CTJ:>Y14 5 Y[ UDPLT;;0W _A'&*6:?'RC?SU*C.
M/;MVI\FI-RQ(QNMSHP0*<;6'.?I37DMXG9I%!(Y+ $J![56CE8)]QVW#ID';
MVJ42N0%<<CC@<#VSTIV%<622TE'RLJR8&T#C^59]Q*BM_KO+<<!V!R*F:VL[
M@;+E2_EON0@$;&_#VI+A5='122V/G&S/'6JCHP86TDD@7YBY7@Y&<_6M2W0I
M(ZR*N5/! XK'TU_*G"+Y83AB%!! ]L<$5KW$K,GF)WZ8&#^(I36H(G,*"0D2
M9SR1C&*;=Q*(53Y4[].*JPQ3/(@?=MSSQU_&IKQI"C)D;,8V@U%M1E2:./[(
M9(T9V484@?>/X57LK=+MR1'*"@R4+'K^(Z5,;N62-(79"L?\07T_S^E36&HI
M'(+=HGW,/EVY(_\ UU3;2 D-H1%\J*-H 5:9]H@1B'5E?J0<"I)IN\D;K(HS
MO4$$UG":*8EF$S'W&<4DF]P-&ZF62/$GRG'0<XK*>VAG""=(Y51@ZAU#?,.A
M^M2>?^]W.I50>I.?K44H$HQ%)A&P<XQG'.,_E5*.EF*_4OF6(1-+(V(XP22H
MZ<9_&BRU"*6W!26&>,G@QD, ?3([CTID")'#M;))7##VQ5&.WM=+LV\B".*-
MGRP1 #D]20.M39MVZ%:6\SIX;B.2([I58,> #R/K65<O';7#*5R#@C;V]JSK
M:2+)(41OCIM/7KGV_P#KU//=.UKN49!4CD<D\XIJ%F3<U;&_MD=P0$;/SR-@
M;O>M"2ZA# 9!-<:DVX*K,=Q4;N>G=NOL<U+;RM*Y^<H(VQL(W;A^'2ATE>X7
M.K%ZA7*].>@JE_:,\DSA63RSC;\I#+ZY]>:I*Q5')#$=%QUIULBF4;N2W9:G
MD2'<TC))+;'Y<G\LUE/.8I&!)!(Q@'DUKE(Q$41B?]G=S6?/;,9 95&W!YZD
M>E$&@9AW5O!=#?-'AP "PP&&.ASVIB6J?97,3.V %+L3^N>.?YU;EW).%3("
M\\KF@QPW &QBK<9&/E.>Y'0^M;WT)(;:"7:BN67/))'4^OO5B2(1QDD.2W.=
MH JG=W,L(D$:/GD%P/;K_6JT+K-;1&27:3A"\AY8].GK19O4#8CD"[0P*.,\
M$C=]33W(7]Y&."0,<CZFLZ)7MD8$2.1R<YZXSWJS#<2-8Q.(@DC$,RR."J\_
M-R.O'(]:B5DQI7%N49(OE#.,9)/3'O50;2JC# *ORX7"@#H.>U:*N[J6#94]
M^@]@,=?K52^M7N["YM899+-IXR%FA W1MC 8&G>R"VHRTA^01HH )W=>3Z_G
M5LM';KY1C.!G!VX'YU%;;$B$ N%N[FU"QW!.-V[&=S8]>OXTZ\9=D332.C!A
MP!G-*_,#5AL>Z1B2V6 P%!SQZC].*K.Z;?,158 X<'AA]:LJG[XQ@>F#T^E0
MSV;2L$;)QDAL\Y/?/MBK5A$\3I*) RM&2PVYX' _6K,6U(\ CUP>YJHEI/$/
ME/F(1R&YQ[U+PL.UT4<XW#C _J*EC(DNRCR!F;K\H!(('I5^QOI'8^9&0""$
M&X_6J+VOFS9C?@Y ^7C-3?8Y5G4@@2(!PN0..O/I0^5@C?2=)%8,JC:<9_#.
M:CN(1Y1? /-90EEW[0AVX[\C-74D)5FVL#CIZUCRV'<=!!O)+"0>GRY!JA-8
MK;2[QP2<G//YU8:[D"J-V06Y#,0<>WO49F\RZ 16VYP23CM5*]P9ER:9#Y-Z
MD4EQ&]Y_K724J4&-OR?W>*+=5MK=(2I")@%QRW P.>_2M,A6^8 C (//%5)H
M/-F50Q.",+T /]:J-D)MLNV\$$@<1D>8,=3@]^GO[U*;0)$'=V<KDDC+''OC
MK4EO%%##@\Y'^34Z0"9=Z-MQQR.]0Y#L8,ZH8"4W@'HLF01SZ'I3[?$DW[PA
M^@(''X5?N;6?O@CU;M[T_3H84<[HAO+9R1G'XU?-H*Q4N$C!,9CW#J0W0GO3
M;#3;.TMQ':P^2"S,!U!).3^IK=:W7[PW#!R,\U3G7YMJH 0I;FL^9,>I'))%
M&^\1Y8\J2>!]*D6\A:'E &/3CK_A526WDV!F0N,<X7D4R$A@"Q7)['M[U7*@
M+<'ER3%=H"GH<=*+R&)6,:, _7@?SK-#O;^9*H%S*BDJF,;SV'M5JWE;4+..
MY9)()63YXV/*^HI/25@MI<IB!7F/[S8^#U&0WUJ>/<CE4(=,[2CKP?\ =YJ"
M[+-%M1U;G/N/K3+03R':7P0<@XQ]?K6FZN27[B=<*H4ACQ@=167/FYN5%RIC
M0?=*D@?_ %QQ5]K8[E,D6),Y# \?B?6GBSC)5]RLZ-GD\'_&DFD,@L=(F.R:
M(^45Y#GH:M6<-\LKQW#-AC@.6!S[UHP79$?SJJJ., TV1@F]HV#?+E0.E0YM
M[CL17D\T5LYM "Z*=I;H35%)KJ73HOMRQ&[VCS&A'R9[XSVI)[EQ-%&5*(G#
M8/WLU8W0I;&0#<W3<.HH4;:A?2Q2C6,L71/, )!)..OI5FS2,+YA8!5X)P34
M*R*0%G7,>3C>1_2I%N+4J5)<#.0ISCZ5;U$7;F(S/E?WB; =Q. 1_6J#(L+$
MR2["W.-V,4CO;,?W;8)XVL2<?2J:ZA%&SJUI).P/) !Q^9HC%@V.,84D ;FD
M4 D\@8^G7KUJ&^>ZBM'&G(@N=I,8/W,XS^O3\:LR,D:;@?EQD #MVZ40JLL?
M "E\8!/RTWJ@6C&V=X[VL,\T'DR,H\U"X8JW<9[C(/-21LMP6W<J!\V0, >_
MK3'@>($[<NG\8&<^O_ZJD6&;82RMC/)09 %"LD'468E(P@R_)*L>J\<BJ:*Y
M0;IF&_G&WD=^?J:M13;Y"DJC/49!Y]ZT;?3DGB5T8\'HPX_"ARY=PW,9;;]T
M9FP2Z;6<@@CJ,$?U%.MV4LJ^8%D'RKE<5>O;?[*P+YV#^[WK,:U7[3%=QW#H
M%#CRB5V/NP>1CMC@^Y]:+W06+S%S"7C) =AN)R3]*<$N%9GQG_:V]O7ZTZ.Y
M$-J%55*ALAE&![\4%IC&-K!U<D\OCGTI:@*6D1RZ0L0W5NP_"J_VJ9RJME8T
M. V2"3TQ2R7L@#1"(QLIV@ENHQSBJ+. 6C7<T9(RN?UY_&G%7!Z%HV;QV\K-
M(9(VP,D?=R>QJND,\$:HS.T8.0=V >>HXJQ%_J91#E%X."<Y%3PZ4+J6,KO$
M41#IB4CD]01TQBE*5M06I1ECPK2;GW.1PSDA?P]*)4&WE578NSL>*Z";3!_"
M6V\]3^GTK.DMC&ZX3 W8.2.:<9W!HJI9ED,C,Q4K\I4YP/3FK<=FS1JJ[P!U
MXXQZ8J_:W5F $+H& QM'8>GO5A4\QRR$%2>>]0YOJ-(S4L_+C5$!$:C@8P /
M3BE:$[<*H8D>N*GO+L6YPYXZ9' K.DU3H/,//0FA)L3+1LXUF9PNUV W[<?A
MD]ZJ.WSXC1&!!&3U_6F"_26-B9.,XR>H[TY55@1+L'888'-4E;<+E32+:X@8
MVQN2]N Q42#=*&)Z$GC YQ6XD 6''!=>3D<XJBJ*K;VD3G&P'@U-/J$43QJ9
M45Y6V*K-@L?3'<U#5MBKN1<2T\Z#*@Y!S@&E73LVQ!')R0/2J$&H&VD9@X(!
M^;<#5Z-+<22WT*,DTP'F98\X'ITI2YEL"L26]E'$H:0$ =,_YZ4_[1:YXQG^
M549+THI,DP"@@$LV./QJG*TC_,F"A/!!SD?44U&[U$:IN(,F-5 49)XR#1OA
ME8@97(X[UC1B64$JQ4>A:G^<\7)W9[@]OQI\@KER>T9I5$8^7(P1CFI19NS8
M(P<<''2J$FIYD"J&^49''^?2I8M1GD9CYVU ?N^HIM2"Z+JV1^;(+''.>,U6
MF1E(W95NPST%*-09<,'R>A!/ _ 5CZ?JUSJ,#W5U8_9)?-90C/NRH.,D8XSZ
M5*O>S':ZN:2R2W,@9!D9R&SP?H*M1//$6;:WJ1QQ5'[258JH!7C:, '\:L*Z
M["6W(^<\$MVZ530B.YF+,Q<G<%^XV>:B@O)&C;<K+DX&#3E#22'YI&./R&?6
MJTUK))$59),*X(=)-N .?K^'>G;0#H;&\68$%U^7C%37";I 3]VL*"5X&5WC
M(4<[NF:V[>Y6Z1@O+KV(K*4;.Z&A4MV,S/YC%& ^7/W35>^MP!O15+#IA?ZT
M^::2$[=NT$]3TJI)<HBD.R\\G/I0D]QB>1@ L '(Z]0/K3RKLC1[XR#_  ]V
MJH\YD7,;*ZGC&<8'XU5,C6SJ\P8#^$[JM*XBQ%:*QPT 5<[P%/ JS':O@E5'
M'0)P1FLC4M6DTV%)+>QFO5:11)ME5?*4_P ?/4>PK0MKF2.Y;,6Z+HI .2<T
M7;T"W4D:.9"1Y@RX'):J/ER*?F)7/OR*TRS3NVW.<X.1R,=Z:UM&^X))CC!P
M<'\*:E814MVVI'&&^;N#5\38;8&.!GM52:U@F5BCR)(O?CBF*I4D[RI0  D9
M./K1HP(UNQ).R9#!#ALGE3[9JT)(E@+&$NI..N *B-L<EE(=R>'"$<>E5_*:
M-E&W+DX4DD!2:>C 9<7*"YM(A;L;>1BKMO'[O R"1W!/'%0,K6UU&\3H4?YV
MQ@97.""/SQBKAC*,#'M<@<''7)Z5!"9(78N(\YPQ91P>_'7\JI 7C&;F();I
M&8UX7G&:J76D3%U9(%Y'.UQ6CI< M0SJRA'Y:(\UH_9O-^='90?X2>E9\_*]
M L<[#=K+<21J-I0A&*QD+D@-@'H>#_DU6O;.:ZAEMK>9K<E\^8K8. >1QV(&
M*OVPAGMDGMRVQ@-OF*4/N"#^=#V5Q;N6;+B0YR.F.PP/Y]Z+J2MT92NG<4SI
M% [S2H@7G+XPOXFKEK/M=8SD*>YZ?ITJ!M.CDMM[H&$O+QNHQGZ4BPW<2%SG
M:PP2.YSW_6C<1>.G6[NS;LR$GGI4EK<&,_9W&"./?-9L5Q';K/Y<BR20IDQ!
MQN''&1VJOX=U+^T]-1YBS2*[1F0KM8X)X(K-S7-REJ#Y>8TI;2=KQC*RM$ZD
MH.C!NN,^E9EP%0A5=5<\G@@C':MR3S $*,-BCDYSDU0EMQ*Y=4WC)X)]>M73
MT(D[F4("@178D#'3 'N,?2K@=2B!,>PQU.*;]F8ON V\E0HSV_QIS(%B"E23
MG*C-:MW)*T\1DE8)]X#)YS@U6:XFM7M#]C>8RRK%N5A\@(.6.>W%-OK2]FL9
M+=;TVUTR;5N81]QLG#8^F./K5[0K;5+>QB&JO:2W*@[GARH/I@']:F4G:Q22
MW-F"V2>+"!0 ,[1R,FKUK EO$J[BS]R3WK%B,EO</ND;RG/R($QM]?F'4=^>
ME6C=I%C;(6^;& :RLV/0V2,CVK#U<LL;$*N,\Y[BKZ7R],C/?GI4%_<PR0E,
MJ20>, _I2@FF)G*07:SW3HJ@!3QGC\O6NDL9A" F[.3GDY_"L,VZQ,P5&>3@
MA$QDCC/'MG-:\< V'"L>-I]/TK:HTQ(@U5R9B4&2/NKNX-8PB=U(<JI!P3[#
MK6O<V?\ H^U-RI&  J\XQ5*,D-N="$;C&,\U4'H)E4RP6MS;P-YK/.VU3'&6
M0'W(Z<5?41SQX20!F['J2.*C\P00L[+*@ W,<],#J%')J.QO;>]L!?6=VD]H
MRY0H,YQV]<^U)RUU8[::(N.K%55H@Q'.>PX_G61;7<%[?RO'%-]HM&,3&> K
MR>1M)Z@X'/:M*SU".XM$GM0[12*"C8*DGOP>G2F2@2??+X;Y<D$XS[]J%KZ!
ML1AS)*'^3Y_O#W_QK3MKE8K8+G+GI@<+5-;:6-6=T8*HP#QG/;\ZD<0[=YW!
MSCC/I[4W9B'7-M'=(#<01N%82%77(R.0?K1&(\-#$1\N"44[>#[=*=!*;D;5
M)0JIP&[U6%[+&05B>23<%VY"_C^%0UU*6NAH"U(+ #S(^<Y%1W%C)"A/FKD$
M#YCCCO\ 6I;><(!)YC'<#UZ]?3UJ&9C-*29"03@Y&<?3-";N(R)9D9R Q>,'
M+,,@GKGIS2JLENRC+,I)^4$'\/3TYJ5A:N!()UD#')QDY]^.O2C["70,.PY(
M)_E6MT*Q+:N)IPC,H3/R*_.[BIA!*DF,*4 R0!][_"JL-M;S,)4 $@&/,49)
M'?)/N*M9ZJJA]O)*,2RGW%2WJ.Q(80L> 0 .Y&21]*E!;R"?.XSUP<?E5.\,
MHA5U4@E@-^.U9OF[KJ.+SB0Q.W#$XQW ]>M%KZ@;MM)L#%2H!;&3G\J;=3N8
M@%R.<<#I5*!98LF5P,?4?G3KAV"Q"8CDY)&3D=NE'+J(DC"L S$NW0C.%!_K
M6A83I;&4,QY/3'W>.W%8Z6[%_F_UG'/_ .OK6M#;;D9B.%('WNM3-(:+\DL=
MPI#':<<-6+</(T\\*V\V%QB4J-K\<[>?PK2CC,,I;(=\<+G^=8>N7EYI\;7%
MI;"XE,J1E'DPH!/+$X. ![5"TU*2OH:$5NT:([L5PW*;N?SJO=)'.S#>P.<[
M<<Y]*=]KD(52<AAGCG(]:2)MY\Q-C;N^3Q^%:*^Y(#33+$!O! 'W W+>II+B
MW6VAC(*[O0L3]>:LFU@>>&[V#>B,L;[CG!QD?H/RJM<V=Y-&K6CP*0Z^894S
MN3/S=.C8Z5/,]V.W0=!/)&B^7\Q8=CG-2?;),APA/7+ <?C3PEM;RXC. K8W
M#YB#CI[5&Z!3@#:IR1M(&3ZU6C)')<NP20H#&X.$'\1^IJAJNIZG%;>9I5K!
M<W"MRDLH08/!_&KT<+L(T" @?WES_D46VBVL;.QC5=SF1U08#-ZU$DGH5%VU
M"&[D^SH-@$S(&,>_.P]\'C-1F\$\J,LZ1LO7Y=V!TZ4X6]P86D(!C0G&3@X[
M=JJPP0Q@LNX,ZYZX8-GC'^>]4DA&G!<VKS2QQ!A(O\13C-8\K:HMWJ N9(5M
MOE\O$&&![G/<5<AD <Q2EWEV@[B.O<5GW-U)=;G,S'!^920!UQWX--1U"Y+:
M7JJ,*LJR#AR5X)QV]:UHKQ9<[I4<C@X!/_ZJY>XED6X_=KY0!R90P)8],+CI
M_*I;2]N!$55C'@_PD#/Y_C5RA?45SJK6W+1ERI_W2?O5<AMBVWC"CG%22;?*
M&U^.QZTBLMJFY22IYZYKE;;+"XA9$+9 C!SC&<"HHGAV>6[*0V60%A\WTJZ)
M%GB&0<,.0:JOIEG)+%));Q,\ (B8KRF>N*AME*W4QY-"M4UU]7X2=XO*8*.&
M'OZXJ73KB"XEG6W8$VTYBG&.=X&?Z@YK9EC_ '055R,\\]J@MHX$AD>*U\MW
M)+J% 9CTR?7ZT)6V&Y7W&S!F.  ,KC-0QYBECBPN,[L@\52N+V]%U=)'IV8H
MT5H7\Y1YK=UP>A'OQ3X)7U QLR>3(.=H/5??W]JM/H2XNURU*CO,<9/;%(]L
M$WM+]PXVC.>:;//Y9R&8X.-U59=1;'!7/("]>:M)O8DFDE2/!6)6"G"@]JIW
M,CD_N^03R"<8]JE:5)1T"D#.".O?BEPNP.B(4QN)/ZU2T$0_:)$14W,P4\Y.
M..^/6HQ*1(2B@,!A@Q]^:D^65?DV.@.5&W!'YT@B9LDQD*!W_P ^M5H -<,(
M_P!Z5 '4 8(J%=ZNCEAM8$;=P':IY(2(L842$'@C)8]L$=*H:?-<3PB2\LFL
MI3Q)!)\^",]&'!%":V';2Y:C2&.Z,K1#S539N YQUQCN*THKU3L1FRK8' _+
MCTK*F@D20[-K(P^ZIY)J/,T 9,CG/ /S<?I1RIBN=,]K&I,JJ#+MVD[N .O2
MLBZ=%5@.Y S[^M,AOV0(&RH^\=W.?6H7>/[5ARR\@D$'G(__ %5,8V8VQ;:;
MY2LI+MVSSCGBFQ+"T3+"L<:Y^ZBC'7K[9ILC&0B,##;2P8+P/QI4LG4J ^UC
MC\L55EN+4K:K=VFD0B[NRPA$J(65>%+$ 9'9<UIQ1E@!O&<[@%/4=J<D,QG$
MCR@0A-H0J.6]2>N,=J;>R1VL2&6=(@S!%W-M^8] #ZU',[ZE670L2W4?E,C_
M -W&T'FLU'C2<LRM*H.34,XC>4,6!(  4]C]/\]:D6W1X3M=D./F .,C/IZ\
MUHDDB"U+>VML(FW!#+($7 R23VQ4CVQW!CL'?<PR:J-(MN",DG;\Q)QP.]6H
MY%@12Q+AL8&<D9J;-%:%=GN1J9B:*1X F\W 4;').-O7.0/:I%=@>(P%)Y &
M/SJW8W5I-,;=9T+1@;H\?,">13]26,,K(PP>":E2UL-HSI-LO[L!6<?=(_A/
ML>]+,\D#?=*1E1G=W/2G?NMRK$V >C8Z#ZU,P,APS\8Y/6KN20PRE@ 3D=L=
MJ/LT,-U-<PQ1B60*LDB+AG Z9/XFIGC"SMN)91\PPO7\J<#%ABIW$C!5A@GZ
M&I=@$,H2-DDV^41F/+8Q]:SEMG6X;RMFSKD#(-7!$K?(!N(X  J_86H )D&W
M!X.!C%.ZB@*<&G><^XM\XZ[D_ES5P6?GGRG0;E'RGG%7H(D,A=>F, &EFN!;
MKDC)S@D5FYML=C.M[/)$9.3&3DX..O2ENI57= .,C(Q3Y+O<6^SN4)YP1G-5
M9D\Z16<+D_WC35V]0*SW02=5(8L1G<#49+27#2.[2 YPNW&U<>W4YJ<64>XN
MA+E4/(/(^E/5/*9BJ,P'0*,'/K[U>@%)5"L%B8D'D@?TJS#;.Q#('))Y;C%-
M>=(W.(06& QS5F&]9)1Y:H Y *DXQ[TVV(DAT^8*7('S#"CKBGO92J@P5SP"
MO:IEU"5HB-H!]6Z'\:Y_6+W5OL<":.UO%(9!YC3KN7R^<XYY-9-R6I25W8Z!
M; #:495 '2G2P6T:9EP><KVY]JR?[0>5?+(9@5!RHX&1V/?O5"94O;JUFN3(
MTMJY>)0Y"EB".W7C-/EE:XM+ZF]+/&B PH=S<'=G\JSKV\N/(=U&UD.2!][\
M.]/B9G;<S%01\B8ZFHKFPM(M175)(U6]6$1^:,DE,GY<_6J2LQ#;=[AP8YKA
MIR4W,J_=&?X1]*;87*ON20R-:+\N2O('3!Q].M2FS\J5I"R*LB$;$' ^I]:K
MI)Y3&6)LK@Y#*2%/05>C$$Z20//)%(P@=ML7F'[HQ^?7--V&ZM1$\<:SHPP8
M^%<^X[4Z2W=W\XL9B#P0=OYBKD4,4)BW#+$%@0""/PH;L.Q3^PVL%L\MTJM*
MP(VD<*,]O\:SK>_MHR\+1LZ1G"M&V/J#Z_6MUXXV+ABY8C 3L/K7*:H\-I-'
M;O8QD(@VM$?O#W/<U</>T8F=S;S,)3'+&<GD'I5IX'E.!M:,GIC!%5KAB8""
MA=@.I."?:K$5X([8,4VG'0G./I7*^Z+&O;7$;L(I2JC!P!FBZ6[N8T6UG2&5
M'4RL\>[>O< 9XSZU-'<),RD.0Q&< =*8)XPYC#E&!P7/?ZU+3>XT[&=%9C39
MW$<MU+-*YD+S,6&#QM]!C'%)<:L+=0MVZ)P"HS\WIFM:- -Q+9^OK7%>(]':
M\U73KZW9WF@G\N1<95D;(/MQ^E)^['W47&TI>\7;;4Y+G5DC,F8W<J0T9STS
MUZ#MR?7%;C*Q+J4*'/RNO]*Q)[B?3UE>&R:[E#(@BC'++G!/X#FM.YGFD1?O
M(A4 KG!'^-5!-.S8IM-72+L:1I;A)!O9CDXZBL*^MC'<J(PY3DDE<D=ZFMI+
M>1B8Y8Y9E4*_DR@D<YY'6H+YVOKT6]E?M#/:NDLX"A@\9ZJP(Z'L>Q%4I\NI
M/)<<\;B*)DP7 .W<"/Y43VTCPY505(W,4X'O@?6K<B^>DBJA65!TZJ?I4<3L
MT1"-CC#<8_(=ZT3ZD%:UCW1!3\H(R-QP:T84*H&*?4LW-5(X"H"D $GAAQ^=
M7(2$(R?WF",D9_"B3!#67#C;SVZ]*K&Y69G*Q.K0NR!9EQO( /![@]C4T['!
MV8'(XZ?I4;,LI&&^Z2?PJ;,H"Z^6CE/+;;NV'G:<=/>J95;@ *AWCMT!J[<0
MMY0? (ZD@=.:41!8MV &;E3Z>^/TJD[(3&_8UCVR@R[E;@CL*JS*WG(/+.U#
MD$=_K6NL\BQM&-DC$#'R_G38HB6R4R3P>P%)2:W$T9<LA@&\Q.Y[[5W'WP!U
MI\=Q&MU(BI(I7#,SKD/]#T_PS5^YACCQ(V1[J,X_&LA[RW6X:UCF9Y@GF>7W
MVDX!_'%-:@7I[HF,8V9#8P&QGC-9\\QN 8W", <@,NX$@Y!H>1OE+.D,:KN8
MN/;UIT$8GM8[BW >)@'20'(9:JT5HQ:[D7S3RE6!/&>!@^]6_*4Q;CG>WW2!
MC\32I8E"2I!([YZYJU''VP2O3Z?C0Y=@1G^4TF[>I(SGKP/0TBQ2Q.80R-'C
M.2>?PK;33I4NB6\HVVWY1SNSGUZ8JS)IZ-$615W]0<9P:CVJ*Y3E%CC2Z$Z*
M!.0(V?H<9R 3W'.:G-RS1!F=2O<9SGW%6[JTD67]XF2._3/X5G6-I%9QK#;1
MJL&YF)()VL3DX!/3^7-7IT#U'7D,\D226;[;B(92.1BL;CC.['?'0]LU>LKA
M+Z!9+4@\;@=VY#SR >YX--V).CQR$&-P593R&!&/\:71],MM,MH;:S7;;Q[@
ML9.0!G. 363BU*_0OF7+8;-<%)Y0 Q)!(]#TX%3QJK*N_KUX_P ]:<ME/;S,
M)"QC<[E*MR#_ )[5;:-(8QC;N'8GI5MKH9CD7R8@P4EB,@CK5)I/*N9+G=*7
M*>65W?+USROK[U!:ZK=7L=R+S3Y++R79$+NK"5>S#'2J.IWDME8R7!^9$_>,
MJ1ERRC@@ =R#P>U0K-<S*LT[&K%<2HVX,<G^Z.*2ZNG;"8)##DU6T>]@U'3U
MNX@VR=0\>_*$#I@@]#4DNY92H"C8V&R3]> .OUJU9LG5;DML^R<9#'((./2D
M>8F3!/497(R6I(9'>8 @$ \\<@^]*8Y$N"K%6VGY0."U'4"Y:0RN9" -Y'#
MC 'IBK$:>7,%.0/IWIUGMC12P4. 1D<FJ,MQ.;I L(?#@N6.W"^H]?I6;UN4
M3ZA;H67*X4 YQ6<R1"-QY:L<DKD<=.V:Z)6$\(#@9(YYZUCWD0>;$>$ '3.,
MTX2Z S.-RP6 1AU&X#"K\N.F.>,U!((RQ!+9!QN49QSWQ6B(&".H)7>3QTPU
M551UW+O7< 4)V\L#U)_SVK5-$E&U2&6\D$4I$<<81F";20HX ]>M:B*?,$:P
MD80=\D_6HUCCC9/*5_+'0,O)/]:9!<B-94>55G+$LO)./KZ4/R$73(=JOE50
M E<#.*B@W2V<<<LN]H^3)M #?@.!]*:\NY<$*1MP1TXJ/][;2KO4E23QG@G%
M3R]1W+DL+W"Q*C*ZC^-..*L?8/W8#'!S\IQC'X4ZVV6]N&D<$]<9Z"EN[PRP
MAASZ!3_.IN[V0Q([8! "V0HR2!_6LS6)KV"QE_L^&.>Y _=Q32; _P"/:IED
M:)3M)&\9*YZ^U3>8EU.JS+]W@C':AIC3,JTBFEME:=&$JJ"YA)8*?TR*9?01
M/*%,>T*,#&1FMBX$GG!$GVH><(!G/UZBG+8V\ZAO)( &,#FJ4K":N1R7,;IN
MWJ^!NX)Z>M5XW,D?WPP /W/Z55>-"J93( PI!.-OI[_C5CRC;J6B50FW(4#'
M3MBBU@+-I=1QRH'D!D*X4'@G .:IF';>371N;AT?.(V?*QDXZ<<?_K]:6*-9
MI$GEB ND!VL<,>1@X(_GWJM=:L+'4;2V-I,XO,IYJ+E5;'1O3@9_EFLY63O(
MN-WI$W1+-]A?RV7S",)O&<>_OQ5*:6)."/XNHX&<9S4\:;X<%B #D$#&#[BJ
MK0(&"OE]O(=CZ\9_E512N0V-/F1,QBE)4\C:?;/Z_G5OSO/<<A2!@+Z^]06T
M#1;F:,G=C&T]!4*2A9_**X!;GC]?_K5=KB)#9Q6UR9S!'YK\&1$"LPQW(&3T
MJ]816\;<N2S ?.WWF ]34/F^="$&6W=,-@KQ6-K.L+HVD37CI-,Z#[D8)().
M/\_2LW%6NRDVW9'12KEG:%,@'C%4AY-M$\A!\SN&Z"GZ9>>8D<BDA)55@6!4
MC(S@@_7FI;T)O;S4.<<L#C'^<4T^@F9OVQY80 .,@X(['O[T1L5N!(9VR5\L
M1[AMZ_>/?/;KC%5I$8-^[E,:ELD=C3X09&&]MQZ9QGOS^'%:V0B[YBMR0WR]
M2W:JBXAD 20LW).[G(ZXYJ>#=G#J<MR!NP/\\_I3&5FF.4#*<@]01[@U*L!/
M#<'RU(VXXR<<TZ:XA*[PI8AL?-P1CV[U&T7EMT^4XQCM_G-5M1FO?LYDTZ)9
M)QM*K)T/(S],C//:D[+4:5] 6];SBGH?O@X YZ5NV]\D:8=LD#DXQ61<QJ@"
MR$!@PP>H(%21JTPY60$\_.>"/:B24D+8EGN#(Y"MN!Z\TD%@+FX!!3>J_> *
MG].14MO9MYX3&U#]YB.#UZ5NP0)!&%15'J0.M1*26B'8SX]/"H5VY9L<OSBK
M"V"*A4A2N.@&*N8I<@'DBLG)L9DRVSA@$7 SR!4MK"N[!/X"K$\\2!MW'O68
MUXB2C#?,2,8ZU:NT(U+^Y2RL9;AXW=(E+%8QEB!Z"J5M?^;9(S !SG<H!&#Z
M<_A0;X%=K$]*S_/#331+%)&$(8LR@*^>N/6I4'?4JZL5[YIYYTGCD 3:4:,Q
MC))(P<]1TQ^-36L"N=O0C'(-&U"I0OUZ D9:K4*P!CMR''1QW'>MMEH3N131
M1P2\2+YB)N=%(# 9Z_2B749$0B.,!L9/0BFGR%>5D0;G7:['DD>]9C12"=1&
M"XSCV4>]$5?X@?D:W]HQN52:=/.=-RH#@GWQU_&F*?-8HK,,#YFQTJOY$"LL
MK+&\Z!E1O+^8 ]<'J.:6*Y9COP/+#<@@YZ=Z.45R#59H]/M_-*2L2P3]VI<C
M/&['IZTUR0B",8B5L;,\X[G/>K=Q+YJ;QO7(SG=C;66+A2(I%;SX""-\3@@X
M/8CCBJBN@,T;9EN'49QN. .W'<9K4G$@W,@P-O!SU_$US\4YG9&4C*-M<#T]
M:Z*VD-[;M"Y&#E>G-3-6U!&3$6L2_F,SB3YF.>_]*+BY(EW$(RGD$CG\ZBO;
M62/4/+DD0Q  Q$#;L'\08]ZKV;RA9#D.!UW $$5:5]0-ZT!DM5*_> YPH Y]
M*K/PY 4EB,A0>GKCWJ]IT06/.-N[&1U^E5+V%(I,$,1UR&P?K62>MBAECJ4T
M\V2FT ^G.#T_&M>:V6XC7!P1R?>N;MXC'=/+"[OD [">!]/0UT-E>&50=A#<
M @MFE-6U0$%U L(P 1GD\]*S+I/*!>$2EQDL!W_+K72LD<YX()'!Q6!JENS2
MS1JSHK@J'0?,IQVHA+H)F=BZ>U!4*Y<]3U^G%(IA<!U=2Z\>7&3GTQ3[**.R
MLUMLL5C&P.YR_P")[GWJ8P"/CSV"C!4$8/TS6R?<3\@MH]VT9#%_E!8@ C_&
MK;Q!R]LHR';<W/*GV]ZM6L2!&D,8:0\DL,54N;B69_*\M$P<@@Y_G47NP)HX
M4PP5V3'&6[U%:P@SN9 $0 [21Q_]:G;Q;VP,K<R'@9Y^E4O/D8M&\?4X8[N0
M?YT)-@2WN )'7!+*.2>@J>RVL@D8$(J\G((S43#[1N3;[')Z]Z1&5HQ#*&\S
M.5(. !Z8I]+#-);9YG<)Q&PRKCM5M[55QM<+Q@Y7K^50V-R0OD[?NCCZ58DO
MD0X*2?4 &L7>]AG.%-S,C$  !N"!D?3K0\[!/+==RX.6.#QV_.B!0&),9(Q@
M,HSCZ4D\(4?)A@?XMN<>F,]ZW)*PD$,I=&#D<[2#UXR,]:O,2A5_+RCY)7/
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M*A+,YP.Q.:H23(L@*C[V>/2J-]J#06[OY<L@7GRXEW,V?04FKH#>GNP.58'
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M&H*,6'\1P>*'16D&^1C@$YST_"JL9=8?-5\N#PO7..H-6[11(A=WPRC&WO\
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M1G# L5^Z?:JYAD^:Y8[&EZ<<@^]:0FL+6Q1Q'+Y@087DDGWJ6K#(!YCA,YP
M,'MBHKNU@13&\99FX#+Q^-(^M">?R4CVQJ!U7D?C4D6^XD8EGY'RKC'%.S6K
M 2STZ&W24QL"[_*6/;':AX6FN-VSG(SD\?\ ZJU;>U 3;(5&2,@4RYFA@<@A
M2W8]\5'.VQV,338GU"&XEN[.2V*.RHLIY=<G!'UK3LH%2V"B7RSG)$@)_G5,
M7<\USL7.W=U'8>I%79Y)3MVM&PQZBG:25FP=F[HYG2;JWU>V@U!+:6(,S(LD
ML6URH)['D GG]:NR1$QL#@@CH> 1C%/,@10BALGU0C IRJ[<2$;0.&)[=S5I
M66HF[O0IZ-92:=#+ UXUQ$6+0HPW"%3T0$\D#L36AYCA5!B(;ID\C ]Q42EY
M'X",%)7=T)&<<?X4Z"=D4AU (X&WGVS24>560W*[NPN+A8H&D<A8H^3Z8]<"
MLV6&"ZFBU"!RY*% ZMN21">?KTX/:M::%;F,%<NK YP/PJFS>4XA2VG$:IDR
M!5V#T'7(/MC\:7778:>FFXQ@V\816P,#:^0?\*E6-@,Q(-Q&,R-V]!Z4VS*2
MVK%(I83N.%D 4L03@C)Z''&?6F*T[S6JK;R,C\2O(PS&?0COZ<<5?,K$V9?0
M.%PX.3G!)%6@Q:!5D() SCJ#6?</=PO']EMVE =4*@JH )Y;GL!S@>F*T+B=
MC'MPOL3Z5#W C64+O3 (*\#&,>M5[BP=D4Q<9&0.QJ6W8EMI"[<?W@3^/I5_
MAEV@G []*&[ 8%N+N&[F#21I9[%$<(AP48'GD=1WZ<5=CG24/%*,XY..0/\
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M,XCQGC)ZBGQ*W$85U?@YSP?_ -=3DDW 1HF5,?ZQ6[_2M=;6W*!XV/8EB<G
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MC\/UH5^:PWM<B:X$J"%L #&#@G<<]_SJKY)RT7F,LP) *MN%/9W252#A73&
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L%M X!;'-03Z@+64Q_9Y2N.&1,@_E3ED9F(;&W';KFF0HS[MS<@XI;[#1_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>drts-20211231x20f035.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 drts-20211231x20f035.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $O ;X# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#TY[2WTN&;
M5+L*GE0EFGQER!SC/<9[>M6-/3[),QC&XR'Y\_3@"LBRU"[OM-C;5+(VEP6(
M>)6W*?<'^M.N+6[U!5>WGDM[4;O.6'B0N.F#CBM];7[BLKV8_7;:'54ECN+/
M[58Q!)V5&S)*Z,"%VCZ#ZTR>U'VA+8"ZDGN%>:.*;)CBPN,,P^ZN<<=3GBM#
M[*)HD=Y)89-I\S!R2,>OJ* EK((DM"#"" 2[D[#R?QYQ3UZ FNI(US]EC43Q
M1+-M (V$*<#D@U6T2!GM0LMW)<1Q*0KSL"3G.03CT./PJ>^"&-'^<!F"G()W
M8[#V_"LB4-IEC=WOVEIX5W2)' I=@IZ<#^+W'&!3LK"UN7X-/229H;6W$%NA
MQ@, "<=!Z8P./I2W5FR7"Q[%=E7=D'E.G(IL4EOJ=G]I$KJ(X@IC"E7$F 6!
M[9&1^=.@N+E)5C=<ATVX9\ $],CN>#TZ4XO3W0>^I;@LKBX6"?SE,01A(OEC
MS&.1@AO0<\>]17EU:QW\%H3YDJ(THB(RV >H]OKZ56GU*\^W6MIIUMNMY.9Y
M3*!Y0Z=/XOPI;3Q)8276IPSP3VC6#"*6Y*Y23C.0PXZ<D=LUFWRLJS:-;=:B
M&WE4$J#N;8W!&/Y5GVD>H?\ "3_VC'J,7V"6(1O921[G7!ZJPX&3ZU*)X'@\
M]2##/M5>#A1CJ:KMYMLKM!@)G$>!G:#UW9XZYZ4^120E)HNR&RN]23RRNZ.0
MYV.5?=CGCN.?UJU':)]MP0NT J4ZCGN#VJB8HHYVU!;2)KJ7"B6)1OVD#J>U
M:45PMS'EX3'+&Q3&\$G_ &LCKFHU6X:= G_T22.1$/EJ0FU".!VSZ#)ZUG-#
M-&Q=4:.(*Q(VDL?\DU@>.M>AL/#]KM03>==F$AC]\*AW@_AQ5;P%XA&LVSZ1
M;--/;PC>LTA :&,DX4Y.6YXR*.>SL5R-QYCH-0G>2RO(+B.X5W1522&'<4SQ
MN_ 9Z]*D6V>TTJW999[]((UPH WO@<$^I[FG3!5FGBNB<J5V2!2!DGI^0YI+
M>ZM;:&)#B,8)VJOZ>W_UZTY>J(OT,V_%^^HP(B1+;,#YTTLN")/X/EQRIR?T
MK4CTT,L%M]I_<KD.H/+@\G']WFGK&-2@-LNQ5?\ B(W?+D9'UJ:\:*SLWP\:
M1HV7+MZ^I'UH<GL!6T;2KJPO;QQ=O-9S2>9&)7+&,8 VC(XZ&M.\\V2PFM[.
MZ$4[*=DP.=C=CCOWK*N+*;4?#USINHWV$F+!Y;=/+*Q]=IR3GC@GO4FF:K8R
MVH>T9+BW@ B'E$-TQ@^O3FL$G>QHWU+-E.TDMR4,)EADQ)$C<JQ Y<=B1@U@
MZA+/';6^IW6EW2332_9G%O-GRE+$%^OW>A]:T=#O;"YUJ^^RVMS'PDCW,HPL
MI;C SSD8QZ8J9X!>S75Q,9K6&$/$(-P:.10?]9@=">??UIQG?5 XV>I+* ]D
ML%J'MS;LH0*,AL=C[=_PJ-KFUTXK:7A:26;+;XHV8L>,EB.G459>&1(7N;0J
M6VADB?A?TJ":]L/.:,JBW,B;0V>IQG /?KVJ[:Z$"L))B%2*1H'8$OT 7K^5
M5KYOLDJK;JQCD=4\E& SDX+?09JW:0?9V$B>;-$Y&&'&".O'4U#>(8]3:X>6
M(!5"H@C^;YA@Y8GUJKZV0C.N+2X_M>&U54@TWRV:3>X8SL>B 'H!US^%6);=
M?+N9?LR,RIA#G9\@YQD=/K27DT$=U]M;SI$C4KL1=P^H].]27>IK-IS+;S([
MS*(E;/7=@'.>, -32:U"]S/T::6XTPRR-"HOMTGD%B=@(^4 C_8"_P ZT[31
MK2ULH Q,6P<QRR%\/U!)R><Y/XUG:E-%I3O=74L44-JAD<*"2J8Z*HR3P,5<
MLKZ34E@GM8XWMYU$J,XY8$94X--^0D12PK97UO=@K(.0UQM!?&/N@5'<S1_:
MA]AM+C<KD%^@<$;N"3QUXK172X)U#( ["3)<C#+[+4%O=G4+F1;NV_<0,0H
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M/2J>MR4)H.H(EG-&NFRVMA:,;>,7$F\R*,C<0>0!VSU&*L7=[!=6:I&D*J6
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MZE86.MIIL5O.KW41#W,*Y11&O )_AXZ8^E6-!M[:.]=+,B&") /)5 !^'?\
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M)]AG\ZB2>EQJQ<U"?= B*8V)&UB5^5\]O?O61I-W<PZE=QSZ=);01SF&!Y"
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M&L&FI:2L96M-R">3YGD /4L>^".:9H4$L]NWVTRSRQR;O.E0(SO_ !<#H!T
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MYCV! ]>>:-]P98N;^+[-'/$Z+ND4(9.F3T^E+!>0^7&;F1&N6<[8T."2#_\
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MU?,T*USC_$=[:_V8\7GR)(^2Q!QCC'X<8K$LM$MKA-1C.8A*/-GD20HS;L9
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ME@61N3QT'TJ2.T\R*222'RFD<%589Z=Q[5T1T6I,G=Z&DEM<B27=-$ D(1&
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M;V)T>PFG0WJW\]S+?Q"VV#9%&F"OX_@./K5BUDAU739[Q;V3RI 0KQKA@P)
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M[V-WUI2=[7 J37+-*?LMU:N8Y?*G&X?(>N&YX(JQJ*QO);N\"O'&V0Y&=IZ
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M(.,'WXK..KL/6PJQP,DD!@>Y1UW*$'7J0&)[YS511?WFGV9AM#:HIW2Q2O\
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M>:J,GHB7KJ7;;2K/3+Z[O4$LCSA3*\DA*G P %Z+^'K4CF* 75Q#L<,F\J.
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MTJOJ^GNT#0,F8"0JL3@KQP?<ULVYDN5B:8*C\XP,D^_MQ3;B);F[C6:%7CY
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MO)7HO/3!K)ZE#-1L(WP2V+K:41T4;D/.&'T_I4%MHTJ1P6UX[72A0TCM_$X
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M99B)&.QL\%>,#KS4 ,D>57/EIEQ@9QQR>:K7\)NY(?(F>,;^J'Y>X.1TJW/
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MJ1>23QH^R-!(K\;68_P#N"/>K$"%$:617="O_+/@\]C1;6<TU['Y)_= Y82
M\\TZSWOJ)MC#B)&.,_=+<_I5W\R3-1HX;.8(%4!SY;%LD#OE>QS4T:&YNO,D
M#NX7(!4'/KP.AP.OO5V\TR./=,S;&)9B".A Z@=3[4\211&-0K&X:$YWMP/<
M_@?R--S70$BG=:(BZG#J40CS'#Y40+$@ L">,]3@<U<LM:M-<BN;>-P9+=S%
M*A&0&Z8_GQ45U932="4! 8>8>,8R0H_IZ5<M1:QQQAIR[A0-O'S?_7J):HI&
M5-"UA;V\$EU+<Q[V8&; ;!.0!M P ,@?SJ_'/:FV\V-0.,H/[I''.>].&F@B
M)YW$A#_+M;C /&2>]/M(FB$\MQ"'W,2!]['^&>*-$K(.H:?YF06NE9-_RB5<
M-TZ>_-5[\WDDR0S1B7(R#M*@'OW%)%=M-.)"@XD(*[</NQ]WK]*U;*??9))-
M";<R'_5L<E2>QQQFI;Y6,CTZS6U 8,7G,*@ACP!D].W4]O2K,]TT!0)")<N!
M+APOEJ<_-SUQCH.:([@1R-;DA7494''S#OCZ5DZY]OA@66T*R9/[R&)MID_W
M2>F.O45BW<I*[-2*6UN$$B, "3TP,GOGWJE<3M):"1)44,1B02=!NQD$=\=*
MI6EE ]X+B&6/RF1DC\G!57)^;/\ GUJ_J4/E:9+]F5&=,.@!"@D=!GH![]JI
M*[L)D%[="-7A=8E\TX5G.X$DX QC_/I5:V5I1$L[Q^9#PI9>OX<#^58&FR'[
M'NM]4_M&<F2=ISB0C!.Y 2,9&=O&/8"MVSOC=6$-RZ,(V!9%>/:0/0 C/6M8
MK30EFPTL85'B$9D/'+!>!Z?G5+4I#]K6+[-+O^\7 ^1O8>IX_#\:@N[=[BU-
MT(?O\>6"5)!Z<]C4(CNVFGM6:XV/"JLQR=OLOH::CUN*Y)?V4VNV\L,ZP-:[
M0'1H]YW @]#UZ"H=:TS5&TF2UM+[[&& =[H+N8;>< $@#D#)/&.,5H:C*UI9
MK+N_T>-22,9+C'.>1Z8_&KEI-::OI,9*J]O=0*5@<8!4CH1_2HD]-BD<[X=T
MNVUJPTKQ!<QW::M'"2SO*0KN0,D@'!7(R!Q@'%7;6ZMDFN-..U+J)1//+$H4
M2-GDGT/?'O[5HQ-]F\Z"TB54AB&(T&!D=A[5SVHZ??:EY=_H$L5G<R3Q?:'E
M4G=&O5,=.^>.M0XM/F1:DGHRQ<W!:!IA<S1 3>5L91\VWG='CG!SC\*?;W\=
MQ=R640\J1"=S%-I5@ <XQCOVJRMO:V059D'VE01O PI..HST'XU%:OC38]UX
MJN(F!DC7@GIQG/Y5ILM"='N-L;F1S(!:2B2)VA:6;Y?-(. P]5_7GI4]W):&
M:.VD4Q3;O,<<E00#Z]3^=16,3O*/+N1)Y8 ;#!MPQP7SR&X//UJU-<)=;1%
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MC!S][)Y[>N#6?,N@[=R9#<N':)P48\9X/ZT3?:3YI50"L;%789(;'&*M*%$
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MK<J^EBYJUM(T?[W&,8!4<GT_"J\\TK2Q+)'*6E4A(T((4@8^]V[5-J=Q*]S
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MV$X&>./Q_"KUO=@Z>CR O, <E1SQZU33M<5T6)1]G%R\4* N"X*X&]L=_4G
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MY4U*\,2^;Y01A+N2-6#@8(0[N03R.!W[8I\.G-<W;74TIB82,-D9(R!C'/\
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M_LYQY,@4DLI'(^G^%7JW8GI<OS64?V_=<8:1L[6 SMX_PJT9 ]LMO:.(]J!
M[#=MQT/O6=)>O>ZRMO;VN46)9)+EB=O+8*#'?&#^/M6H]LD>$PJ \;NF3VZ5
M+L]QZHYO3M'UC1KXHTR7]C+(\LLLYPZ@]$51U';GTKH(;N*.,Q%BK YQN/\
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M8YH0)22%'0G@\=QWJ.RD+A?]7D#!QQP.F!69J>IRRQ)%;8!9BLF1_#WQ5N&
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MYQUXQ535$E@N]T4.\3D%PQW')(]3@#CMZ&A+4"5-9BGT]&FC:.09W1;B<')
MY'7IT -1"Y:"T=+:+8VTR)-(6*KSP6&<_4 UA6?ARZN+D3K<36=Q$K[8A(K
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MR-5YX=01X,(R!MIW'N.?QJM:Z/!8W<CV8* H1Y2@!,L<L2/4GG/6J_ES//\
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13S2P88.1G!'''M5I:78C_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>drts-20211231x20f036.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 drts-20211231x20f036.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &P 7\# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9\8%[P>*A;XPOD>5^N:Z^N%^'WB'7=<%Q_:9L[BV11Y5W;-D.V>01V]:[J@
MHHHH **** "BBB@ KRWXW_\ (&T+_L*1UZE7EOQO_P"0+H7_ &%(Z /4J***
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=7N=.L["ZU!K3_CY>!<K'75>'M?LO$NCPZGI\FZ"3C!ZJ1U!]Z -6O+?C?\
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M7HJ# J>L'P[XMTGQ,)AIEP93 %\S*D8S6]0 4444 %%%% !1110 5Y;\;_\
MD"Z%_P!A2.O4J\M^-_\ R!M"_P"PI'0!ZE1110 4444 %%%% !1110 4444
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M?XF-:^A:O!KNAVFI6[ QW$8?CL>XKP?XS7>KZ_XF%A:V-T]E8#:"J$AW/4T
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M2.>M "T444 <%\2H?"45I!J'B:,R&,%(44_,V>P%9-UX#\$6GA8Z])I4OD+
M)R@8[L&J/Q+-O'\3O"LNK#.D!2'W?=W9/7]*]/>^T@V!#W-J;7;@@N-NV@#F
M_AW:>%1I\]_X87"3D"8$\J1V-=M7D/PH,#>./%KZ5QHYD7R<?=W9[5Z]0 9Q
M6+?>*=*T_6K+29[D?;+PD1(O/3U]*UIXO/@DBW%=ZE<CJ,BO"]3\,1>&OC#X
M5BBNY[@W!+LTS;CQD4 >RZWKVG>'K$W>I7"PQ9P">I/H*H:!XVT3Q+.\&GW6
MZ=!DQN,-CUQ7#?$L"_\ B5X.TJ<;K1Y#(R'HQSW_ "J/Q;!#H7QC\+7&GQ)
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M]C;DCDY4&O5_^$'\,?\ 0$L_^_0H_P"$'\,?] 2S_P"_8H S5^*'@]5 &K1
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M 2S_ ._0K@/C#X8T32O CW5CIMO;SBYB4/&@!P3S0!UW_"T?"'_07C_(T?\
M"T?"'_07B_(U-IO@GPU)I=H[Z-:,S0H23&.3M%6_^$'\,?\ 0$L_^_8H S_^
M%H^$/^@O'^1H_P"%H>$/^@O'^1K0_P"$'\,?] 2S_P"_8H_X0?PQ_P! 2S_[
M]B@#/_X6AX0_Z"\?Y&C_ (6CX0_Z"\?Y&M#_ (0?PQ_T!+/_ +]BC_A!_#'_
M $!+/_OV* ,__A:/A#_H+Q_D:/\ A:/A#_H+Q_D:T/\ A!_#'_0$L_\ OV*J
MZGX*\-1Z5=NFC6@98'((C&0=IH @_P"%H^$,?\A>/\C2_P#"T?"'_07C_(UQ
M_P 'O#&BZKX%6YOM-M[B8W,J[W0$X!X%>@?\(/X8_P"@)9_]^Q0!G_\ "T?"
M'_07C_(TG_"T?"'_ $%X_P C6C_P@_AC_H"6?_?L4?\ "#^&/^@)9_\ ?H4
M9_\ PM'PA_T%XOR-'_"T/"!./[7C_(UH?\(/X8_Z EG_ -^Q1_P@_AC_ * E
MG_W[% '04444 %%%% !1110 4444 0FUMVE\PPQE_P"]M&:FHHH **** "BB
MB@ HHHH 0C(KE?!OA%O"T^KR-<B;[?=&X  QMSVKJZ* "BBB@ HHHH ****
M"N4U/PBU_P"/]*\2BY"K8PM$8MO+9]ZZHG R>E5[.^M;^-I+2XCF16*,R-D
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MRMUQ7HWBKP?I?BZQ6VU&+)1@R2+PR\],^E<7X2\(:KX7\9>9H=W'/X8NU,C
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..444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>drts-20211231x20f037.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 drts-20211231x20f037.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &P 6L# 2(  A$! Q$!_\0
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MC7M2A?4I(S<3 [Y)V_NJ.V<UPMU;0:!XB\,W>B:-JVD++<*C3WDO_'P./X:
M/IAKB%6*M+&"HR06' I(;NWN(R\,\<B#JR,"!7B.JZ%%XD^/-[IEU<7$=H]H
MK2K#(4+@#[N?2G>#]&@T/XL:]X5M99QI,MIEHFD)P"/7UY/- 'M7VZU_Y^8?
M^_@_QIZ7$,C[$EC9L9P&!-?-FM>#-%UGQC'X9\&17+/"V;V]DG+QQCN!74:I
MI:_#SXE^&+V*1S8W$ L9G<\%@,;C_.@#VSSXO,,?F)O SMW#/Y5&]]:1H'>Y
MA52<9,@QGTKR/P5"WB'QGXN\5R$M!'OM+8YXP 02/P'ZUQGA3PC8>(/AYXAU
M.^GNGGLII3;J)2$0@$YQWS0!](/>6T3HCW$2L_W0S@%OI3Y)HX4+RR*BCJS'
M KYK/AFVO?@V/%MQ=WLFJP?ZF1ISB-%; 4"K6OZO>^(M1\*:3J,5_>V1T])Y
MK>S.'G8YY]^E 'T3#<0W";X94D7U1@1^E9_B357T3P[?:G'$)7MHC($8X#$=
MJ\D\":?JFB?$)/[*T76;'P_=18FBO1D(WJ#Z5Z5\0/\ D0=9_P"O5J .!T[X
MF^.M5TV/4;'P4D]I("5D27J!Z5VO@+QO%XUTVXE-J]I=VLGE7$#'.UO8UYKX
M&T7XAWG@>RDT7Q#9VU@Z-Y4+Q991DYY^M;/P/N$@.O:3/"1JD%T7NI]^[S3D
MC^>: /8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>N?,-<II'AO3/"_QZM+'2H/)MSI[.5))^8]Z]JKRNZ_Y.*M/^P8: /5****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH @N[E;.TFN75F6)"Y"C)( S7F9^/?A('!2^S_ -<J]190ZE6
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M'A@,GV9(]D<N?O3#J* /1**!THH **** "BBB@ HHHH **** "BBB@ HHHH
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MMXEBAC6.-> JC % $E%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ[K^Q],_Z!]K_P!^E_PH_L?3/^@?:_\ ?I?\* .%_P"%V^$?[][_ . [4?\
M"[?"/]^]_P# =J[K^Q],_P"@?:_]^E_PH_L?3/\ H'VO_?I?\* .%_X7;X1_
MOWO_ (#M1_PNWPC_ '[W_P !VKNO['TS_H'VO_?I?\*/['TS_H'VO_?I?\*
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M% !1103B@ I&8*"6( '<FLBW\3Z1=:[/HL-[&^H0*&DA!Y'_ ->O,O$^O_\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>drts-20211231x20f038.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 drts-20211231x20f038.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &P 6\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHI,B@!:*3(HS0 M%)FEH #7$^$_$.HZKXU\5Z;=2JUMI\\:6ZA<$
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M)O\ DHO@_P"MS_Z * .U'2B@=** "BBB@ HHHH **** "BBB@ HHHH ****
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MS_KZB_\ 0!7I5>;> O\ DI/CO_KZB_\ 0!0!Z31110 5Q7B;_DHO@_ZW/_H
MKM:XKQ-_R47P?];G_P! % ':T444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!Q/Q0_P"1=L/^PK:?^C!7;5Q/Q/\ ^1=L/^PK:?\ HP5VU !1
M110 4444 %%%% !1110 4444 (:^?[7Q=9>$_&_B2VL=#?6+>:[,AD2++1O_
M !+GTS7T#7@\&O:_X2\6>(!IOA2:YL[N\:4%DYW="0?0]: .S\&^/$\0Z\+$
M>&+C3B8F?SY(PHX[9KT6O.O!OC?7->UX66H>&)-.@,3/Y[=,CM7HM !1110
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MXNZ-C_D'ZG_X#&LKX6:E%J_C;QKJ$*2)'/<1,JR+AA\N.1^%>I&V@_YXQ_\
M?(KSGP H7XC^.P  !=18 _W!0!Z77RW\>/\ DI+_ /7I%_[-7U)7RW\>/^2D
MO_UZ1?\ LU 'F=%%% !5_1/^0_IW_7U'_P"A"J%7]$_Y#^G?]?4?_H0H ^WT
M^XOTIU-3[B_2G4 %%%% !111F@ HHHH **** "BBB@ HHHH \X^-G_(AQ_\
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M_P .?$/AO7CJNIR);V[1,OV57)Y/0XZ<5[10 48HHH *,444 &**** "O-O
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M110 4444 %%%% !1110!YQ\;/^1#C_Z_[?\ ]"K8B_U2_P"Z*Q_C9_R(<?\
MU_V__H5;$7^J7_=% #Z*** .)^)?_(,TC_L*0?\ H5>PK]T?2O'OB7_R#-(_
M["D'_H5>PK]T?2@!:*** "N&^&_7Q/\ ]ARX_I7<UPWPWZ^)_P#L.7']* .Y
MHHHH **** ,;7/"^D^)&M3JEJMPMLQ>-6Z FK]EIUEIT(BL[6*",< 1J!5HU
MXGHWQ0MO#7B[Q#8:_?SW%O\ :C]F=5R(QW6@#VRBN/\ #GQ*\/>*-5_L[39Y
M7N-A?#)@8'6NPH **** "BBB@ HHHH *\U\!?\E)\>?]?47_ * *]*KS7P%_
MR4GQW_U]1?\ H H ]*KY;^/'_)27_P"O2+_V:OJ2OEOX\?\ )27_ .O2+_V:
M@#S.BBB@ J_HG_(?T[_KZC_]"%4*OZ)_R']._P"OJ/\ ]"% 'V^GW%^E.IJ?
M<7Z4Z@ JIJG_ "";S_K@_P#Z":MU4U3_ )!-Y_UP?_T$T <Y\,/^2;:%_P!>
MP_F:ZZN1^&'_ "3;0O\ KV'\S774 %%%% !117/7?C?PY8W<MK<ZI#'/$VUT
M).0?2@#H:*Y@?$/PJ?\ F,V_'7FM/2?$.E:[YG]FWD=QY6-^SMF@#4HHHH \
MX^-G_(AQ_P#7_;_^A5L1?ZI?]T5C_&S_ )$./_K_ +?_ -"K8B_U2_[HH ?1
M110!Q/Q+_P"09I'_ &%(/_0J]A7[H^E>/?$O_D&:1_V%(/\ T*O85^Z/I0 M
M%%<_<>./#-I<R6T^LVL<T3%'1GY4CM0!T%<-\-^OB?\ [#=Q_2M3_A8'A3_H
M.6?_ 'W7'^ ?&'A^P/B'[5JUM%YVKS2Q[G^\IQ@_2@#U6BN;_P"$_P#"G_0=
ML_\ ONM;2]8T_6K8W&G7<=S$&VEHSD ^E %ZBBB@ ->*^*O$5G)XFO-*\.>$
M+?5KR!LW4YCR YZBO:3TKP^'6M0^%OB[7EO='GO-/U*Y^T0W$*Y//8T =!\.
M?$6F:CK4^FW/AV+1M=@CW% F-Z=\5ZC7CO@U]2\:?$\^+I=,DT^PMK0P1>8,
M&0G^=>Q4 %%%<7XO^)&E>%+NSLG_ -)O+B98S#&PR@)QD_G0!VE%8/BSQ1;>
M$O#TNKW<;R1HRJ$3J2W05@^'/B2OB'6H=/70]1MA*I(FFCPHP,]: .\HKS?5
M?B]I^GZK>6UOIMW>6EBX2[NXA\D9S7?:=?V^J:?;WUJX>"XC$B,.X(S0!:KS
M;P%_R4GQW_U]1?\ H KTFO-? 7_)2?'?_7U%_P"@"@#TJOEOX\?\E)?_ *](
MO_9J^I*^6_CQ_P E)?\ Z](O_9J /,Z*** "K^B?\A_3O^OJ/_T(50J_HG_(
M?T[_ *^H_P#T(4 ?;Z?<7Z4ZFI]Q?I4=W/\ 9K.>?&[RHV?'K@9H FJIJG_(
M)O/^N#_^@FO*K7XT7][ )[;PO-)$Q(5Q(,'!HNOBOJUS:30_\(I./,C9,^8.
M,C% '9?##_DFVA_]>P_F:ZZO#?"WQ$U?P[X9L-);PQ/*;:/87W@;JU9/C%JD
M,3R2>%)U1 2Q,@X% 'KM%8_A;7!XD\-V6KB'R1=)OV9SMYQ6Q0 5G2Z'I<\K
M2RZ?;/(YRS-&"2:T:* /.?!^CZ;+XQ\91R6-NR1WL813&"%'ECI7>VNG6=B6
M^RVT4.[[WEH!FN/\&?\ ([>-O^OZ+_T6*[F@ HHHH \X^-G_ "(<?_7_ &__
M *%6Q%_JE_W16/\ &S_D0X_^O^W_ /0JV(O]4O\ NB@!]%%% '$_$O\ Y!FD
M?]A2#_T*O85^Z/I7COQ+_P"07I'_ &%(/_0J]B7[H^E "U\J7UG;W/C#Q*9H
M5<C4I,$_6OJNOEJ?_D;_ !-_V$I/YT 0?V38_P#/K'^5+_9-B!_Q[1_E5RB@
M"E_9-C_SZQ_E7JWP&4+X2U%0, :A(!^0KS8=:]+^!'_(IZE_V$9/Z4 >J444
M4 !KQJ\\8>-_$?B#5+7PYI-K)86%P;<M.H)+#ZU[*:\#LT\::MXV\2W7A)H;
M"W6\\J:-SPSK_%CU- '=>#;CQ\VLB+Q#96D&G>6W,( (;M7H5>?^$+/X@0ZX
M'\27MM+I_EL-L8YW=J] H *\,^+?A;3-$72+ZUB)N[W6$::9SECWQ]*]SKE/
M&_@Q/&5OIT3W1MQ9W2W((&=V.U &;\3?#=UXJ\/V.FVU[!:_Z2DCF8XW #@#
MU.37.VVI^(O!_P 1-,\/ZEJ0U.TU2)O+8QA6C8<<>U=SXQ\'P^+=*AMFN9;:
MXMW$D,\9P485C^'_ (>3V?B.+7]<U>75+^",QP%UP(QZX]: ."\$"-_A9XZ:
M8 RF>;S"W7/:NM^'UYJ]K\&=+GTZT%W>JI$43M@%=Q[_ $IFI_"-[B_U'^SM
M;GLM-U-]]W:JN0QSDXKT32=+MM&TFUTZT7;!;1B-!["@#ACXE^(>/^14M_\
MO_6=\*Y[RY\9^,YM0MUM[MYXC+$IR%.VO5R*\U\ C_BY/CS_ *^HO_0!0!Z5
M7RW\>/\ DI+_ /7I%_[-7U)7RW\>/^2DO_UZ1?\ LU 'F=%%% !5_1/^0_IW
M_7U'_P"A"J%7]$_Y#^G?]?4?_H0H ^WT^XOTJKJW_('O?^N#_P#H)JTGW%^E
M5M5_Y ][_P!<'_\ 030!X'X'_P"14M3[O_Z$:Z+%<[X'X\)VOU;_ -"-=%0
M51U?_D#7O_7!_P"57JI:O_R![W_KB_\ *@#T+X6?\DTT/_KA_4UV%<?\+/\
MDFFA_P#7#_V8UV% !129H)H X?P9_P CMXV_Z_HO_18KN:X;P9_R.OC;_K^B
M_P#18KN: "BDS2T ><?&S_D0X_\ K_M__0JV(O\ 5+_NBL?XV?\ (AQ_]?\
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M+?>=8L\+^;N$9[AA]*]M'2@ HHHH **** "BBB@ KS;P%_R4GQW_ -?47_H
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MKY;G_P"1P\3?]A*3^= $M%%%  .M>E? ?_D4]1_[",G]*\UKTOX$?\BGJ/\
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ML2_='TH 6OEN?_D;_$__ &$I/YU]25\M3_\ (W^)C_U$I/YT 34444 %>E_
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M#J>I,X@$BQ_(,G+' H V:*KV5[;ZC9Q7=K*DL$JAD=3D$58H **** "BBB@
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M M))8[OW4.6) QW(&* .EATC1=?LK6_N]%A#NJRA)X0'0]>?>MY5"*%4  #
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M4^)_#6FZ7X-L_$\/B.XO?$=W(DD,B2Y\UB1D*O48KW3Q7J&B:?X=NI=?:+[
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M:;K5WJUI8Q1WMT<RR <_AZ9H A\&:')X>\'Z7I,[B26VA"N?]KJ?YUOXHHH
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MW Q6GH/A[4_&;&[\?:!9*;8*EJ/XV(^\3[$]J]*AAC@A2*)%2- %55&  .U
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M('M];-HOVA8SM5V*C)8>M3:9X \,+=PZS_PC\%O?N%E9",B-\<\=,UUP&*
M#%+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M***@O+RWL+22YNIDB@C4L[N< "@">J&KZUI^A:>][J5U';VZ=6<_I7G%U\9<
M/)=V'AZ_N](B;:UZJX4^X]JB\17VE^*8+/QM]ICN] TFWDDDL7'+3_PAE]J
M,3Q/80ZD)O'?PZO\740*WL,(P6'=MOKWIO@[X?>&_&WAY=2AUC45U=C_ *9(
M),,).^1Z9Z5GZ%::MH_B+2M3\,S0WEYJ\;W%_I\; 11H3P/; ->T:#X2TK0;
MZ\U"RLQ;W-\0\ZALJI[@?C0!4\%>$;GPI:S17.M7>I&1OE\X\(O;'O75T44
M%%%% !1110 4444 %%%% ", RD'H>#7A^F:G<_"+Q7J.FZM;ROX?U&<SV]U&
MI8(3Z_UKW&J]Y8VM_"8;NWBGB/5)%##]: /!M=30O&K6_ACP3IH9+B\^U7E]
MY9 CSU^8\^M>\6%FEAI]M9QDE((UC4GJ0!BF6&EV.F1>58VD-LG<1(%S5R@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *X;XH^$KWQ9X8:WL+IX[B ^:(0<+-C^$_TKN:0B@#SGX:^*[#7M
M#.@W=G%9ZA8IY-Q9LN P'&X#^=<WX,TJQ3XG^*="T\+<^'9H 98\Y1'/\(^G
M-=%XY^&;:[J]OK.A79TW4]VR>2,[0Z'@GCOC\ZZSPKX4T[PEI*V-A'R?FEE;
MEY&[DF@"/PWX*T/PH93I5H(GEX9V.YL>F>PKH:** "BBB@ HHHH **** "BB
LB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>51
<FILENAME>drts-20211231x20f039.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 drts-20211231x20f039.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %V Q0# 2(  A$! Q$!_\0
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M_A36K_\ 0ZW_ .7_ ->C_A36K_\ 0ZW_ .7_ ->O7Z* /(/^%-:O_P!#K?\
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M* /(/^%-ZO\ ]#K?_E_]>E_X4WJ__0ZW_P"7_P!>O7J* /(?^%-:O_T.M_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV"O+?BO_ ,A_PE_U^_X5UO@.RGL_"-FUV[O=7 -Q*7))W.=V.?3.*Y+XK_\
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M7EWKJC17D:<0S0A?(9CDDOG)'/I61\-='MC?ZSX@M0YL[NX9+$N/^60.25]
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M$O\ K]KU*O+?BO\ \A_PE_U^T >H)]T?2G4U/NCZ4Z@ HHHH **** "BBB@
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M_FO4: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH 1C@$TQ8P"6/+'U[5'=3B(H"/O&JU]J$=O92RLV JYSCI6<I)/4:1+=
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M *$.7_P+6C_A+_&W_0AR_P#@6M 'H-%>??\ "7^-O^A#E_\  M:/^$O\;?\
M0AR_^!:T >@T5Y]_PE_C;_H0Y?\ P+6C_A+_ !M_T(<O_@6M 'H-%>??\)?X
MV_Z$.7_P+6C_ (2_QM_T(<O_ (%K0!Z#7E7Q*D%_XY\):5 =UR+@S,H[*._Z
M5?N?%'Q N8C%9^"Q;SM]V2:Y4J/K4O@_P+J%KK<GB7Q/=+>:U(,)L^Y"OH*
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MIZC'_P!>M[PQ\--"\,W'VU$>\U ];NY.Y_P["NRHH 0#%+110 4444 %%%%
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M>,(H QT[UY]\*M&NKLWGC'64)U'4G/D[NL<78#TS7I] !1110 4444 %%%%
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M)9^-_#FI.R:?JL-XZC++!ER![T =!7E_QA06C>'-:/\ RZ:B@(]B?_K5WO\
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MNV=N/I&*M44 1+;PI]V)!]%%2!0!QQ2T4 )BEQ110 48HHH ,48HHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUA,,=%'Y4FWC&/TH^L3'R(W/^$STHYVBX/\ VR-(?&>FC_EG<'_MD:Q F.@
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M-PN[/:F,G6 E>!35AR<5+%>Q1H=PR>U0B\4'(%&@A[VQ7%(L#-G ITNHJZ*
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M#_2D/Q8\*!<BXNV]A9R?X5R9\*?$]G++XEM4/JMHJ_TJ1?"7Q39<?\)A$O\
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M  (%=)%^SG:AOWNM.1_LQU9C_9WTM2-^JS,/]RCV*#VC.3_L.V!_Y#.F?^!
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M'C?P=;>+]$:VDQ'=Q?O+6<=8W['Z5A_#CQ;>79G\,^(,IKNG\.6X\Y.S#UH
M]$HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *\U^-5RX\(6MC&?GO;V*':/XAFO2J\K^)
MH&J>-?!NC1GYS>?:&],#_P#50!Z98P+:V%O;HH18XU4*.V!5BD%+0 4444 %
M%%% 'E&HQ'PK\:++4A\MIKD?V>0]MXZ?TKU8=*\_^+VER77A :E;Y%SI<JW2
M$#GCK75>%]737?#.GZFG2XA5B,]#WH UZ*** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D/2EK \9ZZOASP
MCJ6J$_-#$=GNQX% '#>%4;Q7\7-:\0R<VVE#[%;?[W<_SKU<=*XGX4Z*VD^!
M[:68?Z3?L;N8^[\_RKMZ "BBB@ (R*\Z^(_@VXO3#XFT%C#KNG_.I7_ELH_A
M/K7HM!H Y3P)XRM_%^AI/@17T7R75N?O1N/;T-=77DWC'1KWP3XE_P"$WT&,
MM;.0NIVB#[R=V%>CZ%K=EX@TF#4K"826\RY!SR#Z'WH TJ*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (YIXK>
M%I9I$CC099G8  >Y-<#J/QC\,VET]M9B\U.53@_8X"Z_G63XN>[\>^.U\$VE
MV\&D6D(GU1XAR[9^5,_E7H.A^&M'\/6:6VEZ?#;1IT*K\Q]R>M '%?\ "Y]/
M_P"A>US_ ,!&_P */^%SZ?\ ]"]KO_@(W^%>F44 >9_\+GT__H7M=_\  1O\
M*R-#U5O&_P 7[35!IM[;6=A9-Y9N8"GS_C]:]CI,4  Z4M%% !1110 4444
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MKTU$5$"JH51P .@IU 'F'_"Q?&'_ $3O4?\ OZM'_"Q?&'_1.]1_[^K7I]%
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MBE75AD$'M7D2Z7XE^&OB.Z;P_I,^KZ#>Y9+2%\?9V_&O8J3 H \Q'Q%\8?\
M1.]1_P"_JT?\+%\8?]$[U'_OZM>GT4 >8?\ "Q?&'_1.]1_[^K4<OQ5UW3\2
MZKX#U2"W[R(P;;[X KU.FLH92",@\$'O0!B^&_%ND>*K+[3I=R'V_P"LB;AX
MSZ$5N5X_XWT,>!-?M/&>@H;> S!-1@C^[(I/7%>M6EPEW9PW$?W)4#K]",T
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M9U!OL]IJ<Z^9.^1&@Q@#V]JOZ?X]T;4+VWM=E]:-=<6SWEJ\*3_[C$8)]N*
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MBI=?^&>IZS9,]M=1V-QYB X>WG1&ROL01_*I;'Q19Z/X%T34-8NI&EN;:%5
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M:;80S6Q5K)[M@/M$1'WD8XP0>" :[^J.I:+I>LQ+'J>G6MXB\JMQ"K@?3(H
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MBR[M-8N=:;[5;M?2"T6*-Q&P+[-G#<=<>E>O:GHFE:U&L>J:=:7J+RHN(5D
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MA!IV: "BBB@ HHHH **** "L0>&X#XN;Q%+/+).+86T43 ;(ESDD=\DUMT4
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M !_PB'Q-_P"AWM?^_#4?\(A\3?\ H=[7_OPU%% !_P (A\3?^AWM?^_#4?\
M"(?$W_H=[7_OPU%% !_PB'Q-_P"AWM?^_#4?\(A\3?\ H=[7_OPU%% !_P (
MA\3?^AWM?^_#4?\ "(?$W_H=[7_OPU%% !_PB'Q-_P"AWM?^_#4?\(A\3?\
MH=[7_OPU%% !_P (A\3?^AWM?^_#4?\ "(?$W_H=[7_OPU%% !_PB'Q-_P"A
MWM?^_#4?\(A\3?\ H=[7_OPU%% !_P (A\3?^AWM?^_#4?\ "(?$W_H=[7_O
MPU%% !_PB'Q-_P"AWM?^_#4?\(A\3?\ H=[7_OPU%% !_P (A\3?^AWM?^_#
M5%-X!^(.HI]GO_':K:OQ(+>%@Q'XFBB@#K?!_@72?!UFT5D'EN)#F:YEQOD/
MO74444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
#'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>52
<FILENAME>drts-20211231x20f040.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 drts-20211231x20f040.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )> Y # 2(  A$! Q$!_\0
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MG]\_G1YLG]\_G3** '^:_P#?;\Z/-?\ OG\Z910 [S9/[Y_.CS9/[Y_.FTE
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M@%%+BCM2 2EHHH ***6@!*.:6B@ HHHH **** "BBEH **** "BBB@ HHHH
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MHHHH 2DIU-H *0TM%,8VBE(I.E "4J_>'UHH7[P^M %J7_6O]:;3I?\ 6O\
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M8I:* #%)BEHH ,4444 %%%% "4444 %%%% !1110 4444 %&*** #%)2T=Z
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M1110 M%)2T@"BBC% !2BBB@ HHHH ***6@!*6BB@ HHHH ***!UH 6BEQ10
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M)0 4A%+24 (:%^^/K2XI%^^/K0,L3?ZY_K3!4DO,S_6F"@!11110 HHH%+0
M444$@#)Z4P"E I%96Z'-.I %%%% !2T4M "48I:2@ Q28IU&* $HI:* $HI>
M]&* $Q2T44 %%%% !112CB@ H(HHH !TI:2B@!:*!10 4M%% "XI#2TAH R-
M;M#=6;H."16!H8^QS&%F.0>]=A*NY2#7&:M!/;7ZRQ<+GF@#M(6!45,#65I5
MV)[=3G)QS6H#F@!U%%%(!#12T4 -HIU)3 3%+CWHHH ,4E+10 4444 )12T4
M )2T44 %)110 9HHHH **** #%)2T4 )BBEHH 2DI:,4 )12XI* #%%%% !1
MVHHH 2BBB@!,44M% "44M)0 4444 %%%% "44M!% "4444 )01113 2BE-)2
M **** "FTZDQ0 F*.E+3: "D-*** &T4II*8!1110 E%%%(04444 )1110 4
M@^\/K2T+]X?6@"Q+_KG^M,I\O^N?ZTR@84 4=Z6@ I:** "J&KB=K)UMSAR.
M#5^AE!&#0P/.DUW5]*D*W,+.@/WA6_IWC&SNL+(P1O0\5LW.GPW"D,@Y]JYS
M4?",$N6B7:WJ*SU6QJN66YU<-U#.H*.#FK KS V6L:2^;>9V4?PMS6G9>-)K
M<B._A9?]KJ*:GW$Z;Z'>XHK+L=>LKY 8Y5R?>M-7#C*D$52=R&FA:*6EQ3$)
M11BB@ Q1BBEQ0 W%+TI:,4 -HI<48H ** *7% "4M%% "44M&* $HI<4N* $
MQ2XHHI %%%%,!:#112 C89K-U"T6:)@16J:AE3<M,#@(-3N--U<VZQDQ@\FN
M]M+A;F%74]16%J.F)(6=5PY[XK,M-8.D7"PSL=K' %(#NAR*6J]K<I<PB1#P
M:L=: "BBB@ I*6C% "4E+10 E%%%, HHHH **** $HI:* $HHI: $HHHH **
M**!!1244#%HHHI %)2T4 )1110 8I*6BF E)3J3&* "DI:* $HHHH **** $
MHI:3% !1110 M)110 F**6B@!*2BB@ HHHH 2BEI* "DI:2@ I,4M% A*2EI
M* "D-+VHH&-HI<4E, I*6DI""BBB@ I"*6B@!*%^\/K1BA?O#ZT#+$O^M?ZT
MRGRC]\_UIE "T44M "4M% H 6BBB@ Q2%0:6EQ0!6EM(Y!RHK(O- AF!^0?E
M70XI"N>U)JY2;1YY=>&&B<O;NT3^JFFPZEKFDGYQ]HC'YUZ \"OU%49].5LX
M%1R]BU/N96G>-K.=A'<YAD]'&*Z2WO;>Y4-%(K ^AKE[[P_;7((EA'UQ6,VA
M:AI[>9IMVX _@8Y%',UN'*I;'I-%<!;>+]0T]A'J=HX7^^HR*ZC3O$FG:BH,
M4ZY/8FJ4DR'%HUZ6D5E=<J01[4N*9(E%+10 44=:6F E)3J#0 E)2XI* "E%
M&** "BBB@ HHHH **** %I<4E&<"@ II%/I"* *<\60:YW4='CN)A+CY@.*Z
MME!'-4YX<'I0!S%EJ$NES;)"?+]ZZRQU""^C#Q2*WT-<[K>EM?6,B0_+(1P:
MQ-&M[C0%7EB3][)I;#/2LT5FZ=JL-X@^8!_2M+@T""DI:,4 )24[%'% #:*=
MBDH 3%&*6B@!,48HHH 3%%+13 3%&*6BD F*3%+13 2BEHH ;13J3% !24N*
M* $HI:* "DI112 2BBBF 4444 )UI*6B@!**7%)0 4444 %%%% "&@444 +2
M444 %%%% !3:=1B@!M%*124 %%%% A**** $HHHQ0,*;3J0B@0E%%&* $I.]
M.I*8Q***2@ HI:2D(****  TB_?'UI:%^\/K0,GF_P!<_P!:;3Y?]<_UIE !
M112T %%%%,!:6FTHI +2TE+0 48HI: "D*YIU% $31!NHJK)9J>1P:OTF,TA
MF)/8HZE9(E8?2L"\\)VLS&2U9K>7L4.*[@Q@BH)+53VYJ7%,I3:.$2?Q%H3=
M3=P#\ZVM-\<V<["*Z#02]P_%;#V[*.F1Z&LJ_P!"L-04B>$!O[P'-*TELRKQ
M>Z.C@NX+E T4BL#Z&IZ\YD\/:II1\S2KLLHY\MSQ4]KXUO+!Q#JUHZ=MX'%'
M/;XD+V=_A9Z!165I_B'3]14&&=<^F:U P89!!%6FGL0XM;BT444Q!112T@$Q
M1BEQ10 E)3J3%,!**7%&* #%%+BBD 4444 +0:!13 ::8Z;A4N*:10,H2PX.
M:JS6L5PA5@-U:S(&%598BIR*!'#ZQ!?V%U$EF63<>6':NBTC7<(L-VQ+#C<:
MT'2.8;95!K'O]&QF6']*FUAG6QR)*H92"#Z4^O*YO%UWH>H):)&9,GE37?Z7
MK4.H0*6'ER$<J:=PL:F.:*,Y%&*8A**6BD V@TM% "44M% #:6C%% "44N**
M $HHHI@%)2XHH 2BE-)0 4444@#%)BEHH 2DI:#3 2BEHH 2BEI*0!1113 *
M2EHH ;BBEHH 2BBB@!*444"@ I*6B@!**** "BBB@!#24N:"* $-%%% A*#1
M10,2BEI*!!11WHH 3%(:=3>E PYHHI*8 124ZFT@"BBDH$%%%% !0OWQ]:*!
M]X?6@98E_P!:_P!:93Y?]:_UIIH 2EHHH *6DHI@%.%(*6D 44"C- "THI!2
MT +2TVESQ0 4O6DI: "D(IU)0 TJ*B>!6ZBI\48%(9GO;,IRIJI<6L-PICN8
M%<'U%;1 -,>)6[46 X6]\$V\C&;3KA[67J-IX_*J*WOBSPZW[V+[; O<=<5W
M[VO=:B974$,NX>]3RE*3V9@Z7\0].NF$5XK6LO0B08YKK+>[@ND#PRHZGN#7
M.7_A[2M34B:!5<_Q 8-<_)X4U72&,NCWK[1SL)R*3DUNBE%2V9Z4**\\M/'&
MH::XAUBR? X\Q177:;XCTW5$!M[A"Q_A)YIJ:9+A)&K10"",@TM60)2TE+2
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M$HHHH *2EI,]L4 %)BEHH 2BEI* "BBB@ HHI,4 +2444 )BBEI#0 4"B@4
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M4 -HIQ%-H *3%+0: &TAIU!I@-HI<4E "44N** $-%+BDH 0TE.I* "BBB@
MHHHH 2BEI* $HI:2@ I#2TE A**6DH 6D[T44 )1110 E%%!Z4 (:2EI*!A0
M:**8#:*4TE(04J_>'UI*5?O#ZT 6)?\ 7/\ 6FBG3?ZY_K3:!A1110 M+24M
M !1110 "EHHH **** %%% HH 6BCM10 4M(*6D 4444P"BF2RI!$\LC;40;F
M/H*HV&O:9J(_T:[C<_W2<'\C346]4(TJ6D!I:0PHHI<4@$I112TP$I:*2D N
M:6FTN: "C%%%, Q1BEHH&-(II4&I*3% %9X%8=*@:!D.5J^12$4@**S,O##(
MJE>Z+I>I@^;"J2'^-.#6NT2MVJN]N1R*3BGHRHR<=4<+J'@;4;:8W6E7[,PZ
M*3@U#!XO\0:&XAU2U:9!U+ ]/K7>AY(SZBEE6VO$\NYA20'LPS6?LK?"S55K
MZ35S/TGQGI.IHI\WR7/4.>/SKH4=9%#(P93T(.17#:K\.]/O&,UA/):2G^Z>
M#7*W=KXU\(RB6UDDGMEZF,;@?J*<7).S)E&#5XGLM%>8:-\6X7<0:Q:-$XX,
MD0_FIKOM,US3=8C#V-Y%-_L@X8?AUK2YE8T:***8@HHHH *6DI: &D55N%;8
M<5;IC+D8H X'5;.Z,[2AG#9X(K,^WSQ#9=P"=/7'->BS6BN.5S65=Z)%*#A,
M&H:*3.43[%=C$$^P_P#/*49IZM>6!_=-)&/;YT/]14U]X<<9*+FL\-J.GG"L
M73^[)S^M)H:9JV^M(LGF3P%&[W%HV"/KC^M;2WL.JQCS#:ZF.V_]W.OT85R?
MVRPNF_TF)K6;^^IQ^HJ1M/E4B6!DG Z,K;'_ #'!_&HL5<Y_XH2I!:Q0()4W
MD'$K%B/;-<CHURL\L:/'U^7<*] \4:;'J%M9?:UD"XVL7(W _A6,OA2&"XC:
M.98D09"Q+RWU)ZU2V)>YT4&A*]FN22K#E64,I_ UGS^#;-'>5()(G ^5K1L#
M/NIK0T_5WT\K;3.)H\<.HY'U%='!-!=H&C89Z@@TKLJR.6T.VGMKW:\X8 ?+
M_"2?0BNC4!R8Y9(MS_>M[M,JQ]CVK1L=-6XGD'V1+HD<QJ^R5AZH?44XV(ED
M-O:WJ2N/^7#4T\J4>P8\&DV-(HK;FT79 +NT.>(=OGP.3Z=Q27:30.%NA-Y8
M'[PP*S1J>N",U!/))IU\EO+;7EFZ\A7DR@)]/:I#(8I/,)F@8_\ +> [@WN1
M_P#6I7'H='I&N0K:A8HH9+<CYC$ P_$=?SK6AET^\&89?*;T7E?R/3\*X=A'
M/B9X(Y7_ .?BS;RY!]0.#3X);KS,Q31WNT?<8^1./Z-0F#1W#VDZ+N"B5/[T
M7/YCK5<$'H<U@6/B62"<1/(R2_\ /&X_=M^!Z&MR/6[6[D"7L&QNS-\K'Z$5
M:J=R'#L/I,5:^S1RC=:W"N.R.<'\^E02H\+;94:,_P"UT/T/2K4DR&FB/%)B
MGXI,50AN*2G$48I ,HI2.:2F 4E+10 E%+10 E)BEI#0 E%+24 %%+24 %)2
MTG>@!**6DH *0TM)0 E%+24""BBB@!*2E-(: %I**#0 AI*4TG>@84444 (:
M2EI* "E7[P^M)2K]X?6@18F_US_6FTZ;_7/]:;0,*6DI: "EI!2T %%%% "T
M4#I10 4M%% "]J*** "@T44@"EH%% !12TE #74.I4C(/!KEM1\#6%V[30[H
M)2<[D..:ZNE K2%24'H)I/<X$6'BS0_^/2[%Y"O_ "SDY-6;;Q]]G<1:QITU
MJ_=U&5KM2H/6J]QI]M=(5FA213V9<UI[6,OC0N5K8@T_7--U-0UI=Q2$_P .
M[!_*M'-<??\ @'3IW,MJTEK+U!C/%4!:>+]"_P"/:Z%_ /X).31[.$OA?WA=
MK='?TM<1:_$".%Q#J]A/9R=V RM=18:SIVI+NL[N*7V#<C\*SE2E'=#33+]'
M:C-%9C"DI:#0 E+24=Z %I:2BF M%%)0,7%)BC-+0 W%(13Z2D!$R!JB>W]*
MM8I,<T 42LD9R*>MQV<5:*@U$\ - &'JWA'0=>4FYLT60_\ +6/Y6KA-1^&&
MK:9(;G0K[S@O*QNVUQ]#7J!B9.F12K,Z?>Y%%@N>4V'C_P 1>'K@6FNV\A0'
M&9T.1]&KO]+\<Z3J*(3(8RW?[R_F.E:MS;V6I0F&\MXIXS_#(@-<?J7PQL)'
M:?1KJ6PF/.T'<A_J*AQ>\6:1E':2._CECE0/&ZNAZ,IR*?7D$D'C#PJY=H7G
M@7K-;-U^H_Q%;&E?%")W$.H18?H>-C#\.AI*HU\2&Z2>L'<](HK,T[Q!IFIX
M%M=H9"/]6YVM^5:9K1-/8S<6MPH(I 01P:6F(0C/:F% :DI:0%5[8-VJA<Z5
M%,""@K9Q2;0: .*O/#:MG8/PK#DTJ\L)"UNSQGVZ'\*].:$'L*KRV:.""H/X
M4K#N>9W-Y<36[0WD&\=F3U^E8ICOICY<"R[1_>XQ7JTVC0.<^6,_2JS:6B#
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M_P"T_$>D'%W;K>Q#^->&_,4O81E_#E]X_:-?$CL:7M7/V/B_3+MA'([6TO\
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M0.Y?S']:MA@1D'(]13N)BT4 T4""EI**8!32<=B:=1Q0 4E+10 E)3J2@8F
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M-B\!(8="#@UZBT8-026RL.E%@/()#J-E^[N(Q<1C^^.1^-+#>02?*LIA<_\
M+.89'X&O3+K28IU(9 ?PKFM1\)12@E%P34N)2D9=MJEY8$?.RI[_ #(:Z+3/
M%9B(8.]N?6,Y0_45Q\VD:EIC$P,VS^Z>1^55A?*K8N8&@?\ OQ=/Q%0XE*1Z
MPE]IVK#S+RV0R=KFU.QQ4DNCRW<)^SSP:I!_SRN!LE'XUYA;W4Z8DMY1*HYW
M1'!_$5LV/B656"R-N(]]K"ILT5<V)]-CMF,:O-92]H;H94_0U2N+::U.^>!X
M?2:$Y4UOV?BI+B/RIS'<Q'@QSCG\ZNI!IEQ_QYW4EBY_Y92#=&:6@SD"YN$_
M>K%=)ZCAA21EON6]P"/^>-P,_D:Z&_\ #\D8,T]GP/\ EXLSD?4K6/-8S%<Q
M^7=Q^@^5Q^%*W8=RHQ2$_O%DM7]5^9#5NWN[BW =273L\)_F*IAG1BH=D_Z9
M3#BF^7$"&VO;/_>C.5-&P'4VWB1G01NRRKW'0UI0R6-Z?D;R9/2N(D68J'DB
M2X7^_'PPI]O>["?*ER?[DW!'XTT^Q+1VDEM<1'@"5?5:A#KG!RI]#6%;ZY-!
M(NYW0_[7(_.M&^UJ$VOF3;2>Q6M%-D.*+AYI",5@Z;K+37!1P0AZ9K>ZUHG<
MS:L(:0TM%,!IIA%/-)0 VBE(I*8"4J_?'UI*5?O#ZT@+$O\ KG^M-ITO^N?Z
MTV@!*4444 +1110 4HI*6@!:*** "G4VEH 6BBCO0 4M%&:0!2TE% "T4G6E
MH 6BDI: "BBB@!:.M)13 1HU888 CWK$U+PII>I F2V57/\ &@P:W<TM5&I*
M.S$TGN>=R^$-8T>0S:-J#X'.PMC_ .L:?!XUU72G$6M:<S ''F(,'_ UZ!@5
M!/:0W"%)8U=3V(S6ZQ"EI45R>2VQF:;XJTC4P!%=*DA_@D^4UM@UR.I> ]-N
MB7MPUO)ZH>/RK(_L_P 5>'CFSN#=0#^$\\?0T_94Y_!+[PYFMT>C45PUE\04
MC<0ZM926\G0LHX_*NJL=9T_4E!M;J.3VS@_E64Z,X;H:DF:%%-S2UD4+2&BE
MH C* CD51NM'L[L'S($)]<5HT549RCLQ.*>YR5QX26-O,LYI(7'3:U1K<^(M
M,X9ENXQV<<_G78$4UHU;J :W6);TFKF?LETT.>MO%]ON"7UO+:OZD96MRVOK
M6\7=;SQR#_9/-5[C2[>=2&C'Y5B7'A=$<R6S/"_8QMBG:C/;0+SCYG5TM<>E
MUKVFD*66[C'9QAJO6OBRU=Q'=Q26TG^T,BIEAY;QU&JJZZ'145##<PW"[H94
M<?[)J7-8--;FB=Q:***0"4$9I:* *MQ907(Q)&"?7'-9<FB36[&2QN&1CU&<
M9_H?QK>-)BE8=SFTU&ZLI-MW P7^_$,9^J]#^&*U+34X;KB-UD/HO##ZJ>:N
MO&DB[64$>A%9=UH-O,=T>8W[$=JFS6P[I[FFDBOG:0<=1W%/KGF&J6)&X"YB
M7^]]X?\  AS4]GK<<IVR-Y3YP$EX_P#'NGYT^;N%NQM45$LRD@-E2>F>A_&I
M*9(44M)0 44M)0 444M "44M% "8I"*=13&,*YJK+ 3G%7<4UEXI <Y?&:(D
M(#^%8[22,X\S)Y[UUTUN'/(JE/IT;#E>:EH:9@RM\]-#5:N[1HFSCCUJGC%<
MSBT;\UR97([U,DY'>J8-.#5-AW-*.XP>#BK<=V>_-8@?'>I%F(/6@#>$D<HP
M<4Q[8'E36:ESZU:BNCV.:=P%>%DZBFHSQG*,5/L:M+<*V :5HHY!D<'VH7D(
MD@UB:/ E&\?K6G!J-O/P&VMZ&L)[=ATYJ$J5/(P:M5&MR7!,ZW@\CD4A%<S#
M?W$!^5\CT-:D&M1O@2KM/K6L:B9FX-%XK43PANU3QS12C*,#3BOM6A)ESV"2
M Y4'\*P[_P -P7 /[L _2NM*\U&R ]10!Y;>^%)K=S);,RD=UXK->6[MODO;
M83H/XL88?C7KDMJK \5EW>CPS@AD%*R'<\]M[B*08M[D!O\ GE/P?P-:4&L7
M5D0LNY%]&Y4_C5O4?"2/EHQS6%)8ZEIN0I,D?='&14.)2D=KIGBIH2-DK1=^
M#E36Z-2TK52&O;95D_Y^+<X->3I=6Y;#H]I)_>7E3^%:$%U=6^'3$B?WXC_2
MHM8JYZ/<Z"US'FSG@U"'KLD.)!^-<]-IGV:8HKR6K_\ /*X'R_@:H67B1E8'
M<0X[J=K"NHM/%"W$0BNTCNXSU60?,*!G-2136YS)$T?H\?*FHW83C$L:3K_>
M7@BNR2RTF^/^A73VDA_Y92'*G\ZRM2\.36V9)+?:.TL!R#^%*P79S>Y(B DY
M,>>8Y.U97C'Q'9Z/:(+/YYG'"YZ&K^HJT8V>;&X]<8.*\A\27WVW5Y2I^1#M
M%7"),F=7X$\0:A?:\T-Q,9%?YL>E>Y1?ZI<^E>$_"VS,VM23XX48KW5>% ST
MK1;F;V'TTTN:;FJ$%)1WHH 2FFG&DI@)2K]\?6DI5^\/K2$6)O\ 7/\ 6FTZ
M7_7/]:90,6BBBF "EI*6D =J6BDH 6EIN:=0 4M)10 M%&:6@ H!HI* '9HI
M*!0 M%%% !2@TE% #J*3-+2 ,4444 %+2=:4<4 +129I<T )00#UHHH HWFD
M65^A6XMXY![K7+7W@"#<9-/N'MWZ@9XKMZ*VA7G#9DN*9YZL_BS0#ALWD"^O
MS<?SK3T_Q]:2,([^"2VD[GJ*ZXH&'(S6;?Z!IVH*1/;(2?X@,&M?;4Y_''[A
M<K6S+=IJ-I>H&MKB.0?[+5:ZUPEUX'EMG\W2[R2)AT4FH4UGQ-H9VWMN;F$?
MQ8SQ]:'AXR_AR#G:W1Z#2URVG^.=,NL)/NMY.X?I71074%R@>&5'4]U.:PE2
MG#XD4FF3<T49HJ!ABD(I:*0$;PHXP5!JA<Z3!<*0R CT(S6G15QG*.S$XI[G
M)S>''@?S+.62%ATV'C\J2/5=9T[BXA%R@_B'#5UA -1201N/F4&MUB;Z35S/
MV5OA=C,L_$UA=$([F"3^[)Q6NCJZAE8,#W!S6/>:!:W0.8QGUK);2M3TQMUC
M<MM'\#'(I^SI5/A=A<TX[JYV%+7*V_BJ:V<1:G:LAZ>8@XKI([A)(ED&0C#(
M)'!K&I2E3^(TC-2V)J3% .:6LRA*,4M)2 0@53N=,MKD'?&,^HZU=HH P&TV
M]L?^/28M'_SS;D'\*?#JXB;9<QO;MZ@;D_+J*V^M136T,ZXD0-]12Y>P[]QL
M5PLJ;U*NG]]#D?\ UJF!##(.16/)HSPOYME,T3^@-,&HW-JV+VW+?]-(^#_@
M:+M;CLF;=%5K:\AN1F"59#_=^ZP_"K <$XSSZ'K333%86BBEH$%%%)F@!U)1
MFBF,*2EHI -*YIC1@BI<48H RKZU+1-LZXKA[RWO[25F0DKG[IZ5Z6R!A5.>
MQ24'*@U+C<:=CSR+5E!VW"&-O7M5^.9)!E&##V-;%]X<AF!*J :YNYT&ZLV+
M0,RX].E9N!:D7\TX-6,NH7-N=MS%D?WA5Z"]@G'R.,^AZU#C8I,NAJD60CI5
M<-3@U0T5<NI<$=:L)<X[XK+#5-$=S>PI6&:ZW1V\]*@DND8\\50EG)X'2H"3
MGK19L>B-,21MWH88'%9H8@]:GBN"#@]*330:,MQ7+QO\K%36G;ZS(F!(-P]:
MPY1D;EIBW81"7/2G&HT)P3.RAU"WG ^8 ^AJP<'D=#7F4FNQB?8'(.>U=KX=
MOFO+0ASDKWKHA4<M&93I\JN:Q%1E >U3D4TBM3,JO"#VJG/8)(#E0<^U:9%-
M*T <C?\ AJ"<'" &N:N?#EU9N7MG9<?W:]/:,'M5>2V5QR!2L%SRF2:6-MM[
M;;B/^6B##"K$$^<&VN _^Q(<-7=7>C0S@Y0?E7-7_A4$EHA@^U2XE*1#%K4M
MNP28%?9QQ^!KI-/\2,,!;ED']UCN4UQ4MOJ%D-CKYL0_A<9J*&XA#\%[=_[I
MY6H<2D^QTGBJZ$MC<76R+<$/,8KP,))=W>Q%+22-P*]LFFAFT]K>9T8.,';6
M%I/A:PM+WSK=6=\\%CD"KCL1+<W/ VC)HUHN1^]898^]=U'+FL.TB$* =ZT$
M8BK6@C1#9H!J"-LBIA3$.HI*6@!#24II*!!2K]X?6DI5^\/K0!8E_P!<_P!:
M93Y?]<_UIE Q:*2EH *!113 6EI!12 *4444 +10** "BBB@!:6DS2]* "BB
MB@!<T4E+0 4444 %+244 +2]Z3-%(!:*2EH *6DHH 6BDSS3J "DHHH ****
M %XIC1JX(8 BG44[M 8NH>%]-OP3);JK_P!Y>#7.S>#]0T]_,TN^<8Z*QQ7>
MT8K:&(G'2Y+@F< GB3Q!I!V7]F9D'\6/ZBM:R\=Z9/A9]\#?[0R*Z22".4$.
MH(]Q6+?^%--O<EH%5CW48K3VE&?Q1MZ"M);&M;:A:7:AH+B.0'^ZU60<UQUI
MX<N-$G>>QD)R,;3S5^#6I(7V7"%&[^E<]114O=V+6VIT8HJI!?Q3*""/J*M
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M7,3-@.,TP H#43P*W:K!Q32* ,R?3XY 05!K&O/#4$W.W!KJ2!3"@- '#?\
M"*1J^3D@5J6^G);(%0 5T#1+Z5$81GI18+F:D6#5A$/I5GR1GI3Q'CM3$1HF
M*F XI0N*7O0 E(:6D-, I***0@I5^^/K24J_>'UH L2_ZU_K3*=+_KG^M-H&
M%%%%,!:*!10 4HI*!2 =124M  *6DHH 7-':BB@ I1244 +10#Q10 M%)2T
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MN%(= 1[BMU7NK35R>6VQ6T[Q#97ZC9( WH:UE<,,@@BN,O\ PJ YEM6:-_\
M9JG#JFKZ,^VX1I8AW[T_91EK!A>VYZ!FC-8.G>)K.] 5GV/Z-Q6TDBNN58$>
MU82@XZ,I.Y+FC--S14@*31FFT9I#%I*0FB@0&DI:*!C2*C= 1C%24TT 57MU
M]!430XZ5>(IA4&BPBEY7M3Q'5G8*-N* (UCJ3&*<!2&F AI*6DQ0 444&@!*
M**3M3$%%%%( I*** "A3\X^M!.*%/SCZT 6)?]<_UIAI9O\ 7/\ 6DS0,*7-
M)10 M%%% !2TE+0 4444P"EI**0#J*3-% "T444 +12"EH **** %S124N:
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M^M $\W^N?ZU'3Y?]<WUIN*!B@YHIM.!H *7O244 +129I: %HI** %HI*6@
MI<TE% "TM)10 M%%% !FEI!0#0 M%%% "T9I** %I:2B@ HHHH ,TM)10 M+
M3:4&@!:2BB@!:*2B@!:**2D N:6DHI@%%&:* %HHHI %%%%, HHHI %%%% !
MFE!I**8"YI*** %I***0"T9I** #-+FDHI@&:6DS24@%S2YI*2F [-%-HS0
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MBFT4 +1FDHH =FBFT4 .I*,T4 %%&:3)H 4TE%% #&16ZBF+;QJV0H!J6B@
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M5H^SOZK0!%1FI?L[^JT?9G]5H CHJ7[._JM'V=_5:0$=&:D^SOZK2_9W]5H
MBI:D^SOZK0+=_5: (J6I?L[>HH^SN>ZT 19HJ46[^JTOV9_5: (:*F^SOZK1
M]G?U%,"&BIOL[^JT?9V]10!%14OV9_5:/LS^JT 1T5)]G?U6E^S/ZK0!%14O
MV=_5:/L[^JT 145+]G?U6C[,_JM $5+4GV9_5:/LS^JT 1T5+]F?U6D^SOZK
M0!'14OV=_5:7[,_JM $)I*G^S/ZK1]F?U6@"&BI?L[^JT?9G]5H BS1FI?LS
M^JTOV9\=5H AS1FI?LS^JT?9G]5H BS14OV9\]5H^S/ZK0!%14OV9_5:/LS^
MJT 145+]F?U6C[,_JM $5%2_9G]5H^S/ZK0!%14OV9_5:/LS^JT 149J7[,_
MJM)]F?U6@"/-)4OV=_5:/LS^JT 149J7[,_JM'V9_5: (LTF:F^S/ZK1]F?U
M6F!#14WV9_5:3[._JM("*BIOLS^JTGV=_5: (J*E^SOZK1]G?U6@"*BI?LS^
MJT?9W]5H BI*F^S/ZK1]F?U6@"+-)FIOLS^JTGV=_5: (314WV9_5:/LS^JT
M 1"CM4OV=_5:3[._JM $=%2?9W]5H^S/_>% $>:3)J3[._JM'V=\]5H CI.U
M2_9W]5H\A\=5H BI*F-N_JM)]G?U6@"(FDJ7[._JM'V=_5: (J*E-N_JM)]G
M?U6@"*BI?L[^JT?9W]5H BI,U-]G?U6C[._JM B&BI3;OZK2?9W]5H BHJ7[
M._JM(;=O5: (J*E^SOZK1]G?U6@"&BI?LS^HH^SOZK0!%25+Y#^JT?9W]5H
AA-%2FW;U6C[._JM $-*OWQ]:D^SOZK2K;ON'*]: /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>53
<FILENAME>drts-20211231x20f041.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 drts-20211231x20f041.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (N T@# 2(  A$! Q$!_\0
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M (OWQ]:*<H^=?K10!8F_US_[U-Q3Y?\ 7O\ 6F4P"EH%+0 4448I %+BBBF
MM %&*6@!,"EI*7% PI<444"#BBBEQ0 F*7%%% !112XH 3%+BBEH **** "B
MEHH **** "BC%+0 E&*6B@!,4M%% !24N*7% "44N** $Q1BEHH 3%+110 4
M444 %%%&* "DI<44 %)2XHH 2BG4F* $HIU)0 E%+10 E%+1B@!M+2XI,4 )
M2T8HQ0 E%+10 F*,444 &*3%+10,0TF*=10(;12T8H 2BBB@!*3%.HH ;13J
M3% #:6C&** $Q1BEHH&)1110 8HQ0** $[4A%.I* $I!2TM AM%%% "8I*=0
M10 VDQ2T4 )2'K3Z:12 0TA%+0<4 -I*<:2G<!IXHI324 "_?7ZT4J_>7ZT4
M 69O]>_^\:9BI)O]<_U-,H ***6@!*6BE H 3%%+BC% !12BEH&)2T44""@"
MEHH *.]+10 E+BEHH ***4"@!*,4M% !111B@ HQ2XI: $HI:* $HI:,4 )2
MXHI: $Q1110 44M&* "DI:7% #:7%+BB@!,48I:* $HI<44 )2T48H 2BEQ1
MB@!**7%&* $HI:,4 )12XHQ0 E%+BC H ;13L4F* $I:,48H 2BEQ10 E%%%
M "8HQ2T4 )24M% "44M&* $HHQ10 4F*6B@!N**6B@!*2G8HQ0 VC%+24#$H
MI:* $HHHH ,4E+10(2BBB@88I*=24A#>]%*124P$Q12T4 )2$4M% #:#2XI*
M $HHHH 2DQ3C3<4@$/O24ZDH %^^/K10GWU^M%,"S-_KG^M,Q4DO^N?_ 'J9
M2 ***<.*8Q *6BBF 44HHI""BBEQ0 E+110 M% I: "BBEH 2EI:2@!:***
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MB@#-+0 48I:* $I<444 %%%+B@ HHI: $I<4 44@#%+113 ,448I: $HI:*
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M:*5!\Z_6B@"Q-_KG^IIE/F_U[_6FTQB4M%+0(2E%%% "T4@IP% "=J*=28H
M*6@"EH **** "EHHH .E%%+B@!*6BB@ HI:* $I:** "BEHH 2BE I: $Q12
MT4 )12T8H 2EI0*6@!*7%+10,2EQQ2@4N*0" 4=.]*Q"+DUGW%V<D+4RFH[C
M2;+ID4'K1YB'H:R#([<Y-*'<=S67MT7[,V 0:*H0W)!&:T(V#K6L)J6Q#BT)
MBC%28HQ5"&8XHQ3\5%+*D8Y-#=@W%VTN*IC4%W8-2K>1GO4*I%]1\K)\4F*5
M65QD&EQ5W$,Q013Z3%,0RBG$<4F* $Q1BEHH 3%)BG4&@!N**=BC% #:2GXI
M* &T4[%)B@!**7%% "44M H ;BC%.Q2T ,Q1BG$4AXZT -HI<@]** &D4F*=
M24 -HI2*,4 )24ZDH 2DI:*!B4AIQI* $Q24ZB@!M%+24 )12T4"$HHHH&%)
M2TE !3:=28YH 2C%*:2D(2DIW:DH 2DIU)B@ 7[Z_6BA?OCZT4 6)O\ 7O\
M6F4^;_7/]:93 *6C%+0 48S12@4  %%+10 4 44O>D 444 4P"EHI: "D[TM
M H ,4M%% !112XH 3%+110 E+1BEQ0 E+110 4448H&%&,TM% @Q12XHH !2
MT4HYH&%*!2@4O '-(!,4.ZH.34$UVD0P#S6;)/)*W7 K&I642XP;)[JY+\+5
M11D\T $4Y1FN.51R=V;QBDA<';@"D%2#B@X/6H<@(SQR*LVMSM.":KD<4W&.
ME5"HXNZ&XIK4WT8.N13L5EVUR4P&-7'NT"\=:[HU8M7.=P:=A;B41*>>:RI&
M:0Y)XJ65S,<DU$W KFJU>9Z;&L(6(=O/2D*U*O)ISIZ5C?0TMJ.M;HPG#'BK
MWVV+'6LEOI2!-QK6%:25C.5-/4VXYDD'RD5)BL16:$Y4UI6UZL@PW!KHIUE+
M1F4J;6Q8HQ3P 1D48K<S(\48I^*3% QF*,4_%&* &8HQ3L48IB&XI,4[%&*!
MC:,4[%&*!#<48IU% #<44[%!P!S2N VDICW"+TY-5WG9NG J742*46R>294'
M)YJC+</(>#@4TG<<$\TNRL)56S2,"2W=@>3FKO45148J[']P5I2E<B<;!24\
MBFD5L0-HI:* $Q24M!H ;12XI* "DQ2T4@$I*6B@!*3%+13 2DI<44 (>E)2
MT4 )1110,3BC%+2&@0@HI:* &T4I HI#&T4N*0T"!?OK]:*5?OK]:* )IO\
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M>@CF)33: V:6J 2DI:2@ HHHH 3%)2FDQ0(**** $HI:2@!*2EHH ;12XI*
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M""BBB@8E%+24"$HQ2TE "44M)0 E!I:2@!**** $-)2TE !2&EHI -HHH-,
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M=KBN5#:IGI1]F4=JLD4F*.4+D'D*.U+Y:CM4N*:13L%QA0>E-V#TJ0CBFT6
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MQ(/]H5@+>GUJ9;P'K33:$XIG2Q>(ATEMS]4-7(M8LI.LA0_[0Q7)K/&W4BI
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M0 [-+FF4M #\TN:CS2YS0 _-*#3,T9H DW4;J9FC- $F12<&FYHS0 %0:C:
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MDBTMX1WJ=+X]ZRL'M2@D4K#NC96[1NM/\R-N]8F\BGB8CO2'H;6T,.#2K//
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M*6@ S3J;2@T@"EI*6@ %+3:7-,!:*2B@!:!124 .I*,T4 %+24M !FC-)10
MM%&:"<=: "BBEH&%%)10 M%)FC- "T444 %%%% !1BBDH =2444 %+244 +2
M444 %+124 +2TE% "TN:2JMUJ$-FRB8D!OXL<"D(MT9JK%J%M/\ ZN9&^C59
M#J>A!IC%I:0T4@%[44E% "T4E&:!"YI,TE% "TE&:,TQA1244 +1FDI": '9
MHS3:*0#LT9YIM+F@!<T9IN:6@!<T4F:* %ZTA HHH 84!IC0 ]JES2T 4GLT
M;^$54ETN-\_(*U\BFD T <W-HBG.!BJ4NCRK]TYKKR@/:F-"#VI6 XA[.XC/
MW348>:,\Y'UKMFM5/455DTZ-^JBBP'+I?2)U)JU'JK+U)K1FT:-LX&*SYM'9
M<[2:-0+<>L>K5@ZG,);DOZFI9+*:,^M5)QC 88-1.]BX;E4G)I,TK8!X--;Z
MUG8TN"\M6M:86,FLJ,?-6BC;8JE+W@D_=-K2"#=[O05T7FY[US&E K&7]:UE
MF/K71$Q9I;J,U368U*KY%423J?G7ZT4U#\Z_6BF LW^N?ZTRGS?Z]_K3* %%
M+244@%[T44G>F M+2"B@!>M+2"ES0 4HI*6@!:,4@Z4M !2TE% #J*04M "@
MT4E -(!:***8"YI:;2YH **** "ES244 +2TE&: %HI.]+0 =Z#SUI** %HS
M244 +1110 48HHH&%%%% "YHI**!"T4E H&+124N: "BBB@ HHHH **** %H
M%)2CK0 M-9%<8901[TN:,T 49M'L9SEH%5O5>#59M%FBYM;V9/9CN%:]%(#$
M/]M6Q_Y93J/3@TJZY+"<75G*GN!D5M4C(K#E0?PH H0ZY93<>:%/H>*N)<12
M#Y)%/XU!-IEI/]^%2?I5&3P_$.8)9(C[&@#9S2U@?8]6MC^ZN1(/1J/[4U"W
M/[^T+ =UHN!OYH%8\7B&U;B0-&?]H5>BO[6;[DRG\:8%JDQ2!@PX(-&?2@0M
M&:2EH&)10:* "C-%!H 3G'%+244 &:***!!FC-)FC- Q<T9IM+0 M&:;FC-
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MU/N*T8/$$$F,L,T[H+&S152/4;>3^*K"S(W1A3$/I,T9HH *0T44 %%&:2@
MHHI* %I,T4F: %S1FFT4 .S1FFYHS0 _-+FF49H ?FD/--S1F@!"@/6HFB7T
MJ8FFT#*[6Z^E,, JW332 IF"F^5ZU<8<TW;0!76.I53%/VT4"%3[Z_6BA#\Z
M_6BF Z;_ %S_ .]3*=-_KG_WJ90 M+FDHH 6E%)2T !HHHH 444E*#0 4M%%
M "TM-I: %H!I*6@!:*0&EH *6DHH =12"B@!:,\49HH 6BDS2T %%%% !FEI
MM+0 M%&:*$P#K1FBB@ HZBBB@!:*2B@!:*,T4 %%':B@ HHHH ,T9HHH ,TN
M:2B@!:,TE% "T4E% "TM-HH =1244 +FD.#110!%);0RC#QJ?J*HRZ);.<Q[
MHSZJ:TZ6BP&(=/O[<Y@NBP'9J!?:C;_ZZVW@=UK:H(!ZBD,RH]=@)Q*K1G_:
M%7HKZWE'R2J?QHDLX)?OQ@_A5*70[=N8]R'U4T:@:@=3T(I:PCIU_;G,%R6'
MHU O]1MN)8-X]11<#>I.]9$>O1=)49#[BKL6H6\OW9!3 M9HS30ZMT(-+F@0
MM&*** #%-*@]0*=12 KRV4$PP\2G\*SY_#ME+R$V'U%;%)0!S+^')HB3;W+#
MV-5VM]8MF[2 >E==2;0>U%AW.276;NWXFAD'X5<A\1Q,0&/YUNO!$X^90?PJ
ME-HME-G=$,^U&H!%J]O)_$*M+=1/]UQ6-+X:C',,C(?K55]*U*WYCE#CWHNP
MT.G#*>C TM<G]LU&V_UD+''<<U(GB)D($@9?J*+A8Z>BL:+7X'ZD5=CU&"3H
MP_.BXK%ND)Q2*ZN,JP-+3 ,TF:":;0 [-%)10 N:,TW-&: '9HS3:3- #LTA
M-)FC- "YII;%!-(>: %SQ2<T4A-  329I**!CE^^OUHI%/SK]:*!#YO]<_U-
M,I\Q_?O_ +QIE Q:*2EH$%.IM&: %HHHH 6BBB@!:*2EH 6BBB@!:*2EH *4
M4E'XT .HI** %HHHH 7-%)10 ZBD%% "YI<TVBD ZBDS2YI@%%%% !2YI**
M%HHS29H 6BC-% !1110 9HHHH *6DHH 6BDH% "FBDHH 6BDHS0 M%)FC- "
MT49HH *6FYI<T +129HS0 M&:3-&: %HI** "EI** %II4-UI:* ();."7[T
M8/X51ET2!N4RA]C6KFBE8#".FWL!S#.3[&D%YJ5O_K(MX'<5O4T@'J!0!DQZ
MZ@($L;(?<5>BU*VEZ2"G26D,F=R U2ET6!CE1M/M1J,TUD1AD,#3LU@MIEU"
M<PS-^-(+G4;?ADW@>E%P.@HK$CUS:<31LOX5936;9SPPIB-*DJNEY#(.&J97
M4]"* '449I* "BC-)0 UHU;J :K3:?;S [XE/X5;I#0!AS^'+20Y52I]JI2>
M')T!$5PV/>NH-)2L.YSVG:=?V3@/.73/0UO@\"EI.]"0A****8!2444 %%)F
MD)H 7-&:3-% "TA-)FB@ HHI"<4 *>E)29HH&%!-(310(5?OK]:*%^^/K10
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M 444E% A:4&DHH 6@<49I: "EI*,4 '>EHHQ0 9YI:3%% "TM)10 N:*2C-
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MM+0(4T9-)FEH 4&BDI<T# 4N:2B@!:6D!I>M @!I:;0* '4M)FB@!:,4E+0
MM&:2@T +UHI,49H 6EI,TM "T4E% "T"BC- !2TE% "TM-HH =1249H 6BD%
M% "YHHHH 6BDHH 6BDHS0 M%)FC- "T4E% "T44E "T9HHH ,T9I*6@ HI*6
M@ S1FDHH **** "BBB@ Q1110 449HS0 44E&: %HI** %S29I*!0 M%%&:
M"BDS10 N:,TE% !FBBDH 7-&:3-)F@!V:0FDHH 7-&:2DH 4TF:2C- !24M(
M30 4$TE% !1BDHS0 'BDS03FEH&(*6DSBDS0 I-)10:!!2$T4E(!:2C-)FF
M4444 "_?'UHI%^^OUHI 2S']^_UIE.F_U[_[QI@-,!U&:04M "T4E+0 M%)2
M@T#"ES1C-)0 M+2 TO6@09HHQ0* %HS29I: %HI** '49I** '9I*2EH *7-
M)10 N:*2EH 6BDS2YH *6DS2T %%)12 6E[TE&:8"T44E "YHS244 +FEI*2
M@!U%)10 M)1FC- !1110 M%)10 M%)10 M&:*2@!<T4E% "YI,T44 ****2@
M!?QI*6DH **** #J**,TF: %S129I,T .I*3-% "TF:.]% !2T49H **3-%
M :,T4E "TE%% !10329H 6DHHH **0T9H #29HHH 2BEI* "C-)FBBP!24O&
M*3- Q>G6D)I**!!1124 +FDHH- !2444 %)0324 !-%-I:& J_?7ZT4B??'U
MHI 23?ZY_K3,TZ;_ %S_ .]3.E,!V:6F\&E% #J*3-% #J*2B@!:7-(#10 Z
MD%)2B@8N:6DHH$+1FDS2T#%R**2@4"%HS24N* %HI*,T .HI,TM !2BDI.:
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M3U6@"'-)4WV5_5:3[,_JM $1XI":F^RR>JT&V?'5: (>U)4WV5_5:/LK^JT
>0YI*F^ROZK0;9_5:0$*_?'UHJ9;9PRG*]:*8'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>54
<FILENAME>drts-20211231x20f042.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 drts-20211231x20f042.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (O TD# 2(  A$! Q$!_\0
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MT;\Z9BEH&/\ -D_YZ-^= ED_OM^=,Q2T /\ -D_YZ-^='FR_\]&_.FT4 /\
M.D_OM^=+YLO]]OSJ.EH =YTO_/1OSI?-E_YZ-^=-P*,4 /\ .E_YZ-^=+YLO
M_/1OSIE% #_.E_YZ-^='G2_\]&_.FT4 /\Z7_GHWYT>;+_ST;\Z;C%% #_-D
M_P">C?G1YTG]]OSIH%% #_.E_P">C?G1YTG_ #T;\Z;BC% #O.E_YZ-^=+YL
MO_/1OSIE+B@!PFE_YZ-^=*)I/^>C?G3,44 /\Z3_ )Z-^=+YLG_/1OSIE+0
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M4N**6@ HI:*  4HYI<44 %**** "EHHH **444 &**7%+0 E+11B@ I:*.]
M!1BEHH **** "BEQ13 2EI<4"@!**7%% "8I:6C% "=J*7'-&* $Q0!3J*0"
M8HI<48H *2EQ2T -HQ2T4 )BBG8HQ0 F**7%&* &GI2XI<44 )BBEI,4 )12
MT4 )S12XHQ0 4=Z,44 )012XHQ0 F**6DQ0 F*,4ZDI@)2=Z=10 VBEQ2<T
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MHHH 0TM%+0 E%%+0 E%%% "8I,4XT4 -HI:* $I,4[%)B@!,4E.I*8"444M
M#<44M% "4AI:*0"8I*=28H 2D-+BB@!M!IU)0 W%)3J3% "8HI:2@!,4=*6B
M@!E%*:*8"4E+UI* $III^*;0 E)BG8I,^M "4A%.(I* &TE.(Q24 )BDI:#0
M W%7,54JY0 V7_7/]:;3YA^^?ZTVD "CO1TH% !2T<XI<4  %+1CFEH ***6
M@ HHI>U !2T4M ""EHI: $I:** "BEHI@%%+0* "@"EHH **4"EH ;BEZ448
MI %+UHHH **6C% !2TH%+0 VEQ3@*,4 -Q1BGXHQ0 S%&*?BC% #,4$4[%)B
M@!E%/P*",4P&44ZDH 3%+BBB@!**6C% "444M "44N*3% !1110 4444 &**
M** $HI:*0"4M%% "44M% "48HI: $I*6C% "4F*=BDH ;13J2@!*3%.Q24P$
MHI:0B@!*,4M)2 2BEHI@-Q12TF*0"4E+13 ;1BEHH ;012XXHI -HZTM)B@!
M*2G4G>F W%%+12 ;28IQIM,!!2&G4E #:",4II* $I*<124 )5RJ=7* $F_U
MS_6F 4^7_7/]:;2 3O2T=Z4"@!:*** %HHHH 6BBEH *4"BEH 2EHQ2T %%%
M% !112TP "EHHQ0 =J6BB@ I11THI +1UHI: $HHI<4 )2XI:*  "EQ0!3@*
M $ IP%*!2G &2<4 )BEQ5&ZU2*'*I\S#TK%GU2YF8C>5'H*RE62V-%3;.GWI
MTW#\Z7@]*XDSS%S^\;\ZLVFJW%O)\S%E]#4JM?<;I'78I,57LK^&\3*D!NXJ
MV5S6R=]C-JQ'BD(J3;28IB(\48IY%)B@!F*3%/I* &XXHI<48H 2DI<48H 3
M%%+13 2BEQ1BD 4E+BC% "44N*3%, [448HH 2BEHH 3%%+10 E%+1BD E%%
M%, I*6BD E%+24 &*3%+10 E%+BD- "8I*=2&@!M&*6B@!M%+BC%,!N**6B@
M!M(:=24 )28IV*3%(!*,4M)0 VBG4V@!,44M)B@!"*0TIHQ3 :124ZD- #31
M2TE "&@BEZTE #:2E(HH 2KE4ZNT -E_US_6F4^;_7/_ +QIG6D( *=24M P
MI:04M !VI112T %+24M !2T"EH **** "EI*7M3 **7%+0 @HI:4"@ Q1BBE
MI (*6BB@ I:2EH ***7% !2@4E.% "BG"FBG@4 !(4%CP!6)?ZD7<QQG"^M2
M:M?;?W2'CO6*7)YQ7-4J7=D;TX=6.!8RG-(R$...M-R=^<$5,><5B:%=T <<
M$5&RX:KLD>1G(-1R1'&<4 5XI9() R$@BNDT[64FQ'/A7['UKG73C.*:00 1
MVJXS<27%,[P$$9!R*0BN9T_67M\)-\T?KZ5TL,T=Q&'C8$5U1FI&$HM"$4FV
MI2*:15$D>*3%/Q3: &FBE(I,4 -HIQ'%)B@!*2G8Q1B@!M%+BB@ I*6C% "4
M4N*,4 )11BB@ HHHH 2BEH[T -I:6DI@%%%% !24M% "44N*2@ I*6BD E!I
M:2@!,44M% #:,4I%)3 2DIU)TH 2DI:,4 )2$4M% #:*6DZ4@$HI>M)0 AHI
M>M)B@!*2EHH :124ZDI@)BDIU-- "4E.IIH *0TM% #:3&*<1Q3<T -J[5,U
M=H ;,/WS_P"]3 *=-_KW^M-%(!:6DI: "EI*6@!:*!2T % HI: "EI*6@ HH
MI:8!2T@IU "4M%*!0 =**.]**0!2TE% !2T44 %%%% !2T@I:8 *>*:*<*0#
MA45W,+>W9R>W%3"L;7Y]B)'GKUJ*DN6-RH*[L8LLQED8GO2(201BH0WS5(K'
M=7'8ZB=02.G:I-I*BHT)!Z<9J120<<=:!$@_U>#1M#)U_6A1C(IR #(XH A\
MLM'UJ+82N..*NJ%)88J,QKEASS0!2V?+TZ5/9WLUD^Y&X[K2E &(!P#410AR
M.#[TT[ U<ZNQU.&]08.V3NIJX17#([PR;D)4]JW]-UP.1%<G#=FKHA5OHS"4
M+:HV<4TBI!AAD$$'I32*V,R/%)BGD4F* &44[%)B@!M)3L48H ;11BC% "44
MM&* "DI:,4 )1110 48HHH *3%+10 E%+1B@!*2EQ24 +244O6@!**7%)3 *
M2EHH 2BC%% "44M%(!*0BEHH ;13L4WI0 A%%+24 )24M%,!M!I2*2D E&*6
MDI@)BBEI.E(!,4E.I#0 T]:3O3N])B@!#24M)3 0TE.ZTE #:0TZDH 2D-.-
M)B@!IJY5,U=YH 9-CSG_ -ZF]:?,/W[_ %IE( I:** "EHI<4  I:2E% "T=
MZ*6@ H%%+0 8I:2EI@+112@4@"CI1FEH ***6@!*6BB@!*6BB@ HI:*8"BBB
MCK2 !3Q31TIPH >*YGQ W^E >@KI:YOQ#$?/5^Q%95?A-*>YCACC(%2*3Q40
MX/M4BD]*YS8F!.14XY(^E5U)Q4J]*3'<L#KGU%2 <@XZU""-O7I4PP5^G-(8
MHPL@]Z<[@.,J#VI. OKCFE;&W(QZXH$0R!=ZY7BHY$0,",BK4C94844DGS19
MV#ZT#*4B#((;/UJ)T(.<?E5UE5DSM[5$R+LR211<+%BPUB:T8))EXO3TKIH)
MXKF,21L"*X>25$&&(^II;75C:R@QR@8[9X-:PJVT9G*G?8[LBFD55T[4HM0A
MRO#CJ*ND5TIIJZ,+6(\4TBGD4F*8AF*0T_%(: &8HQ3L4E #=N**6DQ0 E%%
M% !1110 48HHH 3%%+10 E)3J2@ I,4M% "4"EHH 2EIM'2@!2*2EHI@)G%'
M6D*TM "44M)0 4E+24@"DQ2TE "$<4E.I#0 AI*4T4P$I*6DH *2E(I*0!WI
M*6DI@(:2G4W%(!**6DH 3%'6E(IM !WI"*4CBDI@-I#3C24 (:0TM!H ::O<
MU2JY0 V;_7/]:93YO]<_U-,I %+TH%+0 4M(*6@ I10** %%%%% !2T44P%I
M>U)2XH !3J2EI %%%% "T444 %%%%, HI>M% !112@4 %.%)2T@ =*44@ZT\
M4 %4M2LUNX"/XAR*O4QN*35]!K0XF6%H9"CC!%(I/MQ72:C;0S1EFP&'>N<.
M Y4$9!KGE&QK&5QZDYZ]:E2H%],U(#WYK-HT184\5(AXQFH%(!J16^:I&6$P
M2!ZTY"#QT/2HE.#UJ1<9//O0,D4_)TYZ4BEBN,$\XH 4,<Y.>13991$<J0<T
M@L(7\J)@V!CUKF-6U^.!F2$AF[GM4/B7Q$#NMK<@#HS#N:H:)X;FU,K=WVZ.
MUZJHX:3_  %4HW"]O4KQ2:CJ\VV!6<#JW11^-;5KX>="&N9R3Z)P*Z6*VBMH
MEB@C6.)1PJBD9*>G0+LJV+'36#0$_P# CFN@LM>29@EPNPG^(=*P77GI492J
MC)HB44SNQA@&4@@]Q2;:Y73M5FLW".=\7H>U=1!/'<Q"2)MP_E71&2D82BT+
MBFFI=N*:5JR2.D(I^*0B@9'BBG$4F*!"4F*6B@!N*,4ZDH 0BDI:* $HI<4E
M !1110 4E+1VH 2BEI* "DQ2TE !12T8H 2DQ2T4 )12D4E,!*2G4E( I*6B
M@!,4E+24 )12TF* $-)2T$4P$I,4M(: $Q12TE(!*2EHH 3O2$4=Z6@!O>D-
M+10 E(:6DH 2D-+2&F AI*4TAH *N\52JY0 R;_7R?[U,I\W^O?_ 'C3*0"T
MM)2B@!1112T %+24M !2TE+0 4M(.:7FF 4X4@]Z6D =Z4<4E+0 444M !11
M10 444M, I:2EH *6BDI +2BFCK3J '"EIN:44#%S2-TYI:8_2D!D:IN*$+T
MKE+D2(^X9S7:SQ[ZQ+VQW9(%2T-,R;:[63Y6.&JZOUK)N;5HVR."*?:WNTB.
M;\#64HFBD:RXZ5(K9'N*A4J0"#3P0#631HF6 <X-/&<@YJ!&[=:E4EACTJ2B
M9VV)O')'8URWB+6##&T2-AC][%;5_=B&W9CQM%<'':3^(M96V5B$)W2L.R#K
M0E=CO97-'PUX>DU&X.I7P_T93^[C/\9]37?(JX  P!VJ**)(($AA7;'&H50.
MPJ1<@=:INY([8<9P*C9<]JG4^M(RD_=H J.@)Q4+1\^E6G7:<''^-(R9'2@"
MBT=36=[-92[HR2.ZGH:>4YJ(I0I6!HZVQU"&^C!4@..JFK16N'1Y() \;E2.
MXKH=-UQ9RL5R%1^S=C71&HGHS"4+:HU"*3%6-HIC+6I! 132*F(II% B(BDQ
M4A%-(H&,HI2*2@0E)2FC% "4444 )12T4 )11BB@ HHHH 2BBD- !2]:2EH
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MBGD4TT"&XI*?28H ;111CB@ HHHH 2BBB@ I**6@!**444 )10:* $HI:2@
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MM,(J8;74,I!!Y!'>FE:[3@(2*::D(II%,"/%(14F*:10(8:*7%(: $HHHQ0
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MDHHI %)2TE !3:4FDH *2EI*8!24M)2 *;3J2@!*0TM)0 4E+2=Z $-)2TE
M"&D(I324 )WJ[BJ57:8$,O\ KG_WJ93IO]>_UIE(0ZE%)10 ZEIM*#0,6E%)
M2T %+]*2ES3 6@TF:7/M0 4M)2YH 6EIM+S2 7ITI:;2T +124N: "E%)13
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M4=*04M "T44<4 8^N:?+>6^;>1HIE^ZZD@_I5+2KZ=52U,SM<Q\&*8C]Z/\
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MXM\;?4>E=,)J1A*+1(1334AIA%:$D9%)CFGD4TT --)2TA% "444E !244E
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M29H-%,8AI*7---( -7<U1J]3 KS?Z]_J:93IO]>_UIM(0M+3>]+0 M+2 TM
M"TH-)10 ZBDI: %I:044#%I1244P'4 TE+0 M+WIHI: %I:2E'-( HH[YHH
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MD!)'(JDJ0#2$JDG3@TUPJN#V-22+&4#"@!9=N PH.&3@THC1X^&--C4 ')H
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MI:;2YH&+2TE&: '49I*!0 ZBDS2T +1244 *#S2TVEH 6ESFFT4P'44F:6@
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MZ4E% #J,T@HH =FES3<THI .Z]*4'-,S2T .I<TT4M "TM)VHS0 ZC-)2YH
M6EIO2@&@!U I*,T .I:;2T +124M "T"DI<T *#1UI** '44E% #N**;2YH
M6BDHH =13:,T .HI** %HHI* %HHHH 6@TE% "@T9I*,TP'9I*2EI &>:6FT
M4 .S[TF:2B@!:,TE%,!:7--HI .S29I** '9I,TE% "T4E%,!:*2B@!U+GFF
M4M(!U)249I@!%-Q3C25(#"*C9:E--(IV @:,&HR@%6&'M3"M(9#@4E/(II%
M#311WHQ3 2CO1CFEQ0 @IP&:4+FI%6@0*,4\#F@"G4 ' HHQ13&%&:,4F<"@
M04E&>>!10P#O244E(!:2BDH 6D-)FBF =:2@]:2@ S24$T4 %)110 A.*3.:
M6D/7I0 $U<JB:NT 5IO]<_UIM$Q_?/\ 6FYH =GFE%-S2YI +2@4VES3 6EI
M.M% "T9YHHH ?GBES3* <4@'YI:8#[TH- #L]J*2C- #OK0.M)FCO0 ZEIN:
M6@!:6FTN: %%+3*6@!U+3<TM "T9I,T=: '9HS3:7.* %S2]Z;FC- #J,\T@
MHS0 M+FDS2=Z '9HI** %Z44E&: '9HS244 +129HH 444F:* %HS129Q0 N
M:*3-% #LTF:3.*,T +1129H 6BDS2YH **3-&:8"]Z*3-)FD [%%-S2T +FB
MFTM "YI<TW-&: '44F:.] "YHI,T4 !IIIU(: &$4TBG&DH C(II45(124 1
M;?:DVU+BDQ0!'MI0M/Q2@4 (%IP'M2@8%+F@ Q11S1F@ I.E%&: N!YI.U%)
M0 9I/>BB@ H%)29I@+FFYI?QI.* %Z4TF@FFDDF@!V:2BDH ***0T +249I*
M  FDHS24 (:NYJEFKE %67_7/]:;2RG]\_UIM(!V:.])0*8#A3J92@T .I:;
M0.: '4M-I: %HI*6D 4X<4VEI@+2YXI#12 44M-[4 TP'TM-ZT4@'9I:;1F@
M!U&:;FES0 X&ES3*7- #LT4@-% "TM)0* '44E&: %S1FDHS0 M%)10 XYHS
M29I,T .S1244 .HIN:.: %I<\4W-+F@!<T=J3-&: '9I*3-% "YHI** %I:;
MTH[4 .I*3-% "T9I#10 M&128]:* %S031Q29H *,T=** #-%)1DTP'49IO-
M%(!V:*;FC- #Z*9NI: '9HS3<\T9H .M-(I<T&@!II/K3L4F* &T8I:7% "
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M3O)D_N_K2^1+_=_44 ,I:=Y$O]W]12^1)_=_6F P4N:=Y,H_A_6E\B7^[^M
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M1G%.\B7^[^M'D2_W?U% #=U+3O(E_N?K2>3+_=_6D VC-/\ (E_N_K1Y$O\
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'?^[^M '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>55
<FILENAME>drts-20211231x20f046.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 drts-20211231x20f046.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !L %X# 2(  A$! Q$!_\0
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ME.>R-6JTU_;0<-("WHO)K#FO+B?[\AQ_=' J"OF<7Q:]L-#YR_R7^9U0P?\
M,S3FUB1LB% H]6Y-+I<\LUZYD=F_=GJ?<5EUHZ-_Q^/_ -<S_,5YN7YEBL7F
M%+VTVU?;I]VQK4I0A3?*C;HI"0!DG ]356348$.U-TK>B#-?H-?$T:"O5DE_
M73N>=&,I;(MTUY$B7<[JH]2<5FO<:C/Q% 8A[]?UJ'^R[J5MTLBY]68DUY-;
M.*LM,)0E/S:LOQ_X!M&BE\<DBS-J\*9$2F0^O05GS:E<S<;]B^B<?K5U-%0?
M?F8_[HQ5A-+M4ZH6_P!XUY=;"9[C=*DE!=D[?E=_B:J>'ALKG/DDG)ZT](99
M/N1NWT&:Z1+>&/[D2#W"U+65+A%[U:OW+]6_T&\9V1SR:;=/_P L]H_VB!5A
M-&E/WY47Z#-;-%>G2X7P$/BO+U?^5C)XNH]C.31X1]]W;Z<5:@LX+<[HDPQ&
M"<DU/17J4,LP>':E2II-=>OWLRE5G+=C&BC<Y= W^]S3@ HP  /:N4G^(.DV
M]Q)"]O>EHV*$A$QD'']ZH_\ A8^C_P#/M??]\)_\57:H13NEJ1=G845A:3XL
ML-96Y^R17)E@3S/*95#N/]GGGL.W45F?\+'T?_GVOO\ OA/_ (JJ$=A15#2-
M7MM:L!>6N\(6*E7 #*1V.,^Q_&JVN>)+'0/)%T)7:7.U8@"0!W.2* -BBN6L
M_'FFWUY%:P6E\TLK!5&Q.O\ WUTKJ: "BBB@ HHHH \*U+_D*7?_ %W?_P!"
M-;>A^#KC7-.^V17442[RFUE)/%8FI?\ (4N_^NS_ /H1JWI_B35M*MOLUE=^
M5#N+;?+1N3]0: .OTGP/J6D:G!>PZA!F-OF7:?F7N/RK%\<Z'_9NJ_:X4Q;7
M1+<=%?N/QZ_GZ5-H?BW7+S7+*VGOM\4DH5U\I!D?4+7?ZWI4>LZ3-9R8!89C
M8C[K#H?\]LT >=>!M;73-5:UG<+;77!)/"N.A_I^(]*RO$6KMK6LS763Y7W(
ME/9!T_/K^-9T\$EM<203(4EC8JRGL15[0M)DUK5H;-,A2=TC#^%!U/\ 3ZD4
M =E\/M#\N)M7G7YGRD /8=V_'I^?K7=TR&&.W@CAA0)'&H55'0 =!3Z "BBB
M@ HHHH \*U+_ )"EW_UW?_T(UV'A.Y\.1:+MU1;$W/FL?W\09L<8Y(K(O_">
MNR:A<R)I[LC2LRD,O()/O5?_ (1#7_\ H&R?]]+_ (T =]%J7@Z&598CIL<B
MG*ND*@@^QQ6Y8ZC9ZE$TEG<),BG:2O8UY+_PB&O_ /0-D_[Z7_&N[\#:9>Z7
MIES%>P&%VFW*"0<C:/2@#BO&X \6WN !PA_\<6MSX9@>=J1P,A8P#_WU4'BS
MPYJ^H>([JYM;)Y87";6#+SA0#U/K6MX#T?4-*>_-];-")!'LR0<XW9Z'W% '
M9T444 %%%% !1110!GV^N:9=W9M8;M&FR5V$$9(Z@9'/0]*N7%Q%:P--,VV-
M<9."<<X[5QMEIE^;NU3[/?*8+UY6\YE%N$);YE&<EL$8^IIAL]8>T6 VMVCP
MV/DEBP(=Q*AR,'GY0>?K0!V2WMLT,TPF7RX&99&[*5^]GZ46]Y!=[_(DW[,;
MN".H!'7V(KC[W3+]HKE6L[F6*2:\*)"^W#N1L<_,,KC/KU]ZFATF^GO8(KB.
MX%KYR;]LA7Y1;@=0>FX8H [&BO/]4@OX=-A-W'=L_P!G$,#";&R3S#]X;ADE
M=OK6WXJM]0N?+2TMY'58G*R1$[A)Q@?>4#US@]/?D Z%[B*.>*%Y%$LN=B]V
MQR?RJ2N8\064]T^F2/:7-PL<,HE%NVU@Q5<=QW_E5./2]9;6+0W<EP5$<(+H
M-R@!,2*QWC&3G)P<YR* .KCOK640F.=&$S,D9!^^5SG'TVG\JL5Q5IHKVT6F
MF33;EFM;R3S0K_>#!MK+\W3[F>G0^]0II6M&VU!93=F=P V!@.?-!W*V\]%S
MT48!H [NBHK:VBM+=((0PC3. S%CUSU))-2T <</$^I?;?L1AC\SS/LOF;#C
MSO,QG&>GE\_6F2^*M06WFE46K,T<KI$ =\!1PN'YYSGVYKL/L\.[=Y,>[?OS
MM&=V,9^N.,TTV=J3(3;0YE_UAV#Y_KZT <Q=ZEJ5AX@BAG=&\R&)9944B*$-
M*XS@GJ?E7/\ A3(]5U%&FBLOLZ;6NYF\U6?/EN, ?-QG/X>E=7);P2EC)#&Y
M90K;E!R <@'VS0+6W!)$$0)W9^0<[N6_/OZT <O)K]Q/J-L!]D6/S[9!%(F9
M/WBABRG/'7'2K.N:[>:5J*P1Q+)&Z+*#MZ(NXRY_ #'UK5N-(M;F[MKAUP;<
MAD554#(Z9.,X'IG'M5QX8I2#)$CD J"R@\'J/QH Y$^)]15$E;[*F(XY_)=2
M'F61R%"<]0N/7FI6O]2NEM9IIHU@.J"%$B4JQ"NP^8YP1QTQVKIVM;=FC9H(
MBT7^K)093Z>E+]G@"A1#'@/O VCALYS]?>@#F-"U.ZU+78I9YXBKV+.(8LXC
E_> 889/S>_%=74,=K;PRM+%;Q)(V=SJ@!.>3DU-0 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561881132648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 21, 2022</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Alpha Tau Medical&#160;Ltd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">L3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Kiryat HaMada St. 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Jerusalem<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">9777605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">U.S. GAAP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,529,265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001871321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KOST FORER GABBAY&#160;& KASIERER<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Tel-Aviv, Israel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Uzi Sofer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Kiryat HaMada St. 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Jerusalem<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">9777605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">(3)&#160;577-4115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary shares, no par value <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">DRTS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">40,528,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">13,739,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants to purchase ordinary shares<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">DRTSW<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561882841944">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 23,236<span></span>
</td>
<td class="nump">$ 15,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">618<span></span>
</td>
<td class="nump">576<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedInvestmentsCurrent', window );">Short-term deposits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,080<span></span>
</td>
<td class="nump">30,417<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other receivables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">707<span></span>
</td>
<td class="nump">864<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">32,641<span></span>
</td>
<td class="nump">47,455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_LongTermAssetsAbstract', window );"><strong>Long-term assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Long term prepaid expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,028<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,546<span></span>
</td>
<td class="nump">5,395<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total long-term assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,574<span></span>
</td>
<td class="nump">5,534<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">42,215<span></span>
</td>
<td class="nump">52,989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Trade payables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,203<span></span>
</td>
<td class="nump">964<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other payables and accrued expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,202<span></span>
</td>
<td class="nump">1,124<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,405<span></span>
</td>
<td class="nump">2,088<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_LongTermLiabilitiesAbstract', window );"><strong>LONG-TERM LIABILITIES:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_Warrantliability', window );">Warrants to convertible preferred shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18,623<span></span>
</td>
<td class="nump">5,366<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">23,028<span></span>
</td>
<td class="nump">7,454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible Preferred shares of no-par value per share - Authorized: 25,348,176 shares as of December 31, 2020 and 2021; Issued and outstanding: 13,739,186 shares as of December 31, 2020 and 2021; *)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">53,964<span></span>
</td>
<td class="nump">53,964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' deficiency:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Ordinary shares of no-par value per share - Authorized: 72,423,360 shares as of December 31, 2020 and 2021; Issued and outstanding: 40,433,578 and 40,528,913 shares as of December 31, 2020 and 2021, respectively; *)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18,063<span></span>
</td>
<td class="nump">17,140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(52,840)<span></span>
</td>
<td class="num">(25,569)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' deficiency</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(34,777)<span></span>
</td>
<td class="num">(8,429)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred shares and shareholders' deficiency</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 42,215<span></span>
</td>
<td class="nump">$ 52,989<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Prior period results have been retroactively adjusted to reflect the 1: 0.905292 stock split effected on March&#160;7, 2022. See also note 10, Shareholders&#8217; Deficiency, for details.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_LongTermAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>No definition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_LongTermAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_LongTermLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>No definition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_LongTermLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_Warrantliability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of warrant liability classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_Warrantliability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedInvestmentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the current portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120413209&amp;loc=SL6242269-115581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedInvestmentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561881080536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>CONSOLIDATED BALANCE SHEETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Par value (per share) | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Authorized (in shares)</a></td>
<td class="nump">25,348,176<span></span>
</td>
<td class="nump">25,348,176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Issued (in shares)</a></td>
<td class="nump">13,739,186<span></span>
</td>
<td class="nump">13,739,186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Outstanding (in shares)</a></td>
<td class="nump">13,739,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares par value (per share) | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, authorized (in shares)</a></td>
<td class="nump">72,423,360<span></span>
</td>
<td class="nump">72,423,360<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, issued (in shares)</a></td>
<td class="nump">40,528,913<span></span>
</td>
<td class="nump">40,433,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, outstanding (in shares)</a></td>
<td class="nump">40,528,913<span></span>
</td>
<td class="nump">40,433,578<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561880978712">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENT OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>CONSOLIDATED STATEMENT OF OPERATIONS</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 11,447<span></span>
</td>
<td class="nump">$ 7,544<span></span>
</td>
<td class="nump">$ 6,636<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketingExpense', window );">Marketing expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">482<span></span>
</td>
<td class="nump">288<span></span>
</td>
<td class="nump">397<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,861<span></span>
</td>
<td class="nump">1,412<span></span>
</td>
<td class="nump">977<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,790<span></span>
</td>
<td class="nump">9,244<span></span>
</td>
<td class="nump">8,010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingGainsLosses', window );">Financial (income) expenses, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,474<span></span>
</td>
<td class="num">(520)<span></span>
</td>
<td class="nump">308<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before taxes on income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27,264<span></span>
</td>
<td class="nump">8,724<span></span>
</td>
<td class="nump">8,318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Tax on income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(158)<span></span>
</td>
<td class="num">(146)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27,271<span></span>
</td>
<td class="nump">8,882<span></span>
</td>
<td class="nump">8,464<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: net loss attributable to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Alpha Tau Medical Ltd.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 27,271<span></span>
</td>
<td class="nump">$ 8,882<span></span>
</td>
<td class="nump">$ 8,367<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to ordinary shareholders, basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.67)<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="num">$ (0.25)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to ordinary shareholders, diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.67)<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="num">$ (0.25)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used in computing net loss per share attributable to ordinary shareholders, basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">40,534,697<span></span>
</td>
<td class="nump">40,274,935<span></span>
</td>
<td class="nump">33,815,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used in computing net loss per share attributable to ordinary shareholders, diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">40,534,697<span></span>
</td>
<td class="nump">40,274,935<span></span>
</td>
<td class="nump">33,815,448<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Prior period results have been retroactively adjusted to reflect the 1: 0.905292 stock split effected on March&#160;7, 2022. See also note 10, Shareholders&#8217; Deficiency, for details.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services. Costs of public relations and corporate promotions are typically considered to be marketing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of gains or losses resulting from nonoperating activities (for example, interest and dividend revenue, property, plant and equipment impairment loss, and so forth).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7,9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561967660840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)<br></strong></div></th>
<th class="th"><div>Mar. 07, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>CONSOLIDATED STATEMENT OF OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split ratio</a></td>
<td class="nump">0.905292<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561881158088">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS' DEFICIENCY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Deficiency</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (8,429)<span></span>
</td>
<td class="num">$ (193)<span></span>
</td>
<td class="nump">$ 1,861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of ordinary shares and warrants to ordinary shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_StockIssuedDuringPeriodValueOrdinarySharesUponExerciseOfShareOptions', window );">Issuance of ordinary shares upon exercise of share options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">111<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_StockIssuedDuringPeriodValueExerciseOfWarrants', window );">Exercise of warrants to ordinary shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">1,560<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">812<span></span>
</td>
<td class="nump">596<span></span>
</td>
<td class="nump">546<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(27,271)<span></span>
</td>
<td class="num">(8,882)<span></span>
</td>
<td class="num">(8,367)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: net loss attributable to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(97)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(27,271)<span></span>
</td>
<td class="num">(8,882)<span></span>
</td>
<td class="num">(8,464)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsToMinorityShareholders', window );">Acquisition of non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(946)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(34,777)<span></span>
</td>
<td class="num">(8,429)<span></span>
</td>
<td class="num">(193)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Convertible Preferred Shares | Convertible Preferred Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Deficiency</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 53,964<span></span>
</td>
<td class="nump">$ 25,238<span></span>
</td>
<td class="nump">$ 25,238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, beginning of period (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">13,739,186<span></span>
</td>
<td class="nump">7,229,885<span></span>
</td>
<td class="nump">7,229,885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of series B Preferred shares, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of series B Preferred shares, net (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,509,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 53,964<span></span>
</td>
<td class="nump">$ 53,964<span></span>
</td>
<td class="nump">$ 25,238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, beginning of period (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">13,739,186<span></span>
</td>
<td class="nump">13,739,186<span></span>
</td>
<td class="nump">7,229,885<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Ordinary Common Shares | Class A Common Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Deficiency</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, beginning of period (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">40,433,578<span></span>
</td>
<td class="nump">39,804,163<span></span>
</td>
<td class="nump">33,185,538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_AdjustmentsToAdditionalPaidInCapitalWarrantSharesIssued', window );">Issuance of ordinary shares and warrants to ordinary shares (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,302,132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_StockIssuedDuringPeriodSharesOrdinarySharesUponExerciseOfShareOptions', window );">Issuance of ordinary shares upon exercise of share options (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">86,282<span></span>
</td>
<td class="nump">4,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of warrants to ordinary shares (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,053<span></span>
</td>
<td class="nump">624,445<span></span>
</td>
<td class="nump">5,316,493<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, beginning of period (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">40,528,913<span></span>
</td>
<td class="nump">40,433,578<span></span>
</td>
<td class="nump">39,804,163<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Deficiency</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 17,140<span></span>
</td>
<td class="nump">$ 16,494<span></span>
</td>
<td class="nump">$ 9,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of ordinary shares and warrants to ordinary shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_StockIssuedDuringPeriodValueOrdinarySharesUponExerciseOfShareOptions', window );">Issuance of ordinary shares upon exercise of share options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">111<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_StockIssuedDuringPeriodValueExerciseOfWarrants', window );">Exercise of warrants to ordinary shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">1,560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">812<span></span>
</td>
<td class="nump">596<span></span>
</td>
<td class="nump">546<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsToMinorityShareholders', window );">Acquisition of non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(192)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">18,063<span></span>
</td>
<td class="nump">17,140<span></span>
</td>
<td class="nump">16,494<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Accumulated Deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Deficiency</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(25,569)<span></span>
</td>
<td class="num">(16,687)<span></span>
</td>
<td class="num">(8,320)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(27,271)<span></span>
</td>
<td class="num">(8,882)<span></span>
</td>
<td class="num">(8,367)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (52,840)<span></span>
</td>
<td class="num">$ (25,569)<span></span>
</td>
<td class="num">(16,687)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember', window );">Non-Controlling Interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Deficiency</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">851<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: net loss attributable to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(97)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsToMinorityShareholders', window );">Acquisition of non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (754)<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Prior period results have been retroactively adjusted to reflect the 1: 0.905292 stock split effected on March&#160;7, 2022. See also note 10, Shareholders&#8217; Deficiency, for details.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Net of issuance costs of $<span style="direction:rtl;">35</span>.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_AdjustmentsToAdditionalPaidInCapitalWarrantSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of  Adjustments To Additional Paid In Capital Warrant Shares Issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_AdjustmentsToAdditionalPaidInCapitalWarrantSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_StockIssuedDuringPeriodSharesOrdinarySharesUponExerciseOfShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of ordinary shares upon exercise of share options issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_StockIssuedDuringPeriodSharesOrdinarySharesUponExerciseOfShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_StockIssuedDuringPeriodValueExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_StockIssuedDuringPeriodValueExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_StockIssuedDuringPeriodValueOrdinarySharesUponExerciseOfShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock issued during the period. ordinary shares upon exercise of share options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_StockIssuedDuringPeriodValueOrdinarySharesUponExerciseOfShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>New stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from (to) a noncontrolling interest. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561885717576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS' DEFICIENCY (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS' DEFICIENCY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 35<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561882243736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (27,271)<span></span>
</td>
<td class="num">$ (8,882)<span></span>
</td>
<td class="num">$ (8,464)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">776<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">812<span></span>
</td>
<td class="nump">596<span></span>
</td>
<td class="nump">546<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">(Increase) decrease in prepaid expenses and other receivables</a></td>
<td class="nump">157<span></span>
</td>
<td class="nump">283<span></span>
</td>
<td class="num">(509)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther', window );">Increase in long term prepaid expenses</a></td>
<td class="num">(1,889)<span></span>
</td>
<td class="num">(123)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_IncreaseDecreaseInFairValueOfWarrantsConvertiblePreferredShares', window );">Change in the fair value of warrants to convertible preferred shares</a></td>
<td class="nump">13,257<span></span>
</td>
<td class="nump">203<span></span>
</td>
<td class="nump">994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_IncreaseDecreaseInNonCashFinancialIncomeExpenses', window );">Non-cash financial (income) expenses, net</a></td>
<td class="nump">29<span></span>
</td>
<td class="num">(153)<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Increase in trade payables</a></td>
<td class="nump">239<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Increase in other payables and accrued expenses</a></td>
<td class="nump">2,078<span></span>
</td>
<td class="nump">625<span></span>
</td>
<td class="nump">313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(11,812)<span></span>
</td>
<td class="num">(7,251)<span></span>
</td>
<td class="num">(6,910)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseOfRestrictedInvestments', window );">Investment in short-term deposits</a></td>
<td class="num">(8,082)<span></span>
</td>
<td class="num">(70,200)<span></span>
</td>
<td class="num">(54,270)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfRestrictedInvestments', window );">Redemption of short-term deposits</a></td>
<td class="nump">30,282<span></span>
</td>
<td class="nump">66,150<span></span>
</td>
<td class="nump">45,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(2,927)<span></span>
</td>
<td class="num">(3,767)<span></span>
</td>
<td class="num">(1,293)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="nump">19,273<span></span>
</td>
<td class="num">(7,817)<span></span>
</td>
<td class="num">(10,163)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants', window );">Proceeds from issuance of ordinary shares and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of series B Preferred shares, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">571<span></span>
</td>
<td class="nump">1,019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsToMinorityShareholders', window );">Acquisition of non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(946)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">29,317<span></span>
</td>
<td class="nump">5,323<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash, cash equivalents and restricted cash</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">(Decrease) increase in cash and cash equivalents and restricted cash</a></td>
<td class="nump">7,680<span></span>
</td>
<td class="nump">14,333<span></span>
</td>
<td class="num">(11,768)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at the beginning of the year</a></td>
<td class="nump">16,174<span></span>
</td>
<td class="nump">1,841<span></span>
</td>
<td class="nump">13,609<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at the end of the year</a></td>
<td class="nump">23,854<span></span>
</td>
<td class="nump">16,174<span></span>
</td>
<td class="nump">$ 1,841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract', window );"><strong>Non-cash transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1', window );">Receivables from exercise of warrants to ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income tax payments</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest received</a></td>
<td class="nump">$ 351<span></span>
</td>
<td class="nump">$ 541<span></span>
</td>
<td class="nump">$ 780<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_IncreaseDecreaseInFairValueOfWarrantsConvertiblePreferredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of warrants to convertible preferred shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_IncreaseDecreaseInFairValueOfWarrantsConvertiblePreferredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_IncreaseDecreaseInNonCashFinancialIncomeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in non-cash financial (income) expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_IncreaseDecreaseInNonCashFinancialIncomeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpensesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseOfRestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for the increase (decrease) associated with investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseOfRestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants issued as [noncash or part noncash] consideration for a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholder, which takes precedence over common stockholders in the event of liquidation and from issuance of rights to purchase common shares at a predetermined price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from (to) a noncontrolling interest. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfRestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of investments that are pledged or subject to withdrawal restrictions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfRestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561885718536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GENERAL<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>GENERAL</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">GENERAL</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;1:-</b></span>GENERAL</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Company description:</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Alpha Tau Medical&#160;Ltd. (&#8220;the Company&#8221;) is an Israeli clinical-stage oncology therapeutics company that focuses on research, development and commercialization of Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) for the treatment of solid cancer. The Company was established in November&#160;2015 and began its operations in January&#160;2016, and shortly thereafter acquired the full rights to the Alpha DaRT technology from Althera Medical&#160;Ltd., (&#8220;Althera&#8221;), developed in 2003 at Tel Aviv University.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">In August&#160;2017 the Company established a fully owned subsidiary in the United States&#160;- &#8220;Alpha Tau Medical&#160;Inc.&#8221; (hereafter: ATM Inc). ATM Inc began its activity in August&#160;2018.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">In January&#160;2018 the Company established a subsidiary in Japan &#8220;Alpha Tau Medical KK&#8221; (hereafter: ATM KK). ATM KK began its activity in January&#160;2018, initially as a JV that was jointly owned by the Company (holding more than 90% of ATM KK) and HekaBio K.K. In July&#160;2019, the Company acquired full ownership of ATM KK by virtue of a transaction in which the Company invested additional funds into ATM KK, and ATM KK repurchased its own shares that were held by HekaBio K.K. As of December&#160;31, 2021 and 2020, the Company holds 100%of ATM KK. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">In July&#160;2019, the Company established a fully owned subsidiary in Canada &#8220;Alpha Tau Medical Canada&#160;Inc.&#8221; (hereafter: ATM Canada Inc). ATM Canada Inc began its activity in March&#160;2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">On July&#160;7, 2021, the Company entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) with Healthcare Capital Corp., a Delaware corporation (&#8220;HCCC&#8221;), and Archery Merger Sub&#160;Inc., a Delaware corporation and wholly-owned subsidiary of the Company (&#8220;Merger Sub&#8221;). As part of the completion of business combination on March&#160;7, 2022 (the &#8220;closing date&#8221;), the Merger Sub was merged with and into HCCC (the &#8220;Merger&#8221;), with HCCC survived the merger as a wholly owned subsidiary of the Company (for further information see note 14b).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The novel coronavirus&#160;(&#8220;COVID-19&#8221;)&#160;pandemic has created and may continue to create significant uncertainty in macroeconomic conditions, and the extent of its impact on the Company&#8217;s operational and financial performance will depend on certain developments. The Company considered the impact of&#160;COVID-19&#160;on the estimates and assumptions and determined that there were no material adverse impacts on the consolidated financial statements for the period ended December&#160;31, 2021. As events continue to evolve and additional information becomes available, the Company&#8217;s estimates and assumptions may change materially in future periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;1:-</b></span>GENERAL (Cont.)</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company&#8217;s activities since inception have consisted of performing research and development activities. Successful completion of the Company&#8217;s development programs and, ultimately, the attainment of profitable operations are dependent on future events, including, among other things, its ability to secure financing; obtain further marketing approvals from regulatory authorities; access potential markets; and build a sustainable customer base; attract, retain and motivate qualified personnel; and develop strategic alliances. The Company&#8217;s operations are funded by its shareholders and research and development grants and the Company intends to seek further private or public financing as well as make applications for further research and development grants for continuing its operations. Although management believes that the Company will be able to successfully fund its operations, there can be no assurance that the Company will be able to do so or that the Company will ever operate profitably.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company expects to continue to incur substantial losses over the next several&#160;years during its clinical development phase. To fully execute its business plan, the Company will need to complete registrational clinical studies and certain development activities as well as manufacture the required clinical and commercial products in its manufacturing plants. Further, the Company will seek further regulatory approvals prior to commercialization and the Company will need to establish sales, marketing and logistic infrastructures. These activities may span many&#160;years and require substantial expenditures to complete and may ultimately be unsuccessful. Any delays in completing these activities could adversely impact the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;">As of December&#160;31, 2021, the Company had cash, cash equivalents, short-term deposits and restricted cash of $31,934. During the&#160;year ended December&#160;31, 2021, the Company incurred a net loss of $27,271 and had negative cash flows from operating activities of $11,812. In addition, the Company had an accumulated deficit of $52,840 on December&#160;31, 2021. The Company believes that its existing capital resources will be adequate to satisfy its expected liquidity requirements for at least two&#160;years (for further information see note 13b).</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561886008232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;2:-</b></span>SIGNIFICANT ACCOUNTING POLICIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The consolidated financial statements are prepared according to United States generally accepted accounting principles (&#8220;U.S. GAAP&#8221;). The significant accounting policies are applied in the preparation of the financial statements on a consistent basis, as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">a.&#160;&#160;&#160;&#160;&#160;Use of estimates for the preparation of financial statements:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The preparation of the consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, the Company&#8217;s management evaluates estimates, including those related to fair values of convertible preferred shares warrants, fair values of share-based awards, deferred taxes, and contingent liabilities. Such estimates are based on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;2:-</b></span>SIGNIFICANT ACCOUNTING POLICIES (Cont.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">b.&#160;&#160;&#160;&#160;&#160;Consolidated financial statements in U.S.&#160;dollars:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The accompanying consolidated financial statements have been prepared in U.S.&#160;dollars.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">A substantial portion of the Company&#8217;s expenses are incurred in New Israeli Shekels. However, the Company finances its operations mainly in U.S. dollars, a substantial portion of its expenses are incurred in U.S. dollars and revenues from its primary markets are anticipated to be generated in U.S. dollars. As such, the Company&#8217;s management believes that the U.S. dollar is the currency of the primary economic environment in which the Company operates. Thus, the functional and reporting currency of the Company is the U.S.&#160;dollar.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">A subsidiary&#8217;s functional currency is the currency of the primary economic environment in which the subsidiary operates; normally, that is the currency of the environment in which a subsidiary primarily generates and expends cash. In making the determination of the appropriate functional currency for a subsidiary, the Company considers cash flow indicators, local market indicators, financing indicators and the subsidiary&#8217;s relationship with both the parent company and other subsidiaries. For subsidiaries that are primarily a direct and integral component or extension of the parent entity&#8217;s operations, the U.S. dollar is the functional currency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company has determined the functional currency of its foreign subsidiaries is the U.S.&#160;Dollar. The foreign operations are considered a direct and integral part or extension of the Company&#8217;s operations. The&#160;day-to-day&#160;operations of the foreign subsidiaries are dependent on the economic environment of the U.S.&#160;Dollar.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Transactions and balances denominated in U.S. dollars are presented at their original amounts. Monetary accounts maintained in currencies other than the dollar are&#160;re-measured&#160;into dollars in accordance with Accounting Standards Codification No.&#160;830, &#8220;Foreign Currency Matters&#8221; (&#8220;ASC 830&#8221;). All transaction gains and losses of the&#160;re-measurement&#160;of monetary balance sheet items are reflected in the statements of operations as financial income or expenses, as appropriate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">c.&#160;&#160;&#160;&#160;&#160;Principles of consolidation:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany balances have been eliminated upon consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">d.&#160;&#160;&#160;&#160;&#160;Cash equivalents:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Cash equivalents are short-term, highly liquid investments that are readily convertible into cash with an original maturity of three&#160;months or less, at the date acquired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;2:-</b></span>SIGNIFICANT ACCOUNTING POLICIES (Cont.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">e.&#160;&#160;&#160;&#160;&#160;Restricted cash:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Restricted cash is primarily invested in bank deposits and is used as security for the Company&#8217;s lease commitments. The following table provides a reconciliation of the cash and cash equivalents balances reported on the balance sheets and the cash, cash equivalents and restricted cash balances reported in the statements of cash flows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Cash and cash equivalents, as reported on the balance sheets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,598</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,236</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Restricted cash, as reported on the balance sheets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 576</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.75pt 0pt 0pt;"><span style="font-size:11pt;"> 618</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Cash, cash equivalents, and restricted cash, as reported in the statements of cash flows</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,174</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,854</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">f.&#160;&#160;&#160;&#160;&#160;Short-term deposits:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">A short-term bank deposit is a deposit with a maturity of more than three&#160;months but less than one&#160;year. Deposits in U.S. dollars bear interest at rates ranging from.0.05%-1.65% and 0.01%-0.62%, per annum, as of December&#160;31, 2020 and 2021, respectively. Short-term deposits are presented at cost, which approximates market value due to their short maturities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">g.&#160;&#160;&#160;&#160;&#160;Property and equipment, net:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following rates:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:24.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">%</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Computers and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.91%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">33</p></td></tr><tr><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10 - 15</p></td></tr><tr><td style="vertical-align:bottom;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Furniture and office equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7 - 15</p></td></tr><tr><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Car</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">20</p></td></tr><tr><td style="vertical-align:bottom;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Manufacturing equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10</p></td></tr><tr><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:24.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Over the shorter of the term of the lease or its useful life</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">h.&#160;&#160;&#160;&#160;&#160;Impairment of long-lived assets:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company&#8217;s long-lived assets are reviewed for impairment in accordance with ASC 360, &#8220;Property, Plant and Equipment&#8221; (&#8220;ASC 360&#8221;), whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">For the&#160;years ended December&#160;31, 2019, 2020 and 2021 there were no impairment losses identified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;2:-</b></span>SIGNIFICANT ACCOUNTING POLICIES (Cont.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">i.&#160;&#160;&#160;&#160;&#160;Research and development expenses, net:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Research and development expenses consist of personnel costs (including salaries, benefits and share-based compensation), materials, consulting fees and payments to subcontractors, costs associated with obtaining regulatory approvals, executing pre-clinical and clinical studies and maintenance and prosecution of the Company&#8217;s intellectual property rights. In addition, research and development expenses include overhead allocations consisting of various administrative and facilities related costs. The Company charges research and development expenses as expenses when incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Grants from the Israeli Innovation Authority (IIA) are offset against research and development costs at the later of when grant receipt is assured or the expenses are incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">j.&#160;&#160;&#160;&#160;&#160;Accounting for share-based payments:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company accounts for share based compensation in accordance with ASC No.&#160;718, &#8220;Compensation&#160;- Stock Compensation&#8221; that requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The Company recognizes compensation expenses for the value of its awards granted based on the straight-line attribution method over the requisite service period of each of the awards. The Company recognizes forfeitures of awards as they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">For awards with no performance conditions, the Company recognizes the related share-based compensation expense on a straight-line basis over the requisite service period of the awards, including awards with graded vesting. For awards with performance conditions the share-based compensation expense is recognized if and when the Company concludes that it is probable that the performance condition will be achieved and where the performance condition awards include graded vesting, the share-based compensation expense is recognized based on the accelerated method. The Company reassesses the probability of vesting at each reporting period for awards with performance conditions and adjust compensation cost based on its probability assessment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company selected the Black-Scholes option-pricing model as the most appropriate fair value method for its option awards. The option-pricing model requires a number of assumptions, of which the most significant are the share price, volatility and the expected option term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The fair value of ordinary share underlying the options has historically been determined by management and the board of directors. Because there has been no public market for the Company&#8217;s ordinary shares, the board of directors has determined fair value of an ordinary share at the time of grant of the option by considering a number of objective and subjective factors including financing investment rounds, operating and financial performance, the lack of liquidity of share capital and general and industry specific economic outlook, amongst other factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The fair value of the underlying ordinary shares will be determined by the board of directors until such time as the Company&#8217;s ordinary shares are listed on an established stock exchange.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;2:-</b></span>SIGNIFICANT ACCOUNTING POLICIES (Cont.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The computation of expected volatility is based on actual historical share price volatility of comparable companies. For option grants that are considered to be &#8220;plain vanilla,&#8221; the Company determines the expected term using the simplified method. The simplified method deems the term to be the average of the&#160;time-to-vesting&#160;and the contractual life of the options. The Company has historically not paid dividends and has no foreseeable plans to pay dividends and, therefore, uses an expected dividend yield of zero in the option pricing model. The risk-free interest rate is based on the yield of U.S. treasury bonds with equivalent terms as the expected term of the options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:56.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5.4-7.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2.0-6.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5.0-6.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">85.3%-88.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">90.8%-102.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">85.5%-89.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1.9%-2.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0.1%-0.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0.8%-1.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Total share-based compensation expenses related to employees, consultants and other service providers for the&#160;years ended December&#160;31, 2019, 2020 and 2021, amounted to $546, $596 and $812, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">k.&#160;&#160;&#160;&#160;&#160;Grants and participations:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Royalty-bearing grants from the Israeli Innovation Authority (&#8220;IIA&#8221;) (previously known as Office of the Chief Scientist) of the Ministry of Economy and Industry in Israel for funding of approved research and development projects are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred, and are presented as a deduction from research and development expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Since the payment of royalties is not probable when the grants are received, the Company does not record a liability for amounts received from IIA until the related revenues are recognized.&#160;In the event of failure of a project that was partly financed by IIA, the Company will not be obligated to pay any royalties or repay the amounts received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company recognized participations in research and development as a reduction from research and development expenses in the amount of $ 571, $ 878 and $ 2,459 for the&#160;years ended December&#160;31,2019, 2020 and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">l.&#160;&#160;&#160;&#160;&#160;Convertible preferred shares and convertible preferred shares warrant liability:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company&#8217;s preferred shares are considered a &#8220;freestanding financial instrument&#8221; pursuant to ASC 480 &#8220;Distinguishing Liabilities from Equity&#8221; and are redeemable in a deemed liquidation event, which is not under the control of the Company; thus, the Company classified the shares outside permanent equity pursuant to ASC&#160;480-10-S99.&#160;As of December&#160;31, 2021, and 2020, the Company did not adjust the carrying values of the shares to the deemed liquidation values of such shares since a deemed liquidation event was not probable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;2:-</b></span>SIGNIFICANT ACCOUNTING POLICIES (Cont.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company&#8217;s warrants to purchase the Company&#8217;s convertible preferred shares are considered a &#8220;freestanding financial instrument&#8221; pursuant to ASC 480. The warrants were classified as a liability on the balance sheet, initially and subsequently measured at fair value through earnings, as the underlying shares are contingently redeemable (upon a deemed liquidation event, which is not under the Company&#8217;s control) and, therefore, embody an obligation that is indexed to an obligation to repurchase the Company&#8217;s shares by transferring assets. The change in fair value of the warrants is recognized as a component of financial expenses, net, in the statements of operation (see note 9).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">m.&#160;&#160;&#160;&#160;&#160;Fair value of financial instruments:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company applies ASC 820, &#8220;Fair Value Measurements and Disclosures&#8221; (&#8220;ASC 820&#8221;), pursuant to which fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the &#8220;exit price&#8221;) in an orderly transaction between market participants at the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Fair value is an exit price, representing the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;1-&#160;Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2&#160;- Other than quoted prices included in Level&#160;1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3&#160;- Unobservable inputs which are supported by little or no market activity.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The carrying amounts of cash and cash equivalents, short-term deposits, prepaid expenses, other receivables, trade payables, other accounts payable and accrued expenses approximate their fair value due to the short-term maturity of such instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;2:-</b></span>SIGNIFICANT ACCOUNTING POLICIES (Cont.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The financial instruments carried at fair value on the Company&#8217;s consolidated balance sheets as of December&#160;31, 2019, 2020 and 2021 are warrants to convertible preferred shares classified as a liability (see note&#160;7).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The following methods and assumptions were used by the Company in estimating their fair value disclosures for financial instruments:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The fair value measurement of warrants to convertible preferred shares are measured using unobservable inputs that require a high level of judgment to determine fair value, and thus are classified as Level&#160;3 financial instruments. To calculate the fair value of the warrants, the Company first calculated the underlying preferred share value by using the income approach and the market approach. Then the equity value was allocated by using the hybrid model method utilizing two scenarios of OPM and IPO. Once the preferred shares value was derived from the two scenarios, the Black-Scholes model was utilized to calculate the warrants value in each one of the scenarios. Then, probability for each one of the scenarios was applied by the Company to derive the weighted average fair value of the warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Fair value estimates are made at a specific point in time, based on relevant market information and information about the financial instruments. These estimates are subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. Changes in assumptions could significantly affect these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">n.&#160;&#160;&#160;&#160;&#160;Ordinary share warrants classification and measurement:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance. The assessment considers whether the warrants are freestanding financial instruments, meet the definition of a liability under ASC 480, are indexed to the Company&#8217;s own stock and whether the warrants are eligible for equity classification under ASC 815-40. This assessment is conducted at the time of warrant issuance and as of each subsequent reporting period end date while the warrants are outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Warrants that meet all the criteria for equity classification, are required to be recorded as a component of additional paid-in capital. Warrants that do not meet all the criteria for equity classification, are required to be recorded as liabilities at their initial fair value on the date of issuance and remeasured to fair value through earnings at each balance sheet date thereafter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">As of December 31, 2020, and 2021, the Company had 728,017 and 718,964 outstanding ordinary share warrants, respectively. The warrants were classified as equity (see notes 10d and 10e).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">o.&#160;&#160;&#160;&#160;&#160;Income taxes:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company accounts for income taxes in accordance with ASC 740, &#8220;Income Taxes&#8221; (&#8220;ASC 740&#8221;). ASC 740 prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, to reduce deferred tax assets to their estimated realizable value, if needed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;2:-</b></span>SIGNIFICANT ACCOUNTING POLICIES (Cont.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">ASC 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. As of December&#160;31, 2021, and 2020 no liability for unrecognized tax benefits was recorded as a result of ASC 740.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">p.&#160;&#160;&#160;&#160;&#160;Concentration of credit risks:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents, restricted cash and short-term deposits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Cash, cash equivalents, restricted cash and short-term deposits are deposited in major banks in Israel, United States and Japan. Such investments in Israel and abroad may be in excess of insured limits and are not insured in other jurisdictions. Generally, cash and cash equivalents may be redeemed upon demand and, therefore, bear minimal risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">q.&#160;&#160;&#160;&#160;&#160;Severance pay:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">All the Company&#8217;s employees who are Israeli citizens have subscribed to Section&#160;14 of Israel&#8217;s Severance Pay Law, 5723-1963 (&#8220;Section&#160;14&#8221;). Pursuant to Section&#160;14, employees covered by this section are entitled to&#160;monthly deposits at a rate of 8.33% of their&#160;monthly salary, made on their behalf by the Company. Payments in accordance with Section&#160;14 release the Company from any future severance liabilities in respect of those employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Neither severance pay liability nor severance pay fund under Section&#160;14 for such employees is recorded on the Company&#8217;s consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Severance pay expense for the&#160;years ended December&#160;31, 2019, 2020 and 2021 amounted to $ 117, $ 194 and $ 318, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">r.&#160;&#160;&#160;&#160;&#160;Contingent liabilities:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company accounts for its contingent liabilities in accordance with ASC 450, &#8220;Contingencies&#8221; (&#8220;ASC 450&#8221;). A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">As of December&#160;31, 2019, 2020 and 2021, no provision is recorded.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;2:-</b></span>SIGNIFICANT ACCOUNTING POLICIES (Cont.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">s.&#160;&#160;&#160;&#160;&#160;Basic and diluted net loss per share:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company computes net loss per share using the two-class method required for participating securities. The two-class method requires income available to ordinary shareholders for the period to be allocated between ordinary shares and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. The Company considers its convertible preferred shares to be participating securities as the holders of the convertible preferred shares would be entitled to dividends that would be distributed to the holders of ordinary shares, on a pro-rata basis, on an as-converted basis. These participating securities do not contractually require the holders of such shares to participate in the Company&#8217;s losses. As such, net loss for the periods presented was not allocated to the Company&#8217;s participating securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company&#8217;s basic net loss per share is calculated by dividing net loss attributable to ordinary shareholders by the weighted-average number of shares of ordinary shares outstanding for the period, without consideration of potentially dilutive securities. The diluted net loss per share is calculated by giving effect to all potentially dilutive securities outstanding for the period using the treasury share method or the if-converted method based on the nature of such securities. Diluted net loss per share is the same as basic net loss per share in periods when the effects of potentially dilutive shares of ordinary shares are anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">t.&#160;&#160;&#160;&#160;&#160;Deferred Transaction costs:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Deferred transactions costs consist primarily of accounting, legal, and other fees related to the Company&#8217;s transaction. Upon consummation of the transaction, the deferred transaction costs will be reclassified to shareholders&#8217; deficit and recorded against the proceeds from the transaction. The Company capitalized $1,700 of deferred offering costs within other assets, noncurrent in the consolidated balance sheets as of December&#160;31, 2021. No transaction costs were capitalized as of December&#160;31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">u.&#160;&#160;&#160;&#160;&#160;Non-controlling interest:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The consolidated financial statements included the Company&#8217;s accounts and the accounts of the Company&#8217;s wholly- and majority-owned subsidiaries.&#160;Non-controlling&#160;interest positions of our consolidated entities are reported as a separate component of consolidated equity from the equity attributable to the Company&#8217;s shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">v.&#160;&#160;&#160;&#160;&#160;Recently Issued Accounting Pronouncements and not yet adopted</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">As an &#8220;emerging growth company&#8221;, the Jumpstart Our Business Startups Act (JOBS Act) allows the Company to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. The Company has elected to use this extended transition period under the JOBS Act. The adoption dates discussed below reflect this election.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;2:-</b></span>SIGNIFICANT ACCOUNTING POLICIES (Cont.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">In February&#160;2016, the FASB issued ASU No.&#160;2016-02, Leases, which would require lessees to recognize assets and liabilities on the balance sheet for most leases, whether operating or financing, while continuing to recognize the expenses on their income statements in a manner similar to current practice. Under the new guidance, the Company would also require to provide enhanced disclosures. The guidance states that a lessee would recognize a lease liability for the obligation to make lease payments and a right-to-use asset for the right to use the underlying asset for the lease term. The guidance will be effective for the Company as of January&#160;1, 2022, and interim periods in fiscal&#160;years beginning January&#160;1, 2023. The Company is in the initial stage of its assessment of the new standard and is currently evaluating the timing of adoption, the quantitative impact of adoption, and the related disclosure requirements. The Company anticipates the adoption of this standard will result in an increase in its noncurrent assets, and current and noncurrent liabilities recorded on the consolidated balance sheets. The Company is currently evaluating the effect that ASU No.&#160;2016-02 will have on its consolidated financial statements and related disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">In August&#160;2020, the FASB issued ASU&#160;2020-06,&#160;Debt&#160;- Debt with Conversion and Other Options (Subtopic&#160;470-20)&#160;and Derivatives and Hedging&#160;- Contracts in Entity&#8217;s Own Equity (Subtopic&#160;815-40):&#160;Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity (&#8220;ASU&#160;2020-06&#8221;).&#160;The final guidance issued by the FASB for convertible instruments eliminates two of the three models in ASC&#160;470-20&#160;that require separate accounting for embedded conversion features. Separate accounting is still required in certain cases. Additionally, among other changes, the guidance eliminates some of the conditions for equity classification in ASC&#160;815-40-25&#160;for contracts in an entity&#8217;s own equity. The guidance also requires entities to use the&#160;if-converted&#160;method for all convertible instruments in the diluted earnings per share calculation and include the effect of share settlement for instruments that may be settled in cash or shares, except for certain liability-classified share-based payment awards. ASU&#160;2020-06&#160;is effective for fiscal&#160;years beginning after December&#160;15, 2023, and interim periods within those fiscal&#160;years. The Company is currently evaluating the potential impact of this guidance on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;">In November&#160;2021, the FASB issued ASU No.&#160;2021-10, &#8220;Government Assistance (Topic 832): Disclosure by Business Entities about Government Assistance.&#8221; The new standard improves the transparency of government assistance received by most business entities by requiring the disclosure of: (1)&#160;the types of government assistance received; (2)&#160;the accounting for such assistance; and (3)&#160;the effect of the assistance on a business entity&#8217;s financial statements. This guidance is effective for financial statements issued for annual periods beginning after December&#160;15, 2021. Early adoption is permitted. The Company does not expect the adoption of the standard will have a material impact on its consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561886008232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER RECEIVABLES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>PREPAID EXPENSES AND OTHER RECEIVABLES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_PrepaidExpensesAndOtherReceivablesTextBlock', window );">PREPAID EXPENSES AND OTHER RECEIVABLES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;3:-</b></span>PREPAID EXPENSES AND OTHER RECEIVABLES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Government authorities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 472</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 458</p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 387</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 227</p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22</p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 864</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 707</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_PrepaidExpensesAndOtherReceivablesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for prepaid expenses and other receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_PrepaidExpensesAndOtherReceivablesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561885747112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT, NET</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;4:-</b></span>PROPERTY AND EQUIPMENT, NET</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Manufacturing equipment *)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,058</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,238</p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Computers and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 128</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 394</p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 251</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 719</p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Furniture and office equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50</p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Cars</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 57</p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,565</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,458</p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 170</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 912</p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Depreciated cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,395</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,546</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Depreciation expenses amounted to $ 66, $ 86 and $ 776 for the&#160;years ended December&#160;31, 2019, 2020 and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;">During 2021 total cost of $ 34 and total accumulated depreciation of $ 34 were disposed from the consolidated balance sheets.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561885631352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER PAYABLES AND ACCRUED EXPENSES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_OtherPayablesAndAccruedExpensesAbstract', window );"><strong>OTHER PAYABLES AND ACCRUED EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_OtherPayablesAndAccruedExpensesDisclosureTextBlock', window );">OTHER PAYABLES AND ACCRUED EXPENSES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;5:-</b></span>OTHER PAYABLES AND ACCRUED EXPENSES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Employees and payroll accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 525</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 788</p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 551</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,366</p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48</p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,124</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,202</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_OtherPayablesAndAccruedExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_OtherPayablesAndAccruedExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_OtherPayablesAndAccruedExpensesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other payables and accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_OtherPayablesAndAccruedExpensesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561885710376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENT LIABILITIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;6:-</b></span>COMMITMENTS AND CONTINGENT LIABILITIES</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company&#8217;s facilities are leased under operating lease agreements for periods ending no later than 2035. The Company also leases motor vehicles under various operating leases, the latest of which expires in 2024.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Certain motor vehicles of the Company are rented under non-cancellable operating lease agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;6:-</b></span>COMMITMENTS AND CONTINGENT LIABILITIES (Cont.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Future minimum lease payments under operating leases as of December&#160;31, 2021 are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">As of December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 775</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 722</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 724</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 590</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 605</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,948</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,364</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Rental and lease expenses for the&#160;years ended December&#160;31, 2019, 2020 and 2021 were $ 158, $ 408 and $ 803 respectively.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Guarantee in the amount of $&#160;618 </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">was issued by a bank to secure rent payments.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company has received royalty-bearing grants from the IIA to finance its research and development programs in Israel, through which the Company received IIA participation payments in the aggregate amount of $ 4,065 </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">through December&#160;31, 2021. In return, the Company is committed to pay IIA royalties at a rate of 3-3.5% of future sales of the developed products, up to 100% of the amount of grants received plus interest at LIBOR rate. Through December&#160;31, 2021, no royalties have been paid or accrued. In addition, under the intellectual property purchase agreement with Althera, the Company assumed all of Althera&#8217;s liabilities towards the IIA totaling $ 474 of royalty-bearing grants received by Althera (plus accrued interest at LIBOR rate). The Company&#8217;s liability to the IIA at December&#160;31, 2021, including royalty-bearing grants received by the Company, grants assumed from Althera and the associated LIBOR interest accrued on all such grants, totaled $ 5,061.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">d.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Under the February&#160;2, 2016 intellectual property purchase agreement with Althera, the Company is obligated to pay Althera a fixed rate of 2% (plus VAT) of Company&#8217;s future gross revenues (as defined in the agreement) that are derived from the purchased intellectual property, up to a maximum amount of $ 1,500 </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(plus VAT), in the aggregate, with the potential to set off against certain payments made by the Company to the IIA.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">e.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company also entered into intellectual property agreements with Ramot at Tel Aviv University&#160;Ltd., the technology transfer company of Tel Aviv University (&#8220;Ramot&#8221;) on April&#160;21, 2016 and July&#160;14, 2016, all as amended on May&#160;5, 2019, pursuant to which the Company is obligated to pay Ramot a fixed royalty of 2.5% on net sales of all of the Company&#8217;s products (as defined in the agreement) by the Company and its affiliates, with no set maximum. The royalty will be payable as of the first commercial sale (as defined in the agreement), until the later of: 15&#160;years; or until the last to expire of the patents or patent applications from research developed at Tel Aviv University and assigned to the Company, on a country-by-country, product-by-product basis. The Company is also obligated to pay a 7% royalty (and in no event less than 0.65% of the net sales of Company products sold by the Company&#8217;s licensees in a given&#160;year) on any royalties or revenues received by the Company from its licensees.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;6:-</b></span>COMMITMENTS AND CONTINGENT LIABILITIES (Cont.)</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">f.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Under an Operations Partner Agreement between the Company and services provider HekaBio K.K. of May&#160;21, 2019, the Company makes certain payments to HekaBio K.K. in exchange for consulting and administrative services in Japan, as well as payments upon the achievement of certain clinical and regulatory milestones. In addition, if HekaBio K.K. successfully assists the Company in obtaining regulatory marketing approval of the Company&#8217;s products in Japan, then the Company is to grant to HekaBio K.K. options to acquire 271,588 </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of the Company&#8217;s ordinary shares at a price of $4.42 each, and to pay HekaBio K.K. a royalty of 3.5% of the reimbursement price (as defined in the agreement) of such products in Japan and 10% of revenues received by the Company from distribution receipts (as defined in the agreement) for such products in Japan.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">g.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">On November&#160;18, 2018 and July&#160;29, 2019, the Company entered into research and license agreements with BGN Technologies, the technology transfer company of Ben Gurion University (&#8220;BGN&#8221;), further amended on May&#160;12, 2021, wherein the Company will wholly own any intellectual property that is developed jointly by Ben Gurion University and others (including the Company), and BGN will receive 0.75% royalties on all sales of the Company&#8217;s alpha radiation products, net of certain deductions and irrespective of the intellectual property underlying such sales, or 1.5% royalties on sales of products that contain intellectual property owned by Ben Gurion University, net of certain deductions. BGN will receive 4% of license revenues (as defined in the agreements) that relate to jointly developed intellectual property, and 8% of license revenues that relate to intellectual property developed solely by Ben Gurion University. The parties also agreed that the Company will continue to conduct research at Ben Gurion University for as long as the researchers wish to and the parties have agreed on a research budget in good faith.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">h.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">On December&#160;1, 2020, the Company entered into a clinical trial agreement with Cambridge University Hospitals NHS Trust, wherein Cambridge will receive 5% of any marginal increase in the Company&#8217;s net sales (all as defined in the agreement) generated on account of any patent or patent claim granted from the research performed in such trial, and 2% of the Company&#8217;s net sales (minus the aforementioned marginal increase payment) received for the treatment of Squamous Cell Carcinoma of the vulva, for three&#160;years from the date of first sale, world-wide.</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561881101400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;7:-</b></span>FAIR VALUE MEASUREMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Financial instruments measured at fair value on a recurring basis include warrants to convertible preferred shares (see note 9). The warrants are classified as a liability in accordance with ASC 480-10-25. These warrants were classified as level 3 in the fair value hierarchy since some of the inputs used in the valuation (the share price) were determined based on management&#8217;s assumptions. To calculate the fair value of the warrants, the Company first calculated the underlying preferred share value by using the income approach and the market approach. Then the equity value was allocated by using the hybrid model method utilizing two scenarios of OPM and IPO. Once the preferred shares value was derived from the two scenarios, the <span style="-sec-ix-hidden:Hidden_L9Ato0C33E2LNSpyydoKvQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Black-Scholes model</span></span> was utilized to calculate the warrants value in each one of the scenarios. Then, probability for each one of the scenarios was applied by the Company to derive the weighted average fair value of the warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;7:-</b></span>FAIR VALUE MEASUREMENTS (Cont.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The following table summarizes the assumptions used by the Company in the Black-Scholes model:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:60.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:60.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 78.11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 96.83</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:60.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The change in the fair value of the preferred share warrants liability is summarized below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,163</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,366</p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Change in fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 203</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,257</p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">End of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,366</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,623</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561967660840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;8:-</b></span>INCOME TAXES</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Tax rate applicable to Company:</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The corporate tax rate in Israel in 2019, 2020 and 2021 was 23%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company has the status of an &#8220;Preferred Company&#8221; and &#8220;Preferred Technological Enterprise&#8221;, as defined in the Law for the Encouragement of Capital Investments, 5719-1959 and is subject to a reduced tax rate. The reduced tax rates at development area A in which the Company&#8217;s offices are located is 7.5%, subject to various conditions.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Income taxes on non-Israeli subsidiaries:</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company&#8217;s subsidiaries are separately taxed under the domestic tax laws of the jurisdiction of incorporation of each entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Tax rate applicable to ATM Inc:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">On December&#160;22, 2017, the United States enacted the Tax Cuts and Jobs Act (the &#8220;U.S. Tax Reform&#8221;); a comprehensive tax legislation that includes significant changes to the taxation of business entities. These changes, most of which are effective for tax&#160;years beginning after December&#160;31, 2017, include several key tax provisions that might impact the Company, among others: (i)&#160;a permanent reduction to the statutory federal corporate income tax rate from 35% (top rate) to 21% (flat rate) effective for tax&#160;years beginning after December&#160;31, 2017 ((ii)&#160;stricter limitation on the tax deductibility of business interest expense; (iii)&#160;a shift of the U.S. taxation of multinational corporations from a tax on worldwide income to a territorial system (along with certain rules&#160;designed to prevent erosion of the U.S. income tax base)&#160;(iv)&#160;a&#160;one-time&#160;deemed repatriation tax on accumulated offshore earnings held in cash and illiquid assets, with the latter taxed at a lower rate and (v)&#160;an expansion of the U.S. controlled foreign corporation (&#8220;CFC&#8221;) anti deferral starting with the CFC&#8217;s first tax&#160;year beginning in 2018 intended to tax in the U.S. &#8220;global intangible&#160;low-taxed&#160;income&#8221; (&#8220;GILTI&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;8:-</b></span>INCOME TAXES (Cont.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Tax rate applicable to ATM KK (Japan-Tokyo):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The General Corporation tax (national tax in Japan) rate is 23.2% for fiscal&#160;years beginning after April&#160;2018. Local taxes are also applicable in different rates and may result in a higher effective tax rate (for example, for Tokyo-based companies the effective statutory tax rate would generally be 30.62% for large companies, and 33.6% for small companies). Special rate of 15% is applicable on the first JPY <span style="-sec-ix-hidden:Hidden_Z-DGe3jtHEK1rvKDxu5T2w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8M</span></span> for small and medium companies (19% for larger companies for fiscal&#160;years from April&#160;2019).</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The components of the net loss (income) before tax on income were as follows:</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;width:32.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;ended</b>&#160;<br/><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Domestic (Israel)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,898</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,322</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,089</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (580)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (598)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 175</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,318</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,724</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,264</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Income tax expense was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;width:32.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;ended</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Israel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 146</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 158</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total current income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 146</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 158</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Domestic (Israel)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 146</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 158</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">d.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Net operating losses carry forward:</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company has accumulated losses for tax purposes as of December&#160;31, 2021 in the amount of approximately $ 39,585 which may be carried forward and offset against taxable income in the future for an indefinite period.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">e.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Deferred taxes:</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company&#8217;s deferred tax assets are comprised of operating loss carryforwards and other temporary differences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;8:-</b></span>INCOME TAXES (Cont.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Significant components of the Company&#8217;s deferred tax assets are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reserves and allowances</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">R&amp;D expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 482</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 399</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 134</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss carryforward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,551</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,322</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets before valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,233</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,803</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less - valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,233)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,803)</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Management currently believes that since the Company has a history of losses, and there is uncertainty with respect to future taxable income of the Company, it is more likely than not that the deferred tax assets will not be utilized in the foreseeable future. Thus, a full valuation allowance was provided to reduce deferred tax assets to their realizable value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">In 2020 and 2021 the main reconciling item for the Company&#8217;s tax rate is tax loss carryforwards and temporary differences, for which a full valuation allowance was provided.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">f.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Tax assessment:</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;">The Company has not received assessments since its inception.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561886034952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE PREFERRED SHARES AND WARRANTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_TemporaryEquityTextBlock', window );">CONVERTIBLE PREFERRED SHARES AND WARRANTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;9:-</b></span>CONVERTIBLE PREFERRED SHARES AND WARRANTS</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Composition of the Company&#8217;s Convertible Preferred shares is as follows:</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Authorized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issued&#160;and&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Authorized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issued&#160;and&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#231f20;font-weight:bold;">Carrying&#160;</b><b style="color:#231f20;font-weight:bold;"><br/></b><b style="color:#231f20;font-weight:bold;">amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#231f20;font-weight:bold;">Liquidation&#160;</b><b style="color:#231f20;font-weight:bold;"><br/></b><b style="color:#231f20;font-weight:bold;">preference</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="15" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:33.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:42.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of&#160;shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series A Convertible Preferred shares of no-par value *)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 16,295,256</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 7,229,885</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 16,295,256</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 7,229,885</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 25,238</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 36,437</p></td></tr><tr><td style="vertical-align:bottom;width:33.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series B Convertible Preferred shares of no- par value *)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 9,052,920</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 6,509,301</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 9,052,920</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 6,509,301</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 28,726</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 28,761</p></td></tr><tr><td style="vertical-align:bottom;width:33.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 25,348,176</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 13,739,186</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 25,348,176</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 13,739,186</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 53,964</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 65,198</p></td></tr></table></div><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-left:72pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">*)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Prior period results have been retroactively adjusted to reflect the 1: 0.905292 stock split effected on March&#160;7, 2022. See also note 10, Shareholders&#8217; Deficiency, for details.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company issued Series&#160;A convertible preferred shares in 2018 and Series&#160;B convertible preferred shares in 2020. The Company classifies the convertible preferred shares outside of shareholders&#8217; deficiency as required by ASC 480-10-S99, since these convertible preferred shares are entitled to liquidation preferences which may trigger a deemed liquidation event that is not solely within the Company&#8217;s control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;9:-</b></span>CONVERTIBLE PREFERRED SHARES AND WARRANTS (Cont.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Pursuant to the Company&#8217;s Amended and Restated Articles of Incorporation (the &#8220;AoA&#8221;), a deemed liquidation event would occur, inter alia, upon the closing of the transfer of the Company&#8217;s securities to a person or a group of affiliated persons, in one or a series of related transactions, if immediately after such transaction, such person or group of affiliated persons would hold 50%or more of the outstanding voting shares of the Company and upon the occurrence of the events listed in the AoA. For the&#160;years ended December&#160;31, 2021 and 2020, the Company did not adjust the carrying values of the convertible preferred shares to the deemed liquidation values of such shares since a deemed liquidation event was not probable at each balance sheet date. Subsequent adjustments to increase the carrying values to the ultimate liquidation values will be made only when it becomes probable that such a deemed liquidation event will occur. </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Preferred shares rights:</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Preferred A and the Preferred B shares (collectively, the &#8220;Preferred Shares&#8221;) confer upon their holders all the rights conferred by Ordinary shares, in addition to certain rights stipulated in the Company&#8217;s AoA, inter alia, the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><i style="font-style:italic;">Dividend rights&#160;- </i>the convertible Preferred B shares shall be entitled to receive, prior and in preference to the declaration or payment of any dividend to the holders of any other class of shares, including the Preferred A shares, for each Preferred B share, cumulative dividends (whether paid in cash or otherwise) if and when declared by the Company&#8217;s board of directors, in an amount equal to the Preferred B share original issue price (the &#8220;Series&#160;B Dividend Preference&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Following the payment in full of all of the Series&#160;B Dividend Preference, the convertible Preferred A shares shall be entitled to receive, prior and in preference to the declaration or payment of any dividend to the holders of any other class of shares, including the ordinary shares, for each Preferred A share, cumulative dividends (whether paid in cash or otherwise) if and when declared by the Company&#8217;s board of directors, in an amount equal to 1.25x the Preferred A share original issue price (the &#8220;Series&#160;A Dividend Preference&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Following the payment in full of all of the Series&#160;A Dividend Preference, the holders of the Preferred Shares and the ordinary shares shall be entitled to receive, on a pro-rata, as-converted basis, any and all other dividends distributed by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><i style="font-style:italic;">Liquidation rights&#160;-</i> In the event of any event of liquidation or deemed liquidation event, the Company shall distribute all distributable proceeds first to the holders of the Preferred B shares, on a pro-rata basis among themselves, prior to and in preference to any payments to any of the holders of any other classes of shares, for each Preferred B share, the greater of: (a)&#160;the Preferred B share original issue price, plus an amount equal to the declared but unpaid dividends, less any Series&#160;B Dividend Preference amount previously declared and actually paid, and (b)&#160;the pro rata portion of the distributable proceeds the Preferred B shares would receive if all the distributable proceeds were distributed to all shareholders, on a pro-rata and as-converted-to-ordinary shares basis (the &#8220;Series&#160;B Preference&#8221;). In the event of insufficient distributable proceeds, distribution shall be done ratably among the holders of the Preferred B shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;9:-</b></span>CONVERTIBLE PREFERRED SHARES AND WARRANTS (Cont.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Following payment in full of the Series&#160;B Preference, the Company shall distribute the remaining distributable proceeds to the holders of Preferred A shares, on a pro-rata basis among themselves, prior to and in preference to any payments to any of the holders of any other classes of shares, for each Preferred A share, the greater of: (a)&#160;1.25x the Preferred A share original issue price, plus an amount equal to the declared but unpaid dividends, less any Series&#160;A Dividend Preference amount previously declared and actually paid, and (b)the pro rata portion of the distributable proceeds the Preferred A shares would receive if all the distributable proceeds were distributed to all shareholders, on a pro-rata and as-converted-to-ordinary shares basis (the &#8220;Series&#160;A Preference&#8221;). In the event of insufficient distributable proceeds, distribution shall be done ratably among the holders of the Preferred A shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Following the payment in full of the Series&#160;A Preference, the holders of the ordinary shares shall be entitled to receive, on a pro rata basis among themselves, any and all remaining distributable proceeds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><i style="font-style:italic;">Voting rights</i>&#160;- each holder of Preferred Shares is entitled to one&#160;vote per each share held by it (on an as-converted-to-ordinary share basis).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><i style="font-style:italic;">Conversion</i>&#160;- each Preferred Share is automatically convertible into ordinary shares, at the respective holder&#8217;s option, or automatically upon a qualified IPO of the Company or upon written demand of the Investor Majority (each as defined in the AoA) for each respective class of shares. The initial conversion ratio for each Preferred Share is 1:1.The conversion price per Preferred Share will be adjusted in the event of recapitalizations, share splits, ordinary share dividends, subdivisions and combinations of ordinary shares, as well in the event of certain anti-dilution events.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Financing rounds:</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">In September&#160;2018, the Company entered into a Share Purchase Agreement (as amended, the &#8220;2018 SPA&#8221;) with new and existing investors, pursuant to which 7,229,885 Preferred A shares and 3,614,960 warrants to Preferred A share were issued in consideration of approximately $ 29,150, reflecting a price per share of $ 4.03. Total issuance expenses were amounted to $ 91. The warrants to Preferred A Shares were recorded at fair value in the amount of $ 3,821 and the residual amount was allocated to the Preferred A Shares. The Preferred A shares can be converted into ordinary shares at a conversion ratio of 1:1, however such ratio is subject to amendment in certain situations and was adjusted in the context of the 2020 SPA, as more fully described above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">In April&#160;2020, the Company entered into a Preferred B Share Purchase Agreement (as amended, the &#8220;2020 SPA&#8221;) with new and existing investors, pursuant to which 6,509,301 Preferred B shares were issued in consideration of approximately $ 28,761, reflecting a price per share of $ 4.42. Total issuance expenses amounted to $ 35. The Preferred B shares can be converted into ordinary shares at a conversion ratio of 1:1, subject to adjustment in certain situations, more fully described above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">In conjunction with the 2020 SPA, the Company and the holders of the Preferred A shares agreed on a modified adjustment to the conversion ratio of Preferred A shares into ordinary shares as compared to the AoA in effect at that time. The conversion ratio of the Preferred A shares was adjusted to approximately 1.07:1, such that 7,229,885 Preferred A shares can be converted into 7,761,495 ordinary shares of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;9:-</b></span>CONVERTIBLE PREFERRED SHARES AND WARRANTS (Cont.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The revised Preferred A share conversion ratio, along with other amendments in the new agreement, did not result a substantial change in the fair value of the Preferred A shares. Therefore, the amendment to the agreement was accounted for as a modification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">On July&#160;6, 2021, the Company&#8217;s board of directors approved a 1: 0.905292 stock split which was effected on March&#160;7, 2022. As a result, all Ordinary shares, Convertible preferred shares, options for Ordinary Shares, warrants to Preferred Shares, exercise price and net loss per share amounts were adjusted retroactively for all periods presented in these consolidated financial statements as if the stock split and change in par value had been in effect as of the date of these consolidated financial statements.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">d.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Warrants to purchase Preferred A shares:</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Under the 2018 SPA, the Company had initially granted the Preferred A share investors an aggregate number of 3,614,960 warrants convertible into Preferred A shares of the Company (&#8220;Preferred A Warrants&#8221;), with an exercise price of $ 5.04. The number of warrants issued is subject to similar adjustments as the conversion ratio of the Preferred A shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">In connection with the 2020 SPA, the Warrants agreement was modified, and the Company subsequently granted the Preferred A share investors approximately 7% additional Preferred A Warrants, increasing the aggregate number of Preferred A Warrants to 3,880,777, and reducing the exercise price to $ 3.87 per share. Since the Warrants were classified as a liability and subsequently measured at fair value through earnings, the effect of The Preferred A Warrants modification was reflected in the fair value of the warrants and recognized in earnings. The warrants may be converted at any time until September&#160;16, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">All outstanding Preferred A Warrants are classi&#64257;ed as a long-term liability and are re-measured at each reporting date, as the underlying shares may be redeemed upon an event which is not solely in the control of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;">As of December&#160;31, 2020 and <span style="direction:rtl;">2021</span>, 3,880,777 Preferred A Warrants are outstanding.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_TemporaryEquityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_TemporaryEquityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561885579080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' DEFICIENCY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>SHAREHOLDERS' DEFICIENCY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">SHAREHOLDERS' DEFICIENCY</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;10:-</b></span>SHAREHOLDERS&#8217; DEFICIENCY</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Ordinary share capital is composed as follows:</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">On July&#160;6, 2021, the Company&#8217;s board of directors approved a 1: 0.905292 stock split which was effected on March&#160;7, 2022. As a result, all Ordinary shares, Convertible preferred shares, options for Ordinary Shares, warrants to Preferred Shares, exercise price and net loss per share amounts were adjusted retroactively for all periods presented in these consolidated financial statements as if the stock split and change in par value had been in effect as of the date of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:12.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:12.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Authorized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:12.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issued&#160;and&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Authorized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issued&#160;and&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">outstanding</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:54.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of&#160;shares</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Ordinary shares of no-par value *)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 72,423,360</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,433,578</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 72,423,360</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,528,913</p></td></tr></table></div><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-left:72pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">*)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Prior period results have been retroactively adjusted to reflect the 1: 0.905292 stock split effected on March&#160;7, 2022. See also note 10, Shareholders&#8217; Deficiency, for details.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;10:-</b></span>SHAREHOLDERS&#8217; DEFICIENCY (Cont.)</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Ordinary shares rights:</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Ordinary shares confer upon their holders the right to participate in the general meetings of the Company, to vote at such meetings (each share represents one </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">vote), and to participate in any distribution of dividends or any other distribution of the Company&#8217;s property, including the distribution of surplus assets upon liquidation.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In July&#160;2019, HekaBio K.K. invested an amount of $ 5,250 </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">into the Company, in exchange for 1,302,132 Ordinary shares and 651,067 warrants to ordinary shares of the Company.</span></td></tr></table><div style="margin-top:12pt;"/><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Share option plans:</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company has authorized through its 2016 Share Option Plan (the &#8220;Plan&#8221;), an available pool of Ordinary shares of the Company from which to grant options to officers, directors, advisors, management and other key employees of up to 7,611,725 Ordinary shares. The options granted generally have a four-year vesting period and expire ten&#160;years after the date of grant, subject to the terms set forth in the Plan. Options granted under the Plan that are cancelled or forfeited before expiration become available for future grant. As of December&#160;31, 2021, 442,439 of the Company&#8217;s options are available for future grants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">A summary of the status of options under the Plan as of December&#160;31, 2021 and changes during the relevant period ended on that date is presented below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Employees</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:47.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;ended&#160;December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">intrinsic</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">contractual</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of&#160;options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">life&#160;(years)</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,062,408</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 944,820</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.78</p></td></tr><tr><td style="vertical-align:bottom;width:50.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,321,211</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,809)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited and cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (53,238)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,325,572</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,854,046</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.42</p></td></tr><tr><td style="vertical-align:bottom;width:50.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,233,657</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,184,527</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.56</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Service Providers</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:47.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;ended&#160;December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">intrinsic</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">contractual&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of&#160;options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">life&#160;(years)</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 662,006</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.79</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 313,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.91</p></td></tr><tr><td style="vertical-align:bottom;width:50.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 140,667</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.79</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (81,476)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited and cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 721,197</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,695,213</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.61</p></td></tr><tr><td style="vertical-align:bottom;width:50.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 580,745</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,649,873</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.89</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE 10:-</b></span>SHAREHOLDERS&#8217; DEFICIENCY (Cont.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">A summary of the status of RSUs under the Plan as of December&#160;31, 2021 and changes during the relevant period ended on that date is presented below:</p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;RSU</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:83.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,036,850</p></td></tr><tr><td style="vertical-align:bottom;width:83.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited and cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,600)</p></td></tr><tr><td style="vertical-align:bottom;width:83.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding on December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,031,250</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The total equity-based compensation expense related to all of the Company&#8217;s equity-based awards recognized for the&#160;year ended December&#160;31, 2020 and 2021, was comprised as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;width:32.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;ended&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 380</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 372</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 654</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketing expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 148</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 204</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 151</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total share-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 546</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 596</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 812</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">As of December&#160;31, 2021, there were unrecognized compensation costs of $ 2,280, which are expected to be recognized over a weighted average period of approximately 3.28&#160;years. The weighted average exercise price of the Company&#8217;s options granted during the&#160;year ended December&#160;31, 2019, 2020 and 2021 was $4.06, $4.42 and $9.81, respectively. The weighted-average grant date fair value of options granted during the&#160;years ended December&#160;31, 2021, 2020 and 2019, was $4.45, $0.76 and $0.6, respectively.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">d.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Warrants to investors:</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">As part of 2016 investment round, the Company granted the investors 6,789,694 </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">warrants. In December&#160;2019, these warrants were exercised into 5,316,493 Ordinary shares of no-par value, of them 1,412,520 were exercised on a cash basis in consideration of approximately $ 1,560, and 5,377,174 were exercised on a cashless basis at a ratio of approximately 0.73 Ordinary share per exercised warrant</span><span style="direction:rtl;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">As part of the 2018 SPA, the Company granted 9,053 </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">warrants to ordinary shares to a public service foundation in Israel. The warrants were exercised on July&#160;15, 2021 into 9,053 Ordinary shares of no-par value with no consideration.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(iii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In July&#160;2019, as part of the investment round of HekaBio K.K, the investors received 651,067 </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">warrants to Ordinary shares with an exercise price of $ 5.04 to be exercise within </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4&#160;years</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> from grant date.</span></td></tr></table><div style="margin-top:12pt;"/><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">e.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Warrants to consultants:</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In April&#160;2016, 67,897 </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">warrants to Ordinary shares were issued to a consultant for services received to be exercised within </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7&#160;years</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> from grant date.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE 10:-</b></span>SHAREHOLDERS&#8217; DEFICIENCY (Cont.)</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In April&#160;2020 879,609 </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">warrants were exercised into 556,548 Ordinary shares of no-par value, for $ 30 received in cash and the rest exercised on a cashless basis. In addition, in November&#160;2020, 90,529 warrants were exercised into 67,897 Ordinary shares of no-par value, all on a cashless basis</span><span style="direction:rtl;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561885738824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL EXPENSES, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_FinancialExpensesAbstract', window );"><strong>FINANCIAL EXPENSES, NET</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock', window );">FINANCIAL EXPENSES, NET</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;11:-</b></span>FINANCIAL EXPENSES, NET</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;ended&#160;December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Financial expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign currency transaction loss, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 79</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 412</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Remeasurement of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 994</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 203</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,257</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Others</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total financial expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,084</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 217</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,685</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Financial income:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign currency transaction profit, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 101</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest from deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 776</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 613</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 211</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Others</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total financial income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 776</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 737</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 211</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Financial expenses (income), net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 308</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (520)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,474</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_FinancialExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_FinancialExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -URI http://asc.fasb.org/topic&amp;trid=2122503<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 610<br> -URI http://asc.fasb.org/topic&amp;trid=49130413<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561885726856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIC AND DILUTED NET LOSS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>BASIC AND DILUTED NET LOSS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">BASIC AND DILUTED NET LOSS PER SHARE</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;12:-</b></span>BASIC AND DILUTED NET LOSS PER SHARE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The following table sets forth the computation of the Company&#8217;s basic and diluted net loss per Ordinary share:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:42.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;ended&#160;December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss attributable to Ordinary shareholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,367)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,882)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (27,271)</p></td></tr><tr><td style="vertical-align:bottom;width:55.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:55.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Weighted-average shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,815,448</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,274,935</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,534,697</p></td></tr><tr><td style="vertical-align:bottom;width:55.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss per share attributable to ordinary shareholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.25)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.22)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.67)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;12:-</b></span>BASIC AND DILUTED NET LOSS PER SHARE (Cont.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The potential shares of ordinary shares that were excluded from the computation of diluted net loss per share attributable to ordinary shareholders for the periods presented because including them would have been anti-dilutive are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;ended&#160;December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Convertible preferred shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,229,885</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,739,186</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,739,186</p></td></tr><tr><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding share options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,371,668</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,724,414</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,046,769</p></td></tr><tr><td style="vertical-align:bottom;width:59.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RSU</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,031,250</p></td></tr><tr><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant to Preferred A shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,614,960</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,880,777</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,880,777</p></td></tr><tr><td style="vertical-align:bottom;width:59.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,436,578</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 651,067</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 651,067</p></td></tr><tr><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,653,091</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,995,444</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,349,049</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561886009928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC INFORMATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_GeographicInformationAbstract', window );"><strong>GEOGRAPHIC INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">GEOGRAPHIC INFORMATION</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;13:-GEOGRAPHIC INFORMATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Financial information is available for evaluation by the chief operating decision maker, the Company&#8217;s Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment. Operating segments are defined as components of an enterprise in which separate financial information is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and assessing performance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Property and equipment, net by geographic location are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Israel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,540</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,842</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,855</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,699</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Japan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,395</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,546</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;">Property and equipment, net is attributed to the geographic location in which it is located.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_GeographicInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_GeographicInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561885574104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;14:-SUBSEQUENT EVENTS</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">On January&#160;18, 2022, the Company instituted a floating pledge on its assets in favor of Bank Leumi Le-Israel BM, to support a $ 225 </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">standby letter of credit in favor of the Massachusetts Department of Public Health. The letter of credit was provided in connection with an application by ATM&#160;Inc. for an expansion of the maximum possession limit in its radioactive license for use in the Lawrence, MA site, pursuant to decommissioning financial assurance regulations of the Massachusetts Department of Public Health&#8217;s Radiation Control Program.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Business Combination</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Pursuant to the Merger Agreement described in Note&#160;1a, on March&#160;7, 2022 (the &#8220;Closing Date&#8221;), Archery Merger Sub,&#160;Inc., a Delaware corporation and wholly owned subsidiary of the Company was merged with and into HCCC, with HCCC surviving as a wholly-owned subsidiary of the Company (the &#8220;Business Combination&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE&#160;14:-SUBSEQUENT EVENTS (Cont.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Pursuant to the Merger Agreement, and immediately prior to the consummation of the Merger (the time of such consummation, the &#8220;Effective Time&#8221;), the Company effected a recapitalization whereby (i)&#160;the Company adopted amended and restated articles of association, (i)&#160;each preferred share of the Company was automatically converted into such number of the Company&#8217;s ordinary shares as determined in accordance with the Company&#8217;s existing articles of association; (ii)&#160;each of the Company&#8217;s ordinary shares that was issued and outstanding immediately prior to the Effective Time was split into 0.905292 ordinary shares of the Company (rounded to the nearest whole number), such that the value of each of the Company&#8217;s ordinary shares at the time of execution of the Merger Agreement equaled $10.00 per share, based upon the agreed pre-money equity value of the Company (the &#8220;Share Split&#8221;); and (iii)&#160;outstanding securities convertible into securities of the Company were adjusted to give effect to the foregoing transactions and remain outstanding. As a result, all ordinary shares, convertible preferred shares, options and warrants for ordinary shares, exercise prices and net loss per share amounts were adjusted retroactively for all periods presented in these financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Additionally, concurrently with the closing of the Merger, Alpha Tau issued securities pursuant to the Subscription Agreements executed with certain investors under a PIPE (Private Investment in Public Equity) transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Following the recapitalization, (a)&#160;immediately prior to the Merger, each share of Class&#160;B common stock of HCCC was cancelled automatically and converted into one share of Class&#160;A common stock of HCCC, (b)&#160;after giving effect to the foregoing and in connection with the Merger, each share of Class&#160;A common stock of HCCC issued and outstanding was converted automatically into one Company ordinary share, and (c)&#160;each outstanding warrant of HCCC was converted into a warrant of the Company and convertible into the Company&#8217;s ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">An amount of $ 90,872 of gross cash proceeds were raised by the Company in the aforementioned transactions.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561880998392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates for the preparation of financial statements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">a.&#160;&#160;&#160;&#160;&#160;Use of estimates for the preparation of financial statements:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The preparation of the consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, the Company&#8217;s management evaluates estimates, including those related to fair values of convertible preferred shares warrants, fair values of share-based awards, deferred taxes, and contingent liabilities. Such estimates are based on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Consolidated financial statements in U.S. dollars</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">b.&#160;&#160;&#160;&#160;&#160;Consolidated financial statements in U.S.&#160;dollars:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The accompanying consolidated financial statements have been prepared in U.S.&#160;dollars.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">A substantial portion of the Company&#8217;s expenses are incurred in New Israeli Shekels. However, the Company finances its operations mainly in U.S. dollars, a substantial portion of its expenses are incurred in U.S. dollars and revenues from its primary markets are anticipated to be generated in U.S. dollars. As such, the Company&#8217;s management believes that the U.S. dollar is the currency of the primary economic environment in which the Company operates. Thus, the functional and reporting currency of the Company is the U.S.&#160;dollar.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">A subsidiary&#8217;s functional currency is the currency of the primary economic environment in which the subsidiary operates; normally, that is the currency of the environment in which a subsidiary primarily generates and expends cash. In making the determination of the appropriate functional currency for a subsidiary, the Company considers cash flow indicators, local market indicators, financing indicators and the subsidiary&#8217;s relationship with both the parent company and other subsidiaries. For subsidiaries that are primarily a direct and integral component or extension of the parent entity&#8217;s operations, the U.S. dollar is the functional currency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company has determined the functional currency of its foreign subsidiaries is the U.S.&#160;Dollar. The foreign operations are considered a direct and integral part or extension of the Company&#8217;s operations. The&#160;day-to-day&#160;operations of the foreign subsidiaries are dependent on the economic environment of the U.S.&#160;Dollar.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Transactions and balances denominated in U.S. dollars are presented at their original amounts. Monetary accounts maintained in currencies other than the dollar are&#160;re-measured&#160;into dollars in accordance with Accounting Standards Codification No.&#160;830, &#8220;Foreign Currency Matters&#8221; (&#8220;ASC 830&#8221;). All transaction gains and losses of the&#160;re-measurement&#160;of monetary balance sheet items are reflected in the statements of operations as financial income or expenses, as appropriate.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of consolidation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">c.&#160;&#160;&#160;&#160;&#160;Principles of consolidation:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany balances have been eliminated upon consolidation.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">d.&#160;&#160;&#160;&#160;&#160;Cash equivalents:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Cash equivalents are short-term, highly liquid investments that are readily convertible into cash with an original maturity of three&#160;months or less, at the date acquired.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted cash</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">e.&#160;&#160;&#160;&#160;&#160;Restricted cash:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Restricted cash is primarily invested in bank deposits and is used as security for the Company&#8217;s lease commitments. The following table provides a reconciliation of the cash and cash equivalents balances reported on the balance sheets and the cash, cash equivalents and restricted cash balances reported in the statements of cash flows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Cash and cash equivalents, as reported on the balance sheets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,598</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,236</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Restricted cash, as reported on the balance sheets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 576</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.75pt 0pt 0pt;"><span style="font-size:11pt;"> 618</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Cash, cash equivalents, and restricted cash, as reported in the statements of cash flows</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,174</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,854</p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_ShortTermDepositsPolicyTextBlock', window );">Short-term deposits</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">f.&#160;&#160;&#160;&#160;&#160;Short-term deposits:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">A short-term bank deposit is a deposit with a maturity of more than three&#160;months but less than one&#160;year. Deposits in U.S. dollars bear interest at rates ranging from.0.05%-1.65% and 0.01%-0.62%, per annum, as of December&#160;31, 2020 and 2021, respectively. Short-term deposits are presented at cost, which approximates market value due to their short maturities.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment, net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">g.&#160;&#160;&#160;&#160;&#160;Property and equipment, net:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following rates:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:24.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">%</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Computers and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.91%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">33</p></td></tr><tr><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10 - 15</p></td></tr><tr><td style="vertical-align:bottom;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Furniture and office equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7 - 15</p></td></tr><tr><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Car</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">20</p></td></tr><tr><td style="vertical-align:bottom;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Manufacturing equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10</p></td></tr><tr><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:24.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Over the shorter of the term of the lease or its useful life</p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">h.&#160;&#160;&#160;&#160;&#160;Impairment of long-lived assets:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company&#8217;s long-lived assets are reviewed for impairment in accordance with ASC 360, &#8220;Property, Plant and Equipment&#8221; (&#8220;ASC 360&#8221;), whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">For the&#160;years ended December&#160;31, 2019, 2020 and 2021 there were no impairment losses identified.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development expenses, net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">i.&#160;&#160;&#160;&#160;&#160;Research and development expenses, net:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Research and development expenses consist of personnel costs (including salaries, benefits and share-based compensation), materials, consulting fees and payments to subcontractors, costs associated with obtaining regulatory approvals, executing pre-clinical and clinical studies and maintenance and prosecution of the Company&#8217;s intellectual property rights. In addition, research and development expenses include overhead allocations consisting of various administrative and facilities related costs. The Company charges research and development expenses as expenses when incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Grants from the Israeli Innovation Authority (IIA) are offset against research and development costs at the later of when grant receipt is assured or the expenses are incurred.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Accounting for share-based payments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">j.&#160;&#160;&#160;&#160;&#160;Accounting for share-based payments:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company accounts for share based compensation in accordance with ASC No.&#160;718, &#8220;Compensation&#160;- Stock Compensation&#8221; that requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The Company recognizes compensation expenses for the value of its awards granted based on the straight-line attribution method over the requisite service period of each of the awards. The Company recognizes forfeitures of awards as they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">For awards with no performance conditions, the Company recognizes the related share-based compensation expense on a straight-line basis over the requisite service period of the awards, including awards with graded vesting. For awards with performance conditions the share-based compensation expense is recognized if and when the Company concludes that it is probable that the performance condition will be achieved and where the performance condition awards include graded vesting, the share-based compensation expense is recognized based on the accelerated method. The Company reassesses the probability of vesting at each reporting period for awards with performance conditions and adjust compensation cost based on its probability assessment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company selected the Black-Scholes option-pricing model as the most appropriate fair value method for its option awards. The option-pricing model requires a number of assumptions, of which the most significant are the share price, volatility and the expected option term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The fair value of ordinary share underlying the options has historically been determined by management and the board of directors. Because there has been no public market for the Company&#8217;s ordinary shares, the board of directors has determined fair value of an ordinary share at the time of grant of the option by considering a number of objective and subjective factors including financing investment rounds, operating and financial performance, the lack of liquidity of share capital and general and industry specific economic outlook, amongst other factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The fair value of the underlying ordinary shares will be determined by the board of directors until such time as the Company&#8217;s ordinary shares are listed on an established stock exchange.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;2:-</b></span>SIGNIFICANT ACCOUNTING POLICIES (Cont.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The computation of expected volatility is based on actual historical share price volatility of comparable companies. For option grants that are considered to be &#8220;plain vanilla,&#8221; the Company determines the expected term using the simplified method. The simplified method deems the term to be the average of the&#160;time-to-vesting&#160;and the contractual life of the options. The Company has historically not paid dividends and has no foreseeable plans to pay dividends and, therefore, uses an expected dividend yield of zero in the option pricing model. The risk-free interest rate is based on the yield of U.S. treasury bonds with equivalent terms as the expected term of the options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:56.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5.4-7.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2.0-6.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5.0-6.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">85.3%-88.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">90.8%-102.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">85.5%-89.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1.9%-2.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0.1%-0.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0.8%-1.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Total share-based compensation expenses related to employees, consultants and other service providers for the&#160;years ended December&#160;31, 2019, 2020 and 2021, amounted to $546, $596 and $812, respectively.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_GrantsAndParticipationsPolicyTextBlock', window );">Grants and participations</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">k.&#160;&#160;&#160;&#160;&#160;Grants and participations:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Royalty-bearing grants from the Israeli Innovation Authority (&#8220;IIA&#8221;) (previously known as Office of the Chief Scientist) of the Ministry of Economy and Industry in Israel for funding of approved research and development projects are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred, and are presented as a deduction from research and development expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Since the payment of royalties is not probable when the grants are received, the Company does not record a liability for amounts received from IIA until the related revenues are recognized.&#160;In the event of failure of a project that was partly financed by IIA, the Company will not be obligated to pay any royalties or repay the amounts received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company recognized participations in research and development as a reduction from research and development expenses in the amount of $ 571, $ 878 and $ 2,459 for the&#160;years ended December&#160;31,2019, 2020 and 2021, respectively.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock', window );">Convertible preferred shares and convertible preferred shares warrant liability</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">l.&#160;&#160;&#160;&#160;&#160;Convertible preferred shares and convertible preferred shares warrant liability:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company&#8217;s preferred shares are considered a &#8220;freestanding financial instrument&#8221; pursuant to ASC 480 &#8220;Distinguishing Liabilities from Equity&#8221; and are redeemable in a deemed liquidation event, which is not under the control of the Company; thus, the Company classified the shares outside permanent equity pursuant to ASC&#160;480-10-S99.&#160;As of December&#160;31, 2021, and 2020, the Company did not adjust the carrying values of the shares to the deemed liquidation values of such shares since a deemed liquidation event was not probable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;2:-</b></span>SIGNIFICANT ACCOUNTING POLICIES (Cont.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company&#8217;s warrants to purchase the Company&#8217;s convertible preferred shares are considered a &#8220;freestanding financial instrument&#8221; pursuant to ASC 480. The warrants were classified as a liability on the balance sheet, initially and subsequently measured at fair value through earnings, as the underlying shares are contingently redeemable (upon a deemed liquidation event, which is not under the Company&#8217;s control) and, therefore, embody an obligation that is indexed to an obligation to repurchase the Company&#8217;s shares by transferring assets. The change in fair value of the warrants is recognized as a component of financial expenses, net, in the statements of operation (see note 9).</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair value of financial instruments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">m.&#160;&#160;&#160;&#160;&#160;Fair value of financial instruments:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company applies ASC 820, &#8220;Fair Value Measurements and Disclosures&#8221; (&#8220;ASC 820&#8221;), pursuant to which fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the &#8220;exit price&#8221;) in an orderly transaction between market participants at the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Fair value is an exit price, representing the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;1-&#160;Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2&#160;- Other than quoted prices included in Level&#160;1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3&#160;- Unobservable inputs which are supported by little or no market activity.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The carrying amounts of cash and cash equivalents, short-term deposits, prepaid expenses, other receivables, trade payables, other accounts payable and accrued expenses approximate their fair value due to the short-term maturity of such instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;2:-</b></span>SIGNIFICANT ACCOUNTING POLICIES (Cont.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The financial instruments carried at fair value on the Company&#8217;s consolidated balance sheets as of December&#160;31, 2019, 2020 and 2021 are warrants to convertible preferred shares classified as a liability (see note&#160;7).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The following methods and assumptions were used by the Company in estimating their fair value disclosures for financial instruments:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The fair value measurement of warrants to convertible preferred shares are measured using unobservable inputs that require a high level of judgment to determine fair value, and thus are classified as Level&#160;3 financial instruments. To calculate the fair value of the warrants, the Company first calculated the underlying preferred share value by using the income approach and the market approach. Then the equity value was allocated by using the hybrid model method utilizing two scenarios of OPM and IPO. Once the preferred shares value was derived from the two scenarios, the Black-Scholes model was utilized to calculate the warrants value in each one of the scenarios. Then, probability for each one of the scenarios was applied by the Company to derive the weighted average fair value of the warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Fair value estimates are made at a specific point in time, based on relevant market information and information about the financial instruments. These estimates are subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. Changes in assumptions could significantly affect these estimates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock', window );">Ordinary share warrants classification and measurement</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">n.&#160;&#160;&#160;&#160;&#160;Ordinary share warrants classification and measurement:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance. The assessment considers whether the warrants are freestanding financial instruments, meet the definition of a liability under ASC 480, are indexed to the Company&#8217;s own stock and whether the warrants are eligible for equity classification under ASC 815-40. This assessment is conducted at the time of warrant issuance and as of each subsequent reporting period end date while the warrants are outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Warrants that meet all the criteria for equity classification, are required to be recorded as a component of additional paid-in capital. Warrants that do not meet all the criteria for equity classification, are required to be recorded as liabilities at their initial fair value on the date of issuance and remeasured to fair value through earnings at each balance sheet date thereafter.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">o.&#160;&#160;&#160;&#160;&#160;Income taxes:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company accounts for income taxes in accordance with ASC 740, &#8220;Income Taxes&#8221; (&#8220;ASC 740&#8221;). ASC 740 prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, to reduce deferred tax assets to their estimated realizable value, if needed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;2:-</b></span>SIGNIFICANT ACCOUNTING POLICIES (Cont.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">ASC 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. As of December&#160;31, 2021, and 2020 no liability for unrecognized tax benefits was recorded as a result of ASC 740.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of credit risks</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">p.&#160;&#160;&#160;&#160;&#160;Concentration of credit risks:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents, restricted cash and short-term deposits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Cash, cash equivalents, restricted cash and short-term deposits are deposited in major banks in Israel, United States and Japan. Such investments in Israel and abroad may be in excess of insured limits and are not insured in other jurisdictions. Generally, cash and cash equivalents may be redeemed upon demand and, therefore, bear minimal risk.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_SeverancePayPolicyTextBlock', window );">Severance pay</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">q.&#160;&#160;&#160;&#160;&#160;Severance pay:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">All the Company&#8217;s employees who are Israeli citizens have subscribed to Section&#160;14 of Israel&#8217;s Severance Pay Law, 5723-1963 (&#8220;Section&#160;14&#8221;). Pursuant to Section&#160;14, employees covered by this section are entitled to&#160;monthly deposits at a rate of 8.33% of their&#160;monthly salary, made on their behalf by the Company. Payments in accordance with Section&#160;14 release the Company from any future severance liabilities in respect of those employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Neither severance pay liability nor severance pay fund under Section&#160;14 for such employees is recorded on the Company&#8217;s consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Severance pay expense for the&#160;years ended December&#160;31, 2019, 2020 and 2021 amounted to $ 117, $ 194 and $ 318, respectively.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingent liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">r.&#160;&#160;&#160;&#160;&#160;Contingent liabilities:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company accounts for its contingent liabilities in accordance with ASC 450, &#8220;Contingencies&#8221; (&#8220;ASC 450&#8221;). A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">As of December&#160;31, 2019, 2020 and 2021, no provision is recorded.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and diluted net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">s.&#160;&#160;&#160;&#160;&#160;Basic and diluted net loss per share:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company computes net loss per share using the two-class method required for participating securities. The two-class method requires income available to ordinary shareholders for the period to be allocated between ordinary shares and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. The Company considers its convertible preferred shares to be participating securities as the holders of the convertible preferred shares would be entitled to dividends that would be distributed to the holders of ordinary shares, on a pro-rata basis, on an as-converted basis. These participating securities do not contractually require the holders of such shares to participate in the Company&#8217;s losses. As such, net loss for the periods presented was not allocated to the Company&#8217;s participating securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The Company&#8217;s basic net loss per share is calculated by dividing net loss attributable to ordinary shareholders by the weighted-average number of shares of ordinary shares outstanding for the period, without consideration of potentially dilutive securities. The diluted net loss per share is calculated by giving effect to all potentially dilutive securities outstanding for the period using the treasury share method or the if-converted method based on the nature of such securities. Diluted net loss per share is the same as basic net loss per share in periods when the effects of potentially dilutive shares of ordinary shares are anti-dilutive.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_DeferredTransactionCostsPolicyTextBlock', window );">Deferred Transaction costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">t.&#160;&#160;&#160;&#160;&#160;Deferred Transaction costs:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">Deferred transactions costs consist primarily of accounting, legal, and other fees related to the Company&#8217;s transaction. Upon consummation of the transaction, the deferred transaction costs will be reclassified to shareholders&#8217; deficit and recorded against the proceeds from the transaction. The Company capitalized $1,700 of deferred offering costs within other assets, noncurrent in the consolidated balance sheets as of December&#160;31, 2021. No transaction costs were capitalized as of December&#160;31, 2020.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_NonControllingInterestPolicyTextBlock', window );">Non-controlling interest</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">u.&#160;&#160;&#160;&#160;&#160;Non-controlling interest:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">The consolidated financial statements included the Company&#8217;s accounts and the accounts of the Company&#8217;s wholly- and majority-owned subsidiaries.&#160;Non-controlling&#160;interest positions of our consolidated entities are reported as a separate component of consolidated equity from the equity attributable to the Company&#8217;s shareholders.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements and not yet adopted</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;">v.&#160;&#160;&#160;&#160;&#160;Recently Issued Accounting Pronouncements and not yet adopted</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">As an &#8220;emerging growth company&#8221;, the Jumpstart Our Business Startups Act (JOBS Act) allows the Company to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. The Company has elected to use this extended transition period under the JOBS Act. The adoption dates discussed below reflect this election.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">NOTE&#160;2:-</b></span>SIGNIFICANT ACCOUNTING POLICIES (Cont.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">In February&#160;2016, the FASB issued ASU No.&#160;2016-02, Leases, which would require lessees to recognize assets and liabilities on the balance sheet for most leases, whether operating or financing, while continuing to recognize the expenses on their income statements in a manner similar to current practice. Under the new guidance, the Company would also require to provide enhanced disclosures. The guidance states that a lessee would recognize a lease liability for the obligation to make lease payments and a right-to-use asset for the right to use the underlying asset for the lease term. The guidance will be effective for the Company as of January&#160;1, 2022, and interim periods in fiscal&#160;years beginning January&#160;1, 2023. The Company is in the initial stage of its assessment of the new standard and is currently evaluating the timing of adoption, the quantitative impact of adoption, and the related disclosure requirements. The Company anticipates the adoption of this standard will result in an increase in its noncurrent assets, and current and noncurrent liabilities recorded on the consolidated balance sheets. The Company is currently evaluating the effect that ASU No.&#160;2016-02 will have on its consolidated financial statements and related disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">In August&#160;2020, the FASB issued ASU&#160;2020-06,&#160;Debt&#160;- Debt with Conversion and Other Options (Subtopic&#160;470-20)&#160;and Derivatives and Hedging&#160;- Contracts in Entity&#8217;s Own Equity (Subtopic&#160;815-40):&#160;Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity (&#8220;ASU&#160;2020-06&#8221;).&#160;The final guidance issued by the FASB for convertible instruments eliminates two of the three models in ASC&#160;470-20&#160;that require separate accounting for embedded conversion features. Separate accounting is still required in certain cases. Additionally, among other changes, the guidance eliminates some of the conditions for equity classification in ASC&#160;815-40-25&#160;for contracts in an entity&#8217;s own equity. The guidance also requires entities to use the&#160;if-converted&#160;method for all convertible instruments in the diluted earnings per share calculation and include the effect of share settlement for instruments that may be settled in cash or shares, except for certain liability-classified share-based payment awards. ASU&#160;2020-06&#160;is effective for fiscal&#160;years beginning after December&#160;15, 2023, and interim periods within those fiscal&#160;years. The Company is currently evaluating the potential impact of this guidance on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;">In November&#160;2021, the FASB issued ASU No.&#160;2021-10, &#8220;Government Assistance (Topic 832): Disclosure by Business Entities about Government Assistance.&#8221; The new standard improves the transparency of government assistance received by most business entities by requiring the disclosure of: (1)&#160;the types of government assistance received; (2)&#160;the accounting for such assistance; and (3)&#160;the effect of the assistance on a business entity&#8217;s financial statements. This guidance is effective for financial statements issued for annual periods beginning after December&#160;15, 2021. Early adoption is permitted. The Company does not expect the adoption of the standard will have a material impact on its consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for convertible preferred shares and convertible preferred shares warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_DeferredTransactionCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferred transaction costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_DeferredTransactionCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_GrantsAndParticipationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for grants and participations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_GrantsAndParticipationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_NonControllingInterestPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for non-controlling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_NonControllingInterestPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for ordinary share warrants classification and measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_SeverancePayPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for severance pay.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_SeverancePayPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_ShortTermDepositsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for short-term deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_ShortTermDepositsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123368208&amp;loc=d3e12565-110249<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561967413960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of reconciliation of the cash and cash equivalents balances reported on the balance sheets and the cash, cash equivalents and restricted cash balances reported in the statements of cash flows</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Cash and cash equivalents, as reported on the balance sheets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,598</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,236</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Restricted cash, as reported on the balance sheets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 576</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.75pt 0pt 0pt;"><span style="font-size:11pt;"> 618</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Cash, cash equivalents, and restricted cash, as reported in the statements of cash flows</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,174</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,854</p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_PropertyPlantAndEquipmentUsefulLivesTableTextBlock', window );">Schedule of useful lives of property and equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:24.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">%</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Computers and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.91%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">33</p></td></tr><tr><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10 - 15</p></td></tr><tr><td style="vertical-align:bottom;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Furniture and office equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7 - 15</p></td></tr><tr><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Car</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">20</p></td></tr><tr><td style="vertical-align:bottom;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Manufacturing equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10</p></td></tr><tr><td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:24.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Over the shorter of the term of the lease or its useful life</p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions in the valuation of options</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:56.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5.4-7.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2.0-6.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5.0-6.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">85.3%-88.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">90.8%-102.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">85.5%-89.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1.9%-2.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0.1%-0.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0.8%-1.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_PropertyPlantAndEquipmentUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the useful lives of property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_PropertyPlantAndEquipmentUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561885740488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>PREPAID EXPENSES AND OTHER RECEIVABLES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of prepaid expenses and other receivables</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Government authorities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 472</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 458</p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 387</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 227</p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22</p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 864</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 707</p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561886034952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT, NET</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment, net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Manufacturing equipment *)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,058</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,238</p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Computers and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 128</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 394</p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 251</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 719</p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Furniture and office equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50</p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Cars</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 57</p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,565</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,458</p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 170</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 912</p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Depreciated cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,395</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,546</p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561885614168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER PAYABLES AND ACCRUED EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_OtherPayablesAndAccruedExpensesAbstract', window );"><strong>OTHER PAYABLES AND ACCRUED EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_ScheduleOfOtherPayablesAndAccruedExpensesTableTextBlock', window );">Schedule of other payables and accrued expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Employees and payroll accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 525</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 788</p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 551</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,366</p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48</p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,124</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,202</p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_OtherPayablesAndAccruedExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_OtherPayablesAndAccruedExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_ScheduleOfOtherPayablesAndAccruedExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of accrued liabilities and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_ScheduleOfOtherPayablesAndAccruedExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561885570216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of future minimum operating lease payments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">As of December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 775</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 722</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 724</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 590</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 605</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,948</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,364</p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561881002248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Summary of assumptions in the Black-Scholes model in calculating fair value of warrants</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:60.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:60.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 78.11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 96.83</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:60.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of change in the fair value of the preferred share warrants liability</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,163</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,366</p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Change in fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 203</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,257</p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">End of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,366</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,623</p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561967496056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of components of the net loss (income) before tax on income</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;width:32.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;ended</b>&#160;<br/><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Domestic (Israel)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,898</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,322</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,089</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (580)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (598)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 175</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,318</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,724</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,264</p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of income tax expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;width:32.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;ended</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Israel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 146</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 158</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total current income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 146</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 158</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Domestic (Israel)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 146</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 158</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7</p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of significant components of the deferred tax assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reserves and allowances</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">R&amp;D expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 482</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 399</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 134</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss carryforward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,551</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,322</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets before valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,233</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,803</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less - valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,233)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,803)</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561885749480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE PREFERRED SHARES AND WARRANTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityTableTextBlock', window );">Schedule of composition of Convertible Preferred shares</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Authorized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issued&#160;and&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Authorized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issued&#160;and&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#231f20;font-weight:bold;">Carrying&#160;</b><b style="color:#231f20;font-weight:bold;"><br/></b><b style="color:#231f20;font-weight:bold;">amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#231f20;font-weight:bold;">Liquidation&#160;</b><b style="color:#231f20;font-weight:bold;"><br/></b><b style="color:#231f20;font-weight:bold;">preference</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="15" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:33.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:42.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of&#160;shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series A Convertible Preferred shares of no-par value *)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 16,295,256</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 7,229,885</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 16,295,256</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 7,229,885</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 25,238</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 36,437</p></td></tr><tr><td style="vertical-align:bottom;width:33.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series B Convertible Preferred shares of no- par value *)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 9,052,920</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 6,509,301</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 9,052,920</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 6,509,301</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 28,726</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 28,761</p></td></tr><tr><td style="vertical-align:bottom;width:33.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 25,348,176</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 13,739,186</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 25,348,176</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 13,739,186</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 53,964</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> 65,198</p></td></tr></table></div><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-left:72pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">*)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Prior period results have been retroactively adjusted to reflect the 1: 0.905292 stock split effected on March&#160;7, 2022. See also note 10, Shareholders&#8217; Deficiency, for details.</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561886693128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' DEFICIENCY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>SHAREHOLDERS' DEFICIENCY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of composition of ordinary share capital</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:12.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:12.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Authorized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:12.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issued&#160;and&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Authorized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issued&#160;and&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">outstanding</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:54.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of&#160;shares</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Ordinary shares of no-par value *)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 72,423,360</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,433,578</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 72,423,360</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,528,913</p></td></tr></table></div><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-left:72pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">*)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Prior period results have been retroactively adjusted to reflect the 1: 0.905292 stock split effected on March&#160;7, 2022. See also note 10, Shareholders&#8217; Deficiency, for details.</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of the status of options and changes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Employees</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:47.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;ended&#160;December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">intrinsic</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">contractual</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of&#160;options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">life&#160;(years)</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,062,408</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 944,820</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.78</p></td></tr><tr><td style="vertical-align:bottom;width:50.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,321,211</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,809)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited and cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (53,238)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,325,572</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,854,046</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.42</p></td></tr><tr><td style="vertical-align:bottom;width:50.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,233,657</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,184,527</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.56</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Service Providers</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:47.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;ended&#160;December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">intrinsic</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">contractual&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of&#160;options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">life&#160;(years)</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 662,006</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.79</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 313,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.91</p></td></tr><tr><td style="vertical-align:bottom;width:50.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 140,667</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.79</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (81,476)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited and cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 721,197</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,695,213</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.61</p></td></tr><tr><td style="vertical-align:bottom;width:50.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 580,745</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,649,873</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.89</p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of the status of RSUs and changes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;">A summary of the status of RSUs under the Plan as of December&#160;31, 2021 and changes during the relevant period ended on that date is presented below:</p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;RSU</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:83.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,036,850</p></td></tr><tr><td style="vertical-align:bottom;width:83.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited and cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,600)</p></td></tr><tr><td style="vertical-align:bottom;width:83.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding on December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,031,250</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_ScheduleOfShareBasedCompensationCostsByIncomeStatementLocationTableTextBlock', window );">Schedule equity-based compensation expense related</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;width:32.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;ended&#160;</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 380</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 372</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 654</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketing expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 148</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 204</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 151</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total share-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 546</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 596</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 812</p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_ScheduleOfShareBasedCompensationCostsByIncomeStatementLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based compensation costs incurred by location in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_ScheduleOfShareBasedCompensationCostsByIncomeStatementLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561885621608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL EXPENSES, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_FinancialExpensesAbstract', window );"><strong>FINANCIAL EXPENSES, NET</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of Financial Expenses, Net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;ended&#160;December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Financial expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign currency transaction loss, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 79</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 412</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Remeasurement of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 994</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 203</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,257</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Others</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total financial expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,084</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 217</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,685</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Financial income:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign currency transaction profit, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 101</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest from deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 776</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 613</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 211</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Others</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total financial income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 776</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 737</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 211</p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Financial expenses (income), net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 308</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (520)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,474</p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_FinancialExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_FinancialExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561886477656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIC AND DILUTED NET LOSS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>BASIC AND DILUTED NET LOSS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of basic and diluted net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:42.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;ended&#160;December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss attributable to Ordinary shareholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,367)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,882)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (27,271)</p></td></tr><tr><td style="vertical-align:bottom;width:55.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:55.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Weighted-average shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,815,448</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,274,935</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,534,697</p></td></tr><tr><td style="vertical-align:bottom;width:55.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Net loss per share attributable to ordinary shareholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.25)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.22)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.67)</p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of antidilutive securities excluded from net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;ended&#160;December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Convertible preferred shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,229,885</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,739,186</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,739,186</p></td></tr><tr><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding share options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,371,668</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,724,414</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,046,769</p></td></tr><tr><td style="vertical-align:bottom;width:59.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RSU</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,031,250</p></td></tr><tr><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant to Preferred A shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,614,960</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,880,777</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,880,777</p></td></tr><tr><td style="vertical-align:bottom;width:59.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,436,578</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 651,067</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 651,067</p></td></tr><tr><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,653,091</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,995,444</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,349,049</p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561885621608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_GeographicInformationAbstract', window );"><strong>GEOGRAPHIC INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Geographical Information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:72pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Israel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,540</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,842</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,855</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,699</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Japan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,395</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,546</p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_GeographicInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_GeographicInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561885976712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GENERAL (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_CashCashEquivalentsShortTermDepositsAndRestrictedCash', window );">Cash, cash equivalents, short-term deposits and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27,271)<span></span>
</td>
<td class="num">$ (8,882)<span></span>
</td>
<td class="num">$ (8,464)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,812)<span></span>
</td>
<td class="num">(7,251)<span></span>
</td>
<td class="num">$ (6,910)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (52,840)<span></span>
</td>
<td class="num">$ (25,569)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_CurrentResourcesCoverageOfLiquidityRequirements', window );">Liquidity period to satisfy with current resources</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=drts_AtmKkMember', window );">ATM KK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_DisposalGroupIncludingDiscontinuedOperationOwnershipDisposed', window );">Ownership hold (as a percent)</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_CashCashEquivalentsShortTermDepositsAndRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash, cash equivalents, short-term deposits and restricted cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_CashCashEquivalentsShortTermDepositsAndRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_CurrentResourcesCoverageOfLiquidityRequirements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum period to satisfy expected liquidity requirements with existing capital resources, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_CurrentResourcesCoverageOfLiquidityRequirements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_DisposalGroupIncludingDiscontinuedOperationOwnershipDisposed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of disposal group including discontinued operation ownership disposed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_DisposalGroupIncludingDiscontinuedOperationOwnershipDisposed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=drts_AtmKkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=drts_AtmKkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561882896104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Restricted cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, as reported on the balance sheets</a></td>
<td class="nump">$ 23,236<span></span>
</td>
<td class="nump">$ 15,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash, as reported on the balance sheets</a></td>
<td class="nump">618<span></span>
</td>
<td class="nump">576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, as reported in the statements of cash flows</a></td>
<td class="nump">$ 23,854<span></span>
</td>
<td class="nump">$ 16,174<span></span>
</td>
<td class="nump">$ 1,841<span></span>
</td>
<td class="nump">$ 13,609<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561882649528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Short-term deposits (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Short-term deposits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_ShortTernBankDepositInterestRate', window );">Deposits in U.S. dollars bear interest rates</a></td>
<td class="nump">0.01%<span></span>
</td>
<td class="nump">0.05%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Short-term deposits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_ShortTernBankDepositInterestRate', window );">Deposits in U.S. dollars bear interest rates</a></td>
<td class="nump">0.62%<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_ShortTernBankDepositInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest rates on short-term deposits with banks.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_ShortTernBankDepositInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561882122664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Property and equipment and impairment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">33 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=drts_LaboratoryEquipmentMember', window );">Laboratory equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=drts_LaboratoryEquipmentMember', window );">Laboratory equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and office equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and office equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AutomobilesMember', window );">Cars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Manufacturing equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=drts_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=drts_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AutomobilesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AutomobilesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561882700008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Share-based payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Changes in RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 812<span></span>
</td>
<td class="nump">$ 596<span></span>
</td>
<td class="nump">$ 546<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Changes in RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility - lower range</a></td>
<td class="nump">85.50%<span></span>
</td>
<td class="nump">90.80%<span></span>
</td>
<td class="nump">85.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility - upper range</a></td>
<td class="nump">89.20%<span></span>
</td>
<td class="nump">102.10%<span></span>
</td>
<td class="nump">88.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate - lower range</a></td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate - upper range</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Changes in RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Changes in RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561882790696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Grants and participations &amp; Ordinary share warrants classification and measurement (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred', window );">Recognized participations in research and development as a reduction from research and development expenses</a></td>
<td class="nump">$ 2,459<span></span>
</td>
<td class="nump">$ 878<span></span>
</td>
<td class="nump">$ 571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding ordinary share warrants</a></td>
<td class="nump">718,964<span></span>
</td>
<td class="nump">728,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of customer funding recorded as an offset to costs incurred for a fixed-price, best-efforts research and development cost-sharing arrangement with the Federal Government.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561882273544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Severance pay (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_SeverancePayDepositRate', window );">Severance pay monthly deposit rate</a></td>
<td class="nump">8.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_SeverancePayExpense', window );">Severance pay expense</a></td>
<td class="nump">$ 318<span></span>
</td>
<td class="nump">$ 194<span></span>
</td>
<td class="nump">$ 117<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_SeverancePayDepositRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The monthly deposits at a rate of employees monthly salary deposited  as severance pay, as required by law.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_SeverancePayDepositRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_SeverancePayExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of monthly severance recognized during the period based on the rate prescribed by law.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_SeverancePayExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561886560792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Contingent liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Contingent liability provision</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561885988760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Deferred Transaction costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other assets, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Capitalized deferred offering costs</a></td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040515&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561885949608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER RECEIVABLES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>PREPAID EXPENSES AND OTHER RECEIVABLES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_GovernmentAuthoritiesReceivable', window );">Government authorities</a></td>
<td class="nump">$ 458<span></span>
</td>
<td class="nump">$ 472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent', window );">Prepaid expenses</a></td>
<td class="nump">227<span></span>
</td>
<td class="nump">387<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Other receivables</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Total prepaid expenses and other receivables</a></td>
<td class="nump">$ 707<span></span>
</td>
<td class="nump">$ 864<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_GovernmentAuthoritiesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of government authority receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_GovernmentAuthoritiesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561880253480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET - Schedule of property and equipment, net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 8,458<span></span>
</td>
<td class="nump">$ 5,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">912<span></span>
</td>
<td class="nump">170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">7,546<span></span>
</td>
<td class="nump">5,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">776<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1', window );">Disposed accumulated depreciation</a></td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Manufacturing equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">7,238<span></span>
</td>
<td class="nump">5,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">394<span></span>
</td>
<td class="nump">128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=drts_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">719<span></span>
</td>
<td class="nump">251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AutomobilesMember', window );">Cars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 57<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in accumulated depreciation, depletion and amortization as a result of sale or disposal of property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=drts_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=drts_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AutomobilesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AutomobilesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561882284776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER PAYABLES AND ACCRUED EXPENSES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_OtherPayablesAndAccruedExpensesAbstract', window );"><strong>OTHER PAYABLES AND ACCRUED EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Employees and payroll accruals</a></td>
<td class="nump">$ 788<span></span>
</td>
<td class="nump">$ 525<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">2,366<span></span>
</td>
<td class="nump">551<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Related parties</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total other payables and accrued expenses</a></td>
<td class="nump">$ 3,202<span></span>
</td>
<td class="nump">$ 1,124<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_OtherPayablesAndAccruedExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_OtherPayablesAndAccruedExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561881004168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENT LIABILITIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, Payment, Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">4,948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">8,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rental and lease expenses</a></td>
<td class="nump">$ 803<span></span>
</td>
<td class="nump">$ 408<span></span>
</td>
<td class="nump">$ 158<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561877156760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENT LIABILITIES - Additional (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBankLoansAndNotesPayable', window );">Bank guarantee</a></td>
<td class="nump">$ 618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_RoyaltyRate', window );">Royalty rate</a></td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_MethodOfPaymentRoyaltiesAxis=drts_NetSalesOfAllCompanySProductSoldByCompanySLicensesMember', window );">Net sales of Company products sold by Company's licensees</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_RoyaltyPaymentAsPercentageOfGrants', window );">Royalty payment as a percentage of grants</a></td>
<td class="nump">0.65%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=drts_IsraeliInnovationAuthorityMember', window );">Israeli Innovation Authority (IIA)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_GrantIncome', window );">Grant income</a></td>
<td class="nump">$ 4,065<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAssumed1', window );">Liabilities assumed</a></td>
<td class="nump">$ 5,061<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=drts_IsraeliInnovationAuthorityMember', window );">Israeli Innovation Authority (IIA) | Future sales of developed product</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_RoyaltyPaymentAsPercentageOfGrants', window );">Royalty payment as a percentage of grants</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=drts_IsraeliInnovationAuthorityMember', window );">Israeli Innovation Authority (IIA) | Minimum | Future sales of developed product</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_RoyaltyRate', window );">Royalty rate</a></td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=drts_IsraeliInnovationAuthorityMember', window );">Israeli Innovation Authority (IIA) | Maximum | Future sales of developed product</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_RoyaltyRate', window );">Royalty rate</a></td>
<td class="nump">3.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=drts_AltheraMember', window );">Althera</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAssumed1', window );">Liabilities assumed</a></td>
<td class="nump">$ 474<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_PotentialPayment', window );">Potential payment</a></td>
<td class="nump">$ 1,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=drts_AltheraMember', window );">Althera | Future gross revenues derived from purchased intellectual property</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_RoyaltyRate', window );">Royalty rate</a></td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=drts_RamotMember', window );">Ramot | Net sales of all of the Company's products</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_RoyaltyRate', window );">Royalty rate</a></td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=drts_HekaBioKKMember', window );">HekaBio K.K.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_MilestoneNumberOfOrdinaryStockOptions', window );">Milestone number of ordinary stock options | shares</a></td>
<td class="nump">271,588<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_StockOptionExercisePrice', window );">Stock option exercise price</a></td>
<td class="nump">4.42%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=drts_HekaBioKKMember', window );">HekaBio K.K. | Reimbursement Price</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_RoyaltyRate', window );">Royalty rate</a></td>
<td class="nump">3.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=drts_HekaBioKKMember', window );">HekaBio K.K. | Revenue from distribution receipts</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_RoyaltyRate', window );">Royalty rate</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=drts_BgnTechnologiesMember', window );">BGN Technologies | Sales of alpha radiation products</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_RoyaltyRate', window );">Royalty rate</a></td>
<td class="nump">0.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=drts_BgnTechnologiesMember', window );">BGN Technologies | Sales of product containing intellectual property</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_RoyaltyRate', window );">Royalty rate</a></td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=drts_BgnTechnologiesMember', window );">BGN Technologies | License revenue related to jointly developed intellectual property</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_RoyaltyRate', window );">Royalty rate</a></td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=drts_BgnTechnologiesMember', window );">BGN Technologies | License revenue related to intellectual property</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_RoyaltyRate', window );">Royalty rate</a></td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=drts_CambridgeUniversityHospitalsNhsTrustMember', window );">Cambridge University Hospitals NHS Trust | Revenue generated from patent</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_RoyaltyRate', window );">Royalty rate</a></td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=drts_CambridgeUniversityHospitalsNhsTrustMember', window );">Cambridge University Hospitals NHS Trust | Net sales of treatment for Squamous Cell Carcinoma</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_RoyaltyRate', window );">Royalty rate</a></td>
<td class="nump">2.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_GrantIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_GrantIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_MilestoneNumberOfOrdinaryStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares purchasable through stock options dependent on the achievement of various milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_MilestoneNumberOfOrdinaryStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_PotentialPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum potential amount of payment based on a agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_PotentialPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_RoyaltyPaymentAsPercentageOfGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage at which royalty payments will be paid out on relative to the amount of grants received plus interest at LIBOR rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_RoyaltyPaymentAsPercentageOfGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_RoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage at which royalty payments will be paid out on.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_RoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_StockOptionExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The per share exercise price of option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_StockOptionExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of liabilities assumed in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBankLoansAndNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBankLoansAndNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_MethodOfPaymentRoyaltiesAxis=drts_NetSalesOfAllCompanySProductSoldByCompanySLicensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_MethodOfPaymentRoyaltiesAxis=drts_NetSalesOfAllCompanySProductSoldByCompanySLicensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=drts_IsraeliInnovationAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=drts_IsraeliInnovationAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_MethodOfPaymentRoyaltiesAxis=drts_FutureSalesOfDevelopedProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_MethodOfPaymentRoyaltiesAxis=drts_FutureSalesOfDevelopedProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=drts_AltheraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=drts_AltheraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_MethodOfPaymentRoyaltiesAxis=drts_FutureGrossRevenuesDerivedFromPurchasedIntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_MethodOfPaymentRoyaltiesAxis=drts_FutureGrossRevenuesDerivedFromPurchasedIntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=drts_RamotMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=drts_RamotMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_MethodOfPaymentRoyaltiesAxis=drts_NetSalesOfAllCompanySProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_MethodOfPaymentRoyaltiesAxis=drts_NetSalesOfAllCompanySProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=drts_HekaBioKKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=drts_HekaBioKKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_MethodOfPaymentRoyaltiesAxis=drts_ReimbursementPriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_MethodOfPaymentRoyaltiesAxis=drts_ReimbursementPriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_MethodOfPaymentRoyaltiesAxis=drts_DistributionReceiptsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_MethodOfPaymentRoyaltiesAxis=drts_DistributionReceiptsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=drts_BgnTechnologiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=drts_BgnTechnologiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_MethodOfPaymentRoyaltiesAxis=drts_SalesOfAlphaRadiationProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_MethodOfPaymentRoyaltiesAxis=drts_SalesOfAlphaRadiationProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_MethodOfPaymentRoyaltiesAxis=drts_SalesOfProductContainingIntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_MethodOfPaymentRoyaltiesAxis=drts_SalesOfProductContainingIntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_MethodOfPaymentRoyaltiesAxis=drts_LicenseRevenueToJointlyDevelopedIntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_MethodOfPaymentRoyaltiesAxis=drts_LicenseRevenueToJointlyDevelopedIntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_MethodOfPaymentRoyaltiesAxis=drts_LicenseRevenueRelatedToIntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_MethodOfPaymentRoyaltiesAxis=drts_LicenseRevenueRelatedToIntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=drts_CambridgeUniversityHospitalsNhsTrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=drts_CambridgeUniversityHospitalsNhsTrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_MethodOfPaymentRoyaltiesAxis=drts_RevenueGeneratedFromPatentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_MethodOfPaymentRoyaltiesAxis=drts_RevenueGeneratedFromPatentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_MethodOfPaymentRoyaltiesAxis=drts_NetSalesSquamousCellCarcinomaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_MethodOfPaymentRoyaltiesAxis=drts_NetSalesSquamousCellCarcinomaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561880952440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Valuation Assumptions (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>item</div>
</th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Valuation assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_NumberOfScenariosInAllocatingValueToWarrants', window );">Number of scenarios to allocate equity value to warrants</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingValuationTechniqueExtensibleList', window );">Valuation technique</a></td>
<td class="text">us-gaap:ValuationTechniqueOptionPricingModelMember<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Valuation assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Valuation assumptions</a></td>
<td class="nump">1.25<span></span>
</td>
<td class="nump">2.25<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Valuation assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Valuation assumptions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Valuation assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Valuation assumptions</a></td>
<td class="nump">83.00<span></span>
</td>
<td class="nump">96.83<span></span>
</td>
<td class="nump">78.11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Valuation assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Valuation assumptions</a></td>
<td class="nump">0.75<span></span>
</td>
<td class="nump">0.42<span></span>
</td>
<td class="nump">1.91<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_NumberOfScenariosInAllocatingValueToWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of scenarios used in allocating value of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_NumberOfScenariosInAllocatingValueToWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingValuationTechniqueExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates valuation technique for measuring outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingValuationTechniqueExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561886437992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Changes in fair value (Details) - Warrants - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Change in fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning of year</a></td>
<td class="nump">$ 5,366<span></span>
</td>
<td class="nump">$ 5,163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in fair value</a></td>
<td class="nump">13,257<span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">End of year</a></td>
<td class="nump">$ 18,623<span></span>
</td>
<td class="nump">$ 5,366<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561885788792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Tax rates (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">36 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_IncomeTaxDisclosureLineItems', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Corporate tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_IncomeTaxRateReconciliationPreferredCompanyPercent', window );">Preferred company tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=drts_AtmIncMember', window );">ATM Inc | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_IncomeTaxDisclosureLineItems', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Corporate tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_IncomeTaxRateReconciliationPreferredCompanyPercent', window );">Preferred company tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=drts_AtmKkMember', window );">ATM KK | Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_IncomeTaxDisclosureLineItems', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Corporate tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_IncomeTaxRateReconciliationLargeCompaniesPercent', window );">Effective statutory tax rate, large companies</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">30.62%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_IncomeTaxRateReconciliationSmallCompaniesPercent', window );">Effective statutory tax rate, small companies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_IncomeTaxRateReconciliationSmallCompaniesSpecialRatePercent', window );">Effective statutory special tax rate, small companies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_IncomeTaxRateReconciliationMediumCompaniesSpecialRatePercent', window );">Effective statutory special tax rate, medium companies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_IncomeTaxRateReconciliationLargeCompaniesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of statutory tax rate applicable to pretax income (loss) for large companies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_IncomeTaxRateReconciliationLargeCompaniesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_IncomeTaxRateReconciliationMediumCompaniesSpecialRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of special statutory tax rate applicable to pretax income (loss) for medium companies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_IncomeTaxRateReconciliationMediumCompaniesSpecialRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_IncomeTaxRateReconciliationPreferredCompanyPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of statutory tax rate applicable to pretax income (loss) for preferred company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_IncomeTaxRateReconciliationPreferredCompanyPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_IncomeTaxRateReconciliationSmallCompaniesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of statutory tax rate applicable to pretax income (loss) for small companies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_IncomeTaxRateReconciliationSmallCompaniesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_IncomeTaxRateReconciliationSmallCompaniesSpecialRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of special statutory tax rate applicable to pretax income (loss) for small companies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_IncomeTaxRateReconciliationSmallCompaniesSpecialRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=drts_AtmIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=drts_AtmIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=drts_AtmKkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=drts_AtmKkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561886653256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Net loss (income) before tax (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract', window );"><strong>Components of the net loss (income) before tax on income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic (Israel)</a></td>
<td class="nump">$ 27,089<span></span>
</td>
<td class="nump">$ 9,322<span></span>
</td>
<td class="nump">$ 8,898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">175<span></span>
</td>
<td class="num">(598)<span></span>
</td>
<td class="num">(580)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before taxes on income</a></td>
<td class="nump">$ 27,264<span></span>
</td>
<td class="nump">$ 8,724<span></span>
</td>
<td class="nump">$ 8,318<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561880926552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Income tax expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 158<span></span>
</td>
<td class="nump">$ 146<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current income tax expense</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">158<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 158<span></span>
</td>
<td class="nump">$ 146<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561885667928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - Net operating losses carry (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Accumulated losses for tax purposes</a></td>
<td class="nump">$ 39,585<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561880208664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - Deferred taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Significant components of deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances', window );">Reserves and allowances</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">R&amp;D expenses</a></td>
<td class="nump">399<span></span>
</td>
<td class="nump">482<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Loss carryforward</a></td>
<td class="nump">3,322<span></span>
</td>
<td class="nump">1,551<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets before valuation allowance</a></td>
<td class="nump">3,803<span></span>
</td>
<td class="nump">2,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less - valuation allowance</a></td>
<td class="num">$ (3,803)<span></span>
</td>
<td class="num">$ (2,233)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from estimated returns and sales allowances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561882063000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONVERTIBLE PREFERRED SHARES AND WARRANTS - Composition of Convertible Preferred shares (Details)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 07, 2022</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,348,176<span></span>
</td>
<td class="nump">25,348,176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,739,186<span></span>
</td>
<td class="nump">13,739,186<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,739,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Carrying amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation preference | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split ratio</a></td>
<td class="nump">0.905292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=drts_SeriesConvertiblePreferredSharesMember', window );">Series A Convertible Preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,295,256<span></span>
</td>
<td class="nump">16,295,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,229,885<span></span>
</td>
<td class="nump">7,229,885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,229,885<span></span>
</td>
<td class="nump">7,229,885<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Carrying amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation preference | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=drts_SeriesBConvertiblePreferredSharesMember', window );">Series B Convertible Preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,052,920<span></span>
</td>
<td class="nump">9,052,920<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,509,301<span></span>
</td>
<td class="nump">6,509,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,509,301<span></span>
</td>
<td class="nump">6,509,301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Carrying amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation preference | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=drts_SeriesConvertiblePreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=drts_SeriesConvertiblePreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=drts_SeriesBConvertiblePreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=drts_SeriesBConvertiblePreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561880894696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE PREFERRED SHARES AND WARRANTS - Preferred shares rights (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>Vote</div>
</th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Dividend rate, as a percent of original issue price</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_TemporaryEquityNumberOfVotes', window );">Number of vote entitle to</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Conversion ratio</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=drts_SeriesConvertiblePreferredSharesMember', window );">Series A Convertible Preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_TemporaryEquityDistributionRateFromProceedsOfSaleAnotherClassOfShares', window );">Distribution rate from proceeds of the full payment of Series B Preference, as percent of issue price</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Conversion ratio</a></td>
<td class="nump">1.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_TemporaryEquityDistributionRateFromProceedsOfSaleAnotherClassOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum distribution rate from the proceeds of full payment of another class of temporary equity, as percentage of the original issuance price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_TemporaryEquityDistributionRateFromProceedsOfSaleAnotherClassOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_TemporaryEquityNumberOfVotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of votes each temporary equity is entitled to.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_TemporaryEquityNumberOfVotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion for each share of preferred stock to be converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=drts_SeriesConvertiblePreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=drts_SeriesConvertiblePreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561880708024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE PREFERRED SHARES AND WARRANTS - Financing rounds (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 07, 2022</div></th>
<th class="th">
<div>Jul. 15, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2016 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,053<span></span>
</td>
<td class="nump">556,548<span></span>
</td>
<td class="nump">5,316,493<span></span>
</td>
<td class="nump">7,229,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_SaleOfStockNumberOfWarrantsIssuedInTransaction', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,614,960<span></span>
</td>
<td class="nump">67,897<span></span>
</td>
<td class="nump">3,880,777<span></span>
</td>
<td class="nump">6,789,694<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Consideration for issuance of shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Fair value of warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split ratio</a></td>
<td class="nump">0.905292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=drts_SeriesConvertiblePreferredSharesMember', window );">Series A Convertible Preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_SaleOfStockNumberOfWarrantsIssuedInTransaction', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,614,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Preferred shares that can be converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,229,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=drts_SeriesBConvertiblePreferredSharesMember', window );">Series B Convertible Preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,509,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Consideration for issuance of shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Shares can be issued for conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,761,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split ratio</a></td>
<td class="nump">0.905292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_SaleOfStockNumberOfWarrantsIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants issued in relation to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_SaleOfStockNumberOfWarrantsIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion for each share of preferred stock to be converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of preferred stock and warrants for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=drts_SeriesConvertiblePreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=drts_SeriesConvertiblePreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=drts_SeriesBConvertiblePreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=drts_SeriesBConvertiblePreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561877496968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE PREFERRED SHARES AND WARRANTS - Preferred A shares warrants (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Apr. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_SaleOfStockNumberOfWarrantsIssuedInTransaction', window );">Number of warrants issued</a></td>
<td class="nump">3,614,960<span></span>
</td>
<td class="nump">67,897<span></span>
</td>
<td class="nump">3,880,777<span></span>
</td>
<td class="nump">6,789,694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollar per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,880,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=drts_SeriesConvertiblePreferredSharesMember', window );">Series A Convertible Preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Preferred shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_SaleOfStockNumberOfWarrantsIssuedInTransaction', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,614,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollar per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_WarrantsGrantedIncreaseFromNewFinancing', window );">Additional warrants granted (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_SaleOfStockNumberOfWarrantsIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants issued in relation to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_SaleOfStockNumberOfWarrantsIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_WarrantsGrantedIncreaseFromNewFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage increase in the number of warrants granted due to fresh financing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_WarrantsGrantedIncreaseFromNewFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=drts_SeriesConvertiblePreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=drts_SeriesConvertiblePreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561877253272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' DEFICIENCY - Ordinary share capital (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 07, 2022</div></th>
<th class="th">
<div>Jul. 15, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2016 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>Vote </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>SHAREHOLDERS' DEFICIENCY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,423,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,423,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,528,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,433,578<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,528,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,433,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split ratio</a></td>
<td class="nump">0.905292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_SharesNumberOfVotes', window );">Number of vote entitled to | Vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Consideration for issuance of shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,053<span></span>
</td>
<td class="nump">556,548<span></span>
</td>
<td class="nump">5,316,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,229,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_SaleOfStockNumberOfWarrantsIssuedInTransaction', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,614,960<span></span>
</td>
<td class="nump">67,897<span></span>
</td>
<td class="nump">3,880,777<span></span>
</td>
<td class="nump">6,789,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=drts_HekabioK.k.Member', window );">HekaBio K.K. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>SHAREHOLDERS' DEFICIENCY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,302,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_SaleOfStockNumberOfWarrantsIssuedInTransaction', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">651,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>SHAREHOLDERS' DEFICIENCY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,423,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split ratio</a></td>
<td class="nump">0.905292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Ordinary shares | HekaBio K.K. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>SHAREHOLDERS' DEFICIENCY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Consideration for issuance of shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_SaleOfStockNumberOfWarrantsIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants issued in relation to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_SaleOfStockNumberOfWarrantsIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_SharesNumberOfVotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of votes each share is entitled to.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_SharesNumberOfVotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=drts_HekabioK.k.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=drts_HekabioK.k.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561886203672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' DEFICIENCY - Share option plan (Details) - Share Option Plan [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share option plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Authorized awards (in shares)</a></td>
<td class="nump">7,611,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Available for future grants (in shares)</a></td>
<td class="nump">442,439<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=drts_ShareOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=drts_ShareOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561877275768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' DEFICIENCY - Options changes (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollar per share)</a></td>
<td class="nump">$ 9.81<span></span>
</td>
<td class="nump">$ 4.42<span></span>
</td>
<td class="nump">$ 4.06<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember', window );">Share-based Payment Arrangement, Employee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at beginning of year (in shares)</a></td>
<td class="nump">4,062,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,321,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(4,809)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited and cancelled (in shares)</a></td>
<td class="num">(53,238)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at end of year (in shares)</a></td>
<td class="nump">5,325,572<span></span>
</td>
<td class="nump">4,062,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable options (in shares)</a></td>
<td class="nump">3,233,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at beginning of year (in dollar per share)</a></td>
<td class="nump">$ 3.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollar per share)</a></td>
<td class="nump">9.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollar per share)</a></td>
<td class="nump">4.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited and cancelled (in dollar per share)</a></td>
<td class="nump">5.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at end of year (in dollar per share)</a></td>
<td class="nump">4.97<span></span>
</td>
<td class="nump">$ 3.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable options (in dollar per share)</a></td>
<td class="nump">$ 3.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Aggregate intrinsic value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at year end</a></td>
<td class="nump">$ 17,854,046<span></span>
</td>
<td class="nump">$ 944,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable options</a></td>
<td class="nump">$ 14,184,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding at year end</a></td>
<td class="text">7 years 5 months 1 day<span></span>
</td>
<td class="text">7 years 9 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable options</a></td>
<td class="text">6 years 6 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember', window );">Share-based Payment Arrangement, Nonemployee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at beginning of year (in shares)</a></td>
<td class="nump">662,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">140,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(81,476)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at end of year (in shares)</a></td>
<td class="nump">721,197<span></span>
</td>
<td class="nump">662,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable options (in shares)</a></td>
<td class="nump">580,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at beginning of year (in dollar per share)</a></td>
<td class="nump">$ 2.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollar per share)</a></td>
<td class="nump">9.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollar per share)</a></td>
<td class="nump">1.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at end of year (in dollar per share)</a></td>
<td class="nump">4.34<span></span>
</td>
<td class="nump">$ 2.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable options (in dollar per share)</a></td>
<td class="nump">$ 3.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Aggregate intrinsic value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at year end</a></td>
<td class="nump">$ 2,695,213<span></span>
</td>
<td class="nump">$ 313,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable options</a></td>
<td class="nump">$ 2,649,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding at year end</a></td>
<td class="text">6 years 7 months 9 days<span></span>
</td>
<td class="text">6 years 10 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable options</a></td>
<td class="text">5 hours<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561877447048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' DEFICIENCY - RSUs (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Number of RSU</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Granted</a></td>
<td class="nump">1,036,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations', window );">Forfeited and cancelled</a></td>
<td class="num">(5,600)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Outstanding on December 31, 2021</a></td>
<td class="nump">1,031,250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were either cancelled or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561877161736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' DEFICIENCY - Equity-based compensation expense (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 812<span></span>
</td>
<td class="nump">$ 596<span></span>
</td>
<td class="nump">$ 546<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">unrecognized compensation costs</a></td>
<td class="nump">$ 2,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period of recognition</a></td>
<td class="text">3 years 3 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price of the options granted</a></td>
<td class="nump">$ 9.81<span></span>
</td>
<td class="nump">$ 4.42<span></span>
</td>
<td class="nump">$ 4.06<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of options granted</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.76<span></span>
</td>
<td class="nump">$ 4.45<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 654<span></span>
</td>
<td class="nump">$ 372<span></span>
</td>
<td class="nump">$ 380<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Selling and Marketing Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 151<span></span>
</td>
<td class="nump">$ 204<span></span>
</td>
<td class="nump">$ 148<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561880849560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' DEFICIENCY - Warrants (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 15, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2016 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>SHAREHOLDERS' DEFICIENCY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_SaleOfStockNumberOfWarrantsIssuedInTransaction', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,614,960<span></span>
</td>
<td class="nump">67,897<span></span>
</td>
<td class="nump">3,880,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,789,694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued</a></td>
<td class="nump">9,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">556,548<span></span>
</td>
<td class="nump">5,316,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,229,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_WarrantsExercisedCashBasis', window );">Warrants exercised on cash basis (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,412,520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_WarrantsExercisedCashlessBasis', window );">Warrants exercised on cashless basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,377,174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_StockIssuedDuringPeriodValueExerciseOfWarrants', window );">Warrant exercise consideration | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">$ 1,560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_WarrantsToOrdinaryShareRatioCashlessExercise', window );">Warrants exercise on cashless basis to ordinary shares ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollar per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_NumberOfWarrantsExercised', window );">Warrant exercised</a></td>
<td class="nump">9,053<span></span>
</td>
<td class="nump">90,529<span></span>
</td>
<td class="nump">879,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=drts_HekabioK.k.Member', window );">HekaBio K.K. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>SHAREHOLDERS' DEFICIENCY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_SaleOfStockNumberOfWarrantsIssuedInTransaction', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">651,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,302,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollar per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_NumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants exercised in the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_NumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_SaleOfStockNumberOfWarrantsIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants issued in relation to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_SaleOfStockNumberOfWarrantsIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_StockIssuedDuringPeriodValueExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_StockIssuedDuringPeriodValueExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_WarrantsExercisedCashBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number warrants exercised on a cash basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_WarrantsExercisedCashBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_WarrantsExercisedCashlessBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number warrants exercised on a cashless basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_WarrantsExercisedCashlessBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_WarrantsToOrdinaryShareRatioCashlessExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ratio of warrant to ordinary shares in a cashless exercise of warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_WarrantsToOrdinaryShareRatioCashlessExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=drts_HekabioK.k.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=drts_HekabioK.k.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561885907832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL EXPENSES, NET (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_NonOperatingFinancialExpensesAbstract', window );"><strong>Financial expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionLossBeforeTax', window );">Foreign currency transaction loss, net</a></td>
<td class="nump">$ 412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Remeasurement of warrants</a></td>
<td class="nump">13,257<span></span>
</td>
<td class="nump">$ 203<span></span>
</td>
<td class="nump">994<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Others</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_FinancialExpensesTotal', window );">Total financial expenses</a></td>
<td class="nump">13,685<span></span>
</td>
<td class="nump">217<span></span>
</td>
<td class="nump">1,084<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_NonOperatingFinancialIncomeAbstract', window );"><strong>Financial income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency transaction profit, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeDepositsWithFinancialInstitutions', window );">Interest from deposits</a></td>
<td class="nump">211<span></span>
</td>
<td class="nump">613<span></span>
</td>
<td class="nump">776<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Others</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_FinancialIncomeTotal', window );">Total financial income</a></td>
<td class="nump">211<span></span>
</td>
<td class="nump">737<span></span>
</td>
<td class="nump">776<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingGainsLosses', window );">Financial expenses (income), net</a></td>
<td class="nump">$ 13,474<span></span>
</td>
<td class="num">$ (520)<span></span>
</td>
<td class="nump">$ 308<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_FinancialExpensesTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total expense included in Net Financial Expense (Income).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_FinancialExpensesTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_FinancialIncomeTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total income included in Net Financial Expense (Income).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_FinancialIncomeTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_NonOperatingFinancialExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_NonOperatingFinancialExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_NonOperatingFinancialIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_NonOperatingFinancialIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized loss recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeDepositsWithFinancialInstitutions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest income derived from funds deposited with both domestic and foreign financial institutions including funds in money market and other accounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (a)<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (b)<br> -Subparagraph (1)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeDepositsWithFinancialInstitutions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of gains or losses resulting from nonoperating activities (for example, interest and dividend revenue, property, plant and equipment impairment loss, and so forth).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7,9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561880680136">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>BASIC AND DILUTED NET LOSS PER SHARE (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net loss attributable to Ordinary shareholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (27,271)<span></span>
</td>
<td class="num">$ (8,882)<span></span>
</td>
<td class="num">$ (8,367)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used in computing net loss per share attributable to ordinary shareholders, basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">40,534,697<span></span>
</td>
<td class="nump">40,274,935<span></span>
</td>
<td class="nump">33,815,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used in computing net loss per share attributable to ordinary shareholders, diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">40,534,697<span></span>
</td>
<td class="nump">40,274,935<span></span>
</td>
<td class="nump">33,815,448<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Net loss per share attributable to ordinary shareholders, basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.67)<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="num">$ (0.25)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Net loss per share attributable to ordinary shareholders, diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.67)<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="num">$ (0.25)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from calculation of net loss per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25,349,049<span></span>
</td>
<td class="nump">22,995,444<span></span>
</td>
<td class="nump">23,653,091<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible preferred shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from calculation of net loss per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,739,186<span></span>
</td>
<td class="nump">13,739,186<span></span>
</td>
<td class="nump">7,229,885<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Outstanding share options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from calculation of net loss per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,046,769<span></span>
</td>
<td class="nump">4,724,414<span></span>
</td>
<td class="nump">4,371,668<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">RSU</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from calculation of net loss per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,031,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=drts_WarrantsToPreferredSharesMember', window );">Warrant to Preferred A shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from calculation of net loss per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,880,777<span></span>
</td>
<td class="nump">3,880,777<span></span>
</td>
<td class="nump">3,614,960<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from calculation of net loss per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">651,067<span></span>
</td>
<td class="nump">651,067<span></span>
</td>
<td class="nump">8,436,578<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Prior period results have been retroactively adjusted to reflect the 1: 0.905292 stock split effected on March&#160;7, 2022. See also note 10, Shareholders&#8217; Deficiency, for details.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_DenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_DenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_NumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_NumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4613673-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=drts_WarrantsToPreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=drts_WarrantsToPreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561880209432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC INFORMATION (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract', window );"><strong>Segment Reporting Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 7,546<span></span>
</td>
<td class="nump">$ 5,395<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IL', window );">Israel</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract', window );"><strong>Segment Reporting Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">5,842<span></span>
</td>
<td class="nump">3,540<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract', window );"><strong>Segment Reporting Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,699<span></span>
</td>
<td class="nump">$ 1,855<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract', window );"><strong>Segment Reporting Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140561880872200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 07, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 18, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split ratio</a></td>
<td class="nump">0.905292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Shares | HCCC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_drts_CommonStockCancelledAndConvertedInToShares', window );">Common stock cancelled and converted into share | shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Ordinary Common Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split ratio</a></td>
<td class="nump">0.905292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | HCCC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash proceeds in connection with merger</a></td>
<td class="nump">$ 90,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Ordinary Common Shares | HCCC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split ratio</a></td>
<td class="nump">0.905292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Ordinary share price | $ / shares</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Bank Leumi Le-Israel BM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PledgedFinancialInstrumentsNotSeparatelyReportedSecuritiesForLetterOfCreditFacilities', window );">Standby letter of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_drts_CommonStockCancelledAndConvertedInToShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The common stock cancelled automatically and converted into one share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">drts_CommonStockCancelledAndConvertedInToShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>drts_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PledgedFinancialInstrumentsNotSeparatelyReportedSecuritiesForLetterOfCreditFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount as of the date of the latest financial statement presented of securities which are owned but transferred to serve as collateral for letter of credit arrangements, and for which the transferee does not have the right by contract or custom to sell or re-pledge them to an unrelated party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109249958&amp;loc=SL6224234-111729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PledgedFinancialInstrumentsNotSeparatelyReportedSecuritiesForLetterOfCreditFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=drts_HcccMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=drts_HcccMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=drts_BankLeumiLeIsraelBmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=drts_BankLeumiLeIsraelBmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>drts-20211231x20f_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:drts="http://www.alphatau.com/20211231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="drts-20211231.xsd" xlink:type="simple"/>
    <context id="As_Of_4_30_2016_rW7hRh2E3Emvv6ppXNzIxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
        </entity>
        <period>
            <instant>2016-04-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_o8AlyFK5_0q1GKpbfc38VQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_DDHUZat3sk6fWEo027gkiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_ajdK4nogIEm72h8iR_gO5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_hKjTfEKuFUCkwF-mupksAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_Jm9aG3RQCE2XotHJYhCprg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_6C1-PLSDy0mfoXDzXtxQwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_gKe2q9eKk0e3gwlR_9b76A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_26q-bJ04nk64a6-bSVGKkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_66Y1DeYIKEiZUIV-AiM0QQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_1CGa6Hpjaku4CPgZdTORGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_56RoFMzD20emutTGyd2S_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_wDZnSvtkgU6z66pKDtkfXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_drts_SeriesConvertiblePreferredSharesMember_2rsemjdtU0aLnNvzSudxpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">drts:SeriesConvertiblePreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_drts_SeriesBConvertiblePreferredSharesMember_aujqloiYdUqLgyG-IywV-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">drts:SeriesBConvertiblePreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_drts_SeriesBConvertiblePreferredSharesMember__unz0Gwr4U6xfvew_rt8qg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">drts:SeriesBConvertiblePreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_3_7_2022_To_3_7_2022_us-gaap_BusinessAcquisitionAxis_drts_HcccMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_E1MNaT3WY0K3ZcXXAPmtVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">drts:HcccMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-07</startDate>
            <endDate>2022-03-07</endDate>
        </period>
    </context>
    <context id="Duration_3_7_2022_To_3_7_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_WEfc-vShRUy3Gx5vSV4mVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-07</startDate>
            <endDate>2022-03-07</endDate>
        </period>
    </context>
    <context id="Duration_3_7_2022_To_3_7_2022_zxGQCP-7Fk277229BSbBmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
        </entity>
        <period>
            <startDate>2022-03-07</startDate>
            <endDate>2022-03-07</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HEnHaE37ekigHo4AetBJFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_MouG0PPKQkmZNUQVCP7aqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_bsiFZBQITkihmHXGW4LWHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ykMIzfofVUuPDoPU0k2Pgg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Az5at6t9sUi2LDLd7cWsbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VMREA2dVCUqalyS79-xuRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_hVc9GNOKXk-_jqzkPdtv8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_6ynx3rWt90GJLYzfoH7j8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4ygP12wMPUWWbr6h1XztVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_7_2022_us-gaap_BusinessAcquisitionAxis_drts_HcccMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_iIVxwLK7kE2b1JwNE4XyzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">drts:HcccMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-07</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_2jPIe9FCpk-lk0x3ei7plQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ODoUIImeZUSC5k7f53zukQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_bNVdyxnBY0S_wDAMjuaFkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QBEQ8mAQX0SOz4gXrPGKLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_i1mWmb_nSEecsnGxFg7m_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GocQ7aqoEkCbUnmv9spesw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_aj4GYFUqrka7uJcyVmTHIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4I62Q1RYY0G4dDLq0oH8kA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_kiT9W3vqp0OZhbNgXlCDlw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_N81fmDen3E25LY0nhNqEwg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_H5r7wu2GjkCR2jWr-TITxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_Qp1t4h1WuE20sketeFkQaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_OSPpJbgS_kKHuzfkXV5w1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_lVBebhm2NUeEc6aQ92svqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_kZCpG9oRQUWYe1QTUnt4Mg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_LahhRefsiUeIK16_07ddRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_drts_ShareOptionPlanMember_dFYkG00x2k-k8R6SDAZdBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">drts:ShareOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_-q59_3u_sUqS3xTBriYDrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_u1KsUB5GUkyYW_fz6BxGKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_QL_lHDCdIUaW2VkrmxWUYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zmqejbh0ukqtNgBs60C6XA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Sg0gHG4UoU-lLL3GVY6j-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_jB-0qsL4s0iRjn2iZ1I0eg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_a-Npz0DAckea4fyrLYOJvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_1fUps4YHpUmalFLxoLPtsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_S6irH3nF3kiUBJuvNW1GvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_drts_ShareOptionPlanMember_RIX788L11EWA3ahCtQufmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">drts:ShareOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2019_To_12_31_2019_yCEIW0JlakWqYIDxGbuWtQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_ZaOgQu4r90edkwyq9ZaeAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_drts_LaboratoryEquipmentMember_zGBF3SpbBE-OhZ3qDsbqLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">drts:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_1lJIcyzl2ka-godfGb-vHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_drts_LaboratoryEquipmentMember_DHtJpJcfZ06X41B2GbaKSw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">drts:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_URRNsHmmMUWu9_-B9brINQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_dZomxtzLFkWxB2CX70Casw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AutomobilesMember_MdIVVvN1b0Gj0kdnXqxCvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AutomobilesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_StatementGeographicalAxis_country_US_RZN6ejeNsEmQtCCCNm9spQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_StatementGeographicalAxis_country_JP__8sfu7Pxlk-mMRFbDKhBZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_StatementGeographicalAxis_country_IL_c_kJyhiBYEGoZcGQuB67uA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_srt_StatementGeographicalAxis_country_US_in1yQM0Z10-KwKkqgUSCKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_srt_StatementGeographicalAxis_country_IL_PMTZcbNK3kWZuaPNc0HC8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_BpY3NXZYiUacPgGpq8sVxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_bFz5PWOuYUWTs4rHFVh4Ig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_DR2lnPTSYkOr47Js9w5IFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AutomobilesMember_nSEbQEFkgkqLdoCosAad7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AutomobilesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_drts_LaboratoryEquipmentMember_GAJWzUvUwEyFjKgZHPzslw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">drts:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_JS-1SNXCvUeJpcN2z_gkow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_q_uetuy3B0Wa4ahNzfjYhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_Tsmzg43NZEq8r_rl1YdOkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_kmZMVTkZDk-WlRLrABkDOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AutomobilesMember_50PifpuGVkegwyS9RNi4Cw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AutomobilesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_drts_LaboratoryEquipmentMember_HT92yqEwAU2zKGWsZbh7gA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">drts:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_7_31_2019_srt_CounterpartyNameAxis_drts_HekabioK.k.Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_rNX51eEBuEGWtuOpNs--fw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">drts:HekabioK.k.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="As_Of_4_30_2020_us-gaap_StatementClassOfStockAxis_drts_SeriesBConvertiblePreferredSharesMember_30sMLfKYZ0ukHDW9qDg6NQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">drts:SeriesBConvertiblePreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2018_H4Zwi9gmHkGz2evRAa1_dQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="As_Of_1_18_2022_srt_CounterpartyNameAxis_drts_BankLeumiLeIsraelBmMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_BeRyXpDJ5kGTXPHFaRTfqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">drts:BankLeumiLeIsraelBmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-18</instant>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_4_30_2020_us-gaap_StatementClassOfStockAxis_drts_SeriesBConvertiblePreferredSharesMember_bAcjFcmMGEKODAHgmn7SUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">drts:SeriesBConvertiblePreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_LPp8QInDWUu1wZCHIvnfQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_IbEezU48YkqEkwVicJ4VDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_EKhArHp_YEqXT7Vh3-UQ7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_RAo1T_5iU0emGFXFccTaVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2021_rqAxnV6ZuUS7C0LOKQQJbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_dsprqrhawkyPoi6VXySrYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_Vcye6381VUeQWqckP0fFwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_762hkA1xekWBcZRYtQnetQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_2ghnd2En8UiT0zWguTDZrw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_58F--dymdEiPpkMxGCFxLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_S4dFGjmRIE2hAjthSZNbJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_hb-EpK2zOE6IW_s6W3VP0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_rrpsDYs6x0SIZ6A54vpDQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_s0BI7zNnAEKLzKmtfc-EqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_7_31_2019_srt_CounterpartyNameAxis_drts_HekabioK.k.Member_WD3hZ8b710aQRjZMhkzTsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">drts:HekabioK.k.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_9X1M-BXfgEWsSJdmFxdJhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_XIXddAY3L0yRBxsPKwvT6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="Duration_3_7_2022_To_3_7_2022_us-gaap_BusinessAcquisitionAxis_drts_HcccMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_wb4aa4hMOk-oUeKQrzX1-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">drts:HcccMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-07</startDate>
            <endDate>2022-03-07</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_ugDRsvTNaUmilQmO6qFALQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_CVs6y3ige0mbtcVCtEnhqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_xkz4fyumv021UlW6DLiR0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_MHykc8OPo0iqU-HsSzCVvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_drts_WarrantsToPreferredSharesMember_3xaGNXkiQk215jhKwwMGtA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">drts:WarrantsToPreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_8q6cV2yAM0a3XAboz3EV0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_ywa_0-bXzkKhuRpBh5X1qg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_Woekbq1Vh0m9LF6giXkjAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_drts_WarrantsToPreferredSharesMember_F-36Oqlx4UWKJm0Pn_tXwg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">drts:WarrantsToPreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_83Yv-70FokCNwA9HBVo3Ag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_-g979nKaYE-fgpAUV8oCPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_JaC_a1cel0-cR7a1zDVJ8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_drts_WarrantsToPreferredSharesMember_g4e9gxAYuUqhsD456SMaZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">drts:WarrantsToPreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_o_i3_DfHik6LOoF2B8rb3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember__1I8UfYct0qja66GZyQuYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_jSuYco4A6kWDk0WIg-bOhg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_pPraAX3UkUu0_lMAnsHfJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Y0-0nKnve0qsDthMlv68-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_nhO5-HJ1nk6RNhK67yOGoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_fv33GX4WVUa4CZlwHesWww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_KkiZY-M7yk-YryD1n_upAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_kforSQ4jYUSPrZV_1I2SsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_rhxpidqOe0uEnhSdwKCtbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_drts_SeriesConvertiblePreferredSharesMember_Ciu93EXH3Uu0zKZgtaOVHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">drts:SeriesConvertiblePreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_HekaBioKKMember_KbAb2SB6LkyHj7B8hsEHXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">drts:HekaBioKKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_STmFVK2iUkKhWvfG-Crldw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iKd2bcgAO0yb8cTymXlliw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OA7LnjwMsEWxaEV_8urPuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xyh47eHvfkKb6vxdvq7wAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_u2IRTL2hREuTiBdvWBPJIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_Bx-4ke71BkK7RwJqTEiSgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_YkvYRoxUekOnNqnvzrP72A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_3YDYP2NS1kWrJTyY6tlLEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_9PHxHzoF8EaVkrgQF_FmYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_drts_SeriesConvertiblePreferredSharesMember_UHBSJ1OmqEK-PEYAzs74DA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">drts:SeriesConvertiblePreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_7_31_2019_srt_CounterpartyNameAxis_drts_HekabioK.k.Member_r5R-uUg6Vk-zl0lhq3yl_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">drts:HekabioK.k.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2018_To_9_30_2018_QkwZ1akbskyCxXcB-8mukw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2016_To_4_30_2016_aEGL3Dhxo0CNZ5ITN3VZQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
        </entity>
        <period>
            <startDate>2016-04-01</startDate>
            <endDate>2016-04-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_IsraeliInnovationAuthorityMember_drts_MethodOfPaymentRoyaltiesAxis_drts_FutureSalesOfDevelopedProductMember_srt_RangeAxis_srt_MinimumMember_GIY9mAr40kOVwTeAjK_dRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="drts:MethodOfPaymentRoyaltiesAxis">drts:FutureSalesOfDevelopedProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">drts:IsraeliInnovationAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_IsraeliInnovationAuthorityMember_drts_MethodOfPaymentRoyaltiesAxis_drts_FutureSalesOfDevelopedProductMember_srt_RangeAxis_srt_MaximumMember_FUMYd9CZyEiec-h-1tOPiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="drts:MethodOfPaymentRoyaltiesAxis">drts:FutureSalesOfDevelopedProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">drts:IsraeliInnovationAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_RamotMember_drts_MethodOfPaymentRoyaltiesAxis_drts_NetSalesOfAllCompanySProductMember_xoU_wft5E0-hugLOshOmLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drts:MethodOfPaymentRoyaltiesAxis">drts:NetSalesOfAllCompanySProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">drts:RamotMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_HekaBioKKMember_drts_MethodOfPaymentRoyaltiesAxis_drts_ReimbursementPriceMember_cs_dWcRnWUyl8xd3aQkyBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drts:MethodOfPaymentRoyaltiesAxis">drts:ReimbursementPriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">drts:HekaBioKKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_HekaBioKKMember_drts_MethodOfPaymentRoyaltiesAxis_drts_DistributionReceiptsMember_B9pb87J-lk2fbjT-Lab7cw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drts:MethodOfPaymentRoyaltiesAxis">drts:DistributionReceiptsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">drts:HekaBioKKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_CambridgeUniversityHospitalsNhsTrustMember_drts_MethodOfPaymentRoyaltiesAxis_drts_RevenueGeneratedFromPatentMember_j1N6BX57fkmmH4t4HBjQrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drts:MethodOfPaymentRoyaltiesAxis">drts:RevenueGeneratedFromPatentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">drts:CambridgeUniversityHospitalsNhsTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_CambridgeUniversityHospitalsNhsTrustMember_drts_MethodOfPaymentRoyaltiesAxis_drts_NetSalesSquamousCellCarcinomaMember_oyhYZ1hIYEeJctRg2MllLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drts:MethodOfPaymentRoyaltiesAxis">drts:NetSalesSquamousCellCarcinomaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">drts:CambridgeUniversityHospitalsNhsTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_BgnTechnologiesMember_drts_MethodOfPaymentRoyaltiesAxis_drts_SalesOfProductContainingIntellectualPropertyMember_l6QmPIm-lka3XHyr-5FdgQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drts:MethodOfPaymentRoyaltiesAxis">drts:SalesOfProductContainingIntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">drts:BgnTechnologiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_BgnTechnologiesMember_drts_MethodOfPaymentRoyaltiesAxis_drts_SalesOfAlphaRadiationProductsMember_fGiGrutCqkW4dBwjPHMKtw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drts:MethodOfPaymentRoyaltiesAxis">drts:SalesOfAlphaRadiationProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">drts:BgnTechnologiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_BgnTechnologiesMember_drts_MethodOfPaymentRoyaltiesAxis_drts_LicenseRevenueToJointlyDevelopedIntellectualPropertyMember_E5RwUYMMMkKa7VOuc2eEbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drts:MethodOfPaymentRoyaltiesAxis">drts:LicenseRevenueToJointlyDevelopedIntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">drts:BgnTechnologiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_BgnTechnologiesMember_drts_MethodOfPaymentRoyaltiesAxis_drts_LicenseRevenueRelatedToIntellectualPropertyMember_MPPvAjzvLEWclU5g9v1-PA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drts:MethodOfPaymentRoyaltiesAxis">drts:LicenseRevenueRelatedToIntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">drts:BgnTechnologiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_AltheraMember_drts_MethodOfPaymentRoyaltiesAxis_drts_FutureGrossRevenuesDerivedFromPurchasedIntellectualPropertyMember_nP72Cyn7NkCYPc6GpcX5BA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drts:MethodOfPaymentRoyaltiesAxis">drts:FutureGrossRevenuesDerivedFromPurchasedIntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">drts:AltheraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_IsraeliInnovationAuthorityMember_drts_MethodOfPaymentRoyaltiesAxis_drts_FutureSalesOfDevelopedProductMember_JSAQ3iw-VUSQibua7dXDzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drts:MethodOfPaymentRoyaltiesAxis">drts:FutureSalesOfDevelopedProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">drts:IsraeliInnovationAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_drts_MethodOfPaymentRoyaltiesAxis_drts_NetSalesOfAllCompanySProductSoldByCompanySLicensesMember_gkrRFhGJnEimcQjvPTPPcQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="drts:MethodOfPaymentRoyaltiesAxis">drts:NetSalesOfAllCompanySProductSoldByCompanySLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_AltheraMember_GvfqErhqZEeZc_TxFNeN5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">drts:AltheraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_15_2021_To_7_15_2021_5Bu_BFUidUuMuhyoWEwmhg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
        </entity>
        <period>
            <startDate>2021-07-15</startDate>
            <endDate>2021-07-15</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2020_To_11_30_2020_AqgH_S771EKQA0UT8K6nCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_4_30_2020_MsmjV8uDakyuT86VtP1xdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_dei_LegalEntityAxis_drts_HekaBioKKMember_k78dGWWtOUezu7C6qI5GDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">drts:HekaBioKKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_drts_AtmIncMember_srt_StatementGeographicalAxis_country_US_at7B-1SAeEur5CA5l3wWEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">drts:AtmIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_drts_AtmKkMember_srt_StatementGeographicalAxis_country_JP_7CxdZ9e-1k-8KSkiHCA2Aw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">drts:AtmKkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2019_To_4_30_2019_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_drts_AtmKkMember_srt_StatementGeographicalAxis_country_JP_zK9sUscq3kOiuunJG2qXkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">drts:AtmKkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_IsraeliInnovationAuthorityMember_xhyc0CWH6kS_-vAND8TX1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">drts:IsraeliInnovationAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_drts_AtmKkMember_rsvutQDxxkWFvd6im8QGtQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">drts:AtmKkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_drts_AtmKkMember_25Jj3jm1eU-OcstYM8wmaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">drts:AtmKkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_1_31_2018_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_drts_AtmKkMember_JbImIrkcuUGQZ_vY9-jX-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">drts:AtmKkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="Duration_3_7_2022_To_3_7_2022_us-gaap_BusinessAcquisitionAxis_drts_HcccMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_pSFCWjg1hEmAKs-87AaDOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">drts:HcccMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-07</startDate>
            <endDate>2022-03-07</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zDmmSI986UmJIj-sGT2-Wg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_xeoIhA1uIke-CkfI6GwV9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IJsPnv36fkauy1pWGb0jpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_21_2022_Kx_JzkXasUWXdwjUN5eDyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
        </entity>
        <period>
            <instant>2022-03-21</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8z9inUQaDEqLpH7MXNDp2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_atci3uMJzkOMMdtkZKqeBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_fqhSQAsxpUWRPhj9cc-Pog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001871321</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_item_AGp3CTLP9EiC4gKcttUqYA">
        <measure>drts:item</measure>
    </unit>
    <unit id="Unit_Standard_Vote_yl2FdYUkMUizA1ZcpmmCgA">
        <measure>drts:Vote</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_segment_F1A8hT57kUWQPIMNg0d3ZQ">
        <measure>drts:segment</measure>
    </unit>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="INF"
      id="Hidden_5pqBXfvnT02_Y7HmmjGsmQ"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">40433578</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="INF"
      id="Hidden_n5Y_55bTOECPCpxKVAXYuA"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">40528913</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      id="Hidden_RVax8oe3G0GF7oatptiQ1w"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      id="Hidden_FZkUOFEMHEG5Lz3h0rPFGQ"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg"
      xsi:nil="true"/>
    <us-gaap:CommonStockValueOutstanding
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      id="Hidden_G6MlAfQenUC5KMBm8hIoeQ"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg"
      xsi:nil="true"/>
    <us-gaap:CommonStockValueOutstanding
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      id="Hidden_fD_C-mmYfEiNLNqRvC2r7A"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="2"
      id="Hidden_7qMY6mzvukmls5BKszmgrA"
      unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw">-0.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="2"
      id="Hidden_MNJz6Zx47Uu2O-_9bgST-w"
      unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw">-0.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="2"
      id="Hidden_DePBOIqiEU6BF4SfDX1SRw"
      unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw">-0.67</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="0"
      id="Hidden_m0PgDCiYQU2PjrsApvCBvw"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">33815448</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="0"
      id="Hidden_uci48Mn9D0itSoXcTjZpVg"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">40274935</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="0"
      id="Hidden_pfkY8QG510ql5k4pesQm0w"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">40534697</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_drts_SeriesConvertiblePreferredSharesMember_2rsemjdtU0aLnNvzSudxpQ"
      decimals="INF"
      id="Hidden_H4lBvGB-oU6yVIxNiespoQ"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">7229885</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_drts_SeriesConvertiblePreferredSharesMember_Ciu93EXH3Uu0zKZgtaOVHQ"
      decimals="INF"
      id="Hidden_3KtD8Q5Ax06fscVib8RhUQ"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">7229885</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_drts_SeriesBConvertiblePreferredSharesMember_aujqloiYdUqLgyG-IywV-g"
      decimals="INF"
      id="Hidden_MxvarQWPQ0O-mGg8xiB4BQ"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">6509301</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_drts_SeriesBConvertiblePreferredSharesMember__unz0Gwr4U6xfvew_rt8qg"
      decimals="INF"
      id="Hidden_yaEd_DzkAkqnvAweRetrqw"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">6509301</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="INF"
      id="Hidden_WxKj4-VumkiLILEX7hOihQ"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">13739186</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="0"
      id="Hidden_rUqKycjoM0Cr_UPRnYxNMg"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">33815448</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="0"
      id="Hidden_3p4tQ6odvkuoS9ntZhhmVg"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">40274935</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="0"
      id="Hidden_A7oAnHWdcEGrp4QFwGGNfw"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">40534697</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="2"
      id="Hidden_9qrtnq0_HkyyxzR1T4IENg"
      unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw">-0.25</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="2"
      id="Hidden_JuWMtT2ZnEKtE0_4yW3j7A"
      unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw">-0.22</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="2"
      id="Hidden_FwbXf4amSkamAW_TRYb8dw"
      unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw">-0.67</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:WarrantsAndRightsOutstandingValuationTechniqueExtensibleList
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      id="Hidden_L9Ato0C33E2LNSpyydoKvQ">http://fasb.org/us-gaap/2021-01-31#ValuationTechniqueOptionPricingModelMember</us-gaap:WarrantsAndRightsOutstandingValuationTechniqueExtensibleList>
    <drts:IncomeTaxRateReconciliationSmallCompaniesSpecialRatePercent
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_drts_AtmKkMember_srt_StatementGeographicalAxis_country_JP_7CxdZ9e-1k-8KSkiHCA2Aw"
      decimals="INF"
      id="Hidden_Z-DGe3jtHEK1rvKDxu5T2w"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.0015</drts:IncomeTaxRateReconciliationSmallCompaniesSpecialRatePercent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="INF"
      id="Hidden_FM5Dlv3n_Uq5VkWGqLzMYg"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">40433578</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="INF"
      id="Hidden_4TC6wvDOF0Gs_JaCVjlbqw"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">40528913</us-gaap:CommonStockSharesIssued>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tc_uWKdFz0WZ0ax-nn1pjBfyw_2_1">0001871321</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tc_0Z7YmwCM9kSjTWcvnt6GAg_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tc_NRSSu4fZ3kmmtpRtoHQuqA_4_1">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tc_HEg5GGjQuUyTT9dC5VfKCA_5_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tc_rpFEf0If8USZgy6XaJ1ewQ_6_1">false</dei:AmendmentFlag>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tc_eXwkR2xzXUuSkggz-w21Kg_8_1">Alpha Tau Medical Ltd.</dei:EntityRegistrantName>
    <dei:DocumentType
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Narr_zpJlG1ZVe0aBO7rEBaJxSA">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Narr_Nh_b-RjYNkSW3W_7hReedA">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Narr_CJrC0hNorEiXN7eAxt_XoA">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Narr_6QjYgtzZqkOhu28iPaJ1ug">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Narr_QBC9Ia6XZ0WM9xdO2Ni-Yg">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Narr_I6crHrcQuEye9m5XJZbTpA">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Narr__ICSkj1a90iAgefb6jZGFA">001-41316</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Narr_g1hqOn2rGkmuZh3jfUH3CA">Alpha Tau Medical&#160;Ltd.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Narr_JxCPaXZdLUSJErkswd1NBw">L3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Narr_jTkXV0I9ZUKK25cX0sOL6A">Kiryat HaMada St. 5</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Narr_XCnLp460kEWDHXkUPAc89w">Jerusalem</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Narr_aR2J93RjkECE6JcSsAqOpg">9777605</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Narr_dFEYQUBTnkKJDhYBB1W33w">IL</dei:EntityAddressCountry>
    <dei:ContactPersonnelName
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_fqhSQAsxpUWRPhj9cc-Pog"
      id="Narr_gVwL4Jts70CMZYDRXe-Kuw">Uzi Sofer</dei:ContactPersonnelName>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_fqhSQAsxpUWRPhj9cc-Pog"
      id="Narr_rScbBgphakOmMZDMpxRMSw">972</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_fqhSQAsxpUWRPhj9cc-Pog"
      id="Narr_YgcU3Kcn6E6B3zyG2_UxBA">(3)&#160;577-4115</dei:LocalPhoneNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_fqhSQAsxpUWRPhj9cc-Pog"
      id="Narr_lgsHKxJg3UaOuiY1x7KEJw">Kiryat HaMada St. 5</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_fqhSQAsxpUWRPhj9cc-Pog"
      id="Narr_30FpRhjBaEGUQq0WEYuLuQ">Jerusalem</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_fqhSQAsxpUWRPhj9cc-Pog"
      id="Narr_PsBxWE130ES9B512c9TXVw">9777605</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_fqhSQAsxpUWRPhj9cc-Pog"
      id="Narr_aXdKk36kpEy7MrRmB3HHCw">IL</dei:EntityAddressCountry>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IJsPnv36fkauy1pWGb0jpQ"
      id="Narr_i7WFL4aV9kalFg18EoBodA">Ordinary shares, no par value </dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IJsPnv36fkauy1pWGb0jpQ"
      id="Tc_T3q-rNv2lE2hWb5FYQznPg_2_2">DRTS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IJsPnv36fkauy1pWGb0jpQ"
      id="Narr_hvJS_LQKDUmLHhdLTKpnEA">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_xeoIhA1uIke-CkfI6GwV9A"
      id="Tc_Ju4F53eWD0iVU3ZVW_BiHQ_3_0">Warrants to purchase ordinary shares</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_xeoIhA1uIke-CkfI6GwV9A"
      id="Tc_tla6efP6nE6QGjN69RAcgA_3_2">DRTSW</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_xeoIhA1uIke-CkfI6GwV9A"
      id="Narr_TmW0q46Q3UiRXoJT0gHcNw">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_atci3uMJzkOMMdtkZKqeBw"
      decimals="INF"
      id="Narr_Enib91DN6Em7Vgng3YlE-Q"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">40528913</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8z9inUQaDEqLpH7MXNDp2Q"
      decimals="INF"
      id="Narr_IzPDFfenkUeYbeLl94ujWw"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">13739186</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_3_21_2022_Kx_JzkXasUWXdwjUN5eDyQ"
      decimals="INF"
      id="Narr_uepU1uSQ_EeC1lyUpdEgtA"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">66529265</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Narr_xaUWZNVCPkWcY2MwxiRzDQ">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Narr_49tyxbPUzESeUARqiEGx2A">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Narr_tA6c39l5SUKcAUx3hJrHVA">No</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Narr_FDB6S5NTZE6aNKJVKjekew">No</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Narr_6W5tMNG5AUSqRCzxKev70A">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Narr_ut1QwCLf-kyd9FPav3Vxaw">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Narr_OMP25ffIFE6yHtz-Pu4Q5g">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Narr_96th9629dUOyfsvxElYk_w">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentAccountingStandard
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Narr_LhUhped2eUWEsmfVigHr1A">U.S. GAAP</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Narr_8xTYhAt8WECuRFqs9NK9CA">false</dei:EntityShellCompany>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Narr_pmulj8W3_k6MzZgAt8z05Q">1281</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Narr_CAxMvmoA30i3li56ez09nQ">KOST FORER GABBAY&#160;&amp; KASIERER</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tc__JU6wYcJaEKwqBY_33hTKg_4_0">Tel-Aviv, Israel</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="-3"
      id="Tc_gQZjw0dxZ0uuZt2NCpew0A_6_5"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">15598000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc_5JrrrgdAVkSMzUEgrIhjog_6_8"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">23236000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="-3"
      id="Tc_-R6Jt0ngRk6Tk57L9ejqZw_7_5"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">576000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc_yGZ81pROfU6sguFz0DUZJw_7_8"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">618000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedInvestmentsCurrent
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="-3"
      id="Tc_5RcL1GiaJE2nOurvQAWg5A_8_5"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">30417000</us-gaap:RestrictedInvestmentsCurrent>
    <us-gaap:RestrictedInvestmentsCurrent
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc_T3ST138dUkeren0cHV4T0A_8_8"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">8080000</us-gaap:RestrictedInvestmentsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="-3"
      id="Tc_Mj_0pyaBAkC7pdA4PPKGTg_9_5"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">864000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc_R0190MJSpk-PJGOzM2svpg_9_8"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">707000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="-3"
      id="Tc_5x-xrxgPXEmZLf5kA6jWbQ_11_5"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">47455000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc_Hn1wy7J6kkWt-Zvu4kNkwQ_11_8"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">32641000</us-gaap:AssetsCurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="-3"
      id="Tc_knGeAXaOtUiTJlCq4kCKOw_14_5"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">139000</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc_KTLbOC0LxEupc4K8sZkDtw_14_8"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">2028000</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="-3"
      id="Tc_dowEYBUw4EyP0V-TumCY8w_15_5"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">5395000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc_l3Vtu5gFB0qroPa0UWHw5A_15_8"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">7546000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AssetsNoncurrent
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="-3"
      id="Tc_afvEDEGgh0aZOWlXUcmSzg_17_5"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">5534000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc_WSdcYYqUVUCW_smjL5ypOg_17_8"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">9574000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="-3"
      id="Tc_PccGda70d0W0dtJIrfOSQg_19_5"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">52989000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc_NMIq64kpXEOvMch7H7eEcg_19_8"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">42215000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="-3"
      id="Tc_WfsExRii4UO-5fcM6L6N5Q_6_5"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">964000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc_uj9HesGyhUuxFhu65fsJzw_6_8"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">1203000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="-3"
      id="Tc_PRlmHprLlE6VyLx2oqYckQ_7_5"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">1124000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc_kHJlFr6ZuUOz3kEti9Tuzg_7_8"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">3202000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="-3"
      id="Tc_ywJizeNb0U-i_kAA4R5ZZg_9_5"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">2088000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc_WUnSMBQU_EaUxL3ujivOyQ_9_8"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">4405000</us-gaap:LiabilitiesCurrent>
    <drts:Warrantliability
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="-3"
      id="Tc_HK11ZElTV0SekkZJwdCtCg_12_5"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">5366000</drts:Warrantliability>
    <drts:Warrantliability
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc_XFhR_5XJ3UiazYt4ZsHdUA_12_8"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">18623000</drts:Warrantliability>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="-3"
      id="Tc_LqIGRbNkwEqtMy7XoV5m7g_14_5"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">7454000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc_pEc1RikvVk-pFEEERxKGlQ_14_8"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">23028000</us-gaap:Liabilities>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="INF"
      id="Narr_enq6-sH080WLkDUjoz87iA"
      unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw">0</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="INF"
      id="Narr_CIwFY4V8F0maEioOxd-0eA"
      unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw">0</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="INF"
      id="Narr_xhMOyMBhy0mDzcUr8bOn7g"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">25348176</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="INF"
      id="Narr_4NNlRPZH8EizBWb6ap4mqQ"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">25348176</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="INF"
      id="Narr_aIgjH2LQUk-Ex3rhfQ1N_w"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">13739186</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="INF"
      id="Narr_BrYEmWaffEOK0FhOlfpHxQ"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">13739186</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="-3"
      id="Tc_rVR-ysL_j0WZafYvxyYOJw_18_5"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">53964000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc_Zy7HkBmCZU29s2bBPs0NuA_18_8"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">53964000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="INF"
      id="Narr_Nob06mhTXUGE7tVb1HQ4OQ"
      unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw">0</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="INF"
      id="Narr_Q0IlGIwcHEex_9B4XTKiAA"
      unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw">0</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="INF"
      id="Narr_DAtP0J6IBUy36M_KvKKBnw"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">72423360</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="INF"
      id="Narr_Aebv0_3UMUykFpbQG4r9Mg"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">72423360</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="INF"
      id="Narr_xChUhHR8C0SytmWJPcNnSA"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">40433578</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="INF"
      id="Narr_20u3YKi7jkekiITBdrRxbQ"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">40528913</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="-3"
      id="Tc_xJYc4aPF40-MrdZEKMZgjQ_22_5"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">17140000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc_x_S53JucXEGWKOfL7QDaNw_22_8"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">18063000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="-3"
      id="Tc_JHdyj_-BwEOTe9tA3-pYUg_23_5"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-25569000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc_xUdjV9eF10-aVv1LLnRwVw_23_8"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-52840000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="-3"
      id="Tc_JRAYKoKlEkuEOtDS03KdMw_25_5"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-8429000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc_oU4m9JnwpUCEZbKg3K53jQ_25_8"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-34777000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="-3"
      id="Tc_uCsnxKV_A0-oRzXKxiFnTw_27_5"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">52989000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc_rfzthGoaaECcMEXUBYuWOA_27_8"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">42215000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_3_7_2022_To_3_7_2022_zxGQCP-7Fk277229BSbBmw"
      decimals="INF"
      id="Narr_PF6LO7Z_pkWCYhrPAyClcQ"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.905292</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc_RF5G6OXG40aYfNZDVa6kpA_4_5"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">6636000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Tc_DA5ZE1AfDkyHwbpTNNiQ7A_4_8"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">7544000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Tc_Iz8LbHALzkik2zG1eUkoMw_4_11"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">11447000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:MarketingExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc_oNBllAbV9kmqqB2mZF9d_A_6_5"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">397000</us-gaap:MarketingExpense>
    <us-gaap:MarketingExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Tc_Kx7_ZWtHrke6K6Vc_rlObQ_6_8"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">288000</us-gaap:MarketingExpense>
    <us-gaap:MarketingExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Tc_5sXHPIW0HUWEhlNNJoBzCw_6_11"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">482000</us-gaap:MarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc_ZyT76Y4DqUqXRtd3whrpKQ_8_5"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">977000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Tc_eDvtcyf_BkK-MRFl2-Lmfg_8_8"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">1412000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Tc_LPfg7Bwj80ugh2FZaVyFbA_8_11"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">1861000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc_klcSi4s1NUWn52ulE8STFQ_10_5"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">8010000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Tc_MSnA3TPAH0OGU5C1g9mebg_10_8"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">9244000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Tc_Z65DdLC-hUSaNGpwDXiGTg_10_11"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">13790000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingGainsLosses
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc_uFMx797t_0uc3Izs_UncZg_12_5"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">308000</us-gaap:NonoperatingGainsLosses>
    <us-gaap:NonoperatingGainsLosses
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Tc_cazKacp_QEGcUBkJOdBKpg_12_8"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-520000</us-gaap:NonoperatingGainsLosses>
    <us-gaap:NonoperatingGainsLosses
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Tc_CCqxNzyk6EmGCfYdtThBCA_12_11"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">13474000</us-gaap:NonoperatingGainsLosses>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc_ZaKNdHkgKEGL2w8FmxcfuA_14_5"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">8318000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Tc_URVAllYEM0GXxcJg1Nn4SQ_14_8"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">8724000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Tc_CYnohwC1SEO9WSo5eyIkDA_14_11"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">27264000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc_KYHlN55T10Kk_dEcdVB6LQ_16_5"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-146000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Tc_aJy43ATrXUe1Rad7RsqnGA_16_8"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-158000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Tc_J0n159Ei_0S7cvW56mGoag_16_11"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-7000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc_K42sKET04k6I_Hm9OAsGwQ_18_5"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-8464000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Tc_2TsEVpsr8kKn6zVqzbki-A_18_8"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-8882000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Tc_C7CWLNyW4UyoQ0EpjFFZ6w_18_11"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-27271000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc__PcInAM6Sk6t49uyU_9n8A_20_5"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-97000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc_xrb3rNpHzUiiyZeRIvOYdQ_22_5"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-8367000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Tc_UA726Ubn3Umfr8Ja6e-ASw_22_8"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-8882000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Tc_MV9aSFdvQEKrCuBGTZsRig_22_11"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-27271000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="2"
      id="Tc_p7kyJw94cEWVBTjg-IZiLg_24_5"
      unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw">-0.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="2"
      id="Tc_3qbWUsuMRUOthLWbkBcpjg_24_8"
      unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw">-0.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="2"
      id="Tc_6ghBKrnvMEi0P-AORPDxOg_24_11"
      unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw">-0.67</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="0"
      id="Tc_IYJZigyOHkyJZpyoc1xRsw_26_5"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">33815448</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="0"
      id="Tc_XWLpghrsXUO5fpZiFUwglg_26_8"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">40274935</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="0"
      id="Tc__vRHrcT0Q0SDmSrSq27f1A_26_11"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">40534697</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_3_7_2022_To_3_7_2022_zxGQCP-7Fk277229BSbBmw"
      decimals="INF"
      id="Narr_kX1p4qCW3UmRxPXf4o0zBA"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.905292</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_aj4GYFUqrka7uJcyVmTHIQ"
      decimals="INF"
      id="Tc_0CdjEUrQ60qc-aWGXE0svw_4_2"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">7229885</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_aj4GYFUqrka7uJcyVmTHIQ"
      decimals="-3"
      id="Tc_0n0znmQK4kiznLwqpz-FmA_4_5"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">25238000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4I62Q1RYY0G4dDLq0oH8kA"
      decimals="INF"
      id="Tc_P686uzzh_0240QcKLJnzuw_4_7"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">33185538</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4ygP12wMPUWWbr6h1XztVw"
      decimals="-3"
      id="Tc_lyh0_IXKxUC_nS-q0yyDCw_4_13"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">9330000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_hVc9GNOKXk-_jqzkPdtv8Q"
      decimals="-3"
      id="Tc_T3zJEjDNFkGTCGwsdZE6uA_4_16"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-8320000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_6ynx3rWt90GJLYzfoH7j8Q"
      decimals="-3"
      id="Tc_1OwVenEu-0eEAuydtTNhTw_4_19"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">851000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_XIXddAY3L0yRBxsPKwvT6g"
      decimals="-3"
      id="Tc_8U1wMLEo2UyQSZe3sFuTQQ_4_22"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">1861000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OA7LnjwMsEWxaEV_8urPuA"
      decimals="-3"
      id="Tc_HLrYnSWMTUebuGylxQr1GQ_6_13"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">546000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc_RDFpsZIcN0Whay5dSHdfBw_6_22"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">546000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <drts:AdjustmentsToAdditionalPaidInCapitalWarrantSharesIssued
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zDmmSI986UmJIj-sGT2-Wg"
      decimals="INF"
      id="Tc_6ayeoxB6Tk2byLwQI5jrCA_7_7"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">1302132</drts:AdjustmentsToAdditionalPaidInCapitalWarrantSharesIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OA7LnjwMsEWxaEV_8urPuA"
      decimals="-3"
      id="Tc_zfv5uC0Xb0Omrqonhw5Svg_7_13"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">5250000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc_bEyvMPzQxUWOfmgBVhT40w_7_22"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">5250000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <drts:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zDmmSI986UmJIj-sGT2-Wg"
      decimals="INF"
      id="Tc_N4dcXpQi2EWIR8_33Hbcqg_8_7"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">5316493</drts:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <drts:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OA7LnjwMsEWxaEV_8urPuA"
      decimals="-3"
      id="Tc_9rmSyec0Jk2svKg-cvJglA_8_13"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">1560000</drts:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <drts:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc_UYhuJLC31EuCWlO-rjPvyQ_8_22"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">1560000</drts:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_RAo1T_5iU0emGFXFccTaVQ"
      decimals="-3"
      id="Tc_XIMNv7HkHUON4puP8yly3g_9_16"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-8367000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_LPp8QInDWUu1wZCHIvnfQw"
      decimals="-3"
      id="Tc_BACguXWQ3km7rKVNkBYAaw_9_19"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-97000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc_Po7KSpw1O0uMwNw6XOxkvA_9_22"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-8464000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProceedsFromPaymentsToMinorityShareholders
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OA7LnjwMsEWxaEV_8urPuA"
      decimals="-3"
      id="Tc_X6cTyF74QEyoYZLQew4iyw_10_13"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-192000</us-gaap:ProceedsFromPaymentsToMinorityShareholders>
    <us-gaap:ProceedsFromPaymentsToMinorityShareholders
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_LPp8QInDWUu1wZCHIvnfQw"
      decimals="-3"
      id="Tc_B1jkZZ9YQkK2VBEVvdqLkw_10_19"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-754000</us-gaap:ProceedsFromPaymentsToMinorityShareholders>
    <us-gaap:ProceedsFromPaymentsToMinorityShareholders
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc_VF9sGYTew0yCLtCLPKP2UA_10_22"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-946000</us-gaap:ProceedsFromPaymentsToMinorityShareholders>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_i1mWmb_nSEecsnGxFg7m_g"
      decimals="INF"
      id="Tc_u_LKhmMgwEaHCoxpK9whWw_12_2"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">7229885</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_i1mWmb_nSEecsnGxFg7m_g"
      decimals="-3"
      id="Tc_7ASbk5JcKEOtWKvUjhU-XQ_12_5"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">25238000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GocQ7aqoEkCbUnmv9spesw"
      decimals="INF"
      id="Tc_jCQr6Q1pxUqmv6xXVY9RKw_12_7"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">39804163</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VMREA2dVCUqalyS79-xuRg"
      decimals="-3"
      id="Tc_KJyJAPCCxUepTgIJXxk0WA_12_13"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">16494000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Az5at6t9sUi2LDLd7cWsbg"
      decimals="-3"
      id="Tc_r7OqZTkDyUiuLQbJGIbpmA_12_16"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-16687000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_9X1M-BXfgEWsSJdmFxdJhA"
      decimals="-3"
      id="Tc_56XM67-Ms0yj_sPp4AVY9w_12_22"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-193000</us-gaap:StockholdersEquity>
    <drts:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_u2IRTL2hREuTiBdvWBPJIA"
      decimals="INF"
      id="Tc_q1cgtjuXVEGG9Yq3b3T2lQ_14_7"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">624445</drts:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <drts:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iKd2bcgAO0yb8cTymXlliw"
      decimals="-3"
      id="Tc_KaqDe1STCUqERLc8tUor8Q_14_13"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">30000</drts:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <drts:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Tc_-cjFs9p_y0qxcgojcOH3cg_14_22"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">30000</drts:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <drts:StockIssuedDuringPeriodSharesOrdinarySharesUponExerciseOfShareOptions
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_u2IRTL2hREuTiBdvWBPJIA"
      decimals="INF"
      id="Tc_lw-A74uNxkeBg8FkIefx-w_15_7"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">4970</drts:StockIssuedDuringPeriodSharesOrdinarySharesUponExerciseOfShareOptions>
    <drts:StockIssuedDuringPeriodValueOrdinarySharesUponExerciseOfShareOptions
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iKd2bcgAO0yb8cTymXlliw"
      decimals="-3"
      id="Tc_1Xf3YopFlEKWxgjqU_1b8Q_15_13"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">20000</drts:StockIssuedDuringPeriodValueOrdinarySharesUponExerciseOfShareOptions>
    <drts:StockIssuedDuringPeriodValueOrdinarySharesUponExerciseOfShareOptions
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Tc_0PFDai-W9kye6VhE1Sm9Eg_15_22"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">20000</drts:StockIssuedDuringPeriodValueOrdinarySharesUponExerciseOfShareOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iKd2bcgAO0yb8cTymXlliw"
      decimals="-3"
      id="Tc_Ee4be-8NDUeXyW9iAnMvow_16_13"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">596000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Tc_0Yz9nD3F3Eu7t_m-tLKtBQ_16_22"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">596000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <drts:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_rhxpidqOe0uEnhSdwKCtbg"
      decimals="INF"
      id="Tc_2e32zEawfkeQRIldT_VSig_17_2"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">6509301</drts:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_rhxpidqOe0uEnhSdwKCtbg"
      decimals="-3"
      id="Tc_Rku296PeK0i4awh1scxZVA_17_5"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">28726000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_EKhArHp_YEqXT7Vh3-UQ7g"
      decimals="-3"
      id="Tc_Z-rzjQGOFUGvUZ7jp59gyg_18_16"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-8882000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Tc_g52TISVmvEKFneKfeUaokw_18_22"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-8882000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_bNVdyxnBY0S_wDAMjuaFkg"
      decimals="INF"
      id="Tc_y4vKTxUAcEqA0oTt8NslHA_20_2"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">13739186</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_bNVdyxnBY0S_wDAMjuaFkg"
      decimals="-3"
      id="Tc_0eVudmzgAk2o9n9P9JaYrQ_20_5"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">53964000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QBEQ8mAQX0SOz4gXrPGKLQ"
      decimals="INF"
      id="Tc_kglc91OPek-hdjs6FhlB7A_20_7"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">40433578</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ykMIzfofVUuPDoPU0k2Pgg"
      decimals="-3"
      id="Tc_ZKdYgNzJjUCbyRtM_ftH6w_20_13"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">17140000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_bsiFZBQITkihmHXGW4LWHw"
      decimals="-3"
      id="Tc_uAsIpfpH1EuGwJuct4F3Xw_20_16"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-25569000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="-3"
      id="Tc_76XUmnnJH0WBOHwIejBh7Q_20_22"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-8429000</us-gaap:StockholdersEquity>
    <drts:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xyh47eHvfkKb6vxdvq7wAw"
      decimals="INF"
      id="Tc_nL9XyQV4CkG4-B7KmDLi8A_22_7"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">9053</drts:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <drts:StockIssuedDuringPeriodSharesOrdinarySharesUponExerciseOfShareOptions
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xyh47eHvfkKb6vxdvq7wAw"
      decimals="INF"
      id="Tc_wzpMCVn4Dk-3K4XSHfKwuw_23_7"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">86282</drts:StockIssuedDuringPeriodSharesOrdinarySharesUponExerciseOfShareOptions>
    <drts:StockIssuedDuringPeriodValueOrdinarySharesUponExerciseOfShareOptions
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_STmFVK2iUkKhWvfG-Crldw"
      decimals="-3"
      id="Tc_Uopa-ljNLEucGVKiVdAnQQ_23_13"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">111000</drts:StockIssuedDuringPeriodValueOrdinarySharesUponExerciseOfShareOptions>
    <drts:StockIssuedDuringPeriodValueOrdinarySharesUponExerciseOfShareOptions
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Tc_wc3v0gWttEKQrnR1r1pm9g_23_22"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">111000</drts:StockIssuedDuringPeriodValueOrdinarySharesUponExerciseOfShareOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_STmFVK2iUkKhWvfG-Crldw"
      decimals="-3"
      id="Tc_CKDlYRWLtUa99HS6TucCag_24_13"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">812000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Tc_2NhmfzWUYUGWNeva5tORGg_24_22"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">812000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_IbEezU48YkqEkwVicJ4VDg"
      decimals="-3"
      id="Tc_GUCgKC778kGFzhox86mpfw_25_16"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-27271000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Tc_YEdIdRItVUGVDXJXE_GnCQ_25_22"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-27271000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_2jPIe9FCpk-lk0x3ei7plQ"
      decimals="INF"
      id="Tc_i3xv8QEPgUKYHXUfXzMJLw_27_2"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">13739186</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_2jPIe9FCpk-lk0x3ei7plQ"
      decimals="-3"
      id="Tc_ED3uytwyLEemO4jP3bMLrw_27_5"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">53964000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ODoUIImeZUSC5k7f53zukQ"
      decimals="INF"
      id="Tc_wBe7AwRzvUaMt38Ii5x4Og_27_7"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">40528913</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_MouG0PPKQkmZNUQVCP7aqg"
      decimals="-3"
      id="Tc_CXgll3kXZkGRtrU7Mm5iuw_27_13"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">18063000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HEnHaE37ekigHo4AetBJFg"
      decimals="-3"
      id="Tc_DPen8g3MI0qtSL9TNu5vTQ_27_16"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-52840000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc_pbHeOPec5kCo7burVpgWUw_27_22"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-34777000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_3_7_2022_To_3_7_2022_zxGQCP-7Fk277229BSbBmw"
      decimals="INF"
      id="Narr_9kKryNpo8kWGGsrzUAJiGA"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.905292</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Narr_cQ2WWPXAXE2VTqtKN9rJkQ"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">35000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc_7fRSOt8Bs0mL4WwMCiBf7A_4_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">8464000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Tc_ZridnnB7IESlv8fawEkW9A_4_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">8882000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Tc_kaisS3YwC0KzFfE6-Ex2vQ_4_9"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">27271000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc_PRLmokmeBkywWGZNEoueHQ_7_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">66000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Tc_giC1P3_kjkmnq3jaxUu3rQ_7_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">86000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Tc_s4XWLE_b0USkMbfvM-3CRw_7_9"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">776000</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc_TNqtztJoqkWkRTe-jPPJ4g_8_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">546000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Tc_nRyCMYbqI0-gz6k51TtTcw_8_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">596000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Tc_EBWtlHEA-E2kTUGRRm-Y7A_8_9"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">812000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc_DNAEAoKAAE-QK-Db7e-ZRw_9_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">509000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Tc_GPqwnMdNHUaPBdbRjCj-Jw_9_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-283000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Tc_6i6yQvXZSkeZqvAjBs37Kw_9_9"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-157000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc_rdN0JDCSMkKaqEW8nIMkWw_10_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">16000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Tc_q9gh7BGJMUyfQ13ZSaTbrA_10_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">123000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Tc__8jQM7SbP0mfOdE03Ht9bw_10_9"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">1889000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <drts:IncreaseDecreaseInFairValueOfWarrantsConvertiblePreferredShares
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc_ZREPghhen0y_Cvc0HaHqWA_11_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">994000</drts:IncreaseDecreaseInFairValueOfWarrantsConvertiblePreferredShares>
    <drts:IncreaseDecreaseInFairValueOfWarrantsConvertiblePreferredShares
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Tc_hgxvQVTPlkmig_NRJ33xOw_11_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">203000</drts:IncreaseDecreaseInFairValueOfWarrantsConvertiblePreferredShares>
    <drts:IncreaseDecreaseInFairValueOfWarrantsConvertiblePreferredShares
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Tc_gkfJeRkAEk2lm7wB-w-Tbg_11_9"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">13257000</drts:IncreaseDecreaseInFairValueOfWarrantsConvertiblePreferredShares>
    <drts:IncreaseDecreaseInNonCashFinancialIncomeExpenses
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc_phr66QqvyEyIqFl_ovU0dw_12_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-12000</drts:IncreaseDecreaseInNonCashFinancialIncomeExpenses>
    <drts:IncreaseDecreaseInNonCashFinancialIncomeExpenses
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Tc_hf0mbRdj20mODCER-27IVg_12_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">153000</drts:IncreaseDecreaseInNonCashFinancialIncomeExpenses>
    <drts:IncreaseDecreaseInNonCashFinancialIncomeExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Tc_CNgTXQORlkmVWpPPHZuCMQ_12_9"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-29000</drts:IncreaseDecreaseInNonCashFinancialIncomeExpenses>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc_PeZ0HkP2UEyh8UEeqdXQVQ_13_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">148000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Tc_h94-g7naBkipUgBuyLhFWA_13_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">114000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Tc_bSd7awKAlUS6NOVwvNR-lQ_13_9"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">239000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc_R9yZGFzLvkeTDQ9X6ddC5Q_14_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">313000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Tc_5adSUDCDsE67h8bq25W3_Q_14_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">625000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Tc_PPTc8tf1PUSpBUobgJntmQ_14_9"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">2078000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc_wMXhguSTB0qS5y_Q8zOLpA_16_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-6910000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Tc_k2iHpiNliUeSyEUtLn7xng_16_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-7251000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Tc_ovNsaNt5ckqqp7_g7PciFw_16_9"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-11812000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:IncreaseDecreaseOfRestrictedInvestments
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc_C1plAPderEmm1Po5Wau9PA_19_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">54270000</us-gaap:IncreaseDecreaseOfRestrictedInvestments>
    <us-gaap:IncreaseDecreaseOfRestrictedInvestments
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Tc_PdyFdzbjwE-wtuy6BvjRVQ_19_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">70200000</us-gaap:IncreaseDecreaseOfRestrictedInvestments>
    <us-gaap:IncreaseDecreaseOfRestrictedInvestments
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Tc_PWAsWa-ocE6pX20fff7ctg_19_9"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">8082000</us-gaap:IncreaseDecreaseOfRestrictedInvestments>
    <us-gaap:ProceedsFromSaleOfRestrictedInvestments
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc_8eOuVYshcUWzo5BnJFnTUg_20_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">45400000</us-gaap:ProceedsFromSaleOfRestrictedInvestments>
    <us-gaap:ProceedsFromSaleOfRestrictedInvestments
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Tc_NPP1OpBmtUm9fRcxQ5eiug_20_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">66150000</us-gaap:ProceedsFromSaleOfRestrictedInvestments>
    <us-gaap:ProceedsFromSaleOfRestrictedInvestments
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Tc_Fd9bDjwds0GQLfzVP8SZrA_20_9"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">30282000</us-gaap:ProceedsFromSaleOfRestrictedInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc_rIZJaFsKNUG96kzLe3agGA_21_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">1293000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Tc_a7FifNB0dESKhvuBup83JA_21_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">3767000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Tc_Mo1shavlbkSS-cuVnaDFjg_21_9"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">2927000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc_b4ituS2vk02jLT7X83FXUw_23_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-10163000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Tc_Hw9bCSy1_E-fGgyLLgsyIQ_23_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-7817000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Tc_PNtoe-phikel1QWCLbbbKg_23_9"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">19273000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc_SQhTU8ZbLUm3AqNwDfQwHw_26_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">5250000</us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Tc_2b-i139OcU6LDrughcXyjA_27_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">28726000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc_PrTxfwLclEGLaCbBKLKmcg_28_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">1019000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Tc_QNkeB4uX8Ue2v78sKB3Trg_28_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">571000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Tc_ukvq07Fk80CQOK6H-wNT_A_29_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">20000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Tc_0ovylxA-t0i9uxaEuMurlA_29_9"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">111000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromPaymentsToMinorityShareholders
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc_KEg8zmxGTkGQm9V0tcRPFQ_30_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-946000</us-gaap:ProceedsFromPaymentsToMinorityShareholders>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc_jEbgfhepaUGYQFw1A6CBsw_32_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">5323000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Tc_139r1et5V0qO-QJVWMuQsg_32_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">29317000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Tc_WTx2FkXKv0qWO2k-VQxrpA_32_9"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">111000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc_LZYSwuiBck2CEMO0dJbKdg_34_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-18000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Tc_RM78oJ72G0Gf7SIVPX_y9A_34_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">84000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Tc_NlTkUIq60kmpgxnZvuZRdA_34_9"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">108000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc_h32YjfuCGUebwknwjL0kNQ_36_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-11768000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Tc_fMFfYRM_TU20DaAVswX0WQ_36_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">14333000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Tc_g44W-u2sREi08SwOPjtamw_36_9"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">7680000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2018_XIXddAY3L0yRBxsPKwvT6g"
      decimals="-3"
      id="Tc_ftOhcksQ4EiYnfwgluHehw_37_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">13609000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2019_9X1M-BXfgEWsSJdmFxdJhA"
      decimals="-3"
      id="Tc_teOLd2WFQ0SR1_Xw8HZ9LQ_37_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">1841000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="-3"
      id="Tc_05g_ALlGxUyGHL3HDZqRYA_37_9"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">16174000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2019_9X1M-BXfgEWsSJdmFxdJhA"
      decimals="-3"
      id="Tc_xKcglKBYZkulxhHobj1yLQ_39_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">1841000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="-3"
      id="Tc_eNutqQg4gUyaOU1hn5caiA_39_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">16174000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc_Rg9-mgbPYUKxmfY7MXFOtQ_39_9"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">23854000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc_ypVZ9n8u5UqDx7xr6AW-BQ_42_3"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">541000</us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1>
    <us-gaap:IncomeTaxesPaid
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Tc_styyz4QYuUmKOTRQlx_MOQ_45_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">218000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Tc_O273s4jbQU6hHyXD4uSG3w_45_9"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">103000</us-gaap:IncomeTaxesPaid>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc_kO-7yCedfEKgLpANNOZsOw_46_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">780000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Tc_j2gCwgtXvEWoMhGL7kSTUQ_46_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">541000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Tc_5KNi06n9sEuHBHe-Yaw3Pw_46_9"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">351000</us-gaap:InterestPaidNet>
    <us-gaap:NatureOfOperations
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_SOnb38JKQkqblrjO5Qs8HQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:54pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;NOTE&#160;1:-&lt;/b&gt;&lt;/span&gt;GENERAL&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;a.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Company description:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Alpha Tau Medical&#160;Ltd. (&#x201c;the Company&#x201d;) is an Israeli clinical-stage oncology therapeutics company that focuses on research, development and commercialization of Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) for the treatment of solid cancer. The Company was established in November&#160;2015 and began its operations in January&#160;2016, and shortly thereafter acquired the full rights to the Alpha DaRT technology from Althera Medical&#160;Ltd., (&#x201c;Althera&#x201d;), developed in 2003 at Tel Aviv University.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;In August&#160;2017 the Company established a fully owned subsidiary in the United States&#160;- &#x201c;Alpha Tau Medical&#160;Inc.&#x201d; (hereafter: ATM Inc). ATM Inc began its activity in August&#160;2018.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;In January&#160;2018 the Company established a subsidiary in Japan &#x201c;Alpha Tau Medical KK&#x201d; (hereafter: ATM KK). ATM KK began its activity in January&#160;2018, initially as a JV that was jointly owned by the Company (holding more than 90% of ATM KK) and HekaBio K.K. In July&#160;2019, the Company acquired full ownership of ATM KK by virtue of a transaction in which the Company invested additional funds into ATM KK, and ATM KK repurchased its own shares that were held by HekaBio K.K. As of December&#160;31, 2021 and 2020, the Company holds 100%of ATM KK. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;In July&#160;2019, the Company established a fully owned subsidiary in Canada &#x201c;Alpha Tau Medical Canada&#160;Inc.&#x201d; (hereafter: ATM Canada Inc). ATM Canada Inc began its activity in March&#160;2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;On July&#160;7, 2021, the Company entered into an Agreement and Plan of Merger (the &#x201c;Merger Agreement&#x201d;) with Healthcare Capital Corp., a Delaware corporation (&#x201c;HCCC&#x201d;), and Archery Merger Sub&#160;Inc., a Delaware corporation and wholly-owned subsidiary of the Company (&#x201c;Merger Sub&#x201d;). As part of the completion of business combination on March&#160;7, 2022 (the &#x201c;closing date&#x201d;), the Merger Sub was merged with and into HCCC (the &#x201c;Merger&#x201d;), with HCCC survived the merger as a wholly owned subsidiary of the Company (for further information see note 14b).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The novel coronavirus&#160;(&#x201c;COVID-19&#x201d;)&#160;pandemic has created and may continue to create significant uncertainty in macroeconomic conditions, and the extent of its impact on the Company&#x2019;s operational and financial performance will depend on certain developments. The Company considered the impact of&#160;COVID-19&#160;on the estimates and assumptions and determined that there were no material adverse impacts on the consolidated financial statements for the period ended December&#160;31, 2021. As events continue to evolve and additional information becomes available, the Company&#x2019;s estimates and assumptions may change materially in future periods.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:54pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;NOTE&#160;1:-&lt;/b&gt;&lt;/span&gt;GENERAL (Cont.)&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;b.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The Company&#x2019;s activities since inception have consisted of performing research and development activities. Successful completion of the Company&#x2019;s development programs and, ultimately, the attainment of profitable operations are dependent on future events, including, among other things, its ability to secure financing; obtain further marketing approvals from regulatory authorities; access potential markets; and build a sustainable customer base; attract, retain and motivate qualified personnel; and develop strategic alliances. The Company&#x2019;s operations are funded by its shareholders and research and development grants and the Company intends to seek further private or public financing as well as make applications for further research and development grants for continuing its operations. Although management believes that the Company will be able to successfully fund its operations, there can be no assurance that the Company will be able to do so or that the Company will ever operate profitably.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The Company expects to continue to incur substantial losses over the next several&#160;years during its clinical development phase. To fully execute its business plan, the Company will need to complete registrational clinical studies and certain development activities as well as manufacture the required clinical and commercial products in its manufacturing plants. Further, the Company will seek further regulatory approvals prior to commercialization and the Company will need to establish sales, marketing and logistic infrastructures. These activities may span many&#160;years and require substantial expenditures to complete and may ultimately be unsuccessful. Any delays in completing these activities could adversely impact the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"&gt;As of December&#160;31, 2021, the Company had cash, cash equivalents, short-term deposits and restricted cash of $31,934. During the&#160;year ended December&#160;31, 2021, the Company incurred a net loss of $27,271 and had negative cash flows from operating activities of $11,812. In addition, the Company had an accumulated deficit of $52,840 on December&#160;31, 2021. The Company believes that its existing capital resources will be adequate to satisfy its expected liquidity requirements for at least two&#160;years (for further information see note 13b).&lt;/p&gt;</us-gaap:NatureOfOperations>
    <drts:DisposalGroupIncludingDiscontinuedOperationOwnershipDisposed
      contextRef="Duration_1_1_2018_To_1_31_2018_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_drts_AtmKkMember_JbImIrkcuUGQZ_vY9-jX-g"
      decimals="2"
      id="Narr_y86pt6bBaUCCnvgpBnfHhA"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.90</drts:DisposalGroupIncludingDiscontinuedOperationOwnershipDisposed>
    <drts:DisposalGroupIncludingDiscontinuedOperationOwnershipDisposed
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_drts_AtmKkMember_25Jj3jm1eU-OcstYM8wmaw"
      decimals="2"
      id="Narr_EJun68ZrJESEVRWDCW9ZRg"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">1</drts:DisposalGroupIncludingDiscontinuedOperationOwnershipDisposed>
    <drts:DisposalGroupIncludingDiscontinuedOperationOwnershipDisposed
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_drts_AtmKkMember_rsvutQDxxkWFvd6im8QGtQ"
      decimals="2"
      id="Narr_6d8TGPNnZEKHHVeGvPiXlg"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">1</drts:DisposalGroupIncludingDiscontinuedOperationOwnershipDisposed>
    <drts:CashCashEquivalentsShortTermDepositsAndRestrictedCash
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Narr_UU3Rycg8OEeqC8q7jDVbJQ"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">31934000</drts:CashCashEquivalentsShortTermDepositsAndRestrictedCash>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Narr_IDSpsarAMUqypnld_SZaZA"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-27271000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Narr_qgBv4vKPNUCW04gQViflXA"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-11812000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Narr_zUNXQ7wAc02OlZtWKkJ_Cw"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-52840000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <drts:CurrentResourcesCoverageOfLiquidityRequirements
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Narr_E62Oh_NQUUWMYIW5MtcxlA">P2Y</drts:CurrentResourcesCoverageOfLiquidityRequirements>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_s8O6byrZ2E6Dt-PJymgCnQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:54pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;NOTE&#160;2:-&lt;/b&gt;&lt;/span&gt;SIGNIFICANT ACCOUNTING POLICIES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The consolidated financial statements are prepared according to United States generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;). The significant accounting policies are applied in the preparation of the financial statements on a consistent basis, as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"&gt;a.&#160;&#160;&#160;&#160;&#160;Use of estimates for the preparation of financial statements:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The preparation of the consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, the Company&#x2019;s management evaluates estimates, including those related to fair values of convertible preferred shares warrants, fair values of share-based awards, deferred taxes, and contingent liabilities. Such estimates are based on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:54pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;NOTE&#160;2:-&lt;/b&gt;&lt;/span&gt;SIGNIFICANT ACCOUNTING POLICIES (Cont.)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"&gt;b.&#160;&#160;&#160;&#160;&#160;Consolidated financial statements in U.S.&#160;dollars:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The accompanying consolidated financial statements have been prepared in U.S.&#160;dollars.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;A substantial portion of the Company&#x2019;s expenses are incurred in New Israeli Shekels. However, the Company finances its operations mainly in U.S. dollars, a substantial portion of its expenses are incurred in U.S. dollars and revenues from its primary markets are anticipated to be generated in U.S. dollars. As such, the Company&#x2019;s management believes that the U.S. dollar is the currency of the primary economic environment in which the Company operates. Thus, the functional and reporting currency of the Company is the U.S.&#160;dollar.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;A subsidiary&#x2019;s functional currency is the currency of the primary economic environment in which the subsidiary operates; normally, that is the currency of the environment in which a subsidiary primarily generates and expends cash. In making the determination of the appropriate functional currency for a subsidiary, the Company considers cash flow indicators, local market indicators, financing indicators and the subsidiary&#x2019;s relationship with both the parent company and other subsidiaries. For subsidiaries that are primarily a direct and integral component or extension of the parent entity&#x2019;s operations, the U.S. dollar is the functional currency.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The Company has determined the functional currency of its foreign subsidiaries is the U.S.&#160;Dollar. The foreign operations are considered a direct and integral part or extension of the Company&#x2019;s operations. The&#160;day-to-day&#160;operations of the foreign subsidiaries are dependent on the economic environment of the U.S.&#160;Dollar.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Transactions and balances denominated in U.S. dollars are presented at their original amounts. Monetary accounts maintained in currencies other than the dollar are&#160;re-measured&#160;into dollars in accordance with Accounting Standards Codification No.&#160;830, &#x201c;Foreign Currency Matters&#x201d; (&#x201c;ASC 830&#x201d;). All transaction gains and losses of the&#160;re-measurement&#160;of monetary balance sheet items are reflected in the statements of operations as financial income or expenses, as appropriate.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"&gt;c.&#160;&#160;&#160;&#160;&#160;Principles of consolidation:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany balances have been eliminated upon consolidation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"&gt;d.&#160;&#160;&#160;&#160;&#160;Cash equivalents:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Cash equivalents are short-term, highly liquid investments that are readily convertible into cash with an original maturity of three&#160;months or less, at the date acquired.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:54pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;NOTE&#160;2:-&lt;/b&gt;&lt;/span&gt;SIGNIFICANT ACCOUNTING POLICIES (Cont.)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"&gt;e.&#160;&#160;&#160;&#160;&#160;Restricted cash:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Restricted cash is primarily invested in bank deposits and is used as security for the Company&#x2019;s lease commitments. The following table provides a reconciliation of the cash and cash equivalents balances reported on the balance sheets and the cash, cash equivalents and restricted cash balances reported in the statements of cash flows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:72pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"&gt;Cash and cash equivalents, as reported on the balance sheets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,598&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,236&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"&gt;Restricted cash, as reported on the balance sheets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 576&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.75pt 0pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt; 618&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"&gt;Cash, cash equivalents, and restricted cash, as reported in the statements of cash flows&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,174&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,854&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"&gt;f.&#160;&#160;&#160;&#160;&#160;Short-term deposits:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;A short-term bank deposit is a deposit with a maturity of more than three&#160;months but less than one&#160;year. Deposits in U.S. dollars bear interest at rates ranging from.0.05%-1.65% and 0.01%-0.62%, per annum, as of December&#160;31, 2020 and 2021, respectively. Short-term deposits are presented at cost, which approximates market value due to their short maturities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"&gt;g.&#160;&#160;&#160;&#160;&#160;Property and equipment, net:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following rates:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:72pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;%&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Computers and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.91%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;33&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;10 - 15&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Furniture and office equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;7 - 15&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Car&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;20&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Manufacturing equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;10&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:24.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Over the shorter of the term of the lease or its useful life&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"&gt;h.&#160;&#160;&#160;&#160;&#160;Impairment of long-lived assets:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The Company&#x2019;s long-lived assets are reviewed for impairment in accordance with ASC 360, &#x201c;Property, Plant and Equipment&#x201d; (&#x201c;ASC 360&#x201d;), whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;For the&#160;years ended December&#160;31, 2019, 2020 and 2021 there were no impairment losses identified.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:54pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;NOTE&#160;2:-&lt;/b&gt;&lt;/span&gt;SIGNIFICANT ACCOUNTING POLICIES (Cont.)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"&gt;i.&#160;&#160;&#160;&#160;&#160;Research and development expenses, net:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Research and development expenses consist of personnel costs (including salaries, benefits and share-based compensation), materials, consulting fees and payments to subcontractors, costs associated with obtaining regulatory approvals, executing pre-clinical and clinical studies and maintenance and prosecution of the Company&#x2019;s intellectual property rights. In addition, research and development expenses include overhead allocations consisting of various administrative and facilities related costs. The Company charges research and development expenses as expenses when incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Grants from the Israeli Innovation Authority (IIA) are offset against research and development costs at the later of when grant receipt is assured or the expenses are incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"&gt;j.&#160;&#160;&#160;&#160;&#160;Accounting for share-based payments:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The Company accounts for share based compensation in accordance with ASC No.&#160;718, &#x201c;Compensation&#160;- Stock Compensation&#x201d; that requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The Company recognizes compensation expenses for the value of its awards granted based on the straight-line attribution method over the requisite service period of each of the awards. The Company recognizes forfeitures of awards as they occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;For awards with no performance conditions, the Company recognizes the related share-based compensation expense on a straight-line basis over the requisite service period of the awards, including awards with graded vesting. For awards with performance conditions the share-based compensation expense is recognized if and when the Company concludes that it is probable that the performance condition will be achieved and where the performance condition awards include graded vesting, the share-based compensation expense is recognized based on the accelerated method. The Company reassesses the probability of vesting at each reporting period for awards with performance conditions and adjust compensation cost based on its probability assessment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The Company selected the Black-Scholes option-pricing model as the most appropriate fair value method for its option awards. The option-pricing model requires a number of assumptions, of which the most significant are the share price, volatility and the expected option term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The fair value of ordinary share underlying the options has historically been determined by management and the board of directors. Because there has been no public market for the Company&#x2019;s ordinary shares, the board of directors has determined fair value of an ordinary share at the time of grant of the option by considering a number of objective and subjective factors including financing investment rounds, operating and financial performance, the lack of liquidity of share capital and general and industry specific economic outlook, amongst other factors.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The fair value of the underlying ordinary shares will be determined by the board of directors until such time as the Company&#x2019;s ordinary shares are listed on an established stock exchange.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:54pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;NOTE&#160;2:-&lt;/b&gt;&lt;/span&gt;SIGNIFICANT ACCOUNTING POLICIES (Cont.)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The computation of expected volatility is based on actual historical share price volatility of comparable companies. For option grants that are considered to be &#x201c;plain vanilla,&#x201d; the Company determines the expected term using the simplified method. The simplified method deems the term to be the average of the&#160;time-to-vesting&#160;and the contractual life of the options. The Company has historically not paid dividends and has no foreseeable plans to pay dividends and, therefore, uses an expected dividend yield of zero in the option pricing model. The risk-free interest rate is based on the yield of U.S. treasury bonds with equivalent terms as the expected term of the options.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:72pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:56.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;5.4-7.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2.0-6.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;5.0-6.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;85.3%-88.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;90.8%-102.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;85.5%-89.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;1.9%-2.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0.1%-0.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0.8%-1.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Total share-based compensation expenses related to employees, consultants and other service providers for the&#160;years ended December&#160;31, 2019, 2020 and 2021, amounted to $546, $596 and $812, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"&gt;k.&#160;&#160;&#160;&#160;&#160;Grants and participations:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Royalty-bearing grants from the Israeli Innovation Authority (&#x201c;IIA&#x201d;) (previously known as Office of the Chief Scientist) of the Ministry of Economy and Industry in Israel for funding of approved research and development projects are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred, and are presented as a deduction from research and development expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Since the payment of royalties is not probable when the grants are received, the Company does not record a liability for amounts received from IIA until the related revenues are recognized.&#160;In the event of failure of a project that was partly financed by IIA, the Company will not be obligated to pay any royalties or repay the amounts received.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The Company recognized participations in research and development as a reduction from research and development expenses in the amount of $ 571, $ 878 and $ 2,459 for the&#160;years ended December&#160;31,2019, 2020 and 2021, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"&gt;l.&#160;&#160;&#160;&#160;&#160;Convertible preferred shares and convertible preferred shares warrant liability:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The Company&#x2019;s preferred shares are considered a &#x201c;freestanding financial instrument&#x201d; pursuant to ASC 480 &#x201c;Distinguishing Liabilities from Equity&#x201d; and are redeemable in a deemed liquidation event, which is not under the control of the Company; thus, the Company classified the shares outside permanent equity pursuant to ASC&#160;480-10-S99.&#160;As of December&#160;31, 2021, and 2020, the Company did not adjust the carrying values of the shares to the deemed liquidation values of such shares since a deemed liquidation event was not probable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:54pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;NOTE&#160;2:-&lt;/b&gt;&lt;/span&gt;SIGNIFICANT ACCOUNTING POLICIES (Cont.)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The Company&#x2019;s warrants to purchase the Company&#x2019;s convertible preferred shares are considered a &#x201c;freestanding financial instrument&#x201d; pursuant to ASC 480. The warrants were classified as a liability on the balance sheet, initially and subsequently measured at fair value through earnings, as the underlying shares are contingently redeemable (upon a deemed liquidation event, which is not under the Company&#x2019;s control) and, therefore, embody an obligation that is indexed to an obligation to repurchase the Company&#x2019;s shares by transferring assets. The change in fair value of the warrants is recognized as a component of financial expenses, net, in the statements of operation (see note 9).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"&gt;m.&#160;&#160;&#160;&#160;&#160;Fair value of financial instruments:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The Company applies ASC 820, &#x201c;Fair Value Measurements and Disclosures&#x201d; (&#x201c;ASC 820&#x201d;), pursuant to which fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the &#x201c;exit price&#x201d;) in an orderly transaction between market participants at the measurement date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Fair value is an exit price, representing the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:72pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;1-&#160;Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:72pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 2&#160;- Other than quoted prices included in Level&#160;1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:72pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 3&#160;- Unobservable inputs which are supported by little or no market activity.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The carrying amounts of cash and cash equivalents, short-term deposits, prepaid expenses, other receivables, trade payables, other accounts payable and accrued expenses approximate their fair value due to the short-term maturity of such instruments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:54pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;NOTE&#160;2:-&lt;/b&gt;&lt;/span&gt;SIGNIFICANT ACCOUNTING POLICIES (Cont.)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The financial instruments carried at fair value on the Company&#x2019;s consolidated balance sheets as of December&#160;31, 2019, 2020 and 2021 are warrants to convertible preferred shares classified as a liability (see note&#160;7).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The following methods and assumptions were used by the Company in estimating their fair value disclosures for financial instruments:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The fair value measurement of warrants to convertible preferred shares are measured using unobservable inputs that require a high level of judgment to determine fair value, and thus are classified as Level&#160;3 financial instruments. To calculate the fair value of the warrants, the Company first calculated the underlying preferred share value by using the income approach and the market approach. Then the equity value was allocated by using the hybrid model method utilizing two scenarios of OPM and IPO. Once the preferred shares value was derived from the two scenarios, the Black-Scholes model was utilized to calculate the warrants value in each one of the scenarios. Then, probability for each one of the scenarios was applied by the Company to derive the weighted average fair value of the warrants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Fair value estimates are made at a specific point in time, based on relevant market information and information about the financial instruments. These estimates are subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. Changes in assumptions could significantly affect these estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"&gt;n.&#160;&#160;&#160;&#160;&#160;Ordinary share warrants classification and measurement:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance. The assessment considers whether the warrants are freestanding financial instruments, meet the definition of a liability under ASC 480, are indexed to the Company&#x2019;s own stock and whether the warrants are eligible for equity classification under ASC 815-40. This assessment is conducted at the time of warrant issuance and as of each subsequent reporting period end date while the warrants are outstanding.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Warrants that meet all the criteria for equity classification, are required to be recorded as a component of additional paid-in capital. Warrants that do not meet all the criteria for equity classification, are required to be recorded as liabilities at their initial fair value on the date of issuance and remeasured to fair value through earnings at each balance sheet date thereafter.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;As of December 31, 2020, and 2021, the Company had 728,017 and 718,964 outstanding ordinary share warrants, respectively. The warrants were classified as equity (see notes 10d and 10e).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"&gt;o.&#160;&#160;&#160;&#160;&#160;Income taxes:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The Company accounts for income taxes in accordance with ASC 740, &#x201c;Income Taxes&#x201d; (&#x201c;ASC 740&#x201d;). ASC 740 prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, to reduce deferred tax assets to their estimated realizable value, if needed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:54pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;NOTE&#160;2:-&lt;/b&gt;&lt;/span&gt;SIGNIFICANT ACCOUNTING POLICIES (Cont.)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;ASC 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. As of December&#160;31, 2021, and 2020 no liability for unrecognized tax benefits was recorded as a result of ASC 740.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"&gt;p.&#160;&#160;&#160;&#160;&#160;Concentration of credit risks:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents, restricted cash and short-term deposits.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Cash, cash equivalents, restricted cash and short-term deposits are deposited in major banks in Israel, United States and Japan. Such investments in Israel and abroad may be in excess of insured limits and are not insured in other jurisdictions. Generally, cash and cash equivalents may be redeemed upon demand and, therefore, bear minimal risk.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"&gt;q.&#160;&#160;&#160;&#160;&#160;Severance pay:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;All the Company&#x2019;s employees who are Israeli citizens have subscribed to Section&#160;14 of Israel&#x2019;s Severance Pay Law, 5723-1963 (&#x201c;Section&#160;14&#x201d;). Pursuant to Section&#160;14, employees covered by this section are entitled to&#160;monthly deposits at a rate of 8.33% of their&#160;monthly salary, made on their behalf by the Company. Payments in accordance with Section&#160;14 release the Company from any future severance liabilities in respect of those employees.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Neither severance pay liability nor severance pay fund under Section&#160;14 for such employees is recorded on the Company&#x2019;s consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Severance pay expense for the&#160;years ended December&#160;31, 2019, 2020 and 2021 amounted to $ 117, $ 194 and $ 318, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"&gt;r.&#160;&#160;&#160;&#160;&#160;Contingent liabilities:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The Company accounts for its contingent liabilities in accordance with ASC 450, &#x201c;Contingencies&#x201d; (&#x201c;ASC 450&#x201d;). A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;As of December&#160;31, 2019, 2020 and 2021, no provision is recorded.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:54pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;NOTE&#160;2:-&lt;/b&gt;&lt;/span&gt;SIGNIFICANT ACCOUNTING POLICIES (Cont.)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"&gt;s.&#160;&#160;&#160;&#160;&#160;Basic and diluted net loss per share:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The Company computes net loss per share using the two-class method required for participating securities. The two-class method requires income available to ordinary shareholders for the period to be allocated between ordinary shares and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. The Company considers its convertible preferred shares to be participating securities as the holders of the convertible preferred shares would be entitled to dividends that would be distributed to the holders of ordinary shares, on a pro-rata basis, on an as-converted basis. These participating securities do not contractually require the holders of such shares to participate in the Company&#x2019;s losses. As such, net loss for the periods presented was not allocated to the Company&#x2019;s participating securities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The Company&#x2019;s basic net loss per share is calculated by dividing net loss attributable to ordinary shareholders by the weighted-average number of shares of ordinary shares outstanding for the period, without consideration of potentially dilutive securities. The diluted net loss per share is calculated by giving effect to all potentially dilutive securities outstanding for the period using the treasury share method or the if-converted method based on the nature of such securities. Diluted net loss per share is the same as basic net loss per share in periods when the effects of potentially dilutive shares of ordinary shares are anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"&gt;t.&#160;&#160;&#160;&#160;&#160;Deferred Transaction costs:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Deferred transactions costs consist primarily of accounting, legal, and other fees related to the Company&#x2019;s transaction. Upon consummation of the transaction, the deferred transaction costs will be reclassified to shareholders&#x2019; deficit and recorded against the proceeds from the transaction. The Company capitalized $1,700 of deferred offering costs within other assets, noncurrent in the consolidated balance sheets as of December&#160;31, 2021. No transaction costs were capitalized as of December&#160;31, 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"&gt;u.&#160;&#160;&#160;&#160;&#160;Non-controlling interest:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The consolidated financial statements included the Company&#x2019;s accounts and the accounts of the Company&#x2019;s wholly- and majority-owned subsidiaries.&#160;Non-controlling&#160;interest positions of our consolidated entities are reported as a separate component of consolidated equity from the equity attributable to the Company&#x2019;s shareholders.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"&gt;v.&#160;&#160;&#160;&#160;&#160;Recently Issued Accounting Pronouncements and not yet adopted&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;As an &#x201c;emerging growth company&#x201d;, the Jumpstart Our Business Startups Act (JOBS Act) allows the Company to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. The Company has elected to use this extended transition period under the JOBS Act. The adoption dates discussed below reflect this election.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:54pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;NOTE&#160;2:-&lt;/b&gt;&lt;/span&gt;SIGNIFICANT ACCOUNTING POLICIES (Cont.)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;In February&#160;2016, the FASB issued ASU No.&#160;2016-02, Leases, which would require lessees to recognize assets and liabilities on the balance sheet for most leases, whether operating or financing, while continuing to recognize the expenses on their income statements in a manner similar to current practice. Under the new guidance, the Company would also require to provide enhanced disclosures. The guidance states that a lessee would recognize a lease liability for the obligation to make lease payments and a right-to-use asset for the right to use the underlying asset for the lease term. The guidance will be effective for the Company as of January&#160;1, 2022, and interim periods in fiscal&#160;years beginning January&#160;1, 2023. The Company is in the initial stage of its assessment of the new standard and is currently evaluating the timing of adoption, the quantitative impact of adoption, and the related disclosure requirements. The Company anticipates the adoption of this standard will result in an increase in its noncurrent assets, and current and noncurrent liabilities recorded on the consolidated balance sheets. The Company is currently evaluating the effect that ASU No.&#160;2016-02 will have on its consolidated financial statements and related disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;In August&#160;2020, the FASB issued ASU&#160;2020-06,&#160;Debt&#160;- Debt with Conversion and Other Options (Subtopic&#160;470-20)&#160;and Derivatives and Hedging&#160;- Contracts in Entity&#x2019;s Own Equity (Subtopic&#160;815-40):&#160;Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity (&#x201c;ASU&#160;2020-06&#x201d;).&#160;The final guidance issued by the FASB for convertible instruments eliminates two of the three models in ASC&#160;470-20&#160;that require separate accounting for embedded conversion features. Separate accounting is still required in certain cases. Additionally, among other changes, the guidance eliminates some of the conditions for equity classification in ASC&#160;815-40-25&#160;for contracts in an entity&#x2019;s own equity. The guidance also requires entities to use the&#160;if-converted&#160;method for all convertible instruments in the diluted earnings per share calculation and include the effect of share settlement for instruments that may be settled in cash or shares, except for certain liability-classified share-based payment awards. ASU&#160;2020-06&#160;is effective for fiscal&#160;years beginning after December&#160;15, 2023, and interim periods within those fiscal&#160;years. The Company is currently evaluating the potential impact of this guidance on its consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"&gt;In November&#160;2021, the FASB issued ASU No.&#160;2021-10, &#x201c;Government Assistance (Topic 832): Disclosure by Business Entities about Government Assistance.&#x201d; The new standard improves the transparency of government assistance received by most business entities by requiring the disclosure of: (1)&#160;the types of government assistance received; (2)&#160;the accounting for such assistance; and (3)&#160;the effect of the assistance on a business entity&#x2019;s financial statements. This guidance is effective for financial statements issued for annual periods beginning after December&#160;15, 2021. Early adoption is permitted. The Company does not expect the adoption of the standard will have a material impact on its consolidated financial statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_OU-7vyttZ02jDyGf5HN94w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"&gt;a.&#160;&#160;&#160;&#160;&#160;Use of estimates for the preparation of financial statements:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The preparation of the consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, the Company&#x2019;s management evaluates estimates, including those related to fair values of convertible preferred shares warrants, fair values of share-based awards, deferred taxes, and contingent liabilities. Such estimates are based on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_nJ5GUYwZEUyK6RVMVFTJMA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"&gt;b.&#160;&#160;&#160;&#160;&#160;Consolidated financial statements in U.S.&#160;dollars:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The accompanying consolidated financial statements have been prepared in U.S.&#160;dollars.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;A substantial portion of the Company&#x2019;s expenses are incurred in New Israeli Shekels. However, the Company finances its operations mainly in U.S. dollars, a substantial portion of its expenses are incurred in U.S. dollars and revenues from its primary markets are anticipated to be generated in U.S. dollars. As such, the Company&#x2019;s management believes that the U.S. dollar is the currency of the primary economic environment in which the Company operates. Thus, the functional and reporting currency of the Company is the U.S.&#160;dollar.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;A subsidiary&#x2019;s functional currency is the currency of the primary economic environment in which the subsidiary operates; normally, that is the currency of the environment in which a subsidiary primarily generates and expends cash. In making the determination of the appropriate functional currency for a subsidiary, the Company considers cash flow indicators, local market indicators, financing indicators and the subsidiary&#x2019;s relationship with both the parent company and other subsidiaries. For subsidiaries that are primarily a direct and integral component or extension of the parent entity&#x2019;s operations, the U.S. dollar is the functional currency.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The Company has determined the functional currency of its foreign subsidiaries is the U.S.&#160;Dollar. The foreign operations are considered a direct and integral part or extension of the Company&#x2019;s operations. The&#160;day-to-day&#160;operations of the foreign subsidiaries are dependent on the economic environment of the U.S.&#160;Dollar.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Transactions and balances denominated in U.S. dollars are presented at their original amounts. Monetary accounts maintained in currencies other than the dollar are&#160;re-measured&#160;into dollars in accordance with Accounting Standards Codification No.&#160;830, &#x201c;Foreign Currency Matters&#x201d; (&#x201c;ASC 830&#x201d;). All transaction gains and losses of the&#160;re-measurement&#160;of monetary balance sheet items are reflected in the statements of operations as financial income or expenses, as appropriate.&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_nW-SXvKtN0iwVAY1j6HSXQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"&gt;c.&#160;&#160;&#160;&#160;&#160;Principles of consolidation:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany balances have been eliminated upon consolidation.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_9ZdiZnMUzUmP8yQ1FAICSg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"&gt;d.&#160;&#160;&#160;&#160;&#160;Cash equivalents:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Cash equivalents are short-term, highly liquid investments that are readily convertible into cash with an original maturity of three&#160;months or less, at the date acquired.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_-mPpOeE_wEiVWHOnAn5JAg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"&gt;e.&#160;&#160;&#160;&#160;&#160;Restricted cash:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Restricted cash is primarily invested in bank deposits and is used as security for the Company&#x2019;s lease commitments. The following table provides a reconciliation of the cash and cash equivalents balances reported on the balance sheets and the cash, cash equivalents and restricted cash balances reported in the statements of cash flows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:72pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"&gt;Cash and cash equivalents, as reported on the balance sheets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,598&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,236&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"&gt;Restricted cash, as reported on the balance sheets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 576&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.75pt 0pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt; 618&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"&gt;Cash, cash equivalents, and restricted cash, as reported in the statements of cash flows&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,174&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,854&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_5eYoK2dcJ0qw6e2Ef3eQDA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:72pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"&gt;Cash and cash equivalents, as reported on the balance sheets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,598&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,236&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"&gt;Restricted cash, as reported on the balance sheets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 576&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.75pt 0pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt; 618&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"&gt;Cash, cash equivalents, and restricted cash, as reported in the statements of cash flows&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,174&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,854&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="-3"
      id="Tc_F1-fmF33C0GJ9DacBjFOPA_3_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">15598000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc_aRO_Sd8j802fgSeI0t7GWA_3_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">23236000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="-3"
      id="Tc_iPrFL4hvAki0RZO9zdfyWA_4_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">576000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc_WLES_ZhBBUStRbd3BOTUSw_4_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">618000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="-3"
      id="Tc_gBPS8yVbDkW0koX7-61cRQ_5_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">16174000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc_a8DJH4crn0mZhDPKkvPe7A_5_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">23854000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <drts:ShortTermDepositsPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_pyoMcyi1lUmTOySgJQCKlg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"&gt;f.&#160;&#160;&#160;&#160;&#160;Short-term deposits:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;A short-term bank deposit is a deposit with a maturity of more than three&#160;months but less than one&#160;year. Deposits in U.S. dollars bear interest at rates ranging from.0.05%-1.65% and 0.01%-0.62%, per annum, as of December&#160;31, 2020 and 2021, respectively. Short-term deposits are presented at cost, which approximates market value due to their short maturities.&lt;/p&gt;</drts:ShortTermDepositsPolicyTextBlock>
    <drts:ShortTernBankDepositInterestRate
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_3YDYP2NS1kWrJTyY6tlLEw"
      decimals="4"
      id="Narr_cG0fp660GUmeD71jaOOpaw"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.0005</drts:ShortTernBankDepositInterestRate>
    <drts:ShortTernBankDepositInterestRate
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_9PHxHzoF8EaVkrgQF_FmYw"
      decimals="4"
      id="Narr_UUr3_n1XMUCjnQQ78hrsBQ"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.0165</drts:ShortTernBankDepositInterestRate>
    <drts:ShortTernBankDepositInterestRate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_Bx-4ke71BkK7RwJqTEiSgw"
      decimals="4"
      id="Narr_aAuuSEov5U6BOGRUjlDIxA"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.0001</drts:ShortTernBankDepositInterestRate>
    <drts:ShortTernBankDepositInterestRate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_YkvYRoxUekOnNqnvzrP72A"
      decimals="4"
      id="Narr_DeqmAms2tEKjHP3Xo2QgnQ"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.0062</drts:ShortTernBankDepositInterestRate>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_eBO7DxuVcU6y-bEMaKUzbw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"&gt;g.&#160;&#160;&#160;&#160;&#160;Property and equipment, net:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following rates:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:72pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;%&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Computers and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.91%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;33&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;10 - 15&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Furniture and office equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;7 - 15&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Car&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;20&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Manufacturing equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;10&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:24.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Over the shorter of the term of the lease or its useful life&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <drts:PropertyPlantAndEquipmentUsefulLivesTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_lzOUEedwak6CK5Blc_bV8w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:72pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;%&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Computers and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.91%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;33&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;10 - 15&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Furniture and office equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;7 - 15&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Car&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;20&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Manufacturing equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;10&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:24.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Over the shorter of the term of the lease or its useful life&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</drts:PropertyPlantAndEquipmentUsefulLivesTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_dZomxtzLFkWxB2CX70Casw"
      id="Tc_tP_Y4NkSokal7U8hZx_cWA_2_2">P33Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_drts_LaboratoryEquipmentMember_zGBF3SpbBE-OhZ3qDsbqLA"
      id="Narr_wbkCsKDQOk6DREtqCd6HXw">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_drts_LaboratoryEquipmentMember_DHtJpJcfZ06X41B2GbaKSw"
      id="Narr_kazxDVrZYUad9AUouV-1yg">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_ZaOgQu4r90edkwyq9ZaeAQ"
      id="Narr_ZrwYb7h8pUmEtI5OxJTT2w">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_1lJIcyzl2ka-godfGb-vHA"
      id="Narr_P1hCQEDLa0GJFlev6-LnPQ">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AutomobilesMember_MdIVVvN1b0Gj0kdnXqxCvQ"
      id="Tc_cySrHd-5MUu4KdzyWSHMPg_5_2">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_URRNsHmmMUWu9_-B9brINQ"
      id="Tc_SIc0yoRMjUCHKGpB4xvBYg_6_2">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_iEfIis4_PE6T2c9Tg3vnWQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"&gt;h.&#160;&#160;&#160;&#160;&#160;Impairment of long-lived assets:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The Company&#x2019;s long-lived assets are reviewed for impairment in accordance with ASC 360, &#x201c;Property, Plant and Equipment&#x201d; (&#x201c;ASC 360&#x201d;), whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;For the&#160;years ended December&#160;31, 2019, 2020 and 2021 there were no impairment losses identified.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Narr_fOrO6godREWblz6WH8HG6A"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Narr_ZSyz0M_-VU-wmadw5fDb3Q"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Narr_eUG3J583qUuAX3I0q1gtlw"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_1pkYGgj1mUedcOQ1y9Ud5Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"&gt;i.&#160;&#160;&#160;&#160;&#160;Research and development expenses, net:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Research and development expenses consist of personnel costs (including salaries, benefits and share-based compensation), materials, consulting fees and payments to subcontractors, costs associated with obtaining regulatory approvals, executing pre-clinical and clinical studies and maintenance and prosecution of the Company&#x2019;s intellectual property rights. In addition, research and development expenses include overhead allocations consisting of various administrative and facilities related costs. The Company charges research and development expenses as expenses when incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Grants from the Israeli Innovation Authority (IIA) are offset against research and development costs at the later of when grant receipt is assured or the expenses are incurred.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_0vdcuDyeXku1bL4lDdDxTg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"&gt;j.&#160;&#160;&#160;&#160;&#160;Accounting for share-based payments:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The Company accounts for share based compensation in accordance with ASC No.&#160;718, &#x201c;Compensation&#160;- Stock Compensation&#x201d; that requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The Company recognizes compensation expenses for the value of its awards granted based on the straight-line attribution method over the requisite service period of each of the awards. The Company recognizes forfeitures of awards as they occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;For awards with no performance conditions, the Company recognizes the related share-based compensation expense on a straight-line basis over the requisite service period of the awards, including awards with graded vesting. For awards with performance conditions the share-based compensation expense is recognized if and when the Company concludes that it is probable that the performance condition will be achieved and where the performance condition awards include graded vesting, the share-based compensation expense is recognized based on the accelerated method. The Company reassesses the probability of vesting at each reporting period for awards with performance conditions and adjust compensation cost based on its probability assessment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The Company selected the Black-Scholes option-pricing model as the most appropriate fair value method for its option awards. The option-pricing model requires a number of assumptions, of which the most significant are the share price, volatility and the expected option term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The fair value of ordinary share underlying the options has historically been determined by management and the board of directors. Because there has been no public market for the Company&#x2019;s ordinary shares, the board of directors has determined fair value of an ordinary share at the time of grant of the option by considering a number of objective and subjective factors including financing investment rounds, operating and financial performance, the lack of liquidity of share capital and general and industry specific economic outlook, amongst other factors.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The fair value of the underlying ordinary shares will be determined by the board of directors until such time as the Company&#x2019;s ordinary shares are listed on an established stock exchange.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:54pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;NOTE&#160;2:-&lt;/b&gt;&lt;/span&gt;SIGNIFICANT ACCOUNTING POLICIES (Cont.)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The computation of expected volatility is based on actual historical share price volatility of comparable companies. For option grants that are considered to be &#x201c;plain vanilla,&#x201d; the Company determines the expected term using the simplified method. The simplified method deems the term to be the average of the&#160;time-to-vesting&#160;and the contractual life of the options. The Company has historically not paid dividends and has no foreseeable plans to pay dividends and, therefore, uses an expected dividend yield of zero in the option pricing model. The risk-free interest rate is based on the yield of U.S. treasury bonds with equivalent terms as the expected term of the options.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:72pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:56.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;5.4-7.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2.0-6.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;5.0-6.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;85.3%-88.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;90.8%-102.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;85.5%-89.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;1.9%-2.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0.1%-0.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0.8%-1.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Total share-based compensation expenses related to employees, consultants and other service providers for the&#160;years ended December&#160;31, 2019, 2020 and 2021, amounted to $546, $596 and $812, respectively.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_SEWHMmhP_0WnhelwXhYi3Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:72pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:56.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;5.4-7.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2.0-6.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;5.0-6.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;85.3%-88.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;90.8%-102.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;85.5%-89.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;1.9%-2.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0.1%-0.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0.8%-1.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Sg0gHG4UoU-lLL3GVY6j-w"
      id="Narr_fbLtjuI9tECpemDgDhDKUA">P5Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_jB-0qsL4s0iRjn2iZ1I0eg"
      id="Narr__9yYJbisi0K_efchof4Xjw">P7Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_QL_lHDCdIUaW2VkrmxWUYA"
      id="Narr_1ISHeGM59Ee3pG08g1KReA">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zmqejbh0ukqtNgBs60C6XA"
      id="Narr_O1x2OQSSMEGGMfW_96KpRw">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_-q59_3u_sUqS3xTBriYDrg"
      id="Narr_NJhHSey_p0G6WP4EZcUmdQ">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_u1KsUB5GUkyYW_fz6BxGKQ"
      id="Narr_u835W4ZK0EC5D_S58p5qyw">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_S6irH3nF3kiUBJuvNW1GvQ"
      decimals="3"
      id="Narr_lyNCTSzIAkaCDjiAfji6eA"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.853</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_S6irH3nF3kiUBJuvNW1GvQ"
      decimals="3"
      id="Narr_K0AQzijj3ECCpzxipoxpUA"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.886</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_1fUps4YHpUmalFLxoLPtsg"
      decimals="3"
      id="Narr_yvFw76v1T02WCbQBbMg3DA"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.908</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_1fUps4YHpUmalFLxoLPtsg"
      decimals="3"
      id="Narr_Ul4M9JuP90SMRl4z5ZzJDQ"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">1.021</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_a-Npz0DAckea4fyrLYOJvQ"
      decimals="3"
      id="Narr_sGaSRpmyFE2XPyrLeANx9g"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.855</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_a-Npz0DAckea4fyrLYOJvQ"
      decimals="3"
      id="Narr_YakaxR28mEyxwrp2tnN-AQ"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.892</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_S6irH3nF3kiUBJuvNW1GvQ"
      decimals="3"
      id="Narr_8gyQ0_PebEuoI5wY9GJJFA"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_S6irH3nF3kiUBJuvNW1GvQ"
      decimals="3"
      id="Narr_c-Avej1PY0yw497dVEQ76g"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_1fUps4YHpUmalFLxoLPtsg"
      decimals="3"
      id="Narr_GPas6o_v_UKODpdt11-4Dw"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_1fUps4YHpUmalFLxoLPtsg"
      decimals="3"
      id="Narr_DZcByEjzlUaThktUWnNg4Q"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_a-Npz0DAckea4fyrLYOJvQ"
      decimals="3"
      id="Narr_y-MYWuMPp0aeB7N4aJge2A"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_a-Npz0DAckea4fyrLYOJvQ"
      decimals="3"
      id="Narr_Bsi-MnKl406P40nXT2j6Gg"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_S6irH3nF3kiUBJuvNW1GvQ"
      decimals="2"
      id="Tc_VYloemMCWkOKr6zaXdOs-g_6_2"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_1fUps4YHpUmalFLxoLPtsg"
      decimals="2"
      id="Tc_hGpU85qCXUa13k2TdnktTw_6_4"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_a-Npz0DAckea4fyrLYOJvQ"
      decimals="2"
      id="Tc_VyIipC9G90W3hTMnvgONfA_6_6"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Narr_IcFayP0VlkGDZHAYfbNu-Q"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">546000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Narr_x7gl9hp4PE2wY_I1GM8wTw"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">596000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Narr_t2P4v29nd0mWvjNFOF63Gw"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">812000</us-gaap:AllocatedShareBasedCompensationExpense>
    <drts:GrantsAndParticipationsPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_kF_JJnsSm0eCMUZmaKWB6A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"&gt;k.&#160;&#160;&#160;&#160;&#160;Grants and participations:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Royalty-bearing grants from the Israeli Innovation Authority (&#x201c;IIA&#x201d;) (previously known as Office of the Chief Scientist) of the Ministry of Economy and Industry in Israel for funding of approved research and development projects are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred, and are presented as a deduction from research and development expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Since the payment of royalties is not probable when the grants are received, the Company does not record a liability for amounts received from IIA until the related revenues are recognized.&#160;In the event of failure of a project that was partly financed by IIA, the Company will not be obligated to pay any royalties or repay the amounts received.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The Company recognized participations in research and development as a reduction from research and development expenses in the amount of $ 571, $ 878 and $ 2,459 for the&#160;years ended December&#160;31,2019, 2020 and 2021, respectively.&lt;/p&gt;</drts:GrantsAndParticipationsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Narr_L6yMbRbVlEuNTY9XKy6vkA"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">571000</us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred>
    <us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Narr_QTZBdE5PCE6FjvMsJHJCpw"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">878000</us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred>
    <us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Narr_aw7-kYL160-NeI3xMyoFYg"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">2459000</us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred>
    <drts:ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_kDjeNN4kQkW7s99wOBbRcg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"&gt;l.&#160;&#160;&#160;&#160;&#160;Convertible preferred shares and convertible preferred shares warrant liability:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The Company&#x2019;s preferred shares are considered a &#x201c;freestanding financial instrument&#x201d; pursuant to ASC 480 &#x201c;Distinguishing Liabilities from Equity&#x201d; and are redeemable in a deemed liquidation event, which is not under the control of the Company; thus, the Company classified the shares outside permanent equity pursuant to ASC&#160;480-10-S99.&#160;As of December&#160;31, 2021, and 2020, the Company did not adjust the carrying values of the shares to the deemed liquidation values of such shares since a deemed liquidation event was not probable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:54pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;NOTE&#160;2:-&lt;/b&gt;&lt;/span&gt;SIGNIFICANT ACCOUNTING POLICIES (Cont.)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The Company&#x2019;s warrants to purchase the Company&#x2019;s convertible preferred shares are considered a &#x201c;freestanding financial instrument&#x201d; pursuant to ASC 480. The warrants were classified as a liability on the balance sheet, initially and subsequently measured at fair value through earnings, as the underlying shares are contingently redeemable (upon a deemed liquidation event, which is not under the Company&#x2019;s control) and, therefore, embody an obligation that is indexed to an obligation to repurchase the Company&#x2019;s shares by transferring assets. The change in fair value of the warrants is recognized as a component of financial expenses, net, in the statements of operation (see note 9).&lt;/p&gt;</drts:ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_3AJCHzQhnkKNUO54wuagmg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"&gt;m.&#160;&#160;&#160;&#160;&#160;Fair value of financial instruments:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The Company applies ASC 820, &#x201c;Fair Value Measurements and Disclosures&#x201d; (&#x201c;ASC 820&#x201d;), pursuant to which fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the &#x201c;exit price&#x201d;) in an orderly transaction between market participants at the measurement date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Fair value is an exit price, representing the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:72pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;1-&#160;Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:72pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 2&#160;- Other than quoted prices included in Level&#160;1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:72pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 3&#160;- Unobservable inputs which are supported by little or no market activity.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The carrying amounts of cash and cash equivalents, short-term deposits, prepaid expenses, other receivables, trade payables, other accounts payable and accrued expenses approximate their fair value due to the short-term maturity of such instruments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:54pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;NOTE&#160;2:-&lt;/b&gt;&lt;/span&gt;SIGNIFICANT ACCOUNTING POLICIES (Cont.)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The financial instruments carried at fair value on the Company&#x2019;s consolidated balance sheets as of December&#160;31, 2019, 2020 and 2021 are warrants to convertible preferred shares classified as a liability (see note&#160;7).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The following methods and assumptions were used by the Company in estimating their fair value disclosures for financial instruments:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The fair value measurement of warrants to convertible preferred shares are measured using unobservable inputs that require a high level of judgment to determine fair value, and thus are classified as Level&#160;3 financial instruments. To calculate the fair value of the warrants, the Company first calculated the underlying preferred share value by using the income approach and the market approach. Then the equity value was allocated by using the hybrid model method utilizing two scenarios of OPM and IPO. Once the preferred shares value was derived from the two scenarios, the Black-Scholes model was utilized to calculate the warrants value in each one of the scenarios. Then, probability for each one of the scenarios was applied by the Company to derive the weighted average fair value of the warrants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Fair value estimates are made at a specific point in time, based on relevant market information and information about the financial instruments. These estimates are subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. Changes in assumptions could significantly affect these estimates.&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <drts:OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_6CmUMnvlbEasnwz24bFTKw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"&gt;n.&#160;&#160;&#160;&#160;&#160;Ordinary share warrants classification and measurement:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance. The assessment considers whether the warrants are freestanding financial instruments, meet the definition of a liability under ASC 480, are indexed to the Company&#x2019;s own stock and whether the warrants are eligible for equity classification under ASC 815-40. This assessment is conducted at the time of warrant issuance and as of each subsequent reporting period end date while the warrants are outstanding.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Warrants that meet all the criteria for equity classification, are required to be recorded as a component of additional paid-in capital. Warrants that do not meet all the criteria for equity classification, are required to be recorded as liabilities at their initial fair value on the date of issuance and remeasured to fair value through earnings at each balance sheet date thereafter.&lt;/p&gt;</drts:OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="INF"
      id="Narr_eobfj0sETkCP8yULVX8rpw"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">728017</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="INF"
      id="Narr_t-3oJjmADk-TJ4M_vb0iAw"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">718964</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_GZA_XK571k-tUXoxISwglg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"&gt;o.&#160;&#160;&#160;&#160;&#160;Income taxes:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The Company accounts for income taxes in accordance with ASC 740, &#x201c;Income Taxes&#x201d; (&#x201c;ASC 740&#x201d;). ASC 740 prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, to reduce deferred tax assets to their estimated realizable value, if needed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:54pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;NOTE&#160;2:-&lt;/b&gt;&lt;/span&gt;SIGNIFICANT ACCOUNTING POLICIES (Cont.)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;ASC 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. As of December&#160;31, 2021, and 2020 no liability for unrecognized tax benefits was recorded as a result of ASC 740.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_0tbQ_0v-d0WSuwslbFSiIA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"&gt;p.&#160;&#160;&#160;&#160;&#160;Concentration of credit risks:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents, restricted cash and short-term deposits.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Cash, cash equivalents, restricted cash and short-term deposits are deposited in major banks in Israel, United States and Japan. Such investments in Israel and abroad may be in excess of insured limits and are not insured in other jurisdictions. Generally, cash and cash equivalents may be redeemed upon demand and, therefore, bear minimal risk.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <drts:SeverancePayPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_zjquw4NmPUm6eAIkcHEdpg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"&gt;q.&#160;&#160;&#160;&#160;&#160;Severance pay:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;All the Company&#x2019;s employees who are Israeli citizens have subscribed to Section&#160;14 of Israel&#x2019;s Severance Pay Law, 5723-1963 (&#x201c;Section&#160;14&#x201d;). Pursuant to Section&#160;14, employees covered by this section are entitled to&#160;monthly deposits at a rate of 8.33% of their&#160;monthly salary, made on their behalf by the Company. Payments in accordance with Section&#160;14 release the Company from any future severance liabilities in respect of those employees.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Neither severance pay liability nor severance pay fund under Section&#160;14 for such employees is recorded on the Company&#x2019;s consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Severance pay expense for the&#160;years ended December&#160;31, 2019, 2020 and 2021 amounted to $ 117, $ 194 and $ 318, respectively.&lt;/p&gt;</drts:SeverancePayPolicyTextBlock>
    <drts:SeverancePayDepositRate
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="4"
      id="Narr_qjW5jzHybU2LJokkcDdhqQ"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.0833</drts:SeverancePayDepositRate>
    <drts:SeverancePayExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Narr_tphtKFdt7ECTvYNRUHP8dw"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">117000</drts:SeverancePayExpense>
    <drts:SeverancePayExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Narr_vkaAz87th0eRgX_eQWrGAg"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">194000</drts:SeverancePayExpense>
    <drts:SeverancePayExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Narr_KBumdKZ6YEqVn4qbYk7nMw"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">318000</drts:SeverancePayExpense>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_TljenB4zLEG3Slpel20Vaw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"&gt;r.&#160;&#160;&#160;&#160;&#160;Contingent liabilities:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The Company accounts for its contingent liabilities in accordance with ASC 450, &#x201c;Contingencies&#x201d; (&#x201c;ASC 450&#x201d;). A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;As of December&#160;31, 2019, 2020 and 2021, no provision is recorded.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="As_Of_12_31_2019_9X1M-BXfgEWsSJdmFxdJhA"
      decimals="-3"
      id="Narr_omGZiTtCSE25E6roMS6fUg"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="-3"
      id="Narr_Z6VxYV6S-UqZWlP55Ipzig"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Narr_E2RehG1BGEWUD68MZUcKew"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_8OjorD-sVEeHzdb7WxzxEg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"&gt;s.&#160;&#160;&#160;&#160;&#160;Basic and diluted net loss per share:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The Company computes net loss per share using the two-class method required for participating securities. The two-class method requires income available to ordinary shareholders for the period to be allocated between ordinary shares and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. The Company considers its convertible preferred shares to be participating securities as the holders of the convertible preferred shares would be entitled to dividends that would be distributed to the holders of ordinary shares, on a pro-rata basis, on an as-converted basis. These participating securities do not contractually require the holders of such shares to participate in the Company&#x2019;s losses. As such, net loss for the periods presented was not allocated to the Company&#x2019;s participating securities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The Company&#x2019;s basic net loss per share is calculated by dividing net loss attributable to ordinary shareholders by the weighted-average number of shares of ordinary shares outstanding for the period, without consideration of potentially dilutive securities. The diluted net loss per share is calculated by giving effect to all potentially dilutive securities outstanding for the period using the treasury share method or the if-converted method based on the nature of such securities. Diluted net loss per share is the same as basic net loss per share in periods when the effects of potentially dilutive shares of ordinary shares are anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <drts:DeferredTransactionCostsPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_TzicNbfVwkCb7L9moS2H1g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"&gt;t.&#160;&#160;&#160;&#160;&#160;Deferred Transaction costs:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Deferred transactions costs consist primarily of accounting, legal, and other fees related to the Company&#x2019;s transaction. Upon consummation of the transaction, the deferred transaction costs will be reclassified to shareholders&#x2019; deficit and recorded against the proceeds from the transaction. The Company capitalized $1,700 of deferred offering costs within other assets, noncurrent in the consolidated balance sheets as of December&#160;31, 2021. No transaction costs were capitalized as of December&#160;31, 2020.&lt;/p&gt;</drts:DeferredTransactionCostsPolicyTextBlock>
    <us-gaap:DeferredOfferingCosts
      contextRef="As_Of_12_31_2021_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_S4dFGjmRIE2hAjthSZNbJA"
      decimals="-3"
      id="Narr_PovQzXGzI0KSimsYzxOI8A"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">1700000</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="As_Of_12_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_hb-EpK2zOE6IW_s6W3VP0A"
      decimals="-3"
      id="Narr_tWDEehQUrUK6jP1uL2M33w"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">0</us-gaap:DeferredOfferingCosts>
    <drts:NonControllingInterestPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_nMH1HYsD3ECaUF0xZjUzAQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"&gt;u.&#160;&#160;&#160;&#160;&#160;Non-controlling interest:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The consolidated financial statements included the Company&#x2019;s accounts and the accounts of the Company&#x2019;s wholly- and majority-owned subsidiaries.&#160;Non-controlling&#160;interest positions of our consolidated entities are reported as a separate component of consolidated equity from the equity attributable to the Company&#x2019;s shareholders.&lt;/p&gt;</drts:NonControllingInterestPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_3r1iD-AOY0yEF8emC9LHpw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 54pt;"&gt;v.&#160;&#160;&#160;&#160;&#160;Recently Issued Accounting Pronouncements and not yet adopted&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;As an &#x201c;emerging growth company&#x201d;, the Jumpstart Our Business Startups Act (JOBS Act) allows the Company to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. The Company has elected to use this extended transition period under the JOBS Act. The adoption dates discussed below reflect this election.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:54pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;NOTE&#160;2:-&lt;/b&gt;&lt;/span&gt;SIGNIFICANT ACCOUNTING POLICIES (Cont.)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;In February&#160;2016, the FASB issued ASU No.&#160;2016-02, Leases, which would require lessees to recognize assets and liabilities on the balance sheet for most leases, whether operating or financing, while continuing to recognize the expenses on their income statements in a manner similar to current practice. Under the new guidance, the Company would also require to provide enhanced disclosures. The guidance states that a lessee would recognize a lease liability for the obligation to make lease payments and a right-to-use asset for the right to use the underlying asset for the lease term. The guidance will be effective for the Company as of January&#160;1, 2022, and interim periods in fiscal&#160;years beginning January&#160;1, 2023. The Company is in the initial stage of its assessment of the new standard and is currently evaluating the timing of adoption, the quantitative impact of adoption, and the related disclosure requirements. The Company anticipates the adoption of this standard will result in an increase in its noncurrent assets, and current and noncurrent liabilities recorded on the consolidated balance sheets. The Company is currently evaluating the effect that ASU No.&#160;2016-02 will have on its consolidated financial statements and related disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;In August&#160;2020, the FASB issued ASU&#160;2020-06,&#160;Debt&#160;- Debt with Conversion and Other Options (Subtopic&#160;470-20)&#160;and Derivatives and Hedging&#160;- Contracts in Entity&#x2019;s Own Equity (Subtopic&#160;815-40):&#160;Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity (&#x201c;ASU&#160;2020-06&#x201d;).&#160;The final guidance issued by the FASB for convertible instruments eliminates two of the three models in ASC&#160;470-20&#160;that require separate accounting for embedded conversion features. Separate accounting is still required in certain cases. Additionally, among other changes, the guidance eliminates some of the conditions for equity classification in ASC&#160;815-40-25&#160;for contracts in an entity&#x2019;s own equity. The guidance also requires entities to use the&#160;if-converted&#160;method for all convertible instruments in the diluted earnings per share calculation and include the effect of share settlement for instruments that may be settled in cash or shares, except for certain liability-classified share-based payment awards. ASU&#160;2020-06&#160;is effective for fiscal&#160;years beginning after December&#160;15, 2023, and interim periods within those fiscal&#160;years. The Company is currently evaluating the potential impact of this guidance on its consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"&gt;In November&#160;2021, the FASB issued ASU No.&#160;2021-10, &#x201c;Government Assistance (Topic 832): Disclosure by Business Entities about Government Assistance.&#x201d; The new standard improves the transparency of government assistance received by most business entities by requiring the disclosure of: (1)&#160;the types of government assistance received; (2)&#160;the accounting for such assistance; and (3)&#160;the effect of the assistance on a business entity&#x2019;s financial statements. This guidance is effective for financial statements issued for annual periods beginning after December&#160;15, 2021. Early adoption is permitted. The Company does not expect the adoption of the standard will have a material impact on its consolidated financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <drts:PrepaidExpensesAndOtherReceivablesTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_oVx9mW7qFUyCxhpadinY6g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:54pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;NOTE&#160;3:-&lt;/b&gt;&lt;/span&gt;PREPAID EXPENSES AND OTHER RECEIVABLES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:72pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Government authorities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 472&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 458&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 387&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 227&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Other receivables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 864&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 707&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</drts:PrepaidExpensesAndOtherReceivablesTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_A8bJVpjvxkiVn5zGoVqDFw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:72pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Government authorities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 472&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 458&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 387&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 227&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Other receivables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 864&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 707&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <drts:GovernmentAuthoritiesReceivable
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="-3"
      id="Tc_GyBy6dafM0K-RftMHxD2hA_3_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">472000</drts:GovernmentAuthoritiesReceivable>
    <drts:GovernmentAuthoritiesReceivable
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc_sED1PXDBiE6muKbiR-KqZA_3_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">458000</drts:GovernmentAuthoritiesReceivable>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="-3"
      id="Tc_VE8pUbYQF0CydoTh-R7xtg_4_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">387000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc_sjRJraIkfUaoAbns2L1Eqg_4_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">227000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <us-gaap:OtherReceivables
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="-3"
      id="Tc_bBxWUwQ99kqHfO4aKqxsQA_5_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">5000</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc_3ix18_2mHkWt_QziiY-vaQ_5_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">22000</us-gaap:OtherReceivables>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="-3"
      id="Tc_AuD70tTRBk2opoNUIH6f1A_6_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">864000</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc_-tvmRLhgwEWd1MQJq-okAw_6_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">707000</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_Nwjfq-c0NkqdJpjXGUSf7g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:54pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;NOTE&#160;4:-&lt;/b&gt;&lt;/span&gt;PROPERTY AND EQUIPMENT, NET&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:72pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Cost:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Manufacturing equipment *)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,058&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,238&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Computers and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 128&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 394&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 251&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 719&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Furniture and office equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 37&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 50&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Cars&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 57&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 57&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 34&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,565&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,458&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 170&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 912&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Depreciated cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,395&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,546&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Depreciation expenses amounted to $ 66, $ 86 and $ 776 for the&#160;years ended December&#160;31, 2019, 2020 and 2021, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"&gt;During 2021 total cost of $ 34 and total accumulated depreciation of $ 34 were disposed from the consolidated balance sheets.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_2bQftDLW1kuyoZ8U1hpr_g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:72pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Cost:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Manufacturing equipment *)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,058&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,238&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Computers and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 128&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 394&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 251&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 719&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Furniture and office equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 37&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 50&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Cars&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 57&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 57&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 34&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,565&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,458&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 170&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 912&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Depreciated cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,395&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,546&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_Tsmzg43NZEq8r_rl1YdOkQ"
      decimals="-3"
      id="Tc_QAZyN1g0OUOt-TfwL8XRIw_5_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">5058000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_bFz5PWOuYUWTs4rHFVh4Ig"
      decimals="-3"
      id="Tc_-H7D3yS4PECq3OT2aL3UCA_5_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">7238000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_kmZMVTkZDk-WlRLrABkDOA"
      decimals="-3"
      id="Tc_fIUEfgFaSkO3CSk1OMKi_A_6_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">128000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_DR2lnPTSYkOr47Js9w5IFQ"
      decimals="-3"
      id="Tc_s8I2EXdeyEeRIH2GLWx2Xw_6_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">394000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_drts_LaboratoryEquipmentMember_HT92yqEwAU2zKGWsZbh7gA"
      decimals="-3"
      id="Tc_ev7fLVz-60ah-F3OLbN_bQ_7_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">251000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_drts_LaboratoryEquipmentMember_GAJWzUvUwEyFjKgZHPzslw"
      decimals="-3"
      id="Tc_m28JFWrN7EG3Luy1scLgzA_7_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">719000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_q_uetuy3B0Wa4ahNzfjYhA"
      decimals="-3"
      id="Tc_swQbsozngUWjtsTIpG5WiA_8_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">37000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_BpY3NXZYiUacPgGpq8sVxA"
      decimals="-3"
      id="Tc_NAf_vAAoC0eHDSA2LijDUg_8_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">50000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AutomobilesMember_50PifpuGVkegwyS9RNi4Cw"
      decimals="-3"
      id="Tc_arpLIw1q2kas0XxGr8MCyQ_9_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">57000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AutomobilesMember_nSEbQEFkgkqLdoCosAad7A"
      decimals="-3"
      id="Tc_h9kOZIz-GUWujj8tRG44Sw_9_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">57000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_JS-1SNXCvUeJpcN2z_gkow"
      decimals="-3"
      id="Tc_iz6mJiCjM0OrsPC0VWNoeg_10_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">34000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="-3"
      id="Tc_uSnbjcPGjkGnfjRbjkrJ_g_12_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">5565000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc_NNMJbjXiYUydIdM-7n9Cbw_12_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">8458000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="-3"
      id="Tc_XFdJajl2lUqTbXqKzem7BA_14_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">170000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc_Tqf5ZBHHukm46szhICQycw_14_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">912000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="-3"
      id="Tc_fgsuIuIagU25EJ3Tk_EjEQ_15_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">5395000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc_R9WbglXQukWoEE9OAyL4kQ_15_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">7546000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Narr_fzIyElhJ1UmUou5i9UTV7w"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">66000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Narr_0x7yMYgYj0q8Oj4GBBj9Dg"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">86000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Narr_MRQ19UQtuU6qxkbENG2P1g"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">776000</us-gaap:Depreciation>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Narr_teaz7oUEyEawfEzFhm11JQ"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">34000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Narr_Bdw5VXojXUqQyr03zUYv4w"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">34000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1>
    <drts:OtherPayablesAndAccruedExpensesDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_K7jVViZ4U0Welyk3WPHuBg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:54pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;NOTE&#160;5:-&lt;/b&gt;&lt;/span&gt;OTHER PAYABLES AND ACCRUED EXPENSES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:72pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Employees and payroll accruals&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 525&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 788&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 551&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,366&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 48&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 48&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,124&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,202&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</drts:OtherPayablesAndAccruedExpensesDisclosureTextBlock>
    <drts:ScheduleOfOtherPayablesAndAccruedExpensesTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_Gmwd40FptEiUGD3PF2PGmg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:72pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Employees and payroll accruals&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 525&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 788&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 551&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,366&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Related parties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 48&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 48&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,124&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,202&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</drts:ScheduleOfOtherPayablesAndAccruedExpensesTableTextBlock>
    <us-gaap:AccruedSalariesCurrent
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="-3"
      id="Tc_dwrU8slzm0m24Oo4N4r1Gg_3_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">525000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc_5yPEaAYSXEGRNLj1IerwGg_3_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">788000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="-3"
      id="Tc_MDvyY-k2jEu0D02FvL2heQ_4_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">551000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc_GMD-tWIKcEq-Ha-3b_gDEA_4_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">2366000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableRelatedPartiesCurrent
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="-3"
      id="Tc_TqS1g_q8p0GsGx_H35hAwA_5_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">48000</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:AccountsPayableRelatedPartiesCurrent
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc_9IqpkyUGD0-GChfEvdOcmQ_5_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">48000</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="-3"
      id="Tc_J34WQswSoEuSV9IQFhhimg_6_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">1124000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc_-3WF0pZ3bkqHeK-toAZuZw_6_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">3202000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_qnqHWrHTCE-Sb69GnVPO7w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:54pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;NOTE&#160;6:-&lt;/b&gt;&lt;/span&gt;COMMITMENTS AND CONTINGENT LIABILITIES&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;a.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The Company&#x2019;s facilities are leased under operating lease agreements for periods ending no later than 2035. The Company also leases motor vehicles under various operating leases, the latest of which expires in 2024.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Certain motor vehicles of the Company are rented under non-cancellable operating lease agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:54pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;NOTE&#160;6:-&lt;/b&gt;&lt;/span&gt;COMMITMENTS AND CONTINGENT LIABILITIES (Cont.)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Future minimum lease payments under operating leases as of December&#160;31, 2021 are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:72pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December 31, 2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 775&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 722&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 724&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 590&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 605&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,948&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,364&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Rental and lease expenses for the&#160;years ended December&#160;31, 2019, 2020 and 2021 were $ 158, $ 408 and $ 803 respectively.&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;b.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Guarantee in the amount of $&#160;618 &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;was issued by a bank to secure rent payments.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;c.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The Company has received royalty-bearing grants from the IIA to finance its research and development programs in Israel, through which the Company received IIA participation payments in the aggregate amount of $ 4,065 &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;through December&#160;31, 2021. In return, the Company is committed to pay IIA royalties at a rate of 3-3.5% of future sales of the developed products, up to 100% of the amount of grants received plus interest at LIBOR rate. Through December&#160;31, 2021, no royalties have been paid or accrued. In addition, under the intellectual property purchase agreement with Althera, the Company assumed all of Althera&#x2019;s liabilities towards the IIA totaling $ 474 of royalty-bearing grants received by Althera (plus accrued interest at LIBOR rate). The Company&#x2019;s liability to the IIA at December&#160;31, 2021, including royalty-bearing grants received by the Company, grants assumed from Althera and the associated LIBOR interest accrued on all such grants, totaled $ 5,061.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;d.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Under the February&#160;2, 2016 intellectual property purchase agreement with Althera, the Company is obligated to pay Althera a fixed rate of 2% (plus VAT) of Company&#x2019;s future gross revenues (as defined in the agreement) that are derived from the purchased intellectual property, up to a maximum amount of $ 1,500 &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;(plus VAT), in the aggregate, with the potential to set off against certain payments made by the Company to the IIA.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;e.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The Company also entered into intellectual property agreements with Ramot at Tel Aviv University&#160;Ltd., the technology transfer company of Tel Aviv University (&#x201c;Ramot&#x201d;) on April&#160;21, 2016 and July&#160;14, 2016, all as amended on May&#160;5, 2019, pursuant to which the Company is obligated to pay Ramot a fixed royalty of 2.5% on net sales of all of the Company&#x2019;s products (as defined in the agreement) by the Company and its affiliates, with no set maximum. The royalty will be payable as of the first commercial sale (as defined in the agreement), until the later of: 15&#160;years; or until the last to expire of the patents or patent applications from research developed at Tel Aviv University and assigned to the Company, on a country-by-country, product-by-product basis. The Company is also obligated to pay a 7% royalty (and in no event less than 0.65% of the net sales of Company products sold by the Company&#x2019;s licensees in a given&#160;year) on any royalties or revenues received by the Company from its licensees.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:54pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;NOTE&#160;6:-&lt;/b&gt;&lt;/span&gt;COMMITMENTS AND CONTINGENT LIABILITIES (Cont.)&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;f.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Under an Operations Partner Agreement between the Company and services provider HekaBio K.K. of May&#160;21, 2019, the Company makes certain payments to HekaBio K.K. in exchange for consulting and administrative services in Japan, as well as payments upon the achievement of certain clinical and regulatory milestones. In addition, if HekaBio K.K. successfully assists the Company in obtaining regulatory marketing approval of the Company&#x2019;s products in Japan, then the Company is to grant to HekaBio K.K. options to acquire 271,588 &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;of the Company&#x2019;s ordinary shares at a price of $4.42 each, and to pay HekaBio K.K. a royalty of 3.5% of the reimbursement price (as defined in the agreement) of such products in Japan and 10% of revenues received by the Company from distribution receipts (as defined in the agreement) for such products in Japan.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;g.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;On November&#160;18, 2018 and July&#160;29, 2019, the Company entered into research and license agreements with BGN Technologies, the technology transfer company of Ben Gurion University (&#x201c;BGN&#x201d;), further amended on May&#160;12, 2021, wherein the Company will wholly own any intellectual property that is developed jointly by Ben Gurion University and others (including the Company), and BGN will receive 0.75% royalties on all sales of the Company&#x2019;s alpha radiation products, net of certain deductions and irrespective of the intellectual property underlying such sales, or 1.5% royalties on sales of products that contain intellectual property owned by Ben Gurion University, net of certain deductions. BGN will receive 4% of license revenues (as defined in the agreements) that relate to jointly developed intellectual property, and 8% of license revenues that relate to intellectual property developed solely by Ben Gurion University. The parties also agreed that the Company will continue to conduct research at Ben Gurion University for as long as the researchers wish to and the parties have agreed on a research budget in good faith.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;h.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;On December&#160;1, 2020, the Company entered into a clinical trial agreement with Cambridge University Hospitals NHS Trust, wherein Cambridge will receive 5% of any marginal increase in the Company&#x2019;s net sales (all as defined in the agreement) generated on account of any patent or patent claim granted from the research performed in such trial, and 2% of the Company&#x2019;s net sales (minus the aforementioned marginal increase payment) received for the treatment of Squamous Cell Carcinoma of the vulva, for three&#160;years from the date of first sale, world-wide.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_MXnlhY92N0KtM5lbtJgNrQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:72pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December 31, 2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 775&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 722&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 724&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 590&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 605&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,948&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,364&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc_v_2-A0ENw0qZs-lM4mpf2w_2_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">775000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc_h2NevaM4SEio0tfy8qmJXA_3_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">722000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc_axap3N1jlEKgQQx82eWLXQ_4_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">724000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc_Q_-uF4hanE6p-FmRyzmpVA_5_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">590000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc_04vZbE8EsUqoTX2gttY2cA_6_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">605000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc__5gW6V76kUechUuVjESEqQ_7_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">4948000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc_d9bIYswFNUy-_hkiQY4jtA_8_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">8364000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Narr_XNJ3aOPQdk-paUWZsq4MmQ"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">158000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Narr_V4y47tk9bkigRr6L8tqZfg"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">408000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Narr_IB5FFgibvEqwMp45adD3eA"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">803000</us-gaap:OperatingLeaseExpense>
    <us-gaap:ShortTermBankLoansAndNotesPayable
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Narr_7VeVTuaLqEqf4o89tTvauw"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">618000</us-gaap:ShortTermBankLoansAndNotesPayable>
    <drts:GrantIncome
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_IsraeliInnovationAuthorityMember_xhyc0CWH6kS_-vAND8TX1Q"
      decimals="-3"
      id="Narr_StBjmQqxj06fn54ybNHsgQ"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">4065000</drts:GrantIncome>
    <drts:RoyaltyRate
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_IsraeliInnovationAuthorityMember_drts_MethodOfPaymentRoyaltiesAxis_drts_FutureSalesOfDevelopedProductMember_srt_RangeAxis_srt_MinimumMember_GIY9mAr40kOVwTeAjK_dRA"
      decimals="INF"
      id="Narr_wynE00lxQEi0JL2zEUsMGg"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.03</drts:RoyaltyRate>
    <drts:RoyaltyRate
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_IsraeliInnovationAuthorityMember_drts_MethodOfPaymentRoyaltiesAxis_drts_FutureSalesOfDevelopedProductMember_srt_RangeAxis_srt_MaximumMember_FUMYd9CZyEiec-h-1tOPiQ"
      decimals="3"
      id="Narr_GtDbNlfsrEyZkcGnfgEZBw"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.035</drts:RoyaltyRate>
    <drts:RoyaltyPaymentAsPercentageOfGrants
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_IsraeliInnovationAuthorityMember_drts_MethodOfPaymentRoyaltiesAxis_drts_FutureSalesOfDevelopedProductMember_JSAQ3iw-VUSQibua7dXDzw"
      decimals="INF"
      id="Narr_bLvwG19yjkOfG8wBh9cSgw"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">1</drts:RoyaltyPaymentAsPercentageOfGrants>
    <us-gaap:RoyaltyExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_IsraeliInnovationAuthorityMember_xhyc0CWH6kS_-vAND8TX1Q"
      decimals="-3"
      id="Narr_ISMNpUAgn0qBo9UrEBWETA"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">0</us-gaap:RoyaltyExpense>
    <us-gaap:LiabilitiesAssumed1
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_AltheraMember_GvfqErhqZEeZc_TxFNeN5g"
      decimals="-3"
      id="Narr_y3FbNTMxBUmjC-9d-cilqA"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">474000</us-gaap:LiabilitiesAssumed1>
    <us-gaap:LiabilitiesAssumed1
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_IsraeliInnovationAuthorityMember_xhyc0CWH6kS_-vAND8TX1Q"
      decimals="-3"
      id="Narr_DXEfAwkXjUmUtdQvqjGujA"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">5061000</us-gaap:LiabilitiesAssumed1>
    <drts:RoyaltyRate
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_AltheraMember_drts_MethodOfPaymentRoyaltiesAxis_drts_FutureGrossRevenuesDerivedFromPurchasedIntellectualPropertyMember_nP72Cyn7NkCYPc6GpcX5BA"
      decimals="INF"
      id="Narr_MsvETEHWXUiqi1RWvb6X_Q"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.02</drts:RoyaltyRate>
    <drts:PotentialPayment
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_AltheraMember_GvfqErhqZEeZc_TxFNeN5g"
      decimals="-3"
      id="Narr_HknZo7dJwkKb2lYgl6KuRg"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">1500000</drts:PotentialPayment>
    <drts:RoyaltyRate
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_RamotMember_drts_MethodOfPaymentRoyaltiesAxis_drts_NetSalesOfAllCompanySProductMember_xoU_wft5E0-hugLOshOmLg"
      decimals="3"
      id="Narr_ul90UdyqQUm-4A59mXkepw"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.025</drts:RoyaltyRate>
    <drts:RoyaltyRate
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="INF"
      id="Narr_kAtkdQ6VQkOy5smrUo6BVA"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.07</drts:RoyaltyRate>
    <drts:RoyaltyPaymentAsPercentageOfGrants
      contextRef="Duration_1_1_2021_To_12_31_2021_drts_MethodOfPaymentRoyaltiesAxis_drts_NetSalesOfAllCompanySProductSoldByCompanySLicensesMember_gkrRFhGJnEimcQjvPTPPcQ"
      decimals="4"
      id="Narr_0AMeebIZf0KiEMfaAaVk0g"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.0065</drts:RoyaltyPaymentAsPercentageOfGrants>
    <drts:MilestoneNumberOfOrdinaryStockOptions
      contextRef="As_Of_12_31_2021_dei_LegalEntityAxis_drts_HekaBioKKMember_k78dGWWtOUezu7C6qI5GDg"
      decimals="INF"
      id="Narr_xPxDsEuKwE6FyYTcYxl8-g"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">271588</drts:MilestoneNumberOfOrdinaryStockOptions>
    <drts:StockOptionExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_HekaBioKKMember_KbAb2SB6LkyHj7B8hsEHXQ"
      decimals="4"
      id="Narr_rO2i-7IAx0G039l39H2aPQ"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.0442</drts:StockOptionExercisePrice>
    <drts:RoyaltyRate
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_HekaBioKKMember_drts_MethodOfPaymentRoyaltiesAxis_drts_ReimbursementPriceMember_cs_dWcRnWUyl8xd3aQkyBQ"
      decimals="3"
      id="Narr_XM3U9BwtS0WTK89xc-eMjg"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.035</drts:RoyaltyRate>
    <drts:RoyaltyRate
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_HekaBioKKMember_drts_MethodOfPaymentRoyaltiesAxis_drts_DistributionReceiptsMember_B9pb87J-lk2fbjT-Lab7cw"
      decimals="INF"
      id="Narr_6YV7E_eQ70q48p-kOfdMKQ"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.10</drts:RoyaltyRate>
    <drts:RoyaltyRate
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_BgnTechnologiesMember_drts_MethodOfPaymentRoyaltiesAxis_drts_SalesOfAlphaRadiationProductsMember_fGiGrutCqkW4dBwjPHMKtw"
      decimals="4"
      id="Narr_AwFoqWuYbUeq1nj1M8EtWg"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.0075</drts:RoyaltyRate>
    <drts:RoyaltyRate
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_BgnTechnologiesMember_drts_MethodOfPaymentRoyaltiesAxis_drts_SalesOfProductContainingIntellectualPropertyMember_l6QmPIm-lka3XHyr-5FdgQ"
      decimals="3"
      id="Narr_qH6Hfdf5gECNuSLaOmR76A"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.015</drts:RoyaltyRate>
    <drts:RoyaltyRate
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_BgnTechnologiesMember_drts_MethodOfPaymentRoyaltiesAxis_drts_LicenseRevenueToJointlyDevelopedIntellectualPropertyMember_E5RwUYMMMkKa7VOuc2eEbA"
      decimals="INF"
      id="Narr_xlZmf6qgS0iTVy3NAl5q-w"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.04</drts:RoyaltyRate>
    <drts:RoyaltyRate
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_BgnTechnologiesMember_drts_MethodOfPaymentRoyaltiesAxis_drts_LicenseRevenueRelatedToIntellectualPropertyMember_MPPvAjzvLEWclU5g9v1-PA"
      decimals="INF"
      id="Narr_ss8UXautmUCvpYZtVyFp5w"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.08</drts:RoyaltyRate>
    <drts:RoyaltyRate
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_CambridgeUniversityHospitalsNhsTrustMember_drts_MethodOfPaymentRoyaltiesAxis_drts_RevenueGeneratedFromPatentMember_j1N6BX57fkmmH4t4HBjQrg"
      decimals="INF"
      id="Narr_39hD0WdMuUmQ3c7ZlXA-Pg"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.05</drts:RoyaltyRate>
    <drts:RoyaltyRate
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_drts_CambridgeUniversityHospitalsNhsTrustMember_drts_MethodOfPaymentRoyaltiesAxis_drts_NetSalesSquamousCellCarcinomaMember_oyhYZ1hIYEeJctRg2MllLA"
      decimals="INF"
      id="Narr_iHnyEg4tBEWmPOkO8MR7uA"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.02</drts:RoyaltyRate>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_xuzMFPceAUKIZ9-gUijzRA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:54pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;NOTE&#160;7:-&lt;/b&gt;&lt;/span&gt;FAIR VALUE MEASUREMENTS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Financial instruments measured at fair value on a recurring basis include warrants to convertible preferred shares (see note 9). The warrants are classified as a liability in accordance with ASC 480-10-25. These warrants were classified as level 3 in the fair value hierarchy since some of the inputs used in the valuation (the share price) were determined based on management&#x2019;s assumptions. To calculate the fair value of the warrants, the Company first calculated the underlying preferred share value by using the income approach and the market approach. Then the equity value was allocated by using the hybrid model method utilizing two scenarios of OPM and IPO. Once the preferred shares value was derived from the two scenarios, the &lt;span style="-sec-ix-hidden:Hidden_L9Ato0C33E2LNSpyydoKvQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Black-Scholes model&lt;/span&gt;&lt;/span&gt; was utilized to calculate the warrants value in each one of the scenarios. Then, probability for each one of the scenarios was applied by the Company to derive the weighted average fair value of the warrants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:54pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;NOTE&#160;7:-&lt;/b&gt;&lt;/span&gt;FAIR VALUE MEASUREMENTS (Cont.)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The following table summarizes the assumptions used by the Company in the Black-Scholes model:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:72pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 78.11&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 96.83&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 83.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The change in the fair value of the preferred share warrants liability is summarized below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:72pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Beginning of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,163&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,366&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Change in fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 203&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,257&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;End of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,366&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,623&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <drts:NumberOfScenariosInAllocatingValueToWarrants
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="INF"
      id="Narr_pl6hBlaTXEeJvdMnKew2wA"
      unitRef="Unit_Standard_item_AGp3CTLP9EiC4gKcttUqYA">2</drts:NumberOfScenariosInAllocatingValueToWarrants>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_9GeJDP6220utYp6sGeRjCA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:72pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 78.11&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 96.83&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 83.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2019_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_56RoFMzD20emutTGyd2S_g"
      decimals="0"
      id="Tc_tR4WPj4lY0SD0aE6STZBjQ_3_2"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">3</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_gKe2q9eKk0e3gwlR_9b76A"
      decimals="2"
      id="Tc_-5N4LpejskmGljYiUm6ZFw_3_4"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">2.25</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_ajdK4nogIEm72h8iR_gO5g"
      decimals="2"
      id="Tc_Tgx-Q50_UUategiaMMor9g_3_6"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">1.25</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2019_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_wDZnSvtkgU6z66pKDtkfXQ"
      decimals="2"
      id="Tc_H37tOyHy-ES98QEWfTZV1A_4_2"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_26q-bJ04nk64a6-bSVGKkA"
      decimals="2"
      id="Tc_V4JQ4JmBuUSl24t4-N-RpA_4_4"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_hKjTfEKuFUCkwF-mupksAw"
      decimals="2"
      id="Tc_coMB9NQ7rEmvjeUgjEVPEw_4_6"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2019_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_1CGa6Hpjaku4CPgZdTORGw"
      decimals="2"
      id="Tc_GfyNTtjVxU2ggk8HdSIWuw_5_2"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">78.11</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_6C1-PLSDy0mfoXDzXtxQwA"
      decimals="2"
      id="Tc_CT3Oh7-fDEmi-Y3rrYxltw_5_4"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">96.83</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_DDHUZat3sk6fWEo027gkiw"
      decimals="2"
      id="Tc_IIAy7K9qUEmYhJsxEM5p2Q_5_6"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">83.00</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2019_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_66Y1DeYIKEiZUIV-AiM0QQ"
      decimals="2"
      id="Tc_nMawejZue0iJft-bNoWtbA_6_2"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">1.91</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_Jm9aG3RQCE2XotHJYhCprg"
      decimals="2"
      id="Tc_6lD1eGQPWkO983kzmJJXew_6_4"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.42</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_o8AlyFK5_0q1GKpbfc38VQ"
      decimals="2"
      id="Tc_Jic2gs-Nw0u2shbHdr_uDQ_6_6"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.75</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_Nu4NqvJ9JUOjHenGYgB65w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:72pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Beginning of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,163&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,366&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Change in fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 203&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,257&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;End of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,366&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,623&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2019_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_762hkA1xekWBcZRYtQnetQ"
      decimals="-3"
      id="Tc_wN9DsGgmVUqsoXXMqJJyoQ_2_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">5163000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_Vcye6381VUeQWqckP0fFwQ"
      decimals="-3"
      id="Tc_q5TPX_Usm0G-hrBMR5B0lQ_2_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">5366000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_58F--dymdEiPpkMxGCFxLg"
      decimals="-3"
      id="Tc_PyseJCEAaEW_VqR16KtKeQ_3_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">203000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_2ghnd2En8UiT0zWguTDZrw"
      decimals="-3"
      id="Tc_8XVSXLw6aES0eRA_QKc5eg_3_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">13257000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_Vcye6381VUeQWqckP0fFwQ"
      decimals="-3"
      id="Tc_9umelgUPZUORcE8gROXnEg_4_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">5366000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_dsprqrhawkyPoi6VXySrYA"
      decimals="-3"
      id="Tc_SVJNtq9Fck284daUd4x9mQ_4_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">18623000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_SB6YFDBvvkiYSJVseZCksw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:54pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;NOTE&#160;8:-&lt;/b&gt;&lt;/span&gt;INCOME TAXES&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;a.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Tax rate applicable to Company:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The corporate tax rate in Israel in 2019, 2020 and 2021 was 23%.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The Company has the status of an &#x201c;Preferred Company&#x201d; and &#x201c;Preferred Technological Enterprise&#x201d;, as defined in the Law for the Encouragement of Capital Investments, 5719-1959 and is subject to a reduced tax rate. The reduced tax rates at development area A in which the Company&#x2019;s offices are located is 7.5%, subject to various conditions.&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;b.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Income taxes on non-Israeli subsidiaries:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The Company&#x2019;s subsidiaries are separately taxed under the domestic tax laws of the jurisdiction of incorporation of each entity.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Tax rate applicable to ATM Inc:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;On December&#160;22, 2017, the United States enacted the Tax Cuts and Jobs Act (the &#x201c;U.S. Tax Reform&#x201d;); a comprehensive tax legislation that includes significant changes to the taxation of business entities. These changes, most of which are effective for tax&#160;years beginning after December&#160;31, 2017, include several key tax provisions that might impact the Company, among others: (i)&#160;a permanent reduction to the statutory federal corporate income tax rate from 35% (top rate) to 21% (flat rate) effective for tax&#160;years beginning after December&#160;31, 2017 ((ii)&#160;stricter limitation on the tax deductibility of business interest expense; (iii)&#160;a shift of the U.S. taxation of multinational corporations from a tax on worldwide income to a territorial system (along with certain rules&#160;designed to prevent erosion of the U.S. income tax base)&#160;(iv)&#160;a&#160;one-time&#160;deemed repatriation tax on accumulated offshore earnings held in cash and illiquid assets, with the latter taxed at a lower rate and (v)&#160;an expansion of the U.S. controlled foreign corporation (&#x201c;CFC&#x201d;) anti deferral starting with the CFC&#x2019;s first tax&#160;year beginning in 2018 intended to tax in the U.S. &#x201c;global intangible&#160;low-taxed&#160;income&#x201d; (&#x201c;GILTI&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:54pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;NOTE&#160;8:-&lt;/b&gt;&lt;/span&gt;INCOME TAXES (Cont.)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Tax rate applicable to ATM KK (Japan-Tokyo):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The General Corporation tax (national tax in Japan) rate is 23.2% for fiscal&#160;years beginning after April&#160;2018. Local taxes are also applicable in different rates and may result in a higher effective tax rate (for example, for Tokyo-based companies the effective statutory tax rate would generally be 30.62% for large companies, and 33.6% for small companies). Special rate of 15% is applicable on the first JPY &lt;span style="-sec-ix-hidden:Hidden_Z-DGe3jtHEK1rvKDxu5T2w;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;8M&lt;/span&gt;&lt;/span&gt; for small and medium companies (19% for larger companies for fiscal&#160;years from April&#160;2019).&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;c.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The components of the net loss (income) before tax on income were as follows:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:72pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;width:32.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year&#160;ended&lt;/b&gt;&#160;&lt;br/&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Domestic (Israel)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,898&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,322&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,089&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (580)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (598)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 175&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,318&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,724&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,264&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Income tax expense was as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:72pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;width:32.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year&#160;ended&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Current:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Israel&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 146&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 158&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total current income tax expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 146&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 158&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Domestic (Israel)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total deferred income tax expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Income tax expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 146&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 158&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;d.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Net operating losses carry forward:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The Company has accumulated losses for tax purposes as of December&#160;31, 2021 in the amount of approximately $ 39,585 which may be carried forward and offset against taxable income in the future for an indefinite period.&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;e.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Deferred taxes:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company&#x2019;s deferred tax assets are comprised of operating loss carryforwards and other temporary differences.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:54pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;NOTE&#160;8:-&lt;/b&gt;&lt;/span&gt;INCOME TAXES (Cont.)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Significant components of the Company&#x2019;s deferred tax assets are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:72pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Reserves and allowances&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;R&amp;amp;D expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 482&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 399&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 44&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 134&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Loss carryforward&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,551&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,322&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax assets before valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,233&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,803&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less - valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,233)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,803)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Management currently believes that since the Company has a history of losses, and there is uncertainty with respect to future taxable income of the Company, it is more likely than not that the deferred tax assets will not be utilized in the foreseeable future. Thus, a full valuation allowance was provided to reduce deferred tax assets to their realizable value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;In 2020 and 2021 the main reconciling item for the Company&#x2019;s tax rate is tax loss carryforwards and temporary differences, for which a full valuation allowance was provided.&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;f.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Tax assessment:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"&gt;The Company has not received assessments since its inception.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2019_To_12_31_2021_rqAxnV6ZuUS7C0LOKQQJbw"
      decimals="INF"
      id="Narr_r7XoOBpyu0K2law5Jce99w"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">23</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <drts:IncomeTaxRateReconciliationPreferredCompanyPercent
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="3"
      id="Narr_pi66g6xS5EaYhwhtcSk9kA"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.075</drts:IncomeTaxRateReconciliationPreferredCompanyPercent>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_drts_AtmIncMember_srt_StatementGeographicalAxis_country_US_at7B-1SAeEur5CA5l3wWEA"
      decimals="INF"
      id="Narr_tV2GeW5EREa2Fj2RvHdHKA"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">35</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <drts:IncomeTaxRateReconciliationPreferredCompanyPercent
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_drts_AtmIncMember_srt_StatementGeographicalAxis_country_US_at7B-1SAeEur5CA5l3wWEA"
      decimals="INF"
      id="Narr_5M1N8MMFW0ewEW15U55tTw"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.21</drts:IncomeTaxRateReconciliationPreferredCompanyPercent>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_drts_AtmKkMember_srt_StatementGeographicalAxis_country_JP_7CxdZ9e-1k-8KSkiHCA2Aw"
      decimals="1"
      id="Narr_RSnI7amxGEaDY2ZxY4i0WQ"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">23.2</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <drts:IncomeTaxRateReconciliationLargeCompaniesPercent
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_drts_AtmKkMember_srt_StatementGeographicalAxis_country_JP_7CxdZ9e-1k-8KSkiHCA2Aw"
      decimals="4"
      id="Narr_0JrhebRaaUunQX1NcuoZKw"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.3062</drts:IncomeTaxRateReconciliationLargeCompaniesPercent>
    <drts:IncomeTaxRateReconciliationSmallCompaniesPercent
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_drts_AtmKkMember_srt_StatementGeographicalAxis_country_JP_7CxdZ9e-1k-8KSkiHCA2Aw"
      decimals="3"
      id="Narr_xQHFf-YpbEe8Hl0dmcEJbw"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.336</drts:IncomeTaxRateReconciliationSmallCompaniesPercent>
    <drts:IncomeTaxRateReconciliationMediumCompaniesSpecialRatePercent
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_drts_AtmKkMember_srt_StatementGeographicalAxis_country_JP_7CxdZ9e-1k-8KSkiHCA2Aw"
      decimals="INF"
      id="Narr_QVjue2-xnk-MzO4eMAJW3g"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.15</drts:IncomeTaxRateReconciliationMediumCompaniesSpecialRatePercent>
    <drts:IncomeTaxRateReconciliationLargeCompaniesPercent
      contextRef="Duration_4_1_2019_To_4_30_2019_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_drts_AtmKkMember_srt_StatementGeographicalAxis_country_JP_zK9sUscq3kOiuunJG2qXkg"
      decimals="INF"
      id="Narr_DxAX7LXl5k2iC40uLUf-Pg"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.19</drts:IncomeTaxRateReconciliationLargeCompaniesPercent>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_RmZcztoMLk2G-547xDrnWg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:72pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;width:32.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year&#160;ended&lt;/b&gt;&#160;&lt;br/&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Domestic (Israel)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,898&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,322&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,089&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (580)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (598)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 175&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,318&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,724&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,264&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc_82jhlFwlN0ilFF6EgHMsnQ_3_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">8898000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Tc_PqCjG_6otUiK9XgjqBDK-A_3_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">9322000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Tc_Ul88YUe98kCrtHRlxq0k6A_3_9"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">27089000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc_a1ftvA6ZnEexKIiNLdn05A_4_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-580000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Tc_mVvNxI1CdES1X2NSxYgjag_4_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-598000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Tc_TScSmAeCOEGQnhNn5YAR_w_4_9"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">175000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc_BMh12ZMip0S_Uqx2MY9EUQ_5_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">8318000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Tc_IUQuviWWOkyajM91qGVNpg_5_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">8724000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Tc_twyZPX_Vz0-NEhKnJNRqzg_5_9"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">27264000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_RGOEuEvVwkKyzkkb7TZgAQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:72pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;width:32.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year&#160;ended&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Current:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Israel&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 146&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 158&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total current income tax expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 146&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 158&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Domestic (Israel)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total deferred income tax expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Income tax expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 146&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 158&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc_t-VWuBQYLk-MQbcPq4GPZA_5_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">146000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Tc_SSHABaoEwkumsaIMPMxYcA_5_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">158000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Tc_OMu2rfJLbEqNQVVbot4Zhg_5_9"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">7000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc_KVJ6-dFfV0eCE65m1wkSPg_7_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">146000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Tc_q8loNIHJKk-w9C2Af8JSpQ_7_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">158000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Tc_vehROasGl0-S8cQ-6hZFnQ_7_9"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">7000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc_GBCUVHbZzUmbJTtRfMOoYQ_14_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-146000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Tc_QZpMUrVfu0OG03CIlRc6Hw_14_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-158000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Tc_cK4sYLfTREWNX2gKmJYHTw_14_9"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-7000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Narr_Wyhlk2VorEWca38qnxR9tw"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">39585000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_XJa80iGBA0ad2_pRKI3qlQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:72pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Reserves and allowances&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;R&amp;amp;D expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 482&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 399&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 44&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 134&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Loss carryforward&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,551&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,322&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax assets before valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,233&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,803&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less - valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,233)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,803)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="-3"
      id="Tc__QyktVYOEU6613hmlE4hDg_3_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">22000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc_jKcckGqXZ02MnpCirkMtdQ_3_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">18000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="-3"
      id="Tc_XaXQtB50SUmhAN7ja2c17A_4_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">482000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc_QNsm05hnaUGdpf_a6GxptQ_4_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">399000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="-3"
      id="Tc_wdGIYcY5V0yV0XHWsVjqKg_5_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">44000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc_FuTKtMp86E6GrGaeYoPY7g_5_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">31000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="-3"
      id="Tc_kUCIXnxx_EyX6OusFUGD0g_6_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">134000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc_PBm0XASeVE-c87EZFwPIDw_6_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">33000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="-3"
      id="Tc_tQpCjMUEXkaGyub7eSxyXQ_7_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">1551000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc_cgsyP96e_06lEv2cF67yqw_7_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">3322000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="-3"
      id="Tc_MkgBxPQksUqmtkU8q3Jw-Q_9_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">2233000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc_DqA0ROPFVkm2FLu1xZ2jAA_9_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">3803000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="-3"
      id="Tc_at_Cs4tjoEuGzVXa4DAQhA_10_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">2233000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc_68Ig5nK_7Eqwqgz9wfOhaA_10_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">3803000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <drts:TemporaryEquityTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_OehYXXtojkirkpWRddg-nw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:54pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;NOTE&#160;9:-&lt;/b&gt;&lt;/span&gt;CONVERTIBLE PREFERRED SHARES AND WARRANTS&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;a.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The Composition of the Company&#x2019;s Convertible Preferred shares is as follows:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:72pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:33.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Authorized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issued&#160;and&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Authorized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issued&#160;and&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;Carrying&#160;&lt;/b&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;Liquidation&#160;&lt;/b&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;preference&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="15" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:42.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&#160;shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A Convertible Preferred shares of no-par value *)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"&gt; 16,295,256&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"&gt; 7,229,885&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"&gt; 16,295,256&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"&gt; 7,229,885&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"&gt; 25,238&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"&gt; 36,437&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series B Convertible Preferred shares of no- par value *)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"&gt; 9,052,920&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"&gt; 6,509,301&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"&gt; 9,052,920&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"&gt; 6,509,301&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"&gt; 28,726&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"&gt; 28,761&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"&gt; 25,348,176&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"&gt; 13,739,186&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"&gt; 25,348,176&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"&gt; 13,739,186&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"&gt; 53,964&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"&gt; 65,198&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-left:72pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:72pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"&gt;*)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"&gt;Prior period results have been retroactively adjusted to reflect the 1: 0.905292 stock split effected on March&#160;7, 2022. See also note 10, Shareholders&#x2019; Deficiency, for details.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The Company issued Series&#160;A convertible preferred shares in 2018 and Series&#160;B convertible preferred shares in 2020. The Company classifies the convertible preferred shares outside of shareholders&#x2019; deficiency as required by ASC 480-10-S99, since these convertible preferred shares are entitled to liquidation preferences which may trigger a deemed liquidation event that is not solely within the Company&#x2019;s control.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:54pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;NOTE&#160;9:-&lt;/b&gt;&lt;/span&gt;CONVERTIBLE PREFERRED SHARES AND WARRANTS (Cont.)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Pursuant to the Company&#x2019;s Amended and Restated Articles of Incorporation (the &#x201c;AoA&#x201d;), a deemed liquidation event would occur, inter alia, upon the closing of the transfer of the Company&#x2019;s securities to a person or a group of affiliated persons, in one or a series of related transactions, if immediately after such transaction, such person or group of affiliated persons would hold 50%or more of the outstanding voting shares of the Company and upon the occurrence of the events listed in the AoA. For the&#160;years ended December&#160;31, 2021 and 2020, the Company did not adjust the carrying values of the convertible preferred shares to the deemed liquidation values of such shares since a deemed liquidation event was not probable at each balance sheet date. Subsequent adjustments to increase the carrying values to the ultimate liquidation values will be made only when it becomes probable that such a deemed liquidation event will occur. &lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;b.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Preferred shares rights:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The Preferred A and the Preferred B shares (collectively, the &#x201c;Preferred Shares&#x201d;) confer upon their holders all the rights conferred by Ordinary shares, in addition to certain rights stipulated in the Company&#x2019;s AoA, inter alia, the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;&lt;i style="font-style:italic;"&gt;Dividend rights&#160;- &lt;/i&gt;the convertible Preferred B shares shall be entitled to receive, prior and in preference to the declaration or payment of any dividend to the holders of any other class of shares, including the Preferred A shares, for each Preferred B share, cumulative dividends (whether paid in cash or otherwise) if and when declared by the Company&#x2019;s board of directors, in an amount equal to the Preferred B share original issue price (the &#x201c;Series&#160;B Dividend Preference&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Following the payment in full of all of the Series&#160;B Dividend Preference, the convertible Preferred A shares shall be entitled to receive, prior and in preference to the declaration or payment of any dividend to the holders of any other class of shares, including the ordinary shares, for each Preferred A share, cumulative dividends (whether paid in cash or otherwise) if and when declared by the Company&#x2019;s board of directors, in an amount equal to 1.25x the Preferred A share original issue price (the &#x201c;Series&#160;A Dividend Preference&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Following the payment in full of all of the Series&#160;A Dividend Preference, the holders of the Preferred Shares and the ordinary shares shall be entitled to receive, on a pro-rata, as-converted basis, any and all other dividends distributed by the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;&lt;i style="font-style:italic;"&gt;Liquidation rights&#160;-&lt;/i&gt; In the event of any event of liquidation or deemed liquidation event, the Company shall distribute all distributable proceeds first to the holders of the Preferred B shares, on a pro-rata basis among themselves, prior to and in preference to any payments to any of the holders of any other classes of shares, for each Preferred B share, the greater of: (a)&#160;the Preferred B share original issue price, plus an amount equal to the declared but unpaid dividends, less any Series&#160;B Dividend Preference amount previously declared and actually paid, and (b)&#160;the pro rata portion of the distributable proceeds the Preferred B shares would receive if all the distributable proceeds were distributed to all shareholders, on a pro-rata and as-converted-to-ordinary shares basis (the &#x201c;Series&#160;B Preference&#x201d;). In the event of insufficient distributable proceeds, distribution shall be done ratably among the holders of the Preferred B shares.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:54pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;NOTE&#160;9:-&lt;/b&gt;&lt;/span&gt;CONVERTIBLE PREFERRED SHARES AND WARRANTS (Cont.)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Following payment in full of the Series&#160;B Preference, the Company shall distribute the remaining distributable proceeds to the holders of Preferred A shares, on a pro-rata basis among themselves, prior to and in preference to any payments to any of the holders of any other classes of shares, for each Preferred A share, the greater of: (a)&#160;1.25x the Preferred A share original issue price, plus an amount equal to the declared but unpaid dividends, less any Series&#160;A Dividend Preference amount previously declared and actually paid, and (b)the pro rata portion of the distributable proceeds the Preferred A shares would receive if all the distributable proceeds were distributed to all shareholders, on a pro-rata and as-converted-to-ordinary shares basis (the &#x201c;Series&#160;A Preference&#x201d;). In the event of insufficient distributable proceeds, distribution shall be done ratably among the holders of the Preferred A shares.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Following the payment in full of the Series&#160;A Preference, the holders of the ordinary shares shall be entitled to receive, on a pro rata basis among themselves, any and all remaining distributable proceeds.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;&lt;i style="font-style:italic;"&gt;Voting rights&lt;/i&gt;&#160;- each holder of Preferred Shares is entitled to one&#160;vote per each share held by it (on an as-converted-to-ordinary share basis).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;&lt;i style="font-style:italic;"&gt;Conversion&lt;/i&gt;&#160;- each Preferred Share is automatically convertible into ordinary shares, at the respective holder&#x2019;s option, or automatically upon a qualified IPO of the Company or upon written demand of the Investor Majority (each as defined in the AoA) for each respective class of shares. The initial conversion ratio for each Preferred Share is 1:1.The conversion price per Preferred Share will be adjusted in the event of recapitalizations, share splits, ordinary share dividends, subdivisions and combinations of ordinary shares, as well in the event of certain anti-dilution events.&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;c.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Financing rounds:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;In September&#160;2018, the Company entered into a Share Purchase Agreement (as amended, the &#x201c;2018 SPA&#x201d;) with new and existing investors, pursuant to which 7,229,885 Preferred A shares and 3,614,960 warrants to Preferred A share were issued in consideration of approximately $ 29,150, reflecting a price per share of $ 4.03. Total issuance expenses were amounted to $ 91. The warrants to Preferred A Shares were recorded at fair value in the amount of $ 3,821 and the residual amount was allocated to the Preferred A Shares. The Preferred A shares can be converted into ordinary shares at a conversion ratio of 1:1, however such ratio is subject to amendment in certain situations and was adjusted in the context of the 2020 SPA, as more fully described above.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;In April&#160;2020, the Company entered into a Preferred B Share Purchase Agreement (as amended, the &#x201c;2020 SPA&#x201d;) with new and existing investors, pursuant to which 6,509,301 Preferred B shares were issued in consideration of approximately $ 28,761, reflecting a price per share of $ 4.42. Total issuance expenses amounted to $ 35. The Preferred B shares can be converted into ordinary shares at a conversion ratio of 1:1, subject to adjustment in certain situations, more fully described above.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;In conjunction with the 2020 SPA, the Company and the holders of the Preferred A shares agreed on a modified adjustment to the conversion ratio of Preferred A shares into ordinary shares as compared to the AoA in effect at that time. The conversion ratio of the Preferred A shares was adjusted to approximately 1.07:1, such that 7,229,885 Preferred A shares can be converted into 7,761,495 ordinary shares of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:54pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;NOTE&#160;9:-&lt;/b&gt;&lt;/span&gt;CONVERTIBLE PREFERRED SHARES AND WARRANTS (Cont.)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The revised Preferred A share conversion ratio, along with other amendments in the new agreement, did not result a substantial change in the fair value of the Preferred A shares. Therefore, the amendment to the agreement was accounted for as a modification.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;On July&#160;6, 2021, the Company&#x2019;s board of directors approved a 1: 0.905292 stock split which was effected on March&#160;7, 2022. As a result, all Ordinary shares, Convertible preferred shares, options for Ordinary Shares, warrants to Preferred Shares, exercise price and net loss per share amounts were adjusted retroactively for all periods presented in these consolidated financial statements as if the stock split and change in par value had been in effect as of the date of these consolidated financial statements.&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;d.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Warrants to purchase Preferred A shares:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Under the 2018 SPA, the Company had initially granted the Preferred A share investors an aggregate number of 3,614,960 warrants convertible into Preferred A shares of the Company (&#x201c;Preferred A Warrants&#x201d;), with an exercise price of $ 5.04. The number of warrants issued is subject to similar adjustments as the conversion ratio of the Preferred A shares.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;In connection with the 2020 SPA, the Warrants agreement was modified, and the Company subsequently granted the Preferred A share investors approximately 7% additional Preferred A Warrants, increasing the aggregate number of Preferred A Warrants to 3,880,777, and reducing the exercise price to $ 3.87 per share. Since the Warrants were classified as a liability and subsequently measured at fair value through earnings, the effect of The Preferred A Warrants modification was reflected in the fair value of the warrants and recognized in earnings. The warrants may be converted at any time until September&#160;16, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;All outstanding Preferred A Warrants are classi&#xfb01;ed as a long-term liability and are re-measured at each reporting date, as the underlying shares may be redeemed upon an event which is not solely in the control of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"&gt;As of December&#160;31, 2020 and &lt;span style="direction:rtl;"&gt;2021&lt;/span&gt;, 3,880,777 Preferred A Warrants are outstanding.&lt;/p&gt;</drts:TemporaryEquityTextBlock>
    <us-gaap:TemporaryEquityTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_pEsUQIlbUkeNb4EHT-4aIA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:72pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:33.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Authorized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issued&#160;and&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Authorized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issued&#160;and&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;Carrying&#160;&lt;/b&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;Liquidation&#160;&lt;/b&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="color:#231f20;font-weight:bold;"&gt;preference&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="15" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:42.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&#160;shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A Convertible Preferred shares of no-par value *)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"&gt; 16,295,256&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"&gt; 7,229,885&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"&gt; 16,295,256&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"&gt; 7,229,885&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"&gt; 25,238&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"&gt; 36,437&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series B Convertible Preferred shares of no- par value *)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"&gt; 9,052,920&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"&gt; 6,509,301&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"&gt; 9,052,920&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"&gt; 6,509,301&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"&gt; 28,726&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"&gt; 28,761&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"&gt; 25,348,176&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"&gt; 13,739,186&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"&gt; 25,348,176&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"&gt; 13,739,186&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"&gt; 53,964&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:7pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"&gt; 65,198&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-left:72pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:72pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"&gt;*)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"&gt;Prior period results have been retroactively adjusted to reflect the 1: 0.905292 stock split effected on March&#160;7, 2022. See also note 10, Shareholders&#x2019; Deficiency, for details.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:TemporaryEquityTableTextBlock>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_drts_SeriesConvertiblePreferredSharesMember_2rsemjdtU0aLnNvzSudxpQ"
      decimals="INF"
      id="Tc_Mncq1zZ_106u-MgL5ZmYfQ_4_2"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">16295256</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_drts_SeriesConvertiblePreferredSharesMember_2rsemjdtU0aLnNvzSudxpQ"
      decimals="INF"
      id="Tc_bCFVg1ZD4UWurK2A3yEBXQ_4_4"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">7229885</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_drts_SeriesConvertiblePreferredSharesMember_Ciu93EXH3Uu0zKZgtaOVHQ"
      decimals="INF"
      id="Tc_YjDSifYJrUG3oVqkq2SgEg_4_6"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">16295256</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_drts_SeriesConvertiblePreferredSharesMember_Ciu93EXH3Uu0zKZgtaOVHQ"
      decimals="INF"
      id="Tc_uacO1YxwIEStYz3NeSAvXQ_4_8"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">7229885</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_drts_SeriesConvertiblePreferredSharesMember_Ciu93EXH3Uu0zKZgtaOVHQ"
      decimals="-3"
      id="Tc_p6GIQdGwoEisxTFa-q58vg_4_11"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">25238000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_drts_SeriesConvertiblePreferredSharesMember_Ciu93EXH3Uu0zKZgtaOVHQ"
      decimals="-3"
      id="Tc_X_rrXXIzakKcLMdS4ztcVg_4_14"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">36437000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_drts_SeriesBConvertiblePreferredSharesMember_aujqloiYdUqLgyG-IywV-g"
      decimals="INF"
      id="Tc_LqVqclq_JEi4L6OmBJTt8w_5_2"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">9052920</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_drts_SeriesBConvertiblePreferredSharesMember_aujqloiYdUqLgyG-IywV-g"
      decimals="INF"
      id="Tc_3J9rSQXAI0qEFZmNbnG8ng_5_4"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">6509301</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_drts_SeriesBConvertiblePreferredSharesMember__unz0Gwr4U6xfvew_rt8qg"
      decimals="INF"
      id="Tc_mvSDijtwoESZ6AUjwl0KAw_5_6"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">9052920</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_drts_SeriesBConvertiblePreferredSharesMember__unz0Gwr4U6xfvew_rt8qg"
      decimals="INF"
      id="Tc_YRSWubzyjk6Q31pHq_tmag_5_8"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">6509301</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_drts_SeriesBConvertiblePreferredSharesMember__unz0Gwr4U6xfvew_rt8qg"
      decimals="-3"
      id="Tc_JCJQUF7-VEWmPYo0qwYwow_5_11"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">28726000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_drts_SeriesBConvertiblePreferredSharesMember__unz0Gwr4U6xfvew_rt8qg"
      decimals="-3"
      id="Tc_xatdXIyTzkqqVA0Car8XsQ_5_14"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">28761000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="INF"
      id="Tc_qy4RGCextUKB6JD27IY9xA_6_2"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">25348176</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="INF"
      id="Tc_i4HTP7aEu0am-IfZNSg7og_6_4"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">13739186</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="INF"
      id="Tc_QibM1fnmy0WkhOK_v-RK7w_6_6"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">25348176</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="INF"
      id="Tc_7GHgS0kYdU2JjfO4iSgghw_6_8"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">13739186</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc_49WtNRt7Q0We0O-nLKHS7Q_6_11"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">53964000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc_QTZcMLBNu0KGD0V9RCwmlg_6_14"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">65198000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_3_7_2022_To_3_7_2022_zxGQCP-7Fk277229BSbBmw"
      decimals="INF"
      id="Narr_oAPQ6utGekaS6k0maftYUg"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.905292</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="2"
      id="Narr__qFR1toVP0CoQQB9LeL1sQ"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.50</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="2"
      id="Narr_JODvJIInYEK6Dg4fKVSNCw"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.50</us-gaap:PreferredStockDividendRatePercentage>
    <drts:TemporaryEquityDistributionRateFromProceedsOfSaleAnotherClassOfShares
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_drts_SeriesConvertiblePreferredSharesMember_Ciu93EXH3Uu0zKZgtaOVHQ"
      decimals="4"
      id="Narr_m4XlLY6KgEC7nwIXpe1sww"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.0125</drts:TemporaryEquityDistributionRateFromProceedsOfSaleAnotherClassOfShares>
    <drts:TemporaryEquityDistributionRateFromProceedsOfSaleAnotherClassOfShares
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_drts_SeriesConvertiblePreferredSharesMember_Ciu93EXH3Uu0zKZgtaOVHQ"
      decimals="4"
      id="Narr_ffmnsAWgnEO-_EJzfjqcYg"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.0125</drts:TemporaryEquityDistributionRateFromProceedsOfSaleAnotherClassOfShares>
    <drts:TemporaryEquityNumberOfVotes
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="INF"
      id="Narr_pPjEV6TrW0q9DYrx1tbviA"
      unitRef="Unit_Standard_Vote_yl2FdYUkMUizA1ZcpmmCgA">1</drts:TemporaryEquityNumberOfVotes>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="INF"
      id="Narr_rPUd7br4qEWZUqZEcN3zyw"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">1</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_9_1_2018_To_9_30_2018_QkwZ1akbskyCxXcB-8mukw"
      decimals="INF"
      id="Narr_XI0atcvbekS4Sctp4orEVw"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">7229885</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <drts:SaleOfStockNumberOfWarrantsIssuedInTransaction
      contextRef="Duration_9_1_2018_To_9_30_2018_QkwZ1akbskyCxXcB-8mukw"
      decimals="INF"
      id="Narr_EohPg9P4BUG2e7giWu9fRg"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">3614960</drts:SaleOfStockNumberOfWarrantsIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="Duration_9_1_2018_To_9_30_2018_QkwZ1akbskyCxXcB-8mukw"
      decimals="-3"
      id="Narr_dXqc0ptR80Scme8GVDapvg"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">29150000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="As_Of_9_30_2018_H4Zwi9gmHkGz2evRAa1_dQ"
      decimals="2"
      id="Narr_ANzwCVgKmE-HgdLzqzETJg"
      unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw">4.03</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_9_1_2018_To_9_30_2018_QkwZ1akbskyCxXcB-8mukw"
      decimals="-3"
      id="Narr_kSSzQfJ1Ak2v6P1a3iCyeA"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">91000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="Duration_9_1_2018_To_9_30_2018_QkwZ1akbskyCxXcB-8mukw"
      decimals="-3"
      id="Narr_nNOvcxL_b06iVD3bL_SA_A"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">3821000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_9_30_2018_H4Zwi9gmHkGz2evRAa1_dQ"
      decimals="INF"
      id="Narr_4EDFPy4VXkmaaMCpPHdxYg"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">1</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_StatementClassOfStockAxis_drts_SeriesBConvertiblePreferredSharesMember_bAcjFcmMGEKODAHgmn7SUA"
      decimals="INF"
      id="Narr_oocvvah-HkmykP4mLWOSKA"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">6509301</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_StatementClassOfStockAxis_drts_SeriesBConvertiblePreferredSharesMember_bAcjFcmMGEKODAHgmn7SUA"
      decimals="-3"
      id="Narr_Yg4ukkgUpkaBFnYqsnnO0A"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">28761000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="As_Of_4_30_2020_us-gaap_StatementClassOfStockAxis_drts_SeriesBConvertiblePreferredSharesMember_30sMLfKYZ0ukHDW9qDg6NQ"
      decimals="2"
      id="Narr_UFo83V0a90-XqrlrGDT9xA"
      unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw">4.42</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_4_1_2020_To_4_30_2020_us-gaap_StatementClassOfStockAxis_drts_SeriesBConvertiblePreferredSharesMember_bAcjFcmMGEKODAHgmn7SUA"
      decimals="-3"
      id="Narr_nNa_uukQvEyGffjqFEGhsA"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">35000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_4_30_2020_us-gaap_StatementClassOfStockAxis_drts_SeriesBConvertiblePreferredSharesMember_30sMLfKYZ0ukHDW9qDg6NQ"
      decimals="INF"
      id="Narr_X7-Y9bB82E-PGizGj4cXyQ"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">1</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_drts_SeriesConvertiblePreferredSharesMember_Ciu93EXH3Uu0zKZgtaOVHQ"
      decimals="INF"
      id="Narr_6R79zSJYtE2C5EYq4zIDPQ"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">1.07</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_drts_SeriesConvertiblePreferredSharesMember_UHBSJ1OmqEK-PEYAzs74DA"
      decimals="0"
      id="Narr_MRbhfyKbz0qb0n2PWmDNbA"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">7229885</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_rrpsDYs6x0SIZ6A54vpDQw"
      decimals="INF"
      id="Narr_Zs6enMC1K0KOyjMQjmE_vg"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">7761495</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_3_7_2022_To_3_7_2022_zxGQCP-7Fk277229BSbBmw"
      decimals="INF"
      id="Narr_P_VOaLJT0USFNNTMe7WY_Q"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.905292</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <drts:SaleOfStockNumberOfWarrantsIssuedInTransaction
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_drts_SeriesConvertiblePreferredSharesMember_UHBSJ1OmqEK-PEYAzs74DA"
      decimals="INF"
      id="Narr_0IXW6XAstkqpJZNpxNfzpw"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">3614960</drts:SaleOfStockNumberOfWarrantsIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_drts_SeriesConvertiblePreferredSharesMember_Ciu93EXH3Uu0zKZgtaOVHQ"
      decimals="INF"
      id="Narr_QR9O0lSeuEqqhPN61XD3-A"
      unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw">5.04</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <drts:WarrantsGrantedIncreaseFromNewFinancing
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_drts_SeriesConvertiblePreferredSharesMember_UHBSJ1OmqEK-PEYAzs74DA"
      decimals="2"
      id="Narr_vbgV-UjjXkiAWHahA-tXkA"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.07</drts:WarrantsGrantedIncreaseFromNewFinancing>
    <drts:SaleOfStockNumberOfWarrantsIssuedInTransaction
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="INF"
      id="Narr_5XXxqhoQFkO0oUTyw6CPEA"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">3880777</drts:SaleOfStockNumberOfWarrantsIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="2"
      id="Narr_0MF5f0pXUE2YMmgysr1i4w"
      unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw">3.87</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="INF"
      id="Narr_yrhOHL5fiEqwlUI8LYylbw"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">3880777</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_ft7E9GxXDUSQtRIA6Exygg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:54pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;NOTE&#160;10:-&lt;/b&gt;&lt;/span&gt;SHAREHOLDERS&#x2019; DEFICIENCY&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;a.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Ordinary share capital is composed as follows:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;On July&#160;6, 2021, the Company&#x2019;s board of directors approved a 1: 0.905292 stock split which was effected on March&#160;7, 2022. As a result, all Ordinary shares, Convertible preferred shares, options for Ordinary Shares, warrants to Preferred Shares, exercise price and net loss per share amounts were adjusted retroactively for all periods presented in these consolidated financial statements as if the stock split and change in par value had been in effect as of the date of these consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:72pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:43.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Authorized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issued&#160;and&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Authorized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issued&#160;and&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:54.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&#160;shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Ordinary shares of no-par value *)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 72,423,360&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40,433,578&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 72,423,360&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40,528,913&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-left:72pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:72pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"&gt;*)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"&gt;Prior period results have been retroactively adjusted to reflect the 1: 0.905292 stock split effected on March&#160;7, 2022. See also note 10, Shareholders&#x2019; Deficiency, for details.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:54pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;NOTE&#160;10:-&lt;/b&gt;&lt;/span&gt;SHAREHOLDERS&#x2019; DEFICIENCY (Cont.)&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;b.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Ordinary shares rights:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:72pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(i)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The Ordinary shares confer upon their holders the right to participate in the general meetings of the Company, to vote at such meetings (each share represents one &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;vote), and to participate in any distribution of dividends or any other distribution of the Company&#x2019;s property, including the distribution of surplus assets upon liquidation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:72pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(ii)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;In July&#160;2019, HekaBio K.K. invested an amount of $ 5,250 &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;into the Company, in exchange for 1,302,132 Ordinary shares and 651,067 warrants to ordinary shares of the Company.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;c.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Share option plans:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The Company has authorized through its 2016 Share Option Plan (the &#x201c;Plan&#x201d;), an available pool of Ordinary shares of the Company from which to grant options to officers, directors, advisors, management and other key employees of up to 7,611,725 Ordinary shares. The options granted generally have a four-year vesting period and expire ten&#160;years after the date of grant, subject to the terms set forth in the Plan. Options granted under the Plan that are cancelled or forfeited before expiration become available for future grant. As of December&#160;31, 2021, 442,439 of the Company&#x2019;s options are available for future grants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;A summary of the status of options under the Plan as of December&#160;31, 2021 and changes during the relevant period ended on that date is presented below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:72pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:50.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Employees&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:47.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year&#160;ended&#160;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;of&#160;options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;life&#160;(years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at beginning of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,062,408&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 944,820&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.78&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,321,211&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.81&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,809)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited and cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (53,238)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,325,572&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.97&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,854,046&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.42&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercisable options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,233,657&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,184,527&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.56&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:72pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:50.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Service Providers&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:47.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year&#160;ended&#160;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;contractual&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;of&#160;options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;life&#160;(years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at beginning of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 662,006&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.79&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 313,200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.91&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 140,667&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.79&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (81,476)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited and cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 721,197&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.34&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,695,213&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.61&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercisable options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 580,745&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.05&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,649,873&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.89&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:54pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;NOTE 10:-&lt;/b&gt;&lt;/span&gt;SHAREHOLDERS&#x2019; DEFICIENCY (Cont.)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;A summary of the status of RSUs under the Plan as of December&#160;31, 2021 and changes during the relevant period ended on that date is presented below:&lt;/p&gt;&lt;div style="padding-left:72pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:83.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&#160;RSU&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at beginning of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,036,850&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited and cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,600)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding on December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,031,250&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The total equity-based compensation expense related to all of the Company&#x2019;s equity-based awards recognized for the&#160;year ended December&#160;31, 2020 and 2021, was comprised as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:72pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;width:32.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year&#160;ended&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 380&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 372&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 654&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Marketing expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 148&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 204&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 151&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total share-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 546&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 596&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 812&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;As of December&#160;31, 2021, there were unrecognized compensation costs of $ 2,280, which are expected to be recognized over a weighted average period of approximately 3.28&#160;years. The weighted average exercise price of the Company&#x2019;s options granted during the&#160;year ended December&#160;31, 2019, 2020 and 2021 was $4.06, $4.42 and $9.81, respectively. The weighted-average grant date fair value of options granted during the&#160;years ended December&#160;31, 2021, 2020 and 2019, was $4.45, $0.76 and $0.6, respectively.&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;d.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Warrants to investors:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:72pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(i)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;As part of 2016 investment round, the Company granted the investors 6,789,694 &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;warrants. In December&#160;2019, these warrants were exercised into 5,316,493 Ordinary shares of no-par value, of them 1,412,520 were exercised on a cash basis in consideration of approximately $ 1,560, and 5,377,174 were exercised on a cashless basis at a ratio of approximately 0.73 Ordinary share per exercised warrant&lt;/span&gt;&lt;span style="direction:rtl;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:72pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(ii)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;As part of the 2018 SPA, the Company granted 9,053 &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;warrants to ordinary shares to a public service foundation in Israel. The warrants were exercised on July&#160;15, 2021 into 9,053 Ordinary shares of no-par value with no consideration.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:72pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(iii)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;In July&#160;2019, as part of the investment round of HekaBio K.K, the investors received 651,067 &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;warrants to Ordinary shares with an exercise price of $ 5.04 to be exercise within &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;4&#160;years&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; from grant date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;e.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Warrants to consultants:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:72pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(i)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;In April&#160;2016, 67,897 &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;warrants to Ordinary shares were issued to a consultant for services received to be exercised within &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;7&#160;years&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; from grant date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:54pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;NOTE 10:-&lt;/b&gt;&lt;/span&gt;SHAREHOLDERS&#x2019; DEFICIENCY (Cont.)&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:72pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(ii)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;In April&#160;2020 879,609 &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;warrants were exercised into 556,548 Ordinary shares of no-par value, for $ 30 received in cash and the rest exercised on a cashless basis. In addition, in November&#160;2020, 90,529 warrants were exercised into 67,897 Ordinary shares of no-par value, all on a cashless basis&lt;/span&gt;&lt;span style="direction:rtl;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_3_7_2022_To_3_7_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_WEfc-vShRUy3Gx5vSV4mVw"
      decimals="INF"
      id="Narr_J9CqV8wJmEyicrz56kgtGA"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.905292</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_izIkX3MpjUeGvXEX8BV-HQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:72pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:43.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Authorized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issued&#160;and&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Authorized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issued&#160;and&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:54.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&#160;shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Ordinary shares of no-par value *)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 72,423,360&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40,433,578&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 72,423,360&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40,528,913&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-left:72pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:72pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"&gt;*)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"&gt;Prior period results have been retroactively adjusted to reflect the 1: 0.905292 stock split effected on March&#160;7, 2022. See also note 10, Shareholders&#x2019; Deficiency, for details.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_s0BI7zNnAEKLzKmtfc-EqQ"
      decimals="INF"
      id="Tc_zKoLrJaILEqOC7k0hRBBZw_4_2"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">72423360</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="INF"
      id="Tc_0jQ1wpuXQEOGP5y5qmv7Cw_4_4"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">40433578</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="INF"
      id="Tc_eXulsXfku0q8PNlUW21_FQ_4_6"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">72423360</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="INF"
      id="Tc_pY41TZxAwEWSUj_VLG2PNA_4_8"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">40528913</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_3_7_2022_To_3_7_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_WEfc-vShRUy3Gx5vSV4mVw"
      decimals="INF"
      id="Narr_35U6l95TOUK19U6yQj2MPw"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.905292</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <drts:SharesNumberOfVotes
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="INF"
      id="Narr_nQQJRJYOrkijyiiImm8x4w"
      unitRef="Unit_Standard_Vote_yl2FdYUkMUizA1ZcpmmCgA">1</drts:SharesNumberOfVotes>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="Duration_7_1_2019_To_7_31_2019_srt_CounterpartyNameAxis_drts_HekabioK.k.Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_rNX51eEBuEGWtuOpNs--fw"
      decimals="-3"
      id="Narr_kZSUfCIw0Uyyj0q5en9Fvw"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">5250000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_7_1_2019_To_7_31_2019_srt_CounterpartyNameAxis_drts_HekabioK.k.Member_r5R-uUg6Vk-zl0lhq3yl_w"
      decimals="INF"
      id="Narr_t5aB1KaUqUqnKkcuCFVNCA"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">1302132</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <drts:SaleOfStockNumberOfWarrantsIssuedInTransaction
      contextRef="Duration_7_1_2019_To_7_31_2019_srt_CounterpartyNameAxis_drts_HekabioK.k.Member_r5R-uUg6Vk-zl0lhq3yl_w"
      decimals="INF"
      id="Narr_UNx1-Y4JzUqCMwxTl6t6Tg"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">651067</drts:SaleOfStockNumberOfWarrantsIssuedInTransaction>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_drts_ShareOptionPlanMember_dFYkG00x2k-k8R6SDAZdBQ"
      decimals="INF"
      id="Narr_ipfJnnSvOE2W2_IVd9sFQg"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">7611725</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_drts_ShareOptionPlanMember_RIX788L11EWA3ahCtQufmA"
      id="Narr_0vPTXw6Rv0eJ7VP53jD9kw">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_drts_ShareOptionPlanMember_RIX788L11EWA3ahCtQufmA"
      id="Narr__IgNa9Yj-kikjkYu4atVzQ">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_drts_ShareOptionPlanMember_dFYkG00x2k-k8R6SDAZdBQ"
      decimals="INF"
      id="Narr__fmt8u7zNEif70oinv_BWQ"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">442439</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_y5q9dcuUQ06NsMFlOcL2BA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:72pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:50.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Employees&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:47.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year&#160;ended&#160;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;of&#160;options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;life&#160;(years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at beginning of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,062,408&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 944,820&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.78&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,321,211&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.81&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,809)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited and cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (53,238)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,325,572&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.97&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,854,046&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.42&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercisable options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,233,657&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,184,527&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.56&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:72pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:50.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Service Providers&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:47.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year&#160;ended&#160;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;contractual&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;of&#160;options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;life&#160;(years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at beginning of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 662,006&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.79&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 313,200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.91&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 140,667&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.79&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (81,476)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited and cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 721,197&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.34&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,695,213&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.61&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercisable options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 580,745&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.05&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,649,873&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.89&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_Qp1t4h1WuE20sketeFkQaQ"
      decimals="INF"
      id="Tc_xZNRT1IrpES7dTMsojuYaQ_7_2"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">4062408</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_Qp1t4h1WuE20sketeFkQaQ"
      decimals="2"
      id="Tc_QEj3xNnmmkSMxPnAD4qnMg_7_5"
      unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw">3.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_Qp1t4h1WuE20sketeFkQaQ"
      decimals="-3"
      id="Tc_Lc9CMt6mU0K9rYA-gz4jqA_7_8"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">944820000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_N81fmDen3E25LY0nhNqEwg"
      id="Tc_985cgyof8UKvR0ZLkS30MQ_7_10">P7Y9M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_lVBebhm2NUeEc6aQ92svqw"
      decimals="INF"
      id="Tc_uBubnrqsa0KIiskDrFlYTg_8_2"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">1321211</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_lVBebhm2NUeEc6aQ92svqw"
      decimals="2"
      id="Tc_kezqcKxF1k23Y-LC3Mnnvg_8_5"
      unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw">9.81</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_lVBebhm2NUeEc6aQ92svqw"
      decimals="INF"
      id="Tc_pi_qzLtGjkKTY-4qw_S7GA_9_2"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">4809</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_lVBebhm2NUeEc6aQ92svqw"
      decimals="2"
      id="Tc_fpFV8wG5D0m5H-PFa_2Utw_9_5"
      unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw">4.42</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_lVBebhm2NUeEc6aQ92svqw"
      decimals="INF"
      id="Tc_CoCfE2okrUWscO_RoZtcPQ_10_2"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">53238</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_lVBebhm2NUeEc6aQ92svqw"
      decimals="2"
      id="Tc_9vILTUPZtEekFR3s-o22tA_10_5"
      unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw">5.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_LahhRefsiUeIK16_07ddRQ"
      decimals="INF"
      id="Tc_zZV_xzMg50mVEGa0iYMlJw_12_2"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">5325572</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_LahhRefsiUeIK16_07ddRQ"
      decimals="2"
      id="Tc_yUo2yMYEokaAw2o1CbPhlw_12_5"
      unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw">4.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_LahhRefsiUeIK16_07ddRQ"
      decimals="-3"
      id="Tc_rE2COmFbDESUsTTA37mxXg_12_8"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">17854046000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_lVBebhm2NUeEc6aQ92svqw"
      id="Tc_36jdlp28-0u4Uxpx8CIm0w_12_10">P7Y5M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_LahhRefsiUeIK16_07ddRQ"
      decimals="INF"
      id="Tc_BuxewycFxUKygx9i-bxSag_13_2"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">3233657</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_LahhRefsiUeIK16_07ddRQ"
      decimals="2"
      id="Tc_MsQx1UFJW0u8FhF9AxJUKA_13_5"
      unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw">3.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_LahhRefsiUeIK16_07ddRQ"
      decimals="-3"
      id="Tc_onyd-N69kEq1vor0Q26lBQ_13_8"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">14184527000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_lVBebhm2NUeEc6aQ92svqw"
      id="Tc_0tiMAveKcEy8vvwBJpE0Nw_13_10">P6Y6M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_H5r7wu2GjkCR2jWr-TITxg"
      decimals="INF"
      id="Tc_ZKuhT48880SUledeu5J8VQ_7_2"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">662006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_H5r7wu2GjkCR2jWr-TITxg"
      decimals="2"
      id="Tc_CeIFaqiAkEuLa7fY9EQstg_7_5"
      unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw">2.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_H5r7wu2GjkCR2jWr-TITxg"
      decimals="-3"
      id="Tc_bb79aRXpuE2Fs15E6PbDMQ_7_8"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">313200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_kiT9W3vqp0OZhbNgXlCDlw"
      id="Tc_smHW4DCVeUuH509uZbs9xQ_7_10">P6Y10M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_OSPpJbgS_kKHuzfkXV5w1Q"
      decimals="INF"
      id="Tc_uakGZB61p0G9l0p0U5X78w_8_2"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">140667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_OSPpJbgS_kKHuzfkXV5w1Q"
      decimals="2"
      id="Tc_YtGPJFoEjkmas3ef_VLZLw_8_5"
      unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw">9.79</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_OSPpJbgS_kKHuzfkXV5w1Q"
      decimals="INF"
      id="Tc_--05Jpl3UkOKtv8cKUG1mw_9_2"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">81476</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_OSPpJbgS_kKHuzfkXV5w1Q"
      decimals="2"
      id="Tc_Y8Q-qf5AFEGh6FefHCnC9g_9_5"
      unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw">1.10</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_kZCpG9oRQUWYe1QTUnt4Mg"
      decimals="INF"
      id="Tc_d8B1fAijy0SHGFToFHwBfw_12_2"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">721197</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_kZCpG9oRQUWYe1QTUnt4Mg"
      decimals="2"
      id="Tc_swK_RPx4yEaeJGvh69qOIw_12_5"
      unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw">4.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_kZCpG9oRQUWYe1QTUnt4Mg"
      decimals="-3"
      id="Tc_MSwRpDql7UaytiTE3QfypQ_12_8"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">2695213000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_OSPpJbgS_kKHuzfkXV5w1Q"
      id="Tc_vIAesrghPEqqBiICcyjVyA_12_10">P6Y7M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_kZCpG9oRQUWYe1QTUnt4Mg"
      decimals="INF"
      id="Tc_EwgIHaPZL0ePiE0uerieQg_13_2"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">580745</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_kZCpG9oRQUWYe1QTUnt4Mg"
      decimals="2"
      id="Tc_08NojENtzU6jbUvSXqILcw_13_5"
      unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw">3.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_kZCpG9oRQUWYe1QTUnt4Mg"
      decimals="-3"
      id="Tc_hu8Gd8Zt80e5sojgyewndQ_13_8"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">2649873000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_OSPpJbgS_kKHuzfkXV5w1Q"
      id="Tc_qcbzWDcT5UOf-YelIQc-zQ_13_10">PT5H</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_Z7pK-xJ2NUmLeKz7RTetlQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;A summary of the status of RSUs under the Plan as of December&#160;31, 2021 and changes during the relevant period ended on that date is presented below:&lt;/p&gt;&lt;div style="padding-left:72pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:83.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&#160;RSU&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at beginning of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,036,850&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited and cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,600)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding on December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,031,250&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="INF"
      id="Tc_BSBuRfFfZ0i1XtOgzD6riA_3_2"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">1036850</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="INF"
      id="Tc_alJfpMyA9UG8dFEwgbX9TQ_4_2"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">5600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="INF"
      id="Tc_fUEESHwZlkm5Eor8CBALuA_5_2"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">1031250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <drts:ScheduleOfShareBasedCompensationCostsByIncomeStatementLocationTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_DWEU8jPVGU2Bq3UPhqcFpA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:72pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;width:32.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year&#160;ended&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 380&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 372&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 654&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Marketing expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 148&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 204&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 151&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total share-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 546&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 596&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 812&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</drts:ScheduleOfShareBasedCompensationCostsByIncomeStatementLocationTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_KkiZY-M7yk-YryD1n_upAg"
      decimals="-3"
      id="Tc_TcDtSzk_10mdhFiRTnYygA_3_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">380000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Y0-0nKnve0qsDthMlv68-A"
      decimals="-3"
      id="Tc_eolCbYrwvEC-PZ8ydrex6g_3_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">372000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember__1I8UfYct0qja66GZyQuYw"
      decimals="-3"
      id="Tc_aHl-oGHzy065cc98CjmMqA_3_9"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">654000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_fv33GX4WVUa4CZlwHesWww"
      decimals="-3"
      id="Tc_atiol8ijQEqED5USLmWsZg_4_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">18000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_pPraAX3UkUu0_lMAnsHfJQ"
      decimals="-3"
      id="Tc_-dFMToaoh0u7xw5Az9Hl0g_4_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">20000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_o_i3_DfHik6LOoF2B8rb3A"
      decimals="-3"
      id="Tc_U41muGu2kkagBVQbEc4vTA_4_9"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">7000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_kforSQ4jYUSPrZV_1I2SsQ"
      decimals="-3"
      id="Tc_uu3F-6vSP02BPKOWpAwS-A_5_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">148000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_nhO5-HJ1nk6RNhK67yOGoA"
      decimals="-3"
      id="Tc_95VEcwAVHUmVRWubbXm7jw_5_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">204000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_jSuYco4A6kWDk0WIg-bOhg"
      decimals="-3"
      id="Tc_PyDE67GpjEW6J7HBRr8Kwg_5_9"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">151000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc_MUEO4AYH5UOq5VEkn4X34A_6_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">546000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Tc_9pKfTLxc60GCpxrOsDTZKw_6_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">596000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Tc_IDEKCWyVwE68J83iJHs87w_6_9"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">812000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Narr_QUvWeq5EOU29pcQTVlu-JA"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">2280000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Narr_o-bnOZNr2UWSkmKwcJ9Mow">P3Y3M10D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="2"
      id="Narr_uOEmurDClEGUrmXBNJVwqw"
      unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw">4.06</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="2"
      id="Narr_Dm47Ye4vKkaT_4NV3GcuIA"
      unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw">4.42</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="2"
      id="Narr_6o95YS9by0ScaxKUMaqpww"
      unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw">9.81</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="2"
      id="Narr_z7XKoEaGD0SlUZfhfNwZYg"
      unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw">4.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="2"
      id="Narr_fPp2DXf3dkKZ5rmH3GyxlQ"
      unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw">0.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="2"
      id="Narr_wY_sOa33_0uqZpbbf1L1kg"
      unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw">0.6</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <drts:SaleOfStockNumberOfWarrantsIssuedInTransaction
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="INF"
      id="Narr_vACNhudlwU6_3weOVYC-hg"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">6789694</drts:SaleOfStockNumberOfWarrantsIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_12_1_2019_To_12_31_2019_yCEIW0JlakWqYIDxGbuWtQ"
      decimals="INF"
      id="Narr_NEKZZ3E_5EWEmlEPx9APNw"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">5316493</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <drts:WarrantsExercisedCashBasis
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="INF"
      id="Narr_DUopFt4EokCk6Pb6gY9nRQ"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">1412520</drts:WarrantsExercisedCashBasis>
    <drts:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Narr_JRAI5CN26kO3iJZz0r8YaQ"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">1560000</drts:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <drts:WarrantsExercisedCashlessBasis
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="INF"
      id="Narr_cz3IqLgqBUOTjoXG7mxrmA"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">5377174</drts:WarrantsExercisedCashlessBasis>
    <drts:WarrantsToOrdinaryShareRatioCashlessExercise
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="INF"
      id="Narr_R41yAhPuKky1tQfUWEzo2A"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.73</drts:WarrantsToOrdinaryShareRatioCashlessExercise>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_7_15_2021_To_7_15_2021_5Bu_BFUidUuMuhyoWEwmhg"
      decimals="INF"
      id="Narr_qJaQBHDhdESG6dgW-9igpg"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">9053</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <drts:NumberOfWarrantsExercised
      contextRef="Duration_7_15_2021_To_7_15_2021_5Bu_BFUidUuMuhyoWEwmhg"
      decimals="INF"
      id="Narr_owDOoPTumkKM3d3VcSVMoA"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">9053</drts:NumberOfWarrantsExercised>
    <drts:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="Duration_7_15_2021_To_7_15_2021_5Bu_BFUidUuMuhyoWEwmhg"
      decimals="-3"
      id="Narr_T-cW9avO9Ee98eGjF6jxgA"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">0</drts:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <drts:SaleOfStockNumberOfWarrantsIssuedInTransaction
      contextRef="Duration_7_1_2019_To_7_31_2019_srt_CounterpartyNameAxis_drts_HekabioK.k.Member_r5R-uUg6Vk-zl0lhq3yl_w"
      decimals="INF"
      id="Narr_69nRuO8bjUu5trIc5hbgKg"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">651067</drts:SaleOfStockNumberOfWarrantsIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_7_31_2019_srt_CounterpartyNameAxis_drts_HekabioK.k.Member_WD3hZ8b710aQRjZMhkzTsg"
      decimals="2"
      id="Narr_mo3Od4hsU0yk9FSIoEl0sw"
      unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw">5.04</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_7_31_2019_srt_CounterpartyNameAxis_drts_HekabioK.k.Member_WD3hZ8b710aQRjZMhkzTsg"
      id="Narr_woQf_2bin02kPM4NbUr_ew">P4Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <drts:SaleOfStockNumberOfWarrantsIssuedInTransaction
      contextRef="Duration_4_1_2016_To_4_30_2016_aEGL3Dhxo0CNZ5ITN3VZQg"
      decimals="INF"
      id="Narr_LiotR57YmEW0cZ5inBsAIA"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">67897</drts:SaleOfStockNumberOfWarrantsIssuedInTransaction>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_4_30_2016_rW7hRh2E3Emvv6ppXNzIxA"
      id="Narr_YCeWpVCZm0S9QgNE18-OlQ">P7Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <drts:NumberOfWarrantsExercised
      contextRef="Duration_4_1_2020_To_4_30_2020_MsmjV8uDakyuT86VtP1xdQ"
      decimals="INF"
      id="Narr_mmc1dABeBEewR29_Ytz9jA"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">879609</drts:NumberOfWarrantsExercised>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_4_1_2020_To_4_30_2020_MsmjV8uDakyuT86VtP1xdQ"
      decimals="INF"
      id="Narr_hVy-Gx5mDkudWjnHtobY-Q"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">556548</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <drts:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="Duration_4_1_2020_To_4_30_2020_MsmjV8uDakyuT86VtP1xdQ"
      decimals="-3"
      id="Narr_3VA7ZuUAv0WkFFYuB7jgkQ"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">30000</drts:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <drts:NumberOfWarrantsExercised
      contextRef="Duration_11_1_2020_To_11_30_2020_AqgH_S771EKQA0UT8K6nCw"
      decimals="INF"
      id="Narr_DO7ic--CmUON9AkN7glJbw"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">90529</drts:NumberOfWarrantsExercised>
    <drts:WarrantsExercisedCashlessBasis
      contextRef="Duration_11_1_2020_To_11_30_2020_AqgH_S771EKQA0UT8K6nCw"
      decimals="INF"
      id="Narr_1CPbU9MWFE2SFdALm25OHg"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">67897</drts:WarrantsExercisedCashlessBasis>
    <us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_wkyLmlJSaEm2s3yygG26Pg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:54pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;NOTE&#160;11:-&lt;/b&gt;&lt;/span&gt;FINANCIAL EXPENSES, NET&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:72pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year&#160;ended&#160;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Financial expenses:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Foreign currency transaction loss, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 79&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 412&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Remeasurement of warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 994&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 203&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,257&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Others&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total financial expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,084&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 217&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,685&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Financial income:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Foreign currency transaction profit, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 101&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Interest from deposits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 776&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 613&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 211&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Others&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total financial income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 776&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 737&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 211&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Financial expenses (income), net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 308&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (520)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,474&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_zsJtNPWJDUKanDrYVvttQw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:72pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year&#160;ended&#160;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Financial expenses:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Foreign currency transaction loss, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 79&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 412&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Remeasurement of warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 994&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 203&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,257&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Others&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total financial expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,084&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 217&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,685&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Financial income:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Foreign currency transaction profit, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 101&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Interest from deposits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 776&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 613&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 211&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Others&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total financial income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 776&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 737&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 211&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Financial expenses (income), net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 308&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (520)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,474&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:ForeignCurrencyTransactionLossBeforeTax
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc_wbgYSizneUSuBTZcwsUuDw_5_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">79000</us-gaap:ForeignCurrencyTransactionLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionLossBeforeTax
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Tc_30_IRSuprEOaEPJ4TViFPw_5_9"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">412000</us-gaap:ForeignCurrencyTransactionLossBeforeTax>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc_F-XRcUqwrE6lh1ZiO4HmaA_6_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">994000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Tc_HPigw7LqVEmwnUI-X0JrvQ_6_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">203000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Tc_cDafO42M5kiRqoj-ujVRLw_6_9"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">13257000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc_-8LeYxmzrUS8HGZFwlt1kg_7_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">11000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Tc_r8sUiWxqG0mtxpfPMAnxqQ_7_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">14000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Tc_8BTXerDu60iEM46rYitr9Q_7_9"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">16000</us-gaap:OtherNonoperatingExpense>
    <drts:FinancialExpensesTotal
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc_PWs6mMlF8kClEFmKgMb53g_9_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">1084000</drts:FinancialExpensesTotal>
    <drts:FinancialExpensesTotal
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Tc_4bf8rg6RkUOxG3w7xUZfBw_9_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">217000</drts:FinancialExpensesTotal>
    <drts:FinancialExpensesTotal
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Tc_6UcKUCYdf0qSoB3CbRq5EQ_9_9"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">13685000</drts:FinancialExpensesTotal>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Tc_apbjFTVNAkCjNECUt5ApqQ_13_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">101000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:InterestIncomeDepositsWithFinancialInstitutions
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc_NaL8lodqB0eePHPHBAkUqA_14_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">776000</us-gaap:InterestIncomeDepositsWithFinancialInstitutions>
    <us-gaap:InterestIncomeDepositsWithFinancialInstitutions
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Tc_SCgQihGSzkK3ARtZ3cdyTg_14_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">613000</us-gaap:InterestIncomeDepositsWithFinancialInstitutions>
    <us-gaap:InterestIncomeDepositsWithFinancialInstitutions
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Tc_LiwZ9Z5VE06VnybwdEWe_A_14_9"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">211000</us-gaap:InterestIncomeDepositsWithFinancialInstitutions>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Tc_FbRk1X5g00CthWlS4wGYsg_15_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">23000</us-gaap:OtherNonoperatingIncome>
    <drts:FinancialIncomeTotal
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc_hZfF2yQ0dkuUepAxJR46OA_17_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">776000</drts:FinancialIncomeTotal>
    <drts:FinancialIncomeTotal
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Tc_i8zK64bw3UqrcIsawT2u2g_17_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">737000</drts:FinancialIncomeTotal>
    <drts:FinancialIncomeTotal
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Tc_Ofe2ZHE4SUuPMrBjCzYpZQ_17_9"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">211000</drts:FinancialIncomeTotal>
    <us-gaap:NonoperatingGainsLosses
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc_j4E_cEt9PUa56Ut_SbLA3w_18_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">308000</us-gaap:NonoperatingGainsLosses>
    <us-gaap:NonoperatingGainsLosses
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Tc_tL1w_hK9f0KSFnnoM5EduA_18_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-520000</us-gaap:NonoperatingGainsLosses>
    <us-gaap:NonoperatingGainsLosses
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Tc_1M7WT8ulvUeRTuNgL8yGWA_18_9"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">13474000</us-gaap:NonoperatingGainsLosses>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_rA_JbpENtk2mmHOh9XjiCw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:54pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;NOTE&#160;12:-&lt;/b&gt;&lt;/span&gt;BASIC AND DILUTED NET LOSS PER SHARE&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The following table sets forth the computation of the Company&#x2019;s basic and diluted net loss per Ordinary share:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:72pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:55.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:42.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year&#160;ended&#160;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;    &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Net loss attributable to Ordinary shareholders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,367)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,882)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (27,271)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Weighted-average shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33,815,448&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40,274,935&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40,534,697&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Net loss per share attributable to ordinary shareholders, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.25)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.22)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.67)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:54pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;NOTE&#160;12:-&lt;/b&gt;&lt;/span&gt;BASIC AND DILUTED NET LOSS PER SHARE (Cont.)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;The potential shares of ordinary shares that were excluded from the computation of diluted net loss per share attributable to ordinary shareholders for the periods presented because including them would have been anti-dilutive are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:72pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year&#160;ended&#160;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Convertible preferred shares&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,229,885&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,739,186&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,739,186&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding share options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,371,668&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,724,414&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,046,769&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;RSU&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,031,250&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrant to Preferred A shares&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,614,960&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,880,777&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,880,777&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,436,578&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 651,067&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 651,067&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,653,091&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,995,444&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25,349,049&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_3XbxPe__ykK1MJZkV2ZrRA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:72pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:55.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:42.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year&#160;ended&#160;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;    &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Net loss attributable to Ordinary shareholders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,367)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,882)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (27,271)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Weighted-average shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33,815,448&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40,274,935&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40,534,697&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Net loss per share attributable to ordinary shareholders, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.25)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.22)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.67)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="-3"
      id="Tc_0VZFjQS9sUGKvFibWmr92g_4_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-8367000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="-3"
      id="Tc_jxpA9vyEm02nLmqx-x-h0Q_4_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-8882000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="-3"
      id="Tc_wTx_Xu-CJUWTD1XyKuqAGw_4_9"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">-27271000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="0"
      id="Tc_iJnG7V0VvUWdLsomyegb9g_7_3"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">33815448</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="0"
      id="Tc_OOtWiDlpP0qiYHaI9Xbo3Q_7_6"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">40274935</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="0"
      id="Tc_gVe36pH3V02RnpMqbGPopw_7_9"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">40534697</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="2"
      id="Tc_nmXJ6TLx9Equ4seVjk4ytA_8_3"
      unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw">-0.25</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="2"
      id="Tc_YKLY_poxI0CGrTwjcpvrRw_8_6"
      unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw">-0.22</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="2"
      id="Tc_fQ9RUCqPi0OSGbt7J0WVbw_8_9"
      unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw">-0.67</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_9jg2zIvlwkWGr_JPoGggDg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:72pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:38.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year&#160;ended&#160;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Convertible preferred shares&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,229,885&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,739,186&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,739,186&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding share options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,371,668&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,724,414&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,046,769&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;RSU&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,031,250&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrant to Preferred A shares&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,614,960&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,880,777&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,880,777&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,436,578&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 651,067&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 651,067&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,653,091&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,995,444&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25,349,049&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_JaC_a1cel0-cR7a1zDVJ8Q"
      decimals="0"
      id="Tc_6CeKLGvvHkybTgRkzZ2pqw_3_2"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">7229885</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_Woekbq1Vh0m9LF6giXkjAQ"
      decimals="0"
      id="Tc_w-Ty5g2LcUutMZQbTkncXQ_3_4"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">13739186</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_MHykc8OPo0iqU-HsSzCVvw"
      decimals="0"
      id="Tc_xEHbcl6SMkKsLtPcq3BVzQ_3_6"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">13739186</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_-g979nKaYE-fgpAUV8oCPg"
      decimals="0"
      id="Tc_vAWN4DUme0ytQGQQTEaBTA_4_2"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">4371668</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_ywa_0-bXzkKhuRpBh5X1qg"
      decimals="0"
      id="Tc_z2Bv7dzDW0WzqKVGtYnJ1Q_4_4"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">4724414</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_CVs6y3ige0mbtcVCtEnhqg"
      decimals="0"
      id="Tc_ycps9gner0uDv7NBU26kUA_4_6"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">6046769</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_xkz4fyumv021UlW6DLiR0Q"
      decimals="0"
      id="Tc_20cjkc-3LUi96foz8dJNXg_5_6"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">1031250</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_drts_WarrantsToPreferredSharesMember_g4e9gxAYuUqhsD456SMaZw"
      decimals="0"
      id="Tc_zZsgayPo9UCJRa2fYUQA-w_6_2"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">3614960</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_drts_WarrantsToPreferredSharesMember_F-36Oqlx4UWKJm0Pn_tXwg"
      decimals="0"
      id="Tc_FkAek7faBkKOCNW7WGNLGQ_6_4"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">3880777</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_drts_WarrantsToPreferredSharesMember_3xaGNXkiQk215jhKwwMGtA"
      decimals="0"
      id="Tc_2hsYy2KH5UO21hGSt21Z6A_6_6"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">3880777</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_83Yv-70FokCNwA9HBVo3Ag"
      decimals="0"
      id="Tc_bRRAaotaAkmb10hJ8keamA_7_2"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">8436578</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_8q6cV2yAM0a3XAboz3EV0g"
      decimals="0"
      id="Tc_Z6_g74XQb0iuP44B9NbW8g_7_4"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">651067</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_ugDRsvTNaUmilQmO6qFALQ"
      decimals="0"
      id="Tc_FGjf8BJdNkOSMNASASF6VQ_7_6"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">651067</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw"
      decimals="0"
      id="Tc_8RVCcqwZ30GdIqNqsQHGLg_8_2"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">23653091</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_93THANAqwE2F1vZ2rD1-3Q"
      decimals="0"
      id="Tc_ZAaf2Zqv3kmfMDSFWWhFPg_8_4"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">22995444</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="0"
      id="Tc_ulYUG4NEEESRNkC7adFKkw_8_6"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">25349049</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_Xm5y_OTwFkOcIImKKWp3Nw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;13:-GEOGRAPHIC INFORMATION&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Financial information is available for evaluation by the chief operating decision maker, the Company&#x2019;s Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment. Operating segments are defined as components of an enterprise in which separate financial information is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and assessing performance.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Property and equipment, net by geographic location are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:72pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Israel&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,540&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,842&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;United States&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,855&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,699&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Japan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,395&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,546&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"&gt;Property and equipment, net is attributed to the geographic location in which it is located.&lt;/p&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      decimals="INF"
      id="Narr_Yncpk2ub00avA4GHGku73w"
      unitRef="Unit_Standard_segment_F1A8hT57kUWQPIMNg0d3ZQ">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_i0TAqorfr0mzGXPFmZogRw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:72pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Israel&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,540&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,842&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;United States&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,855&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,699&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Japan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,395&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,546&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2020_srt_StatementGeographicalAxis_country_IL_PMTZcbNK3kWZuaPNc0HC8Q"
      decimals="-3"
      id="Tc_il3SoFr7Y0SyOvnPE5KGqA_3_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">3540000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_srt_StatementGeographicalAxis_country_IL_c_kJyhiBYEGoZcGQuB67uA"
      decimals="-3"
      id="Tc_tX4pkiUD4UWvPUhKbycc6g_3_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">5842000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2020_srt_StatementGeographicalAxis_country_US_in1yQM0Z10-KwKkqgUSCKw"
      decimals="-3"
      id="Tc_crVAUoMPLkSp0LRMRwFxcQ_4_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">1855000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_srt_StatementGeographicalAxis_country_US_RZN6ejeNsEmQtCCCNm9spQ"
      decimals="-3"
      id="Tc_DYSpr-6fV0-y4prewE5sAw_4_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">1699000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_srt_StatementGeographicalAxis_country_JP__8sfu7Pxlk-mMRFbDKhBZw"
      decimals="-3"
      id="Tc_NFf6ChuO20qGMCKgydvxow_5_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">5000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw"
      decimals="-3"
      id="Tc_VbrO8sa3Q062oABjLtMM2w_6_3"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">5395000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A"
      decimals="-3"
      id="Tc_haedi-v5gU2UPVM9idpvhg_6_6"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">7546000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA"
      id="Tb_G0xaic_J8UKqS9wWsPUiqQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;14:-SUBSEQUENT EVENTS&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;a.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;On January&#160;18, 2022, the Company instituted a floating pledge on its assets in favor of Bank Leumi Le-Israel BM, to support a $ 225 &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;standby letter of credit in favor of the Massachusetts Department of Public Health. The letter of credit was provided in connection with an application by ATM&#160;Inc. for an expansion of the maximum possession limit in its radioactive license for use in the Lawrence, MA site, pursuant to decommissioning financial assurance regulations of the Massachusetts Department of Public Health&#x2019;s Radiation Control Program.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;b.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Business Combination&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Pursuant to the Merger Agreement described in Note&#160;1a, on March&#160;7, 2022 (the &#x201c;Closing Date&#x201d;), Archery Merger Sub,&#160;Inc., a Delaware corporation and wholly owned subsidiary of the Company was merged with and into HCCC, with HCCC surviving as a wholly-owned subsidiary of the Company (the &#x201c;Business Combination&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE&#160;14:-SUBSEQUENT EVENTS (Cont.)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Pursuant to the Merger Agreement, and immediately prior to the consummation of the Merger (the time of such consummation, the &#x201c;Effective Time&#x201d;), the Company effected a recapitalization whereby (i)&#160;the Company adopted amended and restated articles of association, (i)&#160;each preferred share of the Company was automatically converted into such number of the Company&#x2019;s ordinary shares as determined in accordance with the Company&#x2019;s existing articles of association; (ii)&#160;each of the Company&#x2019;s ordinary shares that was issued and outstanding immediately prior to the Effective Time was split into 0.905292 ordinary shares of the Company (rounded to the nearest whole number), such that the value of each of the Company&#x2019;s ordinary shares at the time of execution of the Merger Agreement equaled $10.00 per share, based upon the agreed pre-money equity value of the Company (the &#x201c;Share Split&#x201d;); and (iii)&#160;outstanding securities convertible into securities of the Company were adjusted to give effect to the foregoing transactions and remain outstanding. As a result, all ordinary shares, convertible preferred shares, options and warrants for ordinary shares, exercise prices and net loss per share amounts were adjusted retroactively for all periods presented in these financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Additionally, concurrently with the closing of the Merger, Alpha Tau issued securities pursuant to the Subscription Agreements executed with certain investors under a PIPE (Private Investment in Public Equity) transaction.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;Following the recapitalization, (a)&#160;immediately prior to the Merger, each share of Class&#160;B common stock of HCCC was cancelled automatically and converted into one share of Class&#160;A common stock of HCCC, (b)&#160;after giving effect to the foregoing and in connection with the Merger, each share of Class&#160;A common stock of HCCC issued and outstanding was converted automatically into one Company ordinary share, and (c)&#160;each outstanding warrant of HCCC was converted into a warrant of the Company and convertible into the Company&#x2019;s ordinary shares.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"&gt;An amount of $ 90,872 of gross cash proceeds were raised by the Company in the aforementioned transactions.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:PledgedFinancialInstrumentsNotSeparatelyReportedSecuritiesForLetterOfCreditFacilities
      contextRef="As_Of_1_18_2022_srt_CounterpartyNameAxis_drts_BankLeumiLeIsraelBmMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_BeRyXpDJ5kGTXPHFaRTfqA"
      decimals="-3"
      id="Narr_e4JAPs4gD0izZ44PCxaOmQ"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">225000</us-gaap:PledgedFinancialInstrumentsNotSeparatelyReportedSecuritiesForLetterOfCreditFacilities>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_3_7_2022_To_3_7_2022_us-gaap_BusinessAcquisitionAxis_drts_HcccMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_E1MNaT3WY0K3ZcXXAPmtVQ"
      decimals="INF"
      id="Narr_sLtTUA3kJkmLJJ_S2VyAVQ"
      unitRef="Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg">0.905292</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_3_7_2022_us-gaap_BusinessAcquisitionAxis_drts_HcccMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_iIVxwLK7kE2b1JwNE4XyzA"
      decimals="2"
      id="Narr_0Y-LHuwe90OIhZ9p2WUB0g"
      unitRef="Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw">10.00</us-gaap:SharesIssuedPricePerShare>
    <drts:CommonStockCancelledAndConvertedInToShares
      contextRef="Duration_3_7_2022_To_3_7_2022_us-gaap_BusinessAcquisitionAxis_drts_HcccMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_pSFCWjg1hEmAKs-87AaDOg"
      decimals="INF"
      id="Narr_GTOgqSsSyU6NrFCVASkQMA"
      unitRef="Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw">1</drts:CommonStockCancelledAndConvertedInToShares>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="Duration_3_7_2022_To_3_7_2022_us-gaap_BusinessAcquisitionAxis_drts_HcccMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_wb4aa4hMOk-oUeKQrzX1-g"
      decimals="-3"
      id="Narr_2E7RwSkJnU-yQjcxvKT1Jg"
      unitRef="Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg">90872000</us-gaap:CashAcquiredFromAcquisition>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Tc_2e32zEawfkeQRIldT_VSig_17_2"
          xlink:label="Tc_2e32zEawfkeQRIldT_VSig_17_2"
          xlink:type="locator"/>
        <link:footnote id="_3912af17_c1f9_4243_a55a_b4731c1ce7c2" xlink:label="_3912af17_c1f9_4243_a55a_b4731c1ce7c2" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Net of issuance costs of $<xhtml:span style="direction:rtl;">35</xhtml:span>.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_2e32zEawfkeQRIldT_VSig_17_2"
          xlink:to="_3912af17_c1f9_4243_a55a_b4731c1ce7c2"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_Rku296PeK0i4awh1scxZVA_17_5"
          xlink:label="Tc_Rku296PeK0i4awh1scxZVA_17_5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_Rku296PeK0i4awh1scxZVA_17_5"
          xlink:to="_3912af17_c1f9_4243_a55a_b4731c1ce7c2"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Hidden_G6MlAfQenUC5KMBm8hIoeQ"
          xlink:label="Hidden_G6MlAfQenUC5KMBm8hIoeQ"
          xlink:type="locator"/>
        <link:footnote id="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25" xlink:label="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Prior period results have been retroactively adjusted to reflect the 1: 0.905292 stock split effected on March&#160;7, 2022. See also note 10, Shareholders&#x2019; Deficiency, for details.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Hidden_G6MlAfQenUC5KMBm8hIoeQ"
          xlink:to="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Hidden_fD_C-mmYfEiNLNqRvC2r7A"
          xlink:label="Hidden_fD_C-mmYfEiNLNqRvC2r7A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Hidden_fD_C-mmYfEiNLNqRvC2r7A"
          xlink:to="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_P686uzzh_0240QcKLJnzuw_4_7"
          xlink:label="Tc_P686uzzh_0240QcKLJnzuw_4_7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_P686uzzh_0240QcKLJnzuw_4_7"
          xlink:to="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_0CdjEUrQ60qc-aWGXE0svw_4_2"
          xlink:label="Tc_0CdjEUrQ60qc-aWGXE0svw_4_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_0CdjEUrQ60qc-aWGXE0svw_4_2"
          xlink:to="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_jCQr6Q1pxUqmv6xXVY9RKw_12_7"
          xlink:label="Tc_jCQr6Q1pxUqmv6xXVY9RKw_12_7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_jCQr6Q1pxUqmv6xXVY9RKw_12_7"
          xlink:to="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_u_LKhmMgwEaHCoxpK9whWw_12_2"
          xlink:label="Tc_u_LKhmMgwEaHCoxpK9whWw_12_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_u_LKhmMgwEaHCoxpK9whWw_12_2"
          xlink:to="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_kglc91OPek-hdjs6FhlB7A_20_7"
          xlink:label="Tc_kglc91OPek-hdjs6FhlB7A_20_7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_kglc91OPek-hdjs6FhlB7A_20_7"
          xlink:to="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_y4vKTxUAcEqA0oTt8NslHA_20_2"
          xlink:label="Tc_y4vKTxUAcEqA0oTt8NslHA_20_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_y4vKTxUAcEqA0oTt8NslHA_20_2"
          xlink:to="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_wBe7AwRzvUaMt38Ii5x4Og_27_7"
          xlink:label="Tc_wBe7AwRzvUaMt38Ii5x4Og_27_7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_wBe7AwRzvUaMt38Ii5x4Og_27_7"
          xlink:to="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_i3xv8QEPgUKYHXUfXzMJLw_27_2"
          xlink:label="Tc_i3xv8QEPgUKYHXUfXzMJLw_27_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_i3xv8QEPgUKYHXUfXzMJLw_27_2"
          xlink:to="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_8U1wMLEo2UyQSZe3sFuTQQ_4_22"
          xlink:label="Tc_8U1wMLEo2UyQSZe3sFuTQQ_4_22"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_8U1wMLEo2UyQSZe3sFuTQQ_4_22"
          xlink:to="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_lyh0_IXKxUC_nS-q0yyDCw_4_13"
          xlink:label="Tc_lyh0_IXKxUC_nS-q0yyDCw_4_13"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_lyh0_IXKxUC_nS-q0yyDCw_4_13"
          xlink:to="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_1OwVenEu-0eEAuydtTNhTw_4_19"
          xlink:label="Tc_1OwVenEu-0eEAuydtTNhTw_4_19"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_1OwVenEu-0eEAuydtTNhTw_4_19"
          xlink:to="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_T3zJEjDNFkGTCGwsdZE6uA_4_16"
          xlink:label="Tc_T3zJEjDNFkGTCGwsdZE6uA_4_16"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_T3zJEjDNFkGTCGwsdZE6uA_4_16"
          xlink:to="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_0n0znmQK4kiznLwqpz-FmA_4_5"
          xlink:label="Tc_0n0znmQK4kiznLwqpz-FmA_4_5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_0n0znmQK4kiznLwqpz-FmA_4_5"
          xlink:to="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_56XM67-Ms0yj_sPp4AVY9w_12_22"
          xlink:label="Tc_56XM67-Ms0yj_sPp4AVY9w_12_22"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_56XM67-Ms0yj_sPp4AVY9w_12_22"
          xlink:to="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_KJyJAPCCxUepTgIJXxk0WA_12_13"
          xlink:label="Tc_KJyJAPCCxUepTgIJXxk0WA_12_13"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_KJyJAPCCxUepTgIJXxk0WA_12_13"
          xlink:to="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_r7OqZTkDyUiuLQbJGIbpmA_12_16"
          xlink:label="Tc_r7OqZTkDyUiuLQbJGIbpmA_12_16"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_r7OqZTkDyUiuLQbJGIbpmA_12_16"
          xlink:to="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_7ASbk5JcKEOtWKvUjhU-XQ_12_5"
          xlink:label="Tc_7ASbk5JcKEOtWKvUjhU-XQ_12_5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_7ASbk5JcKEOtWKvUjhU-XQ_12_5"
          xlink:to="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_76XUmnnJH0WBOHwIejBh7Q_20_22"
          xlink:label="Tc_76XUmnnJH0WBOHwIejBh7Q_20_22"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_76XUmnnJH0WBOHwIejBh7Q_20_22"
          xlink:to="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_ZKdYgNzJjUCbyRtM_ftH6w_20_13"
          xlink:label="Tc_ZKdYgNzJjUCbyRtM_ftH6w_20_13"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_ZKdYgNzJjUCbyRtM_ftH6w_20_13"
          xlink:to="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_uAsIpfpH1EuGwJuct4F3Xw_20_16"
          xlink:label="Tc_uAsIpfpH1EuGwJuct4F3Xw_20_16"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_uAsIpfpH1EuGwJuct4F3Xw_20_16"
          xlink:to="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_0eVudmzgAk2o9n9P9JaYrQ_20_5"
          xlink:label="Tc_0eVudmzgAk2o9n9P9JaYrQ_20_5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_0eVudmzgAk2o9n9P9JaYrQ_20_5"
          xlink:to="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_pbHeOPec5kCo7burVpgWUw_27_22"
          xlink:label="Tc_pbHeOPec5kCo7burVpgWUw_27_22"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_pbHeOPec5kCo7burVpgWUw_27_22"
          xlink:to="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_CXgll3kXZkGRtrU7Mm5iuw_27_13"
          xlink:label="Tc_CXgll3kXZkGRtrU7Mm5iuw_27_13"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_CXgll3kXZkGRtrU7Mm5iuw_27_13"
          xlink:to="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_DPen8g3MI0qtSL9TNu5vTQ_27_16"
          xlink:label="Tc_DPen8g3MI0qtSL9TNu5vTQ_27_16"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_DPen8g3MI0qtSL9TNu5vTQ_27_16"
          xlink:to="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_ED3uytwyLEemO4jP3bMLrw_27_5"
          xlink:label="Tc_ED3uytwyLEemO4jP3bMLrw_27_5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_ED3uytwyLEemO4jP3bMLrw_27_5"
          xlink:to="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_rVR-ysL_j0WZafYvxyYOJw_18_5"
          xlink:label="Tc_rVR-ysL_j0WZafYvxyYOJw_18_5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_rVR-ysL_j0WZafYvxyYOJw_18_5"
          xlink:to="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_Zy7HkBmCZU29s2bBPs0NuA_18_8"
          xlink:label="Tc_Zy7HkBmCZU29s2bBPs0NuA_18_8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_Zy7HkBmCZU29s2bBPs0NuA_18_8"
          xlink:to="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Hidden_m0PgDCiYQU2PjrsApvCBvw"
          xlink:label="Hidden_m0PgDCiYQU2PjrsApvCBvw"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Hidden_m0PgDCiYQU2PjrsApvCBvw"
          xlink:to="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Hidden_uci48Mn9D0itSoXcTjZpVg"
          xlink:label="Hidden_uci48Mn9D0itSoXcTjZpVg"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Hidden_uci48Mn9D0itSoXcTjZpVg"
          xlink:to="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Hidden_pfkY8QG510ql5k4pesQm0w"
          xlink:label="Hidden_pfkY8QG510ql5k4pesQm0w"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Hidden_pfkY8QG510ql5k4pesQm0w"
          xlink:to="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_IYJZigyOHkyJZpyoc1xRsw_26_5"
          xlink:label="Tc_IYJZigyOHkyJZpyoc1xRsw_26_5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_IYJZigyOHkyJZpyoc1xRsw_26_5"
          xlink:to="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_XWLpghrsXUO5fpZiFUwglg_26_8"
          xlink:label="Tc_XWLpghrsXUO5fpZiFUwglg_26_8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_XWLpghrsXUO5fpZiFUwglg_26_8"
          xlink:to="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc__vRHrcT0Q0SDmSrSq27f1A_26_11"
          xlink:label="Tc__vRHrcT0Q0SDmSrSq27f1A_26_11"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc__vRHrcT0Q0SDmSrSq27f1A_26_11"
          xlink:to="_225cfe21_6a46_4ef1_aa3c_d2f6d1c85d25"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>127
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M%Y/E6_SR1(E%\2+\7B@EDN)PSEG(I;X!/I\*H=8G^@LVOZ4X^A=02P,$%
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MAJWSZ=<^]EYJRX&V;WKN$>. P -4IT5U>E%O.2\_QW3>93>A!T>F?XPY(/
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MW":JBYCJ1?%M>=-PQY7BF_(QHP2\H 'P?<7!0_6+GJ"Y#IO^#5!+ P04
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M!?KH*4KV\>(A@ET2K:(D,3'W\R1*8;[IS?OM0Q@EZ1<(HU6\C*/-\B=<[HA
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M+@W^J)M>9I%GEV%7)GRXE,389N>!)3,<#/#K:P<\7CS8)58)Z43^15F ^[H
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MC5E59FGRK&J3 8#*W&BF)]MN2P,3F$JU:T=>1IIIE_31X%)0<6G%IFGA ]1
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M@4.A:YY0+2%@ ((+L/M@_6';2HL>@(4R^4(T'"@+GWI[-K!#Y/M0M=9FRX'
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M/RJ\CD(9V%.0=$R(:+"IQK'U2-U9+"@P!P2E\4&G$(;YAT!'B4VE;@^$.7E
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M>B0G#D'\&01_39E#T=)CL7A4E>[%B^_PVX4X"I(F7(X3,N!PJ5=\#0D"(:-
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MI("/S/( Z;%M<V=->&9WO)B?-LM(;.6KI&]%P'PO@M$2WSZX/"J.9'Q@Z[
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M)@H#T.\[SM7%, GJ-3S^ U!+ P04    " #;BGQ4B[KGF#<#   @"   &0
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M"(U'4YQ_JM]'O6)DZW; 3AK<*$ZL<86#L@;XOI+2G!3KP/\I6/T'4$L#!!0
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M786J"1([(6R*6&,$Z /@R._?34H_JHD%;RS%@!GHY'?D&*5B)IF>R5:I-+Z
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M_/27:9(,CSXC-)2U*FMV\_KHB%E^L^=:I<O2Y&8!R#D\P2M;6>U4).H+G(1
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MRE*7"R'G\/Q6.2&+D7(B/!CO5EDX]HUBZXG*FEM-Y<T%,0HJ(4+#!<BE6G=
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MXI5;%^%A>S(LGHHGH6.8/D0I<LI,6)8JE.=5R/+QJ,BY!9*;+P><;L&[?Y=
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MI?[1R@Y9IMR(]ZKX1>;5\NW!^(#E8L[KHKI2MY]$(T]"]&:J,/8ONW5KH^2
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M3VD2>D&:;7E6]1!#@Q-\AHAL3:WQU6Q=\!)&\J5? _L'^1[-U5*K>K%D$@=
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M7!H%_+\26$C=PFS0-Z.C?P%02P,$%     @ VXI\5(C-5]1H P  . @  !D
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MM!**=9XKC\VAGZI"%K&2&8>],G@FZ-:LRKS1]J=C]>LOYU'W[,**+S U.#Y
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M<]26I7#A$X L(HV;:;"PUBBGX$C-/37)J&;?>FR7N*@6U,;?.*^%$,\X7Z'
MEA%';Z&9YCT<6H.5<6@*H8+X^+QI1TOTK*]+B],E%"/+=N/<W+)OI[ PBCI=
MX4."L26:#?>W9SC(D(F591"TP;"BP'4 :F_7V4#)@T' V/;5$/I1Z*(@KN_%
ML!6KE$ZXI9-%BD/A(0C<8E=-TJL&,\#"VP2G -C+1>\]0Z31>ATP5T4:U^UG
MBT?H/UF92G$OJV5E;:2IW-%B-"?N>CXT:P;:FJ3++A,CJIP/A?CB &ZLX-*!
M9V)T.QJ*@Y%1<YB.+L?CGL.J6+;NH>?DX6:26^(]VI%>^-RG]$QM(9#R<+\
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M)LKH![GA )G_UO'8GA,B>8Q7:ZVWK)PL0*+QB0"M YZ$E[#<(V'GIB'A B9
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M!&J2=.:XZGZ!(L(+0,87W\]%6GY!#FQJ+684#&W)@ 5J4QDCQ3HGN@*@ -:
M)+[9:,:_%3P%Z BDD:1L09L'D#@P/QP+'$@&9EKLN$ 8R3+NGKRC:F>2B9"(
MN(_7*G""T?XTK$K&.-F?NI=?.9T'"!,W/CW^_M_^]ZW*U&8!$@.=9/;+^70^
M)8\9TW\?.H@C/H$).]UWR>QT='IY$7PQ/Q[-C\^ZQ/$MDYZ>G[F_SV87!.D^
MND=]^(Z7>0+5X2[.1K/SDW@7%Z<G S?OTMV\R\&+<^\XBKL!?;=O>)+E).F9
MYPI-$/]U>,OP@J7N S.BB/UL0*9;52)@1(NV(4[$/X$03G8*E:"W]O)V]9R%
M0C44100<!+(O-B! Z*_P:J)5.9E.IJ<OQ[/)V>E+.C/X/'LYGD[.YB]'Z-.
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MII<F94N*)>>)V+22D4]R<1#4&LX)HRQBB+L31K=IID;)@\'0)&- 7(U.-1?
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M%U,[QUOV_;:@(N,LOP8E"41)[\B_9B>R# 7  ,TPY10EXBA@Y.5B>8BT?*
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M_,F ,+IXNA031, ".-DRB&47]]3#)81R!WFU;P(P&R[@OS% $67C.VEF<-$
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M?K)YHS0#+2K[+E@(C:\,V\WQ60?2&.!Z)H1N!R9 ]U"<_@M02P,$%     @
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MK7(]%YN?L*TGKOD2D2OS2S9-;.0Y)*F4%L46C H*QIN5/F_[< #HO 4(MH#
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M4.^LC1- -J.Y<;0HS3A<"HW#U9AK?,U U@'X/1-"[YPZ@7T?^_\!4$L#!!0
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M%.HN10"Z[MZU8=7"=\R9LM1__;2D!P^U<Z#]0BF[-5R"Y@D=_ =02P,$%
M  @ VXI\5 G@!B.[ P  \PP  !D   !X;"]W;W)K<VAE971S+W-H965T,S N
M>&ULS5=;;^I&$/XK(S<Z(A(GOG$Q"2 E(54C-:=12&^J^K#8 UBQ=^GN$G+^
M?6?78)L4+%3EJ'V!G=VY?[.SX^%&R!>U1-3PEF=<C9REUJM+UU7Q$G.F+L0*
M.9W,A<R9)E(N7+62R!(KE&=NX'D]-V<I=\9#N_<HQT.QUEG*\5&"6N<YDU]O
M,!.;D>,[NXVG=+'49L,=#U=L@5/4/Z\>)5%NJ25)<^0J%1PDSD?.M7]YTS/\
MEN&7%#>JM@83R4R(%T/<)R/',PYAAK$V&AC]O>(M9IE11&[\M=7IE":-8'V]
MT_Z]C9UBF3&%MR+[-4WT<N1$#B0X9^M,/XG-#[B-IVOTQ2)3]A<V!6]OX$"\
M5EKD6V'R($]Y\<_>MGFH"43>$8%@*Q!8OPM#ULL)TVP\E&(#TG"3-K.PH5II
M<B[E!I2IEG2:DIP>WW^Y_>GA#IZO?[N;0NN9S3)4YT-7DVK#X,9;-3>%FN"(
M&C^ !\'U4L$=3S#95^"23Z5CP<ZQFZ!1XP3C"PC]-@1>X#?H"\M 0ZNO>RQ0
M'HL<X9F]P215<2;46B+\<3U36E)I_-E@HE.:Z%@3X1$34[HQR3I#$',@8RO!
MD6ME*+U$X'3#R*J"5FI=.8<9TJ5"T.02U6>Q>RCUS58_?1<%7G@%W_K_=V02
MT* +A WF,Y06G]UYX/D# Y9G$8,)!:-T&D/K7DF&V7G)> 91.QI$-7K0#H.@
M1@?]MA<-@*X=72I>'K2ZD7=>HP911?G]+CP+S;(],Z$?[=']H+-O)NAU&H#O
MEL!W3P:^@-&"BF_4.M5!2)OU_4\AO5U+215]^6'VB\JH(6)6?G!UTL[[ZO [
MO6K=K7#O?WC:BCJ+BVP< /P_<&F"<R1WDN/8'+^/[U-\C'Z?\%/EODWZDVW$
M3?D_U</[XRK.]D \VX/Q#/H-S:-7-H_>R<U#47[3>1HSJJM_OB!ER,91IA1J
M=:BW-)O[^,H[V#AV/>,)%<I75,!X BRC&9#QF,A:%ZYW?NK73Y]8OKJ:[)"H
M6#M1Q1D.!H2:9GR1TL2R34;%677YT(>I%O'+9S.Z)3:II)79B;"\FF&-/X0?
MS2,=,RF_TO.\83*I&-O=KE^Q[KU:__;&UL#<#02O+%L7'I8)JS+;#LC%RH7(
M(X>1'/[<*-:R<K7'TTJ>PQ<:2@Z4U2D-^%#IN[5!-$>YL.,V)5.LN2YFTG*W
MG.BOBT&V8B\^!QZ87*1<089S$O4N^O1DRF+$+@@M5G:LG0E-0[)=+NFK!*5A
MH/.Y$'I'& /E=\[X;U!+ P04    " #;BGQ465#Y:8<#  !S"   &0   'AL
M+W=O<FMS:&5E=',O<VAE970S,2YX;6S-5EN3VC84_BMG:*;39%Q\ V.VP RW
M3'8FV3! DX=.'X1]P.K*EB/)2^BO[Y$-A)TN3-*GOB#IZ%R^<[$^!GNI'G6&
M:.!K+@H];&7&E'>NJY,,<Z;;LL2";K92Y<S04>U<72ID:6V4"S?PO,C-&2]:
MHT$M6ZC10%9&\ (7"G25YTP=)BCD?MCR6R?!DN\R8P7N:%"R':[0_%XN%)W<
MLY>4YUAH+@M0N!VVQO[=I&/U:X5/'/?Z8@\VDXV4C_9PGPY;G@6$ A-C/3!:
MGG"*0EA'!./+T6?K'-(:7NY/WM_6N5,N&Z9Q*L5GGIILV(I;D.*65<(LY?X=
M'O/I6G^)%+K^A7VCVXU:D%3:R/QH3 AR7C0K^WJLPX5![%TQ"(X&08V["52C
MG#'#1@,E]Z"L-GFSFSK5VIK \<(V9644W7*R,Z/IQX=/\^7Z?O)^#HOE_.U\
MN9S/8/5NO)RO8/PP@\_CY7+\L%[!+VNV$:A?#UQ#<:VUFQQC3)H8P948?@ ?
M9&$R#?,BQ?2Y Y< GU$')]23X*;'&29M"'T' B_P;_@+SU4(:W_=*_[6F)=2
MT5#"_$O%S0%F7"="ZDHA_#'>:*-H>OZ\$:AS#M2I X57 JWHHTHK@2"WD$@*
MJGD]G'2<RN()E>%49%C0:*)2F(+.F$+]4LUO!_KYISCPPM_@_[)2QS#?H#IU
MS;MZX__G&./*9%+QOZEL]UI7M+ B!7J)M*$-+W;?H3%E2AWLAN6R*@R\YS00
M*:N;5-9=P2+!?X5^J.H4J(U-PWX8^PH5)[/QS3&P_@OY:\D4/#%1(;QY?7;@
M1T[0[SI!-SJ+>DX0])TX[OZ8TBL(2"6,+P1AY'3"W@GDY'M PC.4?<?K!DZ?
MVAXY7:_OA)[_HNP4,HB=7A ].T8^K*5APJ(+.['C]R+P0Z<7]AT_CJY(OZ70
M#9U^U+D01%W'[\<6W$)QJ:"DY&1*1*/I0=>0L2>$#:*E'J-DPQ[B "S]BUYE
MRM9(2TJ67<!D"/X=>.T^9=0/@%[MY!%T*;@!W&Y)A?1I@#XPE614<3OF09O*
MB<"$EE0N0PX\!U:V@ID4*2IMD?H]^WUL><)IZ@X.$ D3Y1C&A6Z_]!JY%T20
MH]K5=*?II:%1;CCA+#TSZK@ADF_J#1T3UATO- C<DJG7[M';J1J*:PY&EC6M
M;*0ADJJW&?TK0&45Z'XK*:OCP08X_\\8_0-02P,$%     @ VXI\5.-!8_::
M!0  FQ(  !D   !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL[5AM;]LV$/XK
MA#=LS:#*>I><)0'RXK8!UC:(VQ7]2$MGBXLDJB25E_[Z'2E;4MI838=FP(!]
ML4SR[GAWO.>.QX,;+JYD#J#(;5E4\G"2*U7O3Z<RS:&DTN8U5+BRXJ*D"H=B
M/96U )H9IK*8>HX334O*JLG1@9F[$$<'O%$%J^!"$-F4)15W)U#PF\.).]E.
M7+)UKO3$].B@IFM8@'I?7P@<33LI&2NADHQ71,#J<'+L[I_$FMX0_,G@1@[^
M$VW)DO,K/3C/#B>.5@@*2)660/%S#:=0%%H0JO%I(W/2;:D9A_^WTE\8V]&6
M)95PRHL/+%/YX229D Q6M"G4);]Y!1M[0BTOY84TO^2FI0UQQ[21BI<;9AR7
MK&J_]';CAP%#XNQ@\#8,GM&[W<AH>485/3H0_(8(38W2]!]CJN%&Y5BE#V6A
M!*XRY%-'BU?'E_-7;_\XFU\N?B5G\Q?GI^?S-Z<?R;-W=%F W#N8*MQ&$T_3
MC<B35J2W0Z3KD=>\4KDD\RJ#[+Z *>K7*>EME3SQ1B6>06H3W[6(YWCNB#R_
M,]HW\L+O-'I$=-")#HQH?Y=H1$W6%$#XBJ2\K+ED)OIPR$7&*@Q\(G,J@*2T
M9HH6#_EW?(M??DH\Q_^=/-47O0WE$L36X\[.%;=;.6Y4S@7[#!DYE[+!#ZTR
M@DE *OS#JO4C*+[4XTUC]D+/&8=)\O:> Z5>J?CSF@IR38L&R&]['6_L68'G
M6W[4*Q\X5N#[5A@GWZ *O<2:N;X6=R$8%Z0&_&28@B1"79*<7@-9 NBDI 1O
M\TIQ1VCV%^(5#5-<IRN==XC*@;C[Q+%G3NC-/()X3J^(K NF"*Q62(+T&!ZO
MJ4AS$ANO>C99 !!:2([V*13@6&2A3<YYD8&06E<WUL>Q8BF#*KVS"*9G3$:*
MLD+:(V$<=F$<CH=QFZ.UB[4)>$:J,0[GM0YG:0XOS6FU!OE0!(]+?^H(GI=U
MP>\ 0V0[\Q$P2D"GHY$@_E'?#Z84X%8_C! C3F")_&ZZX_5:P)JJ?D: KM0C
M<-L.X19$RF3/R2HE&!;CM)M),<L+#/^&%MW<($1JP5+80+-@*R#/[O 4Y!YY
M.P ]50BE-:N,2LBL27HP6DZ$$'5ZQ/Y,?#MP!L-9$%C)($7%-N+[I:"5=JMK
M^9YK>:ZK">VD/^GYQKB,/$-V9[:'!($=>!T!5OP5,+7)4BFM4KPW:/+0MSP_
MT?2A[49/%L';[Q>N ITR-TX*T;@0TYEG=)_%^'%C*PG1:4&$?D!K-F;J0MZ=
MBM;?MZ(P-K[T?,T66&X28-Z+262'3V_4 L2U#HT+P:^93FC_P_0_#=,(08H]
MP "5GAW/AIAU,>J<'J21/7-[D&+)C:+80'3 -8!HXEI!'&G,N;;;2]F%45,>
MO:<+W^_ :(SIQS70#&P_T(ZQHEF(&<E''T3N@P -$\>*@]# TPE;GF!F);&/
M*2>9C13WJ"ONT3\K[I>+]]^L[..BC[?=W0[A#6);F(6+@F)/9E:^AOI !Y(U
M0GM6\PALYJXQ:K8WLC93X/5)Y>CX3 .(Z8 &"2:TEKKGW/_F ?873=3Q<6&O
MXZNO,HX?8>)U1JJ&%3G.?42AUE_;K45AP0J[(!\Y[;@[[?AQ'0E\:IBZ>ZY[
MV,ST)MA:4].<P*W^;_R+/LP>.O;Q/?XMJ.VJ#]MUSW%G;<MBW'F)@6 NUOHX
M,L!;.J]+#(UA:DJ&MPD_]@:C* STQ?P*E#ZPC9/Z8N4F@WW["PAY"16F]\)L
M2C/LV9G$_*N;A)XU&/(&_7SHDG<<N\*VQ1D[JU[-,!BFWG V'"6N]U (30</
M!B6(M7D6D;A14ZGV[:";[5Y>CML'AYZ\?;9!!R% )"E@A:R.'>/57[1/(>U
M\=H\/RRY4KPT?W.@F 8T :ZO./8XFX'>H'N/.OH;4$L#!!0    ( -N*?%12
M_CAU_@(  %0)   9    >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;+U6;6_:
M,!#^*U8V3:V$FC<@M 4DZ*B&M#)4NK>/)KF U<3.;#/:?[^S R&E!6E3NR^Q
MS[Y[[CG?V9?N6LA[M030Y"'/N.HY2ZV+"]=5\1)RJLY$ 1QW4B%SJE&4"U<5
M$FABC?+,#3RO[>:4<:??M6M3V>^*E<X8AZDD:I7G5#X.(1/KGN,[VX5;MEAJ
ML^#VNP5=P STUV(J47(KE(3EP!43G$A(>\[ OQ@VC;Y5^,9@K6IS8B*9"W%O
MA''2<SQ#"#*(M4&@./R&*\@R X0T?FTPG<JE,:S/M^C7-G:,94X57(GL.TOT
MLN=T')) 2E>9OA7K3[")IV7P8I$I^R7K4C=L.R1>*2WRC3$RR!DO1_JP.8>:
M0<<[8!!L# ++NW1D67ZDFO:[4JR)--J(9B8V5&N-Y!@W29EIB;L,[73_>CP9
M3*[&@\]D]&,ZFLQ&LP:9C.[(R1V=9Z!.NZY&+T;7C3>(PQ(Q.(#H!^1&<+U4
M9,032)X"N$BOXAAL.0Z#HX@?(3XCH=\@@1?X1_#"*N;0XK7^+N8CR,T*N6F1
MPP/(,[PSR2H#(E)RS3CE,:,9&3W@%5*@T OHEP[T..B'=YW "R_)6X\_@4H"
M)F<$3QSR.4A[ZMO]P///30H\FX=:?+")[^+-*?[KB!<8KR?'"R4E\/B1:$FY
MHN7#D F%J>'X &[5WY/HO":8F1]<UE::6.2WD -5*XD#UR;A:RH15:M*[_R\
M63N\L)K[82-H1>2+7H+<:?O^;KJS\]NO?AAW0F/2TF?IV_EL>)T:<S^J,V]W
M6J^?GHH+X['(X?\5TM'"**1(F7Y:&ONUX'O^L[TQUR!!:9)*D6.+*(1BM;*(
MHEU.VWY8.VA_OR;VO07AP:VWJHXR(R^2C\+H"?GG+P(Y*<U/]^]7Z'5JTDDK
M\$YK,I99,VJ^]!Z[M4Z7@US8?JY(+%9<ETVO6JU^&09EI]RIE_\;-U0N&%<D
M@Q1-O;,(VX4L>W@I:%'8OCD7&KNPG2[QMP>D4<#]5 B]%8R#ZD>J_P=02P,$
M%     @ VXI\5*=U[,^8 P  T0D  !D   !X;"]W;W)K<VAE971S+W-H965T
M,S0N>&ULQ59M;^(X$/XKH]SIU$J^)G'>NX $A=56VFT1M%?=1T,,6)O$G.TL
MO7]_XP12T%&TTN[IOF![XGGF\3,SV+V=5%_UAG,#KV51Z;ZS,69[Z[IZN>$E
MTS=RRRO\LI*J9 :7:NWJK>(L;YS*PJ6>%[LE$Y4SZ#6VJ1KT9&T*4?&I EV7
M)5-_CW@A=WW'=PZ&F5AOC#6X@]Z6K?F<F^?M5.'*[5!R4?)*"UF!XJN^,_1O
M1Y'=WVSX0_"=/IJ#/<E"RJ]V<9_W'<\2X@5?&HO </C&[WA16""D\=<>T^E"
M6L?C^0']8W-V/,N":7XGBQ>1FTW?21W(^8K5A9G)W2>^/T]#<"D+W?S"KMT;
M9PXL:VUDN7=&!J6HVI&][G4X<DB]=QSHWH$VO-M #<LQ,VS04W('RNY&-#MI
MCMIX(SE1V:3,C<*O OW,8#2<W]_!\&$,X_O/ST^3,3Q,GN#SXWP.T\D,YI^&
MLPE</;%%P?5USS48TCJZRSW\J(6G[\#[%+[(RFPT3*J<YZ< +G+M"-,#X1&]
MB#CFRQL(? +4H_X%O* 3(&CPHA\0X$*8L L3-F&"=\+,L9ORNN @5[:*Q!)8
ME4,NBMKP'"KLOD)J#5N.#;-ABI^3^G*$WWY)J1=\@/]Z_),S!=QF$S 7O%P@
M99N/PW?J^9E-CM=D"![JDBMFI+K]X<@/!Y68,4HL:F.K$HR$1Y6+"O]26NDV
MLLBYTIW;KW"5DB!.KD\M:4I/+#0A-/&O?[I>8UY);-S+$KPT_QX\_YU]0[76
MO#V)AEJCS**"I2RWM1'5^DRI_$L.>4X.<J;L#M&#@*1^1,(P[4RAAVJ$) NB
M8U,4A"3.DK=,_$025]X-C:Y/EO1DB1F\T(A1UXC1=S<BJXQH:.#% )HO:R6,
M0-7YZ[*H;8&OE"R_LSDO1_V?F_!.5EA71MC<X-V]XDJAY[[&#CY8_S3#MGC+
MN!^0),B(G\;G3(^UT08S::NRK0&YM3>MAI $B4_B.,590D,2^B'$Q MCDL09
MS.;/#9Q//W2C3SRD3R,/7IA2F!=;0M..Z?# -2"QCU49>SA+4X\D27(TV_MJ
M2$D8Q"1*4H@CA(Z3;NP$0J0H(%[F Z4DRVSUAT C$H09,LW.59I[=,WBG]JZ
M>4QH[,VZ,NV-VUF[]\JPO:;?MK>/G2],K04J5? 5NGHW"9:/:A\0[<+(;7-I
M+Z3!)T SW>";BRN[ ;^OI#2'A0W0O>(&_P!02P,$%     @ VXI\5'KI+()G
M @  ? 4  !D   !X;"]W;W)K<VAE971S+W-H965T,S4N>&ULK51M3]LP$/XK
MIVR:-JDB;PT4UE9J@4$G 54+VV<WN381CAUL9X5_O[/3AB!!I4G[$OO>GGON
MG+OA5JI'G2,:>"ZYT",O-Z8Z\WV=YE@R?20K%&192U4R0Z+:^+I2R#(75'(_
M"H)COV2%\,9#IYNK\5#6AA<"YPIT799,O4R1R^W("[V]8E%L<F,5_GA8L0TN
MT3Q4<T62WZ)D18E"%U* PO7(FX1GT[[U=PZ_"MSJSAUL)2LI'ZTPRT9>8 DA
MQ]18!$;''SQ'SBT0T7C:87IM2AO8O>_1?[C:J985TW@N^>\B,_G(&WB0X9K5
MW"SD]AIW]206+Y5<NR]L&]_XQ(.TUD:6NV!B4!:B.=GSK@^=@$'P04"T"X@<
M[R:18WG!#!L/E=R"LMZ$9B^N5!=-Y IA'V5I%%D+BC/CJ\N[J\5D?CT[A]GM
MC[O%S>1^=G<+7^_9BJ/^-O0-);&N?KH#G#: T0> 800W4IA<PZ7(,'L+X!.[
MEF*TISB-#B)>8'H$<=B#*(C" WAQ6W+L\))_*OD <+\%[CO@^ /@)4U,5G,$
MN88KE!O%JKQ(&8>9:*:'?L/W&GH8]<NG013$W^%_G=1.+%>H7$OW2FIMX/H+
M,ZT8\M;P&>)>T@\Z<M(;]"-X$(7!#):&&=2M->P-DJ0C'9^>PD]6,?&&11B]
MLDG@7AIJ4:5HSRCS DQD@$]U4='DFQX(VDO=W/%ITI%/B-OQ>R_G=R:B1+5Q
M<Z\AE;4PS7"TVG:U3)J)>G5O]M(-4YM":."XIM#@Z(3^*]7,>B,86;GY6DE#
MT^JN.:U'5-:![&LIS5ZP"=J%._X+4$L#!!0    ( -N*?%2332_540,   (*
M   9    >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;)U6VV[;.!#]%4+H @F0
M1!=+LES8!A+;;7?;=(.DEV=&HBVB$NF2H[CY^QU2LM;KT&JP+[9(S3ESSH@<
M<KJ3ZH<N&0/RJZZ$GGDEP/:M[^N\9#755W++!+Y92U53P*':^'JK&"TLJ*[\
M* A2OZ9<>/.IG;M3\ZELH.*"W2FBF[JFZOF&57(W\T)O/W'/-R68"7\^W=(-
M>V#P=7NG<.3W+ 6OF=!<"J+8>N9=AV]7$Q-O [YQMM,'S\0X>93RAQG\6<R\
MP AB%<O!,%#\>V(+5E6&"&7\[#B]/J4!'C[OV=]9[^CED6JVD-5W7D Y\S*/
M%&Q-FPKNY>X#Z_PDAB^7E;:_9-?&IK%'\D:#K#LP*JBY:/_IKZX.!P#D<0.B
M#A = ](3@%$'&!T#3DF*.T#\6D#2 :QUO_5N"[>D0.=3)7=$F6AD,P^V^A:-
M]>+"K),'4/B6(P[F[U>?5_?7G\C9D@'EE3XGE^3KPY*<O3DG;P@7Y$LI&TU%
MH:<^8#Z#\O..^Z;ECDYPA^16"B@U68F"%0[\XC?X:(# 1Z.]VVCO]B8:9/R+
MBBLR"B](%(292] P?,GR/3P*'?#EZ^&! [YZ-3R<#!1CU'_ZD>4;G>!;4%U>
MD!Q_"?O9\"=:,0'Z@NA2*K@$IFK<<5NI.6B""P"[@@;%<V"%!;G*UR9,;4+3
MH9[FHW RBJ?^DT-GW.N,!W5^QFY92>U:@(L6&1\DO(S&T3CL,[;?)7ZAZS++
MLNB_42M75)R>4)_TZI/?JK<U;C06#C<4MGA%@8M-VR0Y<.:TEKRT%H99>"1Z
MZ0@;1\E1 5;)2VOI) S<UM+>6CIH[3K/F[JIJ%D1V)MYSL%E)'V9.XFR.#@R
MX@B+DB2=N#6.>XWC08V?."[M@L,SP;)S61"01&/Y]?H9.RV4V&.5PG5O5K=L
M5.[^%L,Y(O+,J-(#6S+KU6;#%?UR2SY^'"":]$230:*_=X(I7?(M*655D#.*
M6]A4($>KYZY./DPW":Z"X ]7989Q87 *N/P?P+82_L%A5S.UL;<,37+9"&A/
M@GZVO\A<V_/[:'Z!%YSV/O(O37L[NJ5JPX4F%5LC97 UQNVCVAM'.P"YM4?J
MHP0\H.UCB9<TIDP OE]+"?N!2=!?^^;_ %!+ P04    " #;BGQ4[A2'/YX"
M  !]!P  &0   'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6R=55U/VS 4_2M6
MM >0&/D.!:61("TLTE8J"MNS26X:"R<NMMNR?S_;"5$I@56\)/XXY]Y[?)R;
M>,OXDZ@ )'JI:2/&5B7EZL*V15Y!C<4I6T&C=DK&:RS5E"]ML>* "T.JJ>TY
M3F37F#16$INU.4]BMI:4-##G2*SK&O._5T#9=FRYUNO"'5E64B_82;S"2UB
M?%C-N9K9?92"U- (PAK$H1Q;E^[%--1X _A-8"MVQD@K>63L24^R8FPYNB"@
MD$L= :O7!E*@5 =293QW,:T^I2;NCE^C7QOM2LLC%I R^H<4LAI;(PL54.(U
ME7=L^P,Z/:; G%%AGFC;81T+Y6LA6=V1504U:=HW?NG.88?@!A\0O([@'4KP
M.X)_*"'H",&AA+ C&.EVJ]T<W 1+G,2<;1'7:!5-#\SI&[8Z+]+H>[*07.T2
MQ9/)(KN99==9>CF[1Y=I>OLPN\]F-VA^^S-+L^D"?4=W("0GN80"Y5A4Z&@"
M$A,JCM7>PV*"CKX=HV^(-.B^8FN!FT+$ME25Z?AVWE5QU5;A?5#%!/)3Y+LG
MR',\=X">'DYW!NB3@^GN^0!]>CA]])9N*S=Z2[S>$L_$"[]FR2<9_#Z#;S+X
M'V1(M8_*J=90>%Z3#:;02'&"L%!?_XIQ;;?ZCF4%ZCNDN,D!F4LV:&Z;+3+9
M=&/:))[O^5%L;W8]?(]RP_!\U*/>2 EZ*<&G4O9NYQ<%M#F"G=(B=[17_GM,
M>!8-%Q_VQ8?_]>%DR 1E#?],&&F%"8DEU)J#6-G&*57C'Y08#G@T"H,]D>]1
M;N2>[:$F ZA1X+X%30= ?N2<[YV8O=.Z](_I%^9+T@A$H50\Y_1,A>%MLV\G
MDJU,-WMD4O5&,ZS4_Q&X!JC]DC'Y.M$-LO_C)O\ 4$L#!!0    ( -N*?%3>
M:7K4;0(   L'   9    >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;+656V_:
M,!3'OXH5J=(FK;E14E0!$H2VB]125-KMV20'8M67S#:C^_:SG9"Q#M(];"_$
M/O;_=V[B>+@3\D65 !J],LK5R"NUKJZ"0.4E,*Q\40$W)VLA&=9F*S>!JB3@
MPHD8#>(P3 *&"??&0V=;R/%0;#4E'!82J2UC6/Z8 A6[D1=Y>\,CV93:&H+Q
ML,(;6()^KA;2[(*64A &7!'!D83UR)M$5^G WG<7OA#8J8,ULIFLA'BQFZP8
M>:$-""CDVA*P^7R'%"BU(!/&MX;IM2ZM\'"]I]^XW$TN*ZP@%?0K*70Y\@8>
M*F"-MU0_BMUG:/+I6UXNJ'*_:%??32X\E&^5%JP1FP@8X?47OS9U.!!$R0E!
MW CBMX)3'GJ-H.<2K2-S:<VPQN.A%#LD[6U#LPM7&Z<VV1!NN[C4TIP2H]/C
M978[SVZR=#)_0I,T?7B>/V7S6[1XN,O2['J)SM&R%%*?:Y#,E*<2BFB%/LQ
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M<H%YG@BA7P?E!DU_._T-4$L#!!0    ( -N*?%1 ?>&1R ,  $T/   9
M>&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;*U7;6^C.!#^*Q;:E5KI"MAY7R61
MVM#=BW1]4=/>?7:#$ZP"YFPG::3[\6<;0I)=,&S5+XEMYGD\\XS-,.,=XV\B
M(D2"]R1.Q<2)I,R^>9Y81B3!PF492=63%>,)EFK*UY[(.,&A 26QAWR_[R68
MILYT;-8>^73,-C*F*7GD0&R2!//]#8G9;N) Y[#P1->1U O>=)SA-5D0^9(]
M<C7S2I:0)B05E*6 D]7$N8;? CC0 &/Q-R4[<3(&.I17QM[T9!Y.'%][1&*R
ME)H"J[\MF9$XUDS*CW\+4J?<4P-/QP?V[R9X%<PK%F3&XG]H**.),W1 2%9X
M$\LGMON3% 'U--^2Q<+\@EUAZSM@N1&2)058>9#0-/_'[X40)P#4JP&@ H#:
M CH%H-,6T"T 7:-,'HK1(< 23\><[0#7UHI-#XR8!JW"IZG.^T)R]90JG)PN
MYC_NY]_GL^O[9W ]FSV\W#_/[W^ QX>_YK/Y[0)<@46$.;G2VH8@PWN5<RG
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M/D2Q+[7YGYOR3W%/Y8IAPU-8HDOOLHVIR5)]RXT6N=6C9Z%1W>PRP1\62&.
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M\2<W5QZ2_1WH$RT:=XQV0IM#Z<+*/!L@;8%9+X70A\2>S/$A2OX 4$L#!!0
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MN[W3!1---VLFBJ]M0UAQI=N+'9;Z P#" /1^SKG:3<P!W2<E^0-02P,$%
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M=</!+1G7[2-K ZLJW]BMLO1,_+*@N43M$NA\IY0]!>ZM]).>_@%02P,$%
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MA#'0ZRGGZC@Q=TOU5V+V'U!+ P04    " #;BGQ4T$:ZL\L#  !Y#P  &0
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M6-MNVDH4_941RD,KM=@SOE<$B<10J,Y)$23M\P!#L&)[Z,P04NE\_!G;$U_
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MG@3(\UM*Q>M.\HDA__ V_!]02P,$%     @ VXI\5-_H!UY  P  8PH  !D
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ME.0..9IOR4*1_H)=9NLY';#<"LFB'*P41#3._O&//! ' &C7 % .0$< 9-8
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M,N\D$K!:A5^H\!M5#)DZ]ZU(ZGT,U.$SW7@X7A*M+%L\I>>BJKIFS.Z!&!1
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M9SD($Z#]6\[5T3 '='^'Y ]02P,$%     @ VXI\5*MSER.Q!0  21L  !D
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MFNP')E7+;H:Q>H8!UP+J_R5C<C_1&Y0/N\E_4$L#!!0    ( -N*?%1K9I(
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M5A&MQV5 I@3 ,V!/(]M#$0)"LO@'$+N,2D V&P51>.6#SYC'Z9M7T+??!]5
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MV'\9/S^ABQ%($B?B$OU ,44O$<L%H:'HV%(EU5![4288% G<$PFPBQX9E9%
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M #1@2!35Y^#>>11NSJEP^S_0Y!=02P,$%     @ VXI\5)>*NQS     $P(
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M_&7YO1/O%\T%Y_JVHCS]!5!+ P04    " #;BGQ4I,C#=_H!  "T*   $P
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MKP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ VXI\5)E<G",0!@
MG"<  !,              ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    " #;BGQ42Z*#4@('  !7(0  &               @($,"   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ VXI\5%A8<GY;!@
MKA<  !@              ("!1 \  'AL+W=O<FMS:&5E=',O<VAE970R+GAM
M;%!+ 0(4 Q0    ( -N*?%03]I74M0(  $,)   8              " @=45
M  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " #;BGQ4=KTP
MG3X%   :$P  &               @(' &   >&PO=V]R:W-H965T<R]S:&5E
M=#0N>&UL4$L! A0#%     @ VXI\5)MLMF_@ 0  U@,  !@
M ("!-!X  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( -N*
M?%16;@_G P@  )8H   8              " @4H@  !X;"]W;W)K<VAE971S
M+W-H965T-BYX;6Q02P$"% ,4    " #;BGQ4]$[;<3@"  #/!   &
M        @(&#*   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%
M  @ VXI\5#DW8&HK!P  .!T  !@              ("!\2H  'AL+W=O<FMS
M:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( -N*?%3P?S2"D0D  -H7   8
M              " @5(R  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"
M% ,4    " #;BGQ4V6%1YJLC  "F<0  &0              @($9/   >&PO
M=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( -N*?%0_CW ^3@(
M )(%   9              " @?M?  !X;"]W;W)K<VAE971S+W-H965T,3$N
M>&UL4$L! A0#%     @ VXI\5(NZYY@W P  ( @  !D              ("!
M@&(  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " #;BGQ4
MP$4D55("  "6!0  &0              @('N90  >&PO=V]R:W-H965T<R]S
M:&5E=#$S+GAM;%!+ 0(4 Q0    ( -N*?%0@3&L$-PH  '$;   9
M      " @7=H  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%
M  @ VXI\5,2V<99H!   )0H  !D              ("!Y7(  'AL+W=O<FMS
M:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " #;BGQ4R\O?IZD)  "<&@
M&0              @(&$=P  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+
M 0(4 Q0    ( -N*?%1G1MG9@PP  !LF   9              " @62!  !X
M;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ VXI\5-V1E66,
M"@  <2   !D              ("!'HX  'AL+W=O<FMS:&5E=',O<VAE970Q
M."YX;6Q02P$"% ,4    " #;BGQ44*E][^\"  !1"0  &0
M@('AF   >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( -N*
M?%1G]=B4]@,  )@*   9              " @0><  !X;"]W;W)K<VAE971S
M+W-H965T,C N>&UL4$L! A0#%     @ VXI\5(C-5]1H P  . @  !D
M         ("!-*   'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
M    " #;BGQ4WRL)@+<&  "N$   &0              @('3HP  >&PO=V]R
M:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( -N*?%3D#RXTO20  /E[
M   9              " @<&J  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL
M4$L! A0#%     @ VXI\5#Q0VB_; P  - H  !D              ("!M<\
M 'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " #;BGQ4H,D>
M3&("  "6!0  &0              @(''TP  >&PO=V]R:W-H965T<R]S:&5E
M=#(U+GAM;%!+ 0(4 Q0    ( -N*?%31RIGEU (  "L'   9
M  " @6#6  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @
MVXI\5*(HK6-G @  F@4  !D              ("!:]D  'AL+W=O<FMS:&5E
M=',O<VAE970R-RYX;6Q02P$"% ,4    " #;BGQ4'[GB!F "  !)!0  &0
M            @($)W   >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4
M Q0    ( -N*?%3[$,89 P,  $X'   9              " @:#>  !X;"]W
M;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ VXI\5 G@!B.[ P
M\PP  !D              ("!VN$  'AL+W=O<FMS:&5E=',O<VAE970S,"YX
M;6Q02P$"% ,4    " #;BGQ465#Y:8<#  !S"   &0              @(',
MY0  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( -N*?%3C
M06/VF@4  )L2   9              " @8KI  !X;"]W;W)K<VAE971S+W-H
M965T,S(N>&UL4$L! A0#%     @ VXI\5%+^.'7^ @  5 D  !D
M     ("!6^\  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -N*?%3>:7K4;0(   L'   9              "
M@5K_  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ VXI\
M5*-0W;EJ P  ZPX  !D              ("!_@$! 'AL+W=O<FMS:&5E=',O
M<VAE970S.2YX;6Q02P$"% ,4    " #;BGQ40'WAD<@#  !-#P  &0
M        @(&?!0$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0
M   ( -N*?%2-CRG*SP(   X'   9              " @9X) 0!X;"]W;W)K
M<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ VXI\5&3J?VQN @  5@8
M !D              ("!I P! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q0
M2P$"% ,4    " #;BGQ4<&$\S!H"   A!0  &0              @(%)#P$
M>&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( -N*?%2VUDL<
M(P(  )0$   9              " @9H1 0!X;"]W;W)K<VAE971S+W-H965T
M-#0N>&UL4$L! A0#%     @ VXI\5.LQ?A!M @  :P8  !D
M ("!]!,! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    " #;
MBGQ4"21 0@X$  #D$   &0              @(&8%@$ >&PO=V]R:W-H965T
M<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( -N*?%3],"W1<0(  &P&   9
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M970U,2YX;6Q02P$"% ,4    " #;BGQ4;<:N9RD#    #   &0
M    @(%P+0$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    (
M -N*?%1Y<[][L0(  %4'   9              " @= P 0!X;"]W;W)K<VAE
M971S+W-H965T-3,N>&UL4$L! A0#%     @ VXI\5,(LB*I^ @  $0<  !D
M             ("!N#,! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"
M% ,4    " #;BGQ4KOBT^@P"  #U P  &0              @(%M-@$ >&PO
M=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( -N*?%1;9KFYW0(
M %8(   9              " @; X 0!X;"]W;W)K<VAE971S+W-H965T-38N
M>&UL4$L! A0#%     @ VXI\5-!&NK/+ P  >0\  !D              ("!
MQ#L! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    " #;BGQ4
MQ$L/L X#   /"0  &0              @('&/P$ >&PO=V]R:W-H965T<R]S
M:&5E=#4X+GAM;%!+ 0(4 Q0    ( -N*?%1M6,EYI 0  (03   9
M      " @0M# 0!X;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%
M  @ VXI\5-_H!UY  P  8PH  !D              ("!YD<! 'AL+W=O<FMS
M:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    " #;BGQ4P%%Y=%@$   _$@
M&0              @(%=2P$ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+
M 0(4 Q0    ( -N*?%1\W?#9? (  "D&   9              " @>Q/ 0!X
M;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @ VXI\5*MSER.Q
M!0  21L  !D              ("!GU(! 'AL+W=O<FMS:&5E=',O<VAE970V
M,RYX;6Q02P$"% ,4    " #;BGQ491X.0$<"  !&!0  &0
M@(&'6 $ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    ( -N*
M?%0'#NFJZ ,  .0-   9              " @05; 0!X;"]W;W)K<VAE971S
M+W-H965T-C4N>&UL4$L! A0#%     @ VXI\5&MFD@!5!   AA$  !D
M         ("!)%\! 'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q02P$"% ,4
M    " #;BGQ4P3<Q-&D#  "&"P  &0              @(&P8P$ >&PO=V]R
M:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( -N*?%1>GC&=1 4  )85
M   9              " @5!G 0!X;"]W;W)K<VAE971S+W-H965T-C@N>&UL
M4$L! A0#%     @ VXI\5*9MUHWD @  5PD  !D              ("!RVP!
M 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"% ,4    " #;BGQ4YJ?)
M;A #   R"0  &0              @('F;P$ >&PO=V]R:W-H965T<R]S:&5E
M=#<P+GAM;%!+ 0(4 Q0    ( -N*?%3$ U%A)@,  !02   -
M  "  2US 0!X;"]S='EL97,N>&UL4$L! A0#%     @ VXI\5)>*NQS
M$P(   L              ( !?G8! %]R96QS+RYR96QS4$L! A0#%     @
MVXI\5!U3H"YT!0  LBX   \              ( !9W<! 'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    ( -N*?%3;=K!Q,0(  (DI   :              "
M 0A] 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( -N*
M?%2DR,-W^@$  +0H   3              "  7%_ 0!;0V]N=&5N=%]4>7!E
<<UTN>&UL4$L%!@    !. $X 614  )R! 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>180</ContextCount>
  <ElementCount>310</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>65</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - CONSOLIDATED STATEMENT OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/StatementConsolidatedStatementOfOperations</Role>
      <ShortName>CONSOLIDATED STATEMENT OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00205 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/StatementConsolidatedStatementsOfOperationsParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00300 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS' DEFICIENCY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/StatementConsolidatedStatementsOfConvertiblePreferredSharesAndShareholdersDeficiency</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS' DEFICIENCY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00305 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS' DEFICIENCY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/StatementConsolidatedStatementsOfConvertiblePreferredSharesAndShareholdersDeficiencyParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS' DEFICIENCY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10101 - Disclosure - GENERAL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureGeneral</Role>
      <ShortName>GENERAL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureSignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10301 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosurePrepaidExpensesAndOtherReceivables</Role>
      <ShortName>PREPAID EXPENSES AND OTHER RECEIVABLES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10401 - Disclosure - PROPERTY AND EQUIPMENT, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10501 - Disclosure - OTHER PAYABLES AND ACCRUED EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureOtherPayablesAndAccruedExpenses</Role>
      <ShortName>OTHER PAYABLES AND ACCRUED EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10601 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilities</Role>
      <ShortName>COMMITMENTS AND CONTINGENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10701 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureFairValueMeasurements</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>10801 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>10901 - Disclosure - CONVERTIBLE PREFERRED SHARES AND WARRANTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrants</Role>
      <ShortName>CONVERTIBLE PREFERRED SHARES AND WARRANTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11001 - Disclosure - SHAREHOLDERS' DEFICIENCY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureShareholdersDeficiency</Role>
      <ShortName>SHAREHOLDERS' DEFICIENCY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11101 - Disclosure - FINANCIAL EXPENSES, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureFinancialExpensesNet</Role>
      <ShortName>FINANCIAL EXPENSES, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11201 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureBasicAndDilutedNetLossPerShare</Role>
      <ShortName>BASIC AND DILUTED NET LOSS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>11301 - Disclosure - GEOGRAPHIC INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureGeographicInformation</Role>
      <ShortName>GEOGRAPHIC INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>11401 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>20202 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>30203 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesTables</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alphatau.com/role/DisclosureSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>30303 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosurePrepaidExpensesAndOtherReceivablesTables</Role>
      <ShortName>PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alphatau.com/role/DisclosurePrepaidExpensesAndOtherReceivables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>30403 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alphatau.com/role/DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>30503 - Disclosure - OTHER PAYABLES AND ACCRUED EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureOtherPayablesAndAccruedExpensesTables</Role>
      <ShortName>OTHER PAYABLES AND ACCRUED EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alphatau.com/role/DisclosureOtherPayablesAndAccruedExpenses</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>30603 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilities</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>30703 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alphatau.com/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>30803 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alphatau.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>30903 - Disclosure - CONVERTIBLE PREFERRED SHARES AND WARRANTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsTables</Role>
      <ShortName>CONVERTIBLE PREFERRED SHARES AND WARRANTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrants</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>31003 - Disclosure - SHAREHOLDERS' DEFICIENCY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureShareholdersDeficiencyTables</Role>
      <ShortName>SHAREHOLDERS' DEFICIENCY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alphatau.com/role/DisclosureShareholdersDeficiency</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>31103 - Disclosure - FINANCIAL EXPENSES, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureFinancialExpensesNetTables</Role>
      <ShortName>FINANCIAL EXPENSES, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alphatau.com/role/DisclosureFinancialExpensesNet</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>31203 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureBasicAndDilutedNetLossPerShareTables</Role>
      <ShortName>BASIC AND DILUTED NET LOSS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alphatau.com/role/DisclosureBasicAndDilutedNetLossPerShare</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>31303 - Disclosure - GEOGRAPHIC INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureGeographicInformationTables</Role>
      <ShortName>GEOGRAPHIC INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alphatau.com/role/DisclosureGeographicInformation</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40101 - Disclosure - GENERAL (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureGeneralDetails</Role>
      <ShortName>GENERAL (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.alphatau.com/role/DisclosureGeneral</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Restricted cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesRestrictedCashDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Restricted cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40202 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Short-term deposits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesShortTermDepositsDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Short-term deposits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40203 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Property and equipment and impairment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentAndImpairmentDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Property and equipment and impairment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40204 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Share-based payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesShareBasedPaymentsDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Share-based payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40205 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Grants and participations &amp; Ordinary share warrants classification and measurement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesGrantsAndParticipationsOrdinaryShareWarrantsClassificationAndMeasurementDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Grants and participations &amp; Ordinary share warrants classification and measurement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40206 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Severance pay (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesSeverancePayDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Severance pay (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40207 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Contingent liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesContingentLiabilitiesDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Contingent liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40208 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Deferred Transaction costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesDeferredTransactionCostsDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Deferred Transaction costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40301 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosurePrepaidExpensesAndOtherReceivablesDetails</Role>
      <ShortName>PREPAID EXPENSES AND OTHER RECEIVABLES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.alphatau.com/role/DisclosurePrepaidExpensesAndOtherReceivablesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40401 - Disclosure - PROPERTY AND EQUIPMENT, NET - Schedule of property and equipment, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET - Schedule of property and equipment, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40501 - Disclosure - OTHER PAYABLES AND ACCRUED EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureOtherPayablesAndAccruedExpensesDetails</Role>
      <ShortName>OTHER PAYABLES AND ACCRUED EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.alphatau.com/role/DisclosureOtherPayablesAndAccruedExpensesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40601 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENT LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>40602 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES - Additional (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesAdditionalDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENT LIABILITIES - Additional (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>40701 - Disclosure - FAIR VALUE MEASUREMENTS - Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureFairValueMeasurementsValuationAssumptionsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>40702 - Disclosure - FAIR VALUE MEASUREMENTS - Changes in fair value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureFairValueMeasurementsChangesInFairValueDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Changes in fair value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>40801 - Disclosure - INCOME TAXES - Tax rates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureIncomeTaxesTaxRatesDetails</Role>
      <ShortName>INCOME TAXES - Tax rates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>40802 - Disclosure - INCOME TAXES - Net loss (income) before tax (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureIncomeTaxesNetLossIncomeBeforeTaxDetails</Role>
      <ShortName>INCOME TAXES - Net loss (income) before tax (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>40803 - Disclosure - INCOME TAXES - Income tax expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails</Role>
      <ShortName>INCOME TAXES - Income tax expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>40804 - Disclosure - INCOME TAXES - Net operating losses carry (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureIncomeTaxesNetOperatingLossesCarryDetails</Role>
      <ShortName>INCOME TAXES - Net operating losses carry (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>40805 - Disclosure - INCOME TAXES - Deferred taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureIncomeTaxesDeferredTaxesDetails</Role>
      <ShortName>INCOME TAXES - Deferred taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>40901 - Disclosure - CONVERTIBLE PREFERRED SHARES AND WARRANTS - Composition of Convertible Preferred shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsCompositionOfConvertiblePreferredSharesDetails</Role>
      <ShortName>CONVERTIBLE PREFERRED SHARES AND WARRANTS - Composition of Convertible Preferred shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>40902 - Disclosure - CONVERTIBLE PREFERRED SHARES AND WARRANTS - Preferred shares rights (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsPreferredSharesRightsDetails</Role>
      <ShortName>CONVERTIBLE PREFERRED SHARES AND WARRANTS - Preferred shares rights (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>40903 - Disclosure - CONVERTIBLE PREFERRED SHARES AND WARRANTS - Financing rounds (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsFinancingRoundsDetails</Role>
      <ShortName>CONVERTIBLE PREFERRED SHARES AND WARRANTS - Financing rounds (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>40904 - Disclosure - CONVERTIBLE PREFERRED SHARES AND WARRANTS - Preferred A shares warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsPreferredSharesWarrantsDetails</Role>
      <ShortName>CONVERTIBLE PREFERRED SHARES AND WARRANTS - Preferred A shares warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>41001 - Disclosure - SHAREHOLDERS' DEFICIENCY - Ordinary share capital (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOrdinaryShareCapitalDetails</Role>
      <ShortName>SHAREHOLDERS' DEFICIENCY - Ordinary share capital (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>41002 - Disclosure - SHAREHOLDERS' DEFICIENCY - Share option plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureShareholdersDeficiencyShareOptionPlanDetails</Role>
      <ShortName>SHAREHOLDERS' DEFICIENCY - Share option plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>41003 - Disclosure - SHAREHOLDERS' DEFICIENCY - Options changes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOptionsChangesDetails</Role>
      <ShortName>SHAREHOLDERS' DEFICIENCY - Options changes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>41004 - Disclosure - SHAREHOLDERS' DEFICIENCY - RSUs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureShareholdersDeficiencyRsusDetails</Role>
      <ShortName>SHAREHOLDERS' DEFICIENCY - RSUs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>41005 - Disclosure - SHAREHOLDERS' DEFICIENCY - Equity-based compensation expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureShareholdersDeficiencyEquityBasedCompensationExpenseDetails</Role>
      <ShortName>SHAREHOLDERS' DEFICIENCY - Equity-based compensation expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>41006 - Disclosure - SHAREHOLDERS' DEFICIENCY - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureShareholdersDeficiencyWarrantsDetails</Role>
      <ShortName>SHAREHOLDERS' DEFICIENCY - Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>41101 - Disclosure - FINANCIAL EXPENSES, NET (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureFinancialExpensesNetDetails</Role>
      <ShortName>FINANCIAL EXPENSES, NET (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.alphatau.com/role/DisclosureFinancialExpensesNetTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>41201 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureBasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>BASIC AND DILUTED NET LOSS PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.alphatau.com/role/DisclosureBasicAndDilutedNetLossPerShareTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>41301 - Disclosure - GEOGRAPHIC INFORMATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureGeographicInformationDetails</Role>
      <ShortName>GEOGRAPHIC INFORMATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.alphatau.com/role/DisclosureGeographicInformationTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="drts-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>41401 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alphatau.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.alphatau.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>70</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="20-F" original="drts-20211231x20f.htm">drts-20211231x20f.htm</File>
    <File>drts-20211231.xsd</File>
    <File>drts-20211231_cal.xml</File>
    <File>drts-20211231_def.xml</File>
    <File>drts-20211231_lab.xml</File>
    <File>drts-20211231_pre.xml</File>
    <File>drts-20211231xex12d1.htm</File>
    <File>drts-20211231xex12d2.htm</File>
    <File>drts-20211231xex13d1.htm</File>
    <File>drts-20211231xex13d2.htm</File>
    <File>drts-20211231xex1d1.htm</File>
    <File>drts-20211231xex2d1.htm</File>
    <File>drts-20211231xex4d8.htm</File>
    <File>drts-20211231xex4d9.htm</File>
    <File>drts-20211231xex8d1.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>drts-20211231x20f002.jpg</File>
    <File>drts-20211231x20f005.jpg</File>
    <File>drts-20211231x20f006.jpg</File>
    <File>drts-20211231x20f007.jpg</File>
    <File>drts-20211231x20f008.jpg</File>
    <File>drts-20211231x20f009.jpg</File>
    <File>drts-20211231x20f010.jpg</File>
    <File>drts-20211231x20f011.jpg</File>
    <File>drts-20211231x20f012.jpg</File>
    <File>drts-20211231x20f013.jpg</File>
    <File>drts-20211231x20f014.jpg</File>
    <File>drts-20211231x20f015.jpg</File>
    <File>drts-20211231x20f016.jpg</File>
    <File>drts-20211231x20f017.jpg</File>
    <File>drts-20211231x20f018.jpg</File>
    <File>drts-20211231x20f019.jpg</File>
    <File>drts-20211231x20f020.jpg</File>
    <File>drts-20211231x20f021.jpg</File>
    <File>drts-20211231x20f022.jpg</File>
    <File>drts-20211231x20f023.jpg</File>
    <File>drts-20211231x20f024.jpg</File>
    <File>drts-20211231x20f025.jpg</File>
    <File>drts-20211231x20f026.jpg</File>
    <File>drts-20211231x20f027.jpg</File>
    <File>drts-20211231x20f028.jpg</File>
    <File>drts-20211231x20f029.jpg</File>
    <File>drts-20211231x20f030.jpg</File>
    <File>drts-20211231x20f031.jpg</File>
    <File>drts-20211231x20f032.jpg</File>
    <File>drts-20211231x20f033.jpg</File>
    <File>drts-20211231x20f034.jpg</File>
    <File>drts-20211231x20f035.jpg</File>
    <File>drts-20211231x20f036.jpg</File>
    <File>drts-20211231x20f037.jpg</File>
    <File>drts-20211231x20f038.jpg</File>
    <File>drts-20211231x20f039.jpg</File>
    <File>drts-20211231x20f040.jpg</File>
    <File>drts-20211231x20f041.jpg</File>
    <File>drts-20211231x20f042.jpg</File>
    <File>drts-20211231x20f046.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="589">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="48">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>133
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "drts-20211231x20f.htm": {
   "axisCustom": 1,
   "axisStandard": 19,
   "contextCount": 180,
   "dts": {
    "calculationLink": {
     "local": [
      "drts-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "drts-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "drts-20211231x20f.htm"
     ]
    },
    "labelLink": {
     "local": [
      "drts-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "drts-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "drts-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 485,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 26,
    "http://www.alphatau.com/20211231": 1,
    "http://xbrl.sec.gov/dei/2021q4": 6,
    "total": 33
   },
   "keyCustom": 53,
   "keyStandard": 257,
   "memberCustom": 28,
   "memberStandard": 34,
   "nsprefix": "drts",
   "nsuri": "http://www.alphatau.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.alphatau.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.alphatau.com/role/DisclosureSignificantAccountingPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "drts:PrepaidExpensesAndOtherReceivablesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES",
     "role": "http://www.alphatau.com/role/DisclosurePrepaidExpensesAndOtherReceivables",
     "shortName": "PREPAID EXPENSES AND OTHER RECEIVABLES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "drts:PrepaidExpensesAndOtherReceivablesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - PROPERTY AND EQUIPMENT, NET",
     "role": "http://www.alphatau.com/role/DisclosurePropertyAndEquipmentNet",
     "shortName": "PROPERTY AND EQUIPMENT, NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "drts:OtherPayablesAndAccruedExpensesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - OTHER PAYABLES AND ACCRUED EXPENSES",
     "role": "http://www.alphatau.com/role/DisclosureOtherPayablesAndAccruedExpenses",
     "shortName": "OTHER PAYABLES AND ACCRUED EXPENSES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "drts:OtherPayablesAndAccruedExpensesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES",
     "role": "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilities",
     "shortName": "COMMITMENTS AND CONTINGENT LIABILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - FAIR VALUE MEASUREMENTS",
     "role": "http://www.alphatau.com/role/DisclosureFairValueMeasurements",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - INCOME TAXES",
     "role": "http://www.alphatau.com/role/DisclosureIncomeTaxes",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "drts:TemporaryEquityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - CONVERTIBLE PREFERRED SHARES AND WARRANTS",
     "role": "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrants",
     "shortName": "CONVERTIBLE PREFERRED SHARES AND WARRANTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "drts:TemporaryEquityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - SHAREHOLDERS' DEFICIENCY",
     "role": "http://www.alphatau.com/role/DisclosureShareholdersDeficiency",
     "shortName": "SHAREHOLDERS' DEFICIENCY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11101 - Disclosure - FINANCIAL EXPENSES, NET",
     "role": "http://www.alphatau.com/role/DisclosureFinancialExpensesNet",
     "shortName": "FINANCIAL EXPENSES, NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.alphatau.com/role/StatementConsolidatedBalanceSheets",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RestrictedInvestmentsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11201 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE",
     "role": "http://www.alphatau.com/role/DisclosureBasicAndDilutedNetLossPerShare",
     "shortName": "BASIC AND DILUTED NET LOSS PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11301 - Disclosure - GEOGRAPHIC INFORMATION",
     "role": "http://www.alphatau.com/role/DisclosureGeographicInformation",
     "shortName": "GEOGRAPHIC INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11401 - Disclosure - SUBSEQUENT EVENTS",
     "role": "http://www.alphatau.com/role/DisclosureSubsequentEvents",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20202 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30203 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "role": "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesTables",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "drts:PrepaidExpensesAndOtherReceivablesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)",
     "role": "http://www.alphatau.com/role/DisclosurePrepaidExpensesAndOtherReceivablesTables",
     "shortName": "PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "drts:PrepaidExpensesAndOtherReceivablesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)",
     "role": "http://www.alphatau.com/role/DisclosurePropertyAndEquipmentNetTables",
     "shortName": "PROPERTY AND EQUIPMENT, NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "drts:OtherPayablesAndAccruedExpensesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "drts:ScheduleOfOtherPayablesAndAccruedExpensesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30503 - Disclosure - OTHER PAYABLES AND ACCRUED EXPENSES (Tables)",
     "role": "http://www.alphatau.com/role/DisclosureOtherPayablesAndAccruedExpensesTables",
     "shortName": "OTHER PAYABLES AND ACCRUED EXPENSES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "drts:OtherPayablesAndAccruedExpensesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "drts:ScheduleOfOtherPayablesAndAccruedExpensesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30603 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Tables)",
     "role": "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesTables",
     "shortName": "COMMITMENTS AND CONTINGENT LIABILITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30703 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "role": "http://www.alphatau.com/role/DisclosureFairValueMeasurementsTables",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:TemporaryEquityParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.alphatau.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:TemporaryEquityParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30803 - Disclosure - INCOME TAXES (Tables)",
     "role": "http://www.alphatau.com/role/DisclosureIncomeTaxesTables",
     "shortName": "INCOME TAXES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "drts:TemporaryEquityTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30903 - Disclosure - CONVERTIBLE PREFERRED SHARES AND WARRANTS (Tables)",
     "role": "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsTables",
     "shortName": "CONVERTIBLE PREFERRED SHARES AND WARRANTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "drts:TemporaryEquityTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31003 - Disclosure - SHAREHOLDERS' DEFICIENCY (Tables)",
     "role": "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyTables",
     "shortName": "SHAREHOLDERS' DEFICIENCY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31103 - Disclosure - FINANCIAL EXPENSES, NET (Tables)",
     "role": "http://www.alphatau.com/role/DisclosureFinancialExpensesNetTables",
     "shortName": "FINANCIAL EXPENSES, NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31203 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE (Tables)",
     "role": "http://www.alphatau.com/role/DisclosureBasicAndDilutedNetLossPerShareTables",
     "shortName": "BASIC AND DILUTED NET LOSS PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31303 - Disclosure - GEOGRAPHIC INFORMATION (Tables)",
     "role": "http://www.alphatau.com/role/DisclosureGeographicInformationTables",
     "shortName": "GEOGRAPHIC INFORMATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "drts:CashCashEquivalentsShortTermDepositsAndRestrictedCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - GENERAL (Details)",
     "role": "http://www.alphatau.com/role/DisclosureGeneralDetails",
     "shortName": "GENERAL (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "drts:CashCashEquivalentsShortTermDepositsAndRestrictedCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Restricted cash (Details)",
     "role": "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesRestrictedCashDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Restricted cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "drts:ShortTermDepositsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_Bx-4ke71BkK7RwJqTEiSgw",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "drts:ShortTernBankDepositInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40202 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Short-term deposits (Details)",
     "role": "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesShortTermDepositsDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Short-term deposits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "drts:ShortTermDepositsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_Bx-4ke71BkK7RwJqTEiSgw",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "drts:ShortTernBankDepositInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "p",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40203 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Property and equipment and impairment (Details)",
     "role": "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentAndImpairmentDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Property and equipment and impairment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "p",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - CONSOLIDATED STATEMENT OF OPERATIONS",
     "role": "http://www.alphatau.com/role/StatementConsolidatedStatementOfOperations",
     "shortName": "CONSOLIDATED STATEMENT OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40204 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Share-based payments (Details)",
     "role": "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesShareBasedPaymentsDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Share-based payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_a-Npz0DAckea4fyrLYOJvQ",
      "decimals": "3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "drts:GrantsAndParticipationsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40205 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Grants and participations & Ordinary share warrants classification and measurement (Details)",
     "role": "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesGrantsAndParticipationsOrdinaryShareWarrantsClassificationAndMeasurementDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Grants and participations & Ordinary share warrants classification and measurement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "drts:GrantsAndParticipationsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "drts:SeverancePayPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "drts:SeverancePayDepositRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40206 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Severance pay (Details)",
     "role": "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesSeverancePayDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Severance pay (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "drts:SeverancePayPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "drts:SeverancePayDepositRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LossContingencyAccrualAtCarryingValue",
       "us-gaap:LossContingencyAccrualAtCarryingValue",
       "p",
       "us-gaap:CommitmentsAndContingenciesPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40207 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Contingent liabilities (Details)",
     "role": "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesContingentLiabilitiesDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Contingent liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LossContingencyAccrualAtCarryingValue",
       "us-gaap:LossContingencyAccrualAtCarryingValue",
       "p",
       "us-gaap:CommitmentsAndContingenciesPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "drts:DeferredTransactionCostsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_S4dFGjmRIE2hAjthSZNbJA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredOfferingCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40208 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Deferred Transaction costs (Details)",
     "role": "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesDeferredTransactionCostsDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Deferred Transaction costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "drts:DeferredTransactionCostsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_S4dFGjmRIE2hAjthSZNbJA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredOfferingCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "drts:PrepaidExpensesAndOtherReceivablesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "drts:GovernmentAuthoritiesReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)",
     "role": "http://www.alphatau.com/role/DisclosurePrepaidExpensesAndOtherReceivablesDetails",
     "shortName": "PREPAID EXPENSES AND OTHER RECEIVABLES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "drts:PrepaidExpensesAndOtherReceivablesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "drts:GovernmentAuthoritiesReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - PROPERTY AND EQUIPMENT, NET - Schedule of property and equipment, net (Details)",
     "role": "http://www.alphatau.com/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
     "shortName": "PROPERTY AND EQUIPMENT, NET - Schedule of property and equipment, net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "drts:ScheduleOfOtherPayablesAndAccruedExpensesTableTextBlock",
       "drts:OtherPayablesAndAccruedExpensesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - OTHER PAYABLES AND ACCRUED EXPENSES (Details)",
     "role": "http://www.alphatau.com/role/DisclosureOtherPayablesAndAccruedExpensesDetails",
     "shortName": "OTHER PAYABLES AND ACCRUED EXPENSES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "drts:ScheduleOfOtherPayablesAndAccruedExpensesTableTextBlock",
       "drts:OtherPayablesAndAccruedExpensesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details)",
     "role": "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesDetails",
     "shortName": "COMMITMENTS AND CONTINGENT LIABILITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShortTermBankLoansAndNotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40602 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES - Additional (Details)",
     "role": "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesAdditionalDetails",
     "shortName": "COMMITMENTS AND CONTINGENT LIABILITIES - Additional (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShortTermBankLoansAndNotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "link:footnote",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_3_7_2022_To_3_7_2022_zxGQCP-7Fk277229BSbBmw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1",
      "reportCount": 1,
      "unitRef": "Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00205 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)",
     "role": "http://www.alphatau.com/role/StatementConsolidatedStatementsOfOperationsParenthetical",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "drts:NumberOfScenariosInAllocatingValueToWarrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_AGp3CTLP9EiC4gKcttUqYA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - FAIR VALUE MEASUREMENTS - Valuation Assumptions (Details)",
     "role": "http://www.alphatau.com/role/DisclosureFairValueMeasurementsValuationAssumptionsDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Valuation Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "drts:NumberOfScenariosInAllocatingValueToWarrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_AGp3CTLP9EiC4gKcttUqYA",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_Vcye6381VUeQWqckP0fFwQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40702 - Disclosure - FAIR VALUE MEASUREMENTS - Changes in fair value (Details)",
     "role": "http://www.alphatau.com/role/DisclosureFairValueMeasurementsChangesInFairValueDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Changes in fair value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_762hkA1xekWBcZRYtQnetQ",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2021_rqAxnV6ZuUS7C0LOKQQJbw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - INCOME TAXES - Tax rates (Details)",
     "role": "http://www.alphatau.com/role/DisclosureIncomeTaxesTaxRatesDetails",
     "shortName": "INCOME TAXES - Tax rates (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2021_rqAxnV6ZuUS7C0LOKQQJbw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40802 - Disclosure - INCOME TAXES - Net loss (income) before tax (Details)",
     "role": "http://www.alphatau.com/role/DisclosureIncomeTaxesNetLossIncomeBeforeTaxDetails",
     "shortName": "INCOME TAXES - Net loss (income) before tax (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentForeignTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40803 - Disclosure - INCOME TAXES - Income tax expense (Details)",
     "role": "http://www.alphatau.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails",
     "shortName": "INCOME TAXES - Income tax expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentForeignTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40804 - Disclosure - INCOME TAXES - Net operating losses carry (Details)",
     "role": "http://www.alphatau.com/role/DisclosureIncomeTaxesNetOperatingLossesCarryDetails",
     "shortName": "INCOME TAXES - Net operating losses carry (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40805 - Disclosure - INCOME TAXES - Deferred taxes (Details)",
     "role": "http://www.alphatau.com/role/DisclosureIncomeTaxesDeferredTaxesDetails",
     "shortName": "INCOME TAXES - Deferred taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:TemporaryEquitySharesAuthorized",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - CONVERTIBLE PREFERRED SHARES AND WARRANTS - Composition of Convertible Preferred shares (Details)",
     "role": "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsCompositionOfConvertiblePreferredSharesDetails",
     "shortName": "CONVERTIBLE PREFERRED SHARES AND WARRANTS - Composition of Convertible Preferred shares (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:TemporaryEquityTableTextBlock",
       "drts:TemporaryEquityTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockDividendRatePercentage",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockDividendRatePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40902 - Disclosure - CONVERTIBLE PREFERRED SHARES AND WARRANTS - Preferred shares rights (Details)",
     "role": "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsPreferredSharesRightsDetails",
     "shortName": "CONVERTIBLE PREFERRED SHARES AND WARRANTS - Preferred shares rights (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockDividendRatePercentage",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockDividendRatePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_7_15_2021_To_7_15_2021_5Bu_BFUidUuMuhyoWEwmhg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40903 - Disclosure - CONVERTIBLE PREFERRED SHARES AND WARRANTS - Financing rounds (Details)",
     "role": "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsFinancingRoundsDetails",
     "shortName": "CONVERTIBLE PREFERRED SHARES AND WARRANTS - Financing rounds (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "As_Of_9_30_2018_H4Zwi9gmHkGz2evRAa1_dQ",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:SaleOfStockPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2020_h1TQxZcxy0-E0CWDpyr6Gw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS' DEFICIENCY",
     "role": "http://www.alphatau.com/role/StatementConsolidatedStatementsOfConvertiblePreferredSharesAndShareholdersDeficiency",
     "shortName": "CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS' DEFICIENCY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2018_XIXddAY3L0yRBxsPKwvT6g",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_9_1_2018_To_9_30_2018_QkwZ1akbskyCxXcB-8mukw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "drts:SaleOfStockNumberOfWarrantsIssuedInTransaction",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40904 - Disclosure - CONVERTIBLE PREFERRED SHARES AND WARRANTS - Preferred A shares warrants (Details)",
     "role": "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsPreferredSharesWarrantsDetails",
     "shortName": "CONVERTIBLE PREFERRED SHARES AND WARRANTS - Preferred A shares warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:WarrantsAndRightsOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - SHAREHOLDERS' DEFICIENCY - Ordinary share capital (Details)",
     "role": "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOrdinaryShareCapitalDetails",
     "shortName": "SHAREHOLDERS' DEFICIENCY - Ordinary share capital (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A",
      "decimals": "INF",
      "lang": null,
      "name": "drts:SharesNumberOfVotes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_Vote_yl2FdYUkMUizA1ZcpmmCgA",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_PlanNameAxis_drts_ShareOptionPlanMember_dFYkG00x2k-k8R6SDAZdBQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41002 - Disclosure - SHAREHOLDERS' DEFICIENCY - Share option plan (Details)",
     "role": "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyShareOptionPlanDetails",
     "shortName": "SHAREHOLDERS' DEFICIENCY - Share option plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_PlanNameAxis_drts_ShareOptionPlanMember_dFYkG00x2k-k8R6SDAZdBQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_PYUoPMcNCkq-0vgimwz2Uw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41003 - Disclosure - SHAREHOLDERS' DEFICIENCY - Options changes (Details)",
     "role": "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOptionsChangesDetails",
     "shortName": "SHAREHOLDERS' DEFICIENCY - Options changes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_lVBebhm2NUeEc6aQ92svqw",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41004 - Disclosure - SHAREHOLDERS' DEFICIENCY - RSUs (Details)",
     "role": "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyRsusDetails",
     "shortName": "SHAREHOLDERS' DEFICIENCY - RSUs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41005 - Disclosure - SHAREHOLDERS' DEFICIENCY - Equity-based compensation expense (Details)",
     "role": "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyEquityBasedCompensationExpenseDetails",
     "shortName": "SHAREHOLDERS' DEFICIENCY - Equity-based compensation expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_bOjyzkldbEiXbhkyzUoY2A",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_9_1_2018_To_9_30_2018_QkwZ1akbskyCxXcB-8mukw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "drts:SaleOfStockNumberOfWarrantsIssuedInTransaction",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41006 - Disclosure - SHAREHOLDERS' DEFICIENCY - Warrants (Details)",
     "role": "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyWarrantsDetails",
     "shortName": "SHAREHOLDERS' DEFICIENCY - Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_8lj8LZ7KJEexZptFTIYCKw",
      "decimals": "INF",
      "lang": null,
      "name": "drts:WarrantsExercisedCashBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ForeignCurrencyTransactionLossBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41101 - Disclosure - FINANCIAL EXPENSES, NET (Details)",
     "role": "http://www.alphatau.com/role/DisclosureFinancialExpensesNetDetails",
     "shortName": "FINANCIAL EXPENSES, NET (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ForeignCurrencyTransactionLossBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41201 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE (Details)",
     "role": "http://www.alphatau.com/role/DisclosureBasicAndDilutedNetLossPerShareDetails",
     "shortName": "BASIC AND DILUTED NET LOSS PER SHARE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_segment_F1A8hT57kUWQPIMNg0d3ZQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41301 - Disclosure - GEOGRAPHIC INFORMATION (Details)",
     "role": "http://www.alphatau.com/role/DisclosureGeographicInformationDetails",
     "shortName": "GEOGRAPHIC INFORMATION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_segment_F1A8hT57kUWQPIMNg0d3ZQ",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "link:footnote",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00305 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS' DEFICIENCY (Parenthetical)",
     "role": "http://www.alphatau.com/role/StatementConsolidatedStatementsOfConvertiblePreferredSharesAndShareholdersDeficiencyParenthetical",
     "shortName": "CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS' DEFICIENCY (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "link:footnote",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "link:footnote",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_3_7_2022_To_3_7_2022_zxGQCP-7Fk277229BSbBmw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1",
      "reportCount": 1,
      "unitRef": "Unit_Standard_pure_jYDIMhCPXkylpJx_z8OQtg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41401 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "role": "http://www.alphatau.com/role/DisclosureSubsequentEventsDetails",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_3_7_2022_To_3_7_2022_us-gaap_BusinessAcquisitionAxis_drts_HcccMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_pSFCWjg1hEmAKs-87AaDOg",
      "decimals": "INF",
      "lang": null,
      "name": "drts:CommonStockCancelledAndConvertedInToShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_50R5oKxE9EuDmju8faMKXw",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n7PY2p7aC0a3o4yt8CshUg",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - GENERAL",
     "role": "http://www.alphatau.com/role/DisclosureGeneral",
     "shortName": "GENERAL",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "drts-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_KGRTzXICPUSXKOzSgm5jTA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 65,
   "tag": {
    "country_IL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Israel"
       }
      }
     },
     "localname": "IL",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureGeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Japan"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureGeographicInformationDetails",
      "http://www.alphatau.com/role/DisclosureIncomeTaxesTaxRatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureGeographicInformationDetails",
      "http://www.alphatau.com/role/DisclosureIncomeTaxesTaxRatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AddressTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.",
        "label": "Address Type [Domain]"
       }
      }
     },
     "localname": "AddressTypeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.alphatau.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.alphatau.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r426",
      "r427",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.alphatau.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r426",
      "r427",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.alphatau.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r426",
      "r427",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.alphatau.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_BusinessContactMember": {
     "auth_ref": [
      "r427",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business contact for the entity",
        "label": "Business Contact Member"
       }
      }
     },
     "localname": "BusinessContactMember",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.alphatau.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.alphatau.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of contact personnel",
        "label": "Contact Personnel Name"
       }
      }
     },
     "localname": "ContactPersonnelName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.alphatau.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.alphatau.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.alphatau.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r426",
      "r427",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.alphatau.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.alphatau.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.alphatau.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.alphatau.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.alphatau.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.alphatau.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.alphatau.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.alphatau.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.alphatau.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.alphatau.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.alphatau.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.alphatau.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Addresses, Address Type [Axis]"
       }
      }
     },
     "localname": "EntityAddressesAddressTypeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.alphatau.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.alphatau.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.alphatau.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.alphatau.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesAdditionalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.alphatau.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.alphatau.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.alphatau.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.alphatau.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.alphatau.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.alphatau.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.alphatau.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.alphatau.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.alphatau.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.alphatau.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r426",
      "r427",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.alphatau.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesAdditionalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.alphatau.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.alphatau.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.alphatau.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.alphatau.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "drts_AdjustmentsToAdditionalPaidInCapitalWarrantSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of  Adjustments To Additional Paid In Capital Warrant Shares Issued.",
        "label": "Adjustments To Additional Paid In Capital Warrant Shares Issued",
        "terseLabel": "Issuance of ordinary shares and warrants to ordinary shares (in shares)"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantSharesIssued",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfConvertiblePreferredSharesAndShareholdersDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "drts_AltheraMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Althera.",
        "label": "Althera [Member]",
        "terseLabel": "Althera"
       }
      }
     },
     "localname": "AltheraMember",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesAdditionalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "drts_AtmIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents ATM Inc.",
        "label": "ATM Inc [Member]",
        "terseLabel": "ATM Inc"
       }
      }
     },
     "localname": "AtmIncMember",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureIncomeTaxesTaxRatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "drts_AtmKkMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents ATM KK.",
        "label": "ATM KK [Member]",
        "terseLabel": "ATM KK"
       }
      }
     },
     "localname": "AtmKkMember",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureGeneralDetails",
      "http://www.alphatau.com/role/DisclosureIncomeTaxesTaxRatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "drts_BankLeumiLeIsraelBmMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Bank Leumi Le-Israel BM.",
        "label": "Bank Leumi Le-Israel BM [Member]",
        "terseLabel": "Bank Leumi Le-Israel BM"
       }
      }
     },
     "localname": "BankLeumiLeIsraelBmMember",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "drts_BasisOfPaymentRoyaltiesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of payment used in determining the amount of royalties paid.",
        "label": "Basis Of Payment, Royalties [Domain]"
       }
      }
     },
     "localname": "BasisOfPaymentRoyaltiesDomain",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesAdditionalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "drts_BgnTechnologiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to BGN Technologies.",
        "label": "BGN Technologies [Member]",
        "terseLabel": "BGN Technologies"
       }
      }
     },
     "localname": "BgnTechnologiesMember",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesAdditionalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "drts_CambridgeUniversityHospitalsNhsTrustMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the Cambridge University Hospitals NHS Trust.",
        "label": "Cambridge University Hospitals NHS Trust [Member]",
        "terseLabel": "Cambridge University Hospitals NHS Trust"
       }
      }
     },
     "localname": "CambridgeUniversityHospitalsNhsTrustMember",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesAdditionalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "drts_CashCashEquivalentsShortTermDepositsAndRestrictedCash": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash, cash equivalents, short-term deposits and restricted cash.",
        "label": "Cash, Cash equivalents, Short-term Deposits and Restricted cash",
        "terseLabel": "Cash, cash equivalents, short-term deposits and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsShortTermDepositsAndRestrictedCash",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureGeneralDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drts_CommitmentsAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Commitments And Contingencies Line Items"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesLineItems",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesAdditionalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "drts_CommonStockCancelledAndConvertedInToShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The common stock cancelled automatically and converted into one share.",
        "label": "Common Stock Cancelled And Converted in to Shares",
        "terseLabel": "Common stock cancelled and converted into share"
       }
      }
     },
     "localname": "CommonStockCancelledAndConvertedInToShares",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "drts_ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for convertible preferred shares and convertible preferred shares warrant liability.",
        "label": "Convertible Preferred Shares And Convertible Preferred Shares Warrant Liability [Policy Text Block]",
        "terseLabel": "Convertible preferred shares and convertible preferred shares warrant liability"
       }
      }
     },
     "localname": "ConvertiblePreferredSharesAndConvertiblePreferredSharesWarrantLiabilityPolicyTextBlock",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "drts_CurrentResourcesCoverageOfLiquidityRequirements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum period to satisfy expected liquidity requirements with existing capital resources, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Current Resources Coverage of Liquidity Requirements",
        "terseLabel": "Liquidity period to satisfy with current resources"
       }
      }
     },
     "localname": "CurrentResourcesCoverageOfLiquidityRequirements",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureGeneralDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "drts_DeferredTransactionCostsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferred transaction costs.",
        "label": "Deferred Transaction Costs [Policy Text Block]",
        "terseLabel": "Deferred Transaction costs"
       }
      }
     },
     "localname": "DeferredTransactionCostsPolicyTextBlock",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "drts_DenominatorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Denominator [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "DenominatorAbstract",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "drts_DisposalGroupIncludingDiscontinuedOperationOwnershipDisposed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of disposal group including discontinued operation ownership disposed.",
        "label": "Disposal Group Including Discontinued Operation Ownership Disposed",
        "terseLabel": "Ownership hold (as a percent)"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOwnershipDisposed",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureGeneralDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "drts_DistributionReceiptsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to revenue from distribution receipts.",
        "label": "Distribution Receipts [Member]",
        "terseLabel": "Revenue from distribution receipts"
       }
      }
     },
     "localname": "DistributionReceiptsMember",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesAdditionalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "drts_FinancialExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "FINANCIAL EXPENSES, NET"
       }
      }
     },
     "localname": "FinancialExpensesAbstract",
     "nsuri": "http://www.alphatau.com/20211231",
     "xbrltype": "stringItemType"
    },
    "drts_FinancialExpensesTotal": {
     "auth_ref": [],
     "calculation": {
      "http://www.alphatau.com/role/DisclosureFinancialExpensesNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingGainsLosses",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total expense included in Net Financial Expense (Income).",
        "label": "Financial Expenses Total",
        "totalLabel": "Total financial expenses"
       }
      }
     },
     "localname": "FinancialExpensesTotal",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureFinancialExpensesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drts_FinancialIncomeTotal": {
     "auth_ref": [],
     "calculation": {
      "http://www.alphatau.com/role/DisclosureFinancialExpensesNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingGainsLosses",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total income included in Net Financial Expense (Income).",
        "label": "Financial Income Total",
        "totalLabel": "Total financial income"
       }
      }
     },
     "localname": "FinancialIncomeTotal",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureFinancialExpensesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drts_FutureGrossRevenuesDerivedFromPurchasedIntellectualPropertyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to future gross revenues derived from purchased intellectual property.",
        "label": "Future Gross Revenues Derived From Purchased Intellectual Property [Member]",
        "terseLabel": "Future gross revenues derived from purchased intellectual property"
       }
      }
     },
     "localname": "FutureGrossRevenuesDerivedFromPurchasedIntellectualPropertyMember",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesAdditionalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "drts_FutureSalesOfDevelopedProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to future sales of a developed product.",
        "label": "Future Sales Of Developed Product [Member]",
        "terseLabel": "Future sales of developed product"
       }
      }
     },
     "localname": "FutureSalesOfDevelopedProductMember",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesAdditionalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "drts_GeographicInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "GEOGRAPHIC INFORMATION"
       }
      }
     },
     "localname": "GeographicInformationAbstract",
     "nsuri": "http://www.alphatau.com/20211231",
     "xbrltype": "stringItemType"
    },
    "drts_GovernmentAuthoritiesReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://www.alphatau.com/role/DisclosurePrepaidExpensesAndOtherReceivablesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of government authority receivables.",
        "label": "Government Authorities Receivable",
        "terseLabel": "Government authorities"
       }
      }
     },
     "localname": "GovernmentAuthoritiesReceivable",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosurePrepaidExpensesAndOtherReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drts_GrantIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose.",
        "label": "Grant Income",
        "terseLabel": "Grant income"
       }
      }
     },
     "localname": "GrantIncome",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesAdditionalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drts_GrantsAndParticipationsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for grants and participations.",
        "label": "Grants and Participations [Policy Text Block]",
        "terseLabel": "Grants and participations"
       }
      }
     },
     "localname": "GrantsAndParticipationsPolicyTextBlock",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "drts_HcccMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This members stands for the merger with HCCC.",
        "label": "HCCC [Member]",
        "terseLabel": "HCCC"
       }
      }
     },
     "localname": "HcccMember",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "drts_HekaBioKKMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to HekaBio K.K.",
        "label": "Heka Bio K K [Member]",
        "terseLabel": "HekaBio K.K."
       }
      }
     },
     "localname": "HekaBioKKMember",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesAdditionalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "drts_HekabioK.k.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents HekaBio K.K.",
        "label": "HekaBio K.K. [Member]"
       }
      }
     },
     "localname": "HekabioK.k.Member",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOrdinaryShareCapitalDetails",
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "drts_IncomeTaxDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Disclosure [Line Items]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureLineItems",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureIncomeTaxesTaxRatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "drts_IncomeTaxDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information pertaining to income taxes.",
        "label": "Income Tax Disclosure [Table]",
        "terseLabel": "Income Tax Disclosure [Table]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTable",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureIncomeTaxesTaxRatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "drts_IncomeTaxRateReconciliationLargeCompaniesPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of statutory tax rate applicable to pretax income (loss) for large companies.",
        "label": "Income Tax Rate Reconciliation, Large Companies, Percent",
        "terseLabel": "Effective statutory tax rate, large companies"
       }
      }
     },
     "localname": "IncomeTaxRateReconciliationLargeCompaniesPercent",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureIncomeTaxesTaxRatesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "drts_IncomeTaxRateReconciliationMediumCompaniesSpecialRatePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of special statutory tax rate applicable to pretax income (loss) for medium companies.",
        "label": "Income Tax Rate Reconciliation, Medium Companies, Special Rate, Percent",
        "terseLabel": "Effective statutory special tax rate, medium companies"
       }
      }
     },
     "localname": "IncomeTaxRateReconciliationMediumCompaniesSpecialRatePercent",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureIncomeTaxesTaxRatesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "drts_IncomeTaxRateReconciliationPreferredCompanyPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of statutory tax rate applicable to pretax income (loss) for preferred company.",
        "label": "Income Tax Rate Reconciliation, Preferred Company, Percent",
        "terseLabel": "Preferred company tax rate"
       }
      }
     },
     "localname": "IncomeTaxRateReconciliationPreferredCompanyPercent",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureIncomeTaxesTaxRatesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "drts_IncomeTaxRateReconciliationSmallCompaniesPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of statutory tax rate applicable to pretax income (loss) for small companies.",
        "label": "Income Tax Rate Reconciliation, Small Companies, Percent",
        "terseLabel": "Effective statutory tax rate, small companies"
       }
      }
     },
     "localname": "IncomeTaxRateReconciliationSmallCompaniesPercent",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureIncomeTaxesTaxRatesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "drts_IncomeTaxRateReconciliationSmallCompaniesSpecialRatePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of special statutory tax rate applicable to pretax income (loss) for small companies.",
        "label": "Income Tax Rate Reconciliation, Small Companies, Special Rate, Percent",
        "terseLabel": "Effective statutory special tax rate, small companies"
       }
      }
     },
     "localname": "IncomeTaxRateReconciliationSmallCompaniesSpecialRatePercent",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureIncomeTaxesTaxRatesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "drts_IncreaseDecreaseInFairValueOfWarrantsConvertiblePreferredShares": {
     "auth_ref": [],
     "calculation": {
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of warrants to convertible preferred shares.",
        "label": "Increase (Decrease) In Fair Value Of Warrants Convertible Preferred Shares",
        "terseLabel": "Change in the fair value of warrants to convertible preferred shares"
       }
      }
     },
     "localname": "IncreaseDecreaseInFairValueOfWarrantsConvertiblePreferredShares",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drts_IncreaseDecreaseInNonCashFinancialIncomeExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in non-cash financial (income) expenses.",
        "label": "Increase (Decrease) In Non Cash Financial (Income) Expenses",
        "negatedLabel": "Non-cash financial (income) expenses, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInNonCashFinancialIncomeExpenses",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drts_IsraeliInnovationAuthorityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the Israeli Innovation Authority (IIA)",
        "label": "Israeli Innovation Authority [Member]",
        "terseLabel": "Israeli Innovation Authority (IIA)"
       }
      }
     },
     "localname": "IsraeliInnovationAuthorityMember",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesAdditionalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "drts_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to equipment used in a laboratory.",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentAndImpairmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "drts_LicenseRevenueRelatedToIntellectualPropertyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to license revenue related to intellectual property.",
        "label": "License Revenue Related To Intellectual Property [Member]",
        "terseLabel": "License revenue related to intellectual property"
       }
      }
     },
     "localname": "LicenseRevenueRelatedToIntellectualPropertyMember",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesAdditionalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "drts_LicenseRevenueToJointlyDevelopedIntellectualPropertyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to sales of alpha radiation products.",
        "label": "License Revenue To Jointly Developed Intellectual Property [Member]",
        "terseLabel": "License revenue related to jointly developed intellectual property"
       }
      }
     },
     "localname": "LicenseRevenueToJointlyDevelopedIntellectualPropertyMember",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesAdditionalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "drts_LongTermAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition",
        "label": "Long Term Assets [Abstract]",
        "terseLabel": "Long-term assets:"
       }
      }
     },
     "localname": "LongTermAssetsAbstract",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "drts_LongTermLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition.",
        "label": "Long Term Liabilities [Abstract]",
        "terseLabel": "LONG-TERM LIABILITIES:"
       }
      }
     },
     "localname": "LongTermLiabilitiesAbstract",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "drts_MethodOfPaymentRoyaltiesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the basis of payment used in determining the amount of royalties paid.",
        "label": "Method Of Payment Royalties [Axis]"
       }
      }
     },
     "localname": "MethodOfPaymentRoyaltiesAxis",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesAdditionalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "drts_MilestoneNumberOfOrdinaryStockOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares purchasable through stock options dependent on the achievement of various milestones.",
        "label": "Milestone Number Of Ordinary Stock Options",
        "terseLabel": "Milestone number of ordinary stock options"
       }
      }
     },
     "localname": "MilestoneNumberOfOrdinaryStockOptions",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesAdditionalDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "drts_NetSalesOfAllCompanySProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to net sales of all of the Company's products.",
        "label": "Net Sales Of All Company's Product [Member]",
        "terseLabel": "Net sales of all of the Company's products"
       }
      }
     },
     "localname": "NetSalesOfAllCompanySProductMember",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesAdditionalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "drts_NetSalesOfAllCompanySProductSoldByCompanySLicensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to net sales of Company products sold by Company's licensees.",
        "label": "Net Sales Of All Company's Product Sold By Company's Licenses [Member]",
        "terseLabel": "Net sales of Company products sold by Company's licensees"
       }
      }
     },
     "localname": "NetSalesOfAllCompanySProductSoldByCompanySLicensesMember",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesAdditionalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "drts_NetSalesSquamousCellCarcinomaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to net sales of treatment for Squamous Cell Carcinoma.",
        "label": "Net Sales Squamous Cell Carcinoma [Member]",
        "terseLabel": "Net sales of treatment for Squamous Cell Carcinoma"
       }
      }
     },
     "localname": "NetSalesSquamousCellCarcinomaMember",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesAdditionalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "drts_NonControllingInterestPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for non-controlling interest.",
        "label": "Non-controlling Interest [Policy Text Block]",
        "terseLabel": "Non-controlling interest"
       }
      }
     },
     "localname": "NonControllingInterestPolicyTextBlock",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "drts_NonOperatingFinancialExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Non Operating Financial Expenses [Abstract]",
        "terseLabel": "Financial expenses:"
       }
      }
     },
     "localname": "NonOperatingFinancialExpensesAbstract",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureFinancialExpensesNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "drts_NonOperatingFinancialIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Non Operating Financial Income [Abstract]",
        "terseLabel": "Financial income:"
       }
      }
     },
     "localname": "NonOperatingFinancialIncomeAbstract",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureFinancialExpensesNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "drts_NumberOfScenariosInAllocatingValueToWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of scenarios used in allocating value of warrants.",
        "label": "Number of Scenarios In Allocating Value to Warrants",
        "terseLabel": "Number of scenarios to allocate equity value to warrants"
       }
      }
     },
     "localname": "NumberOfScenariosInAllocatingValueToWarrants",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureFairValueMeasurementsValuationAssumptionsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "drts_NumberOfWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants exercised in the reporting period.",
        "label": "Number of Warrants Exercised",
        "terseLabel": "Warrant exercised"
       }
      }
     },
     "localname": "NumberOfWarrantsExercised",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "drts_NumeratorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Numerator [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NumeratorAbstract",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "drts_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for ordinary share warrants classification and measurement.",
        "label": "Ordinary Share Warrants Classification and Measurement [Policy Text Block]",
        "terseLabel": "Ordinary share warrants classification and measurement"
       }
      }
     },
     "localname": "OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "drts_OtherPayablesAndAccruedExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "OTHER PAYABLES AND ACCRUED EXPENSES"
       }
      }
     },
     "localname": "OtherPayablesAndAccruedExpensesAbstract",
     "nsuri": "http://www.alphatau.com/20211231",
     "xbrltype": "stringItemType"
    },
    "drts_OtherPayablesAndAccruedExpensesDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other payables and accrued expenses.",
        "label": "Other Payables And Accrued Expenses Disclosure [Text Block]",
        "terseLabel": "OTHER PAYABLES AND ACCRUED EXPENSES"
       }
      }
     },
     "localname": "OtherPayablesAndAccruedExpensesDisclosureTextBlock",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureOtherPayablesAndAccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "drts_PotentialPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum potential amount of payment based on a agreement.",
        "label": "Potential Payment",
        "terseLabel": "Potential payment"
       }
      }
     },
     "localname": "PotentialPayment",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesAdditionalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drts_PrepaidExpensesAndOtherReceivablesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for prepaid expenses and other receivables.",
        "label": "Prepaid Expenses And Other Receivables [Text Block]",
        "terseLabel": "PREPAID EXPENSES AND OTHER RECEIVABLES"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherReceivablesTextBlock",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosurePrepaidExpensesAndOtherReceivables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "drts_PropertyPlantAndEquipmentUsefulLivesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the useful lives of property, plant and equipment.",
        "label": "Property, Plant and Equipment, Useful Lives [Table Text Block]",
        "terseLabel": "Schedule of useful lives of property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLivesTableTextBlock",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "drts_RamotMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Ramot.",
        "label": "Ramot [Member]",
        "terseLabel": "Ramot"
       }
      }
     },
     "localname": "RamotMember",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesAdditionalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "drts_ReimbursementPriceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the reimbursement price.",
        "label": "Reimbursement Price [Member]",
        "terseLabel": "Reimbursement Price"
       }
      }
     },
     "localname": "ReimbursementPriceMember",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesAdditionalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "drts_RevenueGeneratedFromPatentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to revenue generated from patent.",
        "label": "Revenue Generated From Patent [Member]",
        "terseLabel": "Revenue generated from patent"
       }
      }
     },
     "localname": "RevenueGeneratedFromPatentMember",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesAdditionalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "drts_RoyaltyPaymentAsPercentageOfGrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage at which royalty payments will be paid out on relative to the amount of grants received plus interest at LIBOR rate.",
        "label": "Royalty Payment As A Percentage Of Grants",
        "terseLabel": "Royalty payment as a percentage of grants"
       }
      }
     },
     "localname": "RoyaltyPaymentAsPercentageOfGrants",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesAdditionalDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "drts_RoyaltyRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage at which royalty payments will be paid out on.",
        "label": "Royalty Rate",
        "terseLabel": "Royalty rate"
       }
      }
     },
     "localname": "RoyaltyRate",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesAdditionalDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "drts_SaleOfStockNumberOfWarrantsIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants issued in relation to the issuance of shares.",
        "label": "Sale of Stock, Number of Warrants Issued in Transaction",
        "terseLabel": "Number of warrants issued"
       }
      }
     },
     "localname": "SaleOfStockNumberOfWarrantsIssuedInTransaction",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsFinancingRoundsDetails",
      "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsPreferredSharesWarrantsDetails",
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOrdinaryShareCapitalDetails",
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "drts_SalesOfAlphaRadiationProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to sales of alpha radiation products.",
        "label": "Sales Of Alpha Radiation Products [Member]",
        "terseLabel": "Sales of alpha radiation products"
       }
      }
     },
     "localname": "SalesOfAlphaRadiationProductsMember",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesAdditionalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "drts_SalesOfProductContainingIntellectualPropertyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to sales of product containing intellectual property.",
        "label": "Sales Of Product Containing Intellectual Property [Member]",
        "terseLabel": "Sales of product containing intellectual property"
       }
      }
     },
     "localname": "SalesOfProductContainingIntellectualPropertyMember",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesAdditionalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "drts_ScheduleOfCommitmentsAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table providing entire disclosure related to commitments and contingencies of the entity.",
        "label": "Schedule Of Commitments And Contingencies [Table]"
       }
      }
     },
     "localname": "ScheduleOfCommitmentsAndContingenciesTable",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesAdditionalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "drts_ScheduleOfOtherPayablesAndAccruedExpensesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of accrued liabilities and other current liabilities.",
        "label": "Schedule Of Other Payables And Accrued Expenses [Table Text Block]",
        "terseLabel": "Schedule of other payables and accrued expenses"
       }
      }
     },
     "localname": "ScheduleOfOtherPayablesAndAccruedExpensesTableTextBlock",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureOtherPayablesAndAccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "drts_ScheduleOfShareBasedCompensationCostsByIncomeStatementLocationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of share-based compensation costs incurred by location in the income statement.",
        "label": "Schedule of Share-based Compensation Costs By Income Statement Location [Table Text Block]",
        "terseLabel": "Schedule equity-based compensation expense related"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationCostsByIncomeStatementLocationTableTextBlock",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "drts_SeriesBConvertiblePreferredSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Series B Convertible Preferred shares",
        "label": "Series B Convertible Preferred Shares [Member]",
        "terseLabel": "Series B Convertible Preferred shares"
       }
      }
     },
     "localname": "SeriesBConvertiblePreferredSharesMember",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsCompositionOfConvertiblePreferredSharesDetails",
      "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsFinancingRoundsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "drts_SeriesConvertiblePreferredSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Series A Convertible Preferred shares.",
        "label": "Series A Convertible Preferred Shares [Member]",
        "terseLabel": "Series A Convertible Preferred shares"
       }
      }
     },
     "localname": "SeriesConvertiblePreferredSharesMember",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsCompositionOfConvertiblePreferredSharesDetails",
      "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsFinancingRoundsDetails",
      "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsPreferredSharesRightsDetails",
      "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsPreferredSharesWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "drts_SeverancePayDepositRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The monthly deposits at a rate of employees monthly salary deposited  as severance pay, as required by law.",
        "label": "Severance Pay, Deposit Rate",
        "terseLabel": "Severance pay monthly deposit rate"
       }
      }
     },
     "localname": "SeverancePayDepositRate",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesSeverancePayDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "drts_SeverancePayExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of monthly severance recognized during the period based on the rate prescribed by law.",
        "label": "Severance Pay Expense",
        "terseLabel": "Severance pay expense"
       }
      }
     },
     "localname": "SeverancePayExpense",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesSeverancePayDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drts_SeverancePayPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for severance pay.",
        "label": "Severance Pay [Policy Text Block]",
        "terseLabel": "Severance pay"
       }
      }
     },
     "localname": "SeverancePayPolicyTextBlock",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "drts_ShareOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Share Option Plan (the \"Plan\").",
        "label": "Share Option Plan [Member]"
       }
      }
     },
     "localname": "ShareOptionPlanMember",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyShareOptionPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "drts_SharesNumberOfVotes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of votes each share is entitled to.",
        "label": "Shares, Number of Votes",
        "terseLabel": "Number of vote entitled to"
       }
      }
     },
     "localname": "SharesNumberOfVotes",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOrdinaryShareCapitalDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "drts_ShortTermDepositsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for short-term deposits.",
        "label": "Short term Deposits [Policy Text Block]",
        "terseLabel": "Short-term deposits"
       }
      }
     },
     "localname": "ShortTermDepositsPolicyTextBlock",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "drts_ShortTernBankDepositInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rates on short-term deposits with banks.",
        "label": "Short Tern Bank Deposit, Interest Rate",
        "terseLabel": "Deposits in U.S. dollars bear interest rates"
       }
      }
     },
     "localname": "ShortTernBankDepositInterestRate",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesShortTermDepositsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "drts_StockIssuedDuringPeriodSharesExerciseOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants exercised during the current period.",
        "label": "Stock Issued During Period, Shares, Exercise of Warrants",
        "terseLabel": "Exercise of warrants to ordinary shares (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesExerciseOfWarrants",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfConvertiblePreferredSharesAndShareholdersDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "drts_StockIssuedDuringPeriodSharesOrdinarySharesUponExerciseOfShareOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of ordinary shares upon exercise of share options issued during the period.",
        "label": "Stock Issued During Period, Shares, Ordinary Shares Upon Exercise Of Share Options",
        "terseLabel": "Issuance of ordinary shares upon exercise of share options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOrdinarySharesUponExerciseOfShareOptions",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfConvertiblePreferredSharesAndShareholdersDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "drts_StockIssuedDuringPeriodValueExerciseOfWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of warrants.",
        "label": "Stock Issued During Period, Value, Exercise of Warrants",
        "terseLabel": "Exercise of warrants to ordinary shares",
        "verboseLabel": "Warrant exercise consideration"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueExerciseOfWarrants",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyWarrantsDetails",
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfConvertiblePreferredSharesAndShareholdersDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drts_StockIssuedDuringPeriodValueOrdinarySharesUponExerciseOfShareOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock issued during the period. ordinary shares upon exercise of share options",
        "label": "Stock Issued During Period, Value, Ordinary Shares Upon Exercise Of Share Options",
        "terseLabel": "Issuance of ordinary shares upon exercise of share options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOrdinarySharesUponExerciseOfShareOptions",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfConvertiblePreferredSharesAndShareholdersDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drts_StockOptionExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The per share exercise price of option.",
        "label": "Stock Option Exercise Price",
        "terseLabel": "Stock option exercise price"
       }
      }
     },
     "localname": "StockOptionExercisePrice",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesAdditionalDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "drts_TemporaryEquityDistributionRateFromProceedsOfSaleAnotherClassOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum distribution rate from the proceeds of full payment of another class of temporary equity, as percentage of the original issuance price.",
        "label": "Temporary Equity, Distribution Rate from Proceeds of Sale Another Class of Shares",
        "terseLabel": "Distribution rate from proceeds of the full payment of Series B Preference, as percent of issue price"
       }
      }
     },
     "localname": "TemporaryEquityDistributionRateFromProceedsOfSaleAnotherClassOfShares",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsPreferredSharesRightsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "drts_TemporaryEquityNumberOfVotes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of votes each temporary equity is entitled to.",
        "label": "Temporary Equity, Number of Votes",
        "terseLabel": "Number of vote entitle to"
       }
      }
     },
     "localname": "TemporaryEquityNumberOfVotes",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsPreferredSharesRightsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "drts_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity, Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of series B Preferred shares, net (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfConvertiblePreferredSharesAndShareholdersDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "drts_TemporaryEquityTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity [Text Block]",
        "terseLabel": "CONVERTIBLE PREFERRED SHARES AND WARRANTS"
       }
      }
     },
     "localname": "TemporaryEquityTextBlock",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "drts_Warrantliability": {
     "auth_ref": [],
     "calculation": {
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheetss": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of warrant liability classified as noncurrent.",
        "label": "Warrant Liability",
        "terseLabel": "Warrants to convertible preferred shares"
       }
      }
     },
     "localname": "Warrantliability",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "drts_WarrantsExercisedCashBasis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number warrants exercised on a cash basis.",
        "label": "Warrants Exercised, Cash Basis",
        "terseLabel": "Warrants exercised on cash basis (in shares)"
       }
      }
     },
     "localname": "WarrantsExercisedCashBasis",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "drts_WarrantsExercisedCashlessBasis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number warrants exercised on a cashless basis.",
        "label": "Warrants Exercised, Cashless Basis",
        "terseLabel": "Warrants exercised on cashless basis"
       }
      }
     },
     "localname": "WarrantsExercisedCashlessBasis",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "drts_WarrantsGrantedIncreaseFromNewFinancing": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage increase in the number of warrants granted due to fresh financing agreement.",
        "label": "Warrants Granted, Increase From New Financing",
        "terseLabel": "Additional warrants granted (as a percent)"
       }
      }
     },
     "localname": "WarrantsGrantedIncreaseFromNewFinancing",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsPreferredSharesWarrantsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "drts_WarrantsToOrdinaryShareRatioCashlessExercise": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The ratio of warrant to ordinary shares in a cashless exercise of warrant.",
        "label": "Warrants to Ordinary Share Ratio, Cashless Exercise",
        "terseLabel": "Warrants exercise on cashless basis to ordinary shares ratio"
       }
      }
     },
     "localname": "WarrantsToOrdinaryShareRatioCashlessExercise",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyWarrantsDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "drts_WarrantsToPreferredSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of Preferred A stock in accordance with the terms of the instrument.",
        "label": "Warrants To Preferred A Shares [Member]",
        "terseLabel": "Warrant to Preferred A shares"
       }
      }
     },
     "localname": "WarrantsToPreferredSharesMember",
     "nsuri": "http://www.alphatau.com/20211231",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r45",
      "r47",
      "r95",
      "r96",
      "r200",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOrdinaryShareCapitalDetails",
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyWarrantsDetails",
      "http://www.alphatau.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureGeneralDetails",
      "http://www.alphatau.com/role/DisclosureIncomeTaxesTaxRatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r199",
      "r209",
      "r229",
      "r231",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r363",
      "r394",
      "r396",
      "r419",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesAdditionalDetails",
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentAndImpairmentDetails",
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesShareBasedPaymentsDetails",
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesShortTermDepositsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r199",
      "r209",
      "r229",
      "r231",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r363",
      "r394",
      "r396",
      "r419",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesAdditionalDetails",
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentAndImpairmentDetails",
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesShareBasedPaymentsDetails",
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesShortTermDepositsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r199",
      "r209",
      "r227",
      "r229",
      "r231",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r363",
      "r394",
      "r396",
      "r419",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesAdditionalDetails",
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentAndImpairmentDetails",
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesShareBasedPaymentsDetails",
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesShortTermDepositsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r199",
      "r209",
      "r227",
      "r229",
      "r231",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r363",
      "r394",
      "r396",
      "r419",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesAdditionalDetails",
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentAndImpairmentDetails",
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesShareBasedPaymentsDetails",
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesShortTermDepositsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r46",
      "r47",
      "r95",
      "r96",
      "r200",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOrdinaryShareCapitalDetails",
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyWarrantsDetails",
      "http://www.alphatau.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureGeneralDetails",
      "http://www.alphatau.com/role/DisclosureIncomeTaxesTaxRatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r159",
      "r160",
      "r224",
      "r225",
      "r395",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureGeographicInformationDetails",
      "http://www.alphatau.com/role/DisclosureIncomeTaxesTaxRatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r159",
      "r160",
      "r224",
      "r225",
      "r395",
      "r402",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureGeographicInformationDetails",
      "http://www.alphatau.com/role/DisclosureIncomeTaxesTaxRatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r35",
      "r352"
     ],
     "calculation": {
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheetss": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Trade payables"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableRelatedPartiesCurrent": {
     "auth_ref": [
      "r35",
      "r94",
      "r348",
      "r349"
     ],
     "calculation": {
      "http://www.alphatau.com/role/DisclosureOtherPayablesAndAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Related Parties, Current",
        "terseLabel": "Related parties"
       }
      }
     },
     "localname": "AccountsPayableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureOtherPayablesAndAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.alphatau.com/role/DisclosureOtherPayablesAndAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued Liabilities and Other Liabilities",
        "totalLabel": "Total other payables and accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureOtherPayablesAndAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.alphatau.com/role/DisclosureOtherPayablesAndAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureOtherPayablesAndAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalariesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r37"
     ],
     "calculation": {
      "http://www.alphatau.com/role/DisclosureOtherPayablesAndAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Salaries, Current",
        "terseLabel": "Employees and payroll accruals"
       }
      }
     },
     "localname": "AccruedSalariesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureOtherPayablesAndAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r32",
      "r174"
     ],
     "calculation": {
      "http://www.alphatau.com/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in accumulated depreciation, depletion and amortization as a result of sale or disposal of property, plant and equipment.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Sale or Disposal of Property, Plant and Equipment",
        "terseLabel": "Disposed accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r22",
      "r267",
      "r352"
     ],
     "calculation": {
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheetss": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r264",
      "r265",
      "r266",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfConvertiblePreferredSharesAndShareholdersDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r233",
      "r236",
      "r270",
      "r271"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfConvertiblePreferredSharesAndShareholdersDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r214",
      "r221"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfConvertiblePreferredSharesAndShareholdersDeficiencyParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r198",
      "r214",
      "r221"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Issuance of ordinary shares and warrants to ordinary shares"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfConvertiblePreferredSharesAndShareholdersDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r236",
      "r260",
      "r269"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyEquityBasedCompensationExpenseDetails",
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesShareBasedPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from calculation of net loss per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r89",
      "r145",
      "r149",
      "r154",
      "r166",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r309",
      "r315",
      "r332",
      "r350",
      "r352",
      "r368",
      "r381"
     ],
     "calculation": {
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheetss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r44",
      "r89",
      "r166",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r309",
      "r315",
      "r332",
      "r350",
      "r352"
     ],
     "calculation": {
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheetss": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r13",
      "r14",
      "r15",
      "r16",
      "r17",
      "r89",
      "r166",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r309",
      "r315",
      "r332",
      "r350"
     ],
     "calculation": {
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheetss": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total long-term assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AutomobilesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vehicles that are used primarily for transporting people.",
        "label": "Automobiles [Member]",
        "terseLabel": "Cars"
       }
      }
     },
     "localname": "AutomobilesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentAndImpairmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r237",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesDeferredTransactionCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r319",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesDeferredTransactionCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r228",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r228",
      "r230",
      "r304",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "auth_ref": [
      "r65"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).",
        "label": "Cash Acquired from Acquisition",
        "terseLabel": "Cash proceeds in connection with merger"
       }
      }
     },
     "localname": "CashAcquiredFromAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r29",
      "r79"
     ],
     "calculation": {
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesRestrictedCashDetailss": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheetss": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents, as reported on the balance sheets"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesRestrictedCashDetails",
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash and Cash Equivalents [Line Items]",
        "terseLabel": "Short-term deposits"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesShortTermDepositsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r9",
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r9",
      "r80",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r72",
      "r79",
      "r85"
     ],
     "calculation": {
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesRestrictedCashDetailss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at the end of the year",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at the beginning of the year",
        "totalLabel": "Cash, cash equivalents, and restricted cash, as reported in the statements of cash flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesRestrictedCashDetails",
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r72",
      "r337"
     ],
     "calculation": {
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "(Decrease) increase in cash and cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r88",
      "r89",
      "r113",
      "r114",
      "r115",
      "r117",
      "r119",
      "r127",
      "r128",
      "r129",
      "r166",
      "r187",
      "r191",
      "r192",
      "r193",
      "r196",
      "r197",
      "r206",
      "r207",
      "r211",
      "r212",
      "r332",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsCompositionOfConvertiblePreferredSharesDetails",
      "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsFinancingRoundsDetails",
      "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsPreferredSharesRightsDetails",
      "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsPreferredSharesWarrantsDetails",
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOrdinaryShareCapitalDetails",
      "http://www.alphatau.com/role/DisclosureSubsequentEventsDetails",
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfConvertiblePreferredSharesAndShareholdersDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "SHAREHOLDERS' DEFICIENCY"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOrdinaryShareCapitalDetails",
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price of warrants (in dollar per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsPreferredSharesWarrantsDetails",
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Outstanding ordinary share warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesGrantsAndParticipationsOrdinaryShareWarrantsClassificationAndMeasurementDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r39",
      "r184",
      "r371",
      "r385"
     ],
     "calculation": {
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheetss": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENT LIABILITIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r181",
      "r182",
      "r183",
      "r185",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENT LIABILITIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r186",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Contingent liabilities"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "terseLabel": "Class A Common Shares"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSubsequentEventsDetails",
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfConvertiblePreferredSharesAndShareholdersDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r98",
      "r99",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Ordinary shares",
        "terseLabel": "Ordinary Common Shares"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsFinancingRoundsDetails",
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOrdinaryShareCapitalDetails",
      "http://www.alphatau.com/role/DisclosureSubsequentEventsDetails",
      "http://www.alphatau.com/role/DocumentDocumentAndEntityInformation",
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfConvertiblePreferredSharesAndShareholdersDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Ordinary shares par value (per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Ordinary shares, authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOrdinaryShareCapitalDetails",
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Ordinary shares, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOrdinaryShareCapitalDetails",
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r21",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Ordinary shares, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOrdinaryShareCapitalDetails",
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValueOutstanding": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheetss": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
        "label": "Common Stock, Value, Outstanding",
        "terseLabel": "Ordinary shares of no-par value per share - Authorized: 72,423,360 shares as of December 31, 2020 and 2021; Issued and outstanding: 40,433,578 and 40,528,913 shares as of December 31, 2020 and 2021, respectively; *)"
       }
      }
     },
     "localname": "CommonStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Significant components of deferred tax assets"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computers and software"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentAndImpairmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r133",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of credit risks"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r87",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r82",
      "r83",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Converted",
        "terseLabel": "Preferred shares that can be converted"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsFinancingRoundsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "auth_ref": [
      "r82",
      "r83",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Issued",
        "terseLabel": "Shares can be issued for conversion"
       }
      }
     },
     "localname": "ConversionOfStockSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsFinancingRoundsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r206",
      "r207",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible preferred shares"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureBasicAndDilutedNetLossPerShareDetails",
      "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsPreferredSharesRightsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r90",
      "r290"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r90",
      "r290",
      "r296",
      "r297"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current income tax expense"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PREPAID EXPENSES AND OTHER RECEIVABLES"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Schedule of prepaid expenses and other receivables"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosurePrepaidExpensesAndOtherReceivablesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredOfferingCosts": {
     "auth_ref": [
      "r43",
      "r168"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Deferred Offering Costs",
        "terseLabel": "Capitalized deferred offering costs"
       }
      }
     },
     "localname": "DeferredOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesDeferredTransactionCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r282"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Deferred tax assets before valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r288",
      "r289"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "R&amp;D expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r288",
      "r289"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Loss carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r288",
      "r289"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances": {
     "auth_ref": [
      "r288",
      "r289"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from estimated returns and sales allowances.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Returns and Allowances",
        "terseLabel": "Reserves and allowances"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r283"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less - valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r77",
      "r172"
     ],
     "calculation": {
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense",
        "verboseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BASIC AND DILUTED NET LOSS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r57",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r111",
      "r113",
      "r117",
      "r118",
      "r119",
      "r123",
      "r124",
      "r322",
      "r323",
      "r376",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Net loss per share attributable to ordinary shareholders, basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r57",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r113",
      "r117",
      "r118",
      "r119",
      "r123",
      "r124",
      "r322",
      "r323",
      "r376",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Net loss per share attributable to ordinary shareholders, diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r120",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Basic and diluted net loss per share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r120",
      "r121",
      "r122",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "BASIC AND DILUTED NET LOSS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureBasicAndDilutedNetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyEquityBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period of recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyEquityBasedCompensationExpenseDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r261"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "unrecognized compensation costs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyEquityBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Manufacturing equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentAndImpairmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r51",
      "r52",
      "r53",
      "r98",
      "r99",
      "r100",
      "r102",
      "r108",
      "r110",
      "r126",
      "r167",
      "r214",
      "r221",
      "r264",
      "r265",
      "r266",
      "r292",
      "r293",
      "r321",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r397",
      "r398",
      "r399",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DocumentDocumentAndEntityInformation",
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfConvertiblePreferredSharesAndShareholdersDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r77",
      "r201"
     ],
     "calculation": {
      "http://www.alphatau.com/role/DisclosureFinancialExpensesNetDetails": {
       "order": 2.0,
       "parentTag": "drts_FinancialExpensesTotal",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "verboseLabel": "Remeasurement of warrants"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureFinancialExpensesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Valuation assumptions"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureFairValueMeasurementsValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureFairValueMeasurementsValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Summary of assumptions in the Black-Scholes model in calculating fair value of warrants"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r328",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureFairValueMeasurementsChangesInFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureFairValueMeasurementsChangesInFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Change in fair value"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureFairValueMeasurementsChangesInFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r327",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureFairValueMeasurementsChangesInFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r327",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Summary of change in the fair value of the preferred share warrants liability"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)",
        "terseLabel": "Change in fair value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureFairValueMeasurementsChangesInFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r327"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "End of year",
        "periodStartLabel": "Beginning of year"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureFairValueMeasurementsChangesInFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r330",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair value of financial instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r333",
      "r334",
      "r335",
      "r336"
     ],
     "calculation": {
      "http://www.alphatau.com/role/DisclosureFinancialExpensesNetDetails": {
       "order": 1.0,
       "parentTag": "drts_FinancialIncomeTotal",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "terseLabel": "Foreign currency transaction profit, net"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureFinancialExpensesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionLossBeforeTax": {
     "auth_ref": [
      "r335",
      "r336"
     ],
     "calculation": {
      "http://www.alphatau.com/role/DisclosureFinancialExpensesNetDetails": {
       "order": 1.0,
       "parentTag": "drts_FinancialExpensesTotal",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized loss recognized in the income statement.",
        "label": "Foreign Currency Transaction Loss, before Tax",
        "terseLabel": "Foreign currency transaction loss, net"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureFinancialExpensesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Consolidated financial statements in U.S. dollars"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and office equipment"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentAndImpairmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.alphatau.com/role/DisclosureConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyEquityBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GranteeStatusAxis": {
     "auth_ref": [
      "r232",
      "r234",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of recipient to whom award is granted.",
        "label": "Grantee Status [Axis]"
       }
      }
     },
     "localname": "GranteeStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOptionsChangesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GranteeStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of recipient to whom award is granted.",
        "label": "Grantee Status [Domain]"
       }
      }
     },
     "localname": "GranteeStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOptionsChangesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r77",
      "r171",
      "r176"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Impairment losses"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentAndImpairmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r170",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "auth_ref": [
      "r60",
      "r78",
      "r103",
      "r104",
      "r105",
      "r106",
      "r116",
      "r119",
      "r307"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
        "terseLabel": "Net loss attributable to Ordinary shareholders"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r91",
      "r298"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic (Israel)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureIncomeTaxesNetLossIncomeBeforeTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r55",
      "r145",
      "r148",
      "r152",
      "r153",
      "r156",
      "r366",
      "r373",
      "r378",
      "r392"
     ],
     "calculation": {
      "http://www.alphatau.com/role/DisclosureConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before taxes on income"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureIncomeTaxesNetLossIncomeBeforeTaxDetails",
      "http://www.alphatau.com/role/StatementConsolidatedStatementOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r91",
      "r298"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureIncomeTaxesNetLossIncomeBeforeTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]",
        "terseLabel": "Components of the net loss (income) before tax on income"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureIncomeTaxesNetLossIncomeBeforeTaxDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r89",
      "r101",
      "r145",
      "r148",
      "r152",
      "r153",
      "r156",
      "r166",
      "r187",
      "r188",
      "r189",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r308",
      "r323",
      "r332"
     ],
     "calculation": {
      "http://www.alphatau.com/role/DisclosureConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "negatedTotalLabel": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureGeneralDetails",
      "http://www.alphatau.com/role/StatementConsolidatedStatementOfOperations",
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfConvertiblePreferredSharesAndShareholdersDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r54",
      "r57",
      "r101",
      "r103",
      "r104",
      "r105",
      "r106",
      "r113",
      "r117",
      "r118",
      "r323",
      "r372",
      "r374",
      "r376",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Net loss per share attributable to ordinary shareholders, basic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r54",
      "r57",
      "r101",
      "r103",
      "r104",
      "r105",
      "r106",
      "r113",
      "r117",
      "r118",
      "r119",
      "r323",
      "r376",
      "r388",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Net loss per share attributable to ordinary shareholders, diluted"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENT OF OPERATIONS"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r177",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyEquityBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyEquityBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r92",
      "r279",
      "r280",
      "r286",
      "r294",
      "r299",
      "r301",
      "r302",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r93",
      "r109",
      "r110",
      "r144",
      "r277",
      "r295",
      "r300",
      "r393"
     ],
     "calculation": {
      "http://www.alphatau.com/role/DisclosureConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTotalLabel": "Income tax expense",
        "terseLabel": "Tax on income"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails",
      "http://www.alphatau.com/role/StatementConsolidatedStatementOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r50",
      "r275",
      "r276",
      "r280",
      "r281",
      "r285",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r278"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Corporate tax rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureIncomeTaxesTaxRatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r74",
      "r81"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Income tax payments"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "terseLabel": "Increase in trade payables"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Other Accrued Liabilities",
        "terseLabel": "Increase in other payables and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "(Increase) decrease in prepaid expenses and other receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.",
        "label": "Increase (Decrease) in Prepaid Expenses, Other",
        "negatedLabel": "Increase in long term prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpensesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Shareholders' Deficiency"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfConvertiblePreferredSharesAndShareholdersDeficiency"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseOfRestrictedInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow or outflow for the increase (decrease) associated with investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions.",
        "label": "Increase (Decrease) of Restricted Investments",
        "negatedLabel": "Investment in short-term deposits"
       }
      }
     },
     "localname": "IncreaseDecreaseOfRestrictedInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeDepositsWithFinancialInstitutions": {
     "auth_ref": [
      "r377",
      "r430",
      "r431"
     ],
     "calculation": {
      "http://www.alphatau.com/role/DisclosureFinancialExpensesNetDetails": {
       "order": 2.0,
       "parentTag": "drts_FinancialIncomeTotal",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest income derived from funds deposited with both domestic and foreign financial institutions including funds in money market and other accounts.",
        "label": "Interest Income, Deposits with Financial Institutions",
        "terseLabel": "Interest from deposits"
       }
      }
     },
     "localname": "InterestIncomeDepositsWithFinancialInstitutions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureFinancialExpensesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r70",
      "r73",
      "r81"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest received"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of future minimum operating lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r347"
     ],
     "calculation": {
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r347"
     ],
     "calculation": {
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r347"
     ],
     "calculation": {
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r347"
     ],
     "calculation": {
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r347"
     ],
     "calculation": {
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r347"
     ],
     "calculation": {
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r347"
     ],
     "calculation": {
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r36",
      "r89",
      "r150",
      "r166",
      "r187",
      "r188",
      "r189",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r310",
      "r315",
      "r316",
      "r332",
      "r350",
      "r351"
     ],
     "calculation": {
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheetss": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r26",
      "r89",
      "r166",
      "r332",
      "r352",
      "r369",
      "r383"
     ],
     "calculation": {
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheetss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities, convertible preferred shares and shareholders' deficiency"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities, convertible preferred shares and shareholders' deficiency"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAssumed1": {
     "auth_ref": [
      "r82",
      "r83",
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of liabilities assumed in noncash investing or financing activities.",
        "label": "Liabilities Assumed",
        "terseLabel": "Liabilities assumed"
       }
      }
     },
     "localname": "LiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesAdditionalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r38",
      "r89",
      "r166",
      "r187",
      "r188",
      "r189",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r310",
      "r315",
      "r316",
      "r332",
      "r350",
      "r351",
      "r352"
     ],
     "calculation": {
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheetss": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "CURRENT LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r184"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Contingent liability provision"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesContingentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketingExpense": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.alphatau.com/role/DisclosureConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services. Costs of public relations and corporate promotions are typically considered to be marketing costs.",
        "label": "Marketing Expense",
        "terseLabel": "Marketing expenses"
       }
      }
     },
     "localname": "MarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.",
        "label": "Expected dividend yield"
       }
      }
     },
     "localname": "MeasurementInputExpectedDividendRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureFairValueMeasurementsValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Expected term"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureFairValueMeasurementsValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Expected volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureFairValueMeasurementsValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Risk-free interest rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureFairValueMeasurementsValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureFairValueMeasurementsValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureFairValueMeasurementsValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r130",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "GENERAL"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureGeneral"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "terseLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r72",
      "r75",
      "r78"
     ],
     "calculation": {
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "terseLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureGeneralDetails",
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r48",
      "r49",
      "r53",
      "r56",
      "r78",
      "r89",
      "r101",
      "r103",
      "r104",
      "r105",
      "r106",
      "r109",
      "r110",
      "r116",
      "r145",
      "r148",
      "r152",
      "r153",
      "r156",
      "r166",
      "r187",
      "r188",
      "r189",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r323",
      "r332",
      "r375",
      "r389"
     ],
     "calculation": {
      "http://www.alphatau.com/role/DisclosureConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "negatedTotalLabel": "Net loss attributable to Alpha Tau Medical Ltd.",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementOfOperations",
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfConvertiblePreferredSharesAndShareholdersDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r48",
      "r49",
      "r53",
      "r109",
      "r110",
      "r313",
      "r317"
     ],
     "calculation": {
      "http://www.alphatau.com/role/DisclosureConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedLabel": "Less: net loss attributable to noncontrolling interests",
        "terseLabel": "Less: net loss attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementOfOperations",
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfConvertiblePreferredSharesAndShareholdersDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncements and not yet adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed) [Abstract]",
        "terseLabel": "Non-cash transactions:"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1": {
     "auth_ref": [
      "r82",
      "r83",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants issued as [noncash or part noncash] consideration for a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Warrants Issued",
        "terseLabel": "Receivables from exercise of warrants to ordinary shares"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r221",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non-Controlling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfConvertiblePreferredSharesAndShareholdersDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingGainsLosses": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.alphatau.com/role/DisclosureConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.alphatau.com/role/DisclosureFinancialExpensesNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of gains or losses resulting from nonoperating activities (for example, interest and dividend revenue, property, plant and equipment impairment loss, and so forth).",
        "label": "Nonoperating Gains (Losses)",
        "terseLabel": "Financial (income) expenses, net",
        "totalLabel": "Financial expenses (income), net"
       }
      }
     },
     "localname": "NonoperatingGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureFinancialExpensesNetDetails",
      "http://www.alphatau.com/role/StatementConsolidatedStatementOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Non Operating Income (Expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureFinancialExpensesNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segment"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureGeographicInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r145",
      "r148",
      "r152",
      "r153",
      "r156"
     ],
     "calculation": {
      "http://www.alphatau.com/role/DisclosureConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Total operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r346"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Rental and lease expenses"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r287"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Accumulated losses for tax purposes"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureIncomeTaxesNetOperatingLossesCarryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GENERAL"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": {
     "auth_ref": [
      "r226",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.",
        "label": "Other Income and Other Expense Disclosure [Text Block]",
        "terseLabel": "FINANCIAL EXPENSES, NET"
       }
      }
     },
     "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureFinancialExpensesNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r37",
      "r352"
     ],
     "calculation": {
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheetss": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other payables and accrued expenses"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other assets, noncurrent"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesDeferredTransactionCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingExpense": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.alphatau.com/role/DisclosureFinancialExpensesNetDetails": {
       "order": 3.0,
       "parentTag": "drts_FinancialExpensesTotal",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Expense",
        "terseLabel": "Others"
       }
      }
     },
     "localname": "OtherNonoperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureFinancialExpensesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncome": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.alphatau.com/role/DisclosureFinancialExpensesNetDetails": {
       "order": 3.0,
       "parentTag": "drts_FinancialIncomeTotal",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income",
        "terseLabel": "Others"
       }
      }
     },
     "localname": "OtherNonoperatingIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureFinancialExpensesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivables": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.alphatau.com/role/DisclosurePrepaidExpensesAndOtherReceivablesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from parties in nontrade transactions, classified as other.",
        "label": "Other Receivables",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosurePrepaidExpensesAndOtherReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r69"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Issuance expenses"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsFinancingRoundsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r237",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyShareOptionPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyShareOptionPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PledgedFinancialInstrumentsNotSeparatelyReportedSecuritiesForLetterOfCreditFacilities": {
     "auth_ref": [
      "r362"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount as of the date of the latest financial statement presented of securities which are owned but transferred to serve as collateral for letter of credit arrangements, and for which the transferee does not have the right by contract or custom to sell or re-pledge them to an unrelated party.",
        "label": "Pledged Financial Instruments, Not Separately Reported, Securities for Letter of Credit Facilities",
        "terseLabel": "Standby letter of credit"
       }
      }
     },
     "localname": "PledgedFinancialInstrumentsNotSeparatelyReportedSecuritiesForLetterOfCreditFacilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockConvertibleConversionRatio": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common shares issuable upon conversion for each share of preferred stock to be converted.",
        "label": "Preferred Stock, Convertible, Conversion Ratio",
        "terseLabel": "Conversion ratio"
       }
      }
     },
     "localname": "PreferredStockConvertibleConversionRatio",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsFinancingRoundsDetails",
      "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsPreferredSharesRightsDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock.",
        "label": "Preferred Stock, Dividend Rate, Percentage",
        "terseLabel": "Dividend rate, as a percent of original issue price"
       }
      }
     },
     "localname": "PreferredStockDividendRatePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsPreferredSharesRightsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred shares",
        "terseLabel": "Convertible Preferred Shares"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DocumentDocumentAndEntityInformation",
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfConvertiblePreferredSharesAndShareholdersDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.alphatau.com/role/DisclosurePrepaidExpensesAndOtherReceivablesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.",
        "label": "Prepaid Expense and Other Assets",
        "totalLabel": "Total prepaid expenses and other receivables"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosurePrepaidExpensesAndOtherReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r3",
      "r27",
      "r28"
     ],
     "calculation": {
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheetss": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other receivables"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrentAndNoncurrent": {
     "auth_ref": [
      "r370",
      "r386"
     ],
     "calculation": {
      "http://www.alphatau.com/role/DisclosurePrepaidExpensesAndOtherReceivablesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.",
        "label": "Prepaid Expense",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosurePrepaidExpensesAndOtherReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseNoncurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheetss": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.",
        "label": "Prepaid Expense, Noncurrent",
        "terseLabel": "Long term prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.",
        "label": "Proceeds from Issuance of Preferred Stock and Preference Stock",
        "terseLabel": "Proceeds from issuance of series B Preferred shares, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholder, which takes precedence over common stockholders in the event of liquidation and from issuance of rights to purchase common shares at a predetermined price.",
        "label": "Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants",
        "terseLabel": "Proceeds from issuance of ordinary shares and warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock": {
     "auth_ref": [
      "r68"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.",
        "label": "Proceeds from Issuance of Redeemable Convertible Preferred Stock",
        "terseLabel": "Consideration for issuance of shares"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsFinancingRoundsDetails",
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOrdinaryShareCapitalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsToMinorityShareholders": {
     "auth_ref": [],
     "calculation": {
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from (to) a noncontrolling interest. Excludes dividends paid to the noncontrolling interest.",
        "label": "Proceeds from (Payments to) Noncontrolling Interests",
        "terseLabel": "Acquisition of non-controlling interest",
        "verboseLabel": "Acquisition of non-controlling interests"
       }
      }
     },
     "localname": "ProceedsFromPaymentsToMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfConvertiblePreferredSharesAndShareholdersDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfRestrictedInvestments": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale of investments that are pledged or subject to withdrawal restrictions during the period.",
        "label": "Proceeds from Sale of Restricted Investments",
        "terseLabel": "Redemption of short-term deposits"
       }
      }
     },
     "localname": "ProceedsFromSaleOfRestrictedInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r68",
      "r263"
     ],
     "calculation": {
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "verboseLabel": "Proceeds from exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r48",
      "r49",
      "r53",
      "r71",
      "r89",
      "r101",
      "r109",
      "r110",
      "r145",
      "r148",
      "r152",
      "r153",
      "r156",
      "r166",
      "r187",
      "r188",
      "r189",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r308",
      "r312",
      "r314",
      "r317",
      "r318",
      "r323",
      "r332",
      "r378"
     ],
     "calculation": {
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "negatedLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PROPERTY AND EQUIPMENT, NET"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r32",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentAndImpairmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r179",
      "r407",
      "r408",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "PROPERTY AND EQUIPMENT, NET"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosurePropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r31",
      "r173"
     ],
     "calculation": {
      "http://www.alphatau.com/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "verboseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentAndImpairmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r13",
      "r14",
      "r175",
      "r352",
      "r379",
      "r384"
     ],
     "calculation": {
      "http://www.alphatau.com/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheetss": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureGeographicInformationDetails",
      "http://www.alphatau.com/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r30",
      "r175",
      "r407",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r13",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosurePropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r13",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentAndImpairmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentAndImpairmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.",
        "label": "Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Shares"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfConvertiblePreferredSharesAndShareholdersDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred": {
     "auth_ref": [
      "r364"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of customer funding recorded as an offset to costs incurred for a fixed-price, best-efforts research and development cost-sharing arrangement with the Federal Government.",
        "label": "Research and Development Arrangement with Federal Government, Customer Funding to Offset Costs Incurred",
        "terseLabel": "Recognized participations in research and development as a reduction from research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesGrantsAndParticipationsOrdinaryShareWarrantsClassificationAndMeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r274",
      "r364",
      "r421"
     ],
     "calculation": {
      "http://www.alphatau.com/role/DisclosureConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development, net"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyEquityBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and development expenses, net"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r9",
      "r79",
      "r85"
     ],
     "calculation": {
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesRestrictedCashDetailss": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheetss": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "terseLabel": "Restricted cash",
        "verboseLabel": "Restricted cash, as reported on the balance sheets"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesRestrictedCashDetails",
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedInvestmentsCurrent": {
     "auth_ref": [
      "r403",
      "r404"
     ],
     "calculation": {
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheetss": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the current portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions.",
        "label": "Restricted Investments, Current",
        "terseLabel": "Short-term deposits"
       }
      }
     },
     "localname": "RestrictedInvestmentsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r23",
      "r221",
      "r267",
      "r352",
      "r382",
      "r400",
      "r401"
     ],
     "calculation": {
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheetss": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureGeneralDetails",
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r98",
      "r99",
      "r100",
      "r102",
      "r108",
      "r110",
      "r167",
      "r264",
      "r265",
      "r266",
      "r292",
      "r293",
      "r321",
      "r397",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfConvertiblePreferredSharesAndShareholdersDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r61"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "terseLabel": "Royalty expense"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesAdditionalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares issued"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsFinancingRoundsDetails",
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOrdinaryShareCapitalDetails",
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Price per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsFinancingRoundsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of antidilutive securities excluded from net loss per share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureBasicAndDilutedNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesShortTermDepositsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of the cash and cash equivalents balances reported on the balance sheets and the cash, cash equivalents and restricted cash balances reported in the statements of cash flows"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of income tax expense"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of significant components of the deferred tax assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of basic and diluted net loss per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureBasicAndDilutedNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r236",
      "r259",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyEquityBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of components of the net loss (income) before tax on income"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "terseLabel": "Schedule of Financial Expenses, Net"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureFinancialExpensesNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r32",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesPropertyAndEquipmentAndImpairmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r145",
      "r146",
      "r151",
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Geographical Information"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureGeographicInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r237",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOptionsChangesDetails",
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyShareOptionPlanDetails",
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of the status of RSUs and changes"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r243",
      "r251",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of the status of options and changes"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of assumptions in the valuation of options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r41",
      "r88",
      "r127",
      "r128",
      "r202",
      "r204",
      "r205",
      "r206",
      "r207",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOrdinaryShareCapitalDetails",
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r19",
      "r20",
      "r21",
      "r203",
      "r204",
      "r205",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "terseLabel": "Schedule of composition of ordinary share capital"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]",
        "terseLabel": "Segment Reporting Items"
       }
      }
     },
     "localname": "SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureGeographicInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r140",
      "r142",
      "r143",
      "r145",
      "r147",
      "r152",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r161",
      "r162",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "GEOGRAPHIC INFORMATION"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureGeographicInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingAndMarketingExpenseMember": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling and marketing expense.",
        "label": "Selling and Marketing Expense [Member]"
       }
      }
     },
     "localname": "SellingAndMarketingExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyEquityBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyShareOptionPlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesShareBasedPaymentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility - upper range"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesShareBasedPaymentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility - lower range"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesShareBasedPaymentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate - upper range"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesShareBasedPaymentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate - lower range"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesShareBasedPaymentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share option plans",
        "verboseLabel": "Changes in RSUs"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOptionsChangesDetails",
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyShareOptionPlanDetails",
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under non-option equity instrument agreements that were either cancelled or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations",
        "negatedLabel": "Forfeited and cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyRsusDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of non-option equity instruments granted to participants.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyRsusDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r244",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "periodEndLabel": "Outstanding on December 31, 2021",
        "periodStartLabel": "Outstanding at beginning of year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyRsusDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]",
        "terseLabel": "Number of RSU"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyRsusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Authorized awards (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyShareOptionPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Available for future grants (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyShareOptionPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOptionsChangesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable options (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOptionsChangesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable options (in dollar per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOptionsChangesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Forfeited and cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOptionsChangesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited and cancelled (in dollar per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOptionsChangesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOptionsChangesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value of options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyEquityBasedCompensationExpenseDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding at year end"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOptionsChangesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r245",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Balance at end of year (in shares)",
        "periodStartLabel": "Balance at beginning of year (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOptionsChangesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOptionsChangesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Balance at end of year (in dollar per share)",
        "periodStartLabel": "Balance at beginning of year (in dollar per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOptionsChangesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOptionsChangesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r235",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollar per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOptionsChangesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollar per share)",
        "verboseLabel": "Weighted average exercise price of the options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyEquityBasedCompensationExpenseDetails",
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOptionsChangesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r237",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Accounting for share-based payments"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "auth_ref": [
      "r234",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Share-based Payment Arrangement, Employee [Member]"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOptionsChangesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": {
     "auth_ref": [
      "r232",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Share-based Payment Arrangement, Nonemployee [Member]"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementNonemployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOptionsChangesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyShareOptionPlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r256",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesShareBasedPaymentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOptionsChangesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOptionsChangesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding at year end"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOptionsChangesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r223",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).",
        "label": "Shareholders' Equity and Share-based Payments [Text Block]",
        "terseLabel": "SHAREHOLDERS' DEFICIENCY"
       }
      }
     },
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiency"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Balance, beginning of period (in shares)",
        "periodStartLabel": "Balance, beginning of period (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfConvertiblePreferredSharesAndShareholdersDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Ordinary share price"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShortTermBankLoansAndNotesPayable": {
     "auth_ref": [
      "r34",
      "r387"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer.",
        "label": "Short-term Bank Loans and Notes Payable",
        "terseLabel": "Bank guarantee"
       }
      }
     },
     "localname": "ShortTermBankLoansAndNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureCommitmentsAndContingentLiabilitiesAdditionalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r86",
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r19",
      "r20",
      "r21",
      "r88",
      "r89",
      "r113",
      "r114",
      "r115",
      "r117",
      "r119",
      "r127",
      "r128",
      "r129",
      "r166",
      "r187",
      "r191",
      "r192",
      "r193",
      "r196",
      "r197",
      "r206",
      "r207",
      "r211",
      "r212",
      "r214",
      "r332",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsCompositionOfConvertiblePreferredSharesDetails",
      "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsFinancingRoundsDetails",
      "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsPreferredSharesRightsDetails",
      "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsPreferredSharesWarrantsDetails",
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOrdinaryShareCapitalDetails",
      "http://www.alphatau.com/role/DisclosureSubsequentEventsDetails",
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfConvertiblePreferredSharesAndShareholdersDeficiency"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r42",
      "r51",
      "r52",
      "r53",
      "r98",
      "r99",
      "r100",
      "r102",
      "r108",
      "r110",
      "r126",
      "r167",
      "r214",
      "r221",
      "r264",
      "r265",
      "r266",
      "r292",
      "r293",
      "r321",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r397",
      "r398",
      "r399",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DocumentDocumentAndEntityInformation",
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfConvertiblePreferredSharesAndShareholdersDeficiency"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureGeneralDetails",
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesDeferredTransactionCostsDetails",
      "http://www.alphatau.com/role/DisclosureSubsequentEventsDetails",
      "http://www.alphatau.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS' DEFICIENCY"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r126",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureFinancialExpensesNetDetails",
      "http://www.alphatau.com/role/DisclosureGeneralDetails",
      "http://www.alphatau.com/role/DisclosureGeographicInformationDetails",
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesDeferredTransactionCostsDetails",
      "http://www.alphatau.com/role/DocumentDocumentAndEntityInformation",
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfConvertiblePreferredSharesAndShareholdersDeficiency"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of preferred stock and warrants for common stock issued.",
        "label": "Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants",
        "terseLabel": "Fair value of warrants"
       }
      }
     },
     "localname": "StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsFinancingRoundsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-based Payment Arrangement [Member]",
        "terseLabel": "RSU"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r20",
      "r21",
      "r214",
      "r221",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOptionsChangesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Outstanding share options"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r21",
      "r24",
      "r25",
      "r89",
      "r164",
      "r166",
      "r332",
      "r352"
     ],
     "calculation": {
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheetss": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance, beginning of period",
        "periodStartLabel": "Balance, beginning of period",
        "totalLabel": "Total shareholders' deficiency"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheets",
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfConvertiblePreferredSharesAndShareholdersDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders' deficiency:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHAREHOLDERS' DEFICIENCY"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Stock split ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsCompositionOfConvertiblePreferredSharesDetails",
      "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsFinancingRoundsDetails",
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyOrdinaryShareCapitalDetails",
      "http://www.alphatau.com/role/DisclosureSubsequentEventsDetails",
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfConvertiblePreferredSharesAndShareholdersDeficiencyParenthetical",
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r344",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r344",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r344",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r344",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r353",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplemental disclosures of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "auth_ref": [
      "r8",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable.",
        "label": "Temporary Equity, by Class of Stock [Table]"
       }
      }
     },
     "localname": "TemporaryEquityByClassOfStockTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsCompositionOfConvertiblePreferredSharesDetails",
      "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsFinancingRoundsDetails",
      "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsPreferredSharesRightsDetails",
      "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsPreferredSharesWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r187",
      "r191",
      "r192",
      "r193",
      "r196",
      "r197"
     ],
     "calculation": {
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheetss": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "terseLabel": "Convertible Preferred shares of no-par value per share - Authorized: 25,348,176 shares as of December 31, 2020 and 2021; Issued and outstanding: 13,739,186 shares as of December 31, 2020 and 2021; *)"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": {
     "auth_ref": [
      "r40",
      "r89",
      "r166",
      "r332"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests",
        "terseLabel": "Carrying amount"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsCompositionOfConvertiblePreferredSharesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity Disclosure [Abstract]"
       }
      }
     },
     "localname": "TemporaryEquityDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Temporary Equity [Line Items]",
        "terseLabel": "Convertible Preferred shares",
        "verboseLabel": "Convertible Preferred shares"
       }
      }
     },
     "localname": "TemporaryEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsCompositionOfConvertiblePreferredSharesDetails",
      "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsFinancingRoundsDetails",
      "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsPreferredSharesRightsDetails",
      "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsPreferredSharesWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityLiquidationPreference": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Liquidation Preference",
        "terseLabel": "Liquidation preference"
       }
      }
     },
     "localname": "TemporaryEquityLiquidationPreference",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsCompositionOfConvertiblePreferredSharesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "auth_ref": [
      "r8",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.",
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "terseLabel": "Par value (per share)"
       }
      }
     },
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Authorized",
        "terseLabel": "Authorized (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsCompositionOfConvertiblePreferredSharesDetails",
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Issued (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsCompositionOfConvertiblePreferredSharesDetails",
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "terseLabel": "Outstanding (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsCompositionOfConvertiblePreferredSharesDetails",
      "http://www.alphatau.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of series B Preferred shares, net"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/StatementConsolidatedStatementsOfConvertiblePreferredSharesAndShareholdersDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityTableTextBlock": {
     "auth_ref": [
      "r8",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity [Table Text Block]",
        "terseLabel": "Schedule of composition of Convertible Preferred shares"
       }
      }
     },
     "localname": "TemporaryEquityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r131",
      "r132",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates for the preparation of financial statements"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VehiclesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment used primarily for road transportation.",
        "label": "Vehicles [Member]",
        "terseLabel": "Vehicles [Member]"
       }
      }
     },
     "localname": "VehiclesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrants",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureBasicAndDilutedNetLossPerShareDetails",
      "http://www.alphatau.com/role/DisclosureFairValueMeasurementsChangesInFairValueDetails",
      "http://www.alphatau.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Warrants outstanding"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureConvertiblePreferredSharesAndWarrantsPreferredSharesWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "terseLabel": "Valuation assumptions"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureFairValueMeasurementsValuationAssumptionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrant term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureShareholdersDeficiencyWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingValuationTechniqueExtensibleList": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates valuation technique for measuring outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Warrants and Rights Outstanding, Valuation Technique [Extensible Enumeration]",
        "terseLabel": "Valuation technique"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingValuationTechniqueExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureFairValueMeasurementsValuationAssumptionsDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r112",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares used in computing net loss per share attributable to ordinary shareholders, diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureBasicAndDilutedNetLossPerShareDetails",
      "http://www.alphatau.com/role/StatementConsolidatedStatementOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r111",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares used in computing net loss per share attributable to ordinary shareholders, basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.alphatau.com/role/DisclosureBasicAndDilutedNetLossPerShareDetails",
      "http://www.alphatau.com/role/StatementConsolidatedStatementOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.A)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "610",
   "URI": "http://asc.fasb.org/topic&trid=49130413"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=SL116886442-113899"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4549-113899"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "720",
   "URI": "http://asc.fasb.org/topic&trid=2122503"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613673-111683"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.4)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.10)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.16)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.27(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413209&loc=SL6242269-115581"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r422": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r423": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r424": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r425": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r426": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r427": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r428": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r429": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r431": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r432": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r433": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r434": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868656-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.13)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7,9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>134
<FILENAME>0001104659-22-038887-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-22-038887-xbrl.zip
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M9[O/JG:73:^&\)VZ^241['7GGXV[T>3W!D%%0YR3M0-=C8D<WC5E?P\SCBF
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MKB+;[Q3M9>,%_""64P]'+3S'(S2YU,"_3P/OM_=I]T^_L0OX(>S/'@>QN-#
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M*.YB"V(Z:JMH2T+U<1?L6<"N:,\0/<X\_Y=2>&$I"^NUZ'\L1#T!V^_'O#;
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M4[[K#GS52 3'$AD\)=4[,B\0MX&R9[&LPWE+]^^1XV+DO?IO-,)C$ 1\(EW
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M*AQ)F?\F;9%0>I842MFQE),??@CM_ONK,60;MG_5^MT)&^2%S]?<J;8(-="
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MGK/_09MYF-T'QW;2MV\GIWOFR+*<UFU9\DI*^MY]Z4.3L,0-12@@Z5CSZP<
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M;G\+Q%?RNAFR%QLDH7X3=Q?X!:]SR,'[O_'7I6(DS1DY3R 8F2+LE'4@5 V
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M&+J#<8%$L[5FD5!KVF,-!,V+]EQEV"8# R'>W=F$$=@G(&,X]?F@';=I="@
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M2C(J)1_\>AFRRPX/[/_COP%02P,$%     @ VXI\5*_,-2':>@  ,LT' !4
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M]$ZRG8<>_<_B]X/_X@1$SV2>7CEQ?/3#YU^<X'"ZK=&V+_ (;66"4@%[G8Z
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M-VAUOUC/'Y?D>ZNO61),7& [#[UK_(*#B!4F$_4+%:9JZ@/<C;54+C]?J>D
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M44O<$Q@(X6PO!+T1M W/_7[@2H;XF=X-?]0+\\$4)M&9S8KL3'&'TH_^DG!
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MY4+F,/#.NBEEA-MSIGFF0F;!B%DPQBXF"WIB,Y 9UCOG5I\02.DKKY5/?0I
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MLS&>3HUQX_CQ+TYPP/,D.>SXP+0026QI>NEW==8?BN$4!H!!C7TV, S"#?J
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M5#Y#U>X,'#+;&:'TZD6K)V#P:JG 8%>3!2-+^9C&-X(KPS"N5GY$&%CC!).
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M''5SP$&H(W7GFS<9;203MQR?XRCL2\0AUB!_'T>)>D[;T EXW.HIK55TG/4
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MB&-Q"$4W]-R<K\V8YE=NQ01E%:_]YVVZ^()CUT\PV]<H3ES$MXDRU#O2@HX
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M$=@F),N=[41PY@=?9.0%P13X6.WBHK'::V@.Z2U]8[.RS3(N)58SS?2NZ#$
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M"5X<3!W#E:P%4NL**2!^NW25()L%Q8TK)/XLB&0+G6E2(5&13RQ\Q5M :-(
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MA0+4X,*TT$(3RV44T#WK7E]>-H<O'SQ92/FE4@96"4OO$91Y"#\RU]O;@LH
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M8;Y%/G+PU&T[2TK+J&4J]&)UY'+3%:I+B$5\36I)K@JBJY7OE^!.FZ\\/UP
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M(J\&_M,CWMZJ $DJH5TT+I53@<Z\D7][JP*\*0NT &48TFM &0G7M*E,!0:
M>2KP2*K+?DP--_=JQ041B1O?LSGBS;U:@%Q"8%TN9ZWMYEXMB%%2:%WN;?T&
M5K;)NK8W6TAC$G (JNBEK>+!I7*N;%8 ?@[0\DCSB:7+U&\$C "L/,<:KC>^
M]QPG:*7"3JFA' 'D]7]1J6M(JJ&6)V$D^9I*!=AR+/\370/JW3X@CS1??"\0
M)@RNI!Q92J(K0!.RW%K&=_1,,UI'#DHK<P>@(*8=!]2"C0.2!"F]M>>']K_P
M]T2UD4_ 2&D^"\BG[M5%5Q,BUJHA+:-(B"H8 ^&M25A%7VH)2ZUE=,E^KR*&
M:NZ*Z$L'II1:YC@5M*]S@SH3)5W#(/DI^I+P&(HZ3N+1.B.=<"S7U'C%@8!(
M)>@$.]C&](L%-%WG YKB6/UI[X\X4!^%-?7Z_=G7P5Y,?^WA2H0M$X;LA" D
MD:KBH?7R;!%Z'TAJPT<Y/*@!U,6%E;$,H@HO- 6\ NJZ]$+R[^5OX2)$OKQ^
MG."44<OE39+=($A4. -XL,2933D8PJRJ%UG*B:OE.B??==*@\+VON$U+05V]
MF%-2WO9'T?>]]=H.\4X*%%I"'K%/^?EE?_+P,%R@(/EX<MF?X'Q \._.:-B[
M'8Z&BV&+#H@25(8S*O$>!Q5JX_M54R>TX#K+0&^&=][V*)$D+@_N(I:@(DTH
M8U)*HY2W+97EEQO6VOS - )! $"Q6E[WE#*&%F;Q$SC/X 'J?44:J\HVIQS7
M*A.E:+]<HFZT7'3Q:N@/8/B+GUY%#B:MO%&/3R5:KN>$% .?3$S=*=I.5L7P
MX]6GTV8=42E:K@=%5'/O1>3 ,[%FWEC'J1,M=]N$-&,_R[!UJ)DWTG'J1,L[
M^7@UTWN"[RV)>9FVWN@GHA@M;[[C54]%VKTQC:$+63?=T?VSC7KEZ+<H%I8]
M!=KP"YYPI-O>^! .'W[/LNQ8+E%O_D5);_[[SNZ9;ZY]HM-8. D.Z0*@[;D)
MRO.+TMH(UE;.=@BK>V<K9(BN3-:) )@?EM[S1PO8F.]_7J&/[^./,4^ #4?3
MI>$,H&3A:T'BFH(2RN M ZP]Z#DE;1F\L32%R64.?U8'6$XHLN Q16D2.8*-
M'@:^ 1Q[Z+K><ZS9))OL*SD+!*N.4C R03FPO:6$:_S4+P'=GH,B1@PRE)D"
MK<:-+8FJ&5AFQMJCY%S9^[G5 +'D:#QY"@&>7\$/X];V?ON-#-%!D:QXW>[Y
MY5E[8.*1I?%4)@2H;I?N I@KUW.\I4W(4D$NV&K8^"5J/!T) ;R^L7[T;6L)
MOKKV,VP<BO^K%^!4Q,%X%2S\**!82?[:K8:YHIB*9I\(_'#/'P+_.O2%P*_@
M^ $74P4+Q,QOZH K=6G(EE&][!#\H!;VZH-?E0&6#44!;.PNV?QJ7@RX!]NU
MU]&:"%WF=_7 H[Q7%CZV'(VO_:J@:+S04=S_O<TH,N50=7'X ,*59TV>DEVG
MF?=J.'CSI,!3RBJO#("2_::EY):TW)3IB[LU CO(BU#L.F564 MM87P.US?"
MHBKH;+V/4))0E#$ BG('GH'C;= E*YX5F92U#4<UM< 6!^L [;(2-SX64X''
MB;MF4!HW0B?8?+B"L^ZAUJ:1;ZZ, %A#-P2. \PP,IPTHP2+%A4:U9(TLO6A
MZL0 72L4]X^>XZ!$Y(;[.F>:$G8MS4A14F!5G=$T<>:>8]V^IE^.;!,?,R['
M!5I;)\00836HZAF? 7O]&,%&D9*F/A2$LN%$*)L5^*9[]?FJS;@+B:FJT_S.
M#D+??HS0Z^";&3>$+,V,TIIA*RAHXVYQ4@!=:I<V*V-F6'::7Q.9)@K,'-4T
MP[NLQ+)BL6L"/I$ >42@(FQW*;9 $&]%3UI454 -T=ARKNZ)YR/)8F?A_=VS
MW=!YW:Z7Q=A2OC7-6"-9$0E[;M1F3Y*::N%5(0U'(UISI:S\J=OJ3#6.)')]
M 2XZN9(X4N 'VAUAK#J:,:"4N"G@RCDJT\7P_,_(6'M1T(<T[D-5VBY4"-N5
M0*FF&>QE)4Z15\Z?2-F$&Q&N=.&NIQ;V<C<>2\LOR54D,?!#^&C:?.7YX0+X
MZUO#_3'R#!>I8.R%($UX>4 8[GH9A5V>=:\O;AHD3&F(=U2I)KE:>:X(!N2+
M;[CAT#6]=>%QOKV?M4.72T"U4D>1)GQX)'R=P0E,X=QN][.>(+($5"L/$QW$
M9'+3"Z; -Q$82SCD8986#N3L6EI#+BJWELF1$EW0\S=D"VE'"@$Q]<Q5M)>A
M(0BB-;!(5\H4E-26#;RRJI4ZB#! 3#WDG[ -)S%Z1</!81GMD.67LH9=(OF8
M/J"+B4//!>,(.1\F3Q/?LEW#?YV'GOEC@M^Y.&*8IZ*>Z)<7_3@)>JKN(NZD
M&+S 68T= !SG4+A72"B;E?Y<$^"%I*UA ^?(R9CN#=O_9C@1>  &^ALK$'T1
M X?&LYCK8HF8/N>O5;CO#6>=;[W1UT'G8=";?YT-XJ1,[SO;QW7VGM>:)$Q;
M#>ZD)=WSQ5.EL?N]MB\%00"X$^U-;!)V6!,4,Q/Y/NQ;V#OE^NF?V&V^11(?
M.+;_C(J3.!WCD<I8)U[0\Q/+HZM'O0.'PBS>,V-#=Q.%"_C$@@-1K.+JLN=8
M7,C344A7FE*I\, 5NX)R=!+"DH\*%$DU) /R_9@HH /XQ6=D^2NV@AP4=-GT
MX)198YK<V<^V!:?*:/>@%%WR#9P.;3AE5R_/167ZX)7G-\^!,#JDO'M"=?4G
M#;_831[SKHDO,SOX<>\#@((,(9:AL+DA-Z _<P1EUR!(IZ9%Q8@0%':LQRI'
M5046;XWH7-D#THE/?VX"U_!M+QBZ/0<W $7%6EIXOQL^,1Y"I/ZID)'.A ,G
M>V4%JA7V)LD<IQ)#C<_LY2H,)E$8A(9K)4K):GR ?.^!#4W R Y(GN8J3;XQ
MM]B42M>I6N%_1R#SX<RK!'D/F\@J%O[_ZO*-K#)T>)RPQJ-O<?97*$L<''=V
MVS*"&YRYFV;(&YS)PSJVVWF"C^L\H^>=[ :G\!TRLN6@=T3<\[ZZWF, _&<T
MPXX7A\#T7!/6BOLCSZ:FI,>H:]D(X%(6'W6J1 /O\59/MZ_;.^/ZCA$4I73D
MJJ,N=^ID H6 W$K2B4W5=7VH-NHV:.W/59?5W/2JU48*:$T#FB<S7*J;.U-&
M7?H<%7KB6H&B)0WH(E'9W'YNB8_2F;RE1O2Z==NX#ULV[_=6P;_;X2JGG""K
MG2"KRZUYP6VQB"_S63HSGTY!"OMK5[ DB[\!ONU9\]#P0V4\E&652-#A%(LX
M=$T?7>%\!^)_)?<0H6>_]1@5%*ZE=U_'T>3\K7/4KV%)VPGQ>#)PK5R/N#C&
MED*<RV-AO* @C!<4*"1X/JJ;/Q\U'/<G#X/.HO=/?!T];+>#LH:UYR#45BG<
M=\]3:\BYPSC_!.*M\J2R62)?=J\^-9347$#1NSN+181J_(Z,"O=5[5)W#?Z,
M<. GNE5FZ#Z# )\*S7\+P-A8DZX-K-*<,H019\"./;4H03W_$1>W2'(6NL'9
M%93A1RT89RE40A,*WL[4"]>P&U'N2M_[72ET2ZC_8 !ABM;XH$'&[+<?5,C2
MG_5#C"J9HAY-OE$>XH"7)U^ M_2-S<HV#8<TA)/**H-WY?%92$+USD?Q00Z6
MAR(2QUUB664@%X?M '(A"969;P7 _+#TGC^:7N2&_FN,>O('!AW#G7SQ_>O\
M -O=#VH!*03&#DB&."U%[>]3 FI_GVJ%&D&<)LTKO_>#M&?-+*\,A%4&S7)2
M-G[CGVP'7=:+N_TZR6=Y"USP9(>]\!Y N0T'#5<1?*?77?U\#N!:GJ$\Y^B\
MR3O:Z]>.6@>C6'8)B9%5Q31]S>1FQ23E+M5:<;>B#9]DRJ_6_J0X8T:&OP2Q
MG#8(RO&EL(V380N_]*W(<4Z1=+XVTHM<2W.EL(V3X0J_]&IE0:_*E?D&F+;A
MH&(R:)-O+JO#J^[554/Q",=E$*<BU$JG+DZF!V#9T5H>FYCMG0R=RFGB.+G8
MCQ2",@;AR N"^)M;\.3Y6-6" 2FY\ZP' 2GP*1WX6]#YBXT?]!^=1_RH3FB\
MG&:,2F,G6>-W0IBC*P7C7->1[2XG&W31( K,BEFPQY$'V\7L3),;]5PKVTKQ
M[B_KH&\#;Z*,9>-D",D+T+S2U/(5--<W[N"'(+1->1Q/6U24J\U33TJGH&KY
MC=RQDN[AG_:2=%:W?(-OU*Z3VC0EJ^6P:X[9@Q<(@I=<RX*7$F.X+H UH7CP
M!9<IJO*HS_O$M[Y19]^HA((L#Z87&D[C"[_#?2/1)=\E8\D7MX\7>"!^PHDN
M]*X:LHK]R/=!>G5L;G^PJ+<PA"S?8+8W77>OSQL^3,C *V]J),NNY00ST5$R
M_<@IB<XJ4BWEJ".9"42J"2E$9SX1-%W*2)TLFT3T(6N-0)_F-#6F<[&H+?01
M'L>.R8.;F <N6!KH_A8E9KUC$"9=R5VBA0,(^H;OOXI.?J\X]CN\]#EXYP,$
M'1,]Z40GP=<-=?L,V!AJN"#\:?@6*>\2N4*K.O]U4><7E.TXDXHC=?R[Y)63
M/\2Z^S6CNZ>-H]7NJ1ZZ_][8--%;;SP7N8\F3WLH)ZFS&4M:GKK9SO&I^^FS
MNF?XOQ<ZRLJ+J>7"(J<"'/$0?Y?,BV8 Y2X!*/5YSS3]R'""&0@CW\7?.([W
MTW!-0!I$Y#U .>Z5IU*>EC6KZ32X.W2GO@=5$"!501Q74#%WX!DXWF:=CPTK
MV\QI\;",,K3<6<MIYHOG63]MQ\$[.J'A+M'E)/%/O$RC-'%:+!-5A%H!],<;
MBQ$(\-\8=]=*7!;!? 7ANX5S9VN_0-\C;MK6\:C38FQ="E,KW+\N9@O[(@1:
M."T>"NI!K0, M0W-/E0&]R","I\6:<@BRPKH5VK#(R?_]D*P[;*)ERSYFJ?%
M'$[Y$QI]EK-?THS'M.^YS\ /T4QT>PX8#^9HO9W>!X>5'=CH.9,G<@TQ+^M-
M/JMI?S+^-I@MAK>C06<Z&]P/9K/!76?^:V\VF'=ZX[O.[[W9K)=<D[9[IX[W
MU-E[J\[VM3H!?J_6^&<7 ,KD&_YK'"['[:5EUOM^T9!1.GBSV_BBD<G3//3,
M'[2+T=@5E3-)7"CDK4])297)^U.>'-O45OL24VXO(Y97G0J\F.;)(2:R!IS8
MEY-Z<5B^H'(L$ .O8!>'3T0%4Z#.@6^#@#Q3(&?:Y*N9U0/\V+UH>#K*!]4.
MXZK"JII(-1;IMCSTS*I:85].6D63LE:='8X85Z21BBO'"&G#OY#$FK(B68U&
MX0JNB_^U6TC2R7%82W6.T*%E,H-+7"WWQPL5,0R"2(PI<8V38 E%5"WWM N5
M,(G"(#1<RW:7(C39JW827&')J^46]8$F\'X35$!OC7+Z#EW3B9 ^IIZ/P0U#
MWWZ,0C2J+[SBPZ6<$QH)#]*<E'5I2,O]Z)SJX3_67L9/0-X1XJFJ.=7X9=9R
MMQDO55:> T4+8H6,O1#@;^<;!Y]4@^O6 $HZ0SHZ)Q!)M!G=2"5%_O;GG^/:
M93SX968O5Z'PGF(N,9W(GF)NX]#'[_"V?]A8\KJC[1^J9VIX$\25E%2#O:*:
M]@_5HP(OIJ7W#_7AA+3]PVZW>]9MQ?XA$7Q.$75 O6A^@<0NW&WBK*4<'SCQ
M+"!""4%/?E=9!<!+X"9ABUDN U3;3Y*SRZ@ .Z1-$H0DEK1% .GXZ#7+BVR7
MNK.?;0NN*O>2P1M+TNJ"IZKJ?*'#G&=):9G5VG8DC"WYQ5?L2XX],P#EF\1'
M1(&%>ICA@)[KA2O@IWT.&].BH4=*P[IPJ6:-J+5]R<>T<80&X,G3-R_D(E"F
MO,Z\8 NJY>9CULSN3=P.7,5<(Q.YNB[,D2+W<;;_&G>PW]NNX9JVNYQYD6L)
MN]9S"8!%7.O;9W=\_/ WGWIC>8*/YE-7SZKP9DTL*:D&GK2:?.HWW:OK3TI1
M@1?3TC[U1&0-."'-IZX "\3 $_>I*X"Z$MY3!:#FA$J"PU0NZ*T_D]-R[,M)
MJ\OIB[ZW7GLNS^;90;GV<T!,-$G>AR8']EIV1A1 7MI43TAB72P <KDFNDI]
M</L'1X;NPC?< *Z=H'BD58% $ZJSAPYZP?*@JNRMV"\ID#)U,[%I4J(%75@B
M2W2UMCJD^;[C;1^T!804@3(O39YFP )@;6Q]N07Q$$1G>,GV=&%;/8K0<M]E
MKT].?=M$F]K8;+-'N$QQW9@C)*>6QZBFQNLZSC.'M9!V'Y3;E#11IE71C2#"
MLNI[7&IOJRT>QN\B'YU.!/#U+)13\,"X[I6G'9^JT*QN9*M%'\<Y7G4*803M
M)U@EN:OF U622#O!$PL?+V83U0"+=/*362^CPJNS[M7GJU93IYS "6>ZI\"9
MV%H+$B:I=")LH4F;4.5&*ZJH<,Y< SI)D3]U/)YI'@=W\$OZM6@\7.Y.T')'
MS7OI8?.?R7N\A<8U=GOHL4+C%+0XO'>*EI14@S"H>D+C%*0"+Z9%PY"(R!IP
M0E9HG HL$ .O8$K+)^*IA\:I #4G5(?;EN6%;3PT3N&(&14((6T$$)*X\8@9
M%8,;%*0#'45YP0TU6HOF/1U)CTIT,?%Q?K/!"_!-.P!X;W6GJ.37@.@K*].6
M+BR3KP2U@FD(1BD5Y0OZ+^I%I@_@RA^%=(S!S^WYNB)KQ%DUJYOSUA*DLLQ:
M!KBD"NFY5MP7V"FP:55T(4MI6=M_:!C/VA.G\1UXLDT;N.;KQ(<B0S7B7_O&
MQ@X-1\@U>GZ6O]D/.T%_G8SN!K/YOW?N!O?#_G P[O\!?TJ?%[M!.V;\Q-8X
M08L][PP/*+U28[?US<T5L*+M]"U9!=#\GI0:RAD(MM(+'%J"\FG@TJK)S:D"
M 03!+.W?U(<,TOR;*L O!)ZX?U,CU*6< 50!<T[,BN(S>$13#^O #_=PAG\=
M8@R_@L)%Z#H,J#XX!AIK4&#=2<640[B\41<249*+X-A(S\ F\LT5G!SWECZ(
MK=^!R(5F7:BN,IP00C1+A&K"*KBG]2OX83S:WF\??GP@;U_E"BD%935,#OQ!
M?**J9] K3=E8^U.%997A@+QY.[^<-;C^FI["<5Z@2:FA'"/X\:3.[+CDU',S
MZE )U!LS":6SZKKH7GUJ.E^Z3%I09%1KOZ@N2K#W!VA5]"8'2U M=Y"4B-5O
M.9.D"*_6.6M2$ WN*,STU@7%M !<2#@MST2KF<VCK7RJ1PM:GGUN,H%5V^E5
M67"U#D$K&>#94HK(DOLX1YZ/'SB#OYU@:::.X8K&S.1NKJ7$S.!'=6+-=3;P
M82<=+M/4Y;1[?DF$QRW4J057BAL Z1_W9=@3EMAO'=R^[LHD*7-Z/PW?X@RN
MJ=:^<N:'#2@U%*<&;6C@^$=&A[";6U1$/5+4"G#!3)JE#(TX08W=R192CA=,
MG,C04B12<,OV8 )!.7585# KY264LN%43!P@%+E+N.32H&LRC1S)QK$V=:LW
MK!R5CCTTU*3"QL\[-DW=K$N!N24M_3GJ$;L>HDEDM) JM=PK+ZTZ_)]O( BW
MV2F)6V(2'_'&\=JTJ.6^/U;)(UMKCX=:&[QL;!\7CG5&X[:,]D^<V+6I4,]8
M!4GCW;-A.VCB>._Y^"1QS3.5P\=E >M"P#Z?$N>/I5%MS_)B08+^"BE-+,'A
M^5G^PE_:*=[X21TS?M1)[T<T=;%O2_<C5+!J3$"/MA^1M4AM=G#%F3< .G89
M!91-B5PY]>A1*]1Y:O%I1#>*4/<H"DHJ1Q,^V!AP4V33 /!\W]AUG<%ZXWBO
M %"/'/,WH#8]*##3YL*EA-:<-V//!56IDVOC1-C#)[=ZAY_UW6U3@&K'GN[4
MI,*3WVU+UN1[9Y5FGN/<>S[Z43:=J0]3C^+U4$XBM\7U^;;Y1M=?[!BLG_?Q
M<_2AO#@3:^T&%/5*Z@$;O%<"9UI^J$T_^!*'Z"?[0%]\+Y ^H2$_*0O63??J
M\^5;7ZA=P7KN5J>7S&:O_8PW>_"/B9;21-#$B8YP0V\LSAUDKJZ_JIO/-S%)
M7; TPJ2L$C2M" W$X@G8811?7+;;QM]V^YJ,-_.Y;YU IBDOI^ZJN]6:]AE%
MIOIO?>(8ZI64,2&>Z@_<?"]H+ =W1?4EPRURO]7:"W+/>>L%,GL!GWKU3-\@
M#[?? ;K* 5B]9^ ;2Y"Y' 9A^G0L7RCGB^C3AQKTDU;1M9YKYN/HMME>I$_7
MD<OHQKH:K7^=I(>6N%=:Z->KHZ?)>X.WWB:MM]4,RFF.:"REIGIKM+L)O<1;
MCSM:CZN.R]N1JC+.S@8FEY7>Z:U+'FO**1\FM5+H*M)#V[K0.W_K=HJM],[?
M//0\KMT&>AGGT]_&MF-ULBJ O/G_"Q3:LRP[UL/N\'+ .M%;YS,ST%V?=2^Z
M;>U+Q_;JBZOU;>5%MWU#-_1M-[#-;X83'6$FEWV>/CVA-$%KG:5Q:%O?4P*/
M;!4^LL?@K JI";MJ>>!;%R%UD>.I6U^?>04=DB?0,X!.H\+O^YZ+48T,9P'\
M]45-G:?$F[SUJAIZE2P<])VSR3%9G,H]PEC%^R9OW:W>0:P2#KHF.YL%D7"*
MLRN!%&>S^=?3SFMVW;;E[]ASX[X3"S-TH2 1W@$^SIEXT>>K9S:9A)"XG)6B
MK1J6MQIROIZ3 0*/5H_IC;+VV+V( L(I1VB*ZS3.RG3$@2-Y8!:Z\^[5]?5;
M_ZFY_]!4KZ_'2*X.B8$\Q^M!Q%=XZU/'[U-B8+PE"VC_7.^M7RDPU\OVIZJ>
M((X0K>-[@V*5Y+0*30S\"$3]1-<"?J+XR>^Q&Z]C[CV[ ^*'G[03Z5-31G:;
MU#+-F#L'_K-M D+O<_#+P$^3IQDPO:6++KV*@XW[7A &?(GR)3Y+/3/*!+K
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M4JP[%N'KE^XO2S,@C!T?O)'=CT>K>6CN=AE+96&#<)APWM> >V^PS;:\3-F
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M-ZYF3@V4-A+\-@[R<] ,%MOFP=PN716MZ-UO(WS=_CN"KZ[M.\&W('WGUX:
MP2!#M1J7*!RY"+3D=)+CYICD*,Z<S^GIM%M=\TNT=A@^"@)J;;]!JQ-^'VK
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M<<I&7=94WF+EJ>;)FZQ\J6+[>;Q>+S5TLU\5&VVVGI0OP-A\GL_/#OG"V'W
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MO3"(WJ 'WO&^MNT!:660.;4GZA516S-$7YF:)CMZXGWH@=>_+ZO-(=8#_FV
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M(6]>'&XZ\?QXSZ)'(8T/*%(F4Q-;K0(OA&=2AR=T2DF"HI*)QXKA*?6Z/40
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MNP9?@I+0@0H_P<<U%V,LRY<-K FFMN/]")J$!#-=#.D%$O_-&-.QC+5D'ZL
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M@>8\]U@Z1VA%GG[/5LC**0"01./?:H?F__X_GFU?DDV7CR_6L!Z?($[Z [[
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M>+A3SP@Y[Z*>$7BSN6?$K$?^$%#_AVHD@4+Z/Z>1Q!$.BAO+=)O%:V*SI>0
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MZM; K F_80+<LRCT'RMU5F3=G#BSC$.K5IT,LCDT+4$\,]"$5%H(S\KJ;M/
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MEZ=E5A+T/$!T>H(^[..#TT5>"H<)FE;GT&2)3C?7\";#,5UO'0D'WE: "&J
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M;\4=,=J6T0-B<_HU8;!>8TB)U=M_!.K8UYYEX]^^6'ZDL=[:'_AITD G!]A
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MCPM+(*\@ZRO<5"L>>@TV:(Q+#: )59E!2= << 7  M%7S&R1\5',2M'P'*)
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M7?6C&ZP*,-PUI;'[21<.7#&I!$4;ZP_,Y'>+Q?D>!_HW.)*18^ B65P^NKR
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M>_3R?$,K@9KL\=6W-A=@W:$0K]Q6U]SFC0-5"O%.F+N%LW(>Z7V,/IKPR[V
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M*8%)N*52<X8JA!([:]%(0//ZV4PZ[<*P ?.)M4J[;&,[QL.D:,MIY0^LF)+
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M!EHL$/'1COC[<_E?:P1XZ3SK..=$,B<?^)&Z^<B1&W=+[B?G'&("H: IHHZ
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M[DF9TKMB?@^QXJ$_Q=:F1]'3K0#/5@W!KF!>Z9OBH4VVE9X]K,]'60#^PZD
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M?L-+41LE^7$2E6"YP^B?>YKWX'P1R;L;DOCR,O1__]]__NJ/?WZ>CS+]4.(
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M8FU[/Q"&]<26P=]<WI=NZ7)5O1L/9$^/U-*MBFX5_LZUF?^J,GN\0+/>IBD
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M*L]. (L3P.+1&542^P/_\T $NTAXA7MJ-382_X< #"T]))7^/\*=60]7SMH
M3\4FR IB.6'LU(==UGN^!%P'H=0P=F $'?O:BA8WC;5ZQ@JR.E7(4HLC@QMC
MUUQV4JQE#X"*N50BHO+0,EZ $;]XF"7B",/ 8=3+]AX"W6(-M:0FW_@0L>VT
M[\J3;M^O8%:*,MZ-$C<GVGY7(6Z+VPKIKB/*VUKF<\K*,6_N.N@G/L5=. \
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MATT@+P#N ]PC,QMWXY(6/1HZC)WVSL@2L-XNX.Q=\>!FP2\G2YSO9V.L\7A
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M2X7"K9B_5I<(.4$<K@RV-P!DZWSV" PWT^"2\4<2U!6UTDP+7'-7R:E!7@J
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M?<4KBAUY<L@.B+ ;MVAQ>7PU_13-*1SGP/63G.-LVDZL-##I'9++_.AT6J]
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M,00$U1X(ZRAH7%5=QEH*#AM5/7(#7&>7R8CZGO^3I),VFR2A,(74=D9WJ&]
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M\\4O ;+4_I9=<PKY8B>;BZ%ZBW8'VXZC28A,DGO.AE@,:L1V')!BD8'%EL)
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MMNB_#*E9],<OYZ_/DYLLO[HK99"$-H2DO"PJ4FN\IN$VA0U%AZ2XT7XRDPF
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MSR3^KA6!0S#@28HVY&9ODJ9_UXW]Y)A/^CEN[-=BV;[GLK!H*;10M%%8E4%
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M4W9L3]57DV*!^Y @W?(B!SDW5"I 8 G6K0+X:65%KZ>+#.>WTO$G&=_@17%
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MDP/6^YK'B!C*-GO;)<"EP7 !]_LHQ6J6?&/^[_>0-'-$R-QM@'VMH"9HSWF
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M?>I\R;Z)B1. MIG^1&!H/=JK*/A-NY/J![YDNO!5LAT$\6G#H8NN+M!YJ20
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MK"?OWS2J]W-+I0%Y188)S \R51F-HEF)6\02E^]*LM96?4#U6K>K42L1-CD
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MTI)M*"UY*"*LMB[_5(<M\,NA3A;OCAY-*!0)U\V&C%,Q\*IF0[?CX'='^/#
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MW=W[? 1)2$1, FP E,W\^K.>-;P#",FR8TM4-NN>VSNF2. =U_BL9VW$587
M'84&@E@6T'T0'#:T1@O&/"ZGZUMN;+?)P'K)&2M_EJ!"R)#W,E]F^,G#QA0L
M%A?D.301Y4+E3":4(BG%^"J-NEFJ!6DJ@79'Y>@(GV@KQE;ULI5%*N)%.)V9
MK<BNQQS>@KZU.W6ZF73I"(0)^OT#J?DP>NI 2!]*/[C4K";D+!323KX@S^FO
MQS2O417P(8R015XBT$XH,9QZ=4B>X8%+*4M"C$50&V(D&4WO):JJ!!-*16='
M8$EAS&:I)_3)YSZ;75Y4UZW,%^3+5I._?36MFKJ/F.N0!/?[T<'EP<'QX+?E
MU5=).F_^]M4/)"EG^>0K&V$G?VC+V&;O)O!V G6^::R;9A==>'QX/CC'")-O
M[HG4Y)[$TTMWYI_Y2J[-X__&Z:S/+[NZ%D'MH7_?&/ELY8Y+2"3![[O#WE6D
M=CL6X E0 /^;(Y,?.X?/85/^Y;_.3T[/GVZK8?DRKC(2"R@,G&M8*^/TLY8)
M*1!C*TS1ET'!=W!K0CH>(\MIEW\JC/OR$L5*-TW?E[.N/UB71FM1:;3RAL(J
M08/#K>3OF6G,>!C-MF^3*[B[MEMZ;;]E=)!7 5JFNDFNI+5Q@GT2L*\VE$+?
M"T%^:1D8 "2#;4A&/*,Y]=40-4\N+$0W3+((I@W(GB<V\+#IKF4Q3%L,JF<D
M,=.Z5-*L/*#4DY]QK"</45N:!V_I\-LJ*M3 K[,84:M6;80G (PJP'^OHYP$
M@\VB*D>/3V- M3.M'62CT\H@2SI]"["?0W[$6=G:%^35*W*GU2>/$K/\KA8\
MN^4_;)-LVXHPUTZT;5HD5;G0GB]H'$(N(U2[JT_58\AB*O^R8^QHX!08'FQ,
M/ZR@?'%;.6Y4,_?Y:G,_ S,=2X8/4=/=+"D^MUO6=D?1ED5B*D]F^72:%7QG
MSD8'AT]#[_"Q)7#/=PG<70+W0]7$]Z"%(][ZP>ATYW(\$KW\(5OOQFSI3E<K
M^O).Y,%&]9)ZLA<4LDQ*Z?$Q3Z:E$/$$-=VE<3=)0@/ZG3&PCO?13/E.1*41
MJ41 *79 N(RG[TG!.D!:/0>KHGM-AS\WN)=!MN@_I>E<N7"?^6YWFJL)J)>4
MNX:F]9]5:C5%\_Q2RJ'Q,L_O$C2MN_'T;9//L1-N6R_<C.8*Y5+,KNUJ#1!N
MX***/"VV($HR2%ZVR+9)1%QG!9,>.$J?W'K4<%FB&[_,1AD2:%O?9D_:A! W
M2ZAQ*Y7G&![IQN;P$?"WA63EB^L457:](!)"Y]QQ,Z!;SG3EZ)7TAU'Y8/:>
M+!7^"H=(RF2=9W-4QBUSS_5A==Z0;9RHQ)1G9<V=:JPP6D ZC?:1OB+#:(/B
MO(<&Q,;ZVRJG0,RWYY>P5AHJI&#9LTJ7\O[)"I >>BF#3,/<IG)$!;/G1DR2
M>=Z8 FIB5M5DA@/)+/(XG;3"G,K<)JFVBZ1LNU"KFWP!$A0 K14$(]F&[9!C
MW4'<ZQ9_6U9(&U)IXN1"Q"U03]US])P^$JK0;-3I<4L2-%)A?@T('2D8:84W
MXPRK2]3HH]M HG>@0FBR6B.[&Y6D+2Z"@&=N QSU9(<KLF*EUXJK>5 \$0:B
M5,?0@^CN46=WI)IF1PD,PG36-RN5-K*L7/*=%2T#';6XF8OAQ;SHCM&[G>#8
MI!Q,_I&MT?)O(83:4KP4()>XMN%_==W23H-L:) +B\WBL!A["'/_M"!P$4?2
M!JU_##1SC2 ^FM%_*[*3__Y,K0_:;/R[9@>[9@>M9@<OM:KZDMP!Q.<=/9<P
M:X$WBG0$NG(VCLI.#N0ROV;F!]D#,"@>C$;;Y#/L1/Z6BOQGDB%DB:]PYRX$
M[1TXPF),\=WAQ%LEY@.J<EV&6Z":'[$F(=W:'R)3XU**/\*H%C#&1,6R'(]I
MET(8U+N3><SU%XK(QQ2ML\$]%K/E+.=I4>A">^8<;L!M3>S")1,6G ZV+D\V
M,<N6,O 6[>4-S$"]9+ZB7ZF#%Q!@[H3F3FA^V$X&Q:50D]U0<^$\_7;L0"^]
M9S +F<C:12$?BBQLB^AD.> )DVG+,V9;ZP;L!1QF'$ -)AE[#\&4%V1+<43+
MT5-]<L3HC]>S!05K!C;^4,G:%RU8XWY^;8:KT5!Z&DN##_'3F./5XM%*@QCJ
MK7 K'+(H=#*@4N@M],S\]]4B'2=[_\C63;6:IOL?;+380A;1MW_\A9D4'+UR
M!]_=A+=752R[I>^**%^ $^:U3\@T);1\>.M_5BFZ+[$>^7M6K>ITGBUZQND,
M1T@[3V;%S%E#DW0I+(?:;D6<N3A0&*Z7#_?QN0G\CIU*V:F4#ZF4[Y@ G0\>
M I5&MTG/7Z&)TXH/7G0D-09HQ*T3TBPH.$0=&5/O7W$V?$L4!+<D"FG/U#EF
M06,<ZV^SM8U[@^I-&MAP]Y6@FU-7"R2^?9=L"@-0*JV..+-7-WV?)'4! ^TD
MV%GKJ0U=@MZ!RH_S+N-"+=8"@<UZ T>S8+R]4$,W:#89WI6M'89=W-1/#.>)
M!EXBF1F;+B&530EF:'0-M'3]J*.\E#[]*7U7@2FR1Q9^7:>3V0H!9,]LJ3^4
M;'"RY-PDQ'SJWT%?>5->I46F1&W;).UVF<KM%'8O07V>W<AHSI372,SKI\C#
M-[.\FO9A'Z_)@%FC31ZCC:4UG$N$.!F864^ 5#G=RHX[L#72T8?U'"O\#8MS
MZTH(RCM?C.DAG/EQ-MFJ=EVV;R2&_^1%O+ES\I^&#^OD8 >GWL&IMP!.O5-P
MG<-K_?5A)?JCZ1>_([5A\,FW3GA#.+@.:/UO4T2I-'GZQJ(:]T,9H2MP*\'#
M:T:4,*]9[;@>[I]T7=(]EB[AQ ,YIY/50OMP<3.+5<.>B/4(URZUGIJ3_#Y\
MG<.H.7EC5?D.#:P7I?3\5<@IAPLYP+]&:^!581ULN5Z?@V3Y=<XW(7N/U# S
MG(L- _P.)(^5T6H77'KD0K,0Z32+ FUA7;\U2M73(//@=(9.8%+V2T6$+G)R
MS;/B.J_*0E/"TBR/WUC[VF+&%XW7RU0#B!K_DY"CY6\6):V*!:AD700@L$33
MM]:(T .7[8HD)8/")Y#I\M/V&?U0<IVGPFPU1T^G&A&[1:*FXGR](&&%Z**.
M _$Q()H*.CWREFQ>9^P' WS'T<7;#ZHU!LCYF JR5QJZ,ZF\S(G)G-_ID*[1
M-&*.=)6 ANOZ;F]*BZL<0=;,O4N6_BH'3U/87SO5@ &;Q=R*GJ3IBKQ^A_Y.
M@[[U?$*E)_([FDIF\0L)O8X.1@?<%B!S;42XUPMS&YW3>9C/<0]X 66W2,2
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M,_=5T;<G925(1 LA\7="C_ 2#\*/)FX#:M^[7-T-WM1!<F&")V@!Z+::5*L
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MZ<QWXFJ\#Z_8DA#4/5X'_GA8DN-<<G':S=8.P;22@0V!"^L TB@>M5"X^Y.
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M!&>G]1EYHP* #S) 87VA-YEZD)R&VZ/VY!L1DD'R"]U.6J(Y X]Q\["$_'"
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MM:6&6%W(+40,MT$9A.=\:JE9KE3TR1TEQ.,3SXU/UD%B1F.2(0>=$ATKY56
M9U;6V279T:[T)C[[])QL:7PL/BS!1JX%T2<SW#-GOYCY=F-5&LSENIO9BN,
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M1P:J+GP=2S>ID,1BQ5O9:Z][+?U=<R$'$>HM*PL(%(2U1+/4@!7[D*Z!!%9
M*W+G1>85H.;2U\(Q[(?;ZBD>I_FM+)-^H\'N1YD@/=XE2'<)TH>FGDJE6?H-
MH#@C5@P1-<Z>ZZABY^Q)X8R5,=W.VLC)2?_E35EIP>@ZL)(Q9@BZ=,IMZP1#
MN!4-D5^1J"F2G]6\NU#4T8NZ2F%88V(O7H-:X@7]8)WL79@O]I2D^/ T[L1
MGYSO/VC-I[JY6GT06.J]CW=Y&>'4\C=AJZX=80US.5U#ETX-H*K]3IR=)(U.
MG+%GEE5D6$A"S2LD:UD@3*;T5<M85SB0XSK[STHJW)>K\3R7ENIR>E\4VO")
M;?._ERNF!<!Q]"6ZOQ83GE\O^3;7_WC)! ]RC.5=ICE3[=P"-V&*L\V*-C/\
MJ-IXZ2)+?I.726I;W/)W[(>PWR1#Y":_L);I(#%U30&^Z.1OR=G!X#C0]/O2
M'P6*F!/I6=^L"G7L:51+,*YZ /#1Z&L'Y=+OSC-IG&@ENG/Z')PG0M32P=4Z
M2+ZS@X&A^[-$0Q^=F6CXP-;).9"M0YK6RFZ",^90_&GREZOFZ2FI)@MQ)()0
M8QZ&)MM >&-8GB29L^A2E<\@OJ@^5RIOHD+\HMQD._O2(LB8\V\G_>9;]9SA
M* \G/JS1-_.)T GIM2Y_3Z)??3%[8O]U;>8CEXR@.)RVX'#HSJ"&ST:G+C2%
M2MA5%42J<+NS0NM3Z,#PR]D U',8BS.5"0Q8E'+M3=,1=BDJV]O9? .H&CM=
M$+3XH4(7WL/@X(C135:$VN*DY- ("=?&LY9Q-4 8&.$+!'B\"*B>X%-=;&MT
M>-/,&>HN(2<W\>@4+]%O9)$7J%$P0=Y+BA3EXKT &N-N$LN24FG=KRJI&^AS
MQQA2[]<YO87C*"^_?TT2@"Q;FP/X_>A0I7Y'X[CB."^7];K/H;*L"&3^782\
M/$*9Q")^+_6&595\0_/E2GYP^:AD,^IU<H#T 4$KOR43L$64X)NB[FDR/,3X
M@B.Z1R)TWTM'>4R'C'PM>C26D&G;*;\0;ILW645;)?KTPI83^NB9&D+?L2'$
MZW_QYN+9=[V$243HIT>#@T,2@/%>XJUBS\DE.3S "X^.?6V1L-!?EF"LZY,W
MC+1)HY4N&-@K>]1W&A&G5UWXC4;I'[EE;]0ML\$,!T,>XZOO+EZ\?C-@>RDM
M@M< 6L6C.[%")[TGUNI/=6)63$6AA $R,IL>L'3BNQ3$8+0*)=JUB$MK1@+)
M@W*U%-+YBU]_(%-!2/ 8(H<8!!WWFJZ6[@R"V<&A:)C9">[P(/E)CQG?=NY
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MMN^KIU*(PF%&^WV* 8*Q':OP->J!N%[')95+L%Q $B]04>&+.CM?\1*OL$
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MT@RJ4>]O5#YGE75L+' HCD^@MWC$+\M3*UK#BL_8##8,FKU.:1=2+U-] [G
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M:01'KJU9]/[T5(357B ;&P7S3-6WBN=DCQSA:PO"55%DL*?-*"Q*WBJ2$0E
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MQ=!<\L[(]L#I8BZ?(+#5Z5T)(83,H!4QU;,=+D5-%Q5@A)L0Q/4&H8KD8@,
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M'H$PN'S74_!EU=+]+\3]S/L#2N!^IGU;9L&2R.W_==F$+RQ\MWOCMU/4W47
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MI\'@::LB9=//2P<YL](=IGR_IBUAFO:UN(63]00-=F=I[>Q(- _4[BZ9[PW
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M\J0DQ='.OH<_759%6(F[V>S%NO@0G.GC;[/9M^^_"[[_8OS5;^N6%N($01N
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ME4GGA[=)Y]ND\TW7G<*:A7QC S3^W(JO,GWO^.)N.,R#[CS.J@(D![X14>_
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MXCT"X!L+#M+T[M$VW<.^WIZQVS.6G+&_G;P;!$'88U!$5.(7I#;<#FJ S-7
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M"I#MH=B*6XMH!S-[N$<E1D2T S^/8$#:6,=7<8<[!NP.9D%H79^Y@RU<H29
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M21,OM1TWA-B]-+2^+<_1.'1J\P@!K$P]^P3BK)LNKSH-<4P4?QH"3H]YA-4
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MW4*T56@U.[ S@@G;>=T6Z$6A@04":KH\%)0R\8Z"50706/*=8FYT-*,VUF5
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M+2&-[[UWOMKZ_Y=OVB2"_D.)H-?M'.O@N,[IGWW#.3_!R%%Q]Q8#J]_MG=4
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M1GO&%/HG;M_:[I8\+'DTDL=AUSWJV2;/ECP>:7+7GI''P.T.ZJ9Y.]UC.Z>
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MKD7%%C'5Y7EBB]&F.<&&^(Q.[7GTO))+?"@8STD6+//@L@-91Z=-O_$R_W"
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MA&(PIW_' 0Z(*)8QT)S>*-\DIQQ<TG!%X@_OO(@F/;T/4*;AF(C,^1D$")+
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MHJ02QV43$3ZY$K&>RH4SA[&"6+TE0?DQX00DK0LI:&/V3ZMZ66FG$=]=86Y
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MZB*W_AU7^\'@J!0$E:]\P 9,*8\AEV\#BXRTJ)ZRR#D]B023GT6*"A2>7I(
M)!X%!W!PY J^.4/_D[QO@_C0R^-XHLB7C+:[5EJZ#1M_GSSE<SA;G:Y]E&VA
MD<O>@?D/!ZG.A'%FWA4@=K22-!<<8C5E53Q5.CV T1QJM<W!!N2-!\4SO6L,
MPR>ZHN]HIU[3-B9O\!+["M4>L<*9C;*_U&6(A_S2G X<]5:A=W#_9K.*JBA0
MD <'F>RAA$C\B[Z%?Y7HUSZ>K'<*GF(MF\>I4-BA&VY^H%U/6V%,,DJ*Q]I^
M.)*8F:[3A82MD1B<_:O6=*"_'57.>B61DV<:(>B!:!HO2R2ZDV0?Y]2;D.KI
M:'<:KBI?;5(R%HUTV-G927IV^J1G0B..G8O2<4FO,G#RT5.:DW)N.C( ;/V,
MV<;#^YF$>S@FX<8DW-=)PMW=R9^!88[] QDY2,?^]8#92L'^60<7>V;UA;7?
M5\3 ,WD+ZD/_I">_]8\_)[6<D55,TL4.#[T9*_L=P\:)=1<$-:J2O0R,WPL#
M3P=!;O:YA& );ATG9S14P7N[,.;=8(B#NEOHN!3.7]\BQE]&'4@:+,5FM=B9
MLL76.--\F1-RS=P\8BVE-EC"+T*0&Z9W$O"RT=NDO)\F>V!_K&R<SJW\9K!D
MO1ED0HQHTD1/V>T*ZS%HJ,4-&HYDOM/O)(E89$UC,"[]R -R5?),,,2JPR?\
M,?IC;-A.T<E@B!XNI7W\'-P H?JQ]G<D],G?IE;$9N&I#DK"E<WT4H$,JB3(
M;\C+W$P9F=.RVH:OPC-4Y3?P_.]1N&DO\%?AR_9Y5 L%PD>R[;GZO+1Z26;6
MXC6+"-_:R^?.D/=M^'5NQU$QU3?ZWLT\,VV/41C;[".)!!H:]+,)W$HZ+9HW
MPO('LE*R-VOEQSR:K/G8(O-0EWGM17ZU2-&G\SF>-%\$C0/AKC!"F$QVDBO9
MIG4^X;P=TD^QN")7&RT@W_[LZEB)1 ]&CIATE"(2$_ S^#SSVFCZ*.\C;\,;
M<)W@"+.G5M,)K;4%0OH,"4A1B8)#U58\U\S3B,/J@0<Z:+UL)1_EZTRJ,NDI
M3FIB[>G!H;F979(]J.2$5 C(;J8YL1Z'M57V86B!RU:H\#TM"S4*X$1AX8*7
M!O"%$3UEN(J=_!8^=B?MZ!=P* W+!5ZE*[P3DF\*B+G1#<W.A>>]5A<X;$>K
M\[6 _$(%,L5E)HM%'1%SFPM^QUJ U^SXZ"39$]\J_,"Z6'X#(W#/*MB<]S",
MUZ2@\=%[N*1_0Q*,J@25^.#1R?'!\9.'QY[W9KZN'\W2X[WXU( \Y+7F1_QE
M7!]9EB R[?>N-3Y9XH1<C>OE<CXQ4E!7[,Y0KC6 6+/3&1'VWT&>)"R#D(K2
MJRCCANKF&K6[8X@0.=U/:D8AFIS7$'^LEY\^_YGU9V,7R%N<LY,3/9+GU4SU
M5^_LZ,FY^XTM'86>C(5[J<'],<^9'7"=7-BXDMK ]AG_J:75;B'L@3"Z<&4T
MVP>P ]BFOC5WM@_A+<WMY):N6FN/CZ8VT 2LP6X]QTK!7WX=)A0&(P'QV>DE
M6#D[0CMCOM8)E?J#;.3Z7W7"^+8U2&R=KI\[B7A<,9UF/^QK$P,+0&J%K!#"
MV"OGM-CESLNKJKC2]IAQ^YV0C+6A"/_3UEV#_H0.X<@X NNCL3RT9C1!5L:.
MRSQK]>M9.HL;#7^35_478&^ROW<RN+YD*E9-NU("G>>G:#\OZ)ISA^@MAK4S
M1),8\G(2R3J;?A!ULI,7(ZD\"2IAM-C7[<3LEY4&S.D8"ECIB-))S?0()GI=
MH[M)YH7B[KY(>&XM2MUVW79/USZ-+#?[L?''L,\']T.1&S_&/LB]YL[)1#K7
MK]6ZG .2P8>(E*&C(29Y3(-X9K=_<\$/;I;*N'EIWZT+8_SR/=ABR5YJ3R2E
M=\<=*L=S GFD9JHHAM([$;-Z6=/!V_8'G$1"T5D79TMR^,(Z$2[PQ#,@(\@3
M&RO6($;,0<Y!"MR?B7M.5JF)7S=M-?V@M0E;:*9/9E:*C[?JAD]=(T??,AA+
M0%K*K/00U,V^X2<2?PZD2K%)')C.>>/8*"8X8:KG/%]A)Y4&G:)FK2$=#?,[
MPCRP4R3%<&,SLUI.S<2=C_<Y6,"5E&%<VUX9NK:9G4^)H?!%/8FM>BPZ%F8'
M(W]RH&22X79 .JQ-M[2%KX.(6,0A-H:Q-GQI>32C':R6J-2!C=(8Z$\Y6*BV
M>"O0-AO8:M;9D8B7]S5Z$-I+$Z26;0BN7B88Z#79X5B("S]PHFZ"UO,QY"R]
MJ'".C^%QN5\ ,"2_GZXTPAB+=P'CK0LFR,+$^C!%1LU$\-_DF94L@[(N"$76
M5XULJD4$X43Z00+R:RK&<,"(,$2#'G&7$YQY)Y71"Q$/,6+*X?B/EC@M4'3V
M66/ANEAS J;<I\X?ZFHEM97:;!%#Q;G:3=[=!"=-:,\3;%-JW0\)N_:'>Y6G
MAG+'$,A+*-15=08#&+M@N$<6F;FB#?V8/2(,9$F=<V:7D.0.KFTG*JJ!;W\/
MZE;\2&D:SI\&XH>O;3"U615-]0(U:S,6, U:-]3;6,&$R&>,UCAY"<R,3)'&
M@^'CZ'&:"]OURDK5^L%?8_C1V<,?:\9"GNE"(;@B;Q;W-)/Z:,RDCIG4>Y9)
M?8_@I;FJ,S?^^[HU]%"@\M A85518/L:M )5,]5,?S-4'?FDT_=NUO350?3"
MX9BI7/"NR;]2(X,;J7(9GL[V@-[E2YDD-:8#K?W '!I@*J"%2UM=,X"+UF!K
M_M^:3?)352],JHJW2THOU96^/OVO9[W4EU.)YT2@::6\>YZ@J9S*L,BBE-)6
M@JDC1"7K;UI-66--/DGKK@,8F3&DC/OJ#+1G?AC#V: ]"1?:2.M<@_(+'I3>
M6J08)B@CYR@C^RYZCKUQT[N]=U:U\TOY'9P)8>;K34GQM YH1AK::AG3^L^G
MH(#-2^E0AMRG3OK:E70NG2&&0:K"NR62:5LEQ%])CI-9ITSH*7SR3&5<XR5.
M'A);L88TM:U8XJWF)%6RIV;]]K_6&1%Q=D*$L4RW(BH[_)1"D0)KIM"];J5)
MVAV,T4)T*-:D:K/,%:D)#N"?'6&-,0\-1RQO.7Y\%X^/U(?Z!G?H9=I]"0+M
M"=<+&E= CEY5NA6'M]8DYC[[,GKD]FH$YN/5L'WS.N37JL7E,:44<O0E4\9,
M@^PG;J9-FHW526XA)>+YF9Q'UZ@-U<;MS2'"D#@E3:NTR][UI2+;240+QJBE
M<S\4CR#8TQ/5/Z;X;& L"XHG;GJ!7\"L2QR!LO]D$70W2I!GDA"KG(:$*4F8
M;UC/N=A1+_<>_[H!!=>"V&#ZM2KRF=$B4UOW:OSNZ+N2O1K+G!M=D:N?6"N*
M"E-8SMK1 7V)C2M32$RRL/!3W>E$FM;AZJ#=F&#G3 0=>N/%X$)67&0+,_HB
M_Z#<L@I_Q#02NGTH[B<Q;+>7%)([5/5%5NH1[+%6Q?M3TJ[<7''B*%[U44H[
M3)PBI;Y8!]5\;H(<YCU8L$.Y*.I$B"@MV>K]U'Y9KXBM(6EZ:"T.RL,AH0+5
M'N8)<6(6/X,?E\H$EAR0)6Z );NP($8^C+/?.^[Z2E<LQ0PH:$I_=S&7E-VC
M=("-UJR PTLMC0/E7/,L1TWTE58:"_P-@#1O7)1F-#,)_SE5-07<==+0L\38
M:M!JS"089YT/H8L-4P/.!*;K G(Y&,BL/7)%@PPYSSL/ME[3G_%>J!E;$3ID
MF!7.+G0%S8*R@,&^B@PA8A'S]=(4>.W=49I+*)LTNL:)[2$/@6J>3N$K99AV
M2I41MSD8>X6H WZJ/:V.<)>5"P 5X::%] *))A(<I?[MK<QA\FL578E%-J/R
M=NS39M<_5*N8)YC6.2<%A \=H8+R7_.YJH5GK:>\&SMD%Z$AG[DY>'.Q]R7
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MZ;UG%\"FV=VH5[^FSE$&0=0V_GZG:)2I%J6*TKPZC5(W,EY9=[ES2%;T; +
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MIX)[=L[Q&AG.E+0-3UDL:7,.Z)CL@FD4V,KP-F1SV99IM$)&LADX36H6M7K
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MJG\0.*KOXOMHM%N#1F_4?=*G_>-:*;WFX&E:'741Q0]A?%S,@(=<3&:(S?&
MX!P_DE)S]+KH7H*@WVMTVZ/:YGC"YUS;'+7-<1Q2XS=L4?B[BL<D-QX0Q./)
M4N%Q:95[F@9@%C0ZPV%M&CS=0^S7M=BU&7%X@? !6\@'[]4L67\^:3\@.,>/
MI*D<O8*Y7^)4IS'H/GCB;'W.M2%1&Q+/SI!X'=[&D^!]/(MN3MH/".'Q9(GP
M":J@O49KT&^<=_JU'?%T#['??,!$Z-J..#[F_S3LB(O9\D9E(5@2$UQ/\/MR
MTCQI/R#@QH^DL!R]GKDOMGBW?=X8#A\<F:,^ZZ,[ZV&-[_1<+9%-ZSU>XP1;
M>BC3HR.5'AW4P&-BVWG ?P(\J$4 %DRP@%^D25Y;,D]1">Z,&MUNMW'>KMM<
M/.%3[)XW'] 4K6V9[RX^7BS#\4S]Z=\G\>TW3Z33M-MYQAOSB_/),EWP/^'O
M&^[?U&ZVS]7\Y2+-XV6<PMS5+$2&[_:G^LF;G!7-9U$Z2[-?_J5%__=2C[CX
M4C$<O;HY4-HNZ_2;V/DJS28J@_-*E-FO(%PMTZ 5M/"]+^#%^K]IG\PLZ$F<
MP2Q<Y.H7_8<>DI[V);.L:%2F@.T$1B<+\]]"8A5C/N3-T$?9[I3/<H,_^V"S
M^5WE>;"\ 48%A\H$O^"&H: A_'R*W3+350;_;YK'!G!B<8(Y%=Q7K[GA@NQW
M_M^TP%F<*'LS.L,]5DRS.IN%:UC1+]/XBYIXK=V$&OD4-M)CF0:_:1D/0<#4
MK&PK3;G2Z)NFR__$@6!6V3R<\2?284X^^NE/KT"SC/-ECB1T$I\R;8']W&_W
MP8;N!1>SQ4T8? I718(BG?4D-H^T1HU!=[#E]_EJ_'=0< /@0^D"^5B.FG 6
MQ3F1X%V\O(F38-#B\2;AFN;T/LRB&_ZHTVX$G5:GTS22N*;FPU)SYYBI65H%
MW8LB&P&L/[H)X.N:.)\X<7:/F3@-JQUV@,\.^ENH]$;-M'-@M@[&Z^!]UN1G
MN6]-P^'"@U:WT>ZW=XU6'H2*UH<O\V"2PDIA\X-%F"T3E6DV;_C\8-#H#[?-
MM^;S/]Q5ZCV)J]1O=7<P_(+*4I/R\R/E_C&3LL#)UQ3YG"AR<,P4:9@K*M/;
M>*6KA=R%618F, !0Z6(%I!?F*A@V^IWS\E/?JF\+3[^55_?:@T:O>S^>7BO]
M/\YE&A[S91* X)J]/R>*'!TS15HS='3>:)]WO\H,96A;SPP=-<[O9X7R&,8*
MC6YB^,'R)EP&,0;#YS%,O^':H9W^H-'M;_,W[GI'ODA7N6HXPN.K?)C7*.K4
M!#\J[<BWRA68G)[;.=@JG590*5J_=N4/(WMOS9F,VKW&<+"3B&!FER'<Z.!_
M5+)<P=M?A8MX&<Z"=\FMRI=SC&K\UW39+,X?26%YHX)KE:@,?@YW(KP6#P40
MC)H&4WA9$L7PG616X,3W>M=F=LEA,B=4%\U4F&& ]*; UKIX"?T(WX-'03'D
MHS(=UNOT;"A;PMGMGH!_V!C?__U_[15I=-8EK+M#W.Q:G8TS%7X^"Z?PZE_"
MV1U0A*QS-&IV>I8]ZWGA3@3]YFCT<V#_M)%'9S;S\,N9LV5>1@T_I3^B^*_^
MK!0)_:DPJI$MW^U0G(0"2BIP,@K"X"93T__XZ5\^_?&JBL'OYM&?Z"8"\0*S
M7L*1YX8^PS\YQ[N)*OT]K=JL6@EX5"7@_$DH :-6XWPTN+=E-V@,^J.'M^P:
M)==S'6)\?C>GW7H25Z?3Z \'H/26/!Q6&5.3.$\3K8CD_!P6(P0GJ)EU6@98
M[G%71.<R45&:A7AE"EI!\5NDS5] >5 9_E7ZFE^6I[-X\A(Q KTU'V9]/_TI
MI_UMOSS=R<JZO7YC-"HQLXV'^" JON5PPWX#]GSCVS_]$VY2%GR 3^=A!?T4
MON<U%QQDWV3C&///-78,!N0#^-$J1M5:/] 4:$1W"2OU^B!XK<%OF"QM=T3/
M9.NC^@QI@T)<-SP!5!#<IDM,H,*/8VLEP$-1IG _:$$!/+F0;<)W5(6:#(G1
M <*K,[PH=)3X2.5$YB$8URJ8*#5GH_(FO%7P2:+ H"'+!M>1W\0+''"_-WM6
M>^&EV[9\'OX]S>+E.HC@5F4@VBBO3.^C1VT/-/?2=+V7U%+Y:*3R4>>Q,2Y=
MK2<^*XH\ZEPTHR>>MZK"8&6/G0"A&5[H:BY?0=X/X.O34T2V?0F,/5X&;T$/
MS(,3$)D3X/ )\/RQFJ5WIYY.TVVT1JC6]#8NNCABHZ"R5&IJG7ZWT>N4C-6-
M@S:#W\)Q%JN9\0"^)_<ARO;GH(K_]NK]H=1OHXD:M4)O/"@6<Y@,Z9,1<($0
M:#&<3N-9'**Z.67Z0F8)Y!S?*KP'.,*/>D@NP1[ZM)K!A>C$0#IEU<YJ=:"H
M@5['/\U5M *-,=YZ$4M,SE73Z1K?I+,)*YF;/H<Y-8/7"O@82>],78<9E3W@
M XX"#\JN]G_B8WO,CWBDPT'#Q2)+;X%?P&\UC<;HA$_@,\<^ %*>Q\NE@J&1
MJC.8&4TG4ZCF!O,4AHV327P;3U;A#)@<3(>9<M5^A,%<S<<JJQ6,HU$PCCJ?
MF!'4:D7W&=#AT27CODNBV6H"(]OZH<9YIPN*;G^C>O9G%<Z6-U'H1&0O%T">
MP"E___U5<.)(>?F\X,^RCM=VKT->LWN%QHGK\\ @1Q@QK,F@8;Z:8J20_+IQ
M,'>1WI_'\!)YV_/G]$X!Z3:"UUI0\3[A$F=A/,?!UEM?GJE%FJ%&)R]/$9&'
MZQEE/^ JX*[![W$LV*E5$N-L2=+"G@9T(&M>)SZMXJ1AIPS;@K*5_W74O*JB
M</C'955'EVQ=P()Z#H:?+/G0Y@1R59HR\,O9*EGBY9[%_UC%$YHT6!N3VV;P
M_][&P:L;X#<9*2*_S58YS*6A/VL$OX<WH=CK_Q;.%R^#5REZ^Q$Q9;%(8XI2
M"/]R+ 8:3)\]<!Q8$; 1>$@^,YE1>D;(]MZ)31.%0.WQ$DQ/FJ*>'HXL=@O<
MD)"2BRA'!5Z6 #>\"6=3Y[7-X*_ 3\DTF"EMCFQZ/7X-5D>D<G2&S#"=*8AA
MX/ VC&?$PL(\5TN4N"1[4?[@]S@G^#L'9FC=0Z>P/S&,@?("U,4L'J\D7VW;
M+J$E'J'X"9.(%47Z.=I"8G-5S/\"F<9,\7=YGH(TP+6PS,3'S02<%=*7BTQ-
M@:GCNR8*;*R9FF@VOX6=5Z?\D#IHDHV^2[8/OB+0?'?LO4$NP!BV%"UZH(T8
MQ"*(6:"<,+E6=#A_: GY[R_&G-#S@)EB C]$TZN:-_/>3RE!!GP&+@Z;?:T:
MKE1&EQY*]S17J-70V;'L#,?I+?X6T0;H]^BM09(S)'+YYI6<-USYBR0!:S?X
M2 I @X^4M*:Q4DF0I'1Y] 9%M$'R/@_E !0Q1ZO02ARJ"A2C\KP#$[#PQ1&P
M"$%S(!.<1UNK,!,DA&/I'_?4L@N'=79AG5VX-;O0Q<'I-H5''I8+_P^;:!])
M/!^.Y?[AF#W634E:T3+\3%R4523\EA.4TRP7Z2JS#RZN,\7.<RU4+QWFAY]I
M0_%RM4"N:Y\ @TF!51J/=:1&7B>J[T<\0?CJ0Y@MU\$G, WS,"*GD;0TEQF@
M<&=EBP85#4^<F6*( G.?KM U# Q\"G0'PX8SN.>3-4W1FG'3E$)2"[#=)@T4
M""6&CFI1CO,BT0./3M#<HQ%D!T7MJK"SXZQD^%)1 ?H=)O&45(YE,,W2N7LB
MF5DGBSA'/2*Y5T#6^3__GJ]\6B+J&#;[17,0+XRV^HH65HI 8]@#8;5X2/+\
MVBOSRLCB5YS\ <I=AA_-F6$<Z@[]3='A)2D<XAW^)2Z#T,Z.CQB]!7C2Z /-
MU3]6Y)0!^FX@B:QF2])PM<H!@TB.BW99O.+(U/=1%NYW%!_5-5X N"#!GYD2
M#[?]OX:H$::X=9FZC>$5LE]Q@M?<F"ZW\81MC%6.FAI>FR4RE"GRJ&OB1>'F
ME#A6$^_POSK#/D9W] 9LOXJ-X"1-E(VLG+Q2$U6P%D\YO/+7)$:><KD$DLC+
M;VAH6XKC/U]B6)H"=M9NGK<&/^^!MW7*E .&U.0_?OI56"MQ5I>Q7O7[O6[O
M)Y:\WY_*7%T!(V.S</U+G!"+&L_2Z+-'"8YJ4TFDW\=Q(#3_:Y-IG/62[;=C
MD]0ZH&T%%V*:SD#"DF6.],:2=Z$M_XQG?;:@62^=60/9LW C79S,+_18Q&@:
M_V<(UE2VUDYVO"UM%GO( N4F<N PU_\<IV%&WF2#+]NH0J!-/3%'T4I25/H_
M:PX;S<+<7#R1E$X\-5RRE0A[2)%6=)TXZ_K>C'230Y$)#0,,<51%:)4ZC6NA
M/3SQ=#:M8<!:(FQO^= "V&A45F:4C6GB?@G<7?NC9O!AE>4KM*67;-Z'CD<F
MM!X99+X@_Q1H0* KQ7/0SV)F<(LL!E(0Y]"O*Z [=-& -!P#=V-GCHZ""RFX
MJEHCL XI(7$"$HJ1-Z/F)JH5Q]5QNUW88U ,TS'YYC+Z";JTRCO1#!!$^1X#
MJ6R.<X>IK- %APM#SP8Q[>G&=1XKP1IM7A3>/^0&?U^:W<'P_CW>O(:?_O1F
MOIBE:U+-[.S__47\IV;PMRIFI^SO@1:1W$%?(UE<6+L*@<D(&99YFG4[(@G0
M%: ';!:&<5SZ;T3*@1%(10'J@D6@P=QP;!M."F%?<UIY7YL!"(%<N5,6M0@D
M0X;Z*[P!K:,XG=#4;H&QXQHG*W;CT\\T[8K4P+68 ?'=;@Z@]GO#O5.WR )*
M.]+0OC'6CHA5<_"M\$-V&*-&'"<KA9<,5J7P!V,,JN;A#!4=W%V.^BVKEAO.
M\I3&0%X1K<"6G>-3C@?99NTD:8*><;6,A<6DR31&PHM#=*&1_]M1,#D$BZ[#
MN40-,?*:D/QTXI6T-GPL4B'[XO0F^N]SYR21U5D\)_V0#61+!,$LO'M(SO!@
M=^R/A>@\>*LN25LPQ&'('#]>\ Y;RD%OK"[PT$DBVT+HPIAWH=C#+% %*#X=
MYR"?<".-IP-?(:\MI%ZA2GH&IC5?7[KQ9MJ/= B[>=N7:#5;B&3$,>;LSK9Q
MCQC85X91%#X;U U-G&2!]WN)1A*R/1E*V8'6=@3ERMV8I#]NNU;:3G1* FX6
MJIPZ)==ZE-BD15WM]_#N5,MX=--@@%TB\#PC)XSF/=4LT(W'MHO<V<[7F6C#
M+%.<]'-VOX0!NH&9G;/C9K+B^TI)(C"\??,>,X=K2EOG.->(<,V^TIOW&ZCA
MTJ1>%*Q"Z=QJJ_,475"SF!E/3#:F%F/&W[2'&E)(D"#7!E\:=VSM$HE *&4\
M<4-VS0H=@W'-B;P#5W&HX=)WP*5_E[#1@WD/ W8?OE? GDB)#R<@UZR/;#*A
M'0EG!4\G455^DZXPKJ:<T!_Z81Z1TWY% .U[Q_'VT,E_U%#?J [UU:&^74 B
M1V@@@PJ"SF<4_Q]!K)/EOS.:=E#S^8\D^,_53/QZ0_;K-= 1&#IKR?1:V-J-
M<^+@.Q?6H*C'1-SM%XLLGFGX6WI12S):)Z"$<])-H'?PW<<+73@FMBO:U/,4
M-18)96+0LL'R0VM&.UWT3FZO-WM*$SNI2E8E_0@$DAF;LH4RCC!(>HHS:5*'
MW*HA[_><540\"#?%F0T'6C*Z,I?&LVG! W34DL4FC@7:)/L88/UP7-,8,V0D
MFB!F/!T:'P0[UC(,1N56E8LSO<RQ<A6X3>.8MU'T"\_A#F4\Y^$<I6WZ%K@1
MT]S;LW;PFO=,!^/1)KI8DGY"#@D^F/;(K4FPOO0*K=EU^0<GL,? OV8QC$'>
M/@HMBP,E"^Y"H(=,ZT-H7X+NY5CWHFP;LCPM:?3 C-Y]^,/B"U @,KC\</'*
MG8A7%&DM,(=&3XD<MB[LO<HP_]P/^'_;>AH[U\-KT98K)1]&8:XP,V$9S]A<
M@G<Z^50<K:-C:_AOLS$T"R4@:ZN^:OA5XN7HV['2K!R-WWM<FR?9L!YN7CIY
M^;8>%:\*Q*).\(?'^8?(WR[A[F@TEXO@+2/0@9JAB\JDO '..PI-:!0M?CJ)
MNPPMS<0RA70[$\'0JW^=XL0<Y]8]: 9_XVJ?=L^O]F&?8:3B!>??NW.1  $Y
M%MP)D7":K^!'U^@!TJL0KZ89U(Q#3+UX>IOGRN2W0LL%G:MDFT^G:<8.?YD4
MO\+9I&5ZK>@='!'#M-F,IXYI,(X+-7->ZD2PY!;Y\_Q[&B<4Q$OT+O"BR-\"
MNQY/8V;7LG;<CP3_3<X,>L0=D$/B#5UYU6F5SP+%M1:>,B@& *G<A"=U:IX_
M=YXG9[IV!. T8Q%XLE\VIK>\2[V=RTM41=G/VEQL&&&3D"@MC8R[5B*1(!9_
M-?"-*%ZP#G)]C3[?I>+<7S7)36HRB#2X8;"Q?[T,_K4?@,2:$1]-%%$EW3<D
M,W*1@WT*=L>2/8Y4>)F3]Y:+@^)IQ6PB,FYQ:^!E/&].9'#7W6T&;U<9'A=N
MEEGWA@TMOT1.A5)/R;-O($R]$KLQ9SVA$^\ZA1]-0PIF@$(WE[-WZ8 %._S%
MMT))N@&F8-!/]"M\D<EBE#Q'-%N\IC)BPY]TB:/ K8&M0+<6;'<H?C#GWFZZ
MLUB$PU/?^6.*!6(W,\I06R7(P='G3.%*(A8=JN#[RYN)\HCBW*#,\9UT)HBW
MRB:>B(I$&ENHM4".\G!&L[OQEK5$(3*=\L$ZRA>6/@/).?MZ]#I7=Y?.=8=B
M5XA=S>+K6'0'W(S0OR$;E=MOE/Q5PG&'4"Q>WEH4/F51V.Y_FRCL]2M$X2-)
MK'_M?*7 HG\[.S-%^ "[E^5L8!/**YKYI_N)+KI'],+"U<&8$H9T&JX0:W?.
MP-I?&@:\P,MA8!;TZ;C$T#!IOD;&5FH;!:YRE"ST0WQ]O48O)^98D,01UOGG
MK[! T!@@?G@;SE;LD7<UGK8F("G6HN!YV=_@\!%75HI@](G9%X[XFRA-$A79
MFF324U9C6*V5J?KF\Z7[0SMB+L5YXT3"+)G:6)BW-YLXO9-64%YA85E.\N["
M'(>>K,X@F"E.3 ,Q)FXIK8)0D)(=6^F*[B5;?V:$HR2\5ZLEKI.)[1U?177K
MAO\L>T$G%@5Y<IWVG'U6'&4,.1M*KC^0'B4U&-E)>1 KS!6D2^QDQZ,L'BL)
M:[*Z%&I7EY,I:VFF>)^M#KG5UI=$?%*IO+=Q(+LHU%QEPPN* E$#!2"9(EG"
MC_.IL'>[X@:N4!BW=BCEOP _S)!I?3 .PDW7U_%)R,WRO*\O47JFR>2>0R5I
M<E8]G%3093"BN835 [XL^72<.+I>(,_.CLKW0(+'6%=QQJ<(4BZ [0XQT2<^
MU.T0DH]""5U67'TCX%SA)B2D/<(.?2)D*9);-;T7+A2Z@SCQ2@^%+EH$(?)
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M9)>4\1-$4Z( 6*=]2H*F$*.V."592=)C**WT1.+(GH9QPV_]&=%;[!A7*-E
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MQ-RQ&\&N1-]SO*7BDO$T2T^K],JT,'4K4S<J(8E95C+'3E].7\]$SX'&KST
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M'2>#='.O0(\EZ?Q'(PV^*7MT;W]1)>=TNZ7N:1)N/SY'V8"-F:2PU7BDOH(
MS#9+0:7C4)C5#V1)6-NP)2@L'H%I/-/8WZQ@>W:*M_V;M_Y0@:'[^U=# P?@
M]4E"RH&#CC.G<9)_@ <K73(P,A@7*/E.Y6[SQ9+ >AI]WI+-9SV#>R2B45QU
M*Z5BP&1&QN-J61#Y59?);Q2SNSR<P6FKDNOVF/V][ERC#(=.;.\A_!,[$&_+
M<(25J,H<A2PA#>V!F%=Z@:GYC,!B5Q5&M8LRY^C4.@O*]'?8SR L,DTWS^J.
M"D*DF8#CB=RPVL*;=\=)9<J5(FC#/O@N5^-A-W/,2PL@1WG)W)9P\&9*9<_0
M3@^ <8=L8><.;4I$VR_3N9!(N#N6/"/>]SW-L3LUPQ"O(#]JG'.JV]K8KF#G
M,>V35M0,_M ?$-JDA;.@9PD%%>T/<Q"Z005,2JIGY5 VKU2W;-DQ66<;) @G
MO23\2'YA6^ZW(3XU^6XH:<Z!*0G:RL;KPB"T^Y"<P1_83'3HIH_353Y;5]#,
MM[K:]/4Q;6)2V+PIR9&MYV,KXKCWQM<+AT:%/]2-WW^N]EP7U,:L4JK= _.*
M)R4809M1@!CUAV+R6X>K  LRW8NXNQP7:9E^D$7W\N8>9M;Y2)>L^2WQ$E[*
M'J?$_ZH.IQP-#N&G&[6',H(N(U8YD1N@O,!+N$%_,X=FL*CH8V-M<$0TDSZO
M4I_K>J U6K/AQOP&=JB)0A@G>X9</^U@W31'#+"H+WA$IC1R%M/EAKG])<PG
MX3\:I1_QC+'(/"AN056[5Z_$%',#EAM1&?=LH&NZYOK[N4?+V6;PJR#9[Z.*
MVL0L"KJ0"EF19X0\J>#5S2OC<KYWU<D5P?US[9:J-GJN]W%O.[A*F=8)3;[7
MLF(-/MB88$-1(AJJ=_O='K-QYE0/%TW8ZNK>8SGD__;.J>#JYCZ:Q^KJ?DQ'
M]%?8>3O7Z/FRO^E6.#51WI%XR)M[+*'"F^4W"RM4\FU7\%P4?HDE4X_K*>\O
MVS7ODE)VAS-M*5XKOZ<P<3[OW.9B-W;L6$4;)5$H]G6L;5[[_9QL7^%:@_^@
M6^TM?!",!ITVAV:,)XT?#RD??6XSCS:AMW^+Q^UKD@OOX_RZIS5(:3F<7)L6
ML0K29+>0.Y1[K03XRBJ& .ZX>2KH*$7/C'_^5;@HWY3VB9N3*;)7X5\R 4[D
MEX2<M6?ESDL^-!<0X+ N6>KYM\Q2!*4&!H3@.6%E"[YO28'E$8ZYA=X[AX%\
M-$>+M^[7,/J\6@1_L\T@'P\AM#"Q#33GD9OM\.R6'V^V ZO:K. !FDY@9AC,
M!O6<1P9Z]^:;6[@RS\0F&S&B!=&03S,:W:ZCT74T^M#1Z+\F,5ZFRR5YCT[@
M3C=<$'@,((/)FJZ6B/;$ZH_[Q"G]FL(GW(V=KSLB$OCYUKH^1GW!_D[(*N)%
M3#SI1"-]NR5^ITW-3=W6NB>2SXPE<M213II: &F?^KR-Q]1.\C+(-:8\YV["
M,XK]"(;'$8%;+<(U@B\@IXVG6F )2+H#R\GZ@M8A6*'ZV]DY_R%#F]Q-&),D
MQ;7$$S9FY67I9Y6=4HF1VWW1L6+&I;WY/N4I-&9<*5>0^Y>G(<Z4PV@K%12C
MFQ?:S' &CK 1%/HU@IJ&>=5Z_- ]-@RG%L%HB9'O?:F-1:(8<X8;6S7J>D9)
M;["TAL,SIC[AY5.NJ02=I%XQ+,[8)JMN.@A*>2W8,[XYQ%V0.:E7WFH,':1K
MG.44S)HXO['Z;+GRXA@4,PW73@6+EE(/A]*NBQ=+6K1KB/ \Y8;*X9'B9:IM
M9%FVZD:C'5J7@C@?X2G]:UW+V-#<SS:;,U%E(&OK!15 00X\Y>;MB 63X[0T
M^360IH28K/%TWAT9NL'8;)GRV3IN[M GJTI1"TYF:HT0+U=+M7%K"@Z?7/E:
ML(7Y65M,8^EV%T5<V+ZLK';B%PLDS9X-R3=SW#C;P%O3,>B0NM9=1\RKPR;
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M;R9FMY>N&7 CEGWS2!&,;ZI.3-001R#CBUYNJUMI]YJCX=/ \//A\FZ^;1-
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MUJ&A^7DJAOGLP_)S4%;?1=:]$3<>O/KSU(T%4^^-BF&&\TAX]=ABX].(AN,
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M;T\E:>ZM6L*6*[ UOPWG')KV?.,_;WY/H(CW*G3KYA!/[WI4:V,=O'@S5!E
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MB^8N&5:XI%*[SEB^>+#12DJ@F') !9,!9"V&NB00F8,T,0+X'Z+H>>C61?3
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M6?H1;^>-6VKDT&>N#IO+/#3TG]IN0_QY9*YO"_B*;@%-4EP+HL[;L@"YT !
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M=XE<W\>;K9R7-UNA(^<XEWG2N<QXH0%SPV<2$PS4R9H]1:(;!Z7\/S^7M3P
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M4]TXC?)%#&'^F6KPZ06TL<'8#UJZ\X+YO2,WIP@SYNWS@/F]8QBG"#/F[?.
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M,[#1623Y!^*PK=4]L6Y"M4W;O=KPYV9&Q)^1Z5"2B4SR8)-YH;DDN<E (?2
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MZ1K?$*<\>T<6['8G54ISQ5PG6$ $ \6L.IA7?2LO9>LKT>\/QZ56NHF&1E'
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MG1&^&LPC3HKJ]JGJQ)P9^F@1:<Z'4&SA"$N0B5RP;]2CL85K5S><.7KB+[9
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M?^QJDH3D]1)#>&8, A!&H3WH!Y0U^$DYR7<SM?N&*0,SY'W_%SU=!BQ#4^3
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MFZ35$ZR^/ZS^<97T+^K5VN4&GV#D=DJ8B9K;C,5#2Z=Q83VR6' +B5HJM13
MM#7,%[I+E>HDT EQ.1J:G7><Z4YXQ,4+TNZ$1_AP-M#1<<^>J/Z73.*=MI.)
M542THW;<$A2FE"[),:EC]<_,'=Y-8S=CU=EK2TV[@N*4ZOU"-M^?3CPV$<5L
M(LI=LK^<SPC$1R5Z=\$GR+0E/UPGT9#/KB'[;]K2%:1?O$N70\GN8,AWK&9!
MGF26<F'T_38,?R:X(M%N.1H+E2W*'?>LVC2<:+_$O< ,&JAT8C TJ;\B]5=^
M&)#BKS,_;C+08YWY9T98^.O,CXC;A(<]QID)#WN,,Q/<?HPS$]Q^C#-??_#4
MM>J2'NO,CXC;UY^N=*WJHL<Z\R/B]H/J)+?J WSL,B!^"4Q)L0"J >J(IBGJ
MMA6PC8!APG>A@B OA904 ]U%VC )7Y+PY?TE^-TY5C\:DSI_;<.;MJ$,M=\V
M%/YVU5('A\DW6B5FU."=EI*4YYUDK9!/_'FI@VS:EA<9]\H<X*'1?$%X(8;L
ME3]L9'UUL)'T)THA9K0TM,=.M\UGL_&7&=MG6XQ6[]%A5 H19<+!<)@4,1*!
M0@0*P6J"U3>%U9?MQ?VY4/V+L@BE*#-]:9BH4FZ?DUKNI*MIRI_W]?Y(1+9%
MS0$?2,B]>@EQE@9TLY429GRC)'&V8)@<EI"H7H*EB'0DM1+W4RM!I"/)[">9
M_02KB<[G_\S^J^M\<;:52U02LP7/9.CY*V.FZ1!;OY*>%I+&&2L^[;G4;"D-
MC;%4S;'2$.EI*.__0SW-GUG_%PD (0BC1G H /0FZ!-PH*8> 'L1(OQYP)@B
M<)TM)G07_.!GDFFO*](>47[=!7+^3,;@XR+G77,1$HZY4#BFNI:VWF\"W-Y.
MK<&?53TY>R)(HRU"B5C8J2Q5D!QR&34/!LO0HD='4) F'(S'+NB$(E+@1ID+
MD0($.0ER^M=XOL6 R1_+L)UY3G<'[(LQS6A\L;,<CF="C^ZC,$H$AU$8(L'N
MIHSDS $2?S$)(L%NNP[DS'$.@ISW@YSWI5[]@*?5U^K53\4F_D(EHFJ9M*B$
M.G'5!='VB*>;DS@_1"H1BEA\J!(]=A4+AFNH+UI AC@QF0+=PKA RE;N(B.<
MQ.9);/[^\C'O'*L)D[JKZR1,BC I@M4$J^\"JXEG?]-*-R$CDPOMR6H9[[P9
M6U?8N$KMV58-  ]A03QH G.N2, S@1M ,H8Z?@JVAD]8N3P(]T&(JZ0%T'4[
M<26AE^?&HD='L>,_$H^2 @I20$$** A6DP(*4D#AF^LDFN(E(A*^Q^K;#%)<
M4;NC7E9Q/<UF6-Z)V;U)R"X5[60=:7<HAO&Q=O>@91?HM7!'R<!VM/"Z ",8
MT($=^.__/L\4)5)J<74V<94DZ1\=A&V.EE-%GE4!Y?#ZJ"DOBBG[<$39'Z1/
MMP!\L2F:KK>/#[.IX<WB/YU*EV8 RZQX<3%00;V1U^16K]U4ACTZUH,L*1J,
M4/$@2]$DX8RD39"LU+OA,W^D*'V-TV"=YYC1[)2?ANHP\6@-%"DE+"Y&M"4M
M7]L)Q&@B3[\9+AAC+NC<N@N*\Z-P)UET1!SX5AP0Y"3(29#S3I&35&X0Y/0I
M<I+*#8*<OD7.^Q+KOJO<.$+.QZX^J  [H!D6&9+QW43>OF'*P QYW_]%3Y<!
MR] 4.? /"O_G=^PG@>X+!;JOC1?739F\]ND)51 F^*C739@@88*$*@A5$*H@
M5.%'JG@GB__:>''=+/]KG_XCJC@"1^!?UT[D^##IH@%L4=&!S(NF#@%EK=,N
M^.(H8>:FO1=^UFW%VB,V)-1CWT^[J  [KTO&!)0,"^530-#!)YQ(K'@-F:MQ
M/5O-"-FY\!H;3R/QH3OLT5R/CC[]YH(<QQPE5IPG:Y(PG(\*+*Y-<M<MP+CV
MZ8D8)LJI_PHXKGUZ?XOA,U=X[,1GQC0F*;@117<@2*M3X.W#@BLT!T&Y9ICH
M@X1MFTK?L5&B9LNH&#K:O6EH&ER2A^<P@65_)(J'$::5;[8G<[Z8T4%Q  31
M4!=(%*,"CT]%L3]K//S%6*Y>J_'S1UZ[13W681M3GW'-:^# HX;M"1*\=0 1
M@#PR51#62)" L$;"&@E5$*H@5$&HXJOA(8($;R)&!""/3!7K& 9!@C=A#0*0
M1Z8*HD&=#FO<'4 >NT0C*6JHVY(5$"W4<2D-))S/$&#I8 "%90+GZ['DL[#H
MH[5A/W\GIH35JPYNH"5*O]*6W:6>?*&:O44Z41X[8D;]1NNE36C1ZZOD=4$Y
MT53)#<^+K:60D/A9@C):-E>QM%P"0@@U5:+98(R-!VF.-/,E#2+/G/QZD_SF
MJ^D#]\-L_BB- 3]Z9&A0Z;*\S9QJ+0G:CCQ9#1,J8\3U>"U>$%_,.N(XD:??
M$388CX8?AML0L7Y%L7Z!L?/U)%_G)HEZEVI65^%AUZQEBZ7ZQ82W.M2D.%VM
M 34TDL=6-#/2DC$LO-$ >2H89ME@),8]##D1X?V0PINDQ!*LOC^L_G&5]"_&
MV;AJ.;\:&(.VX-321DV@5*8VO+ >^5J47X:556$LI/INPR[W!G8NND#"#PV@
MH6-!.GS!Z?,^(PX?5:_="8_PX0R:H^.>/>W]+YG$.^5F?4O)O";K^9:JC":Y
M;K83+G5RWQ]V=9([O)OH[B2L_'0PS=&\DUT4',D.9]BNQR:B3[^92# 2C9.B
M,S+5Y\Q%9?[2)8B&3#3D6Y_J<P7I-Z);]>6KM'2I$$^E.NFI:T:S/R6X8M&N
M,-'U0H[J)*NY11Z,DZ,8]I-Z%5IAYD.Y12JT2(76NX[BQSKSXV8$/=:9?Z9W
MNK_._(BX37C88YR9\+#'.#/![<<X,\'MQSCS]2>>7*LXZ;'._(BX??V!*=<J
M,7JL,S\B;C^H3G*K/L#'K@7BE\"4% N/7N^(IBGJMA6PC8!APG>)IKL>OD[J
M@>XB<9@$,$D \_Y2_.X<JQ^-29V_NN%M&U+ZH TI?=UBAZ4["L= ;CY0B_WH
M?"G/9[%%8O'GQ0ZR:5N_WIG5[A5 ;&1]=;"1]">*(?12O.O6V^&4F@V'DK'B
M)%U2N$2/85 Q1#Q(15B2#4K$"1$G!*L)5A.L]LUUDLS]<V.U#S/W"5:3/'.2
M9TZPFF@@_L\SO]B@])MTLR.3'/7<0F[V-Z[U@#,U] #8\\/CSP/&%$\LN8?\
M[#-[L'R.UB18>E/!TC,;@@0Y?7]1?N0BQ.E](:=W=2UMO=\$N+V=&QQ_5O7D
M[ E7^&(U+:?:>CBMAMABN-O,#8H+9]%C6.0*YZ)!YL1PK[N@M ,QL/<]&O[U
M0:3"1R#8L:+;2NG]D"-!B/\9#':RA22+W3*FW[7^<^%YEI_*U+]H!M1L33+M
M(J,(:G'4F0^RH92IR7]>-?V1A&R+F@/^6$#N:JL%8RJ&M'&EQ#M2MEU4VG)"
MK]>1@,2]@VCZ <3C@Y0"G#FPX"\N<4]6TB/F\I\Y/D"0\WZ0\[[TJQ_PX_I:
MORIF&ZU5-Y^J"<UNL;IJ#B>1<2OA*YUH(;%S:MBQ;;Y8-_4&;=+327R(="+4
M;^9CG>BQ2Q$P8$-]T0(R1(K)%.@61@92>W 7:;TDJ$V"VB2M[L:PFC"IN[I.
MGSCV;P@JE_+U^XT2?./^]S-N/"Z)/)I8)W&#3;?5A(S,.;0GJV6\\V9LN6'#
M+;5GMS4 /(0%\: )S+DB <^^;@#)&.KX*=C4/F%"IXII[:71*=F"&(_GFM&6
M(Z5$:$*'<5B!HR\8=?<9V9&JADL$'WS/?1Y)"R55#:2J@6 UT11OM:KA-B,@
M5]3NF,IH,EAUA!<AVZF N1BQJXTLUNYP0_X/M;L'JABI #N@&1:I_SCA131,
M&9@A;_$O>KH,6(:FR(%_4/@_GS$($K\_@XR[\HW_I&N$(/>M7R3A4H1+$2Y%
MD)L@-T%N@MQ^1V[.!S?^D\YO'R/WT=G//IOPO(&X=P;UYOL\6 EA[D6=\>JB
MK4B%<#O]_3'>%6#G=<F8@))A61^-.LP*J6$Q%8MQ:C:S&AE++CJ9#A8])N+-
MZ(T%F=AQ]NGY9O0^%N-8AQ0>@7%$B51\,.1^+)6/O?Y1_2T5SQQTV$FSC&E,
M4G CBNY D%:GP-N'!5=H#H)RS3#1!PG;-I6^8XM]#;2,BJ&CW9N&IL$E>7@.
M$UCV1Y+QA9?S<B-OMX5L.]TM=/E>5D_5D61$,8?/)>/-%&;XBXWXL>SB6G,V
M3X!AS71L8^HSYGJM.4$/CRKO1O0)JGR>04I@1,B)<%Z"*H3S$LY+R(F0D]]A
M1,B)D-/?5F405/F\MH/ B)#3%\M!"*I\7E1"8$3(B2A[9ZMFN3\8/5"11E+4
MT%0/*R!::'!'&D@X R3 TL$ BIP%_OL\Z17W7+_!0JR7#:>O 5]$6W^B-7_"
MZE4'W^O%WP R !,4!TT9.H8^_+%F@@$P32#OM]C_LU2FDX]@QK4\B&=24S6D
MJ=22!4ILJM7_O$O_)O#KM=/S>NZ=Z+>OL,LY5^=K0Z'XDNL*@^ZJ7"@M>DRL
MASKGL<$8&P_27)0T%;Y<DL<5B/$CH/S7A7)Z[X7G?#7!XWX8SA\EFN!'CPP-
MWKSE;>9$;@B?9AW77K@E'DRJX7&-[9=+)N8ZD:??$388CX;OD^,0J>X;J7Z!
M"3O5M"'D\Q/P*C13$34VB+ K1[V<[%XD02RQ:*SF@EBV62ZO1);AZA!14>SI
M=Y@*1A@N&*<O.#N>R&XBN_W!64CJ,<'L^\3L']=*_Z(-7MEPLE2M5JRKD]>*
M4&^G:C%Q]OTBG"^IDJGN4--8M?NJ9ANV*<3*DXCB8%42S\/A@E242, +%N[=
M)9\X+MKS&9\X.O?9ZQ/^DE&\4Z:7X_6<R+,QH"K#G!%. #M9R)R90[Q;D9"N
M 9T;LN4\-;.;I7BKXD3FK3IF%5%H=C)!+DR16KT+UNK=(:\X5:?G,UY!M&6B
M+9^I2,]GF'T%*=BOCMV5JLE]7NGV1ZJ[$HP7YOME>7\FP*;]'*C6@!114T:L
M[YCMZ; C>,$:YNDW&P[&8K%/2^K^!U?T_?Y?69G__04][S!Q@R-[G^"X+_X=
M_C("Z/H@QZ#C8/*?J6%A0^*7"3315N9@PU HZI\(>?9VMPO@AR1#,\Q?&]3;
M/!&AWM'C4'"?>HZ"3<B;B3Q3&W1&\ %;1 J(CFT$J "%WOL_\,6;?S&@MKOP
M" 'N0!.G%OBU^6'S2/SM#R/P&)/AMC[@IMQEF<6)*\)@.AV7?_I].I+NHPW6
M3,4P U/<!C-@ LO1;"LP$N<@T = AY_8IH'(8 XT-R#BOIM #L#;-L%  Y(=
ML$<@0/_ZJI$]=4S0&[^D\^51JM9576U:6/967+5NOU?<R_9BB&\PJ+AW^_-J
MF:VG:J%81F5B,8:))YO]Y.0;@]C?9R(5PP;XT^84"D,OB&2A!J)H5_1;5W)%
M-,U>7"V:;F5J<&HGF[7,E9 H*-G$TV_J.4Y%F/AQAU!X[? % 0N](0 & PA.
M"%L(O+)H2B,OT!'#*1G,<Z )0 ">S CH<&<!F@H&L&][O6FLC\3^$TB#@2(I
M0)?<(#H]! @T(C3K^1T.=K?T23-?)="K4>B7MXA(:V 8-K[XY43[I8GZ\/^>
M@!X2FA[Z]=@XS8@#.M:3Z$&\%V;";$^,1,1>/QQC:8F60$QBO.:LQB"@6):#
M\G\@O5DVS@#ZKP,54%9,('FBP-;6[[_=LOTO]0K>#57,KX&30K!YJT!@,I?J
M3*=3ZR:Z/--NS>QB)6X6U#I4'B(GG&188W[&?]A<X=N<LPTMGEW9VV#0GG[Y
M]+L%V;4HH4&%HNY"#,?LQ I 3A* &*# :QJ:HA:8BB;&%<3=X>7A_#X1<:>!
MHD/P*'")M?%BK+G+N77RMY;);B'45K\Z]VFZ0VK(9D77TUO^;(>:HH.-[O75
M+5)?WZ*G*>UI:Y(&1!,9%Z,W'(-%3SU4\LZ.-!) C2DV9V3"&QOAM+7H,7Q3
MU"U$C[^<*50D)!&*C*??@]#FD%_\0O08*/C?__?_?4F5W8/:^JX8+&J&(-0W
M@:B&Q $\V"]16XBNM89B'(IF^I\[^;8^-8)S(/P<B?PSL/MQI]KN[68B+D-[
M%W*0K1G!KM[-1]CRVGQVI&H_O7GJ5BA<[,K?V(#LW@6+@9&)&/4_6M74201'
M/T-"@@Q8\QZ[\ "^_@@R&:Q60/:!NJ0@#K&]6O$K.'\(TU/ $CVQ!Z*,Q#!2
MI,<,I%@O+(<'/5$,2[T!H&61ZD>I*,<]>6_UOI&J5IK54CZ=:/'I9@O^6^8K
MK68UDTHT<YE2M=/L1=EHF(JLOW0>4.^#J _5M2U.;/OVV&\[^3PC@_S=I.JG
MW_OG".P.$JAF N@H 7R6,W+EHR.\01^DRZS11WAN/GNJJXST1]."0@6*$<.Q
MH)[@]85?WY[$Q?J B[*]/AA(O7 X)O?Z\5B\%XMS;#C.T<R &AS<'K3?>[7D
M>&RV9(LO%L(U/BF[LRZ_0(K$VY5QF>W/7(W7^*9LI[)Z9I),]J"E?[RR-.CF
M^$Y2C? N*W6*V?E+W08)N#+R=N5TD6/=BMIJ"EF[HB4:K7J/*Z!G<F]7MLU"
MM4B'&4V8K50YO[+H9+J3@ 8,]79E:U:O"4RC/U9G13H58T,KEU6'O?#QRFJ"
MUL=<J1OCW5ERRC"Y?$.)HY5')]( W8V^KAH\#YI&KQ,*S[69FX KCTY4=?I&
MOL@6,GQS44H9+;%7$H;HF4<GZF9ZV3J_S(1YQ6W;9774FX7B]5[D>)^C0?>U
MR:3F--]<B=.V$BUFJ>H"FFY'*],3=])X'4T+E#NI+1Q+@W0Q&?:XXY5V;O4J
M9I:C-E5=2@Q5JIJ17G/8BQ^OA#(W;XF%<)CJZ)+M]E<O\71WV*.IXZ6)W*IL
MBR$A)+B-R;A9Z+8&W6JB1]/'2P&U6)FQ:I^F0LL,7PW/*U6ULT!JZ]'2'$M-
M<GI6[:A*5S,&^>:J^RK#I2?N7I"7)3U?7 U5-Y(KU$)T+A-*P*4G+K\Y .E,
MI>J8ZF3&SUMRNV[,J_!8T>.ENM*JKWA+"*NIOMM7A=RJ%L_7>_0)L )[-F]:
M8[[)=Q;Q3*/2C@T;#;B!$W"-5C55JZ02!;7#2O'2HA+I6Q"GF!-PY9;C*&W1
M7)-W,\)J%IO*T^%LV&-.P#7,A25YQFIEH>KRP[Z0S?2M*9X[?OS43+M%15)-
MH#8%JLHE&D/>X!*H&];1TF0G4FG%>=X0Q&ZL48]QC<6T6.\Q)X#%*!S'IU.1
MGEJ<#)?C;%X?00I 2Z-'M!*OY#5Q(HE\JMH>O8[3G>1Z:?SM4JG?S@*CK_$J
M4/54KI6U9;V<0&[&HPT,(M%EF$D5H?T$0#0Y+2W%7AY[)-FW2\MTN:</QLVD
MF@IQ3)_7>:J0PMEJ1QLH@B@KKA+:0 !:WJUI!<:90/[#G,"!6IN?Y)+15DU0
M0C95I3M&(M; 2X^/U:T7BHR3<M7L*U]NE4OS901B%G,"7;)E::!JFEFE9M-B
M*"%D5Q8%41LN/3I66)N%HX-:ILN'Q*PZJ60ZRL*!O/($9BU'G7#H-2J'A:8]
MJ64CO>FH.A^BI4>W97-Z4F$R.4<0B[ET-Q&/#J(1_-2C8V673-6951<U56D9
MT R-OTP6?;CT!'&WXLNL&XUW0SP00YEJ,]1D=*W>8T]0K"BHV8@:*=34:CR3
MT_K<(*S7X5Y/(&%N4'E5"D8R387J^6C++)89181+3Z"+$@Z5\LN$Y*C-J+;(
M-G-YFE<7/?;$%>1ST7:CX2XGJF+0<KM5";NT/41+CP1&1182$X:**'Q*BN5-
M[L4,=12\]$AB\(TIUZV_K%ZI;*P5S@XC@JKE\=(CD1&/1ALCDVDD*$9G1L-"
M-)T,M^N]\ D^P/:6W1XE4'$A6FEK?#N43KEA*+%.7$%F;/<:BT5A)!1?9M5Y
M::K,=,BSPB<D>RZ?SDQ?._,P59R5*]5,)]958T.T].A8DA".K=IE\,*GK#3M
M1IJQ[NL,/_4(LR:E0KPX:.;"_&RQBLI.9<Z43;ST" (\*,T3T68F08D-(PTR
MD6(XS.(-'"%ANC2AY_74RJ2RSKSV,BYP_58. NL$9BWH-%OIC1:6D)J/5BF[
MVTC%&/C4$YQP6FCW!E*[WJ":PM)(1K/<I$SAI4? TL=M/9M)+@#%.)&DG!;X
M"DH#@DN/*';LV H_#@W30M;)=Y=*35%-I8Z6'L%5B-:+XU*&3E&AVD(:Q;,S
M]:6'-W ,+&$92XWSJ3X?S;=#1@%PYG(%EYX@F->A5$TUHX,^/YO47D+3;HK/
MO."E1\>*4/-J*;$P$U1G[EIZBUK5J@9>>K37":=:P_(PTA6R;-:I9>/S.6\O
MT-+-7K_F+]U3GJ-0)UZ;H\BND3Q[Z-!0W O\K<W$8Z//-C=OW0O9/'VU6#$:
M>^:8CX+,>Y;8WO,-^,R!9BPV[HO-[R'DT/WE6=4+"(1/#=J]F,1VJ=B']HUC
MOXU:_9P7Z4^FA^^%M/XVVH\<#N0B?' 1#*$(/UQ$[#E*[L$']T XDV\N@G F
M7UP$X4S^N ?"F7QS$80S^>(B8C@@22[B7!?QA[U_/C6G?^[4W*G@W ]5)WS,
ME?\:!MP1"/H'C]P_\:8MP/&___L__</32H:&0/!_3]S3-T_.4L_,=>?,<!_E
M;'P!6"] -#WP %T&LO?CI@V4]QM+!P]!1VCD 6F$^2Z-</CV;YA$&(J.'\&%
M8,'#80%#$2SX:RR(Q6X="^AS",,KM%S]+!WX.#E3!I+A)6B_2;!\^U>4%OL+
MG@68Z*>C/WM9@OB.4<*::(T"R-BP @/3F 0,;VB:/@S@XA)H0P#KU[D%[U5;
MW/[GC*VJ/,/[VL>YQB2<T[W1KU@Q^89U$EPEN$IPE>#JK>%JY'3K<S\BJS\=
M#Y\I5JC63C,LZQ8L!S^@Y&>QA0L<\APM'CZ)$?X$U5QZKC(=WR_0A+]QVI@K
MO<:*!1XL7Z=VII5_2147WR[0K)G&0+'17.43_1IB@T:S:G-)BYJ4PIU%.:4D
M!S%4R< ^_>:"X1--;L_3;8A0'*&XJU$<0QV41%.].-O*)2J)V8)G,O3\E3'3
M=(C]?H/I#RGNU51D74_&\GQ3FW,#<<&KG3BBN"BB.(X[;F- *.[>*>[C:/-=
MD-R%NQ!\2'*JJ%A-]F61HHJKS("/AO@E,Z]#DHL__69B029&?]J2Z!Y\D7N=
M&KP&,_"^)$4# 7VM2Z-/T<\2<B8Z%I!1:>D[GL0[,76OQ:2N?>XS=ODG;AF"
MJP17":X27#TOKA(7XJTC)#&Y[N.0/^(2N?I%$FR]CT,2;+V;0SX$MOZ$\^L\
MA[P;3U :3$T@*=A!1TP.8G+XUCSV)D-<;-34#T=B]\GNA)NZUBA-#'4"DJJ[
MZ&1?*[SA@%R]AQM512\TWY@0+B'<VR?<2P=T/R'<H9*B:VQ/':L3?<:.Q:7@
ML"8B7!32)81+"/>6G'P_3+D7C@M_0KE6N-LI\;T^)335<G\P+X?85 .U4HT_
M_8[%/B)=?[H\/U/\\4B+4%]$L5W4HQ[HUGF-@(?@/[?*;*Z;V'5?NCRFI"0B
MI-0>'9U@,:W*S%[9!6.F=M1&"X3&M5HAC'HP0ZT^$KZ@=D!(D9"B+TCQTMKY
METE1;[BI\DM_EJ="PU54C= MNR4M("FBV:IQ0HJ/28I73KZ\+WW[R[3()SNV
MEN,3(9Y16T*VT9B$7F*)'FZ*SM''2=!WZ(7_5UZ73 !A]6\$;?P32KB$!LM4
M5.0 6"+XH=E1NAPP[!$P4<HF4.:H1_+YZIZN;4P3)\+]>?_NH&IJ0YOI-67F
M]9I'EVDP *8)9-XCSX0N5Q%M)BP+' ^T0WWG*PD^8103"3Y4+X;2_1@(O386
M/3RG(4+%+UCM<6T,)Y1]?Y1]7Y;#MXG\W?G7V=ILH9?E2DX0:TFYWQBGQJ$"
MHG9H8C <2V(!A-A)+.!*MLGYJ3VJ1-WZO/O:5,'K;)X8)RTV5D34#HT8.G(\
MZ/[6PP<;""(S13/T8< &YN3(8"%NDT=PF]Q]E?C5+(PU&[(P$SK!=4RY0A72
MJ699+8HSOL/I^3*>E4@ADX(^=F.2^G%"D/= D%>S!CXCR%E\.(HELX6RX [J
M-/O:%%M],X$($FK]-'.L]1.*? B*)&T=+J:R?T:2/6Y<+\>:_1HU&51EGF)S
M=KR/9212S8,<]Z'C[6Y"#*F1J ^!-R$<! :B8@;FHN;@V?$+T33%=2\(>,7X
M@&CZ(E3G/7,H8*%@#HDT$!<%\4=>UB203=LZP>LRD%[;B%RK@\Z:6%,[0JUM
MZ!3'7$^VFFKPM>%H!'3*[:7F$I43<[,.GK\.#85X_+BW&R%U0NJ$U"]J;%R(
MU$?#Y;S>;M4T=:(,>Y5&@667U04B=11XH$C@@9 Z"3S\M!5S(5H?JH,":*@)
M7F6T26R1#"U"K?X0T3JR;=@@<X>1APH:EX%G7"BZJ$N*J 7^I>B2,0'_WL8=
M@JAY'?&L/()GY9'2IW_8Z("4AH;)9#9TEL=4MO&W?!0-G8[,:+0^F[N\FY]E
MM)XQ%RAY@7>.W* DO9J0ZEWZ0'_64OB4/H],@P$UZ3?D,4--JND4WP@QL7Q[
MB#:,HA,1$IUX4,(D=0^74_&_+T13E6&K6Z\VH"'?[DQKM=RKDRK7T<Y1L^KC
MJ,4=!BWVLXQL4Y1!8"JZI.B!."V(?_*:V4D)28*@MJV:1XPM1)FGNAB!5RJG
MUAB!=T><P(.9W*VW(0-CL140YH@GDA U(6J_9#A]D:A'\7!H&-/%I*I,A6'2
M<4NC#(HDLMB&H$DDD1 U"2_X)TGJBU3=;\HQ<5%,:$(S6JFV%_-*(Z1A48UL
M#?;\QH:?+ NOHGIC6> B:U&23 >00H9O<JSK#:"_N$YRY:/YAI7]O-7A56)Y
MA%E21(S+RDD_9R/NOF8SJ])<!:UT/=Z-RG(J KD9GF7)TA=,@2#D3<C[+LC[
MY^V/KY-W1)2;0CJ5MOAH;,3U9TRDP_8P>4,3),I$"'D3\G[/^"#T?2U+Y.OT
M7:NU),X>T' KTZ1@](<%W9Y@^D;&2)"*?>0YO)G8Q]5IG?A4#LZ]9@VV,;TV
MS[O2H" "$T(@A$ (@1 "(01R/M_^'0#E-CW<E:^,;R>6,;&,_>[X^H'$W4L[
MLR$MHB3 FFG,%1G(25> - E-X@U%)K8$^5%"X*+<'0V=9BM)S9H1MU?G5M72
M--&CHW@L6#!.4R2!EQ X(? KN+//0^ JH^2F2D53!-!T><$NZ;&E/D0$'GWZ
M'0LR$9H0."'P&_1M_P2%7]BA?1X*-^852ZS8$4F=S::QWC!6DY3, E$X*MBE
M@Z?F'=QB-Z*K$SMQ3=R;%4Y\=X1 "($0 B$$0@B$.+<?W+E]<%R\&*KMAF<0
MA"1#,\Q?FVMX^U=-T<$O>(G 1#\=_1D_\Q>^2?B>%&XTHQD+*S PC4E T>?
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M+HA'=M)!)G[)<1V$(?B&1 A#N)\HQ5\Q!#&640:5)"7SS>)H[B2=*<<6,$.
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M=^/T=WEU_3/Z&S/#U&)H=^=\QRB/LJ68VFP)=41_49*!^Y#T1\9]G57K_HP
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M>W%# /2/R9M&C]X_>M_0<&>+:HMO!EK50*I::59+^72BQ:<#F7PE44GE$Z5
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M5814APH/ZVUEH'4AO&DZR-',"4K)ZUNW^S$#@[(!ZMW.!$DO@'3"@2(I]B7
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MROF]MV\ ;4L'[W>[\SUW-8I 6LCAXZFP\) #43$#Z#OKAOZ&CH,7R%4(H3T
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MUET[7;[OK+T$:-X-CGP!6$?-$4[!BM#$O=+$9Y3!?)<R:.HY1M\T9: Y%$>
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M(S,S[>4RXM[MTY/W!R/T3P;8@S-%AV<*Y<SI>X_ND</FEZY%>'\W,8NR)\2
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MH1*3]/ZI_Q*<_3OD>6!/NQ9M^^!,0 +_#O>P9U1G$8UV3/#<+2>4=LXK1[&
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M,S1>;YN)1D4)ISY0PQ*-12F_#BR#,]'DNINL$2^GME#S!P);KBBN?#8MW'G
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M@?:\K=L1)=%N/<76/_Z-GF+5P]6A@:]H;VML;I (M7)\A5^NA6 FL.H'C73
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MH\\SHP_?7CI]D>F;ZQ9^P0I-%$G%?]+I5B)^GVT>3VL^D*QL>#<M/H#/0)J
M.UTQ\+,*S!4,/[H\\^0.\J3[>9 QP)+]Z WU&2574AC'1+S\(V#@'5I>L.%3
M 5.$>RKX-O!+D)..Z17H^?(IO6?AB-\7GH^N5PIWS]G@S8L&")23(RX2VO-=
MPA&N(?<=AKP&PYYB&&>V3-F!(6HF2&(_[04^ @G#'H\;^9U-O_*!0.( 2E1>
M@G__W__'"YV]:1!8MF[\=(1C#]A8UFB0<*(QOL$,),[\X@CO[*>HKL6MZ>2;
MQA^#X3UK=;8-@/9%'N/QOWS[CWL:.:"CC=]S(@>)KO2IPU17]IUN*B"P_#3
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M"#N@B6"\574P 9I,?Z4/@0"T5LP),=FQ!!AG.23IBRV'A/VX,PUM>8QY'":
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M5QVPH_R _5!N!'T$RP17]L9>,%??SAA'WO.'.^I1+[9%#PCQ281(ANF $/=
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MK-4./;#:S7B:*%6+]7IA=!(DRE>R[U#P>R@^U=_[CU'1(M4 *:""B6@R9A9
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M@-(S)![Y^]+(EQ7SVB(]RPUIS6R+Q61/F"U2F2+..*7HDZ$(Y<V""\0\$/-
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M $$!!-T9!-VAA_8!",JWZ]92[':KTH:;E9/D(M>IS%%I+AI!4)R*!A 40%
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MZ4)&/-\P$2$2E#@@+B%D'!9FN @KFJ@[#.H' P4C_$S/JSM154XSBR$5C8P
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M/2N[?]50^Z)@O3_J.03##TW*O1W)?_SQSYZ^IQG6=%'3L3E\I#;&H&JV9-/
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M-;ZT+/0\F\IAS-9";PMT7C!J1_@$[= <<*CW(=/^GHAK,/93:T?6T<[Y<BP
MO\CKSCHXBTI^:!V7"-6.PJ\$2CUFYW4LFKW;Y:F.83N=QN^]W>J)I_D[G23E
M;KAMX]XJQG98#6/CC7GR66JWQI^(L8$;\77PR+5B#H.==)&=28/0!]D@.Z04
M=<R-AD'K1;:?X&R<.] -A%5U2%M.W[@OMFT.1&];(J'X\Y"E./B9^UVXQKGE
MF!_/1*<@\IY:36C0!*Y&6R$FNIEA^;^BC[LOFO#[//SK3@FZZW04 PX!2/QS
MCNP^U(+_<4#P.#*H0R4#R1>"^(>"^XC8XG&,\* 1>.A].A"(#@&X#<)FVR:S
MM8\[,7?TCJ;NGZ%C!C?:#IGN@Z V$=UL@#/^8O8C4%C:UA:>Y80PWE(LQZ?;
MOQYR)(1U^V5S3K17PG/&%$W8GL)*-, O9(.B9=H*P%F6PV1^?#+2H(6$YCP6
MX4Z9FN[R'OR?G=" 077%R;ME>V8)WRQ"4L,1=K0:;3+<TF-S_S0.O2?PX2!S
M)SF7#*2^CR>S.[&PU[BC/-R%B864X,267->X>'4Y(8\-XJ7[O7.J=HY&/FS*
MW"F;7MHGN'F1L.@;7 KTQO.L@0RTQ.W<(^>@#F1U3:GI&@_ &,T6>A6,:E-C
M-W][6OX.AQ+MR:4^7138=%Q=Y7MS0!HKZ'"08<I;['3MCW;O@PKF:T&%[W)"
MYP)ZNF]-]ZC+-4_.A/(5#(&<SR&3'X=  ;4_9^ N)"$9XPP1RL_.J;.G; OK
M07['.^;QB.3M]OYET^$H2>;4>D#& Y97#T[J#@KWOQQ[/_8QL;]/=.J/.MM_
MV"?LY%?.<3X=:<,FHFZ8/H#L;W6>$<\A%\(YA^L4 \A+-,I1$RB4Y:<IT!Q=
M_C1VO[NO?%XE@!.E\))Q@IXC0(_5M.-MO[&?W"]GO]]N)L 5R);QG*EQT B6
M"4'<UB-[_@QA,C ,>_:O*N3=T^'V+$7-,J!KO'^VS?Z\"5\K;VQ5%;(_^CDZ
M6@RD V;38>ZD=.YV\1E:/^-).%$\5SQMU>=Z \\\9@5T<"*%B(3P*\?GZ^>,
M8J_F2-"AOX6?HX;#3,\;:#Y@ZQ$>436LB7.D;SXS_]#A<[1E>ZP:HT JFNP(
M!4=W+/VZ3-S=*?OQ^4IPSKX_9X\%Y^S!.7MPSAZ<LP?G[,^<G+_GG#T2G+-_
M\7/V@S_IXTMZXTWGON.SSH@=9P8*)ZKHV<^9JAZ'Q"]$>;_."/.J,Q($@ZX0
M#)I,%-5@NH+*5O$A6]A.9@N^+UP@&'1YA] W[/)W#N&'74'FL5Q!YMY<0>8*
MKN"%@W_>J-\KP;Z_B^EA+R+Q<5CO-15PK\&\CI.(XL3Q4 !O=Q)H:P!G$T_U
ME1LL%8V3K7LC_L/7@>%&IK+C?ELJM\4M0P[XN:*D!>;BI0AP _ (MU>0]@90
M7P+MBH6T0G6"IF?XWK*9UV9LAV[I76*1S/3U-6F.EB+SXP\4+0\2.UNX1!=F
MD&EO[Z2#Q5,@VU%>T<1^:LZARHO0X;#>#:/P+S//X7Z2AW/.^ 6Q"[K8!VF#
M\C4@#AV?VXDJY"#/41AGNL:5,7<2 UQVW!]5:7,GQ0\=X9T\VTX)X#"DT]"]
MFC&6KU7/DZPT-W-@I8NF:9^+*4B6W5%Y.#G#A&/*W PJ4',#W3:T+,ZP[]BH
M)XE7OPXFT]%DST[^G#L_$"),$6I:?K]SF'V^Z&=T[3?NZK;5I<M\G.;;'1EC
M9Q?:?"5-K[7'\9$>7;#=07LQ8/E*9+M!)V >.8/N;&M_ FPX%Y+021<2NO-M
MW&5M[>\2BF?Z%6(_-[<Y>\NY&::."-KWY)#:/Y7,(X/(L$;H-S0#YQ")UY01
M'&L_!CW;R]K(UH 3.I_$+OF$@\B*CT79.IR)N!HD2 [[U.0P_MZ2P[*0D53>
M5MDHJON(66'0LFV"N7F4D(JN4IZZV79<W992.X'<D>&:I?-3E+G)0!?4]@&A
M_XD,,SO)]21IS+Z<V:SM\]_MZX68"E>$Y!- =]$V>T07YI%;?92'[]QEO'Q]
MI7W6<]+.>B83*.LY.8P0SB]U:34@.6ED2)OTNL>G\(1B21^Y7@RQU760=P;.
M<<6EO-HZ),K[0G$O3W FOQP!J1EM\N8\JNEL9_52^U4_+PSM^,/NI6TM^FQD
M%^X/Y)8W;R6K36M"LA9-M7,4B MBUTI.&M"5CX1H,AI*TMY\<FSEO@)QI->M
MMWU5]^(RROJ!J@;JHUVR$G1UY]#U6-M9S- B^I]+%^;X\/:_JTS'+H""@BEH
MQU&Z=W72 "B!@-O;%6?Q'D2N\]H=-BW&O04/0:F1()J\ A*Y3H:;+R$M($^3
M/HG]H5W1 808W)&-X<97)J_NKA,:L??6Y?!:OZW5RGPE+2UP8BF(RFI+M7VK
ML1WV]"DZ6(E)07F2<EL*+!L,1P['?WU'Y(BG:VA%-:#;X.#+O4QENTIWA*+"
MXD_"N+1=;-E6 >Y8-$Q$//L%+5U4E-EF3CLO'ZSG0$5!1IMGG9B0XS4^.ENZ
M@59W'W><F=9\2DW9^R@UF]OZI$ R$K6D:R07$=,; +W(I->X=?R%YS# =<+M
M#866*[*OQLAAFG#BKH6B:UNZ(;@W<.F=;[83Z%7'I\@+YX!J@-F%1#IHW:?R
M?S3>ER!JI;KDUZ7AB*#%3B8R*@V;S)!!L Q]3"\D[S+$X-Z+8Q0Q=7<774V!
MGJ?&<RYCGP?4FD<^H(^*Y*$1.=KGLN[LGO.8%:0OY_4<(66OXR"^!WD^T3^,
MLIEL;1/M]"2%X\KI>>UIO+:#XC[^80B;:BOH/KD7 YT-@QXU]-AF=A49S;$>
M=^'%G?]EB*;ENF]VXBPB[YGCZ.[7+F" KE$A@]/V[>Q;7RA4B>+=!J^+(R2=
M(VT);A?)@58W U67O+.XSV]]G5G<QXE!?V%].YMQI]9W].@.9M1A\LNW1QPQ
M_"S+*^4<6ZQFF"=!4>/-]@=B*A\VYC6-7RZY*?XD*1NI%E5*W6JSR+S4V,HW
MN^Y.S,X[H>$-K=B^$+4D26C/)2Z55?L+0U6K!/-L<Y#;6K%7(U&$,,JE2;$_
M("SI*=--+C("7?D<H[B=U1*1#L$E";RWT&4]EVDEUPPRBJ/>HEO/&\6?8P\_
MI+R\U[Q6*]S0LJ3ZDMWD)I/9(LOFI@:RYKR!BG-3+'77IM@-Q><3+;M>'.\G
M1ZD$Q>*UG+C-S:)\;U-_SK([MN'V-[S]C;C0O5IDD-(S2W4XQ;:13DW)\Z(
M;SJUQSADGXV=,VQ%&SLG8$=;Y+HG?MSK\S1_]D>7:N&\](.WPV@,VGRGGJ!S
M=H?^@?OEB)K?ZYY+VS@VMQ%Y3VR*+Y=I](D21C?BR6VST#=9*AUC^XOH-I^I
M(0D+$_%GA S54T&4O*(]_DP-D,O2H?V4:A;(JK)@BWB-[3-;(Q[-G.@FXAU4
M.&RV.Q_G7>F=UO OU5ENC*:337&T)18C0J5J7253&3'OC:?[:ZA[I,]N!,0P
M15/MSUUJZ/K<R/0->DTT\P.:B467\TS] T<=S]##\8W\B3$P:*"6TV21*%8W
MLW)]IK!#% 6.(_,Y%$WZ$.,<!D]3"H*;,X]Q<X8.;LX$-V>"FS/!S9FO?W/F
MN-*_S7]_=Y<FN!WSU6_'M.Q#+<B28.R3:W#NNX4P3D;)T+;+ZMPCV1^C&+L#
M$CO<OSLJ".VKRCG%_E%]1VN$RN$YZ9!33A7V1Y9'AYC/YZ8CIQ)^JNUNI1S.
M<5R'=/]NQY_D>3?,AC(MT0>N;\S;0G"[*$!5Q0J6O''8AW8*\YUX_B]49G$\
MXR5R[X-F"+917QMVJERIT"+:S6RETBJ#>+<_K+^U&8)S\H38Y;6V" QB((>5
M0W;^OZ>LV)%#ZJF-&')3EPV;&?=?;;I_]#_TW_T5K*$I"P75#>$C-:@"$Y,U
MPSC2ATY4>9=RL0NFG/;5L"4!SMUIPX'J%@(#J(<S3J<U@&VQV.?:$R?W$,JK
ML7/Y[%"0Z CI\4[:6;![H9YS.WF><F.GP\=1J&CO1Z&WN#^_Y=5!0NP-$F+'
M]Y80VST2EOGNB-JK+QXP3[:MHKLW3D38R68]C0@C67+O$T!A%M N@//ZBCL-
MOC]JM^^<"% U"DC85/LD^1WG%@\<WOO<?$\BW^O2/<8PI<6\,*C,UY7)=KYZ
M6[ZGYVJ,3Q#P[#;+3T^Q3 ;;3?E0 ]RVUR #G*F0*Y_]/DQHW9V,NV]5O8&0
MAG7WRCX//O"!^U?#WPRI-Y)50FX"BUTLIK4*3?8R$9SY\2<6)KS=))WSD8,H
M[OE@EV9QDJ]DB!![H#X]KFK,&<^>Z-S;S4[GT$L%+YYY[3']U(;?'6:%]H=A
M^UOY^VK/[T'"JQXKW1O\O24-P@:_W>;GG&W,N^6R4=(*9(K]_1/_&^O+D=#!
MV[-93Q*9[A,W97"S)Z$3#F]U]'W576C4^<%6:%>I>W<-V$]M^7WQ'==1+ZC.
M7J]8_[D**-;KK1=3K9Z5JH36;FU6=+K&.IFM"2(4CWLIXH@5W$N+WVWYF:)X
M0X;*A13%ZS<2WY/6<SE@)\K9V(28]]HLU2\KPL;023&*U'HXX=W0@SL6QIJ[
M?FL'-K5=LWWSM[$3E)!%S@D*VL0XP34%RH*E>_*\S:FN6<(4 YR.[I\;#H2Z
MSA44D?.4X_W[C^,?-KZZ"6*''%=O(&:OFQQ6X35!A8K _L+N_6>)ZZ@CW,EI
M)4J=@9"-,@,@[YBB?'X;C'2B(-';*2D&%1DXZM;@NWW<GGK_YU]TE(K%_[.G
MH:8*N ETY8R:G)VLCQ_3T;TT;%>Y0+4#(+J%=NK<0O:_O#GJ$^'NI0[<PIG.
M/>=](P$[>G':5>\H65G7Y"L>6+Z^P<31_MKVJV]3"L*Y+G8:^]4=<^&W;B*/
M#P&$Z\V%[J#?\/MLS!W[,.K8P9GJ@<]\$6>C3ZM/I=A$9!<KN9U/E/H;>;1Z
M"<>?9]<CG@X_<TI\)\?7G+T!PP1-)&(T-QF..4B+:#Q"#+D1 8:Q290&-$5&
M(A3XX9SV<;O>S(/EBLY91LHB.$*.##EH#!&X@)3V^<AXN]KE5K(89^DG=;&0
M6?(I.U[!D?3YR)E6$OF5,FNW:2F[(6LK;MZO"$/*^TQ1-23X,C/+INM,*EM)
MULJD7H<CH^<CYWP)GT%\Z$GI>36_DCH+/%Y&(SUO7W2BL<I2Y!I2=4EU*Y2Q
MF(DL T<FSD>.!.DIIY.,)%%-B#23')E55688\<XS,5&(KI+*/[6[?!VL%OEJ
M<RX(P^B0<$>>]+>\B"5T%NX]JJGCA'NA2-@?IJ"U.=[E?K;@6U.RG0/MGE--
MS#B;S*U[F7:S;C;R#,VN-X+@K?;F/V[7@PU 49NC1 '= L'IUAM/MTCBY'C+
M/LAZJI8R;*.Y[P3,9O/I/%M)]X/H[.='9[E[B\Z>'HM@;HD-9*2@_%'-<$PF
MIUO*(\9H'_;T[B/)>UUVPN/+YK31WD1RZ]BRV8DJG5N?_!62Z44GL2HH[$;D
M]6V,E@0SQP0G?U_WY._J%@H_!6-K'XA);6P1\1HDXC8O]2+E^:P-<LL>VTND
M.C@*0U_%Q#C*Z"'"+YO:AV_:ZN5MAO<1T)XD&>[J@;U#H3N3IN'WW FC="7>
M2=0[S6 D#HK,S5\\&#P))QG1U'<OW>4SN?/9:[HS_>G8 ^Y#HI%P)/;/\5Z=
MZ<6C91\]'X*S/H&::;=CN]]QI(5_.]F>J+K<JXF61\;)?B@W@DQNF> SLBXA
MJ\3\3<^C[[V=28Z29L_MC6>H\*P-$T[0 5WND"Y4.$(&A+E#P@0"<U.Z!-)Q
M#U0(I./!Z!((S)T2)A"8NU GZ'980(4K4<&.))Z&<3_D+-YL$Q+OV(2KPL(C
M[0"OR>A#NU+(W^T&18>CR7_.K_/-U\]?YKOT=B7F+UR>]=^_TP.BTQ,=S\G[
MH2C8_@I=P$"792#JI@P4_RP&(D\9*(#>NY.<Q"L;X)#2^^\EUO::&W!O0,E8
MYE3348;;H^#B)U#W,4GIY,TZB^74\6[5HY>_];\C'?OWGU>''256!8P2P,"W
MH.[;7-=[(^5M8" P@^Y.0F[A0,3_UH&(1</QQ%?R0)U;+8[T:1/GOTZ&S"4$
MYU"[Z?>_>!Z R>2FG%3UE@U3-?R0&O-_?UU,8.YLY7]5N>P2MH7//IP*3P0*
MSUBS4#++)TC/>6:AG>1RO'.1\YV[P@VVL[L-;ZDE^WP.H$&D\O%M16788FE;
M5,P)C[.+C]R]/;S!27<[V%SGZ7XM?K@M:B6]P.5+[**:CDO$M)%*#5;#*,IS
MCU.A*!4)17RN6 =B%HC9YXO9E&S5UP-^O2%PEDAW,_.-3N<^5.OR3%0<F]9'
M3(A9G5S-K5Z=K>9JL4ULH2SC:20FT1]_HD0H&HF$8O%$(":!F-Q<3"Y_T^Y]
M&@7T+-GH322+6"1J%;G=A3/*UJ&HT(%&^2Q1L4ND!J)R!Z+RK$:9]Z-D:[!F
M5FRWV9X-.Z4<5:LP4$P2MD:)48E0DO2VA#MSZ':W>CRU+?^>3$>Y\#Y7P0XI
M[,<5,<-D$B@^V1&G*0]OJ0E\E)7A?9Q]#RU,@YV32L7"ATMF<)? GI_L-M88
M@1&'2TW.OV_+NM^7%W[FUEJ<\DK(RT+[5Y?0+@I/+]WK\][4^O''WY>^HPG6
M=%'3W8LW[CTB YMR2^#<CCF]IW/<!<&MSF#?EPFNBWWTNE@DUJ;E9*Q5;1?)
M9)O>U&=4N;9ZZW6QURZ)-0' X,HT5(H!4HL(8<?7G?=W9<%$Y$6@\IN0?2-K
M#$Q.E-W;33YH>7+AZ6ZNZI]/*Z@S[]:9CP=UYO=/#>K,!W7F@SKS7[;._(]]
MQ991)$).$M'DD*)CT6$TSI/#)!B10Y),C*-DE$_$2$\MDEY1V%AZ7R$(JZ^G
M"UH^/HJH]2&YKT6R'\EOFJ5(GU@]22!BQ?FHKD9;1-VOMDMZHRFC^9PS)9$M
M/'7;FVPK(Z^&U)#T/'3#+(PHG&FKK:2,,JN-:K%6!A5-\91LV?#I;'76JE4(
M:]JK"CF"EDO;%1SI?6A!R4^$3&U5EL2*,I/S,VJ@/3%.Z.WLH=VQP1<Z[%2J
M&I6G[&+,2K,F&AD_'TF.33&Y;8FRA&_7A5JR2"RX+AKI?3UMT:TLSN0(@BID
M^BV&DKO1VFH8\RD$DUQ6M^V&P+&*N:XJ5BI=J%-HI&>B,X5*:[FZH1#B5IGV
MRV,BWL7K<*1GHJM,K-XIYH6\M! MO;"<QXE&"SW39_,W53 >906:W52RC>BV
M7^@Q66%(>R=*EOJ9A&B8-(''E#23XI=/.H%&>B;*3^+)EC 3XI+5*>$"7#NI
MX@P<Z9GH<EUB&_E$==KN;BDC.AJD^NO)"H[T3K31$%))<KW$B>:,'*SQE"F6
MR!6TC[VD-S9,O3B==@EE 2W>^*(VGO4%.-([4359%1I4KLKF^)&5F]&%+#FI
MPY&>B:YK>F%>;:Z;;<L"=3P[6$G&?#5,>-]NY4JS<HF6BU)ZFU.V+%'+,:,Z
M'.EY.S/,C;I/^%.\7>PSQ+39(U9M5A@FO<_D6JV.,<DHPS;-I/++=;'#S9_J
M<*3GF2I-MYLUI19GNWE\4EV/S4JKS,#M]#YTT\L.5\T^.R2L>(=*$IG$(%FR
MAWJ>^B07R]-!= LEE)Q)2U-;)56X)I+R/K4944K3XGC=(*R9QCZM*XOY$K(S
MZ5. J<:M$]2@O.78:H\1(U*[P"F:@(9ZMG\\JN :WVJ9[6HDEM&@^TNMT%PC
MW@D(L?&L66FFY'9QK9EL4M#+>,P>ZMTL@TOBB6)E)14'I:A:+97U94= 0T\G
M,.1!DIK0!/Q\$AD/HQ,B/DSRD>@P O_E$A,^3@'OGN5*="ZJM.M$+M.E"KWA
M-!N;^X)JD2\-J"=#Z!*;)RI2+7(EVK++8'E$<!WE%NEDK29)'!U?K[IYN4G5
M_4&U%(UH?8O0UVQ5-!(KB](Z*;BY/KN0S*36U4I=3K7Q2F+6T/))LI(5?$%U
MV\O%"RN1E@@Q_[2HDZTV4=<%/U"MTQ;Y%*NQ6<D:%R<=(Y=EI'C=#U1!O*_4
MJ]-FK)TN*!PGM#.SIKSR!=5EQ>1C@R&9;W?+/7WPE*$4*<+X@:H@5M5TAEU(
M[6XO%D_1TGS4R M^H#I=<VI7F_)Q%A>'<ZE,;70IY0NJW377S%:G3U"C#,5H
MH3MAN.Q3W1=4>]6^E)LPN2U+*0MCN]))?C)@_$"539.=V*H8S;1S<EF:,\UU
MMEME_$"UF6*&J34]'+$B94U'D]RLK/97?J"*/VW:V4U_&&W3])*J<*G)EJLQ
MOJ!:L2 3U]*Z)BGB<K#1H_7E<"/X@6HN/N WY61TRW)Y,M;(1H4&.5OY@6IB
MGL0!%R?)=FY*TTJSUBL\$8P?J,[; D6OU>Z(R/%3DIN/2^J3Q?B!:B]CI#)/
MS("1%FR^4NZDNE(NY@NJNK#(I/IFI-MN,NE%9F$PPPR[\@-5(!:GX[D@65*Q
M10IY@Q6SXZG@!ZKK+A7EMS2Y89NL'#5K<VCW&"M?4*TOM=G69/$"(<;3LY'5
MHFI/Q3H:ZB%]/Q'364N(S%FPD72VO%ID5XK@"ZH,R,0D855HL,IX4NRG%^EB
MOB#X@JJ>J(-Q5E+JA+(Q]+ZXFG4R;-T75)/R=+X5E>832ZF37'U97YNZZ ^J
MM#JF),I("&S.6+57TVXSOA7]0;4LI%23J99&[.(IRA.$%*V40/T85)_I?_1R
MO;AW5)>C+N;3>FSY[UQ/[J1'TJ?7E;-+C7W?PG*C^RXL9V!V..JE"G)?E6-V
MA9GNC6-^BK_NC&506>ISMH%X/0&Z4TC9G )1W_?71L<L-E/9C64XM"'B')4I
M<TLJ"T %.B=C"@"H=/-Y1XX0^MH21?\YT^FBO!_XTR[Z[(23=."67C/>>J#3
M@<\<;F0J.^ZWI7);W#+D@)\K2EI@+GYJC!N 1V<QZ!8YG.1IB7I[ W?5Z=&L
M#-^#%K5>+S0*_:HNB;.-*.85);%&%=,U%7C/6/Q"[)_!&HA0O]RV$AYJHVKE
M4*-"XV1DV92QBSBB,O<H6(@JZ<$!3A>\\V%^A2#GNC:'\K6Q^QO(UGA7:__\
MNX:ESV4+E=DS &0/FT5E<6&ANGA.Q[J[@3J_L\_OA'1W!W7YX[*D%$$F0]@3
MD+B4J&'%<#'L-D%!E4=5MU[D6YH O;N:^OY,.6[78223Z$PY[@ 2_,70S6':
M[LJH(Y';5""Z'#J?H F/1*T8EL+N0?*'&HY7>C$2L"F+S75-JSJO&#@^.3F$
MQB/O.(.NZ1H/P-A 75%0L@RGHAX2#;LP/^)\WX8MIETUTL7(R!%&2H-F>Y+.
MKXCV9C,C%C&@)K-+B)&Q$!7S:11U*Y2T>U&=Z#A4RW/M5OM$)]A7;+MR&1;2
M8PW<:@MT1\*W,B%/%Y&-//Q(+H*W4<MQ!M7K;5K,&)<BBUQ[T5ZH18FWTME.
M)<W\^$.&(@05(B,^B0CG-HS=,.&[;/REVN.T*VL2[T<+V_8B75ZM6S)MTBWA
MQQ\Z1H8(VJ>IPG%I7LU[H>>TK<9'REA_4>U]KYXM?V^>K8T?;IEH;"Y#-G[
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M&75HB_WX$PE'O=7I+V:2WEJT;@(I=P"EEX 4-X'PD4'EW<TN;HTG[^I?<4%
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M]Q5/FJ*Q< QH*?C5QN9[_>?A_I3>&P%A7HTX[ZQ\Y_DZ>.9 TYW-IFW^1J'
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M$A0#^I^+_G@X>M/D9X=#0QX*EKS)$PK8X%X4Q%=);VR2@>[!( H482 !9Y<
MKP)%@'D/:OK(?EV!@ $>T_91-MGC 0,\#N;#3%T_\_F4R1M8/W<A"4<W=W<[
M_)RY^9+'TG=\'54?>'NQ+4UW'VCW.1J?S7"Y8X+/8*&D@,SO,4_NF,H+6//F
M9U/Y00%;4P9^/.XWK ]C_CF'C7+M0D0'K4+Z,G@+1I_.VS#D!BHN7://#?53
M*IY]OG J]L4:3B5]*N^7<<I01M2QB?183=2(<<M &]G&<GC;#4:Z>7O4B# ,
M@]5Y399DF\HQS6HO"DNGTC01PK +UB!_/,G[.156[Q]#SE)B]1HH<A\]3!)R
M-B7,%5;E[((0'71B7-6TA@!9J%]_B7 T%L#*3^O0>)9JK-Y]P7O&E:]68[T&
MI-QLGY1^/QH3:NV9S1$I$Z<XNM)/%J%]POSZ2^)DB,"P $@>RC/X0-%6;*]H
MZ_GE2E4:L1:YF,^P<G?4+PW;6B*IW4?7%7.2:462B:;,VQD*B]G=OAE;0KGR
MR[;&\',V7?GV*[ >A:5[B'1=M 3S-]\Y_7ZG_K)UFH]%OEROS'+]8;VGYC/V
M>J"VFY2#7[$_BKLN,SNM -+H4MK03?.$+6X+:KH;I_$9EHYIV SCJ7:4<7H,
M]/+Q"!:BZ:"CX/5K()S/+;\;D?^<#WY[0G]6E]S\D,Q_T"WO6.E*+J5S8W4B
MF*0\Z#4+W0*$ N"6QR[JEM\M#EPUB>^'9ND=PL;!"=^#,]W54?Q%<MSG6>(&
M%,_G$%Q[1><^_+XICQ_:#;\#7^'(<+!T4<V:IBU+8"F ()X!X$[*=-_<;^@B
M2R?T/XIB5&ZFD;Q:SEL+1LSS:7SB]&+0%6#P4"1Z?-[W)Y":X!PO\"%^E ^Q
M@8A/NQ%,%9T/*#;%I4=T2AYD$M-$; A@!+@10#A^<%#^A[50O)JS<5N0<RG_
MX]KD_>EVXCF]E&\E3$HW!C+8:PD!ABPB"E-1UK3@Q.+:5W$_:II =,2)1X]7
M7+M@\,](50MB9$%@-@C,WC33W2X&W&=@]AI7)6_!+'^@FUT!O1\XTR#@\X#/
M'^'J^R-%T:Z]\ =E]#L'MCL(R1UD',M3Z>RYQO?L]>Q'Y<C9$I%TNZ_)MQB6
MNWCV\/D/"-5N8I:.Z;4JW^K(>+7!3ZU(\<:SAR4FC@]89;S"ZIETJJ&G,DY\
MX,!=(G[]C1)X"(\%%XNO'RL-+A9_+KGW&D)^'\F]II/OU2K+R(H3Y%QZ,:)C
M\W+6%7SJU]](F(P$4G_U:/49TW'O1NR_FGM[#8F_V=S;8MVIS9)S+<H+*TMI
M<&1UL)I5X68QO_X2(3I&A0B<#"3]MA7E!_)EKW4'[@[R91=95C:-X:C"S>=Q
M)9L05^/FBH6;Y2?,TF=/F+VVJ^_;  )T\;:E('](^.;RUZ(";_FAO.4=87G1
M6^:<838C5+H%3*XH'&8#LLG580\GH;=,,5@H&J&">[-W<K(5W+T/W.R/8\,'
MW6R,*>ECKF2M>7K<YQ?U]CQ;$!V(&,#-)L-8 !?W<D 8U,9Z(/_\"S[*#E;L
M^^?X"0=]9#-IB>E:#"93ICX>KF1G*E4A/'@.>B068J(7=-"O+50_.KGA1[CQ
M(]T^NQO_LCI]R8W'MQ(S%_OK5E)L4'QY@'9D+5L5T;4K,:X;3P''^PTW_C\6
M_&+PKZ0L_AZ-O9$3]QN9!MP=R*C*U!9\Y'%W#?S8/$G49,& \CGROV[K,<.O
MW>@][-\7$;G]0NM$Y%G@D!.+=C\(V&IJ0D9_LF<SP(> 1\&X ;I9]CL_0#![
M^^3Q$OSYO_^SNSO/B(2*NJ8;3YO@P<ZVC;Q2\(0+44,9[1NRH*+" *SL2= <
M867ZV\@P82*R.<9_V@8@X$9#QF?^C3S_"M=^1*N)L$1W*.(#(JK) ^O)^]3F
M)1?+-J_II@*)_V3(&N""!5S^_E-=LEOZ['(TWT%5^#]./%-80$8&!-'_:Y03
M)SOCP-^!C -HT_:ZX_@O_?K;\")D P2B#DR]W9)6.*<T:LI41GUBXV$2WV[V
M-DUJC[?'MFDI@]5A+E68 DM_,9OJJ,^ ]_7PT;M+W[3#*S>X.M(H(XERJ5XN
M9)-L@TLBJ6R)+26R; &I-\ +1:[4J&_[$5QH*TZL^].KXL/UL&=82+JF"8:)
M*%/$ HK,!*:KB?R6EZ(,]Q"J*#=W#TBU_Y<D6,*?JZ_UF(5?7NY[@?Q5V-Y'
MA5/B+KCZMT=*U "C8W)/8*)$+T*3D1Z#DUB/I#"B+T2I 1&+_/+D1MAH;'XT
MJ<6C5HS%['9AEHQ*.:N;K4)#YW!D+E%9L%V)::IVR;"2]+)J+LUAC^AAAR-1
M+(JK9(VG^7+<<"8Q+=EG!+9''#\SBR>2F7(&;?+E7(FR!HOZ A>'/?+XF041
M[X-U4Q-.630$LU#0BLE2M1<Y'KD<=X:=+BJV>3M>=432$2<1U>E1QR.C&$_I
M T;JJT3#4=LQMD3E9LZIM=-506FAL0[+R=%4U8JPDWAR7#VUHI4DMK%<FNNJ
M:7.27 F%+M<VG)Y[<+\_<K%$Y]65K1945%*U]01-Q-DE?"9S.'+8R:@M)EGH
M\:U(M5)8E34AYCBG=HD?6S&LQ^>Z*EKODME<9B3G9;9''L]S+<S:K1*6BJF)
M*DZ5R^EXIIB#(X_FZ525H86)6H=#N^NQ:C6P<K=0[9''\Y12B[6MXZ,IIRBQ
MKM@IJ&.\-#Q%(X%ME!6K6A-4NM]@]?I\G2W7AJ=H),WRF5Q>+1<Q0<36ZR0S
MC"=[;(\^'CE&EV-M5*7G')H=2(-.S%Y+O -&'JW=;)JZKO,M *^Y>;&1+*8'
M*:$*1AZMW1XWM=(D'N_S]4QBB+96A,%C<.1F[0<6F/>Y?F]@1;E8>ME.\O6J
M5<NR-+=<#8<].)3P''#P"6!76V^-)L^FHX^PZ16EO0MQDF+.-&'UI$Q=J.QK
MNJAZ(*E, :!93\]&!14YI0V^-.$7S8,='8G@V!/JJ0474NL9ML9ERH4D5ZN[
M^</1?Y DE\HFLEPIT4%^0SLB[!7=^;S3ET_7&NMV-E'AZ^U\>5T?3JAQ@SWR
MQ<21+-F:7!Z<#G+69-,"WPQ<++>^$(SAF*XOQHH VX':<(V?!IA4'.[[KPU_
M=:.S/+K,$25^4I#SZVBM(5L:<!%E4Q1FT#0V;/D2%OVQ1GSFG2CA4I]%3'L"
MWE]!D\T:R6 *T!^&?]7JO(D 8QLH=/A&10-<)KCO)&71]7T]PX#$0PC<9"]U
M?P3]5A.1W)),[@>!ZI,7P->&IH&B2_ FL2PA.C0C! M:"3*BF,C,D$WH@$A(
M7]9TY\DE^(Z.W;.O_<G_U_4^M^Z!9]N)T$Z9F?+3YI?=#:+!YWSS 6IJT;-1
M]XWWG?"&;[H_RPSCV>&6L?G2C2WBS^==)]H,&<9?NQ.QL^J=Q^O@D0.X,[YI
MLOD;A9&;)\_/<< 6O.EB^,:O^\6;H4(?6,&V)5_8WWC%( -O?LC\\G]^*=!%
MA&DR(,0-$ */A(E7+P0&E/@8)3YXQ^8M1'J$WLMO@<'YFSB^VL7PY0Z/_;,<
M67@2=\=M'KV+)7YO7K]'+S!9OM3LT9.#:Q_D?$.O1X_9K[W0\YUJ^]S\XL4S
M&$^]K\I)MX_@Y^LJ<G'HO3SKW1 K?7^IX)>\ZV^_?EC2I]ZQ*#>W@;60G0)_
MW78+@/K,>N)64;P>MVN#U*"+*7C;*@_72=I0_" <'L)(.L10KQ7PO$L5<[EZ
M>X^F66ZQ+-\_UZD8?@<PX/.]#9;,3B5N.5.\)9UJ$R1HN<&LN&)C?)J14IPS
M[+=C#7B& >\GA^@3K?;^W)/ZWK4R 7ML8GK()IP7Z/5C!^E$XL*]&)C?D-70
M+X]7:U63^IS2[H_4U9K7.\1MR?][TO@'/,?5,TY74R<4IQM,(LX6;+9';0P"
M/$2\;1#L7XRZH1M(Y[^?];$#A\9(1BS=$C1$=HF#NA?; &,]4QB1E_!W]^1
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MPZ97K,+VZ@K 1Q0$QY"GHAQ"BBQB A *(3/;,&V_7Q!@)'TR4=QG0W%]KCT
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MS0-X(8C B)1<']2U^TX]1%XJIAMH>F%=_X!U[2WLG9.Q1H+GUP/?V/;W$+B
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MGU2.Y(#ZP7'_XNWC88'-UBWA&LNIW<'3A&AEZL7JBY7OUL2UI@<:5%2CVU>
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MLS$[IS2'&$'<(92'*#KM=F=]?.(U[TJ_*METW.OD74&:+F'BC%>_X5[J56N
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MYO4J%/!7HZE'C1/L73"ONTM7#^^R7;#D-'/S1G?S_O(8^<5S#M#E#?EY-Q1
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MA4&OQYJ_OBO($'+8>1- <;>V@;NKABQW3G_Y8H+QA=]GNP+M=@$75&(J:\H
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M1[M_ITL_*' O<>+FZO-EG/!/?+6W0[K'KWKZDPX+R"]>[#5OC)-_'?J)%VR
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M8W\-24&N=&_-,6TYC7[PDBJ%&TW+N^AQ:TT\\>O(7COM0&^94V^JRJ[2!NW
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MO65A"Q6IND#;<QI>>L6=H"AR4;^;I,KEV3Y1&B9B\,0CK,CF#@DQ>D02*?"
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M/'4R6!-T26GF\Q;P1S5D(#1<ZZ4NUB4)^O)Z4DN$,Q9^ N>=CF12+)./<'H
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M ?)8; &(NGEV[R+O$OC""]I1VQ#57^_;L1*;]4A'"I[>Y6>^!(3JLJ$(V9<
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M'%9-6B!),-KX )SC+(/G?](UVXE7[;4H]E?O7AY8AB>4"Q>=A^]SIEQUZEJ
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MI.% *R''4 19&*!Q.!M_)28\! 9 1XF]V(-SJZ4'GT0 YR@+X8S59TY06&&
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M7[/['?=C5I^[J-BHFWLT+R;Y4>Y2Y4%#NGQ/L*KN[F*+)V1<5D*C;<#;,S#
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M['29U/=1'P:@1U4.F8"N,D=\ZPPDJEI(?6P,A0&".4][J;UDE_T%%&F/&ZF
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M\65Z/=Y3/@Z&LSG !A[OPP#94A>T'V$ 4?A7,/!LJ*E/(M!#\UA0_G?F:3#
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M7M.K'P;X@WM>@>?%7I<&<DTKV5_!I"Y4R2. *\QW#=K(Z\'U5->,^9U>K+_
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MBRLJO%K)*1WMRUF)7/UDX68Q?3E3SNWZK,S\Q5WL1)\/[$\)MR@KCLZ8RCB
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MYN'E51M* SX\#RUI78C/(/PA'F;UO>%*N2\4')#F5II\ILQT4(V[C7ZSB8=
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M$%R#6W"G<8?&&G>&>VO>3-WWWM2\F7\SZ]3:/\Y>^]3^SEE[?=^J.L_SSVN
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MS,I<>O5(-FA_#='HT$5WDR$OMEBK@PNF&3S&MPN:BA*WO_N2>B/$NZY<"CA
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MP:=C;58W%EUI:C]MF?Y,VO6H#_-_WCK3B[B\0 X01](^?K JT@-YX?P 01G
M'F=FH<KN>A(KCC]I?L8%J)$SI'4F:"+0VC98'R1+;MLIN6ROK9B2NH89U][D
M(A-W)0URHAN_<WI/$VS"]2!7W3S5ZEFFXFDY7I""IF"DB8&H%Z6.[6CS?@8$
M"]JTP+$RI;5\[RI3Q/67I7AWS!(3:(_8T.%IZ;U9A%.M!H64RGO/ %!ZVNO
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MR& )W\1$'3R;!%3[1-":N7#>W[T:ZM577F9P0+%<OK _7I7P/1^/ERH W?3
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M:1G*][\#+_SN2D,YQRW!\BZK;_],ESPNEB#V(T?K1*TT'BA?>1JU^*<@#MY
M5%O=4F_*/P:1 [^?P?#91C4TF)58?R0D?R:"I$*K'I>XX(E8JK_-:9.%?6S9
MW4A];XU)*8-I#-=B_$YUTLG- J>K5)V=(\ K*FIZ^J55U@8@_46N<^;:7*L
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M(&VW[OG:X(&[3!0B(IVI<]H?+KW.//%M6B[=U[3C2<]8MKH]?]I[VE@0O.*
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M=)?%HJS%L\[HF%(S)Q28S"W_6YW.45QIL1?)&OY%GB?<AURPF]$K;S3+F6V
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M( -?TU4HMKTSX!HL.]!(^3K./!RG[25:+TR/WU/&\)-7Y"5[]H1'VP=#HR?
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M$^2F$JAETP-L2[TO],XPVGI5B_1L:Y;$I[+[QR@*_;DVPLD':1$Y6S9U?D\
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M8(.F5]K>S588V-XHB-GM4E%@Z'K@XF-+]&H?_,_HMP(^-309XG]@Y-+FZ,5
M9TKNK,2AH_P%3BNA"4<L\R5;2!WA5+HESLCN0/S]* 'K_[FNS+2!IB<2'PF$
MMXH'52SP@:/UNL]3&C)4M@K>NO*@509%41B_K)QB]2-W NZTQ[K[N="O$93^
M4OW!G[-%(S#<TYP:T53<12SB\3O&M*SK63A4M^B/QF=\GDHY\:X\G"72#N>;
M2:5J^SN^UT;=</NBY<:AB"Y</>B>F3B ),[#92N76&:+Y.?,ND+[% U\NZ9!
MVS*G_AAWI$?(DA[7G,:GW$NG'6=*3+#L5O]WLFK9I[C7'->%*RL#H!WO9>I@
M9S0L=)+97X'4,QQ7XH*@QF;MI@!.44,5!AZK5"FV/Z@$I6=^>\'" Z;3ET?L
M/8&\IT?!$21:#1T1V(_6(0,Z*U@< P\[%W-M$DUQUFI3C[2W=A=:,2J-?MS.
MUC!1XV\1B>W6/=1HR6/B]F1=3P#2N@[*0^/%9J/4L@@M'B6^TA &]=5(\YE3
MEF<G\:UHMEOWI)EOY:]LDAV(N#<CW!!MS7]YC<4#H &\ZDW35;O:L"D=J%1<
M*H?X_?P\_]XCZZUDT6V8=M,LI-JZIJ7Q3XX69ESN?:_'?CL>1-8E;EL\0]$U
M1B-FEO:%]Y\6I3"'2A%A(Q4_:Q(FUSY1H7-7@^ A+,43X"/N;9$'J#;)7KJ$
ME]"Q-T-4];O'J-6!,:Z8>8'QIP1=/&EJR.NE'_2OD*/99LW;.B_8U'WUG5.:
MB@\&[0.@SOK]26P?:PH.AD"7%<TJZ4'P Y<E6[#[>675JU5S4<;!G;1?0GLM
M X]8![RJMGS-(VJ%D<7'W!16LH_T7_/O,J_]J%CX[H7@D.T7Q';$ .YL7(N[
MS#UM$E&AEA:]Z_LXN_E]%396]E4O8UZR;B.\:7\Z6SZ!=WI,.6%*?*-I#NZT
MG;X@&1F2<3?2DU)U&6+L?Y4R>_!M^NE1JZT3Q,W2.<%.(*^<0N*P;-_V<J_E
MCK6OL25/ CP?2.O]4ZH^32F&%$8<[Z?LX)5'L2_^!%!$3FE<&*;89@:T)J^,
M8&.')2(U?[$?=J-11U=#2O3T6MH0A80M?_>@7$7MC56I,;GL,7-;NR!E=PGI
MEH@+Y4R^CKJT-9FWU$H4FHE7_[@0E?12[W*%RKK2Y_.$W59+^%@T/T_NYJ>7
MVL.+#J]S+6<=\EN^T'19T!"4BLO(?;]UDSO]38"?7-)C W5=T]UM+SRW@3*G
MI?]$#"4[^A_*^M]L2CZ[S=6>!VZT3!T#@>8I_+WS.(@/84F8OLDH8[E%VVM?
M]W?L[+J0 N:W9E)YN=V5DWK:<+:TO5^*.B]9OM>2_Y<IK1(UFX8XQAX!FDKU
MS8D@NT$&_\X W[D^8K3M1_I;,ELW,;=?X.1%0JZS%706B8VK"N IKV( )S:T
MS/W]!%?2#LO2GZ.&'W3@*U^VE9UYX.7SW\?Q@.G %[=Q_!:AY^>#[E<NS=X+
M:998M=NA 8=M61OC7TIFXVX272/UW?29%N+B+Y#U]A.EY:EV2:O1 Q9<2"=<
MY^[HQ/Y\=6(3%FH ZZ6Z'NY_%U8Y-EM'PVX8SC#+=^]7]S&5B!Y2LG!=+7K&
MW$7#J*XJ^*DI0&!#V*0Z@Z'K-Y:Z486,EL76<?"Y/EU(LR\*$_A1"V8HU>C1
M&.Y9Z?U(6%)Z-\\MV47P:OE@%"_U*#L-=YWCG%M'6Z("VJ%XAQG=.)=ML0.K
MI"T?N8AZQ/$V0T' FN[),J^1[#WOUL5"9J#.J@BO3*L,ZP+4A*ZNU(]EJ19U
MLH8G@!%\4FV?U;&[2X98*_B_N@!M9;G/-;-PRFFUNHB#U2;NH?R(@$"$8S3@
M(NB5/\7I-=R)=?HC*IT9 ]>8SR3^6OQOG(7-^K,C\[I&92>MI ,%,@=C:\-0
MQMRV,5?[^5\5UTF[+NTA<_LA=D^ Y_S+AI\$8@*</!PV+%8$TP[\=G####TZ
MN@SQ(?ACRYIIUC,,@TD'J_6.3/N.!*;+;;X!)$9+_N6""SJ@IN3-=3P4C&QJ
M7G5J@[L7?\]*-&-Y-MX-/*.N)^@2_M]-2OTGIH>![R=:Q;;$E=2@K*H,;]+\
M?3?<R_S5*YX )K?FZC.=&$>;UE)!;1.!C=4I$?D213[ W14X?^^8X2I4X5VS
M\PR)GM_X!TMV($'9I1/Y+_ E3#LBGVIX21"#_"_:H3[B/"KSO/^:/*\!)EKY
M@OB/ [E?*?)0_\XZYD':FBN'WS[=Q$?/X(=$+^5>GTHJZWF/YD3W[JP+X9XR
MXSS""4L54JI4Y:V"XEO5?K3-,\W2'[=5<W>ZGL^%@T^? +'Y,R?Z\C-'N8KS
MWPT&S87OM^\G!16(5MP.V)RP;C,EB5!T-DNOMQAK+6C0KFC[X=YA/6#K*(>T
M9?4P-UFO+C%(K2[=3T:HUI0RO[NKUI>RP6[]_&9D.)^RKV6N^@^%(JW%5M$W
M%H^')(RN][3L^,H\! 1VE%^C^8,81($\ZP/30#AR^+D0!;WY7_/L]S3!)(;\
M1_9=^/5K+.]+;1:721M>^D_B=^]BJ=X@:1$S,EMXE!=:\8K1=VM^9?#VN<0"
M3#Q2ET;:+U896#FKBP>9 B%N6WI.)PX/"I6&3&EW_KAB/]E-Y'#>T D.29@O
M8TVU@8%[3!<?H@3BNGRMV]DY Y[A5!/IVWN]'F1<ZIS4[UQ8).+^4TAW]*H_
M@$V5T%YGC6Z2$\&>KJV;<(0;>/\$>!E?EO>"/\ZJY\/TVKUZHRZ]!J8J4_($
MVLH\S#M^&Q@7E_N@"'R;Z>E<?H-3SR4*PU>=:BTP/$M#; W+**O\3GG]IS1$
M2GXY#X#OM_6SN"'-0A>FN_/(4!*,84M>JJ.64^GQD6#\JP?)L:?O>#\!H2&B
MDFN4)%+M<[QCZT 0]39MZK3N@SUT_5/,4?UK@W6,KD1=!N$QXD?QP\'OT6^\
M=B.ORV/#<EOMWEK"*&1&+&6/VK@;8.P3U>&NX66%4$7>T/03?HGX4Q!TZ\P4
MAE5/>J-6FE!>OVO)3(%U:!CNW['YU_&P1S P,)U7AJGFR"L!\[FOR:/',1W!
M T@RZC)CZ6+X7KD.IL]GCM9%@453,11KD:RQ2O.MG VHDMM]?>!^%Y[M"\UQ
MLV07Z7,A^K2+3XY)+B31.@^LNM77@@$I:1@.AM@A%#KZWL??K7D4H[6]"&6)
M"52N%D'"9;<"PYHSQ6V"2SD5!GE*W^".BZ^=,3$WEZ$\W'V\"5]5SXC!-U_<
M*UK:.'W,9VN<^ A+OM7LL_7%WPB)_67+EL#N()V[D^EOGOXE,%68J%]'U\$6
M2\%HZS;T#.MT)R1V7@4_*P\E7W3TVP%HCEWTC<FE= ,W<S>W_V;IL(X6=PK\
M8(VEV3HB8']<<J+P!$ CO\G#[]_R!IKZ94691[#T&^F1LY7>,!>Y3'D?!YCI
M($X=4^Y:T!'5N^^H6,;_NC.^OY0*K+L5>\9/]:7MS+. L\D9?[?>97>Q-VCQ
MB[/+P2+_0A^Q<V^-#&6A#5=I 9I<'DTI>M03(#R(LQFWG7>V>#8GI"^%(G2*
M(:@Y>#?RMVYND8TW4>=24 @?KZE5OVVAZ\5*[6:1>'LP/N#N;E[S?_W4F/TK
M%._?C+Q)&8#_$^!,OS]=\/%MEE2$CK+$_$Z&UA, [N^J6B7Z$OF/U)-] A"F
MOG^C]XE0@0.M2<<E]M5AO[+.+?R[H4V[:&NCNQ/#6>MM;@U6Z5V8P6C[3Y]B
M0]OY.1 ![@2OB$AN\R+R_ ALNLO,C+^O;?-QD14X>21!=/:NNDIN*R9.]EV:
M/;FEGY<[VE%V!"8_O4LGM1\H96C4)B0L+?:L\0IK[9\^MFES"]W23JP"ILJ;
MG"$=RY-(R=\BSZAU@K[6[9Q)1@+=?2@*H*CZG_2[4ON,YU7-"^1CV86S+7;6
MX4A5 DUEV'[APRN]HGB=9OH_S[^C+_P8Y#],S<G_E29!.Y4_77?;VLA %T.[
M ]NKLQ_[XJ,=V@;2*<@ZD!.AH$]\QIBF(3 @H8G\>&2$9GV:CC2B/HN58)QF
MFK),$AXIQO'YS**6F\E5:,+Z/-:S.N]7.3?EEQ2-(:W$I,++ZVK!VW!;OZUP
M4A=C5+WOV\I@ U7O>Z\5]&[TH]R1>U 1:.RZ6:)CZX3(+@WDY00I *\I\6\F
M/@'<'+V(SL/ZMUY(0I6UZ%JCHR?;^V5.0CT.@79X^$HVUBU-'C9@@2'YCC6L
M";?LRSY;>QAF\Y0[ZF2GZ4<+(N0+2-GZ#1#G3K)$B&31V\^H?EZ"4P]ICA-D
M97OGM[0THJ*4&)N,2IQ&Z3Z2N+EM=$2*;F-)F"YUFG2,+\\+P>WZM>E$/&T9
M[?A7Z3PJ2FZSC[-.+T =$7,/!V#+^&59CLV6+(?DD(E2]#8W<$2ZCVV9,2H]
MB<-+X!SB+(P6[MNL\'T!U8X=UE<_;6"G& 6LZ"S2(69R(!@?'1/QU7%$0#;%
M)?N6*HTX0^\.M6#[HT1@;OD12Y!-_S$V->7O$K!7'4*.>LKQ\.,(O!/V.GE(
M\!C@%OM*O_E]5-6#8,7;T?:%$7$R:L6VKBO,-O0^6NI;ITW1F* C/$&U=3>*
M###%MU.1_;W#47.4$=T$0A7=?HT>NB27-.4CT6N1L$L4F@?]LG%3EEVF(#(F
M&)2!8!T;2N=/%I_J/G+Z#3R>1K.*,P;L4U#T67E'[_>ZP%MI:7_\S-2+>FVP
MIEPOZLP=JN4_IN)+H&*?<2L'*9/9/(R)Z:J=VU*[+E4)-'#MF2!ZJ)BH& 4=
MB"2J9<4:3O:#_25##W:=6C4#!"/?$Q]_:D*#Y$M>CKTZCZ^PF#<K+8V.S->6
M!: #7GH0#W#Y&VYE&6/;:-B!N.M*G.7S/X8QPL+$OU)G7M 0;;=.VW,MVX,_
M"\RY":F*4+S@WCF5%Y>K5CQJ9[[U/.R5H([4Z[?,G',2'3*JXI)&=@A74QCC
MVP6R--9-.ER20Q9I/C4H.4[6EFZDF[D\OFNQF2QA4U$^^)BL@IPV">7!EX,#
M99Q>+NLCGR7I\&&_. SFUIA_9?H_7/F_)YA637FV@0PU KY%WPUD9JQ#2V9H
M\^;3O;,V(%FH]T\ [(?SF,* 0Y*>T$KNH3 HP5Q;4K2+?]4O+\^&CSOF&\;D
M^JM43K_9MS:V(Z/H<A6O@\([\#G_T4YS_/ "-?=EXI=NNZP'"E>/V@=:.M.]
MBNJ[;S[]8PLZ\_[UJ%;G'K<S*&S:\DL2T%!];FE0:@*#$FJ(2%U=U[9#;D$3
M).<-\9OZ3G2'+*9<S$L*Y^-RN%BCMU<5Q=5\&2ZW%K:&MV?)H.FK )%^I'+2
M<FC:8+C_U8KHG58S,OZ8WX\J1U!EVL%]V6]0['"0GME]//OBJI,?N<+VT2YB
M%;WXU!)@W4!"?$)%Q J"2F4L" T<95Z]D<VV6 =FY"@F)RFT+!S554>1"7AZ
MDE+VQYN6#IM)3CI:CUT!SG(-3'S=2<8/?0O7WLQ455NG&AU[O3[YA25=YXL+
M8!?1A/#_@.1'Q]9<TLZ^J6W@AO>Z\G0\KSK&+ML/9RWEKV#C8]9X74:3B JB
MLK*IKJ-7J^6O0 ^!;:5W3?3\H]4T>X=I/_!5RC.7O# HB1&S]]E" 7'O=!$"
M$]\Z]7"^GB0XB[/-AR'N*X((#+RU;)U<:,N< 6^C&_'J7@6+N,S5YK8HR.I7
MMW[[H&(P_(AV2/>2?B;_%':X:Q&AH 0NH-X2PY?+8TXT7)6!.)' ZW1.\Z L
M"0P,EVJ8@#+[\4N^[)6=G7^E]0<7_+_\P[\C+H^BIS2YL0YHS(,=7XAP.PFR
MH"1M(*$[D*D,N@IRX(92IR3?3L.VX90?WKWQVS'06/WH1!NARE&K:&YIXBE:
M_8';Z&S['P54O35JRN^')P/A?,BGCF$@!:'G;^<?&1EZG1[VBUB5U^<NJGK6
M!K^V(><S/U!5[6_)9W-S22FRBB@?XMM5&1H_$?9>FKXE#F>/T*:Q\ZC132$_
MW6SLX1Z 0]PZ86]/>\N <UEO>T6C7\"#O*D:QX1I[N;Z<GOH2.V:(54E]L^Y
M?'KW<-*YFZNM&&D(2L!EH]J[I4N&8L-%0AJQWV?75=9YD])T@7M2(=]JEG>O
MA*])CHWQ ^GJPYE\=X]&XKWX&U^@&7XG7&"BTUQJ>'B[ 9?LR32L';:W%R@L
M%3O,IU42<.N2R)%\>6"?YJ&O*+I<K:Y2PNO(-GCYZQ_]9F;U?QO!^;?G_U.<
MHC\M_@=02P,$%     @ VXI\5/Z)FN^@D@  AIX  !@   !D<G1S+3(P,C$Q
M,C,Q>#(P9C P-RYJ<&>TNV547-NV-5JX0R"X)K@[! B6$#RX4TAP*=Q=0K#"
M78*[%NX27(*[N[N[?>PC]^SS[C[WW?>U]E:U\:.6C=7[&FV./N:8ZV7V917P
M1DI,4@P !0T 0+W^ "\+ !$ (CP\ CP<(@(" A(2(C(J-AHJ"@HJ =9;#&P2
M0C)2$D)BXG>4S#3OR!DIB(EI/] QLK)Q<G*2T? *\+#S,W-PLO]Q$R@D)"14
M%%1\-#1\]O?$[]G_/V\O;0!,1"AO&%,8*'( -"84#";42Q> [/4YX:#^M@'^
ML4%!P\#"P2,@(B&CO)Y0\P8 #04# PT+ P<'"_MZU//U.  6$P[K/=LG^+<*
M>@CDMMCLOE&9B!2?*]IQ%,=.*3GT[;XC(>/BX1,04E'3T-+1<W)Q?^#AY1/Y
M(BHF+B$II:2LHJJFKJ%I8&AD;&)J9F[OX.CD[.+JYO?#/R P*!@<'1,;%Y^0
MF)2<E9V3FY=?4%A4655=4UM7W]#8T=G5W=/;U_][?&)R:GIF=FY^;7UC<VM[
M9W=O_^S\XO+J^N;V[OX/7%  &*A_;G^)"_,5%S0L+ PLPA^XH*"=_S@!$Q;N
M/1L\UB<%!#W;M^3LOHC8GZ,R*]J1*#@43W'T[<:0<2DYUZC._H#V-V3_.V#?
M_Z^0_1>P?^&:!Z#"0+V^/!A,@!#@9I]AA.JV=ZW>.)I&>JBO6Y;\&%W +/VT
MD9_C:6#EX0KHJ5EV'I)$&B;J.O+([(WZ K"[>7[ROMI] ?B/K*4?Z[P 5LJ>
M6X2*59[EM\6S%73L7P HV9U"B\TO@%^Z3VY":_:W)@\)Z3<'+X R\:FB%P"M
M/<5801GOZ_5C_[J>[+3A\>\.7P SV?M3WK&\4;N3:BDO@([=TY$;%N^3F1>
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M=]F\(]=%1&9%+\<5XK_F:= 5<^=F]/,WPG+L8T795*.:+>A47"/*WK5P#OA
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M:JAT%)R*B5PO"26+L_M-"YF9MJOKW=V#TNBR>1QLO^?O*<S(;OK_(YK>SKX
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M\N05R.H2K_1U'F#NAJ]HW$;QUCQ@!%CB=LR)C='$?S"8<T->SY5NJON QS[
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M4M"U)E=P4V,*+#$ @]$3SJ4.[/5^7W.I/7QHLZ:6&%:UW;I4VD04E?- @%O
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MJJJ3M49S5]G;C#6_&/[4SM9KLS_7M4:_;3=XHCE)2Z;^*!U2M[U7:<%-+Z[
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M>#:V^+KJ*$'#L3<DB?,9-[QKRM\N\TR$?"(^E6:SR#43\T)"1C.[;R.WANU
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M2Y%<O4E?_<VZK16K<?L?92=_M%NG)160!FO>'O)1G<U<B>+#\!22RMRL:&Q
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M"X]6!--BH;"R)ELE4T&'JS]48.GA>\B$T^:RE(66_IDX=^EBIO93/=_?ML:
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M$JE;'&H4BNVF(W]^H<O_XY?8_R]02P,$%     @ VXI\5,RZ9*!'(0  924
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MY!<W2=# Y-P*RBJ_5"WK9?+CUCE7<RG(B2$")<N*6>)T5KBP8N;_>2+,NC%
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M,4S4V_&$'6/IP2:J82=XQ7!E.300RY#1+3V4@ZFKLL;EM='=YDJ<G++7?A8
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M(B)VWI'$J-3B_#6_!&$ZXX1!%@/[9 '56A;UNVVUCT%^(4]7I=)LA5JS8>_
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MM9Y4Q8=$IGD>E+7^J^)F-S9S2C/W>,"/WKG]?69Q!^$PW")X8T9> =/I^-&
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MM#<PBB7L6TB<QP!J-=,[EBTL[.K[UKAQXZ:'J&'R@(K:<J;=0*'O45@Z)G0
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M%MYJGI8\'O=BH,#/?[C;AC?*]DAA@-<L ,WB*QTUFVJ?;FEOFN=6E-$!N1T
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M73??#)N*P%;#2:;!6PTK4[ $8TP+5'.5ZI4J,2=,DVS_^#BQ69(##=@0?C<
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M^U0?,,.2L$G#MX"-3X23#+HWL[PF;0+ QM1PK\6:$ AM(S75 ;)V7T1Y7E4
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MO;"ENGWHZ[5SY1YW<UM46]8_Z(I-^BT:(E79E.\[?G+,GZJ_F@+.Y\!T[^%
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M[6IE/?8L%MM925=8?D[(_^JYJ\.:<-OO1W<*.J0;!BCM* F)T0PV^H.4E*#
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M!U;4JK6ONE+8I%5'IJK<('1YZ0EF)NU?7BTW5KE&YS3[WY5PN.;7S3TS3X+
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M*+0JM4F7LM\*5FL_H=))/H.!VV(M^CD$(4]Z0W?B]UGKR]+MP^8RRJS]6L%
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M)V>8Z6@6I5H6SSD)9JS>7O#F5HRB5P^^9.1EX37)?$Q_L)2.A$2@.+$+V48
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M8IP$' <\'"X +C4.'C7.OQ' X__R),#YWP+\'\+!Q<,G("0B)B$E^\^A@PJ
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MH95XPNTRNX4E8:KFH& AIZHX: 34#0Y.CG.EM;9SO&3L4"22T!P)Q7EOC?%
MDA"$.HX:?HI*HWQ9!#V:*CE,4S!??SXN)U(1?4Y\%6#PC"&=^ " ]@_0#E.O
M X HLV3:?'&5GN&?8&F=A_Y^YC@O-#<=6N1(#<*5_XW8*L$#'-T=Y&IGSV(,
M<=C'7JOQPKI8^+#BXCV'FU5NSI'#U7CGL"-TBJZ<%=0NUSM8QL'UX8(H+/HU
MLA4W#"<I:OGY WXGXF*LTO @]-R$Q:&;#V0,FC*I&IN3/.U0L9QX* 1TN!X2
M:Y!&G]\W[2Y_MDY/1[*?@)[)V-HX7[LP7'ZR]JW&43_%:X2Y*TXXIA%5PE)$
MW?N[R2/41CUMLJ9$#Q1A-I&F7,94!@QS1Q0#S 8TLX6BQ+,D*164';A/ '\#
MW3B 4)-;XZA'&4[1I6/(>43<@<#C_-?BW"75!GUMSY/4_G)YIE>DU;I-CK\)
M(X_5:\.QC ]F#T#,A,7>"!$*,E8!!J4'_GK2M L"_HI9)\_I,*B?=_FI:XEK
MGHD4);AEV1")%49&"(X$-6M.<)$?.:>M&(J\,R0F[YGP7NGU3YH9W&D9GU)8
MD/P%EGCP2AL(5)8PP.I04\OA#K@P.[W[C3[T&(72/80G3A\"\DOQ9UI'*@\)
M)N>T9/:.I+V)?O$MQA9FM!V/B2,W(X.ALH5OD*JVZ&'VZ[Q<<G_ !4+:5H@J
M#_][=1<YY+/ D:F.)-<X1O:.CCS)%7P>'8%(F0F'PDS'&Y]ZQ6(#JJ]BT@S@
M1<OQOHT+3AD"MM7,J7G +JB-<+CYC;AE@*I(,5+/9S[?)=79O;12$^*=?H,W
MRSFY7>N//H)2-X.E?\E/"8@JK.2))E\92TK]-.4 _?RP;+'00CW URE(GS$3
MH'INZ@,>0B-UZ/C$+B($$[M_V" ?UNC&,VB;B*:+5^2U7/FJ6<.7$;E #N0L
M+\B0< %ZZ%]5P@YAP1H!%G@LTC5N8CI ,9Z33'-!,5 X/:O09^>/V'!SU).<
M6YRQ\&4Q%NC6<IJYRZ^EX= &I3&FZG#,*M\V$ <OW]'V1F&IW)4;KZ3:AZ75
MB#USDN-F9IT-< WGA*BUD.P.XR^P/>_O/I5>2R/^^ENC2E K"-1*C-&9A)^;
MO++R!3OA!82>6]UNOP;YXKWX[/Q.@"?W0#F6'(UGAM*B.2]B_5WN3^3!\9U>
MH8?LYN@7'"$A6>$9%S0GL93T ?WW5/FG2W")CV7FA*FTVUG8RQ3H#8TD(8$9
MH!MP"CC(MF)A)=]#89:)^!\JS-C#7JO![OF-H15S8V;%%(J"EEA_11/_X^;)
M7!<?;I7HVFD6'[$N\+E%DF"6?RB]Z5DSC_FW:F19\<%E(F%(U>NL%R9HLR8<
M@Z9775SYKRY-&";P62,\V)(E?#>)G,#U=>IEF9\P'11]+J(D1$G//3F\7Q)?
MGQL.!LR.UF9U$1XNEFB&I,=KN%<9V%.JRO]:/F%9V%>5/]TM2N"OT#^KH]H+
MT()>49-+<7T>QQ?CK=8T?N<;RD84UG31\(>)O6\1EU^#FW>(.W4AJ8<USK+0
M/\Q'*3\JA@ ?77,J7PF?FW06'KX9Q1.-5RU3'OA#)/WJ^,]^P' )/8PM[_<-
MH:)[4F@ "HUC>- B', ?45?2<FW6XYH"43]=ZC>-=T6S0DCN9G5=)6-ZVLZ4
M!;:%!09/_0<N\QVU)D$NX>8O+/_K0R\5\K)R6<4 025B3KCI>Q)[]S]-)<NR
MIJ)'CAXCTL9OBL7#4+!@NLRVPJX=X+<*Y4D20OBNT>R<IV3(Z3%A61 8#SB/
M-+L<X/-C Y08J4M1/CSBN#K7)<K6C994R/=',E-'6K*OX!G6\K(\%M\+7^"Z
M4(@? U_#N=!4^^'L7@J*):X<Q=!#3%8IGDLV'[".R_K1,V,B5I@%011>I75
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ML@2EM1$82Q4C: E7CLB#JC(%C_;B[ZJ4/O:N6Q8&CYJJN]HD3&1</^]N_ ?
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MI!$N3<AFSCY!Q76^$]#C=DO9MNQ"&RXXQ7,QPXN,/'U ( KH+W5OL=FEM"K
M;?E1>]5-2LK&<+0OW.PUCQK%':1V@*2+ 3MEE'(SZ>U<K)XANM1=O+GV*.K
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M,G)_"JK644Y!(P?44DQV[&.968X/ -*8T) 7GWK3.DAC\K$#TJ.&RD\QMR<
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M*!P<TL?R,<^M3$[1BFG .<=J10TJ"V]*D5BV.U(JJ8NN*?&L9*@,#W)/8>M
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MRF9\$ 4PM8JR2C?P,"I8$);!/!YZ4Z>-1L 11MZGO35(5L#/X4$,G92#U[4
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MN^#3HW(?@=:0Y* Y)P>@[YJB;C&X#@-RH!-0%QMX&,'-2N&WY'\0Q4)RJJ,
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MD:J(T"DA$VG_   ]_P"52JKFV#2@9WX(]@!00V4)6>.*%5)')?=ZD]*O@)'
MT3 ++,N\X'0"H1$)I?/8Y13G;VXZ#_/I38_WNH%F$CEFYQP!0#,UN%(/'M49
MW*I(P!114G0 ;=T.XTI ([Y]***!$85BI( P/7K43I\N_ ST]Z** (!%\^X,
M<]\T]0I'/'-%% P6-=^=U6 %8;<\T44P'!%7M^M+MP>M%%2 CJV/EIB[E.3^
MM%% $I!+9V]J-N[ W;1113 50RC+CY>V>]-<EER>_2BB@!@4DXR:D5%7@'FB
MB@!1(3D<<=Z:\GF$]N*** (6+%@H/'>A%9I3\V,444#'. K9/;O4T$*RKER5
MP>H[T44Q,7YE3<IXIXD!1BR_-Q110A#1SDJ*=$N6([8+'\!113 ?#N$9DX\Q
M@0@]..3^'3\:<"(D$1.#]Z3'KV7_ !HHI$"Q@(BAADM\S>F.P_&G9"ECNY;A
M?ZT44Q,29O*C  R3UYHM@SEW !(4XY]J**!%@+L:.(I\J+N9O7_)H27,DEU(
M?N= /7I110(J3#:G4'!PP]6_^M5^QM3&J33?P_,H]2?3Z444Q,K7#F:[::0?
MNE.%&?O-[>U7+N62.2"W#,68 D ]23FBB@&/FF:*-MS_ #8VC'0GJ344#,J^
M>S$A1NQ_>/8?GS110'0__]E02P,$%     @ VXI\5#1=7IX0.0  ]CD  !@
M  !D<G1S+3(P,C$Q,C,Q>#(P9C Q,BYJ<&>=N6=44UOX]9L0>@DUFD! 2@02
M$"D!$BG2"1U2 !$]]!*50X@BXM%#:$*,0&A"#$A)!4%!4%#P!*4K18HB(B(@
M" @HS7[.Z_\=MWRY'^Z]S_ZVUQI[K-_><ZUGSK'_F_IO#J#DZ>;A!@"* 0#
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M]7:E7M\D'U*>[A'6?;'TF8F&?B8Z\I](3[-^.Z&#WGO)--]YNS676,K&B#J
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MSU;+Y .>L[^L>+''@\</*N&D#33C)/;FX.#YDI'+N^"?YX2X%MN*6BQ$O8W
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MR0X1M'!:#9.>%(GJ[JB:/65.^">7V->VFGG ES+_++N-CSO8].P_P!/2ZRL
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M(OLL+_7W04Z0<F'PF#37Q+:U0#TGPN(J\C%(;Y$A/\'=9RFJ_J"04RZW3<B
M1Y2_* 8C]8WDSX<E&AZPL@^]./X6)B[K?]E?PM_<]5WJ\TJR[4+ESHO3X(XQ
M2"ZL.3Z(GI64.K'V6]I6.+X>+UXDG&NP3"+.<TEPB@_LGCS=B8F_]1=DAV<X
M+-49DO-7GYT%O26G.%?GQ'/@!_(.W2HLE:AL(I:?VOSF&IEY(TJZK6B:DR\\
MFN4RE!7Y@4P,J[)"3I7VE0/"JGZ1][>]TFV\8"E.^)9O5"G6&E"XXM,51LV3
M4)BB7!NZ8(!LRRLY\:><#8#,>%E5U;5)7+QYNEQ*?!N_'!F,;^=-YX C(^G5
M=C-"'6"S#2E>IFA),YY/3;QPZ\TQC=Y,+YF+AZE!ZXTN95(-T:@?I++F6](-
MR!>%J<P@Q7TMU@N[0L2/]KJ]D4>FY('WIR:O/FA_-Y0T4',#KDY"X^PC>]S
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MR3OW4,"1?I)'(?84BM-]H'4/I80>Z:> AE@5@X:( E9FT)@5I20,7,^Q2J!
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MCA1# 2X^O@=$M]!/T4M9 YRSV;:W$;B5O+)W/!$*4P%O[.$@MMF^=@.OY"I
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M:8#4Y8*[AA*M(AQI@7Q1%7YIL/D9F;%RH0,1XEXDB&&Z)%AM:0/YEG**JU@
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M93B'CB9D6;>3#Q6.+8OT9&I)175&H8'&2XH#$H4()%$\RY!D=2+TYWZ2$11
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MLPO-A0I_6+#"J0G+&C:D/ >QXT8F^;O,(NG)@RRT4Q#<](.1(LC37L"[EFL
MVJQ<D/R)A.G(-< @' F7O[G1I]?EWF]VBPGB0K1:D KC*:X&%,KD0H7:@%%O
MY>^%70.^>@\"5P3R/*8')=QOF7A?Z7^7?Y55?)""%I]R8F;.W!H$>I#X2OZ<
MPH%L07HI<;QJ?K77H7$GY>!G!*F :":Y<]@CHGDAHG-[FNZ+ O2JGOQ^OQ4!
M!!X2H\M[Y7+GYR\;)8P1E]S(9R?P_%I17GW=,SU>-WOS/D*8=,)=WOEBO8;X
M9]'LC&1HG5A*E8]8V.>8H]LC>6)I^*G>*B_I!3AC_^E:!A#!KO$/0]SC0V4
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MHRQC),N7LI(HLL\;.>*$)08/.UH_,%]2#/5+1X1Y\B-] 3XTYU>;E7;37->
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MMRPX ;6<B1YNA5!%F67&4EKRVCE&BRFFJID :3IYN/L)U,R$[L@/'03)6+3
M7IY.2>I.5\?.O04=??166ZO?35#7QE>>!D9/:2[COK6"#_/VIY&<'+J6VV)<
M0A,I]TQ<M.*-FZ=Z2:J2B7GX/H7D)^A7GZEEJJ)YLP>4R3U8/5*CK]@0;Y@/
M\W!I^6S#NV?FXOEP29"DU_F>5_F#MX7N_61Y,9$]Z!6]S5:J CB%0L>%2=7]
M>,8C<7V@^R7JF=7EU8&K))]FJ4;'1N7>WDQ67KB@M\^N# 7K[4R/@PM0@CJ=
M[^Q&(7^8UR?K[GR[S,!=)%=(R5@.0G?*EX1:E)FPQYL_[=C8[P%1%'17OOY
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MGRGS)/YD3OTNV"59B+OH6:%E"TQG*37/R<5,W;'=Q)WJTQ:BJ3DY_^&Z#B6
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MN3'PH.! B?V%7/=FN&,DP)2DD3GD4P^&6.W34C#8XD%ZNU4PUYOV&1@+-U
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M/Q!\\;7PBET,I\L3'_I%9UI^J;<X:YQDNGW-Q2")WG,9BP%1:D\QV6WX(,B
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M)%TYZ@[G/,X*8P5RIGD_XQX-<!&CJ(TIUE0F;UEI-,T4BO8:?*PPC<!O!M
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MTM?0>_&])QY):X6VC<U6T=!'^2V"@APUQ^7!6 %:*(+[,HCJJDV:END&B.F
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MD=J4[!N96U_-PBT:3-&S(:';M3\9>"S?]"S-#).X^@/%IY SN77:M69?5M,
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MZ+XS]P[9%+UD$UL-"*M<4+UGU<'T3=S<X7.U)JP/=-$U%FY< U?ETOB.7V)
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M3O4HO>;38TP'@$"OIS7QPQYW>PGG< LVGF529&1_A\%6[*9?M \L+[P^7,U
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M!GT[I0$F$_RC>5*D#R.S3)4O(4LZC^>PJ]\MAI?5)GH.FEZ%P3RLUY!F]DZ
ME//I(";=5MY 7Y((GH;=<E<I 2R6^$U'B3Y:Y]7HKS 7$D5*[Z6OX VWIQ/S
M!CQJ+)@TYV=#7^-Z5'O$*Z#(D"#-,&5BIUGX0*EGCHQRUF:QDUH43#?3_0-S
M)Z9+-O1%L'5\E;/NE_3X'&P\[0!"2?T(WAF\H'+C$"K-,QLVB^Z)4LBJ^A*Q
M/,1!$R'6LJL4<Z\7_/+Z-$7B]3#3X<-R7S[N^&4QT^ 5*JJW*\P[5X>=)R)M
M5G;*7)QN5Y]=O#;@&4&J!8)[:UJO0?2]!O?U&VPVHG.K]'N;Q7MQ.\?.*G2V
MA#/4QIKY2KQ5D*1&/#.XQES0Z+\R&IPQ8^GVVOYUD5N-OCCN8FLSB0AY^6$"
MS4@?*9%E#=/S#TRLXM=OML.GN'?%<(2U?1U*Y(OT^AV<ES\$5:30*XDURO3*
MZ<O3!AGA365/'YQ#= Y-^M\F1G!NF-QFIAY;8KAU>;:%\[PF^AXF0K[O2?HC
M2-_+I.25VDVL!\.M3TE4[95=N9$W=.:@_'GDBOK4Z]85K 1D+3W!DW2_F(R)
M%KY.4<9:I%;&B[NTLBFM[+<Q(D->PF.@9=6[Y94@VS%0G%6CW==F_74?D,8,
MC\#9=T-\=/*AU>2M7LU>F]5[<*);EGM%YR"B@L!J'K<Q*+^)6Z1L0XU9)O#N
MX'JWHW?-: '.P8S1#_7%M*;$SUA=DI:IO1]O',->"/M@0JFR6#MTOO'C5E+O
MN#?$Q5!"#6D1"AVDX#DZ\'*RPROYP<7H92]OEK7ZN68/BC>' B12?2=Y[S70
M'D1OU<V7XY[BP.P5$]\5]!;/YI!5T&W83=]9ZX,^MIXM!++AS ^V\9G!O4&8
M=DTHK,OEKTU;0\U;SX:C,]71M3?4T++SLIUO\Z-4OU@H681K1WJI-6Z(M"!;
MRH'WO'$22'V=E442\V)11@_:+]^K[ID"SR\J\OW[A@$)#P^[@M_#'FZLW7;H
M%(PQC:S^L8K<BE.EYSZBD#O1-7:VCYB]K,XV5+Z<NC1"*"#FR8,LJ7C<=D9B
M9&Z.B##K]'UR"[Z+-#FU8T\!Z<8Y_G@U1W$PZ@E<[$&&7WF+(\J>(12C0ESV
M_XJ\75&M\U#-K#MICD5;=6. 1#K--&1<Z<S?+1?Y4K6^F'26[V/7XZ]NVJ=G
M^ "BY6F.5@2\(L!;1E#D5DZ^X8ZG2-K%]X+%/<+0<B@%03(F)+(HO4&@0W1:
M6?(JI&C8#!'VV.49GM2I_$_K$L.WTQRQY6*AGA^H5$"EW%B8L0!5+$S(.NDU
MG>Y!?J3E=R$C7MP"$ C3"XZ<]%A_T#I"3;/L+H:\U*)>CQ_7ZMLE?_O .6KZ
M1DP)4GPE_C2'UN^5W@GB,5L:MV5,;TV.0FJPR(C3&^J#_U+\3NMS5=G<#J67
M,8RKVG6O0_Z5S393 <[C3#P<2.J8MTNF>P*RS+FD@2E>HQ(;).X_&PN41_Z'
M0(3O?]?U710;R"LL]UV?,;XD>!"'8>6/_BHL^@Y*W7],TL= 3]A '/K>[*T,
M3>F78&N&$*6?89$F%^ +\,#)-C$*>#8%#A1H.8N 7KDWT!N-=T[J1'&*D#<&
M48":^L"I;+4Z^3RG\L*N#+;@&#V7" M0Q+N=A\:R: 9LI3]-JU:OA2M^C;)E
MEO.58R8?:YYL5".!2V*E1#^E$^,O3U1D?8.I+?(IB;ZNE.M1]FN5A)Z;W5U!
MG_'1&HWZX[^$<AC76C7?!N!\E$TO2VR)O;NTYJ%%$?,6%"^^)# [XK,*N?;U
MEW@>-CV)+40K?>;U)X  '%XV-L/'RR!JWDX=!%LT^/.%3J2$IL/?]ISG)YDW
MS;?G"VH?OL5IK3M06K2H?S7YF'KR5 C6/EZ;MN5M =\E5K6S2CV1=$IQ]!.'
M?I8=NGQ,G [2BZ]\>9^$CYL[G9\6=FPML/ETIH-+2E(:9M!ZT NV?DO)&]_X
ME'^86R/#Q@& 92:.?*-/C=$\?UQG*$U^(*<X]W1;O:"_%7A4$DB^J^OI9?/E
M*:(4>DS+7!+V/'O@$.] WLF:>@J+'"-&,Z=Y<:Y7KYGQF314^TE5?[/VFAGF
M* _,X<# 2X]\(6O8ZS#+#'S7(#$%/[6UZ'32DQDA8<F0VRB1/2*QU-AQC/[@
MH#7E('_A&.G(LN!>;DVY&(^/)>:J#*8RS</ 3J:6ZNL%D^H.*]*1%VKXJS)J
M2"973LTJ9O5O+KR&#B@LGS<4C/Y<=%*K9H,Y?]RP* ,'?QKQ'%?:S!!7-WSZ
M[H,+;BF'1G@ RY3V#P<JHZ+C@H[&LDYE]LCH@=Y7MFG9H&,0;9YL[BW[\><(
MP5&['$G&P?%#\L&HCOH["$F/,6FYLZW2I>*8\\>I_$G$J5V^Z3M[7 L0;;"G
M5GGR^E&U>W'OV]8?7JZME?"M^56+#Y'J3@6B:5%U/&CSQ5]4B@' !&U,;5P2
M(%65!,#@V5M/Q?MU7]:$DI5W<7,&DG0O:%YJ >MT@6]H5(\!%- 594"3V(D"
MQ"N,*VCN,MHIV1MS,ELQ4 !5Q?M,\G](4D1T 7C5E^26>SV#_"HKMW;\I:!M
M)J=>%!1X?ZL<?LYTAMYR$4X@!USS>#,A^^@BL%6D);:E44"W]@0-3OU,_G%W
MMGO A+RM$O@D?UGC.FEG-< S:A8Z;J+JQXS!W>7Y(64T^)R-BX)8@+TL'>PV
M0OJ#@0G<V=9I*][,N:;X^N"B]6.$QT6HL;5M]">F)T>CGF>-S!C1T\T,+H7>
MDN.W\M13+'9F&%U(0K=*V\7(I?W4&6\,Q)(:9.'QN>(SE:H&1[7#^['OA:07
M:CE4KA5JV7["*YI7%H+S5Y]MG]Z#IZIUO+]9S]5U"[KA@I1D;_<VHP+/KWD4
M7:GUU2N]RN2P@\G+;+_8ZP=P=O2L+YR4G\"!3><V'$6KXR7AUR)#'U4_7@SS
MP%PWJ_I Z6>C(3?8#6MICZST6I;BNWBO](VK(.@E_4*A>X[69?_%J)5U>%&!
M&M^BF!R :"6+NLH[]*F!5-R16]>60]9";L/X/L^GS=Z'0^?'_INT5C5PLGW]
M-^1:HX8*!>PQH@#G,5!WHL0=US_ =4-4>%7TJ;ZY'@645Z" +,HP:"#K6JHS
M*;&RG@JW$C4+/@(?VT&V?B*%&=Q.:3#Q,7H,\!P3'#_/H0\H9V,A783SJ:%9
MYB[)SOA1BPNK"*H]1?<CBL1ZN?=>*$(F)M:2Y3GO(?0C<Y# \Q+.+MEV,%L$
M1]#G3UBV>E(#:!UYD\ZUT0$:L_+8\34@L+U_:KX9]Q#9YK!JPI/0SZ=4V@8\
MYZI]I?MKU(V<(D'ZD5^*##9>V^;XR]J0'.F4\8T&K6K<C&1:-)I+G. ,R7)X
M%*I %79+[=!_H0E/C_(YH>,Y$2GNZB74"?LIRH^UC 3I7WH,\]+I5FFN?7<,
M&M9[6QF^5<1%^?J9/ZD["+N:)^C5LO7Y92GI<%>6M-S<7YW:+U)I#@K*;P_.
M?\?ZP#TU"P\E6XH6/: A)-$]VL+I5A7.L]Q?J+'P8F-^6U92$&V)W*A[!UQV
M1_'S-+(AQ,F^+:*S+D9^[9%\/ZP502$R2*Q<^?:UGDYT'>.,OL('G_;I,.NC
M5);S3*MG]M*+T]&.]H(:'+6FY$5\!^KPZNJ7W4'FXOU@JN-.Y_#2S "(J'Y@
M&]@5M$2-/G?:1K0;9NXZ5'*2(=>Q/M$",9K$NVN8XYKN4LY<[LR(KG'4S#_*
M:F;\Z(>&2)?IAB)2R"#TX)LQY4&=WV4##50A-9+S&>$I<(G:;$EZ <%_8@TV
M;SY64;?L#K*3E4E(=HWQ"9_?699V\O&HFI9'E>QDPR^4N+N%S==0P%/+E(K0
M[Y*38C4\;42]?]<HMV1H,9VID'&1O:+33K\HM<,>>(@M@?IL=4?>[@VX ;[,
MA"E<JO[)WN-2!$2EH1>*' V[=:NPFI?^BAUEF]<H5?FAR)SA^0]L)0^!W3YP
MW9KO(_<C>21>V58EXM3W/<T1[XI3VK4:2#6RG@=MET<;C%#^2ON;\GC,.>WI
MD=[TN[=6)G4FV8PBCYF$[ZE[R]BBNEIHCCKJ6AD2! XFNH>T>4?08AC7<42<
M8N#  7,Y6:<O$0JH=:GG29.7:)I@_[3&_?OZ#[E2FM.8R7J-QHPHI+, EO+E
MJ1[X(L<LGU_^[YP.UI>X2+3]&V<>M)U_U@_RZ)^EI,V"(/A*^3DBURHQ(>$4
MIKZ7)QE13<73 %SN3A$4%0FSK,L(:Z0$E=9R6]W$A_YVL1# S'<*>+3'C!%Z
MA88"Z-)\[]M"[@.-.HW$CI]$<'<Q3-SZ[D#__+\J5)-:77>R6EZJ:>K(I-K?
MLWFT^C--6Y"86FN8PN0GNP+^X.67\:,_PU.N!R7'H1GARZ^:IU\?IJ\H!;6;
MXA^Q*+GV4J9?[?E2 A?[8J&B^&T-\M9VA+]YRNV+A]29]MIQ]L#3[:SBF!^(
M%K6C]L6 :NU)X[_T%R?/NM6K#O"IJ2[P>FE5-41QK[ZK5\X>"9.5"B7XB467
MNY&G$8SX79)O^(CL8"Q:9L,!YO_><GC^+91'D</SGY/;NMI&+\=*/]$L'^G\
M"'#^.SYH7SQXCCD35#-$EK#K8,NEB!O(PFC;H.,9P(RN)_4W/R&F=3<3GWLM
MZC8LL>V"M!$%C <WR2'N*7S[6CZ+[4%<'L!KUNH_N)\T_Q#!_6X12RP**/*]
M5 2\;7U@WM>I^#\%4$!OA 55<$=YB@;N"3J7<"\*&(OXN/B[Q!$;[\-XJD59
M<A(^RWJ,G GKXEE>NRH\3C^"/C8^)4DONE>-1'%1D6J,TRE%83Q0/@KVADF/
MI5W=CR+3[.U$C+]R'YBDD@?X[I=_HLC:HW-6HMIY(&&%1R1-]+*L]RFGLDX[
ME8:?:95C@XQC.9;!SW">0/[BS'#-08E@[&_B.3\GB:'B$W5FG$';X*[\PMKQ
M\%2-UPAMLYIGT+'\F+! "V,/)TJ6#HIR"6V/3VZL;@7=GJ>I#?M: 27X\8I%
MSPOG5MG/=HE"W\?"0NO>&TX?9+HR@2-Y3E_-:?85-L?4AF]CFPI/?S470-34
M$! L8BV1>I2Z5C?4/(CI 9;Y'3F9Q1\-ZRG-D\GXXP:;S=W*>E,_,YP#72PJ
MI<5MWA$%BUBIJ3-L0R4+1D@I*X$>/%VVI^;1Z\!T&/F][;!F^Z"3%L+[O588
MR8;UV]M(!VV:;4=,O&&S?I9@,2=-L_IOLJDIX/Y-05+7<$?8P1<I*PG7X0_S
M Y<*Q=9%/ZLYBJ-9ZY[O6$$PO[*].UVG#_V.@5Y<*UOB2>3(:SK:;:4GZU]]
M5GK,F[JA$>I8^:,_MXYD:I;U4>&2V6'FU!.?9[B?<KD9:%LTV%3QEH+2^I[G
M4-QH4:]\R8DF(3&957S6N:^6G(T1*-O!U9"\E6A$V1+T]=TKT?A0#VN1)MMX
MG#M)+W[FVWC0OL[\<@1^ 0;6&T;J1Z5,XOIOUU7+1I\G^JM0<.#!]O4T>Q(A
MKTK\YV9%&+^0##N>\/P9"7IAZLNW.*YQVRDI^J;A0I%4U2AFQ#T(!02[5%!Z
MJR$!P=_CFY-=#NT,:HRQQ%RY)N$51?T;B,8,W%NAF3,Q0GT8WV?.YK8 MH6R
M7+R:DT?;KSPM1""I2(O 9DBA>Y-*:RMR;VY9.$.DP65(F" Q+EKH'FK6800^
M7DY#+$!*"&A\K19[F\P+D@J&!J(].7<$;IDQ"I%M86RW? [@_/CWX.W0<_#)
M08[&L\HQ[O0F*4&+5$^<-6_]-8%;SF/'3:9Z_;"_:6\A3=<J&T_-QKSP!2K>
MS(J2NSMUZ0W-UV;6E;DQJPPE*O@!' !&GOZD,%JFE2?U?01U<Y7."M4H==?P
M2R5@-5U:?,*/?Q0,KK_*.+[\T\9Y<CL:=^^Q2G7'@6?F[BJS=DS;5;A-IU2G
M?OV]\>21\2QTEX;JZD%ZF:GR7<@ZL8U)4#D:C'S@?'X/'A57L:9]TLQ=MG>R
MI\UA(/UJ ]IEKS3>*T"])*T'G(JPZ.%)K\DO!E22;V"X7891MPU;EQXW$'O;
M(+]W.5$N2)5**ZZ\IC7"<VV\#*PV)K+BO7$Y*)^S_<I[\(1\F0H7[XLS(JXS
MG6C"F\G< 3^9]'N!T%:*U9-^EEXD9R:!Z!4HX\\18>#LP;K897^%207MU6,4
M0&/$2'MV+Q9389*)#F?.Q#4FTQOV6L,SG<%:>E7KF/VZB-6]XN5=^KD^_]IT
M=>(WMHW(N%S;6Q@9B&9]<KFE/U@*TMUL=JRW9VBJ:/'+K<B:N^';@A#Y1<-&
MTJ+S:-;M#L;OC^G\SSW,8]1XU(;^V)/BYZ9<7Z[=[I;<>DVY0*B&+4==F+_A
M\]*@W<J2QMWR7>65%O_>FV^.LNQ]Q0Y]&0.:EM8[KT"[ BD?BZ8Q:IU AY=Z
M<"_9,Y_V2F+\C)(#EF>A.LXB^)?J]6*-M4&YHE=4!%VKVHG>W,C$KY^$91K=
M0BUB):=M17^;&*#Y/5XUP7\$.@'G(3T11QJ*3+\H'5" [/0GM.C5 YTI%$!$
M735ZB]T01>;NU/.9MG;B5MJG4,>H_"NRE//WPC=S!?_(U$C@UA*COF7FG/F>
M9[>1RTB&9]=Y._[@F+<J8DZ$>TXCD9;,FPF][_.X&T02(LTJ#?NC3O54-"S]
M;I]PZ64>LE-\BFWZ?E0T?.(Y9(RP%[3<8(?E7B=]O!6/*/%1HP@T-%*@=_%K
M'+&73HSFC$E=O1D#V:VC ')H6T@UGO&[:>$FH::KSI&D3LF154?^W='/$">I
MJ]"U R=]0<G2T[)QK&R2A6I3<ZK-QWN<HRT>/"EL!XF_VG#TC1?ZRD2K?WY-
M5M+B90(B?^]?S=HA^OJN>E=[WPE+"\:2U1)@CF&WYB'U?]U\S'*P8IQ5]TF^
M;0HM.TB1R;:3>K_<^%>^_O6?M:::>/. #\12^^/?P@.-,(K=8X]T)KUEK0MA
M?'HN.PGOHMY5_GBRY7^K)CHA<RY I5UQ*V*R0N!,1848@(IVX1)=CX$(MJZJ
MNMJ(A25SK>Y9,Q1J?\R-%P9](*=ST+LG1-(TO5\7&@6YIYQ ?J\''CRM@_OC
MABYRT*STG9=_&GV0+%]:V:YJMS7((.#>A)BD3"NN-YAG)??4UFU@;^DI80N[
M H/N KVY[U[B#C0]]=ZNH#U?.6#'_*IIC;]\GL')>>Q5J[K1BY(D#$^[4N5G
M>_.;O5V&9._&;]_>F)<=9$4/P$L;KB,]S@&W"K&9FK]I7NVS)6XEANR9+U^<
MR<NCD:KXH0"//H.,<L]9^9*="\\'-4F .;?WM <Q8$N-&=8'>B2SX;RA@@W?
MIV$Z+H@\$V'=[AJ_"EA0\V67\<XC(!SA<Y@L][R DG6]0"8&F1K*T5(8"/.Y
MM6JX[G\JV8002PMO4[-2B\G57NDBV1F]R#?&791CYY$Y2R]*:$J:?O13G(-$
M(C[=VDKYXEF]UTQ" 5;O/JLHF[VAU@YR-G23^2L^XRW]LG(KZ.3R%\,),O5L
M/S5JH%$.YM-]@^/R+WG\/YD6+;SYG3=G3FNN\_[WN1RQ9AV<@+"E2&4YWQ"7
MI@C7KB4#*S)/.P93@_@74^'!SV01?KQ6/[E?V?0U):&_W:;@V7O0P:O5OE3N
M8;IM]74A'7_5)O;_S')1BXNY+I+T"+33(0U7+\N9VL5.P$C?N^ ,%""9YWJ&
MMMTJ.E[=#UUYHO@R W9B -NE&ADKXF+O68L4H,*O65Y8Z+1&%[<CEB3&9:4/
MTJ3QPUF_]4 !SXU!&3<1#VPF4\2U&E W\,N-\Y=3@O2+LGBK54V^^E3-1O->
M-(<U:3.!.]Z/IOG2[M,4VO@M>WVP+4CU)$^ZI\0EK4#$F+XIY=IIC2Q<.=A;
MK;:.RTRYC5Y GH:H+:A-E&"F-1O$P -4__OP]/M.BXU-[CY0K&+?K$R"N%R$
MKO0=U/?NT;0'6<J8>X>'\AW//SFWJ)3^0\=!)P$$=@FT?+W;*,DVM\;$O(,T
M98SA97(BM*2W'P0&)1IJ#O^4QW?0<9I/6ES/>VNAS2DC#?_<H31OU4XU]MN-
M84$*3[$V.ERMGLAD3$IP<FY5@^F5E=^$TT1N)'$7B;JD7;JBGDP /!&"&\D?
M,)4%4$TDOJ-*AT5T'_+K?4D-<5R0*12@S[3NHH9P;KN)6!I4EH%%-RD=%A/M
M@;)!<KTW7-:I=?2\F#/-E(5AI+HO><LCY,M8\I7CH[9U=W,-Q$>72Z+W.V1
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M4?%1@<3K17Z>EK1:$JO#MRYL/4FSDDV(XJ7?\C9<V)(6WZM(WD>*E/#.+]:
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M\]@9YE(Q+*&V-8PQT.&&>6,,!$;8X>Y2%G3;/G]M*SS57)6V36,&_/%_FTX
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MWLI6]BFD4*EIP_L!_!X%> T-YNA%@G@+D4/:V?A&NT)_FLQP6K-_OV#T,]X
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M0X<#Y!J?K99P=FSN87/I.0=39G'(/##K'[)Z_+V)4D&TB5;BN'\SQ,,]_QD
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M.JO6IOU>]6.FIU.8$GY4_)3/=[LUTMLEHOM<CN&2*+URUP%\W6HH<3EN.^J
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M.2=T\!%=_[1=95UXF7;%:SUYC9T^CC@?GU#@1AD[SHMN/7HUK)W.JDP2GGY
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M?X!79TH/#'%(Z;[HF8MX%  S\>X?VU\ _,WISW_+\WM$T%?*:E5& 3[+/I!
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MXZ#9)GX7LOC(E\P8)R>&>79C ;1(CQM(J$]5?*GNB W;\NA4<.HGC^9NIT+
M)RQW,&/W@E:?2J4ML>T56?=8+!<7R.*[_>+>V4/#[(&*_$97A'1OW>J*[AZ?
MKLLR^5$A5TI\;9#,073OV565ZRVPGS+E2WU7Z+F7Q]E3-B>QM/O ,U#.;\\G
M)U==<OL-;6"]'@AQUSI#[635I8'0?K>N7/(7M_@?&Q1 !.G.@2AUO8C ;*4(
MD6T-WA_#AVD52C<M^]7V>1_7@T"I@*1J,R?^WI.PFR?I3J6&2SJVLU^7"W\7
MB6T# IRS,C8NR^+N!&>/ TALG<&UD5KMG0^3\IJON#]/*MU^((8R3T^CG0KR
M.[&)R_1EW'/Y^LE*N5^.<S;)^K1D,"M@8 [!>$\G: IDY.[M5.2]=<2U34&W
M($CO?##5FH8X^0P]X_;*@-9#+OBJG?_/D_G]O[46(TKD<#N5S;-I&S*MB;;G
M)Q@ Z;WFM/WR<.0/PCN6:"7,']!=\4 A?S)5!R/IABX[;[;?N\!?B2?LMO<J
MD]!-;!,4P!"-T+MOJO^7/!G8XY0C9GTWW2A \1ZD4#3&Q[32[N6VT@L[5B#V
MT0^HW&?C5-_MQ+?'[GPBSV:KCMZTAN!$J998,"@3,$\@^+I0 !$$>K^L&Z@I
M0K%[%VU80:L-82^<OK4XMJ]IT?-R4+V(OR^,56)$ 2I%>:)&;O$RV1$+RV45
M91BO^+QXB?G)BU:7#9<,VVS97K>0:YZ3X8.9W_J(LY=;9A'R&E 6J?5C,A@R
M@:;5IV_4FK\^S>*2F<C_](MP7;6:I\>[@#MS(/'QR)4HPX\J$$B<.#1;84ZA
MBW,[A7S_G4 1=M:236+/*K?SD3);9.WPDXZ7V@F2O4R08 T]&0)U*>:JJ?>;
M;3!XRD=A'W5"B_HY/<^BH2@Y D+;WM8(&?/>UW?E[]036/XP6/+FLF@L+%6K
MZ#'W=DB_8?$HJ*7Y.<&5QGI!$H3_M]+IK;28\C"A(*EM*[<;S2^&1]B/TFNJ
M;:=C.*5YJAT+IO_NTM)\6U.8B8KC?/>@+3:HJQ$+MHNIE&9PGPJ*@'TEIDIS
ME:H25B\B4IQ7*[2B$/BQ13(DV:PRH=9>..:LRB_G9FQ:.>-4FOV&7!236N/=
MZV<,BKHI@O#<X5T;J?*P99YAE2 FDJ-]2:T=L$V";.U')M<6.;X)M\1 Y_X/
MTZ6'S(E#8Q<9VW'T-@5ATK:)6*V:+N511%KK;)_34DS#'YE5TCUO*4[LUTIA
MB 9H^#48AL=@68D+5N+$/DHP;8B<&!XUB+HKJLN%\)/F I?OF!-)P]G&Z.]L
M-Q+5'5" 6=PV.M/, 242!@G=YXL.1TK3;PC)&:IE/DN]*\(B6S,MA^@V<.B6
M771'DJA.BFK_71#G+C"/NE&=XL22 3_S>2(]M@*$_8,:?S6Y4[:O0DDP_A^/
MNYY[CS!;Q=P1C?D?3/EA5" )56?8\Q%9V:0-4Z*4EO)&+.^:G;/NX.W3/0$\
M"*?@#9C;D82$W9VAS,1R0[OC86HW/CE"2ICRX@0#.=[S\':&O?*"C?J/$LD;
M6>#AZ6"+)T94M:$U9N=_3S10X-0:\*T^^DII*A $64,[A!'Y_9CWN?_>^>T8
M:.=?@]*RG8JBS?Y"2,>O_V^+RL,[6:'# C.09:5['"T[?:W^V&N&F^I;=)"1
MBPO8JU>ZQD#/YO((^!#$?*\\@0)L8A1#Y^JA-SCE%_^+=WP^T.1*;<@XFQ3^
M'[NVJ#4B@1,V_H)'8D!HJLWXOA8%*%3]$)A1\>6\Q$F%Q_?'_MD>D)#-'4>#
M\L-G3J# YD8#.AI'U#7X95_H08:[!BIM.GD1:XB9HA3HXW,<N'H\_NMO\<A)
MM,O*&'AK/8HVX.7_+'KS&$1UAGZFX9V3I8;.VU=QF=CD)1(7Y89O83QMHW*"
M;G826#6Q^$6<V7P^&PP_DEVSL![5YOVX*)W5'=-Q$2Q-$-6KQ.1)$&4V[KXH
M8UJ[*IT<RI&L5>29\9N.?@0DNBZST>K0C%KO-TCY7B=*LO Q+U_I,K7LA(\Z
MR,;TVTM25M\4=AQ-(SF'_B@RKKM?W#8<82_+7QUZ%TF[MW*^AZGLO^>&$H0,
M![=4E-:GERB]:_;5<G[TL.-9R24:MQ[X)G=*03"UNYT]VUNFA![D;/B%/?OQ
M(/Z7M)^P=KZUY"^%%LQL;+BJQZZX\Z6N\6GF?\]U._\\C_4Q_HXQ^W^Q]I91
M<3W?MNC&"1H($!P"!'=W">X2'((F0-,!@KL'"(T[-![<0W"WX.X$=X+3:".!
MQ^]_SWGCG'ON??>=\=Z'_M![U-Y[U:ZJN>:L6K6J:65N!_)[92YQ ''&@9H6
M$D9WDV\HL^F8H9VVZE$J@S#NI=/$Z*@@I*R6CQ'A^7XNV+51FUO(/A$S,7&
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M4P/G?N8EK#Y[*,G=B, R\M^(Y7GV%&!F(8]>HR#S2%)WQ$WNL J$L C$G]+
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M]3B6>S==?X[ALP+Q&Q9HT:W5" 7:+M""RE>X-=_^C)S=-2MV5D&GDTT5_C%
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M\:P)<-SG1N4BY@DA8O9&\BL&6)7&]P#1OB=@PV5_7>RUTK3]!FE]'&<S!(2
M?OXJF3+G5:0OBHV'7O?=Z0.]0#LKC*M&>=_,R(;MF/AG7QZ)D'CC7U7W&5+@
M;.TKN8_6/T!9V7$G_ _?W'A-1>AC*'%8]1A=Y?3?G[A*H$ENS>N[7CRBPG,A
MMA-5]0>#RE0TEGY]B4,&,G!N<W#UOL?)H; !!)H*"DA0P/!\R10?9$(.#]F*
M^*MV+FBN:8LF9.7 <5),GJ#[ ()YRYPM#H,^4<_P4:/C_?)3&+]7G3XC7,\B
M%;9OV?)VW@3M\L\G)/!"%MXN%:J;9S$BM;?/^"C"BHR(A%VT].%^:+<K[:?W
MXW]W+S6GVK*[VU]-/= 6L$6GX_",U APL'A5/V:6*:M.?ZXM(RX_8LMK:(@T
MIXTTPWWL:#/*06P]['OP43Q[YJ%%:1W//#C"Q&&K),_TVRK:R#?^%>465L%;
M>4/@$L*$,##*]K^-Y?/9V%(E=,4E SNQ+M&]!LPN):@K;;<D6\/]9T^1FN=U
M-F]'Q$7G C[[/9#[=Q*5ROK=?U$GN+48KJGNN\5_MQ!GH-[8JU",[6;0T&RL
MC-\PHP/R$0/3JW 3+UP77TN.6=JC\#*-VG[XXSYWH*#.Z55A%0O+$&3V1>^5
MUL6W),VS5+/,2B(9$)VIUZ)U#GXW"/GX-;G0FO M$<FY\ QK#V_W;JH:**!<
M87\J)('B@-[/HY!KCQ?[5>M]*=LV:>0/U-AZT$)9<K(T=+*N:5&>#T*^6Z1H
M2LWQ?K%PCF)8N*X?JFV=6U*[Q/.KQO<=M 9<U$?[2JTEXYS@DO"SSYA@F4($
M5)<$36BS;N:4A$]:O>&-E-BA.4WWO>Z9+H^#U@^T.D$EC=G:;Y8%?,<]E$FZ
MI/&L!BL__H#EC[V7$D8M6#G(8-#Z@* 7AVJ=1Z,J8<:4LCI@![H4TY;]??6H
M:!0#+8QUB)H #S?E(3<*6N3<8,K0='^;E?%^YQ#]UZW[8=F5.9IHO+D?\3\F
MFZS@/]D.E9%2?'0T'DV@0H7[%W]W[1.3@WAWTH=]O]>89S(TV2P@C7M%KQZI
M^JPW$"Q4&)*=+Z]#PXIYK._%)RH-N;(+I,6C+)G-?K7>ZZ0DTC".VWY=MJ>E
MKP7II]<DS[8RZG%\]L?8L;\<3GV!2V:];])!AJJNJ<V1UY#"/!ELH!3YJ90W
M<E$T7#NWB_AN)D,OIST0Y!QK"63;#K:>N4"6*I9BE/JT21<FM3^HR883_%F
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M;UJZP[]-6>?7KP:>0\%Y>5../N\<(C;J5H__MJ*Y+YA0B7%1@-_E6)CL$P+
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M%S;*RB)[;E;$,+@&6OVD">TS,\3%_8OI] 2L*SP!FS;/E0F-:0A]_J"=<4_
MKPFT!DV3-\^%,$0\K$P?T)^ HW^*!-NO$C\W&.)S8[Z2I%R3]?!_X"5H:^7@
M>/YL$@^JHCY^J9=GM7O[7/\\$FG)I@I?@HK=VT-KZ_$Q^Y$^X?'URMY?C.=J
MK$W_VSN,PP)$01Q1O(=E);7]/SB5:-%'U(XB]W+^PZR_^!?X=Q[8:\TM.,V_
MO*0.]65EQ.;LG8&/<KN>EK0LWL SW6NRN8J0/PT^50S\PE2$?%7Z!"R^C$LR
M Q4^2ISBCL5&L.9@1/U@KC&EO>1[M1+=%WND[TD(%M^]?9^[F]O<?.O!ET 7
MLG"A-$]*#]W9L5>50^&3583P,]DRWBK0UKD8NLYGDNZ%$H[G7)5QCIC[5+ L
M3'%7+RV-N '"L_ 1"!KA&&B^=)U\7AGK8(!YNBE/]<CPW4B^\T!Y2P7JF!L;
M#:*Z$XN:$ K=<=(H%V/&=CMI[=A[I'V-3.2^(DO2&E\?LT0L&#2>0K+9JJ"%
MS)M_\IT84[!YJ*-NWE3>^PN,^AI[DD*'V [4PDWMEGC?9,;OZ[I\VU*%MV#?
M+\,7I-)V]I[45J6[3L'JTE!MLR^@+<"B8;$/:0(CI+;.H1E%)'9S;I<@@*L8
MRWBS[K1V"\L[</='Y%&EL^ZW)EKY^@0'Q%@U8C.(UOH6Q.+S%\W5+,3HS%+.
ME1:MP%'D!-2B<[_$F4Y"AE0NB(+>RV@FQ&W7_&7GN:0F<M=2*<>E &+>J2'O
M&0\ZUR)FA'@0I"MV2,X&PPVB8HF:/XI@P1V)(V]8C?71#$I0O$?(#H/(A7]_
M1Y"%HI>X4RK-CD:(V7ZR/(O^?S'WGF%-1=VZZ$) %(&(]!H4!"04:4H/B("(
M$%!Z%4'I(+T3BH#2BX" %.E(E0[2I","TGM)Z#VA1@C)C=_>I]Q[SW/O/GM_
MY^SS8^9Y5E;)G'.-\8YWC,PYQJ.W/F,I^8]5AY^ZA(S&[<O<DQGO(_-Y%=*M
M\54X\8F&+E?4%2_:1),:^!U0^N3'ZM .]Y.OK5HO4N953[)CK9L^L(@^T( S
M-WQZD<+A#S,L"^_=GR*;+(*9O]UK67\54-,8M68(L?#<BY"84WKIG[GL?)J2
MDR+*.9>[:X@>CCA_,M5ZVPOV]*&0PVE>DLQFCX'DD,J:::_.6F5UYC9+:AE'
M A)\\KSY90U\/[$/>X\EDZ!5Y+>AF_;C;0=!?W.T:2W#PR'+@T_7479ZGCB_
M.P*)O$0!]JLN_I#&_RY@)C6B!+B<95$U<Q:9#?M[?C$<=)5V2E!>2)9KL05C
M= @FXDC0 *>.$Y_2DF=-P4+ I/#?C:_Q@%\6.O_ORKKEMG,&?OA!"$Y\DG!!
M(18")27H0SV!.OJ!T;DXNL(0Z*9QY=]L<)<^VYO95$8XNOH0%>Q ,OALOR'K
M5N]R"W&73<XLAOC"\& 7Z6$D$<2;%]^'A1J>G!]>JOR(VVF5FJR%"#$-V/C=
M?K(:W!W<#P O)8<\5JU8-:]FA<OP(-0]GZAM-=-0I>WNMEDUA5#==\[Z4N:,
M.OBQ@GL]*(W#1@QB=)"4*EVF-T5M7?Z<T4\).6VLL%L;F\>VR=HU9%/9X>@.
MWA$Z.=9VT/YW2/X(\#F#V-(%"I*7$RC9AI&7(<#2HW4"3 7N:-<Z46!N/!I;
M;1VO\;\SNRB<</@H5ZYS_()\UTY('W6:4EY;LNUAXWZJ*K.IJZ$M)YP@!>X)
ME*@@F_V[48:NIS239FQW.<PS\E;7N[ALME[B&-#3C3*LZK*JXY<D[-5XZ^KY
MRS0!K;W$ 0)R>A;162!^?O>[@^;KDG,5G]:$SI=['#XQ.G4;I6;RZ_2CI;K
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MQY=YDO2ZF"L.BZ&,J7UI7&BR0CQ9OL$2'7DCV9X]P_81PLO456=RG9Y5@K;
M^K<_^MGC>2V=ULG6W*.<P&_[8EI*KVS_11?4/?57_I8XN,YU#&@2%U70IR/)
MHIH=RDT,O)AG>?D=8IBW7S-QR@@+=&R0 5><U6LP(2M"9%YI8VKH9F%U.Q=Y
M@Q6=/I(5ER1$($^<LC7Q[&8>&0=UG]C_>&G_?[_TWG"]9W0SK*$V^ TQT,_X
MB@P)Z9.CG#&<WV'G-]A[^?'N-#F[N$.;Z'$?LB6CB?GPX%T3=W'>]B)/HM;8
MOL-SY*J8@-CKQR&NA[(^$4"ZYI3@7L!#&V96+8.RQ-FKT,W^=5"R!O$*AU]N
MD(%')A]ZJ&T%>A,#?_)]#*&F:O2ZNPNZK?G@/G#1A9(LH]13FKB+.<JS_;9U
M1EG8:TV]_P@LH#'CQ8,&9_ $B9D\[T4Z13J5'U]\$G#4__0F_IJ!G!^VL(V6
M*!;11H]]A-8V#$NTDDLGW?^\R].6(&=$$A@DW^,"DM@R7*3'I'M".Q<L#"9?
MQ1@-"BHR'?;\$(9ZQO3*.,,P9CG;/J85R!FAXXM(R\8F@1MJ3%H<\]B*"BUC
M@F\L0UEJYB>'UHWWM)!-FICH2Y@VOB>_Y@T.XF0ZRR;&T<#99JV%,>7^,*6T
MP6EIFZ>T3[XE!AUD]8KO^B@74E7GSMKJ_J$V[JHJDE56432E?)T_>#71(1_>
M42*Z@ZY4%2PW=[K;$X!^J<+E.21]H==L7:>H,5*ZV]U,C]-^6@#Q^V/M&SI,
MX,?>O>^Y'9Q6DD/R!@;+,ZXW3?LP_)"\I"]$ZT4VJWBO%/FQ(93KZQOUN^H9
M7I0O-UL!KNV,>YFVK<4T-O :JD1OWBZIZ/3'T3$W2,UC*V!#7]#*Z648(Z2/
M5Z_Z*,^$??FKP_T[]<9-;-]AQ)O7H*& >?&42J\L.?AFNE5+V/U@WY>/GGUR
M82'[LGWMM+RZRW-1UN$-:FY;2B7\^!/9N4Q]3)2C[-&0W&>+B(Z(N:[9@^X%
MEJZ' 6S-E=^NU\ITSUO(LZ1>N\A+'-LR0&U)A69%NZ?ZJ2[/X0%JD^%[#VCV
MELC+-22AO(QSQ[U/@?F19D^D QQ14%TTU^^8UI/$(Z)R[74JT/\'QM3CXT/>
MXH^^@Y #_4!*<+VW322M-XNCH[$BV3LGJ 5&(<?61R.C?'I'RG@R]NXDJDKE
MG3N?PJP/=>]:Q-&E4*>>"U8-1JK*?<DWH.F[%Y*MGHW+M<9:$U>CH3'-JME;
M <QCZTVUU>/NO,US9<I(UEX09V!NC(BHD2G%A(R):QFCD[LZV&2467;)H3J>
M;L6Q\^7&$=OY>!;UE+;3-Q)42WE;KB,>>/I.V1 !^OH2W>ML#'OG)^1"&&BI
MN#IQYWEY>%[[]<:'NRJI4WS9API;,?[6Q%]:X[Q\5Q8BNP^[RPR]70$O01$B
M[(3=A-W/VCYXG9RLM0?Z<WFZM=6G6,2V,AR]--2B[?9OVL\$2FL5-58CZY)L
M;EZ>Z\V:;*#^^@M@*QD+X&^OPIPNQR>>>K65>>^>NP2JFM88?*BBFS"JLUF:
M+<MTU4D;(P.<M3Y)>Q8[O&]UUR0C&87;.R]6-P?#WXU1&,'NI(CR]8TS-Y))
M<B=>V%]$_!*.S>=)['TVMFYN:1?M%13L"F,^I!Y2*(7Q\.3??A\S[EKYK;EI
M_IGW\,H3=\;7,L)D._KL!K1!3W)30^-K!7Y:') /?O[S+FI5QZ5W,NY;MWJO
MG;UPBDT!#6S16>N!ZI9VQ#IMFNBS]2CF+\:)8F_21)5NSWO::H[//B69X582
M0Z8/WJ;5C]>XU_P\2/E>8#CMB_?(='E2 5[:ANRKR(RG5S7N37=#8CJOVFS#
M\B4M>+*1>?H/KWA21.@Q*Q*SKK3(2+)I3[Q?GL_E7#\IL7%H!TTFE5-.YU2M
ME-LJ-3"M?M:-JU)O:+?UF8:P7@L55)C/J3XZ^ZK3R&'E 6>N$TOBPA9NP9BE
MJ ^__"C\V=<$N8O@#+NT-9>^ O4..2F&5GX$%$6R;..L21N/S+9M#BL;F1H_
MNEG\&</-\'W==X$R?_0*V)$P"HEU?K+(V@;ES0!-14CJ[T<8QATA%QOX<\O>
MS"T]C>W4[<IDFOAD;@*JLTU%%506RLG+(8K++7S<:77*G;8\D6L/Z(EC&DON
M<E,V&B>=3XDZ9=MI#@D[[FR[=KM-2KT^%#J@-[Z@F+#5SGA8=.P!CQ.%C*L[
MB[#2\["YZI4A,AP]FBW+)?M*0'G%B0%(HCUU[E]\AV51;?7@TZ*RK-VB2Y4-
M)3V(<..Q":V60?)?JT47M!*>";VR4^&0):$_4 _>3ULJ6@^3?L\5ID/)&J'S
M\8SD901PV!9H=PWE_^>9=Q@F_*2GN]OG]7R3F^<#Y-Z>K@>7P@8=A8^5(YPJ
M:44+8]8+IC@I:?03L!4WN;.ZT<_I#+A1-)+<WXK_01N'4>DQH_;3L2G"-/VV
MF77XPABROVIU5\M%0Y68WU>3K%'K238O  #+1&K_YHK3_[7R]$&DS#V&#XBJ
MUTUV:G,LH0UUC4KSFB%]O6_MOFC*,TG*HM7^E?_N^/CW%.?.&QC:TM@<_6Q0
M*U(99!IR@62BK#HOG*X;+YKUP^5RBTWA94V?7ZY(<KAO^QQ-ZUG\R\VN:0SO
M5D9.]LP,TU87S&R?7S$N6.(3'B&3E7+=,V'[M^5W)0O&JB=(8'U=6R9<'>A%
M\<"5<LGU^CA$P3-_NVT# 8$U_T,%FOH2#N[$7=VVHSW0Y048H?TIK?&P-'ZF
MX8\E;.BKZNNKJC2WL78[6E;V4D8=T+U/^1=WV["H2!R&3DCSVR&-08%7/%0J
MNBPX\T':Q34C>2E%\"7JGM][^,9'^%E?ME4OI<WW2BSO!5,OL+)E9O'G)AX8
MYL(#K4KLS\R.!J$'\4_[0#&DD41QI?YU:395*34P/."7=@'IC\5Y%UX>\A[F
MXI!X8.E.)(><J)0?!LD$P@)C1NJ?8T]NX:BS4!75V!H<$J=M;[9?L:84!V:
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M+W>2%]?O>)R2T%_:):+Q0%@KA]>2=HQYMA)I1@.$0MV=R='GF^2./%L*5O"
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MG& )->?Q]CCQ'%O</(8;7X5,^A;OTFV ;;#LEH"?,9)<[YR7@K,\C40MB;:
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MA20RS4GI)%N!'1(57M7/'6<V(.'%BR'S!4S-5&;KSN/&6WH=P1T3FOCY)R'
ME67WPB$LT J.3!4M$)I2C]5#.FR_*%&I5:&&@EREHP/Z'<J][^P)!Y4EO:DJ
M'GAJF7+10)%"(&L\>;$*3@=)4&NGG23K#]4)*<LL$SG+T4SK^][6R+57R3Q
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MG1:DE;GK@OVYN28X99'H@H>WET/9KMRL25[PLXA;2687UEV>O9[Q"CNP^T/
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MBGB[4+J]9<: JXOJ"88/!QPXS@WK,A>T6#'(S;MCW!.X/^S9CQ_(%:M=RN0
M6_0TZ(]LEFJ9VSLN%G@WW2N O]PV7T1*:(T'0[_)DJ]#:H?=303-1QV>.E#9
M1+G+1&5OZQ.'@=TEMQ:NZIGV&]4ECFO566M_>J/B";/'?_%((.:\Q.%JDGVA
MK6%I/FUU1/X0XE:DKL;I53,E^M2^9S:#2=T.FL^]#&!!EJ%0:VUG1L(3J=-&
M5=N9KT9!]-Y"]H[%"!5J_;?_EN?A!DW1#G?9I]1%)ENA] @2 <K7C$K2I*C$
MKU&!I9TNF*NI)IZ"Z;'WG]@\8B^A(B=D?F28)4F<\=:?\*ZV9T/3<\:3UA5U
M]LW=YQ=Q=?E0]H].?K]@N043M.Z1+[=MXN6WCVQ:NRNKD[<E)/3V []X&7Y(
MA1;Q#XK.A=;3AZVV:PZZ60\G+FH\B/1N$Z1_PAWQF33R=)\/E+-7Y%^&!4CF
M9NRT7)T]<V8*)W:><'B0K@7I LN&AJ;M_X>]]PR+:LD60#<B( JV2,XH*!DD
M9QI$DH@$R5$D@^34Q,8 2$X*"I(E29*<0;*(Y"BY"9*AF]A"T_W:,^'*F3-G
MYDRX]WWO>S_JHVMO:J]:JU:JJE6K@K=1EE+[!0M2O/<J*DF^B52DI(0O.<MN
M18RK_4JHU_^>4/M=&2K<#*"9,#%L*_/=&C(27O JJV<3E1(%7$RB3;S@:NH5
M=4C+'$-9%[KXR1#EQ0<_CM3@'M"-9_Y+^I: ?=$IY%@D2A #W$3S\FP1;/,R
MXWZ)P #:AT(K--!P/UUXYBX]<^<MY7P;EN?5(PMX$>8?^J%':LRE0MO:ANK#
M6T(J[(]WBA9KJEYY-F@6+YOMIU_83S%5&Q=<K23FW^8LT%?049IB7O4'E194
M+HB7!/HIPQ<UXDW@YW>-UI:V:X8L;^Q*S$.O_' %&CUG\9 I69"Q:XY%AU+Z
M!#N/K40?1V6K(4 C7F0X+9 A;E.E 9J^C3LU)-T+:I7RSN5W-.6M/P>*.)X_
M"=LO(32P4RY AFB,"*X]QCL=<94C*V.N&@W5BO\0.Z(CT@GZ3NE><G+)$+JJ
MT'CU-T\07*NM"MZF#%Y@26"ELG")@5Z<]^#%LZ,AQP"')<^S=R?<;F15?VX;
ML"X9&,_4" MM47'+!87ERY[42PU_335E##<?YS'I,K$5[ J^3ERU$,Z5ML60
M[DLS,:"^1F%P_G"W>VF.HTV0:*EX@?!R^KZD6UCU(B_^5V0PKKO%+>/6D*MX
MG\S&S^N2Y_27(*WH);0:J_Q5[BI5RU>6+^&C%3<ZW*1M5&;'OQQD711- M=Z
M^C\Z^;K9;T;/;L][9WS_U*?7D<M:=W%%[BCFF,3@U5B2W2H\E_#V?7X=&ZSW
M;A'T1V2O\A*MOYI::N<VF'_6G>_3&V;7U"SF'[*7H'/L!LGI&Y6LAP@I1 EV
MBZI?P+W9>/UP=^Y^6=+NMF7P+#DO2_2@EL=-K D^':$<@A2O3VHG$'KH0)9,
M(M[1T0#[QS]H#;N!-+;D*KF&H PEJZ=HG8O!OP]9J&LT-1QVOX3?-.ID5E'U
M()I?IU,M?5OM0XG4^#[HTJHGR7I28KBD/)&(0QVYRI'Y-4?G,'PU_$ >B*XR
MUHZ8+W!_BSK.R<KCFH34!FT7ZZ-*FVUU3-ZLRKE,ZV;I7H)O=[7Z\@KQ@F:-
MYHR57Q1;-<8FN7==H[J%IP@S'OWGLK4PPQ]192%ULY1B,QO"KWEJ Z57;RT=
M%1_7_&I7X!^>U_M[!;]AIPM\47"']+.'*O^#;/L\K^QI,?5-<2=<#'";[M1^
MD"T=E(226P23*#J8P\#47P4-@JHRSI?..5/8C-:R[$LUF2'GQX>4UJYS9N$K
M4.L\B%',*Q% SN0:KC-0#&<F\26,9$2(XKH&L] QC/80(*);]%N[FXWAH8X@
MQ!16Z!=S,0"]] C.]KX.:["?;A:R_I[AZ?4MJ^BL#-BB=$1C])KA;RYDXIB<
MH"5YP!O)4(X^^!!7*NEP[ A_9=W3"Y^8R86SK?.-^0R-%20@^L)E0C6N_GNQ
MVOO^K!I#"]75\0^B?/4>/(PPQ'O$U]5;?ZQEWULZ4*O-Z6;O>X !F%/&_ "'
M%7^U-A%>,Y^&%[$?HC>EP*]X0A:W$MFSD5$SFTY=/=]$6\4.I-,^U]=]'O>3
MR(4\'?[4%.(IO1G>QGXH=#DYO.'R"W-F'>E^LN(ZZ0+4*?7[PD(<S0M2%[)+
M;DTM,(8,E_3RY&>LQ!#T7D&G]:P9-SU;,!9IU^DTI"[[C(],#E'+>Q]Y9R8U
MHJ_ILM;B%M/WC)F QL@PMLP*T=9_<A<-7X7,[<[@Y[#5-J)"_@M'Y-\P &&6
M4HFD46QF)D\A3%L!H-LG7[/^K</[."M--X(O[81+4U>,C%J4&JJ$%BV\M&28
MOR)Q<,W[7):6Z14_.Z;WRM:P$X#,G(,U!JV/^UW7>(&7R-:$O4S%6!/?A?9[
MK#+MR[B;!SIT8<_DX0&O8%LT&_>'$@RA%<%[CI*MPP)7%!:Z:OK)<)Y8+_%V
M3AV430ID9302#G_9DU:=118??_#C@]&+M'ZX7Q7@/DY)W+2POGS4(^!3#KT[
M^P<B8'ORE.&3'3Q;F6%C4JUC=^+=[M9/E)I-!'\J42JF_'D7W>./^:B_*@SV
M",Z[B) 7+-4?A@3#V0L?IG)FIZJD1_6]BZM7<WP[;IO9E _-BD8J"9[8&U9S
ME1EVL"8E^[K-7:_,2P<Q($1:DT])'SA=]9.L$Z9<VU-^2$O2LTXI"?VHQO"Z
MR D795 QS@,M]9,E.)1NI)X8Z'VE;'CZ=A^\F?8Q:;]NT<\%OBB/:,P7X3M-
MTY ]29X(IE=["&V0BH:% 9OE\I#@R,62*RBAD4SX4;1YW.)]5H><]V^@B558
M\V:^!_(Y].7<,+[;QUG/^:*8>]FXF^L>M9XOB0S%WX^+^O@4AR!/J'4C]1RG
MYV1)B*-!*]*RH0)&=^)CO5N\C;5/ROK) ^TC&9PM&"#^0%2*H,LQD?T=,HZ@
MK)F1-VGQPLK(,91C>_3/42KWZV&-$NW"F;2K(N0G<;Q$:7)&_#T+O"&.=]Y[
MT)-Z$:<E\9V"7UGW<D I"FJ_;MHL'&1M]W_W 2L>,V2H&W=+ZFP?PKUWG^QV
M-?#LM(]RTYH.5VXXB;<N6W3-WH](T]!UW,XHJXS[!FN5ITFPD@JR=Q\=7/E\
M]?EWB\K-AR"2]<A\X51!TL.@\%[.PW>=TXO%G)E/EB DV=$],8'Z BFYPT+M
M-^LY($V&*T,E%*2/^&]=>N]TLNSVUM>C>'(6LOTP"F(DZ<IF:3;P[ &![[K#
MB]QN!RX5>3*=D%N_E\Y*5\/WT_Y&R# LRK[RMEF4PF3AS!.I(.^NENJZ&&3V
MSJ,HSIQ1JAXZAUKM#ZXXVYPCO[G/]M,JEXQLWP71^8%S@TIZ1!9/4O&X ?*4
MGPQ*?K&0JO30.J=A\H:-XTVLDT46][[\%$=,2.Y!V((4R$C@,XMNE,X+J(MD
MH0.JC;$S4&SGC&69<?[U0<G_R&YB1J%-G6=C3D_NNF?L])22M$5,0/JA]$(-
MB! E,N9'NK [>;^F%_;FF625F]\7VK*H.?BU9UUB)??_P9E,B]AW>1JC^DHM
M1/S$TF' WJG]QR-ARLA"B(%3V0Q;CR'O172ZO[^XMA4BY/!;\LTW_HZ/#VR,
MZ3YB +9D^W-:UK5=<B;Q1D>ADM=RD%%7K2(4W2D)G9]]8S35V-*[FVS0MBTE
MKO=)J\)%?,K6PZ1Q\(6D8DYUV$J=LO[1Q(4QIA!O_SDW)Z/Q!^D&/9:9AK*B
M[4]4^#& %TM*<["+B:UE_BR2L0.?&R(U'2 3RAH=1RK):/J8YD"%]L18892'
MFU4YTRSFDYL\NYM3C?FJ^%W)NHXIDXA*+$>MO/X]$TYP5H^/OTL]NQ$BPQ#_
M\[(Q:ZCE^-@0FZ24D^/X@Z;.FAJ_&V6+.UOK70.Z$O 4'F;X=C[]:,]T7U+C
MYVZ!@]@G0/6B\9;SCRQY9TZF1<(:\;L6* ^+FTL*CQ@L-ZL.-0AG*";9^@:T
MV!GYQ,2*&/$VDH**0_/6A@WG[(YH%+)OA+T.HZ;A^RQ :4F &[$BQ<$;/#Y6
M)_RF8-4@Z(OPN(]5AECL#>?F.JOI8@&4J)1=?YO0B98TT]A+QO)UGXIRPU+&
M +X@(JDH8H"GGC@J7^HPWLR2>M2#+<O^^_:%ZY_Y:_"B[M,!GN^/5G*%ANP&
MO!GH1_FXXO"K8E!;;P-VJ!BFK==5^?=:I1E&>);KZ@<W<VI>+B]!GEB)=K&N
MZ0A5:,%GT\, [8H80((X.% 4 SQ+' N'M]VN$E$G/%22+.'S@A8Z?NWU(8>,
MMX O0WPP0.LA33G2/W/T\?3"L?;#&X^KJ"\[R]"YKW-^_:=R"?Q'2A[OC21:
MZ[C9Z>F[!#U7G.N;21\,RHQ%+/ 4":EL6?G6-Q-SC0U-7:"AK),;+$_JJH5_
MJX6)B)>$>)VFP(?7EG8XU\&3724&^\>W.%F5I>M2*A![P6&<B>_'^G>@H;U(
MZTX=!N;H'K5I$]ZYZAC4G,8ZY[MBB?:F"V'':EO<]$%1!=2S98J[(=+(G1VM
M"EZZ7@<?02AIQZ'$Z$?]Z!FHV]K!FK)JQV[_#@]$3R<\/^A[U_O][:CC,/F'
M'Z^X@IC"#";VGOX2]E/LJS=26<1_LT;O,0,I1^:Y/MIO3$2(J(.!,5 X=(FH
M^0 !0@=S6)86T8J]&\QZY$':O-4Z O7ZQ 65')UD>R_@",/R-M-?0OTK^S(L
MK;2,C5MP')_J:[M]3]J;>]X79P*I7?1P=]#_9"EVWFU@7'5ACMB&IC++=/WX
MZGK9Y)U.T5$5)47-]_S\]SDCD4S7*)I8* Y=]>5.,ST-E6IL@D4UI>0!G\:?
M'0"=\N$MP?U8KJV%)RRQV2XT\P+5.M+?"@=EJ"9+GN\3NR[S>*@R?-YVI]*_
M^4+ ?%BJPZZ-2 ?^[E9G;'L@1R;/N2<3ET=O_"5!$OIW$R0=CD2WV9- $C;L
M1/QC,Q\9)_HZSH+DZD6[[/;#]J!/#A.=_81+DQ9.BZ^]+9<EC&"K5M^\^&R.
ME37-8/]__PPC)[,Q_%O: JT<WJ9,[!&+"36HM,B'73"IG(?TE1B[[->LGH7&
M<6GZ:>Y&N._IE>INCHB*@*];^VMK)B$Y=F,&'4DS>GWQ=V9&=D$9])%Z-=7!
MZP1/(0E*;\UB@V7)5Y)R@SS ETRD2V"V=!TIP_H,L@QM-8<;>I-:AZ,,(4)T
M5O%'=EZKI[X"0VS%UFT,_!\01 &Z*-\YIM/EAA "\.;QN*I!Y]V[J_,%"NX6
M, W]()<FKC&_$]W*\HJ$Q>Z:%RILUS0,G:^Y^J3EWMW$VM]3G5UZ 97:82>U
M>-$F_=CIAW>#9;QPAYDS&$:%&((GE&:]*K].K"65V5W7FZ3FWC9C4CE?,_UF
M;?@I**_HXDI%/GYVR?2ZYVKKP&TFY8NO]NZ[*O6K2_EO9+P/K^,K(*?6Q[*2
MEM5?M+GV2.3J<*ZX\_/9Q])*;U.2ZQV[1$M$D<*._:@;-U%W>#! )6W?E?CR
M@,N>*Y4^TK^$I+LX.7B.Q7\*TH3]*=,*P8_8U_FD"63.I?"$NB0IC5<KEA<M
MF.A*<7-L<$=L?FO ?BO.^W_"3AGG_8OVP<2%V;7-)_(-'4F3C%R\7T<$SM6B
MN=ZF^MO_LCO4]&Z.N%!GE].]TGC.PF8BP6-V*CRJRQ-Z\?^ _WX)N6:W2;\L
MT<& 7SVZC!X8GMOT2:)OU9H7HQ? JBI!7EIC/9-(R@X^_]0MYP+G@(UCZ^I%
MDR?Z-$<A@AC@RM?OE*7G%/QJ"6;EUCFI']CNR;D-9(='I.<M:"\.'IBDFBB\
M_^!!](Y<\BG(H!7A&CRHZTQP>ITGZ[34R$_D>*YM*KMJY'SB)+/PQ#>Z"O-C
M?Q#,6+@V?]*NB2;LVV?WI)LUSY?5U-XZ^Q,S#"H+[C]*H-"RINZ8Y;5J+J(>
MP8EZ6:%A2'=VC^+NI? B\85+*N6V+M?)HV#J?)'UPG\:9UCJ-#*'MB#>0]PN
MHNR^%GOL!]<)>@&3Z+SD42P?N;:./P'%L;)<<YPJ[>/LDR9.+O/3=!J[42^>
MY=UZ]2Y!2]_T83I(X[=,RS_,]-W_-/$PT93(O1["PQQGK[XFSFG1J5(*'%O0
MC6>,X\!-)B\$4*Q=[2"R9>EA5EH/I+RN )3N=-&-0_^M&=>_6ZY,3[9X.\*-
M[I2U+Q)%\%\H$1SS8W2!;2"+*^J#:8S&2;X?;LYY?:/JRCNU'[$GZ&C>Q3<]
M1H9@ #GR5TKLG.7E!*'Y=XU*?:3&Y7S"[@V-Y5+][-[C+<\T!KVM]M(L%$:P
M_\AODOYC90J&]X6R#%G\[<\K4S/WY<[]*;_)2M!"DF"<")6%Q_E;^TP')2)(
M93)G8T@=6ZQYI)"U]AUU@ X.K/U>AI/)LQE._CI>@ OC>2%1IP":"0-%NO5#
MWSB%./[W'2FO'<#MMZ#B^SZP@+/A8EK_I_?YZ! ?!:6/T'\Y#L[1F(,F5(MJ
M,RT]- ^;S8Q7WM:R9JOO>"FX=<OV!.'M[=+,B-CC0?F++I0,RO,)3]5C'?\G
M?UU']* ]\>=52SW>^FSX,5B9BOT1F<>\JSV6[6=;\M+(9B=+;5A':90F\C6U
MGBH2Q)JDRS"?MVJ8@RF=.^FDPA+Q1\ QL)_T6U.+G]?EQH)^7E&WP7WUJ_2$
MNLFH*R'JT;#*\)D9>>Z*Y,A"6X;AJSL/6Z(1EF5_/D7W_ZKR-[DMZD_EG4SO
MUQB+*V4UL-WAO76#O/XJ@=U>]#-[SV;XRZ*]]B-S+3.!.Q=N3X@Q,8S@K O^
MT334[' GM+)"$'HI[5AHH_X_N2+SWR@X:R8.\%PT&&6& <R\T)5KOY_XDC2L
M?ZBR@-B1^MMP,04D/65K9L2ET2?0-\HG+'_!&-_IRJ2<A9!*,NWM[[6&CSG[
M7G?VSK5*N1CMM/K:/&Z0>&_PL?Y:B&YME%"?<WH@P1(;KKT^8CS$_=).J1U-
MH$I,QJSHHC>1G6_3@&=TD:/^[)0=A8OQUWZZPSTVR')D6:&4;#$CS,C>.\,N
MJ;(UE*>2_B[LFR==6?#D>_] >H[<IZ0/@J?:DQ3"A;)K/HPM*P5]4;W.]5C$
M 4?//'Y#AMXQ8Z&>7G@;<N,I8FC*>M*1.82OI3YG\>U^BR@!;C'[9 2B-V.C
M@#KF=9R%/P:8W=WKJKIP:I^*<-_Q-W/),6K+*\ZZR#E95'%OP%0Y4$'F$P?=
MPX)4 NF#$;ON:_#1PWT- 0/E1G7K;Q-NT28VN&]^+3FQ?KR(G2!WTQ!QA91\
M^X2$ZIC"ITH6CZ@)8Z,E?6@VFF&V$$9TL#WH9!,#! $>^[K7,, E%>P$?E]
M#SIGC6+#/LZ>AQY3%X)WRM%D...#1B$H;E[<'^&HV,'S3X-GH2D2GV -F-4'
M#-#4CU0G,)5W9817-("P&EXHY/00VAJ--# A^'%$M0U] H;)T/N3?X*V#L'!
MIT1CC$=?,<#%I<TF5AOSA>!LEEG6D!.BM<$7(G?]2B2<9YYLA $'=9PQ9SMQ
MMC&PL5HL=[8/&K_" ;<DLQ9TIA.*9W%(O]P4M@0^0XNS* 2*'W-V-UU'W1]X
M!S>>1/JVPR-5_ ),O[Z[AFAP[&)X4YP*"I,FO*+ V#Y&6Q6QW&_DSX9;]I\
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M.I\U+J ")^OGI4:CQ/8I]@-02%(#Q;J!!N5K<D566R*7[[J&2C(/98%G(S3
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M,GJ+%I1@06==Y=+'^1K>'W)@4UG0?P429J\L)+9@"%FH(.@)9G(+-(Q37AK
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MNJ6[NVOH'GHD?X//^YZM^]E[/_LYSSGG_?VQ_IC/K+7N>]WWU==U7U^"=7
M+Z;(R_Z1VL>IFXW?IC.U7[;#3VY;GJ_;Z"3T-U6R+A\>L6KMR7^QYISV7>4
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MIZA-^NZ]7"&9.:@CY[_/\.I;.,CNA1LG_+467^-=^9&C"V!)R(MH[@@>]7^
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M"GY;MUG!$<0#GJ)JU:D&4C+!R/S*/FNK#"$US:1T4^]$3J\CC/^S$%/#1(8
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MS(+;CON6K9& 3>.8@6)3Z]&MA-7(+'-VLKF-DPIVJAFS%'7FHPYH@?==@ *
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M]LRP^)*;E+NUHU9? ]"O 1TY&=> \6(PD_+'%++'F?$#DZD!S+?^W9#RW>H
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M3.[F<@#6/!XA#]TT:VG>%PGDFK^KV<Q]FD ;61]SNZ[6>"6VZ O3. 841-9
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MU5=M"OHN9AGC-2/#G&.&'.'5TO]M2$R,GP$?J_^]RHYB0>G% MY6+98IO1Q
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M#7@[1MU,Z['4T_[,[1)+?-&2,,OO0<R+L=&",JE&Z7OT[$^H9JF7J3* 3R6
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M3$1NOPB*GC]M1MA<7/6P"M?;B VDJ[B$70,0BT<U26IYB;PCLM=T@^/U\P^
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M#&K9IQ:-]QQV%']^3'DW6'9J\O]_VRMY=&%X 1F#_T7K =5_H:V$A0NY@DO
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MOQWZQ+3 O:_O"V5)G9]*Y)F4!<J464Y0<R_H&XL(3.Q(7&U@Y9,H).I$(BI
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M>"YBAN^55=?9W54/>6'Y(^ RXTZVRE8]3*YJOD)T0:[.?4*U_X+*+C.7*K,
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M:&S!<,J\7-*_MO/M;U< _;<#E%$)#5?''.0@ZQS7*BUX@7Y?JS6P+DX_"XI
MSZ>)ASC)\GM.^U4N'5,1Q(?"9)U_>OV2&Z[S;>_5?+"]@Q98_MQI09?/[7IS
MC;;44F4BV42L<O90PG5N1H:GFX([/K7TN3L?_D9PE#RI-A@:^.0YQY/F[E3W
M YF6&_+A!U)BWR?HGPS(Q;>.%0]PQQ@FGQ:&J):M_<,5@O]@S1XPG0)-1<,+
M[-$LPY1K[&SI)Q?SVG?[?_!GXG>5#@?]U"^;L">[_ZG5C5,DL^5.B,%)CA&
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MRKU- 3-4>E>AM$^S[7Z;_&II,>H/D<H"&_K4A'@;._N#;U4A$MX]1AR#.:H
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MMHFA1+?U4<"04R"=.[0CZ>KT(\JG*OOU>UO-9=?:7_XU4-O,XPQ2,V\V*RP
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M+R-!(6)5RCI?B:-RV![X>(/H5F9W,CAZS/#&16=_ZO>H&'Q2)#S4%L9+7(P
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MZC7<\9?K3C-0=QS&XCVS'6$@O]ODN@KG6]$B5%\:#O+^X:';*S8YOZK[G9-
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ME[DVS%%H3/*V83HU2R:(E B8Y#[2KOFY5("ZVYR%U+G)32Z((?E'N_X*IQ:
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MY?5C8UM4-"D/LRE!0"H(;T/6B==4J=]XJ]4\QF$KZJB4W+JK 1@Z=G?2C5@
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M^"GI^/>Q)-('-VB<SR?N(].T5$#,T4,O@J+SJKW9Z$;*W1)J'PX?&XFWWN^
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MMY45OI/H;]?OVN =_;U^^OMBM>Z./;O+O''Y3NN2L=IE&8Y)'"3"-HTU\:T
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M$F.VNWP&S'1Q=T]X)*PVSN#5X]TZ25+1 T7?JBUT4I]OXD*F"]OMO]K>;T1
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MJEP@$@*^A*K4CQV]/W*39:Q0[TG=D3D^_A: 5@.V5J+\?,2\''L;-*N(+K*
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M4A,\OC0LP7'W4;P52OY&R.LSKXDZ2KP\R@"\=US<:$O7I7?6?C.23'(/0,Q
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M]VFHE281A0?D/7X3K'1S4=$\ZFLJWW$Z:4?8H:ICA)Z ,MCZ?GB^8KY\-,]
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M,UHL6Z=E>SZ8 J29LYS)+*5,"+^I=M.@:6_+-A@!5':)-2DT3W:P.RT@=36
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M>X"^,)V^YW='(=68WGPB%7)@62*O?/<LMQ=U!I=V4S3EGFSR/G$[C0)E73W
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M5,T^2_<9V9 !-O66<_:;FC/WPLT+NJ0LKHE^H^6W'?!]S[6DH+( <HL=T9.
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MO*-#$.L,4K.ZVWV+$BI^0962ALSDEPHP?#WW7/Z\Y4=A9S"_I;'FU)QLTS^
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MO:E,O)9  DJ%<;FQX:HQ_>A>\ZY9QP@U,O4=R>L,A<#:7(T!PHG\=S_I4X-
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M[Q]./_Z7P,E8-W#8"EM'S?XG87SI]R5I9<A_"V"@C\;^G,%$K$D\<A]$;W[
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M/VMLF\^X4T"BFGQ^3?ZS\;NA5]EMP.CC:8(>@HA$N';LQ/.4Z%U0<)CU;..
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M++$-*V)[.-9G](2L4)PS3#@SQ>QG=>,/2:73-6Q^G&7BD<-8<4LURBMV=EK
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MYAEK8-LBYV7^4.^GQR\@3'X;IZ;B#".N,BJU:,4[V_PRK^-VB%,M\?5#IX]
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M.BB=7'Y1!%ZK/]DW5--LU;+)&>3"N:6C;45,R7^3]M^Y\+IPR(P\?C>G&Z>
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MAWJO^T\+8K2UA)F]((*SX[Y0AXDE$:>ES4FD:>2*TTV=Y,@I,J-#:"_9GIN
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M#3WHYDK)(7HFJ_CH* ,!)>?D49Q6=3$ <9\?%(/]@L/4N>?))*(*TCQEE*(
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M:JZ"!EW><6R2FBI.OIUT^OB:)FX7.C[ *!"G2%EDJ(_U#BC4F&[5ARJ#6?J
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M*G.B+1X.B$%G_UUEPTZFF-[_@5\'\G4$:E5>Q/J/8D_U-+DJT+9/.F468")
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M34W:./ROD'$[,KF%GYX1PFI\V1M_G]KR]EF:TS?P>SS'K\N^G!Z22S^J4R-
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MR]%TS&4+LOCTC('0:OX,-\](H:YDX('A,05:ZTQF-A4@I/#D%=>%97H>RU]
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MP/N*>W#+Z]=.1@'04HY:2__(UA+A%25_N[1:TGB"UBTM,,G+,C0[SM\E3 C
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MWBE.^9O8#CK>D1ABOWG2=F7HR@#=SC&(,!VV*2XCK">KV9H:G[2Y%TBJ00!
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M<J;9\2J' PSG0JXT,;7EA_;N,^EM&4C:OC.2A_0EZ08P#3EH]O&^"?1+6#X
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MG5/6CK?,@ R;995X( ^OX1U81,_E\Y1)>%1+8#M$<U5'3M 9";@-1F\A;>5
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MV7XFH>JG\&B',,19YJV_:DKZ[SC8.6+.3I*NAY_"=>@/=K@O\_R)AQ$2#$B
M6UZ!O=32$/>IK>T?WE!S7Y+!.FSIV7Z1[R>#$R=*#SC%8'GJG=1E0EO EI/<
M:TG6L]"<,S/-"-4XW)Z=1\^^WX"]-YC0@7_OD-67)#NP_+!X+;#GTO[NYEQ/
MXOTD8/OL&PVL'06AQRB,/$N@F;ES?2!-_%>%U/^.X]EO(\XM@$@M39J<J@*8
M\Z^\Y! [JAJ3H(X<DUTX_/?7HGT[^]Z*!.R'G3U=TY3#?]TJZT"=GS*-[AO*
M=,W1;I\_X*+^UI@HD=-R=.->6 [<\<T'[;2)'C*IIX"3-E^, IM$45A9)9SS
M7NV;AXY<YG@UM 3XKR8SFALD]]J]C,% Q_RIC=$";>][CJT=G/TT[K2^;!@<
M+=X.4M;TQ$KWIS?,Q4N0 '>BHRNI-'K\F(0#A0[M QJ9M9!)42MO4!@XANCL
MC@Z(+#_LBJ/(8-R6D#!6U%"A5DCC(:'?%Z?H9FC]K?D:\?N.OA([\PTCKI3U
M6\7^=3+B^Q*?E:ZL,4H+5M<S]L+CLC]^ C6RH2O_**$0*K-)L&&LEKZ5Y#L0
M3%N:,>WK-VP,G+SO'\VVTEPP*8Q>4WJF2\>-!&3%/T4"FMI+?-20@+AX"!(P
M]@4)&-"N$<5RR=@O$S=! F19<I$ 4!3]3_\YNVA@CYC@P#AF#!:.@U>S7#E[
M>[H>VEC8E:/+HR(99*B:/DCJ\(G+W,6&%"+*=J_@]O\A_Z.U>GQOHZI,\LY9
M-Z8+(1\Y5GA)$Q^9H]B@BY*#[35I0AWIC,-'G-C/1J@XIFQ@(B4"V#=)W^]-
M!CM%)SM,C\D>D#^N@C,-'=\4N%0EUR]W\Q;9-7^N@TW]/@CN<GP-#-V?"[:L
M;AC>\9%9HB4PXAT]FNDPLW(IL?SP4?QHU\MY#-U?8NB7!.SK072#\T(_WO2F
MH!NO\0P7,041KD78%R:"5Z(I\^H15\X+]EJ/XEN7U&K*1Y9UZXL]NKO0A*_E
M%[:F-; AFL; Q=(['KGUWDC S;T0R^%/AR5RW_:\ZM%UHQNJ.=I<9HE,2'&!
M\8MAT VC#ZHUY=C43GW.>]*TS'^Q,C6\-&4VI.E9KO[L\BU)5E"7TAAH:QZT
MSF&8AO&C&">9><:'!#!UJ"(!D'@D8'T4<O$_Q+4Y"TH8PK1L&"%G0?0!3$GJ
M2,";KB4=7-8)=VA0)&0/%9/0MHRMBKE;ZNS=6RH\),@.+R_EF>-FG@3KW=KZ
M[O+"*=)[M39*J^TBI&PP365![G@A@H%/U'$JU8I2C2] Y1/PLP&0+&]J0?R$
MX+"(.O<-QFW6&Q459?QH6U!-.8#I67;KJ"3Q8%]A =.. Y-N_[N/R7>&(Z,Y
M.A%WF;P4POCIR76!A$5*SFY,(=TK;PJI*@EW.U[V241S3 G0B@YKEZ6T(V:X
M."V-/C]>NA?\^D*J>>_6NE>J5W!>:OLB8W+D$#20;Q-MB1^M=S.=>M\JO)%I
M4W-3/V$"'G>#>(+\829.<2!UU#BV</]A 8) 79RJ- SJ[5W(!052^W,RNTUC
MZ04 +OT)MV;KI(C.,%K2[]>J@-4Z7+LA<Z+W\>P4LAA+E_13R$./FO!M>E[F
M3#(W5(N]Q6;^"(_OXD?+U^P=E)HC_0TZ&ICO?SREE.Z]AI<&=E?3G:;EG*VF
MXWVI(U*(6FU_V-SA4]>YBS/Z"YPQ5NEF%-()"R3QD( NGF'05@X2<"%0W C!
MGN^_BJ<50M2B?)2M7[>)^9?/0?W_>9#^>/"T"F*CT/:W>"A]ZW<1\DSP5UG"
M05NDGMD+\%QK-3(P%-T-6&@@U#02M%?*M:I].7"70O.XW]%VP:6GB3Q"@E4?
M7F\B,FP^0M:]>^\T^R7+0R\+)6.G :KUW:N7\_1OT?MHC1=]>2_Z7C*Q@&9X
M!>5?74$(L$V4Q^EQQ45 BT00.6]79F@2O9U@[#<\?"[GNN@))$ XDU#V4S@;
M("]4FPD+,[I:(&P)7TAGY$K ^>4GXPXK3TGR_M?R\/[>0!',:"FJ@YXH;K7]
ML:@KB?PSV6<U&8;DCSA5Q1<[G:(N*SI.J]?" :=KL8Q&?=W9\-2G@3<[14II
MX$?'9P$',1H#QWH0J<\N=1H]F$]);B",U1MUOV]S*"S(S;2%U"TZXB@Y/3B9
MM&BW3]&>?HY+RG&!<3Z 70AW=E$_;5/ZQ?DD:,P_6E6P<U%^1SMT;-T[OR^Z
M=^U#>'T#& ^I6'2_>I_FCFC$1@3"N@8>HH:$L4GX$R<4!_P=:P3\W CSU%P#
M?5 I5EX.P$GR@:3!&O!C8OZKQ^\<H:)I".J -NVF %34SXXBKB??OT-CS2P
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M0B%K-R]T@R-N175>SY_V'^;-3& .UDM9G_),-X_%L=>;+]EP='S/),@W.6B
M05(K;+3DQ-N-DE\X!<"1 /8-Z-:Z*_5-2.:K]:6"X[V+,?JE'<FAEA8B9C#4
MB:W&I+:QO8Z:D&/[MN<]03N*B>%<@-[?F@36/G#.Q]E0VSD56K*6T< 3>CPN
M-07]Z 0/,F9GJM^BC=&JGZ'X,P*5<&WJ^-VM4EE%[]ZO#EUIORGN?.$G4+/8
M8'RJVCBX!'O'8-C_65I'A-+D0*#5UDHS5'[XV?IW_2C^W3M5KQ7%KU4=S_(.
M!.XL #L1V\/8%^80.8"KNQ_#T+9#7F5-G>)*L&QM^I<CA$NEUTITL8UXK6]W
MI]E3Q5WAI?#E-176L_R'C8?=GC@:2J<J]A0(&&W<EZ;;,*+\&V1SYHX/%4Z=
MH2!]0-W"'-77Z]C5+9VW7%3:..A(P,UV85)X(]B,+D4 JR92GRB6RT.@Q>-I
M^Z@C^F:%$J;C?>*H[1K&6[$7(XJ.]O-GH+P6)ULN?8-\HFR>YYAWNJ[6,6K+
M#B1C"PTCO($P&X/=0@K6C92Q4IYZE8)ZLRS<O IBSX@W4$-,ZE 3_:/-7X)2
M_^BQXI$]B_<&UMX#G^+K57&T\['[MK,\<.A!49LGGLR8C]NEW^')U99.1^7G
M&0]M)^)$GMK.+UX8_=_SK=/O#F.'<.9Y)P]W^3\(-WCW[$6D'PG:$X_ P].O
MAS/U06KU8:V.3 5N:XSO)-KL07:3-A><N:-9'AGU42 /[(N6Z$P=H=(M1J-]
M_)E% R4\/]NB/<2#AZM%MJ.%SE8+_>P7;([955HD6H0)9_0AK]F()C9J3SX6
M\X'3NCO7>7L& HZ*8I9H;S%\QS^TG]8!T"Q[ZXAE&2O11S3V%(P;<%XV.SDY
M>##2?EF":>^+ZXMM7(0UD:V:/ SY[O0N>2>C/2"--4R@/;0YIG##_>;KGL_2
MO"+" DX"4P:T.,W?G];H3GH0A4GHA0>^XNC;N>H_TYELY#MQK&1-R"CH/P*#
M'RT*@O#U.JSPQL!6U K,+2]OVQ_M#?F+]J@3;P@-]#X@M^U!=WSGPMY876*$
MT59:HE#0QE\NQ_]R$CWS^@OA-Y!RUR"QS &=XJ[QI +0C1C7M=47FR+?0_H1
M/Q) %'CG&S[+[ <,H,M))D&0_!AC4$NQ=^&FDUJ>:;H7%Y8W3F4CQZ#QD3[G
MD:6VF$*6Y(=22= Y,XI14!)U8+0ITH[37EPB6_PVD]WG]JR$5Z]TI/K\)0C"
MY2X_)?KC]!R0%5['9!D9XWF^38Z1FA7'@4.P%V_ D]PKJ22@]GSQ:TK$KHXR
MYY;^G&=\K>07P2LCT043U<_TS,[=KG*<K[Y>V4Y?-&SZR%0.C<J<* 1YL\R>
M22 !."L. F(]ZF3CMJ>B=HE$E>,T0O+&H8<45\4.:]B+L'01>DLD8$+?7XCY
MP"$,I].\0=KL77L+S2X=O-? 4'X_=S8_=YKQ_9/LZ%>O1<-7Q9GI$B\:JQU;
M\=G2*F\YG;H+.J7TEP$\W-L"YZ1,\1IU\F<EI/#\WJ.-VACS#C=5E"1I-,IX
M,KWHZ@!DF"A/P5TC\-DQ4PX7S!0NTWI\.8+A#^SC%RR@/9BF3XEZ=L[#./L%
M.*^[E:1"[1DK0H"KT*@X@Y#FNQWYJ#M.V*3LIA4G&7 DQ+ZS2,K"V- 76!.]
MF2(5=H=IR* ^P\I^=?HE7\"7"YWL?Z$"_Y^2_#,8)TN/MF+<"3V/J>\ZKSR^
MT2=_MC26+MAS^#>I#=N/F!\D>*(SHF[EZ"D4->:5!;AME>=T+3M-[9-ZA0.^
MU.X[A+F[C!':P))7 GF>LV[HY ] I]Y %6!&B:$N[/684LO:421H6AK#]JXJ
MLO:>MQ,99+YN*WBY!@<W?K!,K"QX2M(WPBJA9MO['^G.<]P9N@[-FJKJVM!O
M<=.KO$K-J6OY\^S73T>.;PQ!BR-691F:/X8'!7IFWH+LW&N$Q8VN8+3<G>SV
M#L]"4=ALTK+^(_L*VNRD-PY2]UBE^LKN=*Q\ND-+];U3_ /6S0ZP*Y5Q(;!X
M/'<F>S>J>JU XFLF@?%62V_!V>&F08]@O'K<-)OSL!NV[-9HK02?S##TK7EX
MW_3==R_'4RL(P=8AV%DT.GPE9_4VHATGK\=5G;D3:3S-G5-/KM@P3/OERLJ&
M5\JK@BSJZZKRU$4HI')U0/@VZCF09'N%B80J]N45]0*!C_EGH[-;FN'MF]V+
M?7K1C+S1%!?/]).B/JK65D>KLJQWX 6+SZ)7$O"=#6"E2MX9!'_#IRW=NVN_
M<<^Y3G*U<BMY\,KP G9T&Y]]E6VEZX[0# 8E)/V7NBG1>]&$%S<9,>F.^Y7F
M?;$,XGF@=^/CPI>Y5XQ(2="4UY3*:X=!%2L!?CW^F, O%!M#F0W[)Q\*]&1M
MG!RHA$D>Z JS2439:DI34EF%'/7>FS50O)F01&=6N=J1!TS>'PO*JAG>)=<K
M-W]O2/PF+0>"O6%T3(*6QA*<KY2+_W"*#4HAJ;L4VV=+O8=OXQ5)=J#NX&27
MQ<#>2JK!$SG:0(*68+/0R]5^*%8'U*09A'SYDIZ.@,9Z."H'G@"KP8$JO)\;
M*>9#MMJ * -86_0UA]H_GFB>R+ F,T[[G8)U&P>W73FL[7>SOC,$!S$L1]Y^
MR'Y, C#[93- VOJ$45LT/_YC;YU/L_H3L_RAS\=( "DDM$#&ZN2^ ],'H=)$
M!0C/\QUQ9WOF9;?341TR>:TWG@J8 U@GN3D3MB=;-[89=$>J &H/;2(^C7-E
MXY^%7K.PM5I?QN!&FI;& ;J$22;,B9H/77%RJ_<"I&D$PQ;8=G==03O>+#BG
MS NFKQ1[7"33.(I5<=5BE'UY.!/L:5Z^ Y'#QP2P6U&AM(L@PIT!([ GD$_?
MK9&KJG$0X@BVSXLS,,5,'#\_1PE%*67 <))<V4<E(YYYK$%I=/'TAZ]%"KCK
M^7(W'TYU2-2TU;X)2WC+GET)1&N\FU!MX)QM%)9L?H^1R9<C9U! 9V0[96&'
M&<:^(J@"WQ?)Q-+W<%8IJU?Y,=&='S'0O;PO1L'_RG[=O_QE-UV_AZC$3N4I
M$@ Q@6NO:(Q"3T9<@,6D[^0M5;/>]HEDXB$!M]Y(XI<1O\B/<[?*XW4V= RU
M]!#G!"?O)?9Q0]F4DJTP4@-VY3ELI;"!2J8/Y.NUX?B-^GG"1\6GQGB5\<U+
M\I7OVY^W-@()ZQ%Y_L(U7!]5,]1JAB$"-/5%3'%+]Y@V!JC&QU@;*L_B:5)\
MJZMKR%KLS)<8\3.&H%Q7C$6;&I.X,T]9@-HWB,R:YT'&-X!2H3-7)G0U:Q!X
M1 ^/6?Q7ROXE:9JTMM[=XB5..GR'<3V**1_E^CV1SK5-V+#''D(.M[\(M&Z:
M.RHNP9(-V:A-U2JQ_+9<C+>[)K6D?263*PC+5GWQ^6UDL-HB7^1M4"Z CNI'
MKOM#*+L@GA<^YZ_CR]]PJ[1;^,931(8!89_YA]W(KQ ,2$!<1"824"OUH="/
MZ6W3 EWP1[I7J9Y63;(I-8OT>$:V%S!(%M"',Z=*M<AM>8UI[;AHT$-P<Q-!
M'05\Y@U_L\+8CB9YA"9KDF!1-YS9 &?%/;'@M+$E3.Z-SB>9NSEK2+UC^S6G
M6O#@D3Y_M8CY3O^:@7Y2R)Y)JZSN,#=CH&6D_.+CSG:>6/GX!<^C'76-^K@C
M-4=&]E8(P=*LOXC)S4VJG;PH!IL4T^FO:SQ<!MAN6 J'X-+08AHD8#+IV]S&
MZ]XP,PPT$=;S^'/MM1!^UGU$\DD,[S=]+99Y'CB!E'),RRQ=O&P=W(*O),R=
M93_S12DJA]$'=,!!RT4V3<<M%P)NQT'."Z<9;96U VF/9.E:Z$3$Z9" *$<-
M['N+>W=:K!Q]\Q@,.;O>VB>0KV!&'N?LQX0MU%65#]-R42W+NRMO'<:);!D1
ME.=%::G40F]HKD9FOJYI8XG)B^)6@4&9C194<YN7^-&R_ON6QK]Z:*H[XY=P
M/CC,<2K5-@MX.G9C\:%K$\VX=5P=[F,9Q@(IC_GX"P ;!@0Z"IW:$*\S&+<
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MHYSX[F,]DID?E . D!/_'U!+ P04    " #<BGQ4 !/TFL<O  "=,P  &
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MM=LI$+LWQ7?J]MKJ2,4:2$IC3_WQ9X)HA '*71#E+ YC6NDVM*YWI#W##>+
M4&.51$'^A8?RVI]M7T>M:*5,31Y?AJ0^W;O7H5!CB7J5]9,_-Q;D!<$ OP'
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MM)3.GYR+3> V2VD*<2)IRF**L!J63O!4,N"$@P<MNSO[.!8Z&NV2Z]&WJ:_
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MI&M6,.FY/HPYT8L8O1"&>07F@<_(>Y$&'\#N=H:&.F\^R]I%595@<D+Y@_#
M?E[!63$5^49M6FG"L4073S90OAH3R;6F4II2:B%&3C.8)E9GJV? FJQ+W4'$
MR\Z2'/HK"AVY@]4W]QS<#L<F3!* LZ&U,;5S_*);9Y2#>HK>J.J35"='R8O3
MRJ8NG8,%NRXP-/.(LX2A;&,:.F)G/[Y]HK-;-4C'R3BCULDSV@?%-W &1WR9
M:*E,J6X1,/SC,'1#9S8ALZSRK+N<G$.E7!+C ]\^;MNC>M<Q+/>DR8EV#V_'
M[\V-4%5'7\%JS;BZ5SK;L06X.ZB'"@@6=I7NN&B%0;W:<R ,OXB_6<<4.=Z4
MV],-%!Q+!E=H!+=:F4(P=NO5R)EO\$;LW%]&6L%UV/ 3MMW']5TCMH<5#\B8
MQLB#V[T<WK*_EN:,[WI]MCIAX[!S0S= V7J,THX[NTK$3%)!_S[V7#FY":YE
MS;5]*\B3P6N?'[-;?K55Q5[:D7U3=TPYN]TKHU\?'3[L4_;F<+8<^2V,G.#H
M&O=MCVGLG>:(._YT.\W@D*N#L.*A=__U<VI$R54U;%,"3\8M'W%;_]/5V,AK
M6%<3H<MR:IOU5W-7V8] [XI&Q^&MRA<7'M*ZC)*]9C4_,^LZ*]&E48P[I4:"
M&]2"HPJ,*[\\3[G&6?;^I-ZOM@P1,9H4$>\> 70:\K/UXY"S</B5^FAC>JWX
M:NH9I^S,00<?FI2ZED_*G<#9JN^K#&+(P\N70K!77M"%X_NB8C R>%']4.##
M7@=B>=V><=LQ7G!%A9-P)YP_+(;$IY,B4FZ2T_3I/0  P(#C$R)W_IBC=>4A
M6C-AV7"?/L,<I+,1:2_?1)4\_KNTSXR"D^XL;5/7K9JT-$TJ7UTFQ,0FZ4G_
M^LR7XU7,-V*6A+AI="<3;AR_ DA"\TP*2F\80LA.0F-*@/(R>&ZS6@OQ_+:^
MH;8QQE$LN&+]-G2WJL+A4)&G\"9XJ+?-I4?6#>)08!:MLZ#+BC[1*30=J7BH
MF8'FJ!9@;=)1G?82E3^']>Z3"^4RSXBSNW4")%<+@<&H<W?8^S1#R;R9O]TY
MM539FJ2/"WPG.9'/;'4JX\!DA*>H$K_=(8ZMEM_U=]DA-8PC@PF J=*GE30G
M9E;=#ACY6UQ74.<'$%I3,R::3&(N^UD35UBAKD[:*#2+,:<D@=D^&7G=Q- V
M#-:XVEUIEV*]J_)-62ZQZ,S)J/WF*>';I2*RHLM'@"9WXJQ$@+"7_M=[C)Z.
M%#(EC^3TF8FEOAD^B(82K1&1(KH!2%GYRT&3439"?\E"F="=-_1>_UHUN8+=
MOFZZ);OHS6)C?->ZD5](E>:7?],FQMZU_'/GR)Q+SOP5D,S*R_8E5$0*?)W7
MV6EI#ROF8 H[G==;&\3?\NE#@@VL'S[__>M>;/#4IJ,->%M+8&]1:YXG"DQV
M^(&1V6YNYKBR6L"*8>R^6O^HB.)/EZ=<E9K&C2\:7^+UN-IKSH2"!FTDY?E$
M]3NZY)HKR,HMW=7!$Z[Y8+BD,TJ ZB7!LZ<;@+VF9B<K?H"9A\B^7L\SGP%V
M==Z++9#$<N]Y^Y!&1^'SV=W5ZZ(&M!TK@>^=6+X9,E)_T]'V,0_^^[%V16!R
M]U70O.1S=DO/Z1C^TO<.DS19^R$+^HA7U=.#M8U$'I3#1.>K;;PA$ZK%0PL3
M;6U" ]WQF.SSYFWR_&1'J1KB2?3IGB[^ZV1WCM,FQP=EAK=,5A_\ O$;/U7L
MA9P-64;G%BJ]45>>UOA J&07O[N4,<EIFR!-JEMX)]?Z>771*&+A-095"NHQ
MQ2/@(E"2%]G_:H,JUCP!@[+0V&040?#JJ>1#]V3]J#F=VU;?)H/M"!Z,6#"B
M+/H949=']G61P"HG./V(-5/-[(!$#)V'>Q1696="00[+9<_)YX2G2!*]6'IP
MYWN#S>HM7V03<N[-*R6?--593XA-GF9)J1+5P5>+=XD+3==!6Y7%AT>3DD+V
M>PKRMY9H9^6F/<LHYVP<31-4\1?42D3[6+2T#M\=5],(%;^4\<S-Y+VM#)^R
M'A/^J-G<X?=R\NPB!H] \X-ML60977X)N9#9%$,9W@3'X-V(/:_IUWU=]E#7
M_%F3NFB5@P:1-JS83O+)1V!%S^+M[><J&Z9[YWJ:FRDY%.G"NJM'(/IM+E3^
MR_;2O!09QT4I#65%BCUPYU?:9G_;]0C,G8KNPV1Z?B.&.3#9'[LZ5NA=$;"?
MO]>_HSPQ>G#7K(?@]:EYO_PH_B9FIO/-28#0CRK.TZZ?85[+#W6TBD4\M*?B
M7H_ $?*>:A&AM;2%A:OUH-,(N_:/P.KQZ*<JUV\PQHV9ZYD'TT1+BX>KE8$4
M>;A1,!R.BL'S4WFP!2GUY)EYCBZFQQRF'DS,M5PJ*HZ&/=^L'+^^$QI7.\%T
MIN)T# LY69Q0\=O4] :O_L B=POEQ319#@PC?'%54E_#)J3EH!OQLB\U]'@F
M'_KFJ -R&,:*\''TI:ZR<I=KNT\(Z$4!=3M6FPN0N-;7:;O-C>\->LD)#.=\
MR73Q@D+CTCW27ESW#K4.,H\ 8N87DUGAF8++6\[E30NOL%N\?<J%7=IRT<->
MPDG-T?='=7=O)'JDJ4):N/<B+7[>O:IP+=&<C>D3L%8U5PQE'R!1!_,CVWK1
M:;PWI6W2I?/112X(#J/*,2WZ-8O'K/7&N"F9VXA$3^*YD-86]7%=74\^"N;0
MEEI*_GO=JLB2]%=6=Q@&$Z'A6JMK:DW$!\V>F8(#W#@38LAJQT$KX91ACBH*
MP!VL\6WC]0/"[)*W9/#.$L$Q[&P(0U]>OAX15S.:;?EZIFC/Z=C;BRGQ<!P,
M546)IT,&;;_&P7P$S*0VF2E8B@,71T4$.@BKU/5:2SB<( 3CF44TIAX!V(H:
M1 '8?[KJ3T3P15&<A?#/Q11ORE\81[D(^7?_=].;?%%7\XI2,7U"\X7=1F \
MY6>IX1 2/Q+FO*9]!==G/T?R=Z-[[2\YT2T<Q(W9AHP7$>;#>*@J82KA7S;W
M*0RI^KZ60*#T?U4E3HQ!K] 7W=?ZFL(7_OMSP")!PF>Q"K8:@2)MD^ONQ&?8
M)]QN">^X;*:I5-S*R12&\[+^9%&3W5K&,D*?/IB5);9K;18'J@#F[WL$TN6O
M(X]SAFVNGT!PXB- Z(4-C+%T;,4^&-V9G1(]N EM"O5EZ#A=AAXR>#J1!J]K
MBQDW8W-Q42AN\OD[4\*^:@$,,%EE :<E(Y\QFKO^J_&_)1 , 4P3ET\''P&6
M!W:W\$> /^.4;$T^VY?@;P[2/Z_,LKBMSH<R85K@LNV4D<2E)S$<)25:9[PG
M@()6W';=7B9T"[YLG]EJKIO:M_K9%(+DD7?+%Z],//3V8_3E9P2!<,#QO[MY
MN4N/X(O6\7-=T@D4[F^PYPNVLHZ_GDD0<0.FU(UGG=B@CK\7H/G[;8Y!\W:F
MUO;CLM%(=MR9^JH1>H6D-R7TM]@?LN@JPV([+7^:M!#^A\W2_X@R]>4)-904
MB)295\_IB="),')9&:#!\Q/?JJ(@=3?K!WY(ED'2_/H.L.$4ON<UHHFH@_1P
M02,R"A#/MG\-HB3EMWW)59  4<\3I_L:N,\2>U-9D!G7M3X,?N9SW6<HKYB1
M)G+5W&"I2.@7X/*<&R!7+8Y1W) 7)>%N<N HVGX_YQC0\21,^Q]A)K<+Z2,]
M?,;P?C]C8'*9RBB4+E0I9&:4R:O6(5IG3AY05]5KI]2)&@;D(I"T/.O/O,Q$
M]/S;.O+^MH/6&QLRBZ,=9>[*VL;F0*5;Q/0Y&>H6VDB/1FA>N_)).AK'O-GE
M,M2=(^TRQ88I W.P_4>HA+W0IRA4P1QVD,V_C.R?AE<P+HS\]^J1?\S._+QS
MZ>I098*1H[&.A'/2*ZZP*>!%4C!L+D+0NB\B#_+;==3 9.#@[M\8;^]17YU3
MB7BA2*$8C#K4:UYKY,+Y)><+U8^,;GWX3^'%^;\:W^1V)AR\H?!)HD?,;T-O
MKU@E498Y5DLRM-PGDF]/%"$BT!XQJHWW3A'6@T/\9AI2MD*&MW@5J-I2W^(/
M'5?47?$M+>$CCRJT)Q&-$M[-_1DM3#3UOPX!OVF+70C._ 8U_W+F=&'HC0U*
MJS(SG0U1^X5*)SQLTQ:-+UW.'T;(0'3Y#HFBE\9/=3Z/E7D4=<V(&RNU72DE
MLX);M'1D.)7;\+ /#J,@( H1IZK8W)FP+51KES-J47N=)<1XH8D$E6[(D\O8
M*/^*J*MAIIXSU,FKI(OX%-_/])DTL\,N'^D4Z)>*>NQ.\R,0XO2J5L'I&'.W
M6K^ORW)-4,JW?J)IMQ^?9PU:DW<5O"I=RCZH=@(=GY>2&6.5?T79G#@P)++D
M?3C$BK5Y7;,C3#HA!<38PBN9A[-+HR5/4/2&'=(#_3.-%4'-93W>V/63##_C
M9<4T'>O1M8D'*\,GK49YR=]?A?PDR6\^&JD(8(0=\9T\WW.-F3F@<H%HZB2Z
M?(QR/F$9X";(1#-L_F[IA");A_AMX$.5Q\LPKH%Q'IC;K4BMBI4Q)*TKFS$S
MZ_+RO"2CL&_VG=7]^- @9G@ Z\!AQ"V5]Z)DY<H)HNVE[R&]RF;.5MV3/\&0
MRKQXDK^?)7'XQ6JU_JP#W35!J^5H(VHZL^%6Q\5&H >CGRDU6BH+X0%=BIM[
MK9Q/ 3Z_YO4K4X-BWAA;6-@IUB(#)$>"/3VW8\'MY?J$%;/2@T.U"S$[#QOC
M2*Y?XS<?_+[%'<[-"N3OS;I(K[QW:&?0E@I5JFN4!I:J)0&HAGL<U(<7N) P
M*-8,>LY#E0ZK,,V>XJ7_ZZ6IW85,;DOD>^+J+>#604^$*=1)0+_;!4,'PFQA
M[K/2$EK2:!2@\$.JF!E13\)>@JAQH*S@F+-DY597=.)4@XE82S5MI/6;64"F
M&]DW*)PP7>=&)(F<&;@AM+OR97MR*33@?BR6*F9^7I[6[*<+OF&K:;XP3!2K
MG;8,/^,MKL:/1Z 9'TLG\.N(]R.@W3!#V=&D'5_=SBQ.2RLM&_+UI="7U-B!
MU=89C*Q(-/U!LYFU/G /9B@3=<>$]*T\&)S6XF+*;^@K<)$C$T1E5<1NN132
MF7Q*N:8K*A^$.\-YDY!BQ%A$_:E^0AS3\GG@@>^[5.;;+> "I^_*5.[$X,AJ
M8[$L(""M]Y85@KO;YQRM>XQ<X L^&Z,,4X"ONDIY4WFL^HD3:]>^B_!=]7Y#
MM)#KM^_,Y/YLHRQ3S_.<?D*0]EK<F#CX=C8TUK3CS-&]JHRB!M(-D.[H?0*)
M;2%HTD>C 6B]96JT9RGL,MI$VD$J;UB( Y89!=# &1:A?=#POM@UCS;1">$$
MSG;<IN27Y.CX;W.)26M!.U/J<4NN*3W-$ BN32ET\+7Y3$+E@LZ;J%)9J@!=
MD3YFX6L94_@R51M2"%JNIB3)^L!8T:"YD\?K^8_H&I?%]$DGVCRW"XZ43T:L
M5ZQ5%[/K;MR7.JNL[97/&3GLUST VJM-ORH'2\]ZRE;L)I,$S9#7XA'J-#A\
MLT*V#W[[#N-M;!0KPBCW6:D0BL6E<[-0P&:$X[3UY*WB!2^=5$20AF3T -6)
MQTK5)#9H6<N52F/[R'PF^:'L^3PWYR%17S['?&W^,RMCGK%AQ#&>$>L=7MWR
MX%SH3KR4&A3*0OP^0@[>WB-VIK5:B'A/<8=+'1UR <V-S!PI'#!J$+^%V86;
MYOXE30EQ.)E57]'5UHCMQ2,TR2LL^V65-[^<=8++1L1C,,1YK@>O9P:N66JY
ML"8Z3FO:(JW-B@L&^;VV%1:@^^:$8GTK']NKE<J65_<-H@:%+/+"X<;/*V]U
MK9'QD;I^,ZG^=2?"F,;8;G6^S H9L>?&O,%?>6; T"7$%DUH*WC)TP].!B[<
MUS-6+E+L+JH\O J7J&8.K3#'F(ULB!KM,:I2#U3)JZBLGC5>W?E40%V-WLZ8
MQC&J/4 W1SFD).^\2S^)+C@;,$O*O1Y>HIMES\"?W[GY7![;&3NOS0O-I1\>
M_NB2A-'C&T]U\,[WR<^]5NYQE\5KDMXW)Y_(%"6O>B0ER;Q=!V5\ 7T'^?*I
MU=FG(YA$R&-HY'M_,R\9CD(=*BW>D*PTM1EM;OXKK!_>T=@4[BDN+^@O)RJ9
M': D)//'TOO854I(<'/#/!-^F99[I87"I&HE?HYTN],C"_/R0.'AG7$##CR0
M+KP1S VHG?_IC'GS8 W)IWEO'\J=8MWN78^+OPA,S%C6'XUD$6KO2'LJUC=I
M+F=/<X;E#RNVQ+$!M^#[\[OM/ZP J:&/EP\O?\_#S8.CHC!\$MD3:^$GYRR,
M9Z(8J.L*<-@WD6]I,T%&=;HM2A@U?+;PW](;;R8)H5T](IGU[Q&'#;+3 J?<
MO9^@+&:E7ZXTT1!C$K0?IMS]YT5^K7,%3>(.DA 9"Y#.Z[#_M/43'O+A\^0<
MV3(:&2HZ99ETJ5B3?U,7:=(;X%D'302L2#]^?ZK6F0[XE[DNO4T66ZY&!=AV
M%'1^:"R*\5M'@WE9^0I!E5_-><Y[L15@K2C%)\YT7Z)PSG /LXA66L>:F^-(
MP*U%IH0T'_T8P.>W93:>Z_I"7)%U<?%TW(Z*T'G_%QI&\,3D2)-^$XGQ%RSO
M3"*('+]L,19G-5T^<0B.&6^Q+\EV)/=@WJK;46:-</>:O4=/_'GB-_ .)7-+
M@#;;EYC?[T64FZ$$/D.?U-D(95YIJ99XP*#NITIXNIVSW[M(A(Q?6DL1N?^R
M]+5O#YR')EUHHU7?)_RZ6#9Y0A]\>*8;$R&TS\2UC8V-,>!4YW(-T-L_0E.(
M<14YMU<;)!:T7Q>CRBN?LRL*(SS)%RPJ9IUME 2H$CVT=X1+92_JNP=]W$=J
M-.(F@?^]S!=WU4]:<??;Y'4W% L2/=CVOKYV>Q\__H+5X$SV$-\@\E F%9E3
MM(O^O@8-H05S*1P=I!59:'DMG Y15B6,AHQ3(2%^,44=@J=GM1NQ8,>ULF]@
MP&F1RT%ZI:"!9C3SM$%[7('F]D4%;&M ZV!NNC25K9:D,_VP_-HU2+WU;X/Y
MWU@:**71/7+T]VW'XX__ 5!+ P04    " #<BGQ4R>\K4*5$  "L4P  &
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M@_W,]N )F(LE6:2_EP7W#^?-9W1;/"WCB([1:<!UGU5"G_0][LQ,_I(<Q%A
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M;&C5T_RZBN]3/_+(;.>QN ,^UVK:V4D!@9HT9UBW&7WIO_#WWV&@("2X<.N
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M]/XIYF;AA&=:B,0@*\(*/Z%."UEQ9C+=$:Z_D\@C^<=;X?@M#ERYD9&3_)8
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M$#7#RMF(373@T-RZ(Z9Y(_N0JVMJHMG/0PP&W&I^NU<1+99\F$%*AX00'\B
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MN7.BAMT_;]%13MD/\C0N#", ]D+<1ANFQ38RO!P1LJ1>792#!Z6O-[\9P2O
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M&XU@1E0-+R=MMB7Q&26[)5,*]]$OR0C('&*TL6]>SDV;+=I2A'@LMAL'+?O
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MK5TXO$JXQG(CM%?T]8I2&U%+V4O&R58&N/;;26HO*OHCX'/*=74L%O6X^^#
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M[WG=7(*>6*3[8=0'+JA<,SX"Q"]>1IUU]I9 )%*7&BK.GGX?RD!^BXSD4,.
M/0R%CY7EY'ANE\W6)E_$.D6WELG,%AE^$4"HE%U'OHD3/?2<4=$5XZP&,;.U
MQL09N2K)8;^5$:I!(HND#8XBVC@M\' H_J ]6*I8HLL2F?@SU0(VZ%,B?G.
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MJV]H[^CLZN[I[>L?GYB<@D_/S")65M?6-S:WMG=V3T[/SB\NKZYO;O_!A01
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M1^-<I 1%VQ_C@KSKQ+81X40;%KJ\BPQ]<YYY2$=V6T\ R^R#Q?=/@/0#WB<
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M=<,6?9NPJ2J(WULZ0T_0#L$-SX 3'6VT]]3?J/O$CM<>F+#/29"O9Z&-C*J
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M6/W*MI*!5!3%!I<17+@0))]X74%AWV<R%^->>H.T$Y$A-(Q7J:*+(&EER.:
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MGS4^<]:K0QDP7?X\EO07X1+<I/^:@8121?Z,/\)O6.T1_\'R\3M\Z3\:E(5
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M^[,53?8L2];K1S_9_H?Z]\$K=^6B@L^[?7&. <>KR#0'W+HD[I_+9:65G%G
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MM=#HVDY1&]S9_4SJ?0QF;A@IYG%8-/8_7#G*TH2/VY8A7OA2,)F)H(-G\9_
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MM6HVIE,WV37L,>2^^BF@^VKZ[Q5'?T?D\MNK.7%TX$6EU?-*_7[#J]>C2>=
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M]V[GE0SXZ/]4P*9,:?N?ZM%1WT_G[6>>7[.LGY+C3)V?<NK_I'DSBI.F!1Q
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MZU13[$D1=A,.]5<A1HZ7HZE6J?5AQ33/A9T5!54LY#S F9VQH[%%UM./3;&
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MMM4@$$ENZ].'WOP%5+3[)JZ<Q"^8[YNND4IY,VU.[#YYZ1!ZL-DI3YEPK:U
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MHMOE2HO7U<J*'+#HYCF?.P*S7P&5MAF*VI!DWKJ0_=/69N=%HMO.K7;DO5=
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M+-?MYA"HQN%??-BG]BE"0N>X)H>^1)-I'.W ),MZ=R(\ N60RZB?&B%KB'M
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MVX\SR_G_5S#RT$U&B!Y  9<5*$!GN/C2\!QO$04TT9VDXPZ=46WI=3D>_-D
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M^T4R1S<#?%ZPF49OI$L.NI:^67E_$3!P+.29Q)'GDBF+JR2LW=5@&I=2N,&
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MI]K(GWF1#Y4>:)V4C,?*>:HOLQA1Q/,(4F ^BR6[,3JV&_&/1 M/#2896[I
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MUFKUS5=TDW9NJ]\KLWI"5EOO0UWFPZ>U7D:%[ET_QU Q5&7#%Y4GCV]M?K&
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MJXNW>+^5NY>ZV5&&L5%:I"2.7_G&Y>/->ZQ,3J\U+>E.W;2[WBA#U",LS_+
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M:]QQB ]H+.L#FX:B@/?NM>"#97NTBT\^QULP;8\IOB9@N;+Q9O;F^ VW':(
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MFHCRBQ^,1[8M<@3)UP\S]S)_F(B:#/)?I(#GP0/-MF\9BI>'SRE%]B_.-']
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M$OB<H"4<F: JP3K3.[QE2*8%,@^_9_YT15%E!$M7.R#+#= I^#>;S9*Q0%O
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M;W;1S;?AJ.C,^,? ?WE#-R%;H=XP-VJD?,5C>I%TDGEY\,O;Y+8'<<GC?T#
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MN:8YT='IX;R'""Y\UEA8#6R94R+&<U_<<2>Z+<H/ZZ_Q.I3>[BM_N3^CG8E
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M.QK$&JK=8# S(ORVE;ECS/]JHVW<GWD'29OVI*6MLNZ5Q+)=OW3O8^?8S)X
M24+;\8X%AB8&EI9QWN CE8J<T<\T5A[W,/P@C<^7S?E< &K9R<_0,07G \IV
M;]_,@SVKI*6@T11@[FI' &:#J.I98 LQAFF-FXV1/Y[%-[AQ0VW#YY7LLY,L
M8OF1FDOBVUN+CN,YGD%#UI6;3_9T@MI+)>'EA-OXCO#6GHGMBZB<:>^<@L*\
M^PP^&5ZZX,Y,2-/'NC!'T^Y43$A(Q<O3TT*9=RWUQ,ZD)^WN,M<<H%F.\CNC
M5SJ%T%Y=>&YP[O&G<XI=]R(O!WE+S03N:Y6M_:=U-&4-N;8Z\XB0LZ[:.8=^
M#;6.%QF#@_,=[RXPHB4W9@-D4@E=!OP\-I0(MGP<:0:TIS%&4 !)QJHTH]I8
MN>0!X>>@%<\@1_LTY^;PI\8!/8B!5\0GY8J_7R7$M"#*?6JATH[=XGJ (.VH
M>%35NWPM8:'TO8R)&KO,[@,:M#OX"GY8L!W=3I;42*\[6+7O[,*/=%M/UH%/
MO2F95W OM-%+UNE$EJE^)- _*(5PW)  ##T!X,8M8+<;.O^?[JK&A%J&05T?
MW7R" F+<D'>V(/Z^ID>3X/T/)DJ2_F35!"=MLOSGVYEG(]G#$4CO_.MC[GZ.
M/.S2\P/8,+I*:S##?["K*@+>BYF45R>:EYO:&^CH2T8'>4&^EJ#U/\JLY]&4
M9[-P9[3,K?A<V-[I@Y$RW]1GB24D^3H:N'\TM9;4^[ <M+SU/0UTHSTXF;#&
M.29M.E"K<_D]#?$MR([*[NF@G: %M;!OZ],3^F$9N\"/ 5(/X)JAXW(3QUIC
M?C&/4_+K&:W/(P0QET[7'MLN8,.1Y:?L<0:[>SS+MQ1=[=R>)P^":-6)/M8/
M<&)L25+$YB <U6(TQL;NV8_$1YWS]!8+RJ@6E(KP<@UV)<\>\_G/^=#T"@I;
MJ!B9@^K4CAHY [<N2J-32FW&;2["%9SM!&8/JHA@GR^GP1\0V)W>1#FIKXEE
MO@RI_OA\EJSDR.9WBR&Q3UN.7B23X(J7]?#MF:H-3ZM;TNV%RCDI*PG.3)/)
M?+3A4)APWZ&WR$W"'V1[$CEGY&4[0'3_$[URC=.$%G:12:=YP<R@#90I8\&"
MD]5!GH#8=K5$EA*JH#GQK.E)ZC/0?@A^1!6K=J8%>*IA@*.>X0U%<*["BEW,
M+9;,.B,YWN\I_L9!L8<74U*^TO!.Z_&M%T-W4G\N[%/><TM ;^DZV[7-CTL>
MDIZ!ON \4PT?@C--5^>74^.#HLNQN3H3%3(7_D\0OJ3+"-YJ*3<;,>M*KZ24
M^C4QUR/O:4I%P!V2W)F)O^T=U;V6MW+'K7W/?JF)DV#-TXV.9IJ!;C2Y2RQU
M JI>K&YNAZ/J%,&8M]C3?!$.;-<XXLT:6F?<0?;6U#8W369^35TX=?TQL!#P
M2NP@W76:O OAT^X9VG5!/GS%,IS=GB^1NF)7*N] <Q\;)SV.C"%HH>PQ'K!=
MCJ2#&FI/6#4E?&<VZF.KKPG_F4,JL-='1.C>9(^5/Y.8K>+A]4PW ,,YDKBC
M.2]<SAV.7B,G&ST:%Y$VJXJFRQ=,WX_6K:0S5F=K&.7&6 \$#D""XHM68M\'
M#U^"?TYGH!=.Z$H0'KX8$5#E=</TG@%M[24: YKRWRM&,L'U E>D^LH=7J0N
M'+(>=IUZWJ7DO!Y3UC;2)<.8,4(0=YS)TM:--,<2YC:]>6YM.<<,/JMS[\\=
M]R5>WN4ZM1OT8K=+V8VJ'AMT>V%#=L*:4;IO9$'V>7L-X;6</WH\+\K:$.PV
M95F305M9V5N_=K5P(IH<<"7^[&8AII)>A$ZDLENE,>5BS$K_AB=[^EF99#@?
MMKG%DO&-'EX^T8;&!)ODFRO?OG@V%]^.A#7UJD7H(SR7H\P?9USHU;]23_?+
MY7484@5?;A,1NK@]!K6F=5R0U=%(#T00GTK<';N7.UO8(T&_;6>,KUIUP+O>
M1II99_*@0NWAC'$VU>?=L>:]<&#GRB9WV$\LIMBF*'YAR]-.($PEJY]Z>8+$
M.=T5H7/B"(*Z0B:_%CM9A:P_P!6?V8N\[X[<"? B[SD5T0$5.X::4$FRM2:$
M0#_4U=N%L49OO(R5V*EI(K;UJPNI7L3U:](;Y77@K\']@ -O68>X$+D8H("(
MA08:8C5,^RMQ>%>J2&I/:1%D;F;!UC6)8I"Y+IY!=2ZVEW6]#-RIB2_:]5K5
M(RE.?4/FE<FG6LNO+CJR+<7O=A5!DE-C%BV(",?"+W1.6[/&'\(GDDT75*Y5
MJ)< 06//3.+?+91^G.?' !G'?[>6'$<K*""C$ 7XX1VJ<8"FKA!M&T6PQ?LQ
M_VY5RUG_#O/=#/Z[F@OY\^ N[E[/\K/DH^(GL_+FJ)G_#U!+ P04    " #<
MBGQ4<F:,(?Q-   M70  &    &1R=',M,C R,3$R,S%X,C!F,#(V+FIP9^R[
M=5A47=LVOFD)01&D0UI2NDM*0+JD14"ZI'- ! $) 0'I[A(<ND0:I$N'[HXA
M!QB&WW@_[W/?^L1;W^^O[_@VQSJ.O9F]UUK7VFM=YWE>U]HWWV\6@3M*\HKR
M  HJ * @_X";&4 &N(6)B86)<0L+"PL;^Q8.'M%M/%Q</#+">P1$5.0TU%3D
ME)2T#)S,M'3L])24+((/V1]Q\_'QT3 +BPOQB''R\O'\K 0%&QL;#Q>/]/9M
M4IX'E ]X_L?'S1?@[BT48=0[:"AT .I=%+2[*#>=  VRGQ@H?QS ?QPHJ&CH
M&)A8M[!Q<)$WU-P!4%'0T%#1T3 PT-&1O_HC?P?0[V(0/N"6QKRG889%YT+$
M$Q2;?8O^<54[L>;H(0/OBU>OL7'NDY"2D3,R,;,\9.7C%Q 4$A:1D9635WBB
MJ*2EK:.K]TS?P-S"\J65M8VMJYN[AZ>7MT_PFY#0MV'A$7'Q'Q(2DSXFI^3D
MYN47%!85EU1_!M?4UM4W-'[MZ.SJ[NGMZQ\;GYB<FO[^ [*TO+*ZMKZQN;4-
M/3H^.3T[AUU<_K0+!4!#^?OQ+^VZB[0+%1T=#1WKIUTHJ)X_;[B+CO& &Y-0
M6@/+S.4>'4_0+:+'L=E5[=CTO)J'Q"]>C>+<9^!;8H3^-.T/R_Y[AKW^7UGV
MIV%_V04!\-!0D"\/[2X@"9RV",J/.X6LGNNJ#SYL_DCBWB=D'M%R ]R:>G<#
M2 TX72TG/;X!8GS;+J\S;P 9_F(I,M/#*.NV$[S:&Z"5Y09X8R=W V19UEU#
M#<#JF'IP>@/F:S2.MH,(R27R4<E-,H<;P$\/ XI_WFF =V0;ZQ7WA%Q14YQ7
M[37*FJ3*O.^C+SO3M%HU>VJ=(CT1[E0\/?KQ2BIL3PS'SRQTCPO,T@BE^_U9
MT)I^MB/['^TH(-O@^EL;QZ6@>W89/$E??1QJ"YD^0$)3&?=FSWKS?[S? QRQ
MT&@SNQL7WI*?'H2)T1,/Y>PPKMX;<&"/X%XGLG?LL8]4Q^SYJZJ?W07]K;NZ
MY40H";\.00Q,'FQZB6D(6B NE0,L05_Y<VZ $9X9!"P7<;><!!&4N'#>93OZ
M7P_-_VOK_^:V)"K+GED;V#>&%KY*G(HU]XM)PTO#3SLMF-M)<0A-Q\QV]0BW
M<1XMTUQ\OP;]3'K:FW6K[:^*-7ZMM,8VO;;4TK-HWN90E7I[V I"#ZP)XE6N
MLZ#6_9M>:4_4L*G0J&:JMWV4MD/=CWN,C<,;/8&B]Y>]-'_9REH;M:*&#WN]
M"=GR*2,A0?&\,"J-W49#R?Q:5X3&]J\?N9Z;:XEJ,C)6H[Q3(:A([X FAJ_6
MHO*?#&%$_PKKE^AD+/Z8"J]*V<,?8;:0-QX'G$]=%IL^43W105^9#V3X]8%?
MEG5=H:VN0<L;/8C_-T^!ZLB\JEKI_+8)#KZFATY.^R]J:\,LUQ)J2R* PE_'
MK,0V@VIT>8S+(D:U3N\)5<+K5[>T!B5EH4EOX7*OSB F^93'.0?<Q!;^;?,H
M@0R^$2-3DJO8H!O 9 RTR11(.]*V,G^ :+-"3I1!6UV3D!N ^AQT>B6)"+73
M#,1AR0D4HKD'<^HFKYH$SSAHJ27)3P*:G",7B>\B'TGEXHE&3OIK?8&L9>2<
M!U T5]\ BF/QR@TD[=7$\O?EV!:H2D>+L@B$02BV*2R'>PNA^^74YXK5OLR&
M(^U,\JNU>N]E+)9K3B0)!A</WB8)@&R/N0C)]AG3A3!U,<)-I0C4\MU/TRMO
M@-Z&XAM@.J_M$CL+=R3.[+&JHCI(R5\!"^[;@UA$Z# "1!IR_[\4XJB*[93$
MU-4;P&J+T/1@Z*@2S,3V,E+3=G6(4Z/:0ZS4")H9MMAZZX6#X"I6'ZU@I3 ]
M?+G.7DQK6=C!X3OLE7*(I=&W:G,OQ!EWEX>3$UY4XY/8X:?5P6HXQ%+J !6P
MIU^D*#J[''H?_')UN^W+L6D8B:#(< 0?B,# 1M,V%A)<M&"05Y*:E!"EZ"@2
M!\)9OW^Y)D'-_+;F5M[K&T!^JIS6.N_Y-SH;-(7>Q4.7V"V3'ZF633,?0P8J
M7+K/-"YC5>VLJ9)32'^DHL<%QD=G)MAZ9C"6V[WJ<EG>4@BO(75_QZ'FF/0B
M"<MNPY%( ?[\B!M2 $770U;=<PGV"=F+6HO*S_^:7[;.?^R7!O]^]84RDIIM
MDF_X]G<;S\:06;/\Q+/=N:J/;-Z.4C3,E/AL*HN!X;A=9(1X$MI^"Z8& -24
MPBMZ*6JEH]0$LGU?Q*%Y(%VF]_%^T&<BI;Q^5>^^+Q4+/>/\/5]O*UGY#S)&
M.GX3C0>O-S&#:SWQSZ"\&-])LQBX"L<A&:.RH]XJY*30J#=XYEM2U,9%MI=.
MX7Y:B_7-DJY4:WL)/>FN'&T23U'%A%Z>B[VH H,(5=Q75/#7AW5;C@YJL+,S
MYG?4CQE8T)Z+H3SNY,$4'O2]_:'1%1QNSEC*<PU%,9&H+]8=^F'!67OXEJ/Y
MDW3<?,/I>18!7DM5JCI,3:"IR$ZDO+, _D"?,SR"SS"]8697---)Z8PI='FE
M@ULA:SM\G31^][P.;0\E*>;CD2"AZ'KYL$"R?<[8LN&3-^D/8A,\K:[CI\IS
M&*R+(HB)GK-& BQHP3";/%B,2G7FE>XZM^VX$7&-0(&P8++BL:#5?L83TGUQ
MUKS+A*10!,=V'8(VG:-\_P2F^W7=J1YUXYO47+1WEX^*''\S"0NAEWF"]!"5
M#!Z"#V6U<:JIL#5^J:G\0:689)Z)'6'9V&.Q> 9+0QX\$"[U*P4J7UWCR6_3
MY&Y'%*7EYAWD"F'/XX<3(M>RL(_A"]TEG3[3%=NMU)\G]T]*PR':(@X]D ?/
M>G%Z;(P>T1<0V.M^<);#HV/)D8W$0]<! K11UG41#V-T8=GY/86MX26&0N\9
MNVJ:P&>Q]D/DJL',$2<JY@BII!O@=(\9\=K6B\-AK\[[CMS]_58#C.$U=3N:
M(_2V&Z#21O+DGM0=:U/H@><-8/KY!MA\6</&]0]4"X-(XV_%RNX&..*T!9UN
M<2%>V\E_KKD!+DCX)2]/D.U(\Z%X$,#.8Z[;X25*T7^> 2PY$?^^E.A5S_6X
MV->NWXYK[3XFBA-BCJ2Q;?JKP3^*CHJJW4>^BWRPMHV&)W#]2.2<",4QHK10
MV44B$Z].J92W8AUWQ,?SI%0;T)!38#CLE(K3?NR#^9Q7BE!#C@CX6=1=@Z/!
M&E)$X"U')OW((_K=A%SCXKK]-*OBTAJ%IS> GBO2>DVD]3H^@3CK8H8KZ8+M
MW1.V]\_'K@L].ASP#P56A(5)=XS%'P"G9%D$Y-,(T9GN*7/9\74&I=LC+>]L
MCJY)L(HWX@U=_!P/9[]%U)*WSTNA&P1/;]IE3;=2PLP[4Y(GW-DPX[;>TXL\
M[7LOXHS/YJL\5@9V$%A0^Q0HY^#81/\T/NA4; 0+8]FNF$."Z;IZ=B^%!L]H
M@()XB)2;/O@ 4KH5P IE+.]Y6^'.]MV)=A)<7#'_@^.KMP.E=/<49=S<<8^8
M7K:QM8_EWH[)[(\NC@'#FN+8H+[PUB/_VP+B:$HAN]2BI E@6*3 &[2K/'H,
MA5J "&7#A (:$\%E,+2]F>S@3O%PG^>LF-"0)]OB:&C9PJ2'7KC+PC9)XN$D
M''NIW.2J$S==1J,:%T\@(H?G66#G#4!"RVV2O-RBU-/>2C7NF-_X>8PC.T7;
M^D>"#YO_8ML<5BNWYJR7J6SC2,XH\WBVOP!MCJCK^^*Z N'>+H"SBK/*+B]T
MS&'OP$D:):2S52DV)KD:90/27'Q:>6_.CZ2A84*@#+\JJT7Y];$BA4KMXPX:
M3I+(C7Q?60T&;@:-B@DYG-P1? P!96O&6E_O!U&+[JRCU:_SJ+-BE( 5]A-)
M]$T$TRB-RI']*9G9>X,>ZT[<CV>12=TR@# ZHF;0.H ;RKLE03W->:IL5^1T
M*KF[5:;[0^>3\0>)I:&ER)4";I.07)A,!P1C?';+0*6F;%\@^:ZJRR;VIGB(
M.4QA:3YA:4"4J:&NMG&2(T7>\,L;FN3OKU'$I6BM*HE0NFP@'NDE,-].@XS2
M7.ERNW=%P\3+1K-E/(;=V+@UJ?M ECF5W6@S+@@_?S&*;G_^84[((@JA3?,T
MBJ)&TI>^E7)1[4.U4/?2%=^BS:DZ$F:4/$O:6A''GGFXG>/\/*ZHU]Y>]A.S
M2(<G*\8EN2,H4H2C/R>ZO/4@0*S\[ 9XSW@#7/LJ(AE-2I-V3<P%JBD2K\&9
M2+R^Q<<%.T?*F,H?-\ )KT%"4C:HIV7A.F#X!LA.F<A"C6#)PB<QA>[GYLW;
M.M@ME;XK%U3"<7*<UR!!M[A04A@.6N!G^KRR578J+M*A,&JJG7(VL)?EGVWV
M@XP6;W^%F;_?:Z6SYQF4+P7CNK:4Y"T'J7_I;F+T@<]*>C+5O8OE,EB#&,ME
MRJR="6E;G&@4]_W^-7-/39>CSKL!*Y'G6?@Q6M"*PI=NZ1(+'<,"+46/CU,Q
M&W2>:4A K;H):EGG*L/VFG4.+X]U:J.6"0V^5>)E^@BJRSR\)%]T.YWT8_9<
MO/;MU)VN)!(QFO+$KP)7XM[G('7F<8TD*'<SP1GGXEMX<WX#. 3MK34:-F43
M!>-%7+#>VG49!'R(:* '-%?!%]H)E'\_^P#\W7G\BX*B>8R08 ?M-"!I&GGY
MI/(P#%9U U1L(#F@;=WO[DNO%?D^_(>O7SFMVG;]<F&-8M^VTKV :. Z(A:7
MMD3R/ &DL^X#O2_>!$K((ZV/]!/ES,]"*"//^ .*%ZZO)"]AIJO6J&N_U$WD
M-GSJ*7EZRH4(T2N)3D94;"!:\Y$]*CD%B&]WS;44:8GU4>^G1O-J:3&$/G19
MEX^)3OU J8[%6 %#C"NV*%MS#"Y]L2&SP"&B[IB8VDL*XYN9>685O46DE/VZ
MH0/OC'[JLWLE^I;/),2HU_*U%&I=G!0>5A%]98L]9,M#UV/4L,.!L(<PQ*B(
M&6T^4"@FPJ?3968K@ 8Q26YNZXI [ P>?5//ZA/>2X1(BG3$=Q[OF&*?I&9[
M+#@$:]6"&^+(;LT.L*"O4LO@T?A-YRHO1?%L='*5SW8Z<D;5U^JD$I#3"E]H
M1V.+[TB  .MX19]VYG NSN=-<2QIK-AT5_GR0L,@ Z!]PL^[TJ NK&+OI)3,
M;0]G9R -O%O=^Q%]C[1;2GB]>A^N4V9C< -$UOB+D#J6.3P'-[HUIG=/<%O9
MV_*@" ^;==D;PH6-9?2@>)#.:44;$&B#_?ZYG'E]&$H078RS77;3H4F\5PKD
M";/.U(LGCH\E &WCTL_10EGXGEVF=YQ.=.[]Z"C@4[1(<D ?;T@_QWM/C (!
M$$S+8+@OB"$3Y]3PRB,.F[I3*80R].F>N,)4)NAP1V&"J=ZS?N*!8:E%34,T
M;M0['KH]XUEWU%HGN*15,<Q6!7.UWWX>Q;%3@+((<#]=#A02MK<X="Q>$BT7
MU)JPB-%J4E8N56XJ2*8RQIY%>X43.S-5 8%+MX+N_[")ERY0MO/V9*R^CO.,
M78)@8\Q08 MMXLLYV@2@CX$'51?4[:(>7R[_4)I)W<EE>4N/92V&%LVKLRM!
MN7GI/AGY:7:;D9V3?'D,J_Z;<^+0(@D5OIJ)-5K?_769?-7#MK"<J?T:[/)=
MI];9/JMU;-5)QE0TM"IB"&RF(XA?#=](#514/E]8)./@NVKZ)/;3T>$,$26G
MTD;$KEK0B>YAU_#;U6A]=D=&[U17^/;N3!V;^6L"I3K/I52V3?";AL1UK?QO
M\>WTBL>\15\X78:)4/J]4DV:#OFCT_.V1#Q*Q11=4%,;L#*JV7H]%5JBE3."
MM]F*F]L2S]L]ZPJFUKOUJI.;D[M_F#\PK"# BCPM5VZB,%R5;:J+MHR62T!_
M][ZBD+5CEMQ]KLRS5@LRD,GI!1&$.#MW8-&D UZ9P5J:]2 <(^M1V(>GPQ3;
MGB1Q30:*]Q<R'9>E^[8BAI(/;H#J9NFB&0@L]N#!!*>L053+CO<=UE;YU;E>
MC0F,2H\QMR9_DB?@<0[/ZXPIQ@AQY*S/16.>:K )(+4^NBZ7!/-_J&M*6,N
MB(Y5B0H/6$IM6J,E0BE]H@M+#!<>3?#/,5])$);FF9):UL6&/BV@E19MC)RV
MRC:5*X+S&X:YX[X[%7A5">%49RB3>NX9!)<AE53B0M#8D'C:N#N((Y)Y9LH_
M"V2^>G%,IQ&B>_JE'"7WA[4$?OTX'RS28\2@MPB;X7I,D>&4(<X:Y5([0S<3
MQ*1NWUAOW^1@0GHJ'N*B.UP,RU1_9KC,V-+R+<Q"69R:D:5TDZKZ673;.#'$
MIO;3_)9/0O[7@U"[U+!5HU/-SKL7>@_+3'MRO%+5QOF<\!>VSVN1_LO&C&B
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M!M90P*ON*^7*'"%Y*X0SL@O:Q)UPNF"3JL.WW_D''CJ$@/,=_,9X1N^F/?=
M3],#29%%97W?X,8VDSP9>LPVW&RZ9&SBX&(19-D<JE[5N;^8('15*"YN-_F;
MA'EH?4DDX"&PO"5[;D/^-G9HWV6&_Q. AI;/\=]4-O^"OOQ3^2WT65KS#Y%1
M(/BW-,=ZYMVV:H48ATP3E9?+WVQ6^E2$GY$:-?0QN,]R+]3X_):)38&&1]J.
M.D*W1@CB)$<5DHY?!8!2,YV^!C+!'"_9-L^M9-_I1!. _58TV8UJ1\==Q,R)
M?TP3',YHUK?63IEE&L3KWZ_K9CFXA6(L\)#"Y53XO&(Y$(=ML-G%?5E(3"OK
M46/TM(*#P2U-(:.+)/3(*M<?\K=F%LKU8,$NY7W+.X:^<E"<K<0S#O:]/+_\
MM#HRYN! $??U0/%_2,CPKX?[S#--P-FR;!"TDZ$)+H4JGHPC29;?RLJTL<PV
M?6)L(8>A5;YE<-:V>/6T85?')-U!7O\M5 M4?V@$<)"%'!VO&V"6IC^O:/&O
M\[_YGS\+:T9Q,63STFUZ.LX^]$&<;Z:4^"!?JL=C!T8/,SN12R_/#A(2/S*(
MC28ZXCC)/@"MG!IKA$9A3&5PWE"C1<*]0U CXS&B+;E"H6-:>05$VL,Q10\>
MGRP,_1&M7.6W>GDD'_"ZQ4A/3GM+X<>I+^*M.%/) ,3-D)C?] +=!/EFL25/
M[FDA]7,/V!1):W7<D[@WI]_02^X;F?E<CP^JO5Q7%GJ6^X!%0G>;[>,68YQL
MA(#G\Z*LQ)=" '[>=-RF1EUG6Q@A+&()UPND8'[[C3W/9\4YZ"5RHM*!6YEW
M/#W'?\#H9>VW#8I1ES[< ,7!K?Z\P3"T'>.VMR?*:OC6'HTZ<0ZA<Z@;E W[
M/;,9UFC?Q P76Y1F.K<$HNQE232#"=Z[K"E&NVZ-I$VDI'E2H\.2<G:2>+)K
MILP,.>1U2$V% ,$KBSW)8+WB^3]9@"Y))\WM&"*8P&7['?ZQRG1[WW"2V)A*
M>FAYR73"DZ*!["C6NX7,+*<B$<.F%Z06R!4EA^2<D$\!%%[O84GM'I[W!"\M
MZZ_X>_>IA/HN(VFZZY(0\F22.Z.@$X$RE:@_(B+K-33$-M2DHQ5<-6S@)UV=
M[7=5-V+K:!(47.$E;V/@+DY+_GP0@WB).H\0]KU<BE2716ZT3]<JWJ9?,['5
M/)<WXCL-J%:KY"B4B9)8OO)_>#2TZ,5P W!+4=V>"&"$Q>/:BGR,?W+8;,$G
M8'YMN2#F>(HU79@E;C>156U(0R#V0/M1T+OG[J*@WKP)H'&BK$RJ_^%Q'M4G
M$8*A2E-0K\0&HD'RB ^HE;G&_#<!<L\;(& 8T4IR0?X7:>%#>?7+U,01L;IL
MRKR\1*Z$QZ63_Y3D^Q<AHG\JOW-ZX]\8_PB&_SU)R^:9R.MJ/ZOK8Q//\H[E
MG23#0:<.ZMOOB[Y_-I[-P$+ZV<U&$KCO''*B(A7*)5D%6D^5#=0+,G7>9> P
ME)WE_W:@[J[LF +15777I&]"-T$-X#Z/_4[SK;S%!-\<TQ?OY%!Q[CKY7JF+
MUH9!MYJO?EQU7FXMFD\X'!WXO"N33V9\W\LP&,H[$]#>[T-M:@0VX!I+/\2D
M.2.AL^R2/R[?>$8U*,X3T7SP<2]II1UI5G O29TC,%'63D1#KZW3(*.CV<M"
M-RLMR0D4.X0+-HXY@(7]1$OR6W/SVQFH';X9CEF^3WPAM>E)*&=G@Z"(^=J&
M7\D'3AO:<1"+^R8OUD=*V$/54%'[/\X"LX7!0HK)'&@/]_+L^,_REA['IK_+
M;-F[ :;XIVP-WI";I(OO#3B$$K'W7!*X&H%>LS-/NN-FWM]6O+K*T9TD@'^.
M*5 X@E_;^3Q4.(\I7#?3/P[8<X='<6%ZF0Q(?8Y[<@/X>M+S*/+B.Y?)8V6M
M\$],BO,BQ"D03<H_Q5B#ONJKM(;\AK('I)S/=K4G0;^$_C2F^7?4\& O' P.
M$=NWI''G9DAQQ/M*&XN[8WTS+\[C?SK5-<_= ";8T8)<2!W,4V:&<:7XPBJ)
MQG-A?*M^XH.]']>(X_J5:>1IS5S)]H;?\YA3]3.T<2&:0.(MHHB2"&(I'$R
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M!S:5-$-)-/,7C?Y26=A^&,L_X&;9_-?=R8SO\C),2..JG?'7&/"%N]RU S$
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M53(8.#0I<-@E+XRB3;QT%_#1:11[_X#,YA96"F2L&2MWYD>0^ZVFV%:'@]A
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MSAP!Y3!9/T(<7]EI7R] ^A[M"^'D9M%((_B+"[[;28B&N/4>$,YW=SUB8$O
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MT4=%,>,DBRIBCTEK#P=YE"1N%97>;G3TJFF/*U='TAESO,*<$BY#HX*7:]/
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M^Z9R]$1(I_VAY-N8.I'/,BC$*#!]< B,/23A<F)TBX(ZT3F/T8C-:K.SHE>
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M'JM%4QGW)TSAL5Y:\?VK5 ^N993L=],[:C86!GZRK<X'@;;?1QE:HDWFY_;
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M2ABEB?;.?MJS*@+9-N"^13O<10+'!(1IE^:[K5.EEH8DH]X\FTC 3 ?'7CB
MGBK9$:1J;>+'GYP63"I/225Z>;9XZ-!BK@6.+A.\[9IHA4&K1/O9YX[/.>?!
M7ML'AN?Z46>D3;[/\%P&\Z 6.-"J>[=0/@O]2PMP#EJ]+BM.CX/4QT<AKY^J
M Z5?>FL7N7/'>T=]%B4ZC KO*&/EM*TT*G\,0Q<9$O@9F<*^"N[2(E^=WW/S
M$7\ZI6+L\K)8!10=99C'L\?3?:U84U]_.*J(Q[1Z^2M;Y:%>#WDF>;^ ""8F
M(]605\><;VO9=AFV]8NY&:EY!RY%ZA\@2$]#$7OP'&L]@5.5X>!BGB_!#V8O
M>>UIQ=JCXKE!;+0S-^5<L F69Z.8OO_<T-P0)Q6L23E]CP+C5H,EICBFDM>A
M$PL+,T5C_Z#$YNEQZ68DV7'$T PQT9QN%7OG+?&X,)?=JZ]L6'-ZWJFNG?)Q
M\&-J6+WVF>CS49[G3<E*,N2T0ZA?"QCFGYC##*4B%(68\G>T?Z@V$'W5;3#=
M*L8SZJ;0R/FTXLJ/?H7?%E&WWTO%/-#[$78-[5/UO@6MZ P5FSB:.%.H4T#T
MSD1:PK*RE.AZ(BRX2QID0W4^G_,736:Z:PEE_HHUEB96(_N-MZ"L4P1??RAM
MA5<A@1?2O[>?B-#\4Z6_+*1<!][P,S?">B6KV/I!FQUNYNX\CD=H&T:O?K3'
M6>GT[[TKKV5_7)5 M#[JC,+J3WR4GEX)#3PVD4X07L=4VW(.>'G/]_%@'ENP
M8]ZL9:]<:L]*1F.UQ3'V@)^[_2V+/[YU12FXC;>&E].:=\1PT<BHVW<@WV A
M78UE7E8,_ $7Q2#POSL3-+SCRSAZ<F/^;6CUE-2"=3SZ"QEEE)U5#]NK_H?/
M9< /!;&?%SSKRX@)>+XEWL=CZ"/3,W_C\[/)Z'1,PVC#BE@WLQY$='&L-'82
M^F;<WJ:,/70>UYKA<V.SGM4/[$APZ!*9GIQ9_81P47#XB[8*H4KJ-3^OJ=1O
MWDU3(U'6^'9Z.V[J6KC+)-?\X,G<#(8Z&!,8L<J$=5&14S%OG[NLL/19Y3HT
M-U_=2^H5C*=1!#7=?W_I9[8V0YAF:$T?8:>-:# 5WKN\$&&?XH6M<4I6T@-(
M2+C(0OTO\;5( /UDT.&6:HI'B48KTH EL>[3[I%<W^>T%1KAM*F&YS_>, KP
M63^>Y*P(GU!M'L[,+Z-+[A$5-4P%-1B=NVR"IZIR$*U1Y>)CKK3#(+8$:Y#Q
MS<_SY"N[4:@C_*'UI1E%DZ=Z;4S);@ SH?#-BQ'0VU:6T?:'BBRAC]]R?=\%
MT!:2?B58UUND*A9L.',ZC<EMXI)1.V^)7Q=-L IC%<.G5%I:RQ00''B/&9<L
MVZE>>=S@V>O=Q[82]1GRY"^8L'6RT45@]5"A*;C5CI,:F!P+2>@1+ ;LWX!9
MIC][)!I."QLY91E%,GO8SGRV^;'U(;)X5H#_%@;77,;A9G3<&'3GJ_U,[.M?
M#WE\82TV-D<\MH_.I_B>KD81<;/J!=I4\.]\7NH.[2L\>+"RS^QK0;=R0]D!
M,F4OG=U)2DBO?!"3W6O\:FEMK+&$4Y>L[7"Y<\#:<<[Z\Y%OO<W#7]/B*R]6
M?- D=9Y.V";)8YHG2<(&/&V%_428NH>[E)X^[K6@&CQI_J 23;!Y2_)U1T75
M.Z:UP"'02MKYVU(@R?@U-+]T]I19A!>\WY%>?AU\6AQ%Y/&<Y>2=/0SZ8'%A
M@9T04]]_,[V=]OA"\^!L.9Q'_R,>J1#CL+P=A.:X]ZC4N3N!8H+"VWGGLL/@
MA0)0&WY=Z/!N[[K0%\9O3<DNQ?2I0(9UTO-=%4T;A4;@<DBFX*<<0W#JO08L
MXV&&^5*AZ3K4O Q0B@=OX!M[:(F>[F)C-E?-E-GK;,=I^N;[OE3;D.\4)0?7
MF!K@/DU71_RF^F1<]O)P6_F%?<92AEN2"<7;,KT)K5LLN26,^D#RN*XY?PSR
M];1;IO0=7CMATPS=94H!^PF%$EB(J@8D@[];:U+8.6N[J_MQ[M%:>MCRQB9\
MK,G3;-;QV7WT=$Y4\=%ZN&%:YL*%:6<2:TGGX%N[U"?#S_#&.,^H9+?5OC=^
M:3A):!HXH-STZ.Q*V\DRH.Y' J&M4X372"#>T??YN"UWT7"EI*.SLW?PBWY1
MU!H9CQVHX#YECV="_JWA^RQ%KE3A7SV/KF]Y^JU%00B>I0*6<TTNR L_G165
MVCQQG5=9M77O+II<)MB#E:ZKA0B"(:^Y=8AFY.CQ<??H!6R@!.6E77T!%Q.^
M/!N&%(?<M>6OYO+F;5*TT36>NA,8GM8C >QY)1'[@SM4WM! =3I>F,PGYM4\
M)3X\'QO76Q>CXU'P08;V[5,$K2!>F/XOB37G#W.1F")P1F^^,:$%P[0K2W!'
M%<]R<"A5$A7YFX0UCX7*[YRUB$S5E&K)$BWB@EHR:[C31@J"&F=1 D>KW%)3
M$]O,2N;1PK3RY48\:'FB!.NFQ@A1QC/NC5:4HH "-?<?]SAVY-JT7QET0UP\
MZ@Q% AP_37>&>B\GVB>LU1[3O;1)_S76FAI0UF2<)6[-&:Q68]5!%$8IP+]:
M]Q3QR+!W"7:7GAO=>![D'IH'38W)XJ>A.W%%EXH+0<IT?V)U7'V]"QSL5R?0
MGD^3AD$>=6OKTPPK2 !]J?8B(..C7$3W[/$9 0>+4J=I$N4JK[\H7+_UJCQI
MOG*4Q=;VZ8>Y^1?/,-C7R[Z+P;5(AV9]]YHDM_RK%7R&MCH?VIJU'%PPT/O2
M;)MY)R0>G(1 (QP%S\/8#TYUWM0T--76\L_?=VKT."'9[>"F(I0=T>(I\J!4
MG#Q(/=)A,XU'- X81XJ$%'REGPK?Z%ZIT#"V'#X18,>YJ-*$1;I8*RZJQS8Z
M=#>UM/26N( //WE$&IV*DGSV:ER[U%P*7!E@)Y!ETN4NV8C6[YO=1@+PDC#'
M#[%5YI^]>3S&55)DG3_>SB"*6W=.*"U[K^R1P*R6R.IVDQ);0K!.+2QH_CO9
M41^#N]U&LV9FZA+EY^_.4K%/=TK3PYQRYV#?2@+BY?@;HM0Z7$+HZZ=8GP2Y
MU2;(HV9G%::I&,: .K?HA6 BJF>(1O\+T%3MR0&^Y:5BU8S5U-1^%U'?UZF<
MEXPY+;G\^I7$F1,W:RD?VP5Q.9H<9W(W].U-=(+K!DV10$?Y.'3S]O@(<EBZ
M$U;[BCUCDH646K.)$".^4$='TI:<[IF87ZTJ!D2:Q$)!GOE)9ACCOQO'09W)
MK>5J=GSOXDQ%6TRU:,Y:/^K<)5KNP> #.!*(<+VEN+NCA9Y.&=V039:]Q >W
M"?+6YG07ZUN/SLN^RS>BC*T9KL=4QQ<1()GY1]A-*;9N,'QOR0;3V[)]:CY3
MPFSJ>()64$)Q/$R:G[A:&_"L7GFJD>V+1H]Z?[4I(AU_:>EL67U<\P#2$*E-
M+V&2RD4.:?:>."X^&F3X;'0>4?\MGD5<@!^<XGEG"-;EPXB=?/#:+(]7C'WD
M>RY!+PN>,?T+:[D7O8QC3^)8NL_2^_O.STO#1>E&;'.\OGYNXJM56"0@'>>F
MLM =RVRL\C^RYF5Y:/6:GU_88GKN"U\ >Q9=WNCF\'G21-HTR4'- -57'(SF
M\!BI5E<2=93+B18OZ' U$KA+&2,80@M/Q_<Q N5U-P>KK(YTJF37WRD(LBWF
M'74;CAEK?)G;?,47LT>I+C<0D'HE[;E?NT)IX*S"5X6SM9!N4%#UV$=)]_ \
M^,?A]M?YG/4@&[0-]#7R[8 #=<3D5P'PPWLK% 6#]D?\.$);Z>"M6QR8\TX_
M3=H$Q5(-0K3Q >ITQ[V VR\2:[^P#YK.D$":%1) +".R]@B0@.CXK>(MS]!/
M ;N[1998N_!.*X+]- (JQNO9$DR7DY<4:88+/\;WKQL08:.?*#;DSTFRI),)
M%9ZB_$P8?C7=^I:TYC*GH*:Y/$%;'LNJ;=UERYJ7 ,?2;;Q76)?E(ZT-^:O]
M#RZW3 JJ\MF\J6=<E%V^W%A1>.E(P*_B;ID4-@^'"-NR-H6X\(0J1!N8OA;K
M53G6<C\+NL-XYTET2(!"]G,#L;7.M_)V,B-$3L&K&X(OK2M4L)G1+_MA%0//
MXPK.5YOYI$4%:D=V]UQ.G:T>*Y3WK> 0[_6?E=;>/KA! Q^A)]Y>(H'=(KOY
M-SG5;H<ZWV-D,E1D^-$064M>7TK=6X)1YZ!=SV]/)T)$<J5O-7JM-<^G&JI'
M=E1_)5I'<7[<9X@4N-1JN,E  IM3T'YH3X;CXW"=DS-S$<5G#Z^WN2\Y'/-A
MX2W'?4U\*\^OI8G'I9V)%1]B"'VJ$*">G-:]P%*I)3-ZH'COQ%^D=:J1<4'J
M7N0W*:S*PB@XY$H2.ES\-^^ 5$&<&0+#3_/W;PQ:UN*,@OL9KGVL=<-[6T"@
M-9W+S<X</2E;FL&D3>C@YG?1@Y\&FW.4MSX6UXG7EK^-@O])%Q::BOHA<W7T
MYZ5]YZ(&C$PF ]W:4N\\AP%];:[!^7!-%K2SV1QU,RM[H:7VNYE%1Y:/X>#U
MUC6)'&(EED8")1WFRZ_)WF!U)!#E8Z\2-<Z>=IB?=VA>A(MO@N!908%\:SO>
MFVH$5?-=7P[_8K\8HPP"'_UU -FJ4'L,F3EF[]D?YDO>T<:)9=?'X!7#G!4P
M]C:-'*PEJ4_>F<G.E&.(H%P8>\=[[<X%JWP5;[E;+8V1 %O57[R1(S-S?\B&
M30?[H9-]\OK+D/SW&A+Y6T ;<5V^[S]PRO[# -:F$PR9Z;]9 61I_^LT[<@(
MD7Y_*U_T_^AOB>K)1/ /V*._VP!(#0O8P_L+GCL0W#X9K7^;<+__;PW_/+][
M@BB\97 JY7\ZE_'/?S&O_"_WG_\XW6$&7Z(8\U9\FW!9DIY"8XLH-PF/V"G.
M)M2=4,8085>H&'79JKX1G&7=,R&3&T_?]SR"-!M;+S_@9L??@;YNMDZ,)S1+
M27^?K>?"@))-LQ^VXZ45ZN&_O_QRNH6N.W_PL>J2MH2MIDQ[O%M,X+"A'!DQ
MRIZ*0IQ4;$_[FBMNL>"#=YAIVDM$05Y0K*V1A<TA1<: @ FJK+#9?ZY=?:$-
M)5:BC<P/X_K>"Q"H6IU"U,=93E,$]? D4$2*ZXYI:/W:'C@XSH<!W\>$3;.L
M/7TS\G7U014S?:,#0J7$>^0L>0UKS5J'!Y$G1@^-1%*^U(<Y@E(H]-M,CK.&
M^')]CZ;1C"TAG4@@Q*U&!:7F<L4T\FDXD.6'55YP(C2OI->;BF/+YK&IIT02
MT1\2\-,_'9C9<I[S$_'\+T4VW&9H%X5[4'5/ZT0N9P?9L\("<S<1$G57AK$J
M[@-J2]V@9*CGV+ E-R*YSFZ%4_Y!CSB3CY=)-J*T.?O"7LQ64:,V[(?,6E_@
M!-$1$KBG?R)Z4_3ME'%:X_!1F&ONQ&X9+'D%MU;S3!6+=*0(KZ!7'W?]2AFK
M\,*^QQ,2^C,)YZDS7I<"K:5=.J> Y&B;B/KEM+2A\0J\T4=KM<E=]TV7\UQG
M1D]LTTML?PBVW,&>8=H_'_0Q\PCN2G(/*AY;O<FAUR+LQ.7\0AL_?%@8F0N#
M8W7-]23F2-LT1/15>WT1+O+*#>'J?/J8DR'P,@DHPXKBOM\DY%B2G!@V-]M4
MOY;PK+('"2P\GW:'Z1QN?N0>?IB-!$RNI-3THNEK&SYT,UE$*Z3V--DY%:P8
MV'''V+^NFGZ2X*/R[DJ.ULY\[^AD+6S_FM49,P]AVJ5UZ5T@$ET51,,MZ_0(
M'AYYOQOPY/DOQY,>&!JT&UNP3G[_2$SXW-UM*UU+,!4\,M]1M$I#"S?9-PTG
MB_I"8P$P16:?%4-"(46+2F_RQ#.6=R@$OD^GF3'A?K[*=Y(=2(6,-1U#&C]=
M,'=6+F@/6N?-P-^.*3VEUGMNVM<KEA>0!-Q%9@*/Q%<(GNRJF2_Q&5 V2XOP
M7EJEK6^>FMWO-OW,](;)/3HNIS02OBE^GJ25C#?'&2+P/!'\IY,1S&A=J1QC
M34RV05EG_N>T(6/W<,,=N#Q(6@W?K5DK41]T-UBU(EB7(MQ)JG/1[A,&G3Z3
M;!-=M$1[:P_:*K?D>+O/CJY%]$ZY_<S\.!LJ_0I6E'X1 $'0)[%7;Y-G+:B,
M23$BRG>*\S+*:*JG2O>7V^=*8>X;NO,[:A+LN1W%(?RRIN-INO!;,HY4Z,.E
M#DE=_;<VQJY79>_]Q0_$R 3_O8H0#/[/M]M^O[\/TV >!+V<L'M:USR^9V?^
M8>,Y?:!!W);<:NGH_W&NC)B'U5YA]+IUCU5F:GAP:%A4.;EBFARN\0P!#:;7
MT65U?^5(9!]=TI'R<9PA%>O9E]5%P9ZKSMHC@]GY!6'>RL]SV@'$0I G,;T*
MQQ%LS+;,/["M26MX)>[8A*S+L$VDT7E:=\PQ00G@N5@"^ZK2.">)2KLY:!XJ
M1O3P6I;*&:XRLTUA_OFH.3"PI.BEN]SK4.7Z\[:-IJ5-/03/>4AI=0E8.[)C
M:5DJZ,06)BN$Z"/?(CC:UJB&DEX43'=0-._GX4[-3;;7) RRQFN(]2U0EJ[*
M^#"B3>>7/?K8:\C<FK"I57YE,]+I^UJ)BY6E28FH'.L%?E2D]=BU5AE#\#4#
MM(BC4_H^9\&._F'6\3,_[A(>(9Q?%F%#1SC!M;9Q+*J8G+49O9+=8BU/QD#J
M<2\-7DV69:J.B=%13N!G1TZN&A&<ZE&A=7NJ2KH*"#97!"MS2>P4N6A71FL#
M[_A7TQO'8-R'O5%LR=IXZT;<[FB[(10_KNN%&O(%MOA7_40#M;24O[5_"O?'
M%R>&K2<%APB+F[IG7-C-JS5J"EHV).U/OWSX[29>RO0)2J022PL+PF?JRTJ1
MPQTG3(HXO4YPEN?)6U86U4'E>R70FY].H%L86J@MG]_R-;&<9X?MK)8(;Z<E
MQW."@[OAU0>06LN5>L)A0M)ZNM+%^E=\#&\DD'>1-#9M!$-\5'+@88Z0'YPP
M5-PE#>=]7Q=N!A#H N=7GT9A'T-9V&*_'5E["[4S%0<)G]!!7DXD-(C&YQ5G
MCK^JJB4JG17.U^ CD'S?5\8VZ>J5PMS5(C+)/1MO\1%2&TO.&T1UEP50-&.V
MKMJ^T#CL:H@LP<RP*F.;KE5T#1=3L,/0=I(5WO 36L2GPF?6H90(ZWYB=<_9
MO)"X#I[2W/W63,M_J^'.*B(_WIT.@C4CA>1<WQ$6*U661W/[<5H(GZ^1C%X,
M=.M.ENP7L$65*D6(DD3/Z6YG2H7L]1_GV&&MW$4'_6A,B$)W5/<M9<(/O=SF
MW.KNF@^/GL?Z<"95Y!C*YU^X#9V]1H^;RX[$>AG?7\9R.!60L>Q--VGGBH,C
M$V/6:%_-;>H9W8O.9\B(-NNL#J,R51JCD>=AOK*6<H;IOD/%% W@^5F3^F2*
MLL.7#!:@7U?3G-35=Z@[0UGT18Q?<_.G1MMZ4N^D:PFD*Y7Z,'!RK_C1=*>V
MA_<7L0@&YF@T5S01@K? F1"$R-+37^',LSD<CGT0W2U8TWW*+XQ=*&R[8AKN
M\5%Q\S8U[MIZV)O9LJ&W:S:[<<QE#]N'=W8E^>6'-Z4:/7R/&34-W^[E!F:#
M(AXE!"M4\ [D,(?X#C6BV<'#345/4+;=^<X2W)3>.3L3\W[+"!_ZP8B5,4C7
M#4LH>O-3OQ-CL;@0?Y98D%\$GP"S'AP64G XKJ6A3"P!  Z8TL:]!1YAYUV\
M<YA?BNG3WB;1\M'=?J_DL$'I\?& BU%'X"<;VYN>D=GLK56W&STU0>'PC&A^
M;L,]C\>VW#>^N[=G/.0F3B:>IH]]U'JAV&3D\R."[7)ZR)V/J]/'T=0F%@*[
MCQ++RR]Z4GDM-F%R:-*<6CC=\*'!?_9+]GBXLU[0YL;'+%&4'GYN%'AU/UTD
M'1Y-(:K8P&,GZWYSA'W8R3+^1<@ W7K0$''"L'+3>,OWKK@@U0^O)XV(9ST2
MM+V9'?,]PA59?UZ_#*5*8FK[7H\.]:(.\A/Q9;Z2W]^H#MM@J/=#8U'X46F1
M*VLS&794HMBM&_2^T*/'3,\JMS)HUL09-</".&)(EM9L$QVAN3+EK;BR3&A9
MXUE:05J"64%Y6#- *;;B'-^KL=D,>&H\?2I.ZX>E:MU#@[#_V!OX#"$$=^16
MV<&<++[M\Y-+/ENOU3^>:[QC.(*?YMS]>!0;O4-Q*=4CL]S);RS1,JN;:UIK
M]#[*CUEJ1]-*1CLX./A6)YR?)3H-DS1_5^VWFZ=7=WAI.XTU,IUJ8+B3D)A*
M<A@4Z)WT%O)FH]_%1(<2.^NGLD<_??G_T[YU1C6U==L#H2C%@@)*EX @W2M5
MZ5)%0$5 0Y,+*$6*%.F$(MA %# ("@DBTD$A)/06 9$6""1*"(@"4HP$B0$-
M)"_XW>\]O.,]7_GYQO?OS#'.F7.MO=:9^^PS]D:ZV*R9HU92,Y8T\>B>\_?
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M$GDWCWOP>:GB%%M.LS?+P020[DCZ3%LK:0)V?^*KL-5@X#S4N=-YSW[]^YR
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M7I>S WYU5:/9SQ2-Q?V?QQ@422$:AFDWGZ_U)C4ZA:AT^Z:G!\-C*?=?DDY
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M^8ST,=0!U3Y/4)8&_Z% C=G]9P6-Z<C"O678DSJA'=<"7\'KF%9D=I5\5&Y
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MT4!5^EZ>H[F/^VQ&TNRZQ&<74OY?#NO\,OJ//W4$_\5?T%\@*BT,%_RKDIV
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M/T#/H6_@@;$PG\\[QQ^7ZF;AE"T.:L$GW%%Y3%.'OO!:S9LG%<KO+MUBE.C
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MG'<U/H$W=>L+'P>+I@4^9LO]FZ".-KY3F3K#(^FF$\TR3B%Q<&":(V'[W*-
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MW<\^PR(:O)FKE]XBNP:BY04MV;O7L6=I<@=%L[!(VIS$ =3].NU9S^M'W@.
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M0Q&W;".&W<[BNG -G-&G<&*N];W$P./*V0#M-P *#>Y&4UP4$.RB"M%[?YR
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MI_* T7?OJ,1J-TA;M\V$5FGMFYN$L I3)&UGU8>?(IC"NVE_:F)?@"/JPQK
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M!4SWP^A'W:#9CQ1F%;EUC:,&SC.'135RE4VL):EF:;T5@0%'2L 0O0!#J\7
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MZV,E10BRN@3W_L)Q+!K7LLD3<BAN4F>O4A1_B5J62T;^<*7\P4'TL\Y9L7,
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MPRV-BJ]ABD;K0L 3')^-3B=3W4FH.0ZCYS5S#7GVG(B8A)2,@9&)^14+'[^
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MP?& 4?<D; 61*[\6<IJW>4K*UK:J%_,]C]P0![=JQ\/A>Z9I*4%BBYT!**U
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M.-Y-URW)6M')KRX+K4TMG(2_GRV<R$^SH1/Q@"[WX5/S N2QZ_F-'8CV[WM
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M0*!E\%HZY7WN$O3'\8-:CC[258SJ//I1"_Z[W%?VGUTUEM.F=,G=3CEE8ZZ
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M:MMU?$=[?G/?/?0$X,Q[I'."E4SX*8[A'[=V/P&:,;0;6BASY"85=9X ()G
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MC%L?4\V? %+I3O?KUO"AZB= EDK]X[W!<-TUGQ)['$M<5R;&U$>VV50T>-I
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M;2O_S?X_UT=@)R3^>T3NKU2X=^;]KCJBH8&T.X$:7MN*_/$T2U )@ 3P_EW
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MG=-WF/>NX,00#J1;7:ML___AS;MZ4RGT.<U(,I(N!S@PH\\R3,D#@JW8^T8
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M)IJS)4X-4Z.Y'SW+1/YSDS@']"Q*6YL1<<#KU4J3 <ZNMDE7SC1R?A-2\(?
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M3GX:Y;ZNDQ:U#:5LS18*8V7N)A6I&]WI>)DXY=EGHS0ORU6_Z.A/:*]^^8#
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M_?S/+&VI?GZ8RX>TKD5X5ZN_Y$F.?/J<ZI@]'U;39P.>X7JL %344L?4]Z3
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M,/;9;X)_4V3%7Q0)>NAO@_)W?SQ^>)H>&OY.$93W[*RO899F-M=<XBRJ&NG
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MGID*SCZ'Z*Z4ZD!QQO\%4$L#!!0    ( -R*?%1>W:3EDE@  "1G   8
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MQ_;2L0_\16SMHA#B)#7^ E-*N4'[S$7@%D-XJ\F_FZ-0:[L'/F5GW0-&]/>
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MJ#71_ZIO_Y[>.6>+U\W$EN?9IG/]2'3PL=DBX%=+=?QIBJ0F&GLW2RKT'D1
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MGKV[6%+ZU4GEL\/853]\57^=IU\0;LJ1E>;3G#&+9:I#Y*,=TM_H]PGN :,
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M%3NEX+C%BF ?7XG9P"D=4?=+1]K<OP&!TE$7J$="X7DQR0*SEX^DO!X/7F[
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MLW=+/7>9[I[)@*_(4:<UN,#[[EVNA'B]>80]=\%-.25(DEC^X>4]77'*M8U
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M]8T=*L(K"U4;V)EKUE>C7?83FPGAZ2Z[<:=XWLL3?V/?8UM"_ZW[!!3:>%Y
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MA8N>:YMP:$%<WA_"9.OM:32]L\&&"PMT?MUU*0\5Q#5DVEJEF5/F."2=!^Q
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M+@%R47O9'C<([\21E_7>>OPF7(_Y:P\DJT#+P:'$?1N.'U?2%BF6;%48U3P
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MN'_!B$U"26WO'.YR]I*2V!);/K76KW[W[3B;+&NE+6_%>+MY9667UXZ'6G_
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MTOZ'HOLO2VCY+^/UM[PSL$L_-Q:YVI#*)MP0+<[PPF*N5%S1_(ZW*?)M<IM
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M0*-<YP+F.UYH"-_ZNG:[ RTDQS"5",E;W6>:0^7M.-CD;PXL6UG1><3:IJ\
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MJ;R@1N"F1E:M6M&\Z"7P<Z17Y"&6DS+(\"(6Z]X3/;\IUN3G$JIC/']1C*.
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M26QJ4V]?5&?173F^7CKC+5GB7J_F=]WFK'G!UN;E4YJ@[\QZGT"5Y9F+SI=
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M"#!WX)NS=]0.V@2$2$IVDJ4?FCDYG^?F\&Q=<.BT5ZT*9#%G[N!&::P'ND*
MYH&B'+_4VTNE:BI'V4W/R5>OLY@G2=UXBJ)9:8B\NZ-W%?*'NXTC WF(Z%*J
MWC:$H>Z9+P$(9S "HB>0!;'WY?,/7K  F;H>U3:B_X/DR)Y88;?IGOU@?B"=
M,U*^Q#K+3FB3)%U4E6%:3/HTH7H_4VKNGA]O_96?< [=:.RXR251;.%\34Q7
M=HJVR'(:N/"7'Q::/-V4+'D3>%]#+TIKTMV,_;%WJ<Q$1:NT_X$T5 3UF04/
MGIL%LCI* PYB2R;+6CZAY1GMC"*7V6I>*Z_PK/=13;-?YGPP7%5#V-G+6T"4
M@Q:2^&T,J^,<SS[+]E>.)(X!^J*GE+IK"Y&]$UU^CEMA)EH4S(1'S*YY8!H5
M7];S&G,&\?0G!%N;,;W!A+C+2I:M(%;?SZ4B<F%_W 8YY4)B$,K2:_3NYH=)
M0@;W(".B+<F3AO;24^S+U?BX$0*I01)92Z=!VU(/EU0[/_/W,_3U6JQGX9I/
M6VTF,%9<T$;A]ET-.^11J@[31AFXNH/508CEO.,/_N#VKE6J)2QQS8(T@=,N
M^;Y&>L$8:>#FLD,:^5\ O$Z(?2W^)F22A>MR:]-P*7G'CX TZ2H'/EHRE]SE
MQ.5=5,Y#ZUO.3H,W?7-M0NJ4&J(0A9'_%Q(>()S-Z07Y9(CA'G;3\WT;[61=
MRQ5J',=XE'G GIG]4[V'MIN1A68"8@BS&1B/'HI:/YCO0Z[YV=?)E)]/@KWZ
M+J3N;X>F^DE+HX]%3X<_EM&3S.Z%,2RTB!(6->5>79)";N=)XC[W1A*!A?WW
MC^Y"YU]K8JC.&C==9#=W:C8&?GB_$TF'4<:BPQ;,CO*,I2EC^WG1%FMFUYW+
MU-O8[[!@*</U.KH=:4N_EN11&>LLHQ=K+U=OT1(C9>.6*K;5Q[55A;_P57\!
M3RNSQW+"T:9GX$+_NVR]1VRH<@)RK 1:>:K!K75-(ZD"%<\A5 /9YB=BS[MF
M3"42PCA;=:* T_X[U7(BS?4\"4;G1,=0ZYK /JHM#TB,3?I*0D,C:"F=50#G
M1<J")?UO[G3\=6Q'S""!]K#R*S=*\E_#1>J(<;(IQ4Z*H'1PE%IJ>_ FVN O
MH+9H^M4AC.L.?IK Q B]H?ZU=.0#&!Z+"!"RN1<PXKE$B%3\<2_>52UE$^;X
MYY!>WF4E V!8\9IKC0S+$JGSYA"K849L>(G[,#WOY'E,L>O#R8Z,DC?;X]N&
MX637@$>/UQZI#:4%&*\/XR]KWTA/DZXWP]*C5CO#A4NU@40)DQ$_(5)$;3]V
M'T8!\2\F= IZ*BQW\>9G@THNX_JPX-VUN5.AI-RN['Z W=%Z\4V=K^L0>D>]
M.'?UZ\);&[6,^WJ'^-@1COAG,/O&=-ED,\/5U]*@N0".T1:';H_?XZ;I,>61
M0@U;CH(>E-2U-)42?P3/'M7"DK(@T?O)KYRA9\,\3D[&.A><E[7G(^(J#H]2
M27<&[H(GM,&/XATW6*LGR7[79!QYCJLZ[ZF8J#52!H:(EGT5N[R"I#;8Z(YP
M+C$M_[=%&W(AI>/DM$3$XI%2OQ8.9,P9G1RU^I7>#ZFR3?;DBW,377[I]<AS
MC?X3TLB 4D^W$%4<<O)8E;FH1?9Y(6&AW5R#"-2+V"9(-6=SSK-Q]*$S+YPU
M&>V'5J9H=:VH?LZ%FR7(WC[G$.2.8[/H?II .KP5%7JJGM49GRY)6QN#4&&C
M%N8W)8P<]K7<VHH46LXQ;7\5 Z^7Y;$9L/UYSP'LPMXJWGTL;1K@"B;-3H53
MVOP^G<F&9)# ^TE!_+U>&_.5HM>]9!T\OOH^RMBR#JUW'6<+3QJNVS(G%>OT
M(Z+MR^K%XJ#]1LTO#BX4_,Q%(<&98\C$LT T?E_'<P?F6[8#FMRHFDMV&@_2
M_C68X3,JO1D=.QD$D)UR>_Q512Q'PI,TAPT&U9/N2EB&K$FD:48.U'SV__$-
M9NGY:_#B]P]0P/ %!I+SW2IPA!L+(>]HAO;U,>9O6]#/OW%N4ZD(E/L='Q@[
MJY1'\K$_^"&(-^L(A?**,&#/K@E#,J9VD+-&QQ3ZF1XW1(9%<W]JB/&5Q?\%
M+)IQ0&%W)3XZ+&N%2@;C\K?&DDZT4<P^AP FXW7>Y'UUV>5".7SL'9/]CJ8K
MCV4?I3QU2_Z<$]!CXGR,0K\O/>YIZ$^YXO ??UH[;SPRG"B+\C!3%1:O)E_)
MZ\.@^U,1;FI.Z<NG&<C8SH)#;@E@6Q8.Q*?@P*;]%Z#4:J[];<8X7 T_GEW"
M(>!L5^IR_ %OP8:U)"PJ%QM8-[B9TO$<&H2N>0!JC,ZWOAE$M.3WQ//;/^$;
M47@SQ_<)4R16J)_DHWG<SQ$0O!EF-O;ZC?DSWB#D))41#22EV,>0D98<JXQM
M]M)99^(.L0\8]GP;\GLA(VJU2PZ,/<T89TS3&MYS2WY[-G83;8 P5^#0*2(J
MH,DM)3O#W%T:8CJ2.16NM? \-+FGQ5]KWC)@7H@8JYX3K^G+;M%=U)ZYUC6)
MJ8@<*HH#3_2,^T<@+Y"KZ/ ZQ(+Z%9(!#<0IXTV/VPBY@W,S>#0@G((&.H@.
M%Q_(OV#<OV*@;+WG=60ZA(%0!.XFCT4_LA-JLV3/Q;--2$E.YX-'^-:_2_(0
M4!_>13X5JF\:G8F',FD83P;1C)'6- S;,Y!2ONY2%C@FK:X6\Y21R6&(@A::
MUE!C3=T9?;M*76[^6Y$H40D7UM5&"[MS>3_P-)23S]",J,I<J%]R3:+JY1?1
MYI\.5ZRU.FH[*^.K-'X<TPDK3QS'6KV3[U?FSV5%;7(,^J'G_?2C697W]E[U
MT$BY#*N]+4DU*MR<2]?VBLZCV Z&EV]71#4@O8Z7#++\)]U*LM*WQ@3.@:"^
M@XOJUJ(0_XN41S #D4DF2"*!RI1(R*^R;J?U'VYB#"]<S+U8!.6#_P(4YE5E
M2E<DV37XMVQ_!?P%')C"L.U4OX:7N--1['\!,[78;R,0+HGA*:I9J4@_,E/2
MO75-=6LI>ZWB]7?VAB]SP<5%80^2>%Q!TIV286C$6E!=@E[?L(V?UV;"_@'*
M% JH-R+9-!A%#@^/O!6'J N('.LS)=Y#.=>+C+-RJ>P>& X/Z3/218\\-?B.
MU#NWE:.!\:]G=IRM*]_.71/:DY?EB+N X(?!$V:?T"N.N\\=9E>:(^9\;%PY
M.;X1[:Z9'&T[VZ*U94E_WS%B1*MMVYEJGFR;LI=__&>ZJM9F:F'7<]_(;ER$
MW/295BW0G/.G]$]@!?K$KSY2D***_\9XCCQ#\]&-7X:2;:22:_/D&3!^=9+&
M8]9:S92HCR.,95*I^)(Y#REZZ/OHE%4Q3D[!)>)ND!:9:I1L\!C1*GGHQ?)^
M65>H^@?N]HN"40ZQ38]/91W;ML\]8JRO+,\5HTI&2&H,88Q<K(FG%U$,GTM?
MWQ\)\S(-C9L^Q:G%E7)9K1$-8.(80[%;YF[$+KX84-'17X[RHAQZ4^U!EYR@
M>^G!.$)DYX7/_%V=.PS,D*2*G3N/MII1Y\_=8VGZ5<$,H%O\G=PQ!+.Y?_;C
MA65("=^=.+7?(?(NU$QK._W>\)T?LT*V#X## /O>9J7<8T:'8_?&[,WB]+QL
M&:N:2*Y>VC CZNI?6?+%YCE#TNMF+&)0..T)&G 7D5!_?*XN,DY1/?D-71SW
M%Q!OGG1/WBG6DX4R[#1*]BYB[N<CG:\ODM ;A/[X]H4$(BRR:&CN@V'/)_\Z
MW7K& #&?(J6?/ LZ\&4(;A2MTH_;-L2.3N>!(>/CX@C]V1*O+#A_A^UR5Q<?
M,,^'?#\5EUSCA46>WQ2RP_Q6WX>:A8V%L*\;WV=M]_06)U &_G&SL<FC##-+
MS]%#LVZS'.B,B)*X6=L^:F@\X;ST0-$\MPHJYICE/Z5J:['&'TV+T=XTH,*5
M'^B&6!^0K/5\3C\7H][44@PAC+5VI[/\.6Z9CJ[*'S5$M8O!D$NMQ'W/"L8>
M+NVHQE_B9RJ+MYD IM1AA%;BS8A5=1_E.&2R515N5.9\KGI2L2NP:J1&1D0+
M>^!71D2!;'TE>VOR5#>X*%^#"*T+T(D^,BO+C@G'>7ZN5%U=J:#' &U]X9L^
MBLTS1?%(QXP9H[./];FL*O@;\_#!ZH:[KC%D7R I=Z6[NWSTQVW=&V\,&9&'
M]^>5C&]F7[YHBZ86>DRQN965D=R?T>9\EHMY2HWPNVS0]1>$U"=C3/H)DW&S
MST8+N6^>P^T9:56N<$3FW8/U(SO\$;DLRHD54M7<?A3DY/0N"NDH^X(@^D0S
M)=.3V>0Z2A.%1([ M7/<,VSE)U<*F*,'5CK6R!-AF@^_&W9, 2TC&*.O4[^9
M'3;,'(W0C5)09HF$WD$J]+RV,R3CEREPOU7#E:?V32S=!,$QZ^_"QY6>8"#_
MTI;IJA8YU5NZE]5E+X#F>5>)=(D!3A'E8(H,UZX1UOIDB6Y5H@6??,$D9P;H
M-6B(IV"-BK4F1^N4?Q0Y[9<\&O;"A8Q?:]O4[@>;^LO/;V_GBB-/@N2R#4,S
M2QHT!.A1&GQTC7XH%S!>.=L8G6/?:WR3P\6@"[&']_-4[V,C'XBTDE6T$_,F
M!(]L8M4!X3#Y5!U'LO3/K1^U;<6OAHS0&XNZS=[<9-]32D3H +**VH0-CPL"
M]\QSSN6"O2 9D$XS.UP4#>3 RN(A6^MG0=O8&.FKJ_H#5^X1KD?>Z *#IYA_
M/G(P=[XN;WULE&:*UN0Y3W:[[[@VW]3;INFC@IB:@MAY73>0B[VE)%&5PI:O
MQM1!UTR]=JL"#P[]C%='9S WHV2KK&3K'1%L O[9Q\QR3:'QOMVR>T)OKE!G
M>M^L%)I3>@4I>S"7.S7"3)H\4#9F-M>%X4JCKHSUG*ITKK49F+9HTXUOI,B"
MR:1]>C0//30J1.J],93ND7WD\OJ$RY0'5L7)J)VTN#S4B"0Z-\C\YQ.J<\U7
M (+/P 0Y\%4E;VUX]KC>411C%\/M+CJRR.:-KSX3C.!\="<6+ /PL&_ (I1,
MBK?\E5J[+W@25L@#WV&<IGC2YVY_S2=QTV&UJ77]BDHIJH+\1+A5'RB%$/==
M'?QQ:Q%KMGGD^,85KG;&;GFQ?Z!1,$>5N'6O15P KT O$_Y8<?C9!@+.0^FK
M5-G\SJ(-0:2UY>M7W#$5VDPUF.+ D!BC-2@A@J;XH"P#^0!.M4ZR@E8@O8PR
M'F9)H!PS9]DO#3V%RB@)/HS%#T3)48>9)W=UYE!E*][2V$$7#\P>-CP]'MA9
M #DVN^*YG..HOK2)LSP(^GC/#3;#D89(!O '/37XL&L^ING58X3:="'U(MTU
MLO'0BB/XYG7LJ8;ST9?QP@9)*X;>21Y@GZ1+SLB)/^\#30B?$YJSLN^S9"S;
MB3."3W\HZPLU=WJ>TYE%P7V"GU_6"97T0*/W8V?W#:><9QH1(U@MC_/,KTI+
M=>9T"OH9283""%TJS*:/LG7S_;E40*HM^TXM;_DI3=9-HB87!M>M._"Y]8LF
M? W>=_>N I4D-JH0G=?YNY2>C#T[ GNKZ;"#4.&,8TU=J.[^4"#M$$&M<A,\
M\?A*UCR ,YH;.+!%+7>^K[YMEW)1Q&-.62M=Z/)STDT^43/K&>#<2LTJZ(@L
M$-\+D0K@X;5J:X3O'UB>+06Q$;&.B/"PEXBIUC)8-K1TX8@*"\]OYA.ZTH12
MEHDQE(/@L+ Y9V_8'I'Y:B&]OKR9\!KH#5\>369HNC:2=2.RP3^K1C6EE_\Z
M^-VZ^<HZEY :'Q YYB,N>S+3,FQ^$P4!Q$XQ&;]06,Y69X@1[P8H+]1*JWE^
M//I$JP5&:.9"YS:O]T].C M4TDF#7(0SM,; 8?@&;6]&P\^QDYHW4G(J?$_V
M5I$X2+=ZVJ'=9+4=KTQ4J$@>D=]>J,G1*<_73URW!*3_&B1,:TD/V:77QL4?
M.1:CR;V$L^41$ YO,5%:;]JAU0_-O:8NEU$+F_607)771;+5*VF)C),::LLJ
MUS0LM#_[)$,)1IV;[CXK<"LE$O1R5W+$U8 S-%A/Z+93A;0WPX4T/L6_W08X
MS*)[OYGQMF?:.:OAP=]"&(>U[.XQC1R&A<W[EHKV;X] GY0*[B%G7@_;FT/+
M '^".2:;U;M[\X2B_80$A7*QYTMA9G4A-H;-Z.T,+5['&[S#Z&VR@;:E:,6H
M/7%(ZHFT$HU1VE?K8L7A;<-7>D<"!_U_ 4'Y,8?-&JUL-H6_4AM@TP9<*\^(
MP+&H\(C6RA];;X[Y;87BN5)9V#2<I@H*LIF%'%2O=3)(_P)LD18K2\<F/):9
MLI0T'$F75:_A(Q9K]7O+6S\CL1FNE#$XK=S#?,@VTY;LGMM\H<R8,,YG(@%.
M;0G^M8!B=M0\KZU%BU-)(\B[R^R^BIE29U-['LO3/360-)_T!(@E!^;L/3;2
M?E\Q^^Z7[Z#752KT+0=?&%ZQAA^#E#3*%DCZ;/?G<#YENJ(IC6IBUN>'@%';
MVW 1XQ0'D2<,XX T;?C!OKG'C'C/<SNF8'ZB.6'NM/L!XR'P#<V+FOO?YVJ,
M;2FW!">5LKV-F+WL)90LKI,:V08WZ?ZXQ7(/#(Z(#:SA Z%:)QZX:\^8X)7!
MPG"A_!]TB,D&5YY#&AX \B8?<I\*#8WG 6+*#<D5HE.KGG:[L>YV)G_!%B:*
M!6:R*/O!IPYF3^M@,$1!] TR#7"T6D%;.\8!$'QIQW V&UIJ#6T+0E\U3DFR
MZZ'*)M2^);<CB_&<Y\:(,1^;("'2B31QTMX&Z&9PM+SO_F\[%Z7>N]KTYP7/
M11I09X:.0+6/JG-625H#E+T\=>QU..Z:=QC53F?6&^R&9D1$98.&] V%3IDB
M0G5WH\7S8JN8U]^A?^]SZL KL2>?_4">O?[.'O3[K84Q9#_$-2\9#P*-1WOL
MK$A',;9F!ZN1'QL?%L7^ZCZ -E@<09_@?/88X6=)3U*[2-/12YN_2JP?^M]_
M"/4C#QX!+GGQ\_P1[!=CRCLMN6J[NKR=+</0KL2;&;_]"$*0]C+>S\5*-P;X
M&CQ$APNZ$>2D@SO5!F7,#Y4I/ES5%-:VF4O"J3+(%:&ZO(=1DFH05L$5<J\R
M\/?JYBAKJ;4O&3#,GY#?KD.V[/%ESJ>KHQ-<&=)](QQ!_$VU^Y0_$=7C1RRR
MI(' W>KO]1IWE4;41L%P?EDF!3G#SAQ8UZ 1[7Z2UM8ED3]64,=\[GX%R&&@
MI:#$+_VS+%<DC0ZO:GNVV5*7/+MP:8$>QX"-MZ+!_D7]OBC*JT./:DD6DH\L
MZG]7:Y6C#I%@$C[+ENV[V&G .4\\J#T!!.!1H?8?5M:MHF@[20A9-9_OGY@S
M*>!$XICXBR^IO:MG)(RGQE*,@'35FPX &GU!:X9VBK=)[!TU)V)#F,_%<HX^
MPG*/34K/:13)W_(-CB$FI?(*Q1;M9(YPWS(W:N5?_I="%TWD>/G'->8/;TI2
M)@K/7WVB;V9.I-L8R&+G9YK=?B];\K5[(LLJ:\;5)M2(<UW /I0^N&^7J2.-
M^!68^:F^)KQ6*+FANUP?V<A.]5CI+:/!@SRCI^9+M1,QN%FV"77SI3H,,_WL
M9*P0M>HDL.*)O/0@W<@(X4RU:C6K*R@V!GC33FA1IHOD:9\NXYD%[CBEPMF+
M!'7S/"@&<ZZ,!M^6$P%GE7<KE(_N8_"@.S.$[DRR7B:@-$I7&O[;K; !\GLD
M)NZGZJ3FG(E1UQRBIB.63\J0T;$81L7Z+3L19(N67Y"TMU(5&M)\ZQ99>.H;
MY-*AV/O@90S&-PSA:HI0LD71H=V,G ^7(*1@L'\MO5M(FE#"#4*38W>FXK51
M,<)AUU,EXJ2Z<BYFK[--<V=8!#D9/&&>!]):S_;ZK$@L, ?RZ3\+I34@_,F4
M6O5C40Y%$Q#@<*7]<L$0]>MC*9[' 75K6K<Q'MB)*?^HZ\?I" (->_R,B&EX
M=#YHU=9> T::1LR8)5<3!Z^( W^[#70>\K9#=A7HUSO-)+GE\UY+,//[/.M8
MWGD7<X9(:1<6TR>ADE77YKHI=T@==EFH>^S.D\[DF$FQ^4I;>I,ZHO=5:. T
M=0+VU)F(^=D;E.DB>:>*P7J] &\PZ F>2U.^T[GMZ-A\G^6A6'=B?06K_-NW
MQNNH\3L'1CLEVS^S9B<-?:Q?3!OWX^]:;BHS&-J]I@U,9FJU?1/+Y1\J%-X:
M9J[9A[  &H'#!W,T#0IU'R7#\)Q_ 32!M:FRZ7ZLPC5X$)84;Z:7XO'CG(3P
M/_T?+>^Y!\V3<50 L\F?C#^%Q@,_Q)AILA'X(-PAQO/EL\^U10^=N\W3'Q4X
MF9UE_05P*&HV-MQSSX-@/(8ZQ9)59/DEGW03K&L_D$U+WZ'L .?4*MDF1]A;
M*/U.GA69[?*<](M-'\:%NML@?L5HH\5]?"(IW,SIC-?;RI$)-UVQ%H-+GM%H
MDC S[0:[/,NRX8R'$?!*H6R>$R%# #D(?ONEC$"JBUY_)*V?FI4_6VFY3DTK
MAP!+_T-?;I,B<16<8\PV\FV #E=A<98O;=0NIL^8H6+LNM?G-#1ZKT KOHLU
MA*6N[?37)\H831\#L"EE@V< Z^">T5T@EL0"SIDZQ5*7 $-1AME&]^-LB[.)
M^+2>O$X\+X0Z@=E_!_RN36-&.>]PYNR#4H*?(O-K LKUGEAQ/M64MS5'OP&T
M4OX8I;MYD2I5=N4MLZOI1/J?]K[5^5DW 4Z>:F4,R>,FG<7%4N\HID45%<I.
M<R-E?37I7NW4UI[7,/+R)GD)3IJ.LR<1^M.8$.98O-:&)?3.K:#IX+SS5\P>
MZLKQZ$C;A53*4]+L;KRN$?9W$JY"ZNTS4I_K)#(7]HCW)M7E-!\%H+8$CT,C
MBH1(9LLR5L-*GS]\R%J-C<AZ3;6F9;OK3DDO7WC]Y\6:!K[*IJO9:SRN.-0T
MIYU$XBJ(!9+Z<L'#@FZU_L[V-4]:I9XJ]AL.Q%;;^RK@X9&B%+O]!'<7PE&X
M%4V^F3PQX>>;4WH3DB+HR>^.A7ULT2\OW>OOQ"MEY_DPD9D%6"@4DT'8ZGP-
MQ(D$/MNC]?TR37G;Z3$!C_'\,>&A\[/32?)Y:@313$MIT%E &"I<:#- (!IZ
M")W[7G#E_+"#ZE,VA<3J;]?Q:'L*T\S"Z@FW]1%A [H,<_+KJ)%=N)35>[[6
M,/4KF=PQH2&,Y<NHV!S9HR'IVYDK=Y#HPL7J$YBG3:[FFD>AM%(N_L"B1=C3
M> /+5=M=WBY$O?M*B*;R7W?NQ._.F+&V'+/,_YJ,$2#1X@MSNZPG]Z9__WUJ
M+7.CR1YFLZ:TSSKJ=\:IYWEY\\KH:W'VB_5RRU4N[P(6DH_-#M/+$,A*XZ7O
M&"MM'>J\^/N'BK.+X:F(4%/F:_$1<KT:'G9QFGT=\DH^W[0G]=?ZR:7$"BZI
M8PN=NJ X3K[#K=W,DH'&B<[!<2;0UF:<GB-: M?F9WW:)PT69I<N,9AIJYZE
MYYRWS4M2S5#Z<;RY()ZTKN5;J]JO]+G!?6WY+Z#LZ/%H>A3!!_B0,2IMM8@,
M@6>9DC(,)<_6:[1>6^W;<%<X:M5#YJB$#^\//3,"GW[C 18T_=#Z7G9.1-O\
M<32*:MQOEK#::*3ZT-OSQ(/XLFC%X,58EH!$8>#E5"N_:(!#6SXWOH[)[$4L
MW608M7*1H\V3_K!(81SCUQ<M#@R@3>&1+4_^:CCXJD%844W^]:/B.7D-[IB4
MF/+BW_\R0$8T_]>'"3>^JO"I7K?[/=%-+'X\;^\,2DYH(D\;Y-VSDY?$?'<K
M2>^9+JQ8SA=]B:GN4W!1[)5+'Y0/*NJ?A$]5M<HX<RU*?UGGE*%%?+/4,EN$
M0-(B6A"0S^IT'&+D&O+!2NN"TSI>B'E>BIH^KTO+IV,@8OL0GC5F+[4[Y7CU
M)SK6>R_N&=\#* S?3&IH(AUX! SR,40TN7CT7X!USH9/E/8.=(WF:7>XHALH
M=T*03TT5+@O"S4KR'4.XK=(+HX;PI"*?.8LQ^Q-"]3F'92*CVC>JI#\O+G8J
MGKMM:O%;$8(+'7>_HKL%?I'[4\I3:_'?F+>K-8G6)561C;^5.!,^[TK.5172
M1@FJP%0XPGX+U4LOG(MG ^B!J5"$-MN904>=U8_:MU=G.E"1JC73]NI#K>?W
MV($ ZBW'](L:56_.$GG493]NV_2$\AU3@#&YG0R^U?FFZWW9ZTD>J+S/()ZM
M[_) XT,U:]N,!Z5I-7%39LEH08!\;I0M&MFW;UIJ93^2W8>;B_ _>&771)ZX
MM96>F;Y: >Y,S!"O)X2*K9--,G(<6-]GJ&C*DF WT O?D$=:[GL-W7E?%OK]
M!1P<6$^O>B'LX<:D&P<FD@FOSW39!M)PKC@JRW8:B(&"L+<T,TM6]<IOO_:2
M@98RU&=!CU<O?3!W :_>/WWJ>MHZ5-'8D36:GA4B7LHPQA ;1=JJ-FN<T9,0
M9W[T -+%]-FW //[1_>,IKSX1M^N/'(R7/"K>UJ\L2^+"]I7T97;<W?\<4I7
MCP%'_(L/&$[)61$5;R+@-:'O1F7&]W7/MZB8KNY[#)<[]066[,%>5U1[J*8>
M?"'8,2+VK'91.B@3T?#BIR!US_-L"8S$N?_>TK[)^+5#N^JT <^+GF?CEH&R
M$]I7(S PEZ)O'_*_V0$;F['$28(V&9K<6'3Q/&NI291TS0BK%DBIU1JFR3O6
MJ$U!R!H;QS$845GMUEE<Q=2>5V'=[^?3,*HKH!K;_]OMPJ>+;)J3,S+$[T[C
M_HIHO<>A@]G:CJ8I"^5&*[WVGNF35C*OK5]R5%%ZPRRX7GF:E^P21@7]"M5C
M<HBQQ>WUZ-D*N,T:B[4:,(4<JT\M'UC;V$]I]_&8\J"XPVX9S[';;:R%*&26
M_B#9-,BBU3MH@EI0:*@5W2@5<XSW['GVD/9Y]+'?FMFP(W#<^$U(8&P'NGO(
M96U=.P S/NX3X<0#7&3[3W(NX%[&RM-:E-#H1VIP]N8_'V]X\>&^[7$V&$T-
M5+ZKW3[F3?=2#NPQ).4S[,M1%._8_UUKH[L:36?FP$[S,TWBYD[*-_Z2:;)V
M8:W%:;3D6OO7O"^K_6KP !IIK-T^ROH,C6O@_KA2N<U3L_O>/;MM[%ZB%6V;
M"@J,!_55OPL.#/$:57=*N\\A,_,^Z7YP@NIG:M7:#Y56(R+&VMX,"H#$W ^"
MQ1W5GED-<[A,M=;' 9<1]$&O1^W*$MCO.FK\#Q+%>(L\EQ@\99.1Z*#HDA_4
M[LZ6?P'^3!80A?.5TC8T48)F\N)8$$]G/##W8N3R=CJ[C37[FE7<&0Z@?"]A
MB,NM0(N(271QGIJ^?^BM,3^C6>4L\,6:^3PKI&'=)Y3N9$B)_)DAM)D_DW/W
MA:+%UZ\K#4IQ'5VVK4+RX\C,5<94#X8PW6MJ:=1NOL?YC0M7[B8^P.R-D8>/
MA4)4=TB==G<27X9I*K&].85/Z55M$$Q6N6N+89B?Y:K&VC3+GT)EDNS@:[*M
M6-]>H@EKDG*#\?0CY1?I="9^XB:3^O"35&N4SJ.X=U%]SV,Y(MP,<LQNI.4(
MLUE]-'>UN)U'H&FE0?_SSV4-D/I,]A<0:@J< \8(,6V\1UMZVB'6^P)KMN(2
MF^+I:8,AO*D>=#/5KN>V!F099R/U%0K:1"5*9%,(,)V:^_-5W9PR+8=.6(OZ
MA.ER!S5RD>586$=X7IZN0&@)3#.6JC.:3TZOWNP.H>FLRG!3F  X#N\J$)XC
M;XU&<]_[3[D_R!2JAAVMZ!\##F8^BA4Q65)O4?ZZG>7J=21C%5(Z79\,=V,.
MOIM_)?(I1I6T,/4OP$S/P5EZJ*U@6UA0;+UY4O9[ ?W %]A $Q;SJ[J,+?27
M<P$$1(:BE)[IC_FI_,#T8X 0X9%#ZAB3N<UKX[:Z(-=R-;'C,;)'U?'9P<:#
MP/1E/VLDPA+XR44^RF0NL(I' C28*D ;MT);O=VM?8 *K-P88:O7<BKBINQG
M]O.\256A:="4Z*FP\A?1#>#(&OX+6,=.A]3/!<_XCC<(Q68:3D)"U.\310%,
MEOXH3UFG>W[Y)O\D#;\#P$.4BC\M)/$DBNJ&N7MP>_93?B2RI<PP\#!-]0@B
MD2<-'X>YE6FU;:(R G\/%OK(SU=O6=+ITG]KBBY,SR^0-(\/#$NOR<T79 <4
M3/09-8W 5Q=E"5?*+>R"4<3\:23*<NT. :Z2V'47M2_1G0HO^XHUE(TM/PM#
M*-G):XP7/K^8S/3H[0):X=8A_QDTG>A*C!"&SZ1G@];7+JHB#GSK'T>%2LO1
M-.CU#?M,8645W8ZU*6$Y (;T5;;J7Y+BZX_]*(V2'"D^:KU.\)%SO..K#!Z8
M7$URXA ?N/Q=TS>4(!1$+VZ60'[[X(T=[2B]M+;TS2-GA3;H9?UV6T"'M[#S
M)(:0<[Z?OGV8Y#L<0-'[W W I]I.&AN-,NE,)BA\$%3XZ_5+_/NM.]OY?I?=
M$L%I+Z.S8J1%:1)E_&*E.+ B?]/FO=;()#E308%'H$3#X=DCQRVLOCZUW$5%
M9[:%/R$*A3+9ZEJS.3PV+/9!^)DY&\AIN-S+_(-__*1;I?Y:E=^,ZS5=4=^<
M8\L;*DB7%K5/%[(5>32W4W7?Z%@L#F.J$#M\:S*O4&E?/4ZJ4D:JU',9"M0V
M%29.2B+-(+VH$U^5IQT&9X1X01^'S,C X^ZS4/J9/^]VS IQBY(%U,!QW=)+
M25RS.Q2VT>>4 @?)8<LZU>(6"@3=M4YSO"\25X"77J].WT=:=L_WX A>''DS
M)JCN2!Y@7O;XH4.D,GVML[+7T=$>@!6C;!4VP9E^SP?.MNR^W9BK^I(CTNR7
M'T'1AKYET>E+UR>F?*;=G:WY6\,S*YC@+%D*RQCY +SDC9/[:]T?WKH*+Z(&
M7OGY!+F<U1^LCJ5RK2,6U#-(-W[+SWYW#EP;-Z4[XY/+3]X9F!'5"-"&F'5;
M/HIX,<(+B[#]XY;13+L:U.'CD/^MBE<&]F$==$=W4;ED6_?O&:2\Z!73.2/5
M X?+S55.C6:7BR1_Y&*E]5&J6J@K+S8!V7N\IU87Y#)0M2BCU<]0.1]A1'$&
MKC+G1NSA=A<EUQ-^S#TZQ3:74;+\9Z&$;Y73#0HZ?PU*5* -O+-_KT%IF-M.
MV40<#8A1IF!M/#3Y155_?TITIDZG+Z7<ITRQ%]O<<')4]O >8C*]4!BQ=!M[
M<-FPB)868\'8BS,TWBX*UBI(9VIZ74'3$J5;-$]H_-;F/V]\22J:^#3."QT#
MC6RQ9[MNANB3+*"*<_N9K+\E1<7$+U&7;Y:X-3%MHI>@CZO8R">5LD=_O<-V
MMPYZ#0CJ5/?W@=[M>QT[:+06<66SZ=6?'F]T]X'P2JV20>02@M3J=(7 F5Q^
ME"Q*%D%*/!79H/OX6/+01<-9<GE-4W2N66='[1SZ/!;[516%U$;6W0NX%[A7
M2%"F+%/I;BU)B!0M^=" ? KYLG)N-ONA87GC!?_9EJV3%2OG+^2M<<1A^)RM
MIV#8T*JGOFZ1%03F+.-;+NFB*+%8>C1R.>0%:Q*KH #_?M\[T\3?46)@]925
MKRL+QID,'1/S,=B4;9#/VTEG/N%F KSWT?QO7E7R<*ERUD*KZP$BYQL/ZS):
M7RYYH*<-NE:-DM77YO75#,U?T0UAR=U&6V6K]68*\/@5:UK'W*S<7M@L/VN1
M6.G4A5.P*+C4-D+>'H;1F5:-U2B\ 9]V)//I,0..ULCN3 T\(9^S#4U3QDVB
M3Z(OZWP?%F<(O;4R]/]1M6\T>/B%-@4MON9PQG;PZ#;-O#757]5@E&QXS<<=
MP2@4G1RN*R-E#*>(*@=H?WO%460;%P?AO\Z%\+C\?*='NV +7YWRZA9JPECE
MC0[^F.[BM'K#.@SX&1:[-#?;U+\</8S_IZ)9I/QYSS[_SYIF@7L?<M F8YY=
M;>R!A?[7M4[FFX#J(/0ZL*Z=MCV+ X NCY[--Z*U;+<C\3*]#<-?U.H/ZWDO
M+2A^C!7;]B([%*H?W?"E$3E23].,;'"O/Q/Q9%F&T$+/[OR7WO%^-.'Y&0;4
MUFX8_/)&) 'X:? X[.@)[BL@H J'?+"NE9PA:"LA\5[]#XW!SXEGF 3X*<0Q
MK'I2^<%PV%A A[OECDLN?][V]8H^\#?RL1OQ_G$2RL%9W0'85"QA=3[N!4P9
M$"?EA!T3Q::]"&'=%MFG=.O*[;BZK%)E*5Z0?^W#S@><4?$%N34PE=WO2G\Y
M.VH6K> 2'7MB_KL"ZB6[\=4_.G5PIB))32=-ZZ084V>$6R7Z8%"%5W]CAXC,
MFO':*$?M?B"<GA$Q'MRA'?Z"E^4O&6B;U<\62_(66/6\T91O+GF:6P=SW?MR
M7^/)'U6LCYMBK7#6]GWXS)Y^,M$6V?(MV(638<TOOW"M^1&H2.<:-!D^9-/9
MDN[TY[LC^H_$?^8!*>7FR'KI+[7]F-P,\I7!K4V&V1L_BRJ52[80RK-'&58]
MJXD)QK(L]5[PR<,@G/JJ5.CHMX>E5J):"EZD@5L*9\#C8,GU)#D%7UH''[.L
M,Q:ZU-.*+Q=CGK 55G>I56_VS:;,-!*_J,>.W^<^3/<XC3UOMF4L-B2D5X5,
M7VR:GM9^?'_7'?P7H.@ZYJ3X:9Q'Q,$/H]/.^1=0/._YKS!A6>T(Y*^P<7^;
MN_6,C[-?VQY&=F":;R"THULT\T9P.WO][')*^.#$T/I'NT73VNL))=V'O,NT
M777D%LV4_K5R15MMYC!;CCR&:U0-R'<4S@E<B^T_,JQ?E!":D'_09*N3T@$=
MN=O[GO%C?Y4\1IWZL?F7$[LY_\NN1.F1.86PLSCJ7,X+*9ZN'.-2@:4EC\S+
M3>I>ZU;GD7DO78]?_"!*7S+X17E(4B;1)<@6E5.>H!D2Q4E+H^!+TRV(?M0A
M-&3C>J.RV<JF@G&E?._(2;7ETX<"[B<W/0CQ(Y8EW-\H<FF3-.Y7CT)H\E6/
M(64[51I??8[91J\]K+Z\-?>VR3*HMGGK-/I-17;(!?8(@MRN V=@P/Y'^7O9
M<3^C-AW1(0>6U^FD!73? &P2J-FX3D*)E#'B* 0;8E.\[@Q?*8N7(HJ!#=(O
MD[)FN8"OAUXDLD"J>8,R<7I29J8!:UV+/L3DJV.$<R7G*ZV/Z8U:M9P^I6D(
MTN%8$'8%VA1PPL4&-^X2<41C>MR_QG2AS!*?DCEJ<893&1M17L@C'DYQTLPV
M]QW\>*:OU).ES,6L]\JMQ\R0P((07EVZ+EJ('!.[2LWDFR:,((R^J/S4]89(
M\%_QJB^DO+&JTS67S7-:3#YD\-!H#2/RT*=)"-:9BM>'UW'8_5FB]/$[*W3@
MB)=;=>KN< 4S+(+V!+U.*!L3P+?$RI.5QU?J]/)VM 3+%# MCH5FJ:0/=DUO
M?BFQ[&((KY&/^?K^ E+=\AQ?9!WQ>(.$BWOF97+?F-2.]P;%0%<2<F=A#=SY
M-DZN7^)J2S%Q.121>LE.%W0*;_7"U%"4CLYM8D3%/H]*W-A]HER4G[XK;),^
MK_;FB2(1EZTU;LS'@-] .[TV/D1WQ82&S@>OC7!\I00H^]V:6:105)IP4@H2
MX;VK>O'F"F5>%>_,R-NY5'#Z2^\6""8JYI"CT5LD:AV&P?R G9K<P(W'_EY>
M;!SPE!)A$'P?QW'7:VU99E6NO9UXKYS4'0S=LMM,W=VH>^(V@#-J:9/.A'\:
M#:G&F'GX>^N31.:XRUK)#W>L[S/XZ\HL/1MS.B<;\ ;A>GN9=%SM]<GNQ,JB
M"UVD%%Q[P/<Y"=-4L#0=M0T$)!0WX9]>.1Q@([--C3%4*4J.>EA!;9/AE?#F
MV[L [\GS-5_&Z*B>GDOB%JK[.R]&UE&>BL1J&?$EH\)1-L7*S^Y:G[SG5G=A
M:ATI[.?(_PVB(VBF#.)TO*A;H+/!_KO#OI='U[DT)H8W/?Y<)#9!>M(4IY8K
MDXV=TNE2^/)9.1H,"T^,OO+43#/2O$M0>CW]BP[&Y84))SO4]%6F)\.PZKE\
MPI[@K=-N;OIP>5RV6;2=*0JU&7NY4]%-WOUI3A8G0@V]0SY6BG'V7F6W5"%$
MQ<;(L]]=((:\B!("1YZ):'9X'ERGOKPZ0)FYTL5&')L\R!EA2U&B=7S>W<Z>
MAPT[_P]IO4S6M2/LJ_ZR6S>P]G6B(Y!'9"VSJQ#=L5,5&^CSPW<MNHOP]_FM
M"<BJ4E9EU)?&4+-#2JC/@*K_;"ZE \\/GJWLB'O_LR+1X^4:7:K7):O&=KM!
M%I[EZ,[/K!7T(6+2<?:=%3^K3GT1#419#W6^DOEQSO69BLW">7(H1P\U8+?"
M:_4KC^LKCS19^)"C+;::8%C%[C-I-:=I>IV>K!50X?=NC&)UAK':4DY8+"2M
MH8/]TXRJG9@7D%BF]L\F1<ELNO'J<GLQ ZOAGQU([&*%5S^!*HNI&7LY=2M]
MAC77TE2J 45\X'8!N!=>=\\N.5[+N&./1&A'T!>XE3PRTI0'6X7;T?E(##.)
MU@MW$=T1U!LH:+$&L5_F+B9FH&3&M;!R\W4M$..[;9%ZIX[@]1E>$7-H#F<H
M185GY,XR1!PX&21 9'?K]Y^A=_23>@.=J?//CR5U&=/CN%[#HCX4=US6& ;-
MU=4QG>2'[&KCTXA6C,J@J RM_BFC68Z4Q^X$F-5IE"\5JV&-VI]0 H1U@UHC
MB;POV!^Y%M309LV 8?RB2?1)J\>>;U>#4QQT</'N">*1&@1%@C50$ZP:MLA.
M)]E]\AZ7H=GM+&E,/H>XA\(O:W;36?P7??/@ZPH48YKO?UXD(T08$WZZ>%HI
M>&[YKIF2)J]IINZ&5EBDONG3'LCH4V\NX2)I]4Z.<(Y#+^$8U3#G;E6HK(8O
ME?F+BU^1DN7UND1_5MY %+QP50U2(V0QT,3LIF8%/&8JM!WY,+\ >SD\&>3@
MZ?0ZGEN0Z=-_9)"7^F1PQ41\<O7[J E69YM71H5><,)V-JR[,9)S;5A<^J??
MXJG4U)!L47H6JLS31U'1_5U;VL9JBQB"VJ)*2L)\CBZ3SIW^SD$B2<E9]N2/
M0 >&^\D@1'"+7O;W#^%5*\B< H9'G18PJ++:&$GKL%&W_.FMHRPUZ9,^6@UK
MBSFJ Q7'5N/>8&J?4NIPH>:?6\2\B<.&H:'XC0^N7XA3X:M=(+:(;.,KQF0]
MVL& 80^.!L?B-@$G=(7DN6/E-$T57%'YP6+^LA?$%DPW<OW>:P/"-CMVKVN+
ML+&8='9Z4=TIV,DPD':-X)YSUGRKBFH P8 X$+1U/M,LECE*_(W^#4B$-'*L
MP;\^?3*8,[U_R,XMYW!FXD'SNPXA-M+Q*K;JN$[RO*7.,$-3X3>*!L^J&).?
M^[ ]T?W ;NNX.\OX2Z#L8[.-1Y,EMN_8]R\@Z3C\AP,@-54Q!L5$9/='PH9_
MS6!8M&R]Q1$:F76?DT 9V_!)=6Q58#AP;>VL:G6CP7HP^H$ZBRL-3^.0*:8C
MQ^7L4XL>.(8ZLDCCN"\?;D+)M S%VG1KN)-)8-*(5*AG-#G^N 6>>GM0-HR_
MBBZ.R-:=2G^-.+V$.W2E11:12Q.U=Q!HVM*/RO*7UARV?21GH4W^5!@C823^
M"[&U>N@;>EV.,$>I"WA+R!I3 ]ASJV8^2^8L[P21#WK WLN;M;>:81?O8:DM
M/FP;+JVE]>A_[83?FB4]3*>FT+X$/!C:N )-,JZ-HU0 ))O1Z1<'ZI/]"NU/
MQF)SX J!O_>B5>SU'%%V,!1^7UN!2W,D@?2_MEWVW*G0M8S&-'5!?[LMOY;8
M113JLFY<ARGRH< -KU\?=XT&S9N')Z;;V!F)0N L>\G32Z$ULMQ:0@%2-E_$
M"[?-/)]1:5*S"(2RLI'5$749>R.;HV9SL,^7QIO8V#GD_J+B$&>'4P>4>?VW
M)7:-NJA.V>1-0%5:\]JCF>PDYU=<;_@_M-](,4%>K'4H>@3<0W*D(93"RPE1
MSLU\=J=9&G^^ ;; GK?&I6FKV%3!',-:T-+S@J]+F8^!LX'?U= V!V9,<PD\
MQL-O.,)C-W]7L0@)7GM\5.WDCH^^Z>X6(G'$4 [PJJ,!NU7ZV0]T@K8!_;;/
MFX=/+)[36P\/#Q^38V&EIX57?X3+\C:[VU;;??83F.*&[2%C1,( G;\ B$%K
M5\:"YXR T" ):)@]FS[E4EW_\_M-.ECU<F,:77#M7M2NP-(Z.A2(E8LL%OHS
M\<GB1X9.DU83/( %0BGWH.SAZ,UN[.0*]^HT6]* )R<[  0HT=$88QO_(7&M
MSA#]E?&F0C<.$ 4.!5_56KJ@!OJS"H\Y=R&GE<28R9]18$D/F.FNSZ2!=;07
M4V'/-$ 6!ZIN>'[F.:,,[0V@57'\T1?$EU:[7>##"8PM[IF;(7%UEB]6)61+
MM=?<-RY_2*:0P-X-M;J24'#*BLV#>_PQ>#;9\F"#SK_YX_ULYA=C=/U'^T;"
M#;33()M F*6_LNC3F&="]..[A$VRM?1ZKSF%E*Z"+VIE5F)5O4ZVQSB?ONQX
MXR<=3LSW/FJC^)#:++IO9+?"V-/ /\J_?U?!N9F+JVT3N@&\21!7KM!EM.'8
MQ:F>TRKKN)&)X3Z+_CZ?X%VU2=1-9]2J\@&<9H1NA9E2W1,=G72A+*=EBB)\
M'\+I@L[*CQ&=;VFKU+8_9W;^K\.G?'/SB@=9O%Y;WH[2&>Q V")J+8@<T+T+
MB:J',F*5V2T_=,54LXKA<)(B: &QHT=LW^B<-#0$YQY#@1<N?K7P80+LR8X%
M.\061DBN9_),_7.Q?MZ^?A[JPML(*;D8<F-0PC2T<,&\PJE.?J4MF[?#2("9
MP.-8$!M8\E2XK+U%]4&>]H9$[$)F1G=RVQN)X[)_F12WNW4,%TW=5E$1-;<C
M,UXEIX0]ML%H+6G?>SE$MOM#PLJ"7J(NZA7/%>YF M[C]/:A2E?Z_"2.Z-@6
M%8JZ+!?D*8'!*==]E)Z-UMWTV \7RL4;OPI<_YQ^IV'3=/\[O4Q&[4V?PD[+
M,IEG\XB(7CUFQ6"<U/8V7#!BA/*^,YR(BSE]^_VT[ B^ZN7<7OR3(AF",I[B
M?_%><%8\JU:BWI%=Z];TDD.MQ4BE"6,&(95/5?OZS>*(I3R9,<ZV$(A]K E^
M+.!(C.S@*&"1W"NWE=ZV9>@W*E;&9@81JMEPR-'[@)JOFZTJ%P_;@W^-(F1W
M_P+F;>BZ6".ANH)@NH7FU9<XA^A%,*5S\VL'IU59*X[#7ZHXD4$\DX&9$RO/
MDZ%H+/+KP4I5=!F,V+R?+=QUT:>+H\3]H:T+2#(GH\-?_*E[S6["U\,A[K3[
MS,B.S=@O7<D8BC6UUT7_@>]/6:>!O0BXU=#KW3_F^*!N)+3'"HUW9A8O6/6F
MFY6[1L#Y9;X9K6L9!'=1=M^+W*R<*,H+KZ9TI'+?HXM\1;;N^3IXBS1M2L/K
M[YB1%>&4!2W!H(^(3;^T3R6A&01.@K#!.^,_W_^33ZH-];#(Y'$PRN#O (0D
M2$0I9=UXE>6;J45H?-/R+*?[FKRB=/:HU?D9<]4D7?;9=-AI<A$GPC"$7W;(
M+(;>0=/5[ V'M 5_JD[^R\^$7N9$A2AV5Z5ALJIL-G8$JUDP;U>8^=/2<FW&
MM\^$8#;*H:WO'CT(TRIM[OTJNOKSQ')QP#W.E_7:#F"!+HZI98U]N#0Z:[O-
MX6,H@\+_K-G26&^$B8O&)MX8E2PT7[@ZH89%Q]$ID[Q 2Z#Y,6QF1UNM"4S5
M._R%]X1XC,_.BW)4+8Z(.AC7#9(HPH?\!2!/3<5X@^W/[LP&ON6^Q+$7[Q31
M#PQWI>8'QF),JRO&2FUKWDWYP20S1Q@0EEF."G8T!N^#CVS(5L4)$A!;;2$3
MOOD<RY"6^W20LD=O1^%<45YY4_SIJ0/MW[)P%#<5"*5S,&5XY,.%YO*2YL?-
M.FV[@?SY] [4Y"PLSS,GC /(\E!I09%D6^!+I2*WVY=[]0#AZ<P^I9;E1WK+
M9J*])2H&^E^MOTA(VS_]7P$>.>'&2QB=<.?,(W [.H'4=/\ ZU/2=/+#%&B8
M';NW=^N,?Y%7KNT"@\@J.@'/3UJE%]GNX7)E7<XW 8PV,'& >U7S+J%GT);0
MW,@5)V4L2?G7N/\ ZU:AM&W*&. .F1_6LB LNU5(&#MV],D5JKJ;$>6S@DG&
M".OM4M-;!N03V+Q'.9%!&#CC/-5H5"2'YU7:,D_=Q]?6MF1A<0@$C>!@@FLB
M32_*N'NH@XE=0IDW$C Y P3Q2YG8:2-2XMFFACDAD1@1@G&<C_/>L_R%B13+
ME"0?E S^&33[>4Q1LP8D ?PGJ:CN+IF!DDSY<0))QD ?3Z4*Z$31,%5LG"%<
MCM^%56V[R7!P>00!SGH*L:;+:7]DL\4L<MK*N^,C.#[U)-'Y7WOF7H,\X]Z:
M:N%B@!)$RLS*I!^;' 'U_P XJ];NI<G9\S?Q9R?K21QB3*R#>AZJ:8\44$I&
M& (P<L.?I3;N!<-N", L21DD#I6;J.G75U/ +2\BA ?]YN4LQ';&.E:D4^T*
MI XZ=ZL +O5@%R>PK*5VK%)V=RNEBMIMRS9QC<O<^])(GF2N!/\ Z0$Y4'H.
MQ&:FU-6CBC*@@9SQZUSW]C&77I-7A+F:2(1,/,^4@=/I2O*R:&E'6YII SJ4
M+$@#()XS_P#7J&01!@&^9@,95<YJ=X9(P6!4@C QTS_^NLFSO[74;5I[25)X
MU=D;JA#*<$8/((-:IW9%C4MV0QJ"C%A_$<'BAT5I!OD8X!.<]/PJK&76'S5?
M+@\+USCJ#5NT42(7=\,HQM[_ $H>FH&-<K*L_F)%(57/+<!@/04]8UN(4,C-
MPWF,>1VP /7FK5X2^!N*L3G'(R/Y4TQL$4NCH> HV^WK6E]!&OINR>!68#/
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M$"JC<[L#@$X"GZ=ZHRJT@R02RGMWJT>54@##'G S4HMTD3);@\<<X^E-.PB
M%@@&/0Y(_P XJ[9R%Y48<KCGL*;%&(XRI7<HX7/7-(LL<<#97+@]<&D]0-*\
MP\6[!&!P#66HCVK@,N20 ..OM3AJ=N&2VEN(S,%#NA(RJGC./2D$HCE^9&8;
MU7Y1DC)P/\:A:(9;EW& HT8W$<>M8JV=Q_:$@F6,VA13"H3Y@_(?..N>#FMZ
M*W=MP4[DSW/(-1S)(A.,J!ZGO0GJ,Q[@O&44*5"8W'MBIX9%5=[/ER>F<97_
M !JY-;&Y@8C;OQS]*S_L8B#@RD<'.1G-:)IH@N(Z2C!/W6SDC[OM23L'!!R5
MX)'<]N/TJF4,,HC65"@Y(#8!-6O.!C"%0'50&;;G_.:5NPS/D@W2<@%1U0M_
M,TV016]W+>0S%KB6)8SE]^U03T7L,]?6KSLRJZ,<#L","J4]M"TPND@3[2H"
M-(8PKE<],]QS3WL"T)4E>ZN5'E[58Y.X8S]!VJ=IF0R1 9(8C&[KZ'-4X2\$
M^Y8\LQ;:"W3\:D%TSP%2H C.YSN [X'XU30C5MI]@999,[CT/I4ODQD;PQPW
M;TK&-RJ.0A)W'^+D_G]*U;2YBFB" D'."*SE%K4:"9(V"I&A90?U]ZSYC)"Q
M98P@'W<'(/K6I/&L?\)_ ]JJ749!)!41CN#G/^-$6#*J7:MA<N<'!?!P:E,$
M.XF-\,I.,':1^55 @C.&!.3P%4Y^M6D\D)R=Q!PJK\N#C^M6_(0^>.<6V8<.
MZGGS'(^7//;KW%*;:WD1A)&K;ES^\&,BD$DK[<H49SSZ<=J=<29X5<-T7GM4
M691GW?ESI) /W8;Y"R.58+[$?Y%1Z3''I]A%9(TLB(.'F<N3GGJ:D:$,RR^0
M8Y W/<$>]2",&8R2;&4' 8-MP?ZU7+&]PYG:QO64[,FTQC!Z>X]:KZ@L:/@*
M,]2,\4EC<^5( Y;#?=)Y_P#U5/(BWTF-I4CJU9;2N'0Y:^LGNM1M;Q+F:)(&
M+;8B/WA]^.E.EED)W*I10-V><X],_P"36K<1/:2[,A%YR^1R*C%S;A L14QA
M</\ +U_QK2*2U2!MO1F;&NZ0PAA&Y&=R=3[5HQ,8?+CS(P/(X.6'O4*2&.X<
MR1PHO&#C+L>XQC _/-1S7K1N)XC\S#Y@3N&,^U5\1.QHRWCF-_+C,^WJ.@4X
M//-9J3.(T,K1&4,"".#[C J%0\\<SH[!2<N!]QA_^JH8;N=;A@JK(NY1%ZKQ
MTS34; :ER06$CRER5.!DG'^ JI&KSR*<D(4*E"<X([CVJU>NTL<;*IBDVX<%
M<Y]ZBTA(H)Y?.=VR3@]E-"TC<#4MM/BLX_WN0[= 3N%6K5P9'R8U5>21WJC<
MZBL\:_9H&;:,#>,'\J;:">[BV&((6/W=V0/KBLFFU=E&GYJM$[*1C/;@&LR[
M+E5FZL/E&VMB&SC@ 5?F8')!Z<U(88I%=6B7!.>1UJ%))CL<RTT4%JDOS[R<
M-EN#5FRC6X@R@V 'E0:J:MHK+=I/!/(4=0AMWP4SG(9<]#VXJFP,/RB:XC/?
MRFZ_4YYK9>\M"7H;MQ:F4F2,9SSR.<YK"-Y)#;2R75E(N+AHE0 NVW@!R!VR
M><=*Z&24J3F55!(P!D,*S9_[0?5X@L$!T\Q9,Q<[Q(<YXZ8Z?G63;5BXI,AW
MF-#Y0V#/RHOW1S_#4D<("*TJLO SSG\JN6T<6 7'0FH;T;)"RINC_NDX(-:W
MZ$6'03%5P7/LN.,=J;- \A++EQTV@=/3ZTV)U(;.3GY@.^/8"H8[X3VY=4DV
M(^W]XA4GGKSVHZCZ$K0L6*SQJSDY)7((%.$91 Y'(&T8Z"I8)IIDD!5F3H">
M:558!L;=W^TQP/6DVT*Q&6E^18XT9@<$LQ''Y'I45P"(">6(!( []\?6KDUI
M^[8A]K,,ED;'ZBHU\M5*(6[!2#T-%^P&;97?VFVCN50QATW;7&TCV(]16E%=
MLJ%CN( ^G%5)D:-BRLS'N&J&WU!9_,2)MZQN8W./N,,9'/ID?G3MIJ'H:PF#
M.!T;C!SFCRHV=G!R#RP-4?M"I-%'R&<$AU7@8Z@GUQVJ=7\ILACNQPP'4?CT
M-3Z#'2X20-@A3P 6Z5/'&L@;8S84@XQ@BHC(X96 )W<Y]!_C4MLQ+M$^Y1T&
M[]#0]@'&,(X^4DGDU7N6*O\ *@P1P35XHVUXR<J1G<#EJH36CME00T:G(.>>
M1Z4HL&4'V"7>=FYA@N?KTS5J"<PN?X@1D@"FFWD3YGC/ECC)(R3V-)+C8"/+
M+#YN>H _SS6FCT)->"[4VWED,I!SGO33>#)5P&)')]*PEU!/XE93NP<'."/6
MI;97D=T?=T.#V&?>I]G;<=S9L;F&-O(8Y<\ACZ>U27$)D!Q@@\'WK,\H0Y94
M5R?X@,D596Y8,R].<*34M:W07[E2>R$1+9)P,8QS33(&QC:I& ,_SS5J6-R7
M??NRO(S5/)$855'MN )_^O5K4"Q!#)E<E!&>1M/<TQXU=>[E2>_6K%M;<),)
M&50#\HP Q]3WXI&V0R$JI<MUJ;ZCL5I;>$6Q<_)(?X64D ]O\:S+V.223S-@
M9LJIVG .#G)'Y5K227+LR12!5VY&X=1Z>_M5$1L;M@TS,Y88&<8'?ZC-7%V$
M)86R7J+<6^'AZJ0WRN><X_&K!B:"=%SL+>AZ5I6-O#!";:",1[26:-!@!CR<
M?4U!>K&J"4J,=?Q]:E3;>HVB:2X(ME<XSG#*>U$23W=J6:/:1QGUSWJE!"ES
M)&DV6 &XMGT[5M02E)-JY(X&,<$5,M-A&-=6@A5>92QZ8'2H("2I7Y48+C:_
M(P.*Z*\MDFP[9!/&?2L*ZBD\YODS\_\ X[W^E5&5T%AG[I OF3,2F.<XR:=;
M+&9V=L&,< 'YF_&D$$.P20(LB_P]'!R?:M"TMX(QYKQ[$7L>,FFVK!;46()Y
MI4@8;GTXJI<PK#<+AMT;G*X/7-7KE4\PL)44'@@^E4I+N-F 8;D/0'O]*E=Q
MC;/_ $AY5$<B&*0I\PVC</3UZ]:V8MT.6<9]:R8GEDWL\<0B4XA9&R?Q_'-:
M=BS3*%D<_*,%3CYCZ^M9MNVI5E?0AU!&N[.1HXPTB_+@<'\#7*!VBG>V-OY9
MCXWJQ8R<^XP*[6-GB:0D;0/;@U@796ZN'>*,*S'@,2 WKQ6E.5M"&C'NHO/N
M$59WB"L-XP#GZ=O:K<<'E[<'S,\Y4GG_ /5R>:D>SDBE$FR+;OQC.0?Y5NV]
M@P:0-&%1QD;:N4TA)&)YCFU(\U% /S(.=V.^*@PGVD2!Q%SN"9 7'J!6E?01
MQ!X@Q8EP68 ';CM6->75O+#YQBV(OR[V[#Z8)Q3CJ!JR1)?KB)I/,<?.-^0!
M_2HIX9$BV#.U!Z DG\Z+2*9+9HF0QJW210>/H:LZ5<1/'+MDCF>,[656!"GT
MX[U+ER]1I7*=N'\P1,&P><*W)K;TVP>!O-4D*>JYZ55@TN[N=2^W?:=L 3:+
M<( "3U)/6NAAA15!"C..W>LIU+Z%<MABL1('; 3&.1SFG;8Y"2K>U1WTJV]N
MSG 'KG%<['>M'<M*)-G'+$Y_,5,8<RN%[&\]DK2EAR.X/>L6[TT><0Y.!]W]
MYCBKT>I!MA89."<]Q5B.[249*9QZBJ7-$-S"MG<N!,S?.>-P_*KSN&Z%N,@\
M]:K1KLBDW/MV<F0]%'K]*(;F&>W$D$BRQ-T9'W*>>3D5;:;$DRPD89R=^.0V
MTMNS45S)M=V?:.?F!/4#VJ(3HSY/<YP>?\GWJE%=L9I;6ZDB:X4%ML9SE2?E
M)]#Z_2C9ZC2N302Q75O'>6A<)(-RG:02/0@]*CDN+>!%>1HU5FP"WR\_3I3F
M<AXXUE D8E=K-UQU _G4B#=\KQY8GJ3S[\_TJEL+2Y))"4BWL56-?F+\84>O
MTJ5/G *, >Q4_?!]#WJRB1O;M$Z!XV!5E;G\#4"VRV\2)$JK&@VI@<#'M47=
M[!96(X[HK(]J 592" PR'R,\'O[TXMYK,"=Y/&,8QZ_A1=0IJ,4*L\\)1Q(C
MQG!!]#D8(()S2C,$ZJ,,3QD'%$;@[#;ATM;22YG^["A8G!;Y0,\?E56RGBOK
M=;FW5A'-\X&PH3D @UIDQ3 HZ(Z[>0XR#[&J\R1B$>2 @ PJKQC'84*]PTL$
M<*R\Q_,.N.]5+%[QD?[5;K"=Y&T/OR.QS_0T)(WF!R6 '(PW)_P%7S<PF%<+
M\V#G)Z^WO5-.X)Z#Q;'=N7: 3DY/%.CMBDFT<IUV@\"J45QP>2,<XZXJ8R$K
MN <MC Q].M)I@6;F)K=A(I(!&"3VJO'*L/SMG!/WB<?7K5I8V<*CL5/'4<U0
MO;)'\R"5%FB<9(?D'OT/\J2[#+=TP*C;AN<C(S]*Q'$@D9./7: 1VZ>PYK5@
MC.T?.".A!JQ_9VYE;:6 Z<]*:DH[DM7,$11;&9EY#<C&"<=L>M3I*&@1GP 0
M>5'^>/:KLT"P/+OC7<QX)[C^E4MQBS&7WH>.F16E[B+!N1&^TG( '/K4_F0E
M"TK!,X^<GC'^-58XD:/>V >JM[_2DE7?\F 5X.".F*FR&3*Y.UDW'#<''6I5
ME\I\,H+'G/4@>@]*;9-R-XP@/7'!J:<1O)@!2V>#G%)[V ;<7HC1&ZGHJ@U2
M:4[E=G!8KDY;&T>E6/LBO]_G!QN)//>J4]G-%.@C1W3/!49QUZTXV OLD)99
MQ(0 ,_ACICM52Y:,B:)?*_>8P[$ XQT]:M(,6Q5CEEZ#')KGY[>VL[FYU ER
MSJH<,2>%Z87MUYQ_2A#+VDQ6FD6YBMO-6-I,MND9SGVST'-7IIF82NC#RP!C
MGCFLBR=+[R)E5UB?YAP02#WP?6NB?1EDM!'$'*-U#<$4FH0M8&V]S!@OU-UY
M6#Q]YEZ?_JK5AOT$<4@8E1D!@W&?2L>YLUTUGGD?; JYD<CD>O-2:=IZ7MNL
M\,4L=LY+JLG4C^]]#U%7)P;M<23M<ZB"[$B'YATY'K275M(\9>'D>AK,B58%
M8;U8L0$&>1]:MVFI2B-UDV[5X&WBL7&VJ'<S_.6R5(UMC#&O\*CH2>3CL*9/
M>N6F4$$*-VT\?_KI]WF[E=O,P57Y@#P?3FL"TB:P*BYNWN)F9@\TJ] 22/H!
MTK2*Z6$^]S8MW%T?G)?'H#4DD$]L'>-D;:> P_J*H!P8BZG;&#E90V#QC!Z?
MI4K:L[;5VL4D.,XQ5.+>PDS0,ZI&.,EFSE1MP3V^G6IH]0>%R,1C<0"S-C'_
M ->J,$X$>)(F*$\*3S[8S[TU+#S+V*_<GS(XR@57^4AB.H[]*AHM'1L Z2>6
MQQU)SWJM;V<CN0YS@@\KVJNMQ)(S&+Y0O7!_2M:.5GMD>4,K9Q\G?ZUF[Q (
M8+=5(RIV-WQ\I_I56XN?-E\I<^2O60-U-5[T.)Y&8KMZ#'\0]ZH13@-LWKL.
M<8/^%$8]17'W4L6'P-I)SGJ&_P *;:V (>20AD/(0C"]?2J=R[1EHTW9W'YB
M..1TJSI\,YF\NZ9BG4;3@ >F:UM9"-G8MO"R2;I$;Y@>_P!*I6TD,5JWDPK#
M$LI#(H'7KG\:;=V=Y?SVRQ7L45E'DS1F,EG&.,'/RU'+.J6ZPHXF<?=-9)79
M3T1KZ?(_GL"H\IE!5]V<FM,84=@*Q+/?\B'@@8P&'%5-7U>:SLI5M[>2\F4C
M9&'";N>[=@*B4>HUJ:&LLD]K); GS&&!M_A/K[5B06F;8*6EFD''F2\LY]3C
MC]*T+)RX#W"K#N&742;AGV/>GK+#;$G:[$L.Y! [GV%7%\JT$T4);2\BN[?_
M %4=BRM]I<L0XX^7;CJ<U?TI?,616'[E-JQ.SY+\<D^]9?B[7+6QT6YGB,K8
MA./*C+_,1@<?6N=\,^(C!H\$&KS2&[""1I9#M#[LG@]\=*QG)*7O.QO"#E"Z
M1T]U?I')#'(!MF?8I525Z<9/;IWIMI!#9*88(4A5<L(U^5>3S_C49Y;$JKD_
M+C@C/TI(Y3*2=Z[3D?,F"#GG-=/)J87T+4L<;LS$9*X!4C!_#VH6*,,7;Y#T
MQ^G]:KB-WX!V'L^,XJ:,@P;GDW=03@ .>AXIM"(Y4@67!(9XOF4[<D9XZ_B:
M%$48Q(5#*<?*<^U*RL6W,W1>A.,'/.?6H@Y,C1D%03SG'7_"J2%<LK.(P4D8
M>V#UXS3XY-YV,VX*N>!^O%8MK926]]<R_:8[B2<Y42(%*(#PN>IK:MV9&\K8
MB@] "#@'IS4*]KM%223T9(0IB)#<]5YZ_7TJ-W<H48 *1D9]14T;@.21\WW?
M0U7N=BG)4A0.<]*:)$=U52<9&,[NGMC'4T(X";G;(/(4C!%1%R P"87I@GG%
M31[%/W3NP26(Z?TIV K-"@DP"P!'?J"?I4)=DPCXX8X/0'\*TPZR1OZJ.A';
MTK(F'F,,*5YSGT_H:J+N!=A*[B&&X,.XZ&I%N60 %3D#[OM19(LL.PE W?/&
M?3BGQV[+(=R_,.AS_2IT&3P223OCD.PR,CK_ )%7$!93YQ!7H,CI67%]KCNY
MI)I(C& HBC"_,">N6S_G%7DN-UL5 7<IY4]ZS>HR0Q (5"=#GCO2Q7/DKDM@
MD]SUJK%>RQ.6;)!X(ZX^E127D<DC*T0RC8;T%'+W$37LGVD?*>6! _\ UUDF
M,* H1@.23_+'X5%;WNH)J$MM>682V<DVTT7S# ['G@]^GM5^YN(!$27",.<C
MKGI54Y7V'.-MRN'*HS<A>F!R1Z?2I8KN)Y03%O Y+'T]35:?S7C.QEP!D_+@
MD^G'-5C+)N?$>!G R_(X]:UM<@UY]0@#;$!![Y''X58ADBFBPXPAP%..I]ZR
M(;:67=*!N"\ID8W5/;!]P(<9)/(. OK]:EQ5AW-584&"K@,>V:5%<2$Y.TC%
M1QE8R"9(S@' /?\ "IFF;*LJ#&,YW9'TK)W&26UNOFE@@]#FGS:1'/\ .05D
M[$<<5:L6+1$$C@\ #I5NLW)IC.0?3Y[&X!=_ESU/((KIXI8_(!WJP(Z@\55U
M< VI91N=.< \XK)AN)6@\AAAD^Z!R"#5ZS5Q;$QGMYGE5U#(1RIP01]*J7&K
MVEONA08C*; IZ'Z>F*E:';N>0G>&!&#@ >A]:P+JUDF3='*C,,Y0=N>GUK6$
M8MZB;8]-3B>-&VA8P>23QCTJU]K>,EHI8Q)MSR01Q_.J=OFSA988BY/R,NT$
MCU-13*MQ=0!8S'!&1N8]SW_K6O*KDFHL,TX$T>V,,!D-GY^,\U2GMY/.DQ>%
M8_E\L! =N.N<]<]JT;%C=0961EPP"Y[9-.N;9R91*JAA\H'\+#M6;WLREIJ8
MVGRSOI[BX@\E@[*N90Y([' QMSCI6C8(S,P.P.5#!2G  'IV-/BMH?) R/,'
MW@W//KZ]*OV]G*EN'9W*!3@YZ_6AM)6#<MV7V2;:"?G"\[ESS[&GE(PYW(A4
M< #K52&$BX,@(48Y7UJO+>3K(RK@*@ .[&02?7O67+=Z%%J2>"%I!D(S'(4D
M8SZ"K4%R)[?!1@5ZJO<5G6,B/>"29>2,[6&X&KMP&WK<1#8 >JG/YBAKH!2N
MK=KR0+Y\D>&#@*0 <'[I]0>E0_8$2Y+K& JG=QZ>E6YI0+@2!5X'((_E4EQY
M?EK/$3SG(SFFM-@;N4Y;6%KU9@1N8#AEP![5H,+>"+>QQ)VP:IS3JD"R[0XQ
M@@$@BJ\,JSW/ELV4/(;KT[^U#3:$30W19_W(W1%L/P<U9N8493+$BLQ88 7!
M^AHCTTI;?NYVDYR&<@$\^U36\%GJ$'F1S>8@^1]CYY'4''<5/,AV*<%I*_(+
MQEN0Q&<?A3VLP4^69I"!U&.?K4T9C@#1B9AL_ASU'I6=?QW4=E+-8N5E93M5
M^1FFY=1)$QCCC@!:7=MZ;01GZ^E5F2.[5R7:.5U*[XGVD5A+/=26,5KJDJ)-
M<#RV$,A/S9S@'''UK;E^T:A%'8V4OV9E8#S$3<Q&><YZ9Z4-Z%)>9CP-.UU)
MI"VD[6"1#S;B1^9">V?US5B_T74KR99K&[MK1-N&#0"0M^9&![5TR6KPJL,:
M*21R&Z$_UK/GOC;7,EJMA._E8_>C!5L]AWXK*44U9FL9N]XC&C)W%8\\=,8)
M_.FX C1D .T\Y'/L:N)%YL.QG+#JI]*ISQ^63AVWXP<_YXKI3Z'./(^3.YE!
MP"2<FK+PQF%6W[9<Y(Q^M10PL45G^4_7M4P4!"6Y9>@;KBDQD%S')O56/3_9
M!R?IFJA4HP#@..F.O3V[5H,JRQ[2/WB#@#H5]J9%;QJ5$J_)_M<D9Z\4TQ%>
M&-)Y,JH\R/Y25(X/H<U'=_:H[NU:'RDM07%QN'S>V/QJZ8C#DMDJ&P'Z9'X?
MRJ*Z#1;B!NC/SX<\?Y]J7Q#3L3VMS%,#O'[U1P_T_G39"+F-_,161@>#W%5(
MD FR$*9&0.W-'VXQP?.<1@98X^[CJ:;BA)E;[9);ZK'9M:2/#+$SK<Y&%8?P
M]<Y.:T("6WY<<#E:@1"RPM"RLK9,4B'=N4C/'M2(75SN4F,^E"7F#9-<17#1
M1_9YO(E1]^%(.]1P5/L<_P J'V7&2<)MY 8]?:H&F5YMBL V1P.3@]\5<B V
M.V>OW>,$?6E:VH[]"L#@;-@R?[HY/XU9C4$JX5F*<C@YZTA";EVJN!P.V?\
M"IXT0H.-N.<!C_G%#8A&VEBRJ,<$@\5$(07"A!D@EI <<_3N*DC?RYB\IQ&W
M8U.6#8!P>.H/44F,K(N-R;M\>XX!(X..:M6^GK(&V2D!N<9_&JCR%>B'' 9E
MXS4UO=F!]SL-A]#G_)H=^@#+:']Z\4SEE5CQP,50.@VJ:M=7L4SRS72JIWA?
MD5,X53C.,G./>M+40E];R(KR1.P_UD;88?\ UZAL8#;6D-N[MNB&Q))"69@.
MY8]ZF[N.V@0VK*0I8$'JP_E6@VE1R1L5"[B00<5$B2*OSD%2>"3WJ9+DVC%9
M&W!L8R>AHE)B2%BMQ$@C<X4=LU0N-.; VJ#$"3QWI'U7?)(##*%5B!O7KCN/
M:K$<WGQA@-H/H*(M[@UT,P0+&S.(\9XR>HI\2MQ&%=7X.<\'_P#74Y)-P$:)
ME3'^L5N_TK76UMR@>-CV)8G)P*IS"Q/8HT<05@!CIBK+NJ#YB!4?FQ(F=R@"
MLN2]6X;)8A,_**Q2<G<9)>3(C;_O,PQMSR:YY+6;_A)/[1B8Q1"%H3:R*<%M
MP(<#H>,\]:UI[-Y'>:,@C X#=/>J\:2Q,9/-4+G)5AD&KY4[:C4K7)=1N(5C
M+%_,(7Y(5."S>F3Q5*40.K"&!1M&YL<]O6HI+B6>1HS-&JC!,1 ^;GJ,UH3(
MMH\LD2H4E3RW7J>,_P \_I6BT(9SUPH8L\4C^9GA<XS]/QJ! 7ECWW28QRN<
MG(ZY]*O7,@B9"ZF,=PX!_'%/M'P9#);@AU)#'D@#U_*MKZ$FE%);KN0I&LZ
M9=?XN_\ D56,$&H8GMY!*'X5U)*CZ57M65HFE0.0QP0PP<Y]^V*N6?F+*BQ*
MT<,7 @P H^GI6333T*T+^C_V?+"LD9W.&*,""/F7@Y!K<*)Y>T*N.PK&%M(Y
M)BVAF.6!&/QJQ]N-JFR5<-SVZU@TV5H4[\3RMY8B.SU'85C32?8F FF^8D<
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MW;1GOZ#WJW)?73* T+ 8SN((X]Z:D]D*W<I[9XBBN'!'RD*-V/P':KL5KO\
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M]].06SSW5Z)6+;YSEN3T/TJ_>QV^F:?=.L6R,_?\E,,6/&>.IJ>.Q4:@KI&
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M!R&!R&JD+1ECD8^66C.0<=ZJZD&J-$1VNQ$G6-R_(W*#5:]T?S"#;$1MZGD
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MOCW%2\PX%O*?]_<TV?5@+*ZJO0R*V<]AG059:*&Z?_.B0O\*=OC^EDW<28Q
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MTERP/T&Q_2'/U[I<SE\&=LD#O=VW"&W1VEZ"LHD'KY8EX<##J^>*T9B"7,T
M?%8'$RFO*N\CZ+XHX?EW3I@V^8\ZT(DVZ_PBDDI]X_T&9/ASCM*S/;G3FGD4
MFY5\(AW.<.YW(7FWG"Q=G[<&*9X(F&SUQ&9'ZN*3[@]8^*!^O0^_/27=5\H>
MWJY4]V"W^/S'7R!&F43P:&X+&",VTLMG>>DH?E:D>I2"F8LS'CL]GCC9U <2
M+'UAJ#__N+UFLE:EW3[.C/X9T+H3D[7=I#V;;,=!HIIH=$QB++HZ/NBV0LV_
M\>- GU@AG'7W"VY6%DEOKG)U4"7?TO(:N/<] PSRB;W8W;!Y]\L4_JUZ;^^S
M-(RNS3/CV'V8PN665>0B@> 0Q"$L$4N6[^7^-Z3&Z#C51]\9F'*@3F^D(-69
MX"Y%FZP*Z?3_!^";'..@1Z9/0P"[!W,TO>6'&4PYX5*A;UK;W)Z.ON]ED0U/
M.EK-(SYA4,*,C"73U'7H8.;> [:O@#6Z62[Y$67'3M;^5#Y$[:O*\0R 0BO[
MSOI5S-K:\F(UL/H37M?!<DP0E-YIAUU&0D'5"^DW;2*L_J,C^A.T]+L"A5R<
MP@,$_?.J7\ZM^M7(S#Z'?[,JCK81#](9S)CTPGXA5)70-<YM"*^)N=L>_,7L
MP@.LJ@UY$V#P=-=S7U8+A+];,Y6.16)CS%0>9=1#._E(U[#<FHJH\)O2M\=I
M=DR:_#E@3"U)KDO"VHO(_*-AFL'*+:MJE?$W1$O@*@8E(G>&Y,7&79+$_IM=
M^#B#/8GQ,5XIT/T"\54<CHY,HPR6%J<]T,WH79^9U8LZ?]PZ8_C&F9\>J8J;
M@A>7[0X;'JZ\/K8\4&\)$-I\TRK'?JR^78HI<@8/T7K+8NWP9L;H7$P+SWE)
MKG>H0YGH7HFFNW/G=]7A6/%6$QY[LW*H3LTZ#"1I5FP_XK2A%@\12S&IZ<L[
MR?HK'DBJQ\ ^O\GQ;7KBBG)/(N(?H!K,DH^^+@-=H%LU?LD;R5,@FVQ5")J(
M2-4*OTPV -4_+,M3+'M,$4P4\@E81"&<'U;/-IS]_?0Z.LK&ZXD^7EG#V*56
M?O9!;LI]T.7>Q=,Q2+WUY^<('[H[6*^H6B![ZUZ93L5P8:DA-^CQ9:%+_M(X
MR+9[]2%*28,SAED>1CM3V.!;LZ[BSU%FW3F4Z.MC@7SJ.5B9+2LMP'E'<N(7
ML)Z8.NP:NFP@OD4G7H<F:F::S?[C+B[S!8[1!@4F]7$RFBM&#RV);!*4&J4M
MKZ@X,N0L(K"-)#G+Y42/.^_N[\NK3F/<Y!RX9N 4#)+<M)S H-[<X!W0B7
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M@)H79MT2_-\=?TI\+=71T']#_>'%?Z[,D"!CKT_ W5"U[F'+T<HJ\[/L6VM
M8MM3W\,<H<FP?W5M$J.,BXOC.[G_K&UPE8-U$-OAYS_G_<FHJD6Z1H:K7,Z,
MJXZ",ONI?LXC)"ZG5-!KR[.C.<=A\H:UD/Y,TWU"\2?+HNUU6:*?L?W ^,>
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M:=K=?1N*VVBM?/E; W*N64]#[US&H:=-%)"++3U%O&I14@^1>3G/!!JJ:N[
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MST-J.!' 7<QR?E ;E><XYJE;Z7>27%U++,C,[?(%8AE /3=W'>H3YL FD*D
M-C;&V>>X.3USTJW!=F2""=9U(E;.8SG [_KP?K[53NMF2-T^VFM&GM!<O*&<
MS2&4@&-",;%]N.IJM-''%.\<;RA3D*$4D GH3]?PJ_*S!BDLJ/&R%9VV#!/?
M\.*F(^UVK_V>RC*[1+UW#MCVI)V#<JVT-RNE*LJQ[>VX8Z'J/3D9J^XA>WWK
M)YDRMR\9[CCH.N/2F"&7[%#;7%R1)NP'Q][V/I6?+=PZ&PLFDACNKG?*B[NN
M,9(SV QGT%)Z@7)X1<W433;592"0_&<#J/?GI4ES''JNGW%M;7D;$N%!'1<$
M97@C/_UZBV/>Z:LLK;Y)%9E48'4'[OX5!I5F+<Q0/B,G+I&HVDXX!8]R  ,U
MG-]"HKJ7Y;=[<Q6T:YM2I4L9#N![ ?J<Y[5<M 8HOLY5AY8"AF.=P[')ZGUH
M\N3S48R@J1AAC'XBB8M&P*J\C,V  .!P>I[#_P"M46"Y,!D ;L\<FL630W>Z
MN&$[K%*0SHLA!)'3\#SGIFM6W$RJ3(H!;! !SM/I5&6"-]3BO"F+V-#$C,Y"
ME"06&!UZ9Y_J:30T[&9&;^.Z\NX)21FQ&D>,+&#CD]STXYQVK0N(XQ<1S"X\
MAE'50,D#J/89IFIVE[+=0-:.D:Y)D>1<Y'H#V/\ A3F M+1C-$MV5)!*8) /
M8YK9)61#>I8,SJOFK(A8 !\#/'8U6U$W!#2PQA@0I&\X!]!5:SD^T7:W :Z\
MLYR7^78W]WT/2KDEWF^6 2*2@&8SR2#T/_UZ=K,"E8WDZ6TK7H5W9@&\I#QG
MU!JWYIBDDAF1Y$4Y&P;B,^OI2W-J$O))ID5HN&C(X*''/U]:DL)S(6CE<L^
MV['7/^10W=72 SX+;[-&C#]]$CY+;OF ([BLNZT^[:]B>(I#P/+" DDD]3^
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MY9VX R3FN?J7<RX;1?M;2JWEA0J8,2G;@\@'&>?KCTIFN2L+8I"B2&1"?F(
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MEF((Z$#J!U/M3Q)%$8U"L;AH3G>W ]S^!_(TW-= 2*=UHB+J<.I1"/,</E1
ML2 "P)XSU.!S5RRUJTUR*YMXW!DMW,4J$9 ;IC^?%175E-)T)0$!AYAXQC)"
MC^GI5RU%K''&&G+N% V\?-_]>HEJBD94T+6%O;P274MS'O9@9L!L$Y &T#
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M[UI2JE\6@N(]]M-'@(5X;US45%[UQQ?0RVTF>72[5;VX#SH$DF>U)C5Y #G
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MVK1TUC-<F["A(I5#+N/)S[=JH7<7DPK.&&UQR=A.!GCC\?PJ];W8.GH\@+S
M')4<\>M4T[7%=%B4?9Q<O%"@+@N"N!O;'?U)P.:SK>]@AL7>]3R)WB\Z2!SN
M$>.3@@<XQ4+7T[VY:U4,9<M\[Y;(Z!1TR?<CMZTZ5'N%C^SQ&2X4[LL=NWU
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M2WNKNR:2Y@$3>8P12.=G:DGTZS6!4N=K018/S'J?4^]7X8RIDP-@)XI-JV@
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MQ[(QN']T<<GO5VWMM2N8'D:^EC&[]WA4SCW^45G)/J"$_L6W\]66ZO-Y&?\
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M>=E?7T)"34U-1TO'04_/(<O'S2?['U_$CP C%4DE"9R4A!\XPTA"RDA"[ 3
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M(DTP[^2.6QP_$7U%-.02XX?+,T]4COIA8.YB$;)0KF\&[D6WO[6\&>&27(Z
MG'*Z5[)'T>HKR+XQ]@#!^1N^^U$1T>&+RNCX<:NG)?>&D6$S6?R;%"N*QC'*
ML*()!A6%&Y7552-F7V(_/% :FO7)"SE)<" ),DS?#W)0-;*^X[2R-E0O%70L
M9BC@1VBN R>#FT^>F?EO&9[?8UA@W+W908*I?4=68NM*A)M;[&-33FN_.<T$
MN]*_F7/O_8>0;[=GPZYPRGE% UW5/66%H^6UU?U%;ZK@M<*?&*"?RBC#N2#
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M3T:E*L^X?##7EO5!9)^PNN$;]RS#2=K?#Z^M/3355^SD<7">8^-^FOQQ+C(
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M,<E2SEBS3%'4-_LA4P\A":7;F3$/J!RH3>6PO@JM#*Y,B%JT//<!<8>###C
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MUN^!+0U=NU(8XT2^>&FZ1\]_?AF$1A/*%4['GOO^><<7V-7 E7^:&WJ%-L0
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M$K_>7E5:CBWE:H*UY++]VO$TT^H>SEROJ):@+*3;TO,2JX'\"AYU&+IJ!)O
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MG#ZSG,&;&I?ZJS1121HN0;:%=42;I+;CL2J'0P#G&)H#-=HV2*>OZVJJZ3(
M>.?2=E$FP1DM9CLN'DP6NE^:U3Y=U)GV=_US1GBWFAOJH5N.8/^\:F3RX]/>
M^!&#W-2.2?1WZ\0+Z23[?%@W.9%G.R<VH\14AB_72&GIP$:4VV<.K?'4<XF&
M'NK74D(F&?]<2/>(L;B43'[6>>OV?M,E]#7]6/K7TA0X59H+9)D^X6W*/O37
M$ VC^ECO5:6)GB7\GHO-)]*5#',CFL_CI8X:+]PL=A/4GB@RZ G#UL<"<8B@
ME@EMI<Z[KA!K&].J6KLI4;<<V%>W0BEY[/)QZ"QI/D7M$W;5AQ1G.D99DXMU
MZU#YHJH1BI/LY4P,<,LD4I7 /M*>6RC5<GS*PHU4S'&R*=IQ, DJ^N;CUPVI
M8$>(8[>A57TD^I(RN^Y[S%8UV?7!Y+?K7/3PU4Z$>)'EM;.?1T38-A*WMRZ2
M^618JZ D9FD[* ]Y/@:I!M#\DW6Z4RR;[#?#"U(,0]'^K#?0NCDN+#%6=-0!
M&HRO?BISCKJ8 F"[7(O((^KK,Q612SL7-WP,\&&TDH0482.7\=7?E?&%.3T&
M,+B!Y5HH9.-P$8W6=-N1G3Q=1%_F][,,[V. :AD&T:M-NEKG%;#!DGK]6V>U
MZQ;(XG=C[S[%*T@;!O ;6TMZ/7S@4+HKPBUG6PB3\\)"$WCUC$;S'7;(5OA(
MW2>S)V+LQ#;"0E(&2&YK@E"4S(CX5Q[C>Q@ 5_CZ.M@J/1#6+[AN.IER#<V
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M?BO#R7 4.O ][+-]T6/.O -3+152;SW96_\J//[O?D*PWDH[_QVQ_^UU:LJ
M LTO#.!I*;)9@X V-VEV9VE1<&+_N-4TU=/EIA'6 AJ]<X4THL\?>LZY<JZ7
M/XPENW4SP9J>-J2= UG*'2IA+[)Y6Y$!C7"]<"][P<@]Z"]H33Z'LEG4J]8Y
M3>-RJ]>6X-PQK@DNZH!:N7M'\=#RW0?%[RR>9)+0_56T$N.G[7DP.Z-_?TW_
MK'58UWEK7^#QY&2Y9\W%+E=_PAJYE/B$2TG<"N%7IHDVW4&']9'FJ(UR-_3=
MYZH*[MTD&@6H?+51^X'!+ ^2"O?%/L?,$C\.>'[P2>1:>03JV5[[-QV;\HMQ
M+H\)T-<Q6RJ\_9%3ZF.1+)'+SC6%80FR0>L,F'V,AC"4;/YS=(XK3%X$2B_&
M B]EE$F )9^=&SE%J+&,%_'2Q. (P^HD(^HIT:)YS=.6@_+<+(W<D0H,\%3>
MOB7"'V=?302?JY8WI,79/#M=\S%+.?5@K>'RX@LZV7S8YY[U7H-"'TOG%\L*
M18M>]<-O^GT#W$8X1MBJ,K>CO#5U& O#I4FMGA U2A5&I;U^X$DQ$<I!R:-7
MKA#ZOF]/,[(+CT4K,[2YW$B;AWCF9[YJ07%V0,[]>/YN=44#;]QL+X!)7B7Q
M8YQ3E^SI!+G#3];1*MYJ3SD2I-/>T\K7^R[IQ&-\6),6?KD/6MY_E?XR0J](
M;M<C,H1BU=,I0<6LEDXG(X)CQR@G07<X4C4^9[K#JS^_F4M3J9CN8WCW*Y6T
M*MY LIG5IAX<UOZ0 -_N>$ 1+YP^&E$@A>SB?GH9VJ27_,NJVS>I2XTIQ>F^
M9=]K_ .-C,X2QIM@ 8X4$4#247#TK^JLY<^9(.7M^(C;A8A<%O*35%+Y^\G,
M59G#&>KGPFMAW^N03-.5=XP7X)$Z-<L'E'NN,ZL\3-3:HNN?[!_OBWW1GO^F
MH=L+_P!7390G9%U<Y.[BOV)+DNCIIUJX<I$OG'6Z[%A4KG_QX$W?\=S#.&N]
M3[=,R$.'?Q0N=G[5J1!,]2BJ66!K6AV\+WE* P\I]# ["V<?Y<?"8M%E1'M_
M<;6-#A7D\_$]N;W 7K?R*QHX2/[J&?]1YC-.RV>#I*\^73[]8E#>=/T1;9$>
MEO4"0TJOSZ_7!A^)BKCOO$K?)[@?;WXX[?1AX*VA,0W_O80H[D ;9M[KT4_N
MXYNPKC#FIB_^4=902V?!BG4W#/"!KO&ZE@S8HY$^7MPK&$) ;<Y]X@L:[,[(
MC*2:QW/;C'L'(8(&(9ZA^IJ0G\'.)NSC56=CD8O3(A,-;DJK,,C7LB>V!_B2
M77IMWJFA-;._-PYM8*E?H,X&=F<$;D2<^.3SLSWI*6M:&9/!XSQI3Z!SQ*T+
MY ^9!UOLD-_&'*#V>LH(RBL=W+4UC]=Z8VLB+AV.N?+9H%I?\<9D>9=/"16Q
M?3&VZF]>75!LNP-+"[/8&,!8[\HZ7V],T?CI,&3VQ@(Z! :H0CD_?7S%7\\&
M\5X"[<B(8V58HXP\3QI-D;F#C;%?TN>O:W,=9J_SWS6.[1%D;"B>KB=@ %D)
M_BM\#619BF/)&P@C;,X012A:=4S_MMK:F7GNAR@4JF),V#X)7S<-];;34OA^
M=0;$;\6!A,_C2H8\Q$]CQ+=KP*@[&2LO-Y"Z'QR"UR9YOBC2WGV(?KG4P)ZS
MG&:N?OG<!'\DB-O^_>$N*X*]Q#9.7VUY-BO/$ZQPUS<3/\.%U!N>)-X<"#,Z
MW?0U7^X[\_(>^#;;=[W$/!B"3 H9CW-+D8R]L#:51+$^;PE$;QTTB>2&_3;E
MAX50,)RN-W0I+K$'+;_).'TUO![ZR[O1<[:#ZY%;L<;E?I&QKQ+"+R%;H\SP
MH3\U?0SDGHGMJFEC/%7\LB:>V"'-)$>4,#^9S0_KG7>YFX?9O<J7/(#=Q48U
MH96N5*)&.-.=T*0I^VX_;.8MS=8N?AS%L^I-,0QPDQ2TU[%7(7TU.QC>H[S<
M670BB5-7MM0^374?MB:&9[&:%VW5H\V2Q!ECD"U<*-Z785.L=L3+9LX:6R_&
M5O@#V;Z8TQ6_BP&/UZ+TV(7+PA3 \W/66('QW:E8X%SG4U/")D^15]7W1#X*
ME;18[ 4%I6XX"+[(=7IU,H8T;P>6;,CKCPWU0<??P522G-3WX7O-P:D9RT;?
M$/F=I\[]<,,7TL56Q==<\HBDKL=&D/8WY#>8"X!SJ;&]=U:8@WE?6Z=N\Q1/
M4:D+GL,SJ+L.B#4<$IZ)<.C1TMNE3CTL\L2&FQ3F][]S@_=:A&B%*CR_!>9*
M4$/9(V_UJ(>,@NFJR+H%RKM)*;Q).>L87Z,*LQX_AMEL2(&'DU.E.:Q#][?$
MER_TF9&E7M+,J&,,4(+<FP3/B*)OZ*3?2@Q:LJ6G$@.<%,[A]2%7VH?GJILF
M827.W/9<DU<;6\ESS.1V$2'&(&.6J*!3]5:H5]K43S"9J6GS_%2X_>J711^E
MWJ[PDR&HFRUBJ,M,1':E&)%ICA7#238""BL7>" I52K 5+,$,0@Q#0<Q5B4Q
M(R)M%3B[]2,X?U[MX((_)H\X'WD.:?'XE(1\<T'XO$BFCD)U:$F$"!R2@^GX
MNAVL%BG,IHZ/_/(]/5[5!8@][0U34'10,Y86:V:49(7Z:V$ Y,L^:^;;;\=*
MT(.^:OZ1C>[]'IRM7ZSRVR+)N)79:XN%F.&7LKC1S^QO/,3%6RB#8+LO9G^D
M##U@5%.)G)QZ.FYP ^D='DB53 ;:A*R#+N.DI<1H 6F+G$(EC;/]5Y,B4[MG
M>7.+M)#J4MV[L7%I/<PZ"IFNB"NUQ/5?]'6^3SR'?S_Z.-=)<&TCYL\YA,^N
M06Q<%+.^SP,1+\JX=<435I"W&TS3EU8O736$TF*B$2,]LVN=/X(EYK#%KA#V
M-3J&.DB;U#=%7ME(Q$:=GDY6&/5GJ;#*)D3V]ET!WS% ,,FR( ;@V;B@O5E,
M;)0<0]MCR$ZE5@%)#:J\:(?. U8%P;5YU*VPS-J;HE34CY3H2DSZ:,-T)Z'W
MMA-%<2MSFMVL+WM%52U5S<5Z.4E1%(_@W!N98\I1JQ:2T2J1WP]YCIR^E;(]
M$NN9C):3TU%OM)?3"-QMXZW_@NVE0_SHDD%+]S2"ZR/OOQ^UX$;8WJ'FR,P$
M\83'Y%\^5:'Q;7!/.UR9:+UVVZY>@X!>;#.32YJ7^*&:)FIC9,?6=KDG_G(L
M>2N]T"(Y)LG%DN67VMU[5PK<0_ZD"VKVN=O2M WP%>5Z3JR='^G<8]%>:BNQ
M^%?6(6LQLU+>]^XRM<N.L0=(&40(_<>/_=Z;\-<+H#[-@^BSEM B<5,,G^B2
MX*F'UA<M"=Z*^_A6<Q=,$[_SRLG /D$F]F[6E7ETG4M7\NS?2FVI[]H:#'3E
M*-Z+X60-\B24."F%Z(U4-:K>KAMSW-__/C\"K>%DJB]3SNC0--TVA0GT,':/
M)9"^5[,U_365>*M/6#5,M%N%&-1=$^V:_>F9N,<[2$C#,2S_8SI]K67ZJ%K$
MKM?LEK$B+/2L.'9T+PNQ]GWX7F>"]!FP0<EM*\,D:'3"ELN=O4+/JUXP;]XL
MM)=>W4]B9[E^__,.%SCL!;5Y'K4EQWJ7I+'/%!<,3C:N ZG1='5*YL'3/^V8
M6T_ENUROQX9F,OLDRT+SS[8BY<HN7TMMD4RS'!G9V@;<#?F.GN\=],QN,R^G
M?AW3"L7=O9BBOVX)6/$P,-U;W6J()-Y-W&F!&,AY8NT8>9S"W,T>YAOI3!3\
M>+7;,G6@?/H#'*;'>%W7')[':.]S\Z&6IP='R=)SX&8CTU/8A<B]2:Q]JQ^O
M]ORGP4T/1TPYX]ZN^NB1BN0R]N6SEX?<MD1FMY?7+_NT,9_6S4^>]-)N<MN9
M?EAH&I.;>.[1D/S)WSK2G#+/+6E.@<1H,EMI'U*%YZ*&'J9=+@Y#STCA"V?,
M$@M%3SQFC)G;QKZ<N[:B"V7VKM,I?NQ-AUMR'4SUQKR1+C!&.7.;$!)1Y[BG
ME\]H?*GUNGP68H4U/"R"-5\<*IY#9SV^N!")$[.Y#4"HF0TT]B@9#4]*Z2_5
M-;P=3S_GUUC;4$ED%=[R/]O1H L[8+G:":2+JE^E\SB-RFCG' ?)QAR+LCRQ
M*?9R3ZR!"E>RJ8 67#X8E684G3N#1 :E\+3]N*L2EJO2!4;MWX[OLU>J&^XN
MN>RJ6:N3JG?V3??\85QJT3)^NK-H-*'C%;OXVTHV,AL"G@J!EV1'?=!IZ?^G
MG>\,BW))]G\1!$1@0#((0U+0(4J2#"(@(DF0G 24, *2,X,B.4D64*+D'(8D
M43)(SD..DAGR2)BY<\[NWMW]GWOWGGWN<[_]/[P?WNFNZ7JKNZM_55U5>"B;
M!\2Q1J*=H$$CTFAD6YL8-\)P1E\TB3\P^FBPV/[$470X2N0]W(3,FH9:Y.PF
ME+BVC66V7=LU!?EH1O5;Y+*DS8;8[8ATG6*<=Z'Z",',^/!?TSUMBQ\BGMAJ
M'\?.4H%'DKT);-I ^28UE\2@32,7*N,!2?^DS]$HG^QH?R=OV&YY'FQ)S]W[
M:LE]OJY68M)2_G;T#L]K1RARNZV0)L[T2^)5/J+A:-D^0-"=8]A;.FL:KWFL
M!']]7IEPLE3_=,58,[T' ]RP[_11U,%U20V[4152[\^R'6ISS_EF)5N7+XY_
M&XWP_+V1-[>61^9>\.[H*=WB7*S%;?0$!U8M$-G4RS=E9^LBJ@0X18V?2+:>
M48VIW%*YV<$:J'A=E[P5O\'6O XEOT(:Z<V2UY/PQNY"(FCLE'+G4\F@#OK[
M2-=E;2L&\![+SYY2 )2?:)%^DM64=:#"JB^>"H4M.B-562IN:EE'H9H WYTG
MTHNLG]EDAVD.<S6>X2&:Y\#QM$QQ5>HX[_[F02/6^%M0,>V?O74L2/ZZ#<TV
MFI6>B[QKCL+5WDY A?DZ+P#;%)'-EA9@)(]T,>#4C+<[@R9+LI]=*[6_DWC2
MX6GD:$)<A/\%N2T?A,?O)VXY=@@M_DM4<\//%?S8.X.!YN.[@3Q520EK#$T$
MACI9+XP4>B455>HJD^04!=^$@S(H<33;D@N@J>"RL2Q1&K+"M%+8!!SZPY=L
M0?*K?FF '6B_*B7P!@8P[%EN_'NACH?[P?.,]N3N9E9+1I-\8&&6+46; W$?
M\>>'R(GGA:3M.J,?+,B\)MF<%J>SZ]TBCPFG0Q"RRW7;FH[C](]<APX9=(5T
M20\8."9#AZ"--KH-U=&GD=-4P^Y1BR?S\+=W@W3)3,WM&-(FZM91. 5D#LMX
M!#4D:*'DC-D:]1\QW]%N9BU@G^_IZ(YZM@(,L& &EUY*@Y>>T[)(^V. "#!R
M,+D5?,CD!VLQN+2^,KJ)H%/.-&)2^.&Y#UZ1VQ#A*"H'75A)=\*#=LX*3'%+
M'_N&+JP\PP"![N-A8%1:"X%]=-1)[@Z9E\(K$J*?:,]'DC\*T8)9LFG2V\48
M8/\0.X0->'I!:_ R:)'MJA,+P64OQ+8^_32I&:RR10M>O:>I>OUR*'> >")K
M6^PW?J:P:&RP/_<* Y@<%)N@+%5D#ETVI/=G8!'*X)U-IV]G]<=>L.EP;%>F
M5A!" (PF/[OY;3<!"Z^;5^3<O?'$X=S2FZ<!_;:E.QOK<LV&#.)F LEE:979
MM0-7UH,C8I*A-%66?/64<FBS9/?S@2H,L*/LA 'X(P0PP+7KSM&^ ZX9S5[%
MHN"=+FWSJR_'<#;?0@'0&><IIV26J/2.N"EL52 'MBB3$\':?DNZIBHC2F^[
MRF1Z7QX-V2S?N?_J*JU!0NIDO/5<8T?=2^'M3]71%ZK[Y-:P#UCX\#1XVFI[
MLMW3?O'G)6289I$F8 Q65,<Q5Z"%(EEB.0O [JKJP+1RV5VZ]=?<5&#K Y*0
M,[RQ!U(?I$X;;7S])HM@W\.0KORK:A@ IB(IA8_B5NRW%/!Y;>/;<1,AT$W_
M4P8+P5AJ87AW/]KX,D8QP,T6]KJ,.S  D72K]-&*"%:H-O%21"@64E@E8U.E
M$%,'097EAZYBE!WB?"F@8X8K2#R&I>=RRWS9A,3EB'?PJL+DH-3#Y(,QD?;@
MJ:#E5'E^XI+:^\F<(-"Z]<6=*<.=7Y>HQ+8@5.G@5276?&*ZBT0^O)''AP$<
M8)U-'\#$WHP80(;!_-=8/G+[N\-[BL=PX$)CQWS*>^?7E'M*VT('?J;O.^N?
M[?.,;*R3FN>7\&,;=YHV\I]V8=:#%U3,2,N@1[OH;GC715QCZ,[MG_T+R#B4
MCR*UF#_(L!BW@UZ 9&%Z<M555/_<6)IH0X/X;JP5P94C)09 *1R;RJ)_P%=R
M]SJ8.EQ)G=;E#W@2G"(>G!W]UOJD:JEGQ!Y4#=U<RMP,Y1.\T#@.A@6(.D>(
MDFKWSL)F^!6Q4P#Z%-CX6I5"ML%\1PVE%6V#;ZV8N+2]''25@!7GN=>.<!*>
MP2-"#&"J%48,/3.7/=;XG2HI=?6NT]+%8 Y]$2*JZMT7TEV!T4#ID:;H0_/5
M7]:#<,X(FDS.<R+C%M^A(] -;\G1O>09[8;W5KW"JP&#,$WC=(#QGE7QR^M4
M%J]7IS3DJ<S^T3/.WZ!3W+6T0&RR59'*'!S_$Z]&-JJS+NJ#)]NF+ZE!7Z0=
M7%1E]>O)K_K7%6CNV:9RMTSW!]/!L<]K]>Y*RD2H^9YL3KAN6KZZ7B5#N"PO
MCSM$K(XW_J5XHUH?'>N08]+.7O/%M4RRD?"LF)X3MT>"IG@.Q=9NO^CC^]Q6
M=B#)=05G# /@0R?>]3LQB2!=:L*.%:ICR><Z+OKTNG07RL^UP6U1U/-&29<"
MR\0YWW*1:[5'L94@?>#XZ?_V4N#()$*'1X(%:D[W:]_>+,@*S9)\7'#8'))N
MDRJ$M(N@^]7_$\$PBK7WQV68DLRO(:8,9C(_Z*Z\(!(W?1$JJ_SWL'2-O'9O
MR$%FWW,P=TX=>'I5LB8R;:11U[E4&M68W>.RA)-OL&JXZ5@\0B:Z4NQB3#,^
M:H0<2,O/50Y^$3PH-^\GM/&W1)W_P^<>Z*E^RT%J?=-M9&1V <61'/GT7M<[
MF=LB 1H-.@=.^@?$GV>LY7:T%_;=I <:#9U+.)940Q%J[W:S/\&^+I1_^W31
M+-W[S?/W_R+L+A5#12W.A(V"0JJH^;;K80/9L+6*J"4I^$85/; F<6,% J/9
ML);"TQGV3M3^N:^P,C,TJ6.LLL)(?]8J=0>+I!9DP^&5'^N_9((:ODSI9&WH
MSR4&"WX2@MSXD'#$(SO(? [V!$;^O3(R?S%"1'-#YZD3K&\]''J5- 40U FU
M;$G37@I8.Y].F!UIQJN"IA9YFK]8H.KV+KU6X$B5[)G6K_J/.,:96/JJ?;4&
MUXS],U!01>1)LH&UI[?P<.ZCPB.PH^<0 14&N)F&59$97H88H$7A-^VWY+2)
M 8YYH<THPH4EXR1YP"/MDL='&AVPZX8!<!@N(6QRXP;8PXEF5T@V9WY&;TI/
M),'.]-X16EK_5.R9.B#V>]K57TV>%V-%F6/.,V&B8X)."AKOCED;[+^G"B>V
MN)ZE,HQ516BO<>TQVJZ]GTMZ:KEI/#<12XFSGH:LPYKZYS3PP4L\>V06FD8J
M#0,\.OV& ?PBT%2;<>H$25B#^.<H!M@PGH0AR9N_1Z$,SV%7-Q'[Z&LB*)T<
M[-JU_,_/,OJSG\6)M5@'<S' 4&,)!EAD@P5XOL(R _L;,PO_)\RD_3?,W -U
M1@@ZSH,GJ;QBK69]XS>K N2(R3]ZT0.KSJ 07[H#K&JVK&[@,SPFF^.-Z]H@
M<6E9KQVDO10?D5!Y/:)HEU ?9PIO').#0EP'Q,9- IDXODT(;C?R:OU\/K)Z
M>,=\O&7#"K?I7RVZ(GLR5*X2LB.D?IPG@:JK]XO159Q;L;6%;J;'[25R98J-
MZ^[8]>X<A=)-O==\H%H?Z 51]B?]@NO3@K,=>8R3 >ZPA6K<56%KJ<_NK]UD
M^Y@29/[^OAI*MPE[XF6ZY6'!U7BIRF,MF8(,K;? QKVQW]* RKU?8H#'^]AS
MN;E0\9++A!8V+#X&V]_Z6QK039I.\+'J"?CBO KVO?T@Z(JB41&-+OYK$M&_
M1=WQ1VKS_XE:^G]%_=>QX0'+D$$:;QD?Z<=UR/B]I%QX;^./"C[FO),.KU=W
MKP/RT&OZB Y[6AQ6F5""=-K\O(Z_W^=0=33H\"D1=Y=2AKX8#Y0E@'O<VO2]
M@X(NB^<@T;%2I>GS:S$C-%W3,P>E9E];TD'\8/(_+1/X[68JESGI6UM-N./,
M-?NL?+9-J&N-JLF]=$_8F)&R^S*T30P'=M'+A;Q5FVXLIQB@**36?3"#JLY8
M>L6'V)W"I.H@]7W@/"Z?B@(A>B=4S5"G6-_PSMQG$?*K'G6Q*\)^0.5/YF<0
MQ%UR.(F$>;L)+#:?OB_Q6K0KU2[E1,EC #;I2"P"96^^$/)LQ&H78VC!?%^)
M]Z/F(1<P^9Q5@NO'QQ-#B %FKXHVKIE!=MS.ZX#G"ZHN:VHL5@X2\OJTWEP_
M?BEE^VRXWW%9.?@KN(6_[[V8MDX FJU+."A_2VRHX8:]Y_;Z540\6W#M8[!&
MY]*86SI((;/2Q<>QZW%5X/KNC,7(5W["20\WIP" Z*>$4+&$9UKXZ[']*;VI
M!:!8X+*LDPWOW8;X$ %4WK%:FJQ*>:;0RG7!0-%YAKN$IYB),Y<C79OM]NF
M@-[VBFA4QPU!X<BC'>B;@H+JB"C!)I$$]/K#N1$_\8+[#-^^>=U4LMO+?F(:
MHMS#]ODZ;KY0;]<!Y)$U]X_H+3[]V=HG]AP5SN]Z-@/9,DX$<:8T#/=*5XS
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MYNV7<A1C'\76\Z?=H8]&2^D/^Q3+JNOL*N7L0KL.KOE)[(E[H7S9MY%1%!C
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M:E+2T<\Z'VV2OPJ@.&1&CNE<E/L@C8H[L1U<32\&AF-><CE$J3:*CW]38<(
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MHB'!$/%U*SBZ1J6=DR%E=M) 'C#;0-_V5Q#+"/6P0 _50H,6HCZ6=>*+OS"
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MNSO;K[?S^G(!DP+^<^ BAS5#]:Z>V,)=@!Q.*C(8U!40%C/ %1(# 4P&>#1
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MU(W+6K>9(M"MG&Z=3D-QSRH<JL5[3=1KA158H$C:>#"^3<:"B53E'RX))^>
M$%WN#P<-"I!(,B [@EU3 C%0&8A PCJ@+TG'^I\X'5,V@69\9 0B+<'<X&"&
MAC84 @2&ZQ/B/I@ #4[,,QO,LWI<PFJ>^4@]X0;;7&[\?'#_$<![\ D"+W!0
M)4!*U,ZTU&OT]+'-!>/[^U))O(5M^N'\<") _H/D7H!#?&P!)X$ N;:;8 &
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MNG^++&@0OEFI=M("CN[MMB7"5TV@HP*(:!O[M\T=J!"4TP!]ZD^EA._#A&#
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MLDBQR.'$@D&,KK.*96P&1DN/Q#:?7AO?[V"!.' !;N(_ G=2/UG#$P.;9&?
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M86:Z@H#*#=QRFL;E@X$IL! (C7>L61@995 <,&^RE&1$BY-@"E!F=DW1 ,I
M@!&*56/P%IG3LP(->!'RA& #'D/(>@D14AI.=CI3['S]XK3$(K;^6[34.\_!
M98FQS9@"I8<E#?'AK3@+HG=!]?:1/H&#Q]..WJ-UKE%.Z'?2,U13MWF4R<L1
MQ$4BIU@RW6\[YH[/KG\VNLRWI51]S_B=BA*[,A%47Z<\XJ-YLT)T9%*;:TO9
MONDUSX4/X7Z%M($5V:1$A'RQE7?;B,AHI+^_NV1[\NIZ\<34T8DN[9$QB3@+
M;$/A5/ZQ19Z3B^&ZB?,NT/W6V**+7J8V8Z=\>="W3\JB"9G!")&2(G>B$0Q/
M9@_8I?7,VB>^-Y/C>5H7]]=#&G<06&^%3VV3!;.'CR=*<*T=^9@A+*XIH:]H
MMN[B?6IR4C H[GLBOXL[9 AM>/!&GB&%+K]IA7WUUGDB5/W(3ROW$"/=7-GM
M3[?MFW2:$NSY=I\/=OQ&XJ#T:2=[TQ\X(X>^=HQY!(V:?E;KNO-IWO:[2SQ-
M:[DF%%K?/?K]KJ^WH$]H=>*=W#CB_*%'YC).G$:J7;+G?46SRDY/PI.'&N3)
M[9"9G#H%I)J%N1F[E)UN_K&1:?'5Y,W4^E BI,5/<Z-S^X2\LN3/-7_#G[#/
M"Y/R;X,/CCZL.)CY94$I@(+0H*K7R!J\1UG<K%UY=\Z!5S$ 75/XWAC<P%H9
MPW=, .'QHE3OZ,Q;RW[](OBSBG<C#4?]>J(&S;[K?\#_ZYSZXE:(G:]OE[^)
M6[:G_MA6M?ZN6K%]R6MS$8-6:HX8A3(P?S:OB N-(L&28<#HLB%G<OMC%;$H
M(J3[2;WROG.+Q(D5Y94E.9P1<G:Y('O^7$R\34&[')<BOT5*1_X-O>OVUJ'O
MI%.:(^V^SYASHN)V>SCO'Q=+<$-6<#;^F\^Y0+MN\/+1UWFG1\+D,S0M#0^5
MXF#_T'?MZ;\F'(J:8P._:+TJ7K2>.INIDE I;*1C=W[HPS"_4- "5I!>+=>K
M._F@U;9?G/8)YHAK&A-__+5"MLE$;]56[G8!%S(ZLX#J='\N14W6;SSA@)@]
M_NQN3(%2K,!NI!5<]-@[AZ,'?U;;TO.?U,FXF1W?C6G-\O3'G!V[:H3]>D<T
MA>>9^H-$ZX>W=^>RS?D\>S8=HC&#]KV?M,$E-5L?^D3\B6^/D=CTO8BY>%-E
MD:SY+U6D-ELOEB6;="N9>G7%QU(;=X/?R$9_-'Q53TBW4C(02_D-22BZ+2;%
MV5A5*.#BU!CI[=7YS7=P1#72+EPYNU,*78O]DB>?HSD:Z??HQ@]\')]BV[Y9
MSI$/^EM[Q33"'"+@ZG%9DMG!#MM"[#G7W+9L'V61C87KE?]ESQ7:".S\X$L>
M_&G6RN+OQ/7-<=D&:]NP&9_V9G&F33^^PT?!7WKWL\BP[?F//F+(T_<'+MZ=
ML_ (O/! ^=EN->)GU0R7L4\(9=F4EGOG2'C<X,BXMXF :BA=.'/"E]?BO<Z8
MTWL]86W6&EU!9=HK-OR+4HR*Z8JCUXWF,%0/J95ZS2@ZC,)^5I$>"S?&1?MP
MC\J40]MT0&C'V#;R_TM*\#KY9P(CEQ6QQC!R]0T13'HGJO7.CKDR,NTHDK'8
MB.UG./F,A4B@0/.\.D)*&&P 1@#7)3/U!BL@?W@E7&$IHH^DHP'3KDOE5"F>
MN*SY<Y]<4]5O2/A%C5[:AU_&IZ/4+9X$IA([A<;[F?':C ]Y+8>3] S)XC<W
M<)Z2[3<6E# ]G1&>WYV^M;Q?XB/.R\9J&PHPX[30P8 @#(?]B:&SU(TL[U63
M\5AJ3D=]0S$AM+CH4:I!5-.PI]AK<<)$3\K>L((.HR UZIK#!SHY?@,K;;(R
MCUV'VC:/77?V"3E+K.3X::,@=:.BRB!A6FP(G*%5]Z95P!?4#*#+\.\JT$2#
MX"6GHW?.O-'VA:6^6I8HS YQ)!^":X[4<13'"%#[-'O>2,AO;X;\K'(=^:*;
M/09-4O@-\5S[8?.Q(=5+ND]P64GQ,L?Q\)S>?JUYZM!;"K%),RZN,\J8GE.+
MF*GT:&^SN'!@V?30:I6UKWV=>UCN^ZV,J)3]RTJA&@H5=&N#$\T1Q(O:8C9[
M0.H.#HU^,?<LP953Y"*^GGQA'H'O22F=1HJ5MVQJI7&H"]SK"_JB8V3%W2CS
M=K5RV_HA/Y4NQ[(OTP P" [\(=K05MS*>N=],[II8&F9I9LC &7'NH Y_VOT
M5PD+N+U[)@?PS+WA]I<;J@C:W-,CM%^O/YZ>PG"XF#A>:LX+YR3AK3B4X<&G
MH&V,_33B, YEMEV6Z'X#/@70O525BK&O*!*XLO9/[/F@VZ^/7YY(,,(<F1UI
MYJ[0X&T!4S]5P@./;R@G<@Q%#.=><"3KGE%[6%PSLVA)=#.6^EF5__3S\Y-(
M 1\Q01^$7;JCURF?-F_!S'=TL9'+ZW&21QKZW]#C;P]8^/#%\>W6R"H].[GL
MU!O1;\5%XOE:S":F,S"(T++>+Y_R_=G=_80,!SU1JH!B\]LI[6IR-<WF44.$
M923;,3;G3<_24X?/_KQ34<VK;-GQ[&!9 $+6IMSPV=U3HWM?!U\1-Q'I''_V
MK<H@KDM;J(>*".?Z4BG37,#V+4DBH2'%=>94H4>I#,GW)+_K\1^>!ZU<S?<:
M9KOYVLENJ/NT(. 4[5RI'K%=U[!MM.@I>,LN-I3>KK&[S]KA1,C+PM.I!H;6
MOJ)KK=96O>]$%\R@SZ/[N/A_0[C)/C^TI>S+GMS.Z1*""/7!+>91!TPB4&Z-
MI'2WX:O&\_:7T@NR5B5T;01%Y17=M,IXB:Y?(5D).6F#H+(9[;+;FEHT1X+T
M4*QM3\$,PCL6?S.-5)D$1$0DAY0XN/H#LBL :CP"$ME!LP#OST!O9UT(T&@J
MDP(/S/#M-\$SV!I8^TE(!98A-"YYX  5]1]AE J>7!*]G[4*Z_@L2'5N=[,C
M31D2O(9?&U7+&##2?ZLAAJFFOWJPH&GSZX-6348Q:00VE+1'$)$8Q.MG NMD
MEPQT$&KEBR.U%OZ#?_."(&WRM0*].4-K&/OG_0H%$I)7JF$TBDKUXG!RC+P@
MY*^=@<IR:WW3)X-4*(5#K/$ET:*V@K'JMC4A5;YI829L$<2G"(B;N,YFIWQO
MD,-62M<=E?H-+YF-L:FHE3NGNQ^:590]9*HBX/Y(QV[ ^I%F#_RW5\YT5R=(
M/-X4[2PT-MCVJZ.>TO&#RQ=7..UYF,9[+7%5H"3%&D\C*5+J?Y6]W\Q[_C0D
M,\[^E,,*7^1&,9S?$0.#$:XA5?G!?;2VCVICI]W[O.F5R@W%Y0V+L)[#%]^G
M^7I T02U<N]GU:-FXRZ?K C'OV5Y61'"56Q>)E?WK[\7>35O=X>:<*&U2,/
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MB[SP56B?<6KV1:*[-;Z6Z.I0KV=J'[I+<S+ZD.."Y=G;'-+E8-*S)3,K$*E
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M:U\A4U*=CY(-(R(5>>VU3+0R"6<!&:MSJH@('*J*B"3Y^GJ+\RU0%*@FFSR
M)#&I:/72FF*FN#&*1T3X^/JZRS"M?7W<)<!7I.A9%&Q%A>3);/AA'&0LNH#'
MQ+O+^(B^+EP>9$($:U\@<31?O88A3R8/@H;\*/55DH,!;#YDQPPCPC>3W&7
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M!)-1\:7*NI%\1LF:D<@,U@O:=AMOXZ>A[:\U?Q!7^:SZE;]^8/01+29]?-_
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M)+E#,X"Q$R3T@+$ 2HI'@[B"KKT"AR28B@("9:7:!N(?A"PDP8PAFP0G0(B
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M+N?P&'NV,=?/ZB;G28AY&M]9@6$^S#1DE7TPJUVIFY:&NYBF/UE*/?A]O;3
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M@D<EM%\"A.75Y,KA4!0$;KF'-X8&<=CO?;V1)=A""L*+NH/+W*6W. UT)Q?
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M 7@J'"EWTV5 7W"^GL] @;NSX2J<MS^$4@6#1$6 [] >MD!\NCCM"/ ZIM\
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MC# ;^4$<*K#P7!H#]\\2?K# D #IWHB3Y9.K2ZUP3!B]#:>5 4EIE2OSA;R
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MVSU(#?:\*M&KT,%ZKPUJ]@L=YWRK6\6;JK2T3-[I^,<?9TP =JBA C+M4%.
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M&Q9Z1PGBD3Q7L7NI>-*5$  MVK!4@5I7ZW& 21>5L@)PLM(/"_$.MLQB2!S
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MVJGMCA9)KX!K@4*Q^9$?&&?X7U!+ P04    " #<BGQ4#@1*QC((  "(,@
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MW[=4*X&9YU>Y3"7:]SN]<9SBH%7?P,4,\0IFP\<ON74*QLFIS#@-'TL7S.7
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M3*4/\N@@+BV!R8//IFJ<4ME,^@$H7>6%A.Q40C_JJ@K-M9XEMM0E;TB%_.;
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MG2JA]PG2[(DZ"AJ37,/KQ(&5LW#KM4_I*W&Q<$0 ;[C5\(KEDC#L+EE,(4)
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MYM[DNS 8%L]E4S5<VWI2+!:%H/SY:\H#8&@H8_\KG;8=$NRUDVEWHC-#R.E
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MBFK)4I%N0ANI3&0&^YT4J)57[,K2CA1F0T^XO$V$SA(!PIACP#)YYRM?=K9
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MZ,/[7SG39!,IN(73A@T-<4T8:+$N>^Y5H/73_^IY"7;*UG.!7.?:ET%?@A@
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MI[WP3H[# !)?<W H$GW-P?=;\^TPM;@W'6&+&+%LC%FP[-M&Y."+XUX/0R>
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MV(H&49' M[$AC0_HXLUI#E\7!DR[Q[DR(EFJ6<.R ?2@O+C*U/2"\<J!H6Y
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MR.Q'J6()*->72<8LK:(>VS3^FPLV89L713'%ENKY1GE^,$)N+:Q2H_<G[Z@
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M_"T+3RF?-/):R6%MYR40$B3%%>@0#[O^+M'HL;,TP01%C7,+.3;2A/E$NWG
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MQM(%1@?26?!U]*,E470*)[J-K= HK0GVBE<43(N+YDN%H7@-8\D[;:0X%32
MU'QG"+5VZY)CEY@M8MX*D':F3-Y6$C;DZ[Y GV'9EXV3I-;$JT1B?>XR%=/>
M.&&=<MTDN\TTMK*1XB%>=Z#BFETK=Z86("H\VHTD=[R&RI9L]NXU1JJH+"R0
MPQ)0\CGF!C@HF6NF6<T%W*92F).G,]&%GIE>])BWL'7CC(;<#VSLT5<EQ21X
M^]/0_"G?:\:. %C6JA1-V:$I-Y%<ZJIVSSAG8+]'+$0J\4Y1/^6$,:@,=Y0
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M_))+ 2#"-$+&DJ/.E=0)FFK]Y<7%8X6",>Q(ZJ(CW=GJ ;+C+(;LP1^G+0A
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MPRZ!9-J&*\DBWZ@8+S 1"B>QIH/\WF$\*ZNK3%2WI1R@F:S19T-AFB@#;#(
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MO!BW>!E(;N,7J_6+BQ'W>42.J6+<W_@%]NBL1%K.&H2R<8T\NP;#E=$_J=K
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M&T]?ZLRC]AQ S,'PZE^5M#<N$ ,UC"LF&3;_8NP'0?W0BKGOZKG)282FGK?
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M767#48/.JO9+Y'KDJCMLO 4:^*)2[O&V[D?KM(+*._>J)M&15"N>MJL504#
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MP,6OO^H["<?EOZ:M&:9?H:;&8ZK1U.D 1]8+1TIW'_5F=<1%S5&R:*9E1<X
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MS\0P$2/TV\&HZD*E8+;<:G;M2@775Z30D0"ZFP1JX.]EL293]-E /K]3A4F
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M:LKQ)]LVA-.>SJFWDLQI9=:?-)<Z:X  FSAZN =[\3HORVI57W2*LG1'+U#
M]AZMYVH:[8,V5C#07RGLW,'(Y^L!SAH&?_1P#BL8DTG\+KFR^'X:$A0!9.%.
MP95II.\B09CY..X=J'YA.TK#-2Z(!_"5PC\)$EFM[]4-3<MT?Q-I,B@-LX!=
M80\D6 EW?8)!=/NR7 58E@0Z*UBU":_>HM4B5QMA0S2"1M-ST6SA-V!!=9H1
M1J>/X*L!$ 7+4.//,]ARC)!O8Z52P9(?YTDV,\B]V):ZXL[.U )! #_1#-$=
MGJZC*XTKZ&VTV=01@0+RSJL"CF:LD5&9<3;]6ZK!Y/RN;J^P%SDL5'KL:3RZ
M,Y@A++6POWN'0[AS5:4NRS$U@>"^@+5I2N7N7RS=<-R_V06ISP)L'W7N\U4"
M/]6T,R4UBY,&._05^ZXW-G=6@H.QK?9JBT+*S<B B$",90+&N)BM#05OF/X2
M)ZJJ$5;P#3?Q.^4N:%VM%?BB?RC[>K^;@\ >1DVU8/!6O&,P%,)R$MXL=;AJ
M2L;]G]/'X^4M"P674UI5(<O4W5RP3:?TOCJ5'NSPT3>DK]0M=D((LK@\;$DS
M4^EU;"^68'17W!:4VMQU(B$' ,.QQ19%G2N;+_+$W-X9=0U%C%@S J/S,LBC
M 7AT!JF]46HSC.Z>H@>JEX(9FX/05[ N<R4-'S69!RB1_J[&>ENSJ@?JT>77
M-V_]VJ[$,"BVQT[+R!;2N'<9#K%ZO@LTVW;GN@2=E$1ETHCL,N#I#2U=^ALM
M:UU[8Q/-[FZIK8,)=/@N5%[N!Q!@-XL%0,R2NK8Z?S6PZ\L[MZZA(4<'/3P9
MA!Z.&+D<[XA!7/=.6_JLZ*9)6@ 7B]F(-UVWY22P]!QVIBJ+;,S$,W9&YTN*
M  W:#O%^E:; TB=KO@"FB8W.PA8OV#!%/A@;@/^^T9KR@K&KB6MG#3;DQ+Z?
MB-ZOF2L!*]M>3FL[OJ?#7&?6]V!'WZ@$]2D'-K]6NBL/_Z(!HI.*N:<1[M2R
M2+IJXH^( H_;V*/*6JCX1+3-J0JT8HU_OS+X4-C 9\/H^["LE,3.,NI/\"D+
M4QW(::V#LW99U+I[,ER3-IO:RK9=8&ND<GQXO+#-E&:C[&(A[0=@XA6>H_P&
M K.AKJK\?.S^3LU+0(&GF>L74J6[7QJ894>^"D649.%K;1RTD0O].BLH#D)S
MB K.K9UJ?)&ZQ-)#6G_O[,B8U-X>X@Y3^ZJ>WE5&375?PA<V!36_@X*:D#$Z
MO"4%N[C&[CTAEY%>Q-WJ&0N%K0QN&2+H(^&F5EFT7C:\GJ"J-IBV0]?C;8V-
M$<;*:Y$P: ^+W4<6!9WOU:Q,J;>9],6NF,](3QK;J(:9@OS"77'&J&KY32=/
M*M*QL/M$63720?Y80^*#*91A5PS>8*T%4;.3LJ'7T)^'KSD<K%\#3N#>_D;M
MDO5S#;HZ@0N:[NDGBU$.>H#1DPF&W"X#]7;;=.!$O)HG>3)F-A%X2FXYX_:\
MIK[:WIYF[Y?)'D1^9Y[% 8"4U$5)O-=U$",;R[%O=/>9 (TH43C21>6IW\$1
MK8K^ZNC1[CZU4<$+,L3 CW8/<+S8 <_/K^,^:=A-2VM3MYX/M)? /:1G9:>^
M8&PC45IK?B%7QNR$R^NV%UH4XI]R.F%2P$%5,W;W:ZDMW6\ZM2^O85%KO%Y3
M7]P//9_:C:0Y*S9>1WX4Y9E:>-UT9"W!0G+5'C/N4IR0G3OB':ZWM2U3U+>H
M+U:?*NI,&'O\9D U"7?6I.XHVOW5.T?O=5'T0.AQ5R$\+:^3C?/FD$1+%,>A
MR;%"Z>;KN?_S8^;'ZO"_7V0-O#%&>C0-ITXPD/.:XRL_/LA^^M]-)?1&<?NC
M5D*__1#]^O;\P_'96?3KF^/3XX^O.]D/]9"C)M%I=\@X78"&8CP?B5$B4E08
M)EF%?09')0PBFLAZFK$.%K3_IKF@]*F=/+D&7>%%LFC*0;-#'^_M/GNXR0Y=
M=X*B=P8/=Q\^VAS!-SV"1R!+#C9G<#\R16_D26L1'%=\S".PO^X@.C0-@DRH
MP?[]ZP\'/]R*'I_O[J\]K7#4N_X??CI\=_+F,#H__"5Z?_SJ[='AN^C=^2L0
MXZ.O+P_\YL?\QSC5 5?\QSO@ :3WX.8OJ8;^JG^^?A%]Z;Q%Y(GRJO=H_AD=
MCF#*:[MQK:?WH'X0_?+O+#HK)W=H4;*ANW71W?I7[5,M.A^^,<EN^.OO@L[O
M!UFO=94?DIEZL6&W&S+\MF2X8: ;ROT^*?<\:W+@H$?33$TP.CU>4(($8R9L
M^.F&*C?\]/M:[H9R-Y3[?2[W._%%+O,P'WW\</[VP_&'\\-WT=GYQZ._1^>G
MAQ_.7A^?<DWJCZ/JI_/37\[.HZ./[T\./_P3G<]4+>N5%?R126##O#;,ZSM<
M[GVBW!O][+\7-_NK<G&1 _,\VHU.E?KZ_E8;XMLXV[_+@]_0^48]6+>S?<-T
M-\1X#XAQPT8WE/M]4JZXW/^!U6(GE:JS=&/R;XAQPT:_M^5N*'=#N=_G<G\'
MGO8WQX?OSM\<'9X>1T>')V_1X7[T\?3D#Y_-O>%(&X[T'2[W/E'N'\9]_FN6
MYUDRB_Y63HMZ0WKWGO0V7'3#1;\;4OX#4B[[QS=<=4.*WYP4-TQT0[G?)^5N
M$M*_9Y?-'XCMF-9+^\]OM7;YDT')V9S^YO0WI_]]GOZ&N0]QP*MM?[84$^C;
MP=7=YY9L-^!3>E._FF:-V@&:':L7\TH16A0\$_V/GM:78%DV95=C"@ULN2[X
MR+MB15Z667H35.2#49E>P_],FUG^T_\'4$L#!!0    ( -R*?%2)G.8QY ,
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M,#(Q,3(S,2YX<V102P$"% ,4    " #;BGQ4%#WY@/ ,   GL   %0
M        @ %O%0  9')T<RTR,#(Q,3(S,5]C86PN>&UL4$L! A0#%     @
MVXI\5$X.)ASJ+P  -/P" !4              ( !DB(  &1R=',M,C R,3$R
M,S%?9&5F+GAM;%!+ 0(4 Q0    ( -N*?%2OS#4AVGH  #+-!P 5
M      "  :]2  !D<G1S+3(P,C$Q,C,Q7VQA8BYX;6Q02P$"% ,4    " #;
MBGQ4S5E&<0-1  !^_@4 %0              @ &\S0  9')T<RTR,#(Q,3(S
M,5]P<F4N>&UL4$L! A0#%     @ VXI\5(R@Y*.OP 4 '&@Q !4
M     ( !\AX! &1R=',M,C R,3$R,S%X,C!F+FAT;5!+ 0(4 Q0    ( -N*
M?%1K_->C5 P   X-   8              "  =3?!@!D<G1S+3(P,C$Q,C,Q
M>#(P9C P,BYJ<&=02P$"% ,4    " #;BGQ4R$[OS]C:  "8-0$ &
M        @ %>[ 8 9')T<RTR,#(Q,3(S,7@R,&8P,#4N:G!G4$L! A0#%
M  @ VXI\5%M2PV ]90  ]VL  !@              ( !;,<' &1R=',M,C R
M,3$R,S%X,C!F,# V+FIP9U!+ 0(4 Q0    ( -N*?%3^B9KOH)(  (:>   8
M              "  =\L" !D<G1S+3(P,C$Q,C,Q>#(P9C P-RYJ<&=02P$"
M% ,4    " #;BGQ4S+IDH$<A  !E)0  &               @ &UOP@ 9')T
M<RTR,#(Q,3(S,7@R,&8P,#@N:G!G4$L! A0#%     @ VXI\5#(H_Q!)'0
M1B$  !@              ( !,N$( &1R=',M,C R,3$R,S%X,C!F,# Y+FIP
M9U!+ 0(4 Q0    ( -N*?%1&QI?,PU\  *-@   8              "  ;'^
M" !D<G1S+3(P,C$Q,C,Q>#(P9C Q,"YJ<&=02P$"% ,4    " #;BGQ4X@0H
M+4=4  #;5   &               @ &J7@D 9')T<RTR,#(Q,3(S,7@R,&8P
M,3$N:G!G4$L! A0#%     @ VXI\5#1=7IX0.0  ]CD  !@
M ( !)[,) &1R=',M,C R,3$R,S%X,C!F,#$R+FIP9U!+ 0(4 Q0    ( -N*
M?%0K9!ATU(D  'O$   8              "  6WL"0!D<G1S+3(P,C$Q,C,Q
M>#(P9C Q,RYJ<&=02P$"% ,4    " #;BGQ4;DP,_&E   "030  &
M        @ %W=@H 9')T<RTR,#(Q,3(S,7@R,&8P,30N:G!G4$L! A0#%
M  @ VXI\5.U],Z2(20  !%L  !@              ( !%K<* &1R=',M,C R
M,3$R,S%X,C!F,#$U+FIP9U!+ 0(4 Q0    ( -N*?%3C6\X\I@\! *$H 0 8
M              "  =0 "P!D<G1S+3(P,C$Q,C,Q>#(P9C Q-BYJ<&=02P$"
M% ,4    " #;BGQ4T@N'3Q/(  #5"@$ &               @ &P$ P 9')T
M<RTR,#(Q,3(S,7@R,&8P,3<N:G!G4$L! A0#%     @ VXI\5&YBX0>"^@
M-3L! !@              ( !^=@, &1R=',M,C R,3$R,S%X,C!F,#$X+FIP
M9U!+ 0(4 Q0    ( -R*?%2 4ME4O0$! ! : 0 8              "  ;'3
M#0!D<G1S+3(P,C$Q,C,Q>#(P9C Q.2YJ<&=02P$"% ,4    " #<BGQ4 !/T
MFL<O  "=,P  &               @ &DU0X 9')T<RTR,#(Q,3(S,7@R,&8P
M,C N:G!G4$L! A0#%     @ W(I\5,GO*U"E1   K%,  !@
M ( !H04/ &1R=',M,C R,3$R,S%X,C!F,#(Q+FIP9U!+ 0(4 Q0    ( -R*
M?%0[UFD,T#@  '0_   8              "  7Q*#P!D<G1S+3(P,C$Q,C,Q
M>#(P9C R,BYJ<&=02P$"% ,4    " #<BGQ4"J*R+&J?  #DJ0  &
M        @ &"@P\ 9')T<RTR,#(Q,3(S,7@R,&8P,C,N:G!G4$L! A0#%
M  @ W(I\5%26C,\[1P  -%0  !@              ( !(B,0 &1R=',M,C R
M,3$R,S%X,C!F,#(T+FIP9U!+ 0(4 Q0    ( -R*?%3ZV\A7]T   $-3   8
M              "  9-J$ !D<G1S+3(P,C$Q,C,Q>#(P9C R-2YJ<&=02P$"
M% ,4    " #<BGQ4<F:,(?Q-   M70  &               @ ' JQ  9')T
M<RTR,#(Q,3(S,7@R,&8P,C8N:G!G4$L! A0#%     @ W(I\5,RX#C)-40
MBF   !@              ( !\OD0 &1R=',M,C R,3$R,S%X,C!F,#(W+FIP
M9U!+ 0(4 Q0    ( -R*?%1RWNIE85D  %%C   8              "  75+
M$0!D<G1S+3(P,C$Q,C,Q>#(P9C R."YJ<&=02P$"% ,4    " #<BGQ4P5C;
MJ>Q;  #C:0  &               @ $,I1$ 9')T<RTR,#(Q,3(S,7@R,&8P
M,CDN:G!G4$L! A0#%     @ W(I\5%TV:#[T20  95,  !@
M ( !+@$2 &1R=',M,C R,3$R,S%X,C!F,#,P+FIP9U!+ 0(4 Q0    ( -R*
M?%2W'(D.4DD  .96   8              "  5A+$@!D<G1S+3(P,C$Q,C,Q
M>#(P9C S,2YJ<&=02P$"% ,4    " #<BGQ47MVDY9)8   D9P  &
M        @ '@E!( 9')T<RTR,#(Q,3(S,7@R,&8P,S(N:G!G4$L! A0#%
M  @ W(I\5+:L3Z14,P  .CH  !@              ( !J.T2 &1R=',M,C R
M,3$R,S%X,C!F,#,S+FIP9U!+ 0(4 Q0    ( -R*?%2^DWI/DGD  "IZ   8
M              "  3(A$P!D<G1S+3(P,C$Q,C,Q>#(P9C S-"YJ<&=02P$"
M% ,4    " #<BGQ43+DQ3["L   VK0  &               @ 'ZFA, 9')T
M<RTR,#(Q,3(S,7@R,&8P,S4N:G!G4$L! A0#%     @ W(I\5 8%RF]!+0
M,C8  !@              ( !X$<4 &1R=',M,C R,3$R,S%X,C!F,#,V+FIP
M9U!+ 0(4 Q0    ( -R*?%2WK,)KT2T  *LV   8              "  5=U
M% !D<G1S+3(P,C$Q,C,Q>#(P9C S-RYJ<&=02P$"% ,4    " #<BGQ4A#B;
MU-\R  !W/   &               @ %>HQ0 9')T<RTR,#(Q,3(S,7@R,&8P
M,S@N:G!G4$L! A0#%     @ W(I\5'V.=127:@  XGH  !@
M ( !<]84 &1R=',M,C R,3$R,S%X,C!F,#,Y+FIP9U!+ 0(4 Q0    ( -R*
M?%3Y/!PW]F<  ,MS   8              "  4!!%0!D<G1S+3(P,C$Q,C,Q
M>#(P9C T,"YJ<&=02P$"% ,4    " #<BGQ4"=/.DP])  !B4@  &
M        @ %LJ14 9')T<RTR,#(Q,3(S,7@R,&8P-#$N:G!G4$L! A0#%
M  @ W(I\5*\371'-0   8DH  !@              ( !L?(5 &1R=',M,C R
M,3$R,S%X,C!F,#0R+FIP9U!+ 0(4 Q0    ( -R*?%1"!1:#B@D  "H*   8
M              "  ;0S%@!D<G1S+3(P,C$Q,C,Q>#(P9C T-BYJ<&=02P$"
M% ,4    " #<BGQ4#@1*QC((  "(,@  &               @ %T/18 9')T
M<RTR,#(Q,3(S,7AE>#$R9#$N:'1M4$L! A0#%     @ W(I\5.*P%N8O"
MBS(  !@              ( !W$46 &1R=',M,C R,3$R,S%X97@Q,F0R+FAT
M;5!+ 0(4 Q0    ( -R*?%24_@Y*+ 4  &X3   8              "  4%.
M%@!D<G1S+3(P,C$Q,C,Q>&5X,3-D,2YH=&U02P$"% ,4    " #<BGQ4>.=-
MJQ,%  !@$P  &               @ &C4Q8 9')T<RTR,#(Q,3(S,7AE>#$S
M9#(N:'1M4$L! A0#%     @ W(I\5,R1)HJB@P  ?E,# !<
M ( ![%@6 &1R=',M,C R,3$R,S%X97@Q9#$N:'1M4$L! A0#%     @ W(I\
M5$5DV</3+@  2^T  !<              ( !P]P6 &1R=',M,C R,3$R,S%X
M97@R9#$N:'1M4$L! A0#%     @ W(I\5+#81'B!#0  FGD  !<
M     ( !RPL7 &1R=',M,C R,3$R,S%X97@T9#@N:'1M4$L! A0#%     @
MW(I\5![0MN_Q3@  U18" !<              ( !@1D7 &1R=',M,C R,3$R
M,S%X97@T9#DN:'1M4$L! A0#%     @ W(I\5(F<YC'D P  &Q4  !<
M         ( !IV@7 &1R=',M,C R,3$R,S%X97@X9#$N:'1M4$L%!@     W
- #< [PX  ,!L%P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
